{
  "category": "Clinical Pathology",
  "subject": {
    "name": "Molecular Pathology and Cytogenetics",
    "url": "https://app.pathprimer.com/curriculum/044e1f91-f85b-4398-89d6-a09c72bc9c5c",
    "lessons": {
      "Fundamentals and Methods of Cytogenetics and Molecular Pathology": {
        "name": "Fundamentals and Methods of Cytogenetics and Molecular Pathology",
        "url": "https://app.pathprimer.com/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
        "topics": {
          "Mendelian Inheritance": {
            "name": "Mendelian Inheritance",
            "url": "https://app.pathprimer.com/document/8d134075-f60d-415b-94c0-47326e23499d/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Mendelian inheritance: Inheritance pattern in single-gene disorders, determined by whether chromosome is autosome or sex chromosome and whether phenotype is dominant or recessive"
                  },
                  {
                    "text": "Autosome: Chromosomes 1-22"
                  },
                  {
                    "text": "Sex chromosome: X and Y chromosomes"
                  },
                  {
                    "text": "Compound heterozygote: Presence of 2 different variant alleles on opposite chromosomes"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Autosomal and X-Linked Inheritance Overview": [
                  {
                    "text": "Inheritance of mutant alleles occurs during meiosisOne copy of each autosome passes into each gameteRegardless of sex of offspring, if parent is heterozygous for mutant allele → 50% chance of transferring mutant allele to offspringMale parent transfers Y chromosome to sons and X chromosome to daughtersMales always pass alleles on X chromosome to daughtersMitochondrial transmission also occurs during meiosis and is inherited solely from mother, regardless of sex of offspringMitochondrial genome mutations do not follow Mendelian inheritance",
                    "sub_points": [
                      "One copy of each autosome passes into each gameteRegardless of sex of offspring, if parent is heterozygous for mutant allele → 50% chance of transferring mutant allele to offspring",
                      "Regardless of sex of offspring, if parent is heterozygous for mutant allele → 50% chance of transferring mutant allele to offspring",
                      "Male parent transfers Y chromosome to sons and X chromosome to daughtersMales always pass alleles on X chromosome to daughters",
                      "Males always pass alleles on X chromosome to daughters",
                      "Mitochondrial transmission also occurs during meiosis and is inherited solely from mother, regardless of sex of offspringMitochondrial genome mutations do not follow Mendelian inheritance",
                      "Mitochondrial genome mutations do not follow Mendelian inheritance"
                    ]
                  }
                ],
                "Autosomal Dominant Transmission": [
                  {
                    "text": "DominantIndividuals generally have 1 mutant copy of gene associated with disease phenotypeDisease phenotype can be seen in heterozygotes, homozygotes, or compound heterozygotesDisease severity often depends whether disease is purely dominant or incompletely dominant",
                    "sub_points": [
                      "Individuals generally have 1 mutant copy of gene associated with disease phenotype",
                      "Disease phenotype can be seen in heterozygotes, homozygotes, or compound heterozygotes",
                      "Disease severity often depends whether disease is purely dominant or incompletely dominant"
                    ]
                  },
                  {
                    "text": "Inheritance of single mutant gene can be inherited from either mother or fatherPresence of nonmutant (wild-type) allele does not prevent disease phenotype",
                    "sub_points": [
                      "Presence of nonmutant (wild-type) allele does not prevent disease phenotype"
                    ]
                  },
                  {
                    "text": "Pure dominanceHeterozygotes and homozygotes show exact same phenotypeRarely seen",
                    "sub_points": [
                      "Heterozygotes and homozygotes show exact same phenotype",
                      "Rarely seen"
                    ]
                  },
                  {
                    "text": "CodominanceExpression of phenotype of both alleles is seen in case of compound heterozygoteMore commonly seene.g., ABO blood group system, A and B alleles have codominant expression",
                    "sub_points": [
                      "Expression of phenotype of both alleles is seen in case of compound heterozygote",
                      "More commonly seen",
                      "e.g., ABO blood group system, A and B alleles have codominant expression"
                    ]
                  },
                  {
                    "text": "Males and females can equally transmit phenotype to both male and female offspring"
                  },
                  {
                    "text": "Phenotype of autosomal dominant disease is typically seen in every generationException is when there is spontaneous new mutationResults in disease of offspring﻿De novo mutations in offspring of unaffected parents are common in autosomal dominant conditions﻿",
                    "sub_points": [
                      "Exception is when there is spontaneous new mutationResults in disease of offspring",
                      "Results in disease of offspring",
                      "﻿De novo mutations in offspring of unaffected parents are common in autosomal dominant conditions﻿"
                    ]
                  },
                  {
                    "text": "In families where 1 parent is affected, offspring have 50% chance of inheriting mutant allele (and condition) from parent"
                  },
                  {
                    "text": "Incomplete penetrance and variable expressivity can affect pedigree of autosomal dominance in that every generation may not have same phenotypic pattern"
                  }
                ],
                "Autosomal Recessive Transmission": [
                  {
                    "text": "RecessiveClassically expressed in homozygotes with 2 mutant alleles and with no wild-type alleleAlso expressed in hemizygotes and compound heterozygotes with no wild-type allele",
                    "sub_points": [
                      "Classically expressed in homozygotes with 2 mutant alleles and with no wild-type allele",
                      "Also expressed in hemizygotes and compound heterozygotes with no wild-type allele"
                    ]
                  },
                  {
                    "text": "Mutant alleles in autosomal recessive transmission﻿ generally cause loss-of-function mutation in gene product﻿Mutant alleles often rare in populationMost people with rare autosomal recessive diseases are compound heterozygotes, as mutant alleles are rareException is with consanguinityAffected offspring inherits same recessive mutant alleles from both parents because parents are related and each carry same mutant allele from common ancestor",
                    "sub_points": [
                      "Mutant alleles often rare in population",
                      "Most people with rare autosomal recessive diseases are compound heterozygotes, as mutant alleles are rareException is with consanguinityAffected offspring inherits same recessive mutant alleles from both parents because parents are related and each carry same mutant allele from common ancestor",
                      "Exception is with consanguinityAffected offspring inherits same recessive mutant alleles from both parents because parents are related and each carry same mutant allele from common ancestor",
                      "Affected offspring inherits same recessive mutant alleles from both parents because parents are related and each carry same mutant allele from common ancestor"
                    ]
                  },
                  {
                    "text": "If both parents are carriers for mutant allele, there is 50% chance each parent will pass mutant allele to offspring25% chance that offspring of 2 carrier parents inherits 2 mutant alleles and is affectedThis risk applies to each offspring and is independent of any other offspring",
                    "sub_points": [
                      "25% chance that offspring of 2 carrier parents inherits 2 mutant alleles and is affected",
                      "This risk applies to each offspring and is independent of any other offspring"
                    ]
                  },
                  {
                    "text": "Frequency is same for males and females with autosomal recessive transmission"
                  },
                  {
                    "text": "Gene frequencyIncidence of allele in given population",
                    "sub_points": [
                      "Incidence of allele in given population"
                    ]
                  }
                ],
                "X-Linked": [
                  {
                    "text": "Females normally have 2 X chromosomes naturally and undergo X-inactivationProcess in which most genes on 1 of 2 X chromosomes are turned off in somatic cells",
                    "sub_points": [
                      "Process in which most genes on 1 of 2 X chromosomes are turned off in somatic cells"
                    ]
                  },
                  {
                    "text": "Terms \"dominant\" and \"recessive\" in X-linked disorders are based on expression of phenotype in female heterozygotesDominantDiseased phenotype is apparent clinically in carrierRecessiveDiseased phenotype is not apparent clinically in carrierFemales may or may not express X-linked disease when they are heterozygotesCan make classification of X-linked disorder as dominant or recessive very difficultDepends on random X-inactivation,proportion of cells expressing mutant X-allele",
                    "sub_points": [
                      "DominantDiseased phenotype is apparent clinically in carrier",
                      "Diseased phenotype is apparent clinically in carrier",
                      "RecessiveDiseased phenotype is not apparent clinically in carrier",
                      "Diseased phenotype is not apparent clinically in carrier",
                      "Females may or may not express X-linked disease when they are heterozygotesCan make classification of X-linked disorder as dominant or recessive very difficultDepends on random X-inactivation,proportion of cells expressing mutant X-allele",
                      "Can make classification of X-linked disorder as dominant or recessive very difficult",
                      "Depends on random X-inactivation,proportion of cells expressing mutant X-allele"
                    ]
                  }
                ],
                "X-Linked Recessive": [
                  {
                    "text": "Diseased phenotype is seen in all males with mutant allele on X-chromosome﻿Generally seen only in males﻿Female carriers (heterozygous) generally do not express phenotypeVariable expression in female heterozygotes likely due to pattern of X-inactivation and amount of somatic cells expressing mutant allele on X-chromosome",
                    "sub_points": [
                      "﻿Generally seen only in males﻿",
                      "Female carriers (heterozygous) generally do not express phenotypeVariable expression in female heterozygotes likely due to pattern of X-inactivation and amount of somatic cells expressing mutant allele on X-chromosome",
                      "Variable expression in female heterozygotes likely due to pattern of X-inactivation and amount of somatic cells expressing mutant allele on X-chromosome"
                    ]
                  },
                  {
                    "text": "Affected males transmit mutant allele to all female offspring﻿Female offspring have 50% chance of transmitting the mutant allele to subsequent male offspringAffected males never transmit mutant allele to their sons",
                    "sub_points": [
                      "Female offspring have 50% chance of transmitting the mutant allele to subsequent male offspring",
                      "Affected males never transmit mutant allele to their sons"
                    ]
                  },
                  {
                    "text": "Isolated cases of X-linked recessive diseases are due to de novo mutations"
                  }
                ],
                "X-Linked Dominant": [
                  {
                    "text": "Diseased phenotype is expressed and clinically apparent in heterozygotes (females)No male-to-male transmission of diseaseThis can be used to distinguish X-linked dominant inheritance from autosomal form of inheritanceIn pedigree of affected males with normal mates, all sons are not affected, and all daughters are affectedIn pedigree of affected males with normal mates, if son is affected or daughter is not affected, consider autosomal form of inheritanceIn regard to affected females, pattern of inheritance seen in offspring is similar to autosomal dominant pattern because females have 2 X-chromosomes50% chance that male and female offspring of affected female will inherit diseased phenotypeAffected females generally have milder phenotype compared with affected males",
                    "sub_points": [
                      "No male-to-male transmission of diseaseThis can be used to distinguish X-linked dominant inheritance from autosomal form of inheritanceIn pedigree of affected males with normal mates, all sons are not affected, and all daughters are affectedIn pedigree of affected males with normal mates, if son is affected or daughter is not affected, consider autosomal form of inheritance",
                      "This can be used to distinguish X-linked dominant inheritance from autosomal form of inheritance",
                      "In pedigree of affected males with normal mates, all sons are not affected, and all daughters are affected",
                      "In pedigree of affected males with normal mates, if son is affected or daughter is not affected, consider autosomal form of inheritance",
                      "In regard to affected females, pattern of inheritance seen in offspring is similar to autosomal dominant pattern because females have 2 X-chromosomes50% chance that male and female offspring of affected female will inherit diseased phenotype",
                      "50% chance that male and female offspring of affected female will inherit diseased phenotype",
                      "Affected females generally have milder phenotype compared with affected males"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "DNA Replication, Transcription, and Translation": {
            "name": "DNA Replication, Transcription, and Translation",
            "url": "https://app.pathprimer.com/document/41514875-e73d-43fb-a92f-0631002d4cf7/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "DNA Replication": {
                "General Principles": [
                  {
                    "text": "Exact duplication of double stranded (ds) DNA takes place prior to cell divisionEach daughter cell will contain exact replica of parent DNA",
                    "sub_points": [
                      "Each daughter cell will contain exact replica of parent DNA"
                    ]
                  },
                  {
                    "text": "Takes place during synthesis (S) phase of cell cycleCell cycle consists of G₀, G₁, S, G₂, and M phases",
                    "sub_points": [
                      "Cell cycle consists of G₀, G₁, S, G₂, and M phases"
                    ]
                  },
                  {
                    "text": "Replication is a semiconservative processEach daughter DNA duplex contains 1 newly synthesized strand and 1 original strand from parent molecule",
                    "sub_points": [
                      "Each daughter DNA duplex contains 1 newly synthesized strand and 1 original strand from parent molecule"
                    ]
                  },
                  {
                    "text": "DNA polymerasesEnzymes involved in DNA replication (α, β, γ, δ, and ε)α and δ replicate nuclear DNAβ and ε are involved in DNA repairγ replicates mitochondrial DNAProcessivity of DNA polymerase enzymesRate at which 4 nucleotides are polymerized into nucleic acid chainMost have processivity of 1,000 bases per minuteFidelity of DNA polymeraseAccuracy in which correct base is incorporated into newly synthesized DNADNA polymerase error ratesVary from 1 in 1,200 to 1 in 1 millionCorrected by DNA proofreading functionsDNA repairUsually takes place in G₂ phase of cell cycleNormal healthy cells will pause for this to occurMalignant cells may not pause and therefore replication errors may persistOncogenesisMay result from incorrect bases being incorporated into newly synthesized strandAltered sequence may change protein function",
                    "sub_points": [
                      "Enzymes involved in DNA replication (α, β, γ, δ, and ε)α and δ replicate nuclear DNAβ and ε are involved in DNA repairγ replicates mitochondrial DNA",
                      "α and δ replicate nuclear DNA",
                      "β and ε are involved in DNA repair",
                      "γ replicates mitochondrial DNA",
                      "Processivity of DNA polymerase enzymesRate at which 4 nucleotides are polymerized into nucleic acid chainMost have processivity of 1,000 bases per minute",
                      "Rate at which 4 nucleotides are polymerized into nucleic acid chain",
                      "Most have processivity of 1,000 bases per minute",
                      "Fidelity of DNA polymeraseAccuracy in which correct base is incorporated into newly synthesized DNA",
                      "Accuracy in which correct base is incorporated into newly synthesized DNA",
                      "DNA polymerase error ratesVary from 1 in 1,200 to 1 in 1 millionCorrected by DNA proofreading functions",
                      "Vary from 1 in 1,200 to 1 in 1 million",
                      "Corrected by DNA proofreading functions",
                      "DNA repairUsually takes place in G₂ phase of cell cycleNormal healthy cells will pause for this to occurMalignant cells may not pause and therefore replication errors may persist",
                      "Usually takes place in G₂ phase of cell cycle",
                      "Normal healthy cells will pause for this to occur",
                      "Malignant cells may not pause and therefore replication errors may persist",
                      "OncogenesisMay result from incorrect bases being incorporated into newly synthesized strandAltered sequence may change protein function",
                      "May result from incorrect bases being incorporated into newly synthesized strand",
                      "Altered sequence may change protein function"
                    ]
                  }
                ],
                "Process Overview": [
                  {
                    "text": "Dissociation of DNA strandsMay be accomplished byChemical or physical conditions such as alkali or high temperatures (i.e., 95°C)Physiological conditions by numerous enzymes (i.e., helicases, topoisomerases)",
                    "sub_points": [
                      "May be accomplished byChemical or physical conditions such as alkali or high temperatures (i.e., 95°C)Physiological conditions by numerous enzymes (i.e., helicases, topoisomerases)",
                      "Chemical or physical conditions such as alkali or high temperatures (i.e., 95°C)",
                      "Physiological conditions by numerous enzymes (i.e., helicases, topoisomerases)"
                    ]
                  },
                  {
                    "text": "Formation of replication forkReplication is initiated at multiple sites/origins where parental DNA duplex is opened up to form Y-shaped replication forkInitiating proteins, primases, and DNA polymerases bind to original parental strand of DNA (replisome)As replication proceeds, replication fork moves along length of parent DNA strand",
                    "sub_points": [
                      "Replication is initiated at multiple sites/origins where parental DNA duplex is opened up to form Y-shaped replication fork",
                      "Initiating proteins, primases, and DNA polymerases bind to original parental strand of DNA (replisome)",
                      "As replication proceeds, replication fork moves along length of parent DNA strand"
                    ]
                  },
                  {
                    "text": "Enzymatic activities generate 2 new nucleic acid strandsDNA polymerase α and δ synthesize nucleic acid molecules from nucleotidesStrands are complementary (base paired) to original parent DNA strands (semiconservative process)Nucleotides are sequentially added according to order of bases in parent strandG:C and A:T pairingNew \"daughter\" strand is antiparallel to parent strand",
                    "sub_points": [
                      "DNA polymerase α and δ synthesize nucleic acid molecules from nucleotides",
                      "Strands are complementary (base paired) to original parent DNA strands (semiconservative process)",
                      "Nucleotides are sequentially added according to order of bases in parent strandG:C and A:T pairing",
                      "G:C and A:T pairing",
                      "New \"daughter\" strand is antiparallel to parent strand"
                    ]
                  },
                  {
                    "text": "DNA polymerase can only read parent DNA in 3' to 5' direction and can only synthesize in 5' to 3' direction."
                  },
                  {
                    "text": "The 2 parent strands are designated as leading and lagging strandsLeading strandRead by DNA polymerase in 3' to 5' directionNew strand of DNA is synthesized continuously in 5' to 3' directionLagging strandSynthesized in discontinuous mannerReplication fork moves in 5' to 3' directionCopied in short stretches forming short DNA fragments (Okazaki fragments)Fragments are joined by ligation into a continuous daughter strand that is complementary to parent DNA lagging strandResults in progressive loss of telomeres",
                    "sub_points": [
                      "Leading strandRead by DNA polymerase in 3' to 5' directionNew strand of DNA is synthesized continuously in 5' to 3' direction",
                      "Read by DNA polymerase in 3' to 5' direction",
                      "New strand of DNA is synthesized continuously in 5' to 3' direction",
                      "Lagging strandSynthesized in discontinuous mannerReplication fork moves in 5' to 3' directionCopied in short stretches forming short DNA fragments (Okazaki fragments)Fragments are joined by ligation into a continuous daughter strand that is complementary to parent DNA lagging strandResults in progressive loss of telomeres",
                      "Synthesized in discontinuous manner",
                      "Replication fork moves in 5' to 3' direction",
                      "Copied in short stretches forming short DNA fragments (Okazaki fragments)",
                      "Fragments are joined by ligation into a continuous daughter strand that is complementary to parent DNA lagging strand",
                      "Results in progressive loss of telomeres"
                    ]
                  }
                ]
              },
              "Transcription": {
                "General Principles": [
                  {
                    "text": "Process of converting DNA sequence to single strand of RNA by RNA polymerase"
                  },
                  {
                    "text": "Transcription requires various proteins (transcription factors) that bind DNA sequence elements in a highly regulated processTranscription factors bind DNA sequence elements to form basal transcription apparatusFixed set of general transcription factorsCoactivators and corepressorsGene- or tissue-specific transcription factorsTranscription factors help position and guide RNA polymeraseTranscription factors recognized by RNA polymerase II include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH",
                    "sub_points": [
                      "Transcription factors bind DNA sequence elements to form basal transcription apparatusFixed set of general transcription factorsCoactivators and corepressorsGene- or tissue-specific transcription factors",
                      "Fixed set of general transcription factors",
                      "Coactivators and corepressors",
                      "Gene- or tissue-specific transcription factors",
                      "Transcription factors help position and guide RNA polymerase",
                      "Transcription factors recognized by RNA polymerase II include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH"
                    ]
                  },
                  {
                    "text": "RNA polymerase requires crucial regulatory DNA sequence elements such as promotors and enhancers"
                  },
                  {
                    "text": "PromoterDNA sequence element often located close to and upstream of a geneRecognized and bound by transcription factorsTATA (i.e., TATAAA), GC box (i.e., GGGCGG) and CAAT box are promoters recognized by RNA polymerase II",
                    "sub_points": [
                      "DNA sequence element often located close to and upstream of a gene",
                      "Recognized and bound by transcription factors",
                      "TATA (i.e., TATAAA), GC box (i.e., GGGCGG) and CAAT box are promoters recognized by RNA polymerase II"
                    ]
                  },
                  {
                    "text": "EnhancerRecognized by tissue-specific transcription factorsEnhance transcriptional activity of specific geneLocated at variable distances from transcription initiation sites",
                    "sub_points": [
                      "Recognized by tissue-specific transcription factors",
                      "Enhance transcriptional activity of specific gene",
                      "Located at variable distances from transcription initiation sites"
                    ]
                  },
                  {
                    "text": "SilencerSimilar to enhancer but functions to inhibit transcriptional activity",
                    "sub_points": [
                      "Similar to enhancer but functions to inhibit transcriptional activity"
                    ]
                  },
                  {
                    "text": "RNA PolymerasesRNA polymerase I: Transcribes genes encoding ribosomal RNARNA polymerase II: Transcribes genes encoding proteins (mRNA) and many functional RNAs (i.e., small nucleolar RNA, microRNA)RNA polymerase III: Transcribes genes encoding transfer RNA (tRNA) and 5S ribosomal RNA",
                    "sub_points": [
                      "RNA polymerase I: Transcribes genes encoding ribosomal RNA",
                      "RNA polymerase II: Transcribes genes encoding proteins (mRNA) and many functional RNAs (i.e., small nucleolar RNA, microRNA)",
                      "RNA polymerase III: Transcribes genes encoding transfer RNA (tRNA) and 5S ribosomal RNA"
                    ]
                  },
                  {
                    "text": "Types of RNAMessenger RNA (mRNA)Transcribed from DNA to carry protein sequence informationTransfer RNA (tRNA)Amino acid-specific adapter molecule involved in translationRibosomal RNA (rRNA)RNA component of ribosomeRibosomes are essential components of protein manufacturing",
                    "sub_points": [
                      "Messenger RNA (mRNA)Transcribed from DNA to carry protein sequence information",
                      "Transcribed from DNA to carry protein sequence information",
                      "Transfer RNA (tRNA)Amino acid-specific adapter molecule involved in translation",
                      "Amino acid-specific adapter molecule involved in translation",
                      "Ribosomal RNA (rRNA)RNA component of ribosomeRibosomes are essential components of protein manufacturing",
                      "RNA component of ribosome",
                      "Ribosomes are essential components of protein manufacturing"
                    ]
                  },
                  {
                    "text": "ExonsSequences in mRNA that code for protein sequence (coding sequences)",
                    "sub_points": [
                      "Sequences in mRNA that code for protein sequence (coding sequences)"
                    ]
                  },
                  {
                    "text": "IntronsNon-coding sequences found in-between exonsSpliced out of mRNA by exonucleases prior to translation",
                    "sub_points": [
                      "Non-coding sequences found in-between exons",
                      "Spliced out of mRNA by exonucleases prior to translation"
                    ]
                  },
                  {
                    "text": "Post-transcription RNA processingRNA splicingRemoval of intronic RNA segmentsRemaining exonic RNA are joined togetherProcess yields overall shorter RNA product5' cappingFollowing initiation, 7-methylguanosine is linked by a 5'-5' phosphodiester bond to first 5' nucleotideProtects RNA transcript from exonuclease activityFacilitates RNA transport from nucleus to cytoplasmFacilitates RNA splicing and attachment of 40S ribosome subunit during translation3' polyadenylationPoly(A) polymerase sequentially adds AMP residues to 3' end (about 200) to produce poly(A) tailFacilitates mRNA transportation, provides stability to mRNA and enhances recognition by ribosomal machinery",
                    "sub_points": [
                      "RNA splicingRemoval of intronic RNA segmentsRemaining exonic RNA are joined togetherProcess yields overall shorter RNA product",
                      "Removal of intronic RNA segments",
                      "Remaining exonic RNA are joined together",
                      "Process yields overall shorter RNA product",
                      "5' cappingFollowing initiation, 7-methylguanosine is linked by a 5'-5' phosphodiester bond to first 5' nucleotideProtects RNA transcript from exonuclease activityFacilitates RNA transport from nucleus to cytoplasmFacilitates RNA splicing and attachment of 40S ribosome subunit during translation",
                      "Following initiation, 7-methylguanosine is linked by a 5'-5' phosphodiester bond to first 5' nucleotide",
                      "Protects RNA transcript from exonuclease activity",
                      "Facilitates RNA transport from nucleus to cytoplasm",
                      "Facilitates RNA splicing and attachment of 40S ribosome subunit during translation",
                      "3' polyadenylationPoly(A) polymerase sequentially adds AMP residues to 3' end (about 200) to produce poly(A) tailFacilitates mRNA transportation, provides stability to mRNA and enhances recognition by ribosomal machinery",
                      "Poly(A) polymerase sequentially adds AMP residues to 3' end (about 200) to produce poly(A) tail",
                      "Facilitates mRNA transportation, provides stability to mRNA and enhances recognition by ribosomal machinery"
                    ]
                  }
                ],
                "Process Overview": [
                  {
                    "text": "DNA must first be bound by general transcription factors (preinitiation complex)"
                  },
                  {
                    "text": "RNA polymerase binds to bound transcription factors to form basal transcription apparatus"
                  },
                  {
                    "text": "Double-stranded DNA bound by RNA polymerase and transcription factors is unwoundUnwound segment of DNA acts as a template for RNA synthesisTransient double-stranded RNA-DNA hybrid forms with the growing RNA strand",
                    "sub_points": [
                      "Unwound segment of DNA acts as a template for RNA synthesis",
                      "Transient double-stranded RNA-DNA hybrid forms with the growing RNA strand"
                    ]
                  },
                  {
                    "text": "RNA polymerase moves from 3′ end of DNA template strand (3'-5') synthesizing RNA from 4 nucleotide precursors (ATP, CTP, GTP, UTP)"
                  },
                  {
                    "text": "Elongation proceeds with addition of ribonucleoside monophosphate residues (AMP, CMP, GMP, UMP) to free 3' hydroxyl group at 3' end of growing RNA strand"
                  },
                  {
                    "text": "Base pairing is identical to that of DNA except that uracil (U) replaces T"
                  },
                  {
                    "text": "RNA synthesis proceeds in 5' to 3' direction until it reaches a stop codon"
                  },
                  {
                    "text": "AAUAAA sequence signals for 3' cleavage at site 15-30 nucleotides downstream"
                  },
                  {
                    "text": "RNA processing (i.e., splicing, 5' capping, and 3' polyadenylation)"
                  }
                ]
              },
              "Translation": {
                "General Principles": [
                  {
                    "text": "Process of converting sequence information from single strand of mRNA into amino acid sequence"
                  },
                  {
                    "text": "Messenger RNA migrates to cytoplasm where it interacts with ribosomal machinery to initiate translation and polypeptide synthesis"
                  },
                  {
                    "text": "RibosomesLarge RNA-protein complexes of ~ 50 different proteins associated with several rRNA moleculesComposed of 2 main subunits1 large 60S subunit and 1 smaller 40S subunit (eukaryotes)Provide structural framework for polypeptide synthesis",
                    "sub_points": [
                      "Large RNA-protein complexes of ~ 50 different proteins associated with several rRNA molecules",
                      "Composed of 2 main subunits1 large 60S subunit and 1 smaller 40S subunit (eukaryotes)",
                      "1 large 60S subunit and 1 smaller 40S subunit (eukaryotes)",
                      "Provide structural framework for polypeptide synthesis"
                    ]
                  },
                  {
                    "text": "Transfer RNA (tRNA)Translation relies on tRNA that carries specific amino acid and recognizes corresponding codon in mRNA sequenceCollection of tRNA molecules bind to specific amino acid to form amino acid-tRNA complex (aminoacyl tRNA)Each tRNA contains anticodon that allows it to recognize codon in mRNA strand",
                    "sub_points": [
                      "Translation relies on tRNA that carries specific amino acid and recognizes corresponding codon in mRNA sequence",
                      "Collection of tRNA molecules bind to specific amino acid to form amino acid-tRNA complex (aminoacyl tRNA)",
                      "Each tRNA contains anticodon that allows it to recognize codon in mRNA strand"
                    ]
                  },
                  {
                    "text": "CodonsSet of 3 basesConvey genetic information to be translated into amino acid sequencesEach codon specifies an amino acid",
                    "sub_points": [
                      "Set of 3 bases",
                      "Convey genetic information to be translated into amino acid sequences",
                      "Each codon specifies an amino acid"
                    ]
                  }
                ],
                "Process Overview": [
                  {
                    "text": "Messenger RNA binds to ribosome in cytoplasm"
                  },
                  {
                    "text": "Ribosomes recognize 5' cap of mRNA to initiate process"
                  },
                  {
                    "text": "Synthesis begins at start codon (AUG)Encodes methionine amino acidEstablishes reading frame of mRNA",
                    "sub_points": [
                      "Encodes methionine amino acid",
                      "Establishes reading frame of mRNA"
                    ]
                  },
                  {
                    "text": "Messenger RNA is read in 5' to 3' direction in groups of 3 nucleotides (codons)"
                  },
                  {
                    "text": "Ribosome travels down mRNA 1 codon at a time as amino acids are added"
                  },
                  {
                    "text": "Protein translation ends at stop codon (UGA, UAG, UAA)"
                  },
                  {
                    "text": "Protein is manufactured form N (amino)-terminal to C (carboxy)-terminal"
                  },
                  {
                    "text": "Completed polypeptide then undergoes post-translational processingAddition of carbohydrate and lipid groupsProtein cleavage",
                    "sub_points": [
                      "Addition of carbohydrate and lipid groups",
                      "Protein cleavage"
                    ]
                  }
                ],
                "Post-Translational Modifications": [
                  {
                    "text": "Modifications allow for different proteins to bind chromatin and subsequently affect condensation and transcriptional activity"
                  },
                  {
                    "text": "ExamplesPhosphorylation (PO₄-)Targets tyrosine, seronine, and threonine via kinasesMethylation (CH₃)Targets lysine via methylasesHydroxylation (OH)Targets proline, lysine, aspartic acidAcetylation (CH₃CO)Targets lysine via acetylaseCarboxylation (COOH)Targets glutamine via γ-carboxylaseGlycosylation (complex carbohydrate)Targets asparagine, serine, threonine, hydroxyproline",
                    "sub_points": [
                      "Phosphorylation (PO₄-)Targets tyrosine, seronine, and threonine via kinases",
                      "Targets tyrosine, seronine, and threonine via kinases",
                      "Methylation (CH₃)Targets lysine via methylases",
                      "Targets lysine via methylases",
                      "Hydroxylation (OH)Targets proline, lysine, aspartic acid",
                      "Targets proline, lysine, aspartic acid",
                      "Acetylation (CH₃CO)Targets lysine via acetylase",
                      "Targets lysine via acetylase",
                      "Carboxylation (COOH)Targets glutamine via γ-carboxylase",
                      "Targets glutamine via γ-carboxylase",
                      "Glycosylation (complex carbohydrate)Targets asparagine, serine, threonine, hydroxyproline",
                      "Targets asparagine, serine, threonine, hydroxyproline"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Structure of Chromosomes and Nucleic Acids": {
            "name": "Structure of Chromosomes and Nucleic Acids",
            "url": "https://app.pathprimer.com/document/95736799-8a86-4a7f-a5bb-e1b4b7337bf0/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "Chromosome Organization": {
                "Overview": [
                  {
                    "text": "Chromosomes consist of linear double-stranded (ds) DNA complexed with proteins and found in nucleus"
                  },
                  {
                    "text": "Human genome contains ~ 10⁹ base pairs of DNA (3.2 x 10⁹ nucleotides)"
                  },
                  {
                    "text": "Chromosome numberPloidyNumber of homologous chromosome sets in cell (e.g., haploid [1N] = 23 chromosomes; diploid [2N] = 46 chromosomes)Diploid (2N) human genome is contained in 46 chromosomes22 pairs of autosomal chromosomes + 2 sex chromosomes (XX in females or XY in males)~ 35,000 genes",
                    "sub_points": [
                      "PloidyNumber of homologous chromosome sets in cell (e.g., haploid [1N] = 23 chromosomes; diploid [2N] = 46 chromosomes)",
                      "Number of homologous chromosome sets in cell (e.g., haploid [1N] = 23 chromosomes; diploid [2N] = 46 chromosomes)",
                      "Diploid (2N) human genome is contained in 46 chromosomes22 pairs of autosomal chromosomes + 2 sex chromosomes (XX in females or XY in males)~ 35,000 genes",
                      "22 pairs of autosomal chromosomes + 2 sex chromosomes (XX in females or XY in males)",
                      "~ 35,000 genes"
                    ]
                  },
                  {
                    "text": "Chromosome numerical abnormalitiesContribute significantly to genetic diseaseAutosomal abnormalities are generally more detrimental than sex chromosome abnormalitiesPolyploidyRefers to cells with extra chromosome set(s) beyond normal set of paired (2N) chromosomes (e.g., haploid [1N] and diploid [2N])AneuploidyRefers to abnormal number of chromosomes in cell either by loss or gains of single or multiple chromosomes (e.g., 47,XXY)Monosomy: Type of aneuploidy resulting from loss of 1 parental chromosome (e.g., 45,XY,-7)Trisomy: Type of aneuploidy resulting in gain of 1 parental chromosome (e.g., 47,XY,+21)Mosaic2 or more cell lines derived from single zygoteChimera2 or more cell lines derived from different zygotes",
                    "sub_points": [
                      "Contribute significantly to genetic disease",
                      "Autosomal abnormalities are generally more detrimental than sex chromosome abnormalities",
                      "PolyploidyRefers to cells with extra chromosome set(s) beyond normal set of paired (2N) chromosomes (e.g., haploid [1N] and diploid [2N])",
                      "Refers to cells with extra chromosome set(s) beyond normal set of paired (2N) chromosomes (e.g., haploid [1N] and diploid [2N])",
                      "AneuploidyRefers to abnormal number of chromosomes in cell either by loss or gains of single or multiple chromosomes (e.g., 47,XXY)Monosomy: Type of aneuploidy resulting from loss of 1 parental chromosome (e.g., 45,XY,-7)Trisomy: Type of aneuploidy resulting in gain of 1 parental chromosome (e.g., 47,XY,+21)",
                      "Refers to abnormal number of chromosomes in cell either by loss or gains of single or multiple chromosomes (e.g., 47,XXY)",
                      "Monosomy: Type of aneuploidy resulting from loss of 1 parental chromosome (e.g., 45,XY,-7)",
                      "Trisomy: Type of aneuploidy resulting in gain of 1 parental chromosome (e.g., 47,XY,+21)",
                      "Mosaic2 or more cell lines derived from single zygote",
                      "2 or more cell lines derived from single zygote",
                      "Chimera2 or more cell lines derived from different zygotes",
                      "2 or more cell lines derived from different zygotes"
                    ]
                  }
                ],
                "Chromosomes": [
                  {
                    "text": "ChromatinForm of genetic material that exists during interphasePackaged state of DNA that allows for mitosis, meiosis, and gene expressionDNA complexed with protein followed by highly ordered coiling and supercoilingHistones are major chromatin binding proteinHistones H2A, H2B, H3, and H4 form octamers147 base pairs of dsDNA are coiled in < 2 turns (1.65 times) around central core of this histone octamerCoiling forms fundamental unit of DNA packaging (nucleosome)Adjacent nucleosomes are connected by short lengths of linker DNANucleosomes are stacked and further coiled (6-8 nucleosomes/turn) into 30 nm fiber (spiral or solenoid arrangement)30 nm fiber makes up chromosome that resides in nucleusPost-translational modificationsMethylation, phosphorylation, and acetylation of chromatin function to regulate gene expressionModifications allow for different proteins to bind chromatin and subsequently affect chromatin condensation and transcriptional activityEuchromatinLoosely packaged form of DNAMost commonly observed during interphaseRepresents areas of active transcription (gene expression)Corresponds to light-staining regions in G-banding stain techniquesHeterochromatinTightly packaged form of DNARepresents areas of inactive transcription (nontranscribed DNA)Corresponds to dark-staining regions in G-banding stain techniques",
                    "sub_points": [
                      "Form of genetic material that exists during interphase",
                      "Packaged state of DNA that allows for mitosis, meiosis, and gene expression",
                      "DNA complexed with protein followed by highly ordered coiling and supercoilingHistones are major chromatin binding proteinHistones H2A, H2B, H3, and H4 form octamers147 base pairs of dsDNA are coiled in < 2 turns (1.65 times) around central core of this histone octamerCoiling forms fundamental unit of DNA packaging (nucleosome)Adjacent nucleosomes are connected by short lengths of linker DNANucleosomes are stacked and further coiled (6-8 nucleosomes/turn) into 30 nm fiber (spiral or solenoid arrangement)30 nm fiber makes up chromosome that resides in nucleus",
                      "Histones are major chromatin binding protein",
                      "Histones H2A, H2B, H3, and H4 form octamers",
                      "147 base pairs of dsDNA are coiled in < 2 turns (1.65 times) around central core of this histone octamer",
                      "Coiling forms fundamental unit of DNA packaging (nucleosome)",
                      "Adjacent nucleosomes are connected by short lengths of linker DNA",
                      "Nucleosomes are stacked and further coiled (6-8 nucleosomes/turn) into 30 nm fiber (spiral or solenoid arrangement)",
                      "30 nm fiber makes up chromosome that resides in nucleus",
                      "Post-translational modificationsMethylation, phosphorylation, and acetylation of chromatin function to regulate gene expressionModifications allow for different proteins to bind chromatin and subsequently affect chromatin condensation and transcriptional activity",
                      "Methylation, phosphorylation, and acetylation of chromatin function to regulate gene expression",
                      "Modifications allow for different proteins to bind chromatin and subsequently affect chromatin condensation and transcriptional activity",
                      "EuchromatinLoosely packaged form of DNAMost commonly observed during interphaseRepresents areas of active transcription (gene expression)Corresponds to light-staining regions in G-banding stain techniques",
                      "Loosely packaged form of DNA",
                      "Most commonly observed during interphase",
                      "Represents areas of active transcription (gene expression)",
                      "Corresponds to light-staining regions in G-banding stain techniques",
                      "HeterochromatinTightly packaged form of DNARepresents areas of inactive transcription (nontranscribed DNA)Corresponds to dark-staining regions in G-banding stain techniques",
                      "Tightly packaged form of DNA",
                      "Represents areas of inactive transcription (nontranscribed DNA)",
                      "Corresponds to dark-staining regions in G-banding stain techniques"
                    ]
                  },
                  {
                    "text": "Chromosome structureEach chromosome contains 2 long arms (q), 2 short arms (p), 1 centromere, and multiple telomeresCentromereConstricted region where duplicated sister chromatids join until anaphaseSeparates short (p) and long (q) armsEssential for attaching chromosomes to mitotic spindle and for chromosome segregationTelomereSpecialized heterochromatic DNA-protein complexes located at ends of chromosomesProtects chromosome ends from deterioration or from fusing with adjacent chromosomesSatellitesSmall chromosomal segment separated by noncentromeric constriction from remaining chromosome",
                    "sub_points": [
                      "Each chromosome contains 2 long arms (q), 2 short arms (p), 1 centromere, and multiple telomeres",
                      "CentromereConstricted region where duplicated sister chromatids join until anaphaseSeparates short (p) and long (q) armsEssential for attaching chromosomes to mitotic spindle and for chromosome segregation",
                      "Constricted region where duplicated sister chromatids join until anaphase",
                      "Separates short (p) and long (q) arms",
                      "Essential for attaching chromosomes to mitotic spindle and for chromosome segregation",
                      "TelomereSpecialized heterochromatic DNA-protein complexes located at ends of chromosomesProtects chromosome ends from deterioration or from fusing with adjacent chromosomes",
                      "Specialized heterochromatic DNA-protein complexes located at ends of chromosomes",
                      "Protects chromosome ends from deterioration or from fusing with adjacent chromosomes",
                      "SatellitesSmall chromosomal segment separated by noncentromeric constriction from remaining chromosome",
                      "Small chromosomal segment separated by noncentromeric constriction from remaining chromosome"
                    ]
                  },
                  {
                    "text": "Chromosome categorization and morphologyNumbered (1-22) according to relative size (largest to smallest)Grouped according to centromere positionMetacentric: Centromere located at or near middleSubmetacentric: Centromere in location that results in clearly unequal lengths of chromosome armsAcrocentric: Centromere located at or near chromosome end",
                    "sub_points": [
                      "Numbered (1-22) according to relative size (largest to smallest)",
                      "Grouped according to centromere positionMetacentric: Centromere located at or near middleSubmetacentric: Centromere in location that results in clearly unequal lengths of chromosome armsAcrocentric: Centromere located at or near chromosome end",
                      "Metacentric: Centromere located at or near middle",
                      "Submetacentric: Centromere in location that results in clearly unequal lengths of chromosome arms",
                      "Acrocentric: Centromere located at or near chromosome end"
                    ]
                  }
                ],
                "Nucleic Acids": [
                  {
                    "text": "Both DNA and RNA are large polymers with long linear backbonesLinear backbone is composed of alternating residues of phosphate group and 5-carbon sugarSugars in DNA differ by lack of hydroxyl group at 2' carbon positionSugars in RNA differ by presence of hydroxyl group at 2' carbon positionNitrogenous base is attached to each sugar to form nucleosideNitrogenous bases of nucleic acid molecule varySequence of nitrogenous bases identifies nucleic acid and determines its function",
                    "sub_points": [
                      "Linear backbone is composed of alternating residues of phosphate group and 5-carbon sugar",
                      "Sugars in DNA differ by lack of hydroxyl group at 2' carbon position",
                      "Sugars in RNA differ by presence of hydroxyl group at 2' carbon position",
                      "Nitrogenous base is attached to each sugar to form nucleosideNitrogenous bases of nucleic acid molecule varySequence of nitrogenous bases identifies nucleic acid and determines its function",
                      "Nitrogenous bases of nucleic acid molecule vary",
                      "Sequence of nitrogenous bases identifies nucleic acid and determines its function"
                    ]
                  },
                  {
                    "text": "Nucleotides form when a phosphate group attaches to 3' or 5' carbon of nucleoside (nitrogenous base + sugar residue) forming phosphodiester bondPhosphodiester bondsStrong covalent bonds between phosphate groupsConnect 5' carbon of 1 nucleoside to 3' carbon of the next nucleosideDetermines nucleic acid polarity (5' → 3')Nucleic acids are composed of chains of nucleotidesSugar group (ribose [RNA] or deoxyribose [DNA]) + purine or pyrimidine base + phosphate group",
                    "sub_points": [
                      "Phosphodiester bondsStrong covalent bonds between phosphate groupsConnect 5' carbon of 1 nucleoside to 3' carbon of the next nucleosideDetermines nucleic acid polarity (5' → 3')",
                      "Strong covalent bonds between phosphate groups",
                      "Connect 5' carbon of 1 nucleoside to 3' carbon of the next nucleoside",
                      "Determines nucleic acid polarity (5' → 3')",
                      "Nucleic acids are composed of chains of nucleotidesSugar group (ribose [RNA] or deoxyribose [DNA]) + purine or pyrimidine base + phosphate group",
                      "Sugar group (ribose [RNA] or deoxyribose [DNA]) + purine or pyrimidine base + phosphate group"
                    ]
                  },
                  {
                    "text": "Deoxyribonucleic acid (DNA)Purine or pyrimidine nitrogenous bases attach to and extend from 1st carbon of sugar groupPurines (adenine [A] and guanine [G]) are composed of 1 joined carbon-nitrogen rings (6 and 5 member rings)Pyrimidines (thymine [T] and cytosine [C]) are composed of single 6 member carbon-nitrogen ringPurines (G and A) pair with pyrimidines (C and T) via hydrogen bonds2 hydrogen bonds form between A and T3 hydrogen bonds form between G and CAdditional hydrogen bond between G and C dramatically increases strength of interaction",
                    "sub_points": [
                      "Purine or pyrimidine nitrogenous bases attach to and extend from 1st carbon of sugar groupPurines (adenine [A] and guanine [G]) are composed of 1 joined carbon-nitrogen rings (6 and 5 member rings)Pyrimidines (thymine [T] and cytosine [C]) are composed of single 6 member carbon-nitrogen ring",
                      "Purines (adenine [A] and guanine [G]) are composed of 1 joined carbon-nitrogen rings (6 and 5 member rings)",
                      "Pyrimidines (thymine [T] and cytosine [C]) are composed of single 6 member carbon-nitrogen ring",
                      "Purines (G and A) pair with pyrimidines (C and T) via hydrogen bonds2 hydrogen bonds form between A and T3 hydrogen bonds form between G and CAdditional hydrogen bond between G and C dramatically increases strength of interaction",
                      "2 hydrogen bonds form between A and T",
                      "3 hydrogen bonds form between G and C",
                      "Additional hydrogen bond between G and C dramatically increases strength of interaction"
                    ]
                  },
                  {
                    "text": "Ribonucleic acid (RNA)In RNA, uracil (U) replaces thymine (T)Normally single stranded2 RNA molecules may associate transiently to form base pairsPurines (G and A) pair with pyrimidines (C and U) via hydrogen bondsHydrogen bonds also allow for formation of DNA-RNA duplexesHydrogen bonds may also form between bases within single RNA or DNA molecule (e.g., hairpin structures)",
                    "sub_points": [
                      "In RNA, uracil (U) replaces thymine (T)",
                      "Normally single stranded",
                      "2 RNA molecules may associate transiently to form base pairsPurines (G and A) pair with pyrimidines (C and U) via hydrogen bonds",
                      "Purines (G and A) pair with pyrimidines (C and U) via hydrogen bonds",
                      "Hydrogen bonds also allow for formation of DNA-RNA duplexes",
                      "Hydrogen bonds may also form between bases within single RNA or DNA molecule (e.g., hairpin structures)"
                    ]
                  },
                  {
                    "text": "Types of RNAMessenger RNA (mRNA)Transcribed from a DNA templateDNA reverse transcribed from mRNA is called cDNAExons encode amino acid sequences in mRNAIntrons are noncoding sequences that are spliced out of mRNA by exonucleases prior to translationTransfer RNA (tRNA)Adapter molecule that binds and transfers amino acids to site of protein synthesis during translationRibosomal RNA (rRNA)RNA component of ribosomeRibosome is a combination of rRNA and ribosomal proteins involved in translation of mRNA into polypeptidesRibozymeRNA molecule that catalyzes chemical reaction",
                    "sub_points": [
                      "Messenger RNA (mRNA)Transcribed from a DNA templateDNA reverse transcribed from mRNA is called cDNAExons encode amino acid sequences in mRNAIntrons are noncoding sequences that are spliced out of mRNA by exonucleases prior to translation",
                      "Transcribed from a DNA template",
                      "DNA reverse transcribed from mRNA is called cDNA",
                      "Exons encode amino acid sequences in mRNA",
                      "Introns are noncoding sequences that are spliced out of mRNA by exonucleases prior to translation",
                      "Transfer RNA (tRNA)Adapter molecule that binds and transfers amino acids to site of protein synthesis during translation",
                      "Adapter molecule that binds and transfers amino acids to site of protein synthesis during translation",
                      "Ribosomal RNA (rRNA)RNA component of ribosomeRibosome is a combination of rRNA and ribosomal proteins involved in translation of mRNA into polypeptides",
                      "RNA component of ribosome",
                      "Ribosome is a combination of rRNA and ribosomal proteins involved in translation of mRNA into polypeptides",
                      "RibozymeRNA molecule that catalyzes chemical reaction",
                      "RNA molecule that catalyzes chemical reaction"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Mitosis and Meiosis": {
            "name": "Mitosis and Meiosis",
            "url": "https://app.pathprimer.com/document/9fdc92a4-0116-47b7-9ff5-35ca4b4478d1/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Mitosis: Process by which somatic cell division results in 2 daughter cells containing identical genetic material to the parent cellSomatic cells have the diploid (2n) chromosome complement (46 chromosomes)",
                    "sub_points": [
                      "Somatic cells have the diploid (2n) chromosome complement (46 chromosomes)"
                    ]
                  },
                  {
                    "text": "Meiosis: Process by which haploid germ cells (gametes) are formed from diploid parent cellsGametes have the haploid (n) complement (23 chromosomes)",
                    "sub_points": [
                      "Gametes have the haploid (n) complement (23 chromosomes)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Mitosis": [
                  {
                    "text": "Before mitosis begins, DNA is replicated to form 2 sister chromatids per chromosome during the cell cycle S (synthesis) phase"
                  },
                  {
                    "text": "ProphaseChromsome condensation beginsMitotic spindle formsCentrosomes (microtubule organizing centers) are the points from which microtubules originateCentrosomes move to the poles of the cell",
                    "sub_points": [
                      "Chromsome condensation begins",
                      "Mitotic spindle forms",
                      "Centrosomes (microtubule organizing centers) are the points from which microtubules originateCentrosomes move to the poles of the cell",
                      "Centrosomes move to the poles of the cell"
                    ]
                  },
                  {
                    "text": "PrometaphaseNuclear membrane breaks down, releasing chromosomes to flow within the cellChromosomes attach to microtubules of the mitotic spindle by their kinetochoresChromosomes move toward a point halfway between the spindle poles",
                    "sub_points": [
                      "Nuclear membrane breaks down, releasing chromosomes to flow within the cell",
                      "Chromosomes attach to microtubules of the mitotic spindle by their kinetochores",
                      "Chromosomes move toward a point halfway between the spindle poles"
                    ]
                  },
                  {
                    "text": "MetaphaseChromosomes reach maximal condensation and align at the center of the cell",
                    "sub_points": [
                      "Chromosomes reach maximal condensation and align at the center of the cell"
                    ]
                  },
                  {
                    "text": "AnaphaseSister chromatids separate at the centromere to form daughter chromosomesDaughter chromosomes move to opposite poles of the cell",
                    "sub_points": [
                      "Sister chromatids separate at the centromere to form daughter chromosomes",
                      "Daughter chromosomes move to opposite poles of the cell"
                    ]
                  },
                  {
                    "text": "TelophaseChromosomes begin to decondenseNuclear membrane reforms around each of the 2 daughter nuclei",
                    "sub_points": [
                      "Chromosomes begin to decondense",
                      "Nuclear membrane reforms around each of the 2 daughter nuclei"
                    ]
                  },
                  {
                    "text": "CytokinesisCytoplasm cleaves, creating 2 daughter cells",
                    "sub_points": [
                      "Cytoplasm cleaves, creating 2 daughter cells"
                    ]
                  }
                ],
                "Meiosis": [
                  {
                    "text": "Meiosis I: Reduction divisionProphase IZygotene: Homologous chromosomes begin to alignSynapsis: Meiotic pairing bringing corresponding DNA sequences into created paired homologues or bivalentsPachytene: Meiotic crossing over occursCrossing over generates genetic diversity by homologous recombinationUnequal crossing over can lead to genetic disorders through deletion and duplication of genetic materialMetaphase ISimilar to metaphase of mitosisNuclear membrane breaks downChromosomes attach to spindleChromosome pairs align at the center of the cellAnaphase IDisjunction: Sister chromatids remain attached but homologous chromsomes separateCauses daughters to have 23 chromosomes, each of which consists of 2 sister chromatidsTelophase IHaploid daughter cells separate and enter meiotic interphase",
                    "sub_points": [
                      "Prophase IZygotene: Homologous chromosomes begin to alignSynapsis: Meiotic pairing bringing corresponding DNA sequences into created paired homologues or bivalentsPachytene: Meiotic crossing over occursCrossing over generates genetic diversity by homologous recombinationUnequal crossing over can lead to genetic disorders through deletion and duplication of genetic material",
                      "Zygotene: Homologous chromosomes begin to align",
                      "Synapsis: Meiotic pairing bringing corresponding DNA sequences into created paired homologues or bivalents",
                      "Pachytene: Meiotic crossing over occursCrossing over generates genetic diversity by homologous recombinationUnequal crossing over can lead to genetic disorders through deletion and duplication of genetic material",
                      "Crossing over generates genetic diversity by homologous recombination",
                      "Unequal crossing over can lead to genetic disorders through deletion and duplication of genetic material",
                      "Metaphase ISimilar to metaphase of mitosisNuclear membrane breaks downChromosomes attach to spindleChromosome pairs align at the center of the cell",
                      "Similar to metaphase of mitosis",
                      "Nuclear membrane breaks down",
                      "Chromosomes attach to spindle",
                      "Chromosome pairs align at the center of the cell",
                      "Anaphase IDisjunction: Sister chromatids remain attached but homologous chromsomes separateCauses daughters to have 23 chromosomes, each of which consists of 2 sister chromatids",
                      "Disjunction: Sister chromatids remain attached but homologous chromsomes separateCauses daughters to have 23 chromosomes, each of which consists of 2 sister chromatids",
                      "Causes daughters to have 23 chromosomes, each of which consists of 2 sister chromatids",
                      "Telophase IHaploid daughter cells separate and enter meiotic interphase",
                      "Haploid daughter cells separate and enter meiotic interphase"
                    ]
                  },
                  {
                    "text": "Meiosis IISimilar to mitosis, but starts with 23 chromosomes with 2 sister chromatids each",
                    "sub_points": [
                      "Similar to mitosis, but starts with 23 chromosomes with 2 sister chromatids each"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Nondisjunction": [
                  {
                    "text": "Errors in chromosome segregation during anaphaseCauses aneuploidy (abnormal number of chromosomes)Mechanism of Down syndrome and other abnormalitiesLeads to 1 daughter cell with an extra copy of a chromosome and the other daughter cell lacking that chromosome",
                    "sub_points": [
                      "Causes aneuploidy (abnormal number of chromosomes)Mechanism of Down syndrome and other abnormalities",
                      "Mechanism of Down syndrome and other abnormalities",
                      "Leads to 1 daughter cell with an extra copy of a chromosome and the other daughter cell lacking that chromosome"
                    ]
                  }
                ],
                "Unequal Crossing Over": [
                  {
                    "text": "Leads to duplications and deletions of genetic material"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Gene Mutations": {
            "name": "Gene Mutations",
            "url": "https://app.pathprimer.com/document/5cb475d8-a78c-4813-93f0-6175475c0f88/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "ETIOLOGY/PATHOGENESIS": {
                "Oncogenesis": [
                  {
                    "text": "Cancer is often a multistep process during which cells acquire a series of mutationsMutations lead to decreased tumor suppressor gene function &/or increased proto-oncogene functionResults in uncontrolled growth and failure to respond to signals that normally lead to cell death (apoptosis)Rapid growth and uncontrolled cell division may lead to abnormal chromosome segregation and additional changes (genetic instability) in chromosome number (aneuploidy)",
                    "sub_points": [
                      "Mutations lead to decreased tumor suppressor gene function &/or increased proto-oncogene function",
                      "Results in uncontrolled growth and failure to respond to signals that normally lead to cell death (apoptosis)",
                      "Rapid growth and uncontrolled cell division may lead to abnormal chromosome segregation and additional changes (genetic instability) in chromosome number (aneuploidy)"
                    ]
                  },
                  {
                    "text": "Proto-oncogenesAn oncogene is the mutated version of a proto-oncogeneCause normal cells to become cancerous when mutatedMutations are typically dominant in nature> 40 different human proto-oncogenes are known~ 14 proto-oncogenes are associated with high propensity for cancerOncogenes arise as result of mutations that increase expression level or activity of a proto-oncogenePoint mutations, deletions, or insertions in promoter region of proto-oncogene may lead to increased transcriptionGene amplification events leading to extrachromosomal copies of proto-oncogeneChromosomal translocation events that relocate proto-oncogene to new chromosomal site that leads to overexpressionChromosomal translocations that lead to fusion between proto-oncogene and 2nd gene, which produces fusion protein with oncogenic activityIncreased production of these proteins leads to increased cell division, decreased cell differentiation, and inhibition of cell deathThese characteristics define cancer cellsOncogenes are therefore important targets for cancer therapy",
                    "sub_points": [
                      "An oncogene is the mutated version of a proto-oncogene",
                      "Cause normal cells to become cancerous when mutatedMutations are typically dominant in nature",
                      "Mutations are typically dominant in nature",
                      "> 40 different human proto-oncogenes are known~ 14 proto-oncogenes are associated with high propensity for cancer",
                      "~ 14 proto-oncogenes are associated with high propensity for cancer",
                      "Oncogenes arise as result of mutations that increase expression level or activity of a proto-oncogenePoint mutations, deletions, or insertions in promoter region of proto-oncogene may lead to increased transcriptionGene amplification events leading to extrachromosomal copies of proto-oncogeneChromosomal translocation events that relocate proto-oncogene to new chromosomal site that leads to overexpressionChromosomal translocations that lead to fusion between proto-oncogene and 2nd gene, which produces fusion protein with oncogenic activity",
                      "Point mutations, deletions, or insertions in promoter region of proto-oncogene may lead to increased transcription",
                      "Gene amplification events leading to extrachromosomal copies of proto-oncogene",
                      "Chromosomal translocation events that relocate proto-oncogene to new chromosomal site that leads to overexpression",
                      "Chromosomal translocations that lead to fusion between proto-oncogene and 2nd gene, which produces fusion protein with oncogenic activity",
                      "Increased production of these proteins leads to increased cell division, decreased cell differentiation, and inhibition of cell deathThese characteristics define cancer cellsOncogenes are therefore important targets for cancer therapy",
                      "These characteristics define cancer cells",
                      "Oncogenes are therefore important targets for cancer therapy"
                    ]
                  },
                  {
                    "text": "Tumor suppressor genesEncode for proteins that repress cell cycle or promote apoptosisSome genes are involved in DNA repair processesRoles may includeRepression of genes essential for continuation of cell cycleCoupling of cell cycle arrest to presence of DNA damageProapoptotic signaling if DNA damage cannot be repairedCell adhesion proteins that help prevent tumor cells from metastasizingDNA repair proteins (e.g., DNA mismatch repair proteins,MEN1-andBRCA1-/BRCA2-encoded proteins)Mutations within tumor suppressor genes result in a loss-of-function (recessive in nature)Loss of heterozygosity and \"two-hit\" hypothesisFirst proposed by geneticist Alfred Knudson in 1971Both tumor suppressor genes must be mutated in order for a particular cell to become cancerous (\"two-hit\" hypothesis)Loss of heterozygosity is a phrase often used to describe process that leads to \"second hit\" and results in loss of remaining functional copy of tumor suppressor geneMutations are oftenPoint mutations or small deletions that disrupt protein functionChromosomal deletions or breaks that delete tumor suppressor geneSomatic recombination during which normal gene copy is replaced with a mutant copyAt least 30 different tumor suppressor genes have been identified",
                    "sub_points": [
                      "Encode for proteins that repress cell cycle or promote apoptosis",
                      "Some genes are involved in DNA repair processes",
                      "Roles may includeRepression of genes essential for continuation of cell cycleCoupling of cell cycle arrest to presence of DNA damageProapoptotic signaling if DNA damage cannot be repairedCell adhesion proteins that help prevent tumor cells from metastasizingDNA repair proteins (e.g., DNA mismatch repair proteins,MEN1-andBRCA1-/BRCA2-encoded proteins)",
                      "Repression of genes essential for continuation of cell cycle",
                      "Coupling of cell cycle arrest to presence of DNA damage",
                      "Proapoptotic signaling if DNA damage cannot be repaired",
                      "Cell adhesion proteins that help prevent tumor cells from metastasizing",
                      "DNA repair proteins (e.g., DNA mismatch repair proteins,MEN1-andBRCA1-/BRCA2-encoded proteins)",
                      "Mutations within tumor suppressor genes result in a loss-of-function (recessive in nature)",
                      "Loss of heterozygosity and \"two-hit\" hypothesisFirst proposed by geneticist Alfred Knudson in 1971Both tumor suppressor genes must be mutated in order for a particular cell to become cancerous (\"two-hit\" hypothesis)Loss of heterozygosity is a phrase often used to describe process that leads to \"second hit\" and results in loss of remaining functional copy of tumor suppressor gene",
                      "First proposed by geneticist Alfred Knudson in 1971",
                      "Both tumor suppressor genes must be mutated in order for a particular cell to become cancerous (\"two-hit\" hypothesis)",
                      "Loss of heterozygosity is a phrase often used to describe process that leads to \"second hit\" and results in loss of remaining functional copy of tumor suppressor gene",
                      "Mutations are oftenPoint mutations or small deletions that disrupt protein functionChromosomal deletions or breaks that delete tumor suppressor geneSomatic recombination during which normal gene copy is replaced with a mutant copy",
                      "Point mutations or small deletions that disrupt protein function",
                      "Chromosomal deletions or breaks that delete tumor suppressor gene",
                      "Somatic recombination during which normal gene copy is replaced with a mutant copy",
                      "At least 30 different tumor suppressor genes have been identified"
                    ]
                  }
                ]
              },
              "Terminology, Definitions, and Concepts": {
                "Introduction": [
                  {
                    "text": "Mutation is thought to imply deleterious genetic sequence variationThis definition is likely overly simplistic, as not all mutations have deleterious effect",
                    "sub_points": [
                      "This definition is likely overly simplistic, as not all mutations have deleterious effect"
                    ]
                  },
                  {
                    "text": "DNA sequence can be altered in various waysChange in actual sequence (sequence variation)Change in amount of given sequence (copy number variation)Change in position (i.e., inversion and translocation)",
                    "sub_points": [
                      "Change in actual sequence (sequence variation)",
                      "Change in amount of given sequence (copy number variation)",
                      "Change in position (i.e., inversion and translocation)"
                    ]
                  },
                  {
                    "text": "Gene mutations/sequence alterations have varying effects, depending on where they occur and whether they alter protein functionGenetic changes that affect 3rd base in codon are less likely to result in incorporation of incorrect amino acid and therefore rarely alter gene code/protein function",
                    "sub_points": [
                      "Genetic changes that affect 3rd base in codon are less likely to result in incorporation of incorrect amino acid and therefore rarely alter gene code/protein function"
                    ]
                  },
                  {
                    "text": "Genotype vs. phenotypeGenotype refers to genetic information as it exists in the form of nucleic acidsPhenotype refers to outwardly observable characteristicsGenotypic alterations may or may not result in alterations in phenotype",
                    "sub_points": [
                      "Genotype refers to genetic information as it exists in the form of nucleic acids",
                      "Phenotype refers to outwardly observable characteristics",
                      "Genotypic alterations may or may not result in alterations in phenotype"
                    ]
                  },
                  {
                    "text": "Somatic mutationsAcquired mutation that is not inherited from parent and also not passed to offspring",
                    "sub_points": [
                      "Acquired mutation that is not inherited from parent and also not passed to offspring"
                    ]
                  },
                  {
                    "text": "Germline mutationsHeritable genetic variation/mutation in germ cell (eggs or sperm) lineagePassed on from parent to offspringReferred to as constitutional mutations in offspring",
                    "sub_points": [
                      "Heritable genetic variation/mutation in germ cell (eggs or sperm) lineage",
                      "Passed on from parent to offspringReferred to as constitutional mutations in offspring",
                      "Referred to as constitutional mutations in offspring"
                    ]
                  },
                  {
                    "text": "Driver mutationsSubset of cancer mutations that provide selective advantage to tumor (e.g.,EGFR, EML4-ALK)Contribute to tumor's growth, progression, and survival (clonal expansion)Cancer cells rely more heavily on driver mutations than other mutations that are often termed passenger mutationsPotential targets of directed therapy",
                    "sub_points": [
                      "Subset of cancer mutations that provide selective advantage to tumor (e.g.,EGFR, EML4-ALK)",
                      "Contribute to tumor's growth, progression, and survival (clonal expansion)",
                      "Cancer cells rely more heavily on driver mutations than other mutations that are often termed passenger mutations",
                      "Potential targets of directed therapy"
                    ]
                  },
                  {
                    "text": "Passenger mutationsTypically comprise larger subset of acquired somatic mutations that are not as important to tumor growth and survivalMay be associated with clonal expansion because they occur in same genome as driver mutationsReferred to as \"hitchhiker\" in evolutionary biology",
                    "sub_points": [
                      "Typically comprise larger subset of acquired somatic mutations that are not as important to tumor growth and survival",
                      "May be associated with clonal expansion because they occur in same genome as driver mutations",
                      "Referred to as \"hitchhiker\" in evolutionary biology"
                    ]
                  },
                  {
                    "text": "Polymorphism vs. gene mutationsNumerous single-nucleotide polymorphisms (SNPs; pronounced snips) have been identified in human genome1 in every 300 nucleotides in human genome is considered polymorphic (i.e., < 1 nucleotide being common in a population)In most cases, SNP has 2 alternative forms (alleles) (i.e., A or G at specified nucleotide position)Conceptually, both SNPs and mutations represent variation in genetic sequenceArbitrary threshold of 1% frequency is widely accepted in making distinction between SNP (polymorphism with frequency of > 1%) and mutation (polymorphism with frequency < 1%)Frequency is thought to be indicative of stability of polymorphism in a populationHigh-frequency SNP alleles are not thought to have major consequential phenotypic effects",
                    "sub_points": [
                      "Numerous single-nucleotide polymorphisms (SNPs; pronounced snips) have been identified in human genome",
                      "1 in every 300 nucleotides in human genome is considered polymorphic (i.e., < 1 nucleotide being common in a population)",
                      "In most cases, SNP has 2 alternative forms (alleles) (i.e., A or G at specified nucleotide position)",
                      "Conceptually, both SNPs and mutations represent variation in genetic sequence",
                      "Arbitrary threshold of 1% frequency is widely accepted in making distinction between SNP (polymorphism with frequency of > 1%) and mutation (polymorphism with frequency < 1%)Frequency is thought to be indicative of stability of polymorphism in a populationHigh-frequency SNP alleles are not thought to have major consequential phenotypic effects",
                      "Frequency is thought to be indicative of stability of polymorphism in a population",
                      "High-frequency SNP alleles are not thought to have major consequential phenotypic effects"
                    ]
                  }
                ],
                "Types of Mutations": [
                  {
                    "text": "Missense mutation/substitutionChange in 1 DNA base pairResults in substitution of 1 amino acid for anotherMay or may not alter protein functionDepends on degree of similarity between amino acids",
                    "sub_points": [
                      "Change in 1 DNA base pair",
                      "Results in substitution of 1 amino acid for another",
                      "May or may not alter protein functionDepends on degree of similarity between amino acids",
                      "Depends on degree of similarity between amino acids"
                    ]
                  },
                  {
                    "text": "Nonsense mutation/substitutionChange in 1 DNA base pairResults in substitution of 1 amino acid for stop codonResults in premature termination of translation and truncated protein that may function improperly or not at all",
                    "sub_points": [
                      "Change in 1 DNA base pair",
                      "Results in substitution of 1 amino acid for stop codon",
                      "Results in premature termination of translation and truncated protein that may function improperly or not at all"
                    ]
                  },
                  {
                    "text": "InsertionAddition of ≥ 1 base to original DNA sequenceIncreases number of DNA bases in geneProtein encoded by gene may not function properly",
                    "sub_points": [
                      "Addition of ≥ 1 base to original DNA sequence",
                      "Increases number of DNA bases in gene",
                      "Protein encoded by gene may not function properly"
                    ]
                  },
                  {
                    "text": "DeletionChange in number of DNA bases by removing piece of DNASmall deletions may remove 1 or a few base pairs within geneLarger deletions can remove entire gene or several adjacent genesDeleted DNA may alter function of resulting protein(s)",
                    "sub_points": [
                      "Change in number of DNA bases by removing piece of DNA",
                      "Small deletions may remove 1 or a few base pairs within gene",
                      "Larger deletions can remove entire gene or several adjacent genes",
                      "Deleted DNA may alter function of resulting protein(s)"
                    ]
                  },
                  {
                    "text": "DuplicationPiece of DNA abnormally copied 1 or more timesMay alter function of resulting protein",
                    "sub_points": [
                      "Piece of DNA abnormally copied 1 or more times",
                      "May alter function of resulting protein"
                    ]
                  },
                  {
                    "text": "FrameshiftAddition or loss of DNA bases that result in change in gene's reading frameReading frame consists of groups of 3 bases (codon) that each code for 1 amino acidShifts grouping of these bases and changes overall amino acid code/sequenceResulting protein is usually nonfunctionalInsertions, deletions, and duplications can all result in frameshift mutationMay result in premature termination if stop codon is formed downstream from mutation",
                    "sub_points": [
                      "Addition or loss of DNA bases that result in change in gene's reading frameReading frame consists of groups of 3 bases (codon) that each code for 1 amino acid",
                      "Reading frame consists of groups of 3 bases (codon) that each code for 1 amino acid",
                      "Shifts grouping of these bases and changes overall amino acid code/sequence",
                      "Resulting protein is usually nonfunctionalInsertions, deletions, and duplications can all result in frameshift mutation",
                      "Insertions, deletions, and duplications can all result in frameshift mutation",
                      "May result in premature termination if stop codon is formed downstream from mutation"
                    ]
                  },
                  {
                    "text": "Repeat expansionShort DNA sequences that are repeated a number of times in a rowe.g., trinucleotide repeat is repeated 3-base pair sequence (e.g., CGT) and tetranucleotide repeat is a repeat of 4-base pair sequence (e.g., CGGT)Increases number of times DNA sequence is repeatedMany genes contain these repeats without any alteration in protein functionWhen repeats exceed \"normal\" range, protein may function improperly or not at all",
                    "sub_points": [
                      "Short DNA sequences that are repeated a number of times in a rowe.g., trinucleotide repeat is repeated 3-base pair sequence (e.g., CGT) and tetranucleotide repeat is a repeat of 4-base pair sequence (e.g., CGGT)",
                      "e.g., trinucleotide repeat is repeated 3-base pair sequence (e.g., CGT) and tetranucleotide repeat is a repeat of 4-base pair sequence (e.g., CGGT)",
                      "Increases number of times DNA sequence is repeated",
                      "Many genes contain these repeats without any alteration in protein function",
                      "When repeats exceed \"normal\" range, protein may function improperly or not at all"
                    ]
                  },
                  {
                    "text": "ConversionSequence change where range of nucleotides are replaced by sequence from elsewhere in genomeAllelic gene conversion occurs during meiotic recombination",
                    "sub_points": [
                      "Sequence change where range of nucleotides are replaced by sequence from elsewhere in genome",
                      "Allelic gene conversion occurs during meiotic recombination"
                    ]
                  },
                  {
                    "text": "Deletion/insertion (indel)Sequence change where ≥ 1 nucleotide is replaced by ≥ 1 other nucleotideIf only 1 nucleotide is replaced by single other nucleotide, this should be referred to as substitution",
                    "sub_points": [
                      "Sequence change where ≥ 1 nucleotide is replaced by ≥ 1 other nucleotide",
                      "If only 1 nucleotide is replaced by single other nucleotide, this should be referred to as substitution"
                    ]
                  },
                  {
                    "text": "TranslocationChromosome rearrangement between parts of nonhomologous chromosomes2 chromosomes break, with fragments joining together at \"breakpoints\"Reciprocal translocation should include description of 1st and 2nd junctionse.g., t(4;X) and t(X;4)",
                    "sub_points": [
                      "Chromosome rearrangement between parts of nonhomologous chromosomes",
                      "2 chromosomes break, with fragments joining together at \"breakpoints\"",
                      "Reciprocal translocation should include description of 1st and 2nd junctionse.g., t(4;X) and t(X;4)",
                      "e.g., t(4;X) and t(X;4)"
                    ]
                  },
                  {
                    "text": "TranspositionSeries or range of nucleotides moves from 1 position to another in genome or sequence (i.e., deletion at 1 position is combined with insertion of deleted sequence at another position)",
                    "sub_points": [
                      "Series or range of nucleotides moves from 1 position to another in genome or sequence (i.e., deletion at 1 position is combined with insertion of deleted sequence at another position)"
                    ]
                  }
                ]
              },
              "Nomenclature": {
                "Introduction": [
                  {
                    "text": "Consistent and uniform use of nomenclature in management of DNA sequence data is critical for accurate and concise communication of test results and genetic risk assessment"
                  },
                  {
                    "text": "Unique letter designationsUpper-case nucleotide symbols are used when describing DNA (i.e., A, G, C, T)Lower-case nucleotide symbols are used when describing RNA (i.e., a, g, c, u)3- or 1-letter amino acid codes are used when describing protein/amino acid sequence change (e.g., GLU and E)\"X\" refers to stop codon",
                    "sub_points": [
                      "Upper-case nucleotide symbols are used when describing DNA (i.e., A, G, C, T)",
                      "Lower-case nucleotide symbols are used when describing RNA (i.e., a, g, c, u)",
                      "3- or 1-letter amino acid codes are used when describing protein/amino acid sequence change (e.g., GLU and E)\"X\" refers to stop codon",
                      "\"X\" refers to stop codon"
                    ]
                  },
                  {
                    "text": "Letter designations used to refer to reference sequenceCoding DNA: c.Genomic DNA: g.Mitochondrial DNA: m.RNA: r.Noncoding RNA: n.Protein: p.",
                    "sub_points": [
                      "Coding DNA: c.",
                      "Genomic DNA: g.",
                      "Mitochondrial DNA: m.",
                      "RNA: r.",
                      "Noncoding RNA: n.",
                      "Protein: p."
                    ]
                  },
                  {
                    "text": "Symbols used to describe changes\">\" indicates substitution at DNA level\"_\" indicates range of affected residues, separating 1st and last residue affected\"del\" indicates deletion\"dup\" indicates duplication\"ins\" indicates insertion\"inv\" indicates inversion\"con\" indicates conversion\"[ ]\" enclose changes from single allele\"( )\" is used when exact position of change is not known; range of uncertainty is described as precisely as possible and listed between parentheses",
                    "sub_points": [
                      "\">\" indicates substitution at DNA level",
                      "\"_\" indicates range of affected residues, separating 1st and last residue affected",
                      "\"del\" indicates deletion",
                      "\"dup\" indicates duplication",
                      "\"ins\" indicates insertion",
                      "\"inv\" indicates inversion",
                      "\"con\" indicates conversion",
                      "\"[ ]\" enclose changes from single allele",
                      "\"( )\" is used when exact position of change is not known; range of uncertainty is described as precisely as possible and listed between parentheses"
                    ]
                  },
                  {
                    "text": "Nucleotide numberingCoding DNA reference sequence (c.)Nucleotide 1 is the A of ATG-translation initiation codonThere is no nucleotide 0Nucleotide 5' of ATG-translation initiation codon is -1, the previous -2, etc.Intronic nucleotidesBeginning of intron is denoted by number of last exon in preceding exon followed by plus sign and position of intronic nucleotides (e.g., c.89+1G)End of intron is denoted by number of 1st nucleotide of following exon, followed by minus sign preceding upstream intronic nucleotide position (c.89-1T)In middle of intron, plus sign will change to minus sign using these rulesGenomic reference sequenceNumbering is arbitrary and starts with 1 at 1st nucleotide of database reference file+, -, or other signs are not used",
                    "sub_points": [
                      "Coding DNA reference sequence (c.)Nucleotide 1 is the A of ATG-translation initiation codonThere is no nucleotide 0Nucleotide 5' of ATG-translation initiation codon is -1, the previous -2, etc.",
                      "Nucleotide 1 is the A of ATG-translation initiation codon",
                      "There is no nucleotide 0",
                      "Nucleotide 5' of ATG-translation initiation codon is -1, the previous -2, etc.",
                      "Intronic nucleotidesBeginning of intron is denoted by number of last exon in preceding exon followed by plus sign and position of intronic nucleotides (e.g., c.89+1G)End of intron is denoted by number of 1st nucleotide of following exon, followed by minus sign preceding upstream intronic nucleotide position (c.89-1T)In middle of intron, plus sign will change to minus sign using these rules",
                      "Beginning of intron is denoted by number of last exon in preceding exon followed by plus sign and position of intronic nucleotides (e.g., c.89+1G)",
                      "End of intron is denoted by number of 1st nucleotide of following exon, followed by minus sign preceding upstream intronic nucleotide position (c.89-1T)",
                      "In middle of intron, plus sign will change to minus sign using these rules",
                      "Genomic reference sequenceNumbering is arbitrary and starts with 1 at 1st nucleotide of database reference file+, -, or other signs are not used",
                      "Numbering is arbitrary and starts with 1 at 1st nucleotide of database reference file",
                      "+, -, or other signs are not used"
                    ]
                  }
                ],
                "Nomenclature Examples": [
                  {
                    "text": "SubstitutionDesignated by \">\"Examplesc.546A>T describes an A to T substitution at nucleotide position 546p.Gln78His describes glutamine to histidine substitution at amino-acid residue 78\">\" not used when describing substitution at protein level",
                    "sub_points": [
                      "Designated by \">\"",
                      "Examplesc.546A>T describes an A to T substitution at nucleotide position 546p.Gln78His describes glutamine to histidine substitution at amino-acid residue 78\">\" not used when describing substitution at protein level",
                      "c.546A>T describes an A to T substitution at nucleotide position 546",
                      "p.Gln78His describes glutamine to histidine substitution at amino-acid residue 78",
                      "\">\" not used when describing substitution at protein level"
                    ]
                  },
                  {
                    "text": "DeletionDesignated by \"del\"Range of deletion indicated by \"_\"Examplesc.546delT, or c.546del describes deletion of T at nucleotide position 546c.586_591del or c.586_591delTGGTCA, or c.586_591del6 describes deletion of 6 nucleotides (TGGTCA) starting at nucleotide position 586 to and ending at position 591",
                    "sub_points": [
                      "Designated by \"del\"",
                      "Range of deletion indicated by \"_\"",
                      "Examplesc.546delT, or c.546del describes deletion of T at nucleotide position 546c.586_591del or c.586_591delTGGTCA, or c.586_591del6 describes deletion of 6 nucleotides (TGGTCA) starting at nucleotide position 586 to and ending at position 591",
                      "c.546delT, or c.546del describes deletion of T at nucleotide position 546",
                      "c.586_591del or c.586_591delTGGTCA, or c.586_591del6 describes deletion of 6 nucleotides (TGGTCA) starting at nucleotide position 586 to and ending at position 591"
                    ]
                  },
                  {
                    "text": "DuplicationDesignated by \"dup\"Range of duplication indicated by \"_\"Examplesc.546dupT, or c.546dup describes duplication of a nucleotide (T) at position 546c.586_591dup, or c.586_591dupTGGTCA or c.586_591dup6 describe a duplication of 6 nucleotides (TGGTCA) starting at nucleotide position 586 and ending at position 591Duplications should not be described as insertions",
                    "sub_points": [
                      "Designated by \"dup\"",
                      "Range of duplication indicated by \"_\"",
                      "Examplesc.546dupT, or c.546dup describes duplication of a nucleotide (T) at position 546c.586_591dup, or c.586_591dupTGGTCA or c.586_591dup6 describe a duplication of 6 nucleotides (TGGTCA) starting at nucleotide position 586 and ending at position 591",
                      "c.546dupT, or c.546dup describes duplication of a nucleotide (T) at position 546",
                      "c.586_591dup, or c.586_591dupTGGTCA or c.586_591dup6 describe a duplication of 6 nucleotides (TGGTCA) starting at nucleotide position 586 and ending at position 591",
                      "Duplications should not be described as insertions"
                    ]
                  },
                  {
                    "text": "InsertionDesignated by \"ins\"Range of insertion is designated by \"_\"Provide inserted sequenceExamplesc.547_548insT describes insertion of nucleotide T between nucleotides at positions 547 and 548c.1087_1088insTGACGT describes insertion of 6 nucleotides (TGACGT) that occurs between nucleotides at positions 1087 and 1088When insertion is large, inserted sequence can be submitted to database and database accession and version number can be written",
                    "sub_points": [
                      "Designated by \"ins\"",
                      "Range of insertion is designated by \"_\"",
                      "Provide inserted sequence",
                      "Examplesc.547_548insT describes insertion of nucleotide T between nucleotides at positions 547 and 548c.1087_1088insTGACGT describes insertion of 6 nucleotides (TGACGT) that occurs between nucleotides at positions 1087 and 1088",
                      "c.547_548insT describes insertion of nucleotide T between nucleotides at positions 547 and 548",
                      "c.1087_1088insTGACGT describes insertion of 6 nucleotides (TGACGT) that occurs between nucleotides at positions 1087 and 1088",
                      "When insertion is large, inserted sequence can be submitted to database and database accession and version number can be written"
                    ]
                  },
                  {
                    "text": "InversionDesignated by \"inv\"Range of inversion is designated by \"_\"Examplec.547_2032inv 1486 describes sequence of 1,486 nucleotides from nucleotide position 547 to 2032 have been inverted",
                    "sub_points": [
                      "Designated by \"inv\"",
                      "Range of inversion is designated by \"_\"",
                      "Examplec.547_2032inv 1486 describes sequence of 1,486 nucleotides from nucleotide position 547 to 2032 have been inverted",
                      "c.547_2032inv 1486 describes sequence of 1,486 nucleotides from nucleotide position 547 to 2032 have been inverted"
                    ]
                  },
                  {
                    "text": "ConversionDesignated by \"con\" after indication of 1st and last nucleotides affected by conversion, followed by description of origin of new nucleotidesRange of conversion is designated by \"_\"Examplec.547_658con918_1029 describes conversion replacing nucleotide sequence at position 547 to 658 with new nucleotide sequence originating from position 918 to 1029g.123_678conNG_012232.1:g.9456_10011 describes conversion replacing nucleotides 123 to 678 with nucleotides 9456 to 10011 from sequence as present in GenBank file NG_012232.1",
                    "sub_points": [
                      "Designated by \"con\" after indication of 1st and last nucleotides affected by conversion, followed by description of origin of new nucleotides",
                      "Range of conversion is designated by \"_\"",
                      "Examplec.547_658con918_1029 describes conversion replacing nucleotide sequence at position 547 to 658 with new nucleotide sequence originating from position 918 to 1029g.123_678conNG_012232.1:g.9456_10011 describes conversion replacing nucleotides 123 to 678 with nucleotides 9456 to 10011 from sequence as present in GenBank file NG_012232.1",
                      "c.547_658con918_1029 describes conversion replacing nucleotide sequence at position 547 to 658 with new nucleotide sequence originating from position 918 to 1029",
                      "g.123_678conNG_012232.1:g.9456_10011 describes conversion replacing nucleotides 123 to 678 with nucleotides 9456 to 10011 from sequence as present in GenBank file NG_012232.1"
                    ]
                  },
                  {
                    "text": "TranslocationDesignated by \"t\"Range indicated by \"_\"Example: t(X;4)(p21.2;q35) (c.857+101_857+102)",
                    "sub_points": [
                      "Designated by \"t\"",
                      "Range indicated by \"_\"",
                      "Example: t(X;4)(p21.2;q35) (c.857+101_857+102)"
                    ]
                  },
                  {
                    "text": "Repeated sequencesThe following format is used when describing repeated sequences: \"Position of 1st repeat unit_[number of repeats]\"Examplesg.123_124[4] describes location of 1st unit of the variable sequence (nucleotide position 123 to 124) with number in brackets describing number of repeats present in alleleAlternatively, g.123TG[4] describes a repeating sequence of TG that repeats 4 times where 1st unit (TG) is present at nucleotide position 123_124 in genomic reference sequence",
                    "sub_points": [
                      "The following format is used when describing repeated sequences: \"Position of 1st repeat unit_[number of repeats]\"",
                      "Examplesg.123_124[4] describes location of 1st unit of the variable sequence (nucleotide position 123 to 124) with number in brackets describing number of repeats present in alleleAlternatively, g.123TG[4] describes a repeating sequence of TG that repeats 4 times where 1st unit (TG) is present at nucleotide position 123_124 in genomic reference sequence",
                      "g.123_124[4] describes location of 1st unit of the variable sequence (nucleotide position 123 to 124) with number in brackets describing number of repeats present in allele",
                      "Alternatively, g.123TG[4] describes a repeating sequence of TG that repeats 4 times where 1st unit (TG) is present at nucleotide position 123_124 in genomic reference sequence"
                    ]
                  },
                  {
                    "text": "SNPDatabase SNP entries designated by \"rs\"Examples: rs2306220: A>G; g.78654 C>G",
                    "sub_points": [
                      "Database SNP entries designated by \"rs\"",
                      "Examples: rs2306220: A>G; g.78654 C>G"
                    ]
                  },
                  {
                    "text": "Deletion/insertionCommonly designated as \"indel\" but may also be designated as \"delins\"Range indicated by \"_\"Examplec.1166_1177delinsAGT describes deletion that extends from nucleotide position 1166 to 1177 with nucleotides AGT inserted in place of deleted sequence",
                    "sub_points": [
                      "Commonly designated as \"indel\" but may also be designated as \"delins\"",
                      "Range indicated by \"_\"",
                      "Examplec.1166_1177delinsAGT describes deletion that extends from nucleotide position 1166 to 1177 with nucleotides AGT inserted in place of deleted sequence",
                      "c.1166_1177delinsAGT describes deletion that extends from nucleotide position 1166 to 1177 with nucleotides AGT inserted in place of deleted sequence"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cytogenetics and FISH": {
            "name": "Cytogenetics and FISH",
            "url": "https://app.pathprimer.com/document/b10bcf0e-42e3-4b0c-9963-bd965f43c3cb/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "Cytogenetics": {
                "History": [
                  {
                    "text": "Historic early explorations1882: German cytologist Walther Flemming published book describing whole process of mitosis; introduced Aniline staining to observe chromosomes during cell division1888: German anatomist Wilhelm von Waldeyer-Hartz introduced term chromosome1902-1903: Walter Sutton and Theodor Boveri proposed chromosomal theory of inheritance1924: Grigory Andreevich Levitsky coined term karyotype1959: American pathologist Peter Nowell and research fellow David Hungerford detected tiny chromosome from 2 patients with chronic myeloid leukemia (CML) known as Philadelphia chromosome1st chromosomal abnormality linked to human neoplasm",
                    "sub_points": [
                      "1882: German cytologist Walther Flemming published book describing whole process of mitosis; introduced Aniline staining to observe chromosomes during cell division",
                      "1888: German anatomist Wilhelm von Waldeyer-Hartz introduced term chromosome",
                      "1902-1903: Walter Sutton and Theodor Boveri proposed chromosomal theory of inheritance",
                      "1924: Grigory Andreevich Levitsky coined term karyotype",
                      "1959: American pathologist Peter Nowell and research fellow David Hungerford detected tiny chromosome from 2 patients with chronic myeloid leukemia (CML) known as Philadelphia chromosome1st chromosomal abnormality linked to human neoplasm",
                      "1st chromosomal abnormality linked to human neoplasm"
                    ]
                  },
                  {
                    "text": "Technical advances1952: T.C. Hsu discovers that hypotonic solution allows for better separation of chromosomesSerendipitous laboratory error had substituted hypotonic for isotonic solution1956: Joe Hin Tjio and Albert Levan introduces perfect method for arresting cells in metaphase by using colchicinePermits correct identification of human chromosome number as 461960: Peter Nowell discovers that phytohemagglutinin stimulates lymphocytes to divide in cultureAllows karyotypes to be produced from normal peripheral blood specimens1968: Torbjorn Caspersson produced 1st chromosome banding pattern using quinacrine mustard (Q banding)Allows chromosomes and chromosomal regions to be easily identified1971: Margery Wayne Shaw pioneers Giemsa bandingSimpler preparation than fluorescent Q banding; opened era of widespread chromosome analysis1972: Janet Rowley discovered that Ph chromosome in CML resulted from translocation between long arms of chromosome 9 and 22This finding established cancer as genetic disease1990s: Optical mapping of genome was originally developed by David Schwartz and his lab at NYUMethod has since been integral to assembly process of many large-scale sequencing projectsOptical genome mapping (OGM) addresses limitations of existing cytogenetic techniquesOffers higher resolution than karyotyping in detecting large-scale structural variants",
                    "sub_points": [
                      "1952: T.C. Hsu discovers that hypotonic solution allows for better separation of chromosomesSerendipitous laboratory error had substituted hypotonic for isotonic solution",
                      "Serendipitous laboratory error had substituted hypotonic for isotonic solution",
                      "1956: Joe Hin Tjio and Albert Levan introduces perfect method for arresting cells in metaphase by using colchicinePermits correct identification of human chromosome number as 46",
                      "Permits correct identification of human chromosome number as 46",
                      "1960: Peter Nowell discovers that phytohemagglutinin stimulates lymphocytes to divide in cultureAllows karyotypes to be produced from normal peripheral blood specimens",
                      "Allows karyotypes to be produced from normal peripheral blood specimens",
                      "1968: Torbjorn Caspersson produced 1st chromosome banding pattern using quinacrine mustard (Q banding)Allows chromosomes and chromosomal regions to be easily identified",
                      "Allows chromosomes and chromosomal regions to be easily identified",
                      "1971: Margery Wayne Shaw pioneers Giemsa bandingSimpler preparation than fluorescent Q banding; opened era of widespread chromosome analysis",
                      "Simpler preparation than fluorescent Q banding; opened era of widespread chromosome analysis",
                      "1972: Janet Rowley discovered that Ph chromosome in CML resulted from translocation between long arms of chromosome 9 and 22This finding established cancer as genetic disease",
                      "This finding established cancer as genetic disease",
                      "1990s: Optical mapping of genome was originally developed by David Schwartz and his lab at NYUMethod has since been integral to assembly process of many large-scale sequencing projectsOptical genome mapping (OGM) addresses limitations of existing cytogenetic techniquesOffers higher resolution than karyotyping in detecting large-scale structural variants",
                      "Method has since been integral to assembly process of many large-scale sequencing projects",
                      "Optical genome mapping (OGM) addresses limitations of existing cytogenetic techniquesOffers higher resolution than karyotyping in detecting large-scale structural variants",
                      "Offers higher resolution than karyotyping in detecting large-scale structural variants"
                    ]
                  }
                ],
                "Sample Requirements": [
                  {
                    "text": "Living cells are absolutely required for chromosome analysisCells must be made to divide in culture for successful karyotyping",
                    "sub_points": [
                      "Cells must be made to divide in culture for successful karyotyping"
                    ]
                  }
                ],
                "Technical Procedure": [
                  {
                    "text": "Living cells are allowed to divide in cultureSpecific mitogens may be required, depending on specimen type and information desired from studyStem cells, blasts, and many malignant cells have capacity to divide autonomouslyTerminally differentiated cells (B cells, T cells, and plasma cells) may need stimulation from additional chemicals &/or interleukins in order to divide",
                    "sub_points": [
                      "Specific mitogens may be required, depending on specimen type and information desired from studyStem cells, blasts, and many malignant cells have capacity to divide autonomouslyTerminally differentiated cells (B cells, T cells, and plasma cells) may need stimulation from additional chemicals &/or interleukins in order to divide",
                      "Stem cells, blasts, and many malignant cells have capacity to divide autonomously",
                      "Terminally differentiated cells (B cells, T cells, and plasma cells) may need stimulation from additional chemicals &/or interleukins in order to divide"
                    ]
                  },
                  {
                    "text": "Colchicine is added to cultureInhibits formation of mitotic spindleDividing cells can no longer progress past metaphaseChromosomes remain in bundled and visible format during this state of \"metaphase arrest\"",
                    "sub_points": [
                      "Inhibits formation of mitotic spindle",
                      "Dividing cells can no longer progress past metaphase",
                      "Chromosomes remain in bundled and visible format during this state of \"metaphase arrest\""
                    ]
                  },
                  {
                    "text": "Hypotonic solution is added to cultureCauses water to enter cell and nucleus, which enhances spreading of chromosomes",
                    "sub_points": [
                      "Causes water to enter cell and nucleus, which enhances spreading of chromosomes"
                    ]
                  },
                  {
                    "text": "Cells are fixed in swollen stateUsing modified Carnoy solution (3:1 methanol:glacial acetic acid)",
                    "sub_points": [
                      "Using modified Carnoy solution (3:1 methanol:glacial acetic acid)"
                    ]
                  },
                  {
                    "text": "Cells are dropped onto glass slides and stainedIn situ cultures may also be prepared in similar fashion",
                    "sub_points": [
                      "In situ cultures may also be prepared in similar fashion"
                    ]
                  },
                  {
                    "text": "Band resolutionNumber of bands visible depends on sample type and preparationMore visible bands yield higher resolution study with greater sensitivityAt 450 band resolution (i.e., 450 bands visible in complete karyotype), each band contains ~ 6 Mb of DNAAt 850 band resolution, each band would contain ~ 3 Mb of DNAG-banding visual resolution on karyotype is ~ 5-10 Mb in routine practiceAbnormalities smaller than this limit will not be detected",
                    "sub_points": [
                      "Number of bands visible depends on sample type and preparationMore visible bands yield higher resolution study with greater sensitivityAt 450 band resolution (i.e., 450 bands visible in complete karyotype), each band contains ~ 6 Mb of DNAAt 850 band resolution, each band would contain ~ 3 Mb of DNA",
                      "More visible bands yield higher resolution study with greater sensitivity",
                      "At 450 band resolution (i.e., 450 bands visible in complete karyotype), each band contains ~ 6 Mb of DNA",
                      "At 850 band resolution, each band would contain ~ 3 Mb of DNA",
                      "G-banding visual resolution on karyotype is ~ 5-10 Mb in routine practiceAbnormalities smaller than this limit will not be detected",
                      "Abnormalities smaller than this limit will not be detected"
                    ]
                  },
                  {
                    "text": "Metaphases are analyzed under light microscope20 metaphases are analyzed in typical case",
                    "sub_points": [
                      "20 metaphases are analyzed in typical case"
                    ]
                  }
                ],
                "Analysis and Nomenclature": [
                  {
                    "text": "Follows International System for Human Cytogenetic Nomenclature (ISCN) guidelines"
                  },
                  {
                    "text": "Chromosomal armsCentromere divides each chromosome in short (p) and long (q) arms",
                    "sub_points": [
                      "Centromere divides each chromosome in short (p) and long (q) arms"
                    ]
                  },
                  {
                    "text": "Chromosomal regionsDivided into regions, bands, and subbandse.g., 9q34 refers to chromosome 9, long arm, region 3, band 4Said aloud as 9 q three four, not 9 q thirty-fourIf bands are further divided into subbands, decimal point is used (e.g., 1p31.1)",
                    "sub_points": [
                      "Divided into regions, bands, and subbands",
                      "e.g., 9q34 refers to chromosome 9, long arm, region 3, band 4Said aloud as 9 q three four, not 9 q thirty-fourIf bands are further divided into subbands, decimal point is used (e.g., 1p31.1)",
                      "Said aloud as 9 q three four, not 9 q thirty-four",
                      "If bands are further divided into subbands, decimal point is used (e.g., 1p31.1)"
                    ]
                  },
                  {
                    "text": "Karyotype descriptionsNumber of chromosomes present is listed 1st, followed by commaNext, sex chromosomes present are listed, followed by commaFinally, any structural &/or numerical abnormalities are listedIf ≥ 2 cell lines are present, they are listed individually, separated by \"/\", and number of counted cells in each cell line is listed in bracketsTerm idem can be used to indicate abnormalities that 2nd cell line shares with 1st",
                    "sub_points": [
                      "Number of chromosomes present is listed 1st, followed by comma",
                      "Next, sex chromosomes present are listed, followed by comma",
                      "Finally, any structural &/or numerical abnormalities are listed",
                      "If ≥ 2 cell lines are present, they are listed individually, separated by \"/\", and number of counted cells in each cell line is listed in bracketsTerm idem can be used to indicate abnormalities that 2nd cell line shares with 1st",
                      "Term idem can be used to indicate abnormalities that 2nd cell line shares with 1st"
                    ]
                  },
                  {
                    "text": "Specific terms for structural abnormalitiesDeletion (del)Part of chromosome is lostInsertion (ins)Part of 1 chromosome is inserted into different areaInversion (inv)Inverted in orientation relative to reference sequenceParacentric inversion affects only 1 chromosomal armPericentric inversion involves both p and q arms and thus includes centromere in inverted segmentTranslocation (t)Exchange of chromosomal regions between 2 different chromosomesDerivative chromosome (der)Structurally rearranged chromosomeMarker chromosome (mar)Abnormal chromosome that cannot be identifiedRing chromosome (r)Circular configuration with chromosome ends fused",
                    "sub_points": [
                      "Deletion (del)Part of chromosome is lost",
                      "Part of chromosome is lost",
                      "Insertion (ins)Part of 1 chromosome is inserted into different area",
                      "Part of 1 chromosome is inserted into different area",
                      "Inversion (inv)Inverted in orientation relative to reference sequenceParacentric inversion affects only 1 chromosomal armPericentric inversion involves both p and q arms and thus includes centromere in inverted segment",
                      "Inverted in orientation relative to reference sequence",
                      "Paracentric inversion affects only 1 chromosomal arm",
                      "Pericentric inversion involves both p and q arms and thus includes centromere in inverted segment",
                      "Translocation (t)Exchange of chromosomal regions between 2 different chromosomes",
                      "Exchange of chromosomal regions between 2 different chromosomes",
                      "Derivative chromosome (der)Structurally rearranged chromosome",
                      "Structurally rearranged chromosome",
                      "Marker chromosome (mar)Abnormal chromosome that cannot be identified",
                      "Abnormal chromosome that cannot be identified",
                      "Ring chromosome (r)Circular configuration with chromosome ends fused",
                      "Circular configuration with chromosome ends fused"
                    ]
                  },
                  {
                    "text": "Criteria for clonalityNot every abnormality seen in analysis is considered clonalRandom genetic errors may occur during cell cultureChromosomes may spread too far during preparation, leading to artifactual \"loss\" of chromosomesClone is defined as2 cells that share same abnormality, if abnormality is chromosome gain or structural abnormality3 cells that share same loss of chromosome",
                    "sub_points": [
                      "Not every abnormality seen in analysis is considered clonalRandom genetic errors may occur during cell cultureChromosomes may spread too far during preparation, leading to artifactual \"loss\" of chromosomes",
                      "Random genetic errors may occur during cell culture",
                      "Chromosomes may spread too far during preparation, leading to artifactual \"loss\" of chromosomes",
                      "Clone is defined as2 cells that share same abnormality, if abnormality is chromosome gain or structural abnormality3 cells that share same loss of chromosome",
                      "2 cells that share same abnormality, if abnormality is chromosome gain or structural abnormality",
                      "3 cells that share same loss of chromosome"
                    ]
                  }
                ],
                "Key Types of Clinical Findings": [
                  {
                    "text": "AneuploidyGains or losses of whole chromosomese.g., Down syndrome, trisomy 21",
                    "sub_points": [
                      "Gains or losses of whole chromosomes",
                      "e.g., Down syndrome, trisomy 21"
                    ]
                  },
                  {
                    "text": "Translocationse.g., t(9;22)(q34.1;q11.2)Exchange of chromosomal material between chromosomes 9 and 22 with breakpoints at designated bands on long arms of eachResults inBCR::ABL1fusion seen in CML and subset of B-lymphoblastic leukemia/lymphoma",
                    "sub_points": [
                      "e.g., t(9;22)(q34.1;q11.2)Exchange of chromosomal material between chromosomes 9 and 22 with breakpoints at designated bands on long arms of eachResults inBCR::ABL1fusion seen in CML and subset of B-lymphoblastic leukemia/lymphoma",
                      "Exchange of chromosomal material between chromosomes 9 and 22 with breakpoints at designated bands on long arms of each",
                      "Results inBCR::ABL1fusion seen in CML and subset of B-lymphoblastic leukemia/lymphoma"
                    ]
                  }
                ],
                "Clinical Utility of Cancer Cytogenetics": [
                  {
                    "text": "For diagnosisEstablish neoplastic diagnosis due to presence of clonee.g., monosomy 7 may permit confident diagnosis of myelodysplastic syndromeEstablish specific subtype of neoplasm due to cytogenetic abnormality characteristic of that neoplasme.g., t(8;21)(q21.3;q22.1) permits diagnosis of specific subtype of acute myeloid leukemia",
                    "sub_points": [
                      "Establish neoplastic diagnosis due to presence of clonee.g., monosomy 7 may permit confident diagnosis of myelodysplastic syndrome",
                      "e.g., monosomy 7 may permit confident diagnosis of myelodysplastic syndrome",
                      "Establish specific subtype of neoplasm due to cytogenetic abnormality characteristic of that neoplasme.g., t(8;21)(q21.3;q22.1) permits diagnosis of specific subtype of acute myeloid leukemia",
                      "e.g., t(8;21)(q21.3;q22.1) permits diagnosis of specific subtype of acute myeloid leukemia"
                    ]
                  },
                  {
                    "text": "For prognosisDetermine likely behavior of neoplasm based on cytogenetic abnormalitiese.g., presence of 17p deletion in chronic lymphocytic leukemia is associated with aggressive disease course",
                    "sub_points": [
                      "Determine likely behavior of neoplasm based on cytogenetic abnormalitiese.g., presence of 17p deletion in chronic lymphocytic leukemia is associated with aggressive disease course",
                      "e.g., presence of 17p deletion in chronic lymphocytic leukemia is associated with aggressive disease course"
                    ]
                  },
                  {
                    "text": "Identifying residual diseaseTrack presence of neoplasm over time based on presence of previously established clonal abnormalities",
                    "sub_points": [
                      "Track presence of neoplasm over time based on presence of previously established clonal abnormalities"
                    ]
                  },
                  {
                    "text": "Identifying clonal evolutionDetect acquisition of additional cytogenetic abnormalities over time in neoplasm, which may be linked to more aggressive behavior",
                    "sub_points": [
                      "Detect acquisition of additional cytogenetic abnormalities over time in neoplasm, which may be linked to more aggressive behavior"
                    ]
                  }
                ]
              },
              "Fluorescence In Situ Hybridization": {
                "History": [
                  {
                    "text": "Radiolabeled probes were cumbersome and dangerous"
                  },
                  {
                    "text": "In 1980, fluorescently labeled probe was 1st usedLimited by dim fluorescent signal of early probes",
                    "sub_points": [
                      "Limited by dim fluorescent signal of early probes"
                    ]
                  },
                  {
                    "text": "By early 1990s, improved probe labeling technology allowed routine detection of target nucleic acids"
                  }
                ],
                "Sample Requirements for FISH": [
                  {
                    "text": "In contrast to chromosome analysis, FISH can be performed on nondividing (interphase) cells, includingFixed cells, paraffin-embedded tissue sections, air-dried smears, touch preparations, or cytospin preparations",
                    "sub_points": [
                      "Fixed cells, paraffin-embedded tissue sections, air-dried smears, touch preparations, or cytospin preparations"
                    ]
                  },
                  {
                    "text": "May also be performed on metaphase cells"
                  }
                ],
                "Technical Procedure": [
                  {
                    "text": "PretreatmentIncludes dehydration of slide with graded ethanol series",
                    "sub_points": [
                      "Includes dehydration of slide with graded ethanol series"
                    ]
                  },
                  {
                    "text": "Codenaturation and hybridizationFluorescently labeled probe specific to DNA target sequence is appliedSlide is heated to denature double-stranded DNASlide is incubated for 14-20 hours at temperature permitting hybridization of probe to target DNA",
                    "sub_points": [
                      "Fluorescently labeled probe specific to DNA target sequence is applied",
                      "Slide is heated to denature double-stranded DNA",
                      "Slide is incubated for 14-20 hours at temperature permitting hybridization of probe to target DNA"
                    ]
                  },
                  {
                    "text": "Final slide preparationExcess probe is washed awayMounting medium with DAPI counterstain is appliedDAPI stains DNA at fluorescent wavelength different from that of probePermits visualization of nuclei under fluorescent microscope",
                    "sub_points": [
                      "Excess probe is washed away",
                      "Mounting medium with DAPI counterstain is appliedDAPI stains DNA at fluorescent wavelength different from that of probePermits visualization of nuclei under fluorescent microscope",
                      "DAPI stains DNA at fluorescent wavelength different from that of probe",
                      "Permits visualization of nuclei under fluorescent microscope"
                    ]
                  }
                ],
                "Key Probe Strategies": [
                  {
                    "text": "Numerical chromosome enumeration probesHybridize near centromeric region of chromosomeDetects presence or absence of specific chromosome",
                    "sub_points": [
                      "Hybridize near centromeric region of chromosome",
                      "Detects presence or absence of specific chromosome"
                    ]
                  },
                  {
                    "text": "Dual-color, dual-fusion probesUsed to detect specific translocations2 genes involved in translocations are labeled in different colors (typically red and green)Translocation will result in 2 fused signalsFused signal often appear yellowPresence of 2 fusion signals in cell is highly specific for translocation in question",
                    "sub_points": [
                      "Used to detect specific translocations2 genes involved in translocations are labeled in different colors (typically red and green)Translocation will result in 2 fused signalsFused signal often appear yellowPresence of 2 fusion signals in cell is highly specific for translocation in question",
                      "2 genes involved in translocations are labeled in different colors (typically red and green)",
                      "Translocation will result in 2 fused signalsFused signal often appear yellow",
                      "Fused signal often appear yellow",
                      "Presence of 2 fusion signals in cell is highly specific for translocation in question"
                    ]
                  },
                  {
                    "text": "Break-apart probesUsed if only 1 gene involved in translocation is knownRed and green probes are labeled on either end of geneIf there is translocation, red and green signals will become separatedPartner gene cannot be identified by this approach",
                    "sub_points": [
                      "Used if only 1 gene involved in translocation is known",
                      "Red and green probes are labeled on either end of geneIf there is translocation, red and green signals will become separatedPartner gene cannot be identified by this approach",
                      "If there is translocation, red and green signals will become separated",
                      "Partner gene cannot be identified by this approach"
                    ]
                  }
                ],
                "Nomenclature": [
                  {
                    "text": "Follows International System for Human Cytogenetic Nomenclature (ISCN) guidelines"
                  },
                  {
                    "text": "Interphase FISH is indicated by \"nuc ish\"Followed by locus designation for probe, \"x,\" and number of signals seenIf signals have become juxtaposed (as with dual-fusion probe), this is indicated with \"con\" followed by, in brackets, number of cells in which abnormality was seene.g., FISH in typical new diagnosis of CML could be written as \"nuc ish(ABL1x3),(BCRx3),(ABL1 con BCRx2)[162/200]\"",
                    "sub_points": [
                      "Followed by locus designation for probe, \"x,\" and number of signals seen",
                      "If signals have become juxtaposed (as with dual-fusion probe), this is indicated with \"con\" followed by, in brackets, number of cells in which abnormality was seen",
                      "e.g., FISH in typical new diagnosis of CML could be written as \"nuc ish(ABL1x3),(BCRx3),(ABL1 con BCRx2)[162/200]\""
                    ]
                  },
                  {
                    "text": "Cases are classified as positive or negative based on established laboratory-specific cutoffs"
                  }
                ],
                "Clinical Utility of FISH": [
                  {
                    "text": "For diagnosise.g., rapid diagnosis of APL by detection ofPML::RARAfusion",
                    "sub_points": [
                      "e.g., rapid diagnosis of APL by detection ofPML::RARAfusion"
                    ]
                  },
                  {
                    "text": "For prognosise.g., detection ofTP53deletion in chronic lymphocytic leukemia",
                    "sub_points": [
                      "e.g., detection ofTP53deletion in chronic lymphocytic leukemia"
                    ]
                  },
                  {
                    "text": "Detection of residual diseaseRequires known FISH detectable abnormality",
                    "sub_points": [
                      "Requires known FISH detectable abnormality"
                    ]
                  },
                  {
                    "text": "Noninvasive detection of fetal aneuploidySuccessfully performed on fetal nucleated RBCs isolated from maternal blood",
                    "sub_points": [
                      "Successfully performed on fetal nucleated RBCs isolated from maternal blood"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Chromosomal Microarray": {
            "name": "Chromosomal Microarray",
            "url": "https://app.pathprimer.com/document/f704b303-7ef2-459a-8e0e-2686eb00ced2/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Chromosomal microarray analysis (CMA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Molecular cytogenetic method used to analyze genomic copy number variations (CNVs)Relative ploidy level of DNA of test sample is compared to a reference sample/reference DNA databaseImproved resolution for detection of genomic microdeletions and microduplications compared to conventional cytogenetics and FISHLocus-specific probes used in FISH requires prior knowledge of an expected chromosomal aberrationPrior knowledge of a chromosomal aberration is not required in CMANo cell culture needed in CMA",
                    "sub_points": [
                      "Relative ploidy level of DNA of test sample is compared to a reference sample/reference DNA database",
                      "Improved resolution for detection of genomic microdeletions and microduplications compared to conventional cytogenetics and FISHLocus-specific probes used in FISH requires prior knowledge of an expected chromosomal aberration",
                      "Locus-specific probes used in FISH requires prior knowledge of an expected chromosomal aberration",
                      "Prior knowledge of a chromosomal aberration is not required in CMA",
                      "No cell culture needed in CMA"
                    ]
                  }
                ],
                "Types of Microarrays": [
                  {
                    "text": "Array-based comparative genomic hybridization (aCGH)Detects copy number changes",
                    "sub_points": [
                      "Detects copy number changes"
                    ]
                  },
                  {
                    "text": "Single nucleotide polymorphism (SNP)-based chromosomal microarray (SNP-CMA)Detects copy number changesAlso detects copy-neutral changesLoss of heterozygosity (LOH)Uniparental disomy (UPD)Identity by descent or consanguinity",
                    "sub_points": [
                      "Detects copy number changes",
                      "Also detects copy-neutral changesLoss of heterozygosity (LOH)Uniparental disomy (UPD)Identity by descent or consanguinity",
                      "Loss of heterozygosity (LOH)",
                      "Uniparental disomy (UPD)",
                      "Identity by descent or consanguinity"
                    ]
                  }
                ]
              },
              "Methods & Techniques": {
                "Array CGH": [
                  {
                    "text": "Microarray platform contains bacterial artificial chromosome (BAC) probes or oligonucleotide probes covering whole genomeBAC probes are ~ 150 kb in sizeEvenly spaced at ~ 1Mb resolution across genomeOligonucleotide probes are ~ 45-60 kb in sizeAverage resolution of ~ 30 kb throughout genome",
                    "sub_points": [
                      "BAC probes are ~ 150 kb in sizeEvenly spaced at ~ 1Mb resolution across genome",
                      "Evenly spaced at ~ 1Mb resolution across genome",
                      "Oligonucleotide probes are ~ 45-60 kb in sizeAverage resolution of ~ 30 kb throughout genome",
                      "Average resolution of ~ 30 kb throughout genome"
                    ]
                  },
                  {
                    "text": "Test DNA and control DNA labeled with different fluorescent dyesCyanin dyes Cy3 and Cy5",
                    "sub_points": [
                      "Cyanin dyes Cy3 and Cy5"
                    ]
                  },
                  {
                    "text": "Both test and control DNAs are hybridized to DNA chip"
                  },
                  {
                    "text": "Relative signal intensity ratio for each individual probe is normalized and converted to a log2 ratioLog2 acts as a proxy for copy number",
                    "sub_points": [
                      "Log2 acts as a proxy for copy number"
                    ]
                  },
                  {
                    "text": "Signal intensity of test DNA is compared to control DNAHigher intensity in specific genomic region indicates duplicationLower intensity in specific genomic region indicates deletion",
                    "sub_points": [
                      "Higher intensity in specific genomic region indicates duplication",
                      "Lower intensity in specific genomic region indicates deletion"
                    ]
                  }
                ],
                "SNP Chromosomal Microarray": [
                  {
                    "text": "SNP microarray contains both nonpolymorphic copy number probes and SNP probesNonpolymorphic copy number probes used to assess copy number changesSNP probes used to assess both genotype and copy number changese.g., Affymetrix CytoScan HD Array contains ~ 750,000 unique SNPs and 1.9 million nonpolymorphic copy number probes",
                    "sub_points": [
                      "Nonpolymorphic copy number probes used to assess copy number changes",
                      "SNP probes used to assess both genotype and copy number changese.g., Affymetrix CytoScan HD Array contains ~ 750,000 unique SNPs and 1.9 million nonpolymorphic copy number probes",
                      "e.g., Affymetrix CytoScan HD Array contains ~ 750,000 unique SNPs and 1.9 million nonpolymorphic copy number probes"
                    ]
                  },
                  {
                    "text": "Only test DNA is hybridized to DNA array"
                  },
                  {
                    "text": "Similar to aCGH, relative signal intensity ratio for each individual probe is normalized and converted to log2 ratio"
                  },
                  {
                    "text": "Signal intensity of test DNA is compared to an in silico DNA reference database to determine specific genomic imbalances"
                  },
                  {
                    "text": "For a given SNP with 2 alleles (A or B), data are represented by 3 allelic tractsAA (homozygous), AB (heterozygous), BB (homozygous)",
                    "sub_points": [
                      "AA (homozygous), AB (heterozygous), BB (homozygous)"
                    ]
                  },
                  {
                    "text": "SNP genotyping allows detection of copy-neutral changes that are not detectable by aCGH platform"
                  }
                ]
              },
              "Chromosomal Aberrations": {
                "Aberrations Detected by aCGH": [
                  {
                    "text": "Genomic copy number losses (i.e., deletions)"
                  },
                  {
                    "text": "Genomic copy number gains (i.e., duplications, triplications, amplifications)"
                  }
                ],
                "Aberrations Detected by SNP CMA": [
                  {
                    "text": "Genomic copy number losses"
                  },
                  {
                    "text": "Genomic copy number gains"
                  },
                  {
                    "text": "Loss of heterozygosity (LOH)"
                  },
                  {
                    "text": "Region of homozygosity (ROH)"
                  },
                  {
                    "text": "Uniparental disomy (UPD), specially isodisomy"
                  }
                ],
                "Limitations of CMA": [
                  {
                    "text": "Cannot detect point mutations"
                  },
                  {
                    "text": "Cannot detect balanced chromosomal rearrangements, including balanced inversions, translocations, insertions"
                  },
                  {
                    "text": "Low-level mosaicism may not be detected"
                  },
                  {
                    "text": "Tetraploidy cannot be detected"
                  },
                  {
                    "text": "Copy number variations (CNVs) of regions not represented on platform will not be detected"
                  },
                  {
                    "text": "Cannot detect epigenetic variations such as methylation"
                  }
                ]
              },
              "Clinical Implications": {
                "Constitutional Abnormalities": [
                  {
                    "text": "Genome-wide detection of clinically significant copy number abnormalitiesChromosomal aneuploidy, microdeletions, microduplicationsSignificantly higher diagnostic yield than conventional karyotype",
                    "sub_points": [
                      "Chromosomal aneuploidy, microdeletions, microduplicationsSignificantly higher diagnostic yield than conventional karyotype",
                      "Significantly higher diagnostic yield than conventional karyotype"
                    ]
                  },
                  {
                    "text": "Detects uniparental disomy (UPD) of imprinted chromosomes and consanguinityUPD and consanguinity are not detectable by aCGH",
                    "sub_points": [
                      "UPD and consanguinity are not detectable by aCGH"
                    ]
                  },
                  {
                    "text": "Prenatal diagnosisCommon indications for prenatal CMA testingAdvanced maternal age (≥ 35 years at expected delivery)Enlarged nuchal translucencyAbnormal ultrasound findingsFamily history of recurrent pregnancy lossAbnormal maternal serum screeningAbnormal noninvasive prenatal screening test using cell-free fetal DNA in maternal circulationPatients with normal fetus undergoing invasive prenatal diagnostic testing (e.g., chorionic villus sampling)Patients with a fetus with ≥ 1 structural abnormalityDNA is usually obtained from chorionic villus sampling or amniocentesis",
                    "sub_points": [
                      "Common indications for prenatal CMA testingAdvanced maternal age (≥ 35 years at expected delivery)Enlarged nuchal translucencyAbnormal ultrasound findingsFamily history of recurrent pregnancy lossAbnormal maternal serum screeningAbnormal noninvasive prenatal screening test using cell-free fetal DNA in maternal circulationPatients with normal fetus undergoing invasive prenatal diagnostic testing (e.g., chorionic villus sampling)Patients with a fetus with ≥ 1 structural abnormality",
                      "Advanced maternal age (≥ 35 years at expected delivery)",
                      "Enlarged nuchal translucency",
                      "Abnormal ultrasound findings",
                      "Family history of recurrent pregnancy loss",
                      "Abnormal maternal serum screening",
                      "Abnormal noninvasive prenatal screening test using cell-free fetal DNA in maternal circulation",
                      "Patients with normal fetus undergoing invasive prenatal diagnostic testing (e.g., chorionic villus sampling)",
                      "Patients with a fetus with ≥ 1 structural abnormality",
                      "DNA is usually obtained from chorionic villus sampling or amniocentesis"
                    ]
                  },
                  {
                    "text": "Products of conception (i.e., fetal demise or stillbirth)Common chromosomal abnormalities seen in products of conceptionWhole chromosome aneuploidies, including autosomal trisomies and monosomy XPolyploidies including triploidy and tetraploidyDNA is obtained from fetal &/or placental tissueCMA testing eliminates need for cell cultureMore complete and faster than fetal chromosomal analysis",
                    "sub_points": [
                      "Common chromosomal abnormalities seen in products of conceptionWhole chromosome aneuploidies, including autosomal trisomies and monosomy XPolyploidies including triploidy and tetraploidy",
                      "Whole chromosome aneuploidies, including autosomal trisomies and monosomy X",
                      "Polyploidies including triploidy and tetraploidy",
                      "DNA is obtained from fetal &/or placental tissue",
                      "CMA testing eliminates need for cell cultureMore complete and faster than fetal chromosomal analysis",
                      "More complete and faster than fetal chromosomal analysis"
                    ]
                  },
                  {
                    "text": "Postnatal diagnosisRecommended as a 1st tier diagnostic test for detection of chromosomal imbalances in patients with clinical suspicion forAutism spectrum disorderNonsyndromic developmental delay/intellectual disabilityMultiple congenital anomaliesDNA is usually obtained from peripheral blood lymphocytes",
                    "sub_points": [
                      "Recommended as a 1st tier diagnostic test for detection of chromosomal imbalances in patients with clinical suspicion forAutism spectrum disorderNonsyndromic developmental delay/intellectual disabilityMultiple congenital anomalies",
                      "Autism spectrum disorder",
                      "Nonsyndromic developmental delay/intellectual disability",
                      "Multiple congenital anomalies",
                      "DNA is usually obtained from peripheral blood lymphocytes"
                    ]
                  }
                ],
                "Neoplastic Conditions": [
                  {
                    "text": "Genome-wide detection of cancer-associated copy number abnormalitiesAcquired whole chromosome aneuploidyAcquired deletions, duplications, amplificationsAcquired segmental UPD, copy neutral loss of heterozygosity (LOH)",
                    "sub_points": [
                      "Acquired whole chromosome aneuploidy",
                      "Acquired deletions, duplications, amplifications",
                      "Acquired segmental UPD, copy neutral loss of heterozygosity (LOH)"
                    ]
                  },
                  {
                    "text": "Hematologic malignanciesChronic lymphocytic leukemia (CLL)Detects deletions of 6q, 11q, 13q, 17p, and trisomy 12SNP array detects both copy number abnormalities and copy-neutral events, such as UPDDNA is typical obtained from diagnostic blood, bone marrow aspirate, or fresh lymph nodeCan also be tested on DNA isolated from diagnostic paraffin-embedded fixed tissuesMyelodysplastic syndrome (MDS)Can detect monosomy 5, del(5q), monosomy 7, del(7q), +8, del(20q), acquired segmental UPD",
                    "sub_points": [
                      "Chronic lymphocytic leukemia (CLL)Detects deletions of 6q, 11q, 13q, 17p, and trisomy 12SNP array detects both copy number abnormalities and copy-neutral events, such as UPDDNA is typical obtained from diagnostic blood, bone marrow aspirate, or fresh lymph nodeCan also be tested on DNA isolated from diagnostic paraffin-embedded fixed tissues",
                      "Detects deletions of 6q, 11q, 13q, 17p, and trisomy 12",
                      "SNP array detects both copy number abnormalities and copy-neutral events, such as UPD",
                      "DNA is typical obtained from diagnostic blood, bone marrow aspirate, or fresh lymph node",
                      "Can also be tested on DNA isolated from diagnostic paraffin-embedded fixed tissues",
                      "Myelodysplastic syndrome (MDS)Can detect monosomy 5, del(5q), monosomy 7, del(7q), +8, del(20q), acquired segmental UPD",
                      "Can detect monosomy 5, del(5q), monosomy 7, del(7q), +8, del(20q), acquired segmental UPD"
                    ]
                  },
                  {
                    "text": "Solid tumorsDetects copy number aberrations and copy neutral LOHMelanomaDeletions of 1p, 3q, 5q, 6q, 9p, 10p, 10q, 11q, 14q and gains of 1q, 6p, 7p, 7q, 8qHelps in differentiating melanoma from benign nevusProstate cancerGenome-wide LOH may be detectedRenal cell carcinomaDeletions of 3p, 1p, 2q, 6q, 9p, monosomy 14 and gains of 5q and 8qDNA isolated from diagnostic paraffin-embedded tissue is suitable for testing",
                    "sub_points": [
                      "Detects copy number aberrations and copy neutral LOH",
                      "MelanomaDeletions of 1p, 3q, 5q, 6q, 9p, 10p, 10q, 11q, 14q and gains of 1q, 6p, 7p, 7q, 8qHelps in differentiating melanoma from benign nevus",
                      "Deletions of 1p, 3q, 5q, 6q, 9p, 10p, 10q, 11q, 14q and gains of 1q, 6p, 7p, 7q, 8q",
                      "Helps in differentiating melanoma from benign nevus",
                      "Prostate cancerGenome-wide LOH may be detected",
                      "Genome-wide LOH may be detected",
                      "Renal cell carcinomaDeletions of 3p, 1p, 2q, 6q, 9p, monosomy 14 and gains of 5q and 8q",
                      "Deletions of 3p, 1p, 2q, 6q, 9p, monosomy 14 and gains of 5q and 8q",
                      "DNA isolated from diagnostic paraffin-embedded tissue is suitable for testing"
                    ]
                  }
                ]
              },
              "Clinical Interpretation": {
                "Pathogenic CNVs": [
                  {
                    "text": "Clinically significant based on multiple peer-reviewed publications"
                  }
                ],
                "CNVs of Uncertain Clinical Significance": [
                  {
                    "text": "Uncertain, likely pathogenicDescribed in a single case reportCompelling genes in CNV interval relevant to patient clinical findings",
                    "sub_points": [
                      "Described in a single case report",
                      "Compelling genes in CNV interval relevant to patient clinical findings"
                    ]
                  },
                  {
                    "text": "Uncertain, likely benignLarge CNVs with no genesDescribed as benign in general population based on a small number of cases",
                    "sub_points": [
                      "Large CNVs with no genes",
                      "Described as benign in general population based on a small number of cases"
                    ]
                  },
                  {
                    "text": "UncertainDescribed in multiple contradictory publications &/or in database",
                    "sub_points": [
                      "Described in multiple contradictory publications &/or in database"
                    ]
                  }
                ],
                "Benign": [
                  {
                    "text": "Known common polymorphismReported in multiple peer-reviewed publications or curated database",
                    "sub_points": [
                      "Reported in multiple peer-reviewed publications or curated database"
                    ]
                  }
                ],
                "Resources for Interpretation of CNVs": [
                  {
                    "text": "Online mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/omim)"
                  },
                  {
                    "text": "Database of Genomic Variants (DGV) (http://dgv.tcag.ca/dgv/app/home)"
                  },
                  {
                    "text": "Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl resources (DECIPHER)(https://decipher.sanger.ac.uk/)"
                  },
                  {
                    "text": "Clinical genome Resource (ClinGen, a.k.a. ISCA) (http://clinicalgenome.org/)"
                  },
                  {
                    "text": "The Copy number variation Project at the Children's Hospital of Philadelphia (CHOP) (http://cnv.chop.edu/)"
                  },
                  {
                    "text": "The Cancer Genome Anatomy Project (CGAP) (http://cgap.nci.nih.gov/)"
                  },
                  {
                    "text": "The Cancer Genome Atlas (TCGA) (www.cancergenome.nih.gov/)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Amplification Methods": {
            "name": "Amplification Methods",
            "url": "https://app.pathprimer.com/document/5ca4a9ae-1eba-48a3-8aa7-6eb9c73be4fc/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Target amplification increases amount of nucleic acid of interestModern molecular methods chiefly rely on polymerase chain reaction (PCR), and modifications of PCRFoundation of molecular pathologyBasis of majority of clinical molecular diagnostic testingMuch faster than earlier methods like Southern blot analysisCan handle high volumes of testingHighly specificHighly sensitiveCan detect as few as 10 target molecules per reaction in some situationsProduces large quantities of product from rare targets, allowing for analysisContamination of preamplification areas must be prevented",
                    "sub_points": [
                      "Modern molecular methods chiefly rely on polymerase chain reaction (PCR), and modifications of PCRFoundation of molecular pathologyBasis of majority of clinical molecular diagnostic testing",
                      "Foundation of molecular pathology",
                      "Basis of majority of clinical molecular diagnostic testing",
                      "Much faster than earlier methods like Southern blot analysis",
                      "Can handle high volumes of testing",
                      "Highly specific",
                      "Highly sensitiveCan detect as few as 10 target molecules per reaction in some situationsProduces large quantities of product from rare targets, allowing for analysisContamination of preamplification areas must be prevented",
                      "Can detect as few as 10 target molecules per reaction in some situations",
                      "Produces large quantities of product from rare targets, allowing for analysis",
                      "Contamination of preamplification areas must be prevented"
                    ]
                  },
                  {
                    "text": "Signal amplification increases detection of target without amplifying nucleic acidsLess contamination riskMainly used in infectious disease testing",
                    "sub_points": [
                      "Less contamination risk",
                      "Mainly used in infectious disease testing"
                    ]
                  }
                ]
              },
              "Polymerase Chain Reaction": {
                "Standard PCR": [
                  {
                    "text": "Most widely used method of nucleic acid amplification"
                  },
                  {
                    "text": "Exponentially amplify target sequences of DNAProducts of each reaction act as templates in additional reactionsExponentially increases copies of region of interestPCR product amplicons are a specific predicted size, bounded by ends of primers used",
                    "sub_points": [
                      "Products of each reaction act as templates in additional reactionsExponentially increases copies of region of interest",
                      "Exponentially increases copies of region of interest",
                      "PCR product amplicons are a specific predicted size, bounded by ends of primers used"
                    ]
                  },
                  {
                    "text": "Reaction mix includes template DNA, primers, DNA polymerase, deoxynucleotide triphosphates (dNTPs), and reaction bufferTemplate DNA may be isolated from fresh, frozen, formalin-fixed paraffin-embedded (FFPE), cDNA derived from RNA, and other specimensTargets are usually short fragments, 200-2,000 base pairs in lengthFFPE specimens usually have DNA fragmentation and produce smaller lengths of DNAAmount of template required depends on nature of source and target sequencePrimers created to target a region of interestPrimer design is most important factor in PCR sensitivity and specificityProvide specificity of reactionShould target a unique sequenceComplementary to opposite strands (forward and reverse)Designed so that amplicon produced will include binding site of opposite primerCan be around or overlap area of interestMust not have intraprimer homology, or partially double-stranded (secondary) structures will occurMust not contain regions complementary to other primer, or primers will hybridize (primer dimer)Primer length affects specificity, reaction temperatures, and reaction efficiencyUsually 17-30 nucleotides in lengthShould have 45-55% GC contentUsually have a G or C at 3' end to improve specificityAnnealing temperature should be 5° lower than melting temperatureMany internet tools for primer design availableHeat-stable DNA polymerase required for modern PCRThermophilus aquaticus-derived polymerase most commonly used (Taq)5' to 3' polymerase activity5' to 3' exonuclease activityError rate: 1 x 10⁻⁴ to 2 x 10⁻⁵ errors per base pairOther polymerases are available with lower error rates and 3' to 5' exonuclease activityImprovedTaqpolymerases with modifications to prevent low temperature activity and mispriming and improve specificity are availableDNTPs (building blocks of DNA) required to synthesize DNAExcess dNTPs leads to decreased specificityReaction buffer controls pH and ion concentrations for optimal performanceOptimum pH usually between 8 and 10Magnesium (Mg²⁺) required for polymerase performanceLower Mg²⁺ increases specificity of primer-template bindingHigher Mg²⁺ decreases reaction specificity and inhibits denaturationMg²⁺ and pH must be optimized for specific primers and desired outcomesAdditives such as bovine serum albumin (BSA) and dimethyl sulfoxide (DMSO) may be included",
                    "sub_points": [
                      "Template DNA may be isolated from fresh, frozen, formalin-fixed paraffin-embedded (FFPE), cDNA derived from RNA, and other specimensTargets are usually short fragments, 200-2,000 base pairs in lengthFFPE specimens usually have DNA fragmentation and produce smaller lengths of DNAAmount of template required depends on nature of source and target sequence",
                      "Targets are usually short fragments, 200-2,000 base pairs in length",
                      "FFPE specimens usually have DNA fragmentation and produce smaller lengths of DNA",
                      "Amount of template required depends on nature of source and target sequence",
                      "Primers created to target a region of interestPrimer design is most important factor in PCR sensitivity and specificityProvide specificity of reactionShould target a unique sequenceComplementary to opposite strands (forward and reverse)Designed so that amplicon produced will include binding site of opposite primerCan be around or overlap area of interestMust not have intraprimer homology, or partially double-stranded (secondary) structures will occurMust not contain regions complementary to other primer, or primers will hybridize (primer dimer)Primer length affects specificity, reaction temperatures, and reaction efficiencyUsually 17-30 nucleotides in lengthShould have 45-55% GC contentUsually have a G or C at 3' end to improve specificityAnnealing temperature should be 5° lower than melting temperatureMany internet tools for primer design available",
                      "Primer design is most important factor in PCR sensitivity and specificity",
                      "Provide specificity of reaction",
                      "Should target a unique sequence",
                      "Complementary to opposite strands (forward and reverse)",
                      "Designed so that amplicon produced will include binding site of opposite primer",
                      "Can be around or overlap area of interest",
                      "Must not have intraprimer homology, or partially double-stranded (secondary) structures will occur",
                      "Must not contain regions complementary to other primer, or primers will hybridize (primer dimer)",
                      "Primer length affects specificity, reaction temperatures, and reaction efficiency",
                      "Usually 17-30 nucleotides in length",
                      "Should have 45-55% GC content",
                      "Usually have a G or C at 3' end to improve specificity",
                      "Annealing temperature should be 5° lower than melting temperature",
                      "Many internet tools for primer design available",
                      "Heat-stable DNA polymerase required for modern PCRThermophilus aquaticus-derived polymerase most commonly used (Taq)5' to 3' polymerase activity5' to 3' exonuclease activityError rate: 1 x 10⁻⁴ to 2 x 10⁻⁵ errors per base pairOther polymerases are available with lower error rates and 3' to 5' exonuclease activityImprovedTaqpolymerases with modifications to prevent low temperature activity and mispriming and improve specificity are available",
                      "Thermophilus aquaticus-derived polymerase most commonly used (Taq)",
                      "5' to 3' polymerase activity",
                      "5' to 3' exonuclease activity",
                      "Error rate: 1 x 10⁻⁴ to 2 x 10⁻⁵ errors per base pair",
                      "Other polymerases are available with lower error rates and 3' to 5' exonuclease activity",
                      "ImprovedTaqpolymerases with modifications to prevent low temperature activity and mispriming and improve specificity are available",
                      "DNTPs (building blocks of DNA) required to synthesize DNAExcess dNTPs leads to decreased specificity",
                      "Excess dNTPs leads to decreased specificity",
                      "Reaction buffer controls pH and ion concentrations for optimal performanceOptimum pH usually between 8 and 10Magnesium (Mg²⁺) required for polymerase performanceLower Mg²⁺ increases specificity of primer-template bindingHigher Mg²⁺ decreases reaction specificity and inhibits denaturationMg²⁺ and pH must be optimized for specific primers and desired outcomesAdditives such as bovine serum albumin (BSA) and dimethyl sulfoxide (DMSO) may be included",
                      "Optimum pH usually between 8 and 10",
                      "Magnesium (Mg²⁺) required for polymerase performance",
                      "Lower Mg²⁺ increases specificity of primer-template binding",
                      "Higher Mg²⁺ decreases reaction specificity and inhibits denaturation",
                      "Mg²⁺ and pH must be optimized for specific primers and desired outcomes",
                      "Additives such as bovine serum albumin (BSA) and dimethyl sulfoxide (DMSO) may be included"
                    ]
                  },
                  {
                    "text": "Reaction depends on temperature cyclingThermocyclers are used to control temperature cyclesTemperatures at each step may be adjusted to alter sensitivity and specificity of reactionSpecimen is heated to the melting point so DNA becomes single stranded (denaturation stage)Usually around 92-94° CMore accurate calculations availableUsually around 1 minute longSpecimen is cooled so that primers and template bind (annealing stage)Annealing stage temperature depends on specific primer length and sequenceTemperature can be adjusted to change specificity of bindingCooler temperatures more stringentWarmer temperatures more permissive of mismatched primer-template bindingUsually ~ 1 minute longLonger times lead to decreased specificitySpecimen is heated to amplification temperature, and synthesis occurs (extension stage)Temperature depends on polymerase, usually 70-80° C forTaqpolymeraseUsually ~ 2 minutes longSpecimen is again heated to melting point (denaturation stage)DNA and primer dissociateSpecimen is again cooled to annealing temperaturePrimers can bind to products of previous amplification step as well as input DNASpecimen is again heated to amplification temperatureResults in exponential production of ampliconsSteps are repeated many times≥ 30 or cycles may be usedNumber of cycles depends on required sensitivity and specificityAmount of product depends on starting level of targetIncrease of 2ⁿ, where n = number of cycles, is expectedProduction eventually plateaus based on reaction components",
                    "sub_points": [
                      "Thermocyclers are used to control temperature cyclesTemperatures at each step may be adjusted to alter sensitivity and specificity of reaction",
                      "Temperatures at each step may be adjusted to alter sensitivity and specificity of reaction",
                      "Specimen is heated to the melting point so DNA becomes single stranded (denaturation stage)Usually around 92-94° CMore accurate calculations availableUsually around 1 minute long",
                      "Usually around 92-94° C",
                      "More accurate calculations available",
                      "Usually around 1 minute long",
                      "Specimen is cooled so that primers and template bind (annealing stage)Annealing stage temperature depends on specific primer length and sequenceTemperature can be adjusted to change specificity of bindingCooler temperatures more stringentWarmer temperatures more permissive of mismatched primer-template bindingUsually ~ 1 minute longLonger times lead to decreased specificity",
                      "Annealing stage temperature depends on specific primer length and sequence",
                      "Temperature can be adjusted to change specificity of binding",
                      "Cooler temperatures more stringent",
                      "Warmer temperatures more permissive of mismatched primer-template binding",
                      "Usually ~ 1 minute long",
                      "Longer times lead to decreased specificity",
                      "Specimen is heated to amplification temperature, and synthesis occurs (extension stage)Temperature depends on polymerase, usually 70-80° C forTaqpolymeraseUsually ~ 2 minutes long",
                      "Temperature depends on polymerase, usually 70-80° C forTaqpolymerase",
                      "Usually ~ 2 minutes long",
                      "Specimen is again heated to melting point (denaturation stage)DNA and primer dissociate",
                      "DNA and primer dissociate",
                      "Specimen is again cooled to annealing temperaturePrimers can bind to products of previous amplification step as well as input DNA",
                      "Primers can bind to products of previous amplification step as well as input DNA",
                      "Specimen is again heated to amplification temperatureResults in exponential production of amplicons",
                      "Results in exponential production of amplicons",
                      "Steps are repeated many times≥ 30 or cycles may be usedNumber of cycles depends on required sensitivity and specificityAmount of product depends on starting level of targetIncrease of 2ⁿ, where n = number of cycles, is expectedProduction eventually plateaus based on reaction components",
                      "≥ 30 or cycles may be used",
                      "Number of cycles depends on required sensitivity and specificity",
                      "Amount of product depends on starting level of target",
                      "Increase of 2ⁿ, where n = number of cycles, is expected",
                      "Production eventually plateaus based on reaction components"
                    ]
                  },
                  {
                    "text": "Products can be analyzed using a number of methods, including sequence-specific methodsGel electrophoresisCapillary electrophoresisMelting curve analysisRestriction fragment length polymorphism analysis (RFLP)Allele-specific oligonucleotide hybridization (dot-blot analysis)Oligonucleotide ligation (sequence-specific oligonucleotide probe) assayDenaturing gradient gel electrophoresisTemperature gradient gel electrophoresisHeteroduplex analysisSingle-strand conformation polymorphismDenaturing high-performance liquid chromatographyProtein truncation testCloningSequencing",
                    "sub_points": [
                      "Gel electrophoresis",
                      "Capillary electrophoresis",
                      "Melting curve analysis",
                      "Restriction fragment length polymorphism analysis (RFLP)",
                      "Allele-specific oligonucleotide hybridization (dot-blot analysis)",
                      "Oligonucleotide ligation (sequence-specific oligonucleotide probe) assay",
                      "Denaturing gradient gel electrophoresis",
                      "Temperature gradient gel electrophoresis",
                      "Heteroduplex analysis",
                      "Single-strand conformation polymorphism",
                      "Denaturing high-performance liquid chromatography",
                      "Protein truncation test",
                      "Cloning",
                      "Sequencing"
                    ]
                  },
                  {
                    "text": "Limitations of PCRContamination must be stringently preventedSmall amounts of DNA contamination leads to exponential amplificationRisk reduced by using good laboratory practices, using dedicated equipment, and separating pre- and post-PCR areasRoutine tissue processing may prevent amplificationDecalcification of bony tissue using solutions containing strong acids significantly induces DNA degradation and prevents amplification of even small targetsFormalin fragments DNA and can prevent amplification of large sequence targetsSome tissue compounds, such as hemoglobin and urea, act as PCR inhibitors",
                    "sub_points": [
                      "Contamination must be stringently preventedSmall amounts of DNA contamination leads to exponential amplificationRisk reduced by using good laboratory practices, using dedicated equipment, and separating pre- and post-PCR areas",
                      "Small amounts of DNA contamination leads to exponential amplification",
                      "Risk reduced by using good laboratory practices, using dedicated equipment, and separating pre- and post-PCR areas",
                      "Routine tissue processing may prevent amplificationDecalcification of bony tissue using solutions containing strong acids significantly induces DNA degradation and prevents amplification of even small targetsFormalin fragments DNA and can prevent amplification of large sequence targetsSome tissue compounds, such as hemoglobin and urea, act as PCR inhibitors",
                      "Decalcification of bony tissue using solutions containing strong acids significantly induces DNA degradation and prevents amplification of even small targets",
                      "Formalin fragments DNA and can prevent amplification of large sequence targets",
                      "Some tissue compounds, such as hemoglobin and urea, act as PCR inhibitors"
                    ]
                  }
                ]
              },
              "Variants of PCR": {
                "Reverse Transcription PCR (RT-PCR)": [
                  {
                    "text": "Allows for analysis of RNA through reverse transcription of cDNAOften used for fusion gene analysisUsed to evaluate gene expressioncDNA is more stable than RNAExtremely sensitive: Even very small input sequences can be amplified",
                    "sub_points": [
                      "Often used for fusion gene analysis",
                      "Used to evaluate gene expression",
                      "cDNA is more stable than RNA",
                      "Extremely sensitive: Even very small input sequences can be amplified"
                    ]
                  },
                  {
                    "text": "Template RNA is isolated from cells or tissue and may be total RNA or mRNARNA is inherently unstable and RNAses are ubiquitous, so careful isolation is requiredmRNA may have complex secondary structures, which interfere with denaturation",
                    "sub_points": [
                      "RNA is inherently unstable and RNAses are ubiquitous, so careful isolation is required",
                      "mRNA may have complex secondary structures, which interfere with denaturation"
                    ]
                  },
                  {
                    "text": "cDNA primers usedOligo dT primers bind to poly A tail on mRNANot useful when region of interest is far (> 1 kb) from 3' end of mRNAGene-specific oligonucleotide primers may be used",
                    "sub_points": [
                      "Oligo dT primers bind to poly A tail on mRNA",
                      "Not useful when region of interest is far (> 1 kb) from 3' end of mRNA",
                      "Gene-specific oligonucleotide primers may be used"
                    ]
                  },
                  {
                    "text": "Reverse transcriptase requiredRNA-dependent DNA polymeraseCreates cDNA from RNA templateMoloney murine leukemia virus or avian myeloblastosis virus polymerases commonly usedEnzymes with both reverse transcriptase and DNA polymerase activity are available",
                    "sub_points": [
                      "RNA-dependent DNA polymerase",
                      "Creates cDNA from RNA template",
                      "Moloney murine leukemia virus or avian myeloblastosis virus polymerases commonly used",
                      "Enzymes with both reverse transcriptase and DNA polymerase activity are available"
                    ]
                  },
                  {
                    "text": "RNase is added to digest RNA after reverse transcription, leaving only cDNA"
                  },
                  {
                    "text": "cDNA produced is used as a template for conventional-type PCR reactions as described above"
                  }
                ],
                "Real-Time PCR": [
                  {
                    "text": "Allows detection and quantification of target DNA moleculeMeasures gene transcripts when combined with RT-PCROften used for residual disease testing, e.g., in CML",
                    "sub_points": [
                      "Measures gene transcripts when combined with RT-PCR",
                      "Often used for residual disease testing, e.g., in CML"
                    ]
                  },
                  {
                    "text": "Based on detection of fluorescence during PCRSignal increases in direct proportion to amount of product formedMeasured during exponential phaseA cycle threshold (CT) is set at which fluorescence signal correlates to inial amount of templateThe higher the input template level, the lower the CTUsually compared to amplification level of a control gene",
                    "sub_points": [
                      "Signal increases in direct proportion to amount of product formed",
                      "Measured during exponential phase",
                      "A cycle threshold (CT) is set at which fluorescence signal correlates to inial amount of template",
                      "The higher the input template level, the lower the CT",
                      "Usually compared to amplification level of a control gene"
                    ]
                  },
                  {
                    "text": "Different types of probes availableIntercalating dyesFluoresce when bound to any double-stranded DNASignal measure at end of each cycle (annealing stage)Not sequence specificCan bind to primer dimers or nonspecific productExamples include SYBR green and ethidium bromide",
                    "sub_points": [
                      "Intercalating dyesFluoresce when bound to any double-stranded DNASignal measure at end of each cycle (annealing stage)Not sequence specificCan bind to primer dimers or nonspecific productExamples include SYBR green and ethidium bromide",
                      "Fluoresce when bound to any double-stranded DNA",
                      "Signal measure at end of each cycle (annealing stage)",
                      "Not sequence specific",
                      "Can bind to primer dimers or nonspecific product",
                      "Examples include SYBR green and ethidium bromide"
                    ]
                  },
                  {
                    "text": "Sequence-specific fluorescent labeled probesMore specific to desired productTaqMan probesShort sequences with a 5' reporter fluorophore and a 3' quencher5' to 3' exonuclease activity ofTaqpolymerase releases reporter from quencher, allowing fluorescenceFluorescence measured during extension phaseMolecular beacon probesLonger sequences with a 5' reporter fluorophore and 3' quencherForm a hairpin structure when not bound to DNA, bringing ends together and quenching fluorescenceBinding to target amplicon by central loop section opens hairpin and separates dyes, leading to fluorescenceFluorescence measured during annealing phaseFluorescence resonance energy transfer (FRET) probes2 separate probes are usedOne has a donor fluorophore, other has an acceptorUsually one is to mutation of interest and the other is to a nearby sequenceWhen both probes bind, energy is transferred from donor to acceptor, and fluorescence occursScorpion primersType of molecular beaconExtremely sensitive, specific, and rapidGives a stronger signal than other types of probesContain a primer with a 5' reporter fluorophore and 3' quencherPrimer forms a hairpin structure, bringing ends together and quenching fluorescenceDuring PCR, hairpin opens and fluorophore is separated from a quencherDuring annealing step, primer acts as a probe and binds to amplicon, separating dyes and leading to fluorescenceDuplex scorpion primersSimilar to original scorpion primers but with 2 separate complementary primers1 is bound to reporter fluorophore and other is bound to quencherResults in lower backgroundOther types of sequence specific probes are available",
                    "sub_points": [
                      "More specific to desired product",
                      "TaqMan probesShort sequences with a 5' reporter fluorophore and a 3' quencher5' to 3' exonuclease activity ofTaqpolymerase releases reporter from quencher, allowing fluorescenceFluorescence measured during extension phase",
                      "Short sequences with a 5' reporter fluorophore and a 3' quencher",
                      "5' to 3' exonuclease activity ofTaqpolymerase releases reporter from quencher, allowing fluorescence",
                      "Fluorescence measured during extension phase",
                      "Molecular beacon probesLonger sequences with a 5' reporter fluorophore and 3' quencherForm a hairpin structure when not bound to DNA, bringing ends together and quenching fluorescenceBinding to target amplicon by central loop section opens hairpin and separates dyes, leading to fluorescenceFluorescence measured during annealing phase",
                      "Longer sequences with a 5' reporter fluorophore and 3' quencher",
                      "Form a hairpin structure when not bound to DNA, bringing ends together and quenching fluorescence",
                      "Binding to target amplicon by central loop section opens hairpin and separates dyes, leading to fluorescence",
                      "Fluorescence measured during annealing phase",
                      "Fluorescence resonance energy transfer (FRET) probes2 separate probes are usedOne has a donor fluorophore, other has an acceptorUsually one is to mutation of interest and the other is to a nearby sequenceWhen both probes bind, energy is transferred from donor to acceptor, and fluorescence occurs",
                      "2 separate probes are used",
                      "One has a donor fluorophore, other has an acceptor",
                      "Usually one is to mutation of interest and the other is to a nearby sequence",
                      "When both probes bind, energy is transferred from donor to acceptor, and fluorescence occurs",
                      "Scorpion primersType of molecular beaconExtremely sensitive, specific, and rapidGives a stronger signal than other types of probesContain a primer with a 5' reporter fluorophore and 3' quencherPrimer forms a hairpin structure, bringing ends together and quenching fluorescenceDuring PCR, hairpin opens and fluorophore is separated from a quencherDuring annealing step, primer acts as a probe and binds to amplicon, separating dyes and leading to fluorescence",
                      "Type of molecular beacon",
                      "Extremely sensitive, specific, and rapid",
                      "Gives a stronger signal than other types of probes",
                      "Contain a primer with a 5' reporter fluorophore and 3' quencher",
                      "Primer forms a hairpin structure, bringing ends together and quenching fluorescence",
                      "During PCR, hairpin opens and fluorophore is separated from a quencher",
                      "During annealing step, primer acts as a probe and binds to amplicon, separating dyes and leading to fluorescence",
                      "Duplex scorpion primersSimilar to original scorpion primers but with 2 separate complementary primers1 is bound to reporter fluorophore and other is bound to quencherResults in lower background",
                      "Similar to original scorpion primers but with 2 separate complementary primers",
                      "1 is bound to reporter fluorophore and other is bound to quencher",
                      "Results in lower background",
                      "Other types of sequence specific probes are available"
                    ]
                  },
                  {
                    "text": "Workflow considerationsHigh-throughput testRequires no post-PCR analysisHighly reproducibleCannot be multiplexed",
                    "sub_points": [
                      "High-throughput testRequires no post-PCR analysisHighly reproducibleCannot be multiplexed",
                      "Requires no post-PCR analysis",
                      "Highly reproducible",
                      "Cannot be multiplexed"
                    ]
                  }
                ],
                "Multiplex PCR": [
                  {
                    "text": "PCR using multiple primers that simultaneously amplify several different targets"
                  },
                  {
                    "text": "Used for detection of sequence at multiple sites, as in massively parallel (next generation) sequencing"
                  },
                  {
                    "text": "Can be multiple sites within 1 gene, or region or in multiple genes"
                  },
                  {
                    "text": "Reaction conditions can be difficult to optimize"
                  }
                ],
                "Amplification-Refractory Mutation System (ARMS)": [
                  {
                    "text": "Best for identification of point mutations or single base pair variants"
                  },
                  {
                    "text": "3' mismatch between primer and target DNA prevents amplificationPrimers are designed with base of interest (e.g., a single base mutation) at 3' endProduction of amplicon indicates presence of base of interestControl primer must also be used to confirm amplification",
                    "sub_points": [
                      "Primers are designed with base of interest (e.g., a single base mutation) at 3' end",
                      "Production of amplicon indicates presence of base of interest",
                      "Control primer must also be used to confirm amplification"
                    ]
                  },
                  {
                    "text": "Most effective with A to G or G to A mismatches"
                  },
                  {
                    "text": "Stringent reaction conditions further increase specificityPCR conditions must be carefully optimized",
                    "sub_points": [
                      "PCR conditions must be carefully optimized"
                    ]
                  },
                  {
                    "text": "Can be combined with multiplex PCR to interrogate for multiple bases of interest"
                  },
                  {
                    "text": "Usually rapid and inexpensive"
                  },
                  {
                    "text": "Cannot screen for unknown mutations"
                  },
                  {
                    "text": "Also called allele-specific PCR (ASPCR), PCR amplification of specific alleles (PASA), and sequence-specific primer (SSP) amplification"
                  }
                ],
                "Nested PCR": [
                  {
                    "text": "1st round of PCR performed using standard PCR methods"
                  },
                  {
                    "text": "2nd round of PCR then performed using primers internal to 1st set of primersTemplate enriched for 2nd round of PCR",
                    "sub_points": [
                      "Template enriched for 2nd round of PCR"
                    ]
                  },
                  {
                    "text": "Increases overall specificityNoise produced in 1st round of PCR eliminated by 2ndCan be used to find extremely rare target sequences",
                    "sub_points": [
                      "Noise produced in 1st round of PCR eliminated by 2nd",
                      "Can be used to find extremely rare target sequences"
                    ]
                  },
                  {
                    "text": "Increases overall sensitivityTemplate is enriched so very low levels of target can be identifiedVery sensitive to contamination",
                    "sub_points": [
                      "Template is enriched so very low levels of target can be identified",
                      "Very sensitive to contamination"
                    ]
                  }
                ],
                "Restriction Site-Generating PCR": [
                  {
                    "text": "Artificially creates a restriction site that can be recognized by RFLP analysis"
                  },
                  {
                    "text": "Primers are designed that include site of interest"
                  },
                  {
                    "text": "Contain a mismatch adjacent to site of interestMismatch incorporated into ampliconCreates a novel restriction siteProduct digested with restriction enzyme and analyzed",
                    "sub_points": [
                      "Mismatch incorporated into amplicon",
                      "Creates a novel restriction site",
                      "Product digested with restriction enzyme and analyzed"
                    ]
                  },
                  {
                    "text": "PCR efficiency is decreased due to mismatched base"
                  },
                  {
                    "text": "Technique not possible at all sequences"
                  }
                ],
                "Multiplex Ligation-Dependent Probe Amplification (MLPA)": [
                  {
                    "text": "Utilizes 2 adjacent DNA probes with generic sequences added to the endsDNA is denatured and probes bind",
                    "sub_points": [
                      "DNA is denatured and probes bind"
                    ]
                  },
                  {
                    "text": "Primers complementary to the generic sequences are used1 primer is fluorescently labeled so that generation of amplicon is measured",
                    "sub_points": [
                      "1 primer is fluorescently labeled so that generation of amplicon is measured"
                    ]
                  },
                  {
                    "text": "All reactions use same generic primers, and therefore same PCR parameters1 reaction can use multiple different-sized probes to different targets with same generic sequenceAmplicons are different sizes and can be separated",
                    "sub_points": [
                      "1 reaction can use multiple different-sized probes to different targets with same generic sequence",
                      "Amplicons are different sizes and can be separated"
                    ]
                  },
                  {
                    "text": "Can identify large deletions and copy number changesMutations in probe binding area may prevent amplification and appear as deletions",
                    "sub_points": [
                      "Mutations in probe binding area may prevent amplification and appear as deletions"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "DNA Methylation Analysis": {
            "name": "DNA Methylation Analysis",
            "url": "https://app.pathprimer.com/document/3d66ebfc-217d-4de3-a45c-0a0f199fc353/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Epigenetic modification of promoter DNA regulates gene expressionMethyl groups are added enzymatically at carbon 5 position by DNA methyltransferase on cytosine bases followed by guanosine (CpG dinucleotides)Promoter regions of genes may contain many CpG dinucleotides, called CpG islands40% of gene promoters contain CpG islandsMethylation of promoter region leads to decreased gene transcription and expressionMethylated CpG sites bind methylated CpG binding proteins 1 and 2 (MECP1/MECP2)MECP decreases transcription through a transcription repression domainMECP proteins bind other factors that cause chromatin condensation and block transcriptionMECP proteins block binding of transcription factors",
                    "sub_points": [
                      "Methyl groups are added enzymatically at carbon 5 position by DNA methyltransferase on cytosine bases followed by guanosine (CpG dinucleotides)",
                      "Promoter regions of genes may contain many CpG dinucleotides, called CpG islands40% of gene promoters contain CpG islands",
                      "40% of gene promoters contain CpG islands",
                      "Methylation of promoter region leads to decreased gene transcription and expressionMethylated CpG sites bind methylated CpG binding proteins 1 and 2 (MECP1/MECP2)MECP decreases transcription through a transcription repression domainMECP proteins bind other factors that cause chromatin condensation and block transcriptionMECP proteins block binding of transcription factors",
                      "Methylated CpG sites bind methylated CpG binding proteins 1 and 2 (MECP1/MECP2)",
                      "MECP decreases transcription through a transcription repression domain",
                      "MECP proteins bind other factors that cause chromatin condensation and block transcription",
                      "MECP proteins block binding of transcription factors"
                    ]
                  },
                  {
                    "text": "Methylation functions in regulation of specific genes, genomic imprinting, and X-chromosome inactivation"
                  },
                  {
                    "text": "Aberrant methylation is associated with imprinting disorders, X-linked recessive disorders, some trinucleotide repeats disorders, defects in gene expression regulation, and cancerLikely plays a role in all human neoplasia",
                    "sub_points": [
                      "Likely plays a role in all human neoplasia"
                    ]
                  },
                  {
                    "text": "Methylation assays distinguish methylated from nonmethylated DNA"
                  }
                ]
              },
              "Methodology": {
                "Non-Bisulfite-Dependent Methods": [
                  {
                    "text": "Restriction endonuclease digestionGenomic DNA incubated with methylation-specific enzymesHpaII andMspI enzymes commonly usedHpaII cannot cleave DNA at its recognition sequence CCGG if a 5-methyl group is present (methylation sensitive)MspI cleaves DNA irrespective of presence of methyl group at this position (methylation insensitive)Digestion products analyzedGel electrophoresis detects size of fragmentsArray hybridization measures relative fluorescent signal intensities of digested and control DNANext generation sequencing compares libraries constructed from digested DNA and randomly fragmented DNACan be used to analyze methylation in large regions of DNA, including whole genomeHigh rate of false-positive results due to incomplete digestion",
                    "sub_points": [
                      "Genomic DNA incubated with methylation-specific enzymes",
                      "HpaII andMspI enzymes commonly usedHpaII cannot cleave DNA at its recognition sequence CCGG if a 5-methyl group is present (methylation sensitive)MspI cleaves DNA irrespective of presence of methyl group at this position (methylation insensitive)",
                      "HpaII cannot cleave DNA at its recognition sequence CCGG if a 5-methyl group is present (methylation sensitive)",
                      "MspI cleaves DNA irrespective of presence of methyl group at this position (methylation insensitive)",
                      "Digestion products analyzedGel electrophoresis detects size of fragmentsArray hybridization measures relative fluorescent signal intensities of digested and control DNANext generation sequencing compares libraries constructed from digested DNA and randomly fragmented DNA",
                      "Gel electrophoresis detects size of fragments",
                      "Array hybridization measures relative fluorescent signal intensities of digested and control DNA",
                      "Next generation sequencing compares libraries constructed from digested DNA and randomly fragmented DNA",
                      "Can be used to analyze methylation in large regions of DNA, including whole genome",
                      "High rate of false-positive results due to incomplete digestion"
                    ]
                  },
                  {
                    "text": "Affinity enrichmentMethylated DNA is purifiedMethylated DNA immunoprecipitation (MeDIP) uses antibodies specific for methylated cytosineMethyl-CpG binding domain-based capture (MBDCap) uses methyl-binding proteinsProduct hybridized to array or analyzed using next generation sequencing techniquesUsed in research settings for whole genome analysis",
                    "sub_points": [
                      "Methylated DNA is purifiedMethylated DNA immunoprecipitation (MeDIP) uses antibodies specific for methylated cytosineMethyl-CpG binding domain-based capture (MBDCap) uses methyl-binding proteins",
                      "Methylated DNA immunoprecipitation (MeDIP) uses antibodies specific for methylated cytosine",
                      "Methyl-CpG binding domain-based capture (MBDCap) uses methyl-binding proteins",
                      "Product hybridized to array or analyzed using next generation sequencing techniques",
                      "Used in research settings for whole genome analysis"
                    ]
                  }
                ],
                "Bisulfite Conversion Methods": [
                  {
                    "text": "Most common method of measuring methylation status"
                  },
                  {
                    "text": "Genomic DNA is isolated and treated with sodium bisulfite"
                  },
                  {
                    "text": "Bisulfite causes chemical conversion of unmethylated cytosines to uracilUracil will be replaced by thymine during PCR5-methyl-cytosine is protected from conversionReplaced by cytosine during PCR",
                    "sub_points": [
                      "Uracil will be replaced by thymine during PCR",
                      "5-methyl-cytosine is protected from conversionReplaced by cytosine during PCR",
                      "Replaced by cytosine during PCR"
                    ]
                  }
                ],
                "Measurement of Bisulfite Conversion": [
                  {
                    "text": "Restriction endonuclease digestionCleave amplified DNA at uracil-guanosine sequencesDo not cleave cytosine-guanosine sequencesSize of resulting fragments is measured",
                    "sub_points": [
                      "Cleave amplified DNA at uracil-guanosine sequences",
                      "Do not cleave cytosine-guanosine sequences",
                      "Size of resulting fragments is measured"
                    ]
                  },
                  {
                    "text": "Methylation-specific PCRUses primers containing 1 to 3 CpG sites with 3' specificity for cytosines converted to uracil, and a separate set with 3' specificity for nonconverted sequencePresence of amplicon in each reaction is measured, e.g., with gel electrophoresis",
                    "sub_points": [
                      "Uses primers containing 1 to 3 CpG sites with 3' specificity for cytosines converted to uracil, and a separate set with 3' specificity for nonconverted sequencePresence of amplicon in each reaction is measured, e.g., with gel electrophoresis",
                      "Presence of amplicon in each reaction is measured, e.g., with gel electrophoresis"
                    ]
                  },
                  {
                    "text": "Real-time methylation-specific PCR can quantitate methylation levelUtilizes probe specific to nonconverted sequence with attached fluorophore and quencherDuring PCR, probe is degraded, resulting in separation of fluorophore and quencherResulting fluorescence is quantifiedResults expressed as methylation index (MI): Ratio of amplification of methylated DNA to control gene",
                    "sub_points": [
                      "Utilizes probe specific to nonconverted sequence with attached fluorophore and quencher",
                      "During PCR, probe is degraded, resulting in separation of fluorophore and quencher",
                      "Resulting fluorescence is quantified",
                      "Results expressed as methylation index (MI): Ratio of amplification of methylated DNA to control gene"
                    ]
                  },
                  {
                    "text": "Sequencing of products with methylation nonspecific primersAmplified DNA is sequenced using a polymerase able to recognize uracilRatio of cytosine to thymine at each potential conversion site is measuredMultiple sequencing methods availableSanger sequencingPyrosequencingNext generation sequencing (includes options for targeted as well as whole genome methylation assessment)",
                    "sub_points": [
                      "Amplified DNA is sequenced using a polymerase able to recognize uracil",
                      "Ratio of cytosine to thymine at each potential conversion site is measured",
                      "Multiple sequencing methods availableSanger sequencingPyrosequencingNext generation sequencing (includes options for targeted as well as whole genome methylation assessment)",
                      "Sanger sequencing",
                      "Pyrosequencing",
                      "Next generation sequencing (includes options for targeted as well as whole genome methylation assessment)"
                    ]
                  },
                  {
                    "text": "Melting curve analysisMethylated DNA has a higher melting temperature than unmethylated DNAHigher GC content due to preservation of cytosineMay be difficult to interpret if methylation is heterogeneous",
                    "sub_points": [
                      "Methylated DNA has a higher melting temperature than unmethylated DNAHigher GC content due to preservation of cytosine",
                      "Higher GC content due to preservation of cytosine",
                      "May be difficult to interpret if methylation is heterogeneous"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Diagnostic and Screening Use": [
                  {
                    "text": "Gene-specific hypermethylationPromoter methylation prevents normal transcription of tumor suppressor genesRASSF1Ain lung, bladder, and breast cancersMLH1andSEPT9in colon cancerRB1in retinoblastomaSHOXin lung cancerBRCA1in breast cancerMGMTin glioma and colon cancerCDKN2Ain bladder cancer and lung cancerGSTP1in prostate cancerMethylation assays commercially available for epigenetic biomarkers",
                    "sub_points": [
                      "Promoter methylation prevents normal transcription of tumor suppressor genesRASSF1Ain lung, bladder, and breast cancersMLH1andSEPT9in colon cancerRB1in retinoblastomaSHOXin lung cancerBRCA1in breast cancerMGMTin glioma and colon cancerCDKN2Ain bladder cancer and lung cancerGSTP1in prostate cancer",
                      "RASSF1Ain lung, bladder, and breast cancers",
                      "MLH1andSEPT9in colon cancer",
                      "RB1in retinoblastoma",
                      "SHOXin lung cancer",
                      "BRCA1in breast cancer",
                      "MGMTin glioma and colon cancer",
                      "CDKN2Ain bladder cancer and lung cancer",
                      "GSTP1in prostate cancer",
                      "Methylation assays commercially available for epigenetic biomarkers"
                    ]
                  },
                  {
                    "text": "Genome wide hypomethylationOccurs to some degree in all tumorsMay be used for screening and risk stratificationLeads to genomic instabilityIncreased crossover events between normally methylated areasActivation of cryptic promoters disrupts normal gene transcriptionHypomethylation of oncogenes can result in activationRRASin gastric cancer",
                    "sub_points": [
                      "Occurs to some degree in all tumorsMay be used for screening and risk stratification",
                      "May be used for screening and risk stratification",
                      "Leads to genomic instabilityIncreased crossover events between normally methylated areasActivation of cryptic promoters disrupts normal gene transcription",
                      "Increased crossover events between normally methylated areas",
                      "Activation of cryptic promoters disrupts normal gene transcription",
                      "Hypomethylation of oncogenes can result in activationRRASin gastric cancer",
                      "RRASin gastric cancer"
                    ]
                  },
                  {
                    "text": "Human androgen receptor assay (HUMARA)Used to demonstrate clonality in female patientsDetermines methylation of human androgen receptor geneGene contains a hypervariable CAG repeat that is usually heterozygousUtilizes methylation-sensitive restriction enzymes to digest unmethylated allelesMethylated maternal: Methylated paternal ratio of > 3:1 or < 1:3 indicates nonrandom X chromosome inactivationOther genes may be analyzed to determine X chromosome inactivation, but are not widely used",
                    "sub_points": [
                      "Used to demonstrate clonality in female patients",
                      "Determines methylation of human androgen receptor geneGene contains a hypervariable CAG repeat that is usually heterozygousUtilizes methylation-sensitive restriction enzymes to digest unmethylated allelesMethylated maternal: Methylated paternal ratio of > 3:1 or < 1:3 indicates nonrandom X chromosome inactivation",
                      "Gene contains a hypervariable CAG repeat that is usually heterozygous",
                      "Utilizes methylation-sensitive restriction enzymes to digest unmethylated alleles",
                      "Methylated maternal: Methylated paternal ratio of > 3:1 or < 1:3 indicates nonrandom X chromosome inactivation",
                      "Other genes may be analyzed to determine X chromosome inactivation, but are not widely used"
                    ]
                  }
                ],
                "Prognostic and Predictive Use": [
                  {
                    "text": "Methylation of specific gene promoters has prognostic significance"
                  },
                  {
                    "text": "Hypermethylation of microRNA is associated with disease progressionmiR-34b/cassociated with metastasis",
                    "sub_points": [
                      "miR-34b/cassociated with metastasis"
                    ]
                  },
                  {
                    "text": "Methylation status of specific gene promoters predicts chemotherapy responsePromoter methylation ofMGMTDNA repair gene predicts response to alkylating therapy in high-grade gliomas",
                    "sub_points": [
                      "Promoter methylation ofMGMTDNA repair gene predicts response to alkylating therapy in high-grade gliomas"
                    ]
                  },
                  {
                    "text": "Small molecule inhibitors of epigenetic regulatorsReverse epigenetic alterationsDNA methyltransferase (DNMT) inhibitorsNucleoside analogues that irreversibly bind DNMTsUsed in myeloid malignancies such as MDS and AMLInclude azacitidine and decitabineOthers in clinical trialsTrials in other cancersHistone deacetylase inhibitorsUsed in lymphoid malignancies such as T-cell lymphomaVorinostat and romidepsinOthers in clinical trialsOther inhibitors in clinical trialsHistone methyltransferaseHistone acetyltransferaseHistone demethylase",
                    "sub_points": [
                      "Reverse epigenetic alterations",
                      "DNA methyltransferase (DNMT) inhibitorsNucleoside analogues that irreversibly bind DNMTsUsed in myeloid malignancies such as MDS and AMLInclude azacitidine and decitabineOthers in clinical trialsTrials in other cancers",
                      "Nucleoside analogues that irreversibly bind DNMTs",
                      "Used in myeloid malignancies such as MDS and AML",
                      "Include azacitidine and decitabine",
                      "Others in clinical trials",
                      "Trials in other cancers",
                      "Histone deacetylase inhibitorsUsed in lymphoid malignancies such as T-cell lymphomaVorinostat and romidepsinOthers in clinical trials",
                      "Used in lymphoid malignancies such as T-cell lymphoma",
                      "Vorinostat and romidepsin",
                      "Others in clinical trials",
                      "Other inhibitors in clinical trialsHistone methyltransferaseHistone acetyltransferaseHistone demethylase",
                      "Histone methyltransferase",
                      "Histone acetyltransferase",
                      "Histone demethylase"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "DNA High-Resolution Melting Curve Analysis": {
            "name": "DNA High-Resolution Melting Curve Analysis",
            "url": "https://app.pathprimer.com/document/d8bd8f1c-021a-40a9-87b2-7cd49c9a0578/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "High-resolution melting (HRM)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "A laboratory technique used to screen for sequence variations, typically in 1 strand of DNA"
                  }
                ]
              },
              "Introduction": {
                "General Features": [
                  {
                    "text": "HRM is mainly used as a screening tool to identify a potential change in sequence (sequence variation)Typically identifies sequence variation in 1 strand of DNADoes not provide information on specific sequence variant or its significance",
                    "sub_points": [
                      "Typically identifies sequence variation in 1 strand of DNA",
                      "Does not provide information on specific sequence variant or its significance"
                    ]
                  },
                  {
                    "text": "Can also be used to detect methylation status (methylation-sensitive HRM)Needs bisulfite DNA conversion prior to amplification and HRM analysis",
                    "sub_points": [
                      "Needs bisulfite DNA conversion prior to amplification and HRM analysis"
                    ]
                  },
                  {
                    "text": "Sensitivity of HRM is generally proportional to degree of sequence variation and its percentageIn general, detection of sequence variations that are due to deletions or insertions are easier",
                    "sub_points": [
                      "In general, detection of sequence variations that are due to deletions or insertions are easier"
                    ]
                  },
                  {
                    "text": "Prior PCR amplification of target DNA neededCurrent instruments can perform both PCR amplification followed by HRM within a closed system",
                    "sub_points": [
                      "Current instruments can perform both PCR amplification followed by HRM within a closed system"
                    ]
                  }
                ]
              },
              "Principles": {
                "Overview": [
                  {
                    "text": "DNA strands are attached to one another by hydrogen bonds between complementary bases"
                  },
                  {
                    "text": "Gradual increase in temperature breaks down hydrogen bonds between the 2 DNA strandsDouble-stranded DNA dissociated into 2 separate strands by gradual increase in temperatureA fluorescent dye bound to double-stranded DNAWhen DNA strands dissociate, dye separates from DNA and its fluorescence decreases",
                    "sub_points": [
                      "Double-stranded DNA dissociated into 2 separate strands by gradual increase in temperatureA fluorescent dye bound to double-stranded DNAWhen DNA strands dissociate, dye separates from DNA and its fluorescence decreases",
                      "A fluorescent dye bound to double-stranded DNA",
                      "When DNA strands dissociate, dye separates from DNA and its fluorescence decreases"
                    ]
                  },
                  {
                    "text": "As temperature increases, information on DNA dissociation is gathered through measuring changes in fluorescence activityCurve that reflects changes in fluorescence intensity is called melting curve",
                    "sub_points": [
                      "Curve that reflects changes in fluorescence intensity is called melting curve"
                    ]
                  },
                  {
                    "text": "In DNA strands with complete homology in sequences, all nucleotide bases at each position are complementary and are annealed via hydrogen bondsSequence variation in 1 allele in a given position prevents annealing and formation of hydrogen bonds in that positionResults in DNA melting at earlier temperature due to lesser numbers of hydrogen bonds to breakShape of melting curve will be different from the one generated by a completely homologous DNA strands",
                    "sub_points": [
                      "Sequence variation in 1 allele in a given position prevents annealing and formation of hydrogen bonds in that positionResults in DNA melting at earlier temperature due to lesser numbers of hydrogen bonds to breakShape of melting curve will be different from the one generated by a completely homologous DNA strands",
                      "Results in DNA melting at earlier temperature due to lesser numbers of hydrogen bonds to break",
                      "Shape of melting curve will be different from the one generated by a completely homologous DNA strands"
                    ]
                  },
                  {
                    "text": "Sequence variation will be missed if specimen does not contain wild-type DNA; therefore, homozygous variants in high concentration will not be detectedMixing specimen with a known wild-type DNA sequence (mixing studies) will enable detection",
                    "sub_points": [
                      "Mixing specimen with a known wild-type DNA sequence (mixing studies) will enable detection"
                    ]
                  },
                  {
                    "text": "Melting curve analysis is based on comparison between melting curve of test ample and a melting curve of known wild-type DNADeviations of melting curve from known wild-type curve indicate presence of a sequence variant",
                    "sub_points": [
                      "Deviations of melting curve from known wild-type curve indicate presence of a sequence variant"
                    ]
                  },
                  {
                    "text": "Temperature at which 50% of double-stranded DNA become single-stranded is called melting temperature (Tm)"
                  }
                ],
                "High Resolution": [
                  {
                    "text": "Ability of melting method to assess sequence variation at high precision"
                  },
                  {
                    "text": "Achieved through 2 main improvementsHighly controlled temperature transitions and data acquisitionBetter fluorescent dyesCan be used at concentrations that produce maximum fluorescence intensity",
                    "sub_points": [
                      "Highly controlled temperature transitions and data acquisition",
                      "Better fluorescent dyesCan be used at concentrations that produce maximum fluorescence intensity",
                      "Can be used at concentrations that produce maximum fluorescence intensity"
                    ]
                  }
                ],
                "Fluorescent Dyes": [
                  {
                    "text": "Intercalating dyes bind to double-stranded DNAWhen bound, they fluoresce brightlyWhen unbound, they fluoresce at a low level",
                    "sub_points": [
                      "When bound, they fluoresce brightly",
                      "When unbound, they fluoresce at a low level"
                    ]
                  },
                  {
                    "text": "Saturating intercalating dyes that do not inhibit PCR used at concentration that produces maximum fluorescenceUsed for HRM (LCGreen I and LCGreen Plus)",
                    "sub_points": [
                      "Used for HRM (LCGreen I and LCGreen Plus)"
                    ]
                  }
                ],
                "Amplicon Sizes": [
                  {
                    "text": "The smaller the amplicon size, the easier to identify smaller sequence variations, such as single-base changesAmplicon size ≤ 50 bp is generally adequate to provide good differentiation for single-base differences",
                    "sub_points": [
                      "Amplicon size ≤ 50 bp is generally adequate to provide good differentiation for single-base differences"
                    ]
                  },
                  {
                    "text": "Amplicons ≥ 300 bp should be avoided"
                  }
                ]
              },
              "Pre-HRM Specimen Preparations": {
                "DNA Isolation and Amplification": [
                  {
                    "text": "DNA is isolated from patient specimenFresh specimen or paraffin-embedded tissue is suitable for analysis",
                    "sub_points": [
                      "Fresh specimen or paraffin-embedded tissue is suitable for analysis"
                    ]
                  },
                  {
                    "text": "DNA is amplified through PCR using specific primers that flank sequence of interestPrimer design is crucial to avoid risk of primer-dimer formationPrimers should produce an amplicon size that is appropriate for HRM",
                    "sub_points": [
                      "Primer design is crucial to avoid risk of primer-dimer formation",
                      "Primers should produce an amplicon size that is appropriate for HRM"
                    ]
                  }
                ]
              },
              "Clinical Implications": {
                "Rapid Screening": [
                  {
                    "text": "Base changes, best for amplicons ≤ 50 bp"
                  },
                  {
                    "text": "Insertions/deletions can be detected in larger amplicon sizes"
                  },
                  {
                    "text": "Sequence confirmation of DNA with abnormal melting curves generally needed"
                  }
                ]
              },
              "Interpretation of Findings": {
                "Quality Controls": [
                  {
                    "text": "Must include positive and negative controls and a control that contains PCR mix but no DNA template (blank)"
                  },
                  {
                    "text": "Samples and quality controls should be preferentially run in replicatesCan help to ensure reproducibility",
                    "sub_points": [
                      "Can help to ensure reproducibility"
                    ]
                  }
                ],
                "Analysis of Results": [
                  {
                    "text": "Melting curves of test DNA compared to melting curves of known controls in same runMelting curves matching with negative controls are interpreted as negativeHomozygous variants should be excluded by mixing studiesMelting curves not matching with negative controls are interpreted as positiveFurther sequencing needed in most casesSequencing defines exact sequence change and its clinical significanceNonpathogenic polymorphisms within amplicon must be excludedIn certain circumstances, a presumptive diagnosis can be rendered based on analysis of melting curveLaboratory must have a fully validated procedure in place for interpretation of a given test if bypassing sequencing confirmation",
                    "sub_points": [
                      "Melting curves matching with negative controls are interpreted as negativeHomozygous variants should be excluded by mixing studies",
                      "Homozygous variants should be excluded by mixing studies",
                      "Melting curves not matching with negative controls are interpreted as positiveFurther sequencing needed in most casesSequencing defines exact sequence change and its clinical significanceNonpathogenic polymorphisms within amplicon must be excluded",
                      "Further sequencing needed in most cases",
                      "Sequencing defines exact sequence change and its clinical significance",
                      "Nonpathogenic polymorphisms within amplicon must be excluded",
                      "In certain circumstances, a presumptive diagnosis can be rendered based on analysis of melting curveLaboratory must have a fully validated procedure in place for interpretation of a given test if bypassing sequencing confirmation",
                      "Laboratory must have a fully validated procedure in place for interpretation of a given test if bypassing sequencing confirmation"
                    ]
                  },
                  {
                    "text": "Potential false-positive resultsPrimer dimers may potentially induce false-positive resultsMelt is typically seen at unusually early temperature compared with a true positive results, which are typically at higher temperatureCareful design of primers can help in preventing primer dimer formation",
                    "sub_points": [
                      "Primer dimers may potentially induce false-positive resultsMelt is typically seen at unusually early temperature compared with a true positive results, which are typically at higher temperatureCareful design of primers can help in preventing primer dimer formation",
                      "Melt is typically seen at unusually early temperature compared with a true positive results, which are typically at higher temperature",
                      "Careful design of primers can help in preventing primer dimer formation"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Southern Blot Analysis": {
            "name": "Southern Blot Analysis",
            "url": "https://app.pathprimer.com/document/91631943-6643-4cbc-988d-ef344a81e1b7/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Southern blot (SB) analysis of antigen receptor genes (ARGs)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Analysis of restriction fragment length polymorphism (RFLP)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Transfer of electrophoretically separated DNA fragments to a filter membrane followed by detection of DNA fragment of interest by specific probe hybridizationMethod of transfer of DNA fragments to a filter membrane was invented by British biologist Edwin Southern in 1975",
                    "sub_points": [
                      "Method of transfer of DNA fragments to a filter membrane was invented by British biologist Edwin Southern in 1975"
                    ]
                  },
                  {
                    "text": "SB technique was extensively used in the past for analysis of clonality of antigen receptor genes in non-Hodgkin lymphomas"
                  },
                  {
                    "text": "In most laboratories, PCR has replaced SB in assessment of antigen receptor genes"
                  }
                ]
              },
              "Steps in Southern Blot Analysis": {
                "DNA Preparation": [
                  {
                    "text": "Extraction and purification of intact genomic DNA from fresh specimen~ 10 μg of DNA is required for routine SB analysisCan use as little as 200 ng if high concentration of gene of interest present, such as in plasmid DNA",
                    "sub_points": [
                      "~ 10 μg of DNA is required for routine SB analysisCan use as little as 200 ng if high concentration of gene of interest present, such as in plasmid DNA",
                      "Can use as little as 200 ng if high concentration of gene of interest present, such as in plasmid DNA"
                    ]
                  }
                ],
                "DNA Digestion": [
                  {
                    "text": "Restriction enzymes are used to cut intact DNARestriction enzymes are bacterial-derivedRestriction enzymes cut DNA at specific sequences known as restriction sitesRestriction sites are typically short sequences of 4-8 bp in lengthAre frequently palindromes (identical sequence on both strands when read from 5' to 3' on both strands)Example of a palindrome restriction site recognized by enzyme EcoRI: GAATTCDNA fragments produced by a specific restriction enzyme produce a reproducible set of DNA fragmentsMutations, indels, or rearrangements may alter size of DNA fragments produced within a geneAlterations in size pattern of DNA fragments called restriction fragment length polymorphism (RFLP)",
                    "sub_points": [
                      "Restriction enzymes are bacterial-derived",
                      "Restriction enzymes cut DNA at specific sequences known as restriction sites",
                      "Restriction sites are typically short sequences of 4-8 bp in length",
                      "Are frequently palindromes (identical sequence on both strands when read from 5' to 3' on both strands)Example of a palindrome restriction site recognized by enzyme EcoRI: GAATTC",
                      "Example of a palindrome restriction site recognized by enzyme EcoRI: GAATTC",
                      "DNA fragments produced by a specific restriction enzyme produce a reproducible set of DNA fragments",
                      "Mutations, indels, or rearrangements may alter size of DNA fragments produced within a geneAlterations in size pattern of DNA fragments called restriction fragment length polymorphism (RFLP)",
                      "Alterations in size pattern of DNA fragments called restriction fragment length polymorphism (RFLP)"
                    ]
                  }
                ],
                "Gel Electrophoresis of DNA Fragments": [
                  {
                    "text": "Agarose gel functions as a sieve that allows separation of DNA fragments"
                  },
                  {
                    "text": "Negatively charged DNA fragments facilitate their movement through an electric field"
                  },
                  {
                    "text": "DNA fragments are fractionated according to their sizes"
                  },
                  {
                    "text": "Gel should be adequately covered by buffer"
                  },
                  {
                    "text": "High voltage should be avoided to prevent melting of agarose gel"
                  },
                  {
                    "text": "Fragments ranging from 200 bp to 20 kbp are typically separated on agarose gel"
                  },
                  {
                    "text": "Analysis of DNA fragments > 20 kbp should be done by pulse field electrophoresis"
                  },
                  {
                    "text": "Fragments < 200 bp can be reliably analyzed using polyacrylamide gel"
                  }
                ],
                "Transfer of DNA to a Nylon Membrane": [
                  {
                    "text": "Dilute solution of hydrochloric acid is applied to gel before transfer to hydrolyze larger DNA fragments"
                  },
                  {
                    "text": "DNA must be denatured before transferTreatment of gel with alkaline denature DNA",
                    "sub_points": [
                      "Treatment of gel with alkaline denature DNA"
                    ]
                  },
                  {
                    "text": "Capillary action of buffer transfers DNA fragments from gel onto membrane"
                  }
                ],
                "Stabilization of Transferred DNA on Membrane": [
                  {
                    "text": "DNA must be stabilized on membrane before probe hybridizationTransferred DNA will firmly adhere to and will be stabilized on nitrocellulose membrane after baking membrane at 80° C in an oven for ~ 2 hoursDNA can also be stabilized by exposing nylon membrane to UV lightUV light induces crosslinks between nucleic acids and amine groups on membrane",
                    "sub_points": [
                      "Transferred DNA will firmly adhere to and will be stabilized on nitrocellulose membrane after baking membrane at 80° C in an oven for ~ 2 hours",
                      "DNA can also be stabilized by exposing nylon membrane to UV lightUV light induces crosslinks between nucleic acids and amine groups on membrane",
                      "UV light induces crosslinks between nucleic acids and amine groups on membrane"
                    ]
                  }
                ],
                "DNA Hybridization": [
                  {
                    "text": "Hybridization probesSingle-stranded specific DNA fragment complementary to target DNA on membraneProbe is labeled with isotopic 32P or nonisotopic systems, such as chemiluminescenceMembrane is washed after completion of hybridization to remove unused and nonspecifically bound probes",
                    "sub_points": [
                      "Single-stranded specific DNA fragment complementary to target DNA on membrane",
                      "Probe is labeled with isotopic 32P or nonisotopic systems, such as chemiluminescence",
                      "Membrane is washed after completion of hybridization to remove unused and nonspecifically bound probes"
                    ]
                  }
                ],
                "Interpretation of SB Analysis of Antigen Receptor Genes": [
                  {
                    "text": "Radioactive hybridized probes are visualized after exposure to an x-ray film and would appear as dark bands"
                  },
                  {
                    "text": "For analysis of antigen receptor genes, patient's DNA sample is digested in parallel with germline DNA sample"
                  },
                  {
                    "text": "Locations of bands in patient's sample are compared to germline DNA bandsPolyclonal or reactive lymphoid populationNumerous different VDJ rearrangements present, but individual rearrangements are too small to be detected as visible nongermline bandsMonoclonal B-cell or T-cell populationAll neoplastic cells are derived from a single transformed cellIdentical gene rearrangements are present in all neoplastic cellsRestriction fragments containing identical gene rearrangements are detected as novel (nongermline) band(s)Presence of nongermline bands in patient's sample indicate a monoclonal antigen receptor gene rearrangementNongermline bands are often of lower molecular sizes compared to germline bandsNongermline bands are sometimes of higher molecular sizes compared to germline bandsA known DNA polymorphic region in EcoRI restriction digest existsThus, presence of a nongermline band in only EcoRI restriction digest must not be interpreted as evidence for clonality",
                    "sub_points": [
                      "Polyclonal or reactive lymphoid populationNumerous different VDJ rearrangements present, but individual rearrangements are too small to be detected as visible nongermline bands",
                      "Numerous different VDJ rearrangements present, but individual rearrangements are too small to be detected as visible nongermline bands",
                      "Monoclonal B-cell or T-cell populationAll neoplastic cells are derived from a single transformed cellIdentical gene rearrangements are present in all neoplastic cellsRestriction fragments containing identical gene rearrangements are detected as novel (nongermline) band(s)Presence of nongermline bands in patient's sample indicate a monoclonal antigen receptor gene rearrangement",
                      "All neoplastic cells are derived from a single transformed cell",
                      "Identical gene rearrangements are present in all neoplastic cells",
                      "Restriction fragments containing identical gene rearrangements are detected as novel (nongermline) band(s)",
                      "Presence of nongermline bands in patient's sample indicate a monoclonal antigen receptor gene rearrangement",
                      "Nongermline bands are often of lower molecular sizes compared to germline bands",
                      "Nongermline bands are sometimes of higher molecular sizes compared to germline bands",
                      "A known DNA polymorphic region in EcoRI restriction digest existsThus, presence of a nongermline band in only EcoRI restriction digest must not be interpreted as evidence for clonality",
                      "Thus, presence of a nongermline band in only EcoRI restriction digest must not be interpreted as evidence for clonality"
                    ]
                  },
                  {
                    "text": "At least 2 nongermline bands in 1 digest or 1 nongermline band in 2 different digests are required to establish a diagnosis of clonal T-cell receptor β (TRB) gene rearrangement"
                  }
                ],
                "SB vs. PCR in Assessment of Clonality in Lymphoid Proliferations": [
                  {
                    "text": "Advantages of SB in assessment of clonalityConsidered to be gold standard for assessment of clonality in lymphoid neoplasmsFewer false-negative results compared with PCR",
                    "sub_points": [
                      "Considered to be gold standard for assessment of clonality in lymphoid neoplasms",
                      "Fewer false-negative results compared with PCR"
                    ]
                  },
                  {
                    "text": "Disadvantages of SB in assessment of clonalityRequires relatively large amounts of fresh, intact DNALower sensitivity (~ 5%) compared to PCR, which has much higher sensitivityHigh cost and labor intensiveLong turn-around-time of ~ 10-14 days",
                    "sub_points": [
                      "Requires relatively large amounts of fresh, intact DNA",
                      "Lower sensitivity (~ 5%) compared to PCR, which has much higher sensitivity",
                      "High cost and labor intensive",
                      "Long turn-around-time of ~ 10-14 days"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sequencing Technologies": {
            "name": "Sequencing Technologies",
            "url": "https://app.pathprimer.com/document/3a5c9afa-f751-4d54-8336-196760844200/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Identification of the order of nucleotides in nucleic acids"
                  }
                ]
              },
              "Sequencing Techniques": {
                "Sanger Sequencing": [
                  {
                    "text": "Method of DNA sequencing based on chain termination strategy"
                  },
                  {
                    "text": "Introduced by Fredrick Sanger in mid 1970s"
                  },
                  {
                    "text": "Original Sanger sequencingSequencing reaction performed in 4 separate tubes (A, T, C, G)DNA template, sequencing primer, all 4 types of deoxynucleotides (dNTPs) and DNA polymerase added to each tubeIn addition, di-deoxy nucleotides (ddNTPs) are added to 4 tubes as followsddATP added to tube A, ddTTP to tube T, ddCTP to tube C, and ddGTP to tube GddNTPs lack hydroxyl group in carbon #3Hydroxyl group is required for addition of nucleotide to growing chainEach time Taq polymerase randomly incorporates a ddNTP, chain synthesis stopsHence term chain terminators used for ddNTPsAt completion of reaction, synthesized DNA fragments in each tube will have same base at their 5' endsElectrophoresis of each tube on sequencing gel will separate fragments according to their sizes in corresponding laneOn radiogram of sequencing gel, sequences are read from bottom to top",
                    "sub_points": [
                      "Sequencing reaction performed in 4 separate tubes (A, T, C, G)",
                      "DNA template, sequencing primer, all 4 types of deoxynucleotides (dNTPs) and DNA polymerase added to each tube",
                      "In addition, di-deoxy nucleotides (ddNTPs) are added to 4 tubes as followsddATP added to tube A, ddTTP to tube T, ddCTP to tube C, and ddGTP to tube GddNTPs lack hydroxyl group in carbon #3Hydroxyl group is required for addition of nucleotide to growing chain",
                      "ddATP added to tube A, ddTTP to tube T, ddCTP to tube C, and ddGTP to tube G",
                      "ddNTPs lack hydroxyl group in carbon #3",
                      "Hydroxyl group is required for addition of nucleotide to growing chain",
                      "Each time Taq polymerase randomly incorporates a ddNTP, chain synthesis stopsHence term chain terminators used for ddNTPs",
                      "Hence term chain terminators used for ddNTPs",
                      "At completion of reaction, synthesized DNA fragments in each tube will have same base at their 5' ends",
                      "Electrophoresis of each tube on sequencing gel will separate fragments according to their sizes in corresponding lane",
                      "On radiogram of sequencing gel, sequences are read from bottom to top"
                    ]
                  },
                  {
                    "text": "Semi-automated Sanger sequencingddNTPs are labeled with different colored fluorescent dyes and added to sequencing reaction in a single tubeCapillary electrophoresis separates DNA fragmentsLaser detector read individual fragment as they pass through capillariesComputer generates colored peaksOrder of the peaks correspond to DNA sequenceDetects point mutations, small insertions/deletionsDetection sensitivity of ~ 20%",
                    "sub_points": [
                      "ddNTPs are labeled with different colored fluorescent dyes and added to sequencing reaction in a single tube",
                      "Capillary electrophoresis separates DNA fragments",
                      "Laser detector read individual fragment as they pass through capillaries",
                      "Computer generates colored peaks",
                      "Order of the peaks correspond to DNA sequence",
                      "Detects point mutations, small insertions/deletionsDetection sensitivity of ~ 20%",
                      "Detection sensitivity of ~ 20%"
                    ]
                  }
                ],
                "Pyrosequencing": [
                  {
                    "text": "Developed by Ronaghi and Nyren in 1996"
                  },
                  {
                    "text": "Method of DNA sequencing based by synthesis"
                  },
                  {
                    "text": "Generates real-time quantitative sequence data"
                  },
                  {
                    "text": "Steps involved in pyrosequencingSingle-stranded DNA template incubated with 4 enzymes and 2 substratesDNA polymerase, ATP sulfurylase, luciferase, apyrase, adenosine 5' phosphosulfate (APS), and luciferinNucleotides are sequentially added in predefined dispensation orderDNA polymerase incorporate complementary nucleotides (dNTPs)Incorporation of nucleotides result in release of pyrophosphateATP sulfurylase converts pyrophosphate to ATP in presence of APSATP powers oxidation of luciferin by luciferaseOxidation of luciferin generates light, which is recorded as peak referred to as pyrogramApyrase removes unincorporated nucleotides and ATP before next dispensation of nucleotidesProcess is repeated with each of the 4 different nucleotides dispensed sequentiallyIntensity of light will determine if > 1 of the same nucleotides are incorporated in a rowFor example, incorporation of 3 of the same nucleotides generates peak 3x in height compared to peak generated by incorporation of 1 nucleotide",
                    "sub_points": [
                      "Single-stranded DNA template incubated with 4 enzymes and 2 substratesDNA polymerase, ATP sulfurylase, luciferase, apyrase, adenosine 5' phosphosulfate (APS), and luciferin",
                      "DNA polymerase, ATP sulfurylase, luciferase, apyrase, adenosine 5' phosphosulfate (APS), and luciferin",
                      "Nucleotides are sequentially added in predefined dispensation order",
                      "DNA polymerase incorporate complementary nucleotides (dNTPs)",
                      "Incorporation of nucleotides result in release of pyrophosphate",
                      "ATP sulfurylase converts pyrophosphate to ATP in presence of APS",
                      "ATP powers oxidation of luciferin by luciferase",
                      "Oxidation of luciferin generates light, which is recorded as peak referred to as pyrogram",
                      "Apyrase removes unincorporated nucleotides and ATP before next dispensation of nucleotides",
                      "Process is repeated with each of the 4 different nucleotides dispensed sequentially",
                      "Intensity of light will determine if > 1 of the same nucleotides are incorporated in a rowFor example, incorporation of 3 of the same nucleotides generates peak 3x in height compared to peak generated by incorporation of 1 nucleotide",
                      "For example, incorporation of 3 of the same nucleotides generates peak 3x in height compared to peak generated by incorporation of 1 nucleotide"
                    ]
                  },
                  {
                    "text": "Pyrosequencing has detection sensitivity of ~ 5%"
                  },
                  {
                    "text": "Limitation of pyrosequencingShort read length is a limiting factorMainly due to decrease in apyrase efficiency in degrading excess nucleotidesSequencing error with homopolymers (multiple consecutive run of same nucleotide)May result in nucleotide misincorporation",
                    "sub_points": [
                      "Short read length is a limiting factorMainly due to decrease in apyrase efficiency in degrading excess nucleotides",
                      "Mainly due to decrease in apyrase efficiency in degrading excess nucleotides",
                      "Sequencing error with homopolymers (multiple consecutive run of same nucleotide)May result in nucleotide misincorporation",
                      "May result in nucleotide misincorporation"
                    ]
                  },
                  {
                    "text": "Analysis of pyrogramDNA sequence is determined by reviewing signal peaks and their heights in pyrogram tracingIn clinical setting, each run must include known positive and negative controls as quality controls and for result interpretation",
                    "sub_points": [
                      "DNA sequence is determined by reviewing signal peaks and their heights in pyrogram tracing",
                      "In clinical setting, each run must include known positive and negative controls as quality controls and for result interpretation"
                    ]
                  }
                ],
                "Massively Parallel Sequencing (MPS)/Next Generation Sequencing (NGS)": [
                  {
                    "text": "Current commonly used platformsIon torrentSequencing based on pH changes induced by release of H ions during nucleotide incorporationProne to error reads and noise calls in homopolymer tractsIlluminaSequencing based on reversible chain terminationBoth share a clonal amplification of barcoded DNA templates followed by massive simultaneous parallel sequencing",
                    "sub_points": [
                      "Ion torrentSequencing based on pH changes induced by release of H ions during nucleotide incorporationProne to error reads and noise calls in homopolymer tracts",
                      "Sequencing based on pH changes induced by release of H ions during nucleotide incorporation",
                      "Prone to error reads and noise calls in homopolymer tracts",
                      "IlluminaSequencing based on reversible chain termination",
                      "Sequencing based on reversible chain termination",
                      "Both share a clonal amplification of barcoded DNA templates followed by massive simultaneous parallel sequencing"
                    ]
                  },
                  {
                    "text": "MPS/NGS applicationsWhole genome sequencingSequencing of entire genome including coding and noncoding regionsVery complex bioinformatics due to enormous amounts of data generatedExome sequencingSequencing of all coding regions of genome (exons)Less complicated than whole genome sequencingLess complex bioinformatics compared to whole genome sequencingTargeted hotspot gene panelsCurrently offered by many CLIA laboratories in United States",
                    "sub_points": [
                      "Whole genome sequencingSequencing of entire genome including coding and noncoding regionsVery complex bioinformatics due to enormous amounts of data generated",
                      "Sequencing of entire genome including coding and noncoding regions",
                      "Very complex bioinformatics due to enormous amounts of data generated",
                      "Exome sequencingSequencing of all coding regions of genome (exons)Less complicated than whole genome sequencingLess complex bioinformatics compared to whole genome sequencing",
                      "Sequencing of all coding regions of genome (exons)",
                      "Less complicated than whole genome sequencing",
                      "Less complex bioinformatics compared to whole genome sequencing",
                      "Targeted hotspot gene panelsCurrently offered by many CLIA laboratories in United States",
                      "Currently offered by many CLIA laboratories in United States"
                    ]
                  },
                  {
                    "text": "Steps involved in NGSfor targeted sequencingMultiplex PCR amplification and DNA library preparationAmplified DNA products are trimmed to partially remove incorporated primersAdaptors (barcodes) are ligated to trimmed DNA fragmentsClonal amplificationPerformed on beads or on a solid-phase substrate depending on platform usedClonally amplified DNA fragments are simultaneously sequenced by reversible chain terminators or by synthesis, depending on platformGenerated data are run through signal processing and base calling that produce DNA sequence of individual readsSummarized data can be viewed in data formats such as FASTQ, SFF, or SAM/BAMSequence analysisSequence data are aligned with known reference sequencesVariants are identified bioinformatically",
                    "sub_points": [
                      "Multiplex PCR amplification and DNA library preparationAmplified DNA products are trimmed to partially remove incorporated primersAdaptors (barcodes) are ligated to trimmed DNA fragments",
                      "Amplified DNA products are trimmed to partially remove incorporated primers",
                      "Adaptors (barcodes) are ligated to trimmed DNA fragments",
                      "Clonal amplificationPerformed on beads or on a solid-phase substrate depending on platform usedClonally amplified DNA fragments are simultaneously sequenced by reversible chain terminators or by synthesis, depending on platformGenerated data are run through signal processing and base calling that produce DNA sequence of individual readsSummarized data can be viewed in data formats such as FASTQ, SFF, or SAM/BAM",
                      "Performed on beads or on a solid-phase substrate depending on platform used",
                      "Clonally amplified DNA fragments are simultaneously sequenced by reversible chain terminators or by synthesis, depending on platform",
                      "Generated data are run through signal processing and base calling that produce DNA sequence of individual reads",
                      "Summarized data can be viewed in data formats such as FASTQ, SFF, or SAM/BAM",
                      "Sequence analysisSequence data are aligned with known reference sequencesVariants are identified bioinformatically",
                      "Sequence data are aligned with known reference sequences",
                      "Variants are identified bioinformatically"
                    ]
                  },
                  {
                    "text": "Gene panels in clinical settingsTargeted panels for solid tumors and hematologic malignanciesTargeted panels for specific inherited conditionsFull validation required in CLIA laboratories",
                    "sub_points": [
                      "Targeted panels for solid tumors and hematologic malignancies",
                      "Targeted panels for specific inherited conditions",
                      "Full validation required in CLIA laboratories"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "High-Throughput Methods in Molecular Pathology": {
            "name": "High-Throughput Methods in Molecular Pathology",
            "url": "https://app.pathprimer.com/document/65ce5610-5623-4c5f-9690-f7a542b1342b/lesson/c0dfb81c-c290-4fbf-b145-ac70441b1e0a",
            "content": {
              "Terminology": {
                "Definitions": [
                  {
                    "text": "Use of computational software algorithms to analyze and interpret DNA, RNA, and epigenomic sequence data from a next generation sequencing (NGS) instrument"
                  }
                ]
              },
              "Next Generation Sequencing Bioinformatics": {
                "Introduction": [
                  {
                    "text": "NGS (a.k.a. massively parallel sequencing) is a revolutionary technique to generate DNA, RNA, and epigenetic sequencing data in a high-throughput mannerData are generated on a single platform without need for multiple instruments for individual techniques (DNA vs. RNA vs. epigenetics)",
                    "sub_points": [
                      "Data are generated on a single platform without need for multiple instruments for individual techniques (DNA vs. RNA vs. epigenetics)"
                    ]
                  },
                  {
                    "text": "NGS is of increasing in importance in areas such as hematopathology, solid tumor diagnostics, molecular microbiology/virology, and HLA laboratories"
                  },
                  {
                    "text": "Obstacles to adoption of NGS technology in a clinical laboratory include need for specialized expertise and training, lack of bioinformatics resources for analysis, instrumentation costs, and large amounts of data generated"
                  }
                ],
                "Operating Systems": [
                  {
                    "text": "Choices of operating systems (OS) includeWindows OS-based systemsLinux-based systems",
                    "sub_points": [
                      "Windows OS-based systems",
                      "Linux-based systems"
                    ]
                  },
                  {
                    "text": "If dedicated bioinformatics personnel are available, Linux-based systems are an optimal choice due to high customizabilityDisadvantages of LinuxSteep learning curveUse of command line interface and need for programming skillsMajority of bioinformatics software is open source, based on Linux platform",
                    "sub_points": [
                      "Disadvantages of LinuxSteep learning curveUse of command line interface and need for programming skills",
                      "Steep learning curve",
                      "Use of command line interface and need for programming skills",
                      "Majority of bioinformatics software is open source, based on Linux platform"
                    ]
                  },
                  {
                    "text": "For a small to medium-sized laboratory, Windows-based systems are appropriateDoes not need a significant bioinformatics overheadAdvantages of using Windows include familiarity with the OS, even for regular lab personnel without a background in bioinformaticsDisadvantagesLack of open-source software for windowsNeed for commercial solutions for data analysisLack of easy customizability",
                    "sub_points": [
                      "Does not need a significant bioinformatics overhead",
                      "Advantages of using Windows include familiarity with the OS, even for regular lab personnel without a background in bioinformatics",
                      "DisadvantagesLack of open-source software for windowsNeed for commercial solutions for data analysisLack of easy customizability",
                      "Lack of open-source software for windows",
                      "Need for commercial solutions for data analysis",
                      "Lack of easy customizability"
                    ]
                  },
                  {
                    "text": "Macintosh OS is often used as a “bridge” into a Linux distribution such as Ubuntu, which can be simultaneously installed on a Mac computer along with MacOSMinimal bioinformatics software is specifically designed for MacOS",
                    "sub_points": [
                      "Minimal bioinformatics software is specifically designed for MacOS"
                    ]
                  }
                ]
              },
              "Computational Hardware": {
                "Hardware Choices": [
                  {
                    "text": "An important issue for a small to medium-sized laboratory starting with clinical NGS"
                  },
                  {
                    "text": "Targeted DNA-seq panels do not require large amounts of computational power for analytical purposes"
                  },
                  {
                    "text": "Clinical exome or whole genome sequencing require large amounts of computational power"
                  },
                  {
                    "text": "Other assays such as RNA-seq and Chip-seq require large amounts of computational resources as well"
                  },
                  {
                    "text": "For a small to medium-sized lab considering targeted DNA-seq assays, an optimal configuration would include an Intel dual-chip processor with 12-16 cores, 2-4 terabytes of hard disk space, and 64 GB of RAM as a minimum configuration within lab"
                  },
                  {
                    "text": "Depending on number of samples run in lab, need for computational power may be higher"
                  },
                  {
                    "text": "Installation of 2 analytical computers to run in parallel and analyze NGS data is preferred, to ensure redundancy of data workflow"
                  }
                ]
              },
              "NGS Data Analysis": {
                "Step 1: Sequence Generation": [
                  {
                    "text": "Primary sequence is data generated from instrument"
                  },
                  {
                    "text": "In all NGS platforms, extensive preprocessing of raw signal is performed to ensure highest signal quality sequencing data"
                  },
                  {
                    "text": "Multiple steps for sequencing data generation include raw signal analysis, base calling, quality score generation, demultiplexing of different sample reads, and finally generating sequence data file"
                  },
                  {
                    "text": "Data generated from an instrument is a FASTQ file, which contains sequencing data and quality scores associated with each base call"
                  },
                  {
                    "text": "FASTQ data is imported manually for further analysis on a local computer or to the cloud for further analysis"
                  }
                ],
                "Step 2: Sequence Alignment": [
                  {
                    "text": "FASTQ raw data are “cleaned up,\" including trimming at ends of raw reads, eliminating low-quality score data, duplicate read removal, and elimination of very short reads"
                  },
                  {
                    "text": "Each of the individual reads from raw FASTQ file is then aligned against reference human genome databaseThis alignment is the most important step for clinical targeted DNA-seq analysis",
                    "sub_points": [
                      "This alignment is the most important step for clinical targeted DNA-seq analysis"
                    ]
                  },
                  {
                    "text": "In targeted DNA-seq sequencing, each location of target is sequenced many times over, resulting in multiple reads at each genomic locationAll of these reads are aligned multiple times for each location, and resulting sequence data are then visualized in the form of a “pile-up” diagram",
                    "sub_points": [
                      "All of these reads are aligned multiple times for each location, and resulting sequence data are then visualized in the form of a “pile-up” diagram"
                    ]
                  }
                ],
                "Step 3: Variant Detection and Annotation": [
                  {
                    "text": "After read alignment, downstream software is used to identify various DNA sequence variants, such as germline single-nucleotide polymorphism (SNP) variants, somatic SNP variants, insertions, deletions, copy number variants, and structural variants"
                  },
                  {
                    "text": "Variant calling is done by comparing sequenced reads to a reference human genome to determine nucleotide locations, which are different from the reference"
                  },
                  {
                    "text": "Sequencing errors, which are common in NGS, are overcome by sequencing a genomic region multiple times to create “read depth”Read depth is the average number of times any given location is sequenced",
                    "sub_points": [
                      "Read depth is the average number of times any given location is sequenced"
                    ]
                  },
                  {
                    "text": "A read depth of 1,000X indicates that any given location in the target sequence has been sequenced 1,000 times over on averageHigher percentages of tumor cells in NGS samples provide more reliable results compared to low tumor percentages",
                    "sub_points": [
                      "Higher percentages of tumor cells in NGS samples provide more reliable results compared to low tumor percentages"
                    ]
                  },
                  {
                    "text": "Once a sequence variant is identified, it needs to be annotated to determine nature of sequence variant"
                  },
                  {
                    "text": "Annotation in high-throughput sequencing is performed by comparing variant against population frequency data in different databases, such as the 1,000 Genomes Project, NHLBI cohort, and dbSNP projectA variant identified in a database at a population frequency level of ≥ 1% is considered to be a benign variantVarious cancer-specific variant databases exist (e.g., COSMIC), against which identified variant can be comparedVarious software prediction algorithms such as SIFT and POLYPHEN utilize the nucleotide and amino acid level changes in the variant to assess the likely pathogenicity of the variantReliability of such predictions has not been comprehensively proven",
                    "sub_points": [
                      "A variant identified in a database at a population frequency level of ≥ 1% is considered to be a benign variant",
                      "Various cancer-specific variant databases exist (e.g., COSMIC), against which identified variant can be compared",
                      "Various software prediction algorithms such as SIFT and POLYPHEN utilize the nucleotide and amino acid level changes in the variant to assess the likely pathogenicity of the variantReliability of such predictions has not been comprehensively proven",
                      "Reliability of such predictions has not been comprehensively proven"
                    ]
                  }
                ]
              },
              "Bioinformatics Analysis": {
                "Quality Control": [
                  {
                    "text": "NGS read generation is an inherently error-prone process that depends on sequencing platform being used (e.g.., Illumina vs. Ion Torrent)"
                  },
                  {
                    "text": "Various steps in the bioinformatics pipeline can contribute to error process, including read filtering, alignment step, and others"
                  },
                  {
                    "text": "Increase in read depth of sequencing can minimize potential false-positives and false-negativesFor purpose of clinical NGS, a rough estimate of read depth of 400X to 500X coverage may be used as a threshold to ensure accuracy of variant detectionIndividual lab needs to set sensitivity limits for detection of variants during validationA sensitivity limit of 5% mutant allele frequency for single-position variants and 10% for insertion/deletion variants represents a conservative and reasonable approach",
                    "sub_points": [
                      "For purpose of clinical NGS, a rough estimate of read depth of 400X to 500X coverage may be used as a threshold to ensure accuracy of variant detection",
                      "Individual lab needs to set sensitivity limits for detection of variants during validationA sensitivity limit of 5% mutant allele frequency for single-position variants and 10% for insertion/deletion variants represents a conservative and reasonable approach",
                      "A sensitivity limit of 5% mutant allele frequency for single-position variants and 10% for insertion/deletion variants represents a conservative and reasonable approach"
                    ]
                  }
                ]
              },
              "NGS Bioinformatics": {
                "Storage Issues": [
                  {
                    "text": "Important to assess potential clinical volume to estimate future data storage requirements well in advance of implementing the assay"
                  },
                  {
                    "text": "Compliant to HIPAA regulations, it is important to estimate data storage needs in a secure manner without any potential direct patient identifiersA local network access storage (NAS) solution may be implemented for a cheap price",
                    "sub_points": [
                      "A local network access storage (NAS) solution may be implemented for a cheap price"
                    ]
                  },
                  {
                    "text": "Important to make both on-site and off-site data backups for future retrieval of data"
                  },
                  {
                    "text": "Close coordination with local IT infrastructure is a crucial requirement to ensure smooth implementation of data storage process"
                  },
                  {
                    "text": "Retrospective, ad-hoc solutions for data storage are likely to result in multiple roadblocks for smooth implementation of clinical NGS over time"
                  }
                ]
              },
              "Commonly Used Software for NGS Analysis": {
                "Windows-Based Software": [
                  {
                    "text": "Commercial solutions that are integrated from end-to-end for NGS workflow"
                  },
                  {
                    "text": "Capable of performing multiple steps of bioinformatics pipeline, including read alignment, single-nucleotide variant detection, indel detection, variant annotation, and visualization on a single platforme.g., Softgenetics, NextGENe, Avadis NGS, CLCBio Genomics Workbench, DNAstar platform",
                    "sub_points": [
                      "e.g., Softgenetics, NextGENe, Avadis NGS, CLCBio Genomics Workbench, DNAstar platform"
                    ]
                  }
                ],
                "Linux-Based Software": [
                  {
                    "text": "Mostly open-source software created and provided by individual research groupsBowtie2 (alignment), BWA (alignment), Novoalign (alignment), SOAP (alignment), GATK (SNV, indel calling), SAMtools (SNV, indel calling), VarScan (SNV, indel calling), SomaticSniper (SNV, indel for somatic samples), ExomeCNV (copy number calling), BreakDancer (structural variant calling), PINDEL (structural variant calling)",
                    "sub_points": [
                      "Bowtie2 (alignment), BWA (alignment), Novoalign (alignment), SOAP (alignment), GATK (SNV, indel calling), SAMtools (SNV, indel calling), VarScan (SNV, indel calling), SomaticSniper (SNV, indel for somatic samples), ExomeCNV (copy number calling), BreakDancer (structural variant calling), PINDEL (structural variant calling)"
                    ]
                  },
                  {
                    "text": "Free of cost; represents latest state-of-art in terms of algorithmic development"
                  },
                  {
                    "text": "Drawbacks include uneven levels of documentation, need to use command line interface to run programs, and need for specialized technical expertise"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Constitutional Disease": {
        "name": "Constitutional Disease",
        "url": "https://app.pathprimer.com/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
        "topics": {
          "Alpha-1-Antitrypsin Deficiency": {
            "name": "Alpha-1-Antitrypsin Deficiency",
            "url": "https://app.pathprimer.com/document/73f35c32-ce91-4101-902b-c8c0805cc0df/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "AAT belongs to serpin family of protease inhibitors"
                  },
                  {
                    "text": "SERPINA1gene"
                  },
                  {
                    "text": "Allele: Glu342Lys is most commonSERPINA1point mutation"
                  },
                  {
                    "text": "Mutant AAT is believed to be aggregated and trapped in endoplasmic reticulum of hepatocytesDecreased amount (approximately 15%) of normal AAT is secreted into plasmaPI*ZZ is most common genotype of clinically significant disease; PI*SZ is associated with increased risk for emphysema",
                    "sub_points": [
                      "Decreased amount (approximately 15%) of normal AAT is secreted into plasma",
                      "PI*ZZ is most common genotype of clinically significant disease; PI*SZ is associated with increased risk for emphysema"
                    ]
                  },
                  {
                    "text": "AAT inhibits large variety of proteases including elastase in lower respiratory tract"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Development of liver and lung disease is variable and often associated with environmental factors"
                  },
                  {
                    "text": "Smoking can greatly contribute to development of panacinar/panlobular emphysema"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Alpha-1-antitrypsin (AAT)"
                  },
                  {
                    "text": "Protease inhibitor (PI)"
                  },
                  {
                    "text": "Chronic obstructive pulmonary disease (COPD)"
                  },
                  {
                    "text": "Periodic acid-Schiff (PAS)"
                  },
                  {
                    "text": "Antinuclear antibody (ANA)"
                  },
                  {
                    "text": "Smooth muscle antibody (SMA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Ecogenetics: Area of genetics that looks at interplay between various human genotypes and environmental factors/substances"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "Autosomal codominant inheritance2 different genes are expressedBoth contribute to phenotypic expression",
                    "sub_points": [
                      "2 different genes are expressedBoth contribute to phenotypic expression",
                      "Both contribute to phenotypic expression"
                    ]
                  },
                  {
                    "text": "PI locus on chromosome 14q32.1SERPINA1gene",
                    "sub_points": [
                      "SERPINA1gene"
                    ]
                  },
                  {
                    "text": "PI locus is highly polymorphic> 100 single nucleotide polymorphisms",
                    "sub_points": [
                      "> 100 single nucleotide polymorphisms"
                    ]
                  },
                  {
                    "text": "PI allele variantsM alleleMost common allele in white ethnic groupsNormal AAT levelsPI*MM indicates normal gene homozygosityAllele frequency > 0.95Z alleleSevere AAT reductionGlu342Lys is most commonSERPINA1point mutationPI*ZZ indicates homozygosity for this mutationPI Z phenotype: AAT levels < 15% of PI MM levels95% of clinically relevant cases are PI*ZZAllele frequency 0.1-0.3S variantMild AAT level reductionAllele frequency 0.2-0.8Single amino acid substitution of valine for glutamic acidPI*SZIncreased risk for emphysemaPI*SSNot associated with increased risk for emphysema",
                    "sub_points": [
                      "M alleleMost common allele in white ethnic groupsNormal AAT levelsPI*MM indicates normal gene homozygosityAllele frequency > 0.95",
                      "Most common allele in white ethnic groups",
                      "Normal AAT levels",
                      "PI*MM indicates normal gene homozygosity",
                      "Allele frequency > 0.95",
                      "Z alleleSevere AAT reductionGlu342Lys is most commonSERPINA1point mutationPI*ZZ indicates homozygosity for this mutationPI Z phenotype: AAT levels < 15% of PI MM levels95% of clinically relevant cases are PI*ZZAllele frequency 0.1-0.3",
                      "Severe AAT reduction",
                      "Glu342Lys is most commonSERPINA1point mutationPI*ZZ indicates homozygosity for this mutationPI Z phenotype: AAT levels < 15% of PI MM levels95% of clinically relevant cases are PI*ZZ",
                      "PI*ZZ indicates homozygosity for this mutation",
                      "PI Z phenotype: AAT levels < 15% of PI MM levels",
                      "95% of clinically relevant cases are PI*ZZ",
                      "Allele frequency 0.1-0.3",
                      "S variantMild AAT level reductionAllele frequency 0.2-0.8Single amino acid substitution of valine for glutamic acidPI*SZIncreased risk for emphysemaPI*SSNot associated with increased risk for emphysema",
                      "Mild AAT level reduction",
                      "Allele frequency 0.2-0.8",
                      "Single amino acid substitution of valine for glutamic acid",
                      "PI*SZIncreased risk for emphysema",
                      "Increased risk for emphysema",
                      "PI*SSNot associated with increased risk for emphysema",
                      "Not associated with increased risk for emphysema"
                    ]
                  },
                  {
                    "text": "Individuals clinically affected by the disease have combination of 2 abnormal/mutant alleles"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "AAT belongs to serpin family of protease inhibitorsAAT inhibits a large variety of proteases including elastaseIn lower respiratory tract, elastase is released by neutrophilsElastase is associated with lung tissue injury and destructionNormally, elastase is bound to active site of AAT protein and thus inactiveWith decreased activity or function of AAT protein, elastase can cause lung injury and destructionPredisposes patient to ﻿panacinar/panlobular emphysema",
                    "sub_points": [
                      "AAT inhibits a large variety of proteases including elastaseIn lower respiratory tract, elastase is released by neutrophilsElastase is associated with lung tissue injury and destructionNormally, elastase is bound to active site of AAT protein and thus inactiveWith decreased activity or function of AAT protein, elastase can cause lung injury and destructionPredisposes patient to ﻿panacinar/panlobular emphysema",
                      "In lower respiratory tract, elastase is released by neutrophils",
                      "Elastase is associated with lung tissue injury and destruction",
                      "Normally, elastase is bound to active site of AAT protein and thus inactive",
                      "With decreased activity or function of AAT protein, elastase can cause lung injury and destruction",
                      "Predisposes patient to ﻿panacinar/panlobular emphysema"
                    ]
                  },
                  {
                    "text": "AAT gene primarily expressed in liverAlso expressed in lung and gut epithelial cellsMutant AAT is believed to be aggregated and trapped in endoplasmic reticulum of hepatocytesAssociated mutation causes structural change in protein causing it to aggregateAccumulation/aggregation in endoplasmic reticulum of hepatocytes contributes to hepatic damage and cirrhosisDecreased amount (approximately 15%) of normal AAT is secreted into plasma",
                    "sub_points": [
                      "Also expressed in lung and gut epithelial cells",
                      "Mutant AAT is believed to be aggregated and trapped in endoplasmic reticulum of hepatocytesAssociated mutation causes structural change in protein causing it to aggregateAccumulation/aggregation in endoplasmic reticulum of hepatocytes contributes to hepatic damage and cirrhosis",
                      "Associated mutation causes structural change in protein causing it to aggregate",
                      "Accumulation/aggregation in endoplasmic reticulum of hepatocytes contributes to hepatic damage and cirrhosis",
                      "Decreased amount (approximately 15%) of normal AAT is secreted into plasma"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "4% carrier rate in whites"
                  },
                  {
                    "text": "1 in 6700 whites affected"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Development of liver and lung disease variable and often associated with environmental factors"
                  },
                  {
                    "text": "Lung disease/COPDSmoking can greatly contribute to development of panacinar/panlobular emphysemaExample of ecogeneticsCan occur at early age",
                    "sub_points": [
                      "Smoking can greatly contribute to development of panacinar/panlobular emphysemaExample of ecogenetics",
                      "Example of ecogenetics",
                      "Can occur at early age"
                    ]
                  },
                  {
                    "text": "Liver diseaseHepatitis, cirrhosis, hepatocellular carcinomaMale sex and obesity contribute to development of liver disease with AAT",
                    "sub_points": [
                      "Hepatitis, cirrhosis, hepatocellular carcinoma",
                      "Male sex and obesity contribute to development of liver disease with AAT"
                    ]
                  },
                  {
                    "text": "Skin disease (rarely occurs)PanniculitisLikely result of similar mechanism seen in lower respiratory tract—unopposed proteolysis",
                    "sub_points": [
                      "Panniculitis",
                      "Likely result of similar mechanism seen in lower respiratory tract—unopposed proteolysis"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Exogenous PIsPooled human plasma AATGoal is to maintain serum AAT levels above protective threshold of 11 μmol/L",
                    "sub_points": [
                      "Pooled human plasma AAT",
                      "Goal is to maintain serum AAT levels above protective threshold of 11 μmol/L"
                    ]
                  },
                  {
                    "text": "No cure exists"
                  },
                  {
                    "text": "Early diagnosis can contribute to lifestyle modifications and early intervention to avoid worsening of lung disease"
                  },
                  {
                    "text": "Supportive management for liver and skin disease"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "ZZ homozygotes60% survival after 60 years10% survival after 60 years in smokers",
                    "sub_points": [
                      "60% survival after 60 years",
                      "10% survival after 60 years in smokers"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "AAT polymers PAS positive with diastase-resistant inclusions"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Serologic Testing": [
                  {
                    "text": "Protective levels of AAT are > 11 μmol/LEmphysema thought to develop with AAT levels < 9 μmol/L",
                    "sub_points": [
                      "Emphysema thought to develop with AAT levels < 9 μmol/L"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Emphysema": [
                  {
                    "text": "Most common cause is tobacco smoking"
                  },
                  {
                    "text": "Emphysema caused by AAT disease is panacinarCentriacinar pattern seen in emphysema due to smoking",
                    "sub_points": [
                      "Centriacinar pattern seen in emphysema due to smoking"
                    ]
                  }
                ],
                "Cystic Fibrosis": [
                  {
                    "text": "Mutation of cystic fibrosis transmembrane regulator gene (CFTR)"
                  },
                  {
                    "text": "Affects many organs including lungs, pancreas, biliary system, sweat glands, intestines"
                  },
                  {
                    "text": "Can manifest at birth with meconium ileusCam manifest later in life with chronic respiratory symptoms",
                    "sub_points": [
                      "Cam manifest later in life with chronic respiratory symptoms"
                    ]
                  }
                ],
                "Autoimmune Hepatitis": [
                  {
                    "text": "Chronic autoimmune disease of liver"
                  },
                  {
                    "text": "Commonly shows positive ANA, SMA, and increased IgG"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Alport Syndrome": {
            "name": "Alport Syndrome",
            "url": "https://app.pathprimer.com/document/9e673ada-5ca5-439f-a1cf-7c4c30210b52/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "AS is hereditary disorder of type IV collagen affecting GBM and resulting in hematuria &/or proteinuria"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "X-linked (80%), autosomal recessive (15%), and autosomal dominant (1%-5%) forms"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Asymptomatic hematuria &/or proteinuria"
                  },
                  {
                    "text": "Progressive ﻿renal failure (males > females, XLAS > ARAS, ADAS)"
                  },
                  {
                    "text": "﻿Sensorineural hearing loss (80%)"
                  },
                  {
                    "text": "Various ﻿ocular abnormalities (20%)"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Renal biopsyLM often normal, interstitial foam cellsIF for α3 and α5 chains (loss of ≥ 1 antigens)EM shows thin and thick basement membranes, scalloping, lamellations",
                    "sub_points": [
                      "LM often normal, interstitial foam cells",
                      "IF for α3 and α5 chains (loss of ≥ 1 antigens)",
                      "EM shows thin and thick basement membranes, scalloping, lamellations"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Alport syndrome (AS)"
                  },
                  {
                    "text": "Glomerular basement membrane (GBM)"
                  },
                  {
                    "text": "X-linked Alport syndrome (XLAS)"
                  },
                  {
                    "text": "Online Mendelian Inheritance in Man (OMIM)"
                  },
                  {
                    "text": "Autosomal recessive Alport syndrome (ARAS)"
                  },
                  {
                    "text": "Autosomal dominant Alport syndrome (ADAS)"
                  },
                  {
                    "text": "End-stage renal disease (ESRD)"
                  },
                  {
                    "text": "Light microscopy (LM)"
                  },
                  {
                    "text": "Immunofluorescence (IF)"
                  },
                  {
                    "text": "Electron microscopy (EM)"
                  },
                  {
                    "text": "Thin basement membrane nephropathy (TBMN)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Hereditary nephritis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "AS: Hereditary disorder of type IV collagen affecting GBM and resulting in hematuria &/or proteinuria"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Alport Syndrome Is a Collagen IV α Chain Abnormality": [
                  {
                    "text": "Collagen IV is composed of α3, α4, and α5 chains"
                  },
                  {
                    "text": "AS is due to inherited or de novo mutations that disrupt expression or function of 1 of the α chains"
                  },
                  {
                    "text": "Collagen IV is expressed in renal glomeruli, cochlea, and eyeAbnormal collagen IV may lead to abnormalities in all structures in which it is expressed",
                    "sub_points": [
                      "Abnormal collagen IV may lead to abnormalities in all structures in which it is expressed"
                    ]
                  }
                ],
                "Inheritance": [
                  {
                    "text": "X-linked (80%), autosomal recessive (15%), and autosomal dominant (1%-5%) forms"
                  },
                  {
                    "text": "X-linked dominant (XLAS, OMIM 303630)Mutations in type IV collagen α5 chain gene are encoded on X chromosome (COL4A5, OMIM 301050)Males more often affected, more severely affected, and have earlier onset than femalesMutationsLarge and small deletionsMissense mutations",
                    "sub_points": [
                      "Mutations in type IV collagen α5 chain gene are encoded on X chromosome (COL4A5, OMIM 301050)",
                      "Males more often affected, more severely affected, and have earlier onset than females",
                      "MutationsLarge and small deletionsMissense mutations",
                      "Large and small deletions",
                      "Missense mutations"
                    ]
                  },
                  {
                    "text": "Autosomal recessive (ARAS, OMIM 203780)Mutations in type IV collagen α3 (OMIM 120070) and α4 (OMIM 120131)Males and females equally affectedMutationsLoss-of-functionMost are missense mutations",
                    "sub_points": [
                      "Mutations in type IV collagen α3 (OMIM 120070) and α4 (OMIM 120131)",
                      "Males and females equally affected",
                      "MutationsLoss-of-functionMost are missense mutations",
                      "Loss-of-function",
                      "Most are missense mutations"
                    ]
                  },
                  {
                    "text": "Autosomal dominant (ADAS, OMIM 104200)Mutations in type IV collagen α3 (COL4A3, OMIM 120070) and α4 chainsMales and females equally affectedMutationsDominant negative, different from those in ARASMissense mutationsSome small deletions",
                    "sub_points": [
                      "Mutations in type IV collagen α3 (COL4A3, OMIM 120070) and α4 chains",
                      "Males and females equally affected",
                      "MutationsDominant negative, different from those in ARASMissense mutationsSome small deletions",
                      "Dominant negative, different from those in ARAS",
                      "Missense mutations",
                      "Some small deletions"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Asymptomatic hematuria &/or proteinuria"
                  },
                  {
                    "text": "Progressive ﻿renal failure (males > females, XLAS > ARAS, ADAS)"
                  },
                  {
                    "text": "﻿Sensorineural hearing loss (80%)"
                  },
                  {
                    "text": "Various ﻿ocular abnormalities (20%)"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Renal transplant for ESRD5% risk of developing anti-GBM disease",
                    "sub_points": [
                      "5% risk of developing anti-GBM disease"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "May have normal LM"
                  },
                  {
                    "text": "Foam cells in interstitium"
                  },
                  {
                    "text": "Fetal type glomeruli"
                  },
                  {
                    "text": "Segmental glomerulosclerosis with timeGlobal glomerulosclerosis with advanced disease",
                    "sub_points": [
                      "Global glomerulosclerosis with advanced disease"
                    ]
                  },
                  {
                    "text": "Tubular atrophy and fibrosis over time"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunofluorescence": [
                  {
                    "text": "Routine IF is negativeIgG, IgM, IgA, C3, C1q, and fibrin are negativeMay have minimal granular mesangial IgM or C3",
                    "sub_points": [
                      "IgG, IgM, IgA, C3, C1q, and fibrin are negative",
                      "May have minimal granular mesangial IgM or C3"
                    ]
                  },
                  {
                    "text": "IF for collage IV α3 and α5 chainsCollagen composed of 3 α chains",
                    "sub_points": [
                      "Collagen composed of 3 α chains"
                    ]
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Thickening and thinning of basement membrane seen in AS on EMNormal GBM thickness 320-360 nm in adultsNormal range varies in children",
                    "sub_points": [
                      "Normal GBM thickness 320-360 nm in adults",
                      "Normal range varies in children"
                    ]
                  },
                  {
                    "text": "Layering/lamellation of basement membrane"
                  },
                  {
                    "text": "Subepithelial scalloping"
                  },
                  {
                    "text": "May show effacement of podocyte foot processes"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Thin Basement Membrane Nephropathy": [
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "Also due to mutations in α3 and α4 but different mutations than ASTBMN homozygotes may overlap with AS",
                    "sub_points": [
                      "TBMN homozygotes may overlap with AS"
                    ]
                  },
                  {
                    "text": "Normal LM and routine IF"
                  },
                  {
                    "text": "IF shows α3 and α5 remain intact"
                  },
                  {
                    "text": "Characterized by uniformly thin basement membranes (< 230 nm)"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Clinical history of kidney disease, hearing loss, ocular abnormalities"
                  },
                  {
                    "text": "Renal biopsyLMIF for α3 and α5 chainsEM",
                    "sub_points": [
                      "LM",
                      "IF for α3 and α5 chains",
                      "EM"
                    ]
                  },
                  {
                    "text": "Genetic testing for collagen IV chain mutations"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Charcot-Marie-Tooth Disease": {
            "name": "Charcot-Marie-Tooth Disease",
            "url": "https://app.pathprimer.com/document/85d9fc69-8196-43c8-8627-15b3be836ade/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "CMT is a group of noninflammatory, slowly progressive, inherited peripheral motor and sensory polyneuropathies with insidious onset"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "﻿Degenerative changes in axons or loss of myelin sheath﻿"
                  },
                  {
                    "text": "All types of inheritance patterns have been observed"
                  },
                  {
                    "text": "Variants in > 80 different genes/loci are causative, and more are suspected﻿"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "﻿Most common inherited neuromuscular disorder﻿"
                  },
                  {
                    "text": "﻿Symptoms are highly variable with some patients showing primarily motor symptoms, primarily sensory symptoms, or both﻿"
                  },
                  {
                    "text": "Patchy slowing on NCS is suggested by acquired demyelinating neuropathies but may be seen in demyelinating CMT"
                  },
                  {
                    "text": "Clinical history, physical examination, family history, and NCS are usually sufficient to establish diagnosis"
                  },
                  {
                    "text": "Arrays detect most common form of CMT, CMT1A, due to duplication in 17p12, which encompassesPMP22gene﻿"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Differential diagnosis is broad and includes hereditary and acquired neuropathies and myopathies"
                  },
                  {
                    "text": "Molecular testing can be used to confirm diagnosis but does not rule out diagnosis when no mutations are found (approximately 30% of cases)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Charcot-Marie-Tooth disease (CMT)"
                  },
                  {
                    "text": "Online Mendelian Inheritance in Man (IMIM)"
                  },
                  {
                    "text": "Nerve conduction study (NCS)"
                  },
                  {
                    "text": "Electromyography (EMG)"
                  },
                  {
                    "text": "Single nucleotide polymorphism (SNP)"
                  },
                  {
                    "text": "Comparative genomic hybridization (CGH)"
                  },
                  {
                    "text": "Adenosine triphosphatase (ATPase)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Charcot-Marie-Tooth neuropathy"
                  },
                  {
                    "text": "Hereditary motor and sensory neuropathy"
                  },
                  {
                    "text": "Hereditary neuropathy with liability to pressure palsies"
                  },
                  {
                    "text": "Peroneal muscular atrophy"
                  }
                ],
                "Definitions": [
                  {
                    "text": "CMT (OMIM PS118220, phenotypic series includes 69 entries): Group of noninflammatory, slowly progressive, inherited peripheral motor and sensory polyneuropathies with insidious onset"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Degeneration of Motor and Sensory Peripheral Nerves": [
                  {
                    "text": "Degenerative changes in axons or loss of myelin sheath"
                  }
                ],
                "Multiple Genes Known to Cause Charcot-Marie-Tooth Disease": [
                  {
                    "text": "Monogenetic disorder but very genetically heterogeneous"
                  },
                  {
                    "text": "69 CMT types noted in OMIM database"
                  },
                  {
                    "text": "Variants in > 80 different genes/loci are causativeMore are suspected",
                    "sub_points": [
                      "More are suspected"
                    ]
                  }
                ],
                "Inheritance": [
                  {
                    "text": "Most mutations are inheritedDe novo cases also reported",
                    "sub_points": [
                      "De novo cases also reported"
                    ]
                  },
                  {
                    "text": "All types of inheritance patterns have been observedAutosomal dominantMost commonAutosomal recessiveLeast commonX-linked recessiveX-linked dominant",
                    "sub_points": [
                      "Autosomal dominantMost common",
                      "Most common",
                      "Autosomal recessiveLeast common",
                      "Least common",
                      "X-linked recessive",
                      "X-linked dominant"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Most common inherited neuromuscular disorder"
                  },
                  {
                    "text": "Prevalence 1:2500"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Onset insidious in first or second decades but may be seen in adulthood."
                  },
                  {
                    "text": "Slowly progressive over many years"
                  },
                  {
                    "text": "Symptoms﻿Symmetric involvement﻿Progressive weakness﻿that begins distallyUsually in feetEventually involves lower legs, hands, and forearms, in that orderDifficulty runningFrequent tripping and ankle twistingLoss of touch sensationLoss of position senseTremorPainNeuropathicMusculoskeletalMuscle cramps",
                    "sub_points": [
                      "﻿Symmetric involvement﻿",
                      "Progressive weakness﻿that begins distallyUsually in feet",
                      "Usually in feet",
                      "Eventually involves lower legs, hands, and forearms, in that order",
                      "Difficulty running",
                      "Frequent tripping and ankle twisting",
                      "Loss of touch sensation",
                      "Loss of position sense",
                      "Tremor",
                      "PainNeuropathicMusculoskeletalMuscle cramps",
                      "Neuropathic",
                      "Musculoskeletal",
                      "Muscle cramps"
                    ]
                  },
                  {
                    "text": "Symptoms highly variableSome patients show primarily motor symptomsSome patients show primarily sensory symptomsSome patients show both motor and sensory symptoms",
                    "sub_points": [
                      "Some patients show primarily motor symptoms",
                      "Some patients show primarily sensory symptoms",
                      "Some patients show both motor and sensory symptoms"
                    ]
                  },
                  {
                    "text": "Physical examination findingsFindings attributable to motor neuropathyMarked muscle wastingTypically in distal distribution—feet, hands, lower legs, forearms\"Stork\" legs—thick thighs, thin calvesDistal weaknessClaw toe deformityDue to contracture of calvesPes cavusHigh plantar archClubfootCurled toesFootdropSteppage gaitCannot point toes upwardScoliosisFindings attributable to sensory neuropathyAbsent deep tendon reflexesLoss of touch sensationLoss of proprioceptionPositive Romberg signSensory ataxiaMay have palpable nerves",
                    "sub_points": [
                      "Findings attributable to motor neuropathyMarked muscle wastingTypically in distal distribution—feet, hands, lower legs, forearms\"Stork\" legs—thick thighs, thin calvesDistal weaknessClaw toe deformityDue to contracture of calvesPes cavusHigh plantar archClubfootCurled toesFootdropSteppage gaitCannot point toes upwardScoliosis",
                      "Marked muscle wastingTypically in distal distribution—feet, hands, lower legs, forearms\"Stork\" legs—thick thighs, thin calvesDistal weakness",
                      "Typically in distal distribution—feet, hands, lower legs, forearms",
                      "\"Stork\" legs—thick thighs, thin calves",
                      "Distal weakness",
                      "Claw toe deformityDue to contracture of calves",
                      "Due to contracture of calves",
                      "Pes cavusHigh plantar arch",
                      "High plantar arch",
                      "ClubfootCurled toes",
                      "Curled toes",
                      "FootdropSteppage gaitCannot point toes upward",
                      "Steppage gait",
                      "Cannot point toes upward",
                      "Scoliosis",
                      "Findings attributable to sensory neuropathyAbsent deep tendon reflexesLoss of touch sensationLoss of proprioceptionPositive Romberg signSensory ataxia",
                      "Absent deep tendon reflexes",
                      "Loss of touch sensation",
                      "Loss of proprioceptionPositive Romberg sign",
                      "Positive Romberg sign",
                      "Sensory ataxia",
                      "May have palpable nerves"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Clinical history, physical examination, family history, NCS usually sufficient to establish diagnosis"
                  },
                  {
                    "text": "NCSMeasures velocity of nerve impulses in m/sec﻿Demyelination results in decreased conduction velocities﻿Uniform slowing of action potentials along ulnar or median nerves (< 38 m/sec) consistent with demyelinating CMTPatchy slowing suggested by acquired demyelinating neuropathies but may be seen in some forms of demyelinating CMTLow amplitudes are seen with axonal loss, including in axonal-type CMTHelps distinguish axonal-type (> 38 m/sec) from demyelination-type CMT (< 38 m/sec)Intermediate CMT shows nerve conduction velocity between 25 m/sec and 45 m/secA normal nerve conduction study decreases the likelihood of a peripheral neuropathy (hereditary or otherwise)",
                    "sub_points": [
                      "Measures velocity of nerve impulses in m/sec",
                      "﻿Demyelination results in decreased conduction velocities﻿",
                      "Uniform slowing of action potentials along ulnar or median nerves (< 38 m/sec) consistent with demyelinating CMTPatchy slowing suggested by acquired demyelinating neuropathies but may be seen in some forms of demyelinating CMT",
                      "Patchy slowing suggested by acquired demyelinating neuropathies but may be seen in some forms of demyelinating CMT",
                      "Low amplitudes are seen with axonal loss, including in axonal-type CMT",
                      "Helps distinguish axonal-type (> 38 m/sec) from demyelination-type CMT (< 38 m/sec)",
                      "Intermediate CMT shows nerve conduction velocity between 25 m/sec and 45 m/sec",
                      "A normal nerve conduction study decreases the likelihood of a peripheral neuropathy (hereditary or otherwise)"
                    ]
                  },
                  {
                    "text": "EMGMay be useful in distinguishing distal myopathy from CMT",
                    "sub_points": [
                      "May be useful in distinguishing distal myopathy from CMT"
                    ]
                  },
                  {
                    "text": "Molecular testingMay be useful in some situationsConfirm diagnosis in equivocal casesConsidered after treatment failure for acquired neuropathyAssist in counseling proband and blood relatives for family planning, prenatal implantation diagnosis, and prenatal diagnosisCounseling should consider genotype-phenotype correlations, intrafamilial variability, and inheritance patternNot all genes have been identified.In 30% of patients, no mutations are identified in the characterized genes.Negative test does not exclude diagnosis of CMTTargeted sequencingNarrow panels available depending on inheritance pattern, clinical features, and NCS findingsBroad gene panels availableExome sequencing may be consideredArray (SNP array or array CGH)Detects most common form of CMT, CMT1A, due to duplication in 17p12, which encompassesPMP22geneDeletion of same locus causes hereditary neuropathy with liability to pressure palsiesWhole-exome sequencing",
                    "sub_points": [
                      "May be useful in some situationsConfirm diagnosis in equivocal casesConsidered after treatment failure for acquired neuropathyAssist in counseling proband and blood relatives for family planning, prenatal implantation diagnosis, and prenatal diagnosisCounseling should consider genotype-phenotype correlations, intrafamilial variability, and inheritance pattern",
                      "Confirm diagnosis in equivocal cases",
                      "Considered after treatment failure for acquired neuropathy",
                      "Assist in counseling proband and blood relatives for family planning, prenatal implantation diagnosis, and prenatal diagnosisCounseling should consider genotype-phenotype correlations, intrafamilial variability, and inheritance pattern",
                      "Counseling should consider genotype-phenotype correlations, intrafamilial variability, and inheritance pattern",
                      "Not all genes have been identified.In 30% of patients, no mutations are identified in the characterized genes.Negative test does not exclude diagnosis of CMT",
                      "In 30% of patients, no mutations are identified in the characterized genes.",
                      "Negative test does not exclude diagnosis of CMT",
                      "Targeted sequencingNarrow panels available depending on inheritance pattern, clinical features, and NCS findingsBroad gene panels available",
                      "Narrow panels available depending on inheritance pattern, clinical features, and NCS findings",
                      "Broad gene panels available",
                      "Exome sequencing may be considered",
                      "Array (SNP array or array CGH)Detects most common form of CMT, CMT1A, due to duplication in 17p12, which encompassesPMP22geneDeletion of same locus causes hereditary neuropathy with liability to pressure palsies",
                      "Detects most common form of CMT, CMT1A, due to duplication in 17p12, which encompassesPMP22gene",
                      "Deletion of same locus causes hereditary neuropathy with liability to pressure palsies",
                      "Whole-exome sequencing"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Progressively debilitating"
                  },
                  {
                    "text": "Marked variability depending on specific type of CMT"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Muscle Biopsy": [
                  {
                    "text": "Muscle fiber groupingType I and type II fibers may be identified by histochemical detection of ATPaseFibers usually randomly positioned resulting in \"checkerboard\" appearance by this methodWith repeated innervation-denervation, fiber types become grouped, and \"checkerboard\" pattern is lost﻿This nonspecific finding may be seen in various other conditions",
                    "sub_points": [
                      "Type I and type II fibers may be identified by histochemical detection of ATPaseFibers usually randomly positioned resulting in \"checkerboard\" appearance by this method",
                      "Fibers usually randomly positioned resulting in \"checkerboard\" appearance by this method",
                      "With repeated innervation-denervation, fiber types become grouped, and \"checkerboard\" pattern is lost﻿",
                      "This nonspecific finding may be seen in various other conditions"
                    ]
                  }
                ],
                "Nerve Biopsy": [
                  {
                    "text": "May help distinguish from inflammatory (acquired) neuropathy, as CMT is noninflammatory neuropathy"
                  },
                  {
                    "text": "Rarely needed"
                  }
                ],
                "Magnetic Resonance Imaging of Nerve Roots": [
                  {
                    "text": "Often thickened in inflammatory neuropathies but rarely in hereditary neuropathies"
                  }
                ],
                "Cerebrospinal Fluid Protein": [
                  {
                    "text": "Often increased (usually > 2g/L) in inflammatory neuropathies"
                  },
                  {
                    "text": "May or may not be increased in hereditary neuropathies (if so > 1g/L but not more than 2g/L), including CMT"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Other Causes of Neuropathies and Myopathies": [
                  {
                    "text": "Differential diagnosis is broadIncludes hereditary and acquired neuropathies and myopathies",
                    "sub_points": [
                      "Includes hereditary and acquired neuropathies and myopathies"
                    ]
                  },
                  {
                    "text": "Inheritance pattern, physical examination findings, clinical history, and NCS usually sufficient for clinical diagnosis"
                  },
                  {
                    "text": "Presence of systemic symptoms is uncharacteristic of CMTMore common in inflammatory neuropathies",
                    "sub_points": [
                      "More common in inflammatory neuropathies"
                    ]
                  },
                  {
                    "text": "Molecular testing can be used to confirm diagnosis but does not rule out diagnosis when no mutations are found (approximately 30% of cases)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Congenital Hearing Loss": {
            "name": "Congenital Hearing Loss",
            "url": "https://app.pathprimer.com/document/619dd589-5ce1-417d-88a1-d59bdb4110c4/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Congenital HL is HL present at birth"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "All modes of inheritance of nonsyndromic HL have been identified"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most common congenital abnormality in developed nations"
                  },
                  {
                    "text": "> 50% of congenital HL is inherited"
                  },
                  {
                    "text": "70% of inherited HL is nonsyndromic HL, and 30% is syndromic HL"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "InfectionCongenital CMV is most common environmental cause of congenital HL﻿Congenital rubella was previously most common cause before advent of vaccineCongenital HIV",
                    "sub_points": [
                      "Congenital CMV is most common environmental cause of congenital HL﻿",
                      "Congenital rubella was previously most common cause before advent of vaccine",
                      "Congenital HIV"
                    ]
                  },
                  {
                    "text": "Trauma"
                  },
                  {
                    "text": "Medications—aminoglycoside antibiotics﻿"
                  },
                  {
                    "text": "Prematurity"
                  },
                  {
                    "text": "Age-related HL (presbycusis)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hearing loss (HL)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  },
                  {
                    "text": "Cytomegalovirus (CMV)"
                  },
                  {
                    "text": "Human immunodeficiency virus (HIV)"
                  },
                  {
                    "text": "Computed tomography (CT)"
                  },
                  {
                    "text": "Online Mendelian Inheritance in Man (OMIM)"
                  },
                  {
                    "text": "American College of Medical Genetics (ACMG)"
                  },
                  {
                    "text": "Auditory brainstem response (ABR)"
                  },
                  {
                    "text": "Evoked otoacoustic emissions (EOAE)"
                  },
                  {
                    "text": "Comparative genomic hybridization (CGH)"
                  },
                  {
                    "text": "Single nucleotide polymorphism (SNP)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Hearing impairment"
                  },
                  {
                    "text": "DeafnessNonmedical term for variable degrees of HL",
                    "sub_points": [
                      "Nonmedical term for variable degrees of HL"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "Congenital HL: HL present at birth or developing in early childhood"
                  },
                  {
                    "text": "Syndromic HL: Inherited HL with associated malformations/anomalies of external ear or other organs"
                  },
                  {
                    "text": "Nonsyndromic HL: Inherited isolated HL"
                  },
                  {
                    "text": "Prelingual HL: HL before language development (typically before age 5 yr)"
                  },
                  {
                    "text": "Postlingual HL: HL after language development"
                  },
                  {
                    "text": "Conductive HL: HL attributable to outer and middle ear abnormality"
                  },
                  {
                    "text": "Sensorineural HL: HL due to inner ear, auditory nerve, or CNS abnormality"
                  },
                  {
                    "text": "Mixed HL: HL with sensorineural and conductive components"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Developmental Anomaly": [
                  {
                    "text": "Mondini malformation accounts for 20% of congenital HLNormal cochlea has 2.5 turnsMondini malformation has 1.5 turnsUnilateral cases usually not inheritedBilateral cases usually inherited",
                    "sub_points": [
                      "Normal cochlea has 2.5 turnsMondini malformation has 1.5 turns",
                      "Mondini malformation has 1.5 turns",
                      "Unilateral cases usually not inheritedBilateral cases usually inherited",
                      "Bilateral cases usually inherited"
                    ]
                  }
                ],
                "Environmental Exposure": [
                  {
                    "text": "MedicationsAminoglycosidesCyclophosphamide",
                    "sub_points": [
                      "Aminoglycosides",
                      "Cyclophosphamide"
                    ]
                  },
                  {
                    "text": "Loud noise"
                  },
                  {
                    "text": "Head trauma"
                  },
                  {
                    "text": "Birth injury"
                  },
                  {
                    "text": "Prematurity"
                  },
                  {
                    "text": "ToxinsMaternal alcohol and drug use",
                    "sub_points": [
                      "Maternal alcohol and drug use"
                    ]
                  },
                  {
                    "text": "Toxemia of pregnancy (Preeclampsia/Eclampsia)"
                  },
                  {
                    "text": "Maternal diabetes"
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "VirusesCMVRubella virusHIV",
                    "sub_points": [
                      "CMV",
                      "Rubella virus",
                      "HIV"
                    ]
                  },
                  {
                    "text": "BacteriaNeisseria meningitidisStreptococcus pneumoniaeHaemophilus influenzaeTreponema pallidum",
                    "sub_points": [
                      "Neisseria meningitidis",
                      "Streptococcus pneumoniae",
                      "Haemophilus influenzae",
                      "Treponema pallidum"
                    ]
                  },
                  {
                    "text": "ParasitesToxoplasma gondii",
                    "sub_points": [
                      "Toxoplasma gondii"
                    ]
                  }
                ],
                "Genetics": [
                  {
                    "text": "50% of HL genetically inherited﻿Mutations in > 400 genes involved in various functions of auditory systemGenes expressed in cochlear hair cells, supporting cells, auditory nerve, extracellular matrixCell adhesion (extracellular matrix and cell junctions)Cell structure (cytoskeleton)Ion transport (membrane potential)Intercellular electrical/metabolic communication (gap junctions)Transcription factors (developmental)",
                    "sub_points": [
                      "Mutations in > 400 genes involved in various functions of auditory system",
                      "Genes expressed in cochlear hair cells, supporting cells, auditory nerve, extracellular matrixCell adhesion (extracellular matrix and cell junctions)Cell structure (cytoskeleton)Ion transport (membrane potential)Intercellular electrical/metabolic communication (gap junctions)Transcription factors (developmental)",
                      "Cell adhesion (extracellular matrix and cell junctions)",
                      "Cell structure (cytoskeleton)",
                      "Ion transport (membrane potential)",
                      "Intercellular electrical/metabolic communication (gap junctions)",
                      "Transcription factors (developmental)"
                    ]
                  },
                  {
                    "text": "Nonsyndromic HL﻿70% of inherited HL﻿Associated with mutations in > 100 known genes",
                    "sub_points": [
                      "﻿70% of inherited HL﻿",
                      "Associated with mutations in > 100 known genes"
                    ]
                  },
                  {
                    "text": "Syndromic HL﻿30% of inherited HL﻿Associated with mutations in > 300 genes",
                    "sub_points": [
                      "﻿30% of inherited HL﻿",
                      "Associated with mutations in > 300 genes"
                    ]
                  },
                  {
                    "text": "Nonsyndromic and syndromic HL show all patterns of inheritance"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Most common congenital abnormality in developed nations"
                  },
                  {
                    "text": "1-3:1000 live births"
                  },
                  {
                    "text": "Incidence of HL in the general population increases with age"
                  }
                ],
                "Presentation": [
                  {
                    "text": "HL impairs speech, language, and learningEarly detection is key to preventing delay in learningPossible lifelong consequencesSocial isolationUnemployment",
                    "sub_points": [
                      "Early detection is key to preventing delay in learning",
                      "Possible lifelong consequencesSocial isolationUnemployment",
                      "Social isolation",
                      "Unemployment"
                    ]
                  },
                  {
                    "text": "50% genetically inheritedApproximately 75% autosomal recessiveApproximately 15% autosomal dominantApproximately 10% X-linkedMitochondrial inheritance least common",
                    "sub_points": [
                      "Approximately 75% autosomal recessive",
                      "Approximately 15% autosomal dominant",
                      "Approximately 10% X-linked",
                      "Mitochondrial inheritance least common"
                    ]
                  },
                  {
                    "text": "Nonsyndromic HLSome ability to distinguish different types based onInheritance patternGenotype-phenotype correlationsAge of onsetSeverity of HLHigh-, intermediate-, or low-frequency sound most impactedConductive, sensorineural, or mixedTemporal bone CT findingsAll modes of inheritance identified in nonsyndromic HLAutosomal dominant (DFNA, 15%)51 OMIM entriesAutosomal recessive (DFNB, 80%)84 OMIM entriesX-linked (DFNX, approximately 1%)6 OMIM entriesMitochondrial (approximately 1%)1 OMIM entry",
                    "sub_points": [
                      "Some ability to distinguish different types based onInheritance patternGenotype-phenotype correlationsAge of onsetSeverity of HLHigh-, intermediate-, or low-frequency sound most impactedConductive, sensorineural, or mixedTemporal bone CT findings",
                      "Inheritance pattern",
                      "Genotype-phenotype correlationsAge of onsetSeverity of HLHigh-, intermediate-, or low-frequency sound most impactedConductive, sensorineural, or mixedTemporal bone CT findings",
                      "Age of onset",
                      "Severity of HL",
                      "High-, intermediate-, or low-frequency sound most impacted",
                      "Conductive, sensorineural, or mixed",
                      "Temporal bone CT findings",
                      "All modes of inheritance identified in nonsyndromic HLAutosomal dominant (DFNA, 15%)51 OMIM entriesAutosomal recessive (DFNB, 80%)84 OMIM entriesX-linked (DFNX, approximately 1%)6 OMIM entriesMitochondrial (approximately 1%)1 OMIM entry",
                      "Autosomal dominant (DFNA, 15%)51 OMIM entries",
                      "51 OMIM entries",
                      "Autosomal recessive (DFNB, 80%)84 OMIM entries",
                      "84 OMIM entries",
                      "X-linked (DFNX, approximately 1%)6 OMIM entries",
                      "6 OMIM entries",
                      "Mitochondrial (approximately 1%)1 OMIM entry",
                      "1 OMIM entry"
                    ]
                  },
                  {
                    "text": "Syndromic HLAll entities are characterized by HL and abnormality of outer ear &/or another organDiagnosis can be made in many cases by clinical correlation with other featuresAt birth, associated clinical findings may be absent or subtlePendred syndrome and Usher syndrome are examples (see table)Clinical diagnosis is difficultACMG recommends that all neonates and children with idiopathic HL be evaluated by clinical geneticist for syndromic HL",
                    "sub_points": [
                      "All entities are characterized by HL and abnormality of outer ear &/or another organ",
                      "Diagnosis can be made in many cases by clinical correlation with other featuresAt birth, associated clinical findings may be absent or subtlePendred syndrome and Usher syndrome are examples (see table)Clinical diagnosis is difficultACMG recommends that all neonates and children with idiopathic HL be evaluated by clinical geneticist for syndromic HL",
                      "At birth, associated clinical findings may be absent or subtlePendred syndrome and Usher syndrome are examples (see table)Clinical diagnosis is difficult",
                      "Pendred syndrome and Usher syndrome are examples (see table)",
                      "Clinical diagnosis is difficult",
                      "ACMG recommends that all neonates and children with idiopathic HL be evaluated by clinical geneticist for syndromic HL"
                    ]
                  },
                  {
                    "text": "Hearing testsNewborn hearing screeningMandated by law in every US stateEarly detection and intervention positively impacts language and learningTests may be performed at any age and are noninvasive and objectiveABR measures neural response to sound using skin surface electrodesEOAE measures sound produced by movements of hair cells using transducers inserted in ear canalOften used together in 2-stage screening processAbnormal ABR and normal EOAE suggest auditory nerve or CNS disorderAbnormal ABR and EOAE suggest cochlear disorderMultiple other noninvasive tests are available to assess different portions of auditory anatomy and functionAudiometryDifferent versions use various sound stimuli and measure behaviorsPatient's response (heard vs. not heard)Changes in behaviorInitial evaluationAssess severity to determine if intervention is warrantedEstablish baseline HLMonitoringProper intervention when HL begins to impair functioningIdentify treatable superimposed causes of HLHelp distinguish conductive and sensorineural HL",
                    "sub_points": [
                      "Newborn hearing screeningMandated by law in every US stateEarly detection and intervention positively impacts language and learningTests may be performed at any age and are noninvasive and objectiveABR measures neural response to sound using skin surface electrodesEOAE measures sound produced by movements of hair cells using transducers inserted in ear canalOften used together in 2-stage screening processAbnormal ABR and normal EOAE suggest auditory nerve or CNS disorderAbnormal ABR and EOAE suggest cochlear disorderMultiple other noninvasive tests are available to assess different portions of auditory anatomy and function",
                      "Mandated by law in every US state",
                      "Early detection and intervention positively impacts language and learning",
                      "Tests may be performed at any age and are noninvasive and objectiveABR measures neural response to sound using skin surface electrodesEOAE measures sound produced by movements of hair cells using transducers inserted in ear canalOften used together in 2-stage screening process",
                      "ABR measures neural response to sound using skin surface electrodes",
                      "EOAE measures sound produced by movements of hair cells using transducers inserted in ear canal",
                      "Often used together in 2-stage screening process",
                      "Abnormal ABR and normal EOAE suggest auditory nerve or CNS disorder",
                      "Abnormal ABR and EOAE suggest cochlear disorder",
                      "Multiple other noninvasive tests are available to assess different portions of auditory anatomy and function",
                      "AudiometryDifferent versions use various sound stimuli and measure behaviorsPatient's response (heard vs. not heard)Changes in behaviorInitial evaluationAssess severity to determine if intervention is warrantedEstablish baseline HLMonitoringProper intervention when HL begins to impair functioningIdentify treatable superimposed causes of HLHelp distinguish conductive and sensorineural HL",
                      "Different versions use various sound stimuli and measure behaviorsPatient's response (heard vs. not heard)Changes in behavior",
                      "Patient's response (heard vs. not heard)",
                      "Changes in behavior",
                      "Initial evaluationAssess severity to determine if intervention is warrantedEstablish baseline HL",
                      "Assess severity to determine if intervention is warranted",
                      "Establish baseline HL",
                      "MonitoringProper intervention when HL begins to impair functioningIdentify treatable superimposed causes of HL",
                      "Proper intervention when HL begins to impair functioning",
                      "Identify treatable superimposed causes of HL",
                      "Help distinguish conductive and sensorineural HL"
                    ]
                  },
                  {
                    "text": "ACMG guidelinesEssential initial stepsClinical historyPhysical examinationFamily historyAudiometryIf acquired etiology is suspectedImaging and laboratory (e.g., CMV, rubella) confirmation is requiredIf acquired etiology is not confirmedorif genetic etiology is consideredMolecular testing should be performed",
                    "sub_points": [
                      "Essential initial stepsClinical historyPhysical examinationFamily historyAudiometry",
                      "Clinical history",
                      "Physical examination",
                      "Family history",
                      "Audiometry",
                      "If acquired etiology is suspectedImaging and laboratory (e.g., CMV, rubella) confirmation is required",
                      "Imaging and laboratory (e.g., CMV, rubella) confirmation is required",
                      "If acquired etiology is not confirmedorif genetic etiology is consideredMolecular testing should be performed",
                      "Molecular testing should be performed"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Molecular testingConfirm genetic etiologyAid in genetic counselingRecurrence riskRisk to family membersGenotype-phenotype correlations may allow prognostication of HLFor syndromic HL, targeted sequencing of specific genes is possibleAlgorithmic testing of specific genes is possible for nonsyndromic HL based onClinical historyInheritance patternAudiometry findingsPopulation-specific frequency of mutationsMultiple next-generation sequencing panels of various sizes are available to test for syndromic &/or nonsyndromic HLDeletions and duplications ofGJB2,GJB3,GJB6,POU3F4, andWFS1can be detected by array CGH or SNP arraysWhole-exome or whole-genome sequencing may be considered",
                    "sub_points": [
                      "Confirm genetic etiology",
                      "Aid in genetic counselingRecurrence riskRisk to family members",
                      "Recurrence risk",
                      "Risk to family members",
                      "Genotype-phenotype correlations may allow prognostication of HL",
                      "For syndromic HL, targeted sequencing of specific genes is possible",
                      "Algorithmic testing of specific genes is possible for nonsyndromic HL based onClinical historyInheritance patternAudiometry findingsPopulation-specific frequency of mutations",
                      "Clinical history",
                      "Inheritance pattern",
                      "Audiometry findings",
                      "Population-specific frequency of mutations",
                      "Multiple next-generation sequencing panels of various sizes are available to test for syndromic &/or nonsyndromic HL",
                      "Deletions and duplications ofGJB2,GJB3,GJB6,POU3F4, andWFS1can be detected by array CGH or SNP arrays",
                      "Whole-exome or whole-genome sequencing may be considered"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Hearing aid"
                  },
                  {
                    "text": "Cochlear implant"
                  },
                  {
                    "text": "Otologic surgery to correct conductive problems"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "HL is usually bilateral and progressive when genetically inherited"
                  },
                  {
                    "text": "Nonsyndromic HL is not life-threateningHas implications for social and occupational functioning in adulthood",
                    "sub_points": [
                      "Has implications for social and occupational functioning in adulthood"
                    ]
                  },
                  {
                    "text": "Syndromic HL has variable prognosis depending on particular syndrome"
                  }
                ]
              },
              "IMAGING": {
                "CT Findings": [
                  {
                    "text": "Temporal bone CT scanMondini malformation (a cochlea with an incomplete number of turns).Michel aplasia (bilateral absence of differentiated inner ear structures)Dilated vestibular aqueductDilation of internal auditory canal",
                    "sub_points": [
                      "Mondini malformation (a cochlea with an incomplete number of turns).",
                      "Michel aplasia (bilateral absence of differentiated inner ear structures)",
                      "Dilated vestibular aqueduct",
                      "Dilation of internal auditory canal"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Exclude Acquired Causes": [
                  {
                    "text": "InfectionsCongenital CMVMost common environmental cause of congenital HL﻿Only 10% of infants with CMV infection are symptomaticTesting to rule out CMV is indicated in congenital HLNegative test excludes CMVPositive test does not establish causation of HL if CMV was acquired postnatallyCongenital rubellaPreviously most common cause before advent of vaccineCongenital HIV",
                    "sub_points": [
                      "Congenital CMVMost common environmental cause of congenital HL﻿Only 10% of infants with CMV infection are symptomaticTesting to rule out CMV is indicated in congenital HLNegative test excludes CMVPositive test does not establish causation of HL if CMV was acquired postnatally",
                      "Most common environmental cause of congenital HL﻿",
                      "Only 10% of infants with CMV infection are symptomatic",
                      "Testing to rule out CMV is indicated in congenital HL",
                      "Negative test excludes CMV",
                      "Positive test does not establish causation of HL if CMV was acquired postnatally",
                      "Congenital rubellaPreviously most common cause before advent of vaccine",
                      "Previously most common cause before advent of vaccine",
                      "Congenital HIV"
                    ]
                  },
                  {
                    "text": "Prematurity"
                  },
                  {
                    "text": "Trauma"
                  },
                  {
                    "text": "Noise"
                  },
                  {
                    "text": "MedicationsAminoglycoside antibiotics",
                    "sub_points": [
                      "Aminoglycoside antibiotics"
                    ]
                  },
                  {
                    "text": "Age-related HL (presbycusis)Genetic and environmental factors play a role",
                    "sub_points": [
                      "Genetic and environmental factors play a role"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cystic Fibrosis": {
            "name": "Cystic Fibrosis",
            "url": "https://app.pathprimer.com/document/85996612-c8d9-4159-b4cb-c7eaf8addbf0/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Autosomal recessive disorder characterized by abnormal electrolyte transport, leading to thick mucus production, chronic obstruction, recurrent infections, and progressive destruction of airways"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Abnormal function of cystic fibrosis transmembrane conductance regulator (CFTR) gene localized on chromosome 7q31.2"
                  },
                  {
                    "text": "F508del most common mutation (70% of cases)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most common lethal hereditary disease in Caucasians"
                  },
                  {
                    "text": "Caucasians of northern European origin: 1:3,200 live births"
                  },
                  {
                    "text": "~ 2-4% of population must be heterozygous carriers"
                  },
                  {
                    "text": "Chloride secretion sweat test shows ≥ 60 mEq/L"
                  }
                ],
                "Macroscopic": [
                  {
                    "text": "Lesions are more prominent in upper lobes"
                  },
                  {
                    "text": "Widespread bronchiectasis with purulent plugs"
                  },
                  {
                    "text": "Focal/widespread pneumonic consolidation"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Widespread bronchiectasis/bronchiolectasis"
                  },
                  {
                    "text": "Purulent mucus plugging"
                  },
                  {
                    "text": "Acute and chronic bronchitis/bronchiolitis"
                  },
                  {
                    "text": "Epithelial sloughing/metaplasia"
                  },
                  {
                    "text": "Bronchial gland hypertrophy (increased Reid index)"
                  },
                  {
                    "text": "Acute organizing/organized pneumonia"
                  },
                  {
                    "text": "Abscesses"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Cystic fibrosis (CF)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Mucoviscidosis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Autosomal recessive disorder characterized by abnormal electrolyte transport, leading to thick mucus production, chronic obstruction, recurrent infections, and progressive destruction of airways"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetic Disorder": [
                  {
                    "text": "Autosomal recessive"
                  },
                  {
                    "text": "Abnormal function of cystic fibrosis transmembrane conductance regulator (CFTR) gene localized on 7q31.2CFTRinvolved in chloride transportGenetic heterogeneity with > 1,900 known mutations, but number of true disease-causing mutations may be lowerF508del (deletion of 3 bases coding for phenylalanine at the 508th position) most common mutation (70% of cases)G551D mutation: 5%",
                    "sub_points": [
                      "CFTRinvolved in chloride transport",
                      "Genetic heterogeneity with > 1,900 known mutations, but number of true disease-causing mutations may be lowerF508del (deletion of 3 bases coding for phenylalanine at the 508th position) most common mutation (70% of cases)G551D mutation: 5%",
                      "F508del (deletion of 3 bases coding for phenylalanine at the 508th position) most common mutation (70% of cases)",
                      "G551D mutation: 5%"
                    ]
                  },
                  {
                    "text": "Mutations have been grouped in 6 classesClass ILarge deletions and stop codon mutations resulting in truncated and mostly nonfunctional CFTR or complete absence of CFTRClass IIAberrantly folded CFTR protein that is degraded before reaching cell surface, causing absence of mature CFTR at apical cell membrane; includes common F508del mutationClass IIIFull-length CFTR protein is incorporated into cell membrane but has defective regulation with no CFTR functionClass IVChannels have defective chloride conductanceClass VDysregulated transcription, resulting in decreased amount of otherwise normal CFTRClass VIDecreased stability of CFTR with altered regulation of separate ion channels",
                    "sub_points": [
                      "Class ILarge deletions and stop codon mutations resulting in truncated and mostly nonfunctional CFTR or complete absence of CFTR",
                      "Large deletions and stop codon mutations resulting in truncated and mostly nonfunctional CFTR or complete absence of CFTR",
                      "Class IIAberrantly folded CFTR protein that is degraded before reaching cell surface, causing absence of mature CFTR at apical cell membrane; includes common F508del mutation",
                      "Aberrantly folded CFTR protein that is degraded before reaching cell surface, causing absence of mature CFTR at apical cell membrane; includes common F508del mutation",
                      "Class IIIFull-length CFTR protein is incorporated into cell membrane but has defective regulation with no CFTR function",
                      "Full-length CFTR protein is incorporated into cell membrane but has defective regulation with no CFTR function",
                      "Class IVChannels have defective chloride conductance",
                      "Channels have defective chloride conductance",
                      "Class VDysregulated transcription, resulting in decreased amount of otherwise normal CFTR",
                      "Dysregulated transcription, resulting in decreased amount of otherwise normal CFTR",
                      "Class VIDecreased stability of CFTR with altered regulation of separate ion channels",
                      "Decreased stability of CFTR with altered regulation of separate ion channels"
                    ]
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Abnormal chloride and HCO₃⁻ transport"
                  },
                  {
                    "text": "Excessive absorption of chloride and water from secretions"
                  },
                  {
                    "text": "Defective CFTR-dependent HCO₃⁻ secretion"
                  },
                  {
                    "text": "Production of thick, viscous mucus with abnormal physicochemical qualities, favoring luminal accumulation in airways and other locations that become secondarily infectedRepeated infections lead to airway destruction",
                    "sub_points": [
                      "Repeated infections lead to airway destruction"
                    ]
                  },
                  {
                    "text": "Hypersalinity of bronchial fluid impairs antibacterial actions of constituents such as lactoferrin, lysozyme"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Most common lethal hereditary disease in Caucasians"
                  },
                  {
                    "text": "Caucasians of northern European origin: 1:3,200 live births"
                  },
                  {
                    "text": "African Americans: 1:17,000 live births"
                  },
                  {
                    "text": "Hispanics: 1:9,200 live births"
                  },
                  {
                    "text": "Asian Americans 1:31,000 live births"
                  },
                  {
                    "text": "~ 2-4% of population must be heterozygous carriers"
                  }
                ],
                "Age": [
                  {
                    "text": "Fetus to young adult"
                  },
                  {
                    "text": "Most cases are diagnosed during 1st year of life"
                  },
                  {
                    "text": "Mean age at diagnosis: 3 years of age"
                  }
                ],
                "Sex": [
                  {
                    "text": "No gender predilection"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Highest prevalence in Caucasians of northern European origin"
                  }
                ],
                "Site": [
                  {
                    "text": "Multisystemic disorder involvingLung and upper respiratory airwaysPancreasGastrointestinal systemHepatobiliary systemGenitourinary system",
                    "sub_points": [
                      "Lung and upper respiratory airways",
                      "Pancreas",
                      "Gastrointestinal system",
                      "Hepatobiliary system",
                      "Genitourinary system"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Wheezing"
                  },
                  {
                    "text": "Chronic cough"
                  },
                  {
                    "text": "Recurrent or chronic respiratory tract infections"
                  },
                  {
                    "text": "Atelectasis"
                  },
                  {
                    "text": "Hemoptysis"
                  },
                  {
                    "text": "Progressive respiratory failure"
                  },
                  {
                    "text": "Digital clubbing"
                  },
                  {
                    "text": "Failure to thrive"
                  },
                  {
                    "text": "Pansinusitis and nasal polyps"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Early diagnosis by neonatal screening"
                  },
                  {
                    "text": "Chloride secretion sweat test shows ≥ 60 mEq/L"
                  },
                  {
                    "text": "Chromosome analysis and sequence may be required"
                  },
                  {
                    "text": "Lung function studies demonstrate obstructive pattern"
                  },
                  {
                    "text": "Sputum cultures are necessary to determine type of bacterial infectionBacterial infections are common and caused byStaphylococcus aureus(% of positive individuals has decreased)Haemophilus influenzaPseudomonas aeruginosa(60-90% of patients are colonized)Burkholderia cepaciaEnterobacteria may also be identified",
                    "sub_points": [
                      "Bacterial infections are common and caused byStaphylococcus aureus(% of positive individuals has decreased)Haemophilus influenzaPseudomonas aeruginosa(60-90% of patients are colonized)Burkholderia cepaciaEnterobacteria may also be identified",
                      "Staphylococcus aureus(% of positive individuals has decreased)",
                      "Haemophilus influenza",
                      "Pseudomonas aeruginosa(60-90% of patients are colonized)",
                      "Burkholderia cepacia",
                      "Enterobacteria may also be identified"
                    ]
                  }
                ],
                "Treatment": [],
                "Options, risks, complications": [
                  {
                    "text": "Intensive follow-up and treatment in specialized CF centers play important role in patient survivalRespiratory therapy and postural drainage",
                    "sub_points": [
                      "Respiratory therapy and postural drainage"
                    ]
                  },
                  {
                    "text": "Respiratory complications includeHyperreactive airwaysAtelectasisPneumothoraxHemoptysisAllergic bronchopulmonary aspergillosisAcute/chronic respiratory failureCor pulmonale",
                    "sub_points": [
                      "Hyperreactive airways",
                      "Atelectasis",
                      "Pneumothorax",
                      "Hemoptysis",
                      "Allergic bronchopulmonary aspergillosis",
                      "Acute/chronic respiratory failure",
                      "Cor pulmonale"
                    ]
                  }
                ],
                "Surgical approaches": [
                  {
                    "text": "Lung transplantation for end-stage lung disease"
                  }
                ],
                "Drugs": [
                  {
                    "text": "Bronchodilators"
                  },
                  {
                    "text": "Inhaled steroids"
                  },
                  {
                    "text": "Prophylactic antibiotics"
                  },
                  {
                    "text": "Mucolytics"
                  },
                  {
                    "text": "Aerosolized rhDNase"
                  },
                  {
                    "text": "Ion transport modulators"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Improved life expectancy, but life span is shortened"
                  },
                  {
                    "text": "Most fatalities related to progressive lung disease"
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Early: Hyperinflation &/or lobar atelectasis, increased perihilar markings"
                  },
                  {
                    "text": "LaterUpper lobe predominant bronchiectasisMultiple small, ill-defined opacities in peripheral lung; persistent atelectasisPneumonia (recurrent)Pulmonary artery enlargementAdenopathy from chronic infections",
                    "sub_points": [
                      "Upper lobe predominant bronchiectasis",
                      "Multiple small, ill-defined opacities in peripheral lung; persistent atelectasis",
                      "Pneumonia (recurrent)",
                      "Pulmonary artery enlargement",
                      "Adenopathy from chronic infections"
                    ]
                  }
                ],
                "CT Findings": [
                  {
                    "text": "Better technique to detect bronchiectasis (cylindrical, varicose, and saccular)"
                  },
                  {
                    "text": "V- or Y- shaped opacities (tree in bud appearance) due to secretions within peripheral small centrilobular bronchioles"
                  },
                  {
                    "text": "Expiration high-resolution CT demonstrates small airway disease (mosaic pattern)"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Lesions more prominent in upper lobes"
                  },
                  {
                    "text": "Bronchial wall thickening, with granulation tissue and fibrosis"
                  },
                  {
                    "text": "Widespread bronchiectasis with purulent plugs"
                  },
                  {
                    "text": "Lobar atelectasis/overdistention"
                  },
                  {
                    "text": "Focal/widespread pneumonic consolidation"
                  },
                  {
                    "text": "Abscesses"
                  },
                  {
                    "text": "Cystic changes: Bronchiectatic, interstitial air, emphysematous bullae"
                  },
                  {
                    "text": "Pleural adhesions and fibrosis"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Large/small airwaysWidespread bronchiectasis/bronchiolectasisPurulent mucus pluggingAcute and chronic bronchitis/bronchiolitisEpithelial sloughing/metaplasiaSubmucosal gland inspissation of secretionBronchostenosisBronchial gland hypertrophy (increased Reid index)Goblet cell hyperplasiaPeribronchiolar scarring",
                    "sub_points": [
                      "Widespread bronchiectasis/bronchiolectasis",
                      "Purulent mucus plugging",
                      "Acute and chronic bronchitis/bronchiolitis",
                      "Epithelial sloughing/metaplasia",
                      "Submucosal gland inspissation of secretion",
                      "Bronchostenosis",
                      "Bronchial gland hypertrophy (increased Reid index)",
                      "Goblet cell hyperplasia",
                      "Peribronchiolar scarring"
                    ]
                  },
                  {
                    "text": "Alveolar/parenchymalAcute organizing/organized pneumoniaAbscessesEmphysema/air trappingSeptal fibrosisInterstitial fibrosisInterstitial inflammatory infiltrate",
                    "sub_points": [
                      "Acute organizing/organized pneumonia",
                      "Abscesses",
                      "Emphysema/air trapping",
                      "Septal fibrosis",
                      "Interstitial fibrosis",
                      "Interstitial inflammatory infiltrate"
                    ]
                  },
                  {
                    "text": "PleuraAdhesions and fibrous thickeningLoss of elasticaSubpleural cysts/blebsCuboidal mesothelium",
                    "sub_points": [
                      "Adhesions and fibrous thickening",
                      "Loss of elastica",
                      "Subpleural cysts/blebs",
                      "Cuboidal mesothelium"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Recurrent Aspiration": [
                  {
                    "text": "Often preexisting neuromuscular abnormalities"
                  },
                  {
                    "text": "Bronchiectasis in lower lobes and posterior segments (i.e., dependent portions of lungs)"
                  },
                  {
                    "text": "Pneumonia can be related to preceding episode of choking or gagging with feeds"
                  }
                ],
                "Bronchopulmonary Dysplasia": [
                  {
                    "text": "History of prematurity"
                  },
                  {
                    "text": "Improves with patient aging"
                  },
                  {
                    "text": "Recurrent aspiration"
                  },
                  {
                    "text": "Gross lung examination shows lower lobes with diffuse firm appearance, bronchiectasis is not commonly seen"
                  },
                  {
                    "text": "Hyaline membranes in dilated alveolar ducts are identified in acute phase"
                  }
                ],
                "Immotile Cilia Syndrome": [
                  {
                    "text": "Association with situs inversus &/or cardiac anomalies"
                  },
                  {
                    "text": "Otitis media is characteristic"
                  },
                  {
                    "text": "Involvement predominantly of lower lobes"
                  },
                  {
                    "text": "Electron microscopy examination of cilia is necessary for diagnosis"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Clinical severity of disease varies considerably; some patients present in neonatal period (most common) and others in late adulthood"
                  },
                  {
                    "text": "Variation of severity is related in part to genetic factors, with some alleles associated with less severe manifestations"
                  },
                  {
                    "text": "Severity and rate of progression of lung disease are important determinants of long-term prognosis"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "None of pathologic findings in lung are specific for CF"
                  },
                  {
                    "text": "Biliary cirrhosis and underdevelopment of male reproductive system are morphologic lesions considered specific for CF"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "X-Linked Muscular Dystrophy: Duchenne and Becker": {
            "name": "X-Linked Muscular Dystrophy: Duchenne and Becker",
            "url": "https://app.pathprimer.com/document/5ef214dc-64be-4534-b835-17c6e87305e0/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Becker muscular dystrophy (BMD)"
                  },
                  {
                    "text": "Duchenne muscular dystrophy (DMD)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Most common molecular defects are deletions (60%)"
                  },
                  {
                    "text": "X-linked recessivePrimarily affects males (and rarely females) through X-inactivation",
                    "sub_points": [
                      "Primarily affects males (and rarely females) through X-inactivation"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "DMD: Symptomatic in early childhood, with progressive loss of motor functionWaddling gaitEnlarged calf musclesGowers sign: Nonspecific manifestation of proximal leg weakness, with patient rising from floor with buttocks up 1st, using arms to climb up legs while buttocks remain elevatedFrequent cardiac involvement",
                    "sub_points": [
                      "Waddling gait",
                      "Enlarged calf muscles",
                      "Gowers sign: Nonspecific manifestation of proximal leg weakness, with patient rising from floor with buttocks up 1st, using arms to climb up legs while buttocks remain elevated",
                      "Frequent cardiac involvement"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "DMD and BMDMyofiber necrosis and regenerationMarked variation in fiber sizesEndomysial fibrosis and fiber \"splitting\"",
                    "sub_points": [
                      "Myofiber necrosis and regeneration",
                      "Marked variation in fiber sizes",
                      "Endomysial fibrosis and fiber \"splitting\""
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "MLPA is the widely used initial method of diagnosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Becker muscular dystrophy (BMD)"
                  },
                  {
                    "text": "Duchenne muscular dystrophy (DMD)"
                  },
                  {
                    "text": "Polymerase chain reaction (PCR)"
                  },
                  {
                    "text": "Multiplex ligation-dependent probe amplification (MLPA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "DMD and BMD: Hereditary diseases caused by mutations of dystrophin gene at locus Xp21"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics and Physiological Defects": [
                  {
                    "text": "X-linked recessivePrimarily affects males (and rarely females) through X-inactivation",
                    "sub_points": [
                      "Primarily affects males (and rarely females) through X-inactivation"
                    ]
                  },
                  {
                    "text": "Dystrophin gene is very large and complexMost common molecular defects are deletions (60%)Deletions are clustered in 5' half of gene or in central region (known as a deletion hotspot)Nonrandom distributionPoint mutations account for 30% of casesRandom distributionDuplications account for 10% of casesDystrophin gene product is most abundant in cardiac and skeletal muscle",
                    "sub_points": [
                      "Most common molecular defects are deletions (60%)Deletions are clustered in 5' half of gene or in central region (known as a deletion hotspot)Nonrandom distribution",
                      "Deletions are clustered in 5' half of gene or in central region (known as a deletion hotspot)",
                      "Nonrandom distribution",
                      "Point mutations account for 30% of casesRandom distribution",
                      "Random distribution",
                      "Duplications account for 10% of cases",
                      "Dystrophin gene product is most abundant in cardiac and skeletal muscle"
                    ]
                  },
                  {
                    "text": "Absence of dystrophin protein causes destabilization of myofiber membrane, allowing calcium into cell and activation of inflammatory and degenerative pathways"
                  },
                  {
                    "text": "High rate of new mutations and asymptomatic female carriers lead to 80% of affected males with no family history of disease"
                  },
                  {
                    "text": "DMD2/3 of cases are result of carrier mother1/3 of cases are result of new mutationMolecular defects cause frameshift or nonsense mutations",
                    "sub_points": [
                      "2/3 of cases are result of carrier mother",
                      "1/3 of cases are result of new mutation",
                      "Molecular defects cause frameshift or nonsense mutations"
                    ]
                  },
                  {
                    "text": "BMDMajority of cases are inherited with only 10% as result of new mutationMaintenance of open reading frame, despite molecular defectsCauses formation of partially functional protein",
                    "sub_points": [
                      "Majority of cases are inherited with only 10% as result of new mutation",
                      "Maintenance of open reading frame, despite molecular defectsCauses formation of partially functional protein",
                      "Causes formation of partially functional protein"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "DMD1 per 3,500 male births",
                    "sub_points": [
                      "1 per 3,500 male births"
                    ]
                  },
                  {
                    "text": "BMD1 per 30,000 male births",
                    "sub_points": [
                      "1 per 30,000 male births"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "DMDSymptomatic in early childhood, with progressive loss of motor functionDifficulty running and climbing, frequent fallsWaddling gaitEnlarged calf musclesGowers sign: patients rise from the floor with buttocks up 1st, using arms to climb up legs while buttocks remain elevated. Manifestation of proximal leg weaknessMarkedly increased creatine kinase (CK)Loss of ambulation by 13 yrs of age (mean 8.5 yrs)Progressive kyphoscoliosisProgressive respiratory muscle weaknessMean age of death in 3rd decade; usually due to respiratory failure and infectionFrequent cardiac involvementAbnormal rate, rhythm, conduction, and EKG",
                    "sub_points": [
                      "Symptomatic in early childhood, with progressive loss of motor functionDifficulty running and climbing, frequent fallsWaddling gaitEnlarged calf musclesGowers sign: patients rise from the floor with buttocks up 1st, using arms to climb up legs while buttocks remain elevated. Manifestation of proximal leg weaknessMarkedly increased creatine kinase (CK)",
                      "Difficulty running and climbing, frequent falls",
                      "Waddling gait",
                      "Enlarged calf muscles",
                      "Gowers sign: patients rise from the floor with buttocks up 1st, using arms to climb up legs while buttocks remain elevated. Manifestation of proximal leg weakness",
                      "Markedly increased creatine kinase (CK)",
                      "Loss of ambulation by 13 yrs of age (mean 8.5 yrs)",
                      "Progressive kyphoscoliosis",
                      "Progressive respiratory muscle weakness",
                      "Mean age of death in 3rd decade; usually due to respiratory failure and infection",
                      "Frequent cardiac involvementAbnormal rate, rhythm, conduction, and EKG",
                      "Abnormal rate, rhythm, conduction, and EKG"
                    ]
                  },
                  {
                    "text": "BMDSeverity of symptoms is less, and age of onset is later, than in DMDMean age at onset: 12 yearsMean age of death in 4th or 5th decadeCardiac involvement common, including X-linked dilated cardiomyopathyInfertility varies with severity",
                    "sub_points": [
                      "Severity of symptoms is less, and age of onset is later, than in DMDMean age at onset: 12 yearsMean age of death in 4th or 5th decade",
                      "Mean age at onset: 12 years",
                      "Mean age of death in 4th or 5th decade",
                      "Cardiac involvement common, including X-linked dilated cardiomyopathy",
                      "Infertility varies with severity"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Glucocorticoids prolong ambulation"
                  },
                  {
                    "text": "Gene therapy approaches - novel and under investigationGene replacementExon skipping with antisense oligonucleotidesUpregulation of genes that act as dystrophin surrogates",
                    "sub_points": [
                      "Gene replacement",
                      "Exon skipping with antisense oligonucleotides",
                      "Upregulation of genes that act as dystrophin surrogates"
                    ]
                  },
                  {
                    "text": "Cell therapy-based treatments augment muscle progenitor cell potential"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "DMD and BMDMyofiber necrosis and regenerationMarked variation in fiber sizesEndomysial fibrosis and fiber \"splitting\"Increase in internally placed nucleiFiber-type distinction by myosin ATPase enzyme histochemistry is diminishedDMD and severe BMD may show similar features, but DMD generally shows greater degree of acute dystrophic features, such asMyofibers necrosisMyophagocytosis by macrophages",
                    "sub_points": [
                      "Myofiber necrosis and regeneration",
                      "Marked variation in fiber sizes",
                      "Endomysial fibrosis and fiber \"splitting\"",
                      "Increase in internally placed nuclei",
                      "Fiber-type distinction by myosin ATPase enzyme histochemistry is diminished",
                      "DMD and severe BMD may show similar features, but DMD generally shows greater degree of acute dystrophic features, such asMyofibers necrosisMyophagocytosis by macrophages",
                      "Myofibers necrosis",
                      "Myophagocytosis by macrophages"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "Multiplex PCR for large deletions"
                  },
                  {
                    "text": "MLPA is widely used initial diagnostic methodDiagnosis of genes with deletions or duplications",
                    "sub_points": [
                      "Diagnosis of genes with deletions or duplications"
                    ]
                  },
                  {
                    "text": "Sanger sequencing for diagnosis of genes with point mutationsUtilized if MLPA is nondiagnosticNext generation sequencing has been proposed as alternate method",
                    "sub_points": [
                      "Utilized if MLPA is nondiagnostic",
                      "Next generation sequencing has been proposed as alternate method"
                    ]
                  },
                  {
                    "text": "Chorionic villi and amniotic fluid samples may be testedPrior detection of deletion, duplication, or mutation must be identified for consideration of prenatal diagnosis",
                    "sub_points": [
                      "Prior detection of deletion, duplication, or mutation must be identified for consideration of prenatal diagnosis"
                    ]
                  }
                ],
                "Immunohistochemistry and Western Blot Analysis": [
                  {
                    "text": "If genetic testing does not identify dystrophin variant, then muscle biopsy can be used for western blot and immunohistochemical analysis"
                  },
                  {
                    "text": "ImmunohistochemistryDMDVariable preservation of N-terminus and extensive loss of C-terminus staining, except for revertant fibersRod domain staining is generally absentBMDPreservation of or mildly diminished N- and C-terminus staining and absence of rod domain staining if antigenic determinant is missingMay be missed if anti-rod domain antibody recognizes preserved portion of rod domain when separate portion is missing",
                    "sub_points": [
                      "DMDVariable preservation of N-terminus and extensive loss of C-terminus staining, except for revertant fibersRod domain staining is generally absent",
                      "Variable preservation of N-terminus and extensive loss of C-terminus staining, except for revertant fibers",
                      "Rod domain staining is generally absent",
                      "BMDPreservation of or mildly diminished N- and C-terminus staining and absence of rod domain staining if antigenic determinant is missingMay be missed if anti-rod domain antibody recognizes preserved portion of rod domain when separate portion is missing",
                      "Preservation of or mildly diminished N- and C-terminus staining and absence of rod domain staining if antigenic determinant is missing",
                      "May be missed if anti-rod domain antibody recognizes preserved portion of rod domain when separate portion is missing"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Other X-linked Myopathies": [
                  {
                    "text": "Emery-Dreifuss muscular dystrophy and Danon disease"
                  }
                ],
                "Severe Autosomal Dominant and Recessive Limb Girdle Muscular Dystrophies": [
                  {
                    "text": "With male involvement, considered in the differential diagnosis of DMD and BMD"
                  },
                  {
                    "text": "Normal dystrophin levels"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Fabry Disease": {
            "name": "Fabry Disease",
            "url": "https://app.pathprimer.com/document/cfcf85a1-9387-45cd-80e8-8ab1323fbfd0/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Fabry disease: Lysosomal storage disease involving inborn error of metabolism of glycosphingolipid pathway due to decrease or lack of activity of enzyme A-Gal A causing accumulation of Gb3"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "X-linked inheritance"
                  },
                  {
                    "text": "Mutations ofGLAgene on chromosome Xq22"
                  },
                  {
                    "text": "Partial or complete deficiency of enzyme A-Gal A within lysosomes"
                  },
                  {
                    "text": "Leads to accumulation of glycosphingolipids, primarily Gb3, within lysosomes of cells throughout body"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Progressive, multisystemic disease includes neuropathic pain, primarily acroparesthesia; GI symptoms; angiokeratoma; ophthalmic problems; hearing impairment; onset of cardiac or renal problems"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Diagnosis is determined by deficiency of A-Gal A activity in leukocytes or dried blood spots or increased Gb3 levels in plasma or urinary sediment"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Globotriaosylceramide (Gb3)"
                  },
                  {
                    "text": "α-Galactosidase A (A-Gal A)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Anderson-Fabry disease"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Fabry disease: Lysosomal storage disease involving inborn error of metabolism of glycosphingolipid pathway due to decrease or lack of activity of enzyme A-Gal A causing accumulation of Gb3"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "X-linked inheritanceOccurs primarily in malesFemales who are obligate heterozygotes can exhibit symptoms of disease",
                    "sub_points": [
                      "Occurs primarily in males",
                      "Females who are obligate heterozygotes can exhibit symptoms of disease"
                    ]
                  },
                  {
                    "text": "Mutations ofGLAgene on chromosome Xq22> 600 different mutations have been identified, many of which are specific to families (\"private\" mutations)Missense or nonsense point mutations, insertions, or deletions",
                    "sub_points": [
                      "> 600 different mutations have been identified, many of which are specific to families (\"private\" mutations)",
                      "Missense or nonsense point mutations, insertions, or deletions"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Partial or complete deficiency of enzyme A-Gal A within lysosomesA-Gal A catalyzes hydrolytic cleavage of terminal galactose of Gb3Gb3 is part of degradative pathway of globoside, a glycosphingolipidLeads to accumulation of glycosphingolipids, primarily Gb3, within lysosomes of cells throughout bodyCells primarily affected are endothelial, renal, cardiac, dorsal root ganglia neurons",
                    "sub_points": [
                      "A-Gal A catalyzes hydrolytic cleavage of terminal galactose of Gb3Gb3 is part of degradative pathway of globoside, a glycosphingolipid",
                      "Gb3 is part of degradative pathway of globoside, a glycosphingolipid",
                      "Leads to accumulation of glycosphingolipids, primarily Gb3, within lysosomes of cells throughout body",
                      "Cells primarily affected are endothelial, renal, cardiac, dorsal root ganglia neurons"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Incidence is estimated at 1:40,000-117,000 males"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Progressive, multisystemic disease"
                  },
                  {
                    "text": "First signs often appear during early childhoodNeuropathic painPrimarily acroparesthesiaGastrointestinal (GI) symptomsAngiokeratomaOphthalmic problemsHearing impairmentOnset of cardiac or renal problems",
                    "sub_points": [
                      "Neuropathic pain",
                      "Primarily acroparesthesia",
                      "Gastrointestinal (GI) symptoms",
                      "Angiokeratoma",
                      "Ophthalmic problems",
                      "Hearing impairment",
                      "Onset of cardiac or renal problems"
                    ]
                  },
                  {
                    "text": "Serious complications usually occur in adulthoodEnd-stage renal diseaseCerebrovascular accidentsProgressive cardiomyopathyArrhythmiasValvular disease",
                    "sub_points": [
                      "End-stage renal disease",
                      "Cerebrovascular accidents",
                      "Progressive cardiomyopathy",
                      "Arrhythmias",
                      "Valvular disease"
                    ]
                  },
                  {
                    "text": "Onset of symptoms for males usually occurs at earlier ageMedian age of onset for males: 6 yrMedian age of onset for females: 9 yr",
                    "sub_points": [
                      "Median age of onset for males: 6 yr",
                      "Median age of onset for females: 9 yr"
                    ]
                  },
                  {
                    "text": "Delays in diagnosis often occur"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Enzyme replacement therapy"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Diagnosis": [
                  {
                    "text": "Deficiency of A-Gal A activity in leukocytes or dried blood spotsA-Gal A levels often normal in female heterozygotesDirect sequencing in females should be done as opposed to other diagnostic methods used for males",
                    "sub_points": [
                      "A-Gal A levels often normal in female heterozygotes",
                      "Direct sequencing in females should be done as opposed to other diagnostic methods used for males"
                    ]
                  },
                  {
                    "text": "Increased Gb3 levels in plasma or urinary sediment"
                  },
                  {
                    "text": "Diagnosis often delayed due to decreased awareness of clinicians and rarity of disease"
                  },
                  {
                    "text": "Genetic analysis used for confirmation of diagnosis"
                  },
                  {
                    "text": "Pedigree analysis often a method of diagnosis after diagnosis of another family member prompts genetic counseling"
                  },
                  {
                    "text": "Tissue diagnosis rarely done but can be helpfulRenal biopsy shows glycolipid accumulationConcentric inclusions with onionskin appearance",
                    "sub_points": [
                      "Renal biopsy shows glycolipid accumulation",
                      "Concentric inclusions with onionskin appearance"
                    ]
                  }
                ],
                "Screening": [
                  {
                    "text": "Genetic counseling is warranted"
                  },
                  {
                    "text": "Diagnosis of an individual should prompt screening of at-risk family members"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Hereditary Hemorrhagic Telangiectasia (HHT/Rendu-Osler-Weber disease)": [
                  {
                    "text": "Patients with Fabry disease have dermatologic problems including telangiectasias"
                  },
                  {
                    "text": "Patients with HHT have telangiectasias and arteriovenous malformations"
                  },
                  {
                    "text": "Spontaneous bleeding including epistaxis and GI bleeding often seen in HHT but not in Fabry disease"
                  }
                ],
                "Idiopathic Hypertrophic Cardiomyopathy": [
                  {
                    "text": "Consider Fabry disease when no other etiology is apparent"
                  }
                ],
                "Renal Failure of Unknown Etiology": [
                  {
                    "text": "Consider Fabry disease when no other etiology is apparent"
                  }
                ],
                "Meniere Disease": [
                  {
                    "text": "Although Fabry disease is associated with hearing impairment, presence of other organ dysfunction (e.g., renal disease, angiokeratomas, ophthalmic problems, cardiac dysfunction) should help to rule out Meniere disease"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Friedreich Ataxia": {
            "name": "Friedreich Ataxia",
            "url": "https://app.pathprimer.com/document/8975faa4-e572-4e0a-8a3c-b436033eca54/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Autosomal recessive"
                  },
                  {
                    "text": "Most affected individuals have an expanded GAA trinucleotide repeat on intron 1 of both alleles of theFXNgene"
                  },
                  {
                    "text": "FXN protein is a mitochondrial protein thought to be involved with iron transport or iron-sulfur assembly transport"
                  },
                  {
                    "text": "FXN protein is largely found in (but not limited to) the CNS, heart, and pancreas"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Freidreich ataxia (FRDA)"
                  },
                  {
                    "text": "Frataxin (FXN)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Progressive hereditary neurodegenerative disorder"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "Autosomal recessive"
                  },
                  {
                    "text": "Loss of function mutation inFXNgene located on chromosome 9q13"
                  },
                  {
                    "text": "Most affected individuals have an expanded GAA trinucleotide repeat in intron 1 of both alleles of theFXNgeneNormal number of GAA repeats: 8-33Premutation range of GAA repeats: 34-100, with uninterrupted repeat tractsStability of repeats is determined by the number of non-GAA repeat interruptionsInterruption stabilizes the repeat against expansionRange of GAA repeats for pathologic alleles: 120-1700",
                    "sub_points": [
                      "Normal number of GAA repeats: 8-33",
                      "Premutation range of GAA repeats: 34-100, with uninterrupted repeat tractsStability of repeats is determined by the number of non-GAA repeat interruptionsInterruption stabilizes the repeat against expansion",
                      "Stability of repeats is determined by the number of non-GAA repeat interruptionsInterruption stabilizes the repeat against expansion",
                      "Interruption stabilizes the repeat against expansion",
                      "Range of GAA repeats for pathologic alleles: 120-1700"
                    ]
                  },
                  {
                    "text": "GAA expansion causes an unusual but stable DNA structure, which interferes with transcription of theFXNgene and decreased translation of the FXN protein"
                  },
                  {
                    "text": "4% of individuals are compound heterozygotes with GAA expansion on one allele and point insertions, deletions, or mutations on the other"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "FXN protein is a mitochondrial protein thought to be involved with iron transport or iron-sulfur assembly transportFRDA patients have normal serum iron and ferritin levels",
                    "sub_points": [
                      "FRDA patients have normal serum iron and ferritin levels"
                    ]
                  },
                  {
                    "text": "Mitochondrial accumulation of iron causes oxidative stress"
                  },
                  {
                    "text": "FXN protein is largely found in (but not limited to) the CNS, heart, and pancreasNeurons and cardiomyocytes depend exclusively on aerobic metabolism and are very susceptible to mitochondrial oxidative stress",
                    "sub_points": [
                      "Neurons and cardiomyocytes depend exclusively on aerobic metabolism and are very susceptible to mitochondrial oxidative stress"
                    ]
                  }
                ],
                "Neuropathology": [
                  {
                    "text": "Loss of neurons of the dorsal root ganglia and atrophy of Clarke column (dorsal nucleus)"
                  },
                  {
                    "text": "Spinal cord shows degeneration of posterior columns, spinocerebellar tracts, and corticospinal motor tracts"
                  },
                  {
                    "text": "Peripheral nerves show atrophy of the large sensory fibers"
                  },
                  {
                    "text": "Brainstem shows severe atrophy of the cuneate and gracile nuclei"
                  },
                  {
                    "text": "Cerebellum shows atrophy of the dentate nuclei and loss of Purkinje cells late in disease"
                  },
                  {
                    "text": "Cerebral cortex shows loss of pyramidal cells, but to a lesser extent than other cells in the nervous system"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Most common hereditary ataxia"
                  },
                  {
                    "text": "Incidence: 2 in 100,000"
                  },
                  {
                    "text": "GAA repeat expansion occurs in individuals primarily of European, Middle Eastern, North African, and Indian descent"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Onset usually before age 25"
                  },
                  {
                    "text": "Neurologic dysfunction"
                  },
                  {
                    "text": "Cardiomyopathy"
                  },
                  {
                    "text": "Diabetes mellitus"
                  },
                  {
                    "text": "Scoliosis"
                  },
                  {
                    "text": "ProgressiveFull extent of features may not be seen for years after initial presentation",
                    "sub_points": [
                      "Full extent of features may not be seen for years after initial presentation"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Mean age of death: 35, most commonly due to cardiomyopathy"
                  }
                ],
                "Diagnosis": [
                  {
                    "text": "Genetic testing for GAA expansionPCR or Southern blot",
                    "sub_points": [
                      "PCR or Southern blot"
                    ]
                  },
                  {
                    "text": "Measurement of FXN protein in whole blood and buccal cellsWestern blots, electrochemiluminescence, or lateral-flow immunoassay",
                    "sub_points": [
                      "Western blots, electrochemiluminescence, or lateral-flow immunoassay"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Atrophy of the spinal cord and medulla"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Ataxia-telangiectasia": [],
                "Ataxia with vitamin E deficiency": [],
                "Mitochondrial DNA depletion syndrome 7": [],
                "Roussy-Lévy variant of Charcot-Marie-Tooth disease": []
              },
              "Selected References": {}
            }
          },
          "Gaucher Disease": {
            "name": "Gaucher Disease",
            "url": "https://app.pathprimer.com/document/889756af-afbb-400d-aa70-307bdd34513e/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Lysosomal storage disease"
                  },
                  {
                    "text": "Accumulation of glucocerebroside in lysosomes of macrophages due to GBA deficiency"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Type 1 treatment: Enzyme replacement therapy"
                  },
                  {
                    "text": "Seen in 1 in 450 people of Ashkenazi Jewish descent"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Reduced GBA enzyme activity in peripheral leukocytes is diagnostic"
                  },
                  {
                    "text": "GCs present on bone marrow biopsy"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Gaucher cells (GCs)"
                  },
                  {
                    "text": "Gaucher disease (GD)"
                  },
                  {
                    "text": "Glucocerebrosidase / glucosylceramidase / acid beta-glucosidase (GBA)"
                  },
                  {
                    "text": "Low-density lipoprotein (LDL)"
                  },
                  {
                    "text": "Tartrate-resistant acid phosphatase (TRAP)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Lysosomal storage disease: Inherited deficiency of GBA causes accumulation of glucocerebroside in lysosomes of histiocytesGD is the most common lysosomal storage diseaseInborn error of metabolism",
                    "sub_points": [
                      "GD is the most common lysosomal storage disease",
                      "Inborn error of metabolism"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "Autosomal recessive disorder"
                  },
                  {
                    "text": "Mutation of GBA1 gene located on chromosome 1q21Most common mutation is a single nucleotide substitutionLeu444Pro is the most common mutation worldwideAsn370Ser is the most common mutation in Ashkenazi JewsInsertions, deletions, and complex alleles account for a minority of mutations",
                    "sub_points": [
                      "Most common mutation is a single nucleotide substitutionLeu444Pro is the most common mutation worldwideAsn370Ser is the most common mutation in Ashkenazi Jews",
                      "Leu444Pro is the most common mutation worldwide",
                      "Asn370Ser is the most common mutation in Ashkenazi Jews",
                      "Insertions, deletions, and complex alleles account for a minority of mutations"
                    ]
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Loss of GBA enzyme activity leads to glucocerebroside accumulation in lysosomes of histiocytes in bone marrow, bone, and visceral organsBone marrowLeads to anemia and thrombocytopeniaBoneMay lead to osteonecrosisVisceral organsIncreased histiocytes result in hepatosplenomegaly",
                    "sub_points": [
                      "Bone marrowLeads to anemia and thrombocytopenia",
                      "Leads to anemia and thrombocytopenia",
                      "BoneMay lead to osteonecrosis",
                      "May lead to osteonecrosis",
                      "Visceral organsIncreased histiocytes result in hepatosplenomegaly",
                      "Increased histiocytes result in hepatosplenomegaly"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "1 in 40,000-100,000 live births"
                  },
                  {
                    "text": "1 in 450 people of Ashkenazi Jewish descent"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Type 1: NonneuronopathicMost common type of GDVariable age of onset from childhood to adulthoodInvolves visceral organs, bone disease, and bleedingDoes not involve central nervous systemAssociated with Parkinson disease (despite nonneuronopathic)Mechanism unknownAssociated with increased rates of hematologic malignanciesMost frequent genotype is Asn370Ser/Leu444ProResults in more severe disease compared with homozygosity",
                    "sub_points": [
                      "Most common type of GD",
                      "Variable age of onset from childhood to adulthood",
                      "Involves visceral organs, bone disease, and bleedingDoes not involve central nervous system",
                      "Does not involve central nervous system",
                      "Associated with Parkinson disease (despite nonneuronopathic)Mechanism unknown",
                      "Mechanism unknown",
                      "Associated with increased rates of hematologic malignancies",
                      "Most frequent genotype is Asn370Ser/Leu444ProResults in more severe disease compared with homozygosity",
                      "Results in more severe disease compared with homozygosity"
                    ]
                  },
                  {
                    "text": "Type 2: Acute neuronopathicAcute and rapidly fatalOnset often in first year of lifeSevere visceral involvementCongenital ichthyosis is a common presentationDue to altered ratio of ceramides to glucosylceramides in skinSevere neurologic involvementDisease progression results in seizures, rigidity, and opisthotonus",
                    "sub_points": [
                      "Acute and rapidly fatalOnset often in first year of life",
                      "Onset often in first year of life",
                      "Severe visceral involvement",
                      "Congenital ichthyosis is a common presentationDue to altered ratio of ceramides to glucosylceramides in skin",
                      "Due to altered ratio of ceramides to glucosylceramides in skin",
                      "Severe neurologic involvementDisease progression results in seizures, rigidity, and opisthotonus",
                      "Disease progression results in seizures, rigidity, and opisthotonus"
                    ]
                  },
                  {
                    "text": "Type 3: Chronic neuronopathicOnset usually before age 2Chronic progressive courseOrganomegaly, bone involvement, and neurologic involvement",
                    "sub_points": [
                      "Onset usually before age 2",
                      "Chronic progressive course",
                      "Organomegaly, bone involvement, and neurologic involvement"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Enzyme replacement therapy with GBATreatment for type 1GBA can not cross blood-brain barrier, so has limited effect on neurologic symptoms in types 2 and 3",
                    "sub_points": [
                      "Treatment for type 1GBA can not cross blood-brain barrier, so has limited effect on neurologic symptoms in types 2 and 3",
                      "GBA can not cross blood-brain barrier, so has limited effect on neurologic symptoms in types 2 and 3"
                    ]
                  },
                  {
                    "text": "Must be started early in the disease to prevent irreversible complications of the deficient enzyme"
                  }
                ]
              },
              "IMAGING": {
                "Initial Features": [
                  {
                    "text": "Must evaluate liver, spleen, and extent of skeletal diseaseCan be used to monitor response to enzyme replacement therapy",
                    "sub_points": [
                      "Can be used to monitor response to enzyme replacement therapy"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Gaucher cellsMacrophages with eccentric nuclei and filled with lipid materialCytoplasm has characteristic \"wrinkled tissue paper\" appearanceStain positively with PAS and TRAPShow diffuse iron staining",
                    "sub_points": [
                      "Macrophages with eccentric nuclei and filled with lipid material",
                      "Cytoplasm has characteristic \"wrinkled tissue paper\" appearance",
                      "Stain positively with PAS and TRAP",
                      "Show diffuse iron staining"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "PCR": [
                  {
                    "text": "Targeted DNA mutation analysisUsed to confirm diagnosisFirst line for carrier identification",
                    "sub_points": [
                      "Used to confirm diagnosis",
                      "First line for carrier identification"
                    ]
                  }
                ],
                "Enzyme Analysis": [
                  {
                    "text": "Reduced GBA enzyme activity in peripheral leukocytes"
                  }
                ],
                "Bone Marrow Biopsy": [
                  {
                    "text": "GCs present on bone marrow biopsy"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Niemann-Pick Disease": [
                  {
                    "text": "Autosomal recessive disorder usually presenting with organomegalyTypes A and B: Work-up shows enzyme deficiency for acid sphingomyelinaseType C: Work-up shows impaired processing and transport of LDL",
                    "sub_points": [
                      "Types A and B: Work-up shows enzyme deficiency for acid sphingomyelinase",
                      "Type C: Work-up shows impaired processing and transport of LDL"
                    ]
                  }
                ],
                "Leukemia": [],
                "Lymphoma": [],
                "Inflammatory diseases": []
              },
              "Selected References": {}
            }
          },
          "Hereditary Hemochromatosis": {
            "name": "Hereditary Hemochromatosis",
            "url": "https://app.pathprimer.com/document/3c8cf683-8adb-4f7b-9f74-9f8911d3c888/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Inherited, autosomal recessive disorder of iron metabolism"
                  },
                  {
                    "text": "Extremely variable penetrance and phenotypic expression"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Most common mutations are inHFEgene2 most common mutations (C282Y and H63D) account for vast majority of cases",
                    "sub_points": [
                      "2 most common mutations (C282Y and H63D) account for vast majority of cases"
                    ]
                  },
                  {
                    "text": "Non-HFE-associated HH occurs less commonly (5-10% of phenotypic cases)"
                  },
                  {
                    "text": "Specific mechanism leading to iron overload in HH is still unknown"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most patients are of Northern European ancestry"
                  },
                  {
                    "text": "Highly variable clinical presentationPresenting signs/symptoms include weakness, evidence of liver disease, cardiac dysfunction, diabetes, skin hyperpigmentation",
                    "sub_points": [
                      "Presenting signs/symptoms include weakness, evidence of liver disease, cardiac dysfunction, diabetes, skin hyperpigmentation"
                    ]
                  },
                  {
                    "text": "Phlebotomy is mainstay of treatment"
                  },
                  {
                    "text": "Patients are at increased risk for hepatocellular carcinoma, even in absence of cirrhosis and adequate iron-depletion therapy"
                  }
                ],
                "Macroscopic": [
                  {
                    "text": "Dark, rusty brown discoloration"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Iron deposition is characteristic featureInitially in zone 1 hepatocytes, but progresses to involve all zonesMay also be present in macrophages, biliary epithelium",
                    "sub_points": [
                      "Initially in zone 1 hepatocytes, but progresses to involve all zones",
                      "May also be present in macrophages, biliary epithelium"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Molecular testing for individual mutations"
                  },
                  {
                    "text": "Liver biopsy with measurement of quantitative iron and hepatic iron index"
                  },
                  {
                    "text": "Serum iron indices"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hereditary hemochromatosis (HH)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Inherited, autosomal recessive disorder of iron metabolismExtremely variable penetrance and phenotypic expression",
                    "sub_points": [
                      "Extremely variable penetrance and phenotypic expression"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetic Mutations": [
                  {
                    "text": "2 most common mutations are inHFEgeneC282Y/C282Y homozygotes80-85% of phenotypic casesCompound C282Y/H63D heterozygotes5% of phenotypic cases",
                    "sub_points": [
                      "C282Y/C282Y homozygotes80-85% of phenotypic cases",
                      "80-85% of phenotypic cases",
                      "Compound C282Y/H63D heterozygotes5% of phenotypic cases",
                      "5% of phenotypic cases"
                    ]
                  },
                  {
                    "text": "Non-HFE-associated HH occurs less commonly5-10% of phenotypic casesTFR2 (transferrin receptor) mutationsFerroportin mutationsJuvenile hemochromatosisRareProgresses rapidly and leads to significant disease before age 30Lower frequency of liver disease",
                    "sub_points": [
                      "5-10% of phenotypic cases",
                      "TFR2 (transferrin receptor) mutations",
                      "Ferroportin mutations",
                      "Juvenile hemochromatosisRareProgresses rapidly and leads to significant disease before age 30Lower frequency of liver disease",
                      "Rare",
                      "Progresses rapidly and leads to significant disease before age 30",
                      "Lower frequency of liver disease"
                    ]
                  },
                  {
                    "text": "Specific mechanism leading to iron overload in HH is still unknown"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Worldwide allele frequenciesC282Y: 1.9%H63D: 8.1%",
                    "sub_points": [
                      "C282Y: 1.9%",
                      "H63D: 8.1%"
                    ]
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Most often Northern European originC282Y frequency higher in Irish individualsH63D frequency higher in Basque individuals",
                    "sub_points": [
                      "C282Y frequency higher in Irish individuals",
                      "H63D frequency higher in Basque individuals"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "4 clinical stagesGenetic predisposition with no clinical or laboratory abnormalityMild iron overload without clinical abnormalityIron overload with early clinical symptomsIron overload with organ damage",
                    "sub_points": [
                      "Genetic predisposition with no clinical or laboratory abnormality",
                      "Mild iron overload without clinical abnormality",
                      "Iron overload with early clinical symptoms",
                      "Iron overload with organ damage"
                    ]
                  },
                  {
                    "text": "Highly variable clinical presentationGeneralized weakness (60%)Liver disease (13-60%)Diabetes mellitus (10-30%)Cardiac dysfunction (15-35%)Skin pigmentation (47%)Sexual dysfunction (10-40%)",
                    "sub_points": [
                      "Generalized weakness (60%)",
                      "Liver disease (13-60%)",
                      "Diabetes mellitus (10-30%)",
                      "Cardiac dysfunction (15-35%)",
                      "Skin pigmentation (47%)",
                      "Sexual dysfunction (10-40%)"
                    ]
                  },
                  {
                    "text": "Symptoms may be vague &/or nonspecificDiagnosis may be missed if index of suspicion is not high",
                    "sub_points": [
                      "Diagnosis may be missed if index of suspicion is not high"
                    ]
                  },
                  {
                    "text": "Prevalence of alcoholic liver disease and hepatitis C appears increased in patients with HH"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Transferrin saturation (> 45%)"
                  },
                  {
                    "text": "Unbound iron binding capacity (< 28 µmol/L)"
                  },
                  {
                    "text": "Serum ferritin (> 300 µg/L in men and 200 µg/L in women)"
                  },
                  {
                    "text": "Liver biopsy with quantitative iron determination and calculation of hepatic iron indexCan be performed directly from paraffin block",
                    "sub_points": [
                      "Can be performed directly from paraffin block"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "PhlebotomyMainstay of therapyWeekly until lab values are desirable, then maintenance over lifetime",
                    "sub_points": [
                      "Mainstay of therapyWeekly until lab values are desirable, then maintenance over lifetime",
                      "Weekly until lab values are desirable, then maintenance over lifetime"
                    ]
                  },
                  {
                    "text": "Avoidance of iron-rich foods and supplements"
                  },
                  {
                    "text": "Chelation therapyOnly recommended if phlebotomy is not option",
                    "sub_points": [
                      "Only recommended if phlebotomy is not option"
                    ]
                  },
                  {
                    "text": "Liver transplantation for advanced liver diseaseOutcome complicated by cardiac dysfunction, recurrence in patients with hepatocellular carcinoma (HCC)",
                    "sub_points": [
                      "Outcome complicated by cardiac dysfunction, recurrence in patients with hepatocellular carcinoma (HCC)"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Numerous significant complicationsCirrhosis/liver failureHCCAssociated with longstanding HH and cirrhosisCases have also been reported in noncirrhotic liversRisk may persist despite adequate iron-depletion therapyHeart failureImpotence",
                    "sub_points": [
                      "Cirrhosis/liver failure",
                      "HCCAssociated with longstanding HH and cirrhosisCases have also been reported in noncirrhotic liversRisk may persist despite adequate iron-depletion therapy",
                      "Associated with longstanding HH and cirrhosisCases have also been reported in noncirrhotic livers",
                      "Cases have also been reported in noncirrhotic livers",
                      "Risk may persist despite adequate iron-depletion therapy",
                      "Heart failure",
                      "Impotence"
                    ]
                  },
                  {
                    "text": "Some studies have shown decreased life expectancy for homozygotes with clinical disease, whereas others have shown no significant decrease in life expectancy"
                  }
                ]
              },
              "IMAGING": {
                "MR Findings": [
                  {
                    "text": "Can provide accurate estimate of iron overload"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Dark, rusty brown discoloration"
                  },
                  {
                    "text": "Hepatosplenomegaly"
                  },
                  {
                    "text": "Cirrhosis"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Iron depositionInitially in periportal (zone 1) hepatocytesProgressively involves all zonesIron often pericanalicular in distributionIron may also be present in biliary epitheliumDeposition of iron in Kupffer cells is nonspecificCan occur in HH, as well as secondary causes of iron overloadSome patients with HH due to ferroportin mutations show predominantly Kupffer cell depositionIron stain highlights pigment accumulationSeveral grading schemes exist for evaluating iron depositionScheuer scheme (estimation of overall iron with assignment of grade 1-4) is most often used in routine practice",
                    "sub_points": [
                      "Initially in periportal (zone 1) hepatocytes",
                      "Progressively involves all zones",
                      "Iron often pericanalicular in distributionIron may also be present in biliary epithelium",
                      "Iron may also be present in biliary epithelium",
                      "Deposition of iron in Kupffer cells is nonspecificCan occur in HH, as well as secondary causes of iron overloadSome patients with HH due to ferroportin mutations show predominantly Kupffer cell deposition",
                      "Can occur in HH, as well as secondary causes of iron overload",
                      "Some patients with HH due to ferroportin mutations show predominantly Kupffer cell deposition",
                      "Iron stain highlights pigment accumulation",
                      "Several grading schemes exist for evaluating iron depositionScheuer scheme (estimation of overall iron with assignment of grade 1-4) is most often used in routine practice",
                      "Scheuer scheme (estimation of overall iron with assignment of grade 1-4) is most often used in routine practice"
                    ]
                  },
                  {
                    "text": "Associated portal and lobular chronic inflammation"
                  },
                  {
                    "text": "Fibrosis is initially portal basedProgresses to periportal fibrosis, bridging, and eventually cirrhosis",
                    "sub_points": [
                      "Progresses to periportal fibrosis, bridging, and eventually cirrhosis"
                    ]
                  },
                  {
                    "text": "Iron-free foci in advanced HH may be early harbinger of HCC"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "PCR": [
                  {
                    "text": "Testing blood for individual mutations"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Anemia of Chronic Disease": [
                  {
                    "text": "Iron deposition in both hepatocytes and Kupffer cells"
                  }
                ],
                "Transfusion-Related Hemosiderosis": [
                  {
                    "text": "Iron deposition in Kupffer cells in early stages"
                  },
                  {
                    "text": "May accumulate in hepatocytes when excessive"
                  }
                ],
                "Chronic Hemolytic Disorders": [
                  {
                    "text": "Iron deposition in both hepatocytes and Kupffer cells"
                  }
                ],
                "Other Chronic Liver Diseases": [
                  {
                    "text": "Nonspecific iron accumulation is common in many other chronic liver diseasesHepatitis CAlcoholic liver diseaseNonalcoholic fatty liver disease",
                    "sub_points": [
                      "Hepatitis C",
                      "Alcoholic liver disease",
                      "Nonalcoholic fatty liver disease"
                    ]
                  },
                  {
                    "text": "HH may coexist with other chronic liver diseases as well"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Increased iron in patients with elevated LFTs"
                  },
                  {
                    "text": "Other signs/symptoms may be highly variable and nonspecific"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Recommend genetic testing, quantitative hepatic iron evaluation in patients with histologic iron overload"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Huntington Disease": {
            "name": "Huntington Disease",
            "url": "https://app.pathprimer.com/document/a3d30bf2-65b7-477c-86c6-e66467c70c81/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "CAG trinucleotide repeat in the HTT gene on chromosome 4p16.3CAG repeats in wild-type alleles: 9-35Borderline number of CAG repeats: 36-39CAG repeat number in HD: ≥ 40",
                    "sub_points": [
                      "CAG repeats in wild-type alleles: 9-35",
                      "Borderline number of CAG repeats: 36-39",
                      "CAG repeat number in HD: ≥ 40"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Onset usually around middle-age"
                  },
                  {
                    "text": "Choreiform movements"
                  },
                  {
                    "text": "Motor function slowly deteriorates with disease progression"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Huntington disease (HD)"
                  },
                  {
                    "text": "Huntingtin gene (﻿HTT)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Neurodegenerative disorder passed down through generations resulting in choreiform movements, dementia, and psychiatric illness"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "CAG trinucleotide repeat in the HTT gene on chromosome 4p16.3CAG repeats in wild-type alleles: 9-35Borderline number of CAG repeats: 36-39May be associated with HD symptomsCAG repeat number in HD: ≥ 40Average number of repeats showing disease: 46",
                    "sub_points": [
                      "CAG repeats in wild-type alleles: 9-35",
                      "Borderline number of CAG repeats: 36-39May be associated with HD symptoms",
                      "May be associated with HD symptoms",
                      "CAG repeat number in HD: ≥ 40Average number of repeats showing disease: 46",
                      "Average number of repeats showing disease: 46"
                    ]
                  },
                  {
                    "text": "AnticipationExpansion of repeats over successive generationsResults in earlier expression of disease and more severe phenotypesPaternal transmission often produces much larger repeat increases",
                    "sub_points": [
                      "Expansion of repeats over successive generationsResults in earlier expression of disease and more severe phenotypesPaternal transmission often produces much larger repeat increases",
                      "Results in earlier expression of disease and more severe phenotypes",
                      "Paternal transmission often produces much larger repeat increases"
                    ]
                  },
                  {
                    "text": "Toxic gain of function"
                  },
                  {
                    "text": "Polyglutamine disorder"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Mutant huntingtin proteinPrimarily expressed in the brainSelective neuronal loss in caudate and putamen (striatum)",
                    "sub_points": [
                      "Primarily expressed in the brain",
                      "Selective neuronal loss in caudate and putamen (striatum)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Prevalence varies geographically; 4-8 per 100,000 in United States"
                  },
                  {
                    "text": "Onset usually around middle-age"
                  },
                  {
                    "text": "Choreiform movementsInvoluntary rapid movements of limbs, trunk, &/or facePresenting and most prominent signMotor function slowly deteriorates with disease progression",
                    "sub_points": [
                      "Involuntary rapid movements of limbs, trunk, &/or face",
                      "Presenting and most prominent sign",
                      "Motor function slowly deteriorates with disease progression"
                    ]
                  },
                  {
                    "text": "Psychiatric illnessOften present in early stage of diseaseDepression is most frequent sign",
                    "sub_points": [
                      "Often present in early stage of disease",
                      "Depression is most frequent sign"
                    ]
                  },
                  {
                    "text": "Dementia"
                  }
                ],
                "Juvenile HD": [
                  {
                    "text": "Signs and symptoms presenting before age 20"
                  },
                  {
                    "text": "Chorea usually absent"
                  },
                  {
                    "text": "CAG repeat length usually > 55 repeats"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Life expectancy approximately 20 years after onset of visible symptoms"
                  }
                ]
              },
              "IMAGING": {
                "MR Findings": [
                  {
                    "text": "Caudate atrophy in late-stage HD"
                  },
                  {
                    "text": "With the availability of genetic testing, imaging not necessary for diagnosis"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "Diagnosis consists of genetic testing and family history, if available"
                  },
                  {
                    "text": "Increased CAG repeats in HTT"
                  },
                  {
                    "text": "1% of people who have typical HD phenotype test negative for HTT genotype"
                  },
                  {
                    "text": "Presymptomatic genetic screening available for those with documented family history"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Neuroacanthocytosis": [],
                "Friedreich ataxia": [],
                "Huntington disease-like 2": [],
                "Benign hereditary chorea": [],
                "Wilson disease": [],
                "Acquired disorders": [
                  {
                    "text": "Drug and toxic exposure"
                  },
                  {
                    "text": "Creutzfeldt-Jakob disease"
                  },
                  {
                    "text": "Tardive dyskinesia"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sex Chromosome Aneuploidies (Klinefelter and Turner Syndromes)": {
            "name": "Sex Chromosome Aneuploidies (Klinefelter and Turner Syndromes)",
            "url": "https://app.pathprimer.com/document/ba66786c-bae2-48ec-8366-629483f9330b/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Nondisjunction refers to failure of chromosomes to properly segregate to daughter cells during cell division"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Turner syndrome: 70%-80% paternal (sperm lacking sex chromosome fertilizes normal egg)"
                  },
                  {
                    "text": "Klinefelter syndrome: 50% paternal, 50% maternal"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Turner syndrome: 45,X, short female with webbed neck, broad chest, infertility, and increased risk of cardiovascular abnormality"
                  },
                  {
                    "text": "Klinefelter syndrome: 45,XXY, tall male with decreased male secondary sex characteristics (low testosterone) and infertility"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Fluorescence in situ hybridization (FISH)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Aneuploidy: Abnormal number of chromosomes due to either gain (i.e., trisomy, tetrasomy) or loss (i.e., monosomy)"
                  },
                  {
                    "text": "Nondisjunction: Failure of chromosomes to properly segregate to daughter cells during cell division"
                  },
                  {
                    "text": "Turner syndrome: 45,X"
                  },
                  {
                    "text": "Klinefelter syndrome: 47,XXY"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Pathogenesis": [
                  {
                    "text": "Most aneuploidies are due to meiotic nondisjunctionTurner syndrome70%-80% paternalSperm lacking sex chromosome fertilizes normal eggNot associated with increased parental ageKlinefelter syndrome50% paternal, 50% maternalRate of maternal meiotic nondisjunction increases with age",
                    "sub_points": [
                      "Turner syndrome70%-80% paternalSperm lacking sex chromosome fertilizes normal eggNot associated with increased parental age",
                      "70%-80% paternalSperm lacking sex chromosome fertilizes normal egg",
                      "Sperm lacking sex chromosome fertilizes normal egg",
                      "Not associated with increased parental age",
                      "Klinefelter syndrome50% paternal, 50% maternalRate of maternal meiotic nondisjunction increases with age",
                      "50% paternal, 50% maternal",
                      "Rate of maternal meiotic nondisjunction increases with age"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Turner Syndrome1/4000 female live births99% fetal loss rateMultiple abnormalitiesMusculoskeletal﻿Short stature﻿CardiacAortic coarctation﻿Neuropsychiatric﻿Low to normal IQNo major behavioral disorders﻿Sexual development﻿Gonadal dysgenesisStreak gonad/infertilityEndocrine abnormalitiesThyroid disordersType 1 and type 2 diabetesOther﻿Webbed neck﻿LymphedemaBroad chestCystic hygroma",
                    "sub_points": [
                      "1/4000 female live births",
                      "99% fetal loss rate",
                      "Multiple abnormalitiesMusculoskeletal﻿Short stature﻿CardiacAortic coarctation﻿Neuropsychiatric﻿Low to normal IQNo major behavioral disorders﻿Sexual development﻿Gonadal dysgenesisStreak gonad/infertilityEndocrine abnormalitiesThyroid disordersType 1 and type 2 diabetesOther﻿Webbed neck﻿LymphedemaBroad chestCystic hygroma",
                      "Musculoskeletal﻿Short stature﻿",
                      "﻿Short stature﻿",
                      "CardiacAortic coarctation",
                      "Aortic coarctation",
                      "﻿Neuropsychiatric﻿Low to normal IQNo major behavioral disorders",
                      "Low to normal IQ",
                      "No major behavioral disorders",
                      "﻿Sexual development﻿Gonadal dysgenesisStreak gonad/infertility",
                      "Gonadal dysgenesis",
                      "Streak gonad/infertility",
                      "Endocrine abnormalitiesThyroid disordersType 1 and type 2 diabetes",
                      "Thyroid disorders",
                      "Type 1 and type 2 diabetes",
                      "Other﻿Webbed neck﻿LymphedemaBroad chestCystic hygroma",
                      "﻿Webbed neck﻿",
                      "Lymphedema",
                      "Broad chest",
                      "Cystic hygroma"
                    ]
                  },
                  {
                    "text": "Klinefelter Syndrome1/600 male live births21% fetal loss rateMultiple abnormalities﻿Musculoskeletal﻿Tall heightIncreased risk of fracture﻿Neuropsychiatric﻿Low to normal IQNo major behavioral disorders﻿Sexual development﻿HypogonadismAzoospermia/infertilityGynecomastiaEndocrine abnormalitiesIncreased risk of metabolic syndrome and type 2 diabetesDecreased testosteroneDecreased body hairCancer riskIncreased risk: breast, lung, non-hodgkin lymphomaDecreased risk: prostate, bladder, non melanoma skin cancers",
                    "sub_points": [
                      "1/600 male live births",
                      "21% fetal loss rate",
                      "Multiple abnormalities﻿Musculoskeletal﻿Tall heightIncreased risk of fracture﻿Neuropsychiatric﻿Low to normal IQNo major behavioral disorders﻿Sexual development﻿HypogonadismAzoospermia/infertilityGynecomastiaEndocrine abnormalitiesIncreased risk of metabolic syndrome and type 2 diabetesDecreased testosteroneDecreased body hairCancer riskIncreased risk: breast, lung, non-hodgkin lymphomaDecreased risk: prostate, bladder, non melanoma skin cancers",
                      "﻿Musculoskeletal﻿Tall heightIncreased risk of fracture",
                      "Tall height",
                      "Increased risk of fracture",
                      "﻿Neuropsychiatric﻿Low to normal IQNo major behavioral disorders",
                      "Low to normal IQ",
                      "No major behavioral disorders",
                      "﻿Sexual development﻿HypogonadismAzoospermia/infertilityGynecomastia",
                      "Hypogonadism",
                      "Azoospermia/infertility",
                      "Gynecomastia",
                      "Endocrine abnormalitiesIncreased risk of metabolic syndrome and type 2 diabetesDecreased testosteroneDecreased body hair",
                      "Increased risk of metabolic syndrome and type 2 diabetes",
                      "Decreased testosterone",
                      "Decreased body hair",
                      "Cancer riskIncreased risk: breast, lung, non-hodgkin lymphomaDecreased risk: prostate, bladder, non melanoma skin cancers",
                      "Increased risk: breast, lung, non-hodgkin lymphoma",
                      "Decreased risk: prostate, bladder, non melanoma skin cancers"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Ultrasonographic Findings": [
                  {
                    "text": "Prenatal ultrasound may show cystic hygroma and cardiac abnormalities in Turner syndrome"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "Cytogenetic studiesFISH for specific chromosome gainsKaryotypeMicroarray",
                    "sub_points": [
                      "FISH for specific chromosome gains",
                      "Karyotype",
                      "Microarray"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Malignant Hyperthermia": {
            "name": "Malignant Hyperthermia",
            "url": "https://app.pathprimer.com/document/aef6b438-1603-4675-bc77-103938424954/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "﻿Autosomal dominant ph﻿armacogenetic disorder characterized by skeletal muscle rigidity resulting in metabolic heat generation (hyperthermia) and rhabdomyolysis due to exposure to certain anesthetic and neuromuscular blocking agents"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "RYR1mutations are seen in 75% of patients;RYR1gene encodes ryanodine receptor, a calcium channel expressed on sarcoplasmic reticulum"
                  },
                  {
                    "text": "CACNA1Smutations are detected in approximately 1% of patients;CACNA1Sgene encodes dihydropyridine receptor, a calcium channel expressed on skeletal muscle cell membrane"
                  },
                  {
                    "text": "In patients with MHS, anesthetics, neuromuscular blocking agents, and caffeine enhance effect of calcium onRYR1channels resulting in exaggerated release of calcium from sarcoplasmic reticulum"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Episodes ﻿of MH occur intraoperatively﻿or less commonly in early postoperative period"
                  },
                  {
                    "text": "Clinical features on exposure to anesthesia include generalized skeletal muscle rigidity (especially masseter muscle), hyperthermia (> 42°C), rhabdomyolysis, and acute renal failure"
                  },
                  {
                    "text": "Likelihood of death is high if dantrolene is not administered immediately﻿; approximately 10% mortality rate in United States"
                  },
                  {
                    "text": "Chemistry laboratory findings﻿Findings attributable to rhabdomyolysis﻿Elevated serum CPK, myoglobinemia, myoglobinuria, hyperkalemia, hyperphosphatemiaFindings attributable to acute renal failure (due to myoglobin nephrotoxicity)﻿Findings attributable to mixed respiratory and metabolic acidosis﻿",
                    "sub_points": [
                      "﻿Findings attributable to rhabdomyolysis﻿",
                      "Elevated serum CPK, myoglobinemia, myoglobinuria, hyperkalemia, hyperphosphatemia",
                      "Findings attributable to acute renal failure (due to myoglobin nephrotoxicity)",
                      "﻿Findings attributable to mixed respiratory and metabolic acidosis﻿"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Malignant hyperthermia (MH)"
                  },
                  {
                    "text": "Calcium channel, voltage-dependent, l type, alpha-1S subunit (OMIM 114208) (CACNA1S)"
                  },
                  {
                    "text": "Ryanodine receptor 1 (OMIM 180901) (RYR1)"
                  },
                  {
                    "text": "Malignant hyperthermia susceptibility (OMIM PS145600, phenotypic series includes 7 entries) (MHS)"
                  },
                  {
                    "text": "Adenosine triphosphate (ATP)"
                  },
                  {
                    "text": "Creatine phosphokinase (CPK)"
                  },
                  {
                    "text": "Disseminated intravascular coagulation (DIC)"
                  },
                  {
                    "text": "Sudden infant death syndrome (SIDS)"
                  },
                  {
                    "text": "In vitro contracture test (IVCT)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Malignant hyperpyrexia"
                  },
                  {
                    "text": "Hyperthermia of anesthesia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "﻿Autosomal dominant﻿pharmacogenetic disorder characterized by skeletal muscle rigidity resulting in metabolic heat generation (hyperthermia) and rhabdomyolysis due to exposure to certain anesthetic and neuromuscular blocking agents"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "﻿Episodes of MH are induced by exposure to volatile anesthetics and neuromuscular blocking agents in genetically susceptible individuals﻿"
                  },
                  {
                    "text": "Offending agentsVolatile anestheticsHalothaneSevofluraneDesfluraneIsofluraneEnfluraneNeuromuscular blocking agents (depolarizing)Suxamethonium (succinylcholine)Decamethonium",
                    "sub_points": [
                      "Volatile anestheticsHalothaneSevofluraneDesfluraneIsofluraneEnflurane",
                      "Halothane",
                      "Sevoflurane",
                      "Desflurane",
                      "Isoflurane",
                      "Enflurane",
                      "Neuromuscular blocking agents (depolarizing)Suxamethonium (succinylcholine)Decamethonium",
                      "Suxamethonium (succinylcholine)",
                      "Decamethonium"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "CACNA1Sgene encodes dihydropyridine receptor, a calcium channel expressed on skeletal muscle cell membraneCACNA1Schannels open in response to action potential and allow entry of Ca²⁺ into cell",
                    "sub_points": [
                      "CACNA1Schannels open in response to action potential and allow entry of Ca²⁺ into cell"
                    ]
                  },
                  {
                    "text": "RYR1gene encodes ryanodine receptor, a calcium channel expressed on sarcoplasmic reticulumIncreased intracellular Ca²⁺ stimulates opening ofRYR1channels to release sarcoplasmic reticulum Ca²⁺ into cytoplasm, further increasing cytosolic Ca²⁺",
                    "sub_points": [
                      "Increased intracellular Ca²⁺ stimulates opening ofRYR1channels to release sarcoplasmic reticulum Ca²⁺ into cytoplasm, further increasing cytosolic Ca²⁺"
                    ]
                  },
                  {
                    "text": "Elevation in cytoplasmic Ca²⁺ is required for required for excitation-contraction coupling"
                  },
                  {
                    "text": "After muscle contraction, Ca²⁺ is pumped out of cell and into sarcoplasmic reticulum, normalizing cytoplasmic Ca²⁺ to resting levels"
                  },
                  {
                    "text": "In patients with MHS, anesthetics, neuromuscular blocking agents, and caffeine enhance the effect of calcium onRYR1channelsResults in exaggerated release of Ca²⁺ from sarcoplasmic reticulum",
                    "sub_points": [
                      "Results in exaggerated release of Ca²⁺ from sarcoplasmic reticulum"
                    ]
                  },
                  {
                    "text": "Excess Ca²⁺ in cytoplasm results in sustained muscle contractions, ATP and glycogen depletion, metabolic heat generation (hyperthermia), lactic acidosis, and muscle cell membrane damage (rhabdomyolysis)Condition may be life-threatening (malignant)Cellular contents (myoglobin, CPK, potassium, phosphate) leak from cell﻿﻿Myoglobinemia can cause renal tubular injury, acute renal failure, and myoglobinuria﻿﻿Hyperkalemia can cause tachycardia and arrhythmia﻿﻿Increased heat generation (hyperthermia) can cause coagulopathy﻿",
                    "sub_points": [
                      "Condition may be life-threatening (malignant)",
                      "Cellular contents (myoglobin, CPK, potassium, phosphate) leak from cell﻿",
                      "﻿Myoglobinemia can cause renal tubular injury, acute renal failure, and myoglobinuria﻿",
                      "﻿Hyperkalemia can cause tachycardia and arrhythmia﻿",
                      "﻿Increased heat generation (hyperthermia) can cause coagulopathy﻿"
                    ]
                  }
                ],
                "Inheritance Pattern": [
                  {
                    "text": "﻿Autosomal dominant ﻿inheritance﻿﻿Incomplete penetrance",
                    "sub_points": [
                      "Incomplete penetrance"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "1 in 10,000-15,000 children"
                  },
                  {
                    "text": "1 in 50,000-100,000 adults"
                  },
                  {
                    "text": "About 10,000 cases/yr in United States"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Clinical features on exposure to anesthesiaEpisodes of MH occur intraoperativelyLess commonly in early postoperative periodGeneralized skeletal muscle rigidity (especially masseter muscle)RhabdomyolysisHyperthermia (> 42°C)Coagulopathy, including DICApneaRespiratory and metabolic acidosisTachycardia, arrhythmia, cardiac arrest (secondary to hyperkalemia)Acute renal failureCompartment syndrome",
                    "sub_points": [
                      "Episodes of MH occur intraoperativelyLess commonly in early postoperative period",
                      "Less commonly in early postoperative period",
                      "Generalized skeletal muscle rigidity (especially masseter muscle)",
                      "Rhabdomyolysis",
                      "Hyperthermia (> 42°C)Coagulopathy, including DIC",
                      "Coagulopathy, including DIC",
                      "Apnea",
                      "Respiratory and metabolic acidosis",
                      "Tachycardia, arrhythmia, cardiac arrest (secondary to hyperkalemia)",
                      "Acute renal failure",
                      "Compartment syndrome"
                    ]
                  },
                  {
                    "text": "Patients otherwise clinically normalHomozygotes may have myopathyAssociation with SIDSMay have episodes secondary to other exposuresViral infectionsAlcoholStimulant drugsMedications (neuroleptics)Intense exercise/exertionHot climates",
                    "sub_points": [
                      "Homozygotes may have myopathy",
                      "Association with SIDS",
                      "May have episodes secondary to other exposuresViral infectionsAlcoholStimulant drugsMedications (neuroleptics)Intense exercise/exertionHot climates",
                      "Viral infections",
                      "Alcohol",
                      "Stimulant drugs",
                      "Medications (neuroleptics)",
                      "Intense exercise/exertion",
                      "Hot climates"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Chemistry laboratory findings﻿Findings attributable to rhabdomyolysis﻿Elevated serum CPKMyoglobinemiaMyoglobinuriaHyperkalemiaHyperphosphatemiaFindings attributable to acute renal failure (due to myoglobin nephrotoxicity)Elevated creatinine﻿Findings attributable to mixed respiratory and metabolic acidosis﻿Acidosis (pH < 7.4)Hypercapnia (PaCO₂ > 60 mm Hg)Anion gap > 8 mEq/L",
                    "sub_points": [
                      "﻿Findings attributable to rhabdomyolysis﻿Elevated serum CPKMyoglobinemiaMyoglobinuriaHyperkalemiaHyperphosphatemia",
                      "Elevated serum CPK",
                      "Myoglobinemia",
                      "Myoglobinuria",
                      "Hyperkalemia",
                      "Hyperphosphatemia",
                      "Findings attributable to acute renal failure (due to myoglobin nephrotoxicity)Elevated creatinine",
                      "Elevated creatinine",
                      "﻿Findings attributable to mixed respiratory and metabolic acidosis﻿Acidosis (pH < 7.4)Hypercapnia (PaCO₂ > 60 mm Hg)Anion gap > 8 mEq/L",
                      "Acidosis (pH < 7.4)",
                      "Hypercapnia (PaCO₂ > 60 mm Hg)",
                      "Anion gap > 8 mEq/L"
                    ]
                  },
                  {
                    "text": "IVCT (a.k.a. caffeine/halothane contracture test)Diagnosis made by observing skeletal muscle contracture in biopsy specimen on exposure to caffeine &/or halothane",
                    "sub_points": [
                      "Diagnosis made by observing skeletal muscle contracture in biopsy specimen on exposure to caffeine &/or halothane"
                    ]
                  },
                  {
                    "text": "Molecular testing forRYR1andCACNA1S﻿RYR1mutations seen in 75% of patientsVarious missense mutations inRYR1cause MHSOther mutations in same gene cause King-Denborough syndrome, central core disease, minicore myopathy with external ophthalmoplegia, and congenital neuromuscular disease with uniform type 1 fiberCACNA1Smutations are detected in approximately 1% of patientsTwo missense mutations at same amino acid position inCACNA1Scause MHSDifferent missense mutations in same gene cause hypokalemic periodic paralysis and thyrotoxic periodic paralysisTesting may be targeted to 1 or both genes or may be part of larger next-generation sequencing panel for hereditary neuromuscular disorders﻿Indications for molecular testing﻿Clinically suspected MHS and positive, unknown, or equivocal in vitro contracture testTesting of family members of index patientIndex patient should be tested first to identify causative mutationTargeted testing can then be performed on family membersUseful in planning future surgeries or pregnanciesNegative test results do not exclude MHS",
                    "sub_points": [
                      "RYR1mutations seen in 75% of patientsVarious missense mutations inRYR1cause MHSOther mutations in same gene cause King-Denborough syndrome, central core disease, minicore myopathy with external ophthalmoplegia, and congenital neuromuscular disease with uniform type 1 fiber",
                      "Various missense mutations inRYR1cause MHS",
                      "Other mutations in same gene cause King-Denborough syndrome, central core disease, minicore myopathy with external ophthalmoplegia, and congenital neuromuscular disease with uniform type 1 fiber",
                      "CACNA1Smutations are detected in approximately 1% of patientsTwo missense mutations at same amino acid position inCACNA1Scause MHSDifferent missense mutations in same gene cause hypokalemic periodic paralysis and thyrotoxic periodic paralysis",
                      "Two missense mutations at same amino acid position inCACNA1Scause MHS",
                      "Different missense mutations in same gene cause hypokalemic periodic paralysis and thyrotoxic periodic paralysis",
                      "Testing may be targeted to 1 or both genes or may be part of larger next-generation sequencing panel for hereditary neuromuscular disorders",
                      "﻿Indications for molecular testing﻿Clinically suspected MHS and positive, unknown, or equivocal in vitro contracture testTesting of family members of index patientIndex patient should be tested first to identify causative mutationTargeted testing can then be performed on family members",
                      "Clinically suspected MHS and positive, unknown, or equivocal in vitro contracture test",
                      "Testing of family members of index patientIndex patient should be tested first to identify causative mutationTargeted testing can then be performed on family members",
                      "Index patient should be tested first to identify causative mutation",
                      "Targeted testing can then be performed on family members",
                      "Useful in planning future surgeries or pregnancies",
                      "Negative test results do not exclude MHS"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "PreventionCareful preoperative past medical history, surgical history, and family historyAvoid volatile anesthetics and depolarizing neuromuscular blocking agents in predisposed individuals",
                    "sub_points": [
                      "Careful preoperative past medical history, surgical history, and family history",
                      "Avoid volatile anesthetics and depolarizing neuromuscular blocking agents in predisposed individuals"
                    ]
                  },
                  {
                    "text": "﻿Dantrolene may be given prophylactically in predisposed patients﻿"
                  },
                  {
                    "text": "MH episodeImmediately discontinue offending agentPrompt intravenous dantroleneCool body with ice and intravenous solutions",
                    "sub_points": [
                      "Immediately discontinue offending agent",
                      "Prompt intravenous dantrolene",
                      "Cool body with ice and intravenous solutions"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Likelihood of death high if dantrolene is not administered immediately"
                  },
                  {
                    "text": "Approximately 10% mortality rate in United States"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Broad Differential Diagnosis Requires Integration of Clinical and Laboratory Findings": [
                  {
                    "text": "Association with anesthetic or neuromuscular blocking agents is key"
                  },
                  {
                    "text": "Neuroleptic malignant syndromeNearly identical features but with exposure to antipsychotic medications",
                    "sub_points": [
                      "Nearly identical features but with exposure to antipsychotic medications"
                    ]
                  },
                  {
                    "text": "Serotonin syndromeOverlapping features but occurs with exposure to selective serotonin reuptake inhibitors",
                    "sub_points": [
                      "Overlapping features but occurs with exposure to selective serotonin reuptake inhibitors"
                    ]
                  },
                  {
                    "text": "Adrenergic crisisOccurs in patients with pheochromocytomasCharacterized by hypertension, tachycardia, and elevated temperature but not rigidity",
                    "sub_points": [
                      "Occurs in patients with pheochromocytomas",
                      "Characterized by hypertension, tachycardia, and elevated temperature but not rigidity"
                    ]
                  },
                  {
                    "text": "ThyrotoxicosisCharacterized by goiter, antithyroid antibodies, hypertension, and elevated temperature but not rigidity",
                    "sub_points": [
                      "Characterized by goiter, antithyroid antibodies, hypertension, and elevated temperature but not rigidity"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Noonan Syndrome": {
            "name": "Noonan Syndrome",
            "url": "https://app.pathprimer.com/document/368ddc4d-1a80-4678-875a-329d098c8fbe/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Genetic multisystem disorder characterized by short stature, facial dysmorphism, developmental delay, learning difficulties, bleeding abnormalities, and a spectrum of congenital heart defects"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "Up to 50% of Noonan syndrome cases due to mutations in the protein-tyrosine-phosphatase, nonreceptor type 11 gene (PTPN11) on chromosome 12q24"
                  },
                  {
                    "text": "Mutations inSOS1, RAF1, KRAS, NRAS, BRAF, SHOC2, andCBLcan also occurVarious mutations lead to different presentations",
                    "sub_points": [
                      "Various mutations lead to different presentations"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "B-lymphoblastic leukemia (B-cell ALL or B-ALL)"
                  },
                  {
                    "text": "Juvenile myelomonocytic leukemia (JMML)"
                  },
                  {
                    "text": "Noonan syndrome (NS1)"
                  },
                  {
                    "text": "Recombinant human growth hormone (rhGH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Male Turner syndrome"
                  },
                  {
                    "text": "Noonan-Ehmke syndrome"
                  },
                  {
                    "text": "Pseudo-Ullrich-Turner syndrome"
                  },
                  {
                    "text": "Ullrich-Noonan syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Noonan syndrome: Genetic multisystem disorder characterized by short stature, facial dysmorphism, developmental delay, learning difficulties, bleeding disorders, and a spectrum of congenital heart defects"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Inheritance": [
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "Expression is variable"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Mutations in the RAS-MAPK signal transduction pathway, in genes that are important in cell growth regulationUp to 50% of Noonan syndrome cases due to mutations in the protein-tyrosine-phosphatase, nonreceptor type 11 gene (PTPN11) on chromosome 12q24Mutations inSOS1, RAF1, KRAS, NRAS, BRAF, SHOC2, andCBLcan also occurVarious mutations lead to different presentations",
                    "sub_points": [
                      "Up to 50% of Noonan syndrome cases due to mutations in the protein-tyrosine-phosphatase, nonreceptor type 11 gene (PTPN11) on chromosome 12q24",
                      "Mutations inSOS1, RAF1, KRAS, NRAS, BRAF, SHOC2, andCBLcan also occurVarious mutations lead to different presentations",
                      "Various mutations lead to different presentations"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Incidence1:1000 to 1:2500",
                    "sub_points": [
                      "1:1000 to 1:2500"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Affects males and females equally"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Affects all ethnic groups"
                  }
                ],
                "Presentation": [
                  {
                    "text": "No set diagnostic criteria due to variations in features that become milder with age"
                  },
                  {
                    "text": "Prenatal and postnatalLymphedemaIncreased nuchal translucencyCystic hygroma",
                    "sub_points": [
                      "Lymphedema",
                      "Increased nuchal translucency",
                      "Cystic hygroma"
                    ]
                  },
                  {
                    "text": "Cardiovascular defects"
                  },
                  {
                    "text": "Abnormal faciesHypertelorismDown-slanting palpebral fissuresWebbed neck",
                    "sub_points": [
                      "Hypertelorism",
                      "Down-slanting palpebral fissures",
                      "Webbed neck"
                    ]
                  },
                  {
                    "text": "Short stature"
                  },
                  {
                    "text": "Chest deformity"
                  },
                  {
                    "text": "Developmental delay"
                  },
                  {
                    "text": "Bleeding abnormalities (coagulation defects and platelet dysfunction)"
                  },
                  {
                    "text": "Associated malignanciesJMMLB-ALLNeuroblastomaRhabdomyosarcoma",
                    "sub_points": [
                      "JMML",
                      "B-ALL",
                      "Neuroblastoma",
                      "Rhabdomyosarcoma"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Cardiac defectsSurgical repair",
                    "sub_points": [
                      "Surgical repair"
                    ]
                  },
                  {
                    "text": "Monitor for coagulopathies"
                  },
                  {
                    "text": "Short statureGrowth hormone therapyIn 2007, FDA approved administration of rhGH to treat patients with short stature associated with Noonan syndrome",
                    "sub_points": [
                      "Growth hormone therapyIn 2007, FDA approved administration of rhGH to treat patients with short stature associated with Noonan syndrome",
                      "In 2007, FDA approved administration of rhGH to treat patients with short stature associated with Noonan syndrome"
                    ]
                  },
                  {
                    "text": "Surveillance for associated malignancies"
                  }
                ]
              },
              "IMAGING": {
                "Ultrasonographic Findings": [
                  {
                    "text": "First-trimester ultrasound performed between 10 and 14 weeks may show evidence of cystic hygroma or increased nuchal fold in presence of normal karyotype"
                  },
                  {
                    "text": "Fetal echocardiographyCardiac anomalies may be seen (e.g., pulmonary stenosis, aortic coarctation)",
                    "sub_points": [
                      "Cardiac anomalies may be seen (e.g., pulmonary stenosis, aortic coarctation)"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "Normal karyotypingIn females suspected of having Noonan syndrome, this is key for distinguishing it from Turner syndrome (they share many features)",
                    "sub_points": [
                      "In females suspected of having Noonan syndrome, this is key for distinguishing it from Turner syndrome (they share many features)"
                    ]
                  },
                  {
                    "text": "Molecular testingIn individuals suggestive of more than one of the syndromes with overlapping features, this helps distinguish them",
                    "sub_points": [
                      "In individuals suggestive of more than one of the syndromes with overlapping features, this helps distinguish them"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Turner Syndrome": [
                  {
                    "text": "Many phenotypic overlapping features shared with Noonan syndrome"
                  },
                  {
                    "text": "Females with Noonan syndrome have a normal karyotype"
                  }
                ],
                "LEOPARD Syndrome": [
                  {
                    "text": "LEOPARD acronymLentiginesElectrocardiogram abnormalitiesOcular hypertelorismPulmonary stenosisAbnormal genitaliaRetardation of growthDeafness",
                    "sub_points": [
                      "Lentigines",
                      "Electrocardiogram abnormalities",
                      "Ocular hypertelorism",
                      "Pulmonary stenosis",
                      "Abnormal genitalia",
                      "Retardation of growth",
                      "Deafness"
                    ]
                  },
                  {
                    "text": "Also caused by eitherPTPN11orRAF1mutations"
                  }
                ],
                "Cardiofaciocutaneous Syndrome": [
                  {
                    "text": "Many phenotypic overlapping features shared with Noonan syndrome"
                  },
                  {
                    "text": "Characteristic facial appearance involves rounder, more bulbous nasal tip, wider nasal base, fuller lips, and coarser facial features (see Digilio MC)"
                  },
                  {
                    "text": "Heterozygous mutations inBRAF,KRAS,MEK1andMEK2"
                  }
                ],
                "Costello Syndrome": [
                  {
                    "text": "Coarse facial features, wide nasal bridge, cardiac abnormalities, increased skin pigmentation, deep palmar and plantar creases, short stature, premature aging and hair loss, intellectual disability"
                  },
                  {
                    "text": "HRASgene mutations"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Phenylketonuria": {
            "name": "Phenylketonuria",
            "url": "https://app.pathprimer.com/document/a5b56e3b-ab36-42be-a2fe-f89a509bbb37/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "PKU is amino acid disorder due to deficiency of PAH, which is necessary to catalyze conversion of Phe to tyrosine"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Inheritance is autosomal recessive"
                  },
                  {
                    "text": "Deficiency in PAH leads to inability to degrade Phe, which results in increase of amino acid and its ketones"
                  },
                  {
                    "text": "BH4 is essential cofactor necessary for PAH activity; impaired recycling or synthesis of this enzyme can be rare cause of PKU"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Increase in concentration of Phe metabolite, phenylacetic acid, in the body and urine causes \"mousy\" odor"
                  },
                  {
                    "text": "Characteristic feature is intellectual disability"
                  },
                  {
                    "text": "Treatment is with Phe-restricted diet"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Newborn screening done at 24 hr of life for all newborns"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Phenylketonuria (PKU)"
                  },
                  {
                    "text": "Phenylalanine hydroxylase (PAH)"
                  },
                  {
                    "text": "Tetrahydrobiopterin (BH4)"
                  },
                  {
                    "text": "Phenylalanine (Phe)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "PKU: Amino acid disorder due to deficiency of PAH, which is necessary to catalyze conversion of phenylalanine to tyrosine, causing neurologic damage"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "Autosomal recessive"
                  },
                  {
                    "text": "Mutation of PAH geneChromosome 12q24.1No single mutation dominatesMost mutations affect structure ofPAHenzyme",
                    "sub_points": [
                      "Chromosome 12q24.1",
                      "No single mutation dominates",
                      "Most mutations affect structure ofPAHenzyme"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Conversion of phenylalanine to tyrosine occurs via PAH"
                  },
                  {
                    "text": "BH4 is essential cofactor necessary for PAH activity"
                  },
                  {
                    "text": "Deficiency in PAH leads to inability to degrade Phe, which results in increase of the amino acid and its ketonesAccumulation of Phe in CNS causes damage early in childhoodMechanism by which Phe destroys CNS is unknown",
                    "sub_points": [
                      "Accumulation of Phe in CNS causes damage early in childhoodMechanism by which Phe destroys CNS is unknown",
                      "Mechanism by which Phe destroys CNS is unknown"
                    ]
                  },
                  {
                    "text": "Impaired BH4 recycling and synthesis is rare cause of PKU"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Affects both sexes equally"
                  },
                  {
                    "text": "Occurs in 1:11,000-15,000 individuals"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Infants are asymptomatic before initiation of Phe in dietPhe is present in breast milk and formula",
                    "sub_points": [
                      "Phe is present in breast milk and formula"
                    ]
                  },
                  {
                    "text": "Classic PKU: Serum Phe > 20 mg/dL or 1000 µmol/L, untreated"
                  },
                  {
                    "text": "Characteristic feature is intellectual disability"
                  },
                  {
                    "text": "Common clinical featuresEpilepsyGait abnormalitiesIncrease in concentration of Phe metabolite, phenylacetic acid, in body and urine causes \"mousy\" odorNeurologic disabilities (physiologic and psychological) may still exist even with early treatment",
                    "sub_points": [
                      "Epilepsy",
                      "Gait abnormalities",
                      "Increase in concentration of Phe metabolite, phenylacetic acid, in body and urine causes \"mousy\" odor",
                      "Neurologic disabilities (physiologic and psychological) may still exist even with early treatment"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Diet with Phe restrictionsAllowed only minimal Phe for normal growth",
                    "sub_points": [
                      "Allowed only minimal Phe for normal growth"
                    ]
                  },
                  {
                    "text": "Restricted diet should be started earlyWithin first week of life",
                    "sub_points": [
                      "Within first week of life"
                    ]
                  },
                  {
                    "text": "BH4Essential cofactor for PAH",
                    "sub_points": [
                      "Essential cofactor for PAH"
                    ]
                  },
                  {
                    "text": "SapropterinSynthetic form of BH4",
                    "sub_points": [
                      "Synthetic form of BH4"
                    ]
                  },
                  {
                    "text": "No actual cure exists"
                  },
                  {
                    "text": "Do not delay treatmentTreatment delays can have detrimental effects on neurologic development",
                    "sub_points": [
                      "Treatment delays can have detrimental effects on neurologic development"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "MR Findings": [
                  {
                    "text": "White matter injuryCommonly periventricular white matterThought to be due to increased Phe causing increased myelin turnover",
                    "sub_points": [
                      "Commonly periventricular white matter",
                      "Thought to be due to increased Phe causing increased myelin turnover"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "Used to determine carrier risks for prenatal purposes and at-risk individuals"
                  }
                ],
                "Serologic Testing": [
                  {
                    "text": "Phe concentrations should be monitored frequentlyFirst year of life: Weekly testing1-12 yr old: Twice-monthly testingPhe concentration goal: 2-6 mg/dL≥ 12 yr old: Monthly testingPhe concentration goal: 2-15 mg/dL",
                    "sub_points": [
                      "First year of life: Weekly testing",
                      "1-12 yr old: Twice-monthly testingPhe concentration goal: 2-6 mg/dL",
                      "Phe concentration goal: 2-6 mg/dL",
                      "≥ 12 yr old: Monthly testingPhe concentration goal: 2-15 mg/dL",
                      "Phe concentration goal: 2-15 mg/dL"
                    ]
                  },
                  {
                    "text": "Tyrosine concentrations usually normal or low normal"
                  }
                ],
                "Newborn Screening": [
                  {
                    "text": "Done at 24 hr of life for all newborns"
                  },
                  {
                    "text": "Heel-prick blood test"
                  },
                  {
                    "text": "Measure Phe levels and Phe-to-tyrosine ratio"
                  },
                  {
                    "text": "Must quickly confirm positive testsAll positive tests are further checked for BH4 responsiveness",
                    "sub_points": [
                      "All positive tests are further checked for BH4 responsiveness"
                    ]
                  },
                  {
                    "text": "Methods of testingGuthrie bacterial inhibition assayFluorometryTandem mass spectrometry",
                    "sub_points": [
                      "Guthrie bacterial inhibition assay",
                      "Fluorometry",
                      "Tandem mass spectrometry"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Non-PKU Hyperphenylalaninemia": [
                  {
                    "text": "Some residual activity remains in mutant PAH enzyme"
                  },
                  {
                    "text": "Plasma Phe above upper limit of normal but less than classic PKUPhe concentrations of > 120 µmol/L but < 1000 µmol/L with normal dietNo phenylketone accumulation",
                    "sub_points": [
                      "Phe concentrations of > 120 µmol/L but < 1000 µmol/L with normal diet",
                      "No phenylketone accumulation"
                    ]
                  },
                  {
                    "text": "Usually with normal phenotype"
                  },
                  {
                    "text": "No treatment"
                  }
                ],
                "Variant PKU": [
                  {
                    "text": "Some residual activity remains in mutant PAH enzyme"
                  },
                  {
                    "text": "Essentially consists of individuals who do not fall into category of classic PKU or non-PKU hyperphenylalaninemia"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Polycystic Kidney Disease, Autosomal Dominant": {
            "name": "Polycystic Kidney Disease, Autosomal Dominant",
            "url": "https://app.pathprimer.com/document/1bb5d0cb-8219-4661-816c-3b11008e72d2/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Autosomal dominant polycystic kidney disease (ADPKD)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Genetic disease, autosomal dominant"
                  },
                  {
                    "text": "Ciliopathy involving proteins of primary ciliumPKD1(polycystin-1) 85%PKD2(polycystin-2) 15%",
                    "sub_points": [
                      "PKD1(polycystin-1) 85%",
                      "PKD2(polycystin-2) 15%"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "1 in 400-1,000 individuals"
                  },
                  {
                    "text": "SymptomsHypertensionRenal failureAbdominal pain/discomfortHematuria, infections",
                    "sub_points": [
                      "Hypertension",
                      "Renal failure",
                      "Abdominal pain/discomfort",
                      "Hematuria, infections"
                    ]
                  },
                  {
                    "text": "No known preventive treatment"
                  },
                  {
                    "text": "~ 50% require dialysis or kidney transplant by age 50"
                  }
                ],
                "Macroscopic": [
                  {
                    "text": "Numerous cysts throughout both kidneys"
                  },
                  {
                    "text": "Kidneys weigh up to 3 or 4 kg"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Numerous cysts at all levels of nephron; bilateral"
                  },
                  {
                    "text": "May be renal cell tumors"
                  },
                  {
                    "text": "Cysts in multiple other organsLiver, pancreas, arachnoid, pineal, seminal vesicle",
                    "sub_points": [
                      "Liver, pancreas, arachnoid, pineal, seminal vesicle"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Acquired cystic disease"
                  },
                  {
                    "text": "Autosomal recessive PKD"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Autosomal dominant polycystic kidney disease (ADPKD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Adult-type polycystic kidney disease (PKD)Misnomer as presentations in utero to adolescence can occur",
                    "sub_points": [
                      "Misnomer as presentations in utero to adolescence can occur"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetic Disease": [
                  {
                    "text": "Classified as a ciliopathy"
                  },
                  {
                    "text": "Autosomal dominantRandom somatic mutation of normal allele in individual cells",
                    "sub_points": [
                      "Random somatic mutation of normal allele in individual cells"
                    ]
                  }
                ],
                "PKD1(Polycystin-1) Mutation": [
                  {
                    "text": "Located on chromosome 16"
                  },
                  {
                    "text": "Accounts for 85% of ADPKD"
                  },
                  {
                    "text": "Component of primary ciliumInteracts with and regulates polycystin-2Mechanosensor for flow",
                    "sub_points": [
                      "Interacts with and regulates polycystin-2",
                      "Mechanosensor for flow"
                    ]
                  }
                ],
                "PKD2(Polycystin-2) Mutation": [
                  {
                    "text": "Located on chromosome 4"
                  },
                  {
                    "text": "Accounts for 15% of ADPKD"
                  },
                  {
                    "text": "May act as cation channel for calcium entry into cell"
                  }
                ],
                "Possible Pathogenic Mechanisms Related to Cilium": [
                  {
                    "text": "Abnormal cell proliferation"
                  },
                  {
                    "text": "Deregulated apoptosis"
                  },
                  {
                    "text": "Defective cellular polarity"
                  },
                  {
                    "text": "Increased secretion of fluids into tubular lumens"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "1 in 1,000 live births"
                  }
                ],
                "Age": [
                  {
                    "text": "Cysts develop progressivelyUsual age range at presentation: 30-40 yearsCan also present anytime from before birth through adolescence",
                    "sub_points": [
                      "Usual age range at presentation: 30-40 years",
                      "Can also present anytime from before birth through adolescence"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Women have more cysts in liver and develop them at earlier age than men"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Typically asymptomatic in pediatric patients"
                  },
                  {
                    "text": "Hematuria"
                  },
                  {
                    "text": "Urinary tract infections"
                  },
                  {
                    "text": "Abdominal pain/discomfort in adults"
                  },
                  {
                    "text": "HypertensionCerebral arterial aneurysms with intracranial hemorrhage in 5-10% of adults",
                    "sub_points": [
                      "Cerebral arterial aneurysms with intracranial hemorrhage in 5-10% of adults"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Genetic tests forPKD1orPKD2mutationsMutation detection rate of 65-70% forPKD1Mutation detection rate of nearly 90% forPKD2",
                    "sub_points": [
                      "Mutation detection rate of 65-70% forPKD1",
                      "Mutation detection rate of nearly 90% forPKD2"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "None effective to slow progressionClinical trials of mTOR inhibitors, vasopressin receptor antagonists",
                    "sub_points": [
                      "Clinical trials of mTOR inhibitors, vasopressin receptor antagonists"
                    ]
                  },
                  {
                    "text": "Bilateral nephrectomy if kidneys are too enlarged or repeat episodes of pyelonephritis"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Rare pediatric cause of end-stage kidney disease"
                  },
                  {
                    "text": "~ 50% of patients will require dialysis or kidney transplant by age of 50"
                  },
                  {
                    "text": "PKD2mutations result in milder clinical course compared toPKD1mutations"
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Numerous cysts throughout kidney"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Numerous, randomly distributed cysts throughout both kidneysRare cases of \"1-sided\" ADPKD",
                    "sub_points": [
                      "Rare cases of \"1-sided\" ADPKD"
                    ]
                  },
                  {
                    "text": "Careful examination of nephrectomy specimens to exclude neoplasiaSection at 1 cm intervals",
                    "sub_points": [
                      "Section at 1 cm intervals"
                    ]
                  }
                ],
                "Size": [
                  {
                    "text": "Kidneys can weigh up to 3 or 4 kg"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Cysts in cortex and medulla up to several centimeters in diameterCan arise from any segment of nephron or collecting ductGlomerular, tubular cystsLined by single layer of flattened to cuboidal epithelial cellsHemorrhage may be presentMay be normal intervening parenchyma, depending on stage",
                    "sub_points": [
                      "Can arise from any segment of nephron or collecting duct",
                      "Glomerular, tubular cysts",
                      "Lined by single layer of flattened to cuboidal epithelial cells",
                      "Hemorrhage may be present",
                      "May be normal intervening parenchyma, depending on stage"
                    ]
                  },
                  {
                    "text": "Diffuse interstitial fibrosis and tubular atrophy"
                  },
                  {
                    "text": "Renal cell tumors sometimes present"
                  }
                ],
                "Extrarenal Pathology": [
                  {
                    "text": "Liver cysts (> 90%)Can predominate over renal disease (rarely)Termed polycystic liver disease",
                    "sub_points": [
                      "Can predominate over renal disease (rarely)",
                      "Termed polycystic liver disease"
                    ]
                  },
                  {
                    "text": "Cysts in pancreas (10%), seminal vesicles (39%), pineal gland (< 5%), arachnoid, and ovaries"
                  },
                  {
                    "text": "Mitral valve prolapse or aortic regurgitation in 25%"
                  },
                  {
                    "text": "Diverticulosis"
                  },
                  {
                    "text": "Inguinal, ventral, hiatal hernias"
                  },
                  {
                    "text": "Cerebral (berry) aneurysms"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Autosomal Recessive PKD": [
                  {
                    "text": "Congenital or childhood onset"
                  },
                  {
                    "text": "Ectatic collecting ducts and bile ducts"
                  }
                ],
                "Nephronophthisis": [
                  {
                    "text": "Polyuria"
                  },
                  {
                    "text": "Polydipsia"
                  },
                  {
                    "text": "Medullary cysts, prominent at corticomedullary junction"
                  },
                  {
                    "text": "> 15 genes identifiedNPHP1toNPHP11,JBTS2,JBTS3,JBTS9,andJBTS11",
                    "sub_points": [
                      "NPHP1toNPHP11,JBTS2,JBTS3,JBTS9,andJBTS11"
                    ]
                  }
                ],
                "Simple Cysts": [
                  {
                    "text": "Isolated cysts and much normal parenchyma"
                  },
                  {
                    "text": "Difficult to distinguish from early stage ADPKD"
                  }
                ],
                "Acquired Cystic Disease": [
                  {
                    "text": "Usually < 1 kg, cysts not as widespread"
                  },
                  {
                    "text": "Underlying renal disease evident"
                  },
                  {
                    "text": "Hyperplastic tubular epithelium"
                  },
                  {
                    "text": "May be present in ADPKD"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Prader-Willi and Angelman Syndromes": {
            "name": "Prader-Willi and Angelman Syndromes",
            "url": "https://app.pathprimer.com/document/0a7325ef-ec51-45c7-a74f-74cba236859e/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Genomic imprinting disorders: Phenotypic expression of disease is dependent on inheritance of mutant allele or chromosome from specific parent of origin (mother vs. father)"
                  },
                  {
                    "text": "Uniparental disomy: Occurs when both copies of gene are from same parent﻿"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Genes for both disorders lie on same locus on chromosome 15However, PWS and AS are caused by 2 different gene deletions in that region",
                    "sub_points": [
                      "However, PWS and AS are caused by 2 different gene deletions in that region"
                    ]
                  },
                  {
                    "text": "PWS: Deletion of chromosome 15q12 in paternal chromosome only (70% of cases)﻿Genes in this region on maternal chromosome are imprinted/inactivatedPaternal gene is normally only gene expressed, so﻿ deletion of paternal gene results in complete loss of gene expression, and PWS",
                    "sub_points": [
                      "Genes in this region on maternal chromosome are imprinted/inactivated",
                      "Paternal gene is normally only gene expressed, so﻿ deletion of paternal gene results in complete loss of gene expression, and PWS"
                    ]
                  },
                  {
                    "text": "AS: Deletion of known geneUBE3A, which is expressed on maternal chromosome﻿Paternal chromosome﻿ in this gene is normally﻿ imprinted/inactivated﻿Maternal copy is only gene normally expressed, so deletion of maternal gene results in complete loss of gene expression, and AS",
                    "sub_points": [
                      "Paternal chromosome﻿ in this gene is normally﻿ imprinted/inactivated﻿",
                      "Maternal copy is only gene normally expressed, so deletion of maternal gene results in complete loss of gene expression, and AS"
                    ]
                  },
                  {
                    "text": "Both syndromes can occur due to uniparental disomy"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Prader-Willi syndrome (PWS)"
                  },
                  {
                    "text": "Angelman syndrome (AS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Genomic imprinting: Transcriptional silencing of paternal or maternal copies of genes during gametogenesis"
                  },
                  {
                    "text": "Imprint control element: Utilizes epigenetic mechanisms, DNA methylation, and chromatin to switch imprinted genes \"on\" or \"off\"To maintain correct expression of imprinted genes, these genes must be turned \"off\" in gonadal cellsWithin egg cells, maternal imprints are activated﻿Within sperm, paternal imprints are activated﻿",
                    "sub_points": [
                      "To maintain correct expression of imprinted genes, these genes must be turned \"off\" in gonadal cellsWithin egg cells, maternal imprints are activated﻿Within sperm, paternal imprints are activated﻿",
                      "Within egg cells, maternal imprints are activated﻿",
                      "Within sperm, paternal imprints are activated﻿"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "Genes for both disorders lie on same locus on chromosome 15However, PWS and AS caused by 2 different gene deletions in that region",
                    "sub_points": [
                      "However, PWS and AS caused by 2 different gene deletions in that region"
                    ]
                  },
                  {
                    "text": "Both typically occur sporadically"
                  },
                  {
                    "text": "PWS: Deletion of chromosome 15q12 in paternal chromosome only (70% of cases)﻿Actual gene not yet knownGenes in this region on maternal chromosome are imprinted/inactivated﻿Only paternal ﻿PWS gene is normally expressed﻿Thus, deletion of paternal gene results in complete loss of gene expression, and PWSCan also be caused by uniparental disomy of maternal chromosome 15 (25% of cases)Chromosome would only carry nonexpressing copy of geneRemaining 5% of cases are due to other chromosomal abnormalities or mutations in imprinting control element",
                    "sub_points": [
                      "Actual gene not yet known",
                      "Genes in this region on maternal chromosome are imprinted/inactivated﻿",
                      "Only paternal ﻿PWS gene is normally expressed﻿Thus, deletion of paternal gene results in complete loss of gene expression, and PWS",
                      "Thus, deletion of paternal gene results in complete loss of gene expression, and PWS",
                      "Can also be caused by uniparental disomy of maternal chromosome 15 (25% of cases)Chromosome would only carry nonexpressing copy of gene",
                      "Chromosome would only carry nonexpressing copy of gene",
                      "Remaining 5% of cases are due to other chromosomal abnormalities or mutations in imprinting control element"
                    ]
                  },
                  {
                    "text": "AS: Deletion of known geneUBE3A, which is expressed on maternal chromosome﻿Paternal chromosome﻿ in this gene is normally﻿ imprinted/inactivatedMaternal copy is only gene normally expressedThus, ﻿deletion of maternal gene r﻿esults in complete loss of gene expression, and AS",
                    "sub_points": [
                      "Paternal chromosome﻿ in this gene is normally﻿ imprinted/inactivated",
                      "Maternal copy is only gene normally expressedThus, ﻿deletion of maternal gene r﻿esults in complete loss of gene expression, and AS",
                      "Thus, ﻿deletion of maternal gene r﻿esults in complete loss of gene expression, and AS"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "PWSSevere hypotonia in infancyCan show some improvement over timeFeeding difficulties during infancyHypoplastic genitaliaDoes not usually improveCan lead to infertilityObesityHyperphagia during childhoodDiabetes type 2Mental retardationOsteoporosis",
                    "sub_points": [
                      "Severe hypotonia in infancyCan show some improvement over time",
                      "Can show some improvement over time",
                      "Feeding difficulties during infancy",
                      "Hypoplastic genitaliaDoes not usually improveCan lead to infertility",
                      "Does not usually improve",
                      "Can lead to infertility",
                      "ObesityHyperphagia during childhoodDiabetes type 2",
                      "Hyperphagia during childhood",
                      "Diabetes type 2",
                      "Mental retardation",
                      "Osteoporosis"
                    ]
                  },
                  {
                    "text": "ASAtaxiaPuppet-like faciesParoxysmal laughterSeizuresSevere mental retardation",
                    "sub_points": [
                      "Ataxia",
                      "Puppet-like facies",
                      "Paroxysmal laughter",
                      "Seizures",
                      "Severe mental retardation"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "No actual treatment, only management of comorbid conditions"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "PWSObesity and diabetes mellitus lead to cardiopulmonary disease, which is major cause of morbidity",
                    "sub_points": [
                      "Obesity and diabetes mellitus lead to cardiopulmonary disease, which is major cause of morbidity"
                    ]
                  },
                  {
                    "text": "ASLifespan is normalEarly intervention and therapies tailored toward comorbid conditions can improve quality of life",
                    "sub_points": [
                      "Lifespan is normal",
                      "Early intervention and therapies tailored toward comorbid conditions can improve quality of life"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Methods of Detection of Uniparental Disomy or Deletion": [
                  {
                    "text": "Methylation analysis via PCR &/or Southern blotting done first on 15q11-13Southern blotting and PCR cannot distinguish between uniparental disomy or deletion as mechanism of cause of PWS and AS",
                    "sub_points": [
                      "Southern blotting and PCR cannot distinguish between uniparental disomy or deletion as mechanism of cause of PWS and AS"
                    ]
                  },
                  {
                    "text": "FISH &/or karyotype can be used to determine method of inheritance"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Failure to Thrive": [
                  {
                    "text": "Patients can present with failure to thrive, which has long list of differential diagnosis"
                  },
                  {
                    "text": "Nutritional causes must be evaluated and ruled out"
                  }
                ],
                "Fragile X Syndrome": [
                  {
                    "text": "Can present with feeding difficulties and hypogonadism; patients have cognitive and developmental delay similar to PWS"
                  },
                  {
                    "text": "Fragile X is caused by trinucleotide repeat, CGG, inFMR1gene"
                  }
                ],
                "Rett Syndrome": [
                  {
                    "text": "During infancy, presentation can be similar to AS, with seizure disorder and hypotonia seen in girls"
                  },
                  {
                    "text": "X-linked dominant; due to loss-of-function mutations ofMECP2gene"
                  }
                ],
                "16p11.2 Microdeletion Syndrome": [
                  {
                    "text": "Impaired speech and language skills; prone to seizures; often obese"
                  },
                  {
                    "text": "Autosomal-dominant condition caused by deletion on chromosome 16p11.2"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Clinical screening is necessary to determine which patients will have genetic testing"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Tay-Sachs Disease": {
            "name": "Tay-Sachs Disease",
            "url": "https://app.pathprimer.com/document/e869b9e1-1feb-40f1-be22-c6d46d36f636/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "TSD is lysosomal storage disease characterized by deficiency of hexosaminidase A disrupting ganglioside catabolism"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Lysosomal enzyme, hexosaminidase A, coded for byHEXAgene on chromosome 15"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Infantile-onset: Most severe form with death in early childhood"
                  },
                  {
                    "text": "Increased incidence in Ashkenazi Jewish population"
                  }
                ],
                "Macroscopic": [
                  {
                    "text": "Rapid visual loss detected by classic cherry-red spot on funduscopic examination seen in severe infantile-onset form"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "High-risk populations should be screened to identify carriers"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Tay-Sachs disease (TSD)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Infantile GM₂ gangliosidosis"
                  },
                  {
                    "text": "HEXAmutation"
                  },
                  {
                    "text": "Hexosaminidase activator deficiency"
                  },
                  {
                    "text": "GM₂ activator deficiency"
                  },
                  {
                    "text": "Hexosaminidase α-subunit deficiency (variant B)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Rare inherited disorder with﻿ progressive neuronal death in brain and spinal cord﻿"
                  },
                  {
                    "text": "Lysosomal storage disease characterized by deficiency of hexosaminidase A disrupting ganglioside catabolismResults in neurodegeneration",
                    "sub_points": [
                      "Results in neurodegeneration"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "﻿Autosomal recessive﻿"
                  },
                  {
                    "text": "HEXAgeneChromosome 15Encodes﻿ lysosomal enzyme, hexosaminidase A﻿",
                    "sub_points": [
                      "Chromosome 15",
                      "Encodes﻿ lysosomal enzyme, hexosaminidase A﻿"
                    ]
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Gangliosides abundant in CNSServe various functions including cell-cell communication",
                    "sub_points": [
                      "Serve various functions including cell-cell communication"
                    ]
                  },
                  {
                    "text": "Hexosaminidase A removes terminal amine from ganglioside, GM₂"
                  },
                  {
                    "text": "Mutated hexosaminidase A leads to ganglioside GM₂ accumulation in lysosomesGM₂ accumulation and its by-products are thought to be toxic, causing cell deathSeverity of disease inversely related to hexosaminidase A activityInfant onsetMost severe2 nonfunctional (null) alleles for enzymeAdult or juvenile onsetMilder diseaseCompound heterozygotes for nullHEXAallele and allele with low hexosaminidase A activity",
                    "sub_points": [
                      "GM₂ accumulation and its by-products are thought to be toxic, causing cell death",
                      "Severity of disease inversely related to hexosaminidase A activityInfant onsetMost severe2 nonfunctional (null) alleles for enzymeAdult or juvenile onsetMilder diseaseCompound heterozygotes for nullHEXAallele and allele with low hexosaminidase A activity",
                      "Infant onsetMost severe2 nonfunctional (null) alleles for enzyme",
                      "Most severe",
                      "2 nonfunctional (null) alleles for enzyme",
                      "Adult or juvenile onsetMilder diseaseCompound heterozygotes for nullHEXAallele and allele with low hexosaminidase A activity",
                      "Milder disease",
                      "Compound heterozygotes for nullHEXAallele and allele with low hexosaminidase A activity"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Incidence﻿1 in 3600 Ashkenazi Jews﻿1 in 360,000 non-Ashkenazi Jewish populations (French Canadians of Quebec, Pennsylvanian Amish community)",
                    "sub_points": [
                      "﻿1 in 3600 Ashkenazi Jews﻿",
                      "1 in 360,000 non-Ashkenazi Jewish populations (French Canadians of Quebec, Pennsylvanian Amish community)"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Infantile onsetNormal until 3-6 months, when neurologic symptoms manifestDevelopmental delay—intellectual disabilityExaggerated startle reaction to loud noisesLoss of motor skillsLoss of turning over, sitting, crawlingEventual paralysisSeizuresVisual loss progresses within first year of life (cherry-red spot on funduscopic examination)Hearing loss",
                    "sub_points": [
                      "Normal until 3-6 months, when neurologic symptoms manifest",
                      "Developmental delay—intellectual disabilityExaggerated startle reaction to loud noises",
                      "Exaggerated startle reaction to loud noises",
                      "Loss of motor skillsLoss of turning over, sitting, crawlingEventual paralysis",
                      "Loss of turning over, sitting, crawling",
                      "Eventual paralysis",
                      "Seizures",
                      "Visual loss progresses within first year of life (cherry-red spot on funduscopic examination)",
                      "Hearing loss"
                    ]
                  },
                  {
                    "text": "Juvenile onsetManifests between 2 and 4 yr oldAtaxiaLoss of vision due to optic atrophy and retinitis pigmentosa (cherry-red spot may not be seen)Spasticity and seizures by second decade of life",
                    "sub_points": [
                      "Manifests between 2 and 4 yr old",
                      "Ataxia",
                      "Loss of vision due to optic atrophy and retinitis pigmentosa (cherry-red spot may not be seen)",
                      "Spasticity and seizures by second decade of life"
                    ]
                  },
                  {
                    "text": "Adult onsetManifests in second decadeMotor symptomsWeaknessAtaxiaSpeech problemsNeuropsychiatric symptomsOphthalmologic examination normalVision not affected in this subset of patients",
                    "sub_points": [
                      "Manifests in second decade",
                      "Motor symptomsWeaknessAtaxiaSpeech problems",
                      "Weakness",
                      "Ataxia",
                      "Speech problems",
                      "Neuropsychiatric symptoms",
                      "Ophthalmologic examination normalVision not affected in this subset of patients",
                      "Vision not affected in this subset of patients"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Management of symptoms and palliative careSeizuresAnticonvulsantsAdult-onset psychosisLithiumElectroconvulsive therapyTraditional antipsychotics not effective",
                    "sub_points": [
                      "SeizuresAnticonvulsants",
                      "Anticonvulsants",
                      "Adult-onset psychosisLithiumElectroconvulsive therapyTraditional antipsychotics not effective",
                      "Lithium",
                      "Electroconvulsive therapy",
                      "Traditional antipsychotics not effective"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Infantile onsetDeath by 2-4 yr",
                    "sub_points": [
                      "Death by 2-4 yr"
                    ]
                  },
                  {
                    "text": "Juvenile onsetDeath in second decade of life",
                    "sub_points": [
                      "Death in second decade of life"
                    ]
                  },
                  {
                    "text": "Adult onsetVariable prognosisPredominance of motor and psychiatric symptoms",
                    "sub_points": [
                      "Variable prognosis",
                      "Predominance of motor and psychiatric symptoms"
                    ]
                  }
                ],
                "Diagnosis": [
                  {
                    "text": "Two requirements:Serum or white blood cellsAbsent or nearly absent hexosaminidase A activityNormal to elevated hexosaminidase B activity",
                    "sub_points": [
                      "Serum or white blood cellsAbsent or nearly absent hexosaminidase A activityNormal to elevated hexosaminidase B activity",
                      "Absent or nearly absent hexosaminidase A activity",
                      "Normal to elevated hexosaminidase B activity"
                    ]
                  },
                  {
                    "text": "Prenatal testing or carrier statusHEXAgene mutational analysis",
                    "sub_points": [
                      "HEXAgene mutational analysis"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "HEXAgene mutational analysis to determine prenatal screen or carrier statusFetal tissue assessed forHEXAmutation or hexosaminidase A deficiency",
                    "sub_points": [
                      "Fetal tissue assessed forHEXAmutation or hexosaminidase A deficiency"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Sandhoff Disease": [
                  {
                    "text": "Mutation of β subunit (coded byHEXBgene located on chromosome 5)"
                  }
                ],
                "Gaucher Disease": [
                  {
                    "text": "Neuropathy seen in type 2 or 3"
                  }
                ],
                "Niemann-Pick Disease Type A": [
                  {
                    "text": "Affected children normal until approximately 1 yr old when they experience progressive cognitive and motor decline"
                  },
                  {
                    "text": "Usually fatal in early childhood"
                  },
                  {
                    "text": "Cherry-red spot seen on eye examination"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Cherry-red spot on retinal examination seen in infantile-onset TSD"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Severe disease with infantile onset"
                  },
                  {
                    "text": "Milder disease with adult onset"
                  },
                  {
                    "text": "High-risk populations should be screened to identify carriers and reduce disease incidence"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Autosomal Aneuploidies (Trisomy 13, Trisomy 18, Trisomy 21)": {
            "name": "Autosomal Aneuploidies (Trisomy 13, Trisomy 18, Trisomy 21)",
            "url": "https://app.pathprimer.com/document/c05b877b-5526-4a93-a44f-855e00a4cad9/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Most are due to maternal meiotic nondisjunction"
                  },
                  {
                    "text": "Rarely due to unbalanced robertsonian translocation"
                  },
                  {
                    "text": "Autosomal aneuploidies lead to various developmental abnormalities, IUGR, and intellectual delay"
                  },
                  {
                    "text": "Risk increases with advancing maternal age"
                  }
                ],
                "Imaging": [
                  {
                    "text": "CNS and cardiac abnormalities can be diagnosed on ultrasound"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "NIPTUses maternal blood sample to screen for chromosomal abnormalities with high negative predictive valueNot entirely specific, so positive NIPT should be followed up with CVS or amniocentesis, and cytogenetics studies",
                    "sub_points": [
                      "Uses maternal blood sample to screen for chromosomal abnormalities with high negative predictive value",
                      "Not entirely specific, so positive NIPT should be followed up with CVS or amniocentesis, and cytogenetics studies"
                    ]
                  },
                  {
                    "text": "Cytogenetics studiesFISHKaryotypeMicroarray",
                    "sub_points": [
                      "FISH",
                      "Karyotype",
                      "Microarray"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Atrial septal defect (ASD)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  },
                  {
                    "text": "Chorionic villus sampling (CVS)"
                  },
                  {
                    "text": "Fluorescence in-situ hybridization (FISH)"
                  },
                  {
                    "text": "Gestational age (GA)"
                  },
                  {
                    "text": "Intrauterine growth restriction (IUGR)"
                  },
                  {
                    "text": "Noninvasive prenatal testing (NIPT)"
                  },
                  {
                    "text": "Ventricular septal defect (VSD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Patau syndrome: Trisomy 13"
                  },
                  {
                    "text": "Edwards syndrome: Trisomy 18"
                  },
                  {
                    "text": "Down syndrome: Trisomy 21"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Aneuploidy: Abnormal number of chromosomes either due gain (e.g., trisomy, tetrasomy) or loss (e.g., monosomy)"
                  },
                  {
                    "text": "Nondisjunction: Failure of chromosomes to properly segregate to daughter cells during cell division"
                  },
                  {
                    "text": "Robertsonian translocation: Chromosomal rearrangement when acrocentric chromosome (13, 14, 15, 21, or 22) has fusion of both long arms into single chromosome with fusion of both short arms into separate chromosome"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Pathogenesis": [
                  {
                    "text": "Most are due to maternal meiotic nondisjunctionRisk increases with advancing maternal age",
                    "sub_points": [
                      "Risk increases with advancing maternal age"
                    ]
                  },
                  {
                    "text": "Rarely due to unbalanced robertsonian translocationNew chromosome with both long arms is segregated into fetus, effectively causing trisomy 13 or trisomy 21",
                    "sub_points": [
                      "New chromosome with both long arms is segregated into fetus, effectively causing trisomy 13 or trisomy 21"
                    ]
                  },
                  {
                    "text": "Autosomal aneuploidies lead to various developmental abnormalities, IUGR, and intellectual delay"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Trisomy 131 per 12,000-20,000 live births97% fetal loss rate, typically by 4 months' GAIUGRSevere intellectual delayMultiple abnormalitiesCNSHoloprosencephalyAgenesis of the corpus callosumSpina bifidaFacialMidline defects; cleft lip or palateOcular abnormalitiesSloping foreheadCardiacASD &/or VSDDextrocardiaRocker-bottom feetClenched fistPostaxial polydactyly",
                    "sub_points": [
                      "1 per 12,000-20,000 live births",
                      "97% fetal loss rate, typically by 4 months' GA",
                      "IUGR",
                      "Severe intellectual delay",
                      "Multiple abnormalitiesCNSHoloprosencephalyAgenesis of the corpus callosumSpina bifidaFacialMidline defects; cleft lip or palateOcular abnormalitiesSloping foreheadCardiacASD &/or VSDDextrocardiaRocker-bottom feetClenched fistPostaxial polydactyly",
                      "CNSHoloprosencephalyAgenesis of the corpus callosumSpina bifida",
                      "Holoprosencephaly",
                      "Agenesis of the corpus callosum",
                      "Spina bifida",
                      "FacialMidline defects; cleft lip or palateOcular abnormalitiesSloping forehead",
                      "Midline defects; cleft lip or palate",
                      "Ocular abnormalities",
                      "Sloping forehead",
                      "CardiacASD &/or VSDDextrocardia",
                      "ASD &/or VSD",
                      "Dextrocardia",
                      "Rocker-bottom feet",
                      "Clenched fist",
                      "Postaxial polydactyly"
                    ]
                  },
                  {
                    "text": "Trisomy 181 per 6,000-8,000 live birthsIUGRSevere intellectual delayMultiple abnormalitiesCNSSpina bifidaFacialMicrognathiaLow-set earsHypotelorismSevere cardiac abnormalitiesOmphaloceleRadial aplasiaClubfoot",
                    "sub_points": [
                      "1 per 6,000-8,000 live births",
                      "IUGR",
                      "Severe intellectual delay",
                      "Multiple abnormalitiesCNSSpina bifidaFacialMicrognathiaLow-set earsHypotelorismSevere cardiac abnormalitiesOmphaloceleRadial aplasiaClubfoot",
                      "CNSSpina bifida",
                      "Spina bifida",
                      "FacialMicrognathiaLow-set earsHypotelorism",
                      "Micrognathia",
                      "Low-set ears",
                      "Hypotelorism",
                      "Severe cardiac abnormalities",
                      "Omphalocele",
                      "Radial aplasia",
                      "Clubfoot"
                    ]
                  },
                  {
                    "text": "Trisomy 211 per 850 live birthsIncreases with advancing maternal ageIUGRMild to moderate intellectual delayMultiple abnormalitiesFacialFlat occiputEnlarged tongueEpicanthal foldsBrushfield spots (white spots on iris)Small ears with overlapping antihelixCardiac abnormalitiesASD &/or VSDAtrioventricular canal defectsDuodenal atresiaIncreased risk of dementiaIncreased risk of acute myeloid leukemia",
                    "sub_points": [
                      "1 per 850 live birthsIncreases with advancing maternal age",
                      "Increases with advancing maternal age",
                      "IUGR",
                      "Mild to moderate intellectual delay",
                      "Multiple abnormalitiesFacialFlat occiputEnlarged tongueEpicanthal foldsBrushfield spots (white spots on iris)Small ears with overlapping antihelixCardiac abnormalitiesASD &/or VSDAtrioventricular canal defectsDuodenal atresia",
                      "FacialFlat occiputEnlarged tongueEpicanthal foldsBrushfield spots (white spots on iris)Small ears with overlapping antihelix",
                      "Flat occiput",
                      "Enlarged tongue",
                      "Epicanthal folds",
                      "Brushfield spots (white spots on iris)",
                      "Small ears with overlapping antihelix",
                      "Cardiac abnormalitiesASD &/or VSDAtrioventricular canal defects",
                      "ASD &/or VSD",
                      "Atrioventricular canal defects",
                      "Duodenal atresia",
                      "Increased risk of dementia",
                      "Increased risk of acute myeloid leukemia"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Trisomy 1350% die within 1 month90% die within 1 year",
                    "sub_points": [
                      "50% die within 1 month",
                      "90% die within 1 year"
                    ]
                  },
                  {
                    "text": "Trisomy 1860% die within 2 months> 95% die within 1 year",
                    "sub_points": [
                      "60% die within 2 months",
                      "> 95% die within 1 year"
                    ]
                  },
                  {
                    "text": "Trisomy 21Life expectancy of ~ 55 years",
                    "sub_points": [
                      "Life expectancy of ~ 55 years"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Ultrasonographic Findings": [
                  {
                    "text": "CNS and cardiac abnormalities can be diagnosed on ultrasound"
                  },
                  {
                    "text": "Increased nuchal translucency seen in trisomy 18 and trisomy 21"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "NIPTUses maternal blood sample to screen for chromosomal abnormalities with high negative predictive valueNot specific; thus, positive NIPT should be followed up with CVS or amniocentesis, and cytogenetics studies",
                    "sub_points": [
                      "Uses maternal blood sample to screen for chromosomal abnormalities with high negative predictive value",
                      "Not specific; thus, positive NIPT should be followed up with CVS or amniocentesis, and cytogenetics studies"
                    ]
                  },
                  {
                    "text": "Cytogenetics studiesFISH for specific chromosome gainsKaryotypeMicroarray",
                    "sub_points": [
                      "FISH for specific chromosome gains",
                      "Karyotype",
                      "Microarray"
                    ]
                  }
                ],
                "Quad Screen": [
                  {
                    "text": "Useful for trisomy 18 and trisomy 21"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "DiGeorge Syndrome": {
            "name": "DiGeorge Syndrome",
            "url": "https://app.pathprimer.com/document/143890d2-883c-4519-a4d7-96904c36e607/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "DGS results from failure of neural crest cells to migrate to 3rd and 4th pharyngeal pouches"
                  },
                  {
                    "text": "22q11.2 deletion is seen in 85-90% of patients with DGS"
                  },
                  {
                    "text": "Deletions of 10p13, 11p13, and 4q21 have been reported to have DGS phenotype"
                  },
                  {
                    "text": "TBX1 point mutations may also result in DGS phenotype"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "DGS, VCFS, and Takao syndrome are clinical syndromes with overlapping clinical features and shared genetic etiologyIn given family (i.e., having same deletion), all 3 clinical syndromes may be representedDGS patients manifest signs and symptoms largely related to parathyroid and thymic hypoplasia/aplasia in neonatal periodVCFS patients present in childhood with signs and symptoms largely related to facial dysmorphology and mild cardiac abnormalitiesTakao syndrome largely characterized by more severe cardiac abnormalities",
                    "sub_points": [
                      "In given family (i.e., having same deletion), all 3 clinical syndromes may be representedDGS patients manifest signs and symptoms largely related to parathyroid and thymic hypoplasia/aplasia in neonatal periodVCFS patients present in childhood with signs and symptoms largely related to facial dysmorphology and mild cardiac abnormalitiesTakao syndrome largely characterized by more severe cardiac abnormalities",
                      "DGS patients manifest signs and symptoms largely related to parathyroid and thymic hypoplasia/aplasia in neonatal period",
                      "VCFS patients present in childhood with signs and symptoms largely related to facial dysmorphology and mild cardiac abnormalities",
                      "Takao syndrome largely characterized by more severe cardiac abnormalities"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "FISH for 22q11.2 locus and separate region on chromosome 22 (control) may be performed on interphase or metaphase preparations"
                  },
                  {
                    "text": "Either aCGH or SNP array may be used to detect deletions"
                  },
                  {
                    "text": "Arrays are preferred method of detectionSome deletions may not be detected by MLPA or FISH",
                    "sub_points": [
                      "Some deletions may not be detected by MLPA or FISH"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Array comparative genomic hybridization (aCGH)"
                  },
                  {
                    "text": "DiGeorge syndrome chromosome region on 22q11.2 (DGCR)"
                  },
                  {
                    "text": "DiGeorge syndrome (DGS) (OMIM 188400)"
                  },
                  {
                    "text": "Multiplex ligation-dependent probe amplification (MLPA)"
                  },
                  {
                    "text": "Single nucleotide polymorphism array (SNP array)"
                  },
                  {
                    "text": "T-box 1 (TBX1) (OMIM 602054)"
                  },
                  {
                    "text": "Velocardiofacial syndrome (VCFS) (OMIM 192430)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Conotruncal anomaly face syndrome: Takao syndrome"
                  },
                  {
                    "text": "VCFS: Shprintzen syndrome"
                  },
                  {
                    "text": "Due to shared genetic etiology and significant overlap in clinical features, terms CATCH22 syndrome and 22q11.2 deletion syndrome are often used to encompass DGS, VCFS, and Takao syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "CATCH22 syndrome: Cardiac abnormality/abnormal facies, T-cell deficit due to thymic hypoplasia, cleft palate, hypocalcemia due to hypoparathyroidism resulting from 22q11 deletion"
                  },
                  {
                    "text": "DGS: Genetic disorder due to deletion of 22q11.2 locus (DGSR) resulting in abnormalities of heart, face, parathyroid glands, and thymus"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Developmental Anomaly": [
                  {
                    "text": "DGS results from failure of neural crest cells to migrate to 3rd and 4th pharyngeal pouchesThese pouches give rise to thymus, parathyroid glands, cardiac structures, and portions of face",
                    "sub_points": [
                      "These pouches give rise to thymus, parathyroid glands, cardiac structures, and portions of face"
                    ]
                  }
                ],
                "Genetic Abnormality": [
                  {
                    "text": "22q11.2 deletion is seen in 85-90% of patients with DGSSegmental duplications are type of repetitive sequence several megabases longSeveral segmental duplications with significant homology are present at 22q11.2 locusThese are substrates for nonallelic homologous recombination events at meiosis that lead to several types of recurrent well-defined deletions and duplicationsDifferent deletions and duplications have somewhat different, but overlapping, clinical featuresCritical gene(s) involved in DGS phenotype has not been precisely defined",
                    "sub_points": [
                      "Segmental duplications are type of repetitive sequence several megabases longSeveral segmental duplications with significant homology are present at 22q11.2 locusThese are substrates for nonallelic homologous recombination events at meiosis that lead to several types of recurrent well-defined deletions and duplicationsDifferent deletions and duplications have somewhat different, but overlapping, clinical features",
                      "Several segmental duplications with significant homology are present at 22q11.2 locusThese are substrates for nonallelic homologous recombination events at meiosis that lead to several types of recurrent well-defined deletions and duplicationsDifferent deletions and duplications have somewhat different, but overlapping, clinical features",
                      "These are substrates for nonallelic homologous recombination events at meiosis that lead to several types of recurrent well-defined deletions and duplications",
                      "Different deletions and duplications have somewhat different, but overlapping, clinical features",
                      "Critical gene(s) involved in DGS phenotype has not been precisely defined"
                    ]
                  },
                  {
                    "text": "Deletions of 10p13, 11p13, and 4q21 have been reported to have DGS phenotype"
                  },
                  {
                    "text": "Point mutations and small deletions in TBX1 may also result in DGS phenotype"
                  }
                ],
                "Inheritance": [
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "~ 6-28% of cases are inheritedOthers are de novo mutations arising in maternal or paternal gametes",
                    "sub_points": [
                      "Others are de novo mutations arising in maternal or paternal gametes"
                    ]
                  },
                  {
                    "text": "Complete penetrance"
                  },
                  {
                    "text": "Markedly variable expressivity both within and between families"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "1 in 2,000-7,000 live births"
                  },
                  {
                    "text": "Most common recurrent microdeletion"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Cardiac abnormalities: Conotruncal/outflow tract abnormalities of heartTetralogy of FallotPulmonic stenosisRight ventricular hypertrophyVentricular septal defectOverriding aortaTruncus arteriosusInterrupted aortic archRight-sided aortic archVentricular septal defectAtrial septal defect",
                    "sub_points": [
                      "Tetralogy of FallotPulmonic stenosisRight ventricular hypertrophyVentricular septal defectOverriding aorta",
                      "Pulmonic stenosis",
                      "Right ventricular hypertrophy",
                      "Ventricular septal defect",
                      "Overriding aorta",
                      "Truncus arteriosus",
                      "Interrupted aortic arch",
                      "Right-sided aortic arch",
                      "Ventricular septal defect",
                      "Atrial septal defect"
                    ]
                  },
                  {
                    "text": "Abnormal faciesMicrognathiaSmall low-set earsAbnormal folded pinnaHypertelorismShort philtrumUp- or down-slanted palpebral fissures",
                    "sub_points": [
                      "Micrognathia",
                      "Small low-set ears",
                      "Abnormal folded pinna",
                      "Hypertelorism",
                      "Short philtrum",
                      "Up- or down-slanted palpebral fissures"
                    ]
                  },
                  {
                    "text": "T-cell deficit due to thymic hypoplasia (or aplasia)Susceptibility to viral and fungal infections",
                    "sub_points": [
                      "Susceptibility to viral and fungal infections"
                    ]
                  },
                  {
                    "text": "Cleft palate (cleft lip is rare)Difficulty feedingHypernasal voice",
                    "sub_points": [
                      "Difficulty feeding",
                      "Hypernasal voice"
                    ]
                  },
                  {
                    "text": "Hypocalcemia due to hypoparathyroidism (parathyroid hypoplasia/aplasia)TetanySeizures",
                    "sub_points": [
                      "Tetany",
                      "Seizures"
                    ]
                  },
                  {
                    "text": "Variety of other notable abnormalitiesShort staturePolydactylyHearing defectsScoliosisMild to moderate learning disabilitySchizophreniaRenal abnormalities",
                    "sub_points": [
                      "Short stature",
                      "Polydactyly",
                      "Hearing defects",
                      "Scoliosis",
                      "Mild to moderate learning disability",
                      "Schizophrenia",
                      "Renal abnormalities"
                    ]
                  },
                  {
                    "text": "DGS, VCFS, and Takao syndrome are clinical syndromes with overlapping clinical features and shared genetic etiologyIt is recognized that in given family (i.e., having same deletion), all 3 clinical syndromes may be representedDGS patients manifest signs and symptoms largely related to parathyroid and thymic hypoplasia/aplasia in neonatal periodVCFS patients present in childhood with signs and symptoms largely related to facial dysmorphology, velopharyngeal insufficiency, and mild cardiac abnormalitiesTakao syndrome is dominated by more severe cardiac abnormalities",
                    "sub_points": [
                      "It is recognized that in given family (i.e., having same deletion), all 3 clinical syndromes may be representedDGS patients manifest signs and symptoms largely related to parathyroid and thymic hypoplasia/aplasia in neonatal periodVCFS patients present in childhood with signs and symptoms largely related to facial dysmorphology, velopharyngeal insufficiency, and mild cardiac abnormalitiesTakao syndrome is dominated by more severe cardiac abnormalities",
                      "DGS patients manifest signs and symptoms largely related to parathyroid and thymic hypoplasia/aplasia in neonatal period",
                      "VCFS patients present in childhood with signs and symptoms largely related to facial dysmorphology, velopharyngeal insufficiency, and mild cardiac abnormalities",
                      "Takao syndrome is dominated by more severe cardiac abnormalities"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "No specific treatment"
                  },
                  {
                    "text": "Genetic counseling"
                  }
                ]
              },
              "IMAGING": {
                "Ultrasonographic Findings": [
                  {
                    "text": "Prenatal ultrasound may show abnormalitiesCardiac abnormalitiesCleft palatePolydactylyDiaphragmatic herniaRenal anomalies",
                    "sub_points": [
                      "Cardiac abnormalities",
                      "Cleft palate",
                      "Polydactyly",
                      "Diaphragmatic hernia",
                      "Renal anomalies"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "In Situ Hybridization": [
                  {
                    "text": "FISH for 22q11.2 locus and separate region on chromosome 22 (control) may be performed on interphase or metaphase preparationsLoss of 1 signal for 22q11.2 locus (and presence of 2 signals for control region) indicates deletion of locusOccasional deletions may not be detected depending on probe placement",
                    "sub_points": [
                      "Loss of 1 signal for 22q11.2 locus (and presence of 2 signals for control region) indicates deletion of locus",
                      "Occasional deletions may not be detected depending on probe placement"
                    ]
                  }
                ],
                "Multiplex Ligation-Dependent Probe Amplification": [
                  {
                    "text": "2 probes designed to be complementary to immediately adjacent regions on chromosomal locus anneal to target region if target region is intact (i.e., no deletion)"
                  },
                  {
                    "text": "DNA ligase ligates probes after annealing to target regionQuantity of ligated product generated is proportional to quantity of target regionSubsequent PCR is used to amplify ligated product to increase sensitivity of detection",
                    "sub_points": [
                      "Quantity of ligated product generated is proportional to quantity of target region",
                      "Subsequent PCR is used to amplify ligated product to increase sensitivity of detection"
                    ]
                  },
                  {
                    "text": "50% product quantity compared to control region (away from target region) suggests heterozygous deletion"
                  },
                  {
                    "text": "Usually multiple probe pairs are placed along target regionOccasional deletions may not detected depending on probe placement",
                    "sub_points": [
                      "Occasional deletions may not detected depending on probe placement"
                    ]
                  }
                ],
                "Sequencing": [
                  {
                    "text": "TBX1 is mutated in some patients with DGS phenotype and may be sequenced, usually as part of next-generation sequencing panel for congenital cardiac abnormalities"
                  }
                ],
                "Array": [
                  {
                    "text": "Either aCGH or single nucleotide polymorphism (SNP) array may be used to detect deletions"
                  },
                  {
                    "text": "Arrays are preferred method of detectionSome deletions may not be detected by MLPA or FISHArrays will also detect deletions on other chromosomes associated with DGSArrays will not detect point mutations in TBX1",
                    "sub_points": [
                      "Some deletions may not be detected by MLPA or FISH",
                      "Arrays will also detect deletions on other chromosomes associated with DGS",
                      "Arrays will not detect point mutations in TBX1"
                    ]
                  }
                ],
                "Karyotype": [
                  {
                    "text": "Chromosome analysis is not useful in diagnosis as 22q11.2 deletions are submicroscopic (microdeletion)"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "22q11.2 Duplication Syndrome": [
                  {
                    "text": "Some clinical overlap with 22q11.2 deletion syndrome"
                  },
                  {
                    "text": "Same region affected as in some 22q11.2 deletion syndrome"
                  },
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "Incomplete penetrance"
                  },
                  {
                    "text": "Markedly variable expressivity"
                  },
                  {
                    "text": "Prevalence of 1:320 to 1:700"
                  },
                  {
                    "text": "No specific signs or symptomsIntellectual disability/learning disabilityDevelopmental delayShort statureHypotonia",
                    "sub_points": [
                      "Intellectual disability/learning disability",
                      "Developmental delay",
                      "Short stature",
                      "Hypotonia"
                    ]
                  },
                  {
                    "text": "~ 70% are inherited mutations"
                  },
                  {
                    "text": "Because most duplications are tandem, metaphase FISH would show single (albeit larger) signal even when region is duplicatedNot diagnostically useful",
                    "sub_points": [
                      "Not diagnostically useful"
                    ]
                  },
                  {
                    "text": "Interphase FISH may be useful"
                  },
                  {
                    "text": "Array is test of choice"
                  }
                ],
                "Cat-Eye Syndrome": [
                  {
                    "text": "Some clinical overlap with 22q11.2 deletion syndromeInvolves similar regions of chromosome",
                    "sub_points": [
                      "Involves similar regions of chromosome"
                    ]
                  },
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "Supernumerary dicentric marker chromosome, inv dup(22)(q11.1)Unusual because it is inherited but typically present in mosaic form due to somatic loss",
                    "sub_points": [
                      "Unusual because it is inherited but typically present in mosaic form due to somatic loss"
                    ]
                  },
                  {
                    "text": "Micrognathia"
                  },
                  {
                    "text": "Low-set ears"
                  },
                  {
                    "text": "Ear pits or tags"
                  },
                  {
                    "text": "Hypertelorism"
                  },
                  {
                    "text": "Down-slanting palpebral fissures"
                  },
                  {
                    "text": "Coloboma of iris, retina, or choroid"
                  },
                  {
                    "text": "Cleft palate"
                  },
                  {
                    "text": "Renal agenesis/aplasia"
                  },
                  {
                    "text": "Heart defect"
                  },
                  {
                    "text": "Anal atresia"
                  }
                ],
                "Syndromes With Clinically Overlapping Features But Involving Different Chromosomal Regions": [
                  {
                    "text": "Smith-Lemli-Opitz syndrome"
                  },
                  {
                    "text": "Alagille syndrome"
                  },
                  {
                    "text": "VATER association"
                  },
                  {
                    "text": "CHARGE syndrome"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Wilson Disease": {
            "name": "Wilson Disease",
            "url": "https://app.pathprimer.com/document/bae7072b-530d-43eb-b37d-489fd1ed9087/lesson/65272a1b-ceec-41c2-b008-806ee3c17165",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "ATP7Bdisruption leads to impaired copper excretion and buildup in target organs, including liver, CNS, cornea, kidney, joints, heart﻿"
                  },
                  {
                    "text": "> 300 pathogenic mutations identified"
                  },
                  {
                    "text": "﻿Autosomal recessive﻿"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Reduced serum ceruloplasmin < 20 mg/dL"
                  },
                  {
                    "text": "Increased 24-hr urine copper > 40 μg/24 hr"
                  },
                  {
                    "text": "Kayser-Fleischer rings"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adenosine triphosphatase (ATPase)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Hepatolenticular degeneration"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "﻿Autosomal recessive﻿"
                  },
                  {
                    "text": "ATP7Bgene located at 13q14.3﻿﻿Copper transporting P-type ATPase﻿",
                    "sub_points": [
                      "﻿Copper transporting P-type ATPase﻿"
                    ]
                  },
                  {
                    "text": "> 300 pathogenic mutations identifiedNonsense and frameshift variants have most severe phenotypeH1069Q more common in EuropeansR778L more common in East Asians",
                    "sub_points": [
                      "Nonsense and frameshift variants have most severe phenotype",
                      "H1069Q more common in Europeans",
                      "R778L more common in East Asians"
                    ]
                  },
                  {
                    "text": "ATP7Bdisruption leads to impaired copper excretion and buildup in target organsLiver, CNS, cornea, kidney, joints, heart",
                    "sub_points": [
                      "Liver, CNS, cornea, kidney, joints, heart"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Carrier rate of 1:90"
                  },
                  {
                    "text": "Worldwide incidence 1:30,000-100,000"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most commonly manifests in late childhood to early adulthood"
                  },
                  {
                    "text": "Variable presentationRelated to stage of disease and extent of copper-mediated organ toxicity",
                    "sub_points": [
                      "Related to stage of disease and extent of copper-mediated organ toxicity"
                    ]
                  },
                  {
                    "text": "﻿Liver﻿Abnormal liver function testsSpecifically elevated transaminasesAcute or chronic hepatitisCirrhosisFulminant hepatitis",
                    "sub_points": [
                      "Abnormal liver function testsSpecifically elevated transaminases",
                      "Specifically elevated transaminases",
                      "Acute or chronic hepatitis",
                      "Cirrhosis",
                      "Fulminant hepatitis"
                    ]
                  },
                  {
                    "text": "CNSDysarthriaGait abnormalityParkinson-like symptomsBradykinesiaTremorNeuropsychiatric symptomsPersonality changesDepressionPsychosis",
                    "sub_points": [
                      "Dysarthria",
                      "Gait abnormality",
                      "Parkinson-like symptomsBradykinesiaTremorNeuropsychiatric symptomsPersonality changesDepressionPsychosis",
                      "Bradykinesia",
                      "Tremor",
                      "Neuropsychiatric symptomsPersonality changesDepressionPsychosis",
                      "Personality changes",
                      "Depression",
                      "Psychosis"
                    ]
                  },
                  {
                    "text": "EyesKayser-Fleischer ringsBrown corneal rings due to copper deposition﻿Cataracts",
                    "sub_points": [
                      "Kayser-Fleischer ringsBrown corneal rings due to copper deposition﻿",
                      "Brown corneal rings due to copper deposition﻿",
                      "Cataracts"
                    ]
                  },
                  {
                    "text": "Joints"
                  },
                  {
                    "text": "KidneyAminoaciduriaNephrolithiasis",
                    "sub_points": [
                      "Aminoaciduria",
                      "Nephrolithiasis"
                    ]
                  },
                  {
                    "text": "Heart—rareCardiomyopathyConduction abnormalities",
                    "sub_points": [
                      "Cardiomyopathy",
                      "Conduction abnormalities"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Chelation therapy to remove excess copperLifelong therapy required",
                    "sub_points": [
                      "Lifelong therapy required"
                    ]
                  },
                  {
                    "text": "Liver transplantationCurative",
                    "sub_points": [
                      "Curative"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Prognosis very good with early diagnosis and treatment"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "Sequencing ofAPT7BgeneNeed full gene sequencing as there are > 300 pathogenic mutationsVariants also identified in noncoding elements including intronic splice sites",
                    "sub_points": [
                      "Need full gene sequencing as there are > 300 pathogenic mutations",
                      "Variants also identified in noncoding elements including intronic splice sites"
                    ]
                  }
                ],
                "Laboratory Evaluation": [
                  {
                    "text": "Decreased serum ceruloplasmin < 20 mg/dL﻿"
                  },
                  {
                    "text": "Increased 24-hr urine copper > 40 μg/24 h﻿r"
                  }
                ],
                "Eye Examination": [
                  {
                    "text": "Kayser-Fleischer rings"
                  }
                ],
                "Liver Biopsy": [
                  {
                    "text": "Evidence of excess copper> 75 μg copper/g dry weight﻿Increased copper binding protein by rhodanine stain",
                    "sub_points": [
                      "> 75 μg copper/g dry weight﻿",
                      "Increased copper binding protein by rhodanine stain"
                    ]
                  },
                  {
                    "text": "Features of cirrhosis may be present"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Inherited Cancer Syndromes: Overview, Hematology, and Solid Tumor": {
        "name": "Inherited Cancer Syndromes: Overview, Hematology, and Solid Tumor",
        "url": "https://app.pathprimer.com/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
        "topics": {
          "Pathology of Familial Tumor Syndromes": {
            "name": "Pathology of Familial Tumor Syndromes",
            "url": "https://app.pathprimer.com/document/5d1fa09c-8964-4832-9a9b-bc6c496e9f5e/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Introduction": {
                "Hereditary Syndromes: Practical Guide to Pathological Recognition": [
                  {
                    "text": "Diverse neoplasias are a common finding in patients with a genetic predisposition to cancer"
                  },
                  {
                    "text": "It is becoming increasingly well recognized that a given familial tumor syndrome may be very heterogeneous in clinical appearance"
                  },
                  {
                    "text": "Patients without overt clinical signs of their underlying syndrome may present initially for treatment of a tumor"
                  },
                  {
                    "text": "As molecular diagnostic testing for these familial diseases has become more readily available, the heterogeneous clinical appearance seen in many syndromes has become better recognized"
                  },
                  {
                    "text": "Awareness of important manifestations associated with each syndrome that might provide additional clues to a hereditary/familial neoplasia syndrome is also important"
                  },
                  {
                    "text": "Identification of hereditary cases and early diagnosis makes preventive surgery and adequate treatment possible"
                  },
                  {
                    "text": "Most of the patients with familial disease are asymptomatic and are discovered through genetic screening in predisposing families"
                  },
                  {
                    "text": "All patients identified as having familial tumors should then be screened for the familial disease's associated mutation"
                  },
                  {
                    "text": "Vast majority of tumors occurring in a familial setting are multiple, bilateral, and involve multiple organs"
                  },
                  {
                    "text": "Many surgical specimens are received from patients who have a known syndrome diagnosis at time of surgeryPathologist may be 1st physician to suggest possibility of a syndromic association based on presence of unique pathologic findings in a tumor resection specimen",
                    "sub_points": [
                      "Pathologist may be 1st physician to suggest possibility of a syndromic association based on presence of unique pathologic findings in a tumor resection specimen"
                    ]
                  },
                  {
                    "text": "Gross and histological features that are evaluated in routine tumor resection specimens might suggest each individual syndrome"
                  },
                  {
                    "text": "In their pathological examinations, it is important for surgical pathologists to be aware of specific gross and microscopic findings that suggest a possible syndromic association"
                  },
                  {
                    "text": "Some tumors frequently display characteristic clinical, biochemical, and histopathological features that, although not pathognomonic, can be helpful in suggesting an inherited disease as the underlying etiology and distinguishing these tumors from sporadic cases"
                  }
                ],
                "Recognition of Morphological Characteristics That Indicate Familial Tumor Syndrome": [
                  {
                    "text": "Awareness of pathologic features of neoplasms seen in a variety of hereditary/familial neoplasia syndromes is crucial for diagnosis"
                  },
                  {
                    "text": "Pathological findings suggestive of a familial or inherited tumor syndromes or findings specific for a syndrome areTumors occurring at a younger age than the sporadic counterpartMultiple tumorsBilateral tumorsTumors involving multiple organs and systemsTumors associated with multiple lesionsTumors associated with multiple hamartomatous lesionsSpecific location of a tumorUnique morphological features of a tumorPresence of precursor lesionsPresence of multiple benign lesions",
                    "sub_points": [
                      "Tumors occurring at a younger age than the sporadic counterpart",
                      "Multiple tumors",
                      "Bilateral tumors",
                      "Tumors involving multiple organs and systems",
                      "Tumors associated with multiple lesions",
                      "Tumors associated with multiple hamartomatous lesions",
                      "Specific location of a tumor",
                      "Unique morphological features of a tumor",
                      "Presence of precursor lesions",
                      "Presence of multiple benign lesions"
                    ]
                  },
                  {
                    "text": "Characteristic and distinct pathology findings in some of these syndromes should alert the pathologist of a possible familial cancer syndromeCorrect histologic interpretation may lead to further molecular genetic evaluation of patient and family members",
                    "sub_points": [
                      "Correct histologic interpretation may lead to further molecular genetic evaluation of patient and family members"
                    ]
                  }
                ],
                "Pathology Reporting": [
                  {
                    "text": "If the constellation of pathology findings strongly suggests a potential syndromic associationConsult medical records for the diagnosis of a potential syndromeContact clinician to discuss possibility of a genetic syndromePathologists should notify clinicians about this possibility, considering appropriate molecular testing",
                    "sub_points": [
                      "Consult medical records for the diagnosis of a potential syndrome",
                      "Contact clinician to discuss possibility of a genetic syndrome",
                      "Pathologists should notify clinicians about this possibility, considering appropriate molecular testing"
                    ]
                  },
                  {
                    "text": "For reporting purposes, diagnosis of a lesion or a neoplasm should use same criteria and terminology as for sporadic lesions and tumorsComment suggesting a possible association with a genetic disease is recommendedTo document possibility of specific genetic association",
                    "sub_points": [
                      "Comment suggesting a possible association with a genetic disease is recommendedTo document possibility of specific genetic association",
                      "To document possibility of specific genetic association"
                    ]
                  },
                  {
                    "text": "Final diagnostic commentary to highlight differential diagnostic issues that frequently arise when these diagnoses are considered"
                  }
                ]
              },
              "Hereditary Syndromes Known to Be Associated With Neoplasia": {
                "Hereditary Syndromes": [
                  {
                    "text": "Some hereditary syndromes are known to be associated with neoplasia and have unique &/or characteristic pathological features"
                  },
                  {
                    "text": "Characteristic and distinct pathology findings in some of these syndromes should alert the pathologist of a possible familial cancer syndrome"
                  }
                ]
              },
              "Endocrine System": {
                "Hereditary Syndromes Known to be Associated With Thyroid Neoplasia": [
                  {
                    "text": "Medullary thyroid carcinoma (MTC)Multiple endocrine neoplasia 2A (MEN2A)Multiple endocrine neoplasia 2B (MEN2B)Familial medullary thyroid carcinoma (FMTC)",
                    "sub_points": [
                      "Multiple endocrine neoplasia 2A (MEN2A)",
                      "Multiple endocrine neoplasia 2B (MEN2B)",
                      "Familial medullary thyroid carcinoma (FMTC)"
                    ]
                  },
                  {
                    "text": "Cribriform morular papillary thyroid carcinomaFamilial adenomatous polyposis (FAP) syndromeCribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) was described originally as FAP-associated thyroid carcinoma",
                    "sub_points": [
                      "Familial adenomatous polyposis (FAP) syndromeCribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) was described originally as FAP-associated thyroid carcinoma",
                      "Cribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) was described originally as FAP-associated thyroid carcinoma"
                    ]
                  },
                  {
                    "text": "Numerous adenomatous nodules, follicular adenomas, and follicular carcinomaPTEN-hamartoma tumor syndrome (PHTS)/Cowden diseasePresence of numerous multiple adenomatous nodules (MANs) or follicular thyroid carcinoma (FC) in younger patients should raise suspicion for diagnosis of PHTSCarney complex",
                    "sub_points": [
                      "PTEN-hamartoma tumor syndrome (PHTS)/Cowden diseasePresence of numerous multiple adenomatous nodules (MANs) or follicular thyroid carcinoma (FC) in younger patients should raise suspicion for diagnosis of PHTS",
                      "Presence of numerous multiple adenomatous nodules (MANs) or follicular thyroid carcinoma (FC) in younger patients should raise suspicion for diagnosis of PHTS",
                      "Carney complex"
                    ]
                  },
                  {
                    "text": "Oncocytic tumorsLi-Fraumeni syndromeFamilial oncocytic neoplasmsMcCune-Albright syndromeTuberous sclerosis complex",
                    "sub_points": [
                      "Li-Fraumeni syndrome",
                      "Familial oncocytic neoplasms",
                      "McCune-Albright syndrome",
                      "Tuberous sclerosis complex"
                    ]
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Adrenal Neoplasia": [
                  {
                    "text": "Adrenal cortical tumorsBeckwith-Wiedemann syndromeLi-Fraumeni syndromeMultiple endocrine neoplasia 1Carney complexLynch syndromeCongenital adrenal hyperplasia",
                    "sub_points": [
                      "Beckwith-Wiedemann syndrome",
                      "Li-Fraumeni syndrome",
                      "Multiple endocrine neoplasia 1",
                      "Carney complex",
                      "Lynch syndrome",
                      "Congenital adrenal hyperplasia"
                    ]
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Parathyroid Neoplasia": [
                  {
                    "text": "Multiple endocrine neoplasia 1"
                  },
                  {
                    "text": "Hereditary hyperparathyroidism-jaw tumor syndrome"
                  },
                  {
                    "text": "Familial isolated hyperparathyroidism syndrome"
                  },
                  {
                    "text": "Multiple endocrine neoplasia 2A"
                  },
                  {
                    "text": "Neonatal severe primary hyperparathyroidism"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Pituitary Neoplasia": [
                  {
                    "text": "Multiple endocrine neoplasia 1"
                  },
                  {
                    "text": "Familial pituitary adenoma syndrome"
                  },
                  {
                    "text": "Familial isolated pituitary adenoma syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Endocrine Pancreas Neoplasia": [
                  {
                    "text": "Multiple endocrine neoplasia 1"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "Tuberous sclerosis complex"
                  },
                  {
                    "text": "Von Hippel-Lindau syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Paragangliom (PGL)/Pheochromocytoma (PCC)": [
                  {
                    "text": "Multiple endocrine neoplasia 2A"
                  },
                  {
                    "text": "Multiple endocrine neoplasia 2B"
                  },
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Neurofibromatosis 1"
                  },
                  {
                    "text": "Familial paraganglioma type 1 (PGL1)"
                  },
                  {
                    "text": "Familial PGL2"
                  },
                  {
                    "text": "Familial PGL3"
                  },
                  {
                    "text": "Familial PGL4"
                  },
                  {
                    "text": "Carney-Stratakis syndrome"
                  },
                  {
                    "text": "Familial pheochromocytoma (PCC) 2q"
                  },
                  {
                    "text": "MAX-related"
                  },
                  {
                    "text": "SDHA-related"
                  }
                ]
              },
              "Genitourinary Tract": {
                "Hereditary Syndromes Known to be Associated With Renal Neoplasia": [
                  {
                    "text": "von Hippel-Lindau"
                  },
                  {
                    "text": "Hereditary papillary renal cell carcinoma (RCC)"
                  },
                  {
                    "text": "Hereditary leiomyomatosis RCC"
                  },
                  {
                    "text": "Birt-Hogg-Dubé"
                  },
                  {
                    "text": "Tuberous sclerosis complex"
                  },
                  {
                    "text": "Succinate dehydrogenase (SDH) germline mutation"
                  },
                  {
                    "text": "Lynch syndrome"
                  },
                  {
                    "text": "Heritable sickle cell hemoglobinopathy and medullary carcinoma of kidney"
                  },
                  {
                    "text": "Hyperparathyroidism-jaw tumor syndrome"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Constitutional chromosome 3 translocation"
                  },
                  {
                    "text": "Wilms tumor syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Testicle Neoplasia": [
                  {
                    "text": "Carney complex"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Renal cell carcinoma and leiomyomas"
                  },
                  {
                    "text": "Xeroderma pigmentosus"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Bladder and Ureter Neoplasia": [
                  {
                    "text": "Lynch syndrome"
                  }
                ]
              },
              "Gastrointestinal Tract": {
                "Hereditary Syndromes Known to be Associated With Esophagus, Stomach, and Intestinal Neoplasia": [
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "Juvenile polyposis"
                  },
                  {
                    "text": "Familial gastrointestinal stromal tumor"
                  },
                  {
                    "text": "Hereditary diffuse gastric cancer"
                  },
                  {
                    "text": "MYH-associated polyposis"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Breast/ovarianBRCA1andBRCA2"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Bloom syndrome"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Gastrointestinal stromal tumor syndrome"
                  },
                  {
                    "text": "Neurofibromatosis 1"
                  },
                  {
                    "text": "Multiple endocrine neoplasia 1"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Pancreas Neoplasia": [
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Breast/ovarianBRCA1andBRCA2"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Juvenile polyposis"
                  },
                  {
                    "text": "Familial melanoma"
                  },
                  {
                    "text": "Multiple endocrine neoplasia 1"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Carney complex"
                  },
                  {
                    "text": "Tuberous sclerosis"
                  },
                  {
                    "text": "Hereditary pancreatic cancer syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Liver Neoplasia": [
                  {
                    "text": "Breast/ovarianBRCA2"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Beckwith-Wiedemann syndrome"
                  },
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Lynch syndrome"
                  }
                ]
              },
              "Central Nervous System": {
                "Hereditary Syndromes Known to be Associated With CNS Neoplasia": [
                  {
                    "text": "Neurofibromatosis 1"
                  },
                  {
                    "text": "Neurofibromatosis 2"
                  },
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Gorlin syndrome"
                  },
                  {
                    "text": "Lynch syndrome"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "Tuberous sclerosis complex"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Constitutional mismatch repair"
                  },
                  {
                    "text": "Melanoma astrocytoma syndrome"
                  },
                  {
                    "text": "Familial uveal melanoma"
                  },
                  {
                    "text": "Rhabdoid predisposition syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Multiple meningoma syndrome"
                  },
                  {
                    "text": "Pleuropulmonary blastoma"
                  }
                ]
              },
              "Skin": {
                "Hereditary Syndromes Known to be Associated With Skin Neoplasia": [
                  {
                    "text": "Carney complex"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Basal cell nevus syndrome"
                  },
                  {
                    "text": "Beckwith-Wiedemann syndrome"
                  },
                  {
                    "text": "Birt-Hogg-Dubé syndrome"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Hereditary multiple melanoma"
                  },
                  {
                    "text": "Howell-Evans syndrome"
                  },
                  {
                    "text": "Melanoma pancreatic carcinoma syndrome"
                  },
                  {
                    "text": "Werner syndrome"
                  }
                ]
              },
              "Breast": {
                "Hereditary Syndromes Known to be Associated With Breast Neoplasia": [
                  {
                    "text": "BRCA1hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "BRCA2hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Familial gastric cancer and breast lobular cancer syndrome"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Ataxia-telangiectasia syndrome"
                  }
                ]
              },
              "Gynecologic": {
                "Hereditary Syndromes Known to be Associated With Uterine Neoplasia": [
                  {
                    "text": "BRCA1hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "BRCA2hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "Lynch syndrome"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Hereditary leiomyomatosis and renal cell carcinoma"
                  },
                  {
                    "text": "von Hippel-Lindau syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Ovarian Neoplasia": [
                  {
                    "text": "BRCA1hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "BRCA2hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Lynch syndrome"
                  }
                ]
              },
              "Lung": {
                "Hereditary Syndromes Known to be Associated With Lung Neoplasia": [
                  {
                    "text": "BRCA2hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma syndrome"
                  },
                  {
                    "text": "Familial pleuropulmonary blastoma"
                  },
                  {
                    "text": "Tuberous sclerosis complex"
                  },
                  {
                    "text": "Carney triad"
                  },
                  {
                    "text": "Bloom syndrome"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Xeroderma pigmentosum"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  }
                ]
              },
              "Head and Neck": {
                "Hereditary Syndromes Known to be Associated With Head and Neck Neoplasia": [
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Fanconi anemia"
                  },
                  {
                    "text": "Xeroderma pigmentosum"
                  },
                  {
                    "text": "Bloom syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma"
                  },
                  {
                    "text": "Neurofibromatosis 2"
                  },
                  {
                    "text": "Basal cell nevus syndrome/Gorlin syndrome"
                  },
                  {
                    "text": "Hyperparathyroidism-jaw tumor syndrome"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "von Hippel-Lindau"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Salivary Gland Neoplasia": [
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Ataxia-telangiectasia syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma syndrome"
                  },
                  {
                    "text": "Brooke-Spiegler syndrome and familial cylindromatosis"
                  }
                ]
              },
              "Bone and Soft Tissue": {
                "Hereditary Syndromes Known to be Associated With Bone Neoplasia": [
                  {
                    "text": "Hereditary multiple exostosis"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma"
                  },
                  {
                    "text": "Familial chordoma syndrome"
                  },
                  {
                    "text": "Tuberous sclerosis complex"
                  },
                  {
                    "text": "Hyperparathyroidism-jaw tumor syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Soft Tissue Neoplasia": [
                  {
                    "text": "Basal cell nevus syndrome"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma"
                  },
                  {
                    "text": "Hereditary multiple exostosis"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "Renal carcinoma with leiomyomas"
                  },
                  {
                    "text": "Neurofibromatosis 1"
                  },
                  {
                    "text": "Neurofibromatosis 2"
                  },
                  {
                    "text": "Carney complex"
                  },
                  {
                    "text": "Beckwith-Wiedemann syndrome"
                  }
                ]
              },
              "Hematology": {
                "Hereditary Syndromes Known to be Associated With Blood and Bone Marrow Neoplasia": [
                  {
                    "text": "Congenital amegakaryocytic thrombocytopenia"
                  },
                  {
                    "text": "Diamond-Blackfan anemia"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Severe congenital neutropenia"
                  },
                  {
                    "text": "Shwachman-Diamond syndrome"
                  },
                  {
                    "text": "Fanconi anemia"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Lymphoma/Leukemia": [
                  {
                    "text": "Familial non-Hodgkin lymphoma"
                  },
                  {
                    "text": "Familial acute myeloid leukemia"
                  },
                  {
                    "text": "Familial chronic lymphocytic leukemia"
                  },
                  {
                    "text": "Familial Hodgkin lymphoma"
                  },
                  {
                    "text": "Fanconi anemia"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Clinical Diagnosis and Management of Familial/Hereditary Tumor Syndromes": {
            "name": "Clinical Diagnosis and Management of Familial/Hereditary Tumor Syndromes",
            "url": "https://app.pathprimer.com/document/fb0875ef-ee90-492e-bf92-b3cba950b646/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Introduction": {
                "Hereditary Cancer": [
                  {
                    "text": "Characterized by mutations associated with a high probability of cancer development, vertical transmission through parents, and an association with other types of tumors"
                  },
                  {
                    "text": "Often have early age of onset"
                  },
                  {
                    "text": "Usually multiple and involve multiple organs"
                  },
                  {
                    "text": "Familial cancers may be associated with (or by combination of these)Chance of clustering of sporadic cancer cases within a familyGenetic variation in lower penetrance genesShared environment",
                    "sub_points": [
                      "Chance of clustering of sporadic cancer cases within a family",
                      "Genetic variation in lower penetrance genes",
                      "Shared environment"
                    ]
                  },
                  {
                    "text": "Molecular genetics have identified a number of genes associated with inherited susceptibility to a specific cancerAlso provides a means of characterizing  specific gene mutation or mutations present in certain individuals and families exhibiting an increased risk of cancer",
                    "sub_points": [
                      "Also provides a means of characterizing  specific gene mutation or mutations present in certain individuals and families exhibiting an increased risk of cancer"
                    ]
                  }
                ],
                "Background": [
                  {
                    "text": "~ 10% of all cancers are attributable to a cancer predisposition gene"
                  },
                  {
                    "text": "Learning the clinical features that suggest possibility of an underlying genetic predisposition to cancer is another easily mastered diagnostic toolIt is crucial to raise awareness among oncologists and other health care providers about the importance of inherited cancer risk in the practice of oncology and cancer prevention",
                    "sub_points": [
                      "It is crucial to raise awareness among oncologists and other health care providers about the importance of inherited cancer risk in the practice of oncology and cancer prevention"
                    ]
                  },
                  {
                    "text": "Study of rare familial clusters became a remarkably productive scientific and clinical enterpriseThese data haveIdentified multiple new susceptibility genesInformed understanding of pathogenesis of hereditary and nonhereditary cancers at individual, population, and laboratory levelsDefined clinical phenotypes of specific disorders more preciselyMuch of the data that form basis of understanding of hereditary cancer syndromes are derived from evaluation of highly selected familiesSingle-gene hereditary syndromes account for only a small fraction of familial clustering on a population basisAccuracy of reports from 1st-degree relatives is substantially better than for 2nd-degree relatives",
                    "sub_points": [
                      "These data haveIdentified multiple new susceptibility genesInformed understanding of pathogenesis of hereditary and nonhereditary cancers at individual, population, and laboratory levelsDefined clinical phenotypes of specific disorders more precisely",
                      "Identified multiple new susceptibility genes",
                      "Informed understanding of pathogenesis of hereditary and nonhereditary cancers at individual, population, and laboratory levels",
                      "Defined clinical phenotypes of specific disorders more precisely",
                      "Much of the data that form basis of understanding of hereditary cancer syndromes are derived from evaluation of highly selected families",
                      "Single-gene hereditary syndromes account for only a small fraction of familial clustering on a population basis",
                      "Accuracy of reports from 1st-degree relatives is substantially better than for 2nd-degree relatives"
                    ]
                  },
                  {
                    "text": "Diagnosis accuracy varies considerably, depending onAge, gender, and cancer status of individualPrimary site of cancer originDegree of relatedness between individual and relativeVital status of affected relativeRecentness of reported cancer diagnosis",
                    "sub_points": [
                      "Age, gender, and cancer status of individual",
                      "Primary site of cancer origin",
                      "Degree of relatedness between individual and relative",
                      "Vital status of affected relative",
                      "Recentness of reported cancer diagnosis"
                    ]
                  },
                  {
                    "text": "Need has never been greater for clinicians to be well groundedIn knowledge of biological and molecular bases of diseases they encounterTo become familiar with related new clinical issues, including predictive risk assessment, genetic counseling, and germline mutation testing for clinical decision makingTo warn at-risk relatives vs. their high-risk patients' right to privacy and confidentiality, and the need for evidence-based, safe, and effective management recommendations for high-risk individuals",
                    "sub_points": [
                      "In knowledge of biological and molecular bases of diseases they encounter",
                      "To become familiar with related new clinical issues, including predictive risk assessment, genetic counseling, and germline mutation testing for clinical decision making",
                      "To warn at-risk relatives vs. their high-risk patients' right to privacy and confidentiality, and the need for evidence-based, safe, and effective management recommendations for high-risk individuals"
                    ]
                  }
                ],
                "Identification of At-Risk Individuals": [
                  {
                    "text": "Accurate identification of patients at increased risk for developing cancer is essential"
                  },
                  {
                    "text": "Assessment of an individual's risk of familial or hereditary cancer is based on a thorough evaluation of the family history"
                  },
                  {
                    "text": "In the process of focusing on molecular biology of human cancer susceptibility, importance of taking a thoughtful family history cannot be emphasized sufficientlyRecording an appropriately focused family history must be performed in course of daily practice",
                    "sub_points": [
                      "Recording an appropriately focused family history must be performed in course of daily practice"
                    ]
                  },
                  {
                    "text": "It is now increasingly routine to undertake a cancer genetics risk assessment, which includes the option of germline mutation testing for 1 or more relevant genes"
                  },
                  {
                    "text": "Identification of individuals at risk for cancer has become an integral part of medicineWill allow health care providers to intervene with appropriateCounseling and educationIncreased cancer surveillanceCancer prevention",
                    "sub_points": [
                      "Will allow health care providers to intervene with appropriateCounseling and educationIncreased cancer surveillanceCancer prevention",
                      "Counseling and education",
                      "Increased cancer surveillance",
                      "Cancer prevention"
                    ]
                  },
                  {
                    "text": "Genetic risk assessment in the context of childhood cancer represents a specific settingMeticulous clinical evaluation often provides essential information upon which to base a syndromic diagnosis",
                    "sub_points": [
                      "Meticulous clinical evaluation often provides essential information upon which to base a syndromic diagnosis"
                    ]
                  },
                  {
                    "text": "The National Comprehensive Cancer Network (NCCN) has established criteria for those individuals who need further genetic risk assessmentMultiple algorithmic approach for tumor syndromes are available at their websitehttp://www.nccn.org/professionals/physician_gls/pdf/genetics_screening",
                    "sub_points": [
                      "Multiple algorithmic approach for tumor syndromes are available at their websitehttp://www.nccn.org/professionals/physician_gls/pdf/genetics_screening",
                      "http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening"
                    ]
                  }
                ]
              },
              "Cancer Susceptibility Testing": {
                "American Society of Clinical Oncology (ASCO): Indications for Testing": [
                  {
                    "text": "ASCO recommends that genetic testing be offered whenIndividual has personal or family history features suggestive of a genetic cancer susceptibility conditionTest can be adequately interpreted, andResults will aid in diagnosis or influence the medical or surgical management of the patient or family members at hereditary risk of cancer",
                    "sub_points": [
                      "Individual has personal or family history features suggestive of a genetic cancer susceptibility condition",
                      "Test can be adequately interpreted, and",
                      "Results will aid in diagnosis or influence the medical or surgical management of the patient or family members at hereditary risk of cancer"
                    ]
                  },
                  {
                    "text": "ASCO recommends that genetic testing only be done in setting of pre- and post-test counseling, which should include discussion of possible risks and benefits of early cancer detection and prevention modalities"
                  }
                ],
                "ASCO: Policy Statement": [
                  {
                    "text": "Advent of syndrome-specific germline mutation testing represents a major advance in the care of cancer-prone individuals"
                  },
                  {
                    "text": "ASCO reaffirms its commitment to integrating cancer risk assessment and management, including molecular analysis of cancer predisposition genes, into the practice of oncology and preventive medicineGenetic testing for cancer susceptibility has become an accepted part of oncologic careAccording to ASCO guidelinesGermline testing for inherited predisposition is well established as part of the care of individuals who may be at hereditary risk for cancers of the breast, ovary, colon, stomach, uterus, thyroid, and other primary sitesGermline genetic testing is distinct from somatic genetic profiling of cancer tissue to predict prognosis or treatment responseGermline testing involves analysis of DNA from blood or saliva for inherited mutations in specific genes that are associated with the type of cancer seen in the individual or family seeking assessmentWhen identified, such high-penetrance mutations usually result in a significant alteration in the function of the corresponding gene product and are associated with large increases in cancer riskOther mutations result in less dramatic increases in risk (intermediate penetrance)Identification of a high-penetrance mutation often justifies an adjustment of clinical care through the modification of surveillance or through preventive surgeryGermline testing for certain high-penetrance predispositions is now part of clinical guidelines and is reimbursed by most 3rd-party payersImpact of intermediate penetrance mutations on clinical care is less clear",
                    "sub_points": [
                      "Genetic testing for cancer susceptibility has become an accepted part of oncologic careAccording to ASCO guidelinesGermline testing for inherited predisposition is well established as part of the care of individuals who may be at hereditary risk for cancers of the breast, ovary, colon, stomach, uterus, thyroid, and other primary sitesGermline genetic testing is distinct from somatic genetic profiling of cancer tissue to predict prognosis or treatment responseGermline testing involves analysis of DNA from blood or saliva for inherited mutations in specific genes that are associated with the type of cancer seen in the individual or family seeking assessmentWhen identified, such high-penetrance mutations usually result in a significant alteration in the function of the corresponding gene product and are associated with large increases in cancer riskOther mutations result in less dramatic increases in risk (intermediate penetrance)Identification of a high-penetrance mutation often justifies an adjustment of clinical care through the modification of surveillance or through preventive surgeryGermline testing for certain high-penetrance predispositions is now part of clinical guidelines and is reimbursed by most 3rd-party payersImpact of intermediate penetrance mutations on clinical care is less clear",
                      "According to ASCO guidelines",
                      "Germline testing for inherited predisposition is well established as part of the care of individuals who may be at hereditary risk for cancers of the breast, ovary, colon, stomach, uterus, thyroid, and other primary sites",
                      "Germline genetic testing is distinct from somatic genetic profiling of cancer tissue to predict prognosis or treatment response",
                      "Germline testing involves analysis of DNA from blood or saliva for inherited mutations in specific genes that are associated with the type of cancer seen in the individual or family seeking assessment",
                      "When identified, such high-penetrance mutations usually result in a significant alteration in the function of the corresponding gene product and are associated with large increases in cancer risk",
                      "Other mutations result in less dramatic increases in risk (intermediate penetrance)",
                      "Identification of a high-penetrance mutation often justifies an adjustment of clinical care through the modification of surveillance or through preventive surgery",
                      "Germline testing for certain high-penetrance predispositions is now part of clinical guidelines and is reimbursed by most 3rd-party payers",
                      "Impact of intermediate penetrance mutations on clinical care is less clear"
                    ]
                  }
                ],
                "ASCO: Clinical Utility of Genetic Testing": [
                  {
                    "text": "Genetic tests may benefit individuals by providing deeper self-knowledge and motivation to pursue healthy behaviors, even if the results do not inform clinical decision making"
                  },
                  {
                    "text": "Tests for high-penetrance mutations in appropriate populations have clinical utility, meaning that they inform clinical decision making and facilitate the prevention or amelioration of adverse health outcomes"
                  },
                  {
                    "text": "Genetic tests for intermediate-penetrance mutations and genomic profiles of SNPS linked to low-penetrance variants are of uncertain clinical utility"
                  }
                ],
                "ASCO: Informed Consent": [
                  {
                    "text": "Proposed elements of informed consent related to testing for inherited cancer susceptibility are set forth"
                  },
                  {
                    "text": "Basic elements of informed consent for cancer susceptibility testingInformation on specific genetic mutation(s) or genomic variant(s) being tested, including whether range of risk associated with variant will impact medical careImplications of a positive and negative resultPossibility that test will not be informativeOptions for risk estimation without genetic or genomic testingRisk of passing a genetic variant to childrenTechnical accuracy of the test including, where required by law, licensure of the testing laboratoryFees involved in testing and counseling and, for direct-to-consumer (DTC) testing, whether the counselor is employed by the testing companyPsychological implications of test results (benefits and risks)Risks and protections against genetic discrimination by employers or insurersConfidentiality issues, including, for DTC testing companies, policies related to privacy and data securityPossible use of DNA testing samples in future researchOptions and limitations of medical surveillance and strategies for prevention after genetic or genomic testingImportance of sharing genetic and genomic test results with at-risk relatives so that they may benefit from this informationPlans for follow-up after testing",
                    "sub_points": [
                      "Information on specific genetic mutation(s) or genomic variant(s) being tested, including whether range of risk associated with variant will impact medical care",
                      "Implications of a positive and negative result",
                      "Possibility that test will not be informative",
                      "Options for risk estimation without genetic or genomic testing",
                      "Risk of passing a genetic variant to children",
                      "Technical accuracy of the test including, where required by law, licensure of the testing laboratory",
                      "Fees involved in testing and counseling and, for direct-to-consumer (DTC) testing, whether the counselor is employed by the testing company",
                      "Psychological implications of test results (benefits and risks)",
                      "Risks and protections against genetic discrimination by employers or insurers",
                      "Confidentiality issues, including, for DTC testing companies, policies related to privacy and data security",
                      "Possible use of DNA testing samples in future research",
                      "Options and limitations of medical surveillance and strategies for prevention after genetic or genomic testing",
                      "Importance of sharing genetic and genomic test results with at-risk relatives so that they may benefit from this information",
                      "Plans for follow-up after testing"
                    ]
                  }
                ],
                "Special Issues Related to Genetic Testing Research": [
                  {
                    "text": "Prospective clinical trials, large registries, and retrospective reviews are the most accurate methods forDeriving relative risks of genetic variantsMeasuring response to and effectiveness of clinical interventions based on genetic cancer risk assessment",
                    "sub_points": [
                      "Deriving relative risks of genetic variants",
                      "Measuring response to and effectiveness of clinical interventions based on genetic cancer risk assessment"
                    ]
                  },
                  {
                    "text": "Tests with uncertain clinical utility become commercially availableIt will be crucial to establish an evidence-based algorithm for clinically responsible use of these testsFor patient safety and effectiveness",
                    "sub_points": [
                      "It will be crucial to establish an evidence-based algorithm for clinically responsible use of these testsFor patient safety and effectiveness",
                      "For patient safety and effectiveness"
                    ]
                  },
                  {
                    "text": "Wherever possible, genetic tests with uncertain clinical utility should be administered in the context of clinical trials"
                  },
                  {
                    "text": "Research should include basic studies of the functional significance of the genetic variants linked to disease riskAs well as prospective, randomized controlled trials of individual genomic markers",
                    "sub_points": [
                      "As well as prospective, randomized controlled trials of individual genomic markers"
                    ]
                  },
                  {
                    "text": "At a translational level, it is important to establish criteria for technologic assessment of genetic and other diagnostic tests"
                  },
                  {
                    "text": "Research should focus on the extent to which personal benefits accrue to individuals who receive tests that have uncertain clinical utilityAs well as the appropriate mechanism for measuring personal utility",
                    "sub_points": [
                      "As well as the appropriate mechanism for measuring personal utility"
                    ]
                  },
                  {
                    "text": "Establishing an evidence-based test for personal utility is particularly important for tests that would not be recommended based on clinical utility"
                  },
                  {
                    "text": "Research is also needed to demonstrate validity and reproducibility of some commercially available tests"
                  },
                  {
                    "text": "Because the algorithms used to convert genotypes into absolute risk estimates are empirically derived, prospective research is needed to confirm calibration of these estimates and to measure the effectiveness of interventions based on individual genomic profiling"
                  },
                  {
                    "text": "If genetic and genomic tests for cancer risk are going to be offered or justified on basis of personal utility, an effort should be made to establish evidence-based tests for these claims"
                  }
                ],
                "Genetic Counseling": [
                  {
                    "text": "Genetic testing should be conducted only in the setting of pre- and post-test counselingPretest counselingAllows for advance consideration of medical options and the impact test results may have on family membersPost-test counselingProvides a valuable opportunity for health care providers to interpret test results, recommend appropriate follow-up, and emphasize the importance of continuing regular prevention activities",
                    "sub_points": [
                      "Pretest counselingAllows for advance consideration of medical options and the impact test results may have on family members",
                      "Allows for advance consideration of medical options and the impact test results may have on family members",
                      "Post-test counseling",
                      "Provides a valuable opportunity for health care providers to interpret test results, recommend appropriate follow-up, and emphasize the importance of continuing regular prevention activities"
                    ]
                  }
                ]
              },
              "Diagnosis": {
                "Established Diagnostic Criteria": [
                  {
                    "text": "Some examples of diagnostic criteria to characterize a syndrome present in individuals with multiple lesions and tumors"
                  },
                  {
                    "text": "Diagnostic criteria for basal cell nevus syndrome"
                  },
                  {
                    "text": "Diagnosis is established if 2 major or 1 major and 2 minor criteria are metMultiple (> 2) basal cell carcinomas, or 1 basal cell carcinoma in patient < 30 years, or > 10 basal cell nevi",
                    "sub_points": [
                      "Multiple (> 2) basal cell carcinomas, or 1 basal cell carcinoma in patient < 30 years, or > 10 basal cell nevi"
                    ]
                  },
                  {
                    "text": "Major criteriaAny odontogenic keratocyst (proven on histology) or polyostotic bone cystPalmar or plantar pits (≥ 3)Ectopic calcification; lamellar or early (patient < 20 years) falx calcificationFamily history of  basal cell nevus syndrome (BCNS)Minor criteriaCongenital skeletal anomaly: Bifid, fused, splayed, or missing rib; or bifid, wedged, or fused vertebraeHead circumference > 97th percentile, with frontal bossingCardiac or ovarian fibromaMedulloblastoma (primitive neuroectodermal tumor [PNET], most often of desmoplastic histology)Lymphomesenteric or pleural cystsCongenital malformation: Cleft lip &/or palate, polydactyly, eye anomaly (cataract, coloboma, microphthalmia)",
                    "sub_points": [
                      "Any odontogenic keratocyst (proven on histology) or polyostotic bone cyst",
                      "Palmar or plantar pits (≥ 3)Ectopic calcification; lamellar or early (patient < 20 years) falx calcificationFamily history of  basal cell nevus syndrome (BCNS)",
                      "Ectopic calcification; lamellar or early (patient < 20 years) falx calcification",
                      "Family history of  basal cell nevus syndrome (BCNS)",
                      "Minor criteriaCongenital skeletal anomaly: Bifid, fused, splayed, or missing rib; or bifid, wedged, or fused vertebraeHead circumference > 97th percentile, with frontal bossingCardiac or ovarian fibromaMedulloblastoma (primitive neuroectodermal tumor [PNET], most often of desmoplastic histology)Lymphomesenteric or pleural cystsCongenital malformation: Cleft lip &/or palate, polydactyly, eye anomaly (cataract, coloboma, microphthalmia)",
                      "Congenital skeletal anomaly: Bifid, fused, splayed, or missing rib; or bifid, wedged, or fused vertebrae",
                      "Head circumference > 97th percentile, with frontal bossing",
                      "Cardiac or ovarian fibroma",
                      "Medulloblastoma (primitive neuroectodermal tumor [PNET], most often of desmoplastic histology)",
                      "Lymphomesenteric or pleural cysts",
                      "Congenital malformation: Cleft lip &/or palate, polydactyly, eye anomaly (cataract, coloboma, microphthalmia)"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria for von Hippel-Lindau(VHL) syndromeDiagnosis is established if there areVHLmutation≥ 2 CNS or retinal hemangioblastomas orSingle CNS or retinal hemangioblastoma, plus 1 of the followingMultiple renal, pancreatic, or hepatic cystsPheochromocytoma (any location)Renal cancerEndolymphatic sac tumor of inner earPapillary cystadenoma of the epididymis or broad ligamentNeuroendocrine tumor of the pancreas orDefinite family history of VHL plus 1 of the followingCNS or retinal hemangioblastomaMultiple renal, pancreatic, or hepatic cystsPheochromocytomaRenal cancer < age 60 yearsEpididymal cystadenomaKey diagnostic pointsMultiple retinal and CNS hemangioblastomasMultiple clear cell RCCs (bilateral), multiple renal cysts (bilateral) with clear cell lining, multiple pancreatic and hepatic cystsMay suspect possibility of syndrome based on constellation of pathologic findings",
                    "sub_points": [
                      "Diagnosis is established if there are",
                      "VHLmutation",
                      "≥ 2 CNS or retinal hemangioblastomas or",
                      "Single CNS or retinal hemangioblastoma, plus 1 of the followingMultiple renal, pancreatic, or hepatic cystsPheochromocytoma (any location)Renal cancerEndolymphatic sac tumor of inner earPapillary cystadenoma of the epididymis or broad ligamentNeuroendocrine tumor of the pancreas or",
                      "Multiple renal, pancreatic, or hepatic cysts",
                      "Pheochromocytoma (any location)",
                      "Renal cancer",
                      "Endolymphatic sac tumor of inner ear",
                      "Papillary cystadenoma of the epididymis or broad ligament",
                      "Neuroendocrine tumor of the pancreas or",
                      "Definite family history of VHL plus 1 of the followingCNS or retinal hemangioblastomaMultiple renal, pancreatic, or hepatic cystsPheochromocytomaRenal cancer < age 60 yearsEpididymal cystadenoma",
                      "CNS or retinal hemangioblastoma",
                      "Multiple renal, pancreatic, or hepatic cysts",
                      "Pheochromocytoma",
                      "Renal cancer < age 60 years",
                      "Epididymal cystadenoma",
                      "Key diagnostic pointsMultiple retinal and CNS hemangioblastomasMultiple clear cell RCCs (bilateral), multiple renal cysts (bilateral) with clear cell lining, multiple pancreatic and hepatic cystsMay suspect possibility of syndrome based on constellation of pathologic findings",
                      "Multiple retinal and CNS hemangioblastomas",
                      "Multiple clear cell RCCs (bilateral), multiple renal cysts (bilateral) with clear cell lining, multiple pancreatic and hepatic cysts",
                      "May suspect possibility of syndrome based on constellation of pathologic findings"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria for Carney complexPRKAR1Agene mutationPatient must have at least 2 of the followingSpotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)Myxoma (cutaneous: Often on the eyelid, external ear, nipple)Cardiac myxomaBreast myxomatosis or fat-suppressed MR findings suggestive of this diagnosisPrimary pigmented nodular adrenocortical disease or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during Liddle diagnostic test for Cushing syndromeAcromegaly due to GH-producing adenoma (somatotropinomas)Large-cell calcifying Sertoli cell tumor of testis or characteristic calcification on testicular ultrasonographyThyroid carcinoma or multiple hypoechoic nodules on thyroid ultrasonography in a young patientPsammomatous melanotic schwannomaBlue nevus, epithelioid blue nevus (multiple)Breast ductal adenoma (multiple) (or mammary tumor with intraductal papilloma)Osteochondromyxoma of bone (histological diagnosis)Diagnostic criteria is also satisfied in a patient meeting any of these criteria and having either affected 1st-degree relative or inactivating mutation ofPRKAR1Agene",
                    "sub_points": [
                      "PRKAR1Agene mutation",
                      "Patient must have at least 2 of the followingSpotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)Myxoma (cutaneous: Often on the eyelid, external ear, nipple)Cardiac myxomaBreast myxomatosis or fat-suppressed MR findings suggestive of this diagnosisPrimary pigmented nodular adrenocortical disease or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during Liddle diagnostic test for Cushing syndromeAcromegaly due to GH-producing adenoma (somatotropinomas)Large-cell calcifying Sertoli cell tumor of testis or characteristic calcification on testicular ultrasonographyThyroid carcinoma or multiple hypoechoic nodules on thyroid ultrasonography in a young patientPsammomatous melanotic schwannomaBlue nevus, epithelioid blue nevus (multiple)Breast ductal adenoma (multiple) (or mammary tumor with intraductal papilloma)Osteochondromyxoma of bone (histological diagnosis)",
                      "Spotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)",
                      "Myxoma (cutaneous: Often on the eyelid, external ear, nipple)",
                      "Cardiac myxoma",
                      "Breast myxomatosis or fat-suppressed MR findings suggestive of this diagnosis",
                      "Primary pigmented nodular adrenocortical disease or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during Liddle diagnostic test for Cushing syndrome",
                      "Acromegaly due to GH-producing adenoma (somatotropinomas)",
                      "Large-cell calcifying Sertoli cell tumor of testis or characteristic calcification on testicular ultrasonography",
                      "Thyroid carcinoma or multiple hypoechoic nodules on thyroid ultrasonography in a young patient",
                      "Psammomatous melanotic schwannoma",
                      "Blue nevus, epithelioid blue nevus (multiple)",
                      "Breast ductal adenoma (multiple) (or mammary tumor with intraductal papilloma)",
                      "Osteochondromyxoma of bone (histological diagnosis)",
                      "Diagnostic criteria is also satisfied in a patient meeting any of these criteria and having either affected 1st-degree relative or inactivating mutation ofPRKAR1Agene"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria forneurofibromatosistype 1 (NF1)NF1mutationDiagnosis requires 2 or more of the followingCafé au lait maculesIn children, ≥ 5  that are ≥ 0.5 cm in diameterIn adults, ≥ 6 that are ≥ 1.5 cm in diameter≥ 2 neurofibromas of any type or 1 plexiform neurofibromaMultiple axillary or inguinal frecklesSphenoid wing dysplasia or congenital bowing or thinning of long bone cortex (± pseudoarthrosis)Bilateral optic nerve gliomas≥ 2 iris Lisch nodules (iris hamartomas)1st-degree relative with NF1 by these criteria",
                    "sub_points": [
                      "NF1mutation",
                      "Diagnosis requires 2 or more of the following",
                      "Café au lait maculesIn children, ≥ 5  that are ≥ 0.5 cm in diameterIn adults, ≥ 6 that are ≥ 1.5 cm in diameter",
                      "In children, ≥ 5  that are ≥ 0.5 cm in diameter",
                      "In adults, ≥ 6 that are ≥ 1.5 cm in diameter",
                      "≥ 2 neurofibromas of any type or 1 plexiform neurofibroma",
                      "Multiple axillary or inguinal freckles",
                      "Sphenoid wing dysplasia or congenital bowing or thinning of long bone cortex (± pseudoarthrosis)",
                      "Bilateral optic nerve gliomas",
                      "≥ 2 iris Lisch nodules (iris hamartomas)",
                      "1st-degree relative with NF1 by these criteria"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria for neurofibromatosis type 2 (NF2)NF2mutationRequires 1 of the following 2 major criteria to be metBilateral 8th nerve masses seen by MR with gadolinium or1st-degree relative with NF2 plus 1 of the followingCT or MR evidence of an unilateral 8th nerve massImaging evidence of intracranial or spinal cord tumorPosterior subcapsular cataract at a young ageGliomas (≥ 2)Neurofibromas (≥ 2)Meningioma (≥ 2)",
                    "sub_points": [
                      "NF2mutation",
                      "Requires 1 of the following 2 major criteria to be met",
                      "Bilateral 8th nerve masses seen by MR with gadolinium or",
                      "1st-degree relative with NF2 plus 1 of the followingCT or MR evidence of an unilateral 8th nerve massImaging evidence of intracranial or spinal cord tumorPosterior subcapsular cataract at a young ageGliomas (≥ 2)Neurofibromas (≥ 2)Meningioma (≥ 2)",
                      "CT or MR evidence of an unilateral 8th nerve mass",
                      "Imaging evidence of intracranial or spinal cord tumor",
                      "Posterior subcapsular cataract at a young age",
                      "Gliomas (≥ 2)",
                      "Neurofibromas (≥ 2)",
                      "Meningioma (≥ 2)"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria for Li-Fraumeni syndrome (LFS)Population to be screenedWhen strict criteria are met,TP53mutations are found in 60-80%If less strict criteria are used (Li-Fraumeni-like [LFL]),TP53mutations are found in up to 40%Chompret criteria for screeningIndividual (proband) must have 1 of the following tumors before age 46: Sarcoma, osteosarcoma, premenopausal breast cancer, brain tumor, adrenal cortical carcinoma, leukemia, or lung lepidic pattern carcinoma, and at least 1 of following 3 criteriaAt least 1 first- or second-degree relative with an LFS tumor before age 56 or with multiple tumorsBreast cancer is not included if proband has breast cancerMultiple tumors (not including breast cancers), 2 of which belong to LFS tumors and 1st of which occurred < age 46Adrenal cortical carcinoma or choroid plexus tumor, irrespective of family history30% of individuals fulfilling these criteria have a germlineTP53mutation",
                    "sub_points": [
                      "Population to be screenedWhen strict criteria are met,TP53mutations are found in 60-80%If less strict criteria are used (Li-Fraumeni-like [LFL]),TP53mutations are found in up to 40%",
                      "When strict criteria are met,TP53mutations are found in 60-80%",
                      "If less strict criteria are used (Li-Fraumeni-like [LFL]),TP53mutations are found in up to 40%",
                      "Chompret criteria for screening",
                      "Individual (proband) must have 1 of the following tumors before age 46: Sarcoma, osteosarcoma, premenopausal breast cancer, brain tumor, adrenal cortical carcinoma, leukemia, or lung lepidic pattern carcinoma, and at least 1 of following 3 criteriaAt least 1 first- or second-degree relative with an LFS tumor before age 56 or with multiple tumorsBreast cancer is not included if proband has breast cancerMultiple tumors (not including breast cancers), 2 of which belong to LFS tumors and 1st of which occurred < age 46Adrenal cortical carcinoma or choroid plexus tumor, irrespective of family history",
                      "At least 1 first- or second-degree relative with an LFS tumor before age 56 or with multiple tumors",
                      "Breast cancer is not included if proband has breast cancer",
                      "Multiple tumors (not including breast cancers), 2 of which belong to LFS tumors and 1st of which occurred < age 46",
                      "Adrenal cortical carcinoma or choroid plexus tumor, irrespective of family history",
                      "30% of individuals fulfilling these criteria have a germlineTP53mutation"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria forLynch syndromeMutations in genes coding for mismatch repair proteins (MLH1, PMS2, MSH2, MSH6)Clinical featuresMultiple epithelial cancers occur at average age of ~ 20 years younger than expectedSeveral guidelines have been proposed to help identify patients who should be tested for Lynch syndromeAmsterdam criteria II≥ 3 relatives with a Lynch-associated cancer≥ 2 successive generations affected≥ 1 relative diagnosed < age 501 should be a 1st-degree relative of the other 2Familial adenomatous polyposis must be excludedRevised Bethesda guidelinesColorectal carcinoma (CRC) diagnosed prior to age 50Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of ageCRC with histologic features suggestive of microsatellite instability in patient < age 60CRC diagnosed in ≥ 1 first-degree relative with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50CRC diagnosed in ≥ 2 first-degree or second-degree relatives with Lynch-associated tumors, regardless of ageNeither of these guidelines is foolproof; hence, many studies recommend testing all CRCs for Lynch syndrome",
                    "sub_points": [
                      "Mutations in genes coding for mismatch repair proteins (MLH1, PMS2, MSH2, MSH6)",
                      "Clinical featuresMultiple epithelial cancers occur at average age of ~ 20 years younger than expected",
                      "Multiple epithelial cancers occur at average age of ~ 20 years younger than expected",
                      "Several guidelines have been proposed to help identify patients who should be tested for Lynch syndromeAmsterdam criteria II≥ 3 relatives with a Lynch-associated cancer≥ 2 successive generations affected≥ 1 relative diagnosed < age 501 should be a 1st-degree relative of the other 2Familial adenomatous polyposis must be excludedRevised Bethesda guidelinesColorectal carcinoma (CRC) diagnosed prior to age 50Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of ageCRC with histologic features suggestive of microsatellite instability in patient < age 60CRC diagnosed in ≥ 1 first-degree relative with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50CRC diagnosed in ≥ 2 first-degree or second-degree relatives with Lynch-associated tumors, regardless of age",
                      "Amsterdam criteria II",
                      "≥ 3 relatives with a Lynch-associated cancer",
                      "≥ 2 successive generations affected",
                      "≥ 1 relative diagnosed < age 50",
                      "1 should be a 1st-degree relative of the other 2",
                      "Familial adenomatous polyposis must be excluded",
                      "Revised Bethesda guidelines",
                      "Colorectal carcinoma (CRC) diagnosed prior to age 50",
                      "Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of age",
                      "CRC with histologic features suggestive of microsatellite instability in patient < age 60",
                      "CRC diagnosed in ≥ 1 first-degree relative with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50",
                      "CRC diagnosed in ≥ 2 first-degree or second-degree relatives with Lynch-associated tumors, regardless of age",
                      "Neither of these guidelines is foolproof; hence, many studies recommend testing all CRCs for Lynch syndrome"
                    ]
                  }
                ],
                "Future Perspectives": [
                  {
                    "text": "Progress of recent years in understanding pathogenesis of familial tumor syndromes is expected to continue to improve patient screeningAlso become, in the long term, a catalyst for development of new therapeutic options for surgically untreatable tumors",
                    "sub_points": [
                      "Also become, in the long term, a catalyst for development of new therapeutic options for surgically untreatable tumors"
                    ]
                  },
                  {
                    "text": "With the fast-moving field, a new syndrome is frequently identified"
                  },
                  {
                    "text": "Awareness of possible syndromes when dealing with patients is critical for proper patient management"
                  },
                  {
                    "text": "Hereditary cancer syndromes in children and adolescents are becoming more recognized in the field of pediatric hematology/oncology"
                  },
                  {
                    "text": "Recently, germline mutations ofDICER1have been identified in patients with rare neoplasms, suggesting existence of a discovered syndrome involving cancer predispositionFamilial pleuropulmonary blastoma tumor predisposition (DICER1) syndromeDICER1mutations were identified in patients with familial pleuropulmonary blastomaAdditional manifestations of syndrome have been identified, including cystic nephroma, medulloepithelioma, Sertoli-Leydig cell tumor, and others",
                    "sub_points": [
                      "Familial pleuropulmonary blastoma tumor predisposition (DICER1) syndrome",
                      "DICER1mutations were identified in patients with familial pleuropulmonary blastoma",
                      "Additional manifestations of syndrome have been identified, including cystic nephroma, medulloepithelioma, Sertoli-Leydig cell tumor, and others"
                    ]
                  },
                  {
                    "text": "Familial pheochromocytoma and paraganglioma (PCC/PGL) syndromes form a heterogeneous group of tumorsExtensive genetic heterogeneity of these tumors came to light the identification of multiple susceptibility genesAt least 13 PPC/PGL syndromes are hereditaryMutations account for at least 30% of these tumors, the highest inheritable proportion of any known human tumor",
                    "sub_points": [
                      "Extensive genetic heterogeneity of these tumors came to light the identification of multiple susceptibility genes",
                      "At least 13 PPC/PGL syndromes are hereditary",
                      "Mutations account for at least 30% of these tumors, the highest inheritable proportion of any known human tumor"
                    ]
                  },
                  {
                    "text": "Importance of learning about them for the practicing physicians"
                  },
                  {
                    "text": "Of particular use for identification of genetic testing resources and regularly updated clinical management information for many of these disorders"
                  },
                  {
                    "text": "There are now a number of additional online resources available that provide more comprehensive information about these conditionsGeneTests website, a resource to those seeing individuals with genetic disorders: http://www. genetests.org/",
                    "sub_points": [
                      "GeneTests website, a resource to those seeing individuals with genetic disorders: http://www. genetests.org/"
                    ]
                  },
                  {
                    "text": "Pathologist plays a crucial role; important for surgical pathologists to be aware of specific pathology findings that suggest a possible tumor syndrome"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Beckwith-Wiedemann Syndrome": {
            "name": "Beckwith-Wiedemann Syndrome",
            "url": "https://app.pathprimer.com/document/5f13690b-b5e3-480f-b254-a7cb6b2138ba/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Beckwith-Wiedemann syndrome (BWS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Wiedemann-Beckwith syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Disorder of growth regulation"
                  },
                  {
                    "text": "Predisposition to embryonal tumors"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "~ 1 in 14,000"
                  }
                ],
                "Gender": [
                  {
                    "text": "M:F = 1:1Exception is monozygotic twinsF:M = 3:1",
                    "sub_points": [
                      "Exception is monozygotic twinsF:M = 3:1",
                      "F:M = 3:1"
                    ]
                  }
                ],
                "Ethnicity Relationship": [
                  {
                    "text": "All ethnicities"
                  }
                ],
                "Age Range": [
                  {
                    "text": "Increased growthIn utero1st few years of life",
                    "sub_points": [
                      "In utero",
                      "1st few years of life"
                    ]
                  },
                  {
                    "text": "Associated malignanciesGenerally present by 8 years",
                    "sub_points": [
                      "Generally present by 8 years"
                    ]
                  }
                ],
                "Other": [
                  {
                    "text": "Associated with assisted reproductionRisk is 1 in 4,000 for in vitro fertilization",
                    "sub_points": [
                      "Risk is 1 in 4,000 for in vitro fertilization"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Highly variable presentationRanges from mild to severe",
                    "sub_points": [
                      "Ranges from mild to severe"
                    ]
                  },
                  {
                    "text": "Somatic overgrowthClassic triadExomphalosGigantismMacroglossia (can cause abnormal feeding/breathing/speech)Initial increased growthIn uteroThrough 1st few years of lifeHeight and weight are often above 90th percentile for age in initial years of lifeNormalizes by childhoodOvergrowth may be unilateral (hemihyperplasia)Visceromegaly can involveLiverSpleenPancreasAdrenalsKidneys: May be associated with renal medullary dysplasia, nephrocalcinosis, or medullary sponge kidneyHeart",
                    "sub_points": [
                      "Classic triadExomphalosGigantismMacroglossia (can cause abnormal feeding/breathing/speech)",
                      "Exomphalos",
                      "Gigantism",
                      "Macroglossia (can cause abnormal feeding/breathing/speech)",
                      "Initial increased growthIn uteroThrough 1st few years of lifeHeight and weight are often above 90th percentile for age in initial years of lifeNormalizes by childhood",
                      "In utero",
                      "Through 1st few years of life",
                      "Height and weight are often above 90th percentile for age in initial years of life",
                      "Normalizes by childhood",
                      "Overgrowth may be unilateral (hemihyperplasia)",
                      "Visceromegaly can involveLiverSpleenPancreasAdrenalsKidneys: May be associated with renal medullary dysplasia, nephrocalcinosis, or medullary sponge kidneyHeart",
                      "Liver",
                      "Spleen",
                      "Pancreas",
                      "Adrenals",
                      "Kidneys: May be associated with renal medullary dysplasia, nephrocalcinosis, or medullary sponge kidney",
                      "Heart"
                    ]
                  },
                  {
                    "text": "Characteristic facies in early childhood (often normal by adulthood)Prominent eyesMidfacial hypoplasiaMacroglossiaProminent mandibleAnterior earlobe creasesPosterior helical pitsNevus flammeus may be present",
                    "sub_points": [
                      "Prominent eyes",
                      "Midfacial hypoplasia",
                      "Macroglossia",
                      "Prominent mandible",
                      "Anterior earlobe creases",
                      "Posterior helical pits",
                      "Nevus flammeus may be present"
                    ]
                  },
                  {
                    "text": "Abdominal wall defectsUmbilical herniaOmphaloceleDiastasis recti",
                    "sub_points": [
                      "Umbilical hernia",
                      "Omphalocele",
                      "Diastasis recti"
                    ]
                  }
                ],
                "Clinical Risk Factors": [
                  {
                    "text": "Risk of malignancyEstimated at 7.5%Range: 4-21%",
                    "sub_points": [
                      "Estimated at 7.5%",
                      "Range: 4-21%"
                    ]
                  }
                ],
                "Pathologic factors and risk": [
                  {
                    "text": "Associated with assisted reproduction"
                  }
                ],
                "Prognostic factors and risk": [
                  {
                    "text": "Worse prognosis with perinatal hypoglycemiaHypoglycemia in 30-50% of BWS",
                    "sub_points": [
                      "Hypoglycemia in 30-50% of BWS"
                    ]
                  },
                  {
                    "text": "Higher risk of tumor development withHemihyperplasiaNephromegalyNephrogenic rests",
                    "sub_points": [
                      "Hemihyperplasia",
                      "Nephromegaly",
                      "Nephrogenic rests"
                    ]
                  }
                ],
                "Imaging Findings": [
                  {
                    "text": "Ultrasonographic findingsUltrasound can also detect large kidneys, large abdominal circumference, omphalocele, and polyhydramnios from obstructed swallowing3D/4D ultrasound can delineate facial features in utero; protuberant tongue or hepatomegaly may be detected",
                    "sub_points": [
                      "Ultrasound can also detect large kidneys, large abdominal circumference, omphalocele, and polyhydramnios from obstructed swallowing",
                      "3D/4D ultrasound can delineate facial features in utero; protuberant tongue or hepatomegaly may be detected"
                    ]
                  }
                ]
              },
              "Genetics": {
                "Inheritance": [
                  {
                    "text": "Sporadic in ~ 85%"
                  },
                  {
                    "text": "Familial in ~ 15%Heterogeneous transmissionSometimes autosomal dominant maternal transmission",
                    "sub_points": [
                      "Heterogeneous transmissionSometimes autosomal dominant maternal transmission",
                      "Sometimes autosomal dominant maternal transmission"
                    ]
                  }
                ],
                "Molecular Pathology": [
                  {
                    "text": "Involves chromosome 11p15.5 in ~ 80% of casesIGF2andKCNQ1OT1are normally expressed from paternal alleleKCNQ1OT1-associated imprinting center (IC2) is usually methylated on maternal alleleH19,CDKN1C, andKCNQ1are normally expressed from maternal alleleH19-associated imprinting center (IC1) is usually methylated on paternal allele",
                    "sub_points": [
                      "IGF2andKCNQ1OT1are normally expressed from paternal alleleKCNQ1OT1-associated imprinting center (IC2) is usually methylated on maternal allele",
                      "KCNQ1OT1-associated imprinting center (IC2) is usually methylated on maternal allele",
                      "H19,CDKN1C, andKCNQ1are normally expressed from maternal alleleH19-associated imprinting center (IC1) is usually methylated on paternal allele",
                      "H19-associated imprinting center (IC1) is usually methylated on paternal allele"
                    ]
                  },
                  {
                    "text": "Different molecular pathology is associated with different clinical phenotypesEpigeneticAltered methylation: Loss of methylation at IC2 occurs in 50%; gain of methylation occurs at IC1 in 10%Loss of methylation at IC2 is associated with decreased risk of renal findings compared with gain of methylation at IC1GeneticMicrodeletionCDKN1CmutationUniparental disomy of 11p15.5 (~ 10-20% of cases; usually paternal allele) is associated with high risk of Wilms tumorDuplication, inversion, translocation of 11p15 in < 1% of cases",
                    "sub_points": [
                      "EpigeneticAltered methylation: Loss of methylation at IC2 occurs in 50%; gain of methylation occurs at IC1 in 10%Loss of methylation at IC2 is associated with decreased risk of renal findings compared with gain of methylation at IC1",
                      "Altered methylation: Loss of methylation at IC2 occurs in 50%; gain of methylation occurs at IC1 in 10%",
                      "Loss of methylation at IC2 is associated with decreased risk of renal findings compared with gain of methylation at IC1",
                      "GeneticMicrodeletionCDKN1CmutationUniparental disomy of 11p15.5 (~ 10-20% of cases; usually paternal allele) is associated with high risk of Wilms tumorDuplication, inversion, translocation of 11p15 in < 1% of cases",
                      "Microdeletion",
                      "CDKN1Cmutation",
                      "Uniparental disomy of 11p15.5 (~ 10-20% of cases; usually paternal allele) is associated with high risk of Wilms tumor",
                      "Duplication, inversion, translocation of 11p15 in < 1% of cases"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Embryonal Tumors/Malignancies": [
                  {
                    "text": "Wilms tumor (nephroblastoma)~ 60% of all tumors in BWSHistopathology: Often characterized by 3 elementsBlastema (embryological structure related to kidney development)Mesenchyme (may be composed of striated muscle, bone, cartilage, fat, fibroblastic tissue)Epithelium",
                    "sub_points": [
                      "~ 60% of all tumors in BWS",
                      "Histopathology: Often characterized by 3 elementsBlastema (embryological structure related to kidney development)Mesenchyme (may be composed of striated muscle, bone, cartilage, fat, fibroblastic tissue)Epithelium",
                      "Blastema (embryological structure related to kidney development)",
                      "Mesenchyme (may be composed of striated muscle, bone, cartilage, fat, fibroblastic tissue)",
                      "Epithelium"
                    ]
                  },
                  {
                    "text": "Adrenal cytomegalyHyperplastic adrenal glandsCharacteristic cytologyLarge, polyhedral cells with eosinophilic granular cytoplasm and enlarged nuclei",
                    "sub_points": [
                      "Hyperplastic adrenal glands",
                      "Characteristic cytologyLarge, polyhedral cells with eosinophilic granular cytoplasm and enlarged nuclei",
                      "Large, polyhedral cells with eosinophilic granular cytoplasm and enlarged nuclei"
                    ]
                  },
                  {
                    "text": "Adrenal cortical carcinomaCells with eosinophilic cytoplasmOften with numerous mitoses and invasive growth pattern",
                    "sub_points": [
                      "Cells with eosinophilic cytoplasm",
                      "Often with numerous mitoses and invasive growth pattern"
                    ]
                  },
                  {
                    "text": "HepatoblastomaHigh levels of α-fetoprotein (100,000-300,000 μg/mL)Different histologic variantsEpithelial (fetal pattern)Embryonal and fetal patternMacrotrabecular patternSmall cell undifferentiated patternMixed epithelial and mesenchymal pattern ± teratoid features",
                    "sub_points": [
                      "High levels of α-fetoprotein (100,000-300,000 μg/mL)",
                      "Different histologic variantsEpithelial (fetal pattern)Embryonal and fetal patternMacrotrabecular patternSmall cell undifferentiated patternMixed epithelial and mesenchymal pattern ± teratoid features",
                      "Epithelial (fetal pattern)",
                      "Embryonal and fetal pattern",
                      "Macrotrabecular pattern",
                      "Small cell undifferentiated pattern",
                      "Mixed epithelial and mesenchymal pattern ± teratoid features"
                    ]
                  },
                  {
                    "text": "RhabdomyosarcomaSubtypes reportedEmbryonal: Dense foci of rhabdomyoblasts with areas of loose, myxoid stromaAlveolar: Small blue cells in aggregates floating in spaces lined by fibrous septae",
                    "sub_points": [
                      "Subtypes reportedEmbryonal: Dense foci of rhabdomyoblasts with areas of loose, myxoid stromaAlveolar: Small blue cells in aggregates floating in spaces lined by fibrous septae",
                      "Embryonal: Dense foci of rhabdomyoblasts with areas of loose, myxoid stroma",
                      "Alveolar: Small blue cells in aggregates floating in spaces lined by fibrous septae"
                    ]
                  },
                  {
                    "text": "NeuroblastomaRound blue cells, sometimes forming rosettes",
                    "sub_points": [
                      "Round blue cells, sometimes forming rosettes"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Tumor Surveillance Protocol": [
                  {
                    "text": "Abdominal ultrasoundEvery 3-4 monthsUntil age 8",
                    "sub_points": [
                      "Every 3-4 months",
                      "Until age 8"
                    ]
                  },
                  {
                    "text": "α-fetoprotein assayEvery 3-4 monthsUntil age 4",
                    "sub_points": [
                      "Every 3-4 months",
                      "Until age 4"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Maternal Diabetes Mellitus": [
                  {
                    "text": "Can cause macrosomia in fetus"
                  },
                  {
                    "text": "May be associated with polyhydramnios"
                  },
                  {
                    "text": "Omphalocele is uncommon"
                  }
                ],
                "Isolated Hemihyperplasia": [
                  {
                    "text": "May be associated with Wilms tumor &/or alterations on 11p15"
                  },
                  {
                    "text": "Diagnosis of exclusion"
                  }
                ],
                "Isolated Omphalocele": [
                  {
                    "text": "May be associated with normal growth or growth restriction"
                  }
                ],
                "Simpson-Golabi-Behmel Syndrome": [
                  {
                    "text": "X-linked recessive"
                  },
                  {
                    "text": "Mutations inGPC3orCXORF5"
                  },
                  {
                    "text": "High mortality in infancy"
                  },
                  {
                    "text": "Macrocephaly, coarse face, macroglossia, polydactyly, heart defects"
                  },
                  {
                    "text": "Increased risk of tumorsWilms tumorHepatoblastomaNeuroblastomaGonadoblastomaHepatocellular carcinoma",
                    "sub_points": [
                      "Wilms tumor",
                      "Hepatoblastoma",
                      "Neuroblastoma",
                      "Gonadoblastoma",
                      "Hepatocellular carcinoma"
                    ]
                  }
                ],
                "Sotos Syndrome": [
                  {
                    "text": "Autosomal dominant, mutation inNSD1"
                  },
                  {
                    "text": "Overgrowth, advanced bone age, mental retardation"
                  },
                  {
                    "text": "Characteristic faciesHigh foreheadInverted pear-shaped headSparse frontal hairPointed chin",
                    "sub_points": [
                      "High forehead",
                      "Inverted pear-shaped head",
                      "Sparse frontal hair",
                      "Pointed chin"
                    ]
                  },
                  {
                    "text": "Cardiac/renal anomalies"
                  },
                  {
                    "text": "Increased risk of tumorsExamplesTeratomaNeuroblastomaAcute lymphoblastic leukemiaWilms tumor",
                    "sub_points": [
                      "ExamplesTeratomaNeuroblastomaAcute lymphoblastic leukemiaWilms tumor",
                      "Teratoma",
                      "Neuroblastoma",
                      "Acute lymphoblastic leukemia",
                      "Wilms tumor"
                    ]
                  }
                ],
                "Perlman Syndrome": [
                  {
                    "text": "Autosomal recessive"
                  },
                  {
                    "text": "Mutation inDIS3L2"
                  },
                  {
                    "text": "Similarities to BWSMacroglossiaOvergrowthNeonatal hypoglycemia",
                    "sub_points": [
                      "Macroglossia",
                      "Overgrowth",
                      "Neonatal hypoglycemia"
                    ]
                  }
                ],
                "Hemihypoplasia": [
                  {
                    "text": "Underdevelopment of 1 side of bodyRelative to underdeveloped side, normal side may be misdiagnosed as being hyperplastic",
                    "sub_points": [
                      "Relative to underdeveloped side, normal side may be misdiagnosed as being hyperplastic"
                    ]
                  }
                ],
                "Syndromic Wilms Tumor": [
                  {
                    "text": "Syndromes related toWT1mutationExamplesWAGR (Wilms tumor, aniridia, genitourinary anomalies, mental retardation) syndromeDenys-Drash syndrome (gonadal dysgenesis, nephropathy, Wilms tumor)Frasier syndrome (pseudohermaphroditism, glomerulonephropathy, gonadoblastoma, rarely Wilms tumor)Genitourinary anomalies syndrome (abnormal external genitalia, Wilms tumor)",
                    "sub_points": [
                      "ExamplesWAGR (Wilms tumor, aniridia, genitourinary anomalies, mental retardation) syndromeDenys-Drash syndrome (gonadal dysgenesis, nephropathy, Wilms tumor)Frasier syndrome (pseudohermaphroditism, glomerulonephropathy, gonadoblastoma, rarely Wilms tumor)Genitourinary anomalies syndrome (abnormal external genitalia, Wilms tumor)",
                      "WAGR (Wilms tumor, aniridia, genitourinary anomalies, mental retardation) syndrome",
                      "Denys-Drash syndrome (gonadal dysgenesis, nephropathy, Wilms tumor)",
                      "Frasier syndrome (pseudohermaphroditism, glomerulonephropathy, gonadoblastoma, rarely Wilms tumor)",
                      "Genitourinary anomalies syndrome (abnormal external genitalia, Wilms tumor)"
                    ]
                  }
                ],
                "Nonsyndromic Wilms Tumor": [
                  {
                    "text": "Wilms tumor not associated with any syndrome (e.g., BWS, WAGR syndrome, Denys-Drash syndrome, Frasier syndrome)"
                  }
                ]
              },
              "Criteria for Diagnosis": {
                "Major Findings": [
                  {
                    "text": "Abdominal wall defectsOmphaloceleUmbilical hernia",
                    "sub_points": [
                      "Omphalocele",
                      "Umbilical hernia"
                    ]
                  },
                  {
                    "text": "Macroglossia"
                  },
                  {
                    "text": "MacrosomiaHeight to weight ratio > 97th percentile",
                    "sub_points": [
                      "Height to weight ratio > 97th percentile"
                    ]
                  },
                  {
                    "text": "Anterior ear lobe creases &/or posterior helical pits"
                  },
                  {
                    "text": "Visceromegaly"
                  },
                  {
                    "text": "Embryonal tumor in childhood"
                  },
                  {
                    "text": "Hemihyperplasia"
                  },
                  {
                    "text": "Cytomegaly of adrenal fetal cortex, usually diffuse and bilateral"
                  },
                  {
                    "text": "Renal abnormalitiesMedullary dysplasiaAbnormality of medullary sponge kidney",
                    "sub_points": [
                      "Medullary dysplasia",
                      "Abnormality of medullary sponge kidney"
                    ]
                  },
                  {
                    "text": "Positive family history of BWS"
                  },
                  {
                    "text": "Cleft palate"
                  }
                ],
                "Minor Findings": [
                  {
                    "text": "Pregnancy-related findingsPolyhydramniosEnlarged placentaThickened umbilical cordPremature onset of labor/deliveryPreeclampsia",
                    "sub_points": [
                      "Polyhydramnios",
                      "Enlarged placenta",
                      "Thickened umbilical cord",
                      "Premature onset of labor/delivery",
                      "Preeclampsia"
                    ]
                  },
                  {
                    "text": "Neonatal hypoglycemia"
                  },
                  {
                    "text": "Nevus flammeus"
                  },
                  {
                    "text": "Cardiomegaly/cardiomyopathy/other abnormalities"
                  },
                  {
                    "text": "Characteristic facies"
                  },
                  {
                    "text": "Diastasis recti"
                  },
                  {
                    "text": "Advanced bone age"
                  }
                ],
                "Criteria Based on Findings": [
                  {
                    "text": "3 major or 1 minor + 2 major findings support BWS diagnosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Bloom Syndrome": {
            "name": "Bloom Syndrome",
            "url": "https://app.pathprimer.com/document/f6eaf29e-3ce4-4adc-925c-3feae0624383/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Bloom syndrome (BSyn)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Bloom-Torre-Machacek syndrome"
                  },
                  {
                    "text": "Congenital telangiectatic erythema"
                  }
                ],
                "Definition": [
                  {
                    "text": "Rare autosomal recessive disorder resulting from mutations in theBLMgene; 1st described by dermatologist Dr. David Bloom in 1954"
                  }
                ]
              },
              "Epidemiology": {
                "Incidence": [
                  {
                    "text": "Exceedingly rare (265 reported cases from 222 families in the Bloom Syndrome Registry as of 2009)"
                  },
                  {
                    "text": "Parental consanguinity common"
                  },
                  {
                    "text": "Cases have been described in North and South America, Europe, Asia, Africa, and Australia"
                  },
                  {
                    "text": "~ 1/4 of people with BSyn are of Jewish descent, particularly Central and Eastern European (Ashkenazi) Jewish backgroundSeen in 1 in 48,000 live births in this population",
                    "sub_points": [
                      "Seen in 1 in 48,000 live births in this population"
                    ]
                  },
                  {
                    "text": "~ 3/4 of people with BSyn are of non-Jewish backgroundFounder mutations have been described in many human populations, includingJapaneseEuropean (Italian, Portuguese)BrazilianNorth American (including Spanish American)",
                    "sub_points": [
                      "Founder mutations have been described in many human populations, includingJapaneseEuropean (Italian, Portuguese)BrazilianNorth American (including Spanish American)",
                      "Japanese",
                      "European (Italian, Portuguese)",
                      "Brazilian",
                      "North American (including Spanish American)"
                    ]
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Molecular Pathogenesis": [
                  {
                    "text": "Caused by biallelic mutations in theBLMgene, located at 15q26.1 (most commonly homozygous; less frequently compound heterozygous)Described mutations include missense, nonsense, insertions/deletions, and splicing defects due to intron mutations",
                    "sub_points": [
                      "Described mutations include missense, nonsense, insertions/deletions, and splicing defects due to intron mutations"
                    ]
                  },
                  {
                    "text": "BLMis a tumor-suppressor gene and belongs to family of RecQ DNA helicasesRecQ helicases are important for repair of DNA damageProtein product (BLM) permits unwinding of DNA in order to resolve disruptive structures that have developed during replicationMutations in other RecQ helicase genes result in additional DNA repair deficiency syndromesWerner syndrome (WRNgene on chromosome 8)Rothmund-Thomson syndrome (RECQL4gene on chromosome 8)",
                    "sub_points": [
                      "RecQ helicases are important for repair of DNA damage",
                      "Protein product (BLM) permits unwinding of DNA in order to resolve disruptive structures that have developed during replication",
                      "Mutations in other RecQ helicase genes result in additional DNA repair deficiency syndromesWerner syndrome (WRNgene on chromosome 8)Rothmund-Thomson syndrome (RECQL4gene on chromosome 8)",
                      "Werner syndrome (WRNgene on chromosome 8)",
                      "Rothmund-Thomson syndrome (RECQL4gene on chromosome 8)"
                    ]
                  }
                ],
                "Immunodeficiency": [
                  {
                    "text": "Pathogenesis of immunodeficiency is not well characterizedHypogammaglobulinemiaDecreased or absent delayed hypersensitivityAbnormal functioning of αβ T cells",
                    "sub_points": [
                      "Hypogammaglobulinemia",
                      "Decreased or absent delayed hypersensitivity",
                      "Abnormal functioning of αβ T cells"
                    ]
                  }
                ]
              },
              "Clinical Features": {
                "Consistent Features": [
                  {
                    "text": "Short stature and microcephaly due to growth retardation, pre- and postnatal, otherwise normal proportions"
                  },
                  {
                    "text": "Paucity of subcutaneous fat in infancy and childhood"
                  },
                  {
                    "text": "High predisposition to hematolymphoid and epithelial neoplasms"
                  }
                ],
                "Variable Features": [
                  {
                    "text": "Photosensitivity with development of erythema or telangiectasias in sun-exposed areas"
                  },
                  {
                    "text": "Patchy areas of hyper- and hypopigmentation"
                  },
                  {
                    "text": "Characteristic facies (long, narrow face with malar hypoplasia, small mandible, and prominent nose)"
                  },
                  {
                    "text": "Affected males experience infertility and affected females undergo early menopause"
                  },
                  {
                    "text": "Average intelligence; some patients with learning disabilities"
                  },
                  {
                    "text": "High-pitched voice"
                  },
                  {
                    "text": "Diarrhea and vomiting at an early age"
                  },
                  {
                    "text": "Immunodeficiency leading to recurrent infections"
                  },
                  {
                    "text": "Increased risk of chronic obstructive lung disease and diabetes mellitus (adult-onset type)"
                  }
                ]
              },
              "Ancillary Tests": {
                "Confirmation of Diagnosis": [
                  {
                    "text": "Cytogenetic testingDiagnostic test: Evaluation for increased number of sister chromatid exchanges (SCE) in any cell (typically peripheral blood lymphocytes)Cells are cultured for 2 cell cycles in a medium containing bromodeoxyuridine (BrDu) and arrested at metaphaseUpon fluorescence-plus-Giemsa coloration, differential staining of the 2 sister chromatids is apparent (1 appears dark, 1 appears light)In BSyn, sister chromatids show an increased number of exchanges (at least 10x increase compared to control)Increase in random chromosome breakage seen on metaphase spread including chromatid gaps, breaks and rearrangements, chromatid interchange configurations such as quadriradial interchange configuration, telomeric associations, anaphase bridges, and lagging chromosomal fragments",
                    "sub_points": [
                      "Diagnostic test: Evaluation for increased number of sister chromatid exchanges (SCE) in any cell (typically peripheral blood lymphocytes)Cells are cultured for 2 cell cycles in a medium containing bromodeoxyuridine (BrDu) and arrested at metaphaseUpon fluorescence-plus-Giemsa coloration, differential staining of the 2 sister chromatids is apparent (1 appears dark, 1 appears light)In BSyn, sister chromatids show an increased number of exchanges (at least 10x increase compared to control)",
                      "Cells are cultured for 2 cell cycles in a medium containing bromodeoxyuridine (BrDu) and arrested at metaphase",
                      "Upon fluorescence-plus-Giemsa coloration, differential staining of the 2 sister chromatids is apparent (1 appears dark, 1 appears light)",
                      "In BSyn, sister chromatids show an increased number of exchanges (at least 10x increase compared to control)",
                      "Increase in random chromosome breakage seen on metaphase spread including chromatid gaps, breaks and rearrangements, chromatid interchange configurations such as quadriradial interchange configuration, telomeric associations, anaphase bridges, and lagging chromosomal fragments"
                    ]
                  },
                  {
                    "text": "Molecular testingTargeted mutation analysis (e.g., evaluation forblmAsh [c.2207_2212del6ins7] in patients of Ashkenazi Jewish descent)Sequence analysis of entire coding regionDeletion/duplication analysis",
                    "sub_points": [
                      "Targeted mutation analysis (e.g., evaluation forblmAsh [c.2207_2212del6ins7] in patients of Ashkenazi Jewish descent)",
                      "Sequence analysis of entire coding region",
                      "Deletion/duplication analysis"
                    ]
                  }
                ],
                "Prenatal Testing": [
                  {
                    "text": "Can be performed via SCE analysis or by specific mutation testing if familial mutation is known (chorionic villous sampling or amniocentesis)"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Increased Cancer Risk": [
                  {
                    "text": "Up to 50% of patients with BSyn will develop a malignancy~ 10% have ≥ 2 primary cancers, with fewer numbers reported to have 3, 4, or even 5 primary neoplasms",
                    "sub_points": [
                      "~ 10% have ≥ 2 primary cancers, with fewer numbers reported to have 3, 4, or even 5 primary neoplasms"
                    ]
                  },
                  {
                    "text": "Mean age of cancer diagnosis: ~ 24 years"
                  },
                  {
                    "text": "Hematolymphoid malignancies predominant in first 2 decades of life"
                  },
                  {
                    "text": "Carcinomas predominant after first 2 decades of life"
                  },
                  {
                    "text": "Increased cancer incidence shortens overall lifespan"
                  }
                ],
                "Hematolymphoid Malignancies": [
                  {
                    "text": "Leukemia (both acute myeloid leukemia and acute lymphoblastic leukemia)There may be preferential occurrence of monosomy 7 (-7) and deletion of long arm of chromosome 7 (del[7q]) in myelodysplastic syndrome/acute myeloid leukemia in BSyn patients",
                    "sub_points": [
                      "There may be preferential occurrence of monosomy 7 (-7) and deletion of long arm of chromosome 7 (del[7q]) in myelodysplastic syndrome/acute myeloid leukemia in BSyn patients"
                    ]
                  },
                  {
                    "text": "Lymphoma (predominantly non-Hodgkin lymphoma, less frequently Hodgkin lymphoma)"
                  }
                ],
                "Carcinomas": [
                  {
                    "text": "Arise in varied sites including skin, head, neck, lung, uterus, breast, and gastrointestinal tract (including esophagus [both squamous cell carcinoma and adenocarcinoma], stomach, and colon)"
                  }
                ],
                "Rare Tumor Types": [
                  {
                    "text": "Medulloblastoma, Wilms tumor, osteogenic sarcoma"
                  }
                ],
                "Carriers": [
                  {
                    "text": "BLMmutation carriers do not have an increased cancer risk"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Patients With BSyn": [
                  {
                    "text": "Markedly increased risk of a variety of malignancies, which occur earlier compared to general population, necessitates careful and broad cancer surveillance throughout patient's life"
                  },
                  {
                    "text": "Exposure to radiation or DNA-damaging chemicals should be avoided"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Diffuse Gastric Cancer": {
            "name": "Hereditary Diffuse Gastric Cancer",
            "url": "https://app.pathprimer.com/document/73cfd0af-f78c-4c0e-b457-528df71256c7/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Hereditary diffuse gastric cancer (HDGC)"
                  }
                ]
              },
              "Epidemiology": {
                "Prevalence": [
                  {
                    "text": "10% of gastric cancers have familial clusteringOf these, 1-3% represent HDGC",
                    "sub_points": [
                      "Of these, 1-3% represent HDGC"
                    ]
                  },
                  {
                    "text": "1st described in Maori families from New Zealand, but syndrome is seen in all ethnic groupsLarge clusters in New Zealand and CanadaAsian countries with high incidence of sporadic gastric carcinoma seem to have low incidence of HDGCReason for this is unknown",
                    "sub_points": [
                      "Large clusters in New Zealand and Canada",
                      "Asian countries with high incidence of sporadic gastric carcinoma seem to have low incidence of HDGCReason for this is unknown",
                      "Reason for this is unknown"
                    ]
                  }
                ]
              },
              "Genetics": {
                "E-Cadherin/CDH1Gene": [
                  {
                    "text": "Mutation inCDH1gene in 30-40% of patients who fit clinical definition of HDGCAutosomal dominantCumulative risk of gastric cancer at age 80 years is 67% for men and 83% for womenLifetime risk of lobular breast carcinoma in women is 39-60%Increased risk of prostate cancer in menIncreased risk of signet ring cell colorectal cancer in both men and womenCell-cell adhesion protein that acts as tumor suppressor geneMutations typically cause truncation of protein and loss of function2nd hit that inactivates good copy of the gene appears to be promoter methylationMay be important mechanism in sporadic diffuse gastric cancerMay be \"drugable\" target",
                    "sub_points": [
                      "Autosomal dominantCumulative risk of gastric cancer at age 80 years is 67% for men and 83% for womenLifetime risk of lobular breast carcinoma in women is 39-60%Increased risk of prostate cancer in menIncreased risk of signet ring cell colorectal cancer in both men and women",
                      "Cumulative risk of gastric cancer at age 80 years is 67% for men and 83% for women",
                      "Lifetime risk of lobular breast carcinoma in women is 39-60%",
                      "Increased risk of prostate cancer in men",
                      "Increased risk of signet ring cell colorectal cancer in both men and women",
                      "Cell-cell adhesion protein that acts as tumor suppressor geneMutations typically cause truncation of protein and loss of function",
                      "Mutations typically cause truncation of protein and loss of function",
                      "2nd hit that inactivates good copy of the gene appears to be promoter methylationMay be important mechanism in sporadic diffuse gastric cancerMay be \"drugable\" target",
                      "May be important mechanism in sporadic diffuse gastric cancer",
                      "May be \"drugable\" target"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Endoscopic Biopsies": [
                  {
                    "text": "Classic lesion is the presence of signet ring cell carcinoma in situSignet ring cells within basement membrane of glands with pagetoid spreadMay also see vacuolization of foveolar epithelium, called globoid changeGloboid change by itself is not specific for HDGC",
                    "sub_points": [
                      "Signet ring cells within basement membrane of glands with pagetoid spread",
                      "May also see vacuolization of foveolar epithelium, called globoid changeGloboid change by itself is not specific for HDGC",
                      "Globoid change by itself is not specific for HDGC"
                    ]
                  },
                  {
                    "text": "1 study has shown that immunohistochemical staining for E-cadherin is negative in 77% of signet ring cell carcinoma foci in HDGC (some foci do stain positively)"
                  },
                  {
                    "text": "If unsure about pathology, best to have case reviewed by a pathologist who has experience with HDGC cases"
                  }
                ],
                "Resection Specimens": [
                  {
                    "text": "Multiple foci of signet ring cell carcinomaSome studies suggest most tumors are found at antral transition zone; others refute this, finding most lesions in fundus and bodySome patients have hundreds of small in situ lesions whereas others have only 1 or 2May need to take hundreds of sections to find small in situ lesionsMay be easier to identify these subtle changes with PAS stainThere are documented cases of patients withCDH1mutations whose prophylactic gastrectomy specimen did not show any carcinoma despite totally embedding entire stomach",
                    "sub_points": [
                      "Some studies suggest most tumors are found at antral transition zone; others refute this, finding most lesions in fundus and body",
                      "Some patients have hundreds of small in situ lesions whereas others have only 1 or 2May need to take hundreds of sections to find small in situ lesionsMay be easier to identify these subtle changes with PAS stainThere are documented cases of patients withCDH1mutations whose prophylactic gastrectomy specimen did not show any carcinoma despite totally embedding entire stomach",
                      "May need to take hundreds of sections to find small in situ lesions",
                      "May be easier to identify these subtle changes with PAS stain",
                      "There are documented cases of patients withCDH1mutations whose prophylactic gastrectomy specimen did not show any carcinoma despite totally embedding entire stomach"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Major Clinical Criteria": [
                  {
                    "text": "2 or more cases of gastric cancer in 1st- or 2nd-degree relatives with ≥ 1 diffuse gastric cancer in a patient < 50 years of age"
                  },
                  {
                    "text": "3 or more cases of gastric cancer in 1st- or 2nd-degree relatives at any age with at least 1 documented case of diffuse gastric cancer"
                  },
                  {
                    "text": "Only 30-40% of cases that fulfill these 2 major criteria will haveCDH1mutation, suggesting other genes may cause a similar syndrome"
                  }
                ],
                "Minor or Additional Clinical Criteria": [
                  {
                    "text": "Diffuse gastric cancer in patient < 40 years of age without family history"
                  },
                  {
                    "text": "Diffuse gastric cancer and lobular breast cancer in 1 patient, or 1 patient with diffuse gastric cancer and family member with lobular breast cancer or signet ring colon cancer"
                  },
                  {
                    "text": "Patients who fulfill these clinical criteria should undergo sequencing of theirCDH1geneSome variability among experts regarding these clinical criteria as some would test a single patient < 45 years with diffuse gastric cancer and no family history> 100 mutations have been reported that lead to HDGC, so entire gene must be sequenced≥ 1 group of physicians recommends waiting until 16 years to test children of affected families",
                    "sub_points": [
                      "Some variability among experts regarding these clinical criteria as some would test a single patient < 45 years with diffuse gastric cancer and no family history",
                      "> 100 mutations have been reported that lead to HDGC, so entire gene must be sequenced",
                      "≥ 1 group of physicians recommends waiting until 16 years to test children of affected families"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Lobular Carcinoma of Breast": [
                  {
                    "text": "Strong evidence that suggests association with HDGC"
                  }
                ],
                "Signet Ring Cell Carcinoma of Colon": [
                  {
                    "text": "Both sexes"
                  },
                  {
                    "text": "Uncommon tumor should raise question of Lynch syndrome or HDGC"
                  }
                ],
                "Prostatic Adenocarcinoma": [
                  {
                    "text": "Weak evidence that suggests association with HDGCLikely unrelated given frequency of prostate cancer",
                    "sub_points": [
                      "Likely unrelated given frequency of prostate cancer"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Endoscopic Surveillance": [
                  {
                    "text": "Early lesions are not evident endoscopicallyNot very effective as number of biopsies needed to ensure adequate sampling is too high1 study found over 1,750 mucosal biopsies would be needed to have a 90% chance of finding an in situ lesionUp to 25% of patients who test positive forCDH1mutation refuse gastrectomyOffered endoscopy with biopsy every 6 months",
                    "sub_points": [
                      "Not very effective as number of biopsies needed to ensure adequate sampling is too high1 study found over 1,750 mucosal biopsies would be needed to have a 90% chance of finding an in situ lesion",
                      "1 study found over 1,750 mucosal biopsies would be needed to have a 90% chance of finding an in situ lesion",
                      "Up to 25% of patients who test positive forCDH1mutation refuse gastrectomyOffered endoscopy with biopsy every 6 months",
                      "Offered endoscopy with biopsy every 6 months"
                    ]
                  }
                ],
                "Prophylactic Total Gastrectomy": [
                  {
                    "text": "Treatment of choice to prevent gastric cancerProcedure has low mortality rate but high morbidityIn New Zealand, recommended after age 20 in known carriersOthers recommend gastrectomy 5 years earlier than earliest known cancer in individual familyRisk of advanced disease is < 1% at age 20 years, 4% at age 30 years, but between 21% and 46% at age 50 years",
                    "sub_points": [
                      "Procedure has low mortality rate but high morbidity",
                      "In New Zealand, recommended after age 20 in known carriersOthers recommend gastrectomy 5 years earlier than earliest known cancer in individual familyRisk of advanced disease is < 1% at age 20 years, 4% at age 30 years, but between 21% and 46% at age 50 years",
                      "Others recommend gastrectomy 5 years earlier than earliest known cancer in individual family",
                      "Risk of advanced disease is < 1% at age 20 years, 4% at age 30 years, but between 21% and 46% at age 50 years"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "PTEN-Hamartoma Tumor Syndromes": {
            "name": "PTEN-Hamartoma Tumor Syndromes",
            "url": "https://app.pathprimer.com/document/ca6bf33d-1f6e-45e9-8620-f69789c6ccd5/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Phosphatase and tensin homolog (PTEN) deleted on chromosome 10"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome (PHTS)"
                  },
                  {
                    "text": "Cowden syndrome (CS)"
                  },
                  {
                    "text": "Cowden disease (CD)"
                  },
                  {
                    "text": "Multiple hamartoma syndrome (MHAM)"
                  },
                  {
                    "text": "Bannayan-Riley-Ruvalcaba syndrome (BRRS)"
                  },
                  {
                    "text": "PTEN-related Proteus syndrome (PRPS)"
                  }
                ],
                "Syndromes": [
                  {
                    "text": "PHTS includesCowden syndromeBannayan-Riley-Ruvalcaba syndromePTEN-related Proteus syndrome and Proteus-like syndromeAutism with macrocephaly",
                    "sub_points": [
                      "Cowden syndrome",
                      "Bannayan-Riley-Ruvalcaba syndrome",
                      "PTEN-related Proteus syndrome and Proteus-like syndrome",
                      "Autism with macrocephaly"
                    ]
                  }
                ],
                "Definition": [
                  {
                    "text": "PHTS is a complex disorder caused by germline inactivating mutations ofPTENtumor suppressor gene, which maps to 10q23.3"
                  },
                  {
                    "text": "PHTS is primarily composed of the Cowden and Bannayan-Riley-Ruvalcaba syndromesSeveral other syndromes have been linked withPTENmutations includingPTEN-related Proteus syndrome, Proteus-like syndrome, and autism with macrocephaly",
                    "sub_points": [
                      "Several other syndromes have been linked withPTENmutations includingPTEN-related Proteus syndrome, Proteus-like syndrome, and autism with macrocephaly"
                    ]
                  },
                  {
                    "text": "Cowden syndromeClinical manifestations of Cowden syndrome includes hamartomatous tumors in multiple organ systems and an increased risk for malignancyAffected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules and present by late 20sMultiple hamartoma syndrome with a high risk for benign and malignant tumors of thyroid, breast, and endometriumLifetime risk of developing breast cancer is 25-50%; reports up to 85%Average age of diagnosis between 38 and 46 years~ 50% of women have benign breast conditions: Ductal hyperplasia, intraductal papillomatosis, adenosis, lobular atrophy, fibroadenomas, fibrocystic change, and/or densely fibrotic hyalinized nodulesIncreased incidence of both multifocality and bilateral involvement has been observed for both benign and malignant breast disorders~ 2/3 of CS patients develop thyroid lesions involving follicular cellsIncludes multinodular goiter, multiple adenomatous nodules, follicular adenoma, follicular carcinoma, and, less frequently, papillary thyroid carcinomaUsually follicular, rarely papillary, but no medullary thyroid cancer has been reportedRisk of thyroid cancer in affected individuals ranges from 3-35% in large case series~ 70x increased incidence of nonmedullary thyroid cancer relative to the general populationRisk for endometrial cancer, although not well defined, may approach ~ 13-28%",
                    "sub_points": [
                      "Clinical manifestations of Cowden syndrome includes hamartomatous tumors in multiple organ systems and an increased risk for malignancy",
                      "Affected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules and present by late 20s",
                      "Multiple hamartoma syndrome with a high risk for benign and malignant tumors of thyroid, breast, and endometrium",
                      "Lifetime risk of developing breast cancer is 25-50%; reports up to 85%Average age of diagnosis between 38 and 46 years",
                      "Average age of diagnosis between 38 and 46 years",
                      "~ 50% of women have benign breast conditions: Ductal hyperplasia, intraductal papillomatosis, adenosis, lobular atrophy, fibroadenomas, fibrocystic change, and/or densely fibrotic hyalinized nodules",
                      "Increased incidence of both multifocality and bilateral involvement has been observed for both benign and malignant breast disorders",
                      "~ 2/3 of CS patients develop thyroid lesions involving follicular cellsIncludes multinodular goiter, multiple adenomatous nodules, follicular adenoma, follicular carcinoma, and, less frequently, papillary thyroid carcinomaUsually follicular, rarely papillary, but no medullary thyroid cancer has been reportedRisk of thyroid cancer in affected individuals ranges from 3-35% in large case series~ 70x increased incidence of nonmedullary thyroid cancer relative to the general population",
                      "Includes multinodular goiter, multiple adenomatous nodules, follicular adenoma, follicular carcinoma, and, less frequently, papillary thyroid carcinoma",
                      "Usually follicular, rarely papillary, but no medullary thyroid cancer has been reported",
                      "Risk of thyroid cancer in affected individuals ranges from 3-35% in large case series",
                      "~ 70x increased incidence of nonmedullary thyroid cancer relative to the general population",
                      "Risk for endometrial cancer, although not well defined, may approach ~ 13-28%"
                    ]
                  },
                  {
                    "text": "Bannayan-Riley-Ruvalcaba syndromeCongenital disorder characterized by macrocephaly, lipomas, intestinal hamartomatous polyposis, vascular hamartomatous lesions, and pigmented macules of glans penisAlthough diagnostic criteria for CS have been established for more than a decade, there are no agreed upon international criteria for the diagnosis of BRRSRate of occurrence and histologic types of thyroid lesions in BRRS have not been widely reported but have appeared similar to those seen in CS, suggesting a single entity",
                    "sub_points": [
                      "Congenital disorder characterized by macrocephaly, lipomas, intestinal hamartomatous polyposis, vascular hamartomatous lesions, and pigmented macules of glans penis",
                      "Although diagnostic criteria for CS have been established for more than a decade, there are no agreed upon international criteria for the diagnosis of BRRS",
                      "Rate of occurrence and histologic types of thyroid lesions in BRRS have not been widely reported but have appeared similar to those seen in CS, suggesting a single entity"
                    ]
                  },
                  {
                    "text": "PTEN-related Proteus syndromeComplex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues as well as connective tissue nevi, epidermal nevi, and hyperostosesThere have been reports ofPTENmutations in some patients with phenotypic similarities to Proteus syndrome (PS)Somatic activating mutations inAKT1oncogene have been delineated as the genetic cause of PSProteus-like syndromeUndefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS",
                    "sub_points": [
                      "Complex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues as well as connective tissue nevi, epidermal nevi, and hyperostoses",
                      "There have been reports ofPTENmutations in some patients with phenotypic similarities to Proteus syndrome (PS)Somatic activating mutations inAKT1oncogene have been delineated as the genetic cause of PS",
                      "Somatic activating mutations inAKT1oncogene have been delineated as the genetic cause of PS",
                      "Proteus-like syndromeUndefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS",
                      "Undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Incidence": [
                  {
                    "text": "Estimated ~ 1 in 200,000-250,000 people"
                  }
                ],
                "Familial": [
                  {
                    "text": "Autosomal dominant inheritance pattern"
                  },
                  {
                    "text": "Only 10-50% of individuals with Cowden syndrome have an affected parent"
                  },
                  {
                    "text": "Each child of an affected individual has a 50% chance of inheriting mutation and developing PHTS"
                  }
                ],
                "Lifetime Risk of Developing Cancer": [
                  {
                    "text": "Lifetime risks for a variety of cancers are increased in patients withPTENmutationsThyroid: 3-35%Breast: 25-85%Endometrium: 13-28%Now extending toColorectal cancer: 9-13%Kidney cancer: 13-34%%Melanoma: 6%",
                    "sub_points": [
                      "Thyroid: 3-35%",
                      "Breast: 25-85%",
                      "Endometrium: 13-28%",
                      "Now extending toColorectal cancer: 9-13%Kidney cancer: 13-34%%Melanoma: 6%",
                      "Colorectal cancer: 9-13%",
                      "Kidney cancer: 13-34%%",
                      "Melanoma: 6%"
                    ]
                  }
                ]
              },
              "Genetics": {
                "PTEN": [
                  {
                    "text": "PTENis a tumor suppressor gene located on 10q23.3"
                  },
                  {
                    "text": "Up to ~ 80% of cases of that met criteria for Cowden syndrome and a small percentage of cases of Cowden-like syndrome result from mutations inPTENgeneInPTENsequencing-negative and clinically positive Cowden syndrome, ~ 10% have large deletions and ~ 10% have promoter mutations",
                    "sub_points": [
                      "InPTENsequencing-negative and clinically positive Cowden syndrome, ~ 10% have large deletions and ~ 10% have promoter mutations"
                    ]
                  },
                  {
                    "text": "PTENmutationInitially reported that up to 83% of individuals meeting clinical criteria for Cowden syndrome had a detectablePTENmutationOverestimate attributable to the highly selected nature of earlier Cowden syndrome cohortsMore recent estimates are that germlinePTENmutations are found in ~ 20-34% of individuals who meet clinical criteria for Cowden syndrome or who meet criteria for genetic testing",
                    "sub_points": [
                      "Initially reported that up to 83% of individuals meeting clinical criteria for Cowden syndrome had a detectablePTENmutationOverestimate attributable to the highly selected nature of earlier Cowden syndrome cohorts",
                      "Overestimate attributable to the highly selected nature of earlier Cowden syndrome cohorts",
                      "More recent estimates are that germlinePTENmutations are found in ~ 20-34% of individuals who meet clinical criteria for Cowden syndrome or who meet criteria for genetic testing"
                    ]
                  },
                  {
                    "text": "Function ofPTENis not entirely understood, but it is a major phosphatase for phosphoinositide-3,4,5-triphosphate"
                  },
                  {
                    "text": "By downregulating the levels of phosphoinositide-3,4,5-triphosphate,PTENproduces an inhibitory (tumor suppressor) effect on the PI3P/Akt pathway, an important carcinogenesis pathway"
                  },
                  {
                    "text": "Loss ofPTENfunction results in escape from programmed cell death and G1 arrest in cell cycle"
                  },
                  {
                    "text": "Proposed thatPTENhas important activity both in cytoplasm and nucleusNuclearPTENmight be required for cell cycle arrest by downregulating cyclin-D1 and preventing phosphorylation of mitogen-activated protein kinase pathwayCytoplasmicPTENseems to be required for apoptosis by downregulating the phosphorylation of Akt and upregulating p27",
                    "sub_points": [
                      "NuclearPTENmight be required for cell cycle arrest by downregulating cyclin-D1 and preventing phosphorylation of mitogen-activated protein kinase pathway",
                      "CytoplasmicPTENseems to be required for apoptosis by downregulating the phosphorylation of Akt and upregulating p27"
                    ]
                  },
                  {
                    "text": "Gene is composed of 9 exons, with a 1,209 bp coding sequence, which is predicted to encode a 403 amino acid proteinMutations are dispersed throughout the 9 exons of thePTENgene, with ~40% of mutations located in exon 5, which represents 20% of coding sequence and is known as mutational \"hot spot\" in PHTS",
                    "sub_points": [
                      "Mutations are dispersed throughout the 9 exons of thePTENgene, with ~40% of mutations located in exon 5, which represents 20% of coding sequence and is known as mutational \"hot spot\" in PHTS"
                    ]
                  },
                  {
                    "text": "Very few germline mutations have been reported in exon 1, and none in exon 9"
                  },
                  {
                    "text": "75% of germline mutations result in truncated protein, lack of protein, or dysfunctional protein"
                  },
                  {
                    "text": "Protein produced fromPTENgene is a tumor suppressor, which means that it normally prevents cells from growing and dividing (proliferating) too rapidly or in an uncontrolled way"
                  },
                  {
                    "text": "Mutations in thePTENgene prevent the protein from regulating cell proliferation effectively, leading to uncontrolled cell division and the formation of hamartomas and cancerous tumors"
                  },
                  {
                    "text": "PTENgene likely has other important functions within cells; however, it is unclear how mutations in this gene cause other features of Cowden syndrome, e.g., macrocephaly and intellectual disability"
                  }
                ],
                "Other Loci": [
                  {
                    "text": "In some patients who lackPTENmutations, hypermethylation of the promoter of theKLLN (Killin)gene, leading to reduced expression ofKLLN, has been describedKLLNgene, which is located on chromosome 10q23 and functions as a p53-regulated inhibitor of DNA synthesis, shares the same transcription site asPTENgene",
                    "sub_points": [
                      "KLLNgene, which is located on chromosome 10q23 and functions as a p53-regulated inhibitor of DNA synthesis, shares the same transcription site asPTENgene"
                    ]
                  },
                  {
                    "text": "Other patients have been reported with mutations in the succinate dehydrogenase(SDH)gene, subunits B and D"
                  },
                  {
                    "text": "GermlinePIK3CAandAKT1mutations have also been reported in phenotypic Cowden syndrome patients withoutPTEN, SDH,orKLLNmutations"
                  }
                ],
                "Diagnosis": [
                  {
                    "text": "Up to 85% of individuals who meet the diagnostic criteria for CS and 65% of individuals with a clinical diagnosis of BRRS have a detectablePTENmutation"
                  },
                  {
                    "text": "Preliminary data suggest that up to 50% of individuals with Proteus-like syndrome and up to 20% of individuals withPTEN-related Proteus syndrome havePTENmutations"
                  },
                  {
                    "text": "PTENsequence analysis, deletion/duplication testing, and FISH testing are available on a clinical basis"
                  },
                  {
                    "text": "Cowden syndromeConsensus diagnostic criteria for CS have been developed and are updated each year by the National Comprehensive Cancer Network (NCCN)Clinical criteria have been divided into 3 categories: Pathognomonic, major, and minorPathognomonic criteriaAdult Lhermitte-Duclos disease (LDD), defined as presence of a cerebellar dysplastic gangliocytomaMucocutaneous lesionsAcral keratosesPapillomatous lesionsMucosal lesionsTrichilemmomas (facial)Major criteriaEpithelial thyroid cancer (nonmedullary), especially follicular thyroid cancerMacrocephaly (occipital frontal circumference ≥ 97th percentile)Endometrial carcinomaBreast cancerMinor criteriaOther thyroid lesions (e.g., adenoma, adenomatous nodules, multinodular goiter)Hamartomatous intestinal polypsFibrocystic disease of the breastLipomasFibromasGenitourinary tumors (especially renal cell carcinoma)Genitourinary malformationUterine fibroidsIntellectual disabilityOperational diagnosis of CS:Made if an individual meets any of the following criteriaPathognomonic mucocutaneous lesions combined with 1 of the following≥ 6 facial papules, of which ≥ 3 must be trichilemmomaCutaneous facial papules and oral mucosal papillomatosis≥ 6 palmoplantar keratosesOral mucosal papillomatosis and acral keratoses≥ 4 minor criteria1 major and ≥ 3 minor criteria≥ 2 major criteria",
                    "sub_points": [
                      "Consensus diagnostic criteria for CS have been developed and are updated each year by the National Comprehensive Cancer Network (NCCN)",
                      "Clinical criteria have been divided into 3 categories: Pathognomonic, major, and minor",
                      "Pathognomonic criteriaAdult Lhermitte-Duclos disease (LDD), defined as presence of a cerebellar dysplastic gangliocytoma",
                      "Adult Lhermitte-Duclos disease (LDD), defined as presence of a cerebellar dysplastic gangliocytoma",
                      "Mucocutaneous lesionsAcral keratosesPapillomatous lesionsMucosal lesionsTrichilemmomas (facial)",
                      "Acral keratoses",
                      "Papillomatous lesions",
                      "Mucosal lesions",
                      "Trichilemmomas (facial)",
                      "Major criteriaEpithelial thyroid cancer (nonmedullary), especially follicular thyroid cancerMacrocephaly (occipital frontal circumference ≥ 97th percentile)Endometrial carcinomaBreast cancer",
                      "Epithelial thyroid cancer (nonmedullary), especially follicular thyroid cancer",
                      "Macrocephaly (occipital frontal circumference ≥ 97th percentile)",
                      "Endometrial carcinoma",
                      "Breast cancer",
                      "Minor criteriaOther thyroid lesions (e.g., adenoma, adenomatous nodules, multinodular goiter)Hamartomatous intestinal polypsFibrocystic disease of the breastLipomasFibromasGenitourinary tumors (especially renal cell carcinoma)Genitourinary malformationUterine fibroidsIntellectual disability",
                      "Other thyroid lesions (e.g., adenoma, adenomatous nodules, multinodular goiter)",
                      "Hamartomatous intestinal polyps",
                      "Fibrocystic disease of the breast",
                      "Lipomas",
                      "Fibromas",
                      "Genitourinary tumors (especially renal cell carcinoma)",
                      "Genitourinary malformation",
                      "Uterine fibroids",
                      "Intellectual disability",
                      "Operational diagnosis of CS:Made if an individual meets any of the following criteriaPathognomonic mucocutaneous lesions combined with 1 of the following≥ 6 facial papules, of which ≥ 3 must be trichilemmomaCutaneous facial papules and oral mucosal papillomatosis≥ 6 palmoplantar keratosesOral mucosal papillomatosis and acral keratoses≥ 4 minor criteria1 major and ≥ 3 minor criteria≥ 2 major criteria",
                      "Pathognomonic mucocutaneous lesions combined with 1 of the following",
                      "≥ 6 facial papules, of which ≥ 3 must be trichilemmoma",
                      "Cutaneous facial papules and oral mucosal papillomatosis",
                      "≥ 6 palmoplantar keratoses",
                      "Oral mucosal papillomatosis and acral keratoses",
                      "≥ 4 minor criteria",
                      "1 major and ≥ 3 minor criteria",
                      "≥ 2 major criteria"
                    ]
                  },
                  {
                    "text": "BRRSDiagnostic criteria for BRRS have not been setBased heavily on the presence of the cardinal featuresMacrocephalyHamartomatous intestinal polyposisLipomasPigmented macules of glans penis~ 60% of patients with BRRS have detectablePTENmutation",
                    "sub_points": [
                      "Diagnostic criteria for BRRS have not been set",
                      "Based heavily on the presence of the cardinal featuresMacrocephalyHamartomatous intestinal polyposisLipomasPigmented macules of glans penis",
                      "Macrocephaly",
                      "Hamartomatous intestinal polyposis",
                      "Lipomas",
                      "Pigmented macules of glans penis",
                      "~ 60% of patients with BRRS have detectablePTENmutation"
                    ]
                  },
                  {
                    "text": "PTEN-related Proteus syndromeHighly variable and appears to affect individuals in a mosaic distributionSomatic activating mutations in theAKT1oncogene have been delineated as the genetic cause of Proteus syndromeIt is frequently misdiagnosed despite the development of consensus diagnostic criteriaMandatory general criteria for diagnosis include mosaic distribution of lesions, progressive course, and sporadic occurrenceRapidly progressive, asymmetric postnatal overgrowth of tissues, with hyperostoses, vascular malformations, dysregulation of fatty tissues (both atrophy and overgrowth), and skin manifestations, such as verrucous epidermal nevi or cerebriform connective tissue neviSpecific criteria for diagnosis includeConnective tissue nevi (pathognomonic)2 of the followingEpidermal nevusDisproportionate overgrowth (≥ 1)Limbs: Arms/legs; hands/feet/digitsSkull: HyperostosesExternal auditory meatus: HyperostosisVertebrae: MegaspondylodysplasiaSpecific tumors before end of 2nd decadeBilateral ovarian cystadenomasParotid monomorphicadenoma3 of the followingDysregulated adipose tissue: Lipomas or regional absence of fatVascular malformations (≥ 1): Capillary, venous, lymphaticFacial phenotype: Dolichocephaly, long face, minor downslanting of palpebral fissures &/or minor ptosis, low nasal bridge, wide or anteverted nares, open mouth at rest",
                    "sub_points": [
                      "Highly variable and appears to affect individuals in a mosaic distributionSomatic activating mutations in theAKT1oncogene have been delineated as the genetic cause of Proteus syndrome",
                      "Somatic activating mutations in theAKT1oncogene have been delineated as the genetic cause of Proteus syndrome",
                      "It is frequently misdiagnosed despite the development of consensus diagnostic criteria",
                      "Mandatory general criteria for diagnosis include mosaic distribution of lesions, progressive course, and sporadic occurrence",
                      "Rapidly progressive, asymmetric postnatal overgrowth of tissues, with hyperostoses, vascular malformations, dysregulation of fatty tissues (both atrophy and overgrowth), and skin manifestations, such as verrucous epidermal nevi or cerebriform connective tissue nevi",
                      "Specific criteria for diagnosis include",
                      "Connective tissue nevi (pathognomonic)",
                      "2 of the followingEpidermal nevusDisproportionate overgrowth (≥ 1)Limbs: Arms/legs; hands/feet/digitsSkull: HyperostosesExternal auditory meatus: HyperostosisVertebrae: MegaspondylodysplasiaSpecific tumors before end of 2nd decadeBilateral ovarian cystadenomasParotid monomorphicadenoma",
                      "Epidermal nevus",
                      "Disproportionate overgrowth (≥ 1)",
                      "Limbs: Arms/legs; hands/feet/digits",
                      "Skull: Hyperostoses",
                      "External auditory meatus: Hyperostosis",
                      "Vertebrae: Megaspondylodysplasia",
                      "Specific tumors before end of 2nd decade",
                      "Bilateral ovarian cystadenomas",
                      "Parotid monomorphicadenoma",
                      "3 of the followingDysregulated adipose tissue: Lipomas or regional absence of fatVascular malformations (≥ 1): Capillary, venous, lymphaticFacial phenotype: Dolichocephaly, long face, minor downslanting of palpebral fissures &/or minor ptosis, low nasal bridge, wide or anteverted nares, open mouth at rest",
                      "Dysregulated adipose tissue: Lipomas or regional absence of fat",
                      "Vascular malformations (≥ 1): Capillary, venous, lymphatic",
                      "Facial phenotype: Dolichocephaly, long face, minor downslanting of palpebral fissures &/or minor ptosis, low nasal bridge, wide or anteverted nares, open mouth at rest"
                    ]
                  },
                  {
                    "text": "Proteus-like syndromeExceedingly rare asymmetric overgrowth syndromeUndefined but describes individuals with significant clinical features of PS yet do not meet diagnostic criteria",
                    "sub_points": [
                      "Exceedingly rare asymmetric overgrowth syndrome",
                      "Undefined but describes individuals with significant clinical features of PS yet do not meet diagnostic criteria"
                    ]
                  }
                ],
                "Genetic Counseling": [
                  {
                    "text": "PHTS is inherited in an autosomal dominant manner"
                  },
                  {
                    "text": "Because CS is likely underdiagnosed, actual proportion of simplex cases (defined as individuals with no obvious family history) and familial cases (defined as ≥ 2 related affected individuals) cannot be determined"
                  },
                  {
                    "text": "Majority of CS cases are simplex"
                  },
                  {
                    "text": "Perhaps 10-50% of individuals with CS have an affected parent"
                  },
                  {
                    "text": "Each child of an affected individual has a 50% chance of inheriting mutation and developing PHTS"
                  },
                  {
                    "text": "Prenatal testing for pregnancies at increased risk is possible if disease-causing mutation in family is known"
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Clinical Testing": [
                  {
                    "text": "Sequence analysisVirtually all missense mutations inPTENare believed to be deleteriousEarly studies suggest that up to 85% of individuals who meet diagnostic criteria for CS and 65% of individuals with a clinical diagnosis of BRRS have a detectablePTENmutationMore recently, it was found that ~ 25% of individuals who meet strict diagnostic criteria for CS have a pathogenicPTENmutation, including large deletionsData suggest that up to 50% of individuals with a Proteus-like syndrome and up to 20% of individuals with Proteus syndrome havePTENmutations",
                    "sub_points": [
                      "Virtually all missense mutations inPTENare believed to be deleterious",
                      "Early studies suggest that up to 85% of individuals who meet diagnostic criteria for CS and 65% of individuals with a clinical diagnosis of BRRS have a detectablePTENmutation",
                      "More recently, it was found that ~ 25% of individuals who meet strict diagnostic criteria for CS have a pathogenicPTENmutation, including large deletions",
                      "Data suggest that up to 50% of individuals with a Proteus-like syndrome and up to 20% of individuals with Proteus syndrome havePTENmutations"
                    ]
                  },
                  {
                    "text": "Deletion/duplication analysisSouthern blotting, real-time PCR, MLPA, and other methods of detecting gene copy number variation can each be used to detect largePTENdeletions and rearrangements that are not detectable by PCR-based sequence analysis",
                    "sub_points": [
                      "Southern blotting, real-time PCR, MLPA, and other methods of detecting gene copy number variation can each be used to detect largePTENdeletions and rearrangements that are not detectable by PCR-based sequence analysis"
                    ]
                  }
                ],
                "Management": [
                  {
                    "text": "Treatment of manifestationsTreatment for benign and malignant manifestations of PHTS is same as for their sporadic counterpartsTopical agents (e.g., 5-fluorouracil), curettage, cryosurgery, or laser ablation may alleviate mucocutaneous manifestations of CSCutaneous lesions should be excised only if malignancy is suspected or symptoms (e.g., pain, deformity) are significant",
                    "sub_points": [
                      "Treatment for benign and malignant manifestations of PHTS is same as for their sporadic counterparts",
                      "Topical agents (e.g., 5-fluorouracil), curettage, cryosurgery, or laser ablation may alleviate mucocutaneous manifestations of CS",
                      "Cutaneous lesions should be excised only if malignancy is suspected or symptoms (e.g., pain, deformity) are significant"
                    ]
                  },
                  {
                    "text": "SurveillanceTo detect tumors at the earliest, most treatable stagesFor children (< 18 years): Yearly thyroid ultrasound and skin check with physical examinationFor adults: Yearly thyroid ultrasound and dermatologic evaluationFor men and women: Colonoscopy beginning at age 35-40 years with frequency dependent on degree of polyposis identified; biennial (every 2 years) renal imaging (CT or MR preferred) beginning at age 40 yearsFor women beginning at age 30 years: Monthly breast self-examinationAnnual breast screening (at minimum mammogram; MR may also be incorporated) and transvaginal ultrasound or endometrial biopsyFor those with family history of a particular cancer type at an early age: Consider initiating screening 5-10 years prior to youngest age of diagnosis in family",
                    "sub_points": [
                      "To detect tumors at the earliest, most treatable stagesFor children (< 18 years): Yearly thyroid ultrasound and skin check with physical examinationFor adults: Yearly thyroid ultrasound and dermatologic evaluationFor men and women: Colonoscopy beginning at age 35-40 years with frequency dependent on degree of polyposis identified; biennial (every 2 years) renal imaging (CT or MR preferred) beginning at age 40 yearsFor women beginning at age 30 years: Monthly breast self-examinationAnnual breast screening (at minimum mammogram; MR may also be incorporated) and transvaginal ultrasound or endometrial biopsyFor those with family history of a particular cancer type at an early age: Consider initiating screening 5-10 years prior to youngest age of diagnosis in family",
                      "For children (< 18 years): Yearly thyroid ultrasound and skin check with physical examination",
                      "For adults: Yearly thyroid ultrasound and dermatologic evaluation",
                      "For men and women: Colonoscopy beginning at age 35-40 years with frequency dependent on degree of polyposis identified; biennial (every 2 years) renal imaging (CT or MR preferred) beginning at age 40 years",
                      "For women beginning at age 30 years: Monthly breast self-examination",
                      "Annual breast screening (at minimum mammogram; MR may also be incorporated) and transvaginal ultrasound or endometrial biopsy",
                      "For those with family history of a particular cancer type at an early age: Consider initiating screening 5-10 years prior to youngest age of diagnosis in family"
                    ]
                  },
                  {
                    "text": "Testing of relatives at riskWhenPTENmutation has been identified in a proband, molecular genetic testing of asymptomatic at-risk relatives can identify those who have family-specific mutation and warrant ongoing surveillance",
                    "sub_points": [
                      "WhenPTENmutation has been identified in a proband, molecular genetic testing of asymptomatic at-risk relatives can identify those who have family-specific mutation and warrant ongoing surveillance"
                    ]
                  }
                ]
              },
              "Associated Lesions and Benign Neoplasms": {
                "Skin": [
                  {
                    "text": "Multiple trichilemmomas, usually on face, are cutaneous hallmark of diseaseTrichilemmomas show differentiation toward hair follicle infundibulum",
                    "sub_points": [
                      "Trichilemmomas show differentiation toward hair follicle infundibulum"
                    ]
                  },
                  {
                    "text": "Mucocutaneous fibromas and neuromas"
                  },
                  {
                    "text": "Acral and palmoplantar keratoses"
                  },
                  {
                    "text": "Oral papillomas involving lips, gums, and tongue"
                  }
                ],
                "Breast": [
                  {
                    "text": "Benign lesions are often bilateral and multipleFibroadenomaAdenosisApocrine cystsHamartomas",
                    "sub_points": [
                      "Fibroadenoma",
                      "Adenosis",
                      "Apocrine cysts",
                      "Hamartomas"
                    ]
                  }
                ],
                "Thyroid": [
                  {
                    "text": "Multiple adenomatous nodules are hallmark of disease"
                  },
                  {
                    "text": "Lymphocytic thyroiditis"
                  },
                  {
                    "text": "Multinodular hyperplasia"
                  },
                  {
                    "text": "C-cell hyperplasia"
                  }
                ],
                "Esophagus": [
                  {
                    "text": "Esophageal glycogen acanthosis is hallmark of CSAbundant glycogen demonstrated on PAS stain ± diastase treatmentPale, ballooned, and vacuolated squamous cellsMultiple nodular foci of squamous cell proliferation",
                    "sub_points": [
                      "Abundant glycogen demonstrated on PAS stain ± diastase treatment",
                      "Pale, ballooned, and vacuolated squamous cells",
                      "Multiple nodular foci of squamous cell proliferation"
                    ]
                  }
                ],
                "Stomach": [
                  {
                    "text": "Most often resemble hyperplastic polyps with prominent foveolar hyperplasiaStromal smooth muscle proliferation may be prominent and mimic Peutz-Jeghers polypsDistinction from gastric polyps in juvenile polyposis difficultPolyps may appear virtually identical to those described in patients with Cronkhite-Canada syndrome",
                    "sub_points": [
                      "Stromal smooth muscle proliferation may be prominent and mimic Peutz-Jeghers polyps",
                      "Distinction from gastric polyps in juvenile polyposis difficult",
                      "Polyps may appear virtually identical to those described in patients with Cronkhite-Canada syndrome"
                    ]
                  }
                ],
                "Colon": [
                  {
                    "text": "Hamartomatous stroma-rich polyps with cystically dilated glands"
                  },
                  {
                    "text": "Ganglioneuromatous polyps with proliferation of Schwann cells and ganglion cells in lamina propria"
                  },
                  {
                    "text": "Inflammatory polyps that may mimic juvenile polyps"
                  },
                  {
                    "text": "Lymphoid polyps with prominent mucosal or submucosal reactive lymphoid aggregates"
                  },
                  {
                    "text": "Lipoma"
                  },
                  {
                    "text": "Colon adenomas may occur in patients with CS at young ageIsolated polyps in rectosigmoid colon may mimic mucosal prolapse",
                    "sub_points": [
                      "Isolated polyps in rectosigmoid colon may mimic mucosal prolapse"
                    ]
                  }
                ],
                "Brain": [
                  {
                    "text": "Dysplastic gangliocytoma of the cerebellum, or adult Lhermitte-Duclos diseaseRefers to a hamartomatous tumor of the cerebellar cortex that can occur in the setting of aPTENmutation",
                    "sub_points": [
                      "Refers to a hamartomatous tumor of the cerebellar cortex that can occur in the setting of aPTENmutation"
                    ]
                  },
                  {
                    "text": "Cavernous hemangioma"
                  }
                ],
                "Soft Tissue": [
                  {
                    "text": "Characteristic disorganized overgrowth of mesenchymal elements (PTENhamartoma of soft tissue)"
                  },
                  {
                    "text": "Vascular proliferations"
                  },
                  {
                    "text": "Hamartomas"
                  }
                ]
              },
              "Associated Malignant Neoplasms": {
                "Breast Carcinoma": [
                  {
                    "text": "Increased risk of female breast cancer: 25-50% lifetime risk; reports up to 85%"
                  },
                  {
                    "text": "Age of diagnosis: 38-46 yearsOccurs 10 years younger than general populationMale breast cancer also occurs",
                    "sub_points": [
                      "Occurs 10 years younger than general population",
                      "Male breast cancer also occurs"
                    ]
                  }
                ],
                "Follicular Thyroid Carcinoma": [
                  {
                    "text": "Increased risk of thyroid cancer: 3-35% lifetime riskRisk increased in both females and males",
                    "sub_points": [
                      "Risk increased in both females and males"
                    ]
                  },
                  {
                    "text": "Predominant thyroid tumor in PHTS"
                  }
                ],
                "Papillary Thyroid Carcinoma": [
                  {
                    "text": "Also reported to have greater risk than general population"
                  }
                ],
                "Endometrial Carcinoma": [
                  {
                    "text": "Increased risk of endometrial adenocarcinoma: 13-28% lifetime risk"
                  }
                ],
                "Renal Cancer": [
                  {
                    "text": "Increased risk of renal cancer"
                  }
                ],
                "Colorectal Adenocarcinoma": [
                  {
                    "text": "Risk of colorectal cancer was estimated at 10x higher that the general population"
                  }
                ],
                "Other Cancers Associated With PHTS": [
                  {
                    "text": "Glioblastoma"
                  },
                  {
                    "text": "Melanoma"
                  },
                  {
                    "text": "Merkel cell carcinoma"
                  },
                  {
                    "text": "Retinal glioma"
                  },
                  {
                    "text": "Lung cancer"
                  },
                  {
                    "text": "Liver cancer"
                  },
                  {
                    "text": "Pancreatic cancer"
                  },
                  {
                    "text": "Ovarian cancer"
                  },
                  {
                    "text": "Bladder cancer"
                  },
                  {
                    "text": "Liposarcoma"
                  }
                ],
                "Other Cancers Rarely Associated With PHTS": [
                  {
                    "text": "Ependymoma"
                  },
                  {
                    "text": "Medullary thyroid carcinoma"
                  },
                  {
                    "text": "Granulosa cell tumor"
                  },
                  {
                    "text": "Lipoblastoma"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Breast": [
                  {
                    "text": "Breast awareness, including prompt reporting to physicians of any changes"
                  },
                  {
                    "text": "Periodic breast self-exams starting at age 18 years"
                  },
                  {
                    "text": "Clinical breast exam every 6-12 months starting at age 25 years or individualized based on earliest known onset of breast cancer in the family"
                  },
                  {
                    "text": "Annual mammography and breast MR screening starting at age 30-35 yearsOr 5-10 years before the earliest known breast cancer in the familyMR screening as an adjunct to mammography",
                    "sub_points": [
                      "Or 5-10 years before the earliest known breast cancer in the family",
                      "MR screening as an adjunct to mammography"
                    ]
                  }
                ],
                "Thyroid": [
                  {
                    "text": "Baseline thyroid ultrasound at 18 years and consideration of repeating annually thereafter"
                  },
                  {
                    "text": "Monthly thyroid examination and palpation starting in adolescence"
                  }
                ],
                "Uterus": [
                  {
                    "text": "Surveillance for endometrial cancer starting at age 35-40 yearsOr 5 years younger than the earliest familial endometrial cancer diagnosis",
                    "sub_points": [
                      "Or 5 years younger than the earliest familial endometrial cancer diagnosis"
                    ]
                  }
                ],
                "Kidney": [
                  {
                    "text": "Annual urinalysis with cytology and renal ultrasound"
                  }
                ],
                "Colon": [
                  {
                    "text": "Consideration of baseline colonoscopy at age 35 yearsThen every 5-10 years or more frequently if patient is symptomatic or polyps are noted",
                    "sub_points": [
                      "Then every 5-10 years or more frequently if patient is symptomatic or polyps are noted"
                    ]
                  }
                ],
                "Other Tumors": [
                  {
                    "text": "Given the high risk of malignancy, cancer surveillance is the major focus of medical management as per American Cancer Society guidelinesAnnual comprehensive physical exam, starting at 18 years of age",
                    "sub_points": [
                      "Annual comprehensive physical exam, starting at 18 years of age"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Familial Adenomatous Polyposis": {
            "name": "Familial Adenomatous Polyposis",
            "url": "https://app.pathprimer.com/document/da48132e-7fdf-4ade-a2de-521e6b10819a/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Familial adenomatous polyposis (FAP)"
                  },
                  {
                    "text": "Attenuated familial adenomatous polyposis (AFAP)"
                  },
                  {
                    "text": "Congenital hypertrophy of retinal pigment epithelium (CHRPE)"
                  },
                  {
                    "text": "Colorectal carcinoma (CRC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Adenomatous polyposis coli (APC), familial polyposis coli, Gardner syndrome, Turcot syndrome, Crail syndrome, Bussey-Gardner polyposis"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "1st adenomas detected between ages 10 and 20 years"
                  },
                  {
                    "text": "Mean age of diagnosis: 34-36 years if not in a known kindred undergoing screening"
                  },
                  {
                    "text": "Mean age of CRC: 40-42 years, but can occur in teenagers"
                  }
                ],
                "Incidence": [
                  {
                    "text": "0.003-0.015% of population"
                  },
                  {
                    "text": "Most common genetic polyposis syndromeFAP accounts for < 1% of all CRCs",
                    "sub_points": [
                      "FAP accounts for < 1% of all CRCs"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Adenomas increase in size and number with agePolyp count and patient age predict cancer riskAs in sporadic adenomas, only a small percentage progress to cancer",
                    "sub_points": [
                      "Polyp count and patient age predict cancer risk",
                      "As in sporadic adenomas, only a small percentage progress to cancer"
                    ]
                  },
                  {
                    "text": "AFAP: Fewer adenomas at a later onset (~ 15 years later than FAP)Upper GI lesions almost always present, but extraintestinal manifestations rareLower risk of developing CRCPhenotype identical toMYH-associated polyposis, which is autosomal recessiveRequires genetic testing to differentiate the 2",
                    "sub_points": [
                      "Upper GI lesions almost always present, but extraintestinal manifestations rare",
                      "Lower risk of developing CRC",
                      "Phenotype identical toMYH-associated polyposis, which is autosomal recessiveRequires genetic testing to differentiate the 2",
                      "Requires genetic testing to differentiate the 2"
                    ]
                  }
                ],
                "Gender": [
                  {
                    "text": "M = F"
                  }
                ]
              },
              "Genetics": {
                "Germline Mutation inAPCGene": [
                  {
                    "text": "Tumor suppressor gene that downregulates β-catenin (Wnt signaling pathway)Controls cell cycle and stabilizes microtubules",
                    "sub_points": [
                      "Controls cell cycle and stabilizes microtubules"
                    ]
                  },
                  {
                    "text": "Located on chromosome 5q21-22"
                  },
                  {
                    "text": "SpecificAPCmutations correlate with phenotypesAFAP associated with mutations at 3' and 5' ends ofAPCgene, whereas CHRPEs, osteomas, desmoids, and epidermal cysts are associated with mutations in middle of geneHot spot for severe polyposis phenotype at codon 1309More polyps and earlier onset of CRC in families with mutations near this hot spot",
                    "sub_points": [
                      "AFAP associated with mutations at 3' and 5' ends ofAPCgene, whereas CHRPEs, osteomas, desmoids, and epidermal cysts are associated with mutations in middle of gene",
                      "Hot spot for severe polyposis phenotype at codon 1309More polyps and earlier onset of CRC in families with mutations near this hot spot",
                      "More polyps and earlier onset of CRC in families with mutations near this hot spot"
                    ]
                  },
                  {
                    "text": "30-40% of FAP cases arise de novo (no family history)Cause of these spontaneous mutations unknown",
                    "sub_points": [
                      "Cause of these spontaneous mutations unknown"
                    ]
                  },
                  {
                    "text": "APCI1307K mutationAutosomal dominant mutation that imparts a 10-20% lifetime CRC riskNo polyposis or extracolonic manifestationsAffects 6% of Ashkenazi JewsRendersAPCgene susceptible to further mutations that lead to CRC",
                    "sub_points": [
                      "Autosomal dominant mutation that imparts a 10-20% lifetime CRC risk",
                      "No polyposis or extracolonic manifestations",
                      "Affects 6% of Ashkenazi Jews",
                      "RendersAPCgene susceptible to further mutations that lead to CRC"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Rectal bleeding, diarrhea, colicky abdominal pain, mucous discharge, intussusception"
                  },
                  {
                    "text": "Rarely, severe electrolyte depletion can occur with diffuse polyposis"
                  },
                  {
                    "text": "Acute pancreatitis due to adenoma obstructing ampulla/pancreatic duct"
                  }
                ],
                "Imaging Findings": [
                  {
                    "text": "Polyps can be detected in both upper GI and lower GI locations, especially with fluoroscopic-guided barium enema"
                  },
                  {
                    "text": "Osteomas of jaw in Gardner syndrome can be identified on radiographs"
                  },
                  {
                    "text": "Desmoid tumors in Gardner syndrome can be identified on CT"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Diagnostic criteria for FAP (any of the following)≥ 100 colorectal adenomas (classical FAP)< 100 colorectal adenomas in AFAPGermlineAPCmutationFamily history of FAP plus at least 1 of the followingEpidermoid cyst, osteoma, desmoid",
                    "sub_points": [
                      "≥ 100 colorectal adenomas (classical FAP)",
                      "< 100 colorectal adenomas in AFAP",
                      "GermlineAPCmutation",
                      "Family history of FAP plus at least 1 of the followingEpidermoid cyst, osteoma, desmoid",
                      "Epidermoid cyst, osteoma, desmoid"
                    ]
                  }
                ],
                "Endoscopic Findings": [
                  {
                    "text": "Hundreds of small sessile adenomas carpet the colonSimilar location as in sporadic adenomas with predilection for rectosigmoidSome larger pedunculated polypsMay have rectal sparing in AFAP",
                    "sub_points": [
                      "Similar location as in sporadic adenomas with predilection for rectosigmoid",
                      "Some larger pedunculated polyps",
                      "May have rectal sparing in AFAP"
                    ]
                  },
                  {
                    "text": "CRC distribution follows adenomas (70-80% left-sided)Often multiple CRCs, either synchronous or metachronous",
                    "sub_points": [
                      "Often multiple CRCs, either synchronous or metachronous"
                    ]
                  }
                ],
                "Specimen Handling": [
                  {
                    "text": "Total resectionAside from taking sections of all large polyps to look for invasive carcinoma, face-down sections of the flat mucosa can be taken to show unicryptal adenomas that are pathognomonic of FAP (so-called Bussey section)",
                    "sub_points": [
                      "Aside from taking sections of all large polyps to look for invasive carcinoma, face-down sections of the flat mucosa can be taken to show unicryptal adenomas that are pathognomonic of FAP (so-called Bussey section)"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "General Features": [
                  {
                    "text": "Colonic adenomas look identical to sporadic counterparts"
                  },
                  {
                    "text": "Presence of unicryptal adenomas in flat mucosa diagnostic of FAP"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Other GI (Extracolonic Lesions)": [
                  {
                    "text": "Small intestineMostly duodenal/ampullary adenomasPossible cocarcinogenic effect of bile10-15 years later than colonic adenomas but 30 years earlier than general population50-100% of FAP patients have these on routine screening (50-100%)Cumulative cancer risk: 2-10%Common cause of death in patients who have had a prophylactic colectomy (20%)",
                    "sub_points": [
                      "Mostly duodenal/ampullary adenomasPossible cocarcinogenic effect of bile10-15 years later than colonic adenomas but 30 years earlier than general population50-100% of FAP patients have these on routine screening (50-100%)Cumulative cancer risk: 2-10%Common cause of death in patients who have had a prophylactic colectomy (20%)",
                      "Possible cocarcinogenic effect of bile",
                      "10-15 years later than colonic adenomas but 30 years earlier than general population",
                      "50-100% of FAP patients have these on routine screening (50-100%)",
                      "Cumulative cancer risk: 2-10%",
                      "Common cause of death in patients who have had a prophylactic colectomy (20%)"
                    ]
                  },
                  {
                    "text": "StomachMostly fundic gland polyps (40-60%)More numerous, occurring at a younger age, and more likely to have dysplasia (up to 25%) than sporadicAntral adenomas (6%)Gastric cancer is rare, but cases have been reported",
                    "sub_points": [
                      "Mostly fundic gland polyps (40-60%)More numerous, occurring at a younger age, and more likely to have dysplasia (up to 25%) than sporadic",
                      "More numerous, occurring at a younger age, and more likely to have dysplasia (up to 25%) than sporadic",
                      "Antral adenomas (6%)",
                      "Gastric cancer is rare, but cases have been reported"
                    ]
                  },
                  {
                    "text": "LiverIncreasing rate of hepatoblastomas in male infantsRare hepatic adenomas and hepatocellular carcinomasRare malignant embryonal tumor",
                    "sub_points": [
                      "Increasing rate of hepatoblastomas in male infants",
                      "Rare hepatic adenomas and hepatocellular carcinomas",
                      "Rare malignant embryonal tumor"
                    ]
                  },
                  {
                    "text": "PancreasAdenocarcinomaRare reports of intraductal mucinous neoplasms",
                    "sub_points": [
                      "Adenocarcinoma",
                      "Rare reports of intraductal mucinous neoplasms"
                    ]
                  },
                  {
                    "text": "Biliary tractAdenocarcinoma and dysplasia of bile ducts and gallbladder",
                    "sub_points": [
                      "Adenocarcinoma and dysplasia of bile ducts and gallbladder"
                    ]
                  }
                ],
                "Extraintestinal Manifestations": [
                  {
                    "text": "Soft tissue (10-30% of FAP patients)Fibromatosis (desmoid tumors)Locally aggressive (even fatal) but \"benign\" tumors: Do not metastasize2nd most common cause of death in FAP patients (after CRC)UnencapsulatedHereditary desmoid disease: RareAPCmutation that causes multiple desmoids and other extraintestinal manifestations without colonic diseaseMost common in small bowel mesenteryOften post surgery/traumaHormones may affect growth (pregnancy, estrogen); tamoxifen sometimes used for treatment",
                    "sub_points": [
                      "Fibromatosis (desmoid tumors)Locally aggressive (even fatal) but \"benign\" tumors: Do not metastasize2nd most common cause of death in FAP patients (after CRC)UnencapsulatedHereditary desmoid disease: RareAPCmutation that causes multiple desmoids and other extraintestinal manifestations without colonic diseaseMost common in small bowel mesenteryOften post surgery/traumaHormones may affect growth (pregnancy, estrogen); tamoxifen sometimes used for treatment",
                      "Locally aggressive (even fatal) but \"benign\" tumors: Do not metastasize",
                      "2nd most common cause of death in FAP patients (after CRC)",
                      "Unencapsulated",
                      "Hereditary desmoid disease: RareAPCmutation that causes multiple desmoids and other extraintestinal manifestations without colonic disease",
                      "Most common in small bowel mesentery",
                      "Often post surgery/trauma",
                      "Hormones may affect growth (pregnancy, estrogen); tamoxifen sometimes used for treatment"
                    ]
                  },
                  {
                    "text": "BonesMultiple osteomas of the skull, long bones, and mandible",
                    "sub_points": [
                      "Multiple osteomas of the skull, long bones, and mandible"
                    ]
                  },
                  {
                    "text": "Teeth (70-80% of FAP patients)Impaction, supernumerary/absent, abnormal roots",
                    "sub_points": [
                      "Impaction, supernumerary/absent, abnormal roots"
                    ]
                  },
                  {
                    "text": "Eye (75-90% of FAP patients)Congenital hypertrophy of retinal pigment epithelium (CHRPE)Pigmented fundus lesionEarliest manifestation of FAP; can be seen in young infants",
                    "sub_points": [
                      "Congenital hypertrophy of retinal pigment epithelium (CHRPE)Pigmented fundus lesionEarliest manifestation of FAP; can be seen in young infants",
                      "Pigmented fundus lesion",
                      "Earliest manifestation of FAP; can be seen in young infants"
                    ]
                  },
                  {
                    "text": "SkinMultiple epidermal inclusion cysts of face and scalpLipomas, fibromas, sebaceous cysts",
                    "sub_points": [
                      "Multiple epidermal inclusion cysts of face and scalp",
                      "Lipomas, fibromas, sebaceous cysts"
                    ]
                  },
                  {
                    "text": "Endocrine systemPapillary thyroid carcinoma, cribriform morular variant, in womenAdrenal cortical neoplasmsPancreatic islet cell neoplasmsRare reports of parathyroid and pituitary adenomas",
                    "sub_points": [
                      "Papillary thyroid carcinoma, cribriform morular variant, in women",
                      "Adrenal cortical neoplasms",
                      "Pancreatic islet cell neoplasms",
                      "Rare reports of parathyroid and pituitary adenomas"
                    ]
                  },
                  {
                    "text": "Brain (Turcot syndrome)Hereditary CRC & brain tumorFAP patients: MedulloblastomasLynch patients: Gliomas",
                    "sub_points": [
                      "Hereditary CRC & brain tumorFAP patients: MedulloblastomasLynch patients: Gliomas",
                      "FAP patients: Medulloblastomas",
                      "Lynch patients: Gliomas"
                    ]
                  },
                  {
                    "text": "Head and neckNasopharyngeal angiofibroma",
                    "sub_points": [
                      "Nasopharyngeal angiofibroma"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Surgery": [
                  {
                    "text": "Prophylactic colectomy with ileoanal pouch anastomosis is surgical treatment of choice"
                  },
                  {
                    "text": "Goal is to do this when patient is in their teens (if diagnosis can be established this early)"
                  },
                  {
                    "text": "Patients will still require surveillance of pouch to remove adenomas"
                  },
                  {
                    "text": "Upper endoscopy with biopsy of gastric and duodenal polypsMost duodenal/ampullary adenomas can be excised endoscopically, but some may require a Whipple procedure",
                    "sub_points": [
                      "Most duodenal/ampullary adenomas can be excised endoscopically, but some may require a Whipple procedure"
                    ]
                  },
                  {
                    "text": "Surgical excision of desmoids (when possible)"
                  }
                ],
                "Medical Management": [
                  {
                    "text": "Chemoprevention of polyps with indomethacin and other NSAIDs"
                  },
                  {
                    "text": "Medical treatment of desmoids includes hormonal therapy, imatinib, and NSAIDs"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Protein truncation test (PTT)Looks for abnormally shortened APC protein in exon 15",
                    "sub_points": [
                      "Looks for abnormally shortened APC protein in exon 15"
                    ]
                  },
                  {
                    "text": "Gene sequencingAPCgene is very large; hence, sequencing is difficultSequencing is done to try and predict phenotype of affected family members (likelihood of desmoids or severe phenotype)Latest techniques are about 95% sensitive in detecting mutations in classic FAP, < 30% in AFAPImportant to test forMYH-associated polyposis if these tests are negativeMultiplex ligation probe amplification (MLPA) is used to look for large deletions and duplications",
                    "sub_points": [
                      "APCgene is very large; hence, sequencing is difficultSequencing is done to try and predict phenotype of affected family members (likelihood of desmoids or severe phenotype)",
                      "Sequencing is done to try and predict phenotype of affected family members (likelihood of desmoids or severe phenotype)",
                      "Latest techniques are about 95% sensitive in detecting mutations in classic FAP, < 30% in AFAPImportant to test forMYH-associated polyposis if these tests are negative",
                      "Important to test forMYH-associated polyposis if these tests are negative",
                      "Multiplex ligation probe amplification (MLPA) is used to look for large deletions and duplications"
                    ]
                  },
                  {
                    "text": "Sequencing of exons 1-14 coupled with PTT of exon 15 is one commonly used testing strategyIf PTT is positive, then exon 15 can be sequenced",
                    "sub_points": [
                      "If PTT is positive, then exon 15 can be sequenced"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Fanconi Anemia": {
            "name": "Fanconi Anemia",
            "url": "https://app.pathprimer.com/document/c119349e-5558-4be7-8eb2-a0cc4c178816/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Fanconi anemia (FA)"
                  }
                ],
                "Definition": [
                  {
                    "text": "Described by pediatrician Dr. Guido Fanconi in 1972"
                  },
                  {
                    "text": "1 of several DNA damage repair deficiency syndromes including ataxia-telangiectasia, Bloom syndrome, Cockayne syndrome, Nijmegen breakage syndrome, Rothmund-Thomson syndrome, trichothiodystrophy, Werner syndrome, and xeroderma pigmentosum"
                  },
                  {
                    "text": "FA is a clinically and genetically heterogeneous inherited disorder characterized byAutosomal or X-linked recessive pattern of inheritanceCongenital abnormalities in majority of patientsLow birth weight/short statureClassic finding of hypoplastic or absent thumbs &/or radiiPigmentation abnormalitiesRenal malformationsDuodenal atresia or other gastrointestinal malformationsMicrocephaly &/or microphthalmiaCongenital heart diseaseEar abnormalities/deafnessHypogonadismNeurologic abnormalitiesEndocrine dysfunction25-40% of patients are phenotypically normalBone marrow failure presenting in 1st decade of lifePancytopenia with marrow aplasia (patients present with sequelae such as anemia, bleeding, and easy bruising)By 5th decade, cumulative incidence of bone marrow failure is 90%Increased risk of hematologic neoplasms and solid tumors",
                    "sub_points": [
                      "Autosomal or X-linked recessive pattern of inheritance",
                      "Congenital abnormalities in majority of patientsLow birth weight/short statureClassic finding of hypoplastic or absent thumbs &/or radiiPigmentation abnormalitiesRenal malformationsDuodenal atresia or other gastrointestinal malformationsMicrocephaly &/or microphthalmiaCongenital heart diseaseEar abnormalities/deafnessHypogonadismNeurologic abnormalitiesEndocrine dysfunction25-40% of patients are phenotypically normal",
                      "Low birth weight/short stature",
                      "Classic finding of hypoplastic or absent thumbs &/or radii",
                      "Pigmentation abnormalities",
                      "Renal malformations",
                      "Duodenal atresia or other gastrointestinal malformations",
                      "Microcephaly &/or microphthalmia",
                      "Congenital heart disease",
                      "Ear abnormalities/deafness",
                      "Hypogonadism",
                      "Neurologic abnormalities",
                      "Endocrine dysfunction",
                      "25-40% of patients are phenotypically normal",
                      "Bone marrow failure presenting in 1st decade of lifePancytopenia with marrow aplasia (patients present with sequelae such as anemia, bleeding, and easy bruising)By 5th decade, cumulative incidence of bone marrow failure is 90%",
                      "Pancytopenia with marrow aplasia (patients present with sequelae such as anemia, bleeding, and easy bruising)",
                      "By 5th decade, cumulative incidence of bone marrow failure is 90%",
                      "Increased risk of hematologic neoplasms and solid tumors"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "4-7 patients per 1 million births"
                  },
                  {
                    "text": "Most cases are autosomal recessive in inheritanceMutations affectingFANCBare X-linked recessive",
                    "sub_points": [
                      "Mutations affectingFANCBare X-linked recessive"
                    ]
                  },
                  {
                    "text": "Increased incidence of FA in the Ashkenazi Jewish population due to specificFANCCmutations (IVS4 + 4A > T) (carrier frequency of 1.1%)"
                  },
                  {
                    "text": "Heterozygote frequency is 1 in 300"
                  },
                  {
                    "text": "Accounts for ~ 20% of cases of childhood aplastic anemia"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "Biallelic mutation in any of (at least) 13 separate genes composing the Fanconi anemia pathway"
                  },
                  {
                    "text": "Collectively, proteins encoded by these genes serve to sense DNA damage and initiate DNA repair"
                  },
                  {
                    "text": "FA pathway proteins fall into 3 separate groups, encoded by the following genesFanconi anemia core complexFANCA,FANCB,FANCC,FANCE,FANCF,FANCG,FANCL,FANCMFANCAis the most frequently mutated gene in this complex (mutations account for ~ 65% of FA cases)ID complexFANCI,FANCD2Downstream effectorsFANCJ,FANCN(a.k.a.BRIP1andPALB2, respectively)FANCD1(a.k.a.BRCA2)",
                    "sub_points": [
                      "Fanconi anemia core complexFANCA,FANCB,FANCC,FANCE,FANCF,FANCG,FANCL,FANCMFANCAis the most frequently mutated gene in this complex (mutations account for ~ 65% of FA cases)",
                      "FANCA,FANCB,FANCC,FANCE,FANCF,FANCG,FANCL,FANCM",
                      "FANCAis the most frequently mutated gene in this complex (mutations account for ~ 65% of FA cases)",
                      "ID complexFANCI,FANCD2",
                      "FANCI,FANCD2",
                      "Downstream effectorsFANCJ,FANCN(a.k.a.BRIP1andPALB2, respectively)FANCD1(a.k.a.BRCA2)",
                      "FANCJ,FANCN(a.k.a.BRIP1andPALB2, respectively)",
                      "FANCD1(a.k.a.BRCA2)"
                    ]
                  },
                  {
                    "text": "Functional interactions of FA proteinsCore complex detects DNA damage and ubiquitinates the ID complex proteinsID complex colocalizes at site of DNA damage with FA downstream effectors and other DNA repair proteins, includingRAD51 protein, which binds and promotes accurate DNA repair via homologous recombinationBRCA1 protein, which binds to facilitate repair and mediate cell cycle checkpoint control",
                    "sub_points": [
                      "Core complex detects DNA damage and ubiquitinates the ID complex proteins",
                      "ID complex colocalizes at site of DNA damage with FA downstream effectors and other DNA repair proteins, includingRAD51 protein, which binds and promotes accurate DNA repair via homologous recombinationBRCA1 protein, which binds to facilitate repair and mediate cell cycle checkpoint control",
                      "RAD51 protein, which binds and promotes accurate DNA repair via homologous recombination",
                      "BRCA1 protein, which binds to facilitate repair and mediate cell cycle checkpoint control"
                    ]
                  },
                  {
                    "text": "Genotype-phenotype correlationsSomeFANCCmutations predispose to early-onset bone marrow failureIncidence of acute myeloid leukemia (AML) and severe cytopenias is higher in patients with someFANCGandFANCAmutationsPatients with biallelic inactivating mutations inFANCD1have a 97% cumulative incidence of midline brain tumors, Wilms tumor, and AML by age 6",
                    "sub_points": [
                      "SomeFANCCmutations predispose to early-onset bone marrow failure",
                      "Incidence of acute myeloid leukemia (AML) and severe cytopenias is higher in patients with someFANCGandFANCAmutations",
                      "Patients with biallelic inactivating mutations inFANCD1have a 97% cumulative incidence of midline brain tumors, Wilms tumor, and AML by age 6"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Confirmation of Diagnosis": [
                  {
                    "text": "Cytogenetic testingDiagnostic test: Chromosomal breakage (typically tests peripheral blood lymphocytes)Cells are stimulated and exposed to diepoxybutane &/or mitomycin C and arrested at mitosisNumber of chromosomal breaks and radial formations is counted (in FA, these significantly exceed normal controls)If negative, consider testing nonhematopoietic cells (e.g., cultured skin fibroblasts) because hematopoietic cells can sometimes undergo reversion mutations, which correct original mutation (hematopoietic mosaics)Cannot detect FA carriers with this test",
                    "sub_points": [
                      "Diagnostic test: Chromosomal breakage (typically tests peripheral blood lymphocytes)Cells are stimulated and exposed to diepoxybutane &/or mitomycin C and arrested at mitosisNumber of chromosomal breaks and radial formations is counted (in FA, these significantly exceed normal controls)If negative, consider testing nonhematopoietic cells (e.g., cultured skin fibroblasts) because hematopoietic cells can sometimes undergo reversion mutations, which correct original mutation (hematopoietic mosaics)",
                      "Cells are stimulated and exposed to diepoxybutane &/or mitomycin C and arrested at mitosis",
                      "Number of chromosomal breaks and radial formations is counted (in FA, these significantly exceed normal controls)",
                      "If negative, consider testing nonhematopoietic cells (e.g., cultured skin fibroblasts) because hematopoietic cells can sometimes undergo reversion mutations, which correct original mutation (hematopoietic mosaics)",
                      "Cannot detect FA carriers with this test"
                    ]
                  },
                  {
                    "text": "Molecular testingSequence analysis and targeted mutation analysis (nontargeted approach difficult given number of large genes that would require evaluation)Carrier and prenatal testing can be performed by specific mutation testing if familial mutation is known",
                    "sub_points": [
                      "Sequence analysis and targeted mutation analysis (nontargeted approach difficult given number of large genes that would require evaluation)",
                      "Carrier and prenatal testing can be performed by specific mutation testing if familial mutation is known"
                    ]
                  }
                ],
                "Evaluation for Hematologic Malignancy": [
                  {
                    "text": "Bone marrow biopsy: Morphologic evaluation is gold standard for diagnosis of myelodysplastic syndrome (MDS)"
                  },
                  {
                    "text": "Cytogenetic analysis: Clonal amplification of chromosome 3q26-q29 often precedes progression to MDS/AML"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Hematologic Neoplasms": [
                  {
                    "text": "By age 45, cumulative incidence of hematologic malignancy is 25%; median diagnosis age: 11-14 years"
                  },
                  {
                    "text": "Predominantly myeloid malignancies (600x increased risk of AML; 5,000x increased risk of MDS)In ~ 25% of cases, leukemia (or cancer) diagnosis precedes recognition of underlying FA",
                    "sub_points": [
                      "In ~ 25% of cases, leukemia (or cancer) diagnosis precedes recognition of underlying FA"
                    ]
                  }
                ],
                "Solid Tumors": [
                  {
                    "text": "Squamous cell carcinoma (head, neck, esophagus, anogenital), hepatocellular carcinoma, brain tumors"
                  },
                  {
                    "text": "By 5th decade, 30% cumulative incidence"
                  }
                ],
                "Breast Cancer Risk": [
                  {
                    "text": "Heterozygous mutations in downstream effectorsFANCJ(a.k.a.BRIP1),FANCN(a.k.a.PALB2),FANCD1(a.k.a.BRCA2) confer breast cancer susceptibility"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Patients With FA": [
                  {
                    "text": "Increased surveillance for commonly associated neoplasms"
                  },
                  {
                    "text": "Exposure to radiation or DNA-damaging chemicals should be avoidedSpecial protocols required for patients undergoing stem cell transplantation",
                    "sub_points": [
                      "Special protocols required for patients undergoing stem cell transplantation"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Breast/Ovarian Cancer Syndrome: BRCA1": {
            "name": "Hereditary Breast/Ovarian Cancer Syndrome: BRCA1",
            "url": "https://app.pathprimer.com/document/6a8348b4-5ec6-473f-ad61-0738fb411d16/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "BRCA1 syndrome"
                  },
                  {
                    "text": "Breast cancer 1 syndrome"
                  },
                  {
                    "text": "Early-onset breast/ovarian cancer syndrome"
                  },
                  {
                    "text": "Online Mendelian Inheritance in Man (OMIM) #113705"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Hereditary breast &/or ovarian cancers resulting from inheritance of a germline mutation inBRCA1Early-onset and multiple primary breast tumorsFamily history of breast or ovarian cancer",
                    "sub_points": [
                      "Early-onset and multiple primary breast tumors",
                      "Family history of breast or ovarian cancer"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Population Incidence": [
                  {
                    "text": "0.1-0.3% of individualsSlightly less common thanBRCA2mutations",
                    "sub_points": [
                      "Slightly less common thanBRCA2mutations"
                    ]
                  },
                  {
                    "text": "Specific mutations are found at increased frequency in ethnic populationsFinns, French Canadians, and many othersAshkenazi Jewish population~ 1% (1 in 40)185delAG and 5382insCThere is also a commonBRCA2mutation",
                    "sub_points": [
                      "Finns, French Canadians, and many others",
                      "Ashkenazi Jewish population~ 1% (1 in 40)185delAG and 5382insCThere is also a commonBRCA2mutation",
                      "~ 1% (1 in 40)",
                      "185delAG and 5382insC",
                      "There is also a commonBRCA2mutation"
                    ]
                  }
                ],
                "Modifiers of Risk": [
                  {
                    "text": "Parity decreases risk of breast cancer"
                  },
                  {
                    "text": "Low-dose ionizing radiation to chest before age 20 increases risk"
                  },
                  {
                    "text": "Mutations in other genesNone yet well definedGenome-wide association studies (GWAS) are investigating possible associations",
                    "sub_points": [
                      "None yet well defined",
                      "Genome-wide association studies (GWAS) are investigating possible associations"
                    ]
                  }
                ],
                "Cancer Incidence": [
                  {
                    "text": "~ 2% of all breast cancers are related toBRCA1germline mutations"
                  },
                  {
                    "text": "~ 50% of all cancers related to an identified germline mutation are due toBRCA1germline mutations"
                  }
                ]
              },
              "Genetics": {
                "BRCA1Gene": [
                  {
                    "text": "Located on 17q21"
                  },
                  {
                    "text": "Large 81 kb geneDoes not share sequence homology withBRCA2or other genes",
                    "sub_points": [
                      "Does not share sequence homology withBRCA2or other genes"
                    ]
                  },
                  {
                    "text": "23 coding exons"
                  },
                  {
                    "text": "Transcript 7,094 base pairsProtein 1,863 amino acids (210 kDa)No sequence homology with other proteins",
                    "sub_points": [
                      "Protein 1,863 amino acids (210 kDa)",
                      "No sequence homology with other proteins"
                    ]
                  },
                  {
                    "text": "Autosomal dominant inheritanceDe novo mutations are rare",
                    "sub_points": [
                      "De novo mutations are rare"
                    ]
                  },
                  {
                    "text": "More than 1,000 different mutations identifiedMajority are small deletions or insertionsResults in frameshift mutations, nonsense mutations, or splice site alterationsProtein may be truncated or absentLess common are full-length proteins with missense mutationsInactivating mutations impair conservative DNA repair and genomic stability functions",
                    "sub_points": [
                      "Majority are small deletions or insertionsResults in frameshift mutations, nonsense mutations, or splice site alterationsProtein may be truncated or absentLess common are full-length proteins with missense mutations",
                      "Results in frameshift mutations, nonsense mutations, or splice site alterations",
                      "Protein may be truncated or absent",
                      "Less common are full-length proteins with missense mutations",
                      "Inactivating mutations impair conservative DNA repair and genomic stability functions"
                    ]
                  }
                ],
                "Protein Function": [
                  {
                    "text": "Central role in DNA repair, cell cycle control, transcriptional regulation, as well as many other functions"
                  },
                  {
                    "text": "Regulation of repair of DNA damageRepair of DNA double-stranded breaks by homologous recombinationCells that lack BRCA1 rely on other less reliable mechanisms for DNA repairIncreases replication errors and genomic instabilityChromosomal instability contributes to tumor formationBRCA1defects are postulated to be initiating oncogenic event",
                    "sub_points": [
                      "Repair of DNA double-stranded breaks by homologous recombinationCells that lack BRCA1 rely on other less reliable mechanisms for DNA repairIncreases replication errors and genomic instability",
                      "Cells that lack BRCA1 rely on other less reliable mechanisms for DNA repair",
                      "Increases replication errors and genomic instability",
                      "Chromosomal instability contributes to tumor formationBRCA1defects are postulated to be initiating oncogenic event",
                      "BRCA1defects are postulated to be initiating oncogenic event"
                    ]
                  },
                  {
                    "text": "Cell cycle regulation, checkpoint controlAccumulating DNA abnormalities enable mutations in genes essential to cell cycle checkpoint activation",
                    "sub_points": [
                      "Accumulating DNA abnormalities enable mutations in genes essential to cell cycle checkpoint activation"
                    ]
                  },
                  {
                    "text": "Transcriptional regulationRequired for transactivation of the estrogen receptor promoterMay explain why ~ 90% ofBRCA1-related cancers are estrogen receptor negative",
                    "sub_points": [
                      "Required for transactivation of the estrogen receptor promoter",
                      "May explain why ~ 90% ofBRCA1-related cancers are estrogen receptor negative"
                    ]
                  },
                  {
                    "text": "Also functional in chromatin remodeling and protein ubiquitination"
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Population to Be Tested": [
                  {
                    "text": "American Society of Clinical Oncology recommends that patients with > 10% mutation risk undergo testing85% of mutation carriers will be detected using a 10% cut-off",
                    "sub_points": [
                      "85% of mutation carriers will be detected using a 10% cut-off"
                    ]
                  },
                  {
                    "text": "National Institute for Health and Clinical Excellence in United Kingdom recommends testing individuals with > 20% risk of having a mutation"
                  },
                  {
                    "text": "Counseling should occur before testing to ensure patient is aware of implications for self and family"
                  }
                ],
                "Clinical Criteria": [
                  {
                    "text": "Personal history of breast cancer in a woman < 40 years of ageRisk increased if cancer is negative for estrogen receptorRisk is 35% for women < 30 if cancer is poorly differentiated and estrogen receptor negative",
                    "sub_points": [
                      "Risk increased if cancer is negative for estrogen receptorRisk is 35% for women < 30 if cancer is poorly differentiated and estrogen receptor negative",
                      "Risk is 35% for women < 30 if cancer is poorly differentiated and estrogen receptor negative"
                    ]
                  },
                  {
                    "text": "Breast cancer in 1st-degree relatives (mother, sister, daughter)Risk increased if cancer diagnosed at young ageRisk increased if individuals have multiple cancers",
                    "sub_points": [
                      "Risk increased if cancer diagnosed at young age",
                      "Risk increased if individuals have multiple cancers"
                    ]
                  },
                  {
                    "text": "Risk increased if ovarian cancers are also present in family"
                  },
                  {
                    "text": "Risk increased if a relative has known mutation"
                  }
                ],
                "Calculating Risk": [
                  {
                    "text": "There are multiple models to predict probability of an individual carrying a germlineBRCA1orBRCA2mutationEmpiric modelsDo not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)Some models can be applied without use of a computerExamples include Penn II model, Myriad II (Frank model), and National Cancer Institute modelGenetic risk prediction modelsMake assumptions about the number of genes and allele frequenciesInclude information about relationships among individuals in a kindredAccuracy depends on validity of assumptionsUsually requires a computer program to calculate riskExamples include BRCAPRO and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/BOADICEA available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html",
                    "sub_points": [
                      "Empiric modelsDo not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)Some models can be applied without use of a computerExamples include Penn II model, Myriad II (Frank model), and National Cancer Institute model",
                      "Do not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)",
                      "Some models can be applied without use of a computer",
                      "Examples include Penn II model, Myriad II (Frank model), and National Cancer Institute model",
                      "Genetic risk prediction modelsMake assumptions about the number of genes and allele frequenciesInclude information about relationships among individuals in a kindredAccuracy depends on validity of assumptionsUsually requires a computer program to calculate riskExamples include BRCAPRO and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/BOADICEA available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html",
                      "Make assumptions about the number of genes and allele frequencies",
                      "Include information about relationships among individuals in a kindred",
                      "Accuracy depends on validity of assumptions",
                      "Usually requires a computer program to calculate risk",
                      "Examples include BRCAPRO and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)",
                      "BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/",
                      "BOADICEA available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html"
                    ]
                  },
                  {
                    "text": "Information included in modelsAge of the individual (proband)Breast (female and male) and ovarian cancerAge at diagnosisNumber of relatives (1st and 2nd degree for most models, also 3rd degree for BOADICEA)Bilateral breast cancerInformation on pathologic features of cancers has not yet been fully integrated into models",
                    "sub_points": [
                      "Age of the individual (proband)",
                      "Breast (female and male) and ovarian cancer",
                      "Age at diagnosis",
                      "Number of relatives (1st and 2nd degree for most models, also 3rd degree for BOADICEA)",
                      "Bilateral breast cancer",
                      "Information on pathologic features of cancers has not yet been fully integrated into models"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Full sequencing required to detect all mutations"
                  },
                  {
                    "text": "Additional testing required to detect deletions and amplifications18% of genetic changes are not detected by standard analysis",
                    "sub_points": [
                      "18% of genetic changes are not detected by standard analysis"
                    ]
                  },
                  {
                    "text": "All testing is performed by Myriad Genetics in USA"
                  }
                ],
                "Interpretation of Results": [
                  {
                    "text": "Mutation associated with breast cancer risk in other familiesPatient classified as having BRCA1 syndromeTesting of additional family members should be considered",
                    "sub_points": [
                      "Patient classified as having BRCA1 syndrome",
                      "Testing of additional family members should be considered"
                    ]
                  },
                  {
                    "text": "Mutation linked to a relative with breast cancerTesting of additional individuals in family may be helpful to establish linkage",
                    "sub_points": [
                      "Testing of additional individuals in family may be helpful to establish linkage"
                    ]
                  },
                  {
                    "text": "Mutation known to be benign or have low clinical significanceMutations that do not change amino acid typeMutations known to occur in individuals without cancer",
                    "sub_points": [
                      "Mutations that do not change amino acid type",
                      "Mutations known to occur in individuals without cancer"
                    ]
                  },
                  {
                    "text": "Variant of uncertain significance (VUS)Not yet linked to an individual with breast cancerDetected in 7% of individuals (> 1,500 identified)More frequent in populations of non-European origin as fewer individuals have been studied",
                    "sub_points": [
                      "Not yet linked to an individual with breast cancer",
                      "Detected in 7% of individuals (> 1,500 identified)",
                      "More frequent in populations of non-European origin as fewer individuals have been studied"
                    ]
                  }
                ],
                "Immunoperoxidase Studies": [
                  {
                    "text": "Majority ofBRCA1-associated carcinomas are negative for hormone receptors and HER2 (triple-negative breast carcinoma [TNBC])These cancers group with basal-like carcinomas by gene expression profilingThere is an 80% overlap between TNBC and basal-like carcinomas",
                    "sub_points": [
                      "These cancers group with basal-like carcinomas by gene expression profiling",
                      "There is an 80% overlap between TNBC and basal-like carcinomas"
                    ]
                  },
                  {
                    "text": "Identifying a cancer as TNBC increases likelihood that a cancer is associated withBRCA1However, > 10% ofBRCA1-associated cancers are not basal-like cancersTherefore, immunohistochemistry cannot be used to exclude this association",
                    "sub_points": [
                      "However, > 10% ofBRCA1-associated cancers are not basal-like cancersTherefore, immunohistochemistry cannot be used to exclude this association",
                      "Therefore, immunohistochemistry cannot be used to exclude this association"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Female Breast Cancer": [
                  {
                    "text": "Risk40-90% by age 70Varies by mutationMay be modified by mutations in additional genes",
                    "sub_points": [
                      "40-90% by age 70Varies by mutationMay be modified by mutations in additional genes",
                      "Varies by mutation",
                      "May be modified by mutations in additional genes"
                    ]
                  },
                  {
                    "text": "Macroscopic findingsCarcinomas typically have pushing borders that are evident grossly and microscopicallyOften completely or partially circumscribed",
                    "sub_points": [
                      "Carcinomas typically have pushing borders that are evident grossly and microscopically",
                      "Often completely or partially circumscribed"
                    ]
                  },
                  {
                    "text": "HistologyPredominantly high-grade, poorly differentiated carcinomasDense lymphocytic infiltrate (predominantly T cell)High nuclear grade, syncytial patternFoci of geographic tumor necrosisHigh proliferative indexMedullary features (syncytial growth pattern, lymphocytic infiltrate)13% fulfill criteria for medullary carcinoma60% have medullary features70-80% negative for estrogen receptor, progesterone receptor, and HER2> 95% poorly differentiatedTP53mutations common (> 90%); ~ 55% positive by immunohistochemistry50-80% positive for CK5/6, CK14, or EGFRBRCA1 regulates the expression of estrogen receptor20-30% positive for estrogen receptor and negative for HER2~ 45% poorly differentiated~ 50% positive by immunohistochemistry for p53< 20% positive for CK5/6, CK14, or EGFRMajority show loss of wild-typeBRCA1alleleMajority (~ 90%) classified as basal-like carcinoma according to mRNA expression profiling~ 15% of basal-like carcinomas are related to germlineBRCA1mutationsER-positive subset are classified as luminal B",
                    "sub_points": [
                      "Predominantly high-grade, poorly differentiated carcinomasDense lymphocytic infiltrate (predominantly T cell)High nuclear grade, syncytial patternFoci of geographic tumor necrosisHigh proliferative index",
                      "Dense lymphocytic infiltrate (predominantly T cell)",
                      "High nuclear grade, syncytial pattern",
                      "Foci of geographic tumor necrosis",
                      "High proliferative index",
                      "Medullary features (syncytial growth pattern, lymphocytic infiltrate)13% fulfill criteria for medullary carcinoma60% have medullary features",
                      "13% fulfill criteria for medullary carcinoma",
                      "60% have medullary features",
                      "70-80% negative for estrogen receptor, progesterone receptor, and HER2> 95% poorly differentiatedTP53mutations common (> 90%); ~ 55% positive by immunohistochemistry50-80% positive for CK5/6, CK14, or EGFRBRCA1 regulates the expression of estrogen receptor",
                      "> 95% poorly differentiated",
                      "TP53mutations common (> 90%); ~ 55% positive by immunohistochemistry",
                      "50-80% positive for CK5/6, CK14, or EGFR",
                      "BRCA1 regulates the expression of estrogen receptor",
                      "20-30% positive for estrogen receptor and negative for HER2~ 45% poorly differentiated~ 50% positive by immunohistochemistry for p53< 20% positive for CK5/6, CK14, or EGFRMajority show loss of wild-typeBRCA1allele",
                      "~ 45% poorly differentiated",
                      "~ 50% positive by immunohistochemistry for p53",
                      "< 20% positive for CK5/6, CK14, or EGFR",
                      "Majority show loss of wild-typeBRCA1allele",
                      "Majority (~ 90%) classified as basal-like carcinoma according to mRNA expression profiling~ 15% of basal-like carcinomas are related to germlineBRCA1mutationsER-positive subset are classified as luminal B",
                      "~ 15% of basal-like carcinomas are related to germlineBRCA1mutations",
                      "ER-positive subset are classified as luminal B"
                    ]
                  }
                ],
                "Male Breast Cancer": [
                  {
                    "text": "1.8% lifetime risk (compared to 0.07% risk in general population)< 4% of male breast cancer cases associated withBRCA1Lower than risk associated withBRCA2",
                    "sub_points": [
                      "< 4% of male breast cancer cases associated withBRCA1",
                      "Lower than risk associated withBRCA2"
                    ]
                  }
                ],
                "Ovarian, Fallopian Tube, and Peritoneal Carcinoma": [
                  {
                    "text": "40-50% lifetime risk"
                  },
                  {
                    "text": "60-85% involve fimbriated end of fallopian tube"
                  },
                  {
                    "text": "Serous tubal intraepithelial carcinoma (80%) and endometrioid tubal carcinoma (20%) are found in ~ 8% of prophylactic surgeriesEntire tube should be examined microscopicallyImmunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful to identify early neoplasiaIf no invasion is seen, risk of recurrence in peritoneum is 4-5%",
                    "sub_points": [
                      "Entire tube should be examined microscopicallyImmunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful to identify early neoplasia",
                      "Immunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful to identify early neoplasia",
                      "If no invasion is seen, risk of recurrence in peritoneum is 4-5%"
                    ]
                  }
                ],
                "Other Cancers": [
                  {
                    "text": "Prostate: Relative risk = 1.8% (age < 65)Risk of prostate cancer may vary depending on location ofBRCA1mutation",
                    "sub_points": [
                      "Risk of prostate cancer may vary depending on location ofBRCA1mutation"
                    ]
                  },
                  {
                    "text": "Pancreas: Relative risk = 2.3% (age < 65)"
                  },
                  {
                    "text": "Cervix: Relative risk = 2.6% (age < 65)"
                  },
                  {
                    "text": "Uterus: Relative risk = 2.6% (age < 65)Potential endometrial cancer risk may be explained by tamoxifen exposure",
                    "sub_points": [
                      "Potential endometrial cancer risk may be explained by tamoxifen exposure"
                    ]
                  },
                  {
                    "text": "ColonInitial reports of increased colon cancer risk have not been replicated",
                    "sub_points": [
                      "Initial reports of increased colon cancer risk have not been replicated"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Chemoprevention": [
                  {
                    "text": "Oral contraceptivesReduces risk of ovarian cancer by 50%Breast cancer risk may be increased by some types of oral contraceptives (results of studies have not been consistent)",
                    "sub_points": [
                      "Reduces risk of ovarian cancer by 50%",
                      "Breast cancer risk may be increased by some types of oral contraceptives (results of studies have not been consistent)"
                    ]
                  },
                  {
                    "text": "TamoxifenReduces riskEvidence derives from observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifenProtective effect observed inBRCA1andBRCA2carriersBRCA1carriers appear to benefit despite predilection to develop ER negative tumor for reasons that remain unclear",
                    "sub_points": [
                      "Reduces riskEvidence derives from observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifen",
                      "Evidence derives from observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifen",
                      "Protective effect observed inBRCA1andBRCA2carriersBRCA1carriers appear to benefit despite predilection to develop ER negative tumor for reasons that remain unclear",
                      "BRCA1carriers appear to benefit despite predilection to develop ER negative tumor for reasons that remain unclear"
                    ]
                  }
                ],
                "Screening": [
                  {
                    "text": "MammographyShould begin at age 10 years younger than youngest affected person in familyMay have limited sensitivity because young women often have dense breast tissue",
                    "sub_points": [
                      "Should begin at age 10 years younger than youngest affected person in family",
                      "May have limited sensitivity because young women often have dense breast tissue"
                    ]
                  },
                  {
                    "text": "Magnetic resonance (MR) imagingWomen withBRCA1mutations are eligible for screening using this modalityMR detects cancer due to blood flow and is more sensitive for detecting cancers in dense breastsFalse-positive results are frequentBreast MR screening reported to be more cost effective inBRCA1vs.BRCA2carriers",
                    "sub_points": [
                      "Women withBRCA1mutations are eligible for screening using this modality",
                      "MR detects cancer due to blood flow and is more sensitive for detecting cancers in dense breasts",
                      "False-positive results are frequent",
                      "Breast MR screening reported to be more cost effective inBRCA1vs.BRCA2carriers"
                    ]
                  }
                ],
                "Prophylactic Surgery": [
                  {
                    "text": "Bilateral mastectomy reduces breast cancer risk by 97%However, not all breast tissue can be removed and achieve acceptable cosmetic resultsGreatest benefit for patients before a diagnosis of cancerAfter cancer has been diagnosed, there may be no benefit if distant metastases are present",
                    "sub_points": [
                      "However, not all breast tissue can be removed and achieve acceptable cosmetic results",
                      "Greatest benefit for patients before a diagnosis of cancerAfter cancer has been diagnosed, there may be no benefit if distant metastases are present",
                      "After cancer has been diagnosed, there may be no benefit if distant metastases are present"
                    ]
                  },
                  {
                    "text": "Bilateral salpingo-oophorectomy reduces breast and ovarian cancer riskBreast cancer risk reduced by 50%Mechanism not well understood but may be due to decreased estrogen productionOvarian and fallopian tube cancer risk reduced by 70-96%There remains a 4-5% risk of papillary serous carcinoma of peritoneum",
                    "sub_points": [
                      "Breast cancer risk reduced by 50%Mechanism not well understood but may be due to decreased estrogen production",
                      "Mechanism not well understood but may be due to decreased estrogen production",
                      "Ovarian and fallopian tube cancer risk reduced by 70-96%There remains a 4-5% risk of papillary serous carcinoma of peritoneum",
                      "There remains a 4-5% risk of papillary serous carcinoma of peritoneum"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Breast/Ovarian Cancer Syndrome: BRCA2": {
            "name": "Hereditary Breast/Ovarian Cancer Syndrome: BRCA2",
            "url": "https://app.pathprimer.com/document/ec4c6103-007a-494c-9176-5a7922c65ca4/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "BRCA2 syndrome"
                  },
                  {
                    "text": "Breast cancer 2 syndrome"
                  },
                  {
                    "text": "Early-onset breast-ovarian cancer syndrome"
                  },
                  {
                    "text": "Online Mendelian Inheritance in Man (OMIM) I #600185"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Hereditary breast &/or ovarian cancers resulting from inheritance of a germline mutation inBRCA2Early-onset and multiple primary breast tumorsFamily history of breast or ovarian cancer",
                    "sub_points": [
                      "Early-onset and multiple primary breast tumors",
                      "Family history of breast or ovarian cancer"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Population Incidence": [
                  {
                    "text": "0.1-0.7% of individualsSlightly more common thanBRCA1mutations",
                    "sub_points": [
                      "Slightly more common thanBRCA1mutations"
                    ]
                  },
                  {
                    "text": "Specific mutations are found at increased frequency in ethnic populationsAshkenazi Jewish population~ 1-3% of individuals6174delTThere are also 2 commonBRCA1mutationsIcelandic population0.6% of individuals999del5 detected in 38% of males and 10.4% of females with breast cancerBRCA2mutations found in 90% of families with male and female breast cancerAlso increased in Quebec (French Canadians) and other populations",
                    "sub_points": [
                      "Ashkenazi Jewish population~ 1-3% of individuals6174delTThere are also 2 commonBRCA1mutations",
                      "~ 1-3% of individuals",
                      "6174delT",
                      "There are also 2 commonBRCA1mutations",
                      "Icelandic population0.6% of individuals999del5 detected in 38% of males and 10.4% of females with breast cancerBRCA2mutations found in 90% of families with male and female breast cancer",
                      "0.6% of individuals",
                      "999del5 detected in 38% of males and 10.4% of females with breast cancer",
                      "BRCA2mutations found in 90% of families with male and female breast cancer",
                      "Also increased in Quebec (French Canadians) and other populations"
                    ]
                  }
                ],
                "Modifiers of Risk": [
                  {
                    "text": "Parity may increase risk (whereas it decreases risk forBRCA1carriers)"
                  },
                  {
                    "text": "Low-dose ionizing radiation to chest before age 20 increases risk"
                  },
                  {
                    "text": "Mutations in other genesNone yet well definedGenome-wide association studies (GWAS) are investigating possible associations",
                    "sub_points": [
                      "None yet well defined",
                      "Genome-wide association studies (GWAS) are investigating possible associations"
                    ]
                  }
                ],
                "Cancer Incidence": [
                  {
                    "text": "~ 2% of all breast cancers are related toBRCA2germline mutations~ 50% of all breast cancers related to an identified germline mutation are due toBRCA2",
                    "sub_points": [
                      "~ 50% of all breast cancers related to an identified germline mutation are due toBRCA2"
                    ]
                  },
                  {
                    "text": "~ 7% of ovarian cancers are related toBRCA2germline mutations~ 27% of ovarian cancers due to an identified germline mutation are related toBRCA2",
                    "sub_points": [
                      "~ 27% of ovarian cancers due to an identified germline mutation are related toBRCA2"
                    ]
                  }
                ]
              },
              "Genetics": {
                "BRCA2Gene": [
                  {
                    "text": "Located on 13q13.1"
                  },
                  {
                    "text": "Large 84 kb geneDoes not share sequence homology withBRCA1or other genes",
                    "sub_points": [
                      "Does not share sequence homology withBRCA1or other genes"
                    ]
                  },
                  {
                    "text": "27 coding exons"
                  },
                  {
                    "text": "Transcript is 10,930 base pairsProtein is 3,418 amino acids (390 kDa)No sequence homology with other proteins",
                    "sub_points": [
                      "Protein is 3,418 amino acids (390 kDa)",
                      "No sequence homology with other proteins"
                    ]
                  },
                  {
                    "text": "Autosomal dominant inheritanceDe novo mutations are rare",
                    "sub_points": [
                      "De novo mutations are rare"
                    ]
                  },
                  {
                    "text": "> 1,000 different mutations identifiedMajority are small deletions or insertionsResults in frameshift mutations, nonsense mutations, or splice site alterationsProtein may be truncated or absentLess common are full-length proteins with missense mutationsInactivating mutations impair conservative DNA repair and genomic stability functions",
                    "sub_points": [
                      "Majority are small deletions or insertionsResults in frameshift mutations, nonsense mutations, or splice site alterationsProtein may be truncated or absentLess common are full-length proteins with missense mutations",
                      "Results in frameshift mutations, nonsense mutations, or splice site alterations",
                      "Protein may be truncated or absent",
                      "Less common are full-length proteins with missense mutations",
                      "Inactivating mutations impair conservative DNA repair and genomic stability functions"
                    ]
                  },
                  {
                    "text": "Central portion of gene designated \"ovarian cancer cluster region\"Mutations in this region are 2x as likely to be associated with ovarian cancer as are mutations in 5' or 3' regionRisk of breast cancer associated with mutation in this region is lower",
                    "sub_points": [
                      "Mutations in this region are 2x as likely to be associated with ovarian cancer as are mutations in 5' or 3' region",
                      "Risk of breast cancer associated with mutation in this region is lower"
                    ]
                  }
                ],
                "Protein Function": [
                  {
                    "text": "Central role in DNA repair, transcription, gametogenesis, and centrosome duplication"
                  },
                  {
                    "text": "Regulation of repair of DNA damageRepair of DNA double-stranded breaks through homologous recombinationPromotes assembly of RAD51 on single-stranded DNA rather than double-stranded DNABRCA2interacts directly with RAD51 for transport to nuclear complex﻿WithBRCA2mutations, RAD51 remains sequestered in cytoplasm",
                    "sub_points": [
                      "Repair of DNA double-stranded breaks through homologous recombination",
                      "Promotes assembly of RAD51 on single-stranded DNA rather than double-stranded DNABRCA2interacts directly with RAD51 for transport to nuclear complex﻿WithBRCA2mutations, RAD51 remains sequestered in cytoplasm",
                      "BRCA2interacts directly with RAD51 for transport to nuclear complex",
                      "﻿WithBRCA2mutations, RAD51 remains sequestered in cytoplasm"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Population to be Tested": [
                  {
                    "text": "American Society of Clinical Oncology recommends that patients with > 10% mutation risk undergo testing85% of mutation carriers will be detected using this 10% cut-off",
                    "sub_points": [
                      "85% of mutation carriers will be detected using this 10% cut-off"
                    ]
                  },
                  {
                    "text": "National Institute for Health and Clinical Excellence in United Kingdom recommends testing individuals with > 20% mutation risk"
                  },
                  {
                    "text": "Counseling should occur before testing to ensure patients are aware of implications for themselves and their families"
                  }
                ],
                "Clinical Criteria": [
                  {
                    "text": "Personal history of breast cancer in women < 40 years of age"
                  },
                  {
                    "text": "Breast cancer in 1st-degree relatives (mother, sister, daughter)Risk increased if cancer diagnosed at young ageRisk increased if individuals have multiple cancers",
                    "sub_points": [
                      "Risk increased if cancer diagnosed at young age",
                      "Risk increased if individuals have multiple cancers"
                    ]
                  },
                  {
                    "text": "Risk increased if a male with breast cancer is in the family"
                  },
                  {
                    "text": "Risk increased if ovarian cancers are also present in the family"
                  },
                  {
                    "text": "Risk increased if a relative has a known mutation"
                  }
                ],
                "Calculating Risk": [
                  {
                    "text": "There are multiple models to predict probability of an individual carrying a germlineBRCA2orBRCA2mutationEmpiric modelsDo not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)Examples include Penn II model, Myriad II (Frank) model, and National Cancer Institute modelGenetic risk prediction modelsMake assumptions about number of genes and allele frequenciesInclude information about relationships among individuals in a kindredAccuracy depends on validity of assumptionsExamples include BRCAPRO and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/BOADICEA available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html",
                    "sub_points": [
                      "Empiric modelsDo not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)Examples include Penn II model, Myriad II (Frank) model, and National Cancer Institute model",
                      "Do not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)",
                      "Examples include Penn II model, Myriad II (Frank) model, and National Cancer Institute model",
                      "Genetic risk prediction modelsMake assumptions about number of genes and allele frequenciesInclude information about relationships among individuals in a kindredAccuracy depends on validity of assumptionsExamples include BRCAPRO and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/BOADICEA available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html",
                      "Make assumptions about number of genes and allele frequencies",
                      "Include information about relationships among individuals in a kindred",
                      "Accuracy depends on validity of assumptions",
                      "Examples include BRCAPRO and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)",
                      "BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/",
                      "BOADICEA available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Full sequencing required to detect all mutations"
                  },
                  {
                    "text": "Additional testing required to detect large deletions and amplifications18% of genetic changes are not detected by standard testing",
                    "sub_points": [
                      "18% of genetic changes are not detected by standard testing"
                    ]
                  },
                  {
                    "text": "Targeted mutation analysis may be population or family specificIndividuals of some ethnic backgrounds are at higher risk for certain mutationsSpecific mutation may be sought if there is an affected relative with a known mutation",
                    "sub_points": [
                      "Individuals of some ethnic backgrounds are at higher risk for certain mutations",
                      "Specific mutation may be sought if there is an affected relative with a known mutation"
                    ]
                  }
                ],
                "Interpretation of Results": [
                  {
                    "text": "Mutation associated with breast cancer in other familiesPatient classified as having BRCA2 syndromeTesting of additional family members should be considered",
                    "sub_points": [
                      "Patient classified as having BRCA2 syndrome",
                      "Testing of additional family members should be considered"
                    ]
                  },
                  {
                    "text": "Mutation linked to a relative with breast cancerTesting of additional individuals in family may be helpful to establish definite linkage",
                    "sub_points": [
                      "Testing of additional individuals in family may be helpful to establish definite linkage"
                    ]
                  },
                  {
                    "text": "Mutation known to be benign or have low clinical significanceMutations that do not change amino acid typeMutations known to occur in individuals without cancer",
                    "sub_points": [
                      "Mutations that do not change amino acid type",
                      "Mutations known to occur in individuals without cancer"
                    ]
                  },
                  {
                    "text": "Variant of uncertain significance (VUS)Not yet linked to an individual with breast cancerDetected in 7% of individuals (> 1,500 identified)More frequent in populations of non-European ancestry",
                    "sub_points": [
                      "Not yet linked to an individual with breast cancer",
                      "Detected in 7% of individuals (> 1,500 identified)",
                      "More frequent in populations of non-European ancestry"
                    ]
                  }
                ],
                "Immunoperoxidase Studies": [
                  {
                    "text": "Majority ofBRCA2-associated carcinomas are positive for estrogen receptor and negative for HER2Therefore, these studies are not useful for distinguishingBRCA2-related cancers from sporadic cancers",
                    "sub_points": [
                      "Therefore, these studies are not useful for distinguishingBRCA2-related cancers from sporadic cancers"
                    ]
                  },
                  {
                    "text": "BRCA2 protein can be detected by immunohistochemistryNormal tissues express protein in nucleusSome, but not all,BRCA2-related cancers will lack positivityThis study is not generally used clinically",
                    "sub_points": [
                      "Normal tissues express protein in nucleus",
                      "Some, but not all,BRCA2-related cancers will lack positivity",
                      "This study is not generally used clinically"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Female Breast Cancer": [
                  {
                    "text": "Risk~ 45% lifetime riskVaries by mutationMay be modified by mutations in additional genesEarly age at onset and multiple primary tumors are characteristic",
                    "sub_points": [
                      "~ 45% lifetime riskVaries by mutationMay be modified by mutations in additional genesEarly age at onset and multiple primary tumors are characteristic",
                      "Varies by mutation",
                      "May be modified by mutations in additional genes",
                      "Early age at onset and multiple primary tumors are characteristic"
                    ]
                  },
                  {
                    "text": "HistologyModerately to poorly differentiatedNo specific histologic typePushing marginsLack of tubule formationSome studies have suggested a higher incidence of tubulolobular and pleomorphic lobular carcinomasOther series have not shown significant differences betweenBRCA2carcinomas and sporadic carcinomasCarcinomas are frequently associated with DCIS",
                    "sub_points": [
                      "Moderately to poorly differentiated",
                      "No specific histologic typePushing marginsLack of tubule formationSome studies have suggested a higher incidence of tubulolobular and pleomorphic lobular carcinomasOther series have not shown significant differences betweenBRCA2carcinomas and sporadic carcinomasCarcinomas are frequently associated with DCIS",
                      "Pushing margins",
                      "Lack of tubule formation",
                      "Some studies have suggested a higher incidence of tubulolobular and pleomorphic lobular carcinomas",
                      "Other series have not shown significant differences betweenBRCA2carcinomas and sporadic carcinomas",
                      "Carcinomas are frequently associated with DCIS"
                    ]
                  },
                  {
                    "text": "Majority are positive for estrogen receptorHER2 overexpression is rare (< 5%), lower than the incidence in sporadic breast cancer",
                    "sub_points": [
                      "HER2 overexpression is rare (< 5%), lower than the incidence in sporadic breast cancer"
                    ]
                  },
                  {
                    "text": "TP53mutations (30-65%) are less common than inBRCA1-associated cancers (> 90%)"
                  },
                  {
                    "text": "Majority classified as luminal B by gene expression profiling"
                  }
                ],
                "Male Breast Cancer": [
                  {
                    "text": "Risk~ 7% lifetime risk (compared to 0.07% in general population)8-16% of male breast cancers are in individuals withBRCA2mutations60-75% chance thatBRCA2mutation exists in families with ≥ male with breast cancerAssociation withBRCA1is less common (< 4% of all male breast cancers)",
                    "sub_points": [
                      "~ 7% lifetime risk (compared to 0.07% in general population)",
                      "8-16% of male breast cancers are in individuals withBRCA2mutations60-75% chance thatBRCA2mutation exists in families with ≥ male with breast cancerAssociation withBRCA1is less common (< 4% of all male breast cancers)",
                      "60-75% chance thatBRCA2mutation exists in families with ≥ male with breast cancer",
                      "Association withBRCA1is less common (< 4% of all male breast cancers)"
                    ]
                  },
                  {
                    "text": "HistologyNo specific histologic features reported",
                    "sub_points": [
                      "No specific histologic features reported"
                    ]
                  }
                ],
                "Ovarian, Fallopian Tube, and Peritoneal Carcinoma": [
                  {
                    "text": "~ 11-18% lifetime riskRisk for ovarian cancer lower than that observed inBRCA1mutation carriers (40-50% lifetime risk)",
                    "sub_points": [
                      "Risk for ovarian cancer lower than that observed inBRCA1mutation carriers (40-50% lifetime risk)"
                    ]
                  },
                  {
                    "text": "AgeAverage onset is 55-58 years compared to 63 years in general populationYoung women (< 40 years) with ovarian/tubal/peritoneal carcinoma are unlikely to have aBRCA1orBRCA2mutationThese women tend to have borderline tumors and cancers of more favorable histologic types",
                    "sub_points": [
                      "Average onset is 55-58 years compared to 63 years in general population",
                      "Young women (< 40 years) with ovarian/tubal/peritoneal carcinoma are unlikely to have aBRCA1orBRCA2mutationThese women tend to have borderline tumors and cancers of more favorable histologic types",
                      "These women tend to have borderline tumors and cancers of more favorable histologic types"
                    ]
                  },
                  {
                    "text": "Fallopian tubeSerous tubal intraepithelial carcinoma (80%) and endometrioid tubal carcinoma (20%) are found in ~ 5-7% of prophylactic salpingo-oophorectomies60-85% involve fimbriated end of fallopian tubeEntire tube should be examined microscopicallyImmunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful",
                    "sub_points": [
                      "Serous tubal intraepithelial carcinoma (80%) and endometrioid tubal carcinoma (20%) are found in ~ 5-7% of prophylactic salpingo-oophorectomies60-85% involve fimbriated end of fallopian tubeEntire tube should be examined microscopicallyImmunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful",
                      "60-85% involve fimbriated end of fallopian tube",
                      "Entire tube should be examined microscopically",
                      "Immunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful"
                    ]
                  },
                  {
                    "text": "OvaryCarcinomas are usually high-grade serous carcinomasOnly ~ 2% of tumors are mucinous or borderlineEndometrioid, clear cell, and papillary carcinomas occur but are rare",
                    "sub_points": [
                      "Carcinomas are usually high-grade serous carcinomasOnly ~ 2% of tumors are mucinous or borderlineEndometrioid, clear cell, and papillary carcinomas occur but are rare",
                      "Only ~ 2% of tumors are mucinous or borderline",
                      "Endometrioid, clear cell, and papillary carcinomas occur but are rare"
                    ]
                  },
                  {
                    "text": "Primary peritoneal carcinomaWomen have ~ 4% risk after bilateral prophylactic salpingo-oophorectomy",
                    "sub_points": [
                      "Women have ~ 4% risk after bilateral prophylactic salpingo-oophorectomy"
                    ]
                  }
                ],
                "Other Cancers": [
                  {
                    "text": "Prostate: Relative risk is 4.6%1-2% of cancers diagnosed before age 65Increased prostate cancer risk is not a consistent finding across all studies",
                    "sub_points": [
                      "1-2% of cancers diagnosed before age 65",
                      "Increased prostate cancer risk is not a consistent finding across all studies"
                    ]
                  },
                  {
                    "text": "Pancreas, gall bladder, & bile duct: Relative risk is 3.5%Presence of pancreatic cancer in a breast cancer family may be predictor of aBRCA2mutation",
                    "sub_points": [
                      "Presence of pancreatic cancer in a breast cancer family may be predictor of aBRCA2mutation"
                    ]
                  },
                  {
                    "text": "GastrointestinalStomach: Relative risk is 2.6%As withBRCA1, initial reports of increased colon cancer risk have generally not been replicated",
                    "sub_points": [
                      "Stomach: Relative risk is 2.6%",
                      "As withBRCA1, initial reports of increased colon cancer risk have generally not been replicated"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Chemoprevention": [
                  {
                    "text": "Oral contraceptivesReduces risk of ovarian cancer by 50%Breast cancer risk may be increased by some types of oral contraceptives; results of studies have not been consistent",
                    "sub_points": [
                      "Reduces risk of ovarian cancer by 50%",
                      "Breast cancer risk may be increased by some types of oral contraceptives; results of studies have not been consistent"
                    ]
                  },
                  {
                    "text": "TamoxifenReduces riskEvidence derives from observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifen",
                    "sub_points": [
                      "Reduces riskEvidence derives from observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifen",
                      "Evidence derives from observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifen"
                    ]
                  }
                ],
                "Screening": [
                  {
                    "text": "MammographyShould begin at 10 years younger than youngest affected family memberMay have limited sensitivity as young women often have dense breast tissue",
                    "sub_points": [
                      "Should begin at 10 years younger than youngest affected family member",
                      "May have limited sensitivity as young women often have dense breast tissue"
                    ]
                  },
                  {
                    "text": "Magnetic resonance (MR) imagingMR detects cancers due to blood flow and is more sensitive in detecting cancer in dense breastsHighly sensitive but not very specific; false-positive results are frequent",
                    "sub_points": [
                      "MR detects cancers due to blood flow and is more sensitive in detecting cancer in dense breasts",
                      "Highly sensitive but not very specific; false-positive results are frequent"
                    ]
                  }
                ],
                "Prophylactic Surgery": [
                  {
                    "text": "Bilateral mastectomy reduces breast cancer risk by 97%However, not all breast tissue can be removed and achieve acceptable cosmetic resultsGreatest benefit for patients before a diagnosis of cancerAfter cancer has been diagnosed, there may be no benefit if distant metastases are present",
                    "sub_points": [
                      "However, not all breast tissue can be removed and achieve acceptable cosmetic results",
                      "Greatest benefit for patients before a diagnosis of cancerAfter cancer has been diagnosed, there may be no benefit if distant metastases are present",
                      "After cancer has been diagnosed, there may be no benefit if distant metastases are present"
                    ]
                  },
                  {
                    "text": "Bilateral salpingo-oophorectomy reduces breast and ovarian cancer riskBreast cancer reduced by 50%Mechanism not well understood but may be due to decreased estrogen productionOvarian and fallopian tube cancer reduced by 70-96%There remains a 4% risk of papillary serous carcinoma of peritoneum",
                    "sub_points": [
                      "Breast cancer reduced by 50%Mechanism not well understood but may be due to decreased estrogen production",
                      "Mechanism not well understood but may be due to decreased estrogen production",
                      "Ovarian and fallopian tube cancer reduced by 70-96%There remains a 4% risk of papillary serous carcinoma of peritoneum",
                      "There remains a 4% risk of papillary serous carcinoma of peritoneum"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Papillary Renal Cell Carcinoma": {
            "name": "Hereditary Papillary Renal Cell Carcinoma",
            "url": "https://app.pathprimer.com/document/2701216f-57fc-4898-8c28-df0cb34942c5/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hereditary papillary renal cell carcinoma (HPRCC)"
                  },
                  {
                    "text": "Papillary renal cell carcinoma (PRCC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Autosomal dominant hereditary disease characterized by development of multiple type 1 PRCCs related to germlineMET (c-MET)mutation"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "PRCC typically develops between 45 and 63 yearsSomewhat late onset for hereditary renal cancer syndrome; however, tumor development as early as 2nd or 3rd decade may occur",
                    "sub_points": [
                      "Somewhat late onset for hereditary renal cancer syndrome; however, tumor development as early as 2nd or 3rd decade may occur"
                    ]
                  }
                ],
                "Gender": [
                  {
                    "text": "More common in men (M:F = 2.4:1)"
                  }
                ],
                "Ethnicity Relationship": [
                  {
                    "text": "No known ethnic relationshipMost cases encountered in Caucasian families; possibly biased by general population ethnic distribution",
                    "sub_points": [
                      "Most cases encountered in Caucasian families; possibly biased by general population ethnic distribution"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "Rare, only ~ 30 families withMETmutation described worldwide1 study did not findMETmutation in 59 clinic-based PRCC cases, including a subset with bilateral &/or multifocal tumorsPRCC represents 5% of familial renal cancers in National Institute of Health (NIH) database",
                    "sub_points": [
                      "1 study did not findMETmutation in 59 clinic-based PRCC cases, including a subset with bilateral &/or multifocal tumors",
                      "PRCC represents 5% of familial renal cancers in National Institute of Health (NIH) database"
                    ]
                  },
                  {
                    "text": "Vast majority of PRCC are sporadic tumors; 2nd most common type of renal epithelial tumorMETmutation also rarely detected in some PRCC type 1 without known family history of PRCC type 1",
                    "sub_points": [
                      "METmutation also rarely detected in some PRCC type 1 without known family history of PRCC type 1"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "Mutation inMETproto-oncogeneGene located in Chr 7q31.1-34MET is receptor for hepatocyte growth factor (HGF) or scatter factor (SF)Most are germline missense mutationsMutation occurs in glycine-rich subdomain adjacent to ATP binding site or in activation loop of tyrosine kinase domainResults in constitutive activation of receptorMET overexpression is frequently observed in HPRCCSuggested as potential therapeutic targetPenetrance suggested to be high",
                    "sub_points": [
                      "Gene located in Chr 7q31.1-34",
                      "MET is receptor for hepatocyte growth factor (HGF) or scatter factor (SF)",
                      "Most are germline missense mutations",
                      "Mutation occurs in glycine-rich subdomain adjacent to ATP binding site or in activation loop of tyrosine kinase domainResults in constitutive activation of receptor",
                      "Results in constitutive activation of receptor",
                      "MET overexpression is frequently observed in HPRCCSuggested as potential therapeutic target",
                      "Suggested as potential therapeutic target",
                      "Penetrance suggested to be high"
                    ]
                  },
                  {
                    "text": "HPRCC cytogeneticsChr +7 detected in HPRCC tumors; similar to sporadic tumorsNo Chr -3p detected",
                    "sub_points": [
                      "Chr +7 detected in HPRCC tumors; similar to sporadic tumors",
                      "No Chr -3p detected"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Diagnosis in index patients from families with HPRCC not different from sporadic PRCCsRenal cancers often detected incidentallyWhen symptomatic, may present with hematuria, abdominal pain, &/or massSuspicion for HPRCC raised by history of multiple family members with renal cancersSubsequent radiologic screening may identify affected family members with asymptomatic renal cancers",
                    "sub_points": [
                      "Renal cancers often detected incidentally",
                      "When symptomatic, may present with hematuria, abdominal pain, &/or mass",
                      "Suspicion for HPRCC raised by history of multiple family members with renal cancers",
                      "Subsequent radiologic screening may identify affected family members with asymptomatic renal cancers"
                    ]
                  },
                  {
                    "text": "Renal cancers can be lethal if not detected and treated at early stage"
                  },
                  {
                    "text": "Estimated prevalence of renal tumors is 1,100-1,300 microscopic papillary tumors in a kidney"
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "METProto-Oncogene Mutation Screening": [
                  {
                    "text": "Not advocated to be performed in every case of PRCC because HPRCC is rare1 study screened 59 patients with PRCC that included 22% with bilateral &/or multifocal tumors and noMETmutation was identified",
                    "sub_points": [
                      "1 study screened 59 patients with PRCC that included 22% with bilateral &/or multifocal tumors and noMETmutation was identified"
                    ]
                  },
                  {
                    "text": "Testing should be performed only if there is clinical suspicion of the diseaseUnusually young age of onset, positive family history, bilateral &/or multifocal PRCCs",
                    "sub_points": [
                      "Unusually young age of onset, positive family history, bilateral &/or multifocal PRCCs"
                    ]
                  },
                  {
                    "text": "Testing can be performed on blood samples (lymphocytes)"
                  }
                ]
              },
              "Associated Neoplasms": {
                "PRCC Type 1": [
                  {
                    "text": "MacroscopyBilateral and multifocal tumors in > 80% of cases of HPRCCReported number of PRCCs ranges from 1-26HPRCC tumors have similar gross appearance to sporadic PRCCWell circumscribed with fibrous pseudocapsuleHemorrhages are common and cause red or dark brown discolorationIntratumoral collections of histiocytes may produce yellow streaks or contrasts",
                    "sub_points": [
                      "Bilateral and multifocal tumors in > 80% of cases of HPRCC",
                      "Reported number of PRCCs ranges from 1-26",
                      "HPRCC tumors have similar gross appearance to sporadic PRCCWell circumscribed with fibrous pseudocapsuleHemorrhages are common and cause red or dark brown discolorationIntratumoral collections of histiocytes may produce yellow streaks or contrasts",
                      "Well circumscribed with fibrous pseudocapsule",
                      "Hemorrhages are common and cause red or dark brown discoloration",
                      "Intratumoral collections of histiocytes may produce yellow streaks or contrasts"
                    ]
                  },
                  {
                    "text": "MicroscopyPredominant histology of PRCC type 1 in HPRCC is similar to those in sporadic typePapillary architecture with fibrovascular core that occasionally contains foamy histiocytesMay also have tubular or tubulopapillary architecture; may impart solid appearance when predominantTumor cells are small with scant to modest amount of basophilic or amphophilic cytoplasmAdmixed areas of clear cells present in > 90% of tumors, more common than in sporadic PRCCsAmount of clear cells varies from 1-70%PRCC lacks delicate vasculature in clear cell RCCElectron microscopy detects intracytoplasmic lipid and glycogen, unlike in usual PRCC cells",
                    "sub_points": [
                      "Predominant histology of PRCC type 1 in HPRCC is similar to those in sporadic typePapillary architecture with fibrovascular core that occasionally contains foamy histiocytesMay also have tubular or tubulopapillary architecture; may impart solid appearance when predominantTumor cells are small with scant to modest amount of basophilic or amphophilic cytoplasm",
                      "Papillary architecture with fibrovascular core that occasionally contains foamy histiocytes",
                      "May also have tubular or tubulopapillary architecture; may impart solid appearance when predominant",
                      "Tumor cells are small with scant to modest amount of basophilic or amphophilic cytoplasm",
                      "Admixed areas of clear cells present in > 90% of tumors, more common than in sporadic PRCCsAmount of clear cells varies from 1-70%PRCC lacks delicate vasculature in clear cell RCCElectron microscopy detects intracytoplasmic lipid and glycogen, unlike in usual PRCC cells",
                      "Amount of clear cells varies from 1-70%",
                      "PRCC lacks delicate vasculature in clear cell RCC",
                      "Electron microscopy detects intracytoplasmic lipid and glycogen, unlike in usual PRCC cells"
                    ]
                  },
                  {
                    "text": "ImmunohistochemistryAMACR(+), CK7(+), and EMA(+)",
                    "sub_points": [
                      "AMACR(+), CK7(+), and EMA(+)"
                    ]
                  },
                  {
                    "text": "Suggested to be more aggressive than sporadic PRCCPatients typically survive into 7th decade of life",
                    "sub_points": [
                      "Patients typically survive into 7th decade of life"
                    ]
                  }
                ],
                "PRCC Type 2": [
                  {
                    "text": "HPRCC with mixture of PRCC types 1 and 2 reported; association not established as in type 1"
                  },
                  {
                    "text": "Suggested that some PRCC type 1 classified before 1997 are perhaps type 2"
                  }
                ],
                "Papillary Adenoma": [
                  {
                    "text": "Small (≤ 5 mm) tumor nodule in renal parenchyma with papillary, tubular, or tubulopapillary architectures"
                  },
                  {
                    "text": "Similar cytology to PRCC type 1Distinguished from PRCC type 1 by size criteria",
                    "sub_points": [
                      "Distinguished from PRCC type 1 by size criteria"
                    ]
                  },
                  {
                    "text": "Like PRCC, multiple adenomas are present in kidney"
                  },
                  {
                    "text": "Similar genetic and immunophenotypic profiles to PRCC type 1"
                  },
                  {
                    "text": "Benign tumor with no metastatic potential"
                  }
                ],
                "Other Tumors": [
                  {
                    "text": "No known extrarenal manifestations, in contrast to most other hereditary renal cancer syndromes"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Management": [
                  {
                    "text": "Observation can be performed for smaller tumorsNo standard size cut-off for therapeutic intervention; some follows 3 cm as cut-off, similar to criterion used for VHL disease",
                    "sub_points": [
                      "No standard size cut-off for therapeutic intervention; some follows 3 cm as cut-off, similar to criterion used for VHL disease"
                    ]
                  },
                  {
                    "text": "Nephron-sparing surgery prioritized to preserve renal function"
                  },
                  {
                    "text": "Radical surgery if tumor is large or kidney is extensively involved"
                  },
                  {
                    "text": "Treatment withMETinhibitors (e.g., SK1363089 or ARQ197) in phase 2 trials shows promising results"
                  }
                ],
                "Surveillance": [
                  {
                    "text": "Lifelong clinical surveillance of affected family members should be performed"
                  },
                  {
                    "text": "Baseline radiographic examination of kidneys to detect asymptomatic tumor"
                  },
                  {
                    "text": "Regular follow-up to detect new tumor and careful monitoring for progression of smaller tumors"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Li-Fraumeni Syndrome/Li-Fraumeni-Like Syndrome": {
            "name": "Li-Fraumeni Syndrome/Li-Fraumeni-Like Syndrome",
            "url": "https://app.pathprimer.com/document/522abd5a-274e-4717-805b-1a220cc7ff15/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Li-Fraumeni Syndrome (LFS)"
                  },
                  {
                    "text": "Li-Fraumeni-Like (LFL) syndrome"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "LFSSarcoma family syndrome of Li and FraumeniSarcoma, breast, leukemia, and adrenal gland (SBLA) syndromeOnline Mendelian Inheritance in Man (OMIM) #151623",
                    "sub_points": [
                      "Sarcoma family syndrome of Li and Fraumeni",
                      "Sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome",
                      "Online Mendelian Inheritance in Man (OMIM) #151623"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "LFSConstellation of tumor types occurring in patients and kindreds0-10 years: Brain tumors, adrenal cortical carcinomas, soft tissue sarcomas, and leukemia11-20 years: Bone sarcomas> 20 years: Breast cancers and brain tumorsAutosomal dominant inheritanceClassic LFS criteriaIndividual (proband) diagnosed with sarcoma before age 451st-degree relative with any cancer before age 451st- or 2nd-degree relative with any cancer before age 45, or sarcoma at any age~ 70-80% of individuals with classic LFS criteria carry a germlineTP53mutation",
                    "sub_points": [
                      "Constellation of tumor types occurring in patients and kindreds0-10 years: Brain tumors, adrenal cortical carcinomas, soft tissue sarcomas, and leukemia11-20 years: Bone sarcomas> 20 years: Breast cancers and brain tumors",
                      "0-10 years: Brain tumors, adrenal cortical carcinomas, soft tissue sarcomas, and leukemia",
                      "11-20 years: Bone sarcomas",
                      "> 20 years: Breast cancers and brain tumors",
                      "Autosomal dominant inheritance",
                      "Classic LFS criteriaIndividual (proband) diagnosed with sarcoma before age 451st-degree relative with any cancer before age 451st- or 2nd-degree relative with any cancer before age 45, or sarcoma at any age",
                      "Individual (proband) diagnosed with sarcoma before age 45",
                      "1st-degree relative with any cancer before age 45",
                      "1st- or 2nd-degree relative with any cancer before age 45, or sarcoma at any age",
                      "~ 70-80% of individuals with classic LFS criteria carry a germlineTP53mutation"
                    ]
                  },
                  {
                    "text": "LFL syndromeBirch definition requires following 3 criteriaPatient diagnosed with any childhood cancer or sarcoma, brain tumor, or adrenal cortical carcinoma before age 451st- or 2nd-degree relative with sarcoma, leukemia, breast cancer, brain tumor, or adrenal cortical carcinoma, or leukemia at any age1st- or 2nd-degree relative with any cancer diagnosed before age 60Eeles definition2 first- or second-degree relatives with sarcoma, leukemia, breast cancer, brain tumor, or adrenal cortical carcinoma at any ageUp to 40% of individuals with LFL carry a germlineTP53mutation",
                    "sub_points": [
                      "Birch definition requires following 3 criteriaPatient diagnosed with any childhood cancer or sarcoma, brain tumor, or adrenal cortical carcinoma before age 451st- or 2nd-degree relative with sarcoma, leukemia, breast cancer, brain tumor, or adrenal cortical carcinoma, or leukemia at any age1st- or 2nd-degree relative with any cancer diagnosed before age 60",
                      "Patient diagnosed with any childhood cancer or sarcoma, brain tumor, or adrenal cortical carcinoma before age 45",
                      "1st- or 2nd-degree relative with sarcoma, leukemia, breast cancer, brain tumor, or adrenal cortical carcinoma, or leukemia at any age",
                      "1st- or 2nd-degree relative with any cancer diagnosed before age 60",
                      "Eeles definition2 first- or second-degree relatives with sarcoma, leukemia, breast cancer, brain tumor, or adrenal cortical carcinoma at any age",
                      "2 first- or second-degree relatives with sarcoma, leukemia, breast cancer, brain tumor, or adrenal cortical carcinoma at any age",
                      "Up to 40% of individuals with LFL carry a germlineTP53mutation"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Population Incidence": [
                  {
                    "text": "TP53germline mutations1/5,000 to 1/25,000 individualsA population in southeastern Brazil has 1/300 incidenceDue to specific mutationR337H(c.1010G> A,p.Arg337His)Lifetime risk of ~ 50-60% for cancerHigh incidence of childhood adrenal cortical carcinomasAlso increased risk for thyroid cancer and renal cancer; these cancers are not typical of LFS in other kindreds",
                    "sub_points": [
                      "1/5,000 to 1/25,000 individuals",
                      "A population in southeastern Brazil has 1/300 incidenceDue to specific mutationR337H(c.1010G> A,p.Arg337His)Lifetime risk of ~ 50-60% for cancerHigh incidence of childhood adrenal cortical carcinomasAlso increased risk for thyroid cancer and renal cancer; these cancers are not typical of LFS in other kindreds",
                      "Due to specific mutationR337H(c.1010G> A,p.Arg337His)",
                      "Lifetime risk of ~ 50-60% for cancer",
                      "High incidence of childhood adrenal cortical carcinomas",
                      "Also increased risk for thyroid cancer and renal cancer; these cancers are not typical of LFS in other kindreds"
                    ]
                  }
                ],
                "Incidence Among Women With Breast Carcinoma": [
                  {
                    "text": "TP53germline mutations are associated with ~ 1% of breast carcinomas in women < 40 years of age"
                  },
                  {
                    "text": "Responsible for ~ 3% of all breast cancers due to a germline mutation"
                  },
                  {
                    "text": "Somatic mutations are common in nonhereditary breast cancersMost common in triple negative/basal-like carcinomas (~ 1/3) and HER2(+) tumors (~ 1/5)",
                    "sub_points": [
                      "Most common in triple negative/basal-like carcinomas (~ 1/3) and HER2(+) tumors (~ 1/5)"
                    ]
                  }
                ],
                "Modifiers of Risk": [
                  {
                    "text": "Increased sensitivity to ionizing radiation"
                  },
                  {
                    "text": "Radiation exposure may increase risk of malignancyMore likely to develop radiation-induced secondary malignancies when treated for cancerScreening procedures should take possibly elevated risk for radiation-induced cancer into account",
                    "sub_points": [
                      "More likely to develop radiation-induced secondary malignancies when treated for cancer",
                      "Screening procedures should take possibly elevated risk for radiation-induced cancer into account"
                    ]
                  }
                ]
              },
              "Genetics": {
                "TP53Gene": [
                  {
                    "text": "Located on 17p13.120 kb, 11 coding exons, 393 amino acids",
                    "sub_points": [
                      "20 kb, 11 coding exons, 393 amino acids"
                    ]
                  },
                  {
                    "text": "Belongs to a family of growth-regulating genesConstitutively expressed in most cells",
                    "sub_points": [
                      "Constitutively expressed in most cells"
                    ]
                  },
                  {
                    "text": "Autosomal dominant inheritanceLifetime risk higher and age of onset earlier in women than in men",
                    "sub_points": [
                      "Lifetime risk higher and age of onset earlier in women than in men"
                    ]
                  },
                  {
                    "text": "Types of germlineTP53mutationsMajority of cases (~ 75%) are missense mutationsMost are within central DNA binding domain: 85% in exons 5 through 8Alter DNA binding capacity or destabilize 3-dimensional structure of proteinAltered protein can have a dominant-negative effect: Abnormal protein interferes with function of wild-type proteinUnlike other recessive germline tumor suppressor genes, 2/3 of tumors in individuals with missense mutations retain the wild-type alleleRetention likely due to lower selective pressure to lose wild-type proteinMinority of cases are null mutationsMay be due to nonsense mutations, splice mutations, deletions, or insertionsResults in nonfunctional proteinLoss of wild-type allele is necessary to alter normalP53functionActs like other recessive tumor-suppressor genes: Majority of tumors exhibit loss of the wild-type allele",
                    "sub_points": [
                      "Majority of cases (~ 75%) are missense mutationsMost are within central DNA binding domain: 85% in exons 5 through 8Alter DNA binding capacity or destabilize 3-dimensional structure of proteinAltered protein can have a dominant-negative effect: Abnormal protein interferes with function of wild-type proteinUnlike other recessive germline tumor suppressor genes, 2/3 of tumors in individuals with missense mutations retain the wild-type alleleRetention likely due to lower selective pressure to lose wild-type protein",
                      "Most are within central DNA binding domain: 85% in exons 5 through 8",
                      "Alter DNA binding capacity or destabilize 3-dimensional structure of protein",
                      "Altered protein can have a dominant-negative effect: Abnormal protein interferes with function of wild-type protein",
                      "Unlike other recessive germline tumor suppressor genes, 2/3 of tumors in individuals with missense mutations retain the wild-type allele",
                      "Retention likely due to lower selective pressure to lose wild-type protein",
                      "Minority of cases are null mutationsMay be due to nonsense mutations, splice mutations, deletions, or insertionsResults in nonfunctional proteinLoss of wild-type allele is necessary to alter normalP53functionActs like other recessive tumor-suppressor genes: Majority of tumors exhibit loss of the wild-type allele",
                      "May be due to nonsense mutations, splice mutations, deletions, or insertions",
                      "Results in nonfunctional protein",
                      "Loss of wild-type allele is necessary to alter normalP53function",
                      "Acts like other recessive tumor-suppressor genes: Majority of tumors exhibit loss of the wild-type allele"
                    ]
                  },
                  {
                    "text": "535 germline mutations in 532 families have been reportedTP53Mutation Database is maintained by the International Agency for Research on Cancer (IARC) and is updated each year",
                    "sub_points": [
                      "TP53Mutation Database is maintained by the International Agency for Research on Cancer (IARC) and is updated each year"
                    ]
                  }
                ],
                "Function of TP53 Protein": [
                  {
                    "text": "Central role in cell cycle control, DNA replication, DNA repair, and apoptosisBinds to double-stranded DNATransactivation function for promoter sequences",
                    "sub_points": [
                      "Binds to double-stranded DNA",
                      "Transactivation function for promoter sequences"
                    ]
                  },
                  {
                    "text": "Activated in response to various stress signals"
                  },
                  {
                    "text": "Loss of function is thought to suppress a mechanism of protection against accumulation of genetic alterationsCell cycle arrest allows repair of genetic damage prior to DNA replication and fixation of mutationsTerminally damaged cells undergo apoptosis",
                    "sub_points": [
                      "Cell cycle arrest allows repair of genetic damage prior to DNA replication and fixation of mutations",
                      "Terminally damaged cells undergo apoptosis"
                    ]
                  }
                ],
                "Genotype/Phenotype Correlations": [
                  {
                    "text": "Missense mutationsIndividuals have an earlier age of onset of tumors by 8 years when compared to individuals with loss of function mutations",
                    "sub_points": [
                      "Individuals have an earlier age of onset of tumors by 8 years when compared to individuals with loss of function mutations"
                    ]
                  },
                  {
                    "text": "Mutations in codons 152 and 158Higher incidence of adrenal cortical carcinomasLower penetrance",
                    "sub_points": [
                      "Higher incidence of adrenal cortical carcinomas",
                      "Lower penetrance"
                    ]
                  },
                  {
                    "text": "Missense mutations in loops opposing the DNA-binding surfaceAdrenal cortical cancer",
                    "sub_points": [
                      "Adrenal cortical cancer"
                    ]
                  },
                  {
                    "text": "Mutations outside the DNA-binding surfaceLater age onset breast cancer",
                    "sub_points": [
                      "Later age onset breast cancer"
                    ]
                  },
                  {
                    "text": "Missense mutations in DNA binding loop that contacts minor grooveBrain tumors",
                    "sub_points": [
                      "Brain tumors"
                    ]
                  },
                  {
                    "text": "MDM2 SNP309 allele or shortened telomere lengthEarlier age at onset",
                    "sub_points": [
                      "Earlier age at onset"
                    ]
                  }
                ],
                "Li-Fraumeni-Like Syndrome": [
                  {
                    "text": "Individuals who fulfill some but not all criteria for LFS"
                  },
                  {
                    "text": "~ 20-40% carry germlineTP53mutations"
                  },
                  {
                    "text": "Others due to mutations inBRCA2, Fanconi genes (BRIP1,PALB2, andRAD51C), and DNA mismatch repair genes"
                  },
                  {
                    "text": "In the past, some cases of LFL were attributed toCHEK2germline mutationsMost common tumor associated withCHEK2is early-onset breast carcinomaSome kindreds also have other tumorsFull spectrum of tumors associated with LFS is not seen",
                    "sub_points": [
                      "Most common tumor associated withCHEK2is early-onset breast carcinoma",
                      "Some kindreds also have other tumors",
                      "Full spectrum of tumors associated with LFS is not seen"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Population to be Screened": [
                  {
                    "text": "When strict criteria are met,TP53mutations are found in 60-80%"
                  },
                  {
                    "text": "If less strict criteria are used (LFL),TP53mutations are found in 15-35%"
                  }
                ],
                "Chompret Criteria for Screening": [
                  {
                    "text": "Individual (proband) must have 1 of the following tumors before age 46: Soft tissue sarcoma, osteosarcoma, premenopausal breast cancer, brain tumor, adrenal cortical carcinoma, leukemia, or lepidic pattern of lung adenocarcinoma, and at least 1 of 3 criteria listed belowAt least 1 first- or second-degree relative with an LFS tumor before age 56 or with multiple tumorsBreast cancer is not included if proband has breast cancerProband has multiple tumors (not including breast cancers), 2 of which belong to LFS tumors and 1st of which occurred before age 46Proband has adrenal cortical carcinoma or choroid plexus tumor, irrespective of family history",
                    "sub_points": [
                      "At least 1 first- or second-degree relative with an LFS tumor before age 56 or with multiple tumorsBreast cancer is not included if proband has breast cancer",
                      "Breast cancer is not included if proband has breast cancer",
                      "Proband has multiple tumors (not including breast cancers), 2 of which belong to LFS tumors and 1st of which occurred before age 46",
                      "Proband has adrenal cortical carcinoma or choroid plexus tumor, irrespective of family history"
                    ]
                  },
                  {
                    "text": "30% of individuals fulfilling these criteria have a germlineTP53mutation"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "DNA sequencing is gold standard for identifyingTP53mutations"
                  },
                  {
                    "text": "Sequence analysis of exons 2 through 11 detects ~ 95% of mutations"
                  },
                  {
                    "text": "Deletions of the gene, promoter region, or exon 1 may be present in ~ 1% of families"
                  },
                  {
                    "text": "Duplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis"
                  }
                ],
                "Immunohistochemistry for p53": [
                  {
                    "text": "TP53 protein degrades rapidly and has 20-minute half-lifeSome mutant forms of p53 cannot transcriptionally activate MDM2Loss of this negative feedback loop results in p53 accumulation",
                    "sub_points": [
                      "Some mutant forms of p53 cannot transcriptionally activate MDM2",
                      "Loss of this negative feedback loop results in p53 accumulation"
                    ]
                  },
                  {
                    "text": "Immunohistochemistry does not detect normal levels of p53 in nontumor cellsIncreased p53 protein is also not seen in normal cells of individuals with germline mutations",
                    "sub_points": [
                      "Increased p53 protein is also not seen in normal cells of individuals with germline mutations"
                    ]
                  },
                  {
                    "text": "Many antibodies to p53 are availableTarget different epitopes on the proteinMay detect only wild-type protein, mutant protein, or both",
                    "sub_points": [
                      "Target different epitopes on the protein",
                      "May detect only wild-type protein, mutant protein, or both"
                    ]
                  },
                  {
                    "text": "Increased p53 protein is only associated with ~ 2/3 of mutationsSome mutant forms of p53 have half-lives of up to 4 hoursStrong diffuse (> 10-20%) immunoreactivity is a specific, but not sensitive, test for p53 mutationsNull mutations will not be detectedThese mutations may have the greatest deleterious effect",
                    "sub_points": [
                      "Some mutant forms of p53 have half-lives of up to 4 hours",
                      "Strong diffuse (> 10-20%) immunoreactivity is a specific, but not sensitive, test for p53 mutations",
                      "Null mutations will not be detectedThese mutations may have the greatest deleterious effect",
                      "These mutations may have the greatest deleterious effect"
                    ]
                  },
                  {
                    "text": "Weak &/or focal p53 positivity may be present when mutations are absentNormal cells with DNA damageWild-type p53 bound to other proteins can result in a longer half-lifeWild-type p53 may increase in response to inflammation or senescence",
                    "sub_points": [
                      "Normal cells with DNA damage",
                      "Wild-type p53 bound to other proteins can result in a longer half-life",
                      "Wild-type p53 may increase in response to inflammation or senescence"
                    ]
                  },
                  {
                    "text": "Results of immunohistochemistry for p53 have not been reported for tumors in LFS kindreds"
                  }
                ]
              },
              "Associated Neoplasms: TP53": {
                "Any Tumor": [
                  {
                    "text": "< 20% of affected individuals develop a cancer in childhood30% of tumors occur in individuals < 15 years of age",
                    "sub_points": [
                      "30% of tumors occur in individuals < 15 years of age"
                    ]
                  },
                  {
                    "text": "> 90% of affected individuals develop some type of tumor by age 7080% are breast, sarcoma, brain, or adrenal tumors7-20% of individuals with multiple primary tumors have LFS",
                    "sub_points": [
                      "80% are breast, sarcoma, brain, or adrenal tumors",
                      "7-20% of individuals with multiple primary tumors have LFS"
                    ]
                  },
                  {
                    "text": "Risk for malignancy is 100x greater than for unaffected individuals"
                  },
                  {
                    "text": "Penetrance varies with type of mutationMutations resulting in loss of transactivation function and dominant-negative effects are more highly penetrant",
                    "sub_points": [
                      "Mutations resulting in loss of transactivation function and dominant-negative effects are more highly penetrant"
                    ]
                  },
                  {
                    "text": "Individuals with cancer have greater risk of developing 2nd cancer15% have 2 cancers, 4% have 3 cancers, 2% have 4 cancersIncreased risk if 1st cancer occurred at early ageRadiation treatment for 1st cancer may elevate riskUsually occurs 6-12 years after 1st cancer",
                    "sub_points": [
                      "15% have 2 cancers, 4% have 3 cancers, 2% have 4 cancers",
                      "Increased risk if 1st cancer occurred at early age",
                      "Radiation treatment for 1st cancer may elevate risk",
                      "Usually occurs 6-12 years after 1st cancer"
                    ]
                  }
                ],
                "Breast Cancer": [
                  {
                    "text": "Most common malignancy in LFS (~ 33% of total)"
                  },
                  {
                    "text": "Increased risk for females starts at age 20 and continues into adulthood6% of women diagnosed before age 31 have a germlineTP53mutation",
                    "sub_points": [
                      "6% of women diagnosed before age 31 have a germlineTP53mutation"
                    ]
                  },
                  {
                    "text": "~ 55% of women will develop breast cancer by age 45 (average age at diagnosis is 33)~ 100% lifetime risk for women~ 2% per year will develop subsequent contralateral breast cancerOverall, 25% will have multiple breast cancersBreast cancer in men has not been reported",
                    "sub_points": [
                      "~ 100% lifetime risk for women",
                      "~ 2% per year will develop subsequent contralateral breast cancerOverall, 25% will have multiple breast cancers",
                      "Overall, 25% will have multiple breast cancers",
                      "Breast cancer in men has not been reported"
                    ]
                  },
                  {
                    "text": "Invasive carcinoma, no special type is most common histology reportedOther histologies (lobular, mucinous, medullary) have been reportedDistribution similar to that for sporadic breast tumors",
                    "sub_points": [
                      "Other histologies (lobular, mucinous, medullary) have been reported",
                      "Distribution similar to that for sporadic breast tumors"
                    ]
                  },
                  {
                    "text": "~ 55% of invasive carcinomas are positive for hormone receptors and HER2This pattern is present in < 20% of sporadic breast carcinomasLeast common pattern is negativity for both hormone receptors and HER2 (present in ~ 5%)",
                    "sub_points": [
                      "This pattern is present in < 20% of sporadic breast carcinomas",
                      "Least common pattern is negativity for both hormone receptors and HER2 (present in ~ 5%)"
                    ]
                  },
                  {
                    "text": "Increased incidence of phyllodes tumor reported in LFS compared with general populationPhyllodes tumor may be component of LFS",
                    "sub_points": [
                      "Phyllodes tumor may be component of LFS"
                    ]
                  }
                ],
                "Soft Tissue Sarcoma": [
                  {
                    "text": "2nd most common malignancy in this syndrome (~ 20% of total)Many types: Only Ewing sarcoma has not been associated with LFS",
                    "sub_points": [
                      "Many types: Only Ewing sarcoma has not been associated with LFS"
                    ]
                  },
                  {
                    "text": "Most commonly develop in childhood (< 10 years of age)5-10% of children with sarcomas have a germlineTP53mutation",
                    "sub_points": [
                      "5-10% of children with sarcomas have a germlineTP53mutation"
                    ]
                  },
                  {
                    "text": "Rhabdomyosarcoma most common in individuals < 5 years of age9% of individuals with this sarcoma have LFS",
                    "sub_points": [
                      "9% of individuals with this sarcoma have LFS"
                    ]
                  }
                ],
                "Osteosarcoma": [
                  {
                    "text": "~ 15% of LFS tumors2-3% of persons with osteosarcoma have LFS",
                    "sub_points": [
                      "2-3% of persons with osteosarcoma have LFS"
                    ]
                  },
                  {
                    "text": "Most commonly develop during adolescence"
                  },
                  {
                    "text": "10% of individuals with an osteosarcoma diagnosed before age 20 have a germlineTP53mutation"
                  }
                ],
                "Brain Tumors": [
                  {
                    "text": "Often develop in childhood2-10% of children with brain tumors have LFS",
                    "sub_points": [
                      "2-10% of children with brain tumors have LFS"
                    ]
                  },
                  {
                    "text": "Smaller 2nd peak in incidence in 4th-5th decades"
                  },
                  {
                    "text": "Glioblastomas are most common type (13%)Also astrocytomas and medulloblastomas",
                    "sub_points": [
                      "Also astrocytomas and medulloblastomas"
                    ]
                  },
                  {
                    "text": "Choroid plexus tumors in children are characteristic"
                  }
                ],
                "Adrenal Cortical Carcinoma": [
                  {
                    "text": "80% of children with this carcinoma have LFSMedian age of onset is 3 yearsSome are due to de novo mutations",
                    "sub_points": [
                      "Median age of onset is 3 years",
                      "Some are due to de novo mutations"
                    ]
                  },
                  {
                    "text": "Cases in adults usually occur before 50 years of age"
                  }
                ],
                "Hematologic Malignancies": [
                  {
                    "text": "Include both lymphoma and leukemia"
                  }
                ],
                "Other Cancers": [
                  {
                    "text": "Lung cancer (lepidic pattern)"
                  },
                  {
                    "text": "Gastrointestinal cancers (colon, gastric, pancreatic)"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Screening": [
                  {
                    "text": "Screening recommendations vary in different countriesInternational consensus does not yet exist",
                    "sub_points": [
                      "International consensus does not yet exist"
                    ]
                  },
                  {
                    "text": "In USA, National Comprehensive Cancer Network (NCCN) has published screening guidelinesChildren and adults should have yearly comprehensive physical examinations including skin and neurological assessmentBreast cancerBreast self-exam (BSE) training and regular monthly BSE starting at age 18Clinical breast exam, starting at age 20-25 years (or 5-10 years before earliest breast cancer in family, whichever 1st), 2x per yearAnnual mammogram &/or MR when clinical breast exams startProphylactic mastectomy can be consideredMen and women should be screened for colorectal cancer every 2-5 years starting at age 25Organ targeted surveillance may be performed depending on pattern of cancers in specific families",
                    "sub_points": [
                      "Children and adults should have yearly comprehensive physical examinations including skin and neurological assessment",
                      "Breast cancerBreast self-exam (BSE) training and regular monthly BSE starting at age 18Clinical breast exam, starting at age 20-25 years (or 5-10 years before earliest breast cancer in family, whichever 1st), 2x per yearAnnual mammogram &/or MR when clinical breast exams startProphylactic mastectomy can be considered",
                      "Breast self-exam (BSE) training and regular monthly BSE starting at age 18",
                      "Clinical breast exam, starting at age 20-25 years (or 5-10 years before earliest breast cancer in family, whichever 1st), 2x per year",
                      "Annual mammogram &/or MR when clinical breast exams start",
                      "Prophylactic mastectomy can be considered",
                      "Men and women should be screened for colorectal cancer every 2-5 years starting at age 25",
                      "Organ targeted surveillance may be performed depending on pattern of cancers in specific families"
                    ]
                  }
                ],
                "Chemoprevention": [
                  {
                    "text": "Benefit of tamoxifen in patients with LFS is unclear"
                  }
                ],
                "Prophylactic Surgery": [
                  {
                    "text": "Prophylactic mastectomy reduces risk of breast cancer in females"
                  }
                ],
                "Other Interventions": [
                  {
                    "text": "Affected individuals should not use tobaccoIncreased risk of lung cancer",
                    "sub_points": [
                      "Increased risk of lung cancer"
                    ]
                  },
                  {
                    "text": "Affected individuals should avoid ionizing radiationMay increase risk of subsequent cancerBilateral mastectomy is preferable for women undergoing treatment for breast carcinoma",
                    "sub_points": [
                      "May increase risk of subsequent cancer",
                      "Bilateral mastectomy is preferable for women undergoing treatment for breast carcinoma"
                    ]
                  },
                  {
                    "text": "Prenatal screeningPreimplantation diagnosis is possible",
                    "sub_points": [
                      "Preimplantation diagnosis is possible"
                    ]
                  },
                  {
                    "text": "CounselingPsychosocial needs of children and adults with LFS and LFL, or at risk for these syndromes, are lifelong",
                    "sub_points": [
                      "Psychosocial needs of children and adults with LFS and LFL, or at risk for these syndromes, are lifelong"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lynch Syndrome": {
            "name": "Lynch Syndrome",
            "url": "https://app.pathprimer.com/document/13def6ce-8966-4691-9f2e-7341bbee42c8/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "Hereditary nonpolyposis colorectal cancer (HNPCC)"
                  }
                ]
              },
              "Epidemiology": {
                "Prevalence": [
                  {
                    "text": "Lynch syndrome is most common heritable cause of cancer"
                  },
                  {
                    "text": "~ 3% of all colorectal cancers (CRCs)"
                  }
                ]
              },
              "Genetics": {
                "Lynch Syndrome": [
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "Mutations in genes coding for mismatch repair proteins (MLH1, PMS2, MSH2, MSH6)Mutation inEPCAM(a gene immediately adjacent toMSH2) leads to epigenetic silencing ofMSH2Immunostains for MSH2 and MSH6 will be negative, implying anMSH2mutation, but sequencing will not findMSH2mutation",
                    "sub_points": [
                      "Mutation inEPCAM(a gene immediately adjacent toMSH2) leads to epigenetic silencing ofMSH2Immunostains for MSH2 and MSH6 will be negative, implying anMSH2mutation, but sequencing will not findMSH2mutation",
                      "Immunostains for MSH2 and MSH6 will be negative, implying anMSH2mutation, but sequencing will not findMSH2mutation"
                    ]
                  }
                ],
                "Constitutional Mismatch Repair-Deficiency (CMMR-D) Syndrome": [
                  {
                    "text": "Autosomal recessive (very rare)Patient inherits a mutated copy of mismatch repair gene from each parent (biallelic mutation)",
                    "sub_points": [
                      "Patient inherits a mutated copy of mismatch repair gene from each parent (biallelic mutation)"
                    ]
                  },
                  {
                    "text": "Early childhood cancers (lymphoma/leukemia plus Lynch-associated solid tumors)Café au lait spots similar to neurofibromatosis type 1",
                    "sub_points": [
                      "Café au lait spots similar to neurofibromatosis type 1"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Clinical Features": [
                  {
                    "text": "Multiple epithelial cancers occur at average age of ~ 20 years younger than expected"
                  },
                  {
                    "text": "Several guidelines have been proposed to help identify patients who should be tested for Lynch syndromeAmsterdam criteria IIAt least 3 relatives with a Lynch-associated cancer2 or more successive generations affected1 or more relatives diagnosed before age 501 should be a 1st-degree relative of the other 2Familial adenomatous polyposis must be excludedRevised Bethesda guidelinesCRC diagnosed prior to age 50Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of ageCRC with histologic features suggestive of microsatellite instability (MSI) in patients < age 60CRC diagnosed in 1 or more 1st-degree relatives with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50CRC diagnosed in 2 or more 1st-degree or 2nd-degree relatives with Lynch-associated tumors, regardless of age",
                    "sub_points": [
                      "Amsterdam criteria IIAt least 3 relatives with a Lynch-associated cancer2 or more successive generations affected1 or more relatives diagnosed before age 501 should be a 1st-degree relative of the other 2Familial adenomatous polyposis must be excluded",
                      "At least 3 relatives with a Lynch-associated cancer",
                      "2 or more successive generations affected",
                      "1 or more relatives diagnosed before age 50",
                      "1 should be a 1st-degree relative of the other 2",
                      "Familial adenomatous polyposis must be excluded",
                      "Revised Bethesda guidelinesCRC diagnosed prior to age 50Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of ageCRC with histologic features suggestive of microsatellite instability (MSI) in patients < age 60CRC diagnosed in 1 or more 1st-degree relatives with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50CRC diagnosed in 2 or more 1st-degree or 2nd-degree relatives with Lynch-associated tumors, regardless of age",
                      "CRC diagnosed prior to age 50",
                      "Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of age",
                      "CRC with histologic features suggestive of microsatellite instability (MSI) in patients < age 60",
                      "CRC diagnosed in 1 or more 1st-degree relatives with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50",
                      "CRC diagnosed in 2 or more 1st-degree or 2nd-degree relatives with Lynch-associated tumors, regardless of age"
                    ]
                  },
                  {
                    "text": "Neither of these guidelines is foolproof; hence, many studies recommend testing all CRCs for Lynch syndrome"
                  }
                ],
                "Immunohistochemistry (IHC)": [
                  {
                    "text": "Immunostains for MLH1, PMS2, MSH2, and MSH6 have become fairly routine5-10% false-negative rate, as protein may be antigenic but still not function due to mutationAdvantage of IHC over microsatellite instability (MSI-H) testing is that IHC reveals which gene is mutated",
                    "sub_points": [
                      "5-10% false-negative rate, as protein may be antigenic but still not function due to mutation",
                      "Advantage of IHC over microsatellite instability (MSI-H) testing is that IHC reveals which gene is mutated"
                    ]
                  }
                ],
                "Microsatellite Instability": [
                  {
                    "text": "Mutations in proofreading genes lead to replication errors in DNAThese replication errors can be detected in short DNA repeats called microsatellites~ 95% of all Lynch syndrome colorectal cancers have MSI-HCan be tested easily using formalin-fixed paraffin-embedded tissueNeed both normal and neoplastic tissue for comparison",
                    "sub_points": [
                      "These replication errors can be detected in short DNA repeats called microsatellites",
                      "~ 95% of all Lynch syndrome colorectal cancers have MSI-HCan be tested easily using formalin-fixed paraffin-embedded tissueNeed both normal and neoplastic tissue for comparison",
                      "Can be tested easily using formalin-fixed paraffin-embedded tissue",
                      "Need both normal and neoplastic tissue for comparison"
                    ]
                  },
                  {
                    "text": "MSI-H is also seen in 10-15% of sporadic colon cancers (not specific for Lynch syndrome)Sporadic tumors often haveBRAF V600Emutations &/or methylation ofMLH1Neither of these are present in Lynch tumors",
                    "sub_points": [
                      "Sporadic tumors often haveBRAF V600Emutations &/or methylation ofMLH1Neither of these are present in Lynch tumors",
                      "Neither of these are present in Lynch tumors"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Gastrointestinal Tract Tumors": [
                  {
                    "text": "Colorectal cancer80% lifetime riskHistologic features are often characteristicIncreased numbers of tumor-infiltrating lymphocytes and a Crohn-like reaction around edge of tumorMore likely to be well or poorly differentiatedMore likely to have mucinous differentiation and lack dirty necrosisMore often right sidedMore likely to have a circumscribed growth pattern and to exhibit histologic heterogeneity",
                    "sub_points": [
                      "80% lifetime risk",
                      "Histologic features are often characteristicIncreased numbers of tumor-infiltrating lymphocytes and a Crohn-like reaction around edge of tumorMore likely to be well or poorly differentiatedMore likely to have mucinous differentiation and lack dirty necrosisMore often right sidedMore likely to have a circumscribed growth pattern and to exhibit histologic heterogeneity",
                      "Increased numbers of tumor-infiltrating lymphocytes and a Crohn-like reaction around edge of tumor",
                      "More likely to be well or poorly differentiated",
                      "More likely to have mucinous differentiation and lack dirty necrosis",
                      "More often right sided",
                      "More likely to have a circumscribed growth pattern and to exhibit histologic heterogeneity"
                    ]
                  },
                  {
                    "text": "Adenocarcinoma of stomach, small bowel, appendix, ampulla, and biliary treeMay share some of histologic features listed above for colon cancers",
                    "sub_points": [
                      "May share some of histologic features listed above for colon cancers"
                    ]
                  }
                ],
                "Nongastrointestinal Tract Tumors": [
                  {
                    "text": "Endometrium40-60% lifetime riskEndometrioid carcinomas with mucinous differentiation, histologic heterogeneity, dedifferentiation, and increased host response",
                    "sub_points": [
                      "40-60% lifetime risk",
                      "Endometrioid carcinomas with mucinous differentiation, histologic heterogeneity, dedifferentiation, and increased host response"
                    ]
                  },
                  {
                    "text": "Ovaries4-12% lifetime riskClear cell and endometrioid carcinomas",
                    "sub_points": [
                      "4-12% lifetime risk",
                      "Clear cell and endometrioid carcinomas"
                    ]
                  },
                  {
                    "text": "AdrenalAs many as 5% of adrenal cortical carcinomas may be associated with Lynch syndrome",
                    "sub_points": [
                      "As many as 5% of adrenal cortical carcinomas may be associated with Lynch syndrome"
                    ]
                  },
                  {
                    "text": "ProstateLynch patients have 2x the risk of prostate cancer as general population",
                    "sub_points": [
                      "Lynch patients have 2x the risk of prostate cancer as general population"
                    ]
                  },
                  {
                    "text": "Kidney, ureters, bladderUrothelial carcinomasMSH2mutations may selectively increase risk of bladder cancers compared to other mismatch repair gene mutations",
                    "sub_points": [
                      "Urothelial carcinomasMSH2mutations may selectively increase risk of bladder cancers compared to other mismatch repair gene mutations",
                      "MSH2mutations may selectively increase risk of bladder cancers compared to other mismatch repair gene mutations"
                    ]
                  },
                  {
                    "text": "SkinSebaceous neoplasms and multiple keratoacanthomas = Muir-Torre syndromeCafé au lait spots in CMMR-D syndrome",
                    "sub_points": [
                      "Sebaceous neoplasms and multiple keratoacanthomas = Muir-Torre syndrome",
                      "Café au lait spots in CMMR-D syndrome"
                    ]
                  },
                  {
                    "text": "BrainGlioblastoma in Turcot syndrome variant of Lynch syndrome",
                    "sub_points": [
                      "Glioblastoma in Turcot syndrome variant of Lynch syndrome"
                    ]
                  },
                  {
                    "text": "Leukemia/lymphomaOccurs in patients with CMMR-D",
                    "sub_points": [
                      "Occurs in patients with CMMR-D"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Surveillance Endoscopy": [
                  {
                    "text": "Every 1-2 years starting between ages 20 and 25"
                  }
                ],
                "Surgery": [
                  {
                    "text": "Prophylactic colectomy is an option, but most patients opt for colonoscopic surveillance"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Multiple Endocrine Neoplasia Type 1": {
            "name": "Multiple Endocrine Neoplasia Type 1",
            "url": "https://app.pathprimer.com/document/6f938ebd-453e-4983-96ca-eee6333d76f6/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Multiple endocrine neoplasia type 1 (MEN1)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Wermer syndrome"
                  },
                  {
                    "text": "Multiple endocrine adenomatosis type 1"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Rare autosomal dominant disease resulting in proliferative lesions of multiple endocrine organs involving mainly parathyroid, endocrine pancreas/duodenum, and pituitary glands"
                  }
                ]
              },
              "Epidemiology": {
                "Etiology": [
                  {
                    "text": "Caused by mutations inMEN1gene"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "MEN1gene is a 10 exon gene that encodes 610-amino acid protein menin"
                  },
                  {
                    "text": "Function is unknown; may act as regulator of gene transcription, cell proliferation, apoptosis, and genome stability"
                  }
                ],
                "Incidence": [
                  {
                    "text": "1:20,000-50,000"
                  }
                ],
                "Age": [
                  {
                    "text": "Penetrance increases with age"
                  }
                ],
                "Gender": [
                  {
                    "text": "1:1 sex distribution"
                  }
                ]
              },
              "Genetics": {
                "MEN1Gene": [
                  {
                    "text": "Located on chromosome 11q13"
                  },
                  {
                    "text": "Consists of 10 exons and encodes menin"
                  }
                ],
                "Mutation Spectrum": [
                  {
                    "text": "> 1,300 different mutations ofMEN1gene have been characterized"
                  },
                  {
                    "text": "Penetrance ofMEN1mutations is high: 45% by age 30, 82% by age 50, 96% by age 70"
                  },
                  {
                    "text": "Spread over entire coding and intronic sequence> 60% truncating mutation, 20% missense mutation, 10% in frame deletions or insertions, 10% others",
                    "sub_points": [
                      "> 60% truncating mutation, 20% missense mutation, 10% in frame deletions or insertions, 10% others"
                    ]
                  },
                  {
                    "text": "Most are inactivating mutations, consistent with those expected in tumor suppressor genePrecise role of menin in tumor suppression remains elusive",
                    "sub_points": [
                      "Precise role of menin in tumor suppression remains elusive"
                    ]
                  },
                  {
                    "text": "Clinical recommendation cannot be based on genotypeTruncating mutations: Increased risk of pancreatic endocrine tumorFrameshift mutations in exon 2: Increased incidence of pituitary tumor",
                    "sub_points": [
                      "Truncating mutations: Increased risk of pancreatic endocrine tumor",
                      "Frameshift mutations in exon 2: Increased incidence of pituitary tumor"
                    ]
                  },
                  {
                    "text": "5-25% of patients with MEN1 may not harbor germline mutation inMEN1gene-coding regionWhole or partial deletions or mutations in promoter region",
                    "sub_points": [
                      "Whole or partial deletions or mutations in promoter region"
                    ]
                  }
                ],
                "Testing": [
                  {
                    "text": "MEN1mutational analysis should be undertaken inIndex case with 2 or more MEN1-associated endocrine tumorsAsymptomatic 1st-degree relative1st-degree relative ofMEN1mutation carrierPatients with suspicious or atypical MEN1",
                    "sub_points": [
                      "Index case with 2 or more MEN1-associated endocrine tumors",
                      "Asymptomatic 1st-degree relative",
                      "1st-degree relative ofMEN1mutation carrier",
                      "Patients with suspicious or atypical MEN1"
                    ]
                  },
                  {
                    "text": "Genetic counseling useful for individuals and families with nonclassic MEN1 presentations"
                  },
                  {
                    "text": "Testing should be undertaken as soon as possible, even before the age of 5"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Presentation": [
                  {
                    "text": "Hyperparathyroidism(HPT)Present in > 90% of MEN1 patientsOccurs at younger ages (19 years)  than sporadic counterpart (50 years)Percentage of patients who develop biochemical evidence of hyperparathyroidism increases with age43% and 94% at age 20 and 50 years, respectivelyMost are asymptomatic, severe cases with \"moans, groans, bones, and stones\"  as hallmarks of hypercalcemiaMultiglandular disorderHigh recurrence rate",
                    "sub_points": [
                      "Present in > 90% of MEN1 patientsOccurs at younger ages (19 years)  than sporadic counterpart (50 years)",
                      "Occurs at younger ages (19 years)  than sporadic counterpart (50 years)",
                      "Percentage of patients who develop biochemical evidence of hyperparathyroidism increases with age43% and 94% at age 20 and 50 years, respectively",
                      "43% and 94% at age 20 and 50 years, respectively",
                      "Most are asymptomatic, severe cases with \"moans, groans, bones, and stones\"  as hallmarks of hypercalcemia",
                      "Multiglandular disorder",
                      "High recurrence rate"
                    ]
                  },
                  {
                    "text": "Pituitary tumorsFound in 10-60% of MEN1 patients; mean age 38Initial clinical manifestation of MEN1 in 10% and 20% of familial and sporadic cases, respectivelyMEN1 pituitary adenomas tend to be larger and more aggressive than sporadic counterpartsProlactinomas (PRL) (60%), growth hormone (GH) secreting adenoma (10%), adrenocorticotrophin (ACTH) secreting (5%), and nonsecreting adenomas (15%)Women with PRL adenoma: Major clinical signs are amenorrhea, infertility, galactorrheaMen with PRL adenoma: HypogonadismGH adenoma: AcromegalyACTH-secreting adenoma: Cushing disease",
                    "sub_points": [
                      "Found in 10-60% of MEN1 patients; mean age 38",
                      "Initial clinical manifestation of MEN1 in 10% and 20% of familial and sporadic cases, respectively",
                      "MEN1 pituitary adenomas tend to be larger and more aggressive than sporadic counterparts",
                      "Prolactinomas (PRL) (60%), growth hormone (GH) secreting adenoma (10%), adrenocorticotrophin (ACTH) secreting (5%), and nonsecreting adenomas (15%)Women with PRL adenoma: Major clinical signs are amenorrhea, infertility, galactorrheaMen with PRL adenoma: HypogonadismGH adenoma: AcromegalyACTH-secreting adenoma: Cushing disease",
                      "Women with PRL adenoma: Major clinical signs are amenorrhea, infertility, galactorrhea",
                      "Men with PRL adenoma: Hypogonadism",
                      "GH adenoma: Acromegaly",
                      "ACTH-secreting adenoma: Cushing disease"
                    ]
                  },
                  {
                    "text": "Endocrine pancreatic/duodenal tumorsFamilial Zollinger-Ellison syndrome (ZES)Most frequent clinical manifestation related to duodenal &/or pancreatic gastrinoma observed in MEN1 patientsInitial symptoms, such as abdominal pain or gastroesophageal reflux disease, caused by gastric acid hypersecretionSevere complications include bleeding, perforation, and esophageal stricturesIn 90% of MEN1 patients with ZES, lesions are often multiple, small, and located in duodenumInsulinomas2nd most frequent pancreatic tumor in setting of MEN1HypoglycemiaGlucagonoma, VIPoma, and other pancreatic endocrine tumorsOccur in < 5% of MEN1 patients~ 80% of glucagonomas and 40% of VIPomas are malignantGlucagonomas induce necrolytic migratory erythema associated with diabetes mellitus, which is secondary to abnormal glucagon secretionVIPomas induce classical Verner-Morrison syndrome associated with watery diarrhea, hypokalemia, and achlorhydriaNonfunctioning pancreatic endocrine tumors20-40% of MEN1 patientsWhen misdiagnosed, often discovered after local compression &/or hepatic metastases",
                    "sub_points": [
                      "Familial Zollinger-Ellison syndrome (ZES)Most frequent clinical manifestation related to duodenal &/or pancreatic gastrinoma observed in MEN1 patientsInitial symptoms, such as abdominal pain or gastroesophageal reflux disease, caused by gastric acid hypersecretionSevere complications include bleeding, perforation, and esophageal stricturesIn 90% of MEN1 patients with ZES, lesions are often multiple, small, and located in duodenum",
                      "Most frequent clinical manifestation related to duodenal &/or pancreatic gastrinoma observed in MEN1 patients",
                      "Initial symptoms, such as abdominal pain or gastroesophageal reflux disease, caused by gastric acid hypersecretion",
                      "Severe complications include bleeding, perforation, and esophageal strictures",
                      "In 90% of MEN1 patients with ZES, lesions are often multiple, small, and located in duodenum",
                      "Insulinomas2nd most frequent pancreatic tumor in setting of MEN1Hypoglycemia",
                      "2nd most frequent pancreatic tumor in setting of MEN1",
                      "Hypoglycemia",
                      "Glucagonoma, VIPoma, and other pancreatic endocrine tumorsOccur in < 5% of MEN1 patients~ 80% of glucagonomas and 40% of VIPomas are malignantGlucagonomas induce necrolytic migratory erythema associated with diabetes mellitus, which is secondary to abnormal glucagon secretionVIPomas induce classical Verner-Morrison syndrome associated with watery diarrhea, hypokalemia, and achlorhydria",
                      "Occur in < 5% of MEN1 patients",
                      "~ 80% of glucagonomas and 40% of VIPomas are malignant",
                      "Glucagonomas induce necrolytic migratory erythema associated with diabetes mellitus, which is secondary to abnormal glucagon secretion",
                      "VIPomas induce classical Verner-Morrison syndrome associated with watery diarrhea, hypokalemia, and achlorhydria",
                      "Nonfunctioning pancreatic endocrine tumors20-40% of MEN1 patientsWhen misdiagnosed, often discovered after local compression &/or hepatic metastases",
                      "20-40% of MEN1 patients",
                      "When misdiagnosed, often discovered after local compression &/or hepatic metastases"
                    ]
                  },
                  {
                    "text": "OthersAdrenal cortical lesionsObserved in 20-40% of MEN1 patientsOften detected about 7 years after diagnosis of MEN1Most are adenomas and may produce aldosterone and cortisolOften small, benign, and nonfunctionalSurgery for lesions < 3 cmGastric ECLomasThought to originate from proliferation of enterochromaffin-like (ECL) cells in gastric mucosaOften small and multipleCan be treated with endoscopic polypectomy if lesion is < 1 cmGood prognosisThymic and bronchial neuroendocrine tumorObserved in 5-10% of MEN1 patientsThymic carcinoids are predominantly in malesPoor prognosis with local invasion, recurrence, and distant metastasisCutaneous proliferationsPresent in 40-80% of MEN1 patientsNodular lipomas (30%)Collagenomas (5%)Angiofibromas are multiple and often on face (75%)Soft tissue tumorsEsophageal leiomyomaRenal angiomyolipomaMalignant gastrointestinal stromal tumorsCentral nervous system tumorsSpinal ependymomas, meningioma, and astrocytoma have been described in MEN1 cases",
                    "sub_points": [
                      "Adrenal cortical lesionsObserved in 20-40% of MEN1 patientsOften detected about 7 years after diagnosis of MEN1Most are adenomas and may produce aldosterone and cortisolOften small, benign, and nonfunctionalSurgery for lesions < 3 cm",
                      "Observed in 20-40% of MEN1 patients",
                      "Often detected about 7 years after diagnosis of MEN1",
                      "Most are adenomas and may produce aldosterone and cortisol",
                      "Often small, benign, and nonfunctional",
                      "Surgery for lesions < 3 cm",
                      "Gastric ECLomasThought to originate from proliferation of enterochromaffin-like (ECL) cells in gastric mucosaOften small and multipleCan be treated with endoscopic polypectomy if lesion is < 1 cmGood prognosis",
                      "Thought to originate from proliferation of enterochromaffin-like (ECL) cells in gastric mucosa",
                      "Often small and multiple",
                      "Can be treated with endoscopic polypectomy if lesion is < 1 cm",
                      "Good prognosis",
                      "Thymic and bronchial neuroendocrine tumorObserved in 5-10% of MEN1 patientsThymic carcinoids are predominantly in malesPoor prognosis with local invasion, recurrence, and distant metastasis",
                      "Observed in 5-10% of MEN1 patients",
                      "Thymic carcinoids are predominantly in males",
                      "Poor prognosis with local invasion, recurrence, and distant metastasis",
                      "Cutaneous proliferationsPresent in 40-80% of MEN1 patientsNodular lipomas (30%)Collagenomas (5%)Angiofibromas are multiple and often on face (75%)",
                      "Present in 40-80% of MEN1 patients",
                      "Nodular lipomas (30%)",
                      "Collagenomas (5%)",
                      "Angiofibromas are multiple and often on face (75%)",
                      "Soft tissue tumorsEsophageal leiomyomaRenal angiomyolipomaMalignant gastrointestinal stromal tumors",
                      "Esophageal leiomyoma",
                      "Renal angiomyolipoma",
                      "Malignant gastrointestinal stromal tumors",
                      "Central nervous system tumorsSpinal ependymomas, meningioma, and astrocytoma have been described in MEN1 cases",
                      "Spinal ependymomas, meningioma, and astrocytoma have been described in MEN1 cases"
                    ]
                  }
                ]
              },
              "Clinical Diagnosis": {
                "Basis for MEN1 Diagnosis": [
                  {
                    "text": "Diagnosis of MEN1 may be established by 1 of 3 criteria"
                  },
                  {
                    "text": "ClinicalOccurrence of 2 or more primary MEN1-associated endocrine tumors: Parathyroid adenoma, enteropancreatic tumor, and pituitary adenoma",
                    "sub_points": [
                      "Occurrence of 2 or more primary MEN1-associated endocrine tumors: Parathyroid adenoma, enteropancreatic tumor, and pituitary adenoma"
                    ]
                  },
                  {
                    "text": "FamilialOccurrence of 1 MEN1-associated tumor in 1st-degree relative of patient with clinical diagnosis of MEN1",
                    "sub_points": [
                      "Occurrence of 1 MEN1-associated tumor in 1st-degree relative of patient with clinical diagnosis of MEN1"
                    ]
                  },
                  {
                    "text": "GeneticIdentification of germlineMEN1mutation in an individual who may be asymptomatic and has not yet developed serum biochemical or radiological abnormalities is indicative of tumor development",
                    "sub_points": [
                      "Identification of germlineMEN1mutation in an individual who may be asymptomatic and has not yet developed serum biochemical or radiological abnormalities is indicative of tumor development"
                    ]
                  }
                ],
                "Diagnostic Criteria": [
                  {
                    "text": "Presence of ≥ 2 of the followingPrimary hyperparathyroidism with multiglandular hyperplasia &/or adenoma or recurrent primary hyperparathyroidismDuodenal &/or pancreatic endocrine tumors, gastric enterochromaffin-like tumorsBoth functioning and nonfunctioning or multisecreting tumorAnterior pituitary adenomaFunctioning (GH-secreting tumor, prolactinoma)Nonfunctioning or multisecretingAdrenal cortical tumorBoth functioning and nonfunctioningThymic &/or bronchial endocrine tumors (foregut carcinoids)1st-degree relative with MEN1",
                    "sub_points": [
                      "Primary hyperparathyroidism with multiglandular hyperplasia &/or adenoma or recurrent primary hyperparathyroidism",
                      "Duodenal &/or pancreatic endocrine tumors, gastric enterochromaffin-like tumorsBoth functioning and nonfunctioning or multisecreting tumor",
                      "Both functioning and nonfunctioning or multisecreting tumor",
                      "Anterior pituitary adenomaFunctioning (GH-secreting tumor, prolactinoma)Nonfunctioning or multisecreting",
                      "Functioning (GH-secreting tumor, prolactinoma)",
                      "Nonfunctioning or multisecreting",
                      "Adrenal cortical tumorBoth functioning and nonfunctioning",
                      "Both functioning and nonfunctioning",
                      "Thymic &/or bronchial endocrine tumors (foregut carcinoids)",
                      "1st-degree relative with MEN1"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Pituitary adenoma can express 1 or several hormonesProlactin, ACTH, HGH, LH, FSH, TSH",
                    "sub_points": [
                      "Prolactin, ACTH, HGH, LH, FSH, TSH"
                    ]
                  },
                  {
                    "text": "Pancreatic endocrine tumor can express 1 or several hormonesInsulin, gastrin, glucagon, pancreatic polypeptide, VIP, somatostatin, or serotonin",
                    "sub_points": [
                      "Insulin, gastrin, glucagon, pancreatic polypeptide, VIP, somatostatin, or serotonin"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Screening": [
                  {
                    "text": "Optimal screening age, test, and frequencies not established, but recommend starting annual biochemical test by 5 yearsFor known carriers ofMEN1mutationsGlucose, insulin, prolactin, and IGF-1 levels",
                    "sub_points": [
                      "For known carriers ofMEN1mutationsGlucose, insulin, prolactin, and IGF-1 levels",
                      "Glucose, insulin, prolactin, and IGF-1 levels"
                    ]
                  },
                  {
                    "text": "Finding of MEN1 in a patient has important implications for family members1st-degree relatives have 50% risk of developing disease and can often be identified byMEN1mutational analysis",
                    "sub_points": [
                      "1st-degree relatives have 50% risk of developing disease and can often be identified byMEN1mutational analysis"
                    ]
                  },
                  {
                    "text": "Serologic testsStarting at age 8: PTH and calcium levelsStarting at age 20: Fasting serum gastrin, pancreatic polypeptide, VIP, and glucagonRecommended serologic testsSerum Ca, PTH: HyperparathyroidismPRL, GH, ACTH, others: Pituitary adenomaGastrin, insulin, glucagon, pancreatic polypeptide, and serum chromogranin-A: GI neuroendocrine tumorsOther markers: 5-HIAA, calcitonin",
                    "sub_points": [
                      "Starting at age 8: PTH and calcium levels",
                      "Starting at age 20: Fasting serum gastrin, pancreatic polypeptide, VIP, and glucagon",
                      "Recommended serologic testsSerum Ca, PTH: HyperparathyroidismPRL, GH, ACTH, others: Pituitary adenomaGastrin, insulin, glucagon, pancreatic polypeptide, and serum chromogranin-A: GI neuroendocrine tumorsOther markers: 5-HIAA, calcitonin",
                      "Serum Ca, PTH: Hyperparathyroidism",
                      "PRL, GH, ACTH, others: Pituitary adenoma",
                      "Gastrin, insulin, glucagon, pancreatic polypeptide, and serum chromogranin-A: GI neuroendocrine tumors",
                      "Other markers: 5-HIAA, calcitonin"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Pituitary adenomaMedical and surgical treatment for prolactin or GH-producing tumors",
                    "sub_points": [
                      "Medical and surgical treatment for prolactin or GH-producing tumors"
                    ]
                  },
                  {
                    "text": "Endocrine pancreatic/duodenal tumorsSurgery in most cases",
                    "sub_points": [
                      "Surgery in most cases"
                    ]
                  },
                  {
                    "text": "HyperparathyroidismTotal parathyroidectomy with autotransplantation or subtotal resection",
                    "sub_points": [
                      "Total parathyroidectomy with autotransplantation or subtotal resection"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "MEN1 patients have decreased life expectancy, and outcomes of current treatments are not as successful  due toMultiple tumorsTumors may be larger, more aggressive, and resistant to treatmentConcurrence of metastases",
                    "sub_points": [
                      "Multiple tumorsTumors may be larger, more aggressive, and resistant to treatment",
                      "Tumors may be larger, more aggressive, and resistant to treatment",
                      "Concurrence of metastases"
                    ]
                  },
                  {
                    "text": "Same prognosis for pituitary adenoma in MEN1 as in sporadic counterparts"
                  },
                  {
                    "text": "Malignancy of duodenal and pancreatic endocrine tumorsGastrinomas > 40%, glucagonoma > 80%, VIPoma > 40%, nonfunctioning tumor > 70%",
                    "sub_points": [
                      "Gastrinomas > 40%, glucagonoma > 80%, VIPoma > 40%, nonfunctioning tumor > 70%"
                    ]
                  },
                  {
                    "text": "Prognosis for MEN1 patients might be improved by presymptomatic tumor detection"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Multiple Endocrine Neoplasia Type 2/Familial Medullary Thyroid Carcinoma": {
            "name": "Multiple Endocrine Neoplasia Type 2/Familial Medullary Thyroid Carcinoma",
            "url": "https://app.pathprimer.com/document/4c513558-bcea-4b1d-8f94-ae1eaa128c0d/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Multiple endocrine neoplasia type 2 (MEN2)Multiple endocrine neoplasia type 2A (MEN2A)Multiple endocrine neoplasia type 2B (MEN2B)",
                    "sub_points": [
                      "Multiple endocrine neoplasia type 2A (MEN2A)",
                      "Multiple endocrine neoplasia type 2B (MEN2B)"
                    ]
                  },
                  {
                    "text": "Familial medullary thyroid carcinoma (FMTC)"
                  }
                ]
              },
              "Epidemiology": {
                "Incidence": [
                  {
                    "text": "MEN2Overall incidence is 1 in 30,000 live birthsHereditary medullary thyroid carcinoma (MTC) accounts for 25% of all MTC",
                    "sub_points": [
                      "Overall incidence is 1 in 30,000 live birthsHereditary medullary thyroid carcinoma (MTC) accounts for 25% of all MTC",
                      "Hereditary medullary thyroid carcinoma (MTC) accounts for 25% of all MTC"
                    ]
                  },
                  {
                    "text": "MEN2AUnknown; estimated 1.25-7.5 per 10 million per yearPrevalence is 1 per 35,000",
                    "sub_points": [
                      "Unknown; estimated 1.25-7.5 per 10 million per year",
                      "Prevalence is 1 per 35,000"
                    ]
                  },
                  {
                    "text": "MEN2BComprises about 5% of cases of MEN2",
                    "sub_points": [
                      "Comprises about 5% of cases of MEN2"
                    ]
                  },
                  {
                    "text": "FMTCComprises about 10-20% of cases with MEN2",
                    "sub_points": [
                      "Comprises about 10-20% of cases with MEN2"
                    ]
                  },
                  {
                    "text": "Overall incidence of MTC in patients with familial disease is 25%This group represents ~ 5% of all thyroid tumors and ~ 15% of all thyroid cancer-related deaths",
                    "sub_points": [
                      "This group represents ~ 5% of all thyroid tumors and ~ 15% of all thyroid cancer-related deaths"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "MEN2AIn late adolescence or early adulthoodPeak incidence of medullary carcinoma in these patients is in 4th decade",
                    "sub_points": [
                      "In late adolescence or early adulthood",
                      "Peak incidence of medullary carcinoma in these patients is in 4th decade"
                    ]
                  },
                  {
                    "text": "MEN2BPatients usually develop medullary carcinoma early in life, diagnosed in infancy or early childhood",
                    "sub_points": [
                      "Patients usually develop medullary carcinoma early in life, diagnosed in infancy or early childhood"
                    ]
                  },
                  {
                    "text": "FMTCInherited medullary carcinoma without associated endocrinopathiesSimilar to other types of thyroid cancers, peak incidence is between age 40 and 50 years",
                    "sub_points": [
                      "Inherited medullary carcinoma without associated endocrinopathiesSimilar to other types of thyroid cancers, peak incidence is between age 40 and 50 years",
                      "Similar to other types of thyroid cancers, peak incidence is between age 40 and 50 years"
                    ]
                  }
                ],
                "Gender": [
                  {
                    "text": "MEN2F:M = 1:1",
                    "sub_points": [
                      "F:M = 1:1"
                    ]
                  }
                ]
              },
              "Genetics": {
                "RETProto-Oncogene": [
                  {
                    "text": "Maps to chromosome 10q11.2 and encodes a receptor tyrosine kinase called \"rearranged during transfection\"Tyrosine kinase plays integral role in transducing signals for growth and differentiation in tissues derived from neural crest",
                    "sub_points": [
                      "Tyrosine kinase plays integral role in transducing signals for growth and differentiation in tissues derived from neural crest"
                    ]
                  },
                  {
                    "text": "MEN2A:RETmutation in > 98% of cases"
                  },
                  {
                    "text": "MEN2B:RETmutation in 100% of cases"
                  },
                  {
                    "text": "FMTC:RETmutation in > 85% of cases"
                  },
                  {
                    "text": "MEN2 is caused by gain-of-function mutations that produce constitutively active protein or ↓ substrate specificity"
                  },
                  {
                    "text": "In contrast, loss-of-function mutations are associated with a subset of Hirschsprung disease (HSCR)"
                  },
                  {
                    "text": "Pathologic allelic variants: Major disease-causing mutations are nonconservative gain-of-function substitutions located in 1 of 6 cysteine codons in extracellular domain of encoded proteinInclude codons 609, 611, 618, and 620 in exon 10 and codons 630 and 634 in exon 11All of these variants have been identified in families with MEN2A, and some have been identified in families with FMTCMutations in these sites have been detected in 98% of families with MEN2A~ 95% of all individuals with MEN2B have single-point mutation at codon 918 in exon 162nd point mutation at codon 883 in exon 15 has been found in 3-5% of individuals with MEN2B",
                    "sub_points": [
                      "Include codons 609, 611, 618, and 620 in exon 10 and codons 630 and 634 in exon 11",
                      "All of these variants have been identified in families with MEN2A, and some have been identified in families with FMTCMutations in these sites have been detected in 98% of families with MEN2A",
                      "Mutations in these sites have been detected in 98% of families with MEN2A",
                      "~ 95% of all individuals with MEN2B have single-point mutation at codon 918 in exon 16",
                      "2nd point mutation at codon 883 in exon 15 has been found in 3-5% of individuals with MEN2B"
                    ]
                  },
                  {
                    "text": "For families in which MEN2A and HSCR cosegregate, models to explain how same mutation can cause gain of function and loss of function have been proposed"
                  }
                ],
                "Genotype-Phenotype Correlations": [
                  {
                    "text": "1st clear genotype-phenotype associations to be found in inherited neoplasia syndromes:RETgenotype- and MEN2-phenotype correlations"
                  },
                  {
                    "text": "Most striking observation: Gain-of-function mutations affected several hotspot codons, with great majority mutating cysteine residues in exons 10 and 11"
                  },
                  {
                    "text": "Notably, mutations of codon 634 in exon 11 are highly associated with full-blown phenotype of MEN2A, i.e., with high prevalence of pheochromocytoma and hyperparathyroidismAssociated fulminant course with p.C634R, which is associated with higher probability of having metastases at diagnosis of MTC than other codon 634 mutationsAlthough 25% of FMTC kindreds harbor a mutation in codon 634 (most commonly p.C634Y), p.C634R mutations are virtually absent in this subtypeCodon 634 mutations are also associated with development of cutaneous lichen amyloidosis (36%)",
                    "sub_points": [
                      "Associated fulminant course with p.C634R, which is associated with higher probability of having metastases at diagnosis of MTC than other codon 634 mutations",
                      "Although 25% of FMTC kindreds harbor a mutation in codon 634 (most commonly p.C634Y), p.C634R mutations are virtually absent in this subtype",
                      "Codon 634 mutations are also associated with development of cutaneous lichen amyloidosis (36%)"
                    ]
                  },
                  {
                    "text": "RETgermline p.M918T mutations are associated only with MEN2BSomatic mutations at this codon are frequently observed in MTC in individuals with no known family history of MTCOverrepresented in individuals with sporadic MTC who have particular germlineRETvariant, c.2439C/T",
                    "sub_points": [
                      "Somatic mutations at this codon are frequently observed in MTC in individuals with no known family history of MTCOverrepresented in individuals with sporadic MTC who have particular germlineRETvariant, c.2439C/T",
                      "Overrepresented in individuals with sporadic MTC who have particular germlineRETvariant, c.2439C/T"
                    ]
                  },
                  {
                    "text": "Genotype-phenotype correlations suggest that exon 10 codon mutations, in particular at codons 609 and 611, have incidence of MTC in 77%, pheochromocytoma in 17%, and HPT in 3%"
                  },
                  {
                    "text": "Mutations involving cysteine codons 609, 618, and 620 in exon 10 ofRETare associated with MEN2A or FMTC cosegregating with HSCR"
                  },
                  {
                    "text": "Mutations at codons 768, 804, and 891 are associated with FMTC and in rare families with MEN2A"
                  },
                  {
                    "text": "Mutations in codons 790 or 804 may be associated with papillary thyroid carcinoma (PTC) as well as MTC40% of family members with p.V804M mutation had concomitant medullary and PTC",
                    "sub_points": [
                      "40% of family members with p.V804M mutation had concomitant medullary and PTC"
                    ]
                  },
                  {
                    "text": "American Thyroid Association Guidelines Task Force has classified mutations based on risk for aggressive MTCMay be used in predicting phenotype and recommendations for age at which to perform prophylactic thyroidectomy and to begin biochemical screening for pheochromocytoma and hyperparathyroidism",
                    "sub_points": [
                      "May be used in predicting phenotype and recommendations for age at which to perform prophylactic thyroidectomy and to begin biochemical screening for pheochromocytoma and hyperparathyroidism"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Presentation": [
                  {
                    "text": "MEN2A, FMTC, and MEN2B can all be diagnosed based on clinical features"
                  },
                  {
                    "text": "With advances ofRETtesting, genotype-specific risks, and management, molecular genetic testing is virtually mandatoryMost often used to distinguish sporadic from hereditary MTC",
                    "sub_points": [
                      "Most often used to distinguish sporadic from hereditary MTC"
                    ]
                  },
                  {
                    "text": "MEN2ADiagnosed clinically by occurrence of ≥ 2 specific endocrine tumors (MTC, pheochromocytoma, or parathyroid adenoma/hyperplasia) in single individual or in close relativesMakes up ~ 70-80% of cases of MEN2~ 100% of individuals with MEN2A develop MTC10-60% develop pheochromocytoma and 10-30% develop hyperparathyroidism",
                    "sub_points": [
                      "Diagnosed clinically by occurrence of ≥ 2 specific endocrine tumors (MTC, pheochromocytoma, or parathyroid adenoma/hyperplasia) in single individual or in close relatives",
                      "Makes up ~ 70-80% of cases of MEN2",
                      "~ 100% of individuals with MEN2A develop MTC",
                      "10-60% develop pheochromocytoma and 10-30% develop hyperparathyroidism"
                    ]
                  },
                  {
                    "text": "MEN2BDiagnosed clinically by presence of mucosal neuromas of lips and tongue, as well as medullated corneal nerve fibers, distinctive facies with enlarged lips, asthenic \"Marfanoid\" body habitus, and MTCComprises ~ 5% of cases of MEN2Characterized by early development of aggressive form of MTC associated with C-cell hyperplasia (CCH)50% develop pheochromocytoma60-90% have ganglioneuromatosisPresence of mucosal neuromas is identified early in life~ 100% have asthenic \"Marfanoid\" body habitus",
                    "sub_points": [
                      "Diagnosed clinically by presence of mucosal neuromas of lips and tongue, as well as medullated corneal nerve fibers, distinctive facies with enlarged lips, asthenic \"Marfanoid\" body habitus, and MTC",
                      "Comprises ~ 5% of cases of MEN2",
                      "Characterized by early development of aggressive form of MTC associated with C-cell hyperplasia (CCH)",
                      "50% develop pheochromocytoma",
                      "60-90% have ganglioneuromatosis",
                      "Presence of mucosal neuromas is identified early in life",
                      "~ 100% have asthenic \"Marfanoid\" body habitus"
                    ]
                  },
                  {
                    "text": "FMTCHistorically, operationally diagnosed in families with ≥ 4 cases of MTC in absence of pheochromocytoma or parathyroid adenoma/hyperplasiaBecauseRETmutation accounts for all clinical subtypes of MEN2, FMTC may be viewed as MEN2A with reduced organ-specific penetranceComprises 10-20% of cases of MEN2MTC is the only clinical manifestation of FMTC",
                    "sub_points": [
                      "Historically, operationally diagnosed in families with ≥ 4 cases of MTC in absence of pheochromocytoma or parathyroid adenoma/hyperplasia",
                      "BecauseRETmutation accounts for all clinical subtypes of MEN2, FMTC may be viewed as MEN2A with reduced organ-specific penetrance",
                      "Comprises 10-20% of cases of MEN2",
                      "MTC is the only clinical manifestation of FMTC"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "MTC: In provocative testing, plasma calcitonin concentration is measured before (basal levels) as well as 2 and 5 minutes after intravenous administration of calcium (stimulated level)Other calcitonin secretagogues, e.g., pentagastrin, are also usedReference levels for basal calcitonin vary across laboratories: < 10 pg/mL for adult males and < 5 pg/mL for adult females are typically considered normalBasal or stimulated calcitonin level of ≥ 100 pg/mL is indication for surgeryCaution should be used when interpreting calcitonin levels in children younger than 5 years",
                    "sub_points": [
                      "Other calcitonin secretagogues, e.g., pentagastrin, are also used",
                      "Reference levels for basal calcitonin vary across laboratories: < 10 pg/mL for adult males and < 5 pg/mL for adult females are typically considered normal",
                      "Basal or stimulated calcitonin level of ≥ 100 pg/mL is indication for surgeryCaution should be used when interpreting calcitonin levels in children younger than 5 years",
                      "Caution should be used when interpreting calcitonin levels in children younger than 5 years"
                    ]
                  },
                  {
                    "text": "Pheochromocytomais suspected when biochemical screening reveals elevated secretion of catecholamines and catecholamine metabolitesIn MEN2, pheochromocytomas consistently produce epinephrine or both epinephrine and norepinephrine",
                    "sub_points": [
                      "In MEN2, pheochromocytomas consistently produce epinephrine or both epinephrine and norepinephrine"
                    ]
                  },
                  {
                    "text": "Diagnosis ofparathyroid abnormalitiesis made when biochemical screening reveals simultaneously elevated serum concentrations of calcium and elevated or high to normal parathyroid hormone"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "MTC: Calcitonin, calcitonin gene-related peptide (CGRP), chromogranin, and CEA"
                  },
                  {
                    "text": "Pheochromocytoma (PCC): Neuroendocrine markers; RET staining is not helpful to distinguish MEN2-associated PCC from sporadic counterpart"
                  }
                ],
                "Imaging Features": [
                  {
                    "text": "May be used in predicting phenotype and recommendations for age at which to perform prophylactic thyroidectomy and to begin biochemical screening for pheochromocytoma and hyperparathyroidismMR is more sensitive than CT in detection of pheochromocytoma",
                    "sub_points": [
                      "MR is more sensitive than CT in detection of pheochromocytoma"
                    ]
                  },
                  {
                    "text": "18F-fluorodopamine positron emission tomography (PET) is best overall imaging modality in localization of pheochromocytomas"
                  },
                  {
                    "text": "Postoperative parathyroid localizing studies with Tc-99m sestamibi scintigraphy may be helpful if HPT recurs"
                  },
                  {
                    "text": "For preoperative adenoma localization, 3D single-photon emission CT may also be used"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Precursor Lesions": [
                  {
                    "text": "Neoplastic C-cell hyperplasia (NCCH)NCCH is precursor lesion in hereditary MTCClusters should have > 50 C cellsa.k.a. C-cell carcinoma in situ or medullary carcinoma in situThese lesions harbor germlineRETmutationsPostulated that CCH progresses to medullary microcarcinoma (MMC) and eventually to MTCFound in vicinity of medullary carcinomasDistinguishing CCH from MMC or intrathyroid spread of MTC may be difficult",
                    "sub_points": [
                      "NCCH is precursor lesion in hereditary MTC",
                      "Clusters should have > 50 C cells",
                      "a.k.a. C-cell carcinoma in situ or medullary carcinoma in situ",
                      "These lesions harbor germlineRETmutations",
                      "Postulated that CCH progresses to medullary microcarcinoma (MMC) and eventually to MTC",
                      "Found in vicinity of medullary carcinomas",
                      "Distinguishing CCH from MMC or intrathyroid spread of MTC may be difficult"
                    ]
                  },
                  {
                    "text": "Adrenal medullary hyperplasia (AMH)Common in multiple endocrine neoplasia 2A and 2B; absent or very rare in other pheochromocytoma/paraganglioma syndromesAdrenals removed for pheochromocytoma should be carefully examined for additional nodules as a clue to presence of MEN2AMH may present with signs of catecholamine excess or be discovered incidentally after adrenalectomy for pheochromocytomaAdrenal medulla normally confined to central region (\"body\") of glandAMH often identifiable by gross extension of gray medullary tissue into alae and tailNodules often superimposed on diffuse hyperplasia",
                    "sub_points": [
                      "Common in multiple endocrine neoplasia 2A and 2B; absent or very rare in other pheochromocytoma/paraganglioma syndromes",
                      "Adrenals removed for pheochromocytoma should be carefully examined for additional nodules as a clue to presence of MEN2",
                      "AMH may present with signs of catecholamine excess or be discovered incidentally after adrenalectomy for pheochromocytoma",
                      "Adrenal medulla normally confined to central region (\"body\") of glandAMH often identifiable by gross extension of gray medullary tissue into alae and tailNodules often superimposed on diffuse hyperplasia",
                      "AMH often identifiable by gross extension of gray medullary tissue into alae and tail",
                      "Nodules often superimposed on diffuse hyperplasia"
                    ]
                  }
                ],
                "Medullary Thyroid Carcinoma": [
                  {
                    "text": "Often presents as painless \"cold\" noduleUp to 50% have nodal metastasesUp to 20% may present with distant metastasesSymptoms of carcinoid and Cushing syndromes may be present",
                    "sub_points": [
                      "Up to 50% have nodal metastases",
                      "Up to 20% may present with distant metastases",
                      "Symptoms of carcinoid and Cushing syndromes may be present"
                    ]
                  },
                  {
                    "text": "Typically at junction of upper and middle 1/3 of lobeHereditary tumors are usually multicentric and bilateralSporadic tumors tend to present as solitary mass ± lymph node involvementAlways associated with C-cell hyperplasia in MEN2",
                    "sub_points": [
                      "Hereditary tumors are usually multicentric and bilateralSporadic tumors tend to present as solitary mass ± lymph node involvement",
                      "Sporadic tumors tend to present as solitary mass ± lymph node involvement",
                      "Always associated with C-cell hyperplasia in MEN2"
                    ]
                  }
                ],
                "Pheochromocytoma": [
                  {
                    "text": "≥ 30% of PCCs/paraganglioma are hereditary tumors~ 1/3 of these are MEN2 patientsOccult germline mutations of susceptibility genes are common in patients with apparently sporadic pheochromocytomas",
                    "sub_points": [
                      "~ 1/3 of these are MEN2 patients",
                      "Occult germline mutations of susceptibility genes are common in patients with apparently sporadic pheochromocytomas"
                    ]
                  },
                  {
                    "text": "Affected by genotypeMultiple tumors or tumors presenting in children suggest hereditary diseaseSporadic tumors are solitary, usually in adultsTumors withRETmutations are almost always intraadrenal",
                    "sub_points": [
                      "Multiple tumors or tumors presenting in children suggest hereditary diseaseSporadic tumors are solitary, usually in adults",
                      "Sporadic tumors are solitary, usually in adults",
                      "Tumors withRETmutations are almost always intraadrenal"
                    ]
                  }
                ],
                "Parathyroid Hyperplasia and Adenoma": [
                  {
                    "text": "20-30% of MEN2A are associated with parathyroid hyperplasia or adenoma"
                  },
                  {
                    "text": "Almost never initial presentation of MEN2AIn contrast, hyperparathyroidism is common presentation in MEN1 (> 80%)",
                    "sub_points": [
                      "In contrast, hyperparathyroidism is common presentation in MEN1 (> 80%)"
                    ]
                  }
                ],
                "Ganglioneuroma of Gastrointestinal Tract": [
                  {
                    "text": "~ 40% of MEN2B-affected individuals have diffuse intestinal ganglioneuromatosis"
                  }
                ],
                "Mucosal Neuroma": [
                  {
                    "text": "May be identified in infancy and early childhood"
                  },
                  {
                    "text": "On palate, anterior dorsal surface of tongue, or pharynx"
                  },
                  {
                    "text": "Neuromas in eyelids"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Genetic Testing, MEN2": [
                  {
                    "text": "RETis the only gene known to be associated with MEN2"
                  },
                  {
                    "text": "RETmolecular genetic testing is indicated in all individuals with diagnosis of MTC, clinical diagnosis of MEN2, or primary CCH"
                  },
                  {
                    "text": "Algorithm for testing is summarized in most recent American Thyroid Association MTC Practice GuidelinesYoung age of onset, significant CCH, &/or multifocal disease suggest inherited disorderAll individuals with MTC, regardless of other features or family history, and those with clinical features suspicious for MEN2 &/or with family history suspicious of MEN2 should be offered germlineRETtesting for exons 10, 11, and 13-16",
                    "sub_points": [
                      "Young age of onset, significant CCH, &/or multifocal disease suggest inherited disorder",
                      "All individuals with MTC, regardless of other features or family history, and those with clinical features suspicious for MEN2 &/or with family history suspicious of MEN2 should be offered germlineRETtesting for exons 10, 11, and 13-16"
                    ]
                  },
                  {
                    "text": "MEN2A: 98% of families haveRETmutation in exon 10 or 11"
                  },
                  {
                    "text": "Families with FMTC:RETmutation in > 85%"
                  },
                  {
                    "text": "Individuals with features suggestive of MEN2B: Mutation analysis or sequencing of exons 16 and 15 to detect p.M918T and p.A883F mutationsIf mutation negative, testing for p.V804M in exon 14 followed by sequencing of entireRETcoding region should be performedAlthough isolated p.V804M mutation is associated with FMTC, p.V804M co-occurring with 2ndRETvariant seems to result in MEN2BThis strategy will detect > 98% of mutations in individuals with MEN2B",
                    "sub_points": [
                      "If mutation negative, testing for p.V804M in exon 14 followed by sequencing of entireRETcoding region should be performed",
                      "Although isolated p.V804M mutation is associated with FMTC, p.V804M co-occurring with 2ndRETvariant seems to result in MEN2B",
                      "This strategy will detect > 98% of mutations in individuals with MEN2B"
                    ]
                  },
                  {
                    "text": "RETmolecular genetic testing may be warranted in subsets of individuals presenting with apparently isolated adrenal pheochromocytomaOther differential diagnoses, such as VHL and succinate dehydrogenase-associated pheochromocytoma, should also be consideredTesting algorithms for genes associated with paraganglioma and pheochromocytoma have been proposed based on age of onset, location, laterality, malignancy, and family historyUnexpected germlineRETmutations are rarely (if ever) found in head and neck paraganglioma in absence of other features of MEN2 or family history of MEN2 phenotype",
                    "sub_points": [
                      "Other differential diagnoses, such as VHL and succinate dehydrogenase-associated pheochromocytoma, should also be considered",
                      "Testing algorithms for genes associated with paraganglioma and pheochromocytoma have been proposed based on age of onset, location, laterality, malignancy, and family history",
                      "Unexpected germlineRETmutations are rarely (if ever) found in head and neck paraganglioma in absence of other features of MEN2 or family history of MEN2 phenotype"
                    ]
                  },
                  {
                    "text": "Other clinical presentations may prompt consideration of genetic testingExon 10 sequencing should be considered in individuals with HSCR",
                    "sub_points": [
                      "Exon 10 sequencing should be considered in individuals with HSCR"
                    ]
                  },
                  {
                    "text": "Differential diagnosis in persons with intestinal ganglioneuromatosis should include MEN2B, and RET testing may be considered"
                  },
                  {
                    "text": "Rarely, germlineRETmutation may not be detected in family with clinical diagnosis of MEN2A, MEN2B, or FMTC"
                  }
                ],
                "Genetic Testing, FMTC": [
                  {
                    "text": "Germline point mutation inRETgene on chromosome 10q11.2 is responsible for hereditary MTC"
                  }
                ],
                "Testing of Relatives at Risk": [
                  {
                    "text": "At-risk relatives should be periodically screened forMTC with neck ultrasound examination and basal &/or stimulated calcitonin measurementsHPT with albumin-corrected calcium or ionized calciumPCC with measurement of plasma or 24-hour urine metanephrine and normetanephrine",
                    "sub_points": [
                      "MTC with neck ultrasound examination and basal &/or stimulated calcitonin measurements",
                      "HPT with albumin-corrected calcium or ionized calcium",
                      "PCC with measurement of plasma or 24-hour urine metanephrine and normetanephrine"
                    ]
                  },
                  {
                    "text": "RETmolecular genetic testing should be offered to probands with any MEN2 subtype and to all at-risk kindreds when a germlineRETmutation has been identified in an affected family member"
                  },
                  {
                    "text": "American Society of Clinical Oncologists identifies MEN2 as group 1 disorder, i.e., well-defined hereditary cancer syndrome for which genetic testing is considered part of standard management for at-risk family members"
                  },
                  {
                    "text": "RETmolecular genetic testing should be performed as soon as possible after birth in all children known to be at risk for MEN2B"
                  },
                  {
                    "text": "In families with MEN2A or FMTC, molecular genetic testing should be offered to at-risk children by age 5 years, as MTC has been documented in childhood"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "MYH-associated Polyposis": {
            "name": "MYH-associated Polyposis",
            "url": "https://app.pathprimer.com/document/614ae311-418c-4a93-a8aa-c4e0c6cb1257/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Mut Y homologue (MYH)"
                  },
                  {
                    "text": "MYH-associated polyposis (MAP)"
                  }
                ]
              },
              "Epidemiology": {
                "Prevalence": [
                  {
                    "text": "< 1 in 10,000"
                  },
                  {
                    "text": "Mean age at diagnosis is 45, with a reported age range of 12-68 yearsRisk of colorectal cancer (CRC) is 80% at age 70 with 50% of patients found to have CRC at time of polyposis diagnosisPatients tend to be older than familial adenomatous polyposis (FAP) patients but slightly younger than typical CRC patientsMay have right-sided CRC in younger patient suggestive of Lynch syndrome",
                    "sub_points": [
                      "Risk of colorectal cancer (CRC) is 80% at age 70 with 50% of patients found to have CRC at time of polyposis diagnosis",
                      "Patients tend to be older than familial adenomatous polyposis (FAP) patients but slightly younger than typical CRC patientsMay have right-sided CRC in younger patient suggestive of Lynch syndrome",
                      "May have right-sided CRC in younger patient suggestive of Lynch syndrome"
                    ]
                  }
                ]
              },
              "Genetics": {
                "MYHGene": [
                  {
                    "text": "Base excision repair geneBiallelic germline mutations inMYHlead to G:C to T:A transversions in somatic genes (i.e.,APC,KRAS)Oxidation of guanine is normally repaired by MYHOxidated guanine binds to adenine instead of cytosine, hence the G:C to T:A transversionsSomatic mutations inAPCgene leads to polyposis similar to FAP",
                    "sub_points": [
                      "Biallelic germline mutations inMYHlead to G:C to T:A transversions in somatic genes (i.e.,APC,KRAS)Oxidation of guanine is normally repaired by MYHOxidated guanine binds to adenine instead of cytosine, hence the G:C to T:A transversionsSomatic mutations inAPCgene leads to polyposis similar to FAP",
                      "Oxidation of guanine is normally repaired by MYH",
                      "Oxidated guanine binds to adenine instead of cytosine, hence the G:C to T:A transversions",
                      "Somatic mutations inAPCgene leads to polyposis similar to FAP"
                    ]
                  },
                  {
                    "text": "Autosomal recessive1-2% of population carry a single deleterious mutationParents of affected patient are both carriersUnclear if carriers have an increased rate of colon cancerSome reports have found slightly increased risk (1.5-2.1 relative risk) of CRC, whereas other studies have failed to show this",
                    "sub_points": [
                      "1-2% of population carry a single deleterious mutation",
                      "Parents of affected patient are both carriers",
                      "Unclear if carriers have an increased rate of colon cancerSome reports have found slightly increased risk (1.5-2.1 relative risk) of CRC, whereas other studies have failed to show this",
                      "Some reports have found slightly increased risk (1.5-2.1 relative risk) of CRC, whereas other studies have failed to show this"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Clinical Profile": [
                  {
                    "text": "Multiple adenomas but typically not in overwhelming numbers as seen in FAP"
                  },
                  {
                    "text": "Easy to miss diagnosis since there is no family history and patients have fewer polyps at an older age than typical FAP patients"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "In patients without a family history of polyposis, need to test for both FAP and MAP as 30% of FAP cases arise de novo"
                  },
                  {
                    "text": "2 common mutations inMYHgene account for 80% of cases (especially in people of Northern European descent)Most cost-effective method currently is to sequenceAPCgene and test for the 2 commonMYHmutationsIf this fails to identify mutations, then sequencingMYHwill be necessaryIf patients are not of Northern European descent, may be more cost effective to sequenceMYHfrom the start",
                    "sub_points": [
                      "Most cost-effective method currently is to sequenceAPCgene and test for the 2 commonMYHmutationsIf this fails to identify mutations, then sequencingMYHwill be necessary",
                      "If this fails to identify mutations, then sequencingMYHwill be necessary",
                      "If patients are not of Northern European descent, may be more cost effective to sequenceMYHfrom the start"
                    ]
                  },
                  {
                    "text": "Can measure G:C to T:A transversion in tumor DNA, especially inAPCandKRASgenes"
                  },
                  {
                    "text": "MAP carcinomas are typically microsatellite stable (as opposed to Lynch cancers that are unstable)"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Identical to FAP": [
                  {
                    "text": "Multiple adenomas and increased risk of CRCUp to 42% of MAP patients have 10-100 polyps, similar to attenuated FAPUp to 29% will have > 100 adenomas and resemble classic FAPMay have unicryptal or microadenomasMay also have serrated polyps (hyperplastic polyps and sessile serrated adenomas have been reported)",
                    "sub_points": [
                      "Up to 42% of MAP patients have 10-100 polyps, similar to attenuated FAP",
                      "Up to 29% will have > 100 adenomas and resemble classic FAP",
                      "May have unicryptal or microadenomas",
                      "May also have serrated polyps (hyperplastic polyps and sessile serrated adenomas have been reported)"
                    ]
                  },
                  {
                    "text": "Extracolonic neoplasms18-25% have duodenal adenomas4% lifetime risk of duodenal carcinomaFundic gland polyps similar to FAPCongenital hypertrophy of retinal pigment epithelium, dermal cysts, osteomas, dental abnormalities, and desmoids have also been reportedPrevalence of these lesions may be lower than in FAP, but given rarity of syndrome, good data do not existOvarian, bladder, and skin cancers have been reported (which can be suggestive of Lynch syndrome)",
                    "sub_points": [
                      "18-25% have duodenal adenomas4% lifetime risk of duodenal carcinoma",
                      "4% lifetime risk of duodenal carcinoma",
                      "Fundic gland polyps similar to FAP",
                      "Congenital hypertrophy of retinal pigment epithelium, dermal cysts, osteomas, dental abnormalities, and desmoids have also been reportedPrevalence of these lesions may be lower than in FAP, but given rarity of syndrome, good data do not exist",
                      "Prevalence of these lesions may be lower than in FAP, but given rarity of syndrome, good data do not exist",
                      "Ovarian, bladder, and skin cancers have been reported (which can be suggestive of Lynch syndrome)"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Surveillance": [
                  {
                    "text": "Patients with knownMYHmutations should have colonoscopic surveillance beginning between ages 20 and 30If no polyps are found, may continue surveillance every 3-5 yearsIf polyps are found, may go to annual surveillance",
                    "sub_points": [
                      "If no polyps are found, may continue surveillance every 3-5 years",
                      "If polyps are found, may go to annual surveillance"
                    ]
                  },
                  {
                    "text": "Upper tract endoscopic surveillance is recommended beginning at age 30-35 yearsIf no polyps are found, may continue surveillance every 3-5 yearsIf polyps are found,  annual surveillance may be recommended",
                    "sub_points": [
                      "If no polyps are found, may continue surveillance every 3-5 years",
                      "If polyps are found,  annual surveillance may be recommended"
                    ]
                  }
                ],
                "Surgery": [
                  {
                    "text": "When polyps become too numerous, prophylactic colectomy with ileoanal anastomosis is treatment of choice"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Retinoblastoma": {
            "name": "Hereditary Retinoblastoma",
            "url": "https://app.pathprimer.com/document/7351a8cd-1868-4482-8226-54ab82e1cd63/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Definition": [
                  {
                    "text": "Familial cancer syndrome with predisposition for retinoblastoma development, often multiple, and other cancers resulting from germline mutations in tumor suppressor geneRB1"
                  }
                ]
              },
              "Epidemiology": {
                "Retinoblastoma": [
                  {
                    "text": "Most common intraocular malignancy in childrenIncidence: 1 in 15,000-34,000 birthsNo gender or ethnic predilection",
                    "sub_points": [
                      "Incidence: 1 in 15,000-34,000 births",
                      "No gender or ethnic predilection"
                    ]
                  }
                ]
              },
              "Genetics": {
                "Germline Mutations inRB1Gene": [
                  {
                    "text": "Located at chromosomal region 13q14"
                  },
                  {
                    "text": "5-10% of retinoblastomas inherited in autosomal dominant fashion"
                  },
                  {
                    "text": "Autosomal dominant inheritance with high penetrance60-80% of carriers develop retinoblastomas",
                    "sub_points": [
                      "60-80% of carriers develop retinoblastomas"
                    ]
                  },
                  {
                    "text": "RB1encodes for ubiquitously expressed nuclear proteinImportant role in cell cycle control, cellular differentiation, and survivalUndergoes phosphorylation in cell cycle-dependent fashionRegulator of restriction (R) point of cell cycleUnphosphorylated (active) in G₀ → hypophosphorylated in G₁ → hyperphosphorylated (inactive) as cell passes through R point → dephosphorylated (reactivated) by PP1 phosphatase at M/G₁ transition",
                    "sub_points": [
                      "Important role in cell cycle control, cellular differentiation, and survival",
                      "Undergoes phosphorylation in cell cycle-dependent fashion",
                      "Regulator of restriction (R) point of cell cycleUnphosphorylated (active) in G₀ → hypophosphorylated in G₁ → hyperphosphorylated (inactive) as cell passes through R point → dephosphorylated (reactivated) by PP1 phosphatase at M/G₁ transition",
                      "Unphosphorylated (active) in G₀ → hypophosphorylated in G₁ → hyperphosphorylated (inactive) as cell passes through R point → dephosphorylated (reactivated) by PP1 phosphatase at M/G₁ transition"
                    ]
                  },
                  {
                    "text": "13q-deletion syndrome (< 5% of retinoblastomas)Retinoblastoma in association with moderate growth and mental retardation, facial abnormalities, microphthalmia, cardiac anomalies, anal atresia, colobomas, cataracts, and muscle hypotonia",
                    "sub_points": [
                      "Retinoblastoma in association with moderate growth and mental retardation, facial abnormalities, microphthalmia, cardiac anomalies, anal atresia, colobomas, cataracts, and muscle hypotonia"
                    ]
                  },
                  {
                    "text": "GermlineRB1mutations in 25% of retinoblastoma patients without family history (i.e., new mutations)Progeny may be affected",
                    "sub_points": [
                      "Progeny may be affected"
                    ]
                  },
                  {
                    "text": "Polymorphisms in other genes may affect risk for retinoblastoma development (e.g.,MDM2,MDM4)"
                  }
                ],
                "Somatic Mutations inRB1": [
                  {
                    "text": "Reported in sarcomas, small cell lung carcinoma, bladder carcinoma, and breast carcinoma"
                  },
                  {
                    "text": "Promoter hypermethylation (epigenetic inactivation) in astrocytomas and lymphoma subsets"
                  }
                ],
                "Knudson \"2-Hit\" Hypothesis": [
                  {
                    "text": "Model for classic tumor suppressor genes"
                  },
                  {
                    "text": "2 inactivating mutations required for tumor development"
                  },
                  {
                    "text": "1st mutation may be either somatic (sporadic) or germinal (inherited)"
                  },
                  {
                    "text": "2nd mutation is sporadic"
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Presentation and Complications": [
                  {
                    "text": "Earlier age of presentation for hereditary retinoblastomaMean age at presentation of sporadic retinoblastoma: 18-24 monthsMean age at presentation of hereditary retinoblastoma: 12 months",
                    "sub_points": [
                      "Mean age at presentation of sporadic retinoblastoma: 18-24 months",
                      "Mean age at presentation of hereditary retinoblastoma: 12 months"
                    ]
                  },
                  {
                    "text": "Sporadic retinoblastoma is usually unilateral whereas hereditary retinoblastoma is often bilateral (~ 60%)"
                  },
                  {
                    "text": "Increased risk for 2nd primary tumors, particularly craniofacial locations~ 70% of 2nd primaries develop in irradiation field or at boundaryMedian age of presentation: 13 years for craniofacial location, but risk continues through lifeRisk highest for patients receiving external beam radiotherapy in 1st year of lifeAddition of chemotherapy also increases riskExtent of resection important prognostic factor",
                    "sub_points": [
                      "~ 70% of 2nd primaries develop in irradiation field or at boundary",
                      "Median age of presentation: 13 years for craniofacial location, but risk continues through life",
                      "Risk highest for patients receiving external beam radiotherapy in 1st year of life",
                      "Addition of chemotherapy also increases risk",
                      "Extent of resection important prognostic factor"
                    ]
                  },
                  {
                    "text": "2nd primary tumors are leading cause of death in hereditary retinoblastoma patients in developed countriesHigher risk of 2nd primary malignancies in patients with recurrent nonsenseRB1mutations compared with low penetrance mutations in some studiesNo significant increase in mortality due to nonneoplastic disorders",
                    "sub_points": [
                      "Higher risk of 2nd primary malignancies in patients with recurrent nonsenseRB1mutations compared with low penetrance mutations in some studies",
                      "No significant increase in mortality due to nonneoplastic disorders"
                    ]
                  }
                ]
              },
              "Microscopic findings": {
                "Retinoblastoma": [
                  {
                    "text": "Small round blue cell tumorEvidence of retinoblastic differentiation: Flexner-Wintersteiner rosettes and fleurettesHomer Wright (neuroblastic) rosettes may also be presentNecrosis and calcifications commonMay invade optic nerve and secondarily brain and CSF",
                    "sub_points": [
                      "Evidence of retinoblastic differentiation: Flexner-Wintersteiner rosettes and fleurettes",
                      "Homer Wright (neuroblastic) rosettes may also be present",
                      "Necrosis and calcifications common",
                      "May invade optic nerve and secondarily brain and CSF"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Retinoma/Retinocytoma": [
                  {
                    "text": "Composed entirely of photoreceptor differentiationLacks mitotic activity and necrosis",
                    "sub_points": [
                      "Lacks mitotic activity and necrosis"
                    ]
                  },
                  {
                    "text": "Usually benign, but may develop malignant transformation into retinoblastoma"
                  },
                  {
                    "text": "Inactivation of bothRB1gene copies, but lacks additional alterations typical of retinoblastoma"
                  }
                ],
                "Pineoblastoma/CNS PNET": [
                  {
                    "text": "Part of \"trilateral\" retinoblastoma syndrome (bilateral retinoblastoma + pineoblastoma or suprasellar PNET)"
                  },
                  {
                    "text": "Occurs in < 1% of patients with retinoblastoma"
                  },
                  {
                    "text": "Intracranial tumor frequently (~ 80%) in pineal region = pineoblastoma (\"3rd eye\")"
                  }
                ],
                "Soft Tissue and Bone Sarcomas": [
                  {
                    "text": "Susceptibility secondary to germline predisposition (i.e.,RB1mutations) and radiation therapy"
                  },
                  {
                    "text": "Encompass ~ 1/2 of 2nd cancers in survivors of hereditary retinoblastoma"
                  },
                  {
                    "text": "Bone sarcomas: Osteosarcoma (most common), chondrosarcoma and Ewing sarcoma"
                  },
                  {
                    "text": "Soft tissue tumorsPathologic subtypes include leiomyosarcoma, fibrosarcoma, rhabdomyosarcoma, pleomorphic sarcoma, liposarcoma/lipomatous tumorsLeiomyosarcoma most common pathology in some studiesMajority of leiomyosarcomas in women are uterine (i.e., outside of radiation field)Most of nonleiomyosarcoma soft tissue tumors in radiation field",
                    "sub_points": [
                      "Pathologic subtypes include leiomyosarcoma, fibrosarcoma, rhabdomyosarcoma, pleomorphic sarcoma, liposarcoma/lipomatous tumorsLeiomyosarcoma most common pathology in some studiesMajority of leiomyosarcomas in women are uterine (i.e., outside of radiation field)Most of nonleiomyosarcoma soft tissue tumors in radiation field",
                      "Leiomyosarcoma most common pathology in some studies",
                      "Majority of leiomyosarcomas in women are uterine (i.e., outside of radiation field)",
                      "Most of nonleiomyosarcoma soft tissue tumors in radiation field"
                    ]
                  }
                ],
                "Others": [
                  {
                    "text": "Melanoma of skin; carcinomas of bladder, lung, upper respiratory tract, and skin; tumors of the central nervous system/meningiomas"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Familial Acute Myeloid Leukemia": {
            "name": "Familial Acute Myeloid Leukemia",
            "url": "https://app.pathprimer.com/document/54516f92-711e-4042-9133-1c3b612fe2e7/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Myelodysplastic syndromes (MDS)"
                  },
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "Autosomal dominant (AD)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "MDS: Heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, clinical cytopenia(s), dysplasia in 1 or more myeloid lineages, and increased risk of evolution to AML"
                  },
                  {
                    "text": "AML: Heterogeneous group of clonal hematopoietic neoplasms characterized by ≥ 20% blasts or blast equivalents in peripheral blood or bone marrowExceptions include AML with specific recurrent genetic abnormalities (t[15;17], t[8;21], inv[16]/t[16;16]) or acute erythroid leukemia",
                    "sub_points": [
                      "Exceptions include AML with specific recurrent genetic abnormalities (t[15;17], t[8;21], inv[16]/t[16;16]) or acute erythroid leukemia"
                    ]
                  },
                  {
                    "text": "Familial MDS/AML is defined as > 1 first- or second-degree relative with MDS/AML; some cases are genetically defined but most familial clusters are of unknown etiology"
                  },
                  {
                    "text": "Familial MDS/AML syndromes with defined genetic lesions includeFamilial platelet disorder with propensity to developacutemyeloid leukemia (FPD/AML)Rare AD disease characterized byRUNX1mutation, platelet dysfunction, clinical thrombocytopenia, and increased risk of MDS/AML (incidence of MDS/AML in affected patients is > 40%; no specific subtype)FamilialCEBPAmutationRare AD disease characterized by AML including frequent Auer rods, aberrant CD7 expression, and no abnormalities detected on conventional cytogenetic analysis (near-complete penetrance)FamilialGATA2mutationRare AD disease characterized by MDS/AML and poor clinical outcome (highly penetrant; no specific MDS/AML subtype)RecentlydescribedGATA2mutation in MonoMAC syndromeMonoMAC syndrome (a.k.a. DCML deficiency) is an inherited (AD transmission) or sporadic immunodeficiencyCharacterized by disseminated nontuberculous mycobacterial infections (typicallyMycobacterium aviumcomplex [MAC]), human papillomavirus (HPV) infections, primary alveolar proteinosis, opportunistic fungal infections, profound monocytopenia, decreased/absent NK and B cells, decreased circulating/tissue dendritic cellsPredisposition to MDS/AML in 50% of patients (few myelodysplastic/myeloproliferative overlap cases also reported)Recently describedGATA2mutation in Emberger syndromeInherited (AD transmission with incomplete penetrance) or sporadic disorderCharacterized by primary lymphedema secondary to lymphatic hypoplasia and predisposition to MDS/AMLPatients may also have immune dysfunction as evidenced by disseminated cutaneous warts, as well as sensorineural deafnessOther well-defined syndromes with variable predisposition to MDS/AML includeBone marrow failure syndromes: Congenital amegakaryocytic thrombocytopenia, Diamond-Blackfan anemia, dyskeratosis congenita, severe congenital neutropenia, Shwachman-Diamond syndromeDNA damage repair deficiency syndromes: RecQ helicase deficiencies (Bloom syndrome, Rothmund-Thomson syndrome, Werner syndrome); Fanconi anemiaCell cycle and cell differentiation defects:Neurofibromatosis type 1, Noonan syndrome, and Noonan-like syndrome (juvenile myelomonocytic leukemia)Li-Fraumeni syndrome",
                    "sub_points": [
                      "Familial platelet disorder with propensity to developacutemyeloid leukemia (FPD/AML)Rare AD disease characterized byRUNX1mutation, platelet dysfunction, clinical thrombocytopenia, and increased risk of MDS/AML (incidence of MDS/AML in affected patients is > 40%; no specific subtype)",
                      "Rare AD disease characterized byRUNX1mutation, platelet dysfunction, clinical thrombocytopenia, and increased risk of MDS/AML (incidence of MDS/AML in affected patients is > 40%; no specific subtype)",
                      "FamilialCEBPAmutationRare AD disease characterized by AML including frequent Auer rods, aberrant CD7 expression, and no abnormalities detected on conventional cytogenetic analysis (near-complete penetrance)",
                      "Rare AD disease characterized by AML including frequent Auer rods, aberrant CD7 expression, and no abnormalities detected on conventional cytogenetic analysis (near-complete penetrance)",
                      "FamilialGATA2mutationRare AD disease characterized by MDS/AML and poor clinical outcome (highly penetrant; no specific MDS/AML subtype)",
                      "Rare AD disease characterized by MDS/AML and poor clinical outcome (highly penetrant; no specific MDS/AML subtype)",
                      "RecentlydescribedGATA2mutation in MonoMAC syndromeMonoMAC syndrome (a.k.a. DCML deficiency) is an inherited (AD transmission) or sporadic immunodeficiencyCharacterized by disseminated nontuberculous mycobacterial infections (typicallyMycobacterium aviumcomplex [MAC]), human papillomavirus (HPV) infections, primary alveolar proteinosis, opportunistic fungal infections, profound monocytopenia, decreased/absent NK and B cells, decreased circulating/tissue dendritic cellsPredisposition to MDS/AML in 50% of patients (few myelodysplastic/myeloproliferative overlap cases also reported)",
                      "MonoMAC syndrome (a.k.a. DCML deficiency) is an inherited (AD transmission) or sporadic immunodeficiency",
                      "Characterized by disseminated nontuberculous mycobacterial infections (typicallyMycobacterium aviumcomplex [MAC]), human papillomavirus (HPV) infections, primary alveolar proteinosis, opportunistic fungal infections, profound monocytopenia, decreased/absent NK and B cells, decreased circulating/tissue dendritic cells",
                      "Predisposition to MDS/AML in 50% of patients (few myelodysplastic/myeloproliferative overlap cases also reported)",
                      "Recently describedGATA2mutation in Emberger syndromeInherited (AD transmission with incomplete penetrance) or sporadic disorderCharacterized by primary lymphedema secondary to lymphatic hypoplasia and predisposition to MDS/AMLPatients may also have immune dysfunction as evidenced by disseminated cutaneous warts, as well as sensorineural deafness",
                      "Inherited (AD transmission with incomplete penetrance) or sporadic disorder",
                      "Characterized by primary lymphedema secondary to lymphatic hypoplasia and predisposition to MDS/AML",
                      "Patients may also have immune dysfunction as evidenced by disseminated cutaneous warts, as well as sensorineural deafness",
                      "Other well-defined syndromes with variable predisposition to MDS/AML includeBone marrow failure syndromes: Congenital amegakaryocytic thrombocytopenia, Diamond-Blackfan anemia, dyskeratosis congenita, severe congenital neutropenia, Shwachman-Diamond syndromeDNA damage repair deficiency syndromes: RecQ helicase deficiencies (Bloom syndrome, Rothmund-Thomson syndrome, Werner syndrome); Fanconi anemiaCell cycle and cell differentiation defects:Neurofibromatosis type 1, Noonan syndrome, and Noonan-like syndrome (juvenile myelomonocytic leukemia)Li-Fraumeni syndrome",
                      "Bone marrow failure syndromes: Congenital amegakaryocytic thrombocytopenia, Diamond-Blackfan anemia, dyskeratosis congenita, severe congenital neutropenia, Shwachman-Diamond syndrome",
                      "DNA damage repair deficiency syndromes: RecQ helicase deficiencies (Bloom syndrome, Rothmund-Thomson syndrome, Werner syndrome); Fanconi anemia",
                      "Cell cycle and cell differentiation defects:Neurofibromatosis type 1, Noonan syndrome, and Noonan-like syndrome (juvenile myelomonocytic leukemia)",
                      "Li-Fraumeni syndrome"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Mutations inRUNX1,CEBPA, andGATA2": [
                  {
                    "text": "All are rare; reports of different entities range from 5 to > 20 affected families"
                  }
                ]
              },
              "Genetics": {
                "General Points": [
                  {
                    "text": "Underlying genetic cause of many clusters of familial MDS/AML have not yet been elucidated"
                  },
                  {
                    "text": "Given variable penetrance and latency periods, single germline mutations that have been described likely predispose to MDS/AML by rendering families highly susceptible to additional, somatic mutations"
                  }
                ],
                "Transcription Factor Mutations": [
                  {
                    "text": "RUNX1mutation in FPD/AMLRunt-related transcription factor 1 (RUNX1), a.k.a. acute myeloid leukemia 1 (AML1), a.k.a. core-binding factor subunit α-2 (CBFA2)RUNX1(21q22.3) encodes α-subunit of core binding factor transcription factor, which plays a role in normal hematopoiesis and myeloid differentiationNumber ofRUNX1mutations have been described in FPD/AML (large intragenic deletions, Runt domain mutations) and tend to be specific to families; mutational heterogeneity may be reason for variable phenotypeRUNX1mutations/translocations also occur in sporadic cases of MDS/AML",
                    "sub_points": [
                      "Runt-related transcription factor 1 (RUNX1), a.k.a. acute myeloid leukemia 1 (AML1), a.k.a. core-binding factor subunit α-2 (CBFA2)RUNX1(21q22.3) encodes α-subunit of core binding factor transcription factor, which plays a role in normal hematopoiesis and myeloid differentiationNumber ofRUNX1mutations have been described in FPD/AML (large intragenic deletions, Runt domain mutations) and tend to be specific to families; mutational heterogeneity may be reason for variable phenotypeRUNX1mutations/translocations also occur in sporadic cases of MDS/AML",
                      "RUNX1(21q22.3) encodes α-subunit of core binding factor transcription factor, which plays a role in normal hematopoiesis and myeloid differentiation",
                      "Number ofRUNX1mutations have been described in FPD/AML (large intragenic deletions, Runt domain mutations) and tend to be specific to families; mutational heterogeneity may be reason for variable phenotype",
                      "RUNX1mutations/translocations also occur in sporadic cases of MDS/AML"
                    ]
                  },
                  {
                    "text": "CEBPAmutationCCAAT/enhancer binding protein α (CEBPA)CEBPA(19q13.1) encodes a transcription factor (C/EBPα) that can act as a homodimer or a heterodimer with C/EBPβ and C/EBPγ and plays a role in myeloid differentiationCEBPAmutations also occur in sporadic cases of AMLCEBPApoint mutations are commonly biallelic (2 acquired in sporadic AML, 1 germline and 1 acquired in familial AML) manifesting as a dominant-negative N-terminal mutation and a C-terminal mutation (in familial AML, germline mutation is always N-terminal mutation)",
                    "sub_points": [
                      "CCAAT/enhancer binding protein α (CEBPA)CEBPA(19q13.1) encodes a transcription factor (C/EBPα) that can act as a homodimer or a heterodimer with C/EBPβ and C/EBPγ and plays a role in myeloid differentiationCEBPAmutations also occur in sporadic cases of AMLCEBPApoint mutations are commonly biallelic (2 acquired in sporadic AML, 1 germline and 1 acquired in familial AML) manifesting as a dominant-negative N-terminal mutation and a C-terminal mutation (in familial AML, germline mutation is always N-terminal mutation)",
                      "CEBPA(19q13.1) encodes a transcription factor (C/EBPα) that can act as a homodimer or a heterodimer with C/EBPβ and C/EBPγ and plays a role in myeloid differentiation",
                      "CEBPAmutations also occur in sporadic cases of AML",
                      "CEBPApoint mutations are commonly biallelic (2 acquired in sporadic AML, 1 germline and 1 acquired in familial AML) manifesting as a dominant-negative N-terminal mutation and a C-terminal mutation (in familial AML, germline mutation is always N-terminal mutation)"
                    ]
                  },
                  {
                    "text": "GATA2mutationGATA binding protein 2 (GATA2)GATA2(3q21.3) encodes a member of the GATA family of zinc-finger transcription factors (named for promoter consensus sequence to which they bind) and plays a role in hematopoiesis and other nonhematopoietic processes> 30 mutations inGATA2have been described in sporadic and familial MDS/AML, MonoMAC and Emberger (e.g., missense, nonsense, frameshift, small and large deletions)Aberrant activation or overexpression ofGATA2has also been described in de novo AML",
                    "sub_points": [
                      "GATA binding protein 2 (GATA2)GATA2(3q21.3) encodes a member of the GATA family of zinc-finger transcription factors (named for promoter consensus sequence to which they bind) and plays a role in hematopoiesis and other nonhematopoietic processes> 30 mutations inGATA2have been described in sporadic and familial MDS/AML, MonoMAC and Emberger (e.g., missense, nonsense, frameshift, small and large deletions)Aberrant activation or overexpression ofGATA2has also been described in de novo AML",
                      "GATA2(3q21.3) encodes a member of the GATA family of zinc-finger transcription factors (named for promoter consensus sequence to which they bind) and plays a role in hematopoiesis and other nonhematopoietic processes",
                      "> 30 mutations inGATA2have been described in sporadic and familial MDS/AML, MonoMAC and Emberger (e.g., missense, nonsense, frameshift, small and large deletions)",
                      "Aberrant activation or overexpression ofGATA2has also been described in de novo AML"
                    ]
                  }
                ],
                "Additionally Reported Genetic Abnormalities": [
                  {
                    "text": "Telomere maintenance mutations: Telomerase reverse transcriptase(TERT)and telomerase RNA component(TERC)mutations have been described in 5 families with MDS/AML (most also with aplastic anemia [AA]) but lacking phenotypic characteristics of bone marrow failure syndrome dyskeratosis congenita (variable penetrance; no specific MDS/AML subtype)Telomerase is a ribonuclease that maintains telomere length by addition of telomere repeat TTAGGGTERT(5p15.33) encodes reverse transcriptase protein component of telomerase (hTERT)TERC(3q26) encodes RNA component (hTR), which provides template for telomere repeatMutations inTERTandTERCunderlie a subset of dyskeratosis congenital cases and have been described in de novo MDS, idiopathic pulmonary fibrosis (familial and sporadic), and AA;TERTmutations have been described in de novo AML",
                    "sub_points": [
                      "Telomerase is a ribonuclease that maintains telomere length by addition of telomere repeat TTAGGGTERT(5p15.33) encodes reverse transcriptase protein component of telomerase (hTERT)TERC(3q26) encodes RNA component (hTR), which provides template for telomere repeat",
                      "TERT(5p15.33) encodes reverse transcriptase protein component of telomerase (hTERT)",
                      "TERC(3q26) encodes RNA component (hTR), which provides template for telomere repeat",
                      "Mutations inTERTandTERCunderlie a subset of dyskeratosis congenital cases and have been described in de novo MDS, idiopathic pulmonary fibrosis (familial and sporadic), and AA;TERTmutations have been described in de novo AML"
                    ]
                  },
                  {
                    "text": "Monosomy 7: Described in families with early onset of MDS (pathogenesis is poorly understood)Apparently AD inheritance patternOccurs in sporadic MDS/AML as well as in syndromic MDS/AMLChildren with early onset MDS and monosomy 7 may represent children with MDS/AML-predisposition syndrome that is otherwise phenotypically silentAlternatively, these families may have as of yet unidentified gene mutation(s) rendering affected members vulnerable to loss of a chromosome 7",
                    "sub_points": [
                      "Apparently AD inheritance pattern",
                      "Occurs in sporadic MDS/AML as well as in syndromic MDS/AML",
                      "Children with early onset MDS and monosomy 7 may represent children with MDS/AML-predisposition syndrome that is otherwise phenotypically silent",
                      "Alternatively, these families may have as of yet unidentified gene mutation(s) rendering affected members vulnerable to loss of a chromosome 7"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Familial vs. Sporadic MDS/AML": [
                  {
                    "text": "Younger age of presentation in familial MDS/AML"
                  },
                  {
                    "text": "Relatives of AML patients < 21 years old at diagnosis have 6.5x increase risk of MDS/AML and 3x risk of any myeloid malignancy"
                  }
                ],
                "FPD/AML": [
                  {
                    "text": "Patients often present with mild to moderate bleeding"
                  },
                  {
                    "text": "Platelet aggregation study shows impaired response to collagen and absent 2nd wave of epinephrine-induced aggregation; decreased aggregation with arachidonate is also seen (author observation)"
                  },
                  {
                    "text": "Subset of affected patients (over 40%) develop MDS/AML at a younger age than sporadic AML (median age 33)"
                  }
                ],
                "CEBPAMutation": [
                  {
                    "text": "Eosinophilia common"
                  },
                  {
                    "text": "Favorable prognosis of AML, even with relapse"
                  },
                  {
                    "text": "Wide range in age of onset (as young as 4 to over 35), consistent with evidence of secondary mutations in addition to germline mutations in affected families"
                  }
                ],
                "GATA2Mutation": [
                  {
                    "text": "In families withGATA2mutations and early onset MDS/AML alone, prognosis is poor"
                  },
                  {
                    "text": "In MonoMAC patients, some morphologic features of MDS are different than those commonly observed in de novo MDSFrequent marrow hypocellularity, frequent marrow fibrosis, presence of CD56-positive plasma cells, consistent trilineage dysplasia, and frequent hemophagocytic histiocytes",
                    "sub_points": [
                      "Frequent marrow hypocellularity, frequent marrow fibrosis, presence of CD56-positive plasma cells, consistent trilineage dysplasia, and frequent hemophagocytic histiocytes"
                    ]
                  },
                  {
                    "text": "No clear genotype-phenotype correlations"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Stem Cell Transplantation": [
                  {
                    "text": "Genetic screening is advised when evaluating relatives as potential donors for patients undergoing allogeneic stem cell transplantation"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Familial Gastrointestinal Stromal Tumor": {
            "name": "Familial Gastrointestinal Stromal Tumor",
            "url": "https://app.pathprimer.com/document/8f5a9822-d958-4fdf-ab16-e389f14871f2/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Gastrointestinal stromal tumor (GIST)"
                  },
                  {
                    "text": "Familial GIST (FGIST)"
                  }
                ]
              },
              "Epidemiology": {
                "Incidence": [
                  {
                    "text": "Most common mesenchymal tumor arising in gut6.8 cases per million per year in USA, 14.5 cases per million per year in SwedenVast majority are sporadic, not familial",
                    "sub_points": [
                      "6.8 cases per million per year in USA, 14.5 cases per million per year in SwedenVast majority are sporadic, not familial",
                      "Vast majority are sporadic, not familial"
                    ]
                  },
                  {
                    "text": "Sporadic GISTs are typically seen in middle-aged to older patients"
                  },
                  {
                    "text": "Familial GISTs tend to occur in younger patients and there are often synchronous or metachronous tumors"
                  }
                ]
              },
              "Syndromes/Genetics": {
                "Germline Mutations ofKIT": [
                  {
                    "text": "Patients have multiple GISTs, hyperpigmentation, urticaria pigmentosa, and dysphagia"
                  },
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "Most mutations are in exon 11Mutations in other exons tend not to be associated with hyperpigmentation",
                    "sub_points": [
                      "Mutations in other exons tend not to be associated with hyperpigmentation"
                    ]
                  }
                ],
                "Germline Mutations of Platelet-Derived Growth Factor Receptor Alpha (PDGFRA)": [
                  {
                    "text": "GISTs are typically epithelioid or mixed"
                  },
                  {
                    "text": "Patients have multiple GISTswithouthyperpigmentation, urticaria pigmentosa, and dysphagia1 kindred also had large hands associated with multiple GISTs, and intestinal neurofibromatosis1 patient from a different kindred with a uniquePDGFRAmutation also had multiple lipomas and fibrous tumors of small bowel",
                    "sub_points": [
                      "1 kindred also had large hands associated with multiple GISTs, and intestinal neurofibromatosis",
                      "1 patient from a different kindred with a uniquePDGFRAmutation also had multiple lipomas and fibrous tumors of small bowel"
                    ]
                  }
                ],
                "Carney-Stratakis Syndrome": [
                  {
                    "text": "Germline mutations in succinate dehydrogenase (SDH) complex B, C, and D subunits"
                  },
                  {
                    "text": "Patients have dyad of GISTs and paragangliomasAutosomal dominantGISTs are typically epithelioid or mixed, and are often multinodularHistologically, these tumors appear malignant with high mitotic rate and increased cellularity, but they often behave in a benign fashionMay have lymph node metastases, but still have a good prognosisRespond to sunitinib much more than imatinibDyad GISTs are wild type forKITandPDGFRAmutations (also referred to as pediatric GISTs)Loss of SDH immmunostaining may be used to screen for tumors withSDHmutation",
                    "sub_points": [
                      "Autosomal dominant",
                      "GISTs are typically epithelioid or mixed, and are often multinodularHistologically, these tumors appear malignant with high mitotic rate and increased cellularity, but they often behave in a benign fashionMay have lymph node metastases, but still have a good prognosisRespond to sunitinib much more than imatinib",
                      "Histologically, these tumors appear malignant with high mitotic rate and increased cellularity, but they often behave in a benign fashion",
                      "May have lymph node metastases, but still have a good prognosis",
                      "Respond to sunitinib much more than imatinib",
                      "Dyad GISTs are wild type forKITandPDGFRAmutations (also referred to as pediatric GISTs)Loss of SDH immmunostaining may be used to screen for tumors withSDHmutation",
                      "Loss of SDH immmunostaining may be used to screen for tumors withSDHmutation"
                    ]
                  }
                ],
                "Carney Triad": [
                  {
                    "text": "Gastric GISTs, paragangliomas, and pulmonary chondromasAlso may have adrenal cortical adenomas and esophageal leiomyomasGISTs are typically epithelioid or mixed, and are often multinodularHistologically, these GISTs appear malignant with high mitotic rate and increased cellularity, but they often behave in a benign fashionUp to 29% have reported lymph node metastasis (nonsyndromic adult GISTs rarely spread to lymph nodes)Even with these metastases, patients still have an excellent prognosisRespond to sunitinib much more than imatinib",
                    "sub_points": [
                      "Also may have adrenal cortical adenomas and esophageal leiomyomas",
                      "GISTs are typically epithelioid or mixed, and are often multinodular",
                      "Histologically, these GISTs appear malignant with high mitotic rate and increased cellularity, but they often behave in a benign fashionUp to 29% have reported lymph node metastasis (nonsyndromic adult GISTs rarely spread to lymph nodes)Even with these metastases, patients still have an excellent prognosisRespond to sunitinib much more than imatinib",
                      "Up to 29% have reported lymph node metastasis (nonsyndromic adult GISTs rarely spread to lymph nodes)",
                      "Even with these metastases, patients still have an excellent prognosis",
                      "Respond to sunitinib much more than imatinib"
                    ]
                  },
                  {
                    "text": "85% of patients are young femalesOriginally thought to be an X-linked trait as all of the 1st reported patients were all women, but now not thought to be familial",
                    "sub_points": [
                      "Originally thought to be an X-linked trait as all of the 1st reported patients were all women, but now not thought to be familial"
                    ]
                  },
                  {
                    "text": "Genetic defect unknownLosses of chromosome 1p have been found in tumors (not germline)Immunostains for SDH subunits may be negative, but germline mutations are not found in Carney triad patients",
                    "sub_points": [
                      "Losses of chromosome 1p have been found in tumors (not germline)",
                      "Immunostains for SDH subunits may be negative, but germline mutations are not found in Carney triad patients"
                    ]
                  }
                ],
                "Neurofibromatosis Type 1 (NF1)": [
                  {
                    "text": "May have multiple small intestinal GISTs (as well as the usual neurogenic tumors and other stigmata of NF1)NF1 patients 150x more likely than the general population to get GISTs",
                    "sub_points": [
                      "NF1 patients 150x more likely than the general population to get GISTs"
                    ]
                  },
                  {
                    "text": "Autosomal dominant due to mutation inNF1(tumor suppressor gene)"
                  },
                  {
                    "text": "GISTs in NF1 often wild type forKITandPDGFRAOverall good prognosis and respond to sunitinib much better than imatinib",
                    "sub_points": [
                      "Overall good prognosis and respond to sunitinib much better than imatinib"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Unique Features of Syndromic GISTs": [
                  {
                    "text": "Presence of synchronous or metachronous stromal tumors or tumors in young patients should alert pathologist to possibility of familial syndromesEpithelioid or mixed histology gastric tumors in young people should prompt work-up for paragangliomas and pulmonary chondromasImmunostains for SDH subunits may be helpful to triage germline sequencingGermline sequencing ofPDGFRAmay also be helpful if family history is positive and no paragangliomas are foundMultiple small bowel GISTs should raise the question of NF1Presence of multiple GISTs in patients with hyperpigmented skin should prompt germlineKITsequencing",
                    "sub_points": [
                      "Epithelioid or mixed histology gastric tumors in young people should prompt work-up for paragangliomas and pulmonary chondromasImmunostains for SDH subunits may be helpful to triage germline sequencingGermline sequencing ofPDGFRAmay also be helpful if family history is positive and no paragangliomas are found",
                      "Immunostains for SDH subunits may be helpful to triage germline sequencing",
                      "Germline sequencing ofPDGFRAmay also be helpful if family history is positive and no paragangliomas are found",
                      "Multiple small bowel GISTs should raise the question of NF1",
                      "Presence of multiple GISTs in patients with hyperpigmented skin should prompt germlineKITsequencing"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Juvenile Polyposis": {
            "name": "Juvenile Polyposis",
            "url": "https://app.pathprimer.com/document/b6b1a3f8-3439-46cb-acfa-7dd75fe4235c/lesson/2dd52e41-c4e7-4c2f-9783-682f858518e0",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Juvenile polyp (JP)"
                  },
                  {
                    "text": "Juvenile polyposis syndrome (JPS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Hamartomatous polypMay occur sporadically (most juvenile polyps are nonsyndromic)90% of all polyps found in children20-50% may have > 1 polypNo increase in cancer risk in sporadic JPMay be manifestation of inherited familial polyposis syndromePatients with JPS have increased risk of colorectal carcinoma",
                    "sub_points": [
                      "May occur sporadically (most juvenile polyps are nonsyndromic)90% of all polyps found in children20-50% may have > 1 polypNo increase in cancer risk in sporadic JP",
                      "90% of all polyps found in children",
                      "20-50% may have > 1 polyp",
                      "No increase in cancer risk in sporadic JP",
                      "May be manifestation of inherited familial polyposis syndromePatients with JPS have increased risk of colorectal carcinoma",
                      "Patients with JPS have increased risk of colorectal carcinoma"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria for JPS (any 1 of the following 3)> 5 juvenile polyps (most patients have 50-200)Presence of at least 1 JP outside of colonAny number of polyps in patient with positive family history",
                    "sub_points": [
                      "> 5 juvenile polyps (most patients have 50-200)",
                      "Presence of at least 1 JP outside of colon",
                      "Any number of polyps in patient with positive family history"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Incidence": [
                  {
                    "text": "1 in 100,000  worldwide"
                  }
                ],
                "Age": [
                  {
                    "text": "Typically presents in 1st decade of life"
                  }
                ],
                "Inheritance": [
                  {
                    "text": "75% of cases show autosomal dominant inheritance"
                  },
                  {
                    "text": "25% of cases appear de novo in patients without family history"
                  }
                ]
              },
              "Genetics": {
                "Specific Mutations": [
                  {
                    "text": "Germline mutations inSMAD4 (DPC4)gene on 18q21 present in 20-30% of JPS patientsExon 9 deletion is most common abnormalityPatients withSMAD4germline mutations are more likely to have polyps in upper gastrointestinal tract and positive family historySignificant proportion withSMAD4mutation may also have hereditary hemorrhagic telangiectasiaRecent study found that 81% of JPS patients withSMAD4mutations had hereditary hemorrhagic telangiectasia and another 14% were suspected of having it",
                    "sub_points": [
                      "Exon 9 deletion is most common abnormality",
                      "Patients withSMAD4germline mutations are more likely to have polyps in upper gastrointestinal tract and positive family history",
                      "Significant proportion withSMAD4mutation may also have hereditary hemorrhagic telangiectasiaRecent study found that 81% of JPS patients withSMAD4mutations had hereditary hemorrhagic telangiectasia and another 14% were suspected of having it",
                      "Recent study found that 81% of JPS patients withSMAD4mutations had hereditary hemorrhagic telangiectasia and another 14% were suspected of having it"
                    ]
                  },
                  {
                    "text": "Germline mutations inBMPR1Agene on 10q23 present in similar proportion of JPS cases (20-30%)"
                  },
                  {
                    "text": "Germline mutations inENGmay also lead to JPS in unknown proportion of patientsData suggest early childhood onset of polyps withENGmutationsAlso associated with hereditary hemorrhagic telangiectasia similar toSMAD4mutations",
                    "sub_points": [
                      "Data suggest early childhood onset of polyps withENGmutations",
                      "Also associated with hereditary hemorrhagic telangiectasia similar toSMAD4mutations"
                    ]
                  },
                  {
                    "text": "All 3 genes involved with transforming growth factor-β (TGF-β) pathway"
                  },
                  {
                    "text": "Older literature suggestsPTENmutations were also found in juvenile polyposis, but recent studies suggest these cases are better classified as Cowden/PTEN-hamartoma tumor syndrome instead of JPS"
                  }
                ]
              },
              "Clinical Implications": {
                "Presentation": [
                  {
                    "text": "Hematochezia"
                  },
                  {
                    "text": "Anemia"
                  },
                  {
                    "text": "Diarrhea"
                  },
                  {
                    "text": "Prolapse"
                  }
                ],
                "Juvenile Polyposis Coli": [
                  {
                    "text": "Most common inherited form"
                  },
                  {
                    "text": "Present clinically in 1st decade of life"
                  },
                  {
                    "text": "Polyps confined to colon"
                  }
                ],
                "Generalized Juvenile Polyposis": [
                  {
                    "text": "Diffuse involvement of gastrointestinal tract"
                  },
                  {
                    "text": "Colon, stomach, and small intestine involved"
                  }
                ],
                "Gastric Juvenile Polyposis": [
                  {
                    "text": "Rare form of disease"
                  },
                  {
                    "text": "Polyps confined to stomach"
                  },
                  {
                    "text": "Patients may present with protein-losing enteropathy and mimic Cronkhite-Canada syndrome"
                  }
                ],
                "Juvenile Polyposis of Infancy": [
                  {
                    "text": "Rare"
                  },
                  {
                    "text": "Usually associated with death in infancy due to protein-losing enteropathy"
                  },
                  {
                    "text": "Initially thought to be autosomal recessive due to lack of family history, but recent studies have found large de novo chromosome 10 deletions containing both theBMPR1AandPTENgenes in affected individuals"
                  }
                ],
                "Associated Manifestations": [
                  {
                    "text": "Present in 2/3 of JPS patientsHydrocephalus and mental retardationPulmonary arteriovenous malformationCleft palate and polydactylyMalrotation of gutMeckel diverticulum",
                    "sub_points": [
                      "Hydrocephalus and mental retardation",
                      "Pulmonary arteriovenous malformation",
                      "Cleft palate and polydactyly",
                      "Malrotation of gut",
                      "Meckel diverticulum"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Colorectal Adenocarcinoma": [
                  {
                    "text": "Mean age of developing cancer reported to be between 35 and 43 years"
                  },
                  {
                    "text": "Risk of developing colon cancer increases to 68% at age 60"
                  }
                ],
                "Gastric Adenocarcinoma": [
                  {
                    "text": "Associated withSMAD4mutations and severe gastric polyposis"
                  }
                ],
                "Small Intestinal and Pancreatic Adenocarcinoma": [
                  {
                    "text": "Rare reports of duodenal, ampullary, and pancreatic adenocarcinoma in patients with JPS"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Genetic Testing": [
                  {
                    "text": "Direct sequencing ofSMAD4andBMPR1Awill identify about 40-50% of cases"
                  },
                  {
                    "text": "Multiplex ligation probe-dependent amplification (MLPA) can pick up another 4-5% of cases by identifying large deletions and duplications in eitherSMAD4orBMPR1A"
                  }
                ],
                "Screening": [
                  {
                    "text": "In suspected patients, endoscopic screening generally starts at ~ age 15 and consists of upper and lower endoscopy as well as small bowel imaging with either capsule endoscopy or MR enterography"
                  },
                  {
                    "text": "In known JPS patients, screening endoscopy should be done annually"
                  }
                ],
                "Surgery": [
                  {
                    "text": "If patients are symptomatic or endoscopic surveillance is not feasible due to number of polyps, then surgery may be needed"
                  },
                  {
                    "text": "Patients who develop dysplasia or have a high prevalence of colon cancer in their families typically have a total colectomyContinued surveillance is still required after colectomy to remove polyps in rectal cuff",
                    "sub_points": [
                      "Continued surveillance is still required after colectomy to remove polyps in rectal cuff"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "Gross Features": [
                  {
                    "text": "Most patients have > 50 polyps"
                  },
                  {
                    "text": "Most polyps are pedunculated (> 2/3)"
                  },
                  {
                    "text": "Sessile polyps are infrequent, usually smaller in size, and often with smooth surface"
                  },
                  {
                    "text": "Size is variable, but most measure ~ 1.0 cm in greatest dimension"
                  },
                  {
                    "text": "Larger lesions are multilobulated and show surface ulceration"
                  },
                  {
                    "text": "Gross appearance may resemble adenomas"
                  },
                  {
                    "text": "Cut surface in larger polyps is soft, gelatinous due to mucin-filled cysts"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Epithelial component in colonic polypsSurface erosion or ulcerationGranulation tissue cap may be presentMarkedly dilated cystsCysts filled with mucin or distended with crypt abscessesEpithelium lining cysts is of variable height and may be completely flattenedHyperplastic regenerative changes may be presentRandom sections from grossly normal mucosa in colectomy specimens may show early \"incipient\" JP with cystically dilated and inflamed cryptsDysplasia or carcinoma may be presentCrypt:stroma ratio in polyps is higher in patients withSMAD4mutations as compared to those withBMPR1Amutations",
                    "sub_points": [
                      "Surface erosion or ulceration",
                      "Granulation tissue cap may be present",
                      "Markedly dilated cystsCysts filled with mucin or distended with crypt abscessesEpithelium lining cysts is of variable height and may be completely flattened",
                      "Cysts filled with mucin or distended with crypt abscesses",
                      "Epithelium lining cysts is of variable height and may be completely flattened",
                      "Hyperplastic regenerative changes may be present",
                      "Random sections from grossly normal mucosa in colectomy specimens may show early \"incipient\" JP with cystically dilated and inflamed crypts",
                      "Dysplasia or carcinoma may be present",
                      "Crypt:stroma ratio in polyps is higher in patients withSMAD4mutations as compared to those withBMPR1Amutations"
                    ]
                  },
                  {
                    "text": "Stromal component in colonic polypsMarked expansion of lamina propriaLoose edematous and inflamed (neutrophils or lymphoid follicles) stromaDegree of inflammation is variableMucin extravasation from ruptured cysts accentuates inflammatory responseHemorrhage and hemosiderin deposits present in larger polyps with torsion injurySmooth muscle proliferation may be present in larger pedunculated polypsMust distinguish from Peutz-Jeghers polypGanglioneuromas have been described previously, but these cases were probablyPTEN-hamartoma/Cowden syndrome, not JPSPolyps from patients withBMPR1Ahave been reported to have a higher stroma:crypt ratio than those from patients withSMAD4mutations",
                    "sub_points": [
                      "Marked expansion of lamina propria",
                      "Loose edematous and inflamed (neutrophils or lymphoid follicles) stromaDegree of inflammation is variableMucin extravasation from ruptured cysts accentuates inflammatory response",
                      "Degree of inflammation is variable",
                      "Mucin extravasation from ruptured cysts accentuates inflammatory response",
                      "Hemorrhage and hemosiderin deposits present in larger polyps with torsion injury",
                      "Smooth muscle proliferation may be present in larger pedunculated polypsMust distinguish from Peutz-Jeghers polyp",
                      "Must distinguish from Peutz-Jeghers polyp",
                      "Ganglioneuromas have been described previously, but these cases were probablyPTEN-hamartoma/Cowden syndrome, not JPS",
                      "Polyps from patients withBMPR1Ahave been reported to have a higher stroma:crypt ratio than those from patients withSMAD4mutations"
                    ]
                  },
                  {
                    "text": "Gastric polypsCystic epithelial component lined by foveolar-type epitheliumVariable degree of inflammationPolyps resemble hyperplastic polyps or those seen in Cronkhite-Canada syndromeDifficult to separate various hamartomatous gastric polyps without clinical information",
                    "sub_points": [
                      "Cystic epithelial component lined by foveolar-type epithelium",
                      "Variable degree of inflammation",
                      "Polyps resemble hyperplastic polyps or those seen in Cronkhite-Canada syndromeDifficult to separate various hamartomatous gastric polyps without clinical information",
                      "Difficult to separate various hamartomatous gastric polyps without clinical information"
                    ]
                  },
                  {
                    "text": "Dysplasia and carcinomaNot present in sporadic juvenile polypsMay be present in larger (> 1 cm) polyps in syndromic patientsPathologist must be wary of overinterpreting reactive atypia due to inflammationPrevalence of dysplasia ranges from 8-20%Higher incidence of dysplastic change present in polyps with villous architectureJPS patients may have adenomas as well as juvenile polypsAdenocarcinomas are more common in distal colon and rectumCarcinoma involving stomach or small bowel is rare",
                    "sub_points": [
                      "Not present in sporadic juvenile polyps",
                      "May be present in larger (> 1 cm) polyps in syndromic patientsPathologist must be wary of overinterpreting reactive atypia due to inflammation",
                      "Pathologist must be wary of overinterpreting reactive atypia due to inflammation",
                      "Prevalence of dysplasia ranges from 8-20%",
                      "Higher incidence of dysplastic change present in polyps with villous architecture",
                      "JPS patients may have adenomas as well as juvenile polyps",
                      "Adenocarcinomas are more common in distal colon and rectum",
                      "Carcinoma involving stomach or small bowel is rare"
                    ]
                  },
                  {
                    "text": "Differential diagnosisInflammatory polyposisSmall polyps are identical to inflammatory pseudopolypsBiopsies of flat mucosa to rule out idiopathic inflammatory bowel disease may be warranted in some casesPeutz-Jeghers polyposis (PJP)Pedunculated juvenile polyps with prolapse-type changes may mimic those seen in PJPLobules in PJP are separated by compact smooth muscle bundles, unlike disarrayed proliferation seen in some juvenile polypsEpithelial component in PJP is arranged in distinct lobular configurationMucocutaneous manifestations typical of PJP not seen in juvenile polyposisPTEN-hamartoma tumor syndrome/Cowden syndromePolyps may be indistinguishable, but stroma in Cowden more fibrotic and less inflamedCronkhite-Canada syndrome (CCS)Polyps may be very similar to JPSEctodermal manifestations (onychodystrophy, alopecia, hyperpigmentation) diagnostic of CCSHereditary mixed polyposis syndromePatients get juvenile polyps, serrated polyps, and adenomasEasily confused with JPS since patients with JPS often have adenomasAutosomal dominant inheritanceIncreased risk of colon cancerNo extraintestinal manifestations",
                    "sub_points": [
                      "Inflammatory polyposisSmall polyps are identical to inflammatory pseudopolypsBiopsies of flat mucosa to rule out idiopathic inflammatory bowel disease may be warranted in some cases",
                      "Small polyps are identical to inflammatory pseudopolyps",
                      "Biopsies of flat mucosa to rule out idiopathic inflammatory bowel disease may be warranted in some cases",
                      "Peutz-Jeghers polyposis (PJP)Pedunculated juvenile polyps with prolapse-type changes may mimic those seen in PJPLobules in PJP are separated by compact smooth muscle bundles, unlike disarrayed proliferation seen in some juvenile polypsEpithelial component in PJP is arranged in distinct lobular configurationMucocutaneous manifestations typical of PJP not seen in juvenile polyposis",
                      "Pedunculated juvenile polyps with prolapse-type changes may mimic those seen in PJP",
                      "Lobules in PJP are separated by compact smooth muscle bundles, unlike disarrayed proliferation seen in some juvenile polyps",
                      "Epithelial component in PJP is arranged in distinct lobular configuration",
                      "Mucocutaneous manifestations typical of PJP not seen in juvenile polyposis",
                      "PTEN-hamartoma tumor syndrome/Cowden syndromePolyps may be indistinguishable, but stroma in Cowden more fibrotic and less inflamed",
                      "Polyps may be indistinguishable, but stroma in Cowden more fibrotic and less inflamed",
                      "Cronkhite-Canada syndrome (CCS)Polyps may be very similar to JPSEctodermal manifestations (onychodystrophy, alopecia, hyperpigmentation) diagnostic of CCS",
                      "Polyps may be very similar to JPS",
                      "Ectodermal manifestations (onychodystrophy, alopecia, hyperpigmentation) diagnostic of CCS",
                      "Hereditary mixed polyposis syndromePatients get juvenile polyps, serrated polyps, and adenomasEasily confused with JPS since patients with JPS often have adenomasAutosomal dominant inheritanceIncreased risk of colon cancerNo extraintestinal manifestations",
                      "Patients get juvenile polyps, serrated polyps, and adenomas",
                      "Easily confused with JPS since patients with JPS often have adenomas",
                      "Autosomal dominant inheritance",
                      "Increased risk of colon cancer",
                      "No extraintestinal manifestations"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Inherited Cancer Syndromes: Skin, Nervous System, and Soft Tissue": {
        "name": "Inherited Cancer Syndromes: Skin, Nervous System, and Soft Tissue",
        "url": "https://app.pathprimer.com/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
        "topics": {
          "Carney Complex Including LAMB Syndrome": {
            "name": "Carney Complex Including LAMB Syndrome",
            "url": "https://app.pathprimer.com/document/fd02ae12-95de-4dc5-a54b-a1e103c079f0/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Carney complex (CNC)"
                  },
                  {
                    "text": "Lentigines, atrial myxomas, mucocutaneous myxomas, and blue nevi syndrome  (LAMB)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Nevi, atrial myxoma, myxoid neurofibroma, and ephelides (NAME) syndrome"
                  },
                  {
                    "text": "Carney syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Multiple neoplasia syndrome featuring cardiac, endocrine, cutaneous, and neural tumors, as well as variety of pigmented lesions of skin and mucosae"
                  },
                  {
                    "text": "CNC may simultaneously involve multiple endocrine glands, as in classic multiple endocrine neoplasia syndromes 1 and 2"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "Mean age at diagnosis is 10-20 years"
                  }
                ],
                "Gender": [
                  {
                    "text": "M = F"
                  }
                ],
                "Incidence": [
                  {
                    "text": "> 400 patients have been diagnosed with CNC"
                  },
                  {
                    "text": "Cardiac myxomas are most common primary cardiac tumor and occur in 7 per 10,000 individuals"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Autosomal dominant disorder characterized by complex of myxomas, spotty pigmentation, and endocrine overactivitySeveral patients described in earlier years under acronyms NAME and LAMB probably had CNCCNC is not only multiple neoplasia syndrome but also causes variety of pigmented lesions of skin and mucosae",
                    "sub_points": [
                      "Several patients described in earlier years under acronyms NAME and LAMB probably had CNC",
                      "CNC is not only multiple neoplasia syndrome but also causes variety of pigmented lesions of skin and mucosae"
                    ]
                  },
                  {
                    "text": "Genetic mutation inPRKAR1Agene (17q22-24) and chromosome 2p16PRKAR1Aencodes regulatory R1 α-subunit of protein kinase A",
                    "sub_points": [
                      "PRKAR1Aencodes regulatory R1 α-subunit of protein kinase A"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "SkinMultiple facial lentigines and mucosal labial pigmentationSubcutaneous myxoid neurofibromasEpithelioid blue nevus",
                    "sub_points": [
                      "Multiple facial lentigines and mucosal labial pigmentation",
                      "Subcutaneous myxoid neurofibromas",
                      "Epithelioid blue nevus"
                    ]
                  },
                  {
                    "text": "Endocrine organsAdrenalPrimary pigmented nodular adrenocortical disease (PPNAD)Cushing syndromeThyroidThyroid nodulesPituitary adenomaAcromegaly/gigantism or galactorrhea, depending on tumor type",
                    "sub_points": [
                      "AdrenalPrimary pigmented nodular adrenocortical disease (PPNAD)Cushing syndrome",
                      "Primary pigmented nodular adrenocortical disease (PPNAD)",
                      "Cushing syndrome",
                      "ThyroidThyroid nodules",
                      "Thyroid nodules",
                      "Pituitary adenomaAcromegaly/gigantism or galactorrhea, depending on tumor type",
                      "Acromegaly/gigantism or galactorrhea, depending on tumor type"
                    ]
                  },
                  {
                    "text": "HeartAtrial myxomas are most common primary tumor of heartMajority of tumors arise from left atrial septum near fossa ovalisLesions arising from right atrium or in young adults are more likely to be associated with familial syndromeMay present with tumor emboli",
                    "sub_points": [
                      "Atrial myxomas are most common primary tumor of heart",
                      "Majority of tumors arise from left atrial septum near fossa ovalis",
                      "Lesions arising from right atrium or in young adults are more likely to be associated with familial syndrome",
                      "May present with tumor emboli"
                    ]
                  },
                  {
                    "text": "TestisLarge cell calcifying Sertoli cell tumor (LCCSCT), often bilateral",
                    "sub_points": [
                      "Large cell calcifying Sertoli cell tumor (LCCSCT), often bilateral"
                    ]
                  },
                  {
                    "text": "Gastrointestinal tractPsammomatous melanotic schwannoma in esophagus and stomach",
                    "sub_points": [
                      "Psammomatous melanotic schwannoma in esophagus and stomach"
                    ]
                  },
                  {
                    "text": "Psammomatous melanotic schwannomas"
                  },
                  {
                    "text": "Breast ductal adenoma"
                  },
                  {
                    "text": "Osteochondromyxoma"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Depends on main pathologyBilateral adrenalectomyRemoval of cardiac myxomasSurgery with removal of testicular tumorsSurgery with removal of other tumors",
                    "sub_points": [
                      "Bilateral adrenalectomy",
                      "Removal of cardiac myxomas",
                      "Surgery with removal of testicular tumors",
                      "Surgery with removal of other tumors"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Most tumors associated with CNC are slow growing with no malignant potential"
                  },
                  {
                    "text": "Sudden death due to cardiac myxoma may occurDecreased lifespan expected",
                    "sub_points": [
                      "Decreased lifespan expected"
                    ]
                  },
                  {
                    "text": "Complications of Cushing syndrome"
                  }
                ]
              },
              "MACROSCOPIC": {
                "Atrial Myxoma": [
                  {
                    "text": "Mobile, pedunculated, ball-shaped mass"
                  }
                ],
                "PPNAD": [
                  {
                    "text": "Small to normal-sized adrenal glands"
                  },
                  {
                    "text": "Multiple bilateral, small cortical nodules (0.1-0.3 cm)May be pigmented, brown, or black; some may be pale to bright yellow",
                    "sub_points": [
                      "May be pigmented, brown, or black; some may be pale to bright yellow"
                    ]
                  }
                ],
                "Large Cell Calcifying Sertoli Cell Tumor": [
                  {
                    "text": "Ranges in size from microscopic to large tumor replacing entire testis"
                  },
                  {
                    "text": "Usually multicentric, bilateral, and calcified"
                  }
                ],
                "Psammomatous Melanotic Schwannoma": [
                  {
                    "text": "Black, multiple nodules that occur simultaneously or asynchronously at different sites"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Atrial myxomaComposed of plump, stellate, or spindled cells arranged in cords and primitive-appearing vessels in loose, myxoid stromaStroma often contains hemorrhage or hemosiderin with variable numbers of inflammatory cellsHeterologous elements such as glands or extramedullary hematopoiesis can be found in small minority of cases (2%)",
                    "sub_points": [
                      "Composed of plump, stellate, or spindled cells arranged in cords and primitive-appearing vessels in loose, myxoid stromaStroma often contains hemorrhage or hemosiderin with variable numbers of inflammatory cells",
                      "Stroma often contains hemorrhage or hemosiderin with variable numbers of inflammatory cells",
                      "Heterologous elements such as glands or extramedullary hematopoiesis can be found in small minority of cases (2%)"
                    ]
                  },
                  {
                    "text": "PPNADNodules composed of cells with compact eosinophilic cytoplasm, with abundant brown granular pigment (lipofuscin)Cell nuclei are vesicular and may contain prominent nucleoliIntervening cortical tissue is atrophic",
                    "sub_points": [
                      "Nodules composed of cells with compact eosinophilic cytoplasm, with abundant brown granular pigment (lipofuscin)",
                      "Cell nuclei are vesicular and may contain prominent nucleoli",
                      "Intervening cortical tissue is atrophic"
                    ]
                  },
                  {
                    "text": "Large cell calcifying Sertoli cell tumorTumor has ill-defined peripheryMultiple cellular arrangement patterns of distribution: Usually solid or trabecularLarge tumor cells with abundant granular and eosinophilic cytoplasmLaminated calcospherites are characteristicMay be only few or multiple, and often with confluenceMitoses are rareNeutrophilic infiltration is usually present",
                    "sub_points": [
                      "Tumor has ill-defined periphery",
                      "Multiple cellular arrangement patterns of distribution: Usually solid or trabecular",
                      "Large tumor cells with abundant granular and eosinophilic cytoplasm",
                      "Laminated calcospherites are characteristicMay be only few or multiple, and often with confluence",
                      "May be only few or multiple, and often with confluence",
                      "Mitoses are rare",
                      "Neutrophilic infiltration is usually present"
                    ]
                  },
                  {
                    "text": "Pituitary adenomaAdenoma with solid growth patternRound and polygonal cells with granular eosinophilic cytoplasm and round to oval nucleiUsually growth hormone (GH) &/or prolactin-producing tumors",
                    "sub_points": [
                      "Adenoma with solid growth pattern",
                      "Round and polygonal cells with granular eosinophilic cytoplasm and round to oval nuclei",
                      "Usually growth hormone (GH) &/or prolactin-producing tumors"
                    ]
                  },
                  {
                    "text": "Psammomatous melanotic schwannomaPeripheral nerve sheath tumor affecting posterior spinal nerve roots, alimentary tract, bone, and skinSpindle and epithelioid cells intermixed with melanin, psammoma bodies, and adipose tissue~ 10% are malignant and metastasize",
                    "sub_points": [
                      "Peripheral nerve sheath tumor affecting posterior spinal nerve roots, alimentary tract, bone, and skin",
                      "Spindle and epithelioid cells intermixed with melanin, psammoma bodies, and adipose tissue",
                      "~ 10% are malignant and metastasize"
                    ]
                  }
                ]
              },
              "Diagnosis": {
                "Criteria": [
                  {
                    "text": "Definite diagnosis of CNC is given if 2 or more major manifestations are present"
                  },
                  {
                    "text": "Major diagnostic criteria for CNCSpotty skin pigmentation with typical distribution on such sites as the lips, conjunctiva and inner or outer canthi, or vaginal and penile mucosaMyxoma (cutaneous and mucosal)Cardiac myxomaBreast myxomatosis or fat-suppressed MR imaging findings are suggestivePPNAD or paradoxical positive response of urinary glucocorticosteroid excretion to dexamethasone administration during Liddle testAcromegaly due to GH-producing adenomaLarge cell calcifying Sertoli cell tumorThyroid carcinoma or multiple adenomatous nodules in young patientPsammomatous melanotic schwannomasBlue nevus, epithelioid blue nevusBreast ductal adenomaOsteochondromyxoma",
                    "sub_points": [
                      "Spotty skin pigmentation with typical distribution on such sites as the lips, conjunctiva and inner or outer canthi, or vaginal and penile mucosa",
                      "Myxoma (cutaneous and mucosal)",
                      "Cardiac myxoma",
                      "Breast myxomatosis or fat-suppressed MR imaging findings are suggestive",
                      "PPNAD or paradoxical positive response of urinary glucocorticosteroid excretion to dexamethasone administration during Liddle test",
                      "Acromegaly due to GH-producing adenoma",
                      "Large cell calcifying Sertoli cell tumor",
                      "Thyroid carcinoma or multiple adenomatous nodules in young patient",
                      "Psammomatous melanotic schwannomas",
                      "Blue nevus, epithelioid blue nevus",
                      "Breast ductal adenoma",
                      "Osteochondromyxoma"
                    ]
                  },
                  {
                    "text": "Supplementary criteriaAffected 1st-degree relativeInactivating mutation ofPRKAR1Agene",
                    "sub_points": [
                      "Affected 1st-degree relative",
                      "Inactivating mutation ofPRKAR1Agene"
                    ]
                  },
                  {
                    "text": "Cutaneous manifestations constitute 3 of the major disease manifestationsCutaneous or mucosal myxomaBlue nevi (multiple) or epithelioid blue nevus",
                    "sub_points": [
                      "Cutaneous or mucosal myxoma",
                      "Blue nevi (multiple) or epithelioid blue nevus"
                    ]
                  },
                  {
                    "text": "Findings suggestive of,or possibly associated with CNC, but not diagnosticIntense freckling (without darkly pigmented spots or typical distribution)Multiple blue nevi of common typeCafé au lait spots or other birthmarksElevated IGF1 levels, abnormal GTT, or paradoxical GH response to TRH testing in absence of clinical acromegalyCardiomyopathyPilonidal sinusHistory of Cushing syndrome, acromegaly, or sudden death in extended familyMultiple skin tags or other skin lesions, including lipomas and angiofibromasColonic polyps (usually in association with acromegaly)Hyperprolactinemia (usually mild and almost always combined with clinical or subclinical acromegaly)Single, benign thyroid nodule in young patient; multiple thyroid nodules in older patient (detected on ultrasound)Family history of carcinoma, particularly of thyroid, colon, pancreas, and ovary; other multiple benign or malignant tumorsRelationship between cutaneous and noncutaneous manifestations of CNC appears to be essential clue to molecular etiology> 1/2 of CNC patients present with both characteristic dermatological and endocrine signsSignificant number of patients present with skin lesions that are only suggestive, not characteristic, of CNC",
                    "sub_points": [
                      "Intense freckling (without darkly pigmented spots or typical distribution)",
                      "Multiple blue nevi of common type",
                      "Café au lait spots or other birthmarks",
                      "Elevated IGF1 levels, abnormal GTT, or paradoxical GH response to TRH testing in absence of clinical acromegaly",
                      "Cardiomyopathy",
                      "Pilonidal sinus",
                      "History of Cushing syndrome, acromegaly, or sudden death in extended family",
                      "Multiple skin tags or other skin lesions, including lipomas and angiofibromas",
                      "Colonic polyps (usually in association with acromegaly)",
                      "Hyperprolactinemia (usually mild and almost always combined with clinical or subclinical acromegaly)",
                      "Single, benign thyroid nodule in young patient; multiple thyroid nodules in older patient (detected on ultrasound)",
                      "Family history of carcinoma, particularly of thyroid, colon, pancreas, and ovary; other multiple benign or malignant tumors",
                      "Relationship between cutaneous and noncutaneous manifestations of CNC appears to be essential clue to molecular etiology",
                      "> 1/2 of CNC patients present with both characteristic dermatological and endocrine signsSignificant number of patients present with skin lesions that are only suggestive, not characteristic, of CNC",
                      "Significant number of patients present with skin lesions that are only suggestive, not characteristic, of CNC"
                    ]
                  },
                  {
                    "text": "Classification based on both dermatological and endocrine markers has subgrouped CNC patients asMultisymptomatic (with extensive endocrine and skin signs)Intermediate (with few dermatological and endocrine manifestations)Paucisymptomatic (with isolated PPNAD and no cutaneous signs)",
                    "sub_points": [
                      "Multisymptomatic (with extensive endocrine and skin signs)",
                      "Intermediate (with few dermatological and endocrine manifestations)",
                      "Paucisymptomatic (with isolated PPNAD and no cutaneous signs)"
                    ]
                  }
                ],
                "Diagnostic Criteria for Clinical Diagnosis": [
                  {
                    "text": "Patient must have ≥ 2 of the followingSpotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)Myxoma (cutaneous: Often on the eyelid, external ear, nipple)Cardiac myxomaBreast myxomatosis or fat-suppressed MR findings suggestive of this diagnosisAcromegaly due to GH-producing adenoma (somatotropinoma)PPNAD or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during diagnostic test for Cushing syndromeThyroid carcinoma or multiple hypoechoic nodules on thyroid ultrasonography in a young patientLCCSCT of testis or characteristic calcification on testicular ultrasonographyPsammomatous melanotic schwannomaBlue nevus, epithelioid blue nevus (multiple)Breast ductal adenoma, or mammary tumor with intraductal papillomaOsteochondromyxoma of boneAdditionally, criteria is satisfied by a patient meeting only 1 of these criteria, but having eitherAffected 1st-degree relative orInactivating mutation of thePRKAR1Agene",
                    "sub_points": [
                      "Spotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)",
                      "Myxoma (cutaneous: Often on the eyelid, external ear, nipple)",
                      "Cardiac myxoma",
                      "Breast myxomatosis or fat-suppressed MR findings suggestive of this diagnosis",
                      "Acromegaly due to GH-producing adenoma (somatotropinoma)",
                      "PPNAD or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during diagnostic test for Cushing syndrome",
                      "Thyroid carcinoma or multiple hypoechoic nodules on thyroid ultrasonography in a young patient",
                      "LCCSCT of testis or characteristic calcification on testicular ultrasonography",
                      "Psammomatous melanotic schwannoma",
                      "Blue nevus, epithelioid blue nevus (multiple)",
                      "Breast ductal adenoma, or mammary tumor with intraductal papilloma",
                      "Osteochondromyxoma of bone",
                      "Additionally, criteria is satisfied by a patient meeting only 1 of these criteria, but having eitherAffected 1st-degree relative orInactivating mutation of thePRKAR1Agene",
                      "Affected 1st-degree relative or",
                      "Inactivating mutation of thePRKAR1Agene"
                    ]
                  }
                ],
                "Similar Clinical and Pathological Features": [
                  {
                    "text": "Peutz-Jeghers syndrome (PJS), with which it shares mucosal lentiginosis and unusual gonadal tumor, and large cell calcifying Sertoli cell tumor"
                  },
                  {
                    "text": "McCune-Albright syndrome: Sporadic condition also characterized by multiple endocrine and nonendocrine tumors"
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Atrial myxomaCells stain positive for CD34, CD31, and S100Calretinin is positive in 74-100% of cases and can be useful to distinguish this lesion from myxoid thrombus",
                    "sub_points": [
                      "Cells stain positive for CD34, CD31, and S100",
                      "Calretinin is positive in 74-100% of cases and can be useful to distinguish this lesion from myxoid thrombus"
                    ]
                  },
                  {
                    "text": "PPNADIncreased expression of glucocorticoid receptor",
                    "sub_points": [
                      "Increased expression of glucocorticoid receptor"
                    ]
                  },
                  {
                    "text": "Large cell calcifying Sertoli cell tumorPositive for vimentin, inhibin-α, NSE, S100, desmin, and smooth muscle actinNegative for α-fetoprotein, HCG, PLAP, podoplanin, OCT3/4, and cytokeratin (may be focally positive)",
                    "sub_points": [
                      "Positive for vimentin, inhibin-α, NSE, S100, desmin, and smooth muscle actin",
                      "Negative for α-fetoprotein, HCG, PLAP, podoplanin, OCT3/4, and cytokeratin (may be focally positive)"
                    ]
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "Genetic heterogeneity with ≥ 2 main loci for candidate genesChromosome 2 locus at 2p15-16Mutations ofPRKAR1Agene on chromosome 17 (17q22-24)",
                    "sub_points": [
                      "Chromosome 2 locus at 2p15-16",
                      "Mutations ofPRKAR1Agene on chromosome 17 (17q22-24)"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Other Syndromes": [
                  {
                    "text": "Share clinical features and molecular pathways with several other familial lentiginosis syndromes, such asMcCune-Albright syndromePeutz-Jeghers syndromeLEOPARD (multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness)Noonan syndromePTEN-hamartoma tumor syndromes (e.g., Cowden disease [CD] and Bannayan-Ruvalcaba-Riley syndrome [BRRS])In all of these conditions, skin lesions accompany underlying endocrine &/or other abnormalities, and, similarly to CNC, are considered important diagnostic sign",
                    "sub_points": [
                      "McCune-Albright syndrome",
                      "Peutz-Jeghers syndrome",
                      "LEOPARD (multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness)",
                      "Noonan syndrome",
                      "PTEN-hamartoma tumor syndromes (e.g., Cowden disease [CD] and Bannayan-Ruvalcaba-Riley syndrome [BRRS])",
                      "In all of these conditions, skin lesions accompany underlying endocrine &/or other abnormalities, and, similarly to CNC, are considered important diagnostic sign"
                    ]
                  }
                ],
                "McCune-Albright Syndrome": [
                  {
                    "text": "Probably the closest to CNC in terms of molecular pathway link"
                  },
                  {
                    "text": "Patients have characteristic lesions that affect predominantly 3 systems: Skin, endocrine system, and skeleton"
                  },
                  {
                    "text": "Café au lait spots in McCune-Albright syndrome patients are similar to those observed in CNCTend to be more intensely pigmented",
                    "sub_points": [
                      "Tend to be more intensely pigmented"
                    ]
                  },
                  {
                    "text": "Caused by post-zygotic activating mutations ofGNAS1"
                  }
                ],
                "Peutz-Jeghers Syndrome": [
                  {
                    "text": "Autosomal dominant familial lentiginosis syndrome characterized by melanocytic macules of lips, buccal mucosa, and digits, multiple gastrointestinal hamartomatous polyps, and increased risk of various neoplasms"
                  },
                  {
                    "text": "Lentigines observed in Peutz-Jeghers syndrome patients show similar density and distribution to those in CNC patients"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome was first mapped to chromosome 19p13.3, and gene-encoding serine threonine kinase 11 (STK11a.k.a.LKB1) was found to be mutated in most patients"
                  }
                ],
                "LEOPARD": [
                  {
                    "text": "Multiplelentigines,electrocardiographic conduction abnormalities,ocular hypertelorism,pulmonic stenosis,abnormal genitalia,retardation of growth, and sensorineuraldeafness"
                  }
                ],
                "Cowden Disease and Bannayan-Ruvalcaba-Riley Syndrome (PTEN-Hamartoma Tumor Syndromes)": [
                  {
                    "text": "Cowden disease and BRRS share clinical characteristics, such as mucocutaneous lesions, hamartomatous polyps of gastrointestinal tract, and increased risk of developing neoplasms"
                  },
                  {
                    "text": "Both conditions are caused by mutations inPTENgenePTENis located on 10q23.31 and encodes phosphatidylinositol-3,4,5-triphosphate 3-phosphataseTumor suppressor gene that has been found mutated in a number of tumors",
                    "sub_points": [
                      "PTENis located on 10q23.31 and encodes phosphatidylinositol-3,4,5-triphosphate 3-phosphataseTumor suppressor gene that has been found mutated in a number of tumors",
                      "Tumor suppressor gene that has been found mutated in a number of tumors"
                    ]
                  },
                  {
                    "text": "Thyroid is usually affected by numerous adenomatous nodules, follicular adenomas, and follicular carcinomaFindings are similar to those familial syndromes characterized by predominance of nonthyroidal tumorsPTEN-hamartoma tumor syndrome, Carney complex, Werner syndrome, and Pendred syndrome",
                    "sub_points": [
                      "Findings are similar to those familial syndromes characterized by predominance of nonthyroidal tumorsPTEN-hamartoma tumor syndrome, Carney complex, Werner syndrome, and Pendred syndrome",
                      "PTEN-hamartoma tumor syndrome, Carney complex, Werner syndrome, and Pendred syndrome"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "McCune Albright Syndrome": {
            "name": "McCune Albright Syndrome",
            "url": "https://app.pathprimer.com/document/4065ace1-e051-4d48-b871-1b59ab492818/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "MAS consists of at least2features of the triadAutonomous endocrine hyperfunction, such as precocious puberty, hyperthyroidism, and hypercortisolismPolyostotic fibrous dysplasiaCafé au lait pigmented skin lesions",
                    "sub_points": [
                      "Autonomous endocrine hyperfunction, such as precocious puberty, hyperthyroidism, and hypercortisolism",
                      "Polyostotic fibrous dysplasia",
                      "Café au lait pigmented skin lesions"
                    ]
                  },
                  {
                    "text": "MAS iscaused by activating mutations in complex GNAS locus at 20q13"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Rare disease with estimated prevalence between 1:100,000-1,000,000"
                  },
                  {
                    "text": "Diagnosis of MAS is often made within 1st decade of life"
                  }
                ],
                "Imaging": [
                  {
                    "text": "FD: Ground-glass appearance on radiograph"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Endocrine organ hyperplasia or adenomaThyroid with multinodular hyperplasiaAdrenal gland with macronodular hyperplasiaPituitary gland with pituitary adenoma",
                    "sub_points": [
                      "Thyroid with multinodular hyperplasia",
                      "Adrenal gland with macronodular hyperplasia",
                      "Pituitary gland with pituitary adenoma"
                    ]
                  },
                  {
                    "text": "Fibrous dysplasia\"Chinese writing\" pattern, characterized by thin and disconnected bone trabeculae with interspersed fibrous tissueSpicules of woven bone are surrounded by flat lining cells with retracted cell bodies, forming pseudolacunar spaces",
                    "sub_points": [
                      "\"Chinese writing\" pattern, characterized by thin and disconnected bone trabeculae with interspersed fibrous tissue",
                      "Spicules of woven bone are surrounded by flat lining cells with retracted cell bodies, forming pseudolacunar spaces"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "McCune-Albright syndrome (MAS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "MAS consists of at least 2 features of the triad of polyostotic fibrous dysplasia: Café au lait pigmented skin lesions and autonomous endocrine hyperfunction"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "MAS is usually caused by early embryonic postzygotic somatic activating mutations in theGNAS1gene (GNASlocus at 20q13.2-q13.3)"
                  },
                  {
                    "text": "Most common mutations are point mutations with Arg201 (most commonly R201H and R201C)"
                  },
                  {
                    "text": "Activating mutations lead to increased cAMP levels, which has multiple effects in different organs"
                  },
                  {
                    "text": "Significant variability observed in extent and severity of clinical presentation is due to somatic mosaicism ofGNAS1mutations"
                  },
                  {
                    "text": "Nonmosaic state of activating mutations are presumably lethal to the embryo"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare disease with estimated prevalence between 1:100,000-1,000,000"
                  }
                ],
                "Age": [
                  {
                    "text": "Diagnosis of MAS is often made within 1st decade of life"
                  }
                ],
                "Sex": [
                  {
                    "text": "Occurs equally in both sexes"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Endocrine hyperfunctionPrecocious pubertyIn girls, clinical presentation includes vaginal bleeding or spotting, development of breast tissueCaused by gonadotropin-independent secretion of estrogen from large ovarian folliclesIn boys, testicular and penile enlargement and precocious sexual behaviorTesticular enlargement often results from maturation and growth of seminiferous tubulesThyroidHyperthyroidism due to multinodular hyperplasiaAdrenal glandHypercortisolism often due to macronodular cortical hyperplasiaPituitary glandAcromegaly or gigantism due to pituitary adenomaOthersChronic liver disease, tachycardia, and hypophosphatemiaHyperphosphaturic hypophosphatemic ricketsOsteomalacia",
                    "sub_points": [
                      "Precocious pubertyIn girls, clinical presentation includes vaginal bleeding or spotting, development of breast tissueCaused by gonadotropin-independent secretion of estrogen from large ovarian folliclesIn boys, testicular and penile enlargement and precocious sexual behaviorTesticular enlargement often results from maturation and growth of seminiferous tubules",
                      "In girls, clinical presentation includes vaginal bleeding or spotting, development of breast tissue",
                      "Caused by gonadotropin-independent secretion of estrogen from large ovarian follicles",
                      "In boys, testicular and penile enlargement and precocious sexual behavior",
                      "Testicular enlargement often results from maturation and growth of seminiferous tubules",
                      "ThyroidHyperthyroidism due to multinodular hyperplasia",
                      "Hyperthyroidism due to multinodular hyperplasia",
                      "Adrenal glandHypercortisolism often due to macronodular cortical hyperplasia",
                      "Hypercortisolism often due to macronodular cortical hyperplasia",
                      "Pituitary glandAcromegaly or gigantism due to pituitary adenoma",
                      "Acromegaly or gigantism due to pituitary adenoma",
                      "OthersChronic liver disease, tachycardia, and hypophosphatemiaHyperphosphaturic hypophosphatemic ricketsOsteomalacia",
                      "Chronic liver disease, tachycardia, and hypophosphatemia",
                      "Hyperphosphaturic hypophosphatemic rickets",
                      "Osteomalacia"
                    ]
                  },
                  {
                    "text": "Polyostotic fibrous dysplasia(POFD)Benign fibro-osseous bone lesion involving multiple bone sitesClinical presentation includesAbnormal gaitVisible bony deformities (leg length discrepancy, Shepherd's crook deformity, facial asymmetry or bony enlargement)Bone painJoint stiffness with painPathological fracturesNerve compressionLocationMost commonly in femur, tibia, humerus, ribs, and craniofacial bonesPOFD is thought to be secondary to increased proliferation and decreased osteoblastic differentiation of bone marrow stromal cells",
                    "sub_points": [
                      "Benign fibro-osseous bone lesion involving multiple bone sites",
                      "Clinical presentation includesAbnormal gaitVisible bony deformities (leg length discrepancy, Shepherd's crook deformity, facial asymmetry or bony enlargement)Bone painJoint stiffness with painPathological fracturesNerve compression",
                      "Abnormal gait",
                      "Visible bony deformities (leg length discrepancy, Shepherd's crook deformity, facial asymmetry or bony enlargement)",
                      "Bone pain",
                      "Joint stiffness with pain",
                      "Pathological fractures",
                      "Nerve compression",
                      "LocationMost commonly in femur, tibia, humerus, ribs, and craniofacial bones",
                      "Most commonly in femur, tibia, humerus, ribs, and craniofacial bones",
                      "POFD is thought to be secondary to increased proliferation and decreased osteoblastic differentiation of bone marrow stromal cells"
                    ]
                  },
                  {
                    "text": "Caféau lait pigmented skin lesionsFlat macules that often follow a segmental pattern of distribution of developmental lines of BlaschkoOften, these lesions are on same side affected by fibrous dysplasiaPigmentation becomes more obvious with age and may darken after sun exposureLikely result from increased intracellular cAMP in melanocytes, which leads to increased melanin production",
                    "sub_points": [
                      "Flat macules that often follow a segmental pattern of distribution of developmental lines of Blaschko",
                      "Often, these lesions are on same side affected by fibrous dysplasia",
                      "Pigmentation becomes more obvious with age and may darken after sun exposure",
                      "Likely result from increased intracellular cAMP in melanocytes, which leads to increased melanin production"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Endocrine hyperfunctionManagement depends on individual presentation",
                    "sub_points": [
                      "Management depends on individual presentation"
                    ]
                  },
                  {
                    "text": "Fibrous dysplasiaBony disease is very difficult to treat and no specific treatments are availableBisphosphonates are often used to reduce bone pain, frequency of pathological fractures",
                    "sub_points": [
                      "Bony disease is very difficult to treat and no specific treatments are availableBisphosphonates are often used to reduce bone pain, frequency of pathological fractures",
                      "Bisphosphonates are often used to reduce bone pain, frequency of pathological fractures"
                    ]
                  },
                  {
                    "text": "Café au lait skin lesionsTotally benign and no treatment is needed",
                    "sub_points": [
                      "Totally benign and no treatment is needed"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "MAS is not associated with significantly increased mortality risk"
                  },
                  {
                    "text": "Sudden cardiac death has been reported"
                  }
                ],
                "Complications": [
                  {
                    "text": "Osteosarcoma in 1% of patients with POFD"
                  },
                  {
                    "text": "Females may have greater risk for breast cancer"
                  },
                  {
                    "text": "Secondary osteomyelitis"
                  },
                  {
                    "text": "Thyroid carcinoma"
                  },
                  {
                    "text": "Myositis"
                  },
                  {
                    "text": "Compressive neuropathy"
                  },
                  {
                    "text": "Sympathetic algodystrophy"
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Fibrous dysplasiaRadiograph: Ground-glass appearance",
                    "sub_points": [
                      "Radiograph: Ground-glass appearance"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Endocrine hyperfunctionOvary with enlarged folliclesThyroid with multinodular hyperplasiaMultiple nodules with different sizeVarying degree of cellularity and colloidSanderson polsters (papillary-type projections into lumens of follicles)Adrenal gland with macronodular hyperplasiaShows multiple macronodulesMacronodules are composed of hypertrophied, globoid, lipid-depleted adrenocortical cellsResidual normal gland is often atrophicPituitary gland with pituitary adenomaSolid, diffuse, trabecular, sinusoidal, and papillary growth patterns are commonTumor cells with typical neuroendocrine cell featuresFinely dispersed chromatin with distinct nucleoliCytoplasmic granularity gives 3 morphologically distinct cell types: Chromophobic, eosinophilic, and basophilic",
                    "sub_points": [
                      "Ovary with enlarged follicles",
                      "Thyroid with multinodular hyperplasiaMultiple nodules with different sizeVarying degree of cellularity and colloidSanderson polsters (papillary-type projections into lumens of follicles)",
                      "Multiple nodules with different size",
                      "Varying degree of cellularity and colloid",
                      "Sanderson polsters (papillary-type projections into lumens of follicles)",
                      "Adrenal gland with macronodular hyperplasiaShows multiple macronodulesMacronodules are composed of hypertrophied, globoid, lipid-depleted adrenocortical cellsResidual normal gland is often atrophic",
                      "Shows multiple macronodules",
                      "Macronodules are composed of hypertrophied, globoid, lipid-depleted adrenocortical cells",
                      "Residual normal gland is often atrophic",
                      "Pituitary gland with pituitary adenomaSolid, diffuse, trabecular, sinusoidal, and papillary growth patterns are commonTumor cells with typical neuroendocrine cell featuresFinely dispersed chromatin with distinct nucleoliCytoplasmic granularity gives 3 morphologically distinct cell types: Chromophobic, eosinophilic, and basophilic",
                      "Solid, diffuse, trabecular, sinusoidal, and papillary growth patterns are common",
                      "Tumor cells with typical neuroendocrine cell features",
                      "Finely dispersed chromatin with distinct nucleoli",
                      "Cytoplasmic granularity gives 3 morphologically distinct cell types: Chromophobic, eosinophilic, and basophilic"
                    ]
                  },
                  {
                    "text": "Fibrous dysplasia (FD)Composed of fibrous tissue and immature woven boneSpindle-shaped fibroblasts arranged in parallel arrays or in whorlsWoven bone with \"Chinese writing\" patternSpicules of woven bone are surrounded by flat lining cells with retracted cell bodies, forming pseudolacunar spaces",
                    "sub_points": [
                      "Composed of fibrous tissue and immature woven boneSpindle-shaped fibroblasts arranged in parallel arrays or in whorlsWoven bone with \"Chinese writing\" patternSpicules of woven bone are surrounded by flat lining cells with retracted cell bodies, forming pseudolacunar spaces",
                      "Spindle-shaped fibroblasts arranged in parallel arrays or in whorls",
                      "Woven bone with \"Chinese writing\" pattern",
                      "Spicules of woven bone are surrounded by flat lining cells with retracted cell bodies, forming pseudolacunar spaces"
                    ]
                  },
                  {
                    "text": "Café au lait skin lesionsNo change in number of melanocytes but increase in number of melanin-containing pigment melanosomes",
                    "sub_points": [
                      "No change in number of melanocytes but increase in number of melanin-containing pigment melanosomes"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Cytology": [
                  {
                    "text": "Multinodular hyperplasia thyroidAbundant colloidLow cellularityDegenerative featuresBenign nuclear featuresCellular atypia my be presentOncocytic changesNuclear clearingSignet ring changes",
                    "sub_points": [
                      "Abundant colloid",
                      "Low cellularity",
                      "Degenerative features",
                      "Benign nuclear features",
                      "Cellular atypia my be present",
                      "Oncocytic changes",
                      "Nuclear clearing",
                      "Signet ring changes"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Activating mutation ofGNAS1at Arg201 codon"
                  },
                  {
                    "text": "Mutation spectrumMissense mutations on Arg201R201HR201CR201GR201LR201S",
                    "sub_points": [
                      "Missense mutations on Arg201R201HR201CR201GR201LR201S",
                      "R201H",
                      "R201C",
                      "R201G",
                      "R201L",
                      "R201S"
                    ]
                  },
                  {
                    "text": "TestsSequencing",
                    "sub_points": [
                      "Sequencing"
                    ]
                  }
                ],
                "Serologic Testing": [
                  {
                    "text": "Sexual precocity with increase of luteinizing hormone (LH), and follicle-stimulating hormone (FSH)"
                  },
                  {
                    "text": "Elevated serum alkaline phosphatase"
                  },
                  {
                    "text": "Elevated hormone level (thyroid hormone, cortisone, growth hormone, or estrogen)"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Neurofibromatosis": [
                  {
                    "text": "Café au lait spots are also presented in neurofibromatosis (autosomal dominant)"
                  },
                  {
                    "text": "Multiple neurofibromas, Lisch nodules are often present"
                  }
                ],
                "Osteofibrous Dysplasia": [
                  {
                    "text": "Rare, benign, nonneoplastic self-limited intracortical fibroosseous lesion"
                  },
                  {
                    "text": "Most lesions of osteofibrous dysplasia affect cortex of tibiae and fibulae of children"
                  },
                  {
                    "text": "Radiograph shows that cortex is often expanded and thinned, with multiple radiolucencies"
                  },
                  {
                    "text": "Microscopically, lesion is composed of spindle cell proliferation with production of woven bone trabeculae with prominent osteoblastic rimming"
                  }
                ],
                "Mazabraud Syndrome": [
                  {
                    "text": "Combination of polyostotic fibrous dysplasia and intramuscular myxomas"
                  },
                  {
                    "text": "Also caused byGNAS1mutations"
                  }
                ],
                "Hyperparathyroidism-Jaw Tumor Syndrome (HPT-JT)": [
                  {
                    "text": "Hyperparathyroidism is often caused by parathyroid adenoma or carcinoma with severe hypercalcemia"
                  },
                  {
                    "text": "Ossifying fibroma in jaw can be confused with fibrous dysplasia clinically, radiographically, and histologically"
                  },
                  {
                    "text": "HPT-JT is caused by mutation ofHRPT2gene, which encodes parafibromin"
                  }
                ],
                "Carney Complex": [
                  {
                    "text": "Autosomal dominant disease"
                  },
                  {
                    "text": "Shares some similarities with MAS"
                  },
                  {
                    "text": "Multiple endocrine neoplasia syndrome featuring cardiac, endocrine, cutaneous, and neural tumors"
                  },
                  {
                    "text": "Presence of a variety of mucocutaneous pigmented lesions"
                  },
                  {
                    "text": "Involve several endocrine glands simultaneouslyAdrenal cortexGonadsPituitaryThyroid",
                    "sub_points": [
                      "Adrenal cortex",
                      "Gonads",
                      "Pituitary",
                      "Thyroid"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Neurofibromatosis Type 1": {
            "name": "Neurofibromatosis Type 1",
            "url": "https://app.pathprimer.com/document/7942c2f4-3b5d-4e6c-8be1-fa4f12d4aca0/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Neurofibromatosis type 1 (NF1)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "von Recklinghausen disease"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Genetic syndrome resulting from germline mutations inNF1gene encoding for neurofibromin"
                  }
                ]
              },
              "Epidemiology": {
                "Incidence": [
                  {
                    "text": "~ 1 in 2,500-3,000 births (1 of the most common inherited syndromes)"
                  },
                  {
                    "text": "Occurs in all races and geographic regions"
                  }
                ]
              },
              "Genetics": {
                "NF1Gene": [
                  {
                    "text": "Located in chromosome region 17q11.2"
                  },
                  {
                    "text": "Ubiquitously expressed, but levels highest in nervous system"
                  },
                  {
                    "text": "Encodes for neurofibromin, a tumor suppressor GTPase-activating protein that negatively regulates RASConstitutive activation of MAPK and AKT/mTOR signaling pathwaysAlso may regulate cAMP levels, which affect central nervous system manifestations",
                    "sub_points": [
                      "Constitutive activation of MAPK and AKT/mTOR signaling pathways",
                      "Also may regulate cAMP levels, which affect central nervous system manifestations"
                    ]
                  },
                  {
                    "text": "Mosaicism or \"segmental\" neurofibromatosis manifests as involvement of an isolated anatomical region"
                  },
                  {
                    "text": "Penetrance is ~ 100% with appropriate follow-up although manifestations are variable between individuals and within families"
                  }
                ],
                "Genetic Modifiers": [
                  {
                    "text": "Modifier genes identified in mice and families with NF1Associated with disease severityAffect predisposition to peripheral nerve and central nervous system tumors",
                    "sub_points": [
                      "Associated with disease severity",
                      "Affect predisposition to peripheral nerve and central nervous system tumors"
                    ]
                  }
                ],
                "NF1-Associated Tumors": [
                  {
                    "text": "Loss of heterozygosity inNF1is a feature of associated tumors"
                  },
                  {
                    "text": "Haploinsufficient cells in tumor microenvironment (macrophages/microglia, mast cells) also contribute to tumorigenesis"
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Diagnostic Criteria (NIH 1991)": [
                  {
                    "text": "2 or more of the following featuresCafé au lait macules (≥ 6), with a diameter of 0.5 cm in children, or 1.5 cm after pubertyCutaneous or subcutaneous neurofibromas (≥ 2) or plexiform neurofibromaFreckling of the axillary or groin regionGlioma of the optic pathwaysLisch nodules identified by slit-lamp examination (≥ 2)Dysplasias of skeletal system (sphenoid wing, long bone bowing, pseudoarthrosis)Diagnosis of NF1 in a 1st-degree relative",
                    "sub_points": [
                      "Café au lait macules (≥ 6), with a diameter of 0.5 cm in children, or 1.5 cm after puberty",
                      "Cutaneous or subcutaneous neurofibromas (≥ 2) or plexiform neurofibroma",
                      "Freckling of the axillary or groin region",
                      "Glioma of the optic pathways",
                      "Lisch nodules identified by slit-lamp examination (≥ 2)",
                      "Dysplasias of skeletal system (sphenoid wing, long bone bowing, pseudoarthrosis)",
                      "Diagnosis of NF1 in a 1st-degree relative"
                    ]
                  }
                ]
              },
              "Nonneoplastic Manifestations": {
                "Ophthalmic": [
                  {
                    "text": "Lisch nodules: Nodular, hamartomatous aggregates of melanin-containing cells on surface of iris, usually asymptomatic"
                  }
                ],
                "Central Nervous System": [
                  {
                    "text": "Unknown bright objects (UBOs): Asymptomatic focal areas of ↑ T2 signal on MRMay represent localized myelin abnormalities/edema",
                    "sub_points": [
                      "May represent localized myelin abnormalities/edema"
                    ]
                  },
                  {
                    "text": "Macrocephaly, cognitive disabilities, developmental delays, and behavioral disturbances"
                  }
                ],
                "Skin": [
                  {
                    "text": "Café au lait spots: One of the earliest manifestations"
                  },
                  {
                    "text": "Axillary/inguinal (intertriginous skin) freckling"
                  }
                ],
                "Musculoskeletal": [
                  {
                    "text": "Sphenoid wing dysplasia/hypoplasia, scoliosis, pseudoarthrosis, bowing of long bones"
                  }
                ],
                "Cardiovascular System": [
                  {
                    "text": "Cerebral arteriopathy (Moyamoya disease)"
                  },
                  {
                    "text": "Pulmonary artery stenosis"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Central Nervous System": [
                  {
                    "text": "Pilocytic astrocytomaMost frequent central nervous system neoplasm in NF1Predilection for optic pathways (15-20% of children with NF1)May also occur in brainstem and anywhere along neuraxis",
                    "sub_points": [
                      "Most frequent central nervous system neoplasm in NF1",
                      "Predilection for optic pathways (15-20% of children with NF1)",
                      "May also occur in brainstem and anywhere along neuraxis"
                    ]
                  },
                  {
                    "text": "Diffuse astrocytomasGrades II-IVUsually develop after childhood yearsAggressive as sporadic counterparts",
                    "sub_points": [
                      "Grades II-IV",
                      "Usually develop after childhood years",
                      "Aggressive as sporadic counterparts"
                    ]
                  },
                  {
                    "text": "Indeterminate astrocytomasSubset of low-grade astrocytomas in patients with NF1 difficult to classifyMay demonstrate phenotypic or ultrastructural evidence of neuronal differentiation",
                    "sub_points": [
                      "Subset of low-grade astrocytomas in patients with NF1 difficult to classify",
                      "May demonstrate phenotypic or ultrastructural evidence of neuronal differentiation"
                    ]
                  },
                  {
                    "text": "Glioneuronal tumorsGangliogliomas and dysembryoplastic neuroepithelial tumors previously reported in NF1",
                    "sub_points": [
                      "Gangliogliomas and dysembryoplastic neuroepithelial tumors previously reported in NF1"
                    ]
                  }
                ],
                "Peripheral Nervous System": [
                  {
                    "text": "NeurofibromaLocalized neurofibromaCutaneous, soft tissue or intraneuralLow cellularityVariable contents of Schwann cells, perineurial cells, fibroblasts, mast cells, and axonsDiffuse neurofibromaMay develop in patients with NF1 but is not exclusive for the syndromeUsually large cutaneous plaques infiltrating dermis &/or subcutisMay arise in internal organsCellular neurofibromaAreas of increased cellularity and even limited fascicular architectureLack pronounced atypia and mitotic activityDifferential diagnosis with low-grade MPNST challenging, particularly when associated with plexiform neurofibromaAtypical neurofibromaDegenerative nuclear atypiaLacks hypercellularity and mitotic activityPlexiform neurofibromaComplex neoplasms that by definition involve multiple peripheral nerve fascicles or a large plexusCharacteristic \"worm-like\" gross appearanceDeep/large plexiform neurofibromas essentially restricted to patients with NF1Propensity for malignant degenerationMassive soft tissue neurofibromaLarge neoplasm displaying prominent soft tissue infiltration, often containing hypercellular, round cell areas, and pseudo-meissnerian corpusclesUsually benign, but some contain a plexiform neurofibroma component with a propensity for malignant degenerationArises only in patients with NF1Rare findings in neurofibroma include presence of melanin pigment, metaplastic bone, and glandular differentiation",
                    "sub_points": [
                      "Localized neurofibromaCutaneous, soft tissue or intraneuralLow cellularityVariable contents of Schwann cells, perineurial cells, fibroblasts, mast cells, and axons",
                      "Cutaneous, soft tissue or intraneural",
                      "Low cellularity",
                      "Variable contents of Schwann cells, perineurial cells, fibroblasts, mast cells, and axons",
                      "Diffuse neurofibromaMay develop in patients with NF1 but is not exclusive for the syndromeUsually large cutaneous plaques infiltrating dermis &/or subcutisMay arise in internal organs",
                      "May develop in patients with NF1 but is not exclusive for the syndrome",
                      "Usually large cutaneous plaques infiltrating dermis &/or subcutis",
                      "May arise in internal organs",
                      "Cellular neurofibromaAreas of increased cellularity and even limited fascicular architectureLack pronounced atypia and mitotic activityDifferential diagnosis with low-grade MPNST challenging, particularly when associated with plexiform neurofibroma",
                      "Areas of increased cellularity and even limited fascicular architecture",
                      "Lack pronounced atypia and mitotic activity",
                      "Differential diagnosis with low-grade MPNST challenging, particularly when associated with plexiform neurofibroma",
                      "Atypical neurofibromaDegenerative nuclear atypiaLacks hypercellularity and mitotic activity",
                      "Degenerative nuclear atypia",
                      "Lacks hypercellularity and mitotic activity",
                      "Plexiform neurofibromaComplex neoplasms that by definition involve multiple peripheral nerve fascicles or a large plexusCharacteristic \"worm-like\" gross appearanceDeep/large plexiform neurofibromas essentially restricted to patients with NF1Propensity for malignant degeneration",
                      "Complex neoplasms that by definition involve multiple peripheral nerve fascicles or a large plexus",
                      "Characteristic \"worm-like\" gross appearance",
                      "Deep/large plexiform neurofibromas essentially restricted to patients with NF1",
                      "Propensity for malignant degeneration",
                      "Massive soft tissue neurofibromaLarge neoplasm displaying prominent soft tissue infiltration, often containing hypercellular, round cell areas, and pseudo-meissnerian corpusclesUsually benign, but some contain a plexiform neurofibroma component with a propensity for malignant degenerationArises only in patients with NF1",
                      "Large neoplasm displaying prominent soft tissue infiltration, often containing hypercellular, round cell areas, and pseudo-meissnerian corpuscles",
                      "Usually benign, but some contain a plexiform neurofibroma component with a propensity for malignant degeneration",
                      "Arises only in patients with NF1",
                      "Rare findings in neurofibroma include presence of melanin pigment, metaplastic bone, and glandular differentiation"
                    ]
                  },
                  {
                    "text": "Malignant peripheral nerve sheath tumor (MPNST)Afflicts 8-13% of patients with NF1Usually aggressive, high-grade spindle cell neoplasmsDifferentiation is predominantly schwannian but may also be perineurialPresence of heterologous elements relatively more common in NF1 setting (skeletal muscle, cartilaginous, osseous, angiosarcomatous, glandular or smooth muscle)\"Low-grade MPNST\" applied to tumors arising in transition from neurofibroma, usually in patients with NF1Hypercellularity, nuclear enlargement (~ 3x the size of a neurofibroma nucleus), and hyperchromasiaMitotic activity may also be present but is not required for diagnosis",
                    "sub_points": [
                      "Afflicts 8-13% of patients with NF1",
                      "Usually aggressive, high-grade spindle cell neoplasms",
                      "Differentiation is predominantly schwannian but may also be perineurial",
                      "Presence of heterologous elements relatively more common in NF1 setting (skeletal muscle, cartilaginous, osseous, angiosarcomatous, glandular or smooth muscle)",
                      "\"Low-grade MPNST\" applied to tumors arising in transition from neurofibroma, usually in patients with NF1Hypercellularity, nuclear enlargement (~ 3x the size of a neurofibroma nucleus), and hyperchromasiaMitotic activity may also be present but is not required for diagnosis",
                      "Hypercellularity, nuclear enlargement (~ 3x the size of a neurofibroma nucleus), and hyperchromasia",
                      "Mitotic activity may also be present but is not required for diagnosis"
                    ]
                  }
                ],
                "Other": [
                  {
                    "text": "Pheochromocytoma: Usually unilateral but may be bilateral in NF1"
                  },
                  {
                    "text": "Glomus tumorRecently recognized component of NF1NF1-biallelic inactivation, mitotic recombination not uncommon",
                    "sub_points": [
                      "Recently recognized component of NF1",
                      "NF1-biallelic inactivation, mitotic recombination not uncommon"
                    ]
                  },
                  {
                    "text": "Intestinal ganglioneuromatosis (involving primarily the submucosal plexus)"
                  },
                  {
                    "text": "Gastrointestinal stromal tumor (GIST)LacksKITmutations in contrast to sporadic GIST",
                    "sub_points": [
                      "LacksKITmutations in contrast to sporadic GIST"
                    ]
                  },
                  {
                    "text": "Gastrointestinal schwannomaMore common in NF1 than NF2Loss of heterozygosity inNF1gene",
                    "sub_points": [
                      "More common in NF1 than NF2",
                      "Loss of heterozygosity inNF1gene"
                    ]
                  },
                  {
                    "text": "Neuroendocrine neoplasms (carcinoid tumors)"
                  },
                  {
                    "text": "Juvenile myelomonocytic leukemia (JMML)100x increased risk in children with NF1",
                    "sub_points": [
                      "100x increased risk in children with NF1"
                    ]
                  },
                  {
                    "text": "Breast carcinomaIncreased risk and earlier age of occurrence in women with NF1",
                    "sub_points": [
                      "Increased risk and earlier age of occurrence in women with NF1"
                    ]
                  },
                  {
                    "text": "Rhabdomyosarcoma"
                  }
                ]
              },
              "Molecular biology": {
                "Central Nervous System": [
                  {
                    "text": "NF1-associated gliomas demonstrate completeNF1inactivation"
                  },
                  {
                    "text": "Haploinsufficient stromal components (e.g., microglia) also required in mouse models of NF1-associated low-grade glioma"
                  },
                  {
                    "text": "Development of high-grade glioma requires losses in additional tumor suppressors (e.g.,TP53,PTEN)"
                  }
                ],
                "Peripheral Nerve": [
                  {
                    "text": "Haploinsufficient microenvironment cell components (e.g., mast cells) important for neurofibroma formation in some NF1 mouse models"
                  },
                  {
                    "text": "Nonmyelinating Schwann cell progenitors and Dsh(+) Schwann cell precursors are candidate cells of origin of plexiform neurofibromas in mouse models"
                  },
                  {
                    "text": "Neural crest-derived cutaneous neural stem cell/progenitor candidate cell of origin for cutaneous neurofibroma"
                  },
                  {
                    "text": "Malignant peripheral nerve sheath tumors in addition toNF1loss develop oncogene amplification (e.g.,EGFR) and tumor suppressor loss (e.g.,P16,TP53)"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Neurofibromatosis Type 2 (NF2)": [
                  {
                    "text": "Mutations in theNF2gene encoding for merlin/schwannomin"
                  },
                  {
                    "text": "Gliomas, café au lait spots, and neurofibromas may present in patients with NF2 although at a lower frequency and number than in those with NF1"
                  },
                  {
                    "text": "Ependymoma, meningioma, and multiple schwannomas are not a feature of NF1"
                  }
                ],
                "Noonan Syndrome": [
                  {
                    "text": "Results from mutations in various components of the RAS/MAPK signaling pathwayPTPN11,KRAS,SOS1,NRAS, andRAF1",
                    "sub_points": [
                      "PTPN11,KRAS,SOS1,NRAS, andRAF1"
                    ]
                  },
                  {
                    "text": "Distinctive facial features, developmental delay, short stature, congenital heart disease, café au lait spots"
                  },
                  {
                    "text": "Tumor predisposition lower than NF1"
                  }
                ],
                "Legius Syndrome": [
                  {
                    "text": "Results from loss-of-functionSPRED1mutations leading to ↑ RAS-MAPK pathway activity"
                  },
                  {
                    "text": "Mild NF1-like phenotypeCafé au lait spots, macrocephalyLack Lisch nodules, bone abnormalities, gliomas, and peripheral nerve sheath tumors",
                    "sub_points": [
                      "Café au lait spots, macrocephaly",
                      "Lack Lisch nodules, bone abnormalities, gliomas, and peripheral nerve sheath tumors"
                    ]
                  }
                ],
                "Constitutional Mismatch Repair-Deficiency Syndrome": [
                  {
                    "text": "Homozygous or compound heterozygous mutations in mismatch repair genes"
                  },
                  {
                    "text": "Multiple cancers, including gliomas, colon cancer"
                  },
                  {
                    "text": "May be associated with clinical features of NF1 (e.g., café au lait spots)"
                  }
                ],
                "McCune-Albright Syndrome": [
                  {
                    "text": "Somatic mutations inGNAS1gene resulting in increased cAMP signaling"
                  },
                  {
                    "text": "May have café au lait spots (unilateral) but no axillary freckling"
                  },
                  {
                    "text": "Polyostotic fibrous dysplasia"
                  }
                ],
                "Proteus Syndrome": [
                  {
                    "text": "Somatic (mosaic) activating mutations inAKT1in most cases"
                  },
                  {
                    "text": "Localized tissue overgrowth clinically mimicking plexiform neurofibroma; scoliosis, hyperostoses, \"cerebriform\" connective tissue nevus, and epidermal nevi; monomorphic parotid gland adenomas, ovarian cystadenomas"
                  }
                ],
                "Familial Café Au Lait Spots": [
                  {
                    "text": "Rare autosomal dominant disorder"
                  },
                  {
                    "text": "Lack neurofibromas and noncutaneous manifestations of NF1"
                  }
                ],
                "Multiple Endocrine Neoplasia Type 2B (MEN2B)": [
                  {
                    "text": "Caused by genetic alterations inRETproto-oncogene"
                  },
                  {
                    "text": "Develop pheochromocytomas but also mucosal neuromas (notneurofibromas)Diffuse and extensive involvement of all intestinal layers by ganglioneuromatosis is relatively specific to MEN2B",
                    "sub_points": [
                      "Diffuse and extensive involvement of all intestinal layers by ganglioneuromatosis is relatively specific to MEN2B"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Neurofibromatosis Type 2": {
            "name": "Neurofibromatosis Type 2",
            "url": "https://app.pathprimer.com/document/2f42fc65-a731-47c8-8bf9-2ef4dc23a309/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Neurofibromatosis type 2 (NF2)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Inherited tumor predisposition syndrome caused by germline mutations in theNF2gene encoding for merlin/schwannomin"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "1 in  33,000 to 40,000 births"
                  },
                  {
                    "text": "Similar proportion of male and female patients"
                  }
                ]
              },
              "Genetics and Molecular Biology": {
                "NF2Gene Encodes for Merlin": [
                  {
                    "text": "Inherited in 1/2 of patients and new germline mutation in remaining 1/2"
                  },
                  {
                    "text": "Located in chromosomal region 22q12.2"
                  },
                  {
                    "text": "Merlin associates with cell junctional complexes and participates in contact-dependent inhibition"
                  },
                  {
                    "text": "More severe phenotype in patients with frameshift or nonsense mutations"
                  },
                  {
                    "text": "Germline mosaicism occurs in 20-30% of patients without family history"
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Nonneoplastic Manifestations": [
                  {
                    "text": "Ophthalmic: Posterior subcapsular cataracts, retinal hamartomas, and epiretinal membranes"
                  },
                  {
                    "text": "Central nervous system: Glial microhamartomas"
                  },
                  {
                    "text": "Peripheral nervous system: Polyneuropathy"
                  },
                  {
                    "text": "Skin: Café au lait spots but at a lesser frequency than NF1; also hairy cutaneous plaques"
                  },
                  {
                    "text": "Musculoskeletal: Scoliosis"
                  }
                ],
                "Classification Criteria": [
                  {
                    "text": "Manchester criteria (1992)Bilateral vestibular schwannomaorNF2 in 1st-degree relative plus unilateral vestibular schwannoma or any 2 of the following: Neurofibroma, meningioma, glioma, schwannoma, posterior subcapsular lens opacityorUnilateral vestibular schwannoma plus any 2 of the following: Neurofibroma, meningioma, glioma, schwannoma, posterior subscapular lens opacityor≥ 2 meningiomas plus unilateral vestibular schwannoma or any 2 of the following: Neurofibroma, glioma, schwannoma, or cataract",
                    "sub_points": [
                      "Bilateral vestibular schwannomaor",
                      "NF2 in 1st-degree relative plus unilateral vestibular schwannoma or any 2 of the following: Neurofibroma, meningioma, glioma, schwannoma, posterior subcapsular lens opacityor",
                      "Unilateral vestibular schwannoma plus any 2 of the following: Neurofibroma, meningioma, glioma, schwannoma, posterior subscapular lens opacityor",
                      "≥ 2 meningiomas plus unilateral vestibular schwannoma or any 2 of the following: Neurofibroma, glioma, schwannoma, or cataract"
                    ]
                  },
                  {
                    "text": "Baser criteria (2011)Manifests an effort to incorporate genetic information into clinical classifications",
                    "sub_points": [
                      "Manifests an effort to incorporate genetic information into clinical classifications"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Schwannoma": [
                  {
                    "text": "Similar histologic features as sporadic tumorsCompact Antoni A areas alternating with loose Antoni B areasVerocay bodies, hyalinized vessels, hemosiderin depositionS100, SOX10, and pericellular collagen IV immunoreactivity; EMA limited to perineurium and neurofilament protein to rare entrapped axons",
                    "sub_points": [
                      "Compact Antoni A areas alternating with loose Antoni B areas",
                      "Verocay bodies, hyalinized vessels, hemosiderin deposition",
                      "S100, SOX10, and pericellular collagen IV immunoreactivity; EMA limited to perineurium and neurofilament protein to rare entrapped axons"
                    ]
                  },
                  {
                    "text": "Features occurring more frequently in NF2-associated schwannomas include whorl formation, multiple tumors involving a single nerve, and juxtaposition to meningiomaMosaic pattern of INI1 immunostaining in majority of syndrome-associated schwannomas",
                    "sub_points": [
                      "Mosaic pattern of INI1 immunostaining in majority of syndrome-associated schwannomas"
                    ]
                  },
                  {
                    "text": "Bilateral vestibular schwannomas are a hallmark of NF2 (90-95% of patients)"
                  },
                  {
                    "text": "Plexiform schwannomas may occur in NF2 but are not specific to the syndromeNodular Schwann cell proliferation favoring cutaneous and mucosal sitesMay be multiple",
                    "sub_points": [
                      "Nodular Schwann cell proliferation favoring cutaneous and mucosal sites",
                      "May be multiple"
                    ]
                  }
                ],
                "Neurofibroma": [
                  {
                    "text": "Relatively rare in NF2 compared to NF1 but may contribute to clinical diagnosis if other criteria present"
                  }
                ],
                "Meningioma": [
                  {
                    "text": "Intracranial meningiomas found in ~ 1/2 of NF2 patients"
                  },
                  {
                    "text": "Skull base involvement is less frequent than in sporadic tumors"
                  },
                  {
                    "text": "\"Saltatory growth\": Periods of growth followed by quiescence"
                  },
                  {
                    "text": "Relatively high frequency of fibroblastic, transitional, and grade II meningiomas in NF2 patients but also histologic heterogeneity"
                  },
                  {
                    "text": "MeningioangiomatosisGrowth of meningothelial-like cells into superficial cortical vessels and leptomeningesAssociated with seizuresEMA(+) or  EMA(-), collagen rich (Masson trichrome)",
                    "sub_points": [
                      "Growth of meningothelial-like cells into superficial cortical vessels and leptomeninges",
                      "Associated with seizures",
                      "EMA(+) or  EMA(-), collagen rich (Masson trichrome)"
                    ]
                  }
                ],
                "Ependymoma": [
                  {
                    "text": "Cervical cord and cervicomedullary junction are favored sites in NF2"
                  },
                  {
                    "text": "Majority of NF2-associated ependymomas are low grade and asymptomatic"
                  },
                  {
                    "text": "Associated with a relatively high rate of truncatingNF2mutations"
                  }
                ],
                "Other": [
                  {
                    "text": "Conventional MPNST and MPNST ex-schwannomas reported in NF2 but very rare"
                  },
                  {
                    "text": "Some malignant neoplasms may be irradiation-induced"
                  },
                  {
                    "text": "Nonependymal glial neoplasms may occur"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Peutz-Jeghers Syndrome": {
            "name": "Peutz-Jeghers Syndrome",
            "url": "https://app.pathprimer.com/document/72db179b-9c88-42d8-a7ff-3fe838e1d4f4/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Peutz-Jeghers syndrome (PJS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "PJS is characterized byPigmented melanotic lesions around lips, oral cavity, and genitalsHamartomatous polyposis of gastrointestinal (GI) tractIncreased risk of cancers in the GI tract, pancreas, gynecologic tract, testis, breast, lung, and thyroidAutosomal dominant inheritance25% of cases appear de novo",
                    "sub_points": [
                      "Pigmented melanotic lesions around lips, oral cavity, and genitals",
                      "Hamartomatous polyposis of gastrointestinal (GI) tract",
                      "Increased risk of cancers in the GI tract, pancreas, gynecologic tract, testis, breast, lung, and thyroid",
                      "Autosomal dominant inheritance25% of cases appear de novo",
                      "25% of cases appear de novo"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Prevalence": [
                  {
                    "text": "Exact prevalence is unknown; estimates range from 1 in 8,500 to 1 in 300,000 live births"
                  },
                  {
                    "text": "No gender or racial predominance"
                  }
                ]
              },
              "Genetics": {
                "LKB1Gene": [
                  {
                    "text": "Also known asSTK11"
                  },
                  {
                    "text": "Serine-threonine kinase that is thought to behave like a tumor suppressor gene"
                  },
                  {
                    "text": "Important in controlling cell proliferation"
                  },
                  {
                    "text": "Regulates mTOR pathwayClinical trials using mTOR pathway inhibitors (rapamycin analogues) for chemoprevention are currently underway in PJS patients and have shown promising early results",
                    "sub_points": [
                      "Clinical trials using mTOR pathway inhibitors (rapamycin analogues) for chemoprevention are currently underway in PJS patients and have shown promising early results"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Clinical Presentation": [
                  {
                    "text": "Pigmentation of lips and oral and genital mucosa seen in infancy and early childhoodLips most common site (> 95%)Pigmentation may fade with age",
                    "sub_points": [
                      "Lips most common site (> 95%)",
                      "Pigmentation may fade with age"
                    ]
                  },
                  {
                    "text": "GI tract symptomsAbdominal pain due to obstruction/intussusceptionPolyps arise in stomach (50%), small bowel (65%), and colon (50%)Anemia due to occult or frank GI tract bleedingHematemesis in patients with gastric and duodenal polyposisProlapse of rectal polyps",
                    "sub_points": [
                      "Abdominal pain due to obstruction/intussusceptionPolyps arise in stomach (50%), small bowel (65%), and colon (50%)",
                      "Polyps arise in stomach (50%), small bowel (65%), and colon (50%)",
                      "Anemia due to occult or frank GI tract bleedingHematemesis in patients with gastric and duodenal polyposis",
                      "Hematemesis in patients with gastric and duodenal polyposis",
                      "Prolapse of rectal polyps"
                    ]
                  },
                  {
                    "text": "Associated skeletal abnormalitiesClub foot and scoliosis",
                    "sub_points": [
                      "Club foot and scoliosis"
                    ]
                  }
                ],
                "Diagnostic Criteria": [
                  {
                    "text": "≥ 2 histologically confirmed Peutz-Jeghers polyps (PJPs)Even patients with only a single PJP seem to have an increased risk of cancer",
                    "sub_points": [
                      "Even patients with only a single PJP seem to have an increased risk of cancer"
                    ]
                  },
                  {
                    "text": "Any number of PJPs in a patient with a family history of PJS"
                  },
                  {
                    "text": "Any number of PJPs in a patient with mucocutaneous pigmentation"
                  },
                  {
                    "text": "Mucocutaneous pigmentation in a patient with a family history of PJS"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Sequencing theLKB1gene identifies a mutation in 50-70% of casesNeed to look for both protein-truncating mutations as well as large deletions",
                    "sub_points": [
                      "Need to look for both protein-truncating mutations as well as large deletions"
                    ]
                  },
                  {
                    "text": "Gene inactivation theorized in cases that test negative"
                  }
                ]
              },
              "Associated Neoplasms": {
                "GI Tract Neoplasms": [
                  {
                    "text": "Adenocarcinoma of small bowelCumulative risk: 13%",
                    "sub_points": [
                      "Cumulative risk: 13%"
                    ]
                  },
                  {
                    "text": "Adenocarcinoma of colonCumulative risk: 39%Mean age of diagnosis: ~ 46 years",
                    "sub_points": [
                      "Cumulative risk: 39%",
                      "Mean age of diagnosis: ~ 46 years"
                    ]
                  },
                  {
                    "text": "Adenocarcinoma of pancreasCumulative risk: 36% (100x risk in general population)",
                    "sub_points": [
                      "Cumulative risk: 36% (100x risk in general population)"
                    ]
                  },
                  {
                    "text": "Adenocarcinoma of stomachCumulative risk: 29%",
                    "sub_points": [
                      "Cumulative risk: 29%"
                    ]
                  }
                ],
                "Other Neoplasms": [
                  {
                    "text": "Carcinoma of breastAbsolute risk: ~ 54%",
                    "sub_points": [
                      "Absolute risk: ~ 54%"
                    ]
                  },
                  {
                    "text": "Ovarian sex cord tumors with annular tubules"
                  },
                  {
                    "text": "Adenoma malignum of cervix"
                  },
                  {
                    "text": "Mucinous tumors of ovaries and fallopian tubesAbsolute risk: 10%",
                    "sub_points": [
                      "Absolute risk: 10%"
                    ]
                  },
                  {
                    "text": "Bronchioalveolar carcinomas of lung"
                  },
                  {
                    "text": "Testicular sex cord and Sertoli cell tumorsAbsolute risk: 9%",
                    "sub_points": [
                      "Absolute risk: 9%"
                    ]
                  },
                  {
                    "text": "Papillary thyroid cancer"
                  },
                  {
                    "text": "Overall cumulative cancer risk: 93% at age 65"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Hamartomatous Polyps": [
                  {
                    "text": "Polyps classically have arborizing bands of smooth muscle with a papillary architectureBest seen in small bowel polyps; stomach and colon polyps may lack classic features and thus can be difficult to diagnose",
                    "sub_points": [
                      "Best seen in small bowel polyps; stomach and colon polyps may lack classic features and thus can be difficult to diagnose"
                    ]
                  },
                  {
                    "text": "Epithelium is nonneoplastic and has a lobular growth patternEpithelium frequently is trapped in bands of smooth muscle; do not overinterpret this finding as carcinomaDysplasia has hardly ever been found in PJPs, suggesting that cancer may arise by a different mechanism",
                    "sub_points": [
                      "Epithelium frequently is trapped in bands of smooth muscle; do not overinterpret this finding as carcinoma",
                      "Dysplasia has hardly ever been found in PJPs, suggesting that cancer may arise by a different mechanism"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Endoscopic Surveillance": [
                  {
                    "text": "Baseline upper and lower endoscopy at age 8, to be repeated every 2-3 years"
                  },
                  {
                    "text": "Endoscopic removal of small polypsSurgery may be necessary for obstructing polyps or intussusception",
                    "sub_points": [
                      "Surgery may be necessary for obstructing polyps or intussusception"
                    ]
                  }
                ],
                "Radiologic Surveillance": [
                  {
                    "text": "Transvaginal ultrasound, serum CA-125, and Pap smears annually beginning between age 20 and 25 for gynecologic (GYN) tumors"
                  },
                  {
                    "text": "Endoscopic ultrasound, abdominal CT, and CA-19-9 every 1-2 years starting between age 25 and 30 for pancreas tumors"
                  },
                  {
                    "text": "Mammography or MR annually starting at age 25 for breast cancer"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Rendu-Osler-Weber Syndrome": {
            "name": "Rendu-Osler-Weber Syndrome",
            "url": "https://app.pathprimer.com/document/5bad9756-e404-4647-8506-021e96f7b765/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hereditary hemorrhagic telangiectasia (HHT)"
                  },
                  {
                    "text": "Transforming growth factor β (TGFβ)"
                  },
                  {
                    "text": "Arteriovenous malformation (AVM)"
                  },
                  {
                    "text": "Vascular endothelial growth factor receptor (VEGFR)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "HHT"
                  },
                  {
                    "text": "Osler-Weber-Rendu syndrome"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Gender": [
                  {
                    "text": "Incidence in males and females approximately equal"
                  }
                ],
                "Ethnicity Relationship": [
                  {
                    "text": "No predilection for ethnicity"
                  }
                ],
                "Incidence": [
                  {
                    "text": "1 in 5000-10,000 live births"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "﻿Autosomal dominant inheritance﻿"
                  },
                  {
                    "text": "﻿Mutations in TGFβ signaling pathway﻿ENG(HHT1)ACVRL1(HHT2)GDF2SMAD4RASA1",
                    "sub_points": [
                      "ENG(HHT1)",
                      "ACVRL1(HHT2)",
                      "GDF2",
                      "SMAD4",
                      "RASA1"
                    ]
                  },
                  {
                    "text": "85% of cases of HHT have mutat﻿ions inENGorACVRL1﻿"
                  },
                  {
                    "text": "Hundreds of different causative mutations identifiedMutations are loss of functionNo common hotspots",
                    "sub_points": [
                      "Mutations are loss of function",
                      "No common hotspots"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Vascular malformationsTelangiectasias and AVMs﻿Malformations lead to recurrent bleedingEpistaxis in > 90% of patientsMay lead to embolization from shunting through pulmonary AVMs",
                    "sub_points": [
                      "Telangiectasias and AVMs﻿",
                      "Malformations lead to recurrent bleedingEpistaxis in > 90% of patients",
                      "Epistaxis in > 90% of patients",
                      "May lead to embolization from shunting through pulmonary AVMs"
                    ]
                  },
                  {
                    "text": "Involve multiple sitesSkinMucous membranesLungLiverBrainGastrointestinal tract",
                    "sub_points": [
                      "Skin",
                      "Mucous membranes",
                      "Lung",
                      "Liver",
                      "Brain",
                      "Gastrointestinal tract"
                    ]
                  }
                ],
                "Diagnosis": [
                  {
                    "text": "Curacao criteria establish clinical diagnosis of HHT﻿Spontaneous and recurrent epistaxisMucocutaneous telangiectasiasVisceral AVMs (lung, liver, brain)Diagnosis of HHT in first-degree relative",
                    "sub_points": [
                      "Spontaneous and recurrent epistaxis",
                      "Mucocutaneous telangiectasias",
                      "Visceral AVMs (lung, liver, brain)",
                      "Diagnosis of HHT in first-degree relative"
                    ]
                  },
                  {
                    "text": "3 or 4 of 4 criteria: Definite HHT"
                  },
                  {
                    "text": "2 of 4 criteria: Possible HHT"
                  },
                  {
                    "text": "0 or 1 of 4 criteria: Unlikely HHT"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Mechanical controlPacking",
                    "sub_points": [
                      "Packing"
                    ]
                  },
                  {
                    "text": "InterventionalEmbolizationAblation",
                    "sub_points": [
                      "Embolization",
                      "Ablation"
                    ]
                  },
                  {
                    "text": "ProcoagulantsTranexamic acidVEGFR antagonistsBevacizumabRecombinant factor VIIa",
                    "sub_points": [
                      "Tranexamic acid",
                      "VEGFR antagonistsBevacizumab",
                      "Bevacizumab",
                      "Recombinant factor VIIa"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sturge-Weber Syndrome": {
            "name": "Sturge-Weber Syndrome",
            "url": "https://app.pathprimer.com/document/13f13766-08e2-46e4-b35d-ed7453a2df6a/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Sturge-Weber syndrome (OMIM 185300) (SWS)"
                  },
                  {
                    "text": "Guanine nucleotide binding protein, Q polypeptide (OMIM 600998) (GNAQ)"
                  },
                  {
                    "text": "Guanosine triphosphate (GTP)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "SWS: Encephalotrigeminal angiomatosis"
                  },
                  {
                    "text": "Port-wine stain: Nevus flammeus"
                  }
                ],
                "Definitions": [
                  {
                    "text": "SWS: Congenital neurocutaneous syndrome characterized by facial port-wine stains and ipsilateral leptomeningeal angiomatosis﻿"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "Presentation at birth"
                  }
                ],
                "Incidence": [
                  {
                    "text": "1 in 20,000-50,000 live births"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Somatic Mosaicism in GNAQ Mutations": [
                  {
                    "text": "Caused by p.R183Q mutationGNAQ is α subunit of trimeric G protein-coupled receptorsIt is a GTP binding protein homologous toKRAS,NRAS,HRASp.R183Q results in decreased GTP hydrolysis and constitutive GNAQ signaling﻿Same mutation is seen in uveal melanomas and blue nevi﻿",
                    "sub_points": [
                      "GNAQ is α subunit of trimeric G protein-coupled receptors",
                      "It is a GTP binding protein homologous toKRAS,NRAS,HRAS",
                      "p.R183Q results in decreased GTP hydrolysis and constitutive GNAQ signaling",
                      "﻿Same mutation is seen in uveal melanomas and blue nevi﻿"
                    ]
                  },
                  {
                    "text": "Risk factors for acquiring mutations unknown"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "NonsyndromicPatients have﻿isolated port-wine stains﻿",
                    "sub_points": [
                      "Patients have﻿isolated port-wine stains﻿"
                    ]
                  },
                  {
                    "text": "SyndromicPort-wine stains and other findings",
                    "sub_points": [
                      "Port-wine stains and other findings"
                    ]
                  },
                  {
                    "text": "﻿Highly variable phenotype﻿"
                  },
                  {
                    "text": "Macrocephaly"
                  },
                  {
                    "text": "Almost all patients have port-wine stain in ophthalmic division of trigeminal nerve distribution present at birth﻿Some have bilateral port-wine stainsMany have port-wine stains on other parts of body",
                    "sub_points": [
                      "Some have bilateral port-wine stains",
                      "Many have port-wine stains on other parts of body"
                    ]
                  },
                  {
                    "text": "Ipsilateral hemangiomas of leptomeninges in parietal and occipital distribution﻿Compression of underlying cortex and focal atrophyStasis of blood flow, calcifications, laminar cortical necrosisSeizures/status epilepticusStroke-like episodesMental disabilityHemiparesis",
                    "sub_points": [
                      "Compression of underlying cortex and focal atrophy",
                      "Stasis of blood flow, calcifications, laminar cortical necrosis",
                      "Seizures/status epilepticus",
                      "Stroke-like episodes",
                      "Mental disability",
                      "Hemiparesis"
                    ]
                  },
                  {
                    "text": "Ipsilateral vascular glaucomaMay lead to optic atrophyBuphthalmos (eye enlargement)Hemianopsia",
                    "sub_points": [
                      "May lead to optic atrophy",
                      "Buphthalmos (eye enlargement)",
                      "Hemianopsia"
                    ]
                  },
                  {
                    "text": "Ipsilateral soft tissue and bony hypertrophyHearing loss",
                    "sub_points": [
                      "Hearing loss"
                    ]
                  }
                ],
                "Imaging Findings": [
                  {
                    "text": "Leptomeningeal angioma"
                  },
                  {
                    "text": "Cortical white matter atrophy"
                  },
                  {
                    "text": "Gyral calcifications"
                  },
                  {
                    "text": "Thickened choroid plexus"
                  },
                  {
                    "text": "Eye findings variably present"
                  },
                  {
                    "text": "Bone and soft tissue hypertrophy variably present"
                  }
                ],
                "Molecular Testing": [
                  {
                    "text": "Clinical and radiologic findings sufficient to establish diagnosis"
                  },
                  {
                    "text": "Testing of affected tissue required to detect GNAQ mutation﻿Surrounding tissue is negative",
                    "sub_points": [
                      "Surrounding tissue is negative"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Tuberous Sclerosis Complex": {
            "name": "Tuberous Sclerosis Complex",
            "url": "https://app.pathprimer.com/document/b1929ad0-3805-43c3-8021-dc6960229d0a/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Tuberous sclerosis complex (TSC)"
                  },
                  {
                    "text": "Subependymal Giant Cell Astrocytoma (SEGA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Inherited tumor predisposition syndrome resulting from mutations inTSC1orTSC2genes leading to mTOR pathway activation"
                  }
                ]
              },
              "Epidemiology": {
                "Incidence": [
                  {
                    "text": "~ 1:5,000-10,0002nd most common hereditary tumor syndrome involving the CNS",
                    "sub_points": [
                      "2nd most common hereditary tumor syndrome involving the CNS"
                    ]
                  }
                ]
              },
              "Genetics": {
                "Germline Mutations inTSC1orTSC2": [
                  {
                    "text": "Encode for tumor suppressor part of protein complex that inhibits RHEB and regulates mTOR activationTSC1located in chromosome region 9q34 (encodes for hamartin)TSC2located in chromosome region 16p13.3 (encodes for tuberin)RHEB is a small GTPase/homolog ofRASand is kept in an inactive state byTSC1/TSC2complex",
                    "sub_points": [
                      "TSC1located in chromosome region 9q34 (encodes for hamartin)",
                      "TSC2located in chromosome region 16p13.3 (encodes for tuberin)",
                      "RHEB is a small GTPase/homolog ofRASand is kept in an inactive state byTSC1/TSC2complex"
                    ]
                  },
                  {
                    "text": "mTOR is a key downstream mediator of PI3K/AKT activation"
                  },
                  {
                    "text": "Protein mTOR exists as part of 2 different multiprotein complexesmTORC1 contains PRAS40, RAPTOR, and mLST8/GBLIncreases protein translation, cell growth, and survivalmTORC2 contains RICTOR, mSIN1, PROTOR, and mLST8Functional role less understood than mTORC1 complexRegulates metabolism and survival through activation of AKTPlays a role in cytoskeletal organizationActivation leads to increased protein translationEffective pharmacologic inhibition by rapamycin and analogs",
                    "sub_points": [
                      "mTORC1 contains PRAS40, RAPTOR, and mLST8/GBLIncreases protein translation, cell growth, and survival",
                      "Increases protein translation, cell growth, and survival",
                      "mTORC2 contains RICTOR, mSIN1, PROTOR, and mLST8Functional role less understood than mTORC1 complexRegulates metabolism and survival through activation of AKTPlays a role in cytoskeletal organization",
                      "Functional role less understood than mTORC1 complex",
                      "Regulates metabolism and survival through activation of AKT",
                      "Plays a role in cytoskeletal organization",
                      "Activation leads to increased protein translation",
                      "Effective pharmacologic inhibition by rapamycin and analogs"
                    ]
                  },
                  {
                    "text": "Majority of patients (70-80%) have new \"spontaneous\" mutations and lack a family historyTSC1andTSC2mutation frequency similar in familial casesMutations inTSC2more frequent thanTSC1in nonfamilial cases",
                    "sub_points": [
                      "TSC1andTSC2mutation frequency similar in familial cases",
                      "Mutations inTSC2more frequent thanTSC1in nonfamilial cases"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Diagnostic Criteria": [
                  {
                    "text": "Definite TSC: 2 major features or 1 major + 2 minor"
                  },
                  {
                    "text": "Probable TSC: 1 major + 1 minor"
                  },
                  {
                    "text": "Possible TSC: 1 major or > 1 minor"
                  },
                  {
                    "text": "Major features: Cortical tuber, subependymal nodule, subependymal giant cell astrocytoma (SEGA), facial angiofibroma/forehead plaque, ungual/periungual fibroma, > 3 hypomelanotic macules, Shagreen patch, multiple retinal hamartomas, cardiac rhabdomyoma, renal angiomyolipoma/lymphangioleiomyomatosis (LAM)"
                  },
                  {
                    "text": "Minor features: White matter migration lines, transmantle cortical dysplasia, retinal patch, hamartomatous rectal polyps, gingival fibroma, dental pits, hypomelanotic clustered skin lesions, bone cysts, renal cysts, nonrenal hamartomas"
                  }
                ]
              },
              "Nonneoplastic Manifestations": {
                "Skin": [
                  {
                    "text": "Hypomelanotic macules (\"ash leaf spot\")"
                  },
                  {
                    "text": "Shagreen patch"
                  }
                ],
                "Nervous System": [
                  {
                    "text": "Epilepsy and mental retardation"
                  },
                  {
                    "text": "Cortical tubersLocalized cortical areas with abnormal developmentAbnormal lamination, dysmorphic neurons, microcalcificationsGiant/balloon cells: Pale cytoplasm, variably immunoreactive with glial (S100, GFAP) and neuronal markers (synaptophysin, neurofilament)",
                    "sub_points": [
                      "Localized cortical areas with abnormal developmentAbnormal lamination, dysmorphic neurons, microcalcifications",
                      "Abnormal lamination, dysmorphic neurons, microcalcifications",
                      "Giant/balloon cells: Pale cytoplasm, variably immunoreactive with glial (S100, GFAP) and neuronal markers (synaptophysin, neurofilament)"
                    ]
                  },
                  {
                    "text": "Cortical cytoarchitectural abnormalities may also be present outside tubers"
                  },
                  {
                    "text": "Subependymal nodules (\"candle guttering lesions\")Giant cells arranged in clusters and fascicles with mixed glial/neuronal phenotype",
                    "sub_points": [
                      "Giant cells arranged in clusters and fascicles with mixed glial/neuronal phenotype"
                    ]
                  }
                ],
                "Retinal Hamartoma/Astrocytoma": [
                  {
                    "text": "Small lesions involving nerve fiber layer of retina in ~ 50% of TSC patients"
                  },
                  {
                    "text": "Larger lesions may grow and cause retinal detachment"
                  },
                  {
                    "text": "Histologically similar to SEGA"
                  }
                ],
                "Renal Cysts": [
                  {
                    "text": "Usually asymptomatic"
                  },
                  {
                    "text": "TSC2/PKD1contiguous gene syndrome: Coexisting TSC and autosomal dominant polycystic kidney disease (severe)"
                  }
                ],
                "Micronodular Pneumocyte Hyperplasia": [
                  {
                    "text": "Small nodules of bland type II pneumocytes"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Cutaneous Angiofibroma": [
                  {
                    "text": "Dermal sclerosis"
                  },
                  {
                    "text": "Dilatation/proliferation of small vessels"
                  },
                  {
                    "text": "Stellate fibroblasts/multinucleated cells"
                  }
                ],
                "Subependymal Giant Cell Astrocytoma": [
                  {
                    "text": "Slow growth"
                  },
                  {
                    "text": "WHO grade I"
                  },
                  {
                    "text": "Mitotic activity rare to absent"
                  },
                  {
                    "text": "Microcalcifications in a subset, necrosis rare"
                  },
                  {
                    "text": "Pseudorosettes may be present and simulate ependymal neoplasms"
                  },
                  {
                    "text": "Composed of large cells with eosinophilic cytoplasm and macronucleoli"
                  },
                  {
                    "text": "Evidence of glial and neuronal differentiation by immunohistochemistry and electron microscopyConsistent S100 expression, GFAP variableVariable expression of synaptophysin, chromogranin, and neurofilament protein",
                    "sub_points": [
                      "Consistent S100 expression, GFAP variable",
                      "Variable expression of synaptophysin, chromogranin, and neurofilament protein"
                    ]
                  },
                  {
                    "text": "Excellent response to mTOR inhibitors in clinical trials"
                  }
                ],
                "Angiomyolipoma": [
                  {
                    "text": "Usually benign, but large tumors associated with risk for life-threatening bleeding"
                  },
                  {
                    "text": "Most common cause of mortality in TSC adult patients"
                  },
                  {
                    "text": "May be classic or epithelioid subtype"
                  },
                  {
                    "text": "May be a cause of LAM"
                  },
                  {
                    "text": "Partial response to mTOR inhibitors in some studies"
                  }
                ],
                "Lymphangioleiomyomatosis": [
                  {
                    "text": "Occurs in 30% of women with tuberous sclerosis"
                  },
                  {
                    "text": "Progressive pulmonary disorder involving lung"
                  },
                  {
                    "text": "Cystic changes, respiratory failure"
                  },
                  {
                    "text": "Lung biopsies demonstrate smooth muscle cells involving lymphatics, vessels, airways, and alveolar septa"
                  },
                  {
                    "text": "SMA(+), HMB-45(+)"
                  },
                  {
                    "text": "Majority of cases associated with tuberous sclerosis haveTSC2mutations (rather thanTSC1) and loss of heterozygosity"
                  },
                  {
                    "text": "Loss of heterozygosity inTSC2also frequent in sporadic LAM"
                  }
                ],
                "Cardiac Rhabdomyoma": [
                  {
                    "text": "~ 50% of patients with TSC"
                  },
                  {
                    "text": "Most frequent initial imaging finding in TSC patients"
                  },
                  {
                    "text": "May cause cardiac arrhythmias but also may regress with age"
                  }
                ],
                "Pancreatic Neuroendocrine Tumor": [
                  {
                    "text": "Not part of diagnostic criteria, but recognized in rare TSC patients"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "von Hippel-Lindau Syndrome": {
            "name": "von Hippel-Lindau Syndrome",
            "url": "https://app.pathprimer.com/document/01fbfa63-7e01-4018-a940-75ef4c0437e2/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "von Hippel-Lindau (VHL) syndrome"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "von Hippel-Lindau disease"
                  },
                  {
                    "text": "Familial cerebelloretinal angiomatosis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Rare autosomal dominant genetic disease resulting from mutation inVHLtumor suppressor gene on chromosome 3p25.3"
                  },
                  {
                    "text": "Characterized by retinal and CNS hemangioblastomas, pheochromocytomas, pancreatic serous cystadenoma, café au lait spots, and renal cell carcinomaIf no family history, diagnosis requires 2 cardinal manifestationsIncluding retinal and CNS involvementExcluding cystsWith positive family history1 cardinal manifestation, excluding cysts",
                    "sub_points": [
                      "If no family history, diagnosis requires 2 cardinal manifestationsIncluding retinal and CNS involvementExcluding cysts",
                      "Including retinal and CNS involvement",
                      "Excluding cysts",
                      "With positive family history1 cardinal manifestation, excluding cysts",
                      "1 cardinal manifestation, excluding cysts"
                    ]
                  },
                  {
                    "text": "Member of phacomatosis familial cancer syndromes"
                  }
                ]
              },
              "Epidemiology": {
                "Incidence": [
                  {
                    "text": "1 case per 36,000 newborns"
                  },
                  {
                    "text": "6,000-7,000 patients in United States"
                  }
                ],
                "Age": [
                  {
                    "text": "Age at diagnosis varies from infancy to 60-70 years"
                  }
                ],
                "Gender": [
                  {
                    "text": "No predilection is noted"
                  }
                ]
              },
              "Genetics and Molecular Biology": {
                "Tumorigenesis": [
                  {
                    "text": "VHLgene encodes VHL protein, which is an E3 ubiquitin ligaseMajor regulator of hypoxic response by targeting transcription factor hypoxia inducible factor (HIF) for degradation",
                    "sub_points": [
                      "Major regulator of hypoxic response by targeting transcription factor hypoxia inducible factor (HIF) for degradation"
                    ]
                  },
                  {
                    "text": "VHL disease demonstrates marked phenotypic variability and age-dependent penetranceGenotype-phenotype associations in VHL disease form basis of clinical classification",
                    "sub_points": [
                      "Genotype-phenotype associations in VHL disease form basis of clinical classification"
                    ]
                  },
                  {
                    "text": "Presumed that clinical presentation reflects quantitative or qualitative altered VHL protein function"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "Germline mutation ofVHLgene (3p25.3)VHLmutation in 50% of sporadic renal cell carcinoma (RCC)2nd inactivating event predisposes to neoplasms",
                    "sub_points": [
                      "VHLmutation in 50% of sporadic renal cell carcinoma (RCC)",
                      "2nd inactivating event predisposes to neoplasms"
                    ]
                  },
                  {
                    "text": "VHL proteinPromotes destruction of hypoxia inducible factor 1 α (HIF-1-α) via ubiquitin pathwayLoss of function leads to increased levels of vascular endothelial growth factor (VEGF)HIF-independent regulation of primary cilium and apoptosis via NF-κB pathwayLoss of function promotes renal cysts",
                    "sub_points": [
                      "Promotes destruction of hypoxia inducible factor 1 α (HIF-1-α) via ubiquitin pathwayLoss of function leads to increased levels of vascular endothelial growth factor (VEGF)",
                      "Loss of function leads to increased levels of vascular endothelial growth factor (VEGF)",
                      "HIF-independent regulation of primary cilium and apoptosis via NF-κB pathwayLoss of function promotes renal cysts",
                      "Loss of function promotes renal cysts"
                    ]
                  }
                ],
                "Subtypes": [
                  {
                    "text": "ClassificationType 1: Caused by deletions or truncation mutations of VHL geneTypes 2A, B, C: Caused by missense point mutations",
                    "sub_points": [
                      "Type 1: Caused by deletions or truncation mutations of VHL gene",
                      "Types 2A, B, C: Caused by missense point mutations"
                    ]
                  },
                  {
                    "text": "Genotype-phenotype correlationsType 1VHL(truncating and exon deletions)Low risk of pheochromocytomaType 2 VHL (missense mutations)High risk of pheochromocytomaType 2A: Low risk of RCCType 2B: High risk of RCCType 2C: Familial pheochromocytoma without hemangioblastoma or RCC",
                    "sub_points": [
                      "Type 1VHL(truncating and exon deletions)Low risk of pheochromocytoma",
                      "Low risk of pheochromocytoma",
                      "Type 2 VHL (missense mutations)High risk of pheochromocytomaType 2A: Low risk of RCCType 2B: High risk of RCCType 2C: Familial pheochromocytoma without hemangioblastoma or RCC",
                      "High risk of pheochromocytoma",
                      "Type 2A: Low risk of RCC",
                      "Type 2B: High risk of RCC",
                      "Type 2C: Familial pheochromocytoma without hemangioblastoma or RCC"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Surgical Approaches": [
                  {
                    "text": "Nephron-sparing surgery"
                  },
                  {
                    "text": "Tumor resection when other organs affected"
                  },
                  {
                    "text": "Surgery for > 3 cm endocrine pancreatic tumor"
                  },
                  {
                    "text": "Adrenalectomy for pheochromocytoma"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Death due to renal cell carcinoma in 50%Metastases to liver, lung, and bone",
                    "sub_points": [
                      "Metastases to liver, lung, and bone"
                    ]
                  },
                  {
                    "text": "Pheochromocytoma is cured after surgeryMetastatic pheochromocytoma has not been reported",
                    "sub_points": [
                      "Metastatic pheochromocytoma has not been reported"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Hemangioblastoma": [
                  {
                    "text": "Most common lesion associated with VHL disease"
                  },
                  {
                    "text": "Clinical, radiologic, and pathologic features similar in sporadic and VHL-associated tumors"
                  },
                  {
                    "text": "Cerebellum and spinal cord tumors cause major central nervous system manifestationsAffect 60-84% of patients",
                    "sub_points": [
                      "Affect 60-84% of patients"
                    ]
                  },
                  {
                    "text": "Benign vascular tumor, but may cause significant morbidity due to neurological deficits"
                  },
                  {
                    "text": "Retinal hemangioblastomas are typical ocular lesions of VHL diseasePreviously referred to as hemangiomas, but histologically identical to CNS counterpartsUsually multifocal and bilateralClinically, patients present with painless loss of visual acuity or visual field",
                    "sub_points": [
                      "Previously referred to as hemangiomas, but histologically identical to CNS counterparts",
                      "Usually multifocal and bilateral",
                      "Clinically, patients present with painless loss of visual acuity or visual field"
                    ]
                  },
                  {
                    "text": "Histologic featuresWell-circumscribed tumorsPiloid gliosis with Rosenthal fibers is common in adjacent CNS parenchymaHighly vascular with large and small thin-walled vesselsAbsent to rare mitotic activityReticular typeComposed of small nests/sheets of vacuolated cells known as stromal or interstitialReticulin abundant and highlights small lobules and individual cellsCellular typeArchitecture characterized by larger lobulesIncreased cytoplasm, vacuolation inconspicuousGlioma-like areas expressing GFAPLess reticulinNuclear pleomorphism may be presentExtramedullary hematopoiesis",
                    "sub_points": [
                      "Well-circumscribed tumors",
                      "Piloid gliosis with Rosenthal fibers is common in adjacent CNS parenchyma",
                      "Highly vascular with large and small thin-walled vessels",
                      "Absent to rare mitotic activity",
                      "Reticular typeComposed of small nests/sheets of vacuolated cells known as stromal or interstitialReticulin abundant and highlights small lobules and individual cells",
                      "Composed of small nests/sheets of vacuolated cells known as stromal or interstitial",
                      "Reticulin abundant and highlights small lobules and individual cells",
                      "Cellular typeArchitecture characterized by larger lobulesIncreased cytoplasm, vacuolation inconspicuousGlioma-like areas expressing GFAPLess reticulin",
                      "Architecture characterized by larger lobules",
                      "Increased cytoplasm, vacuolation inconspicuous",
                      "Glioma-like areas expressing GFAP",
                      "Less reticulin",
                      "Nuclear pleomorphism may be present",
                      "Extramedullary hematopoiesis"
                    ]
                  },
                  {
                    "text": "Histochemistry and immunohistochemistryLipid in stromal cells may be highlighted by oil red O in frozen sectionsImmunophenotype typically inhibin (+), NSE(+), GFAP(+/-)EMA usually negative (very rarely positive), CD10(-), CK(-)Low Ki-67 labeling index",
                    "sub_points": [
                      "Lipid in stromal cells may be highlighted by oil red O in frozen sections",
                      "Immunophenotype typically inhibin (+), NSE(+), GFAP(+/-)",
                      "EMA usually negative (very rarely positive), CD10(-), CK(-)",
                      "Low Ki-67 labeling index"
                    ]
                  },
                  {
                    "text": "Molecular cytogeneticsDifferent cytogenetic profiles in reticular and cellular subtypes of hemangioblastoma by comparative genomic hybridizationLoss of chromosome 6 associated with cellular subtypeLoss of 19/19p more frequent in reticular variant",
                    "sub_points": [
                      "Different cytogenetic profiles in reticular and cellular subtypes of hemangioblastoma by comparative genomic hybridizationLoss of chromosome 6 associated with cellular subtypeLoss of 19/19p more frequent in reticular variant",
                      "Loss of chromosome 6 associated with cellular subtype",
                      "Loss of 19/19p more frequent in reticular variant"
                    ]
                  }
                ],
                "Renal Cell Carcinoma": [
                  {
                    "text": "Patients with VHL disease are at high risk of developing multiple renal cysts and RCC, affecting 2/3 of VHL patients"
                  },
                  {
                    "text": "RCC is clear cell type, often multicentric &/or bilateral"
                  }
                ],
                "Pheochromocytoma": [
                  {
                    "text": "Catecholamine-producing neuroendocrine tumor related to chromaffin cells that arise from adrenal medulla or extraadrenal chromaffin tissue (paraganglia)"
                  },
                  {
                    "text": "Pheochromocytoma associated with VHL is usually asymptomatic"
                  },
                  {
                    "text": "Hallmark of type 2 VHL disease"
                  },
                  {
                    "text": "Patients with VHL disease are often very young (< 40 years)"
                  },
                  {
                    "text": "Tumor is usually bilateral, multiple, or extraadrenalHypertension with headache and sweating is most common presentation",
                    "sub_points": [
                      "Hypertension with headache and sweating is most common presentation"
                    ]
                  },
                  {
                    "text": "HistologyVHL pheochromocytoma have distinct pathological features from multiple endocrine neoplasia type 2 (MEN2) pheochromocytomasPresence of thick fibrous capsuleMyxoid and hyalinized stromaSmall to medium-sized tumor cellsAbsence of cytoplasmic hyaline globulesLack of nuclear atypiaAbsence of adrenomedullary hyperplasia",
                    "sub_points": [
                      "VHL pheochromocytoma have distinct pathological features from multiple endocrine neoplasia type 2 (MEN2) pheochromocytomasPresence of thick fibrous capsuleMyxoid and hyalinized stromaSmall to medium-sized tumor cellsAbsence of cytoplasmic hyaline globulesLack of nuclear atypiaAbsence of adrenomedullary hyperplasia",
                      "Presence of thick fibrous capsule",
                      "Myxoid and hyalinized stroma",
                      "Small to medium-sized tumor cells",
                      "Absence of cytoplasmic hyaline globules",
                      "Lack of nuclear atypia",
                      "Absence of adrenomedullary hyperplasia"
                    ]
                  }
                ],
                "Pancreatic Endocrine Tumor and Pancreatic Cysts": [
                  {
                    "text": "Tumors present in 10% of VHL patients are usually multiple and well circumscribed"
                  },
                  {
                    "text": "Tumors in VHL patients are usually nonsecretory"
                  },
                  {
                    "text": "Endocrine pancreatic tumors are characterized by solid, trabecular, &/or glandular architecture"
                  },
                  {
                    "text": "Stomal collagen is usually present"
                  },
                  {
                    "text": "Most tumors have clear cells"
                  },
                  {
                    "text": "Marked nuclear atypia may be present"
                  },
                  {
                    "text": "Mitoses are rare"
                  }
                ],
                "Other Associated Lesions": [
                  {
                    "text": "Papillary cystadenoma of epididymis"
                  },
                  {
                    "text": "Endolymphatic sac tumor"
                  },
                  {
                    "text": "Papillary cystadenoma of broad ligament and mesosalpinx"
                  },
                  {
                    "text": "Cysts of pancreas, kidney, adrenal, testis, and ovary"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Cystic Renal Diseases Associated With Renal Neoplasms": [
                  {
                    "text": "Acquired cystic kidney diseaseCyst frequency proportional to duration of ESRDDiverse array of RCCs",
                    "sub_points": [
                      "Cyst frequency proportional to duration of ESRD",
                      "Diverse array of RCCs"
                    ]
                  },
                  {
                    "text": "Tuberous sclerosis complex/autosomal dominant polycystic kidney disease (ADPKD) contiguous gene syndromeDiffusely cystic kidneys identical to ADPKDMultiple and bilateral angiomyolipomasRarely, clear cell RCC",
                    "sub_points": [
                      "Diffusely cystic kidneys identical to ADPKD",
                      "Multiple and bilateral angiomyolipomas",
                      "Rarely, clear cell RCC"
                    ]
                  },
                  {
                    "text": "Autosomal dominant polycystic kidney diseaseRisk of RCC may be increased but controversialFar more numerous cysts than in VHL",
                    "sub_points": [
                      "Risk of RCC may be increased but controversial",
                      "Far more numerous cysts than in VHL"
                    ]
                  }
                ],
                "Tuberous Sclerosis Complex": [
                  {
                    "text": "Angiomyolipomas common"
                  },
                  {
                    "text": "Renal cancer and renal cysts rare"
                  },
                  {
                    "text": "Rare pancreatic lesions"
                  },
                  {
                    "text": "Calcified cortical lesions (i.e., tubers), subependymal nodules, and subependymal giant cell astrocytoma"
                  }
                ],
                "Neurofibromatosis Type 1": [
                  {
                    "text": "May develop multiple pheochromocytomas, but CNS lesions are astrocytomas rather than hemangioblastomas"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Early Diagnosis": [
                  {
                    "text": "Improves prognosis of most VHL manifestationsComprehensive screening program starting in childhoodLifelong routine screening for hemangioblastomas (CNS and retinal), RCCs, and pheochromocytomas",
                    "sub_points": [
                      "Comprehensive screening program starting in childhood",
                      "Lifelong routine screening for hemangioblastomas (CNS and retinal), RCCs, and pheochromocytomas"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Dyskeratosis Congenita": {
            "name": "Dyskeratosis Congenita",
            "url": "https://app.pathprimer.com/document/e29d18b2-bb7c-4a5b-ae75-6ad6397efc2e/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "Terminology": {
                "Definition": [
                  {
                    "text": "Syndrome with 3 characteristic featuresOral leukoplakiaAbnormal nailsReticulate hyperpigmentation",
                    "sub_points": [
                      "Oral leukoplakia",
                      "Abnormal nails",
                      "Reticulate hyperpigmentation"
                    ]
                  },
                  {
                    "text": "Secondary to defective telomere maintenance"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Zinsser-Cole-Engman syndrome"
                  },
                  {
                    "text": "Hoyeraal-Hreidarsson syndrome"
                  },
                  {
                    "text": "Revesz syndrome"
                  }
                ]
              },
              "Epidemiology": {
                "Prevalence": [
                  {
                    "text": "~ 1 in 1 million"
                  },
                  {
                    "text": "~ 500 reported cases in literature from 1910-2008"
                  }
                ],
                "Gender": [
                  {
                    "text": "Male predominance for X-linked form"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Phenotype variableSeverely affected patients may die early from bone marrow failure",
                    "sub_points": [
                      "Severely affected patients may die early from bone marrow failure"
                    ]
                  },
                  {
                    "text": "Median overall survival age: 42 years"
                  }
                ],
                "Age of Onset": [
                  {
                    "text": "Variable, but classically1st decadeSkin hyperpigmentationOral leukoplakiaNail changes2nd decadeBone marrow failureMedian age: 29 years for development of cancer",
                    "sub_points": [
                      "1st decadeSkin hyperpigmentationOral leukoplakiaNail changes",
                      "Skin hyperpigmentation",
                      "Oral leukoplakia",
                      "Nail changes",
                      "2nd decadeBone marrow failure",
                      "Bone marrow failure",
                      "Median age: 29 years for development of cancer"
                    ]
                  }
                ]
              },
              "Genetics": {
                "Germline Mutations": [
                  {
                    "text": "TERT, TERC, DKC1, TINF2genes; documented in ~ 50% of casesThese function in maintaining telomeresTERTandTERCencode telomerase, which maintains telomere length; telomerase is a ribonucleoprotein with 2 componentsTERCencodes RNA component of telomeraseTERTencodes telomerase reverse transcriptase enzymeTERTandTERCmutations also described in cases of idiopathic pulmonary fibrosis &/or aplastic anemiaDKC1encodes dyskerin, which stabilizes telomerase complexDyskerin: 58 kD nucleolar protein, associates with small nucleolar RNAsDyskerin binds to telomerase RNATINF2is related to shelterin complex, which helps protect telomeresShelterin made of 6 proteinsShelterin protects telomere ends from destruction &/or DNA repair",
                    "sub_points": [
                      "These function in maintaining telomeres",
                      "TERTandTERCencode telomerase, which maintains telomere length; telomerase is a ribonucleoprotein with 2 componentsTERCencodes RNA component of telomeraseTERTencodes telomerase reverse transcriptase enzymeTERTandTERCmutations also described in cases of idiopathic pulmonary fibrosis &/or aplastic anemia",
                      "TERCencodes RNA component of telomerase",
                      "TERTencodes telomerase reverse transcriptase enzyme",
                      "TERTandTERCmutations also described in cases of idiopathic pulmonary fibrosis &/or aplastic anemia",
                      "DKC1encodes dyskerin, which stabilizes telomerase complexDyskerin: 58 kD nucleolar protein, associates with small nucleolar RNAsDyskerin binds to telomerase RNA",
                      "Dyskerin: 58 kD nucleolar protein, associates with small nucleolar RNAs",
                      "Dyskerin binds to telomerase RNA",
                      "TINF2is related to shelterin complex, which helps protect telomeresShelterin made of 6 proteinsShelterin protects telomere ends from destruction &/or DNA repair",
                      "Shelterin made of 6 proteins",
                      "Shelterin protects telomere ends from destruction &/or DNA repair"
                    ]
                  },
                  {
                    "text": "Other genes (also involved in telomere maintenance)NOLA2(encodes NOP10), NOLA3(encodes NHP2), RTEL1, CTC1, TCAB1, WRAP53",
                    "sub_points": [
                      "NOLA2(encodes NOP10), NOLA3(encodes NHP2), RTEL1, CTC1, TCAB1, WRAP53"
                    ]
                  },
                  {
                    "text": "Patients with dyskeratosis congenita have short telomeresException is subset of dyskeratosis congenita with mutations inUSB1(C16orf57)This subset has overlapping features with poikiloderma with neutropenia and Rothmund-Thomson syndrome",
                    "sub_points": [
                      "Exception is subset of dyskeratosis congenita with mutations inUSB1(C16orf57)This subset has overlapping features with poikiloderma with neutropenia and Rothmund-Thomson syndrome",
                      "This subset has overlapping features with poikiloderma with neutropenia and Rothmund-Thomson syndrome"
                    ]
                  },
                  {
                    "text": "Telomeres are noncoding sequences at chromosome endsTelomeres become shorter with each cell divisionTelomerase adds genetic repeat TTAGGG to 3' end of DNA after replication, to prevent shortening of telomeresRapidly dividing cells are most at risk for telomere shortening; these cells (germ cells, stem cells) have telomeraseCells with shortened telomeres become apoptotic through p53 pathway",
                    "sub_points": [
                      "Telomeres become shorter with each cell division",
                      "Telomerase adds genetic repeat TTAGGG to 3' end of DNA after replication, to prevent shortening of telomeres",
                      "Rapidly dividing cells are most at risk for telomere shortening; these cells (germ cells, stem cells) have telomerase",
                      "Cells with shortened telomeres become apoptotic through p53 pathway"
                    ]
                  },
                  {
                    "text": "Genetic anticipationDisease presents at a progressively earlier age in subsequent generationsSeen in families withTERCmutations",
                    "sub_points": [
                      "Disease presents at a progressively earlier age in subsequent generations",
                      "Seen in families withTERCmutations"
                    ]
                  }
                ],
                "Inheritance": [
                  {
                    "text": "X-linked recessiveWhen secondary toDKC1mutations, located on X chromosome",
                    "sub_points": [
                      "When secondary toDKC1mutations, located on X chromosome"
                    ]
                  },
                  {
                    "text": "Autosomal dominantWhen secondary toTERCorTINF2mutations",
                    "sub_points": [
                      "When secondary toTERCorTINF2mutations"
                    ]
                  },
                  {
                    "text": "Autosomal dominant or recessiveWhen secondary toTERTmutations",
                    "sub_points": [
                      "When secondary toTERTmutations"
                    ]
                  },
                  {
                    "text": "Autosomal recessiveWhen secondary toCTC1, WRAP53, NHP2, NOP10",
                    "sub_points": [
                      "When secondary toCTC1, WRAP53, NHP2, NOP10"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Clinical Presentation": [
                  {
                    "text": "Variable severity: Ranges from mild skin findings with normal bone marrow to early bone marrow failure and deathHoyeraal-Hreidarsson syndrome more severeCerebellar hypoplasiaMicrocephalySevere immunodeficiencyAplastic anemiaEnteropathyIntrauterine growth retardationDevelopmental delayRevesz syndromeBilateral exudative retinopathyDevelopmental delayOral leukoplakia, abnormal nails, reticulate hyperpigmentationCerebellar hypoplasiaBone marrow hypoplasiaPhenotypic variability correlated with genotypeTINF2mutations cause severe disease with early death; age of onset often < 5 years, aplastic anemia often before 10 yearsDisease secondary toTERCmutations less severe thanDKC1mutations, but bone marrow failure may present earlier withTERCmutationsCancer more common in disease secondary toTERTandTERCmutations (may be because patients withTERTandTERCmutations live longer)Cancer less common in disease secondary toTINF2mutations",
                    "sub_points": [
                      "Hoyeraal-Hreidarsson syndrome more severeCerebellar hypoplasiaMicrocephalySevere immunodeficiencyAplastic anemiaEnteropathyIntrauterine growth retardationDevelopmental delay",
                      "Cerebellar hypoplasia",
                      "Microcephaly",
                      "Severe immunodeficiency",
                      "Aplastic anemia",
                      "Enteropathy",
                      "Intrauterine growth retardation",
                      "Developmental delay",
                      "Revesz syndromeBilateral exudative retinopathyDevelopmental delayOral leukoplakia, abnormal nails, reticulate hyperpigmentationCerebellar hypoplasiaBone marrow hypoplasia",
                      "Bilateral exudative retinopathy",
                      "Developmental delay",
                      "Oral leukoplakia, abnormal nails, reticulate hyperpigmentation",
                      "Cerebellar hypoplasia",
                      "Bone marrow hypoplasia",
                      "Phenotypic variability correlated with genotypeTINF2mutations cause severe disease with early death; age of onset often < 5 years, aplastic anemia often before 10 yearsDisease secondary toTERCmutations less severe thanDKC1mutations, but bone marrow failure may present earlier withTERCmutationsCancer more common in disease secondary toTERTandTERCmutations (may be because patients withTERTandTERCmutations live longer)Cancer less common in disease secondary toTINF2mutations",
                      "TINF2mutations cause severe disease with early death; age of onset often < 5 years, aplastic anemia often before 10 years",
                      "Disease secondary toTERCmutations less severe thanDKC1mutations, but bone marrow failure may present earlier withTERCmutations",
                      "Cancer more common in disease secondary toTERTandTERCmutations (may be because patients withTERTandTERCmutations live longer)",
                      "Cancer less common in disease secondary toTINF2mutations"
                    ]
                  },
                  {
                    "text": "Classic triadAppears in 1st decadeOral leukoplakia (~ 80% of cases)Abnormal nails (~ 90% of cases)Reticulate hyperpigmentation (~ 90% of cases)",
                    "sub_points": [
                      "Appears in 1st decade",
                      "Oral leukoplakia (~ 80% of cases)",
                      "Abnormal nails (~ 90% of cases)",
                      "Reticulate hyperpigmentation (~ 90% of cases)"
                    ]
                  },
                  {
                    "text": "Associations (% generally based on London registry)Bone marrowFailure (~ 85%): Most common cause of death by 3rd decade (~ 60-70%), presents in 2nd decadeAplastic anemia (in up to 86% of patients)Myelodysplastic syndromeLeukemiaImmunologic abnormalities may be the initial presentation (i.e., lymphopenia, low B-cell counts, hypogammaglobulinemia, decreased T-cell function)Cancers of head/neck/skin/anogenital region (52/552 patients on literature review)Lead to mortality in up to 60%Cumulative incidence of cancer 40-50% by age 50Head/neck squamous cell carcinoma: 40% of patients on reviewPulmonary fibrosis (~ 20%)Leads to mortality in ~ 10-15%Narrow/blocked tear ducts causing epiphora (~ 30%)Mental retardation (~ 25%)Short stature (~ 20%)Dental problemsExtensive caries (~ 17%)Esophageal stricture (~ 17%)AlopeciaPremature graying (~ 16%)Palmoplantar keratodermaOsteoporosis, avascular necrosis (hip/shoulder) (~ 5%)Liver disease (~ 7%)Cerebellar hypoplasia (~ 7%)Hypogonadism (~ 6%)Microcephaly (~ 6%)Urethral stenosis (~ 5%)Deafness (~ 1%)",
                    "sub_points": [
                      "Bone marrowFailure (~ 85%): Most common cause of death by 3rd decade (~ 60-70%), presents in 2nd decadeAplastic anemia (in up to 86% of patients)Myelodysplastic syndromeLeukemiaImmunologic abnormalities may be the initial presentation (i.e., lymphopenia, low B-cell counts, hypogammaglobulinemia, decreased T-cell function)",
                      "Failure (~ 85%): Most common cause of death by 3rd decade (~ 60-70%), presents in 2nd decade",
                      "Aplastic anemia (in up to 86% of patients)",
                      "Myelodysplastic syndrome",
                      "Leukemia",
                      "Immunologic abnormalities may be the initial presentation (i.e., lymphopenia, low B-cell counts, hypogammaglobulinemia, decreased T-cell function)",
                      "Cancers of head/neck/skin/anogenital region (52/552 patients on literature review)Lead to mortality in up to 60%Cumulative incidence of cancer 40-50% by age 50Head/neck squamous cell carcinoma: 40% of patients on review",
                      "Lead to mortality in up to 60%",
                      "Cumulative incidence of cancer 40-50% by age 50",
                      "Head/neck squamous cell carcinoma: 40% of patients on review",
                      "Pulmonary fibrosis (~ 20%)Leads to mortality in ~ 10-15%",
                      "Leads to mortality in ~ 10-15%",
                      "Narrow/blocked tear ducts causing epiphora (~ 30%)",
                      "Mental retardation (~ 25%)",
                      "Short stature (~ 20%)",
                      "Dental problemsExtensive caries (~ 17%)",
                      "Extensive caries (~ 17%)",
                      "Esophageal stricture (~ 17%)",
                      "Alopecia",
                      "Premature graying (~ 16%)",
                      "Palmoplantar keratoderma",
                      "Osteoporosis, avascular necrosis (hip/shoulder) (~ 5%)",
                      "Liver disease (~ 7%)",
                      "Cerebellar hypoplasia (~ 7%)",
                      "Hypogonadism (~ 6%)",
                      "Microcephaly (~ 6%)",
                      "Urethral stenosis (~ 5%)",
                      "Deafness (~ 1%)"
                    ]
                  }
                ],
                "Management": [
                  {
                    "text": "Bone marrow failureConsider treatment if Hgb < 8 g/dL, PLT < 30,000/mm³, neutrophils below 1,000/mm³Mainstay of treatment: Stem cell transplantation",
                    "sub_points": [
                      "Consider treatment if Hgb < 8 g/dL, PLT < 30,000/mm³, neutrophils below 1,000/mm³",
                      "Mainstay of treatment: Stem cell transplantation"
                    ]
                  },
                  {
                    "text": "Less severe cases: Treatment optionsAnabolic steroid oxymetholoneGranulocyte-macrophage colony-stimulating factorGranulocyte colony-stimulating factor &/or erythropoietin",
                    "sub_points": [
                      "Anabolic steroid oxymetholone",
                      "Granulocyte-macrophage colony-stimulating factor",
                      "Granulocyte colony-stimulating factor &/or erythropoietin"
                    ]
                  },
                  {
                    "text": "Prevent pulmonary fibrosisAvoid busulfan and other agents associated with fibrosis",
                    "sub_points": [
                      "Avoid busulfan and other agents associated with fibrosis"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Based on 552 Reported Cases of Dyskeratosis Congenita": [
                  {
                    "text": "Squamous cell carcinoma of head/neck (especially tongue)24 cases in 22 patientsMetachronous cancers documented",
                    "sub_points": [
                      "24 cases in 22 patients",
                      "Metachronous cancers documented"
                    ]
                  },
                  {
                    "text": "Skin cancer8 cases",
                    "sub_points": [
                      "8 cases"
                    ]
                  },
                  {
                    "text": "Anorectal carcinoma6 cases",
                    "sub_points": [
                      "6 cases"
                    ]
                  },
                  {
                    "text": "Gastric carcinoma2 adenocarcinoma (2 unspecified)",
                    "sub_points": [
                      "2 adenocarcinoma (2 unspecified)"
                    ]
                  },
                  {
                    "text": "Lung carcinoma2 bronchial, 1 adenocarcinoma, 1 unspecified",
                    "sub_points": [
                      "2 bronchial, 1 adenocarcinoma, 1 unspecified"
                    ]
                  },
                  {
                    "text": "Esophageal carcinoma3 cases",
                    "sub_points": [
                      "3 cases"
                    ]
                  },
                  {
                    "text": "Hodgkin lymphoma3 cases",
                    "sub_points": [
                      "3 cases"
                    ]
                  },
                  {
                    "text": "Colorectal carcinoma2 adenocarcinomas (1 unspecified)",
                    "sub_points": [
                      "2 adenocarcinomas (1 unspecified)"
                    ]
                  },
                  {
                    "text": "Other2 pancreatic adenomas, 2 liver adenomas, 1 retinoblastoma, 1 cervical squamous cell carcinoma, 1 non-Hodgkin lymphoma",
                    "sub_points": [
                      "2 pancreatic adenomas, 2 liver adenomas, 1 retinoblastoma, 1 cervical squamous cell carcinoma, 1 non-Hodgkin lymphoma"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Prevention": [
                  {
                    "text": "Avoid radiotherapy"
                  },
                  {
                    "text": "Avoid smoking"
                  },
                  {
                    "text": "Limit sun exposure, use sunscreen/sun protection"
                  }
                ],
                "Leukemia": [
                  {
                    "text": "CBC annually (or more often if abnormal)"
                  },
                  {
                    "text": "Consider annual bone marrow aspirate after baseline examination"
                  }
                ],
                "Squamous Cell Carcinoma (Head/Neck, Anogenital)": [
                  {
                    "text": "Monthly self examination (oral/head/neck)"
                  },
                  {
                    "text": "Annual skin examination by oncology &/or dermatology"
                  },
                  {
                    "text": "Biannual dental examination"
                  },
                  {
                    "text": "Annual gynecologic examination"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Isolated Aplastic Anemia": [
                  {
                    "text": "Can be secondary to mutations in telomere maintenance genes like dyskeratosis congenita"
                  },
                  {
                    "text": "Other features of dyskeratosis congenita absent"
                  }
                ],
                "Fanconi Anemia": [
                  {
                    "text": "Pigmentary changes"
                  },
                  {
                    "text": "Short stature"
                  },
                  {
                    "text": "Eye abnormalities"
                  },
                  {
                    "text": "CNS malformations, developmental delay"
                  },
                  {
                    "text": "Urogenital/cardiac/gastrointestinal/oral abnormalities"
                  },
                  {
                    "text": "Acute myeloid leukemia and other hematologic malignancies"
                  },
                  {
                    "text": "Solid tumors, including Wilms tumor and squamous cell carcinoma (head/neck, gynecologic)"
                  }
                ],
                "Other Inherited Bone Marrow Failure Syndromes": [
                  {
                    "text": "Diamond-Blackfan anemia"
                  },
                  {
                    "text": "Shwachman-Diamond syndrome"
                  },
                  {
                    "text": "Severe congenital neutropenia"
                  },
                  {
                    "text": "Amegakaryocytic thrombocytopenia"
                  },
                  {
                    "text": "Thrombocytopenia absent radii"
                  }
                ],
                "Idiopathic Pulmonary Fibrosis": [
                  {
                    "text": "Can be secondary to mutations in telomere maintenance genes like dyskeratosis congenita"
                  },
                  {
                    "text": "Other features of dyskeratosis congenita absent"
                  }
                ]
              },
              "Criteria for Diagnosis": {
                "Suggested Criteria": [
                  {
                    "text": "2 of 4 major with at least 2 minor"
                  },
                  {
                    "text": "Major criteriaOral leukoplakiaNail dystrophyReticulate hyperpigmentationBone marrow failure",
                    "sub_points": [
                      "Oral leukoplakia",
                      "Nail dystrophy",
                      "Reticulate hyperpigmentation",
                      "Bone marrow failure"
                    ]
                  },
                  {
                    "text": "Minor criteriaEpiphoraShort statureDental caries/lossPremature hair loss/grayingHyperhidrosisIntrauterine growth retardationPulmonary diseaseLiver diseaseEsophageal strictureHypogonadism, undescended testes, urethral stricture/phimosisOsteoporosis, aseptic necrosis, scoliosisMental retardation, developmental delayMicrocephaly, cerebellar hypoplasia, ataxia, deafnessMalignancy",
                    "sub_points": [
                      "Epiphora",
                      "Short stature",
                      "Dental caries/loss",
                      "Premature hair loss/graying",
                      "Hyperhidrosis",
                      "Intrauterine growth retardation",
                      "Pulmonary disease",
                      "Liver disease",
                      "Esophageal stricture",
                      "Hypogonadism, undescended testes, urethral stricture/phimosis",
                      "Osteoporosis, aseptic necrosis, scoliosis",
                      "Mental retardation, developmental delay",
                      "Microcephaly, cerebellar hypoplasia, ataxia, deafness",
                      "Malignancy"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Familial Uveal Melanoma": {
            "name": "Familial Uveal Melanoma",
            "url": "https://app.pathprimer.com/document/3573c097-6d42-4e5d-9ff5-09939ce346ac/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "Terminology": {
                "Description": [
                  {
                    "text": "Malignant intraocular neoplasm with melanocytic differentiation arising in choroid, ciliary body, or iris"
                  }
                ]
              },
              "Epidemiology": {
                "Uveal Melanoma": [
                  {
                    "text": "Most frequent primary intraocular neoplasm in adults"
                  },
                  {
                    "text": "Annual incidence: 5-6 per 1 million in United StatesPredominantly disease of adults (mean age ~ 60 years)Predilection for whites, light-colored eyes; no gender predilection",
                    "sub_points": [
                      "Predominantly disease of adults (mean age ~ 60 years)",
                      "Predilection for whites, light-colored eyes; no gender predilection"
                    ]
                  }
                ],
                "Familial Uveal Melanoma": [
                  {
                    "text": "Families with multiple members with uveal melanoma very rare (< 1%)"
                  },
                  {
                    "text": "If cancers other than uveal melanoma are considered, familial predisposition for uveal melanoma is much higher (~ 10%)"
                  }
                ]
              },
              "Genetics": {
                "BAP1-Associated Tumor Predisposition Syndrome": [
                  {
                    "text": "Autosomal dominant syndrome associated with mutations inBRCA1-associated protein 1 (BAP1) located in chromosome region 3p21.1"
                  },
                  {
                    "text": "Encodes for a nuclear ubiquitin carboxy-terminal hydroxylaseBindsBRCA1andASXL1Plays role in DNA damage response, apoptosis, senescence, chromatin modulation/stem cell biology, and regulation of cell cycle",
                    "sub_points": [
                      "BindsBRCA1andASXL1",
                      "Plays role in DNA damage response, apoptosis, senescence, chromatin modulation/stem cell biology, and regulation of cell cycle"
                    ]
                  },
                  {
                    "text": "Inactivating somatic mutations in 1/2 of uveal melanomas, particularly when metastatic"
                  },
                  {
                    "text": "Inactivating somatic mutations in a small subset of lung and breast cancers"
                  },
                  {
                    "text": "Monosomy 3 (containingBAP1) strongly associated with metastatic risk in uveal melanoma"
                  },
                  {
                    "text": "Germline mutations associated with increased risk in families for uveal melanoma, cutaneous melanoma, malignant mesothelioma, renal cell carcinoma, and other cancersFrequent epithelioid/rhabdoid cytology",
                    "sub_points": [
                      "Frequent epithelioid/rhabdoid cytology"
                    ]
                  },
                  {
                    "text": "Protein loss may be identified by immunohistochemistry in tumor tissues"
                  }
                ],
                "CDKN2A": [
                  {
                    "text": "Encodes tumor suppressorsp14ARFandP16"
                  },
                  {
                    "text": "Best known high-risk melanoma susceptibility gene"
                  },
                  {
                    "text": "Germline mutations strongly associated with cutaneous melanoma, but rare in uveal melanoma (< 1% of patients)"
                  }
                ],
                "GNAQandGNA11": [
                  {
                    "text": "Somatic mutations frequent in uveal melanomaEarly genetic events leading to MAPK pathway activation",
                    "sub_points": [
                      "Early genetic events leading to MAPK pathway activation"
                    ]
                  },
                  {
                    "text": "Germline mutations not a feature of familial uveal melanoma"
                  }
                ],
                "BRAF": [
                  {
                    "text": "Somatic mutations frequent in cutaneous melanoma but very rare in uveal melanoma"
                  },
                  {
                    "text": "Germline mutations associated with cardiofaciocutaneous syndrome but not with melanoma predisposition"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Uveal Melanoma": [
                  {
                    "text": "High propensity for metastases (~ 50%), particularly the liver"
                  },
                  {
                    "text": "Composed of 3 main cell types in various proportionsSpindle A: Narrow nuclei, inconspicuous nucleoliSpindle B: Oval, plump nuclei with prominent nucleoliEpithelioid: Abundant cytoplasm, prominent nucleoli, associated with poor prognosis",
                    "sub_points": [
                      "Spindle A: Narrow nuclei, inconspicuous nucleoli",
                      "Spindle B: Oval, plump nuclei with prominent nucleoli",
                      "Epithelioid: Abundant cytoplasm, prominent nucleoli, associated with poor prognosis"
                    ]
                  },
                  {
                    "text": "Gene expression profilesClass 1: Low metastatic riskClass 2: High metastatic risk, frequent monosomy 3",
                    "sub_points": [
                      "Class 1: Low metastatic risk",
                      "Class 2: High metastatic risk, frequent monosomy 3"
                    ]
                  },
                  {
                    "text": "Other prognostic factors include tumor size, extracellular matrix patterns (i.e., vascular mimicry), mitotic activity, extraocular extension, necrosis, and lymphocytic infiltrates"
                  }
                ],
                "Cutaneous Melanoma and Atypical Melanocytic Lesions": [
                  {
                    "text": "MelanocyticBAP1-mutated atypical intradermal tumors (MBAIT) or nevoid melanoma-like melanocytic proliferations (NEMMP)Terms proposed for a subset of tumors with spitzoid features and high prevalence of somaticBRAF(V600E) mutation in patients with germlineBAP1mutationsTerminology not uniformly acceptedCombined somaticBAP1andBRAFmutations also found in a subset of atypical Spitz tumors/nevi",
                    "sub_points": [
                      "Terms proposed for a subset of tumors with spitzoid features and high prevalence of somaticBRAF(V600E) mutation in patients with germlineBAP1mutationsTerminology not uniformly accepted",
                      "Terminology not uniformly accepted",
                      "Combined somaticBAP1andBRAFmutations also found in a subset of atypical Spitz tumors/nevi"
                    ]
                  }
                ],
                "Astrocytoma": [
                  {
                    "text": "Melanoma-astrocytoma predisposition recognized in rare families"
                  },
                  {
                    "text": "Associated withCDKN2Amutations, particularly when exons coding forp14ARFare involved"
                  },
                  {
                    "text": "Astrocytomas pathologically high grade (i.e., glioblastomas)"
                  }
                ],
                "Mesothelioma": [
                  {
                    "text": "Genetic factors importantSome patients develop mesothelioma after short exposure to asbestos whereas others do not, even after heavy exposure",
                    "sub_points": [
                      "Some patients develop mesothelioma after short exposure to asbestos whereas others do not, even after heavy exposure"
                    ]
                  },
                  {
                    "text": "Recognized component ofBAP1-associated tumor predisposition syndrome"
                  },
                  {
                    "text": "BAP1mutations also occur is sporadic mesothelioma (up to 60%)More frequent in tumors with epithelioid morphology",
                    "sub_points": [
                      "More frequent in tumors with epithelioid morphology"
                    ]
                  }
                ],
                "Renal Cell Carcinoma": [
                  {
                    "text": "Recognized component ofBAP1-associated tumor predisposition syndromeClear cell histology",
                    "sub_points": [
                      "Clear cell histology"
                    ]
                  },
                  {
                    "text": "SomaticBAP1mutations in 8-14% of clear cell renal carcinomas"
                  }
                ],
                "Others": [
                  {
                    "text": "Meningioma, lung adenocarcinoma, neuroendocrine carcinoma, paraganglioma"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Uveal Melanoma Families": [
                  {
                    "text": "Members with uveal melanomas and other possibly related cancers (e.g., cutaneous melanomas and mesotheliomas) should be screened forBAP1mutations"
                  },
                  {
                    "text": "Ophthalmologic and dermatologic exams; avoid environmental insults (e.g., sun exposure)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Cutaneous Melanoma": {
            "name": "Hereditary Cutaneous Melanoma",
            "url": "https://app.pathprimer.com/document/b058317e-9799-4704-8c38-b962414676b0/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "Terminology": {
                "Definition of Hereditary Cutaneous Melanoma": [
                  {
                    "text": "≥ 3 blood relatives with cutaneous melanoma in areas with high sun exposure"
                  },
                  {
                    "text": "≥ 2 blood relatives with cutaneous melanoma in areas with low sun exposure"
                  }
                ]
              },
              "Epidemiology": {
                "Incidence of Hereditary Cutaneous Melanoma": [
                  {
                    "text": "5-7% of cutaneous melanoma patients are from high-risk familiesIn individuals with multiple relatives with cutaneous melanomaPercentage increases to ~ 54%In individuals with multiple primary cutaneous melanomasPercentage increases to ~ 15%",
                    "sub_points": [
                      "In individuals with multiple relatives with cutaneous melanomaPercentage increases to ~ 54%",
                      "Percentage increases to ~ 54%",
                      "In individuals with multiple primary cutaneous melanomasPercentage increases to ~ 15%",
                      "Percentage increases to ~ 15%"
                    ]
                  }
                ],
                "Hereditary vs. Sporadic Cutaneous Melanoma": [
                  {
                    "text": "Most cutaneous melanoma is sporadicLikely secondary to somatic mutationsMay be induced by ultraviolet light, especially with intermittent sun exposure and sunburn",
                    "sub_points": [
                      "Likely secondary to somatic mutationsMay be induced by ultraviolet light, especially with intermittent sun exposure and sunburn",
                      "May be induced by ultraviolet light, especially with intermittent sun exposure and sunburn"
                    ]
                  },
                  {
                    "text": "Up to 10% of cases of cutaneous melanomaSecondary to germline mutationsMutations are currently detectable in up to 40% of families with suspected hereditary cutaneous melanoma",
                    "sub_points": [
                      "Secondary to germline mutations",
                      "Mutations are currently detectable in up to 40% of families with suspected hereditary cutaneous melanoma"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Mean age at presentation with cutaneous melanoma: 34 years"
                  }
                ]
              },
              "Genetics": {
                "CDKN2AMutations (Tumor Suppressor Gene on 9p21)": [
                  {
                    "text": "In 20-40% of cutaneous melanoma kindreds; present in 0.2-2% of all cutaneous melanoma patientsMelanoma penetrance30% by age 50 years67% by age 80 yearsLifetime risk of cutaneous melanoma53% in Europe75% in United States91% in Australia",
                    "sub_points": [
                      "Melanoma penetrance30% by age 50 years67% by age 80 years",
                      "30% by age 50 years",
                      "67% by age 80 years",
                      "Lifetime risk of cutaneous melanoma53% in Europe75% in United States91% in Australia",
                      "53% in Europe",
                      "75% in United States",
                      "91% in Australia"
                    ]
                  },
                  {
                    "text": "Risk ofCDKN2Amutation carriage~ 50% risk if relative with knownCDKN2Amutation50% risk if 3 or more relatives with cutaneous melanoma45% risk if 1 relative with multiple cutaneous melanomas20-45% risk if 2 or more relatives with cutaneous melanoma10-20% risk if multiple primary cutaneous melanomas and no family history of cutaneous melanoma~ 20% risk if affected by cutaneous melanoma and pancreatic cancer< 1% if early onset of 1 cutaneous melanoma",
                    "sub_points": [
                      "~ 50% risk if relative with knownCDKN2Amutation",
                      "50% risk if 3 or more relatives with cutaneous melanoma",
                      "45% risk if 1 relative with multiple cutaneous melanomas",
                      "20-45% risk if 2 or more relatives with cutaneous melanoma",
                      "10-20% risk if multiple primary cutaneous melanomas and no family history of cutaneous melanoma",
                      "~ 20% risk if affected by cutaneous melanoma and pancreatic cancer",
                      "< 1% if early onset of 1 cutaneous melanoma"
                    ]
                  },
                  {
                    "text": "Mutations are generally inactivatingOften missense leading to loss of function of p16INK4ASometimes affect both p16INK4A and p14ARFLess commonly, deletions, insertions, and splice site mutations affect p14ARF alone",
                    "sub_points": [
                      "Often missense leading to loss of function of p16INK4A",
                      "Sometimes affect both p16INK4A and p14ARF",
                      "Less commonly, deletions, insertions, and splice site mutations affect p14ARF alone"
                    ]
                  },
                  {
                    "text": "Gene transcripts ofCDKN2Ap16INK4APart of retinoblastoma pathwayPhysiologic targets include CDK4 and CDK6Thought to cause senescence in melanocytes and melanocytic nevip14ARFPart of p53 pathwayFunction is to block HDM2-mediated degradation of p53",
                    "sub_points": [
                      "p16INK4APart of retinoblastoma pathwayPhysiologic targets include CDK4 and CDK6Thought to cause senescence in melanocytes and melanocytic nevi",
                      "Part of retinoblastoma pathway",
                      "Physiologic targets include CDK4 and CDK6",
                      "Thought to cause senescence in melanocytes and melanocytic nevi",
                      "p14ARFPart of p53 pathwayFunction is to block HDM2-mediated degradation of p53",
                      "Part of p53 pathway",
                      "Function is to block HDM2-mediated degradation of p53"
                    ]
                  }
                ],
                "Linkage to 1p36 and 1p22": [
                  {
                    "text": "1p36Multiple cutaneous melanomas and dysplastic nevi may be seen",
                    "sub_points": [
                      "Multiple cutaneous melanomas and dysplastic nevi may be seen"
                    ]
                  }
                ],
                "CDK4Mutations (Oncogene on 12q14)": [
                  {
                    "text": "CDK4 functions in retinoblastoma pathway"
                  },
                  {
                    "text": "Mutations in exon 2, codon 24 disrupts binding to p16INK4A"
                  }
                ],
                "BAP1Mutations": [
                  {
                    "text": "Associated with ocular melanoma"
                  },
                  {
                    "text": "Rarely, kindreds with ocular melanoma also have increased risk of cutaneous melanoma"
                  },
                  {
                    "text": "Unusually, may be seen in hereditary cutaneous melanoma kindreds"
                  },
                  {
                    "text": "Cutaneous melanomasUniquely nevoid",
                    "sub_points": [
                      "Uniquely nevoid"
                    ]
                  }
                ],
                "Genes With Low Associated Risk of Cutaneous Melanoma": [
                  {
                    "text": "MC1R(melanocortin-1 receptor gene)Risk of cutaneous melanomaIncreased 2-4xCan alter risk of cutaneous melanoma forCDKN2Amutation carriersAssociated with red hair, Fitzpatrick skin type I, frecklingAssociated withBRAF-mutant cutaneous melanomas",
                    "sub_points": [
                      "Risk of cutaneous melanomaIncreased 2-4x",
                      "Increased 2-4x",
                      "Can alter risk of cutaneous melanoma forCDKN2Amutation carriers",
                      "Associated with red hair, Fitzpatrick skin type I, freckling",
                      "Associated withBRAF-mutant cutaneous melanomas"
                    ]
                  },
                  {
                    "text": "Other genes with low associated risk of cutaneous melanomaMany of these genes found in genome-wide association studiesExamples includeOCA2, TYR, TYRP1, TPCN2, ASIP,GSTM1, VDR",
                    "sub_points": [
                      "Many of these genes found in genome-wide association studies",
                      "Examples includeOCA2, TYR, TYRP1, TPCN2, ASIP,GSTM1, VDR",
                      "OCA2, TYR, TYRP1, TPCN2, ASIP,GSTM1, VDR"
                    ]
                  },
                  {
                    "text": "Genes associated with other hereditary syndromes, with slightly increased risk of cutaneous melanomaBRCA1, BRCA2P53RB1WRNPTEN",
                    "sub_points": [
                      "BRCA1, BRCA2",
                      "P53",
                      "RB1",
                      "WRN",
                      "PTEN"
                    ]
                  }
                ],
                "Inheritance": [
                  {
                    "text": "Autosomal dominant"
                  }
                ],
                "Genotype-Phenotype Correlation": [
                  {
                    "text": "CDKN2AmutationsAlso associated with pancreatic cancerIncreased lifetime risk of 11-25%Mutations in p14ARF functionAssociated with astrocytoma",
                    "sub_points": [
                      "Also associated with pancreatic cancerIncreased lifetime risk of 11-25%",
                      "Increased lifetime risk of 11-25%",
                      "Mutations in p14ARF functionAssociated with astrocytoma",
                      "Associated with astrocytoma"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Clinical Presentation": [
                  {
                    "text": "Familial atypical multiple mole-melanoma syndromeMutations inCDKN2AandCDK4genes may be foundIncreased risk of cutaneous melanoma and pancreatic cancer",
                    "sub_points": [
                      "Mutations inCDKN2AandCDK4genes may be found",
                      "Increased risk of cutaneous melanoma and pancreatic cancer"
                    ]
                  },
                  {
                    "text": "Xeroderma pigmentosumMutations inXPA, XPB/ERCC3, XPC, XPD/ERCC2, XPE/DDB1,XPF/ERCC4, XPG/ERCC5, POLHSun sensitivity (can be extreme)High risk of cutaneous melanoma, basal cell carcinoma, and squamous cell carcinoma",
                    "sub_points": [
                      "Mutations inXPA, XPB/ERCC3, XPC, XPD/ERCC2, XPE/DDB1,XPF/ERCC4, XPG/ERCC5, POLH",
                      "Sun sensitivity (can be extreme)",
                      "High risk of cutaneous melanoma, basal cell carcinoma, and squamous cell carcinoma"
                    ]
                  },
                  {
                    "text": "Examples of other syndromes with occasional development of cutaneous melanomaHereditary breast and ovarian cancer syndromeBRCA1andBRCA2mutationsIncreased risk of breast and ovarian cancersRisk of cutaneous melanoma appears to be increased in patients < age 65Li-Fraumeni syndromeMutations inP53Most common cancers include osteosarcoma, other sarcomas, leukemia, breast cancer, adrenal cortical carcinoma, and brain cancerIncreased risk of cutaneous melanoma, but exact quantification of risk is unknownHereditary retinoblastomaRB1mutationsIncreased risk of retinoblastoma, osteosarcoma, cutaneous melanoma, and other sarcomasWerner syndromeMutations inWRNPremature aging with increased risk of cancer, including cutaneous melanoma",
                    "sub_points": [
                      "Hereditary breast and ovarian cancer syndromeBRCA1andBRCA2mutationsIncreased risk of breast and ovarian cancersRisk of cutaneous melanoma appears to be increased in patients < age 65",
                      "BRCA1andBRCA2mutations",
                      "Increased risk of breast and ovarian cancers",
                      "Risk of cutaneous melanoma appears to be increased in patients < age 65",
                      "Li-Fraumeni syndromeMutations inP53Most common cancers include osteosarcoma, other sarcomas, leukemia, breast cancer, adrenal cortical carcinoma, and brain cancerIncreased risk of cutaneous melanoma, but exact quantification of risk is unknown",
                      "Mutations inP53",
                      "Most common cancers include osteosarcoma, other sarcomas, leukemia, breast cancer, adrenal cortical carcinoma, and brain cancer",
                      "Increased risk of cutaneous melanoma, but exact quantification of risk is unknown",
                      "Hereditary retinoblastomaRB1mutationsIncreased risk of retinoblastoma, osteosarcoma, cutaneous melanoma, and other sarcomas",
                      "RB1mutations",
                      "Increased risk of retinoblastoma, osteosarcoma, cutaneous melanoma, and other sarcomas",
                      "Werner syndromeMutations inWRNPremature aging with increased risk of cancer, including cutaneous melanoma",
                      "Mutations inWRN",
                      "Premature aging with increased risk of cancer, including cutaneous melanoma"
                    ]
                  }
                ],
                "Clinical Risk Factors": [
                  {
                    "text": "Cutaneous melanoma in 1 first-degree relative2.5-3x increased risk of cutaneous melanoma than general population",
                    "sub_points": [
                      "2.5-3x increased risk of cutaneous melanoma than general population"
                    ]
                  },
                  {
                    "text": "Cutaneous melanoma in a parent and a sibling9x increased risk of cutaneous melanoma than general population",
                    "sub_points": [
                      "9x increased risk of cutaneous melanoma than general population"
                    ]
                  },
                  {
                    "text": "CDKN2Amutation carrier75-100x greater risk of cutaneous melanoma than general population",
                    "sub_points": [
                      "75-100x greater risk of cutaneous melanoma than general population"
                    ]
                  },
                  {
                    "text": "Degree/amount of sun exposurePresence of extensive sun damage to skinPrior history of skin cancers",
                    "sub_points": [
                      "Presence of extensive sun damage to skin",
                      "Prior history of skin cancers"
                    ]
                  },
                  {
                    "text": "Geographic location"
                  },
                  {
                    "text": "Number of nevi, especially if > 50Number of nevi with atypical featuresSize > 6 mm, irregular/ill-defined borders, irregular color",
                    "sub_points": [
                      "Number of nevi with atypical featuresSize > 6 mm, irregular/ill-defined borders, irregular color",
                      "Size > 6 mm, irregular/ill-defined borders, irregular color"
                    ]
                  },
                  {
                    "text": "Very fair skin with inability to tan"
                  },
                  {
                    "text": "Presence of many freckles"
                  },
                  {
                    "text": "Hair color, especially red or blonde"
                  },
                  {
                    "text": "Eye color, especially blue"
                  },
                  {
                    "text": "Genetic mutations and modifier genes"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Malignant Melanoma": [
                  {
                    "text": "Cutaneous"
                  },
                  {
                    "text": "Ocular (uveal tract)Increased risk only in certain families (linked to 9p12.32)No increased risk in families withCDKN2Amutations",
                    "sub_points": [
                      "Increased risk only in certain families (linked to 9p12.32)",
                      "No increased risk in families withCDKN2Amutations"
                    ]
                  }
                ],
                "Dysplastic Melanocytic Nevi (Atypical Melanocytic Nevi, Clark Nevi)": [
                  {
                    "text": "Originally described in kindreds with increased risk of cutaneous melanoma"
                  },
                  {
                    "text": "Subsequently described in individuals with no increased risk of cutaneous melanoma"
                  },
                  {
                    "text": "Controversial on many levelsDefinition not universalClinical vs. histopathologic: Clinically atypical nevi are not necessarily histopathologically atypical, and vice versa",
                    "sub_points": [
                      "Definition not universalClinical vs. histopathologic: Clinically atypical nevi are not necessarily histopathologically atypical, and vice versa",
                      "Clinical vs. histopathologic: Clinically atypical nevi are not necessarily histopathologically atypical, and vice versa"
                    ]
                  },
                  {
                    "text": "Clinically dysplastic melanocytic neviSize > 6 mmIrregular colorIrregular bordersAsymmetricHistory of changePresence of elevated and flat (papular and macular) components",
                    "sub_points": [
                      "Size > 6 mm",
                      "Irregular color",
                      "Irregular borders",
                      "Asymmetric",
                      "History of change",
                      "Presence of elevated and flat (papular and macular) components"
                    ]
                  },
                  {
                    "text": "Histopathologic criteria for dysplastic melanocytic neviInclude cytologic and architectural criteriaCytologic criteriaNuclear sizePleomorphismArchitectural featuresSingle melanocytes vs. nestsNest sizeDistribution of nestsBridging of retePagetoid scatterFibroplasia, sometimes lamellarExtension of junctional component past dermal componentLymphocytic infiltrate",
                    "sub_points": [
                      "Include cytologic and architectural criteria",
                      "Cytologic criteriaNuclear sizePleomorphism",
                      "Nuclear size",
                      "Pleomorphism",
                      "Architectural featuresSingle melanocytes vs. nestsNest sizeDistribution of nestsBridging of retePagetoid scatterFibroplasia, sometimes lamellarExtension of junctional component past dermal componentLymphocytic infiltrate",
                      "Single melanocytes vs. nests",
                      "Nest size",
                      "Distribution of nests",
                      "Bridging of rete",
                      "Pagetoid scatter",
                      "Fibroplasia, sometimes lamellar",
                      "Extension of junctional component past dermal component",
                      "Lymphocytic infiltrate"
                    ]
                  }
                ],
                "Pancreatic Cancer": [
                  {
                    "text": "Average age is 5.8 years younger than patients affected by sporadic pancreatic cancer"
                  }
                ],
                "Astrocytoma": [
                  {
                    "text": "Linked to mutations inCDKN2A(p14ARF)"
                  }
                ],
                "Breast Carcinoma": [
                  {
                    "text": "Possible 4x increased risk in families withCDKN2Amutations"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Photoprotection": [
                  {
                    "text": "Sunscreen, sun protective clothing, avoidance of sunburn"
                  }
                ],
                "Skin Examination": [
                  {
                    "text": "Head-to-toe examination (including scalp and genitalia)Baseline at age 10 yearsRepeat every 6-12 monthsMay increase frequency during puberty or pregnancyMay use dermoscopy or other modalitiesMonthly self-examination of skin",
                    "sub_points": [
                      "Baseline at age 10 years",
                      "Repeat every 6-12 months",
                      "May increase frequency during puberty or pregnancy",
                      "May use dermoscopy or other modalities",
                      "Monthly self-examination of skin"
                    ]
                  },
                  {
                    "text": "Baseline photography may be helpful"
                  }
                ],
                "Suspicious Lesions": [
                  {
                    "text": "Prompt excision and histopathologic evaluation"
                  }
                ],
                "Education": [
                  {
                    "text": "On photoprotection and characteristics of melanoma"
                  }
                ],
                "Pancreatic Cancer Surveillance": [
                  {
                    "text": "Multimodal screeningEndoscopic ultrasound, computed tomography, endoscopic retrograde cholangiopancreatography, and magnetic resonance imaging",
                    "sub_points": [
                      "Endoscopic ultrasound, computed tomography, endoscopic retrograde cholangiopancreatography, and magnetic resonance imaging"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Leiomyomatosis and Renal Cell Carcinoma": {
            "name": "Hereditary Leiomyomatosis and Renal Cell Carcinoma",
            "url": "https://app.pathprimer.com/document/6ece3969-6fba-4b80-9c09-575d88f21155/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Multiple cutaneous and uterine leiomyomatosis syndrome"
                  },
                  {
                    "text": "Reed syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Autosomal inherited disorder characterized by development of multiple cutaneous and uterine smooth muscle tumors and renal cell carcinoma (RCC) linked to fumarate hydratase(FH)mutation"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "Smooth muscle tumors and RCC develop at younger age in patients with HLRCC than in those with sporadic onsetMales: By age 35, nearly all will have cutaneous leiomyomasFemales: By age 45, risk for cutaneous leiomyomas is > 70%Uterine leiomyomas: Mean age at diagnosis: 30 years (range: 18-53 years)",
                    "sub_points": [
                      "Males: By age 35, nearly all will have cutaneous leiomyomas",
                      "Females: By age 45, risk for cutaneous leiomyomas is > 70%Uterine leiomyomas: Mean age at diagnosis: 30 years (range: 18-53 years)",
                      "Uterine leiomyomas: Mean age at diagnosis: 30 years (range: 18-53 years)"
                    ]
                  },
                  {
                    "text": "Median age of patients with RCC: 42-44 yearsYounger than in sporadic RCCs with papillary or tubulopapillary architectures",
                    "sub_points": [
                      "Younger than in sporadic RCCs with papillary or tubulopapillary architectures"
                    ]
                  }
                ],
                "Gender": [
                  {
                    "text": "Risk of disease is greater in men vs. womenHowever, number of cutaneous tumors is more numerous in womenRenal tumor: M:F = 1.1:1",
                    "sub_points": [
                      "However, number of cutaneous tumors is more numerous in women",
                      "Renal tumor: M:F = 1.1:1"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "Rare;FHmutation predisposing to HLRCC has been described in ~ 180 families worldwide"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Most patients initially present with multiple skin lesions due to smooth muscle tumorsUsually multiple, involving limbs and trunkSometimes itchy, painful; can be disfiguring",
                    "sub_points": [
                      "Usually multiple, involving limbs and trunk",
                      "Sometimes itchy, painful; can be disfiguring"
                    ]
                  },
                  {
                    "text": "Gynecologic symptoms at reproductive age due to uterine smooth muscle tumorsMetrorrhagia, menorrhagia, pelvic pain, and fertility problems",
                    "sub_points": [
                      "Metrorrhagia, menorrhagia, pelvic pain, and fertility problems"
                    ]
                  }
                ]
              },
              "Genetics": {
                "FHMutation": [
                  {
                    "text": "FH in chromosome 1q42-1q44"
                  },
                  {
                    "text": "Mutation found in 76-100% of families with clinical manifestation of HLRCC"
                  },
                  {
                    "text": "Heterozygous germline mutationMajority are missense (~ 58%); nonsense (~ 11%) or frameshift (~ 18%) mutationsSplice site mutations, in-frame deletions or insertions, exon 7 duplications, exon 1 deletions, and whole gene deletion also reported",
                    "sub_points": [
                      "Majority are missense (~ 58%); nonsense (~ 11%) or frameshift (~ 18%) mutations",
                      "Splice site mutations, in-frame deletions or insertions, exon 7 duplications, exon 1 deletions, and whole gene deletion also reported"
                    ]
                  },
                  {
                    "text": "Mutations of 2 alleles seen in associated tumors (\"2-hit\" hypothesis)FHsuggested as a tumor suppressor gene",
                    "sub_points": [
                      "FHsuggested as a tumor suppressor gene"
                    ]
                  },
                  {
                    "text": "> 100 differentFHgermline mutations have been reported"
                  },
                  {
                    "text": "FHgene encodes an enzyme in Krebs cycle that catalyzes hydration of fumarate to L-malateMutation causes accumulation of fumarate and succinateMutation causes aberrant stabilization and overexpression of hypoxia inducible factor 1 (HIF1) transcription factorHIF1 regulates transcription of genes important for vascularization, glucose transport, and glycolysis, all of which are important for tumor growthSomewhat similar mechanism with inactivation ofVHLin hereditary clear cell RCC, which causes nondegradation and accumulation of HIF1",
                    "sub_points": [
                      "Mutation causes accumulation of fumarate and succinate",
                      "Mutation causes aberrant stabilization and overexpression of hypoxia inducible factor 1 (HIF1) transcription factorHIF1 regulates transcription of genes important for vascularization, glucose transport, and glycolysis, all of which are important for tumor growthSomewhat similar mechanism with inactivation ofVHLin hereditary clear cell RCC, which causes nondegradation and accumulation of HIF1",
                      "HIF1 regulates transcription of genes important for vascularization, glucose transport, and glycolysis, all of which are important for tumor growth",
                      "Somewhat similar mechanism with inactivation ofVHLin hereditary clear cell RCC, which causes nondegradation and accumulation of HIF1"
                    ]
                  },
                  {
                    "text": "Unrelated biallelic mutations ofFHresult infumarate hydratase (FH) deficiency(fumaric aciduria)Rare recessive syndrome with severe neurological symptoms, muscle hypotonia, and microcephalyMarked decrease in FH activity results in metabolic crises and infant deathSymptoms not seen in HLRCCUnclear why manifestations are completely different",
                    "sub_points": [
                      "Rare recessive syndrome with severe neurological symptoms, muscle hypotonia, and microcephaly",
                      "Marked decrease in FH activity results in metabolic crises and infant death",
                      "Symptoms not seen in HLRCC",
                      "Unclear why manifestations are completely different"
                    ]
                  }
                ],
                "Comparative Genomic Hybridization": [
                  {
                    "text": "27% of HLRCC renal tumors show gains in Chr 2, 7, and 17 and losses in 13q12.3-q21.1, 14, 18, and XGains in Chr 7 and 17 are common in sporadic papillary renal cell carcinoma",
                    "sub_points": [
                      "Gains in Chr 7 and 17 are common in sporadic papillary renal cell carcinoma"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "FHMutation Testing": [
                  {
                    "text": "Usually by direct sequencing ofFHcoding regionReveals genetic alterations in ~ 90% of families suspected for HLRCC",
                    "sub_points": [
                      "Reveals genetic alterations in ~ 90% of families suspected for HLRCC"
                    ]
                  },
                  {
                    "text": "If clinically highly suspicious and initial test is negative, additional methods such as multiplex ligation probe amplification (MLPA) are recommended"
                  }
                ]
              },
              "Associated Neoplasms": {
                "SmoothMuscle Tumors": [
                  {
                    "text": "Cutaneous leiomyomas (piloleiomyomas)With age, eventually up to 100% of men and 80% of women will develop themOriginate from hair follicle arrector pili musclesSize range: 2 mm to 4 cmVast majority are benign, with rare reports of leiomyosarcomaHistologic hallmark of inclusion-like orangeophilic nucleolus with perinuclear clearing",
                    "sub_points": [
                      "With age, eventually up to 100% of men and 80% of women will develop them",
                      "Originate from hair follicle arrector pili muscles",
                      "Size range: 2 mm to 4 cm",
                      "Vast majority are benign, with rare reports of leiomyosarcoma",
                      "Histologic hallmark of inclusion-like orangeophilic nucleolus with perinuclear clearing"
                    ]
                  },
                  {
                    "text": "Uterine smooth muscle tumorsWith age, up to 77% of women will develop uterine leiomyomasUsually multiple (up to 20)Size range: 1-8.5 cmGrossly shows firm, solid, white-tan, whorled cut surface; similar in appearance to sporadic tumorsMostly benign (leiomyomas)Fascicles of spindle cells with elongated, blunt-edged nucleiCan show increased atypia, multinucleation, &/or mitotic activity (up to 6 per HPF)Histologic hallmark of nuclei with inclusion-like orangeophilic nucleolus with perinuclear clearingUterine leiomyosarcomas have been reported in 6 cases from HLRCC families",
                    "sub_points": [
                      "With age, up to 77% of women will develop uterine leiomyomas",
                      "Usually multiple (up to 20)",
                      "Size range: 1-8.5 cm",
                      "Grossly shows firm, solid, white-tan, whorled cut surface; similar in appearance to sporadic tumors",
                      "Mostly benign (leiomyomas)Fascicles of spindle cells with elongated, blunt-edged nucleiCan show increased atypia, multinucleation, &/or mitotic activity (up to 6 per HPF)Histologic hallmark of nuclei with inclusion-like orangeophilic nucleolus with perinuclear clearing",
                      "Fascicles of spindle cells with elongated, blunt-edged nuclei",
                      "Can show increased atypia, multinucleation, &/or mitotic activity (up to 6 per HPF)",
                      "Histologic hallmark of nuclei with inclusion-like orangeophilic nucleolus with perinuclear clearing",
                      "Uterine leiomyosarcomas have been reported in 6 cases from HLRCC families"
                    ]
                  }
                ],
                "RCC": [
                  {
                    "text": "Risk of developing RCC is lower and often manifests later than smooth muscle tumorsSeen in ~ 20-25% ofFHmutation-positive families",
                    "sub_points": [
                      "Seen in ~ 20-25% ofFHmutation-positive families"
                    ]
                  },
                  {
                    "text": "6.5x greater risk than general population; higher in younger patientsRisk is 230x greater in patients 15-29 years old and 45x increase in patients 30-44 years oldYoungest patient reported was 11 years old",
                    "sub_points": [
                      "Risk is 230x greater in patients 15-29 years old and 45x increase in patients 30-44 years old",
                      "Youngest patient reported was 11 years old"
                    ]
                  },
                  {
                    "text": "When symptomatic, patients with renal tumor present with back pain, fatigue, and weight loss; discovery after work-up for suspicion of HLRCC after cutaneous lesion manifestation is not uncommon"
                  },
                  {
                    "text": "Usually involves 1 person inFHmutation-positive family"
                  },
                  {
                    "text": "MacroscopyTumors are predominantly unilateral and solitary, unlike other RCCs in hereditary setting",
                    "sub_points": [
                      "Tumors are predominantly unilateral and solitary, unlike other RCCs in hereditary setting"
                    ]
                  },
                  {
                    "text": "MicroscopyMost RCCs in HLRCC were previously classified as papillary RCC (PRCC) type 2 and collecting duct carcinoma (CDC) but now considered as a different type of RCCExhibit features different from papillary RCC and CDC; possibly a distinct subtype of RCCVariable architecture that includes papillary (most common), tubulopapillary, tubular, solid, and mixedPapillae are thick with abundant collagenCells are large, high grade with abundant eosinophilic cytoplasmNuclei pseudostratification is common and may resemble rosettesMitoses common (2-6/10 HPF)May have focal clear cell areaHistologic hallmark of nuclei with inclusion-like orangeophilic nucleolus with perinuclear clearing, resembling cytomegalovirus cytopathic changeNuclear features are widespread, detected in almost all cells, including in foci of clear cells if presentMucicarmine stain is negative for mucin, unlike in CDC",
                    "sub_points": [
                      "Most RCCs in HLRCC were previously classified as papillary RCC (PRCC) type 2 and collecting duct carcinoma (CDC) but now considered as a different type of RCC",
                      "Exhibit features different from papillary RCC and CDC; possibly a distinct subtype of RCCVariable architecture that includes papillary (most common), tubulopapillary, tubular, solid, and mixedPapillae are thick with abundant collagenCells are large, high grade with abundant eosinophilic cytoplasmNuclei pseudostratification is common and may resemble rosettesMitoses common (2-6/10 HPF)May have focal clear cell areaHistologic hallmark of nuclei with inclusion-like orangeophilic nucleolus with perinuclear clearing, resembling cytomegalovirus cytopathic changeNuclear features are widespread, detected in almost all cells, including in foci of clear cells if present",
                      "Variable architecture that includes papillary (most common), tubulopapillary, tubular, solid, and mixed",
                      "Papillae are thick with abundant collagen",
                      "Cells are large, high grade with abundant eosinophilic cytoplasm",
                      "Nuclei pseudostratification is common and may resemble rosettes",
                      "Mitoses common (2-6/10 HPF)",
                      "May have focal clear cell area",
                      "Histologic hallmark of nuclei with inclusion-like orangeophilic nucleolus with perinuclear clearing, resembling cytomegalovirus cytopathic change",
                      "Nuclear features are widespread, detected in almost all cells, including in foci of clear cells if present",
                      "Mucicarmine stain is negative for mucin, unlike in CDC"
                    ]
                  },
                  {
                    "text": "ImmunohistochemistryCK7(-), unlike in PRCCCD10(-), CK20(-), and TFE3(-)HMWK (34bE12)(-), unlike in CDC",
                    "sub_points": [
                      "CK7(-), unlike in PRCC",
                      "CD10(-), CK20(-), and TFE3(-)",
                      "HMWK (34bE12)(-), unlike in CDC"
                    ]
                  },
                  {
                    "text": "Aggressive, most present with higher stage (≥ pT3a)Frequent metastasis to lymph nodes and involvement of adrenal glandsMost aggressive RCC among hereditary renal tumors",
                    "sub_points": [
                      "Frequent metastasis to lymph nodes and involvement of adrenal glands",
                      "Most aggressive RCC among hereditary renal tumors"
                    ]
                  },
                  {
                    "text": "Rare reports of concurrent clear cell RCC in bilateral cases; unclear if associated or incidental"
                  }
                ],
                "OtherTumors": [
                  {
                    "text": "Rarely reported"
                  },
                  {
                    "text": "Adrenal gland adenomas, breast tumor, bladder tumor, brain tumor, lymphoid malignancy, basal cell carcinomas, thyroid tumors, ovarian cystadenomas"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Diagnosis": [
                  {
                    "text": "Proposed practical criteria for diagnosis"
                  },
                  {
                    "text": "If clinical features are suggestive, genetic counseling and molecular testing should be performed forIndividual with multiple cutaneous leiomyomas, ≥ 1 histologically confirmedIndividual with leiomyoma and family history of HLRCCIndividual with ≥ 1 tubulopapillary RCCs showing large inclusion-like nucleolus and perinucleolar clearing",
                    "sub_points": [
                      "Individual with multiple cutaneous leiomyomas, ≥ 1 histologically confirmed",
                      "Individual with leiomyoma and family history of HLRCC",
                      "Individual with ≥ 1 tubulopapillary RCCs showing large inclusion-like nucleolus and perinucleolar clearing"
                    ]
                  },
                  {
                    "text": "All family members of a person with germlineFHmutation should be tested"
                  }
                ],
                "Surveillance": [
                  {
                    "text": "Currently, no consensusLifelong clinical surveillance warranted in individuals who are at riskNo established standard for age of surveillance for RCC, but ideally should start at earliest age due to aggressive natureFor renal tumors, baseline renal ultrasound and abdominal CT scan with contrast or MR at age 20 years, then annual MR or semiannual ultrasoundFor uterine tumors, annual gynecologic ultrasound at age 20 yearsDermatologic examination for lesions suspicious for cutaneous leiomyomas",
                    "sub_points": [
                      "Lifelong clinical surveillance warranted in individuals who are at risk",
                      "No established standard for age of surveillance for RCC, but ideally should start at earliest age due to aggressive natureFor renal tumors, baseline renal ultrasound and abdominal CT scan with contrast or MR at age 20 years, then annual MR or semiannual ultrasoundFor uterine tumors, annual gynecologic ultrasound at age 20 yearsDermatologic examination for lesions suspicious for cutaneous leiomyomas",
                      "For renal tumors, baseline renal ultrasound and abdominal CT scan with contrast or MR at age 20 years, then annual MR or semiannual ultrasound",
                      "For uterine tumors, annual gynecologic ultrasound at age 20 years",
                      "Dermatologic examination for lesions suspicious for cutaneous leiomyomas"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Smooth muscle tumorsSurgical excision for solitary skin tumorsMyomectomy desired for smaller uterine tumors to retain fertility",
                    "sub_points": [
                      "Surgical excision for solitary skin tumors",
                      "Myomectomy desired for smaller uterine tumors to retain fertility"
                    ]
                  },
                  {
                    "text": "Renal cell carcinomasRadical surgery preferred, even if small in size because of its aggressive natureThis approach is in contrast to renal tumors in other hereditary settings that are usually observed until a certain size is reachedChemotherapy using inhibitors for HIF1-activated targets is being triedLDHA inhibition has been shown to cause increase apoptosis in FH-deficient cells in xenograft mouse model, suggesting a possible therapeutic strategy",
                    "sub_points": [
                      "Radical surgery preferred, even if small in size because of its aggressive natureThis approach is in contrast to renal tumors in other hereditary settings that are usually observed until a certain size is reached",
                      "This approach is in contrast to renal tumors in other hereditary settings that are usually observed until a certain size is reached",
                      "Chemotherapy using inhibitors for HIF1-activated targets is being triedLDHA inhibition has been shown to cause increase apoptosis in FH-deficient cells in xenograft mouse model, suggesting a possible therapeutic strategy",
                      "LDHA inhibition has been shown to cause increase apoptosis in FH-deficient cells in xenograft mouse model, suggesting a possible therapeutic strategy"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Melanoma/Pancreatic Carcinoma Syndrome": {
            "name": "Melanoma/Pancreatic Carcinoma Syndrome",
            "url": "https://app.pathprimer.com/document/7bf05f8f-04db-47bf-a502-14ed5dc670a7/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "Terminology": {
                "Definition": [
                  {
                    "text": "Hereditary melanomaIn geographic areas with high sun exposure: ≥ 3 affected blood relativesIn geographic areas with lower sun exposure: ≥ 2 affected blood relatives",
                    "sub_points": [
                      "In geographic areas with high sun exposure: ≥ 3 affected blood relatives",
                      "In geographic areas with lower sun exposure: ≥ 2 affected blood relatives"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Incidence of Hereditary Cutaneous Melanoma": [
                  {
                    "text": "5-7% of cutaneous melanoma patients are from high-risk families"
                  }
                ],
                "Incidence of Hereditary Pancreatic Cancer": [
                  {
                    "text": "Considered to be low (1-3%), but possibly up to 10% of pancreatic cancer has a familial basis"
                  }
                ]
              },
              "Genetics": {
                "CDKN2AMutations": [
                  {
                    "text": "Splice sites or ankyrin repeats 3 and 4 tend to be affected"
                  },
                  {
                    "text": "Lifetime risk of melanoma: ~ 75%"
                  },
                  {
                    "text": "Lifetime risk of pancreatic cancer may be close to 20%"
                  },
                  {
                    "text": "Mutations are generally inactivating"
                  }
                ],
                "Inheritance": [
                  {
                    "text": "Generally autosomal dominant"
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Clinical Presentation": [
                  {
                    "text": "Familial atypical multiple mole-melanoma syndromeIncreased risk of cutaneous melanoma and pancreatic cancerPatients may have > 100 atypical melanocytic nevi",
                    "sub_points": [
                      "Increased risk of cutaneous melanoma and pancreatic cancer",
                      "Patients may have > 100 atypical melanocytic nevi"
                    ]
                  },
                  {
                    "text": "Some kindreds have cutaneous melanoma and pancreatic cancer without increased numbers of atypical melanocytic nevi"
                  }
                ],
                "Clinical Risk Factors": [
                  {
                    "text": "Number of relatives affected by melanoma or pancreatic cancer"
                  },
                  {
                    "text": "CDKN2Amutation carrier"
                  },
                  {
                    "text": "Number of nevi, especially if > 50"
                  },
                  {
                    "text": "Very fair skin with inability to tan"
                  },
                  {
                    "text": "Presence of many freckles"
                  },
                  {
                    "text": "Hair color, especially red or blonde"
                  },
                  {
                    "text": "Eye color, especially blue"
                  },
                  {
                    "text": "Degree/amount of sun exposurePresence of extensively sun-damaged skin",
                    "sub_points": [
                      "Presence of extensively sun-damaged skin"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Malignant Melanoma": [
                  {
                    "text": "Cutaneous"
                  }
                ],
                "Dysplastic Melanocytic Nevi (Atypical Melanocytic Nevi, Clark Nevi)": [
                  {
                    "text": "Originally described in kindreds with increased risk of cutaneous melanoma"
                  },
                  {
                    "text": "Subsequently described in individuals with no increased risk of cutaneous melanoma"
                  },
                  {
                    "text": "Clinically dysplastic melanocytic neviSize often > 6 mm, irregular color, irregular borders, asymmetric, may have history of change, may have elevated (papular) and flat (macular) components",
                    "sub_points": [
                      "Size often > 6 mm, irregular color, irregular borders, asymmetric, may have history of change, may have elevated (papular) and flat (macular) components"
                    ]
                  },
                  {
                    "text": "Histopathologic criteria for dysplastic melanocytic neviAtypical cytology &/or disordered architectureSingle melanocytes, irregular nests, bridged rete, pagetoid scatter, fibroplasia",
                    "sub_points": [
                      "Atypical cytology &/or disordered architectureSingle melanocytes, irregular nests, bridged rete, pagetoid scatter, fibroplasia",
                      "Single melanocytes, irregular nests, bridged rete, pagetoid scatter, fibroplasia"
                    ]
                  }
                ],
                "Pancreatic Cancer": [
                  {
                    "text": "Cumulative lifetime risk: 11-17%"
                  },
                  {
                    "text": "Average age is 5.8 years younger than patients affected by sporadic pancreatic cancer"
                  }
                ],
                "Breast Cancer": [
                  {
                    "text": "Risk is higher in kindreds without multiple atypical melanocytic nevi"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Photoprotection": [
                  {
                    "text": "Sunscreen, sun protective clothing, avoidance of sunburn"
                  }
                ],
                "Avoidance of Other Carcinogens": [
                  {
                    "text": "Cigarette smoking increases pancreatic cancer risk"
                  }
                ],
                "Skin Examination": [
                  {
                    "text": "Head-to-toe examination (including scalp and genitalia)Baseline at age 10 yearsRepeat every 6-12 monthsMay increase frequency during puberty or pregnancyMay use dermoscopyMonthly self-examination of skin",
                    "sub_points": [
                      "Baseline at age 10 years",
                      "Repeat every 6-12 months",
                      "May increase frequency during puberty or pregnancy",
                      "May use dermoscopy",
                      "Monthly self-examination of skin"
                    ]
                  },
                  {
                    "text": "Baseline photography may be helpful"
                  }
                ],
                "Suspicious Lesions": [
                  {
                    "text": "Prompt excision and histopathologic evaluation"
                  }
                ],
                "Education": [
                  {
                    "text": "On photoprotection and characteristics of melanoma"
                  }
                ],
                "Pancreatic Cancer": [
                  {
                    "text": "Suggested age to initiate screening10 years before youngest age of diagnosis of pancreatic cancer in a given familyorage 50 years",
                    "sub_points": [
                      "10 years before youngest age of diagnosis of pancreatic cancer in a given familyorage 50 years"
                    ]
                  },
                  {
                    "text": "Screening is controversialMultimodal screeningEndoscopic ultrasoundComputed tomography, magnetic resonance imagingEndoscopic retrograde cholangiopancreatography",
                    "sub_points": [
                      "Multimodal screeningEndoscopic ultrasoundComputed tomography, magnetic resonance imagingEndoscopic retrograde cholangiopancreatography",
                      "Endoscopic ultrasound",
                      "Computed tomography, magnetic resonance imaging",
                      "Endoscopic retrograde cholangiopancreatography"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Disorders With Chronic Pancreatic Inflammation": [
                  {
                    "text": "Familial pancreatic cancerGenerally not associated with melanomaFamilies with ≥ 2 first-degree relatives with confirmed exocrine pancreatic cancerExclusion of other inherited tumor syndromes with associated pancreatic cancerExamples includes melanoma/pancreatic carcinoma syndrome, hereditary breast and ovarian cancer, hereditary pancreatitisMutations inBRCA2, PALB2,andATMin some families",
                    "sub_points": [
                      "Generally not associated with melanoma",
                      "Families with ≥ 2 first-degree relatives with confirmed exocrine pancreatic cancer",
                      "Exclusion of other inherited tumor syndromes with associated pancreatic cancerExamples includes melanoma/pancreatic carcinoma syndrome, hereditary breast and ovarian cancer, hereditary pancreatitis",
                      "Examples includes melanoma/pancreatic carcinoma syndrome, hereditary breast and ovarian cancer, hereditary pancreatitis",
                      "Mutations inBRCA2, PALB2,andATMin some families"
                    ]
                  },
                  {
                    "text": "Hereditary pancreatitis"
                  },
                  {
                    "text": "Cystic fibrosis"
                  }
                ],
                "Other Hereditary Tumor Syndromes With Increased Risk of Pancreatic Cancer": [
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Hereditary breast and ovarian cancers"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Hereditary nonpolyposis colorectal carcinoma"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  }
                ],
                "Hereditary Multiple Melanoma": [
                  {
                    "text": "Some kindreds with hereditary melanoma have no associated risk of pancreatic cancer"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Basal Cell Nevus Syndrome/Gorlin Syndrome": {
            "name": "Basal Cell Nevus Syndrome/Gorlin Syndrome",
            "url": "https://app.pathprimer.com/document/434a0d40-03df-4fb2-961a-e4975a2ad5ac/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "Nevoid basal cell carcinoma syndrome"
                  },
                  {
                    "text": "Basal cell carcinoma nevus syndrome"
                  },
                  {
                    "text": "Gorlin-Goltz syndrome"
                  }
                ]
              },
              "Epidemiology": {
                "Age at Presentation": [
                  {
                    "text": "From birth (may not be detected until later)Bony abnormalities",
                    "sub_points": [
                      "Bony abnormalities"
                    ]
                  },
                  {
                    "text": "1st decadeJaw cysts (of mandible/maxilla)",
                    "sub_points": [
                      "Jaw cysts (of mandible/maxilla)"
                    ]
                  },
                  {
                    "text": "2nd decadePalmoplantar pitting",
                    "sub_points": [
                      "Palmoplantar pitting"
                    ]
                  },
                  {
                    "text": "Childhood but more often late puberty/adulthoodBasal cell carcinomas (sometimes resembling skin tags)",
                    "sub_points": [
                      "Basal cell carcinomas (sometimes resembling skin tags)"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "~ 1 in 19,000 births"
                  }
                ]
              },
              "Genetics": {
                "Inheritance": [
                  {
                    "text": "Autosomal dominant"
                  }
                ],
                "PTCH1Gene": [
                  {
                    "text": "Mutations in this gene found in ~ 60-75% of those tested"
                  },
                  {
                    "text": "PTCH1Located on chromosome 9qPart of sonic hedgehog pathwayPTCH1encodes patched proteinPatched protein inhibits smoothenedMutatedPTCH1leads to disinhibition of smoothened and tumor growth",
                    "sub_points": [
                      "Located on chromosome 9q",
                      "Part of sonic hedgehog pathway",
                      "PTCH1encodes patched protein",
                      "Patched protein inhibits smoothened",
                      "MutatedPTCH1leads to disinhibition of smoothened and tumor growth"
                    ]
                  },
                  {
                    "text": "No clear genotype/phenotype correlation"
                  }
                ]
              },
              "Clinical Implications and Imaging Findings": {
                "Clinical Findings": [
                  {
                    "text": "Triggers that should prompt evaluation for Gorlin syndromeKeratocystic odontogenic tumor if age < 20 years oldBasal cell carcinoma if age < 20 years oldPalmar or plantar pitsLamellar calcification of falx cerebriMedulloblastoma, desmoplastic",
                    "sub_points": [
                      "Keratocystic odontogenic tumor if age < 20 years old",
                      "Basal cell carcinoma if age < 20 years old",
                      "Palmar or plantar pits",
                      "Lamellar calcification of falx cerebri",
                      "Medulloblastoma, desmoplastic"
                    ]
                  },
                  {
                    "text": "Characteristic faciesFrontal bossingHypoplastic maxillaBroad nasal root (and hypertelorism)",
                    "sub_points": [
                      "Frontal bossing",
                      "Hypoplastic maxilla",
                      "Broad nasal root (and hypertelorism)"
                    ]
                  }
                ],
                "Imaging Findings": [
                  {
                    "text": "HeadCalcification ofFalx, tentorium cerebelli, sella turcicaJaw cystsPanorex (digital if possible)Cleft lip/palate",
                    "sub_points": [
                      "Calcification ofFalx, tentorium cerebelli, sella turcica",
                      "Falx, tentorium cerebelli, sella turcica",
                      "Jaw cystsPanorex (digital if possible)",
                      "Panorex (digital if possible)",
                      "Cleft lip/palate"
                    ]
                  },
                  {
                    "text": "TrunkRibsBifid, missing, splayedSpineScoliosis, vertebral anomalies",
                    "sub_points": [
                      "RibsBifid, missing, splayed",
                      "Bifid, missing, splayed",
                      "SpineScoliosis, vertebral anomalies",
                      "Scoliosis, vertebral anomalies"
                    ]
                  },
                  {
                    "text": "Long bonesBone cysts",
                    "sub_points": [
                      "Bone cysts"
                    ]
                  },
                  {
                    "text": "Hands/feetFlame-shaped lucencies",
                    "sub_points": [
                      "Flame-shaped lucencies"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Skin": [
                  {
                    "text": "Basal cell carcinomaMay look like skin tags in childrenOften sun-exposed skinMay be non-sun-exposed areasTypical clinical morphologyPearly, pink, telangiectatic papules or nodulesErythematous, scaly, thin macules or plaquesMay be eroded/ulceratedAll histopathologic subtypesSuperficial multicentric with buds of basaloid islands off epidermal baseNodular with islands of basaloid cells with peripheral palisading in dermisMay be pigmentedMicronodular, morpheaform, infiltrative, infundibulocystic, etc.",
                    "sub_points": [
                      "May look like skin tags in children",
                      "Often sun-exposed skin",
                      "May be non-sun-exposed areas",
                      "Typical clinical morphologyPearly, pink, telangiectatic papules or nodulesErythematous, scaly, thin macules or plaquesMay be eroded/ulcerated",
                      "Pearly, pink, telangiectatic papules or nodules",
                      "Erythematous, scaly, thin macules or plaques",
                      "May be eroded/ulcerated",
                      "All histopathologic subtypesSuperficial multicentric with buds of basaloid islands off epidermal baseNodular with islands of basaloid cells with peripheral palisading in dermisMay be pigmentedMicronodular, morpheaform, infiltrative, infundibulocystic, etc.",
                      "Superficial multicentric with buds of basaloid islands off epidermal base",
                      "Nodular with islands of basaloid cells with peripheral palisading in dermis",
                      "May be pigmented",
                      "Micronodular, morpheaform, infiltrative, infundibulocystic, etc."
                    ]
                  },
                  {
                    "text": "Palmoplantar pitsSeveral millimeters in diameterPink in colorHistopathology: Basaloid proliferation",
                    "sub_points": [
                      "Several millimeters in diameter",
                      "Pink in color",
                      "Histopathology: Basaloid proliferation"
                    ]
                  },
                  {
                    "text": "Epidermal inclusion cyst/milium"
                  }
                ],
                "Musculoskeletal": [
                  {
                    "text": "Odontogenic keratocystMay become secondarily infectedThin capsule with lining of stratified squamous epitheliumSitesMandibular molar/ramus (~ 40%)Mandibular canine/incisor (~ 20%)Maxillary molar tuberosity (~ 10%)",
                    "sub_points": [
                      "May become secondarily infected",
                      "Thin capsule with lining of stratified squamous epithelium",
                      "SitesMandibular molar/ramus (~ 40%)Mandibular canine/incisor (~ 20%)Maxillary molar tuberosity (~ 10%)",
                      "Mandibular molar/ramus (~ 40%)",
                      "Mandibular canine/incisor (~ 20%)",
                      "Maxillary molar tuberosity (~ 10%)"
                    ]
                  }
                ],
                "Central Nervous System": [
                  {
                    "text": "MedulloblastomaEspecially desmoplastic",
                    "sub_points": [
                      "Especially desmoplastic"
                    ]
                  },
                  {
                    "text": "MeningiomaMay be consequence of radiation treatment of medulloblastoma",
                    "sub_points": [
                      "May be consequence of radiation treatment of medulloblastoma"
                    ]
                  }
                ],
                "Genitourinary": [
                  {
                    "text": "Ovarian fibroma/fibrosarcoma"
                  }
                ],
                "Cardiac": [
                  {
                    "text": "Fibroma"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Multidisciplinary Care": [
                  {
                    "text": "Dermatology, surgery, dental/oral medicine, orthopaedics, ophthalmology, neurology, genetics"
                  },
                  {
                    "text": "Regular skin examinations necessaryEvery 6 months to 1 year (every 4 months in adults)",
                    "sub_points": [
                      "Every 6 months to 1 year (every 4 months in adults)"
                    ]
                  },
                  {
                    "text": "MedulloblastomaBaseline MR of brain with contrast and epilepsy protocolAnnually until age 8",
                    "sub_points": [
                      "Baseline MR of brain with contrast and epilepsy protocolAnnually until age 8",
                      "Annually until age 8"
                    ]
                  },
                  {
                    "text": "Minimize ionizing radiation exposure, as it can induce basal cell carcinomasConsider MR over serial CT scans",
                    "sub_points": [
                      "Consider MR over serial CT scans"
                    ]
                  },
                  {
                    "text": "Treatments/interventions to prevent new basal cell carcinomasOral retinoidsSun avoidance/sun protection",
                    "sub_points": [
                      "Oral retinoids",
                      "Sun avoidance/sun protection"
                    ]
                  },
                  {
                    "text": "PTCH1gene testing: Not mandatory for diagnosisScenarios in which testing is recommendedPrenatal testing if known mutation within familyCases highly suspicious for Gorlin syndrome but not yet meeting criteriaPredictive testing for patients with affected family member",
                    "sub_points": [
                      "Scenarios in which testing is recommendedPrenatal testing if known mutation within familyCases highly suspicious for Gorlin syndrome but not yet meeting criteriaPredictive testing for patients with affected family member",
                      "Prenatal testing if known mutation within family",
                      "Cases highly suspicious for Gorlin syndrome but not yet meeting criteria",
                      "Predictive testing for patients with affected family member"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Early Onset Basal Cell Carcinomas (Sporadic)": [
                  {
                    "text": "Increasingly, patients < age 40 are developing basal cell carcinomaMay be linked to tanning",
                    "sub_points": [
                      "May be linked to tanning"
                    ]
                  },
                  {
                    "text": "No other stigmata of Gorlin syndrome"
                  }
                ],
                "Bazex-Dupré-Christol Syndrome": [
                  {
                    "text": "Similarities to Gorlin syndromeMultiple basal cell carcinomas (may have earlier onset than in Gorlin syndrome)Milia",
                    "sub_points": [
                      "Multiple basal cell carcinomas (may have earlier onset than in Gorlin syndrome)",
                      "Milia"
                    ]
                  },
                  {
                    "text": "Distinguishing features from Gorlin syndromeX-linked dominant inheritanceHypotrichosisFollicular atrophodermaHypohidrosis",
                    "sub_points": [
                      "X-linked dominant inheritance",
                      "Hypotrichosis",
                      "Follicular atrophoderma",
                      "Hypohidrosis"
                    ]
                  }
                ],
                "Rombo Syndrome": [
                  {
                    "text": "Reported in 1 large Swedish family"
                  },
                  {
                    "text": "Similarities to Gorlin syndromeMultiple basal cell carcinomasMilia",
                    "sub_points": [
                      "Multiple basal cell carcinomas",
                      "Milia"
                    ]
                  },
                  {
                    "text": "Distinguishing features from Gorlin syndromeMultiple trichoepitheliomasAtrophoderma vermiculataAcral cyanosis",
                    "sub_points": [
                      "Multiple trichoepitheliomas",
                      "Atrophoderma vermiculata",
                      "Acral cyanosis"
                    ]
                  }
                ],
                "Brooke-Spiegler Syndrome": [
                  {
                    "text": "Multiple facial papules, often clustered on central face (previously termed multiple trichoepitheliomas)"
                  },
                  {
                    "text": "Papulonodules may predominate on scalp (previously termed cylindromatosis)"
                  },
                  {
                    "text": "HistopathologyTrichoepithelioma (not basal cell carcinomas)Basaloid islands, often with advanced follicular differentiation (e.g., horn cysts)Peripheral palisadingClefts between fibrotic stroma and unaffected dermisCylindromaJigsaw puzzle arrangement of islands with ductal differentiation surrounded by thickened basement membraneSpiradenomaBlue islands in dermis with alternating pattern of light and dark cells",
                    "sub_points": [
                      "Trichoepithelioma (not basal cell carcinomas)Basaloid islands, often with advanced follicular differentiation (e.g., horn cysts)Peripheral palisadingClefts between fibrotic stroma and unaffected dermis",
                      "Basaloid islands, often with advanced follicular differentiation (e.g., horn cysts)",
                      "Peripheral palisading",
                      "Clefts between fibrotic stroma and unaffected dermis",
                      "CylindromaJigsaw puzzle arrangement of islands with ductal differentiation surrounded by thickened basement membrane",
                      "Jigsaw puzzle arrangement of islands with ductal differentiation surrounded by thickened basement membrane",
                      "SpiradenomaBlue islands in dermis with alternating pattern of light and dark cells",
                      "Blue islands in dermis with alternating pattern of light and dark cells"
                    ]
                  }
                ],
                "Familial Multiple Basaloid Follicular Hamartomas": [
                  {
                    "text": "Multiple facial papules"
                  },
                  {
                    "text": "Presenting in childhood"
                  },
                  {
                    "text": "HistopathologyBasaloid follicular hamartoma (not basal cell carcinoma)Interconnecting cells with squamoid appearance with interspersed horn cysts, mucinous stromaCK20(+) cells present",
                    "sub_points": [
                      "Basaloid follicular hamartoma (not basal cell carcinoma)Interconnecting cells with squamoid appearance with interspersed horn cysts, mucinous stromaCK20(+) cells present",
                      "Interconnecting cells with squamoid appearance with interspersed horn cysts, mucinous stroma",
                      "CK20(+) cells present"
                    ]
                  }
                ],
                "Generalized Basaloid Follicular Hamartoma Syndrome": [
                  {
                    "text": "Reported in 1 large North Carolina family"
                  },
                  {
                    "text": "Similarities to Gorlin syndromePalmoplantar pitting",
                    "sub_points": [
                      "Palmoplantar pitting"
                    ]
                  },
                  {
                    "text": "Distinguishing features from Gorlin syndromeNo basal cell carcinomasNo jaw cystsMultiple basaloid follicular hamartomasDepicted in this syndrome as buds of basaloid islands arranged around 1 follicle or small cystic structure",
                    "sub_points": [
                      "No basal cell carcinomas",
                      "No jaw cysts",
                      "Multiple basaloid follicular hamartomasDepicted in this syndrome as buds of basaloid islands arranged around 1 follicle or small cystic structure",
                      "Depicted in this syndrome as buds of basaloid islands arranged around 1 follicle or small cystic structure"
                    ]
                  }
                ],
                "Hereditary Infundibulocystic Basal Cell Carcinoma": [
                  {
                    "text": "Distinguishing features from Gorlin syndromeMultiple small papules on central faceAbsence of palmar pitsNo jaw cystsHistopathology shows infundibulocystic basal cell carcinomaSquamoid, ramifying appearance superficially, often with more typical nodular basal cell carcinoma at base",
                    "sub_points": [
                      "Multiple small papules on central face",
                      "Absence of palmar pits",
                      "No jaw cysts",
                      "Histopathology shows infundibulocystic basal cell carcinomaSquamoid, ramifying appearance superficially, often with more typical nodular basal cell carcinoma at base",
                      "Squamoid, ramifying appearance superficially, often with more typical nodular basal cell carcinoma at base"
                    ]
                  }
                ],
                "Other Syndromes With Basal Cell Carcinoma": [
                  {
                    "text": "Defective DNA repair syndromes (e.g., xeroderma pigmentosum)"
                  }
                ]
              },
              "Criteria for Diagnosis": {
                "Major Criteria": [
                  {
                    "text": "Basal cell carcinoma1 if patient < 20 years of age2 or more if patient > 20 years of age",
                    "sub_points": [
                      "1 if patient < 20 years of age",
                      "2 or more if patient > 20 years of age"
                    ]
                  },
                  {
                    "text": "Palmoplantar pitting3 or more",
                    "sub_points": [
                      "3 or more"
                    ]
                  },
                  {
                    "text": "Odontogenic keratocystPatient age: < 20 years",
                    "sub_points": [
                      "Patient age: < 20 years"
                    ]
                  },
                  {
                    "text": "Calcification of falx cerebriSometimes the tentorium cerebelli or sella turcicaPatient age: < 20 years",
                    "sub_points": [
                      "Sometimes the tentorium cerebelli or sella turcica",
                      "Patient age: < 20 years"
                    ]
                  },
                  {
                    "text": "Family history of Gorlin syndrome"
                  },
                  {
                    "text": "Medulloblastoma (primitive neuroectodermal tumor)Patient age: ≤ 2 years",
                    "sub_points": [
                      "Patient age: ≤ 2 years"
                    ]
                  }
                ],
                "Minor Criteria": [
                  {
                    "text": "TumorsCardiac fibromaOvarian fibromaLymphomesenteric cysts",
                    "sub_points": [
                      "Cardiac fibroma",
                      "Ovarian fibroma",
                      "Lymphomesenteric cysts"
                    ]
                  },
                  {
                    "text": "Skeletal/developmental abnormalitiesBifid/fused/splayed/missing ribBifid/wedged/fused vertebra, kyphoscoliosisShort 4th metacarpal, postaxial polydactylyMacrocephalyCleft lip/palate",
                    "sub_points": [
                      "Bifid/fused/splayed/missing rib",
                      "Bifid/wedged/fused vertebra, kyphoscoliosis",
                      "Short 4th metacarpal, postaxial polydactyly",
                      "Macrocephaly",
                      "Cleft lip/palate"
                    ]
                  },
                  {
                    "text": "Ocular abnormalitiesStrabismusCongenital cataractHypertelorismGlaucomaColoboma",
                    "sub_points": [
                      "Strabismus",
                      "Congenital cataract",
                      "Hypertelorism",
                      "Glaucoma",
                      "Coloboma"
                    ]
                  }
                ],
                "Number of Criteria Needed": [
                  {
                    "text": "2 major,or"
                  },
                  {
                    "text": "1 major and 2 minor,or"
                  },
                  {
                    "text": "1 major and molecular confirmation"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Ataxia-Telangiectasia Syndrome": {
            "name": "Ataxia-Telangiectasia Syndrome",
            "url": "https://app.pathprimer.com/document/5d97d749-1611-4788-ae46-1f44496a6d40/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Ataxia-telangiectasia (AT)"
                  },
                  {
                    "text": "Ataxia-telangiectasia mutated (ATM) gene"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "1 per 40,000-100,000"
                  },
                  {
                    "text": "Occurs in all geographic regions with variable local prevalence"
                  }
                ],
                "Gender": [
                  {
                    "text": "Similar frequency in males and females"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Ataxia of gait, stance, and trunk most frequentProgresses to affect extremities and eye movements",
                    "sub_points": [
                      "Progresses to affect extremities and eye movements"
                    ]
                  },
                  {
                    "text": "Dysarthria"
                  },
                  {
                    "text": "Late cerebellar tremor in variant AT rather than profound ataxia"
                  }
                ],
                "Imaging Findings": [
                  {
                    "text": "Atrophy of cerebellar vermis and hemispheres in older children (not evident in early childhood)"
                  }
                ]
              },
              "Genetics": {
                "Autosomal Recessive Disease": [
                  {
                    "text": "Caused by germline inactivation of ataxia-telangiectasia mutated (ATM) gene"
                  },
                  {
                    "text": "Chromosomal region 11q22-23"
                  },
                  {
                    "text": "Encodes for ~ 300 kDa serine/threonine protein kinase with sequence homology to PI3K familyPredominantly a nuclear proteinMajor function is regulation of DNA repair secondary to double-strand DNA breaksNormally in the form of inactive dimersActivated ATM protein monomers recruited to areas of DNA damageMRN  (MRE11A/RAD50/NBS1) complex required for optimal activation of ATM in areas of double-stranded DNA breaksSeveral protein kinases (e.g., CHK2) and p53 key substrates phosphorylated by ATMOther functions include regulation of cell cycle, apoptosis, telomere maintenance, response to oxidative stress, mitochondrial homeostasis, insulin signaling",
                    "sub_points": [
                      "Predominantly a nuclear protein",
                      "Major function is regulation of DNA repair secondary to double-strand DNA breaks",
                      "Normally in the form of inactive dimers",
                      "Activated ATM protein monomers recruited to areas of DNA damage",
                      "MRN  (MRE11A/RAD50/NBS1) complex required for optimal activation of ATM in areas of double-stranded DNA breaks",
                      "Several protein kinases (e.g., CHK2) and p53 key substrates phosphorylated by ATM",
                      "Other functions include regulation of cell cycle, apoptosis, telomere maintenance, response to oxidative stress, mitochondrial homeostasis, insulin signaling"
                    ]
                  },
                  {
                    "text": "In classic AT, ATM is almost completely absent secondary to severe/truncating mutations"
                  }
                ],
                "Heterozygous Carriers ofATMMutations Predisposed to Cancers": [
                  {
                    "text": "Contributes to small subset of familial breast and ovarian cancer"
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Hypersensitivity to Ionizing Radiation": [
                  {
                    "text": "Most characteristic biologic feature"
                  }
                ],
                "↑ α-Fetoprotein in Serum": [
                  {
                    "text": "Useful biomarker"
                  },
                  {
                    "text": "Rising serum levels typical"
                  },
                  {
                    "text": "Not a feature of other ataxia and immunodeficiency syndromes in differential diagnosis"
                  }
                ],
                "Early Diagnosis": [
                  {
                    "text": "Allows genetic counseling and avoidance of extended medical work-ups"
                  }
                ]
              },
              "Nonneoplastic Manifestations": {
                "Central Nervous System Degeneration": [
                  {
                    "text": "Progressive ataxia starts early (6-18 months of age)Wheelchair bound by 1st decade of lifeCerebellar atrophy, particularly vermisExtensive Purkinje and granule cell lossCell loss in inferior olives (retrograde)Ectopic Purkinje cells may be found in molecular layerPeripheral nervous system may also be affected and contribute to symptoms",
                    "sub_points": [
                      "Wheelchair bound by 1st decade of life",
                      "Cerebellar atrophy, particularly vermis",
                      "Extensive Purkinje and granule cell loss",
                      "Cell loss in inferior olives (retrograde)",
                      "Ectopic Purkinje cells may be found in molecular layer",
                      "Peripheral nervous system may also be affected and contribute to symptoms"
                    ]
                  },
                  {
                    "text": "Mental deficiency"
                  },
                  {
                    "text": "Posterior spinal column dysfunction"
                  }
                ],
                "Skin and Eye": [
                  {
                    "text": "TelangiectasiasInvolve bulbar conjunctivae and eventually bridge of noseAppear between ages 2 and 8 years",
                    "sub_points": [
                      "Involve bulbar conjunctivae and eventually bridge of nose",
                      "Appear between ages 2 and 8 years"
                    ]
                  },
                  {
                    "text": "Seborrheic dermatitis common"
                  },
                  {
                    "text": "Cutaneous granulomas"
                  },
                  {
                    "text": "Café au lait spots"
                  },
                  {
                    "text": "Gray hair, skin atrophy"
                  }
                ],
                "Deficiency of Cellular Immunity": [
                  {
                    "text": "Hypoplasia of thymus, tonsil, and adenoids"
                  },
                  {
                    "text": "Lymphopenia"
                  },
                  {
                    "text": "↓ IgA, IgE, IgG2"
                  }
                ],
                "Respiratory Infections and Bronchiectasis": [
                  {
                    "text": "Important cause of death in AT in addition to cancer"
                  }
                ],
                "Endocrine Abnormalities": [
                  {
                    "text": "Hypogonadism/infertility"
                  },
                  {
                    "text": "Insulin resistance/type 2 diabetes"
                  },
                  {
                    "text": "Short stature"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Hematolymphoid Malignancies": [
                  {
                    "text": "Predominant neoplasms affecting AT patients (> 100x risk compared to general population)"
                  },
                  {
                    "text": "T-cell and B-cell lineage"
                  },
                  {
                    "text": "Myeloid leukemia very uncommon"
                  }
                ],
                "Solid Tumors": [
                  {
                    "text": "More evident as patients are living longer"
                  },
                  {
                    "text": "Ovarian carcinoma, breast carcinoma, thyroid carcinoma, salivary gland tumors, gastric carcinoma, melanoma, and leiomyomas/leiomyosarcomas may develop"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Lifetime Cancer Risk": [
                  {
                    "text": "30% in AT patients"
                  },
                  {
                    "text": "Avoid x-ray-based tests if possible given characteristic radiosensitivity of AT"
                  }
                ]
              },
              "Differential Diagnosis": {
                "AT-Like Disorder": [
                  {
                    "text": "Usually caused by hypomorphic mutations inATMor mutations in genes encoding related proteins (e.g.,MRE11A)Missense or splice-site rather than truncating mutations inATMmore common than in classic ATMilder phenotype",
                    "sub_points": [
                      "Missense or splice-site rather than truncating mutations inATMmore common than in classic AT",
                      "Milder phenotype"
                    ]
                  }
                ],
                "Nijmegen Breakage Syndrome (NBS)": [
                  {
                    "text": "Caused by mutations inNBS1Encodes for another component of MRN protein complex",
                    "sub_points": [
                      "Encodes for another component of MRN protein complex"
                    ]
                  },
                  {
                    "text": "Patients also demonstrate immunodeficiency, radiosensitivity, and cancer predisposition"
                  },
                  {
                    "text": "Microcephaly and mental retardation, but lack progressive ataxia and telangiectasias"
                  }
                ],
                "Disorders Associated With Defects in DNA Single-Strand Break (SSB) Repair": [
                  {
                    "text": "Ataxia with oculomotor apraxia types 1 and 2, spinocerebellar ataxia with axonal neuropathy type 1"
                  },
                  {
                    "text": "Neurodegenerative syndromes and neurologic features overlap with AT"
                  },
                  {
                    "text": "No manifestations outside of nervous system"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Schwannomatosis": {
            "name": "Schwannomatosis",
            "url": "https://app.pathprimer.com/document/5ebd4aed-5f52-470a-9e65-72da5fe55790/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "Affects ~ 1 in 40,000 individuals (similar incidence as neurofibromatosis type 2 [NF2])"
                  },
                  {
                    "text": "Similar incidence in males and females"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Inheritance Pattern": [
                  {
                    "text": "75-85% sporadic, 15-25% inherited"
                  }
                ],
                "Germline Mutations inSMARCB1Tumor Suppressor Gene": [
                  {
                    "text": "40-50% of familial cases"
                  },
                  {
                    "text": "8-10% of sporadic cases"
                  },
                  {
                    "text": "4-hit hypothesis: (1) germlineSMARCB1mutation → loss of Chr 22 with remaining (2)SMARCB1allele and (3)NF2gene → loss of remaining (4)NF2allele"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Onset is usually in 2nd and 3rd decadesWide range of ages at initial presentation (children < 10 years through senior patients)",
                    "sub_points": [
                      "Wide range of ages at initial presentation (children < 10 years through senior patients)"
                    ]
                  },
                  {
                    "text": "Multiple schwannomas, usually sparing vestibular nerveRestricted to 1 anatomical region in 1/3 of patientsUnilateral vestibular schwannomas may occur at a low frequency and do not exclude the diagnosis",
                    "sub_points": [
                      "Restricted to 1 anatomical region in 1/3 of patients",
                      "Unilateral vestibular schwannomas may occur at a low frequency and do not exclude the diagnosis"
                    ]
                  },
                  {
                    "text": "Chronic pain is most common symptom, often debilitatingNo clear relationship to tumor size, location, or burden",
                    "sub_points": [
                      "No clear relationship to tumor size, location, or burden"
                    ]
                  },
                  {
                    "text": "Mood disorders, including depression and anxiety, are frequent"
                  },
                  {
                    "text": "Lack of family history in a majority of patients"
                  },
                  {
                    "text": "Meningiomas occur at a low frequency in schwannomatosis patients (~ 5%)Rare families with schwannomatosis, multiple meningiomas, and germlineSMARCB1mutationPreferential location in falx cerebriUsually solitary rather than multiple in schwannomatosis in contrast to NF2",
                    "sub_points": [
                      "Rare families with schwannomatosis, multiple meningiomas, and germlineSMARCB1mutation",
                      "Preferential location in falx cerebri",
                      "Usually solitary rather than multiple in schwannomatosis in contrast to NF2"
                    ]
                  },
                  {
                    "text": "Ependymoma not a feature"
                  },
                  {
                    "text": "Ophthalmologic manifestations not present at a higher frequency in schwannomatosis (in contrast to NF2)"
                  }
                ],
                "Imaging Findings": [
                  {
                    "text": "Peripheral schwannoma location (89%)Arms and legs most common",
                    "sub_points": [
                      "Arms and legs most common"
                    ]
                  },
                  {
                    "text": "Spinal schwannomas (74%)"
                  },
                  {
                    "text": "Intracranial schwannoma (nonvestibular) (9%)"
                  }
                ],
                "Diagnostic Criteria": [
                  {
                    "text": "Several clinical criteria proposed to distinguish schwannomatosis from NF2Lack of bilateral vestibular schwannoma; lack of NF2 in 1st-degree relative; lack of germlineNF2mutation",
                    "sub_points": [
                      "Lack of bilateral vestibular schwannoma; lack of NF2 in 1st-degree relative; lack of germlineNF2mutation"
                    ]
                  },
                  {
                    "text": "Recent proposals incorporate molecular testing"
                  }
                ],
                "Proposed Criteria for Schwannomatosis (2011 International Schwannomatosis Workshop)": [
                  {
                    "text": "Molecular diagnosisSchwannomas or meningiomas (≥ 2 pathologically proven)and≥ 2 tumors with chromosome 22 loss of heterozygosity + 2 differentNF2mutationsorschwannoma or meningioma + germlineSMARCB1mutation",
                    "sub_points": [
                      "Schwannomas or meningiomas (≥ 2 pathologically proven)and",
                      "≥ 2 tumors with chromosome 22 loss of heterozygosity + 2 differentNF2mutationsorschwannoma or meningioma + germlineSMARCB1mutation"
                    ]
                  },
                  {
                    "text": "Clinical diagnosis≥ 2 schwannomas (not intradermal), 1 pathologically confirmed; no vestibular schwannomas on high-quality MR studyorSchwannoma, pathologically confirmed, or intracranial meningioma and 1st-degree relative with schwannomatosis",
                    "sub_points": [
                      "≥ 2 schwannomas (not intradermal), 1 pathologically confirmed; no vestibular schwannomas on high-quality MR studyor",
                      "Schwannoma, pathologically confirmed, or intracranial meningioma and 1st-degree relative with schwannomatosis"
                    ]
                  },
                  {
                    "text": "Possibleschwannomatosis≥ 2 nonintradermal schwannomaswithoutpathologic confirmation",
                    "sub_points": [
                      "≥ 2 nonintradermal schwannomaswithoutpathologic confirmation"
                    ]
                  },
                  {
                    "text": "Excludes schwannomatosisPatient with diagnostic criteria for NF2, germlineNF2mutation, 1st-degree relative with NF2, or multiple schwannomas in a prior irradiated field only",
                    "sub_points": [
                      "Patient with diagnostic criteria for NF2, germlineNF2mutation, 1st-degree relative with NF2, or multiple schwannomas in a prior irradiated field only"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Schwannomas": [
                  {
                    "text": "Histologic features similar to sporadic tumorsCompact Antoni A areas alternating with loose Antoni B areas, Verocay bodies, hyalinized vessels, and well-formed capsule",
                    "sub_points": [
                      "Compact Antoni A areas alternating with loose Antoni B areas, Verocay bodies, hyalinized vessels, and well-formed capsule"
                    ]
                  },
                  {
                    "text": "Myxoid changes (\"myxoid schwannoma\"), intraneural growth, and peritumoral edema overrepresented in schwannomatosis-associated cases"
                  },
                  {
                    "text": "Nerve edema"
                  },
                  {
                    "text": "Rare schwannoma variants reported in schwannomatosis patients include plexiform, cellular, and neuroblastoma-like"
                  },
                  {
                    "text": "S100 and collagen IV (pericellular) positive by immunohistochemistry; EMA(-)"
                  },
                  {
                    "text": "Mosaic pattern of INI1 immunostaining (i.e., loss in a subset of neoplastic cells) in most schwannomatosis-associated schwannomas"
                  }
                ],
                "Neurofibromas": [
                  {
                    "text": "Neurofibromas, in addition to schwannomas, are a recognized feature of neurofibromatosis type 2"
                  },
                  {
                    "text": "Not usually a feature of schwannomatosis patients but previously reported in at least 2 patients"
                  }
                ],
                "Hybrid Tumors": [
                  {
                    "text": "Tumors with hybrid neurofibroma/schwannoma features overrepresented in syndrome-associated peripheral nerve tumors, particularly in schwannomatosis"
                  },
                  {
                    "text": "Neurofilament (+) axons in neurofibroma-like component in 1/2 of cases"
                  },
                  {
                    "text": "GLUT1/EMA (+) perineurial-like cells in neurofibroma-like areas"
                  },
                  {
                    "text": "CD34(+) in Antoni B and neurofibroma-like areas, negative in Antoni A areas"
                  }
                ]
              },
              "Genetics and Molecular Biology": {
                "SMARCB1Function": [
                  {
                    "text": "Tumor suppressor gene"
                  },
                  {
                    "text": "Other synonyms includeINI1,BAF47,hSNF5"
                  },
                  {
                    "text": "Encodes for a component of the SWI/SNF protein complexChromatin-remodeling complex, ATP dependentInteracts with HIV-1 integrase",
                    "sub_points": [
                      "Chromatin-remodeling complex, ATP dependent",
                      "Interacts with HIV-1 integrase"
                    ]
                  }
                ],
                "Germline Mutations inSMARCB1": [
                  {
                    "text": "Nontruncating, missense, or splice site in familial schwannomatosis (unlike atypical teratoid rhabdoid tumor)"
                  },
                  {
                    "text": "Mutations usually located at ends ofSMARCB1"
                  },
                  {
                    "text": "Inherited in an autosomal dominant fashion, incomplete penetrance"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Xeroderma Pigmentosum": {
            "name": "Xeroderma Pigmentosum",
            "url": "https://app.pathprimer.com/document/85d1cb63-9928-4d61-ab8b-83b86df4f70a/lesson/dd917a59-95f4-4563-9fef-ab39204b0ee9",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Xeroderma pigmentosum (XP)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "DeSanctis-Cacchione syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Inherited disorder of nucleotide excision repair"
                  },
                  {
                    "text": "Characterized by photosensitivity and early onset of skin cancer and solar lentigines"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "~ 1 in 1 million in United States"
                  },
                  {
                    "text": "~ 1 in 40,000 in Japan"
                  }
                ],
                "Age Range": [
                  {
                    "text": "Evidence of photodamage of skin (solar lentigines)As early as 1-2 years of age",
                    "sub_points": [
                      "As early as 1-2 years of age"
                    ]
                  },
                  {
                    "text": "Median age of onset of nonmelanoma skin cancer: 9 years"
                  },
                  {
                    "text": "Mean age of presentation of hearing loss: 19 years"
                  },
                  {
                    "text": "Median age of onset of cutaneous melanoma: 22 years"
                  },
                  {
                    "text": "Often multiple primary cutaneous tumors by age 20 years"
                  },
                  {
                    "text": "XP variantLater disease onsetAge 10-20 years",
                    "sub_points": [
                      "Later disease onsetAge 10-20 years",
                      "Age 10-20 years"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Cause of deathSkin cancer34% of patientsNeurologic degeneration31% of patientsInternal malignancy17% of patients",
                    "sub_points": [
                      "Skin cancer34% of patients",
                      "34% of patients",
                      "Neurologic degeneration31% of patients",
                      "31% of patients",
                      "Internal malignancy17% of patients",
                      "17% of patients"
                    ]
                  },
                  {
                    "text": "Median age at death, if no neurologic degeneration present37 years",
                    "sub_points": [
                      "37 years"
                    ]
                  },
                  {
                    "text": "Median age at death, if neurologic degeneration present29 years",
                    "sub_points": [
                      "29 years"
                    ]
                  }
                ]
              },
              "Genetics": {
                "Inheritance": [
                  {
                    "text": "Autosomal recessive"
                  }
                ],
                "Mutations": [
                  {
                    "text": "In genes involved in nucleotide excision repairResults in high number of UV signature mutations (C to T or CC to TT)",
                    "sub_points": [
                      "Results in high number of UV signature mutations (C to T or CC to TT)"
                    ]
                  },
                  {
                    "text": "Complementation groupsComplementation is capacity of cells from 1 XP cell line to compensate for repair defects of another cell line when these 2 cell lines are fusedGroups A to G, defective nucleotide excision repair of UV light-induced damageGroup A: Mutation inXPAGroup B: Mutation inXPB/ERCC3Group C: Mutation inXPCGroup D: Mutation inXPD/ERCC2Group E: Mutation inXPE/DDB2Group F: Mutation inXPF/ERCC4Group G: Mutation inXPG/ERCC5XP variant: Mutation inPOLH(defective DNA polymerase) causing incorrect replication of DNA",
                    "sub_points": [
                      "Complementation is capacity of cells from 1 XP cell line to compensate for repair defects of another cell line when these 2 cell lines are fused",
                      "Groups A to G, defective nucleotide excision repair of UV light-induced damageGroup A: Mutation inXPAGroup B: Mutation inXPB/ERCC3Group C: Mutation inXPCGroup D: Mutation inXPD/ERCC2Group E: Mutation inXPE/DDB2Group F: Mutation inXPF/ERCC4Group G: Mutation inXPG/ERCC5",
                      "Group A: Mutation inXPA",
                      "Group B: Mutation inXPB/ERCC3",
                      "Group C: Mutation inXPC",
                      "Group D: Mutation inXPD/ERCC2",
                      "Group E: Mutation inXPE/DDB2",
                      "Group F: Mutation inXPF/ERCC4",
                      "Group G: Mutation inXPG/ERCC5",
                      "XP variant: Mutation inPOLH(defective DNA polymerase) causing incorrect replication of DNA"
                    ]
                  },
                  {
                    "text": "Genotype-phenotype correlationsComplementation groups A, B, D, and GBlistering burns with minimal sun exposureMore likely to have neurologic degenerationComplementation groups C, E, and variantGenerally lack acute sunburnsDevelop evidence of chronic sun damage, often by age 2 years, manifesting as freckling and lentiginesComplementation groups C, E, F, XP variantGenerally absent neurologic degeneration",
                    "sub_points": [
                      "Complementation groups A, B, D, and GBlistering burns with minimal sun exposureMore likely to have neurologic degeneration",
                      "Blistering burns with minimal sun exposure",
                      "More likely to have neurologic degeneration",
                      "Complementation groups C, E, and variantGenerally lack acute sunburnsDevelop evidence of chronic sun damage, often by age 2 years, manifesting as freckling and lentigines",
                      "Generally lack acute sunburns",
                      "Develop evidence of chronic sun damage, often by age 2 years, manifesting as freckling and lentigines",
                      "Complementation groups C, E, F, XP variantGenerally absent neurologic degeneration",
                      "Generally absent neurologic degeneration"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Clinical Presentation": [
                  {
                    "text": "Childhood onset of photosensitivityManifests as blistering (sunburn) with minimal acute sun exposure or as early-onset lentiginesBy age 18 months in 50% of patientsBy age 4 years in 75% of patientsBy age 15 years in 95% of patientsChronic changes, primarily in sun-exposed areasPoikiloderma (dyspigmentation with atrophy and telangiectasias), lentigines, xerosis, tumors",
                    "sub_points": [
                      "Manifests as blistering (sunburn) with minimal acute sun exposure or as early-onset lentiginesBy age 18 months in 50% of patientsBy age 4 years in 75% of patientsBy age 15 years in 95% of patients",
                      "By age 18 months in 50% of patients",
                      "By age 4 years in 75% of patients",
                      "By age 15 years in 95% of patients",
                      "Chronic changes, primarily in sun-exposed areasPoikiloderma (dyspigmentation with atrophy and telangiectasias), lentigines, xerosis, tumors",
                      "Poikiloderma (dyspigmentation with atrophy and telangiectasias), lentigines, xerosis, tumors"
                    ]
                  },
                  {
                    "text": "Eye changesTelangiectasias of conjunctiva, photophobia, cataracts, keratitis, corneal opacification and vascularization",
                    "sub_points": [
                      "Telangiectasias of conjunctiva, photophobia, cataracts, keratitis, corneal opacification and vascularization"
                    ]
                  },
                  {
                    "text": "Neurologic in 25-30% of patientsAbsent deep tendon reflexesHigh-frequency sensorineural hearing lossEspecially in patients in complementation groups A and DCognitive impairmentDifficulty swallowingLoss of ability to ambulateSeizures",
                    "sub_points": [
                      "Absent deep tendon reflexes",
                      "High-frequency sensorineural hearing lossEspecially in patients in complementation groups A and D",
                      "Especially in patients in complementation groups A and D",
                      "Cognitive impairment",
                      "Difficulty swallowing",
                      "Loss of ability to ambulate",
                      "Seizures"
                    ]
                  }
                ],
                "Ancillary Testing": [
                  {
                    "text": "No consistent routine laboratory abnormalities are present in xeroderma pigmentosum patients"
                  },
                  {
                    "text": "Specialized laboratory studies include cellular hypersensitivity to UV radiation and chromosomal breakage studies, complementation studies, and gene sequencing to identify specific gene complementation group"
                  },
                  {
                    "text": "Prenatal diagnosis can be accomplished using similar chromosomal breakage studies on amniocytes (obtained by amniocentesis or chorionic villi sampling) from at-risk fetuses"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Nonmelanoma Skin Cancer": [
                  {
                    "text": "Basal cell carcinoma and squamous cell carcinoma10,000x increase in XP patients < 20 years old compared to general population",
                    "sub_points": [
                      "10,000x increase in XP patients < 20 years old compared to general population"
                    ]
                  }
                ],
                "Melanoma": [
                  {
                    "text": "Cutaneous melanoma has 2,000x increase in XP patients < 20 years old compared to general population"
                  },
                  {
                    "text": "Ocular melanoma has 1,000x increase in XP patients < 20 years old compared to general population"
                  }
                ],
                "Other Malignancies": [
                  {
                    "text": "10-20x increase compared to general population"
                  },
                  {
                    "text": "CNS tumors"
                  },
                  {
                    "text": "Carcinomas"
                  },
                  {
                    "text": "Leukemias"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Ultraviolet Light Protection (From Sunlight and Artificial Light)": [
                  {
                    "text": "Of skin and eyes"
                  },
                  {
                    "text": "From day 1 of life"
                  },
                  {
                    "text": "Oral vitamin D and calcium supplementation"
                  }
                ],
                "Regular Examination": [
                  {
                    "text": "Mucocutaneous"
                  },
                  {
                    "text": "Ocular"
                  }
                ],
                "Avoidance of Other Carcinogens": [
                  {
                    "text": "e.g., tobacco smoke"
                  }
                ],
                "Possible Prophylaxis": [
                  {
                    "text": "Oral retinoids"
                  },
                  {
                    "text": "T4 endonuclease V (bacterial DNA repair enzyme)"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Includes": [
                  {
                    "text": "Trichothiodystrophy"
                  },
                  {
                    "text": "Cockayne syndrome"
                  },
                  {
                    "text": "UV-sensitive syndrome"
                  },
                  {
                    "text": "Bloom syndrome"
                  },
                  {
                    "text": "Rothmund-Thomson syndrome"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Somatic Alterations in Cancer: Hematology": {
        "name": "Somatic Alterations in Cancer: Hematology",
        "url": "https://app.pathprimer.com/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
        "topics": {
          "BCR-ABL1Fusion Gene": {
            "name": "BCR-ABL1Fusion Gene",
            "url": "https://app.pathprimer.com/document/f9a013ff-5e25-4889-8fb8-7ce2dec987c9/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Philadelphia (Ph) chromosomeTerminology extensively used forBCR::ABL1fusion",
                    "sub_points": [
                      "Terminology extensively used forBCR::ABL1fusion"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "BCR::ABL1fusion due to reciprocal translocation involving long arms of chromosomes 9 and 22"
                  }
                ],
                "Historical View": [
                  {
                    "text": "1960: Discovered and named Ph-chromosome by Nowell and HungerfordCalled aberrant acrocentric chromosome 22 in 7 patients with chronic myeloid leukemia (CML)1st recurrent chromosomal abnormality linked to human malignancy",
                    "sub_points": [
                      "Called aberrant acrocentric chromosome 22 in 7 patients with chronic myeloid leukemia (CML)",
                      "1st recurrent chromosomal abnormality linked to human malignancy"
                    ]
                  },
                  {
                    "text": "1973: Janet Rowley utilized chromosomal banding techniques to demonstrate underlying t(9;22)(q34.1;q11.2)"
                  },
                  {
                    "text": "1998: Imatinib (Gleevec) targeted therapy introduced"
                  },
                  {
                    "text": "2001: Imatinib approved as 1st-line therapy for CML2nd- (dasatinib, nilotinib, bosutinib) and 3rd- (ponatinib) generation tyrosine kinase inhibitor (TKI) therapies also availableAllosteric inhibitors ofBCR::ABL1kinase activity (asciminib) and plant alkaloid derived pharmaceuticals (omacetaxine) are other approved treatments",
                    "sub_points": [
                      "2nd- (dasatinib, nilotinib, bosutinib) and 3rd- (ponatinib) generation tyrosine kinase inhibitor (TKI) therapies also available",
                      "Allosteric inhibitors ofBCR::ABL1kinase activity (asciminib) and plant alkaloid derived pharmaceuticals (omacetaxine) are other approved treatments"
                    ]
                  }
                ],
                "Normal Function ofBCR": [
                  {
                    "text": "Localizes to chromosome 22q11.2"
                  },
                  {
                    "text": "Protein with regulatory activities toward small GTP-binding proteins through GTPase activity modulation, including RAC1"
                  },
                  {
                    "text": "Amino terminus contains intrinsic kinase activity"
                  }
                ],
                "Normal Function ofABL1": [
                  {
                    "text": "Localizes to chromosome 9q34.1"
                  },
                  {
                    "text": "Protooncogene involved in variety of cellular processes, including cell division, adhesion, differentiation, and stress responses"
                  },
                  {
                    "text": "Encodes cytoplasmic and nuclear nonreceptor tyrosine kinase"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "t(9;22)(q34.1;q11.2)": [
                  {
                    "text": "Reciprocal translocation following breakpoints withinBCRandABL1lociEncodes oncogenicBCR::ABL1fusion proteinTranslocation is balanced in majority of casesLoss of portion of reciprocalABL1::BCRfound in derivative chromosome 9 in ~ 10% of CML cases",
                    "sub_points": [
                      "Encodes oncogenicBCR::ABL1fusion protein",
                      "Translocation is balanced in majority of cases",
                      "Loss of portion of reciprocalABL1::BCRfound in derivative chromosome 9 in ~ 10% of CML cases"
                    ]
                  },
                  {
                    "text": "t(9;22)(q34.1;q11.2) fuses 3' sequences fromABL1to 5' sequences fromBCR"
                  },
                  {
                    "text": "ABL1breakpoint typically between exons 1-2 (a2)RareABL1breakpoints occur between exons 2-3 (a3)Known a3 fusions include e13a3, e14a3, and e1a3",
                    "sub_points": [
                      "RareABL1breakpoints occur between exons 2-3 (a3)",
                      "Known a3 fusions include e13a3, e14a3, and e1a3"
                    ]
                  },
                  {
                    "text": "BCRwith at least 3 different breakpoint regionsMajor breakpoint cluster region (M-BCR)Breakpoints occur in region spanning exon 12-16 (a.k.a. exons b1-b5)Mostly between exons 13-14 or exons 14-15Fusions withABL1 a2lead to mRNA products referred to as e13a2 or e14a2Result in 210 kDa fusion protein (p210)Minor breakpoint cluster region (m-BCR)Arise 5' of M-BCR between exons 1-2 (e1)Fusion withABL1 a2results in e1a2 transcriptsResults in 190 kDa fusion protein (p190)Micro breakpoint cluster region (μ-BCR)RareBCRbreakpoint between exons 17-20Results in 230 kDa fusion protein (p230)",
                    "sub_points": [
                      "Major breakpoint cluster region (M-BCR)Breakpoints occur in region spanning exon 12-16 (a.k.a. exons b1-b5)Mostly between exons 13-14 or exons 14-15Fusions withABL1 a2lead to mRNA products referred to as e13a2 or e14a2Result in 210 kDa fusion protein (p210)",
                      "Breakpoints occur in region spanning exon 12-16 (a.k.a. exons b1-b5)Mostly between exons 13-14 or exons 14-15",
                      "Mostly between exons 13-14 or exons 14-15",
                      "Fusions withABL1 a2lead to mRNA products referred to as e13a2 or e14a2Result in 210 kDa fusion protein (p210)",
                      "Result in 210 kDa fusion protein (p210)",
                      "Minor breakpoint cluster region (m-BCR)Arise 5' of M-BCR between exons 1-2 (e1)Fusion withABL1 a2results in e1a2 transcriptsResults in 190 kDa fusion protein (p190)",
                      "Arise 5' of M-BCR between exons 1-2 (e1)",
                      "Fusion withABL1 a2results in e1a2 transcriptsResults in 190 kDa fusion protein (p190)",
                      "Results in 190 kDa fusion protein (p190)",
                      "Micro breakpoint cluster region (μ-BCR)RareBCRbreakpoint between exons 17-20Results in 230 kDa fusion protein (p230)",
                      "RareBCRbreakpoint between exons 17-20",
                      "Results in 230 kDa fusion protein (p230)"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Chronic Myeloid Leukemia": [
                  {
                    "text": "BCR::ABL1is required to diagnose CMLFISH &/or RT-PCR must be performed in suspected cases with negative cytogeneticsFISH &/or RT-PCR may identify cryptic fusions missed by conventional karyotypingVery rare cryptic fusions may also be missed by FISH but can be detected by RT-PCR",
                    "sub_points": [
                      "FISH &/or RT-PCR must be performed in suspected cases with negative cytogeneticsFISH &/or RT-PCR may identify cryptic fusions missed by conventional karyotypingVery rare cryptic fusions may also be missed by FISH but can be detected by RT-PCR",
                      "FISH &/or RT-PCR may identify cryptic fusions missed by conventional karyotyping",
                      "Very rare cryptic fusions may also be missed by FISH but can be detected by RT-PCR"
                    ]
                  },
                  {
                    "text": "Multipotent hematopoietic progenitor is affectedFusion gene present in all stages of granulocytic, erythroid, and megakaryocytic lineages",
                    "sub_points": [
                      "Fusion gene present in all stages of granulocytic, erythroid, and megakaryocytic lineages"
                    ]
                  },
                  {
                    "text": "Major breakpoint cluster region (M-BCR, p210 transcripts) involved in ~ 99% of CML cases"
                  },
                  {
                    "text": "Primary fusion involving minor breakpoint cluster region (m-BCR, p190 transcripts) in only 1% of CML"
                  },
                  {
                    "text": "> 90% of cases with p210 will have low-level p190 transcripts detectable at initial diagnosisLow-level p190 due to alternative splicing ofBCR",
                    "sub_points": [
                      "Low-level p190 due to alternative splicing ofBCR"
                    ]
                  },
                  {
                    "text": "Primary micro breakpoint cluster region fusions (μ-BCR, p230 transcripts) are rareCases with p230 show prominent mature neutrophilia &/or conspicuous thrombocytosis",
                    "sub_points": [
                      "Cases with p230 show prominent mature neutrophilia &/or conspicuous thrombocytosis"
                    ]
                  }
                ],
                "B-Lymphoblastic Leukemia/Lymphoma": [
                  {
                    "text": "~ 25% of adult B-ALL cases areBCR::ABL1-positive~ 60% of Ph(+) cases involve m-BCR (p190)Remaining 40% involve M-BCR (p210)",
                    "sub_points": [
                      "~ 60% of Ph(+) cases involve m-BCR (p190)",
                      "Remaining 40% involve M-BCR (p210)"
                    ]
                  },
                  {
                    "text": "~ 2-4% of childhood B-ALL areBCR::ABL1-positive~ 90% of cases involve m-BCR (p190)",
                    "sub_points": [
                      "~ 90% of cases involve m-BCR (p190)"
                    ]
                  },
                  {
                    "text": "WHO 5th edition classification for B-ALL withBCR::ABL1is unchanged from prior edition"
                  },
                  {
                    "text": "International Consensus Classification (ICC) system dividesBCR::ABL1-positive ALL into 2 biologically distinct subsetsOne subset is biologically closer to CML presenting in lymphoid blast phaseDistinguished by detection ofBCR::ABL1fusion in both leukemic lymphoblasts and non-ALL lymphocytes/granulocytesSuggests multipotent hematopoietic progenitor is affected byBCR::ABL1fusionThis subset is distinguished on basis of FISH analysis and is not identifiable byBCR::ABL1fusion transcript analysisMay require cell sorting or granulocyte enrichment step prior to FISH to obtain sufficient cells for analysisWill demonstrate higherBCR::ABL1fusion levels thanIGH/TCRrearrangements when monitoring for minimal residual disease (MRD)2nd subset is closer to more conventional lymphoblastic leukemia/lymphomaBCR::ABL1fusion is present only in lymphoblasts",
                    "sub_points": [
                      "One subset is biologically closer to CML presenting in lymphoid blast phaseDistinguished by detection ofBCR::ABL1fusion in both leukemic lymphoblasts and non-ALL lymphocytes/granulocytesSuggests multipotent hematopoietic progenitor is affected byBCR::ABL1fusionThis subset is distinguished on basis of FISH analysis and is not identifiable byBCR::ABL1fusion transcript analysisMay require cell sorting or granulocyte enrichment step prior to FISH to obtain sufficient cells for analysisWill demonstrate higherBCR::ABL1fusion levels thanIGH/TCRrearrangements when monitoring for minimal residual disease (MRD)",
                      "Distinguished by detection ofBCR::ABL1fusion in both leukemic lymphoblasts and non-ALL lymphocytes/granulocytesSuggests multipotent hematopoietic progenitor is affected byBCR::ABL1fusionThis subset is distinguished on basis of FISH analysis and is not identifiable byBCR::ABL1fusion transcript analysisMay require cell sorting or granulocyte enrichment step prior to FISH to obtain sufficient cells for analysisWill demonstrate higherBCR::ABL1fusion levels thanIGH/TCRrearrangements when monitoring for minimal residual disease (MRD)",
                      "Suggests multipotent hematopoietic progenitor is affected byBCR::ABL1fusion",
                      "This subset is distinguished on basis of FISH analysis and is not identifiable byBCR::ABL1fusion transcript analysis",
                      "May require cell sorting or granulocyte enrichment step prior to FISH to obtain sufficient cells for analysis",
                      "Will demonstrate higherBCR::ABL1fusion levels thanIGH/TCRrearrangements when monitoring for minimal residual disease (MRD)",
                      "2nd subset is closer to more conventional lymphoblastic leukemia/lymphomaBCR::ABL1fusion is present only in lymphoblasts",
                      "BCR::ABL1fusion is present only in lymphoblasts"
                    ]
                  }
                ],
                "Acute Myeloid Leukemia WithBCR::ABL1": [
                  {
                    "text": "Rare acute myeloid leukemia (AML) subtype (< 1%) recognized by both WHO 5th edition and ICC systemsDe novo AML with no evidence of prior CMLMost cases involve M-BCR (p210)≥ 20% blasts required for diagnosis by both WHO and ICCVariable anemia and thrombocytopeniaLower peripheral blood basophilia (usually < 2%)",
                    "sub_points": [
                      "De novo AML with no evidence of prior CML",
                      "Most cases involve M-BCR (p210)",
                      "≥ 20% blasts required for diagnosis by both WHO and ICC",
                      "Variable anemia and thrombocytopenia",
                      "Lower peripheral blood basophilia (usually < 2%)"
                    ]
                  }
                ],
                "Mixed Phenotype Acute Leukemia WithBCR::ABL1": [
                  {
                    "text": "p190 transcript is more common than p210 transcript"
                  },
                  {
                    "text": "If p210 transcript detected, CML in mixed blast crisis should be considered; especially if 2 distinct myeloid and lymphoid blast populations are present"
                  }
                ]
              },
              "Methods of Detection": {
                "Conventional Cytogenetics": [
                  {
                    "text": "Detects t(9;22)(q34.1;q11.2) in ~ 95% of casesPresumptive evidence forBCR::ABL1fusion gene",
                    "sub_points": [
                      "Presumptive evidence forBCR::ABL1fusion gene"
                    ]
                  },
                  {
                    "text": "Also identifies variant t(9;22) translocations as well as other chromosomal aberrancies if present"
                  },
                  {
                    "text": "Cryptic translocations are not detected"
                  },
                  {
                    "text": "Inappropriate for disease monitoring; low detection sensitivity (~ 5%)Not useful for MRD detection",
                    "sub_points": [
                      "Not useful for MRD detection"
                    ]
                  }
                ],
                "FISH": [
                  {
                    "text": "IdentifiesBCR::ABL1fusion in > 95% of casesDetects most cryptic rearrangementsRare cryptic rearrangements may be missed",
                    "sub_points": [
                      "Detects most cryptic rearrangements",
                      "Rare cryptic rearrangements may be missed"
                    ]
                  },
                  {
                    "text": "More sensitive than conventional cytogenetics but insufficient for MRD or early relapse detection"
                  },
                  {
                    "text": "Cannot differentiate between various fusion transcripts"
                  }
                ],
                "Quantitative Real-Time PCR": [
                  {
                    "text": "Reliably determines type ofBCR::ABL1transcript"
                  },
                  {
                    "text": "More accurately quantifiesBCR::ABL1transcripts"
                  },
                  {
                    "text": "Standard for monitoring treatment response, MRD, and early relapse detection"
                  },
                  {
                    "text": "International Scale was developed to standardize inter-laboratory quantitative reporting of transcript levels"
                  },
                  {
                    "text": "Basic principles for quantitative real-time PCRRNA extraction from fresh blood, bone marrow, or other involved sitesReverse transcription to convert RNA to cDNAReal-time PCR amplification using primer sets to cover desiredBCR::ABL1fusionsSmall probes of ~ 25 bases in lengthMany laboratories in USA use \"European network probes\" complementary to portion ofABL1sequences in proximity of fusion withBCRSimultaneous PCR amplification of internal control gene, such asABL1,B2M,GUSB, or other genesInclusion of serially diluted positive cell line/plasmid controls",
                    "sub_points": [
                      "RNA extraction from fresh blood, bone marrow, or other involved sites",
                      "Reverse transcription to convert RNA to cDNA",
                      "Real-time PCR amplification using primer sets to cover desiredBCR::ABL1fusions",
                      "Small probes of ~ 25 bases in lengthMany laboratories in USA use \"European network probes\" complementary to portion ofABL1sequences in proximity of fusion withBCR",
                      "Many laboratories in USA use \"European network probes\" complementary to portion ofABL1sequences in proximity of fusion withBCR",
                      "Simultaneous PCR amplification of internal control gene, such asABL1,B2M,GUSB, or other genes",
                      "Inclusion of serially diluted positive cell line/plasmid controls"
                    ]
                  }
                ],
                "Digital Droplet PCR": [
                  {
                    "text": "May be feasible alternate to quantitative real-time PCR"
                  },
                  {
                    "text": "Returns absolute quantification, which may also be expressed as percentage on IS"
                  }
                ]
              },
              "Disease Monitoring in CML and Ph(+) B-ALL": {
                "Detection of Minimal Residual Disease and Treatment Response in Chronic Myeloid Leukemia": [
                  {
                    "text": "Quantitative real-time PCR is recommended at diagnosis and for monitoring"
                  },
                  {
                    "text": "Level ofBCR::ABL1transcripts can be expressed using 2 different methodsRatio ofBCR::ABL1toABL1internal control gene (or other selected internal control gene) methodRatios of ≥ 0.1 are typically present at diagnosis and indicate high copy numbers of transcriptsMajor molecular response (MMR) is defined asBCR::ABL1toABL1ratio with ≥ 3 log reduction from baselineDisease burden as determined by International Standard (IS) methodTranscript levels at initial diagnosis set as 100% ISMajor molecular response (≥ 3 log reduction, MR3.0) defined as IS value of ≤ 0.1%Ongoing lack of consensus regarding levels for deep molecular response (DMR)MR4.0 (IS ≤ 0.01%) and MR4.5 (IS ≤ 0.0032%) both in useAchieving and maintaining DMR required for consideration of discontinuing TKI therapy",
                    "sub_points": [
                      "Ratio ofBCR::ABL1toABL1internal control gene (or other selected internal control gene) methodRatios of ≥ 0.1 are typically present at diagnosis and indicate high copy numbers of transcriptsMajor molecular response (MMR) is defined asBCR::ABL1toABL1ratio with ≥ 3 log reduction from baseline",
                      "Ratios of ≥ 0.1 are typically present at diagnosis and indicate high copy numbers of transcripts",
                      "Major molecular response (MMR) is defined asBCR::ABL1toABL1ratio with ≥ 3 log reduction from baseline",
                      "Disease burden as determined by International Standard (IS) methodTranscript levels at initial diagnosis set as 100% ISMajor molecular response (≥ 3 log reduction, MR3.0) defined as IS value of ≤ 0.1%Ongoing lack of consensus regarding levels for deep molecular response (DMR)MR4.0 (IS ≤ 0.01%) and MR4.5 (IS ≤ 0.0032%) both in useAchieving and maintaining DMR required for consideration of discontinuing TKI therapy",
                      "Transcript levels at initial diagnosis set as 100% IS",
                      "Major molecular response (≥ 3 log reduction, MR3.0) defined as IS value of ≤ 0.1%",
                      "Ongoing lack of consensus regarding levels for deep molecular response (DMR)MR4.0 (IS ≤ 0.01%) and MR4.5 (IS ≤ 0.0032%) both in useAchieving and maintaining DMR required for consideration of discontinuing TKI therapy",
                      "MR4.0 (IS ≤ 0.01%) and MR4.5 (IS ≤ 0.0032%) both in use",
                      "Achieving and maintaining DMR required for consideration of discontinuing TKI therapy"
                    ]
                  },
                  {
                    "text": "Peripheral blood is suitable for monitoring diseaseBCR::ABL1transcripts are present in all myeloid lineages, including in segmented neutrophils",
                    "sub_points": [
                      "BCR::ABL1transcripts are present in all myeloid lineages, including in segmented neutrophils"
                    ]
                  },
                  {
                    "text": "Bone marrow specimen is not typically needed for disease monitoring"
                  }
                ],
                "Detection of Treatment Response and Early Relapse in Ph(+) ALL": [
                  {
                    "text": "Quantitative real-time PCR is recommended test for disease monitoringTherapeutic aim is complete molecular response with attainment of negativity forBCR::ABL1transcriptsDetection of low-levelBCR::ABL1transcripts following complete molecular response predicts recurrent disease at early molecular relapse stageIS reporting is not applicable to Ph(+) B-ALL",
                    "sub_points": [
                      "Therapeutic aim is complete molecular response with attainment of negativity forBCR::ABL1transcriptsDetection of low-levelBCR::ABL1transcripts following complete molecular response predicts recurrent disease at early molecular relapse stageIS reporting is not applicable to Ph(+) B-ALL",
                      "Detection of low-levelBCR::ABL1transcripts following complete molecular response predicts recurrent disease at early molecular relapse stage",
                      "IS reporting is not applicable to Ph(+) B-ALL"
                    ]
                  },
                  {
                    "text": "Bone marrow preferred for disease monitoring in Ph(+) B-ALLIn contrast to CML,BCR::ABL1transcripts may be limited to B lymphoblastsPeripheral blood has low detection sensitivity for patients in morphologic remission",
                    "sub_points": [
                      "In contrast to CML,BCR::ABL1transcripts may be limited to B lymphoblasts",
                      "Peripheral blood has low detection sensitivity for patients in morphologic remission"
                    ]
                  }
                ]
              },
              "BCR::ABL1-Resistant Mutations": {
                "Mutations inABL1Kinase Domain": [
                  {
                    "text": "Most common cause of acquired tyrosine kinase inhibitor (TKI) resistance"
                  },
                  {
                    "text": "> 80 mutations reported, mostly single nucleotide substitutionsMutations at G250, Y253, E255, T315, M351, F359, and H396 codons account for ~ 60% of all mutationsT315I/A and mutations in codon F317 and V299 associated with dasatinib resistanceY253H, E255K/V, T315I, and F359C/V/I mutations are associated with nilotinib resistanceL248V, G250E, V299L, T315I, F317L, and F359C mutations are associated with bosutinib resistancePonatinib (3rd-generation kinase inhibitor), asciminib (allosteric inhibitor), and omacetaxine may be used in some treatment-resistant CML cases with any mutations, including T315I",
                    "sub_points": [
                      "Mutations at G250, Y253, E255, T315, M351, F359, and H396 codons account for ~ 60% of all mutations",
                      "T315I/A and mutations in codon F317 and V299 associated with dasatinib resistance",
                      "Y253H, E255K/V, T315I, and F359C/V/I mutations are associated with nilotinib resistance",
                      "L248V, G250E, V299L, T315I, F317L, and F359C mutations are associated with bosutinib resistance",
                      "Ponatinib (3rd-generation kinase inhibitor), asciminib (allosteric inhibitor), and omacetaxine may be used in some treatment-resistant CML cases with any mutations, including T315I"
                    ]
                  },
                  {
                    "text": "Analysis of RNA required to ensureABL1kinase domain mutation is within fusion transcript"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "PDGFRA,PDGFRB, andFGFR1Rearrangements Detection": {
            "name": "PDGFRA,PDGFRB, andFGFR1Rearrangements Detection",
            "url": "https://app.pathprimer.com/document/22f906aa-c230-4860-8817-68ca04ec549d/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "PDGFRAHGNC name: Platelet-derived growth factor receptor, alpha polypeptideHGNC ID: 8803Chromosomal location: 4q12",
                    "sub_points": [
                      "HGNC name: Platelet-derived growth factor receptor, alpha polypeptide",
                      "HGNC ID: 8803",
                      "Chromosomal location: 4q12"
                    ]
                  },
                  {
                    "text": "PDGFRBHGNC name: Platelet-derived growth factor receptor, beta polypeptideHGNC ID: 8804Chromosomal location: 5q33.1",
                    "sub_points": [
                      "HGNC name: Platelet-derived growth factor receptor, beta polypeptide",
                      "HGNC ID: 8804",
                      "Chromosomal location: 5q33.1"
                    ]
                  },
                  {
                    "text": "FGFR1HGNC name: Fibroblast growth factor receptor 1HGNC ID: 3688Chromosomal location: 8p11.23-p11.22",
                    "sub_points": [
                      "HGNC name: Fibroblast growth factor receptor 1",
                      "HGNC ID: 3688",
                      "Chromosomal location: 8p11.23-p11.22"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Fusion Gene Formation": [
                  {
                    "text": "PDGFRA,PDGFRB, andFGFR1encode tyrosine kinases"
                  },
                  {
                    "text": "Rearrangements generate fusion genes leading to abnormal kinase signaling"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "General Clinical Implications": [
                  {
                    "text": "Rearrangements of these genes are diagnostic of WHO 2008 entities \"myeloid and lymphoid neoplasms with eosinophilia and abnormalities ofPDGFRA,PDGFRB, orFGFR1\""
                  }
                ],
                "PDGFRARearrangement": [
                  {
                    "text": "Diagnostic feature of \"myeloid and lymphoid neoplasms withPDGFRArearrangement\" (WHO 2008)"
                  },
                  {
                    "text": "Note thatPDGFRAmutations (rather than rearrangements), which may be seen in diverse neoplasms, are not encompassed by WHO diagnosis"
                  }
                ],
                "PDGFRBRearrangement": [
                  {
                    "text": "Diagnostic feature of \"myeloid neoplasms withPDGFRBrearrangement\" (WHO 2008)Note thatPDGFRBrearrangements are now described in lymphoblastic leukemia/lymphoma (i.e., despite absence of \"lymphoid\" from WHO 2008 specific description)",
                    "sub_points": [
                      "Note thatPDGFRBrearrangements are now described in lymphoblastic leukemia/lymphoma (i.e., despite absence of \"lymphoid\" from WHO 2008 specific description)"
                    ]
                  }
                ],
                "FGFR1Rearrangement": [
                  {
                    "text": "Diagnostic feature of \"myeloid and lymphoid neoplasms withFGFR1abnormalities\" (WHO 2008)"
                  }
                ],
                "Therapeutic Implications": [
                  {
                    "text": "Neoplasms withPDGFRAandPDGFRBrearrangements are responsive to tyrosine kinase inhibitors (e.g., imatinib)"
                  },
                  {
                    "text": "Neoplasms withFGFR1rearrangements are resistant to 1st generation tyrosine kinase inhibitors, but may respond to newer agents (e.g., ponatinib)"
                  }
                ],
                "Clinical Presentation": [
                  {
                    "text": "EosinophiliaCharacteristically present in these neoplasms, but may not be seen in all cases",
                    "sub_points": [
                      "Characteristically present in these neoplasms, but may not be seen in all cases"
                    ]
                  },
                  {
                    "text": "Variable disease phenotypeIncludes presentation with features ofChronic eosinophilic leukemiaAcute myeloid leukemiaLymphoblastic leukemia/lymphomaChronic myelomonocytic leukemiaMixed phenotype acute leukemiaOther myeloid or immature lymphoid neoplasms",
                    "sub_points": [
                      "Includes presentation with features ofChronic eosinophilic leukemiaAcute myeloid leukemiaLymphoblastic leukemia/lymphomaChronic myelomonocytic leukemiaMixed phenotype acute leukemiaOther myeloid or immature lymphoid neoplasms",
                      "Chronic eosinophilic leukemia",
                      "Acute myeloid leukemia",
                      "Lymphoblastic leukemia/lymphoma",
                      "Chronic myelomonocytic leukemia",
                      "Mixed phenotype acute leukemia",
                      "Other myeloid or immature lymphoid neoplasms"
                    ]
                  },
                  {
                    "text": "Gene-defined entitiesRegardless of clinical presentation, presence ofPDGFRA,PDGFRB, orFGFR1rearrangement is key diagnostic finding",
                    "sub_points": [
                      "Regardless of clinical presentation, presence ofPDGFRA,PDGFRB, orFGFR1rearrangement is key diagnostic finding"
                    ]
                  }
                ]
              },
              "Testing for PDGFRA,PDGFRB, and FGFR1 Rearrangements": {
                "Karyotype vs. FISH/RT-PCR": [
                  {
                    "text": "Karyotype willnotdetect typicalPDGFRArearrangementFISH or RT-PCR is necessary for this purpose",
                    "sub_points": [
                      "FISH or RT-PCR is necessary for this purpose"
                    ]
                  },
                  {
                    "text": "Karyotype will detect typicalPDGFRBandFGFR1translocationsFISH is indicated to confirm these rearrangements",
                    "sub_points": [
                      "FISH is indicated to confirm these rearrangements"
                    ]
                  }
                ]
              },
              "Detection of PDGFRA Rearrangement": {
                "CommonFIP1L1-PDGFRAFusion": [
                  {
                    "text": "Fusion ofPDGFRAwithFIP1L1is characteristic type ofPDGFRArearrangementFIP1L1HGNC name: Factor interacting with PAPOLA and CPSF1HGNC ID: 19124",
                    "sub_points": [
                      "FIP1L1HGNC name: Factor interacting with PAPOLA and CPSF1HGNC ID: 19124",
                      "HGNC name: Factor interacting with PAPOLA and CPSF1",
                      "HGNC ID: 19124"
                    ]
                  },
                  {
                    "text": "This rearrangement occurs due to small interstitial deletion at 4q12Because of small size of deletion, this change isnotvisible on routine karyotypingThus, FISH or RT-PCR is necessary to identify rearrangementBoth are clinically available",
                    "sub_points": [
                      "Because of small size of deletion, this change isnotvisible on routine karyotyping",
                      "Thus, FISH or RT-PCR is necessary to identify rearrangementBoth are clinically available",
                      "Both are clinically available"
                    ]
                  },
                  {
                    "text": "1 popular FISH strategy uses 3 probes, 1 of which hybridizes at or nearCHIC2(in deleted region), with the others flankingPDGFRAandFIP1L1CHIC2HGNC name: Cysteine-rich hydrophobic domain 2HGNC ID: 1935",
                    "sub_points": [
                      "CHIC2HGNC name: Cysteine-rich hydrophobic domain 2HGNC ID: 1935",
                      "HGNC name: Cysteine-rich hydrophobic domain 2",
                      "HGNC ID: 1935"
                    ]
                  },
                  {
                    "text": "Probe pattern for negative case is tricolor fusion signal, indicating presence ofPDGFRA,CHIC2, andFIP1L1in same vicinity"
                  },
                  {
                    "text": "Probe pattern for positive case is fusion ofPDGFRA- andFIP1L1-specific signals only, without interveningCHIC2-specific signalIndicates deletion of region betweenPDGFRAandFIP1L1with loss ofCHIC2, resulting in fusion betweenPDGFRAandFIP1L1Though this test is sometimes referred to colloquially as \"CHIC2deletion,\"CHIC2is in fact an irrelevant bystander in formation of pathogenicFIP1L1-PDGFRAfusion",
                    "sub_points": [
                      "Indicates deletion of region betweenPDGFRAandFIP1L1with loss ofCHIC2, resulting in fusion betweenPDGFRAandFIP1L1Though this test is sometimes referred to colloquially as \"CHIC2deletion,\"CHIC2is in fact an irrelevant bystander in formation of pathogenicFIP1L1-PDGFRAfusion",
                      "Though this test is sometimes referred to colloquially as \"CHIC2deletion,\"CHIC2is in fact an irrelevant bystander in formation of pathogenicFIP1L1-PDGFRAfusion"
                    ]
                  }
                ],
                "Other RarePDGFRARearrangements": [
                  {
                    "text": "Rare translocations involvingPDGFRAhave also been described with other partner genesKIF5B(10p11.22)CDK5RAP2(9q33.3)STRN(2p22.2)ETV6(12p13)BCR(22q11.23)",
                    "sub_points": [
                      "KIF5B(10p11.22)",
                      "CDK5RAP2(9q33.3)",
                      "STRN(2p22.2)",
                      "ETV6(12p13)",
                      "BCR(22q11.23)"
                    ]
                  },
                  {
                    "text": "These reciprocal translocations are typically detected on routine karyotypingWould also generally give rise to abnormal variant FISH patterns with tricolorFIP1L1/CHIC2/PDGFRAprobe set",
                    "sub_points": [
                      "Would also generally give rise to abnormal variant FISH patterns with tricolorFIP1L1/CHIC2/PDGFRAprobe set"
                    ]
                  },
                  {
                    "text": "RT-PCR for specificFIP1L1-PDGFRAfusion would be negative in the case of these alternative partners"
                  }
                ]
              },
              "Detection of PDGFRB Rearrangement": {
                "CommonETV6-PDGFRBFusion": [
                  {
                    "text": "Fusion ofPDGFRBwithETV6(12p13) is the most common type ofPDGFRBrearrangement"
                  }
                ],
                "AlternativePDGFRBRearrangements": [
                  {
                    "text": "> 19 alternative reciprocal translocation partners are also seen"
                  }
                ],
                "Karyotyping forPDGFRBRearrangements": [
                  {
                    "text": "PDGFRBrearrangements are typically detected on routine karyotyping"
                  },
                  {
                    "text": "Of note, not all t(5;12)(q31~33;p13) translocations involvePDGFRB&/orETV6FISH is therefore recommended to confirm presence ofPDGFRBrearrangement in cases with 5q31~33 abnormality",
                    "sub_points": [
                      "FISH is therefore recommended to confirm presence ofPDGFRBrearrangement in cases with 5q31~33 abnormality"
                    ]
                  }
                ],
                "FISH forPDGFRBRearrangements": [
                  {
                    "text": "Breakapart probe strategy is commonly employedUseful for confirming presence ofPDGFRBrearrangement",
                    "sub_points": [
                      "Useful for confirming presence ofPDGFRBrearrangement"
                    ]
                  },
                  {
                    "text": "Very rare cases of karyotypically crypticPDGFRBrearrangements (detectable only by FISH) are also described"
                  }
                ]
              },
              "Detection of FGFR1 Rearrangement": {
                "Karyotyping forFGFR1Rearrangement": [
                  {
                    "text": "Most common translocation is withZMYM2(HGNC ID: 12989, previously known asZNF198) at 13q11-q12"
                  },
                  {
                    "text": "At least 13 other reciprocal translocation partner genes have also been described forFGFR1However, not all 8p11 translocations involveFGFR1In particular,KAT6A(HGNC: 13013, previously known asMYST3) at 8p11 is also rearranged in some myeloid neoplasmsThus, FISH may be indicated for confirmation",
                    "sub_points": [
                      "However, not all 8p11 translocations involveFGFR1In particular,KAT6A(HGNC: 13013, previously known asMYST3) at 8p11 is also rearranged in some myeloid neoplasmsThus, FISH may be indicated for confirmation",
                      "In particular,KAT6A(HGNC: 13013, previously known asMYST3) at 8p11 is also rearranged in some myeloid neoplasms",
                      "Thus, FISH may be indicated for confirmation"
                    ]
                  }
                ],
                "FISH forFGFR1Rearrangement": [
                  {
                    "text": "Breakapart probe strategy is commonly employed"
                  },
                  {
                    "text": "Useful for confirming presence ofFGFR1rearrangement in cases with 8p11 abnormality"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "PML-RARAFusion Gene": {
            "name": "PML-RARAFusion Gene",
            "url": "https://app.pathprimer.com/document/7c2e2150-ce15-4af3-9006-a126472d9705/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "PML::RARAfusion due to reciprocal translocation involving long arms of chromosomes 15 and 17, leading to acute promyelocytic leukemia (APL)t(15;17)(q24.1;q21.2)Alternative rearrangements ofRARAassociated with development of APL with alternativeRARAfusions",
                    "sub_points": [
                      "t(15;17)(q24.1;q21.2)",
                      "Alternative rearrangements ofRARAassociated with development of APL with alternativeRARAfusions"
                    ]
                  }
                ],
                "Normal Function ofRARA": [
                  {
                    "text": "Official name: Retinoic acid receptor alpha"
                  },
                  {
                    "text": "HGNC ID: 9864"
                  },
                  {
                    "text": "Chromosomal location: 17q21.2"
                  },
                  {
                    "text": "Gene family: Nuclear hormone receptors17 exons with 2 isoforms differing in N-terminal domain",
                    "sub_points": [
                      "17 exons with 2 isoforms differing in N-terminal domain"
                    ]
                  },
                  {
                    "text": "Nuclear retinoic acid receptor"
                  },
                  {
                    "text": "Regulates gene transcriptionBinds DNA and regulates genes involved in differentiation, apoptosis, and granulopoiesisExists as heterodimer",
                    "sub_points": [
                      "Binds DNA and regulates genes involved in differentiation, apoptosis, and granulopoiesis",
                      "Exists as heterodimer"
                    ]
                  },
                  {
                    "text": "Present in most tissue typesLocalizes to cell nucleus",
                    "sub_points": [
                      "Localizes to cell nucleus"
                    ]
                  }
                ],
                "Normal Function ofPML": [
                  {
                    "text": "Official name: PML nuclear body scaffold"
                  },
                  {
                    "text": "HGNC ID: 9113"
                  },
                  {
                    "text": "Chromosomal location: 15q24.1"
                  },
                  {
                    "text": "Gene family: Tripartite motif containing RING finger proteinsContains 10 exons; undergoes extensive alternative splicing3 domains mediate protein interactions and are included in all isoformsRING finger domain2 B-box zinc finger domainsCoiled-coil region",
                    "sub_points": [
                      "Contains 10 exons; undergoes extensive alternative splicing",
                      "3 domains mediate protein interactions and are included in all isoformsRING finger domain2 B-box zinc finger domainsCoiled-coil region",
                      "RING finger domain",
                      "2 B-box zinc finger domains",
                      "Coiled-coil region"
                    ]
                  },
                  {
                    "text": "Transcription factor"
                  },
                  {
                    "text": "Tumor suppressorRegulatesTP53Functions in cell deathRegulates apoptosis induced by FAS ligand and tumor necrosis factor α",
                    "sub_points": [
                      "RegulatesTP53",
                      "Functions in cell deathRegulates apoptosis induced by FAS ligand and tumor necrosis factor α",
                      "Regulates apoptosis induced by FAS ligand and tumor necrosis factor α"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "t(15;17)(q24.1;q21.2)": [
                  {
                    "text": "Reciprocal translocation following breakpoints atPMLandRARAloci"
                  },
                  {
                    "text": "Results in novel fusion gene on chromosome 15"
                  },
                  {
                    "text": "Hallmark of APL2nd marker demonstrating genetic basis of human cancer discovered",
                    "sub_points": [
                      "2nd marker demonstrating genetic basis of human cancer discovered"
                    ]
                  }
                ],
                "PML::RARAFusion": [
                  {
                    "text": "3 categories ofPML::RARAfusion transcripts detected"
                  },
                  {
                    "text": "Consistent breakpoints in intron 2 ofRARA"
                  },
                  {
                    "text": "Heterogeneous breakpoints inPMLlead to different transcript sizesLong formbcr-150-60% of APLBreakpoint inPMLintron 6Results inPMLexon 6 toRARAexon 3 fusionVariable formbcr-25% of APLBreakpoint inPMLexon 6Breakpoints occur at different points in exon, leading to variable lengthResults in partialPMLexon 6 andRARAexon 3 fusionShort formbcr-335-45% of APLBreakpoint inPMLintron 3Results inPMLexon 3 toRARAexon 3 fusionAlternative splicing of long and variable form transcripts gives further heterogeneity",
                    "sub_points": [
                      "Long formbcr-150-60% of APLBreakpoint inPMLintron 6Results inPMLexon 6 toRARAexon 3 fusion",
                      "bcr-1",
                      "50-60% of APL",
                      "Breakpoint inPMLintron 6",
                      "Results inPMLexon 6 toRARAexon 3 fusion",
                      "Variable formbcr-25% of APLBreakpoint inPMLexon 6Breakpoints occur at different points in exon, leading to variable lengthResults in partialPMLexon 6 andRARAexon 3 fusion",
                      "bcr-2",
                      "5% of APL",
                      "Breakpoint inPMLexon 6Breakpoints occur at different points in exon, leading to variable length",
                      "Breakpoints occur at different points in exon, leading to variable length",
                      "Results in partialPMLexon 6 andRARAexon 3 fusion",
                      "Short formbcr-335-45% of APLBreakpoint inPMLintron 3Results inPMLexon 3 toRARAexon 3 fusion",
                      "bcr-3",
                      "35-45% of APL",
                      "Breakpoint inPMLintron 3",
                      "Results inPMLexon 3 toRARAexon 3 fusion",
                      "Alternative splicing of long and variable form transcripts gives further heterogeneity"
                    ]
                  },
                  {
                    "text": "Fusion gene prevents normal DNA transcriptionBinds to nuclear corepressor (NCOR)-histone deacetylase complex and enhances histone deacetylase functionLeads to aberrant chromatin deacetylationPrevents gene transcriptionBlocks differentiation of myeloid cellsGives survival advantage to cellHas dominant negative function, suppressing normal retinoic acid receptor function",
                    "sub_points": [
                      "Binds to nuclear corepressor (NCOR)-histone deacetylase complex and enhances histone deacetylase functionLeads to aberrant chromatin deacetylationPrevents gene transcription",
                      "Leads to aberrant chromatin deacetylation",
                      "Prevents gene transcription",
                      "Blocks differentiation of myeloid cells",
                      "Gives survival advantage to cell",
                      "Has dominant negative function, suppressing normal retinoic acid receptor function"
                    ]
                  },
                  {
                    "text": "Critical in leukemogenesis but not sufficient to cause leukemia without other genetic alterationsFLT3,WT1,NRAS, andKRASare most commonly mutatedAdditional cytogenetic abnormalities, such as +8 and -7q",
                    "sub_points": [
                      "FLT3,WT1,NRAS, andKRASare most commonly mutated",
                      "Additional cytogenetic abnormalities, such as +8 and -7q"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Acute Promyelocytic Leukemia": [
                  {
                    "text": "Distinct subtype of acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "Defined by t(15;17)(q24.1;q21.2)/PML::RARAVariant translocations involvingRARAalso implicated",
                    "sub_points": [
                      "Variant translocations involvingRARAalso implicated"
                    ]
                  },
                  {
                    "text": "Increased blasts and abnormal promyelocytes"
                  },
                  {
                    "text": "Blockage of maturation at promyelocyte stage"
                  },
                  {
                    "text": "Associated with disseminated intravascular coagulation"
                  },
                  {
                    "text": "Treatment with all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and chemotherapy results in remission in majority of casesATRA and ATO induce fusion protein degradation",
                    "sub_points": [
                      "ATRA and ATO induce fusion protein degradation"
                    ]
                  }
                ]
              },
              "Common Methods of Detection": {
                "Quantitative Real-Time RT-PCR": [
                  {
                    "text": "General informationDetects RNA transcripts rather than DNAUseful for study of fusion gene transcriptsUseful for translocations, as RNA transcript is shorter than DNAUseful in APL, as introns predominate in breakpoint regionAccurately quantifiesPML::RARAtranscriptsSensitive assay for monitoring treatment response, measurable residual disease (MRD), early relapse detectionReliably determines type ofPML::RARAtranscriptsCan identify cases with cryptic translocationsRNA is isolated from blood or bone marrow",
                    "sub_points": [
                      "Detects RNA transcripts rather than DNAUseful for study of fusion gene transcriptsUseful for translocations, as RNA transcript is shorter than DNAUseful in APL, as introns predominate in breakpoint region",
                      "Useful for study of fusion gene transcripts",
                      "Useful for translocations, as RNA transcript is shorter than DNA",
                      "Useful in APL, as introns predominate in breakpoint region",
                      "Accurately quantifiesPML::RARAtranscriptsSensitive assay for monitoring treatment response, measurable residual disease (MRD), early relapse detection",
                      "Sensitive assay for monitoring treatment response, measurable residual disease (MRD), early relapse detection",
                      "Reliably determines type ofPML::RARAtranscriptsCan identify cases with cryptic translocations",
                      "Can identify cases with cryptic translocations",
                      "RNA is isolated from blood or bone marrow"
                    ]
                  },
                  {
                    "text": "Recommended method for monitoringReverse transcribed to produce cDNAcDNA synthesized by reverse transcriptase (RNA-dependent DNA polymerase)cDNA amplified with standard PCR using control primer set forABL1(internal control gene) and 3 different primer sets forPML::RARAbcr-1 forward primer anneals at 3' end of exon 6Amplifies bcr-1 and low percentage of bcr-2bcr-2 forward primer sits at beginning of exon 6Multiple bcr-2 variable primers existbcr-2 breakpoints result in different length transcriptsTranscripts can be large (~ 300 bp)No single standard curve is practically possible due to size variationIn cases with bcr-2, selection of most appropriate primer improves assay sensitivitybcr-3 forward primer anneals exon 3Common reverse primer is used for all transcripts",
                    "sub_points": [
                      "Reverse transcribed to produce cDNAcDNA synthesized by reverse transcriptase (RNA-dependent DNA polymerase)",
                      "cDNA synthesized by reverse transcriptase (RNA-dependent DNA polymerase)",
                      "cDNA amplified with standard PCR using control primer set forABL1(internal control gene) and 3 different primer sets forPML::RARA",
                      "bcr-1 forward primer anneals at 3' end of exon 6Amplifies bcr-1 and low percentage of bcr-2",
                      "Amplifies bcr-1 and low percentage of bcr-2",
                      "bcr-2 forward primer sits at beginning of exon 6Multiple bcr-2 variable primers existbcr-2 breakpoints result in different length transcriptsTranscripts can be large (~ 300 bp)No single standard curve is practically possible due to size variationIn cases with bcr-2, selection of most appropriate primer improves assay sensitivity",
                      "Multiple bcr-2 variable primers exist",
                      "bcr-2 breakpoints result in different length transcripts",
                      "Transcripts can be large (~ 300 bp)",
                      "No single standard curve is practically possible due to size variation",
                      "In cases with bcr-2, selection of most appropriate primer improves assay sensitivity",
                      "bcr-3 forward primer anneals exon 3",
                      "Common reverse primer is used for all transcripts"
                    ]
                  },
                  {
                    "text": "Real-time quantitationBased on detection of fluorescent signal during amplificationSignal increases as PCR product is formedMeasurement of signal occurs during amplificationFixed threshold is used to define backgroundCycle threshold (Ct) is point where reaction fluorescence exceeds thresholdSequence-specific probes commonly usedFusion transcript probe fluorescence compared to signal from control geneABL1commonly used as internal control gene",
                    "sub_points": [
                      "Based on detection of fluorescent signal during amplificationSignal increases as PCR product is formedMeasurement of signal occurs during amplification",
                      "Signal increases as PCR product is formed",
                      "Measurement of signal occurs during amplification",
                      "Fixed threshold is used to define backgroundCycle threshold (Ct) is point where reaction fluorescence exceeds threshold",
                      "Cycle threshold (Ct) is point where reaction fluorescence exceeds threshold",
                      "Sequence-specific probes commonly usedFusion transcript probe fluorescence compared to signal from control geneABL1commonly used as internal control gene",
                      "Fusion transcript probe fluorescence compared to signal from control gene",
                      "ABL1commonly used as internal control gene"
                    ]
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "RNA fusion sequencing can identify various translocations and specific breakpoints"
                  },
                  {
                    "text": "Can screen for additional genetic changesMajority of cases have ≥ 1 somatic mutations",
                    "sub_points": [
                      "Majority of cases have ≥ 1 somatic mutations"
                    ]
                  },
                  {
                    "text": "Limited utility for rapid diagnosis due to long turnaround times"
                  }
                ],
                "Karyotype": [
                  {
                    "text": "Can identify usual t(15;17) fusion as well as fusions with other partners or complex fusions"
                  },
                  {
                    "text": "Can identify additional cytogenetic abnormalities that may have prognostic impactAdditional abnormalities present in 40% of APL",
                    "sub_points": [
                      "Additional abnormalities present in 40% of APL"
                    ]
                  },
                  {
                    "text": "Not sensitive for MRD monitoring"
                  },
                  {
                    "text": "Unable to detect cryptic translocations, such as microinsertionsMicroinsertions missed by conventional karyotype",
                    "sub_points": [
                      "Microinsertions missed by conventional karyotype"
                    ]
                  },
                  {
                    "text": "Long turnaround times"
                  }
                ],
                "Fluorescence In Situ Hybridization": [
                  {
                    "text": "Use targeted probes to detect fusionBreak-apart probes can identify variable translocations",
                    "sub_points": [
                      "Break-apart probes can identify variable translocations"
                    ]
                  },
                  {
                    "text": "More sensitive than karyotype but insufficient for MRD monitoring"
                  },
                  {
                    "text": "More sensitive for microinsertionsSome small insertions still may be missedCryptic translocations account for 2-4% of APL",
                    "sub_points": [
                      "Some small insertions still may be missed",
                      "Cryptic translocations account for 2-4% of APL"
                    ]
                  },
                  {
                    "text": "Provides rapid genetic confirmation of APL"
                  }
                ]
              },
              "Disease Monitoring in Acute Promyelocytic Leukemia": {
                "Minimal Residual Disease and Treatment Response in Acute Promyelocytic Leukemia": [
                  {
                    "text": "Quantitative real-time PCR recommended at diagnosisIdentifies different types of transcriptsMay allow selection of more sensitive primers, e.g., if bcr-2 is involved",
                    "sub_points": [
                      "Identifies different types of transcriptsMay allow selection of more sensitive primers, e.g., if bcr-2 is involved",
                      "May allow selection of more sensitive primers, e.g., if bcr-2 is involved"
                    ]
                  },
                  {
                    "text": "Tested again at end of consolidation therapyMost clinical labs have sensitivity level of ~ 10⁻⁴Negative test constitutes major molecular responseTesting prior to end of consolidation less useful, as differentiated cells still carry translocation post treatmentPositive result requires confirmation to prove relapse2nd sample run in 2-4 weeksBone marrow testing more sensitive than blood",
                    "sub_points": [
                      "Most clinical labs have sensitivity level of ~ 10⁻⁴Negative test constitutes major molecular response",
                      "Negative test constitutes major molecular response",
                      "Testing prior to end of consolidation less useful, as differentiated cells still carry translocation post treatment",
                      "Positive result requires confirmation to prove relapse2nd sample run in 2-4 weeksBone marrow testing more sensitive than blood",
                      "2nd sample run in 2-4 weeks",
                      "Bone marrow testing more sensitive than blood"
                    ]
                  },
                  {
                    "text": "Monitor high-risk patients every 3 months for 2 yearsTesting in same laboratory recommended",
                    "sub_points": [
                      "Testing in same laboratory recommended"
                    ]
                  },
                  {
                    "text": "Testing at suspicion of relapse"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Reverse Transcription PCR for Other Myeloid Leukemia Transcripts": {
            "name": "Reverse Transcription PCR for Other Myeloid Leukemia Transcripts",
            "url": "https://app.pathprimer.com/document/3765e689-5d84-438b-8906-4ad51faf9967/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "RUNX1::RUNX1T1": {
                "Definition and Etiology/Pathogenesis": [
                  {
                    "text": "Previously known asAML1-ETO"
                  },
                  {
                    "text": "RUNX1is component of core-binding factor (CBF) (α-subunit)CBF transcription factor is essential component of normal hematopoiesis",
                    "sub_points": [
                      "CBF transcription factor is essential component of normal hematopoiesis"
                    ]
                  },
                  {
                    "text": "Pathologic fusion gene binds DNA as negative competitor with normalRUNX1productResults in transcriptional repression of normal target genesImpairs normal hematopoiesisIs not sufficient by itself to cause leukemia in mouse modelsNeed additional mutations to incite leukemia",
                    "sub_points": [
                      "Results in transcriptional repression of normal target genes",
                      "Impairs normal hematopoiesis",
                      "Is not sufficient by itself to cause leukemia in mouse modelsNeed additional mutations to incite leukemia",
                      "Need additional mutations to incite leukemia"
                    ]
                  },
                  {
                    "text": "Can dimerize with CBF β-subunit"
                  },
                  {
                    "text": "Altered transcriptional regulation of target genes downstream ofRUNX1"
                  },
                  {
                    "text": "Structure ofRUNX1::RUNX1T1fusion productRUNX1on chromosome 21 with 12 exonsBreakpoints are clustered in intron 5RUNX1T1on chromosome 8 with 20 exonsBreakpoints clustered in introns 1a and 1bCoding region ofRUNX1T1fused toRUNX1N-terminus containing DNA-binding domainFusion product is same regardless of breakpoint variations",
                    "sub_points": [
                      "RUNX1on chromosome 21 with 12 exonsBreakpoints are clustered in intron 5",
                      "Breakpoints are clustered in intron 5",
                      "RUNX1T1on chromosome 8 with 20 exonsBreakpoints clustered in introns 1a and 1b",
                      "Breakpoints clustered in introns 1a and 1b",
                      "Coding region ofRUNX1T1fused toRUNX1N-terminus containing DNA-binding domainFusion product is same regardless of breakpoint variations",
                      "Fusion product is same regardless of breakpoint variations"
                    ]
                  }
                ],
                "Acute Myeloid Leukemia With Recurrent Genetic Abnormality t(8;21)(q21.3;q22.12);RUNX1::RUNX1T1": [
                  {
                    "text": "Incidence5-12% of de novo adult acute myeloid leukemia (AML)More common in pediatric population (~ 10-13%)",
                    "sub_points": [
                      "5-12% of de novo adult acute myeloid leukemia (AML)",
                      "More common in pediatric population (~ 10-13%)"
                    ]
                  },
                  {
                    "text": "Other featuresComplex karyotype commonConcurrentKIT(20-40%) &/orFLT3ITD (up to 16%) mutations commonAssociated with maturation morphologyDoes not require ≥ 20% blasts if genetic abnormality is presentMay present with myeloid sarcoma",
                    "sub_points": [
                      "Complex karyotype common",
                      "ConcurrentKIT(20-40%) &/orFLT3ITD (up to 16%) mutations common",
                      "Associated with maturation morphology",
                      "Does not require ≥ 20% blasts if genetic abnormality is present",
                      "May present with myeloid sarcoma"
                    ]
                  },
                  {
                    "text": "PrognosisGood response to chemotherapyRelapse still seen in up to 35%, although up to 60% are salvageableKITorFLT3ITD mutation negatively affects prognosis",
                    "sub_points": [
                      "Good response to chemotherapyRelapse still seen in up to 35%, although up to 60% are salvageable",
                      "Relapse still seen in up to 35%, although up to 60% are salvageable",
                      "KITorFLT3ITD mutation negatively affects prognosis"
                    ]
                  }
                ],
                "Testing": [
                  {
                    "text": "Quantitative RT-PCR is available for this fusion gene transcriptConsistently detected in patients with t(8;21) AMLRUNX1breakpoint consistently in intron 5RUNX1T1breakpoints upstream of exon 2, clustered in introns 1a and 1bDespiteRUNX1T1breakpoint variation, all results in single type of fusion gene transcriptEspecially useful for minimal residual disease (MRD) monitoringSensitivity up to 1 copy in 100,000Copy number > 500 in bone marrow or > 100 in peripheral blood predictive of relapseUnlike inv(16), low-level MRD is still compatible with durable remissionNormalized ratio and copy number are generated using reference gene",
                    "sub_points": [
                      "Consistently detected in patients with t(8;21) AMLRUNX1breakpoint consistently in intron 5RUNX1T1breakpoints upstream of exon 2, clustered in introns 1a and 1bDespiteRUNX1T1breakpoint variation, all results in single type of fusion gene transcript",
                      "RUNX1breakpoint consistently in intron 5",
                      "RUNX1T1breakpoints upstream of exon 2, clustered in introns 1a and 1b",
                      "DespiteRUNX1T1breakpoint variation, all results in single type of fusion gene transcript",
                      "Especially useful for minimal residual disease (MRD) monitoringSensitivity up to 1 copy in 100,000Copy number > 500 in bone marrow or > 100 in peripheral blood predictive of relapseUnlike inv(16), low-level MRD is still compatible with durable remissionNormalized ratio and copy number are generated using reference gene",
                      "Sensitivity up to 1 copy in 100,000",
                      "Copy number > 500 in bone marrow or > 100 in peripheral blood predictive of relapse",
                      "Unlike inv(16), low-level MRD is still compatible with durable remission",
                      "Normalized ratio and copy number are generated using reference gene"
                    ]
                  },
                  {
                    "text": "Alternative methodsConventional karyotypingUsually detectableLower assay sensitivity; not good for minimal residual disease testingFISHUsually count 200 cells, so not good for MRD testingExcellent for rapid diagnosis",
                    "sub_points": [
                      "Conventional karyotypingUsually detectableLower assay sensitivity; not good for minimal residual disease testing",
                      "Usually detectable",
                      "Lower assay sensitivity; not good for minimal residual disease testing",
                      "FISHUsually count 200 cells, so not good for MRD testingExcellent for rapid diagnosis",
                      "Usually count 200 cells, so not good for MRD testing",
                      "Excellent for rapid diagnosis"
                    ]
                  }
                ]
              },
              "CBFB::MYH11": {
                "Definition and Etiology/Pathogenesis": [
                  {
                    "text": "MYH11codes for smooth muscle myosin heavy chain"
                  },
                  {
                    "text": "CBFBcodes for CBF-β, subunit of heterodimer transcription factorCBFB protein binds RUNX proteins (RUNX 1, 2, or 3) and stabilizes its interaction with DNACBFB protein may also prevent ubiquitin-mediated degradation of RUNX protein",
                    "sub_points": [
                      "CBFB protein binds RUNX proteins (RUNX 1, 2, or 3) and stabilizes its interaction with DNA",
                      "CBFB protein may also prevent ubiquitin-mediated degradation of RUNX protein"
                    ]
                  },
                  {
                    "text": "Fusion gene is formedSame chromosomal breakpoints for inv(16) and t(16;16)Several breakpoints are possible, leading to several subtypes of fusion geneFusion protein binds with greater affinity to RUNX1 proteinSuppresses normal function through multiple mechanisms, including sequestration and active repressionBlocks differentiation of myeloid leukemic cellsThis fusion is insufficient by itself to cause leukemogenesisAs withRUNX1::RUNX1T1, other mutations are required to incite leukemogenesis",
                    "sub_points": [
                      "Same chromosomal breakpoints for inv(16) and t(16;16)",
                      "Several breakpoints are possible, leading to several subtypes of fusion gene",
                      "Fusion protein binds with greater affinity to RUNX1 proteinSuppresses normal function through multiple mechanisms, including sequestration and active repressionBlocks differentiation of myeloid leukemic cells",
                      "Suppresses normal function through multiple mechanisms, including sequestration and active repression",
                      "Blocks differentiation of myeloid leukemic cells",
                      "This fusion is insufficient by itself to cause leukemogenesisAs withRUNX1::RUNX1T1, other mutations are required to incite leukemogenesis",
                      "As withRUNX1::RUNX1T1, other mutations are required to incite leukemogenesis"
                    ]
                  },
                  {
                    "text": "BothRUNX1::RUNX1T1andCBFB::MYH11are included in category known as CBF group of AML because they each include subunit of CBF in fusion gene product"
                  }
                ],
                "Acute Myeloid Leukemia With Recurring Genetic Abnormality inv(16)(p13.1q22) or t(16;16)(p13.1;q22)": [
                  {
                    "text": "Incidence5-9% of cases of AMLUsually younger patients",
                    "sub_points": [
                      "5-9% of cases of AML",
                      "Usually younger patients"
                    ]
                  },
                  {
                    "text": "Other featuresMajority have inv(16) rather than t(16;16)Monocytic and granulocytic differentiationAbnormal eosinophilsMyeloid sarcomas (extramedullary presentation) more frequent",
                    "sub_points": [
                      "Majority have inv(16) rather than t(16;16)",
                      "Monocytic and granulocytic differentiation",
                      "Abnormal eosinophils",
                      "Myeloid sarcomas (extramedullary presentation) more frequent"
                    ]
                  },
                  {
                    "text": "PrognosisGenerally favorableRelapse occurs in up to 35%, although up to 60% are salvageablePrognosis is same for inv(16) and for t(16;16)Worse prognosis with concurrentKITmutations",
                    "sub_points": [
                      "Generally favorableRelapse occurs in up to 35%, although up to 60% are salvageable",
                      "Relapse occurs in up to 35%, although up to 60% are salvageable",
                      "Prognosis is same for inv(16) and for t(16;16)",
                      "Worse prognosis with concurrentKITmutations"
                    ]
                  }
                ],
                "Testing": [
                  {
                    "text": "Quantitative RT-PCR is available for this fusion gene transcriptAt least 10 different fusion gene transcripts have been reported> 85% have type A transcript~ 5% each have types D and EMost assays just assess for types A, D, and EOther types are uncommonUseful in detection of minimal residual diseaseSensitivity up to 1 copy in 100,000Copy number > 50 in bone marrow or > 10 in peripheral blood is predictive of relapseRelapse at much lower MRD levels than t(8;21) AML",
                    "sub_points": [
                      "At least 10 different fusion gene transcripts have been reported> 85% have type A transcript~ 5% each have types D and EMost assays just assess for types A, D, and EOther types are uncommon",
                      "> 85% have type A transcript",
                      "~ 5% each have types D and E",
                      "Most assays just assess for types A, D, and E",
                      "Other types are uncommon",
                      "Useful in detection of minimal residual diseaseSensitivity up to 1 copy in 100,000Copy number > 50 in bone marrow or > 10 in peripheral blood is predictive of relapseRelapse at much lower MRD levels than t(8;21) AML",
                      "Sensitivity up to 1 copy in 100,000",
                      "Copy number > 50 in bone marrow or > 10 in peripheral blood is predictive of relapse",
                      "Relapse at much lower MRD levels than t(8;21) AML"
                    ]
                  },
                  {
                    "text": "Alternative methodsChromosomal karyotypingLower sensitivity; not good for MRD detectionOccasionally negative in cryptic casesSubtle rearrangement may be overlooked in suboptimal metaphase preparationsSecondary abnormalities are common, seen in ~ 40% of cases+22 is fairly specific to this type of AMLFISHGood method for detecting cryptic inversions or translocationsWill detect subtypes other than A, D, and EFairly rapid diagnosisNot good for minimal residual disease testing",
                    "sub_points": [
                      "Chromosomal karyotypingLower sensitivity; not good for MRD detectionOccasionally negative in cryptic casesSubtle rearrangement may be overlooked in suboptimal metaphase preparationsSecondary abnormalities are common, seen in ~ 40% of cases+22 is fairly specific to this type of AML",
                      "Lower sensitivity; not good for MRD detection",
                      "Occasionally negative in cryptic cases",
                      "Subtle rearrangement may be overlooked in suboptimal metaphase preparations",
                      "Secondary abnormalities are common, seen in ~ 40% of cases",
                      "+22 is fairly specific to this type of AML",
                      "FISHGood method for detecting cryptic inversions or translocationsWill detect subtypes other than A, D, and EFairly rapid diagnosisNot good for minimal residual disease testing",
                      "Good method for detecting cryptic inversions or translocations",
                      "Will detect subtypes other than A, D, and E",
                      "Fairly rapid diagnosis",
                      "Not good for minimal residual disease testing"
                    ]
                  }
                ]
              },
              "Others": {
                "Other Gene Fusion Transcripts": [
                  {
                    "text": "Have been detected by RT-PCR in research setting but are not commonly available as commercial testsEntities in AML with defining genetic abnormalitiesDEK::NUP214MECOMrearrangementsRBM15::MRTFAKMT2A::MLLT3OtherKMT2ArearrangementsNUP98rearrangementsRecognized fusion gene transcripts but not included in AML with defining genetic abnormalitiesKAT6A::CREBBPMYB::GATA1MNX1::ETV6",
                    "sub_points": [
                      "Entities in AML with defining genetic abnormalitiesDEK::NUP214MECOMrearrangementsRBM15::MRTFAKMT2A::MLLT3OtherKMT2ArearrangementsNUP98rearrangements",
                      "DEK::NUP214",
                      "MECOMrearrangements",
                      "RBM15::MRTFA",
                      "KMT2A::MLLT3",
                      "OtherKMT2Arearrangements",
                      "NUP98rearrangements",
                      "Recognized fusion gene transcripts but not included in AML with defining genetic abnormalitiesKAT6A::CREBBPMYB::GATA1MNX1::ETV6",
                      "KAT6A::CREBBP",
                      "MYB::GATA1",
                      "MNX1::ETV6"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "FLT3,NPM1, andCEBPAMutations": {
            "name": "FLT3,NPM1, andCEBPAMutations",
            "url": "https://app.pathprimer.com/document/338d8af0-1539-419d-81be-fbf8e58ae242/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "FLT3Official name: Fms-related tyrosine kinase 3Aliases:CD135,FLK2,STK1HGNC ID: 3765Chromosomal location: 13q12.2Preferred protein name: Receptor-type tyrosine-protein kinase FLT3Alternative protein names: FL cytokine receptor, fetal liver kinase-2, fms-like tyrosine kinase 3, stem cell tyrosine kinase 1, CD135",
                    "sub_points": [
                      "Official name: Fms-related tyrosine kinase 3Aliases:CD135,FLK2,STK1",
                      "Aliases:CD135,FLK2,STK1",
                      "HGNC ID: 3765",
                      "Chromosomal location: 13q12.2",
                      "Preferred protein name: Receptor-type tyrosine-protein kinase FLT3Alternative protein names: FL cytokine receptor, fetal liver kinase-2, fms-like tyrosine kinase 3, stem cell tyrosine kinase 1, CD135",
                      "Alternative protein names: FL cytokine receptor, fetal liver kinase-2, fms-like tyrosine kinase 3, stem cell tyrosine kinase 1, CD135"
                    ]
                  },
                  {
                    "text": "NPM1Official name: Nucleophosmin 1Aliases:B23,NPMHGNC ID: 7910Chromosomal location: 5q35.1Preferred protein name: NucleophosminAlternative protein names: Nucleolar phosphoprotein B23, nucleolar protein NO38, numatrin",
                    "sub_points": [
                      "Official name: Nucleophosmin 1Aliases:B23,NPM",
                      "Aliases:B23,NPM",
                      "HGNC ID: 7910",
                      "Chromosomal location: 5q35.1",
                      "Preferred protein name: NucleophosminAlternative protein names: Nucleolar phosphoprotein B23, nucleolar protein NO38, numatrin",
                      "Alternative protein names: Nucleolar phosphoprotein B23, nucleolar protein NO38, numatrin"
                    ]
                  },
                  {
                    "text": "CEBPAOfficial name: CCAAT enhancer binding protein alphaAliases:CEBP, C/EBP-αHGNC ID: 1833Chromosomal location: 19q13.11Preferred protein name: CCAAT/enhancer-binding protein alpha",
                    "sub_points": [
                      "Official name: CCAAT enhancer binding protein alphaAliases:CEBP, C/EBP-α",
                      "Aliases:CEBP, C/EBP-α",
                      "HGNC ID: 1833",
                      "Chromosomal location: 19q13.11",
                      "Preferred protein name: CCAAT/enhancer-binding protein alpha"
                    ]
                  }
                ]
              },
              "Gene Function": {
                "Fms-Related Tyrosine Kinase 3 (FLT3)": [
                  {
                    "text": "Type III receptor tyrosine kinase5 immunoglobulin-like domains in extracellular regionTransmembrane domainJuxtamembrane domainSplit tyrosine kinase domain with 2 variable-length insertions by hydrophobic enterokinase sequence",
                    "sub_points": [
                      "5 immunoglobulin-like domains in extracellular region",
                      "Transmembrane domain",
                      "Juxtamembrane domain",
                      "Split tyrosine kinase domain with 2 variable-length insertions by hydrophobic enterokinase sequence"
                    ]
                  },
                  {
                    "text": "Binds FLT3 ligand (FL)Constitutively expressed by bone marrow fibroblasts1 FL binds 2 receptors, bringing them into close proximityTransphosphorylation occurs and results in activation of receptor tyrosine kinaseFollowing binding, ligand is rapidly degraded",
                    "sub_points": [
                      "Constitutively expressed by bone marrow fibroblasts",
                      "1 FL binds 2 receptors, bringing them into close proximity",
                      "Transphosphorylation occurs and results in activation of receptor tyrosine kinase",
                      "Following binding, ligand is rapidly degraded"
                    ]
                  },
                  {
                    "text": "Phosphorylation and activation of downstream signaling cascadesPI3K-Akt pathwayBlocks apoptosisIncreases proliferationRas-MAP kinase pathwayIncreases transcription and proliferation",
                    "sub_points": [
                      "PI3K-Akt pathwayBlocks apoptosisIncreases proliferation",
                      "Blocks apoptosis",
                      "Increases proliferation",
                      "Ras-MAP kinase pathwayIncreases transcription and proliferation",
                      "Increases transcription and proliferation"
                    ]
                  },
                  {
                    "text": "Expressed by hematopoietic progenitor cells in bone marrow, thymus, and lymph nodesRegulates transcription, proliferation, differentiation, and apoptosisDecreases time in G1 phase of cell cycleImportant for B- and T-lymphocyte developmentWorks with IL-7 to induce proliferation of early B-cell progenitors and pro-B cellsSynergizes with IL-3 to accelerate B-cell developmentRegulator of dendritic cell development and activityGenerates both classic and plasmacytoid dendritic cellsRegulates dendritic cell-mediated NK-cell activationInduces monocyte differentiationDoes not play role in megakaryocyte development",
                    "sub_points": [
                      "Regulates transcription, proliferation, differentiation, and apoptosisDecreases time in G1 phase of cell cycle",
                      "Decreases time in G1 phase of cell cycle",
                      "Important for B- and T-lymphocyte developmentWorks with IL-7 to induce proliferation of early B-cell progenitors and pro-B cellsSynergizes with IL-3 to accelerate B-cell development",
                      "Works with IL-7 to induce proliferation of early B-cell progenitors and pro-B cells",
                      "Synergizes with IL-3 to accelerate B-cell development",
                      "Regulator of dendritic cell development and activityGenerates both classic and plasmacytoid dendritic cellsRegulates dendritic cell-mediated NK-cell activation",
                      "Generates both classic and plasmacytoid dendritic cells",
                      "Regulates dendritic cell-mediated NK-cell activation",
                      "Induces monocyte differentiation",
                      "Does not play role in megakaryocyte development"
                    ]
                  },
                  {
                    "text": "Activity regulated by cytokinesTNF-α downregulates activityTGF-β downregulates activity",
                    "sub_points": [
                      "TNF-α downregulates activity",
                      "TGF-β downregulates activity"
                    ]
                  }
                ],
                "Nucleophosmin (NPM1)": [
                  {
                    "text": "Nucleolar phosphoproteinN-terminal homooligomerization domainLeads to formation of NPM1 dimers and hexamersHeterodimerization domainForms dimers of NPM with other proteins, including nucleolin and ARFC-terminal nucleic acid binding domainAllows interaction with ribosomal processing RNA",
                    "sub_points": [
                      "N-terminal homooligomerization domainLeads to formation of NPM1 dimers and hexamers",
                      "Leads to formation of NPM1 dimers and hexamers",
                      "Heterodimerization domainForms dimers of NPM with other proteins, including nucleolin and ARF",
                      "Forms dimers of NPM with other proteins, including nucleolin and ARF",
                      "C-terminal nucleic acid binding domainAllows interaction with ribosomal processing RNA",
                      "Allows interaction with ribosomal processing RNA"
                    ]
                  },
                  {
                    "text": "Nucleus-cytoplasm shuttling proteinRegulates ribosomal protein assembly and transportControls centrosome duplicationRegulates tumor suppressor pathways, such as TP53 and ARFStabilizes TP53Prevents proteasomal degradation of TP53Regulates stability of nuclear proteinsInhibits caspase-activated DNasePrevents apoptosis",
                    "sub_points": [
                      "Regulates ribosomal protein assembly and transport",
                      "Controls centrosome duplication",
                      "Regulates tumor suppressor pathways, such as TP53 and ARFStabilizes TP53Prevents proteasomal degradation of TP53",
                      "Stabilizes TP53",
                      "Prevents proteasomal degradation of TP53",
                      "Regulates stability of nuclear proteins",
                      "Inhibits caspase-activated DNase",
                      "Prevents apoptosis"
                    ]
                  }
                ],
                "CCAAT/Enhancer-Binding Protein Alpha (CEBPA)": [
                  {
                    "text": "Basic region leucine zipper (bZIP) transcription regulatorForms homo- or heterodimers with other bZIP proteinsCan bind coactivators or corepressorsDimerized protein binds promoter region of numerous genes",
                    "sub_points": [
                      "Forms homo- or heterodimers with other bZIP proteinsCan bind coactivators or corepressors",
                      "Can bind coactivators or corepressors",
                      "Dimerized protein binds promoter region of numerous genes"
                    ]
                  },
                  {
                    "text": "2 possible start sitesMajor translational start site produces 42 kDa protein (p42)Internal downstream start site produces 30 kDa protein (p30)p30 lacks N-terminal transactivation domainHas altered transcriptional activityp30 can heterodimerize with p42, preventing normal transcriptional activating functionRatio of p42 to p30 is dependent on mTOR activityRarely, extended 46 kDa protein may be produced from upstream start site",
                    "sub_points": [
                      "Major translational start site produces 42 kDa protein (p42)",
                      "Internal downstream start site produces 30 kDa protein (p30)p30 lacks N-terminal transactivation domainHas altered transcriptional activityp30 can heterodimerize with p42, preventing normal transcriptional activating function",
                      "p30 lacks N-terminal transactivation domain",
                      "Has altered transcriptional activity",
                      "p30 can heterodimerize with p42, preventing normal transcriptional activating function",
                      "Ratio of p42 to p30 is dependent on mTOR activity",
                      "Rarely, extended 46 kDa protein may be produced from upstream start site"
                    ]
                  },
                  {
                    "text": "Expressed in hepatocytes, adipocytes, type II pneumocytes, and granulocytesInvolved in granulocyte differentiation and maturationInduces transcription of regulatory proteins required for lineage maturationCEBPA expression increases as cells matureCEBPA-deleted mice show markedly reduced neutrophils and monocytes with elevated platelets and lymphocytesDecreased CEBPA expression is associated with increased monocytesExpression downregulates cell cycle progression",
                    "sub_points": [
                      "Involved in granulocyte differentiation and maturationInduces transcription of regulatory proteins required for lineage maturationCEBPA expression increases as cells matureCEBPA-deleted mice show markedly reduced neutrophils and monocytes with elevated platelets and lymphocytesDecreased CEBPA expression is associated with increased monocytes",
                      "Induces transcription of regulatory proteins required for lineage maturation",
                      "CEBPA expression increases as cells mature",
                      "CEBPA-deleted mice show markedly reduced neutrophils and monocytes with elevated platelets and lymphocytes",
                      "Decreased CEBPA expression is associated with increased monocytes",
                      "Expression downregulates cell cycle progression"
                    ]
                  }
                ]
              },
              "Gene Mutations": {
                "FLT3Mutations": [
                  {
                    "text": "Most common type of mutation is 6-30 bp internal tandem duplication (ITD) insertionsITD sizes from 3 to > 400 bases have been describedMost common length is 20-60 bpInframe mutationsInvolve exons 14 and 15 in juxtamembrane domainOccasionally occur in tyrosine kinase domainInterfere with inhibitory function of juxtamembrane domainReceptor shows ligand-independent dimerizationResults in production of constitutively active tyrosine kinaseActivates downstream RAS, MAPK, and STAT5 signalingLeads to proliferation and cell survivalSTAT5 signaling is unique to mutated receptor",
                    "sub_points": [
                      "ITD sizes from 3 to > 400 bases have been describedMost common length is 20-60 bp",
                      "Most common length is 20-60 bp",
                      "Inframe mutations",
                      "Involve exons 14 and 15 in juxtamembrane domainOccasionally occur in tyrosine kinase domain",
                      "Occasionally occur in tyrosine kinase domain",
                      "Interfere with inhibitory function of juxtamembrane domainReceptor shows ligand-independent dimerizationResults in production of constitutively active tyrosine kinaseActivates downstream RAS, MAPK, and STAT5 signalingLeads to proliferation and cell survival",
                      "Receptor shows ligand-independent dimerization",
                      "Results in production of constitutively active tyrosine kinase",
                      "Activates downstream RAS, MAPK, and STAT5 signaling",
                      "Leads to proliferation and cell survival",
                      "STAT5 signaling is unique to mutated receptor"
                    ]
                  },
                  {
                    "text": "Point mutationsKinase domain activation loop (TKD) mutations in exon 20 are most commonResults in constitutive phosphorylation and activationPromotes signaling through different pathways than ITD-typeFLT3mutationsOncogenic potential and prognostic significance is not well establishedJuxtamembrane domain mutations have also been described",
                    "sub_points": [
                      "Kinase domain activation loop (TKD) mutations in exon 20 are most commonResults in constitutive phosphorylation and activationPromotes signaling through different pathways than ITD-typeFLT3mutationsOncogenic potential and prognostic significance is not well established",
                      "Results in constitutive phosphorylation and activation",
                      "Promotes signaling through different pathways than ITD-typeFLT3mutations",
                      "Oncogenic potential and prognostic significance is not well established",
                      "Juxtamembrane domain mutations have also been described"
                    ]
                  }
                ],
                "NPM1Mutation": [
                  {
                    "text": "Most common type of mutation is 4 bp insertion in exon 12Point mutations and deletions have also been describedMutation leads to frameshift, altering C-terminal region of protein",
                    "sub_points": [
                      "Point mutations and deletions have also been described",
                      "Mutation leads to frameshift, altering C-terminal region of protein"
                    ]
                  },
                  {
                    "text": "Mutations are heterozygous, occurring on only 1 alleleMay have dominant negative effectNormal NPM forms dimers with mutant form",
                    "sub_points": [
                      "May have dominant negative effect",
                      "Normal NPM forms dimers with mutant form"
                    ]
                  },
                  {
                    "text": "Mutations disrupt nucleolar localization signal or create export signalMutatedNPM1is found in cytoplasm rather than nucleus",
                    "sub_points": [
                      "MutatedNPM1is found in cytoplasm rather than nucleus"
                    ]
                  },
                  {
                    "text": "NPM1mutation alone not sufficient for leukemogenesis"
                  },
                  {
                    "text": "NPM1translocationsOccurs in several hematologic malignanciesNPM1::ALKin anaplastic large cell lymphomaNPM1::RARAin acute myeloid leukemia (AML) with variantRARAtranslocation",
                    "sub_points": [
                      "Occurs in several hematologic malignanciesNPM1::ALKin anaplastic large cell lymphomaNPM1::RARAin acute myeloid leukemia (AML) with variantRARAtranslocation",
                      "NPM1::ALKin anaplastic large cell lymphoma",
                      "NPM1::RARAin acute myeloid leukemia (AML) with variantRARAtranslocation"
                    ]
                  }
                ],
                "CEBPAMutation": [
                  {
                    "text": "N-terminus mutationNonsense or frameshift mutationMutation occurs between major translational start site and downstream start siteOnly transcription of shorter (p30) protein isoform can occurShorter protein has dominant negative effect due to heterodimer formationGermline mutations are commonly N-terminus mutationsN-terminus mutations do not meet criteria for AML with in-frame bZIPCEBPAmutations",
                    "sub_points": [
                      "Nonsense or frameshift mutation",
                      "Mutation occurs between major translational start site and downstream start siteOnly transcription of shorter (p30) protein isoform can occur",
                      "Only transcription of shorter (p30) protein isoform can occur",
                      "Shorter protein has dominant negative effect due to heterodimer formation",
                      "Germline mutations are commonly N-terminus mutations",
                      "N-terminus mutations do not meet criteria for AML with in-frame bZIPCEBPAmutations"
                    ]
                  },
                  {
                    "text": "C-terminus mutationIn-frame insertion or deletion or nonsense mutationLocated in basic leucine zipper domainReduces DNA binding and homo- and heterodimerizationNormal transcription promoter functions do not occurMutated protein still binds NF-κBInduces BCL2 and inhibits apoptosisC-terminus mutations are more commonly secondary, somatic mutations in patients with germline N-terminus mutationsAssociated with favorable prognosisDiagnostic of AML with in-frame bZIPCEBPAmutationsSubset of cases have biallelic mutations typically involving both regionsEach allele harbors different mutationNo wildtype protein is producedBiallelic mutations show distinct gene expression signatureDifferent mutations have synergistic effect in leukemogenesisNo difference in prognosis between biallelic mutations and in-frame bZIP mutation onlyGene expression may also be dysregulated by other genes or epigenetic modification",
                    "sub_points": [
                      "In-frame insertion or deletion or nonsense mutation",
                      "Located in basic leucine zipper domain",
                      "Reduces DNA binding and homo- and heterodimerizationNormal transcription promoter functions do not occur",
                      "Normal transcription promoter functions do not occur",
                      "Mutated protein still binds NF-κBInduces BCL2 and inhibits apoptosis",
                      "Induces BCL2 and inhibits apoptosis",
                      "C-terminus mutations are more commonly secondary, somatic mutations in patients with germline N-terminus mutations",
                      "Associated with favorable prognosis",
                      "Diagnostic of AML with in-frame bZIPCEBPAmutationsSubset of cases have biallelic mutations typically involving both regionsEach allele harbors different mutationNo wildtype protein is producedBiallelic mutations show distinct gene expression signatureDifferent mutations have synergistic effect in leukemogenesisNo difference in prognosis between biallelic mutations and in-frame bZIP mutation onlyGene expression may also be dysregulated by other genes or epigenetic modification",
                      "Subset of cases have biallelic mutations typically involving both regionsEach allele harbors different mutationNo wildtype protein is producedBiallelic mutations show distinct gene expression signatureDifferent mutations have synergistic effect in leukemogenesisNo difference in prognosis between biallelic mutations and in-frame bZIP mutation only",
                      "Each allele harbors different mutation",
                      "No wildtype protein is produced",
                      "Biallelic mutations show distinct gene expression signature",
                      "Different mutations have synergistic effect in leukemogenesis",
                      "No difference in prognosis between biallelic mutations and in-frame bZIP mutation only",
                      "Gene expression may also be dysregulated by other genes or epigenetic modification"
                    ]
                  },
                  {
                    "text": "Germline mutations occur in familial myeloid neoplasm susceptibility syndromesConstitutional N-terminal mutationC-terminal mutation occurs as \"2nd hit\" leading to leukemogenesisPatients with N-terminalCEBPAmutations should undergo further work-up to evaluate for germline mutation",
                    "sub_points": [
                      "Constitutional N-terminal mutationC-terminal mutation occurs as \"2nd hit\" leading to leukemogenesis",
                      "C-terminal mutation occurs as \"2nd hit\" leading to leukemogenesis",
                      "Patients with N-terminalCEBPAmutations should undergo further work-up to evaluate for germline mutation"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Acute Myeloid Leukemia": [
                  {
                    "text": "Most common acute leukemia in adultsOutcomes are poor5-year survival < 50% overall5-year survival < 20% in patients > 60 years of ageDiagnosis and risk stratification relies on identification of cytogenetic and molecular abnormalitiesAML with mutatedNPM1and AML with in-frame bZIPCEBPAmutations represent specific AML entities in ICC and WHO classificationsPrognosis may be further refined by identification ofFLT3mutationsAML with normal cytogenetics show variable prognosisPrognosis may be refined by identification ofFLT3,NPM1, andCEBPAmutations",
                    "sub_points": [
                      "Outcomes are poor5-year survival < 50% overall5-year survival < 20% in patients > 60 years of age",
                      "5-year survival < 50% overall",
                      "5-year survival < 20% in patients > 60 years of age",
                      "Diagnosis and risk stratification relies on identification of cytogenetic and molecular abnormalitiesAML with mutatedNPM1and AML with in-frame bZIPCEBPAmutations represent specific AML entities in ICC and WHO classificationsPrognosis may be further refined by identification ofFLT3mutationsAML with normal cytogenetics show variable prognosisPrognosis may be refined by identification ofFLT3,NPM1, andCEBPAmutations",
                      "AML with mutatedNPM1and AML with in-frame bZIPCEBPAmutations represent specific AML entities in ICC and WHO classificationsPrognosis may be further refined by identification ofFLT3mutations",
                      "Prognosis may be further refined by identification ofFLT3mutations",
                      "AML with normal cytogenetics show variable prognosisPrognosis may be refined by identification ofFLT3,NPM1, andCEBPAmutations",
                      "Prognosis may be refined by identification ofFLT3,NPM1, andCEBPAmutations"
                    ]
                  }
                ],
                "Clinical Significance ofFLT3Mutations": [
                  {
                    "text": "Most common mutation in hematologic malignancy"
                  },
                  {
                    "text": "FLT3mutations occur in 20-30% of AMLMore common in cases with normal karyotypeDetected in ~ 30-35% of AML cases with normal karyotypeRare in infant AMLMost common in older adultsAssociated with higher WBC counts at diagnosisFound in 5-10% of myelodysplastic syndrome cases5-10% of chronic myeloid leukemia cases, particularly in accelerated and blast phaseOften seen concurrently in cases withNPM1mutation",
                    "sub_points": [
                      "More common in cases with normal karyotypeDetected in ~ 30-35% of AML cases with normal karyotype",
                      "Detected in ~ 30-35% of AML cases with normal karyotype",
                      "Rare in infant AML",
                      "Most common in older adults",
                      "Associated with higher WBC counts at diagnosis",
                      "Found in 5-10% of myelodysplastic syndrome cases",
                      "5-10% of chronic myeloid leukemia cases, particularly in accelerated and blast phase",
                      "Often seen concurrently in cases withNPM1mutation"
                    ]
                  },
                  {
                    "text": "Considered high-risk abnormalityAssociated with increased relapseNo difference in treatment response rateShorter overall survivalLength of ITD does not correlate with prognostic impactITD in tyrosine kinase domain is associated with particularly poor outcomes",
                    "sub_points": [
                      "Associated with increased relapse",
                      "No difference in treatment response rate",
                      "Shorter overall survival",
                      "Length of ITD does not correlate with prognostic impact",
                      "ITD in tyrosine kinase domain is associated with particularly poor outcomes"
                    ]
                  },
                  {
                    "text": "High mutant:wildtype ratio (allelic ratio) is associated with worse outcomesPatients withFLT3ITD high allelic ratio may significantly benefit from allogeneic stem cell transplantation in 1st clinical remission",
                    "sub_points": [
                      "Patients withFLT3ITD high allelic ratio may significantly benefit from allogeneic stem cell transplantation in 1st clinical remission"
                    ]
                  },
                  {
                    "text": "Prognostic significance of point mutations in tyrosine kinase domain (TKD) is not well established"
                  },
                  {
                    "text": "Treatment implicationsFLT3 tyrosine kinase inhibitors offer targeted therapyBest studied inFLT3ITD mutations but also recommended with TKD mutationsAllogeneic hematopoietic stem cell transplant in 1st remission is recommended in cases with highFLT3ITD allelic ratio",
                    "sub_points": [
                      "FLT3 tyrosine kinase inhibitors offer targeted therapyBest studied inFLT3ITD mutations but also recommended with TKD mutations",
                      "Best studied inFLT3ITD mutations but also recommended with TKD mutations",
                      "Allogeneic hematopoietic stem cell transplant in 1st remission is recommended in cases with highFLT3ITD allelic ratio"
                    ]
                  }
                ],
                "Clinical Significance ofNPM1Mutation": [
                  {
                    "text": "AML with mutatedNPM1represents diagnostic entity in ICC and WHO classificationsCan be diagnosed with ≥ 10% blasts in ICC and WHOCases with < 10% blasts with mutation should be monitored very closely for progression",
                    "sub_points": [
                      "Can be diagnosed with ≥ 10% blasts in ICC and WHO",
                      "Cases with < 10% blasts with mutation should be monitored very closely for progression"
                    ]
                  },
                  {
                    "text": "Occurs in 25-35% of adult AML45-64% of cases with normal karyotype2-8% of pediatric AMLMore common in womenAssociated with higher WBC count and blast countAssociated with anemia and thrombocytopeniaAssociated with monocytic differentiation80-90% of acute monocytic leukemia haveNPM1mutationAssociated with dysplastic features in 25% of casesPresence does not impact prognosisAssociated with tissue involvementMay involve gums, lymph nodes, or skinAML withNPM1mutation also harborsFLT3-ITD mutation in 40% of casesNPM1mutation precedesFLT3mutationThese cases are more genetically stable in disease progressionOther common secondary mutations includeDNMT3A,IDH2,KRAS,NRASNPM1andCEBPAmutations are mutually exclusive",
                    "sub_points": [
                      "45-64% of cases with normal karyotype",
                      "2-8% of pediatric AML",
                      "More common in women",
                      "Associated with higher WBC count and blast count",
                      "Associated with anemia and thrombocytopenia",
                      "Associated with monocytic differentiation80-90% of acute monocytic leukemia haveNPM1mutation",
                      "80-90% of acute monocytic leukemia haveNPM1mutation",
                      "Associated with dysplastic features in 25% of casesPresence does not impact prognosis",
                      "Presence does not impact prognosis",
                      "Associated with tissue involvementMay involve gums, lymph nodes, or skin",
                      "May involve gums, lymph nodes, or skin",
                      "AML withNPM1mutation also harborsFLT3-ITD mutation in 40% of casesNPM1mutation precedesFLT3mutationThese cases are more genetically stable in disease progression",
                      "NPM1mutation precedesFLT3mutation",
                      "These cases are more genetically stable in disease progression",
                      "Other common secondary mutations includeDNMT3A,IDH2,KRAS,NRAS",
                      "NPM1andCEBPAmutations are mutually exclusive"
                    ]
                  },
                  {
                    "text": "Considered favorable risk abnormalityGood response to induction therapyCases with normal karyotype and absence ofFLT3-ITD have favorable prognosisAssociated with better overall and disease-free survival and lower cumulative incidence of relapseAlso associated with improved prognosis in cytogenetically abnormal casesPrognosis similar to core-binding factor leukemias in younger patientsCoexistingFLT3mutation overrides positive effects ofNPM1mutationThese cases have intermediate prognosis betweenNPM1-only mutated andFLT3-only mutated cases",
                    "sub_points": [
                      "Good response to induction therapy",
                      "Cases with normal karyotype and absence ofFLT3-ITD have favorable prognosisAssociated with better overall and disease-free survival and lower cumulative incidence of relapseAlso associated with improved prognosis in cytogenetically abnormal casesPrognosis similar to core-binding factor leukemias in younger patients",
                      "Associated with better overall and disease-free survival and lower cumulative incidence of relapseAlso associated with improved prognosis in cytogenetically abnormal cases",
                      "Also associated with improved prognosis in cytogenetically abnormal cases",
                      "Prognosis similar to core-binding factor leukemias in younger patients",
                      "CoexistingFLT3mutation overrides positive effects ofNPM1mutationThese cases have intermediate prognosis betweenNPM1-only mutated andFLT3-only mutated cases",
                      "These cases have intermediate prognosis betweenNPM1-only mutated andFLT3-only mutated cases"
                    ]
                  },
                  {
                    "text": "Cases withNPM1mutation often also have del 9q"
                  },
                  {
                    "text": "Treatment implicationsNPM1-mutated AML withoutFLT3mutations is not treated with allogeneic bone marrow transplant in 1st remissionOlder patients withNPM1mutations may receive attenuated chemotherapy regimens",
                    "sub_points": [
                      "NPM1-mutated AML withoutFLT3mutations is not treated with allogeneic bone marrow transplant in 1st remission",
                      "Older patients withNPM1mutations may receive attenuated chemotherapy regimens"
                    ]
                  },
                  {
                    "text": "NPM1mutations offer target for measurable residual disease testing"
                  }
                ],
                "Clinical Significance ofCEBPAMutation": [
                  {
                    "text": "AML with in-frame bZIPCEBPAmutation (ICC)/AML withCEBPAmutation (WHO) represents distinct diagnostic entity"
                  },
                  {
                    "text": "Requires mutation in C-terminal bZIP region5-11% of adult AML5% of pediatric AML10-18% of cases with normal karyotypeN-terminal mutations should be further worked up for possibility of germline mutation with predisposition to develop AMLAssociated with higher blast countsAssociated with higher hemoglobin levels and lower platelet levels than other AMLAML withCEBPAmutation can be diagnosed with ≥ 10% blasts in ICC classification≥ 20% required for WHORarely involves extramedullary tissuesAML withCEBPAmutation also harborsFLT3mutation in 22-33% of casesCEBPAandNPM1mutations usually mutually exclusive5-10% of N-terminal mutations are germline and associated with increased risk of early AMLMedian age at diagnosis: 24.5 years",
                    "sub_points": [
                      "5-11% of adult AML",
                      "5% of pediatric AML",
                      "10-18% of cases with normal karyotype",
                      "N-terminal mutations should be further worked up for possibility of germline mutation with predisposition to develop AML",
                      "Associated with higher blast counts",
                      "Associated with higher hemoglobin levels and lower platelet levels than other AML",
                      "AML withCEBPAmutation can be diagnosed with ≥ 10% blasts in ICC classification≥ 20% required for WHO",
                      "≥ 20% required for WHO",
                      "Rarely involves extramedullary tissues",
                      "AML withCEBPAmutation also harborsFLT3mutation in 22-33% of cases",
                      "CEBPAandNPM1mutations usually mutually exclusive",
                      "5-10% of N-terminal mutations are germline and associated with increased risk of early AMLMedian age at diagnosis: 24.5 years",
                      "Median age at diagnosis: 24.5 years"
                    ]
                  },
                  {
                    "text": "Treatment implicationsAML withCEBPAmutation is not treated with allogeneic bone marrow transplant in 1st remissionAssociated with greater chemosensitivity",
                    "sub_points": [
                      "AML withCEBPAmutation is not treated with allogeneic bone marrow transplant in 1st remission",
                      "Associated with greater chemosensitivity"
                    ]
                  },
                  {
                    "text": "Epigenetic silencing ofCEBPAis associated with worse outcome"
                  }
                ]
              },
              "Testing for FLT3, NPM1, and CEBPA Mutations": {
                "FLT3Mutation Testing": [
                  {
                    "text": "Exons 14 and 15 harboring ITD are amplified and PCR product is analyzedAmplification by labeled primer followed by fragment analysis by capillary electrophoresis for sizingBoth shorter wildtype peak and longer mutated peaks due to ITD are present in mutated casesDirect sequencing by Sanger sequencing can demonstrate presence of duplicated sequenceQuantitative RT-PCR using patient-specific primers encompassing ITD is sensitive and may be useful for minimal residual disease testingNext-generation sequencing can be used to identify ITDSoftware with high sensitivity for insertions is recommendedLonger ITDs may not be recognized by standard analysis pipelineMay give inaccurate mutant:wildtype allele ratiosDeep sequencing is highly sensitive and can be used for MRDReporting should includeFLT3ITD allelic ratio in all mutated cases for prognostication",
                    "sub_points": [
                      "Amplification by labeled primer followed by fragment analysis by capillary electrophoresis for sizingBoth shorter wildtype peak and longer mutated peaks due to ITD are present in mutated cases",
                      "Both shorter wildtype peak and longer mutated peaks due to ITD are present in mutated cases",
                      "Direct sequencing by Sanger sequencing can demonstrate presence of duplicated sequence",
                      "Quantitative RT-PCR using patient-specific primers encompassing ITD is sensitive and may be useful for minimal residual disease testing",
                      "Next-generation sequencing can be used to identify ITDSoftware with high sensitivity for insertions is recommendedLonger ITDs may not be recognized by standard analysis pipelineMay give inaccurate mutant:wildtype allele ratiosDeep sequencing is highly sensitive and can be used for MRD",
                      "Software with high sensitivity for insertions is recommendedLonger ITDs may not be recognized by standard analysis pipelineMay give inaccurate mutant:wildtype allele ratios",
                      "Longer ITDs may not be recognized by standard analysis pipeline",
                      "May give inaccurate mutant:wildtype allele ratios",
                      "Deep sequencing is highly sensitive and can be used for MRD",
                      "Reporting should includeFLT3ITD allelic ratio in all mutated cases for prognostication"
                    ]
                  },
                  {
                    "text": "TKD may be sequenced to identify point mutations in exon 20"
                  }
                ],
                "NPM1Mutation Testing": [
                  {
                    "text": "Region that harbors insertion mutation, including exon 12, is amplified and PCR product is analyzedAmplification by labeled primer followed by fragment analysis by capillary electrophoresis for sizing of amplified productsBoth shorter wildtype peak and longer mutated peak due to insertion are present in mutated casesDirect sequencing by Sanger sequencing can demonstrate presence of duplicated sequenceQuantitative RT-PCR using mixture of primers targeting different insertion types is sensitive and may be useful for minimal residual disease testingNext-generation sequencing can be used to identify insertionsRT-PCR is highly sensitive and can be used for disease monitoring and MRD detection",
                    "sub_points": [
                      "Amplification by labeled primer followed by fragment analysis by capillary electrophoresis for sizing of amplified productsBoth shorter wildtype peak and longer mutated peak due to insertion are present in mutated cases",
                      "Both shorter wildtype peak and longer mutated peak due to insertion are present in mutated cases",
                      "Direct sequencing by Sanger sequencing can demonstrate presence of duplicated sequence",
                      "Quantitative RT-PCR using mixture of primers targeting different insertion types is sensitive and may be useful for minimal residual disease testing",
                      "Next-generation sequencing can be used to identify insertionsRT-PCR is highly sensitive and can be used for disease monitoring and MRD detection",
                      "RT-PCR is highly sensitive and can be used for disease monitoring and MRD detection"
                    ]
                  },
                  {
                    "text": "Identification of cytoplasmic localization can serve as surrogate indicator of gene mutationImmunohistochemical, cytochemical, and immunofluorescent studies are availableThese tests may be difficult to interpret, and nucleic acid-based molecular testing is preferred",
                    "sub_points": [
                      "Immunohistochemical, cytochemical, and immunofluorescent studies are availableThese tests may be difficult to interpret, and nucleic acid-based molecular testing is preferred",
                      "These tests may be difficult to interpret, and nucleic acid-based molecular testing is preferred"
                    ]
                  }
                ],
                "CEBPAMutation Testing": [
                  {
                    "text": "Coding sequence is amplified, and product is analyzedDirect sequencing by Sanger sequencing can identify mutationsNext-generation sequencing can be used to identify mutationsCEBPAhas high GC content, which may lead to decreased sequencing and lower analytic sensitivity",
                    "sub_points": [
                      "Direct sequencing by Sanger sequencing can identify mutations",
                      "Next-generation sequencing can be used to identify mutationsCEBPAhas high GC content, which may lead to decreased sequencing and lower analytic sensitivity",
                      "CEBPAhas high GC content, which may lead to decreased sequencing and lower analytic sensitivity"
                    ]
                  }
                ]
              },
              "Predictive Testing Summary": {
                "Test Interpretation": [
                  {
                    "text": "Prognostic significance clearest in cytogenetically normal AML"
                  },
                  {
                    "text": "FLT3ITD and TKD mutations associated with unfavorable outcomeFLT3tyrosine kinase inhibitors are available",
                    "sub_points": [
                      "FLT3tyrosine kinase inhibitors are available"
                    ]
                  },
                  {
                    "text": "NPM1mutation associated with favorable outcome in absence ofFLT3-ITD mutationsAML with bothFLT3andNPM1mutations may have intermediate outcome",
                    "sub_points": [
                      "AML with bothFLT3andNPM1mutations may have intermediate outcome"
                    ]
                  },
                  {
                    "text": "In-frame bZIPCEBPAmutation associated with favorable outcome in AML"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "JAK2Mutations and Rearrangements": {
            "name": "JAK2Mutations and Rearrangements",
            "url": "https://app.pathprimer.com/document/6c0e67a5-a304-4e8d-9d8b-4ea1b91193f6/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: Janus kinase 2"
                  },
                  {
                    "text": "Official symbol:JAK2"
                  },
                  {
                    "text": "HGNC ID: 6192"
                  },
                  {
                    "text": "Genomic position: Ch9: 4,984,390-5,129,948 (GRCh38.p14)"
                  },
                  {
                    "text": "Chromosomal location: 9p24.1"
                  },
                  {
                    "text": "Number of exons: 28"
                  },
                  {
                    "text": "Alias: JTK10"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Normal Function ofJAK2": [
                  {
                    "text": "Encodes JAK2 tyrosine kinase protein involved in subset of cytokine receptor signaling pathwayPossess N-terminal FERM (band 4.1, ezrin, radixin, moesin-homology), SRC homology-2 (SH2)-like, pseudokinase (JH2), and C-terminal (JH1) domainsN-terminal domain is associated with binding to cytokine receptorsSH2 domain that binds STAT transcription factorsJH1 is activated via transphosphorylation of tandem tyrosines in activation loopJH2 has autoinhibitory activity and regulates activity of JH1Involved mainly in JAK-STAT signaling pathwayAlso interacts with RAS/MAPK, PI3K, and AKT downstream pathwaysJAK2is downstream target of pleiotropic cytokine IL6Dysregulation of IL6/JAK2/STAT3 signaling pathways produces increased cellular proliferationConstitutively associated with prolactin receptorRequired for response to γ-interferonLack of JAK2 expression in mice leads to embryonic lethality due to absence of definitive erythropoiesis",
                    "sub_points": [
                      "Possess N-terminal FERM (band 4.1, ezrin, radixin, moesin-homology), SRC homology-2 (SH2)-like, pseudokinase (JH2), and C-terminal (JH1) domainsN-terminal domain is associated with binding to cytokine receptorsSH2 domain that binds STAT transcription factorsJH1 is activated via transphosphorylation of tandem tyrosines in activation loopJH2 has autoinhibitory activity and regulates activity of JH1",
                      "N-terminal domain is associated with binding to cytokine receptors",
                      "SH2 domain that binds STAT transcription factors",
                      "JH1 is activated via transphosphorylation of tandem tyrosines in activation loop",
                      "JH2 has autoinhibitory activity and regulates activity of JH1",
                      "Involved mainly in JAK-STAT signaling pathwayAlso interacts with RAS/MAPK, PI3K, and AKT downstream pathways",
                      "Also interacts with RAS/MAPK, PI3K, and AKT downstream pathways",
                      "JAK2is downstream target of pleiotropic cytokine IL6Dysregulation of IL6/JAK2/STAT3 signaling pathways produces increased cellular proliferation",
                      "Dysregulation of IL6/JAK2/STAT3 signaling pathways produces increased cellular proliferation",
                      "Constitutively associated with prolactin receptor",
                      "Required for response to γ-interferon",
                      "Lack of JAK2 expression in mice leads to embryonic lethality due to absence of definitive erythropoiesis"
                    ]
                  }
                ],
                "Abnormal Function of AlteredJAK2": [
                  {
                    "text": "JAK2V617F mutationPoint mutation in exon 14 of pseudokinase domainSubstitution of G to T at 1849 position (c.1849G>T)1849G>T leads to substitution of valine for phenylalanine (V617F)p.V617F destabilizes fold of domain that leads to constitutive activation of JAK2Mutation involves myeloid lineages and is absent in lymphocytesConsequences ofJAK2V617F mutationGain-of-function somatic mutationConstitutive activation of STAT-mediated transcription in absence of EPO ligandAlso activates ERK/MAPK and PI3/AKT pathways in absence of alternative cytokine stimulationMost common mutationBCR::ABL1-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)",
                    "sub_points": [
                      "Point mutation in exon 14 of pseudokinase domainSubstitution of G to T at 1849 position (c.1849G>T)1849G>T leads to substitution of valine for phenylalanine (V617F)p.V617F destabilizes fold of domain that leads to constitutive activation of JAK2Mutation involves myeloid lineages and is absent in lymphocytes",
                      "Substitution of G to T at 1849 position (c.1849G>T)",
                      "1849G>T leads to substitution of valine for phenylalanine (V617F)",
                      "p.V617F destabilizes fold of domain that leads to constitutive activation of JAK2",
                      "Mutation involves myeloid lineages and is absent in lymphocytes",
                      "Consequences ofJAK2V617F mutationGain-of-function somatic mutationConstitutive activation of STAT-mediated transcription in absence of EPO ligandAlso activates ERK/MAPK and PI3/AKT pathways in absence of alternative cytokine stimulation",
                      "Gain-of-function somatic mutation",
                      "Constitutive activation of STAT-mediated transcription in absence of EPO ligand",
                      "Also activates ERK/MAPK and PI3/AKT pathways in absence of alternative cytokine stimulation",
                      "Most common mutationBCR::ABL1-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)"
                    ]
                  },
                  {
                    "text": "JAK2exon 12 mutationsMutations involve region adjacent to start of pseudokinase domain from codons 536 to 547Uncommon, except inJAK2V617F-negative PVPresent in ~ 3% of PV casesAbout 40 different mutations reportedMutations include deletions, duplications/insertions, and nonsynonymous base substitutionsCommon mutationsN542-E543delE543-D544delF537-K539delinsLR541-E543delinsKK539L, F537I, L545VJAK2exon 12 mutations appear to result specifically in erythrocytosis phenotypeCan also occur in patients with myelodysplastic/MPN withSF3B1mutation and thrombocytosisPatients withJAK2exon 12-mutated PV show significantly longer overall survival than patients withJAK2V617F-mutated PV",
                    "sub_points": [
                      "Mutations involve region adjacent to start of pseudokinase domain from codons 536 to 547Uncommon, except inJAK2V617F-negative PVPresent in ~ 3% of PV casesAbout 40 different mutations reportedMutations include deletions, duplications/insertions, and nonsynonymous base substitutions",
                      "Uncommon, except inJAK2V617F-negative PV",
                      "Present in ~ 3% of PV cases",
                      "About 40 different mutations reported",
                      "Mutations include deletions, duplications/insertions, and nonsynonymous base substitutions",
                      "Common mutationsN542-E543delE543-D544delF537-K539delinsLR541-E543delinsKK539L, F537I, L545V",
                      "N542-E543del",
                      "E543-D544del",
                      "F537-K539delinsL",
                      "R541-E543delinsK",
                      "K539L, F537I, L545V",
                      "JAK2exon 12 mutations appear to result specifically in erythrocytosis phenotype",
                      "Can also occur in patients with myelodysplastic/MPN withSF3B1mutation and thrombocytosis",
                      "Patients withJAK2exon 12-mutated PV show significantly longer overall survival than patients withJAK2V617F-mutated PV"
                    ]
                  },
                  {
                    "text": "JAK2rearrangementsPCM1::JAK2fusionResults from t(8;9)(p22;p24.1) translocationMost cases present with MPNSome cases show overlap MPN and myelodysplastic syndrome (MPN/MDS)Also occurs in subset ofBCR::ABL1-like (Ph-like) B-lymphoblastic leukemia (B-ALL)Rarely reported in T-lymphoblastic leukemiaETV6::JAK2fusionResults from t(9;12)(p24.1;p13.2) translocationPresent in subset ofBCR::ABL1-like B-ALLRarely reported in MDSBCR::JAK2fusionResults from t(9;22)(p24.1;q11.23) translocationPresent in subset ofBCR::ABL1-like B-ALLReported in MDS/MPNCrucial to distinguish from t(9;22)(q34;q11.2);BCR::ABL1Resistant to imatinibSSBP2::JAK2fusionResults from t(5;9)(q14.1;p24.1) translocationPresent in subset ofBCR::ABL1-like B-ALLSTRN3::JAK2fusionResults from t(9;14)(p24.1;q12) translocationPresent in subset ofBCR::ABL1-like, B-ALLPAX5::JAK2fusionResults from t(9;9)(p13.2;p24.1) translocationOccurs in subset ofBCR::ABL1-like B-ALLJAK2::PABPC1fusionReported in subset of ALK(-) anaplastic large cell lymphoma",
                    "sub_points": [
                      "PCM1::JAK2fusionResults from t(8;9)(p22;p24.1) translocationMost cases present with MPNSome cases show overlap MPN and myelodysplastic syndrome (MPN/MDS)Also occurs in subset ofBCR::ABL1-like (Ph-like) B-lymphoblastic leukemia (B-ALL)Rarely reported in T-lymphoblastic leukemia",
                      "Results from t(8;9)(p22;p24.1) translocation",
                      "Most cases present with MPN",
                      "Some cases show overlap MPN and myelodysplastic syndrome (MPN/MDS)",
                      "Also occurs in subset ofBCR::ABL1-like (Ph-like) B-lymphoblastic leukemia (B-ALL)",
                      "Rarely reported in T-lymphoblastic leukemia",
                      "ETV6::JAK2fusionResults from t(9;12)(p24.1;p13.2) translocationPresent in subset ofBCR::ABL1-like B-ALLRarely reported in MDS",
                      "Results from t(9;12)(p24.1;p13.2) translocation",
                      "Present in subset ofBCR::ABL1-like B-ALL",
                      "Rarely reported in MDS",
                      "BCR::JAK2fusionResults from t(9;22)(p24.1;q11.23) translocationPresent in subset ofBCR::ABL1-like B-ALLReported in MDS/MPNCrucial to distinguish from t(9;22)(q34;q11.2);BCR::ABL1Resistant to imatinib",
                      "Results from t(9;22)(p24.1;q11.23) translocation",
                      "Present in subset ofBCR::ABL1-like B-ALL",
                      "Reported in MDS/MPN",
                      "Crucial to distinguish from t(9;22)(q34;q11.2);BCR::ABL1",
                      "Resistant to imatinib",
                      "SSBP2::JAK2fusionResults from t(5;9)(q14.1;p24.1) translocationPresent in subset ofBCR::ABL1-like B-ALL",
                      "Results from t(5;9)(q14.1;p24.1) translocation",
                      "Present in subset ofBCR::ABL1-like B-ALL",
                      "STRN3::JAK2fusionResults from t(9;14)(p24.1;q12) translocationPresent in subset ofBCR::ABL1-like, B-ALL",
                      "Results from t(9;14)(p24.1;q12) translocation",
                      "Present in subset ofBCR::ABL1-like, B-ALL",
                      "PAX5::JAK2fusionResults from t(9;9)(p13.2;p24.1) translocationOccurs in subset ofBCR::ABL1-like B-ALL",
                      "Results from t(9;9)(p13.2;p24.1) translocation",
                      "Occurs in subset ofBCR::ABL1-like B-ALL",
                      "JAK2::PABPC1fusionReported in subset of ALK(-) anaplastic large cell lymphoma",
                      "Reported in subset of ALK(-) anaplastic large cell lymphoma"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Nonchronic Myeloid Leukemia Myeloproliferative Neoplasms": [
                  {
                    "text": "PVJAK2V617F in ~ 95% of casesJAK2exon 12 mutations in ~ 3% of cases",
                    "sub_points": [
                      "JAK2V617F in ~ 95% of cases",
                      "JAK2exon 12 mutations in ~ 3% of cases"
                    ]
                  },
                  {
                    "text": "ETJAK2V617F in ~ 50% of casesMostJAK2V617F-negative cases harbor eitherCALRorMPLmutationJAK2exon 12 mutations are typically absent in ET",
                    "sub_points": [
                      "JAK2V617F in ~ 50% of cases",
                      "MostJAK2V617F-negative cases harbor eitherCALRorMPLmutation",
                      "JAK2exon 12 mutations are typically absent in ET"
                    ]
                  },
                  {
                    "text": "PMFJAK2V617F in ~ 60% of casesMostJAK2V617F-negative PMF cases harborCALRorMPLmutationJAK2mutations typically mutually exclusive with mutations inCALRandMPLgenes",
                    "sub_points": [
                      "JAK2V617F in ~ 60% of cases",
                      "MostJAK2V617F-negative PMF cases harborCALRorMPLmutation",
                      "JAK2mutations typically mutually exclusive with mutations inCALRandMPLgenes"
                    ]
                  },
                  {
                    "text": "JAK2mutations not reported in healthy individuals"
                  },
                  {
                    "text": "JAK2mutations are driver mutations"
                  },
                  {
                    "text": "Additional recurrent somatic mutations in other genes that may modulate disease progression in MPNsTET2,ASXL1, DNMT3A,CBL,SH2B3, IDH1,IDH2,EZH2,TP53,SRSF2",
                    "sub_points": [
                      "TET2,ASXL1, DNMT3A,CBL,SH2B3, IDH1,IDH2,EZH2,TP53,SRSF2"
                    ]
                  }
                ],
                "Other Myeloid Neoplasms": [
                  {
                    "text": "MDS/MPN withSF3B1mutation and thrombocytosisJAK2V617F is detected in ~ 50% of casesJAK2exon 12 mutations can also occur",
                    "sub_points": [
                      "JAK2V617F is detected in ~ 50% of cases",
                      "JAK2exon 12 mutations can also occur"
                    ]
                  },
                  {
                    "text": "Chronic myelomonocytic leukemia (CMML)JAK2V617F reported in small subset of cases",
                    "sub_points": [
                      "JAK2V617F reported in small subset of cases"
                    ]
                  },
                  {
                    "text": "Acute myeloid leukemia (AML) and MDSSporadic reports ofJAK2V617F(+) MDS and AML cases",
                    "sub_points": [
                      "Sporadic reports ofJAK2V617F(+) MDS and AML cases"
                    ]
                  }
                ],
                "Neoplasms WithJAK2Fusion": [
                  {
                    "text": "Small numbers of cases with MPN, MPN/MDS, and subset of B-ALLJAK2fusion withPCM1,ETV6,BCR,SSBP2,PAX5, andSTRN3partner genesLeads to constitutive activation of JAK2-STAT signaling pathwaysPossible response to JAK2 inhibitors with some but not allJAK2gene fusions",
                    "sub_points": [
                      "JAK2fusion withPCM1,ETV6,BCR,SSBP2,PAX5, andSTRN3partner genes",
                      "Leads to constitutive activation of JAK2-STAT signaling pathways",
                      "Possible response to JAK2 inhibitors with some but not allJAK2gene fusions"
                    ]
                  },
                  {
                    "text": "B-ALL withPAX5::JAK2fusionDoes not result in constitutive activation of JAK2-STAT",
                    "sub_points": [
                      "Does not result in constitutive activation of JAK2-STAT"
                    ]
                  },
                  {
                    "text": "Classic Hodgkin lymphoma2 isolated case reports withSEC31A::JAK2fusionResulted from t(4;9)(q21.22;p24.1) translocation",
                    "sub_points": [
                      "2 isolated case reports withSEC31A::JAK2fusion",
                      "Resulted from t(4;9)(q21.22;p24.1) translocation"
                    ]
                  }
                ],
                "JAK2 Inhibitors": [
                  {
                    "text": "JAK2 inhibitor ruxolitinib approved by FDA in 2011Indicated in treatment of high-risk PMF, post-PV and post-ET myelofibrosisHas broad anticytokine effectSignificantly reduces constitutional symptomsReduces splenomegaly",
                    "sub_points": [
                      "Indicated in treatment of high-risk PMF, post-PV and post-ET myelofibrosis",
                      "Has broad anticytokine effect",
                      "Significantly reduces constitutional symptoms",
                      "Reduces splenomegaly"
                    ]
                  }
                ],
                "Suggested Testing Algorithm": [
                  {
                    "text": "JAK2V617F with reflex toJAK2exon 12 mutations in suspected cases of PV"
                  },
                  {
                    "text": "JAK2V617F with reflex toCALRandMPLmutations in suspected cases of ET and PMF"
                  }
                ],
                "Molecular Diagnostic Techniques": [
                  {
                    "text": "Sanger sequencingMethod used in original reports ofJAK2V617FSequencing of amplified genomic DNA or cDNA",
                    "sub_points": [
                      "Method used in original reports ofJAK2V617F",
                      "Sequencing of amplified genomic DNA or cDNA"
                    ]
                  },
                  {
                    "text": "PyrosequencingSequence based on synthesis in real time with no need to post PCR analysis procedureSemiquantitative",
                    "sub_points": [
                      "Sequence based on synthesis in real time with no need to post PCR analysis procedure",
                      "Semiquantitative"
                    ]
                  },
                  {
                    "text": "Allele-specific PCR (amplification refractory mutation system)DetectsJAK2V617F with 1-2% sensitivity",
                    "sub_points": [
                      "DetectsJAK2V617F with 1-2% sensitivity"
                    ]
                  },
                  {
                    "text": "Quantitative real-time PCRCan quantify mutated allele burdenMay need granulocyte enrichment for reliable quantification",
                    "sub_points": [
                      "Can quantify mutated allele burden",
                      "May need granulocyte enrichment for reliable quantification"
                    ]
                  },
                  {
                    "text": "DNA melting curve assayCost-effective method for screening ofJAK2exon 12Useful method to detect presence of point mutations and indels",
                    "sub_points": [
                      "Cost-effective method for screening ofJAK2exon 12",
                      "Useful method to detect presence of point mutations and indels"
                    ]
                  },
                  {
                    "text": "Next-generation sequencing (NGS)Powerful technique with ability to simultaneously detect additional mutations in targeted panel",
                    "sub_points": [
                      "Powerful technique with ability to simultaneously detect additional mutations in targeted panel"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "MPLMutations": {
            "name": "MPLMutations",
            "url": "https://app.pathprimer.com/document/8360b563-aad7-4bb1-b96d-634d6e937040/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: MPL protooncogene, thrombopoietin receptor"
                  },
                  {
                    "text": "Official symbol:MPL"
                  },
                  {
                    "text": "HGNC ID: 7217"
                  },
                  {
                    "text": "Gene locus: 1p34.2"
                  },
                  {
                    "text": "RefSeq: NG 007525.1"
                  },
                  {
                    "text": "Genomic positionCh1: 43,337,818-43,354,466 (GRCh38.p14)",
                    "sub_points": [
                      "Ch1: 43,337,818-43,354,466 (GRCh38.p14)"
                    ]
                  },
                  {
                    "text": "Number of exons: 12"
                  },
                  {
                    "text": "Aliases: MPLV, TPOR, C-MPL, CD110, THCYT2, THPOR"
                  }
                ]
              },
              "MPL FUNCTION": {
                "Encodes Thrombopoietin Receptor": [
                  {
                    "text": "Thrombopoietin receptor (TPO-R) may alternatively be called c-MplProtein is also designated as CD110Major protein isoform includes all exonsAlternative transcripts described, including potentially soluble form that lacks exons 9 and 10",
                    "sub_points": [
                      "Protein is also designated as CD110",
                      "Major protein isoform includes all exonsAlternative transcripts described, including potentially soluble form that lacks exons 9 and 10",
                      "Alternative transcripts described, including potentially soluble form that lacks exons 9 and 10"
                    ]
                  },
                  {
                    "text": "TPO binding induces TPO-R receptor dimerization, activating JAK-STAT signaling cascade"
                  },
                  {
                    "text": "Primary regulator of megakaryopoiesis and platelet productionIts ligand (TPO) produced primarily by liver with smaller amounts made in kidney and bone marrowReceptor present on platelets, megakaryocytes, and hematopoietic stem cellsBinding to platelet-based receptors removes TPO from circulation; receptor-ligand complex is internalized and degradedTPO and TPO-R primarily function to control platelet numbers rather than maturationBoth TPO and TPO-R knockout mice are viable but have 90% reduction in platelet countsPlatelets produced in absence of TPO and TPO-R are morphologically and functionally normal",
                    "sub_points": [
                      "Its ligand (TPO) produced primarily by liver with smaller amounts made in kidney and bone marrow",
                      "Receptor present on platelets, megakaryocytes, and hematopoietic stem cellsBinding to platelet-based receptors removes TPO from circulation; receptor-ligand complex is internalized and degraded",
                      "Binding to platelet-based receptors removes TPO from circulation; receptor-ligand complex is internalized and degraded",
                      "TPO and TPO-R primarily function to control platelet numbers rather than maturationBoth TPO and TPO-R knockout mice are viable but have 90% reduction in platelet countsPlatelets produced in absence of TPO and TPO-R are morphologically and functionally normal",
                      "Both TPO and TPO-R knockout mice are viable but have 90% reduction in platelet counts",
                      "Platelets produced in absence of TPO and TPO-R are morphologically and functionally normal"
                    ]
                  },
                  {
                    "text": "TPO-R also important in maintaining regenerative capacity of stem cellsc-Mpl knockout mice show markedly reduced numbers and repopulating capacity of CD34(+) hematopoietic stem cellsDeficiencies are not limited to megakaryocytic lineageCommon myeloid progenitor cell expresses TPO-R but not IL7RCommon lymphoid progenitor cell expresses IL7R but not TPO-R",
                    "sub_points": [
                      "c-Mpl knockout mice show markedly reduced numbers and repopulating capacity of CD34(+) hematopoietic stem cellsDeficiencies are not limited to megakaryocytic lineage",
                      "Deficiencies are not limited to megakaryocytic lineage",
                      "Common myeloid progenitor cell expresses TPO-R but not IL7R",
                      "Common lymphoid progenitor cell expresses IL7R but not TPO-R"
                    ]
                  }
                ],
                "Significant Somatic Variants": [
                  {
                    "text": "Somatically acquired cytokine-independent activating mutations mostly in exon 10These affect protein juxtamembrane domainMutation results in constitutive activation of JAK-STAT signaling pathwaySingle-base substitutions most commonly describedRare activating insertion/deletion mutations have also been describedAmino acid 515, tryptophan (W515), most commonly involved80-90% of significant variants occur at this codon in myeloproliferative neoplasms~ 70% have tryptophan replaced by leucine:MPL, c.1544G>T, p.W515L~ 10% have tryptophan replaced by lysine:MPL, c.1543-1544delinsAA, p.W515KOther uncommon amino acid replacements at codon 515 have been described in myeloproliferative neoplasmsp.W515R (accounts for ~ 7% of codon 515 mutations)p.W515S (accounts for ~ 3% of codon 515 mutations)p.W515A (accounts for ~ 3% of codon 515 mutations)MPLp.S505N may be found as sporadic mutation in rare myeloproliferative neoplasm casesMany 2nd-site mutations can enhance constitutive signaling by canonical exon 10 mutation",
                    "sub_points": [
                      "These affect protein juxtamembrane domain",
                      "Mutation results in constitutive activation of JAK-STAT signaling pathwaySingle-base substitutions most commonly describedRare activating insertion/deletion mutations have also been described",
                      "Single-base substitutions most commonly described",
                      "Rare activating insertion/deletion mutations have also been described",
                      "Amino acid 515, tryptophan (W515), most commonly involved80-90% of significant variants occur at this codon in myeloproliferative neoplasms~ 70% have tryptophan replaced by leucine:MPL, c.1544G>T, p.W515L~ 10% have tryptophan replaced by lysine:MPL, c.1543-1544delinsAA, p.W515K",
                      "80-90% of significant variants occur at this codon in myeloproliferative neoplasms",
                      "~ 70% have tryptophan replaced by leucine:MPL, c.1544G>T, p.W515L",
                      "~ 10% have tryptophan replaced by lysine:MPL, c.1543-1544delinsAA, p.W515K",
                      "Other uncommon amino acid replacements at codon 515 have been described in myeloproliferative neoplasmsp.W515R (accounts for ~ 7% of codon 515 mutations)p.W515S (accounts for ~ 3% of codon 515 mutations)p.W515A (accounts for ~ 3% of codon 515 mutations)",
                      "p.W515R (accounts for ~ 7% of codon 515 mutations)",
                      "p.W515S (accounts for ~ 3% of codon 515 mutations)",
                      "p.W515A (accounts for ~ 3% of codon 515 mutations)",
                      "MPLp.S505N may be found as sporadic mutation in rare myeloproliferative neoplasm casesMany 2nd-site mutations can enhance constitutive signaling by canonical exon 10 mutation",
                      "Many 2nd-site mutations can enhance constitutive signaling by canonical exon 10 mutation"
                    ]
                  },
                  {
                    "text": "ActivatingMPLmutations outside of exon 10 have also been describedMay be found in ~ 10% of so-called \"triple-negative\" essential thrombocythemia and primary myelofibrosis casesMutations may be present in exons 3-6 and 12Triple-negative cases are negative forJAK2p.V617F,CALRexon 9, andMPLexon 10 mutations",
                    "sub_points": [
                      "May be found in ~ 10% of so-called \"triple-negative\" essential thrombocythemia and primary myelofibrosis casesMutations may be present in exons 3-6 and 12Triple-negative cases are negative forJAK2p.V617F,CALRexon 9, andMPLexon 10 mutations",
                      "Mutations may be present in exons 3-6 and 12",
                      "Triple-negative cases are negative forJAK2p.V617F,CALRexon 9, andMPLexon 10 mutations"
                    ]
                  }
                ],
                "Significant Germline Variants": [
                  {
                    "text": "FamilialMPLp.S505N mutation has been associated with inherited thrombocythemiaAutosomal dominant diseaseAssociated with high thrombotic riskSplenomegaly and progression to marrow fibrosis are common",
                    "sub_points": [
                      "Autosomal dominant disease",
                      "Associated with high thrombotic risk",
                      "Splenomegaly and progression to marrow fibrosis are common"
                    ]
                  },
                  {
                    "text": "MPLc.1238G>T, p.K39NKnown informally asMPLBaltimoreFound in ~ 7% in Black AmericansAssociated with higher platelet counts than wildtype controls",
                    "sub_points": [
                      "Known informally asMPLBaltimore",
                      "Found in ~ 7% in Black Americans",
                      "Associated with higher platelet counts than wildtype controls"
                    ]
                  },
                  {
                    "text": "MPLloss-of-function mutations found in congenital amegakaryocytic thrombocytopenia (CAMT)Autosomal recessive diseaseUnlike activating mutations, variety of CAMT-associated mutations may be located throughout geneTransfusion-dependent thrombocytopeniaAbsent or near-absent megakaryocytesFrequent progression to multilineage bone marrow failureOther organ dysfunction due to hemorrhagic events",
                    "sub_points": [
                      "Autosomal recessive disease",
                      "Unlike activating mutations, variety of CAMT-associated mutations may be located throughout gene",
                      "Transfusion-dependent thrombocytopenia",
                      "Absent or near-absent megakaryocytes",
                      "Frequent progression to multilineage bone marrow failure",
                      "Other organ dysfunction due to hemorrhagic events"
                    ]
                  }
                ],
                "Methods of Detection": [
                  {
                    "text": "Variety of sequencing modalities may be usedSanger sequencing, pyrosequencing, and next-generation sequencing (NGS) are all commonly used methodsPresent assays are mostly targeted to exon 10Evaluation of other exons may become more common with gene panel-based NGS testing",
                    "sub_points": [
                      "Sanger sequencing, pyrosequencing, and next-generation sequencing (NGS) are all commonly used methods",
                      "Present assays are mostly targeted to exon 10",
                      "Evaluation of other exons may become more common with gene panel-based NGS testing"
                    ]
                  },
                  {
                    "text": "Bone marrow or peripheral blood are suitable for evaluationBone marrow specimens may have higher detection sensitivity",
                    "sub_points": [
                      "Bone marrow specimens may have higher detection sensitivity"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Diagnosis inBCR::ABL1-Negative Myeloproliferative Neoplasms": [
                  {
                    "text": "Presence of activatingMPLmutation is major diagnostic criteria for diagnosis of essential thrombocythemia (ET) and primary myelofibrosis (PMF)MPLmutation is present in 1-3% of ETET cases are more likely to show eitherJAK2V617F mutation (50-55%) orCALRmutation (23-32%)MPLmutation is present in 5-10% of primary myelofibrosis (PMF)PMF cases are more likely to show eitherJAK2V617F mutation (55-60%) orCALRmutation (25-35%)~ 10% of triple-negative ET and PMF cases will carry activating mutations inMPLoutside of exon 10Generally, triple-negative cases of PMF show decreased survival and greater propensity to blast transformationTriple-negative patients with non-exon-10 mutatedMPLmay have better clinical course",
                    "sub_points": [
                      "MPLmutation is present in 1-3% of ETET cases are more likely to show eitherJAK2V617F mutation (50-55%) orCALRmutation (23-32%)",
                      "ET cases are more likely to show eitherJAK2V617F mutation (50-55%) orCALRmutation (23-32%)",
                      "MPLmutation is present in 5-10% of primary myelofibrosis (PMF)PMF cases are more likely to show eitherJAK2V617F mutation (55-60%) orCALRmutation (25-35%)",
                      "PMF cases are more likely to show eitherJAK2V617F mutation (55-60%) orCALRmutation (25-35%)",
                      "~ 10% of triple-negative ET and PMF cases will carry activating mutations inMPLoutside of exon 10Generally, triple-negative cases of PMF show decreased survival and greater propensity to blast transformationTriple-negative patients with non-exon-10 mutatedMPLmay have better clinical course",
                      "Generally, triple-negative cases of PMF show decreased survival and greater propensity to blast transformation",
                      "Triple-negative patients with non-exon-10 mutatedMPLmay have better clinical course"
                    ]
                  },
                  {
                    "text": "MPLmutations are not seen in polycythemia vera (PV)Identification ofMPLmutation generally excludes diagnosis of PV",
                    "sub_points": [
                      "Identification ofMPLmutation generally excludes diagnosis of PV"
                    ]
                  },
                  {
                    "text": "MPLmutations are not specifically diagnostic for ET or PMF, and morphologic evaluation is important in resolving diagnosisET typically showsIncreased platelets > 450 x 10⁹/LNormocellular to modestly hypercellular bone marrowAtypical megakaryocytes with \"staghorn\" hypersegmented nucleiPMF typically showsHypercellular bone marrowGranulocytic and megakaryocytic proliferationTightly clustered, bizarre megakaryocytes with increased nuclear:cytoplasmic ratioReticulin fibrosis (in fibrotic stage of disease)",
                    "sub_points": [
                      "ET typically showsIncreased platelets > 450 x 10⁹/LNormocellular to modestly hypercellular bone marrowAtypical megakaryocytes with \"staghorn\" hypersegmented nuclei",
                      "Increased platelets > 450 x 10⁹/L",
                      "Normocellular to modestly hypercellular bone marrow",
                      "Atypical megakaryocytes with \"staghorn\" hypersegmented nuclei",
                      "PMF typically showsHypercellular bone marrowGranulocytic and megakaryocytic proliferationTightly clustered, bizarre megakaryocytes with increased nuclear:cytoplasmic ratioReticulin fibrosis (in fibrotic stage of disease)",
                      "Hypercellular bone marrow",
                      "Granulocytic and megakaryocytic proliferation",
                      "Tightly clustered, bizarre megakaryocytes with increased nuclear:cytoplasmic ratio",
                      "Reticulin fibrosis (in fibrotic stage of disease)"
                    ]
                  },
                  {
                    "text": "Somatically acquired activating mutations inMPL,CALR, andJAK2p.V617F are typically mutually exclusive in myeloproliferative neoplasms"
                  }
                ],
                "Molecular Approach toMPLAnalysis": [
                  {
                    "text": "BCR::ABL1fusion must be ruled out to exclude chronic myeloid leukemia (CML)CML may present with striking thrombocytosis",
                    "sub_points": [
                      "CML may present with striking thrombocytosis"
                    ]
                  },
                  {
                    "text": "Suspected polycythemia vera should be tested forJAK2p.V617F and other non-V617F mutations (e.g., exon 12 mutations)"
                  },
                  {
                    "text": "If diagnosis of ET or PMF is favored, recommend evaluating forJAK2p.V617F,CALRexon 9, andMPLexon 10 mutationsThese mutations are typically mutually exclusive, thus stepwise reflexive testing may be usedBased on frequency, best order isJAK2p.V617F >CALR>MPLSingle NGS multitarget panel analysis is also common workflow",
                    "sub_points": [
                      "These mutations are typically mutually exclusive, thus stepwise reflexive testing may be usedBased on frequency, best order isJAK2p.V617F >CALR>MPL",
                      "Based on frequency, best order isJAK2p.V617F >CALR>MPL",
                      "Single NGS multitarget panel analysis is also common workflow"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Calreticulin (CALR) Mutations": {
            "name": "Calreticulin (CALR) Mutations",
            "url": "https://app.pathprimer.com/document/b19f01d2-3ad0-4826-aca8-3f60988a4796/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: Calreticulin"
                  },
                  {
                    "text": "Official symbol:CALR"
                  },
                  {
                    "text": "HGNC ID: 1455"
                  },
                  {
                    "text": "Gene locus: 19p13.13"
                  },
                  {
                    "text": "RefSeq: NG_029662.1"
                  },
                  {
                    "text": "Genomic positionCh19: 12,938,609-12,944,489 (GRCh38.p14)",
                    "sub_points": [
                      "Ch19: 12,938,609-12,944,489 (GRCh38.p14)"
                    ]
                  },
                  {
                    "text": "Number of exons: 9"
                  }
                ]
              },
              "CALR Function": {
                "Encodes Calreticulin Protein": [
                  {
                    "text": "Multifunctional proteinHighly conserved protein folding chaperoneCalcium-binding; helps regulate intracellular free calcium homeostasisRegulation of steroid-mediated gene transcription",
                    "sub_points": [
                      "Highly conserved protein folding chaperone",
                      "Calcium-binding; helps regulate intracellular free calcium homeostasis",
                      "Regulation of steroid-mediated gene transcription"
                    ]
                  },
                  {
                    "text": "Localizes primarily in endoplasmic reticulum (ER) but also found in cytoplasm and nucleus"
                  }
                ],
                "HomozygousCALRKnockout Mouse": [
                  {
                    "text": "Embryonically lethal at day 18 or earlier"
                  },
                  {
                    "text": "Embryos show marked decrease in ventricular wall thickness and develop omphaloceleCalreticulin is essential for early stages of cardiogenesis",
                    "sub_points": [
                      "Calreticulin is essential for early stages of cardiogenesis"
                    ]
                  }
                ]
              },
              "CALR Mutations": {
                "Somatically Acquired Driver Mutation": [
                  {
                    "text": "Associated with myeloproliferative neoplasms (MPNs)Detected in ~ 30% of both essential thrombocythemia (ET) and primary myelofibrosis (PMF)CALR,JAK2, andMPLmutations generally considered mutually exclusive eventsCo-mutation events uncommon but reportedCALRmutations are usually absent in polycythemia vera",
                    "sub_points": [
                      "Detected in ~ 30% of both essential thrombocythemia (ET) and primary myelofibrosis (PMF)",
                      "CALR,JAK2, andMPLmutations generally considered mutually exclusive eventsCo-mutation events uncommon but reported",
                      "Co-mutation events uncommon but reported",
                      "CALRmutations are usually absent in polycythemia vera"
                    ]
                  },
                  {
                    "text": "CALRmutations in familial cases of ET and PMF are also somatically acquired mutationsMutations are detected in patient-derived, flow-sorted, highly enriched hematopoietic stem cells, common myeloid progenitors, granulocyte-macrophage progenitors, and megakaryocyte-erythroid progenitorsIndicating that mutations occur in multipotent progenitor capable of generating both myeloid and erythroid progenyCALRmutations are not detected in T lymphocytes",
                    "sub_points": [
                      "Mutations are detected in patient-derived, flow-sorted, highly enriched hematopoietic stem cells, common myeloid progenitors, granulocyte-macrophage progenitors, and megakaryocyte-erythroid progenitorsIndicating that mutations occur in multipotent progenitor capable of generating both myeloid and erythroid progenyCALRmutations are not detected in T lymphocytes",
                      "Indicating that mutations occur in multipotent progenitor capable of generating both myeloid and erythroid progenyCALRmutations are not detected in T lymphocytes",
                      "CALRmutations are not detected in T lymphocytes"
                    ]
                  }
                ],
                "Common Somatic Mutations": [
                  {
                    "text": "Clinically relevant mutations limited to exon 9> 50 different mutations reportedAll are insertion/deletions causing -1/+2 bp shift to novel reading frame",
                    "sub_points": [
                      "> 50 different mutations reported",
                      "All are insertion/deletions causing -1/+2 bp shift to novel reading frame"
                    ]
                  },
                  {
                    "text": "2 most common variant typesType 1 mutation52-bp deletion (c.1092_1143del, p.L367fs*46) found in ~ 53% of casesIncurs loss of Ca2+ binding sites, compared to type 2 mutantsDepleted ER Ca2+ activates IRE1α/XBP1 pathway of unfolded protein responseType 2 mutation5-bp insertion (c.1154_1155insTTGTC, p.K385fs*47)",
                    "sub_points": [
                      "Type 1 mutation52-bp deletion (c.1092_1143del, p.L367fs*46) found in ~ 53% of casesIncurs loss of Ca2+ binding sites, compared to type 2 mutantsDepleted ER Ca2+ activates IRE1α/XBP1 pathway of unfolded protein response",
                      "52-bp deletion (c.1092_1143del, p.L367fs*46) found in ~ 53% of cases",
                      "Incurs loss of Ca2+ binding sites, compared to type 2 mutantsDepleted ER Ca2+ activates IRE1α/XBP1 pathway of unfolded protein response",
                      "Depleted ER Ca2+ activates IRE1α/XBP1 pathway of unfolded protein response",
                      "Type 2 mutation5-bp insertion (c.1154_1155insTTGTC, p.K385fs*47)",
                      "5-bp insertion (c.1154_1155insTTGTC, p.K385fs*47)"
                    ]
                  },
                  {
                    "text": "Less common mutations2-bp insertion1-bp deletion8-bp deletionOther rare variants also reported",
                    "sub_points": [
                      "2-bp insertion",
                      "1-bp deletion",
                      "8-bp deletion",
                      "Other rare variants also reported"
                    ]
                  }
                ],
                "Abnormal Activation of Signaling Pathways": [
                  {
                    "text": "All frameshifts lead to same novel C-terminal protein sequence"
                  },
                  {
                    "text": "CALR-mutant protein chaperone abnormally interacts with thrombopoietin receptor (TPOR) in ERTPOR coupled with mutant-CALRexported to cell surfacePhysical interaction leads to constitutive cytokine-independent activation of TPOR signalingTPOR signaling mediated by JAK-STAT pathway",
                    "sub_points": [
                      "TPOR coupled with mutant-CALRexported to cell surface",
                      "Physical interaction leads to constitutive cytokine-independent activation of TPOR signalingTPOR signaling mediated by JAK-STAT pathway",
                      "TPOR signaling mediated by JAK-STAT pathway"
                    ]
                  },
                  {
                    "text": "CALRmutations also shown to activate MAPK and PI3K/AKT signaling pathways"
                  }
                ],
                "Constitutional Disorders": [
                  {
                    "text": "CALRallele may be lost along with several other genes in rare 19p13.13 deletion syndrome19p13.13 microdeletion is not inherited but arises during formation of gametes or in early fetal developmentFeatures may include macrocephaly, moderate intellectual disability, delayed speech, vision impairment, hypotonia, and poor coordination",
                    "sub_points": [
                      "19p13.13 microdeletion is not inherited but arises during formation of gametes or in early fetal development",
                      "Features may include macrocephaly, moderate intellectual disability, delayed speech, vision impairment, hypotonia, and poor coordination"
                    ]
                  }
                ]
              },
              "Testing Methods for Detection": {
                "Gene Sequencing": [
                  {
                    "text": "Whole-exome sequencing was used in discovery ofCALRmutations inJAK2andMPLnonmutated MPNs"
                  },
                  {
                    "text": "Sequencing (targeted or gene panel) methods are commonMost comprehensive method for assessment of sequence mutationsSome larger indels could be missed with earlier types of bioinformatic data analysis",
                    "sub_points": [
                      "Most comprehensive method for assessment of sequence mutations",
                      "Some larger indels could be missed with earlier types of bioinformatic data analysis"
                    ]
                  }
                ],
                "Fragment Sizing Analysis": [
                  {
                    "text": "Targeted PCR amplification of exon 9 followed by fragment sizing by capillary electrophoresis"
                  },
                  {
                    "text": "Changes in amplicon size compared to wildtype indicateCALRmutation"
                  },
                  {
                    "text": "Type ofCALRmutation may determined by difference in sizes of wildtype vs. mutant peak"
                  }
                ]
              },
              "Clinical Implications": {
                "Essential Thrombocythemia WithCALRMutation": [
                  {
                    "text": "Affected individuals are relatively younger than those withJAK2mutation"
                  },
                  {
                    "text": "Characterized by markedly elevated platelet counts"
                  },
                  {
                    "text": "Lower hemoglobin level and WBC count compared toJAK2-mutated cases"
                  },
                  {
                    "text": "Relatively low risk of thrombosisMuch lower thanJAK2-mutated ET casesCytoreduction may be preferred over antiplatelet therapy in symptomatic patientsGenotype does not alter treatment algorithms for high-risk pregnancies",
                    "sub_points": [
                      "Much lower thanJAK2-mutated ET cases",
                      "Cytoreduction may be preferred over antiplatelet therapy in symptomatic patients",
                      "Genotype does not alter treatment algorithms for high-risk pregnancies"
                    ]
                  },
                  {
                    "text": "Increased risk of progression to myelofibrosis compared toJAK2-mutated cases"
                  },
                  {
                    "text": "Longer overall survival compared toJAK2-mutated cases"
                  }
                ],
                "Primary Myelofibrosis WithCALRMutation": [
                  {
                    "text": "Longer overall survival compared to PMF cases withJAK2orMPLmutationsType 1 mutations associated with superior survival than type 2CALRmutations",
                    "sub_points": [
                      "Type 1 mutations associated with superior survival than type 2CALRmutations"
                    ]
                  },
                  {
                    "text": "Presence ofCALRmutation attenuates, but does not fully overcome, unfavorable prognosis seen in PMF with mutatedASXL1"
                  }
                ],
                "General Significance in Myeloid Neoplasms": [
                  {
                    "text": "Potential target for signaling pathway blockadeRuxolitinib (JAK signaling inhibitor) has been used in treatment ofCALR-mutant MPNsMAPK, PI3K/AKT, and ATR-CHK1 signaling pathways identified as potential therapeutic targets inCALR-mutant MPNsPharmacologic inhibition of IRE1α/XBP1 signaling reported to induce cell death inCALRtype 1 but not type 2 mutants",
                    "sub_points": [
                      "Ruxolitinib (JAK signaling inhibitor) has been used in treatment ofCALR-mutant MPNs",
                      "MAPK, PI3K/AKT, and ATR-CHK1 signaling pathways identified as potential therapeutic targets inCALR-mutant MPNs",
                      "Pharmacologic inhibition of IRE1α/XBP1 signaling reported to induce cell death inCALRtype 1 but not type 2 mutants"
                    ]
                  },
                  {
                    "text": "Compared toJAK2-mutant cases,CALR-mutant MPN shows decreased responsiveness to interferon therapy"
                  },
                  {
                    "text": "CALRmutation is detected in subset of myelodysplastic/MPNs withSF3B1mutation and thrombocytosisCALR-mutated cases are generally wildtype forJAK2andMPL",
                    "sub_points": [
                      "CALR-mutated cases are generally wildtype forJAK2andMPL"
                    ]
                  },
                  {
                    "text": "Uncommon in acute myeloid leukemia"
                  },
                  {
                    "text": "Rarely reported in myelodysplastic syndrome (< 1%)"
                  },
                  {
                    "text": "CALRexon 9 frameshift alterations not reported in normal individuals3-bp inframeCALRmutation has been reported in one individual with no evidence of MPN",
                    "sub_points": [
                      "3-bp inframeCALRmutation has been reported in one individual with no evidence of MPN"
                    ]
                  }
                ],
                "Myeloproliferative Neoplasms Wildtype forCALR,JAK2, andMPL": [
                  {
                    "text": "~ 8-9% of PMF cases lack mutations inJAK2,MPL, andCALRgenes (triple negative)Reported median survival of only 2.5 years in one studyTriple-negative PMF cases show very poor prognosisCALRwildtype/ASXL1-mutated genotype showed most detrimental mutation profile in one study",
                    "sub_points": [
                      "Reported median survival of only 2.5 years in one study",
                      "Triple-negative PMF cases show very poor prognosis",
                      "CALRwildtype/ASXL1-mutated genotype showed most detrimental mutation profile in one study"
                    ]
                  },
                  {
                    "text": "Triple-negative ET is not homogeneous entity"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Other Mutations and Gene Panel Testing in Myeloid Neoplasms": {
            "name": "Other Mutations and Gene Panel Testing in Myeloid Neoplasms",
            "url": "https://app.pathprimer.com/document/b48bc594-3b24-4d04-86fd-8f1b829f6730/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "CLINICAL IMPLICATIONS": {
                "Mutational Landscape of Acute Myeloid Leukemia": [
                  {
                    "text": "Large-scale next-generation sequencing (NGS) studies have identified most commonly mutated genes in de novo acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "Cases of AML show relatively few mutationsMuch lower mutational burden than solid tumors",
                    "sub_points": [
                      "Much lower mutational burden than solid tumors"
                    ]
                  },
                  {
                    "text": "Some 237 genes are recurrently mutated"
                  },
                  {
                    "text": "~ 26 genes have been found to be mutated at significant frequency (i.e., > 1%)"
                  }
                ],
                "Biological Categories of Acute Myeloid Leukemia Mutations": [
                  {
                    "text": "AML gene mutations may be grouped into several categories based on cellular function of encoded proteinsCell signaling (59%)FLT3,KRAS,NRAS,KITDNA methylation (44%)TET2,DNMT3A,IDH1,IDH2Chromatin modification (30%)ASXL1,KMT2A,EZH2NPM1, representing its own subcategory (27%)Transcription factors (22%)CEBPA,RUNX1,SETBP1,BCOR,BCORL1,ETV6Tumor suppressor genes (16%)TP53,WT1,PHF6Spliceosome component (14%)SF3B1,SRSF2,U2AF1,ZRSR2Cohesin complex (13%)SMC1A,STAG2,RAD21",
                    "sub_points": [
                      "Cell signaling (59%)FLT3,KRAS,NRAS,KIT",
                      "FLT3,KRAS,NRAS,KIT",
                      "DNA methylation (44%)TET2,DNMT3A,IDH1,IDH2",
                      "TET2,DNMT3A,IDH1,IDH2",
                      "Chromatin modification (30%)ASXL1,KMT2A,EZH2",
                      "ASXL1,KMT2A,EZH2",
                      "NPM1, representing its own subcategory (27%)",
                      "Transcription factors (22%)CEBPA,RUNX1,SETBP1,BCOR,BCORL1,ETV6",
                      "CEBPA,RUNX1,SETBP1,BCOR,BCORL1,ETV6",
                      "Tumor suppressor genes (16%)TP53,WT1,PHF6",
                      "TP53,WT1,PHF6",
                      "Spliceosome component (14%)SF3B1,SRSF2,U2AF1,ZRSR2",
                      "SF3B1,SRSF2,U2AF1,ZRSR2",
                      "Cohesin complex (13%)SMC1A,STAG2,RAD21",
                      "SMC1A,STAG2,RAD21"
                    ]
                  },
                  {
                    "text": "Most frequently mutated genes in AML includeNPM1,FLT3,CEBPA,DNMT3A,IDH1,IDH2,TET2,ASXL1,RUNX1,TP53, andKIT",
                    "sub_points": [
                      "NPM1,FLT3,CEBPA,DNMT3A,IDH1,IDH2,TET2,ASXL1,RUNX1,TP53, andKIT"
                    ]
                  }
                ],
                "Genes Required for AML Diagnosis and Risk Stratification": [
                  {
                    "text": "ASXL1,BCOR,CEBPA,DDX41,EZH2,FLT3ITD,FLT3TKD,IDH1,IDH2,NPM1,RUNX1,SF3B1,SRSF2,STAG2,TP53,U2AF1,ZRSR2"
                  }
                ],
                "Additional Genes Recommended to Test at Acute Myeloid Leukemia Diagnosis and For Use in Disease Monitoring": [
                  {
                    "text": "ANKRD26,BCORL1,BRAF,CALR,CBL,CSF3R,DNMT3A,ETV6,GATA2,JAK2,KIT,KRAS,MPL,NRAS,NF1,PHF6,PPM1D,PTPN11,RAD21,SETBP1,TET2,WT1Testing forNPM1,FLT3,CEBPA, and, in some cases,KITis standard of care",
                    "sub_points": [
                      "Testing forNPM1,FLT3,CEBPA, and, in some cases,KITis standard of care"
                    ]
                  },
                  {
                    "text": "Extended testing for additional genes is now offered by many molecular diagnostic laboratories on routine basisMultiple genes are simultaneously assessed via NGS panels",
                    "sub_points": [
                      "Multiple genes are simultaneously assessed via NGS panels"
                    ]
                  },
                  {
                    "text": "Additional genes are assessed in broader myeloid gene panels by some laboratories"
                  },
                  {
                    "text": "Several systems have been proposed for risk-stratifying patients based on these resultsWidespread implementation and acceptance into consensus guidelines",
                    "sub_points": [
                      "Widespread implementation and acceptance into consensus guidelines"
                    ]
                  },
                  {
                    "text": "Some NGS assays can also differentiate clonal from subclonal mutations"
                  },
                  {
                    "text": "Relatively high sensitivity of some NGS panels, especially at deep coverage, may facilitate minimal residual disease monitoring"
                  },
                  {
                    "text": "Some myeloid-associated mutations may be seen in blood and bone marrow of older individuals without evidence of overt myeloid malignancySomatic mutations inDNMT3A,ASXL1, andTET2seen in ~ 2% of peripheral blood samples in large screening studyMay represent clonal hematopoiesis of indeterminate potential (CHIP) with variant allele frequency of ≥ 2%More common in older patients and presents risk for progression to overt hematologic malignancyThus, clinical and pathologic correlation remains critical",
                    "sub_points": [
                      "Somatic mutations inDNMT3A,ASXL1, andTET2seen in ~ 2% of peripheral blood samples in large screening studyMay represent clonal hematopoiesis of indeterminate potential (CHIP) with variant allele frequency of ≥ 2%More common in older patients and presents risk for progression to overt hematologic malignancy",
                      "May represent clonal hematopoiesis of indeterminate potential (CHIP) with variant allele frequency of ≥ 2%",
                      "More common in older patients and presents risk for progression to overt hematologic malignancy",
                      "Thus, clinical and pathologic correlation remains critical"
                    ]
                  }
                ],
                "Extended Multigene Panel in MPN and Mastocytosis": [
                  {
                    "text": "ASXL1,CALR,CBL,CSF3R,DNMT3A,EZH2,IDH1,IDH2,JAK2,KIT,KRAS,MPL,NRAS,PTPN11,RUNX1,SETBP1,SF3B1,SH2B3,SRSF2,TET2,U2AF1,ZRSR2"
                  }
                ],
                "Extended Multigene Testing in MDS/MPN and Cytopenia": [
                  {
                    "text": "ASXL1,BCOR,BCORL1,CBL,CEBPA,CSF3R,DDX41,DNMT3A,ETV6,ETNK1,EZH2,FLT3ITD,FLT3TKD,GATA2,GNB1,IDH1,IDH2,JAK2,KIT,KRAS,KMT2A-PTD,NF1,NPM1,NRAS,PHF6,PPM1D,PRPF8,PTPN11,RAD21,RUNX1,SAMD9,SAMD9L,SETBP1,SF3B1,SRSF2,STAG2,TET2,TP53,U2AF1,UBA1,WT1,ZRSR2"
                  },
                  {
                    "text": "Most frequently mutated genes in MDS includeASXL1,BCOR,DNMT3A,EZH2,IDH1,IDH2,NRAS,RUNX1,SF3B1,SRSF2,STAG2,TET2,U2AF1, andZRSR2SF3B1mutations associated with ring sideroblastsDNMT3A,TET2, andASXL1are often present in preleukemic stem or progenitor cellsOccur early in leukemogenesisMutations in genes, such asASXL1,TET2, andDNMT3A, and, less frequently, splicing factor genes, such asSF3B1andSRSF2, can also occur in older healthy individuals as clonal hematopoiesis without evidence of MDSMDS-associated somatic mutations alone arenotconsidered diagnostic of MDS",
                    "sub_points": [
                      "ASXL1,BCOR,DNMT3A,EZH2,IDH1,IDH2,NRAS,RUNX1,SF3B1,SRSF2,STAG2,TET2,U2AF1, andZRSR2SF3B1mutations associated with ring sideroblastsDNMT3A,TET2, andASXL1are often present in preleukemic stem or progenitor cellsOccur early in leukemogenesisMutations in genes, such asASXL1,TET2, andDNMT3A, and, less frequently, splicing factor genes, such asSF3B1andSRSF2, can also occur in older healthy individuals as clonal hematopoiesis without evidence of MDSMDS-associated somatic mutations alone arenotconsidered diagnostic of MDS",
                      "SF3B1mutations associated with ring sideroblasts",
                      "DNMT3A,TET2, andASXL1are often present in preleukemic stem or progenitor cellsOccur early in leukemogenesis",
                      "Occur early in leukemogenesis",
                      "Mutations in genes, such asASXL1,TET2, andDNMT3A, and, less frequently, splicing factor genes, such asSF3B1andSRSF2, can also occur in older healthy individuals as clonal hematopoiesis without evidence of MDSMDS-associated somatic mutations alone arenotconsidered diagnostic of MDS",
                      "MDS-associated somatic mutations alone arenotconsidered diagnostic of MDS"
                    ]
                  },
                  {
                    "text": "Most frequently mutated genes in nonchronic myeloid leukemia and MPNJAK2,CALR,MPLASXL1andTP53mutations in MPN predict poor overall survival",
                    "sub_points": [
                      "JAK2,CALR,MPL",
                      "ASXL1andTP53mutations in MPN predict poor overall survival"
                    ]
                  },
                  {
                    "text": "Most frequently mutated genes in MDS/MPNASXL1,CBL,SRSF2,SF3B1,EZH2,IDH1,IDH2,TP53,CALRSF3B1more common in MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN withSF3B1mutation and thrombocytosis)JAK2,CALR, andMPLmutations can be seen in MDS/MPN withSF3B1mutation and thrombocytosis and in MDS/MPN with ring sideroblasts and thrombocytosis",
                    "sub_points": [
                      "ASXL1,CBL,SRSF2,SF3B1,EZH2,IDH1,IDH2,TP53,CALRSF3B1more common in MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN withSF3B1mutation and thrombocytosis)JAK2,CALR, andMPLmutations can be seen in MDS/MPN withSF3B1mutation and thrombocytosis and in MDS/MPN with ring sideroblasts and thrombocytosis",
                      "SF3B1more common in MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN withSF3B1mutation and thrombocytosis)JAK2,CALR, andMPLmutations can be seen in MDS/MPN withSF3B1mutation and thrombocytosis and in MDS/MPN with ring sideroblasts and thrombocytosis",
                      "JAK2,CALR, andMPLmutations can be seen in MDS/MPN withSF3B1mutation and thrombocytosis and in MDS/MPN with ring sideroblasts and thrombocytosis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Immunoglobulin Heavy (IGH) Chain Gene Rearrangements": {
            "name": "Immunoglobulin Heavy (IGH) Chain Gene Rearrangements",
            "url": "https://app.pathprimer.com/document/a20f0f36-cbce-4ac7-b049-79dc3d7f36d4/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Immunoglobulin heavy locus (IGH)HGNC ID: 5477Chromosomal location: 14q32.33Genomic positionCh14: 105,586,437-106,879,844Includes variable (VH), diversity (DH), joining (JH), and constant (CH) gene segments",
                    "sub_points": [
                      "HGNC ID: 5477",
                      "Chromosomal location: 14q32.33",
                      "Genomic positionCh14: 105,586,437-106,879,844",
                      "Ch14: 105,586,437-106,879,844",
                      "Includes variable (VH), diversity (DH), joining (JH), and constant (CH) gene segments"
                    ]
                  },
                  {
                    "text": "Immunoglobulin kappa (IGK) and lambda (IGL) lociChromosomal location: 2p11.2 and 22q11.22, respectivelyHGNC ID forIGK: 5715HGNC ID forIGL: 5853Include variable (V), joining (J), and constant (C) gene segmentsIGKalso includes immunoglobulin kappa deleting element (IGKDE)",
                    "sub_points": [
                      "Chromosomal location: 2p11.2 and 22q11.22, respectivelyHGNC ID forIGK: 5715HGNC ID forIGL: 5853",
                      "HGNC ID forIGK: 5715",
                      "HGNC ID forIGL: 5853",
                      "Include variable (V), joining (J), and constant (C) gene segments",
                      "IGKalso includes immunoglobulin kappa deleting element (IGKDE)"
                    ]
                  }
                ]
              },
              "Immunoglobulin Structure": {
                "Immunoglobulin Heavy Chain": [
                  {
                    "text": "Y-shaped molecule composed of 2 heavy and 2 light chains connected by disulfide bondsFragment antigen-binding (Fab) portion at tip of Ig molecule contains antigen-binding siteFragment crystallizable (Fc) portion interacts with complement system and Fc receptors on certain cells",
                    "sub_points": [
                      "Fragment antigen-binding (Fab) portion at tip of Ig molecule contains antigen-binding site",
                      "Fragment crystallizable (Fc) portion interacts with complement system and Fc receptors on certain cells"
                    ]
                  },
                  {
                    "text": "5 different types of heavy chains exist: α, δ, ε, γ, and μHeavy chain type corresponds to specific class of Ig: IgA, IgD, IgE, IgG, and IgMConsist of variable and constant regionsVariable region is encoded by VH, DH, and JH gene segmentsIncludes conserved sequences that constitute 4 framework regions (FR1, FR2, FR3, and FR4)Between FRs are 3 hypervariable complementarity determining regions (CDR1, CDR2, and CDR3) involved in antigen bindingCDR3 is most variable regionConstant region is encoded by CH segment",
                    "sub_points": [
                      "Heavy chain type corresponds to specific class of Ig: IgA, IgD, IgE, IgG, and IgM",
                      "Consist of variable and constant regions",
                      "Variable region is encoded by VH, DH, and JH gene segmentsIncludes conserved sequences that constitute 4 framework regions (FR1, FR2, FR3, and FR4)Between FRs are 3 hypervariable complementarity determining regions (CDR1, CDR2, and CDR3) involved in antigen bindingCDR3 is most variable region",
                      "Includes conserved sequences that constitute 4 framework regions (FR1, FR2, FR3, and FR4)",
                      "Between FRs are 3 hypervariable complementarity determining regions (CDR1, CDR2, and CDR3) involved in antigen binding",
                      "CDR3 is most variable region",
                      "Constant region is encoded by CH segment"
                    ]
                  }
                ],
                "Immunoglobulin Light Chains": [
                  {
                    "text": "Light chains include κ and λ"
                  },
                  {
                    "text": "Similar structure to heavy chain exceptVariable region encoded byIGKorIGLV and J gene segmentsNo D segments inIGKandIGLShorter constant region",
                    "sub_points": [
                      "Variable region encoded byIGKorIGLV and J gene segments",
                      "No D segments inIGKandIGL",
                      "Shorter constant region"
                    ]
                  },
                  {
                    "text": "Immunoglobulins are seen in 2 physical formsSoluble form secreted by plasma cells and present in peripheral blood, body fluids, and secretionsMembrane-bound form found on surface of B cells and referred to as surface Ig (sIg)sIg (IgM or IgD) is main component of B-cell receptor (BCR)CD79A/CD79B heterodimer is BCR 2nd component",
                    "sub_points": [
                      "Soluble form secreted by plasma cells and present in peripheral blood, body fluids, and secretions",
                      "Membrane-bound form found on surface of B cells and referred to as surface Ig (sIg)sIg (IgM or IgD) is main component of B-cell receptor (BCR)CD79A/CD79B heterodimer is BCR 2nd component",
                      "sIg (IgM or IgD) is main component of B-cell receptor (BCR)",
                      "CD79A/CD79B heterodimer is BCR 2nd component"
                    ]
                  },
                  {
                    "text": "Steps involved in generation of diversity are similar in both BCR and T-cell receptor (TCR)Somatic hypermutations are unique to Ig genes",
                    "sub_points": [
                      "Somatic hypermutations are unique to Ig genes"
                    ]
                  }
                ]
              },
              "Overview of B-Cell Development": {
                "Antigen-Independent Stages": [
                  {
                    "text": "Occur in bone marrow, progress throughIGHandIGK/IGLrearrangements, and lead to surface BCR assembly"
                  },
                  {
                    "text": "IGH,IGK, andIGLare in germline configuration in hematopoietic stem cells"
                  },
                  {
                    "text": "Early and late progenitor B cells (pro B cells)IGHundergoes DH to JH rearrangement followed by VH to DH-JH rearrangement",
                    "sub_points": [
                      "IGHundergoes DH to JH rearrangement followed by VH to DH-JH rearrangement"
                    ]
                  },
                  {
                    "text": "Large precursor B cells (pre B cells)Express surface pre B-cell receptor composed of μ heavy chain and surrogate light chainSuccessful assembly triggers allelic exclusion to preventIGHrearrangements on 2nd alleleNonproductive rearrangements of bothIGHalleles lead to cell death",
                    "sub_points": [
                      "Express surface pre B-cell receptor composed of μ heavy chain and surrogate light chain",
                      "Successful assembly triggers allelic exclusion to preventIGHrearrangements on 2nd allele",
                      "Nonproductive rearrangements of bothIGHalleles lead to cell death"
                    ]
                  },
                  {
                    "text": "Small precursor B cells (pre B cells)IGKundergoes Vκ to Jκ rearrangementIfIGKrearrangements are unproductive on both alleles, thenIGLundergoes rearrangements",
                    "sub_points": [
                      "IGKundergoes Vκ to Jκ rearrangement",
                      "IfIGKrearrangements are unproductive on both alleles, thenIGLundergoes rearrangements"
                    ]
                  },
                  {
                    "text": "Immature B cellsAssemble BCR composed of μ heavy chain (IgM), and κ or λ light chain on cell surface",
                    "sub_points": [
                      "Assemble BCR composed of μ heavy chain (IgM), and κ or λ light chain on cell surface"
                    ]
                  },
                  {
                    "text": "Mature naive B cellsEnter peripheral circulation and migrate to secondary lymphoid tissuesExpress surface IgM and IgD through alternative splicing",
                    "sub_points": [
                      "Enter peripheral circulation and migrate to secondary lymphoid tissues",
                      "Express surface IgM and IgD through alternative splicing"
                    ]
                  }
                ],
                "Antigen-Dependent Stages": [
                  {
                    "text": "T-cell independent B-cell reaction in paracortexSome antigens may activate B cells directly without T-cell cooperation in paracortex of lymph node; consequently, mature naive B cells transform into proliferating extrafollicular B blastsTheir progeny can mature into short-lived plasma cells secreting low-affinity IgMNo memory B cells are generated",
                    "sub_points": [
                      "Some antigens may activate B cells directly without T-cell cooperation in paracortex of lymph node; consequently, mature naive B cells transform into proliferating extrafollicular B blastsTheir progeny can mature into short-lived plasma cells secreting low-affinity IgMNo memory B cells are generated",
                      "Their progeny can mature into short-lived plasma cells secreting low-affinity IgM",
                      "No memory B cells are generated"
                    ]
                  },
                  {
                    "text": "T-cell dependent B-cell reaction in germinal centerProliferating blasts migrate to primary follicles, form germinal centers (GC), and become centroblastsSelected cells with BCRs to specific antigen present in GC survive and continue to proliferateCentroblasts undergosomatic hypermutations (SHM)that introduce point mutations in variable regions of heavy and light chainsCentroblasts mature into nonproliferating centrocytes and then undergo selection processCells capable of producing high-affinity Ig are \"rescued\" from apoptosisAffinity maturationis direct result of SHM and selection processSubset of centrocytes undergoclass switch recombination (CSR)to produce IgG, IgA, or, rarely, IgE, instead of IgMCSR changes Ig functional characteristics but does not affect antigen specificityDifferentiation into effector cells (post-GC step)Memory B cells are detectable in peripheral blood and marginal zone of lymphoid tissues and include IgM and class-switched subsetsLong-lived plasma cells secrete Ig of all classes and can be found in lymph node medulla, splenic cords, and bone marrowIn adults, new B cells are continuously produced in bone marrow",
                    "sub_points": [
                      "Proliferating blasts migrate to primary follicles, form germinal centers (GC), and become centroblastsSelected cells with BCRs to specific antigen present in GC survive and continue to proliferate",
                      "Selected cells with BCRs to specific antigen present in GC survive and continue to proliferate",
                      "Centroblasts undergosomatic hypermutations (SHM)that introduce point mutations in variable regions of heavy and light chains",
                      "Centroblasts mature into nonproliferating centrocytes and then undergo selection processCells capable of producing high-affinity Ig are \"rescued\" from apoptosisAffinity maturationis direct result of SHM and selection process",
                      "Cells capable of producing high-affinity Ig are \"rescued\" from apoptosis",
                      "Affinity maturationis direct result of SHM and selection process",
                      "Subset of centrocytes undergoclass switch recombination (CSR)to produce IgG, IgA, or, rarely, IgE, instead of IgMCSR changes Ig functional characteristics but does not affect antigen specificity",
                      "CSR changes Ig functional characteristics but does not affect antigen specificity",
                      "Differentiation into effector cells (post-GC step)Memory B cells are detectable in peripheral blood and marginal zone of lymphoid tissues and include IgM and class-switched subsetsLong-lived plasma cells secrete Ig of all classes and can be found in lymph node medulla, splenic cords, and bone marrow",
                      "Memory B cells are detectable in peripheral blood and marginal zone of lymphoid tissues and include IgM and class-switched subsets",
                      "Long-lived plasma cells secrete Ig of all classes and can be found in lymph node medulla, splenic cords, and bone marrow",
                      "In adults, new B cells are continuously produced in bone marrow"
                    ]
                  }
                ]
              },
              "IGH Rearrangements": {
                "Overview": [
                  {
                    "text": "Sequence of somatic recombination events occurring at pro B-cell stages in B-cell lineage precursorsJoins gene segments that are spatially separated in germline configuration",
                    "sub_points": [
                      "Joins gene segments that are spatially separated in germline configuration"
                    ]
                  },
                  {
                    "text": "General order of Ig gene rearrangementsIGH1st followed byIGK, followed byIGLif rearrangedIGKin both alleles is nonproductive",
                    "sub_points": [
                      "IGH1st followed byIGK, followed byIGLif rearrangedIGKin both alleles is nonproductive"
                    ]
                  }
                ],
                "IGHLocus": [
                  {
                    "text": "IGHvariable region gene cluster contains comparable number of V segments toIGK,IGL,TRA, andTRBlociNumbers of V segments vary between individualsOf ~ 123-139 VH segments, only 46-52 are functionalBelong to 7 V families based on homologySeveral VH segments are considered pseudogenes",
                    "sub_points": [
                      "Numbers of V segments vary between individuals",
                      "Of ~ 123-139 VH segments, only 46-52 are functionalBelong to 7 V families based on homologySeveral VH segments are considered pseudogenes",
                      "Belong to 7 V families based on homology",
                      "Several VH segments are considered pseudogenes"
                    ]
                  },
                  {
                    "text": "Additionally,IGHlocus contains 26 DH segments, 9 JH segments, and 11 CH segments"
                  }
                ],
                "Recombination Process": [
                  {
                    "text": "Requires many enzymes and other proteinsEnzymes expressed only in developing lymphocytesRAG1 and RAG2 encoded by recombination activating genes are key componentsTerminal deoxynucleotidyl transferase (TdT)Ubiquitously expressed DNA-modifying proteins normally involved in DNA repair and other cellular processesKu70:Ku80 heterodimer, DNA dependent protein kinase, Artemis nuclease, DNA ligase IV",
                    "sub_points": [
                      "Enzymes expressed only in developing lymphocytesRAG1 and RAG2 encoded by recombination activating genes are key componentsTerminal deoxynucleotidyl transferase (TdT)",
                      "RAG1 and RAG2 encoded by recombination activating genes are key components",
                      "Terminal deoxynucleotidyl transferase (TdT)",
                      "Ubiquitously expressed DNA-modifying proteins normally involved in DNA repair and other cellular processesKu70:Ku80 heterodimer, DNA dependent protein kinase, Artemis nuclease, DNA ligase IV",
                      "Ku70:Ku80 heterodimer, DNA dependent protein kinase, Artemis nuclease, DNA ligase IV"
                    ]
                  },
                  {
                    "text": "Recombination proceeds in regulated stepwise fashionBegins with RAG complex recognizing and cutting DNA at recombination signal sequences (RSS)RSS located immediately downstream of VH segments, at both sides of DH segments and upstream of JH segmentsRSS are composed of conserved heptamer, 12 or 23 bp spacer, and conserved nonamer sequencesSegments with RSS having 12 bp and 23 bp spacers (12/23 rule) are usually joined (to prevent nonproductive rearrangements, e.g., VH to VH)Next step involves formation of hairpin structure (stem loop) at ends of coding segmentsBlunt ends of RSS are ligated together into circular DNA containing all intervening sequencesOther proteins bind to and open hairpin at random site to yield single-stranded DNA endsPalindromic (P) nucleotides originate from complementary strand of hairpin that is asymmetrically openedExonuclease and TdT randomly cleave and add nontemplated nucleotides (N), resulting in junctional diversityFinally, DNA ligase joins rearranging gene segmentsDH to JH rearrangement is followed by VH to DH-JH rearrangement to form recombined complete VDJRepertoire of inherited gene segments accounts for Ig combinatorial diversityCombinatorial and junctional diversitytogether create essentially limitless repertoire of variable region sequences",
                    "sub_points": [
                      "Begins with RAG complex recognizing and cutting DNA at recombination signal sequences (RSS)RSS located immediately downstream of VH segments, at both sides of DH segments and upstream of JH segmentsRSS are composed of conserved heptamer, 12 or 23 bp spacer, and conserved nonamer sequencesSegments with RSS having 12 bp and 23 bp spacers (12/23 rule) are usually joined (to prevent nonproductive rearrangements, e.g., VH to VH)",
                      "RSS located immediately downstream of VH segments, at both sides of DH segments and upstream of JH segments",
                      "RSS are composed of conserved heptamer, 12 or 23 bp spacer, and conserved nonamer sequences",
                      "Segments with RSS having 12 bp and 23 bp spacers (12/23 rule) are usually joined (to prevent nonproductive rearrangements, e.g., VH to VH)",
                      "Next step involves formation of hairpin structure (stem loop) at ends of coding segmentsBlunt ends of RSS are ligated together into circular DNA containing all intervening sequences",
                      "Blunt ends of RSS are ligated together into circular DNA containing all intervening sequences",
                      "Other proteins bind to and open hairpin at random site to yield single-stranded DNA endsPalindromic (P) nucleotides originate from complementary strand of hairpin that is asymmetrically openedExonuclease and TdT randomly cleave and add nontemplated nucleotides (N), resulting in junctional diversity",
                      "Palindromic (P) nucleotides originate from complementary strand of hairpin that is asymmetrically opened",
                      "Exonuclease and TdT randomly cleave and add nontemplated nucleotides (N), resulting in junctional diversity",
                      "Finally, DNA ligase joins rearranging gene segments",
                      "DH to JH rearrangement is followed by VH to DH-JH rearrangement to form recombined complete VDJRepertoire of inherited gene segments accounts for Ig combinatorial diversityCombinatorial and junctional diversitytogether create essentially limitless repertoire of variable region sequences",
                      "Repertoire of inherited gene segments accounts for Ig combinatorial diversity",
                      "Combinatorial and junctional diversitytogether create essentially limitless repertoire of variable region sequences"
                    ]
                  },
                  {
                    "text": "Transcription step is followed by RNA splicing, leading to joining of V region to neighboring C segmentAlternative RNA splicing results in expression of μ or δ heavy chainsClass-switch recombination is required for α, ε, and γ heavy chain expressionSwitch from membrane-bound to soluble Ig also occurs at RNA processing step via alternate splicing",
                    "sub_points": [
                      "Alternative RNA splicing results in expression of μ or δ heavy chainsClass-switch recombination is required for α, ε, and γ heavy chain expression",
                      "Class-switch recombination is required for α, ε, and γ heavy chain expression",
                      "Switch from membrane-bound to soluble Ig also occurs at RNA processing step via alternate splicing"
                    ]
                  },
                  {
                    "text": "Translation and Ig assembly are final steps"
                  },
                  {
                    "text": "All Ig and TCR gene rearrangements follow similar steps and use same enzymes and cellular machineryRearrangedIGK/IGLhave reduced junctional diversity compared toIGH",
                    "sub_points": [
                      "RearrangedIGK/IGLhave reduced junctional diversity compared toIGH"
                    ]
                  }
                ],
                "Other Related Processes": [
                  {
                    "text": "Both SHM and CSR also result in somatic changes to germline sequence of Ig genes"
                  },
                  {
                    "text": "Utilize different enzymes and cellular mechanismsActivation-induced cytidine deaminase is important enzyme in this process",
                    "sub_points": [
                      "Activation-induced cytidine deaminase is important enzyme in this process"
                    ]
                  }
                ]
              },
              "Clonality Testing": {
                "General Comments": [
                  {
                    "text": "Clonality does not equal malignancyBenign and reactive conditions can produce clonal patterns due to antigen-driven lymphocyte expansions",
                    "sub_points": [
                      "Benign and reactive conditions can produce clonal patterns due to antigen-driven lymphocyte expansions"
                    ]
                  },
                  {
                    "text": "Clonal rearrangements are not lineage specificB-cell malignancies (especially of B-cell precursors) often have clonal T-cell receptor gene rearrangementsT-cell malignancies can have clonal Ig gene rearrangements",
                    "sub_points": [
                      "B-cell malignancies (especially of B-cell precursors) often have clonal T-cell receptor gene rearrangements",
                      "T-cell malignancies can have clonal Ig gene rearrangements"
                    ]
                  },
                  {
                    "text": "Results of clonality testing should always be interpreted within appropriate clinical context and in conjunction with morphologic findings"
                  }
                ],
                "Antibody-Based Methods": [
                  {
                    "text": "Based on evaluation of light chain restriction in B cells &/or plasma cellsRatio of κ to λ is calculated/estimatedResults outside of established normal range are indicative of clonality",
                    "sub_points": [
                      "Ratio of κ to λ is calculated/estimatedResults outside of established normal range are indicative of clonality",
                      "Results outside of established normal range are indicative of clonality"
                    ]
                  },
                  {
                    "text": "Flow cytometry (FC), in situ hybridization (ISH), and immunohistochemistry (IHC) can be usedSeveral limitations existFresh tissue requirement for FC, inability to evaluate light chain restriction in majority of B cells by IHC/ISH",
                    "sub_points": [
                      "Several limitations existFresh tissue requirement for FC, inability to evaluate light chain restriction in majority of B cells by IHC/ISH",
                      "Fresh tissue requirement for FC, inability to evaluate light chain restriction in majority of B cells by IHC/ISH"
                    ]
                  }
                ],
                "Nucleic Acid-Based Methods": [
                  {
                    "text": "Southern blot hybridizationUsed to be gold standard for clonality analysis in old days, now largely replaced by PCR-based approachesBased on principle that antigen receptor gene rearrangements alter restriction-digested DNA fragments compared with germline DNAGenes with significant combinatorial diversity, such asIGH,IGK, andTRB, are suitable targets for analysisRequires significant amount of high-quality DNASensitivity of this method is ~ 5-10%ProtocolGenomic DNA digestion by restriction enzymesSize fractionation by gel electrophoresisTransfer to membrane and hybridization with labeled DNA probes targeting J or C regionWash and visualization stepIndividual gene rearrangements are not detected unless they are overrepresented at ≥ 5% in background lymphoid cellsPolyclonal sample appears as germline bands onlyClonal rearrangements appear as novel bands",
                    "sub_points": [
                      "Used to be gold standard for clonality analysis in old days, now largely replaced by PCR-based approaches",
                      "Based on principle that antigen receptor gene rearrangements alter restriction-digested DNA fragments compared with germline DNAGenes with significant combinatorial diversity, such asIGH,IGK, andTRB, are suitable targets for analysis",
                      "Genes with significant combinatorial diversity, such asIGH,IGK, andTRB, are suitable targets for analysis",
                      "Requires significant amount of high-quality DNA",
                      "Sensitivity of this method is ~ 5-10%",
                      "ProtocolGenomic DNA digestion by restriction enzymesSize fractionation by gel electrophoresisTransfer to membrane and hybridization with labeled DNA probes targeting J or C regionWash and visualization step",
                      "Genomic DNA digestion by restriction enzymes",
                      "Size fractionation by gel electrophoresis",
                      "Transfer to membrane and hybridization with labeled DNA probes targeting J or C region",
                      "Wash and visualization step",
                      "Individual gene rearrangements are not detected unless they are overrepresented at ≥ 5% in background lymphoid cellsPolyclonal sample appears as germline bands onlyClonal rearrangements appear as novel bands",
                      "Polyclonal sample appears as germline bands only",
                      "Clonal rearrangements appear as novel bands"
                    ]
                  },
                  {
                    "text": "PCR-based approachesCurrent gold standard for clonality analysisBased on principle that somatic Ig gene rearrangements bring V, (D), and J segments together, enabling their PCR amplificationEach rearrangement is unique in length and sequence due to combinatorial and junctional diversityIGHandIGKare usually testedTestingIGLadds little to overall ability to detect clonal rearrangements and is not widely usedCan be performed on variety of specimen types, including formalin-fixed, paraffin-embedded tissueTissues exposed to strong acid-based decalcification solutions are not suitable for PCR amplificationTissues exposed to heparin-based decalcification solution are suitable for PCR amplificationPCR protocolGenomic DNA is extracted andIGHandIGKCDR3 regions are PCR amplifiedBIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is most commonly usedCommercial kits are available (e.g., IGH + IGK B-cell clonality assay from Invivoscribe)ForIGH,primers targeting multiple VH families within FR1, 2, and 3 plus single consensus primer for JH segment (3 separate reactions) are usedSHM can interfere with primers bindingIGKtube A includes 6 Vκ primers plus 2 Jκ primersIGKtube B includes 6 Vκ primers and Jκ-Cκ intron primer plus 1 IGKDE primer (to detect rearrangements involving IGKDE)Not affected by SHM (main advantage)Fractionation by capillary electrophoresis (CE)One of PCR primers requires fluorescent labelingSeparates amplicons based on length onlyConventional gel electrophoresis can also be used as alternative, but it is more labor intensive and time consuming with lesser resolutionInterpretation should be assay and specimen specificPolyclonal B cells generate normal (Gaussian) distribution of amplicon of different sizesClonal B cells produce 1 or 2 prominent amplicons within diminished polyclonal backgroundGenerally not suitable for minimal residual disease (MRD) monitoring, unless specific primers for patient-specific clone are designed",
                    "sub_points": [
                      "Current gold standard for clonality analysis",
                      "Based on principle that somatic Ig gene rearrangements bring V, (D), and J segments together, enabling their PCR amplificationEach rearrangement is unique in length and sequence due to combinatorial and junctional diversityIGHandIGKare usually testedTestingIGLadds little to overall ability to detect clonal rearrangements and is not widely used",
                      "Each rearrangement is unique in length and sequence due to combinatorial and junctional diversity",
                      "IGHandIGKare usually tested",
                      "TestingIGLadds little to overall ability to detect clonal rearrangements and is not widely used",
                      "Can be performed on variety of specimen types, including formalin-fixed, paraffin-embedded tissueTissues exposed to strong acid-based decalcification solutions are not suitable for PCR amplificationTissues exposed to heparin-based decalcification solution are suitable for PCR amplification",
                      "Tissues exposed to strong acid-based decalcification solutions are not suitable for PCR amplification",
                      "Tissues exposed to heparin-based decalcification solution are suitable for PCR amplification",
                      "PCR protocol",
                      "Genomic DNA is extracted andIGHandIGKCDR3 regions are PCR amplifiedBIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is most commonly usedCommercial kits are available (e.g., IGH + IGK B-cell clonality assay from Invivoscribe)ForIGH,primers targeting multiple VH families within FR1, 2, and 3 plus single consensus primer for JH segment (3 separate reactions) are usedSHM can interfere with primers bindingIGKtube A includes 6 Vκ primers plus 2 Jκ primersIGKtube B includes 6 Vκ primers and Jκ-Cκ intron primer plus 1 IGKDE primer (to detect rearrangements involving IGKDE)Not affected by SHM (main advantage)",
                      "BIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is most commonly usedCommercial kits are available (e.g., IGH + IGK B-cell clonality assay from Invivoscribe)",
                      "Commercial kits are available (e.g., IGH + IGK B-cell clonality assay from Invivoscribe)",
                      "ForIGH,primers targeting multiple VH families within FR1, 2, and 3 plus single consensus primer for JH segment (3 separate reactions) are usedSHM can interfere with primers binding",
                      "SHM can interfere with primers binding",
                      "IGKtube A includes 6 Vκ primers plus 2 Jκ primers",
                      "IGKtube B includes 6 Vκ primers and Jκ-Cκ intron primer plus 1 IGKDE primer (to detect rearrangements involving IGKDE)Not affected by SHM (main advantage)",
                      "Not affected by SHM (main advantage)",
                      "Fractionation by capillary electrophoresis (CE)One of PCR primers requires fluorescent labelingSeparates amplicons based on length onlyConventional gel electrophoresis can also be used as alternative, but it is more labor intensive and time consuming with lesser resolution",
                      "One of PCR primers requires fluorescent labeling",
                      "Separates amplicons based on length only",
                      "Conventional gel electrophoresis can also be used as alternative, but it is more labor intensive and time consuming with lesser resolution",
                      "Interpretation should be assay and specimen specificPolyclonal B cells generate normal (Gaussian) distribution of amplicon of different sizesClonal B cells produce 1 or 2 prominent amplicons within diminished polyclonal background",
                      "Polyclonal B cells generate normal (Gaussian) distribution of amplicon of different sizes",
                      "Clonal B cells produce 1 or 2 prominent amplicons within diminished polyclonal background",
                      "Generally not suitable for minimal residual disease (MRD) monitoring, unless specific primers for patient-specific clone are designed"
                    ]
                  },
                  {
                    "text": "Next-generation sequencing approachesHigh throughput sequencing may identifies MRD deeper than conventional clinical cutoff of 0.01 by flow cytometryHigh specificity attributable to resolution of rearrangements by size and sequenceHigh sensitivity suitable for MRD monitoringClaimed to have lower false-negative rate compared to flow cytometry",
                    "sub_points": [
                      "High throughput sequencing may identifies MRD deeper than conventional clinical cutoff of 0.01 by flow cytometry",
                      "High specificity attributable to resolution of rearrangements by size and sequence",
                      "High sensitivity suitable for MRD monitoring",
                      "Claimed to have lower false-negative rate compared to flow cytometry"
                    ]
                  },
                  {
                    "text": "IGHrearrangements analysis using RNA sequencing (RNAseq)Patient's specificIGHrearrangements is identified in initial presentation for MRD monitoring in lymphoblastic leukemia patientsRNAseq data is generated using antigen receptor research tool (ARResT): http://bat.infspire.orgTool is built within EuroClonality NGS Working GroupRNAseq data is analyzed using ARResT to interrogate and identify possible MRD markersSimilar strategy can be employed for disease monitoring in other lymphomas and multiple myeloma",
                    "sub_points": [
                      "Patient's specificIGHrearrangements is identified in initial presentation for MRD monitoring in lymphoblastic leukemia patients",
                      "RNAseq data is generated using antigen receptor research tool (ARResT): http://bat.infspire.orgTool is built within EuroClonality NGS Working Group",
                      "Tool is built within EuroClonality NGS Working Group",
                      "RNAseq data is analyzed using ARResT to interrogate and identify possible MRD markers",
                      "Similar strategy can be employed for disease monitoring in other lymphomas and multiple myeloma"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "T-Cell Receptor Gamma (TRG) and Delta (TRD) Chain Rearrangements": {
            "name": "T-Cell Receptor Gamma (TRG) and Delta (TRD) Chain Rearrangements",
            "url": "https://app.pathprimer.com/document/b9ff12dc-98ad-4bad-8e3d-47ccdb122c06/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "T-cell receptor (TCR) gamma locus (TRG)HGNC ID: 12271Chromosomal location: 7p14.1IncludesVariable (Vγ) segmentsJoining (Jγ) segmentsConstant (Cγ) segments",
                    "sub_points": [
                      "HGNC ID: 12271",
                      "Chromosomal location: 7p14.1",
                      "IncludesVariable (Vγ) segmentsJoining (Jγ) segmentsConstant (Cγ) segments",
                      "Variable (Vγ) segments",
                      "Joining (Jγ) segments",
                      "Constant (Cγ) segments"
                    ]
                  },
                  {
                    "text": "TCR delta locus (TRD)HGNC ID: 12252Chromosomal location: 14q11.2Located within TCR alpha (TRA) locusIncludesVariable (Vδ) segmentsJoining (Jδ) segmentsDiversity (Dδ) segmentsConstant (Cδ) segments",
                    "sub_points": [
                      "HGNC ID: 12252",
                      "Chromosomal location: 14q11.2Located within TCR alpha (TRA) locus",
                      "Located within TCR alpha (TRA) locus",
                      "IncludesVariable (Vδ) segmentsJoining (Jδ) segmentsDiversity (Dδ) segmentsConstant (Cδ) segments",
                      "Variable (Vδ) segments",
                      "Joining (Jδ) segments",
                      "Diversity (Dδ) segments",
                      "Constant (Cδ) segments"
                    ]
                  }
                ]
              },
              "TCR Structure": {
                "Background": [
                  {
                    "text": "T cells play major role in cell-mediated immunity"
                  },
                  {
                    "text": "Cell surface molecule responsible for recognizing antigens presented to T cells in context of major histocompatibility complex (MHC) molecules"
                  },
                  {
                    "text": "TCRs serve primary antigen recognition function in adaptive immune response"
                  },
                  {
                    "text": "TCRs composed of 2 different protein chains (heterodimer) connected by disulfide bondαβ T cellsAccount for majority of T cellsExpress TCR composed of α and β chainsγδ T cellsAccount for minority of T cells in circulationDominant T-cell subset found in epithelial tissues (gastrointestinal tract and skin)Express TCR composed of γ and δ chainsCan recognize antigens that are not associated with MHC molecules",
                    "sub_points": [
                      "αβ T cellsAccount for majority of T cellsExpress TCR composed of α and β chains",
                      "Account for majority of T cells",
                      "Express TCR composed of α and β chains",
                      "γδ T cellsAccount for minority of T cells in circulationDominant T-cell subset found in epithelial tissues (gastrointestinal tract and skin)Express TCR composed of γ and δ chainsCan recognize antigens that are not associated with MHC molecules",
                      "Account for minority of T cells in circulation",
                      "Dominant T-cell subset found in epithelial tissues (gastrointestinal tract and skin)",
                      "Express TCR composed of γ and δ chains",
                      "Can recognize antigens that are not associated with MHC molecules"
                    ]
                  },
                  {
                    "text": "Each chain (α, β, γ, or δ) is composed of2 extracellular domains that include variable and constant regionsTransmembrane domainShort cytoplasmic tail",
                    "sub_points": [
                      "2 extracellular domains that include variable and constant regions",
                      "Transmembrane domain",
                      "Short cytoplasmic tail"
                    ]
                  },
                  {
                    "text": "V, D, and J segments inTRDandTRB"
                  },
                  {
                    "text": "Only V and J segments inTRGandTRAConserved sequences within variable region constitute framework regions (FRs)Hypervariable complementarity determining regions (CDRs)Involved in antigen binding and are interspersed with FRsCDR3 is most variable region",
                    "sub_points": [
                      "Conserved sequences within variable region constitute framework regions (FRs)",
                      "Hypervariable complementarity determining regions (CDRs)Involved in antigen binding and are interspersed with FRsCDR3 is most variable region",
                      "Involved in antigen binding and are interspersed with FRs",
                      "CDR3 is most variable region"
                    ]
                  },
                  {
                    "text": "Extracellular constant region, transmembrane domain, and cytoplasmic tail are encoded by C gene segment"
                  },
                  {
                    "text": "TCR couples with other signaling molecules to achieve signal propagation due to short cytoplasmic tail"
                  },
                  {
                    "text": "Resultant octameric protein complex is known asTCR complexand consists ofTCR αβ or γδ heterodimer3 dimeric signaling modules, includingCD3 δ/ε, CD3 γ/ε, and CD247 ζ/ζThese associated invariant molecules are also necessary for transport of TCR to cell membrane",
                    "sub_points": [
                      "TCR αβ or γδ heterodimer",
                      "3 dimeric signaling modules, includingCD3 δ/ε, CD3 γ/ε, and CD247 ζ/ζThese associated invariant molecules are also necessary for transport of TCR to cell membrane",
                      "CD3 δ/ε, CD3 γ/ε, and CD247 ζ/ζ",
                      "These associated invariant molecules are also necessary for transport of TCR to cell membrane"
                    ]
                  },
                  {
                    "text": "Signal originating from TCR complex is enhanced bySimultaneous binding of MHC molecules on antigen presenting cells to specific TCR coreceptors on T cellsCD4 is specific for MHC class IICD8 is specific for MHC class I",
                    "sub_points": [
                      "Simultaneous binding of MHC molecules on antigen presenting cells to specific TCR coreceptors on T cellsCD4 is specific for MHC class IICD8 is specific for MHC class I",
                      "CD4 is specific for MHC class II",
                      "CD8 is specific for MHC class I"
                    ]
                  }
                ]
              },
              "TRG Rearrangements": {
                "Overview": [
                  {
                    "text": "Sequence of somatic recombination eventsOccur at early stage of T-cell development in both αβ and γδ T-cell lineage precursorsJoins gene segments that are spatially separated in germline configuration",
                    "sub_points": [
                      "Occur at early stage of T-cell development in both αβ and γδ T-cell lineage precursors",
                      "Joins gene segments that are spatially separated in germline configuration"
                    ]
                  },
                  {
                    "text": "General order of TCR gene rearrangementsTRD,TRG,TRB, followed byTRASequence of rearrangements is not obligateNot all αβ T-cells have rearrangedTRG",
                    "sub_points": [
                      "TRD,TRG,TRB, followed byTRA",
                      "Sequence of rearrangements is not obligateNot all αβ T-cells have rearrangedTRG",
                      "Not all αβ T-cells have rearrangedTRG"
                    ]
                  }
                ],
                "TRG": [
                  {
                    "text": "Located at 7p14.1"
                  },
                  {
                    "text": "~ 128 kb in size"
                  },
                  {
                    "text": "TRGvariable region gene cluster containsComparable number of V segments toTRDFar simpler compared toTRB,TRA,IGH,IGK, andIGLgenesIncludes 14 Vγ gene segments, 10 of which can undergo rearrangementOnly 6 Vγ-rearranged gene segments are functionalRearranging Vγ gene segments can be grouped into 4 families based on sequence homologyVγI family is largest and includes Vγ2, Vγ3, Vγ4, Vγ5, Vγ7, and Vγ8 gene segmentsRemaining 3 are single-member families that include Vγ9, Vγ10, and Vγ11Exceptionally, Vγ12 is rearranged, which is rarely targeted in diagnostic PCR strategiesSeveral Vγ gene segments are designated as pseudogenes",
                    "sub_points": [
                      "Comparable number of V segments toTRD",
                      "Far simpler compared toTRB,TRA,IGH,IGK, andIGLgenes",
                      "Includes 14 Vγ gene segments, 10 of which can undergo rearrangementOnly 6 Vγ-rearranged gene segments are functional",
                      "Only 6 Vγ-rearranged gene segments are functional",
                      "Rearranging Vγ gene segments can be grouped into 4 families based on sequence homologyVγI family is largest and includes Vγ2, Vγ3, Vγ4, Vγ5, Vγ7, and Vγ8 gene segmentsRemaining 3 are single-member families that include Vγ9, Vγ10, and Vγ11",
                      "VγI family is largest and includes Vγ2, Vγ3, Vγ4, Vγ5, Vγ7, and Vγ8 gene segments",
                      "Remaining 3 are single-member families that include Vγ9, Vγ10, and Vγ11",
                      "Exceptionally, Vγ12 is rearranged, which is rarely targeted in diagnostic PCR strategies",
                      "Several Vγ gene segments are designated as pseudogenes"
                    ]
                  },
                  {
                    "text": "TRGJγ-Cγ clusters1st cluster includes 3 Jγ (all functional) and 1 Cγ gene segment2nd cluster includes 2 Jγ (both functional and highly homologous to Jγ segments in 1st cluster) and 1 Cγ gene segment",
                    "sub_points": [
                      "1st cluster includes 3 Jγ (all functional) and 1 Cγ gene segment",
                      "2nd cluster includes 2 Jγ (both functional and highly homologous to Jγ segments in 1st cluster) and 1 Cγ gene segment"
                    ]
                  },
                  {
                    "text": "TRGshows limitedcombinatorial diversitydue to restricted germline repertoire in comparison toTRB"
                  },
                  {
                    "text": "Junctional activityis also limitedRelatively few nucleotide additionsRestricted to single Vγ-Jγ junction",
                    "sub_points": [
                      "Relatively few nucleotide additions",
                      "Restricted to single Vγ-Jγ junction"
                    ]
                  }
                ],
                "Recombination Process": [
                  {
                    "text": "TRGrearrangements follow similar stepsUse same enzymes and cellular machinery as other TCR and immunoglobulin gene rearrangements",
                    "sub_points": [
                      "Use same enzymes and cellular machinery as other TCR and immunoglobulin gene rearrangements"
                    ]
                  },
                  {
                    "text": "Consist of single step of Vγ to Jγ rearrangement"
                  },
                  {
                    "text": "TRGrearrangements occurring in healthy individuals are characterized by nonrandom distribution of Vγ and Jγ gene segmentsγδ T-cells can demonstrate \"canonical\"TRGrearrangementsMost commonly involves Vγ9 and Jγ1.2 segmentsOccurs in ~ 1% of peripheral blood T lymphocytesCorresponds to accumulation of γδ T cells in aging individuals",
                    "sub_points": [
                      "γδ T-cells can demonstrate \"canonical\"TRGrearrangementsMost commonly involves Vγ9 and Jγ1.2 segmentsOccurs in ~ 1% of peripheral blood T lymphocytesCorresponds to accumulation of γδ T cells in aging individuals",
                      "Most commonly involves Vγ9 and Jγ1.2 segments",
                      "Occurs in ~ 1% of peripheral blood T lymphocytes",
                      "Corresponds to accumulation of γδ T cells in aging individuals"
                    ]
                  },
                  {
                    "text": "Steps involved in generation of diversity are similar in both TCR and B-cell receptor"
                  }
                ]
              },
              "Clonality Testing": {
                "General Comments": [
                  {
                    "text": "Clonality does not equal malignancyBenign and reactive conditions can produce clonal patterns due to antigen-driven lymphocyte expansions",
                    "sub_points": [
                      "Benign and reactive conditions can produce clonal patterns due to antigen-driven lymphocyte expansions"
                    ]
                  },
                  {
                    "text": "Clonal rearrangements are not lineage specificB-cell malignancies, especially of B-cell precursor origin, often have clonal TCR rearrangementsT-cell malignancies can also have clonal immunoglobulin gene rearrangements",
                    "sub_points": [
                      "B-cell malignancies, especially of B-cell precursor origin, often have clonal TCR rearrangements",
                      "T-cell malignancies can also have clonal immunoglobulin gene rearrangements"
                    ]
                  },
                  {
                    "text": "Results of clonality testing should always be interpreted within appropriate clinical context and in conjunction with morphologic findings"
                  },
                  {
                    "text": "Rationales for usingTRGas target for clonality assessmentRestrictedTRGgermline repertoire with very limited number of Vγ and Jγ segmentsMakes PCR assay design easierMay make interpretation difficult (i.e., distinction between clonal and polyclonal PCR products)TRGis rearranged at early stage of T lymphoid development in both αβ and γδ T-lineage precursorsTRGis retained during subsequentTRBandTRArearrangements; therefore, TRG still detectable in malignancies of αβ T-cell originIn contrast,TRDis deleted during subsequentTRArearrangement in αβ T-cell precursorsTRD testing is essentially not practical for clonality assessment",
                    "sub_points": [
                      "RestrictedTRGgermline repertoire with very limited number of Vγ and Jγ segmentsMakes PCR assay design easierMay make interpretation difficult (i.e., distinction between clonal and polyclonal PCR products)",
                      "Makes PCR assay design easier",
                      "May make interpretation difficult (i.e., distinction between clonal and polyclonal PCR products)",
                      "TRGis rearranged at early stage of T lymphoid development in both αβ and γδ T-lineage precursorsTRGis retained during subsequentTRBandTRArearrangements; therefore, TRG still detectable in malignancies of αβ T-cell origin",
                      "TRGis retained during subsequentTRBandTRArearrangements; therefore, TRG still detectable in malignancies of αβ T-cell origin",
                      "In contrast,TRDis deleted during subsequentTRArearrangement in αβ T-cell precursorsTRD testing is essentially not practical for clonality assessment",
                      "TRD testing is essentially not practical for clonality assessment"
                    ]
                  },
                  {
                    "text": "TRGrearrangements testing is usually sufficient approach in T-cell clonality assessmentAddition ofTRBrearrangement analysis may improve clinical sensitivity in certain cases",
                    "sub_points": [
                      "Addition ofTRBrearrangement analysis may improve clinical sensitivity in certain cases"
                    ]
                  }
                ],
                "Nucleic Acid-Based Methods": [
                  {
                    "text": "PCR-based approachesCurrent gold standard for clonality analysisBased on principle that somatic TCR gene rearrangements bring V, (D), and J segments together enabling their PCR amplificationNo PCR product is generated if germline configuration is retainedEach rearrangement is unique in length and sequence as result of combinatorial and junctional diversityCan be performed on variety of specimen types, including formalin-fixed, paraffin-embedded (FFPE) tissue",
                    "sub_points": [
                      "Current gold standard for clonality analysis",
                      "Based on principle that somatic TCR gene rearrangements bring V, (D), and J segments together enabling their PCR amplificationNo PCR product is generated if germline configuration is retained",
                      "No PCR product is generated if germline configuration is retained",
                      "Each rearrangement is unique in length and sequence as result of combinatorial and junctional diversity",
                      "Can be performed on variety of specimen types, including formalin-fixed, paraffin-embedded (FFPE) tissue"
                    ]
                  },
                  {
                    "text": "ProtocolGenomic DNA is extracted and CDR3 region is PCR amplifiedBIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is assay used in some laboratoriesCommercial kits are available (e.g., T-cell receptor gamma gene clonality assay from Invivoscribe)2 multiplex tube design that allows detection of vast majority of clonalTRGrearrangementsEach tube targets 2 Vγ families and 4 Jγ segmentsJγ1.2 segment, which is rarely involved in clonal rearrangements, is excluded from this strategy to minimize false-positive results due to presence of canonical Vγ9-Jγ1.2 rearrangementsTube A contains VγI family and Vγ10 primers plus Jγ1.1/2.1 and Jγ1.3/2.3 primersTube B contains Vγ9 and Vγ11 primers plus Jγ1.1/2.1 and Jγ1.3/2.3 primersGreiner et al primer strategy is used as alternative by other laboratoriesSingle multiplex tube design allows detection of vast majority of clonalTRGrearrangementsAll 4 Vγ families are targeted using 5 forward primers [specific for Vγ2 (also amplifies Vγ4-8), Vγ3, Vγ9, Vγ10, and Vγ11]All 5 Jγ segments are targeted using 3 reverse primers (specific for Jγ1.1/2.1, Jγ1.2, Jγ1.3/2.3)Additionally, multiplex tube can be split into separate PCR reactions to identify which Vγ family is involved in clonal rearrangementClonality is assigned based on results from multiplex reactionOther more comprehensive primer strategies also exist with commercially available kits (e.g., T-cell receptor gamma gene rearrangement assays from Invivoscribe)Fractionation by capillary electrophoresis (CE)One of PCR primes requires fluorescent labelingSeparates amplicons based on length onlyNo sequence is evaluatedConventional gel electrophoresis can also be used as alternative to CEMore labor intensive and time consumingLow resolutionGenerally not suitable for minimal residual disease (MRD) monitoring, unless specific primers are designed to detect patient-specific clone within polyclonal background",
                    "sub_points": [
                      "Genomic DNA is extracted and CDR3 region is PCR amplifiedBIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is assay used in some laboratoriesCommercial kits are available (e.g., T-cell receptor gamma gene clonality assay from Invivoscribe)2 multiplex tube design that allows detection of vast majority of clonalTRGrearrangementsEach tube targets 2 Vγ families and 4 Jγ segmentsJγ1.2 segment, which is rarely involved in clonal rearrangements, is excluded from this strategy to minimize false-positive results due to presence of canonical Vγ9-Jγ1.2 rearrangementsTube A contains VγI family and Vγ10 primers plus Jγ1.1/2.1 and Jγ1.3/2.3 primersTube B contains Vγ9 and Vγ11 primers plus Jγ1.1/2.1 and Jγ1.3/2.3 primersGreiner et al primer strategy is used as alternative by other laboratoriesSingle multiplex tube design allows detection of vast majority of clonalTRGrearrangementsAll 4 Vγ families are targeted using 5 forward primers [specific for Vγ2 (also amplifies Vγ4-8), Vγ3, Vγ9, Vγ10, and Vγ11]All 5 Jγ segments are targeted using 3 reverse primers (specific for Jγ1.1/2.1, Jγ1.2, Jγ1.3/2.3)Additionally, multiplex tube can be split into separate PCR reactions to identify which Vγ family is involved in clonal rearrangementClonality is assigned based on results from multiplex reactionOther more comprehensive primer strategies also exist with commercially available kits (e.g., T-cell receptor gamma gene rearrangement assays from Invivoscribe)",
                      "BIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is assay used in some laboratoriesCommercial kits are available (e.g., T-cell receptor gamma gene clonality assay from Invivoscribe)2 multiplex tube design that allows detection of vast majority of clonalTRGrearrangementsEach tube targets 2 Vγ families and 4 Jγ segmentsJγ1.2 segment, which is rarely involved in clonal rearrangements, is excluded from this strategy to minimize false-positive results due to presence of canonical Vγ9-Jγ1.2 rearrangementsTube A contains VγI family and Vγ10 primers plus Jγ1.1/2.1 and Jγ1.3/2.3 primersTube B contains Vγ9 and Vγ11 primers plus Jγ1.1/2.1 and Jγ1.3/2.3 primers",
                      "Commercial kits are available (e.g., T-cell receptor gamma gene clonality assay from Invivoscribe)",
                      "2 multiplex tube design that allows detection of vast majority of clonalTRGrearrangements",
                      "Each tube targets 2 Vγ families and 4 Jγ segments",
                      "Jγ1.2 segment, which is rarely involved in clonal rearrangements, is excluded from this strategy to minimize false-positive results due to presence of canonical Vγ9-Jγ1.2 rearrangements",
                      "Tube A contains VγI family and Vγ10 primers plus Jγ1.1/2.1 and Jγ1.3/2.3 primers",
                      "Tube B contains Vγ9 and Vγ11 primers plus Jγ1.1/2.1 and Jγ1.3/2.3 primers",
                      "Greiner et al primer strategy is used as alternative by other laboratoriesSingle multiplex tube design allows detection of vast majority of clonalTRGrearrangementsAll 4 Vγ families are targeted using 5 forward primers [specific for Vγ2 (also amplifies Vγ4-8), Vγ3, Vγ9, Vγ10, and Vγ11]All 5 Jγ segments are targeted using 3 reverse primers (specific for Jγ1.1/2.1, Jγ1.2, Jγ1.3/2.3)Additionally, multiplex tube can be split into separate PCR reactions to identify which Vγ family is involved in clonal rearrangementClonality is assigned based on results from multiplex reaction",
                      "Single multiplex tube design allows detection of vast majority of clonalTRGrearrangements",
                      "All 4 Vγ families are targeted using 5 forward primers [specific for Vγ2 (also amplifies Vγ4-8), Vγ3, Vγ9, Vγ10, and Vγ11]",
                      "All 5 Jγ segments are targeted using 3 reverse primers (specific for Jγ1.1/2.1, Jγ1.2, Jγ1.3/2.3)",
                      "Additionally, multiplex tube can be split into separate PCR reactions to identify which Vγ family is involved in clonal rearrangement",
                      "Clonality is assigned based on results from multiplex reaction",
                      "Other more comprehensive primer strategies also exist with commercially available kits (e.g., T-cell receptor gamma gene rearrangement assays from Invivoscribe)",
                      "Fractionation by capillary electrophoresis (CE)One of PCR primes requires fluorescent labelingSeparates amplicons based on length onlyNo sequence is evaluatedConventional gel electrophoresis can also be used as alternative to CEMore labor intensive and time consumingLow resolution",
                      "One of PCR primes requires fluorescent labeling",
                      "Separates amplicons based on length onlyNo sequence is evaluated",
                      "No sequence is evaluated",
                      "Conventional gel electrophoresis can also be used as alternative to CEMore labor intensive and time consumingLow resolution",
                      "More labor intensive and time consuming",
                      "Low resolution",
                      "Generally not suitable for minimal residual disease (MRD) monitoring, unless specific primers are designed to detect patient-specific clone within polyclonal background"
                    ]
                  }
                ],
                "Diagnostic Interpretation": [
                  {
                    "text": "Interpretation should be assay and specimen specific, and based on in-house validation procedurePolyclonal T cells typically generate a bell-shaped (Gaussian) distribution of different sized ampliconsMultiple but limited numbers of peaks represent either oligoclonal T-cell expansion or few T cells in specimenSpecimens with scant T cells may result in pseudoclonalityClonal T cells produce 1 or 2 prominent peaks (uni- or biallelic rearrangements) within diminished polyclonal backgroundVarious strategies for calling clonal results have been proposedRatio of clonal peak height to height of polyclonal background with cutoff of ≥ 2.0 is often usedIn general, height of 3rd tallest peak is considered as height of polyclonal background",
                    "sub_points": [
                      "Polyclonal T cells typically generate a bell-shaped (Gaussian) distribution of different sized amplicons",
                      "Multiple but limited numbers of peaks represent either oligoclonal T-cell expansion or few T cells in specimenSpecimens with scant T cells may result in pseudoclonality",
                      "Specimens with scant T cells may result in pseudoclonality",
                      "Clonal T cells produce 1 or 2 prominent peaks (uni- or biallelic rearrangements) within diminished polyclonal background",
                      "Various strategies for calling clonal results have been proposedRatio of clonal peak height to height of polyclonal background with cutoff of ≥ 2.0 is often usedIn general, height of 3rd tallest peak is considered as height of polyclonal background",
                      "Ratio of clonal peak height to height of polyclonal background with cutoff of ≥ 2.0 is often used",
                      "In general, height of 3rd tallest peak is considered as height of polyclonal background"
                    ]
                  },
                  {
                    "text": "Next-generation sequencing (NGS) approachesCurrently used in clinical practiceGenomic DNA is extracted and enriched for rearrangedTRGsequences by PCR amplificationLibrary preparation is followed by pooling multiple samples and sequencing stepAnalysis is performed by custom software packageReads are assigned Vγ and Jγ gene segments based on sequence comparison with ImMunoGeneTics information system (IMGT) reference databaseFollowing additional computing steps, clusters containing same types of reads (based on Vγ, Jγ, and junction sequence, i.e., same types of rearrangements) are generatedReads belonging to each cluster are counted and expressed as percent of total readsClonal samples contain 1 or 2 predominant clusters when compared to background (3rd most common cluster is considered background)Polyclonal sample does not contain predominant cluster, and significant proportion of clusters contain only single readCutoff for calling results clonal in 1st-time samples is set to match sensitivity of PCR followed by CE method",
                    "sub_points": [
                      "Currently used in clinical practiceGenomic DNA is extracted and enriched for rearrangedTRGsequences by PCR amplificationLibrary preparation is followed by pooling multiple samples and sequencing stepAnalysis is performed by custom software packageReads are assigned Vγ and Jγ gene segments based on sequence comparison with ImMunoGeneTics information system (IMGT) reference databaseFollowing additional computing steps, clusters containing same types of reads (based on Vγ, Jγ, and junction sequence, i.e., same types of rearrangements) are generatedReads belonging to each cluster are counted and expressed as percent of total readsClonal samples contain 1 or 2 predominant clusters when compared to background (3rd most common cluster is considered background)Polyclonal sample does not contain predominant cluster, and significant proportion of clusters contain only single readCutoff for calling results clonal in 1st-time samples is set to match sensitivity of PCR followed by CE method",
                      "Genomic DNA is extracted and enriched for rearrangedTRGsequences by PCR amplification",
                      "Library preparation is followed by pooling multiple samples and sequencing step",
                      "Analysis is performed by custom software packageReads are assigned Vγ and Jγ gene segments based on sequence comparison with ImMunoGeneTics information system (IMGT) reference databaseFollowing additional computing steps, clusters containing same types of reads (based on Vγ, Jγ, and junction sequence, i.e., same types of rearrangements) are generatedReads belonging to each cluster are counted and expressed as percent of total readsClonal samples contain 1 or 2 predominant clusters when compared to background (3rd most common cluster is considered background)Polyclonal sample does not contain predominant cluster, and significant proportion of clusters contain only single readCutoff for calling results clonal in 1st-time samples is set to match sensitivity of PCR followed by CE method",
                      "Reads are assigned Vγ and Jγ gene segments based on sequence comparison with ImMunoGeneTics information system (IMGT) reference database",
                      "Following additional computing steps, clusters containing same types of reads (based on Vγ, Jγ, and junction sequence, i.e., same types of rearrangements) are generated",
                      "Reads belonging to each cluster are counted and expressed as percent of total reads",
                      "Clonal samples contain 1 or 2 predominant clusters when compared to background (3rd most common cluster is considered background)",
                      "Polyclonal sample does not contain predominant cluster, and significant proportion of clusters contain only single read",
                      "Cutoff for calling results clonal in 1st-time samples is set to match sensitivity of PCR followed by CE method"
                    ]
                  },
                  {
                    "text": "Advantages of NGS-based approachHigh specificity attributable to resolution of rearrangements not only by size but also by sequenceSensitivity for detection of clonal rearrangement in 1st-time sample is similar to one obtained from PCR/CE approachHigh sensitivity is achieved in follow-up specimens owing to known patient-specific junction sequence and Vγ and Jγ gene segments usedHighly suitable for disease monitoring and MRD detection",
                    "sub_points": [
                      "High specificity attributable to resolution of rearrangements not only by size but also by sequence",
                      "Sensitivity for detection of clonal rearrangement in 1st-time sample is similar to one obtained from PCR/CE approach",
                      "High sensitivity is achieved in follow-up specimens owing to known patient-specific junction sequence and Vγ and Jγ gene segments usedHighly suitable for disease monitoring and MRD detection",
                      "Highly suitable for disease monitoring and MRD detection"
                    ]
                  },
                  {
                    "text": "Caveats of NGS-based approachNGS will not eliminate all interpretation problemsSpecimens with paucity of T cells may produce limited diversity in NGS data as well as in other PCR-based strategiesMay results in false-positive diagnosisMorphology review is still critical to determine clinically relevant clonality",
                    "sub_points": [
                      "NGS will not eliminate all interpretation problems",
                      "Specimens with paucity of T cells may produce limited diversity in NGS data as well as in other PCR-based strategiesMay results in false-positive diagnosisMorphology review is still critical to determine clinically relevant clonality",
                      "May results in false-positive diagnosis",
                      "Morphology review is still critical to determine clinically relevant clonality"
                    ]
                  },
                  {
                    "text": "T-cell receptor gene rearrangements analysis using RNA sequencing (RNAseq) in T-lymphoblastic leukemiaPatient's specific T-cell receptor gene rearrangement is identified at initial presentation for follow-up MRD detectionRNAseq data is generated using antigen receptor research tool (ARResT): http://bat.infspire.orgARResT is built within EuroClonality NGS working GroupRNAseq data is analyzed using ARResT to interrogate and identify possible markers for MRD detectionThis strategy can likely be employed for disease monitoring in other subtypes of lymphoid malignancies and multiple myeloma",
                    "sub_points": [
                      "Patient's specific T-cell receptor gene rearrangement is identified at initial presentation for follow-up MRD detection",
                      "RNAseq data is generated using antigen receptor research tool (ARResT): http://bat.infspire.orgARResT is built within EuroClonality NGS working Group",
                      "ARResT is built within EuroClonality NGS working Group",
                      "RNAseq data is analyzed using ARResT to interrogate and identify possible markers for MRD detection",
                      "This strategy can likely be employed for disease monitoring in other subtypes of lymphoid malignancies and multiple myeloma"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "T-Cell Receptor Beta (TRB) Chain Gene Rearrangements": {
            "name": "T-Cell Receptor Beta (TRB) Chain Gene Rearrangements",
            "url": "https://app.pathprimer.com/document/c5f49a0c-6aa0-49db-aef1-5d45bee09503/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "T-cell receptor beta locus (TRB)Chromosomal location: 7q34IncludesVariable (Vβ) segmentsDiversity (Dβ) segmentsConstant (C) segmentsJoining (Jβ) segments",
                    "sub_points": [
                      "Chromosomal location: 7q34",
                      "IncludesVariable (Vβ) segmentsDiversity (Dβ) segmentsConstant (C) segmentsJoining (Jβ) segments",
                      "Variable (Vβ) segments",
                      "Diversity (Dβ) segments",
                      "Constant (C) segments",
                      "Joining (Jβ) segments"
                    ]
                  }
                ]
              },
              "T-Cell Development Overview": {
                "Antigen-Independent T-Cell Differentiation": [
                  {
                    "text": "ProthymocytestageT cells originate from common lymphoid progenitors in bone marrowT cells then migrate to thymusSubsequent stages of development occur in thymus",
                    "sub_points": [
                      "T cells originate from common lymphoid progenitors in bone marrowT cells then migrate to thymus",
                      "T cells then migrate to thymus",
                      "Subsequent stages of development occur in thymus"
                    ]
                  },
                  {
                    "text": "Thymocyte stageEarliest thymic precursorsCan differentiate into T or NK cellsThymic microenvironment and Notch signalingCrucial for proper T-cell developmentT-cell receptor delta (TRD) and T-cell receptor gamma (TRG)1st T-cell receptor genes that undergo somatic rearrangements during T-cell developmentT cells then go through several stages of maturation in thymus",
                    "sub_points": [
                      "Earliest thymic precursorsCan differentiate into T or NK cellsThymic microenvironment and Notch signalingCrucial for proper T-cell development",
                      "Can differentiate into T or NK cells",
                      "Thymic microenvironment and Notch signalingCrucial for proper T-cell development",
                      "Crucial for proper T-cell development",
                      "T-cell receptor delta (TRD) and T-cell receptor gamma (TRG)1st T-cell receptor genes that undergo somatic rearrangements during T-cell developmentT cells then go through several stages of maturation in thymus",
                      "1st T-cell receptor genes that undergo somatic rearrangements during T-cell development",
                      "T cells then go through several stages of maturation in thymus"
                    ]
                  },
                  {
                    "text": "CD4/CD8 double-negativesubcapsular thymocytesLack expression of T-cell receptor (TCR) complex and CD3 (a.k.a. triple-negative cells)Give rise to 2 T-cell subtypesγδ and αβ T-cellsEarly double-negative thymocytes undergoTRBDβ to Jβ rearrangementLate double-negative thymocytes undergoTRBVβ to Dβ-Jβ rearrangementExpression of pre-TCR (composed of β chain and surrogate α chain) occurs subsequent toTRBrearrangementsPre-TCR-expressing cells undergo several cycles of proliferation",
                    "sub_points": [
                      "Lack expression of T-cell receptor (TCR) complex and CD3 (a.k.a. triple-negative cells)",
                      "Give rise to 2 T-cell subtypesγδ and αβ T-cells",
                      "γδ and αβ T-cells",
                      "Early double-negative thymocytes undergoTRBDβ to Jβ rearrangement",
                      "Late double-negative thymocytes undergoTRBVβ to Dβ-Jβ rearrangement",
                      "Expression of pre-TCR (composed of β chain and surrogate α chain) occurs subsequent toTRBrearrangements",
                      "Pre-TCR-expressing cells undergo several cycles of proliferation"
                    ]
                  },
                  {
                    "text": "CD4/CD8 double-positivecortical thymocytes [CD4(+)/CD8(+)]Comprise vast majority of thymocytesInitially continue to express pre-TCREarly double-positive thymocytes then undergoTRAVα to Jα rearrangementNext, subset of resting double-positive thymocytes begin to express low levels of TCR α/β and undergo selection processThymocytes with strong reactivity with self major histocompatibility complex (MHC) molecules on thymic epithelial cells arepositively selectedMost thymocytes (~ 97%) fail selection process and undergo apoptosis within thymusInteraction with MHC class I and II molecules is essential for development of CD8(+) and CD4(+) T-cells, respectivelyThymocytes with antiself specificity (self-reacting clones)Bind to self-antigens presented by thymic dendritic cells (in context of MHC molecules)Die by apoptosis in process ofnegative selectionT cells that pass selection process migrate to thymic medulla",
                    "sub_points": [
                      "Comprise vast majority of thymocytes",
                      "Initially continue to express pre-TCR",
                      "Early double-positive thymocytes then undergoTRAVα to Jα rearrangement",
                      "Next, subset of resting double-positive thymocytes begin to express low levels of TCR α/β and undergo selection process",
                      "Thymocytes with strong reactivity with self major histocompatibility complex (MHC) molecules on thymic epithelial cells arepositively selectedMost thymocytes (~ 97%) fail selection process and undergo apoptosis within thymus",
                      "Most thymocytes (~ 97%) fail selection process and undergo apoptosis within thymus",
                      "Interaction with MHC class I and II molecules is essential for development of CD8(+) and CD4(+) T-cells, respectively",
                      "Thymocytes with antiself specificity (self-reacting clones)Bind to self-antigens presented by thymic dendritic cells (in context of MHC molecules)Die by apoptosis in process ofnegative selection",
                      "Bind to self-antigens presented by thymic dendritic cells (in context of MHC molecules)",
                      "Die by apoptosis in process ofnegative selection",
                      "T cells that pass selection process migrate to thymic medulla"
                    ]
                  },
                  {
                    "text": "CD4 or CD8 single-positivemedullary thymocytesAfter maturation is complete, these cells are exported from thymus as mature naive T cells expressing either CD4(+) or CD8(+)Mature naive T-cells are present in circulation and in paracortical region of lymph nodesMain function of mature naive T-cells is surveillance",
                    "sub_points": [
                      "After maturation is complete, these cells are exported from thymus as mature naive T cells expressing either CD4(+) or CD8(+)",
                      "Mature naive T-cells are present in circulation and in paracortical region of lymph nodesMain function of mature naive T-cells is surveillance",
                      "Main function of mature naive T-cells is surveillance"
                    ]
                  }
                ],
                "Antigen Dependent T-Cell Differentiation": [
                  {
                    "text": "Occurs inLymph node paracortexPeriarteriolar lymphoid sheath of spleenOther extranodal sites",
                    "sub_points": [
                      "Lymph node paracortex",
                      "Periarteriolar lymphoid sheath of spleen",
                      "Other extranodal sites"
                    ]
                  },
                  {
                    "text": "Interaction of TCR complex with MHC molecules on surface of antigen presenting cells (APC) is required for T-cell activation in response to antigenAs part of this process, TCR coreceptors CD4 or CD8 on T cells bind to MHC class II or I molecules on APC, respectivelyMature T cells transform to T immunoblastsTypes of T cells originated from T immunoblastsAntigen-specific effector T cellsMemory T cells of either CD4(+) or CD8(+)Effector CD4(+) and CD8(+) T cells typically act as T helper and T suppressor cells, respectivelyBoth subsets can be cytotoxic (provided that antigen is displayed in appropriate MHC class context)Different subsets of specialized CD4(+) effector T cells are now recognizedT helper 1 (Th1), Th2, and Th17 are involved mainly in cytokine productionFollicular T helper cells play role in B-cell responseT regulatory (T-reg) cells limit expansion of immune response",
                    "sub_points": [
                      "As part of this process, TCR coreceptors CD4 or CD8 on T cells bind to MHC class II or I molecules on APC, respectively",
                      "Mature T cells transform to T immunoblasts",
                      "Types of T cells originated from T immunoblastsAntigen-specific effector T cellsMemory T cells of either CD4(+) or CD8(+)",
                      "Antigen-specific effector T cells",
                      "Memory T cells of either CD4(+) or CD8(+)",
                      "Effector CD4(+) and CD8(+) T cells typically act as T helper and T suppressor cells, respectively",
                      "Both subsets can be cytotoxic (provided that antigen is displayed in appropriate MHC class context)",
                      "Different subsets of specialized CD4(+) effector T cells are now recognizedT helper 1 (Th1), Th2, and Th17 are involved mainly in cytokine productionFollicular T helper cells play role in B-cell responseT regulatory (T-reg) cells limit expansion of immune response",
                      "T helper 1 (Th1), Th2, and Th17 are involved mainly in cytokine production",
                      "Follicular T helper cells play role in B-cell response",
                      "T regulatory (T-reg) cells limit expansion of immune response"
                    ]
                  },
                  {
                    "text": "In adults, T-cell numbers are generally maintained through division of mature T cells outside of central lymphoid organs (thymus)"
                  }
                ]
              },
              "TRB Rearrangements": {
                "Overview": [
                  {
                    "text": "Sequence of somatic recombination events occurring at double-negative thymocyte stage in αβ T-cell lineage precursorsJoins gene segments that are spatially separated in germline configuration",
                    "sub_points": [
                      "Joins gene segments that are spatially separated in germline configuration"
                    ]
                  },
                  {
                    "text": "General order of TCR gene rearrangementsTRD,TRG, andTRB, followed byTRANot all αβ T-cells have rearrangedTRG; therefore, above sequence of rearrangements is not obligate",
                    "sub_points": [
                      "TRD,TRG, andTRB, followed byTRA",
                      "Not all αβ T-cells have rearrangedTRG; therefore, above sequence of rearrangements is not obligate"
                    ]
                  }
                ],
                "TRBLocus": [
                  {
                    "text": "Located at 7q34 and ~ 685 kb in size"
                  },
                  {
                    "text": "TRBvariable region gene cluster contains comparable number of V segments toIGH,IGK,IGL, andTRAloci but is far more complex thanTRDandTRGlociIncludes ~ 65 Vβ gene segments belonging to 34 families39-47 Vβ gene segments (23 families) are functional10-16 Vβ gene segments are designated as pseudogenesAll but 1 Vβ gene segments are located upstream of 2 Dβ-Jβ-Cβ clusters",
                    "sub_points": [
                      "Includes ~ 65 Vβ gene segments belonging to 34 families39-47 Vβ gene segments (23 families) are functional10-16 Vβ gene segments are designated as pseudogenes",
                      "39-47 Vβ gene segments (23 families) are functional",
                      "10-16 Vβ gene segments are designated as pseudogenes",
                      "All but 1 Vβ gene segments are located upstream of 2 Dβ-Jβ-Cβ clusters"
                    ]
                  },
                  {
                    "text": "TRBDβ-Jβ-Cβ clusters1st cluster includes 1 Dβ, 6 Jβ (all functional), and 1 Cβ gene segments2nd cluster includes 1 Dβ, 7 Jβ (also all functional), and 1 Cβ gene segmentsIn comparison withIGHlocus, both clusters combined contain more J segments but significantly fewer D segmentsIn contrast toIGH, constant-region gene cluster encoding several C segments is responsible for different functional properties of corresponding immunoglobulins;TRBCβ1 and Cβ2 gene segments are functionally indistinguishable",
                    "sub_points": [
                      "1st cluster includes 1 Dβ, 6 Jβ (all functional), and 1 Cβ gene segments",
                      "2nd cluster includes 1 Dβ, 7 Jβ (also all functional), and 1 Cβ gene segments",
                      "In comparison withIGHlocus, both clusters combined contain more J segments but significantly fewer D segments",
                      "In contrast toIGH, constant-region gene cluster encoding several C segments is responsible for different functional properties of corresponding immunoglobulins;TRBCβ1 and Cβ2 gene segments are functionally indistinguishable"
                    ]
                  },
                  {
                    "text": "TRBshows extensivecombinatorial diversityowing to broad germline-encoded repertoire of available gene segments"
                  },
                  {
                    "text": "Junctional diversityis also significant at both Dβ-Jβ and Vβ-Dβ junctions"
                  }
                ],
                "Recombination Process": [
                  {
                    "text": "TRBrearrangements follow similar steps and use same enzymes and cellular machinery as other TCR and immunoglobulin gene rearrangements"
                  },
                  {
                    "text": "Consists of 2 consecutive steps: Dβ to Jβ rearrangement, followed by Vβ to Dβ-Jβ rearrangementDβ1 segment may join either Jβ1 or Jβ2 segments; however, Dβ2 can only join Jβ2 segments",
                    "sub_points": [
                      "Dβ1 segment may join either Jβ1 or Jβ2 segments; however, Dβ2 can only join Jβ2 segments"
                    ]
                  },
                  {
                    "text": "Owing to presence of 2 consecutive Dβ-Jβ-Cβ clusters, 2 Dβ-Jβ rearrangements can be detected on 1 allele, howeverOnly 1 of them can progress to complete Vβ-Dβ-Jβ rearrangement",
                    "sub_points": [
                      "Only 1 of them can progress to complete Vβ-Dβ-Jβ rearrangement"
                    ]
                  },
                  {
                    "text": "TRBrearrangements occurring in healthy individuals are characterized by nonrandom distribution of Vβ and Jβ gene segmentsSome Vβ families are more commonly rearranged than others (e.g., Vβ1-Vβ5 rearranged cells are common in peripheral blood T cells)Jβ2 cluster is used more frequently than Jβ1 cluster",
                    "sub_points": [
                      "Some Vβ families are more commonly rearranged than others (e.g., Vβ1-Vβ5 rearranged cells are common in peripheral blood T cells)",
                      "Jβ2 cluster is used more frequently than Jβ1 cluster"
                    ]
                  }
                ]
              },
              "Clonality Testing": {
                "General Comments": [
                  {
                    "text": "Clonality does not equal malignancyBenign conditions can produce clonal patterns due to antigen-driven lymphocyte expansions",
                    "sub_points": [
                      "Benign conditions can produce clonal patterns due to antigen-driven lymphocyte expansions"
                    ]
                  },
                  {
                    "text": "Clonal rearrangements are not lineage specificB-cell malignancies (especially of B-cell precursors) often have clonal TCR gene rearrangementsT-cell malignancies can also have clonal immunoglobulin gene rearrangements",
                    "sub_points": [
                      "B-cell malignancies (especially of B-cell precursors) often have clonal TCR gene rearrangements",
                      "T-cell malignancies can also have clonal immunoglobulin gene rearrangements"
                    ]
                  },
                  {
                    "text": "Results of clonality testing always should be interpreted within appropriate clinical context and in conjunction with morphologic findings"
                  },
                  {
                    "text": "Rationales for usingTRBlocus as target for clonality assessmentExtensive combinatorial diversity in conjunction with significant junctional diversity provide background for highly specific detection of clonal populationsPolymerase chain reaction (PCR) assay design is more challenging due to extensive combinatorial diversityTargeting solelyTRGrearrangements is usually sufficient approach in T-cell clonality assessmentComplementing it withTRBrearrangement analysis can improve clinical sensitivity and be valuable in certain cases",
                    "sub_points": [
                      "Extensive combinatorial diversity in conjunction with significant junctional diversity provide background for highly specific detection of clonal populationsPolymerase chain reaction (PCR) assay design is more challenging due to extensive combinatorial diversity",
                      "Polymerase chain reaction (PCR) assay design is more challenging due to extensive combinatorial diversity",
                      "Targeting solelyTRGrearrangements is usually sufficient approach in T-cell clonality assessmentComplementing it withTRBrearrangement analysis can improve clinical sensitivity and be valuable in certain cases",
                      "Complementing it withTRBrearrangement analysis can improve clinical sensitivity and be valuable in certain cases"
                    ]
                  },
                  {
                    "text": "Commercially available monoclonal antibodies specific to various TCR Vβ regionsAlternative to nucleic acid-based assays for detection of clonality",
                    "sub_points": [
                      "Alternative to nucleic acid-based assays for detection of clonality"
                    ]
                  }
                ],
                "Nucleic Acid-Based Methods": [
                  {
                    "text": "Southern blot hybridizationUsed to be gold standard for clonality analysis, now largely replaced by PCR-based approachesBased on principle that antigen receptor gene rearrangements alter restriction-digested DNA fragments compared with germline DNAGenes with significant combinatorial diversity, such asIGH,IGK, andTRBare suitable targetsRequires significant amount of high-quality intact DNASensitivity of this method is ~ 5-10%Individual gene rearrangements are not detected unless they are overrepresented at ≥ 5% in background lymphoid cellsPolyclonal sample appears as germline bands onlyClonal rearrangements appear as novel bandsAt least 2 nongermline bands required to reliably diagnose clonalTRBrearrangementDNA polymorphism may lead to nongermline band that could be confused with clonal population",
                    "sub_points": [
                      "Used to be gold standard for clonality analysis, now largely replaced by PCR-based approaches",
                      "Based on principle that antigen receptor gene rearrangements alter restriction-digested DNA fragments compared with germline DNAGenes with significant combinatorial diversity, such asIGH,IGK, andTRBare suitable targets",
                      "Genes with significant combinatorial diversity, such asIGH,IGK, andTRBare suitable targets",
                      "Requires significant amount of high-quality intact DNA",
                      "Sensitivity of this method is ~ 5-10%",
                      "Individual gene rearrangements are not detected unless they are overrepresented at ≥ 5% in background lymphoid cellsPolyclonal sample appears as germline bands onlyClonal rearrangements appear as novel bandsAt least 2 nongermline bands required to reliably diagnose clonalTRBrearrangementDNA polymorphism may lead to nongermline band that could be confused with clonal population",
                      "Polyclonal sample appears as germline bands only",
                      "Clonal rearrangements appear as novel bands",
                      "At least 2 nongermline bands required to reliably diagnose clonalTRBrearrangementDNA polymorphism may lead to nongermline band that could be confused with clonal population",
                      "DNA polymorphism may lead to nongermline band that could be confused with clonal population"
                    ]
                  },
                  {
                    "text": "PCR-based approachesCurrent gold standard for clonality analysisBased on principle that somaticTCRrearrangements bring V, (D), and J segments together, enabling their PCR amplificationNo PCR product is generated if germline configuration is retainedEach rearrangement is unique in length and sequence due to combinatorial and junctional diversityCan be performed on variety of specimen types, including formalin-fixed, paraffin-embedded tissue",
                    "sub_points": [
                      "Current gold standard for clonality analysis",
                      "Based on principle that somaticTCRrearrangements bring V, (D), and J segments together, enabling their PCR amplificationNo PCR product is generated if germline configuration is retained",
                      "No PCR product is generated if germline configuration is retained",
                      "Each rearrangement is unique in length and sequence due to combinatorial and junctional diversity",
                      "Can be performed on variety of specimen types, including formalin-fixed, paraffin-embedded tissue"
                    ]
                  },
                  {
                    "text": "ProtocolGenomic DNA is extracted and CDR3 region (as most variable) is PCR amplifiedBIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is most commonly usedCommercial kits are available (e.g.,TRBGene Clonality Assay from Invivoscribe)3 multiplex tubes design allows detection of vast majority of complete and incomplete clonalTRBrearrangementsTube A: 23 Vβ primers plus 6 Jβ1 and 3 Jβ2 primersTube B: 23 Vβ primers plus 4 Jβ2 primersTube C: 2 Dβ primers plus 13 Jβ primers (for incomplete rearrangements detection)Fractionation by capillary electrophoresis (CE)One of PCR primes requires fluorescent labelingSeparates amplicons based on length onlyNo sequence is evaluatedConventional gel electrophoresis can also be used as alternative, but it is more labor intensive and time consuming with much lower resolutionInterpretation should be assay and specimen specific and based on in-house validation procedurePolyclonal T cells generate gaussian (bell-shaped) distribution of amplicon sizesMultiple peaks represent either oligoclonal T-cell expansion or few T cells in specimenClonal T cells produce 1 or 2 prominent peaks within diminished polyclonal backgroundVarious strategies for calling clonal results have been proposedGenerally not suitable for minimal residual disease (MRD) monitoring, unless specific primers are designed to detect patient-specific clone",
                    "sub_points": [
                      "Genomic DNA is extracted and CDR3 region (as most variable) is PCR amplifiedBIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is most commonly usedCommercial kits are available (e.g.,TRBGene Clonality Assay from Invivoscribe)3 multiplex tubes design allows detection of vast majority of complete and incomplete clonalTRBrearrangementsTube A: 23 Vβ primers plus 6 Jβ1 and 3 Jβ2 primersTube B: 23 Vβ primers plus 4 Jβ2 primersTube C: 2 Dβ primers plus 13 Jβ primers (for incomplete rearrangements detection)",
                      "BIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is most commonly usedCommercial kits are available (e.g.,TRBGene Clonality Assay from Invivoscribe)3 multiplex tubes design allows detection of vast majority of complete and incomplete clonalTRBrearrangementsTube A: 23 Vβ primers plus 6 Jβ1 and 3 Jβ2 primersTube B: 23 Vβ primers plus 4 Jβ2 primersTube C: 2 Dβ primers plus 13 Jβ primers (for incomplete rearrangements detection)",
                      "Commercial kits are available (e.g.,TRBGene Clonality Assay from Invivoscribe)",
                      "3 multiplex tubes design allows detection of vast majority of complete and incomplete clonalTRBrearrangements",
                      "Tube A: 23 Vβ primers plus 6 Jβ1 and 3 Jβ2 primers",
                      "Tube B: 23 Vβ primers plus 4 Jβ2 primers",
                      "Tube C: 2 Dβ primers plus 13 Jβ primers (for incomplete rearrangements detection)",
                      "Fractionation by capillary electrophoresis (CE)One of PCR primes requires fluorescent labelingSeparates amplicons based on length onlyNo sequence is evaluatedConventional gel electrophoresis can also be used as alternative, but it is more labor intensive and time consuming with much lower resolution",
                      "One of PCR primes requires fluorescent labeling",
                      "Separates amplicons based on length onlyNo sequence is evaluated",
                      "No sequence is evaluated",
                      "Conventional gel electrophoresis can also be used as alternative, but it is more labor intensive and time consuming with much lower resolution",
                      "Interpretation should be assay and specimen specific and based on in-house validation procedurePolyclonal T cells generate gaussian (bell-shaped) distribution of amplicon sizesMultiple peaks represent either oligoclonal T-cell expansion or few T cells in specimenClonal T cells produce 1 or 2 prominent peaks within diminished polyclonal backgroundVarious strategies for calling clonal results have been proposed",
                      "Polyclonal T cells generate gaussian (bell-shaped) distribution of amplicon sizes",
                      "Multiple peaks represent either oligoclonal T-cell expansion or few T cells in specimen",
                      "Clonal T cells produce 1 or 2 prominent peaks within diminished polyclonal background",
                      "Various strategies for calling clonal results have been proposed",
                      "Generally not suitable for minimal residual disease (MRD) monitoring, unless specific primers are designed to detect patient-specific clone"
                    ]
                  },
                  {
                    "text": "Next-generation sequencing(NGS)approachesUsed for risk stratification mainly in pediatric and young adult patients with acute lymphoblastic leukemia (ALL) post chemotherapy and hematopoietic stem cell transplantHighly sensitive minimal residual disease (MRD) detection of specificIGHor T-cell receptor gene rearrangementsDetects blasts at levels ≤ 10⁻⁶ cellsHigh specificity attributable to resolution of rearrangements not only by size but also by sequence",
                    "sub_points": [
                      "Used for risk stratification mainly in pediatric and young adult patients with acute lymphoblastic leukemia (ALL) post chemotherapy and hematopoietic stem cell transplantHighly sensitive minimal residual disease (MRD) detection of specificIGHor T-cell receptor gene rearrangementsDetects blasts at levels ≤ 10⁻⁶ cells",
                      "Highly sensitive minimal residual disease (MRD) detection of specificIGHor T-cell receptor gene rearrangementsDetects blasts at levels ≤ 10⁻⁶ cells",
                      "Detects blasts at levels ≤ 10⁻⁶ cells",
                      "High specificity attributable to resolution of rearrangements not only by size but also by sequence"
                    ]
                  }
                ],
                "Antibody-Based Methods": [
                  {
                    "text": "TCR Vβ analysisby flow cytometryValid alternative to nucleic acid-based methodsFresh tissue requirement is major drawbackAbility to separately interrogate populations of interest based on phenotype is main advantagePrinciples of methodMonoclonal antibodies (mAb) to specific TCR Vβ regions are commercially available (e.g., IOTest Beta Mark Kit from Beckman Coulter)Polyclonal T cells express diverse TCR Vβ and stain with mixture of mAbsMonoclonal T cells stain with single mAb type (specific to TCR Vβ expressed by these T-cells)Alternatively, if specific Vβ expressed by monoclonal T-cells is not covered, significant population of T cells will not stain at allUtilizes innovative staining strategy combining 3 mAb with only 2 fluorophores in single vial, thereby minimizing number of vials needed1st and 2nd mAb are FITC or PE-conjugated, respectively, and 3rd mAb is conjugated with mixture of both fluorophores8 vials with mAb corresponding to 24 different specificities (covering ~ 70% of normal human TCR Vβ repertoire) are generally usedMonoclonal antibodies for additional T-cell markers, such as CD3, CD4, and CD8, conjugated to 3rd fluorophore can be used for gating purposes",
                    "sub_points": [
                      "Valid alternative to nucleic acid-based methodsFresh tissue requirement is major drawbackAbility to separately interrogate populations of interest based on phenotype is main advantage",
                      "Fresh tissue requirement is major drawback",
                      "Ability to separately interrogate populations of interest based on phenotype is main advantage",
                      "Principles of methodMonoclonal antibodies (mAb) to specific TCR Vβ regions are commercially available (e.g., IOTest Beta Mark Kit from Beckman Coulter)Polyclonal T cells express diverse TCR Vβ and stain with mixture of mAbsMonoclonal T cells stain with single mAb type (specific to TCR Vβ expressed by these T-cells)Alternatively, if specific Vβ expressed by monoclonal T-cells is not covered, significant population of T cells will not stain at all",
                      "Monoclonal antibodies (mAb) to specific TCR Vβ regions are commercially available (e.g., IOTest Beta Mark Kit from Beckman Coulter)Polyclonal T cells express diverse TCR Vβ and stain with mixture of mAbsMonoclonal T cells stain with single mAb type (specific to TCR Vβ expressed by these T-cells)Alternatively, if specific Vβ expressed by monoclonal T-cells is not covered, significant population of T cells will not stain at all",
                      "Polyclonal T cells express diverse TCR Vβ and stain with mixture of mAbs",
                      "Monoclonal T cells stain with single mAb type (specific to TCR Vβ expressed by these T-cells)",
                      "Alternatively, if specific Vβ expressed by monoclonal T-cells is not covered, significant population of T cells will not stain at all",
                      "Utilizes innovative staining strategy combining 3 mAb with only 2 fluorophores in single vial, thereby minimizing number of vials needed1st and 2nd mAb are FITC or PE-conjugated, respectively, and 3rd mAb is conjugated with mixture of both fluorophores8 vials with mAb corresponding to 24 different specificities (covering ~ 70% of normal human TCR Vβ repertoire) are generally used",
                      "1st and 2nd mAb are FITC or PE-conjugated, respectively, and 3rd mAb is conjugated with mixture of both fluorophores",
                      "8 vials with mAb corresponding to 24 different specificities (covering ~ 70% of normal human TCR Vβ repertoire) are generally used",
                      "Monoclonal antibodies for additional T-cell markers, such as CD3, CD4, and CD8, conjugated to 3rd fluorophore can be used for gating purposes"
                    ]
                  }
                ],
                "Chimeric Antigen Receptor-Modified T Cells": [
                  {
                    "text": "CAR-modified T cells have been developed targeting antigens, includingCD30, CD37, TRB constant region 1 (TRBC1), and CD1A",
                    "sub_points": [
                      "CD30, CD37, TRB constant region 1 (TRBC1), and CD1A"
                    ]
                  },
                  {
                    "text": "Anti-Vβ8 CAR-modified T cells can recognize and kill Vβ8(+) malignant T-cells while sparing malignant or healthy Vβ8-negative T cells"
                  },
                  {
                    "text": "In vitro studies have demonstrated promising results in selective CAR-modified T-cell therapy to eradicate T-cell malignancies"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "EZH2Mutation": {
            "name": "EZH2Mutation",
            "url": "https://app.pathprimer.com/document/217ec88b-97d4-4f3f-91b2-83f5cec5b972/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: Enhancer of zeste 2 polycomb repressive complex 2 subunit"
                  },
                  {
                    "text": "Official symbol:EZH2"
                  },
                  {
                    "text": "HGNC ID: 3527"
                  },
                  {
                    "text": "Chromosomal location: 7q36.1"
                  },
                  {
                    "text": "Genomic coordinates (GRCh38):Ch7:148,807,383-148,884,291"
                  },
                  {
                    "text": "Number of exons: 26"
                  },
                  {
                    "text": "Aliases:ENX1,KMT6,KMT6A"
                  }
                ]
              },
              "Normal EZH2 Function": {
                "Encodes EZH2 Protein": [
                  {
                    "text": "Member of polycomb-group (PcG) family, which functions as gene silencers"
                  },
                  {
                    "text": "Enzyme that methylates lysine 27 of histone H3 (H3K27)SET is catalytic domain of EZH2, and it transfers up to 3 methyl groupsFunctions as part of complex containing other proteins, including EED, SUZ12, and RBBP7Histone methylation leads to more condensed chromatin state and transcriptional repressionRemoval of methyl group by demethylases, such as UTX and JMJD3, reverses action of EZH2",
                    "sub_points": [
                      "SET is catalytic domain of EZH2, and it transfers up to 3 methyl groups",
                      "Functions as part of complex containing other proteins, including EED, SUZ12, and RBBP7",
                      "Histone methylation leads to more condensed chromatin state and transcriptional repression",
                      "Removal of methyl group by demethylases, such as UTX and JMJD3, reverses action of EZH2"
                    ]
                  },
                  {
                    "text": "Plays role in hematopoietic and central nervous system development"
                  }
                ]
              },
              "Somatic EZH2 Mutations": {
                "Gain-of-Function Mutations": [
                  {
                    "text": "Seen in lymphomasEZH2functions as oncogene in lymphomas",
                    "sub_points": [
                      "EZH2functions as oncogene in lymphomas"
                    ]
                  },
                  {
                    "text": "Almost all are missense mutations occurring at codon 646Result in replacement of single tyrosine (Tyr646) in SET domain ofEZH2",
                    "sub_points": [
                      "Result in replacement of single tyrosine (Tyr646) in SET domain ofEZH2"
                    ]
                  },
                  {
                    "text": "Mutations in codons 682 and 692 have been reported in follicular lymphomas (FLs) and diffuse large B-cell lymphoma (DLBCL), such as A692V and A682G"
                  },
                  {
                    "text": "All mutations are heterozygous"
                  }
                ],
                "Loss-of-Function Mutations": [
                  {
                    "text": "Are seen in myeloid neoplasms and T-acute lymphoblastic leukemia (T-ALL)EZH2functions as tumor suppressor gene in myeloid neoplasia",
                    "sub_points": [
                      "EZH2functions as tumor suppressor gene in myeloid neoplasia"
                    ]
                  },
                  {
                    "text": "> 50 different mutations reported"
                  },
                  {
                    "text": "Mutations are either missense or truncatingMissense mutations involve evolutionary highly conserved residues that are located in domain II and CXC-SET domainsTruncating mutations are dispersed throughout geneInclude both nonsense and frameshift due to deletions or insertions1 mutation is reported at splice site",
                    "sub_points": [
                      "Missense mutations involve evolutionary highly conserved residues that are located in domain II and CXC-SET domains",
                      "Truncating mutations are dispersed throughout geneInclude both nonsense and frameshift due to deletions or insertions1 mutation is reported at splice site",
                      "Include both nonsense and frameshift due to deletions or insertions",
                      "1 mutation is reported at splice site"
                    ]
                  },
                  {
                    "text": "Can be homozygous, hemizygous, or heterozygous"
                  },
                  {
                    "text": "Loss of function ofEZH2in myeloid neoplasms can also occur due to del(7q) or -7"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "Gain-of-function mutations in lymphomas~ 22% in DLBCL7-27% in FL",
                    "sub_points": [
                      "~ 22% in DLBCL",
                      "7-27% in FL"
                    ]
                  },
                  {
                    "text": "Loss-of-function mutations in myeloid malignancies and lymphoid leukemias~ 12% in myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN)3-7% in MDS~ 6% in MPN< 2% in acute myeloid leukemia (AML)~ 18% in T-ALL",
                    "sub_points": [
                      "~ 12% in myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN)",
                      "3-7% in MDS",
                      "~ 6% in MPN",
                      "< 2% in acute myeloid leukemia (AML)",
                      "~ 18% in T-ALL"
                    ]
                  },
                  {
                    "text": "Increased expression ofEZH2has been found in many solid tumorsBroad range of incidence reported",
                    "sub_points": [
                      "Broad range of incidence reported"
                    ]
                  }
                ]
              },
              "Method of Detection": {
                "Whole-Exome Sequencing": [
                  {
                    "text": "Considered for myeloid neoplasmsTypically performed using massively parallel sequencing (next-generation sequencing)All coding exons of gene should be sequencedTumor percentage should be at least 2x of sensitivity limit of detection for heterozygous mutations",
                    "sub_points": [
                      "Typically performed using massively parallel sequencing (next-generation sequencing)",
                      "All coding exons of gene should be sequenced",
                      "Tumor percentage should be at least 2x of sensitivity limit of detection for heterozygous mutations"
                    ]
                  },
                  {
                    "text": "Can be performed on formalin-fixed, paraffin-embedded tissue or fresh tissue"
                  }
                ],
                "Targeted Sequencing": [
                  {
                    "text": "Can be performed by Sanger sequencing, pyrosequencing, or next-generation sequencing"
                  },
                  {
                    "text": "For cases of DLBCL and FL, selective sequencing of codon 646 is sufficientAll mutations are heterozygousTumor percentage in specimen should be at least 2x of sensitivity limit of assay",
                    "sub_points": [
                      "All mutations are heterozygous",
                      "Tumor percentage in specimen should be at least 2x of sensitivity limit of assay"
                    ]
                  }
                ],
                "High-Resolution Melting Curve Analysis": [
                  {
                    "text": "Inexpensive screening method to detect codon 646 mutations in FL and DLBCLAmplified DNA of interest should not exceed 300 bpAmplification of DNA regions that might potentially harbor single-nucleotide polymorphism (SNP) must be avoidedPositive cases demonstrate abnormal melting curve when compared to wildtypePositive results should be confirmed by sequencing",
                    "sub_points": [
                      "Amplified DNA of interest should not exceed 300 bp",
                      "Amplification of DNA regions that might potentially harbor single-nucleotide polymorphism (SNP) must be avoided",
                      "Positive cases demonstrate abnormal melting curve when compared to wildtypePositive results should be confirmed by sequencing",
                      "Positive results should be confirmed by sequencing"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Performed on formalin-fixed, paraffin-embedded tissue"
                  },
                  {
                    "text": "Used to detect EZH2 protein overexpressionPositive nuclear staining indicates EZH2 overexpressionResults are reported as positive or negative for solid tumors in majority of published studies with no minimal requirement for percentage of positive cells",
                    "sub_points": [
                      "Positive nuclear staining indicates EZH2 overexpression",
                      "Results are reported as positive or negative for solid tumors in majority of published studies with no minimal requirement for percentage of positive cells"
                    ]
                  },
                  {
                    "text": "Positive prognostic impact of EZH2 overexpression in DLBCLRequires ≥ 70% positivity among tumor cells",
                    "sub_points": [
                      "Requires ≥ 70% positivity among tumor cells"
                    ]
                  }
                ],
                "Fluorescence In Situ Hybridization": [
                  {
                    "text": "Available for formalin-fixed, paraffin-embedded tissue"
                  },
                  {
                    "text": "Detects gene amplification"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "Most common form of non-Hodgkin lymphoma (NHL)"
                  },
                  {
                    "text": "Can be classified according to cell of origin into 2 major broad categoriesGerminal center B-cell (GCB) typeAssociated with better prognosisFrequently show t(14;18)Activated B-cell typeAssociated with worse prognosisCell of origin determination in DLBCL is done by gene expression profiling (GEP)Panel of antibodies by immunohistochemistry can be used as alternative or surrogate marker for GEP",
                    "sub_points": [
                      "Germinal center B-cell (GCB) typeAssociated with better prognosisFrequently show t(14;18)",
                      "Associated with better prognosis",
                      "Frequently show t(14;18)",
                      "Activated B-cell typeAssociated with worse prognosis",
                      "Associated with worse prognosis",
                      "Cell of origin determination in DLBCL is done by gene expression profiling (GEP)Panel of antibodies by immunohistochemistry can be used as alternative or surrogate marker for GEP",
                      "Panel of antibodies by immunohistochemistry can be used as alternative or surrogate marker for GEP"
                    ]
                  },
                  {
                    "text": "EZH2mutations in DLBCL are almost exclusively seen in GCB subtype of DLBCLRarely,EZH2mutation may be seen in non-GCB subtype of DLBCL in setting of immunodeficiencyMutations are rare or absent in GCB subtype of primary DLBCL of central nervous system",
                    "sub_points": [
                      "Rarely,EZH2mutation may be seen in non-GCB subtype of DLBCL in setting of immunodeficiency",
                      "Mutations are rare or absent in GCB subtype of primary DLBCL of central nervous system"
                    ]
                  },
                  {
                    "text": "Overexpression of EZH2 in absence of mutation occurs in both GCB and activated B-cell (ABC) subtypes of DLBCLsHigh levels of expression (≥ 70% ) are associated with superior overall survivalHighest survival rate in ABC subtype with EZH2 overexpression",
                    "sub_points": [
                      "High levels of expression (≥ 70% ) are associated with superior overall survivalHighest survival rate in ABC subtype with EZH2 overexpression",
                      "Highest survival rate in ABC subtype with EZH2 overexpression"
                    ]
                  },
                  {
                    "text": "No correlation betweenEZH2mutation and EZH2 protein overexpression"
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "2nd most common type of NHL"
                  },
                  {
                    "text": "Neoplasm of follicle center B cells that usually has at least partially follicular growth pattern"
                  },
                  {
                    "text": "Majority of cases demonstrate t(14;18), resulting inIGH::BCL2fusion"
                  },
                  {
                    "text": "EZH2mutation is early event in FLIn 20% of mutant cases, mutation is only detected in subset of neoplastic cells (subclonal mutation)",
                    "sub_points": [
                      "In 20% of mutant cases, mutation is only detected in subset of neoplastic cells (subclonal mutation)"
                    ]
                  }
                ],
                "Other Lymphoid Malignancies": [
                  {
                    "text": "Natural killer/T-cell lymphoma (NK-/T-cell lymphoma)Predominantly extranodal lymphoma showing NK-cell &/or cytotoxic T-cell phenotypeAngiodestructive and angiocentric patternsProminent necrosisStrong association with Epstein-Barr virus (EBV)EZH2 protein is overexpressed in majority of NK-/T-cell lymphomasOverexpression is associated with poorer outcome",
                    "sub_points": [
                      "Predominantly extranodal lymphoma showing NK-cell &/or cytotoxic T-cell phenotypeAngiodestructive and angiocentric patternsProminent necrosisStrong association with Epstein-Barr virus (EBV)",
                      "Angiodestructive and angiocentric patterns",
                      "Prominent necrosis",
                      "Strong association with Epstein-Barr virus (EBV)",
                      "EZH2 protein is overexpressed in majority of NK-/T-cell lymphomasOverexpression is associated with poorer outcome",
                      "Overexpression is associated with poorer outcome"
                    ]
                  },
                  {
                    "text": "T-lymphoblastic leukemia/lymphomaNeoplasm of lymphoblasts committed to T-cell lineageBlasts are small to medium-sized cells with scant cytoplasm and dispersed chromatinBlasts are detected in peripheral blood &/or bone marrowEarly T-cell precursor ALL is distinct subtypeArise from neoplastic cells with very early arrest in T-cell differentiationShow higher prevalence of mutations associated with myeloid neoplasmsAssociated with particularly poor prognosisEZH2mutations are common in T-ALL, including early T-ALLEZH2mutations are frequently seen concurrently withNOTCH1mutations",
                    "sub_points": [
                      "Neoplasm of lymphoblasts committed to T-cell lineageBlasts are small to medium-sized cells with scant cytoplasm and dispersed chromatinBlasts are detected in peripheral blood &/or bone marrow",
                      "Blasts are small to medium-sized cells with scant cytoplasm and dispersed chromatin",
                      "Blasts are detected in peripheral blood &/or bone marrow",
                      "Early T-cell precursor ALL is distinct subtypeArise from neoplastic cells with very early arrest in T-cell differentiationShow higher prevalence of mutations associated with myeloid neoplasmsAssociated with particularly poor prognosis",
                      "Arise from neoplastic cells with very early arrest in T-cell differentiation",
                      "Show higher prevalence of mutations associated with myeloid neoplasms",
                      "Associated with particularly poor prognosis",
                      "EZH2mutations are common in T-ALL, including early T-ALL",
                      "EZH2mutations are frequently seen concurrently withNOTCH1mutations"
                    ]
                  },
                  {
                    "text": "Burkitt lymphoma (BL)B-cell lymphoma with extremely short doubling time often presenting in extranodal sitesCharacterized by translocation involvingMYCat 8q24Divided into 3 broad categoriesEndemic: Equatorial Africa, mainly in childrenSporadic: Throughout world in children and adultsImmunodeficiency associated, mainly seen in patients with HIVEZH2mutations similar to those seen in DLBCL have been reported in BL associated with immunodeficiency",
                    "sub_points": [
                      "B-cell lymphoma with extremely short doubling time often presenting in extranodal sitesCharacterized by translocation involvingMYCat 8q24",
                      "Characterized by translocation involvingMYCat 8q24",
                      "Divided into 3 broad categoriesEndemic: Equatorial Africa, mainly in childrenSporadic: Throughout world in children and adultsImmunodeficiency associated, mainly seen in patients with HIV",
                      "Endemic: Equatorial Africa, mainly in children",
                      "Sporadic: Throughout world in children and adults",
                      "Immunodeficiency associated, mainly seen in patients with HIV",
                      "EZH2mutations similar to those seen in DLBCL have been reported in BL associated with immunodeficiency"
                    ]
                  }
                ],
                "EZH2Mutations in Myeloid Neoplasms": [
                  {
                    "text": "Generally associated with worse outcomeMutations can be homozygous, hemizygous, or heterozygousHomozygous mutations might be associated with poorer survival than heterozygous",
                    "sub_points": [
                      "Mutations can be homozygous, hemizygous, or heterozygousHomozygous mutations might be associated with poorer survival than heterozygous",
                      "Homozygous mutations might be associated with poorer survival than heterozygous"
                    ]
                  },
                  {
                    "text": "In general, cases that contain karyotypically visible abnormalities of chromosome 7, including del(7q) or -7, are mostly negative forEZH2mutations"
                  },
                  {
                    "text": "Cases with karyotypically invisible abnormalities of chromosome 7 (unipaternal disomy for 7q or 7q36 microdeletion) are frequently associated withEZH2mutations"
                  }
                ],
                "EZH2Mutations in Specific Categories of Myeloid Neoplasms": [
                  {
                    "text": "Myelodysplastic syndromesGroup of clonal hematopoietic stem cell diseases characterized byCytopeniasDysplasia in ≥ 1 of myeloid cell linesIneffective hematopoiesisIncreased risk of development of AMLRevised International Prognostic Scoring System (IPSS-R) is used to predict prognosisIncorporates severity of cytopenias, bone marrow blasts percentage, and cytogenetic abnormalitiesEZH2mutations are present in subset of casesAssociated with worse outcome if present, even in patients with favorable IPSS-RLower risk patients with myelodysplastic syndromes who haveEZH2mutations may require more aggressive treatment than would be predicted by IPSS-R",
                    "sub_points": [
                      "Group of clonal hematopoietic stem cell diseases characterized byCytopeniasDysplasia in ≥ 1 of myeloid cell linesIneffective hematopoiesisIncreased risk of development of AML",
                      "Cytopenias",
                      "Dysplasia in ≥ 1 of myeloid cell lines",
                      "Ineffective hematopoiesis",
                      "Increased risk of development of AML",
                      "Revised International Prognostic Scoring System (IPSS-R) is used to predict prognosisIncorporates severity of cytopenias, bone marrow blasts percentage, and cytogenetic abnormalities",
                      "Incorporates severity of cytopenias, bone marrow blasts percentage, and cytogenetic abnormalities",
                      "EZH2mutations are present in subset of casesAssociated with worse outcome if present, even in patients with favorable IPSS-RLower risk patients with myelodysplastic syndromes who haveEZH2mutations may require more aggressive treatment than would be predicted by IPSS-R",
                      "Associated with worse outcome if present, even in patients with favorable IPSS-R",
                      "Lower risk patients with myelodysplastic syndromes who haveEZH2mutations may require more aggressive treatment than would be predicted by IPSS-R"
                    ]
                  },
                  {
                    "text": "MDS/MPNClonal myeloid neoplasms that at time of initial presentation are associated with some findings that support diagnosis of MDS and other findings more consistent with MPNEZH2mutations are present in 10% of casesFrequently cooccur withTET2(58%),RUNX1(40%), andASXL1(34%) mutationsAssociated with poorer outcome",
                    "sub_points": [
                      "Clonal myeloid neoplasms that at time of initial presentation are associated with some findings that support diagnosis of MDS and other findings more consistent with MPN",
                      "EZH2mutations are present in 10% of casesFrequently cooccur withTET2(58%),RUNX1(40%), andASXL1(34%) mutationsAssociated with poorer outcome",
                      "Frequently cooccur withTET2(58%),RUNX1(40%), andASXL1(34%) mutations",
                      "Associated with poorer outcome"
                    ]
                  },
                  {
                    "text": "Primary myelofibrosisClonal MPN characterized by proliferation of predominantly megakaryocytes and granulocytes in bone marrowAssociated with reactive deposition of fibrous tissue and extramedullary hematopoiesis in fibrotic phase of diseaseMost patients have splenomegalyMost cases demonstrate mutations inJAK2,MPL, orCALREZH2mutation is associated with significantly higher leukocyte count, blast count, and larger spleen at diagnosis",
                    "sub_points": [
                      "Clonal MPN characterized by proliferation of predominantly megakaryocytes and granulocytes in bone marrowAssociated with reactive deposition of fibrous tissue and extramedullary hematopoiesis in fibrotic phase of diseaseMost patients have splenomegalyMost cases demonstrate mutations inJAK2,MPL, orCALR",
                      "Associated with reactive deposition of fibrous tissue and extramedullary hematopoiesis in fibrotic phase of disease",
                      "Most patients have splenomegaly",
                      "Most cases demonstrate mutations inJAK2,MPL, orCALR",
                      "EZH2mutation is associated with significantly higher leukocyte count, blast count, and larger spleen at diagnosis"
                    ]
                  },
                  {
                    "text": "AMLGroup of relatively well-defined hematopoietic neoplasms involving precursor cells committed to myeloid lineageClassified into 4 major groupsAML with recurrent genetic abnormalitiesAML with myelodysplasia-related changesTherapy-related myeloid neoplasmsAML, not otherwise specifiedEZH2mutations have been reported in small minority of casesMore common in male patientsAssociated with lower blast percentage (21-30%) in bone marrowNo influence on achieving complete remission or overall survival",
                    "sub_points": [
                      "Group of relatively well-defined hematopoietic neoplasms involving precursor cells committed to myeloid lineage",
                      "Classified into 4 major groupsAML with recurrent genetic abnormalitiesAML with myelodysplasia-related changesTherapy-related myeloid neoplasmsAML, not otherwise specified",
                      "AML with recurrent genetic abnormalities",
                      "AML with myelodysplasia-related changes",
                      "Therapy-related myeloid neoplasms",
                      "AML, not otherwise specified",
                      "EZH2mutations have been reported in small minority of casesMore common in male patientsAssociated with lower blast percentage (21-30%) in bone marrowNo influence on achieving complete remission or overall survival",
                      "More common in male patients",
                      "Associated with lower blast percentage (21-30%) in bone marrow",
                      "No influence on achieving complete remission or overall survival"
                    ]
                  }
                ],
                "EZH2 Protein Overexpression in Solid Tumors": [
                  {
                    "text": "Overexpression of EZH2 was first described in several nonhematological malignanciesSteadily increases as disease progression takes place, which is particularly notable in breast cancerAssociated with poorer outcome",
                    "sub_points": [
                      "Steadily increases as disease progression takes place, which is particularly notable in breast cancer",
                      "Associated with poorer outcome"
                    ]
                  },
                  {
                    "text": "MYC overexpression parallels overexpression of EZH2 and is known to induce EZH2 expressionBinds directly to promoter region ofEZH2and activates its transcription",
                    "sub_points": [
                      "Binds directly to promoter region ofEZH2and activates its transcription"
                    ]
                  },
                  {
                    "text": "EZH2inhibition might be promising therapeutic target in solid tumors"
                  },
                  {
                    "text": "No correlation between EZH2 protein overexpression and presence ofEZH2mutation"
                  },
                  {
                    "text": "Specific examples and implicationsBreast carcinomaInvasive ductal carcinomaInvasive lobular carcinomaAssociated with poor response to tamoxifen therapy in metastatic breast carcinomaCorrelates with higher rate of locoregional recurrence in inflammatory breast carcinoma after radiotherapyCentral nervous system tumorsGlioblastoma multiformeMay contribute to temozolomide therapy resistance in glioblastomasChildhood ependymomaEndocrine tumorsMedullary and anaplastic thyroid carcinoma, parathyroid adenoma and carcinomaFemale patient genital tract tumorsCervical intraepithelial neoplasia (CIN) and invasive squamous cell carcinomaEndometrial carcinomaOvarian serous carcinomaOverexpression of EZH2 contributes to acquired cisplatinum resistance in ovarian cancerGenitourinary tumorsProstate adenocarcinomaAssociated with adverse outcome and may confer poor response to immunotherapyBladder and upper tract urothelial carcinomaRenal cell carcinomaGastrointestinal tumorsEsophageal squamous cell carcinomaGastric carcinomaPositively correlates with tumor size, lymphatic invasion and TNM stage, and poor disease-free survival and overall survival of patientsCombined inhibition of EZH2 and EGFR produces synergic effect on tumor growth inhibitionColon adenocarcinomaInhibition of EZH2 may enhance efficacy of EGFR inhibitor therapy in colon cancerGallbladder carcinomaEZH2 overexpression is seen in ~ 50% of gallbladder carcinomas and is associated with poor differentiation, lymph node metastasis, and invasionCholangiocarcinomaIHC for EZH2 can help differentiate cholangiocarcinoma (positive) from ductular reaction and bile duct adenoma (negative)Pancreatic intraductal mucinous neoplasmHepatic carcinomaIHC for EZH2 can help differentiate malignant hepatic (positive) from benign hepatic (negative) tumorsEZH2 inhibition has been shown to make hepatocellular carcinoma cells more sensitive to sorafenibLung cancerAdenocarcinomaIHC for EZH2 can help differentiate malignant neoplasms (positive) in pleural effusion cytology from reactive mesothelial cells (negative)Oral cavity tumorsSquamous cell carcinomaOverexpression of EZH2 as evaluated by IHC predicts progression to invasive squamous cell carcinoma in premalignant lesions presenting as leukoplakiaSkin cancerSquamous cell carcinomaIHC for EZH2 can help differentiate squamous cell carcinoma (positive) from actinic keratosis (negative)Soft tissue tumorsEmbryonal rhabdomyosarcomaSynovial sarcoma",
                    "sub_points": [
                      "Breast carcinomaInvasive ductal carcinomaInvasive lobular carcinomaAssociated with poor response to tamoxifen therapy in metastatic breast carcinomaCorrelates with higher rate of locoregional recurrence in inflammatory breast carcinoma after radiotherapy",
                      "Invasive ductal carcinoma",
                      "Invasive lobular carcinomaAssociated with poor response to tamoxifen therapy in metastatic breast carcinomaCorrelates with higher rate of locoregional recurrence in inflammatory breast carcinoma after radiotherapy",
                      "Associated with poor response to tamoxifen therapy in metastatic breast carcinoma",
                      "Correlates with higher rate of locoregional recurrence in inflammatory breast carcinoma after radiotherapy",
                      "Central nervous system tumorsGlioblastoma multiformeMay contribute to temozolomide therapy resistance in glioblastomasChildhood ependymoma",
                      "Glioblastoma multiformeMay contribute to temozolomide therapy resistance in glioblastomas",
                      "May contribute to temozolomide therapy resistance in glioblastomas",
                      "Childhood ependymoma",
                      "Endocrine tumorsMedullary and anaplastic thyroid carcinoma, parathyroid adenoma and carcinoma",
                      "Medullary and anaplastic thyroid carcinoma, parathyroid adenoma and carcinoma",
                      "Female patient genital tract tumorsCervical intraepithelial neoplasia (CIN) and invasive squamous cell carcinomaEndometrial carcinomaOvarian serous carcinomaOverexpression of EZH2 contributes to acquired cisplatinum resistance in ovarian cancer",
                      "Cervical intraepithelial neoplasia (CIN) and invasive squamous cell carcinoma",
                      "Endometrial carcinoma",
                      "Ovarian serous carcinomaOverexpression of EZH2 contributes to acquired cisplatinum resistance in ovarian cancer",
                      "Overexpression of EZH2 contributes to acquired cisplatinum resistance in ovarian cancer",
                      "Genitourinary tumorsProstate adenocarcinomaAssociated with adverse outcome and may confer poor response to immunotherapyBladder and upper tract urothelial carcinomaRenal cell carcinoma",
                      "Prostate adenocarcinomaAssociated with adverse outcome and may confer poor response to immunotherapy",
                      "Associated with adverse outcome and may confer poor response to immunotherapy",
                      "Bladder and upper tract urothelial carcinoma",
                      "Renal cell carcinoma",
                      "Gastrointestinal tumorsEsophageal squamous cell carcinomaGastric carcinomaPositively correlates with tumor size, lymphatic invasion and TNM stage, and poor disease-free survival and overall survival of patientsCombined inhibition of EZH2 and EGFR produces synergic effect on tumor growth inhibitionColon adenocarcinomaInhibition of EZH2 may enhance efficacy of EGFR inhibitor therapy in colon cancerGallbladder carcinomaEZH2 overexpression is seen in ~ 50% of gallbladder carcinomas and is associated with poor differentiation, lymph node metastasis, and invasionCholangiocarcinomaIHC for EZH2 can help differentiate cholangiocarcinoma (positive) from ductular reaction and bile duct adenoma (negative)Pancreatic intraductal mucinous neoplasmHepatic carcinomaIHC for EZH2 can help differentiate malignant hepatic (positive) from benign hepatic (negative) tumorsEZH2 inhibition has been shown to make hepatocellular carcinoma cells more sensitive to sorafenib",
                      "Esophageal squamous cell carcinoma",
                      "Gastric carcinomaPositively correlates with tumor size, lymphatic invasion and TNM stage, and poor disease-free survival and overall survival of patientsCombined inhibition of EZH2 and EGFR produces synergic effect on tumor growth inhibition",
                      "Positively correlates with tumor size, lymphatic invasion and TNM stage, and poor disease-free survival and overall survival of patients",
                      "Combined inhibition of EZH2 and EGFR produces synergic effect on tumor growth inhibition",
                      "Colon adenocarcinomaInhibition of EZH2 may enhance efficacy of EGFR inhibitor therapy in colon cancer",
                      "Inhibition of EZH2 may enhance efficacy of EGFR inhibitor therapy in colon cancer",
                      "Gallbladder carcinomaEZH2 overexpression is seen in ~ 50% of gallbladder carcinomas and is associated with poor differentiation, lymph node metastasis, and invasion",
                      "EZH2 overexpression is seen in ~ 50% of gallbladder carcinomas and is associated with poor differentiation, lymph node metastasis, and invasion",
                      "CholangiocarcinomaIHC for EZH2 can help differentiate cholangiocarcinoma (positive) from ductular reaction and bile duct adenoma (negative)",
                      "IHC for EZH2 can help differentiate cholangiocarcinoma (positive) from ductular reaction and bile duct adenoma (negative)",
                      "Pancreatic intraductal mucinous neoplasm",
                      "Hepatic carcinomaIHC for EZH2 can help differentiate malignant hepatic (positive) from benign hepatic (negative) tumorsEZH2 inhibition has been shown to make hepatocellular carcinoma cells more sensitive to sorafenib",
                      "IHC for EZH2 can help differentiate malignant hepatic (positive) from benign hepatic (negative) tumors",
                      "EZH2 inhibition has been shown to make hepatocellular carcinoma cells more sensitive to sorafenib",
                      "Lung cancerAdenocarcinomaIHC for EZH2 can help differentiate malignant neoplasms (positive) in pleural effusion cytology from reactive mesothelial cells (negative)",
                      "AdenocarcinomaIHC for EZH2 can help differentiate malignant neoplasms (positive) in pleural effusion cytology from reactive mesothelial cells (negative)",
                      "IHC for EZH2 can help differentiate malignant neoplasms (positive) in pleural effusion cytology from reactive mesothelial cells (negative)",
                      "Oral cavity tumorsSquamous cell carcinomaOverexpression of EZH2 as evaluated by IHC predicts progression to invasive squamous cell carcinoma in premalignant lesions presenting as leukoplakia",
                      "Squamous cell carcinomaOverexpression of EZH2 as evaluated by IHC predicts progression to invasive squamous cell carcinoma in premalignant lesions presenting as leukoplakia",
                      "Overexpression of EZH2 as evaluated by IHC predicts progression to invasive squamous cell carcinoma in premalignant lesions presenting as leukoplakia",
                      "Skin cancerSquamous cell carcinomaIHC for EZH2 can help differentiate squamous cell carcinoma (positive) from actinic keratosis (negative)",
                      "Squamous cell carcinomaIHC for EZH2 can help differentiate squamous cell carcinoma (positive) from actinic keratosis (negative)",
                      "IHC for EZH2 can help differentiate squamous cell carcinoma (positive) from actinic keratosis (negative)",
                      "Soft tissue tumorsEmbryonal rhabdomyosarcomaSynovial sarcoma",
                      "Embryonal rhabdomyosarcoma",
                      "Synovial sarcoma"
                    ]
                  }
                ],
                "EZH2 Inhibition": [
                  {
                    "text": "Role of EZH2 inhibition in cancer therapy is currently being investigated in numerous clinical trialsMalignancies include but are not limited to: DLBCL, mantle cell lymphoma, prostate cancer, mesothelioma, urothelial carcinoma, and rhabdoid tumorsEvaluation of combination therapy with EZH2 inhibitors and other therapies, including immunotherapy, conventional chemotherapy, and targeted therapies, are also currently underway",
                    "sub_points": [
                      "Malignancies include but are not limited to: DLBCL, mantle cell lymphoma, prostate cancer, mesothelioma, urothelial carcinoma, and rhabdoid tumors",
                      "Evaluation of combination therapy with EZH2 inhibitors and other therapies, including immunotherapy, conventional chemotherapy, and targeted therapies, are also currently underway"
                    ]
                  },
                  {
                    "text": "3 main mechanisms for EZH2 inhibitionInhibition of methyltransferase enzymatic activity mainly through small molecular competitive inhibitorsExamples: Tazemetostat, GSK126, CPI-1205Breaking down PRC2 structureExamples: Astemizole, SAH-EZH2, AZD9291Triggering EZH2 degradationExamples: GNA022, ANCR, FBW7",
                    "sub_points": [
                      "Inhibition of methyltransferase enzymatic activity mainly through small molecular competitive inhibitorsExamples: Tazemetostat, GSK126, CPI-1205",
                      "Examples: Tazemetostat, GSK126, CPI-1205",
                      "Breaking down PRC2 structureExamples: Astemizole, SAH-EZH2, AZD9291",
                      "Examples: Astemizole, SAH-EZH2, AZD9291",
                      "Triggering EZH2 degradationExamples: GNA022, ANCR, FBW7",
                      "Examples: GNA022, ANCR, FBW7"
                    ]
                  },
                  {
                    "text": "Tazemetostat (EPZ-6438) is only EZH2 inhibitor that is currently approved by FDAOral pyridine-based competitive inhibitor of SAM pocket of EZH2 SET domain, inhibiting both wildtype and mutant forms ofEZH2Highly selective for EZH2 with 35x increased potency relative to EZH1Approved by FDA for following indicationsRelapsed or refractory FL positive forEZH2mutation and patient who received at least 2 lines of systemic therapy or have no alternative treatment optionsPatients 16 years or older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection",
                    "sub_points": [
                      "Oral pyridine-based competitive inhibitor of SAM pocket of EZH2 SET domain, inhibiting both wildtype and mutant forms ofEZH2",
                      "Highly selective for EZH2 with 35x increased potency relative to EZH1",
                      "Approved by FDA for following indicationsRelapsed or refractory FL positive forEZH2mutation and patient who received at least 2 lines of systemic therapy or have no alternative treatment optionsPatients 16 years or older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection",
                      "Relapsed or refractory FL positive forEZH2mutation and patient who received at least 2 lines of systemic therapy or have no alternative treatment options",
                      "Patients 16 years or older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection"
                    ]
                  },
                  {
                    "text": "Resistance to EZH2 inhibitor therapyEZH2W113C mutation in lymphoma confers resistance to Tazemetostat",
                    "sub_points": [
                      "EZH2W113C mutation in lymphoma confers resistance to Tazemetostat"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "MYD88Mutation": {
            "name": "MYD88Mutation",
            "url": "https://app.pathprimer.com/document/c523c992-4132-45f5-bf0b-1e3348f356a4/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: Innate immune signal transduction adaptorPrevious name: Myeloid differentiation primary response 88",
                    "sub_points": [
                      "Previous name: Myeloid differentiation primary response 88"
                    ]
                  },
                  {
                    "text": "Official symbol:MYD88"
                  },
                  {
                    "text": "HGNC ID: 7562"
                  },
                  {
                    "text": "Chromosomal location: 3p22.2"
                  },
                  {
                    "text": "Molecular location: Base pairs 38,138, 661 to 38, 143, 022 (GRCh38 assembly)"
                  },
                  {
                    "text": "Number of exons: 5"
                  }
                ]
              },
              "Molecular Features": {
                "MYD88": [
                  {
                    "text": "Encodes cytosolic adapter protein (MYD88 protein)Critical signal transducer in interleukin-1 receptor (IL-1R) and toll-like receptor (TLR) signaling pathwaysUpon activation, promotes phosphorylation of interleukin-1 receptor-associated kinases (IRAK)Subsequent activation of nuclear factor κ-light chain enhancer of activated B cells (NF-κB) transcription factors (e.g., p50, p65)Alternative signaling through activation of mitogen-activated protein kinases (MAPK), phosphatidylinositide 3-kinase-AKT (PI3K/AKT), and interferon regulatory factors 3, 5, and 7Overall increased nuclear prosurvival signalsMYD88 protein structureN-terminal end (death domain)Central portion (intermediate domain that enables interactions with IRAK kinase family of proteins)C-terminal end [toll interleukin 1 receptor (TIR) domain]",
                    "sub_points": [
                      "Critical signal transducer in interleukin-1 receptor (IL-1R) and toll-like receptor (TLR) signaling pathwaysUpon activation, promotes phosphorylation of interleukin-1 receptor-associated kinases (IRAK)Subsequent activation of nuclear factor κ-light chain enhancer of activated B cells (NF-κB) transcription factors (e.g., p50, p65)Alternative signaling through activation of mitogen-activated protein kinases (MAPK), phosphatidylinositide 3-kinase-AKT (PI3K/AKT), and interferon regulatory factors 3, 5, and 7",
                      "Upon activation, promotes phosphorylation of interleukin-1 receptor-associated kinases (IRAK)",
                      "Subsequent activation of nuclear factor κ-light chain enhancer of activated B cells (NF-κB) transcription factors (e.g., p50, p65)",
                      "Alternative signaling through activation of mitogen-activated protein kinases (MAPK), phosphatidylinositide 3-kinase-AKT (PI3K/AKT), and interferon regulatory factors 3, 5, and 7",
                      "Overall increased nuclear prosurvival signals",
                      "MYD88 protein structureN-terminal end (death domain)Central portion (intermediate domain that enables interactions with IRAK kinase family of proteins)C-terminal end [toll interleukin 1 receptor (TIR) domain]",
                      "N-terminal end (death domain)",
                      "Central portion (intermediate domain that enables interactions with IRAK kinase family of proteins)",
                      "C-terminal end [toll interleukin 1 receptor (TIR) domain]"
                    ]
                  },
                  {
                    "text": "Cellular functionsRegulation of proinflammatory genesImportant role in adaptive and innate immune responsesControl of important proliferation/survival pathways",
                    "sub_points": [
                      "Regulation of proinflammatory genes",
                      "Important role in adaptive and innate immune responses",
                      "Control of important proliferation/survival pathways"
                    ]
                  }
                ],
                "MYD88Mutations": [
                  {
                    "text": "Most common mutation inMYD88Single nucleotide change of thymine to cytosine (T>C) in exon 5Results in switch of leucine to proline at amino acid position 265 (L265P)HGVS nomenclature: NM_002468.4 (MYD88): c.794T>C (p.Leu265Pro)",
                    "sub_points": [
                      "Single nucleotide change of thymine to cytosine (T>C) in exon 5",
                      "Results in switch of leucine to proline at amino acid position 265 (L265P)",
                      "HGVS nomenclature: NM_002468.4 (MYD88): c.794T>C (p.Leu265Pro)"
                    ]
                  },
                  {
                    "text": "Overexpression of MYD88 protein secondary to L265P mutation will cause activation of NF-κBIncreased Bruton tyrosine kinase (BTK) phosphorylationIncreased IRAK1/IRAK4 recruitment and signalingActivation and phosphorylation of TRAF6 and TAK1",
                    "sub_points": [
                      "Increased Bruton tyrosine kinase (BTK) phosphorylation",
                      "Increased IRAK1/IRAK4 recruitment and signaling",
                      "Activation and phosphorylation of TRAF6 and TAK1"
                    ]
                  },
                  {
                    "text": "Additional concomitant loss ofTNFAIP3tumor suppressor gene (encoding for A20 protein) acts as enhancing 2nd genetic alteration"
                  },
                  {
                    "text": "Results in increased cellular growth and survivalIncreased production of IL-6 and CXCL10 leading to upregulation of JAK/STAT pathway",
                    "sub_points": [
                      "Increased production of IL-6 and CXCL10 leading to upregulation of JAK/STAT pathway"
                    ]
                  },
                  {
                    "text": "Numerous additional low-frequency (< 1%) mutations have been also described"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "MYD88L265P Mutation and B-Cell Lymphomas": [
                  {
                    "text": "One of most recurrent mutations in hematologic malignancies, found in ~ 20% of all lymphomasImportant oncogenic pathway in lymphomagenesis",
                    "sub_points": [
                      "Important oncogenic pathway in lymphomagenesis"
                    ]
                  },
                  {
                    "text": "Present in significant number of B-cell non-Hodgkin lymphomas"
                  },
                  {
                    "text": "Most important and frequent association with lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM)Very high prevalence of this mutation in numerous published studies (85-100%)ConcurrentCXCR4mutationsConfers resistance to Ibrutinib therapy in LPL",
                    "sub_points": [
                      "Very high prevalence of this mutation in numerous published studies (85-100%)",
                      "ConcurrentCXCR4mutationsConfers resistance to Ibrutinib therapy in LPL",
                      "Confers resistance to Ibrutinib therapy in LPL"
                    ]
                  },
                  {
                    "text": "Frequent genomic abnormality in diffuse large B-cell lymphomas (DLBCL) of activated B-cell-like (ABC) origin (C5/MCD subgroups by gene expression profiling)Primary DLBCL of central nervous system (70%)Primary cutaneous DLBCL, leg type (60%)Testicular DLBCL (75%)DLBCL, not otherwise specified (NOS), ABC subtype (25%)",
                    "sub_points": [
                      "Primary DLBCL of central nervous system (70%)",
                      "Primary cutaneous DLBCL, leg type (60%)",
                      "Testicular DLBCL (75%)",
                      "DLBCL, not otherwise specified (NOS), ABC subtype (25%)"
                    ]
                  },
                  {
                    "text": "Rarely detected in DLBCL of germinal center B-cell-like subtype"
                  },
                  {
                    "text": "Low prevalence in other B-cell lymphomas, includingMarginal zone B-cell lymphoma (uncommon)Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Burkitt lymphoma",
                    "sub_points": [
                      "Marginal zone B-cell lymphoma (uncommon)",
                      "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)",
                      "Burkitt lymphoma"
                    ]
                  },
                  {
                    "text": "Presence ofMYD88L265P mutation serves as useful tool to differentiate LPL/WM from other low-grade B-cell lymphomas"
                  },
                  {
                    "text": "Prognostic significance ofMYD88-mutated monoclonal gammopathy of unknown significance (MGUS)IgM subtype mutated MGUS cases have been associated with higher risk of disease progression and disease burdenTypically exhibit higher levels of IgMUsually have lower levels of IgG and IgAHigher incidence of Bence-Jones proteinuria",
                    "sub_points": [
                      "IgM subtype mutated MGUS cases have been associated with higher risk of disease progression and disease burdenTypically exhibit higher levels of IgMUsually have lower levels of IgG and IgAHigher incidence of Bence-Jones proteinuria",
                      "Typically exhibit higher levels of IgM",
                      "Usually have lower levels of IgG and IgA",
                      "Higher incidence of Bence-Jones proteinuria"
                    ]
                  },
                  {
                    "text": "Potential for targeted therapies by blocking of associated cellular pathwaysMost successful target BTKBTK inhibitor Ibrutinib reduces binding strength of BTK toMYD88L265P and increases cellular apoptosisIn DLBCL, ABC type presence ofMYD88mutations alone confers resistance to Ibrutinib; however, sensitivity is increased with concomitantCD79AorCD79BmutationsIn LPL/WM, mutation confers sensitivity to Ibrutinib",
                    "sub_points": [
                      "Most successful target BTK",
                      "BTK inhibitor Ibrutinib reduces binding strength of BTK toMYD88L265P and increases cellular apoptosisIn DLBCL, ABC type presence ofMYD88mutations alone confers resistance to Ibrutinib; however, sensitivity is increased with concomitantCD79AorCD79BmutationsIn LPL/WM, mutation confers sensitivity to Ibrutinib",
                      "In DLBCL, ABC type presence ofMYD88mutations alone confers resistance to Ibrutinib; however, sensitivity is increased with concomitantCD79AorCD79Bmutations",
                      "In LPL/WM, mutation confers sensitivity to Ibrutinib"
                    ]
                  }
                ]
              },
              "TESTING FOR MYD88 L265P MUTATION": {
                "Testing Strategies": [
                  {
                    "text": "Varies depending on desired level of sensitivity and specificity"
                  },
                  {
                    "text": "Most strategies are PCR based"
                  },
                  {
                    "text": "Selection of appropriate tissue sample for molecular testingFresh diagnostic specimen is desiredFormalin-fixed, paraffin-embedded diagnostic tissue is acceptableFrequent PCR failure in decalcified bone marrow core biopsies when strong acid is used for decalcificationEDTA-based decalcified bone marrow biopsy could be acceptable for PCR-based testing",
                    "sub_points": [
                      "Fresh diagnostic specimen is desired",
                      "Formalin-fixed, paraffin-embedded diagnostic tissue is acceptable",
                      "Frequent PCR failure in decalcified bone marrow core biopsies when strong acid is used for decalcification",
                      "EDTA-based decalcified bone marrow biopsy could be acceptable for PCR-based testing"
                    ]
                  }
                ],
                "Sanger Sequencing": [
                  {
                    "text": "a.k.a. traditional or 1st-generation sequencing"
                  },
                  {
                    "text": "Sequence by chain terminationBased on selective incorporation of chain-terminating dideoxynucleotides (ddNTPs)Addition of label (dye) to ddNTPs allows for fluorescent detection and reading of sequences",
                    "sub_points": [
                      "Based on selective incorporation of chain-terminating dideoxynucleotides (ddNTPs)",
                      "Addition of label (dye) to ddNTPs allows for fluorescent detection and reading of sequences"
                    ]
                  },
                  {
                    "text": "Sensitivity~ 15-20% detection of heterozygous mutated alleles",
                    "sub_points": [
                      "~ 15-20% detection of heterozygous mutated alleles"
                    ]
                  }
                ],
                "Pyrosequencing": [
                  {
                    "text": "Sequence by synthesis method"
                  },
                  {
                    "text": "Relies on detection of pyrophosphate released upon incorporation of nucleotidesLight is emitted after incorporation of complementary nucleotide and sequentially detected to identify specific sequence",
                    "sub_points": [
                      "Light is emitted after incorporation of complementary nucleotide and sequentially detected to identify specific sequence"
                    ]
                  },
                  {
                    "text": "Limitation due to short DNA reads"
                  },
                  {
                    "text": "Sensitivity~ 10% detection sensitivity for heterozygous mutated alleles",
                    "sub_points": [
                      "~ 10% detection sensitivity for heterozygous mutated alleles"
                    ]
                  }
                ],
                "Allele-Specific PCR": [
                  {
                    "text": "a.k.a. amplification refractory mutation system (ARMS)1 primer includes desired mutational sequence (matched primer)Mismatched primer will not initiate replication, while matched primer willTherefore, generation of amplified products will indicate presence of targeted genotype",
                    "sub_points": [
                      "1 primer includes desired mutational sequence (matched primer)",
                      "Mismatched primer will not initiate replication, while matched primer willTherefore, generation of amplified products will indicate presence of targeted genotype",
                      "Therefore, generation of amplified products will indicate presence of targeted genotype"
                    ]
                  },
                  {
                    "text": "High level of sensitivity (Ideal testing method)~ 0.1% detection of mutated alleles",
                    "sub_points": [
                      "~ 0.1% detection of mutated alleles"
                    ]
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "Newer and most advanced technology for sequencingMassive parallel sequencingDecreased costs of sequencing, while improving coverageMYD88mutation testing is usually included as part of panelMay miss up to 1/3 of mutated cases",
                    "sub_points": [
                      "Massive parallel sequencing",
                      "Decreased costs of sequencing, while improving coverage",
                      "MYD88mutation testing is usually included as part of panel",
                      "May miss up to 1/3 of mutated cases"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Pearls": [
                  {
                    "text": "MYD88mutations play very important role in lymphomagenesis via upregulation of JAK/STAT pathway"
                  },
                  {
                    "text": "Mutations are frequently detected inLPL/WMDLBCL of ABC origin (C5/MCD subtypes by GEP)Primary DLBCL of central nervous systemPrimary cutaneous DLBCL, leg typeTesticular DLBCLDLBCL, NOS, ABC subtype",
                    "sub_points": [
                      "LPL/WM",
                      "DLBCL of ABC origin (C5/MCD subtypes by GEP)Primary DLBCL of central nervous systemPrimary cutaneous DLBCL, leg typeTesticular DLBCLDLBCL, NOS, ABC subtype",
                      "Primary DLBCL of central nervous system",
                      "Primary cutaneous DLBCL, leg type",
                      "Testicular DLBCL",
                      "DLBCL, NOS, ABC subtype"
                    ]
                  },
                  {
                    "text": "MYD88mutations are uncommon in marginal zone lymphoma (MZL) and CLL/SLL"
                  },
                  {
                    "text": "Detection ofMYD88mutation is helpful in distinction of LPL/WM from MZL with plasmacytic differentiation"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "EBV-Associated Human Neoplasms": {
            "name": "EBV-Associated Human Neoplasms",
            "url": "https://app.pathprimer.com/document/a15f9b58-b5a4-471e-a1bd-536a140d3f60/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Epstein-Barr virus (EBV)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Lymphoid and nonlymphoid human neoplasms associated with monoclonal episomal EBV"
                  }
                ]
              },
              "EBV Structure and Genome": {
                "EBV Virion": [
                  {
                    "text": "Double-stranded DNA virus172 kb in lengthWrapped in protein capsidContains variable numbers of homologous tandem 500-bp repeats (TRs) at each terminusLinear termini are joined in host cells to form episomal (circular) formsEpisomal forms are present in EBV-infected tumor cells and cell linesVariability in numbers of TRs generates episomes with variable numbers of TRsEBV-associated monoclonal cell lines or tumorsIdentical-sized EBV episome in all cellsDigestion with restriction enzymes generate homogeneously sized terminal fragmentsEBV-associated polyclonal processesDifferent-sized EBV linear forms are presentRestriction enzyme digestion generates heterogeneously sized terminal fragmentsTerminal fragments will differ from each other with increments of 500 bp",
                    "sub_points": [
                      "172 kb in length",
                      "Wrapped in protein capsid",
                      "Contains variable numbers of homologous tandem 500-bp repeats (TRs) at each terminus",
                      "Linear termini are joined in host cells to form episomal (circular) formsEpisomal forms are present in EBV-infected tumor cells and cell lines",
                      "Episomal forms are present in EBV-infected tumor cells and cell lines",
                      "Variability in numbers of TRs generates episomes with variable numbers of TRs",
                      "EBV-associated monoclonal cell lines or tumorsIdentical-sized EBV episome in all cellsDigestion with restriction enzymes generate homogeneously sized terminal fragments",
                      "Identical-sized EBV episome in all cells",
                      "Digestion with restriction enzymes generate homogeneously sized terminal fragments",
                      "EBV-associated polyclonal processesDifferent-sized EBV linear forms are presentRestriction enzyme digestion generates heterogeneously sized terminal fragmentsTerminal fragments will differ from each other with increments of 500 bp",
                      "Different-sized EBV linear forms are present",
                      "Restriction enzyme digestion generates heterogeneously sized terminal fragments",
                      "Terminal fragments will differ from each other with increments of 500 bp"
                    ]
                  }
                ]
              },
              "Biology of EBV Infection": {
                "EBV Lytic Infection": [
                  {
                    "text": "Primary EBV infection~ 95% of adults are infected by EBVAsymptomatic in childrenPresent as infectious mononucleosis in adultsPrimary infection results in lytic (productive) lifecycleEBV DNA is linear in lytic cycleEBV infects both B cells and epithelial cellsEpithelial cells are likely major site of EBV lytic cycleShort lytic infection cycle will follow latent EBV infection in B cellsEBV is episomal (circular) in latently infected cellsEBV latent infection persists for host's lifetime and cannot be eradicated",
                    "sub_points": [
                      "~ 95% of adults are infected by EBV",
                      "Asymptomatic in children",
                      "Present as infectious mononucleosis in adults",
                      "Primary infection results in lytic (productive) lifecycle",
                      "EBV DNA is linear in lytic cycle",
                      "EBV infects both B cells and epithelial cellsEpithelial cells are likely major site of EBV lytic cycleShort lytic infection cycle will follow latent EBV infection in B cellsEBV is episomal (circular) in latently infected cellsEBV latent infection persists for host's lifetime and cannot be eradicated",
                      "Epithelial cells are likely major site of EBV lytic cycle",
                      "Short lytic infection cycle will follow latent EBV infection in B cells",
                      "EBV is episomal (circular) in latently infected cells",
                      "EBV latent infection persists for host's lifetime and cannot be eradicated"
                    ]
                  }
                ],
                "EBV Latent Infection": [
                  {
                    "text": "Viral DNA is not usually integrated into host chromosome"
                  },
                  {
                    "text": "Viral DNA is present as extrachromosomal episome within nucleus of host cells"
                  },
                  {
                    "text": "Latent virus may become reactivated in certain circumstancesReactivation of virus from latency depends on expression of viral BZLF1 protein",
                    "sub_points": [
                      "Reactivation of virus from latency depends on expression of viral BZLF1 protein"
                    ]
                  },
                  {
                    "text": "EBV-associated tumorsEpisomal EBV is present in every tumor cellViral RNAs and proteins are also present in tumor cells1st EBV RNAs identified are designated as EBER (EBV-encoded RNA)EBERs are noncoding RNAsEBERs are not required for B-cell transformationEBERs are abundant with up to 1 million copies present in infected cellHigh abundance of EBERs have made EBER stain superb marker to detect EBVEBV is clonal in EBV-associated neoplasmsViral clonality can be demonstrated by analysis of restriction enzyme-digested EBV DNA terminal repeats fragmentsDetection of clonal EBV episomes in tumor suggests that malignant cells are also clonal",
                    "sub_points": [
                      "Episomal EBV is present in every tumor cell",
                      "Viral RNAs and proteins are also present in tumor cells",
                      "1st EBV RNAs identified are designated as EBER (EBV-encoded RNA)EBERs are noncoding RNAsEBERs are not required for B-cell transformationEBERs are abundant with up to 1 million copies present in infected cellHigh abundance of EBERs have made EBER stain superb marker to detect EBV",
                      "EBERs are noncoding RNAs",
                      "EBERs are not required for B-cell transformation",
                      "EBERs are abundant with up to 1 million copies present in infected cell",
                      "High abundance of EBERs have made EBER stain superb marker to detect EBV",
                      "EBV is clonal in EBV-associated neoplasmsViral clonality can be demonstrated by analysis of restriction enzyme-digested EBV DNA terminal repeats fragmentsDetection of clonal EBV episomes in tumor suggests that malignant cells are also clonal",
                      "Viral clonality can be demonstrated by analysis of restriction enzyme-digested EBV DNA terminal repeats fragments",
                      "Detection of clonal EBV episomes in tumor suggests that malignant cells are also clonal"
                    ]
                  },
                  {
                    "text": "Latency patterns in EBV-associated neoplasmsLatency pattern IEBNA1, EBER1, and EBER2 are expressedLatency pattern IIEBNA1, LMP1, LMP2, EBER1, and EBER2 are expressedLatency pattern IIIEBNA1, EBNA2, EBNA3, LMP1, LMP2, EBER1, and EBER2 are all expressed",
                    "sub_points": [
                      "Latency pattern IEBNA1, EBER1, and EBER2 are expressed",
                      "EBNA1, EBER1, and EBER2 are expressed",
                      "Latency pattern IIEBNA1, LMP1, LMP2, EBER1, and EBER2 are expressed",
                      "EBNA1, LMP1, LMP2, EBER1, and EBER2 are expressed",
                      "Latency pattern IIIEBNA1, EBNA2, EBNA3, LMP1, LMP2, EBER1, and EBER2 are all expressed",
                      "EBNA1, EBNA2, EBNA3, LMP1, LMP2, EBER1, and EBER2 are all expressed"
                    ]
                  }
                ]
              },
              "EBV-Associated Lymphomas": {
                "Burkitt Lymphoma": [
                  {
                    "text": "EBV is present in almost all endemic Burkitt lymphoma, ~ 10-20% of sporadic Burkitt lymphoma, and ~ 40% of HIV-related Burkitt lymphoma"
                  },
                  {
                    "text": "Restricted pattern of expression of latency proteins limited to EBNA1 and EBERs (latency pattern I)"
                  },
                  {
                    "text": "Expression of EBNA1 is crucial in maintenance and replication of EBV genome"
                  },
                  {
                    "text": "EBER may induce expression of IL-10 and may show antiapoptotic activitiesMay play oncogenic role in development of Burkitt lymphoma",
                    "sub_points": [
                      "May play oncogenic role in development of Burkitt lymphoma"
                    ]
                  }
                ],
                "EBV(+) Diffuse Large B-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "In patients without known immunodeficiency or prior lymphoma"
                  },
                  {
                    "text": "Majority present with extranodal disease"
                  },
                  {
                    "text": "Latency pattern III, including expression of EBNA2"
                  },
                  {
                    "text": "Other EBV(+) well-defined lymphoma categories are excluded"
                  }
                ],
                "Plasmablastic Lymphoma": [
                  {
                    "text": "Diffuse proliferation of large, immunoblastic-appearing cells with prominent nucleoli"
                  },
                  {
                    "text": "High incidence in HIV patients"
                  },
                  {
                    "text": "Occurs predominantly in oral cavity and other extranodal sites"
                  },
                  {
                    "text": "Expression of CD138 and (-) or weak expression of CD20, PAX5, and CD45"
                  },
                  {
                    "text": "Very high proliferation rate with Ki-67 index (> 90%)"
                  },
                  {
                    "text": "EBV(+) in vast majority of cases"
                  }
                ],
                "Lymphomatoid Granulomatosis": [
                  {
                    "text": "Angiocentric and angiodestructive B-cell proliferation with predominance of T cells"
                  },
                  {
                    "text": "Lung is most common site of involvement"
                  },
                  {
                    "text": "Other extranodal sites of involvement include CNS, kidney, liver, and skin"
                  },
                  {
                    "text": "Neoplastic B cells vary in numbers and are EBV(+)"
                  },
                  {
                    "text": "Spectrum of histologic grade depending on proportion of EBV(+) B cells< 5 EBV(+) B cells per HPF in grade 15-20 EBV(+) B cells per HPF in grade 2> 20 EBV(+) B cells per HPF in grade 3Cases with sheets of EBV(+) large B cells should be classified as diffuse large B-cell lymphoma (DLBCL)",
                    "sub_points": [
                      "< 5 EBV(+) B cells per HPF in grade 1",
                      "5-20 EBV(+) B cells per HPF in grade 2",
                      "> 20 EBV(+) B cells per HPF in grade 3",
                      "Cases with sheets of EBV(+) large B cells should be classified as diffuse large B-cell lymphoma (DLBCL)"
                    ]
                  }
                ],
                "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation": [
                  {
                    "text": "Develops in patients with longstanding history of pyothorax following induction of pneumothorax for treatment of tuberculosis"
                  },
                  {
                    "text": "EBV(+) DLBCL that occur in context of longstanding chronic inflammation"
                  },
                  {
                    "text": "Pyothorax-associated DLBCL accounts for > 90% of cases"
                  },
                  {
                    "text": "Other sites of involvement include bone, joint, and periarticular soft tissue"
                  },
                  {
                    "text": "Aggressive lymphoma with 5-year survival of ~ 20-35% in pyothorax-associated DLBCL"
                  }
                ],
                "Fibrin-Associated Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "Subtype of DLBCL associated with chronic inflammation (in ICC)"
                  },
                  {
                    "text": "Fibrin-associated large B-cell lymphoma (new entity in WHO-HAEM5)"
                  },
                  {
                    "text": "Localized, microscopic DLBCL found incidentally in fibrinous materialWithin wall of pseudocysts in spleen, adrenal gland, paratesticular regionAlso reported within cardiac fibrin thrombus, subdural hematoma, synthetic tube graft",
                    "sub_points": [
                      "Within wall of pseudocysts in spleen, adrenal gland, paratesticular region",
                      "Also reported within cardiac fibrin thrombus, subdural hematoma, synthetic tube graft"
                    ]
                  },
                  {
                    "text": "Does not form mass and not associated with systemic disease"
                  },
                  {
                    "text": "All EBV(+) with highly favorable clinical course"
                  }
                ],
                "EBV(+) Mucocutaneous Ulcer": [
                  {
                    "text": "Upgraded from provisional to distinct entity in ICC"
                  },
                  {
                    "text": "Included in \"Lymphoid proliferation and lymphoma associated with immune deficiency and dysregulation\" in WHO-HAEM5"
                  },
                  {
                    "text": "Present in age-related or iatrogenic immunosuppression"
                  },
                  {
                    "text": "Involves mucosal or cutaneous sitesMost common site is oral cavity",
                    "sub_points": [
                      "Most common site is oral cavity"
                    ]
                  },
                  {
                    "text": "Dense, polymorphic infiltrate beneath ulcer with B-cell lineage Hodgkin and Reed-Sternberg-like cellsCD20, PAX5, OCT2, MUM1, and EBER (+)CD10 and BCL6 (-)",
                    "sub_points": [
                      "CD20, PAX5, OCT2, MUM1, and EBER (+)",
                      "CD10 and BCL6 (-)"
                    ]
                  },
                  {
                    "text": "Indolent courseSpontaneous regression in some cases",
                    "sub_points": [
                      "Spontaneous regression in some cases"
                    ]
                  }
                ],
                "Hydroa Vacciniforme Lymphoproliferative Disorder": [
                  {
                    "text": "Listed under \"Clinical spectrum of chronic active EBV disease (CAEBVD)\" in WHO-HAEM5Varies from indolent \"Severe mosquito bite allergy and hydroa vacciniform LPD classic form to systemic disease with fever, organomegaly and adenopathy\"",
                    "sub_points": [
                      "Varies from indolent \"Severe mosquito bite allergy and hydroa vacciniform LPD classic form to systemic disease with fever, organomegaly and adenopathy\""
                    ]
                  },
                  {
                    "text": "Listed as entity in ICC2 forms recognized: Classic and systemicClassic form is indolent, but systemic form is severe with fever, adenopathy, and liver involvement and more common in Asian and Latin Americans",
                    "sub_points": [
                      "2 forms recognized: Classic and systemicClassic form is indolent, but systemic form is severe with fever, adenopathy, and liver involvement and more common in Asian and Latin Americans",
                      "Classic form is indolent, but systemic form is severe with fever, adenopathy, and liver involvement and more common in Asian and Latin Americans"
                    ]
                  },
                  {
                    "text": "Typically occurs in childrenHighly favorable clinical courseVesicles and crust formation on sun-exposed areas of skinDermal infiltrate of predominantly small lymphoid cellsMajority of cases show CD8(+) T-cell immunophenotype~ 30% of cases show NK-cell immunophenotype with expression of CD56Clonal expansion of γ/δ T cells detectable in peripheral blood in most casesLymphoid cells are EBV(+), often CD30(+)May resolves spontaneouslyCan progress to to systemic form with severe and extensive skin lesions, fever, hepatosplenomegaly, and lymphadenopathyClonal rearrangements of T-cell receptor genes in most cases",
                    "sub_points": [
                      "Highly favorable clinical course",
                      "Vesicles and crust formation on sun-exposed areas of skin",
                      "Dermal infiltrate of predominantly small lymphoid cells",
                      "Majority of cases show CD8(+) T-cell immunophenotype",
                      "~ 30% of cases show NK-cell immunophenotype with expression of CD56",
                      "Clonal expansion of γ/δ T cells detectable in peripheral blood in most cases",
                      "Lymphoid cells are EBV(+), often CD30(+)",
                      "May resolves spontaneouslyCan progress to to systemic form with severe and extensive skin lesions, fever, hepatosplenomegaly, and lymphadenopathy",
                      "Can progress to to systemic form with severe and extensive skin lesions, fever, hepatosplenomegaly, and lymphadenopathy",
                      "Clonal rearrangements of T-cell receptor genes in most cases"
                    ]
                  }
                ],
                "Classic Hodgkin Lymphoma": [
                  {
                    "text": "EBV is detected in subset of classic Hodgkin lymphoma (CHL)~ 75% of mixed-cellularity subtype CHLUp to 40% of nodular sclerosis subtype CHL~ 100% in CHL arising in HIV-infected patients",
                    "sub_points": [
                      "~ 75% of mixed-cellularity subtype CHL",
                      "Up to 40% of nodular sclerosis subtype CHL",
                      "~ 100% in CHL arising in HIV-infected patients"
                    ]
                  },
                  {
                    "text": "EBV is detectable only in Hodgkin and Reed-Sternberg (HRS) cells and absent in background cellsExclusive localization of EBV to only neoplastic cells of CHL supports role in pathogenesis",
                    "sub_points": [
                      "Exclusive localization of EBV to only neoplastic cells of CHL supports role in pathogenesis"
                    ]
                  },
                  {
                    "text": "EBV-infected HRS cells show latency pattern IIEBERs, LMP1, LMP2A, and EBNA1 are expressedLMP1 may play role in prevention of apoptosis by upregulating BCL2 proteinLMP1 may also activate NF-kB signaling pathway and promote proliferation of HRS cells",
                    "sub_points": [
                      "EBERs, LMP1, LMP2A, and EBNA1 are expressedLMP1 may play role in prevention of apoptosis by upregulating BCL2 proteinLMP1 may also activate NF-kB signaling pathway and promote proliferation of HRS cells",
                      "LMP1 may play role in prevention of apoptosis by upregulating BCL2 protein",
                      "LMP1 may also activate NF-kB signaling pathway and promote proliferation of HRS cells"
                    ]
                  }
                ],
                "Posttransplant Lymphoproliferative Disorder": [
                  {
                    "text": "Lymphoproliferative disorders following allogeneic hematopoietic stem cell or solid organ transplantation"
                  },
                  {
                    "text": "Develops as result of immunosuppression"
                  },
                  {
                    "text": "Spectrum ranging from infectious mononucleosis-like to malignant lymphoma or plasma cell myeloma"
                  },
                  {
                    "text": "Histologic categories of PTLD (in ICC)Nondestructive PTLDPlasmacytic hyperplasia; infectious mononucleosis; florid follicular hyperplasiaPolymorphic PTLDMonomorphic PTLDCHL PTLD",
                    "sub_points": [
                      "Nondestructive PTLDPlasmacytic hyperplasia; infectious mononucleosis; florid follicular hyperplasia",
                      "Plasmacytic hyperplasia; infectious mononucleosis; florid follicular hyperplasia",
                      "Polymorphic PTLD",
                      "Monomorphic PTLD",
                      "CHL PTLD"
                    ]
                  },
                  {
                    "text": "Histologic categories of PTLD (in WHO-HAEM5)HyperplasiasPlasma-cell hyperplasia, mononucleosis-like hyperplasia, follicular hyperplasiaPolymorphic lymphoproliferative disorderLymphoma (classify as immunocompetent patients)CHL PTLDIncludes viral association in reportEBV(+/-),HHV8 (+/-)",
                    "sub_points": [
                      "HyperplasiasPlasma-cell hyperplasia, mononucleosis-like hyperplasia, follicular hyperplasia",
                      "Plasma-cell hyperplasia, mononucleosis-like hyperplasia, follicular hyperplasia",
                      "Polymorphic lymphoproliferative disorder",
                      "Lymphoma (classify as immunocompetent patients)",
                      "CHL PTLDIncludes viral association in reportEBV(+/-),HHV8 (+/-)",
                      "Includes viral association in reportEBV(+/-),HHV8 (+/-)",
                      "EBV(+/-),HHV8 (+/-)"
                    ]
                  },
                  {
                    "text": "~ 80% of PTLD cases are EBV associatedEarly PTLD (≤ 1 year post transplant) almost 100% EBV associatedDecreased cytotoxic T cells induced by immunosuppression play significant role in development of PTLDEBV(+) PTLD shows latency pattern IIIEBNA1, EBNA2, EBNA3, LMP1, LMP2, and EBERs are expressed",
                    "sub_points": [
                      "Early PTLD (≤ 1 year post transplant) almost 100% EBV associated",
                      "Decreased cytotoxic T cells induced by immunosuppression play significant role in development of PTLD",
                      "EBV(+) PTLD shows latency pattern IIIEBNA1, EBNA2, EBNA3, LMP1, LMP2, and EBERs are expressed",
                      "EBNA1, EBNA2, EBNA3, LMP1, LMP2, and EBERs are expressed"
                    ]
                  },
                  {
                    "text": "~ 20% of PTLD EBV(-)Typically develops > 5 years after transplantUnclear underlying etiology",
                    "sub_points": [
                      "Typically develops > 5 years after transplant",
                      "Unclear underlying etiology"
                    ]
                  }
                ],
                "Extranodal NK-/T-Cell Lymphoma, Nasal Type (in ICC)": [
                  {
                    "text": "Qualifier \"nasal type\" has been dropped in WHO-HAEM5"
                  },
                  {
                    "text": "Angiocentric and angiodestructive neoplasm with aggressive clinical courseMajority are true NK cell originLess frequently derived from cytotoxic T cells",
                    "sub_points": [
                      "Majority are true NK cell origin",
                      "Less frequently derived from cytotoxic T cells"
                    ]
                  },
                  {
                    "text": "Strong association with EBV, regardless of ethnicityMechanism of infection of T cells by EBV is not entirely clearEBV type 1 fails to infect mature T cells in cultureIn contrast, recent study reports that EBV type 2 infect T cells in vitroLatency pattern II has been reportedEBNA1, LMP1, LMP2, and EBER are expressed30-bp deletion present inLMP1in most cases",
                    "sub_points": [
                      "Mechanism of infection of T cells by EBV is not entirely clearEBV type 1 fails to infect mature T cells in cultureIn contrast, recent study reports that EBV type 2 infect T cells in vitro",
                      "EBV type 1 fails to infect mature T cells in culture",
                      "In contrast, recent study reports that EBV type 2 infect T cells in vitro",
                      "Latency pattern II has been reportedEBNA1, LMP1, LMP2, and EBER are expressed",
                      "EBNA1, LMP1, LMP2, and EBER are expressed",
                      "30-bp deletion present inLMP1in most cases"
                    ]
                  }
                ],
                "EBV-Associated Lymphomas in HIV(+) Patients": [
                  {
                    "text": "Lymphomas are 2nd most common malignancy in HIV(+) patients"
                  },
                  {
                    "text": "Incidence is significantly decreased since introduction of antiretroviral therapy"
                  },
                  {
                    "text": "Majority of lymphomas are high grade and B-cell origin"
                  },
                  {
                    "text": "Lymphomas that are more often seen in HIV settingPrimary effusion lymphoma (PEL)Distinct type of lymphoma that involves body cavities without tumor mass formationUnclear lineage by immunophenotype, including lack of B-cell antigens, but monoclonalIGHrearrangements presentPredominantly HHV-8 associatedVariable association with EBV with type II latency patternBoth EBV and HHV-8 detected in > 50% of casesPlasmablastic lymphomaAggressive lymphoma with immunoblastic morphologyMost frequently involve oral cavity but can present in other extranodal sitesImmunophenotype of plasma cells with expression of CD138, CD38, and MUM1 but weakly (+) or (-) for CD20, PAX5, and CD45ClonalIGHrearrangements",
                    "sub_points": [
                      "Primary effusion lymphoma (PEL)Distinct type of lymphoma that involves body cavities without tumor mass formationUnclear lineage by immunophenotype, including lack of B-cell antigens, but monoclonalIGHrearrangements presentPredominantly HHV-8 associatedVariable association with EBV with type II latency patternBoth EBV and HHV-8 detected in > 50% of cases",
                      "Distinct type of lymphoma that involves body cavities without tumor mass formation",
                      "Unclear lineage by immunophenotype, including lack of B-cell antigens, but monoclonalIGHrearrangements present",
                      "Predominantly HHV-8 associated",
                      "Variable association with EBV with type II latency pattern",
                      "Both EBV and HHV-8 detected in > 50% of cases",
                      "Plasmablastic lymphomaAggressive lymphoma with immunoblastic morphologyMost frequently involve oral cavity but can present in other extranodal sitesImmunophenotype of plasma cells with expression of CD138, CD38, and MUM1 but weakly (+) or (-) for CD20, PAX5, and CD45ClonalIGHrearrangements",
                      "Aggressive lymphoma with immunoblastic morphology",
                      "Most frequently involve oral cavity but can present in other extranodal sites",
                      "Immunophenotype of plasma cells with expression of CD138, CD38, and MUM1 but weakly (+) or (-) for CD20, PAX5, and CD45",
                      "ClonalIGHrearrangements"
                    ]
                  },
                  {
                    "text": "Lymphoma subtypes that usually occur in immunocompetent patientsBurkitt lymphomaAccounts for ~ 30% of HIV-associated lymphomaEBV is detected in ~ 50% of casesDLBCLAccounts for ~ 30% of HIV-associated lymphoma~ 30% of cases are EBV associatedMost cases exhibit centroblastic or immunoblastic morphologyPrimary central nervous system (CNS) lymphomaAccounts for ~ 25% of HIV-associated lymphomasAlmost all cases are EBV-associatedTypically express all EBV latency pattern III",
                    "sub_points": [
                      "Burkitt lymphomaAccounts for ~ 30% of HIV-associated lymphomaEBV is detected in ~ 50% of cases",
                      "Accounts for ~ 30% of HIV-associated lymphoma",
                      "EBV is detected in ~ 50% of cases",
                      "DLBCLAccounts for ~ 30% of HIV-associated lymphoma~ 30% of cases are EBV associatedMost cases exhibit centroblastic or immunoblastic morphology",
                      "Accounts for ~ 30% of HIV-associated lymphoma",
                      "~ 30% of cases are EBV associated",
                      "Most cases exhibit centroblastic or immunoblastic morphology",
                      "Primary central nervous system (CNS) lymphomaAccounts for ~ 25% of HIV-associated lymphomasAlmost all cases are EBV-associatedTypically express all EBV latency pattern III",
                      "Accounts for ~ 25% of HIV-associated lymphomas",
                      "Almost all cases are EBV-associated",
                      "Typically express all EBV latency pattern III"
                    ]
                  }
                ],
                "EBV-Associated Smooth Muscle Tumors in AIDS Patients": [
                  {
                    "text": "Occurs in advanced stage of HIV infection with low CD4 count"
                  },
                  {
                    "text": "Cranial and spinal epidural are common sites of involvement"
                  },
                  {
                    "text": "Typically multifocal with different EBV clones in different sites"
                  }
                ]
              },
              "EBV(+) Nonlymphoid Neoplasms": {
                "Nasopharyngeal Carcinoma": [
                  {
                    "text": "Derived from nasopharyngeal epitheliumArises in Rosenmüller fossa in most casesHigh incidence in Southern China and Hong KongRare in Europe and North America",
                    "sub_points": [
                      "Arises in Rosenmüller fossa in most cases",
                      "High incidence in Southern China and Hong Kong",
                      "Rare in Europe and North America"
                    ]
                  },
                  {
                    "text": "EBV and nasopharyngeal carcinoma (NPC)Virtually all NPC EBV associated, including keratinizing subtypes when sensitive detection methods are usedEBV likely plays key role in pathogenesis of NPCEBV is localized to neoplastic cells and is absent in background nonneoplastic cellsEBV is also present in precancerous tissue, including carcinoma in situ and dysplastic epithelium adjacent to invasive carcinomaEBV is clonal in NPC by Southern blot analysisFurther supports important role of EBV in pathogenesis of NPCNPC shows latency pattern IIEBER, LMP, and EBNA1 are expressed",
                    "sub_points": [
                      "Virtually all NPC EBV associated, including keratinizing subtypes when sensitive detection methods are used",
                      "EBV likely plays key role in pathogenesis of NPCEBV is localized to neoplastic cells and is absent in background nonneoplastic cellsEBV is also present in precancerous tissue, including carcinoma in situ and dysplastic epithelium adjacent to invasive carcinoma",
                      "EBV is localized to neoplastic cells and is absent in background nonneoplastic cells",
                      "EBV is also present in precancerous tissue, including carcinoma in situ and dysplastic epithelium adjacent to invasive carcinoma",
                      "EBV is clonal in NPC by Southern blot analysisFurther supports important role of EBV in pathogenesis of NPC",
                      "Further supports important role of EBV in pathogenesis of NPC",
                      "NPC shows latency pattern IIEBER, LMP, and EBNA1 are expressed",
                      "EBER, LMP, and EBNA1 are expressed"
                    ]
                  },
                  {
                    "text": "EBV serology in NPCElevated IgG and IgA against viral capsid antigen (VCA) and diffuse component of early antigen (EA)Elevated IgA against VCA is most specific for NPCDetected in > 80% of NPC casesSerologic testing of these antibodies may prove useful as screening methodElevated IgA against EBNA1Reported in ~ 90% of NPC casesElevated IgG against EBV replication activator (ZEBRA)Present in ~ 25% of IgA VCA(-) NPC casesPositive serology for EBV infection does not provide direct evidence for presence of EBV in tumor cells",
                    "sub_points": [
                      "Elevated IgG and IgA against viral capsid antigen (VCA) and diffuse component of early antigen (EA)Elevated IgA against VCA is most specific for NPCDetected in > 80% of NPC casesSerologic testing of these antibodies may prove useful as screening method",
                      "Elevated IgA against VCA is most specific for NPC",
                      "Detected in > 80% of NPC cases",
                      "Serologic testing of these antibodies may prove useful as screening method",
                      "Elevated IgA against EBNA1Reported in ~ 90% of NPC cases",
                      "Reported in ~ 90% of NPC cases",
                      "Elevated IgG against EBV replication activator (ZEBRA)Present in ~ 25% of IgA VCA(-) NPC cases",
                      "Present in ~ 25% of IgA VCA(-) NPC cases",
                      "Positive serology for EBV infection does not provide direct evidence for presence of EBV in tumor cells"
                    ]
                  }
                ],
                "Gastric Carcinoma": [
                  {
                    "text": "Frequency of EBV-associated gastric carcinoma varies across globe"
                  },
                  {
                    "text": "EBV detected in ~ 9% of gastric carcinoma per The Cancer Genome Atlas (TCGA) project~ 65% of EBV(+) cases involve malesAll EBV(+) tumors clustered together in unsupervised clustering of CpG methylation on unpaired tumor samplesExtreme CpG island-methylator phenotype is evident in all EBV-associated gastric carcinoma distinct from those with MSI subtypeHigher prevalence of DNA hypermethylation than any cancers reported by TCGAAll EBV(+) gastric tumors showCDKN2Apromoter hypermethylationEBV(+) tumors lackMLH1promoter hypermethylation in contrast to MSI-associated tumorsPIK3CAmutations in 80% of EBV(+) gastric carcinomaPI(3) kinase inhibition may warrant further evaluation in EBV(+) gastric carcinomasARID1Amutations in 55%BCORmutations in 23%TP53mutations are rareHighly transcribed EBV viral mRNAs and miRNAs fell within BAMH1A restriction region of viral genome",
                    "sub_points": [
                      "~ 65% of EBV(+) cases involve males",
                      "All EBV(+) tumors clustered together in unsupervised clustering of CpG methylation on unpaired tumor samplesExtreme CpG island-methylator phenotype is evident in all EBV-associated gastric carcinoma distinct from those with MSI subtypeHigher prevalence of DNA hypermethylation than any cancers reported by TCGA",
                      "Extreme CpG island-methylator phenotype is evident in all EBV-associated gastric carcinoma distinct from those with MSI subtype",
                      "Higher prevalence of DNA hypermethylation than any cancers reported by TCGA",
                      "All EBV(+) gastric tumors showCDKN2Apromoter hypermethylation",
                      "EBV(+) tumors lackMLH1promoter hypermethylation in contrast to MSI-associated tumors",
                      "PIK3CAmutations in 80% of EBV(+) gastric carcinomaPI(3) kinase inhibition may warrant further evaluation in EBV(+) gastric carcinomas",
                      "PI(3) kinase inhibition may warrant further evaluation in EBV(+) gastric carcinomas",
                      "ARID1Amutations in 55%",
                      "BCORmutations in 23%",
                      "TP53mutations are rare",
                      "Highly transcribed EBV viral mRNAs and miRNAs fell within BAMH1A restriction region of viral genome"
                    ]
                  }
                ],
                "Lymphoepithelioma-Like Salivary Gland Carcinoma": [
                  {
                    "text": "Very rare undifferentiated carcinoma of salivary gland with abundant lymphoid stroma"
                  },
                  {
                    "text": "Relatively higher incidence among Eskimos of Alaska, Greenland, and China"
                  },
                  {
                    "text": "EBV detected by EBER stain in virtually all cases"
                  }
                ],
                "Inflammatory Pseudotumor-Like Follicular Dendritic Cell Sarcoma of Liver and Spleen": [
                  {
                    "text": "Uncommon neoplasm of unknown etiology"
                  },
                  {
                    "text": "Only sporadic case reports and small case seriesEncapsulated and well-circumscribed tumors on gross and radiologic examinationAbundant background lymphocytes and plasma cells with at least focal follicular dendritic cell proliferationExpression of 1 or more follicular dendritic cell markers, such as CD21, CD35, and CD23Low malignant potential with recurrence reported in subset of cases",
                    "sub_points": [
                      "Encapsulated and well-circumscribed tumors on gross and radiologic examination",
                      "Abundant background lymphocytes and plasma cells with at least focal follicular dendritic cell proliferation",
                      "Expression of 1 or more follicular dendritic cell markers, such as CD21, CD35, and CD23",
                      "Low malignant potential with recurrence reported in subset of cases"
                    ]
                  },
                  {
                    "text": "Virtually all reported cases in liver and spleen are EBV-associatedEBV is localized to follicular dendritic cells and is absent in background lymphocytes and plasma cellsEBV is clonal by Southern blot analysisClonal EBV detected in these cases supports neoplastic nature of these tumorsInflammatory pseudotumors and follicular dendritic cell sarcomas in other locations are EBV(-)",
                    "sub_points": [
                      "EBV is localized to follicular dendritic cells and is absent in background lymphocytes and plasma cells",
                      "EBV is clonal by Southern blot analysisClonal EBV detected in these cases supports neoplastic nature of these tumors",
                      "Clonal EBV detected in these cases supports neoplastic nature of these tumors",
                      "Inflammatory pseudotumors and follicular dendritic cell sarcomas in other locations are EBV(-)"
                    ]
                  }
                ]
              },
              "Detection of EBV by Molecular Techniques": {
                "Nucleic Acid Hybridization Techniques": [
                  {
                    "text": "In situ hybridization for EBERMost sensitive method for detection of EBV in latently infected cellsEBERs are abundantly transcribed in EBV-infected cells (~ 10⁶ copies per cell)Ability to precisely localize virus in infected tumor cellsCan be performed on paraffin-embedded fixed tissue",
                    "sub_points": [
                      "Most sensitive method for detection of EBV in latently infected cellsEBERs are abundantly transcribed in EBV-infected cells (~ 10⁶ copies per cell)",
                      "EBERs are abundantly transcribed in EBV-infected cells (~ 10⁶ copies per cell)",
                      "Ability to precisely localize virus in infected tumor cells",
                      "Can be performed on paraffin-embedded fixed tissue"
                    ]
                  },
                  {
                    "text": "DNA in situ hybridizationNot currently used due to low sensitivity",
                    "sub_points": [
                      "Not currently used due to low sensitivity"
                    ]
                  },
                  {
                    "text": "Southern blot techniquesAnalysis of restriction enzyme-digested EBV DNA terminal repeats fragmentsAbility to determine clonality of EBV-infected tumor cellsAbility to distinguish lytic infection (i.e., infectious mononucleosis) from latent infectionFresh tissues with intact genomic DNA required",
                    "sub_points": [
                      "Analysis of restriction enzyme-digested EBV DNA terminal repeats fragmentsAbility to determine clonality of EBV-infected tumor cellsAbility to distinguish lytic infection (i.e., infectious mononucleosis) from latent infectionFresh tissues with intact genomic DNA required",
                      "Ability to determine clonality of EBV-infected tumor cells",
                      "Ability to distinguish lytic infection (i.e., infectious mononucleosis) from latent infection",
                      "Fresh tissues with intact genomic DNA required"
                    ]
                  }
                ],
                "PCR Analysis of EBV DNA": [
                  {
                    "text": "Highly sensitive for detection of EBV DNANot useful for disease-specific purposes given ubiquitous nature of virusUseful in detection of presumably oncogenic EBVLMP1with 30 bp deletion",
                    "sub_points": [
                      "Not useful for disease-specific purposes given ubiquitous nature of virus",
                      "Useful in detection of presumably oncogenic EBVLMP1with 30 bp deletion"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Work-Up of Lymphoid Neoplasms": {
            "name": "Molecular Work-Up of Lymphoid Neoplasms",
            "url": "https://app.pathprimer.com/document/0c847cf4-80b0-44f8-a04a-d98d776b4f4c/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "Molecular/Genetic Techniques Commonly Used": {
                "Clonality Testing": [
                  {
                    "text": "Application of PCR-based molecular analysis unique to work-up of lymphoid neoplasms"
                  },
                  {
                    "text": "Immunoglobulin molecules and T-cell receptors must recognize vast array of antigensAccomplished by random selection of specific V regions, J regions, and in some cases D regions to join together within individual maturing lymphocytes",
                    "sub_points": [
                      "Accomplished by random selection of specific V regions, J regions, and in some cases D regions to join together within individual maturing lymphocytes"
                    ]
                  },
                  {
                    "text": "Polyclonal population of lymphocytes is characterized by diversity at these rearranged regions"
                  },
                  {
                    "text": "Monoclonal population of lymphocytes shows single characteristic arrangement"
                  },
                  {
                    "text": "PCR using consensus primers generates products that can be sized using capillary or gel electrophoresisGaussian (bell-shaped) distribution of amplicon sizes in polyclonal lymphoid populationSingle or double prominent peaks, usually standing out from polyclonal background in monoclonal lymphoid population",
                    "sub_points": [
                      "Gaussian (bell-shaped) distribution of amplicon sizes in polyclonal lymphoid population",
                      "Single or double prominent peaks, usually standing out from polyclonal background in monoclonal lymphoid population"
                    ]
                  }
                ],
                "FISH": [
                  {
                    "text": "Used to detect specific chromosomal translocations that can assist in diagnosis and subclassification of lymphoid neoplasmsDetection ofCCND1::IGHin mantle cell lymphomaDetection ofBCL2::IGHfusion is diagnostic of B-cell lymphoma with differential diagnosis of follicular lymphoma; diffuse large B-cell lymphoma; detection ofMYCandBCL2&/orBCL6rearrangements in high-grade B-cell lymphoma (double-/triple-hit lymphomas)",
                    "sub_points": [
                      "Detection ofCCND1::IGHin mantle cell lymphoma",
                      "Detection ofBCL2::IGHfusion is diagnostic of B-cell lymphoma with differential diagnosis of follicular lymphoma; diffuse large B-cell lymphoma; detection ofMYCandBCL2&/orBCL6rearrangements in high-grade B-cell lymphoma (double-/triple-hit lymphomas)"
                    ]
                  },
                  {
                    "text": "In most cases, because both partners in translocation are known, dual-color dual fusion probe sets are used"
                  },
                  {
                    "text": "Break-apart probe strategy can also be used (e.g.,MYCbreak-apart probe) to detect rearrangement with immunoglobulin light chain partners or with heavy chaine.g.,MYCbreak-apart probe to detect rearrangement with immunoglobulin light chain partners or with heavy chain",
                    "sub_points": [
                      "e.g.,MYCbreak-apart probe to detect rearrangement with immunoglobulin light chain partners or with heavy chain"
                    ]
                  }
                ],
                "Karyotype": [
                  {
                    "text": "Identifies characteristic chromosomal translocationsMay also identify abnormalities beyond those seen with usual targeted FISH probes",
                    "sub_points": [
                      "May also identify abnormalities beyond those seen with usual targeted FISH probes"
                    ]
                  },
                  {
                    "text": "Fresh tissue is required"
                  },
                  {
                    "text": "For most lymphoid neoplasms, stimulation with mitogens is required to induce neoplastic cells to divide"
                  }
                ],
                "RT-PCR for Gene Fusions": [
                  {
                    "text": "Available for common gene fusions such asIGH::BCL2More suitable for the purpose of disease monitoring and minimal residual disease detection",
                    "sub_points": [
                      "More suitable for the purpose of disease monitoring and minimal residual disease detection"
                    ]
                  },
                  {
                    "text": "In practice, FISH is typically preferred modality"
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "Whole-genome, exome, and targeted sequencing have identified many gene alterations in several subtypes of lymphomasBRAFV600E mutation in hairy cell leukemiaMYD88L265P,CXCR4, andARID1A mutations in lymphoplasmacytic lymphomaRecurrentKMT2DandCARD11mutations in primary cold agglutininATM,CCND1,KMT2D, andNOTCH1mutations in mantle cell lymphomaSF3B1,NOTCH1,TP53,ATM,BIRC3,POT1, andMYD88mutations in 3-15% of chronic lymphocytic leukemia (CLL)KLF2andNOTCH2mutations in splenic marginal zone lymphomaEZH2,ARID1A,MEF2B,EP300,FOXO1,CREBBP, andCARD11mutation analysis useful in clinical prognostication in follicular lymphomaOther genes mutated in follicular lymphoma includeEPHA7,BCL2,BCL6,TNFRSF14, andTNFAIP3STAT3mutations in T-cell large granular lymphocytic leukemiaATM,TP53,JAK3,JAK1, andSTAT5Bmutations in T-cell prolymphocytic leukemiaPLCG1,PRKCB,VAV1,IRF4,FYN,CARD11, andSTAT3mutations in adult T-cell leukemia/lymphomaSETD2,INO80,ARID1B, andSTAT5Bmutations in hepatosplenic T-cell lymphomaTET2,IDH2,DNMT3A, andRHOAoverlapping mutations and less commonFYN,PLCG1,CD28,STAT3, andEP300mutations in angioimmunoblastic T-cell lymphoma",
                    "sub_points": [
                      "BRAFV600E mutation in hairy cell leukemia",
                      "MYD88L265P,CXCR4, andARID1A mutations in lymphoplasmacytic lymphoma",
                      "RecurrentKMT2DandCARD11mutations in primary cold agglutinin",
                      "ATM,CCND1,KMT2D, andNOTCH1mutations in mantle cell lymphoma",
                      "SF3B1,NOTCH1,TP53,ATM,BIRC3,POT1, andMYD88mutations in 3-15% of chronic lymphocytic leukemia (CLL)",
                      "KLF2andNOTCH2mutations in splenic marginal zone lymphoma",
                      "EZH2,ARID1A,MEF2B,EP300,FOXO1,CREBBP, andCARD11mutation analysis useful in clinical prognostication in follicular lymphoma",
                      "Other genes mutated in follicular lymphoma includeEPHA7,BCL2,BCL6,TNFRSF14, andTNFAIP3",
                      "STAT3mutations in T-cell large granular lymphocytic leukemia",
                      "ATM,TP53,JAK3,JAK1, andSTAT5Bmutations in T-cell prolymphocytic leukemia",
                      "PLCG1,PRKCB,VAV1,IRF4,FYN,CARD11, andSTAT3mutations in adult T-cell leukemia/lymphoma",
                      "SETD2,INO80,ARID1B, andSTAT5Bmutations in hepatosplenic T-cell lymphoma",
                      "TET2,IDH2,DNMT3A, andRHOAoverlapping mutations and less commonFYN,PLCG1,CD28,STAT3, andEP300mutations in angioimmunoblastic T-cell lymphoma"
                    ]
                  }
                ],
                "Detection of Somatic Hypermutation": [
                  {
                    "text": "Somatic hypermutation is physiologic process in which B cells randomly mutate their immunoglobulin heavy chain variable regions (IGHV) to produce molecule with greater affinity for given antigens"
                  },
                  {
                    "text": "In this assay, heavy chain region sequence is obtained from clonal population and compared to closest germline sequenceSignificant divergence from best matched germline sequence indicates that B-cell clone has undergone somatic hypermutation",
                    "sub_points": [
                      "Significant divergence from best matched germline sequence indicates that B-cell clone has undergone somatic hypermutation"
                    ]
                  },
                  {
                    "text": "Useful in prognostic determination in CLL"
                  }
                ]
              },
              "Purposes of Molecular Analysis": {
                "Establish Diagnosis": [
                  {
                    "text": "Detection of specific abnormalities may establish presence of lymphomae.g., clonal T-cell receptor gene rearrangement may assist in identifying T-cell lymphoma",
                    "sub_points": [
                      "e.g., clonal T-cell receptor gene rearrangement may assist in identifying T-cell lymphoma"
                    ]
                  }
                ],
                "Establish Subtype of Lymphoma": [
                  {
                    "text": "Certain molecular findings may help to establish presence of specific subtype of lymphomae.g., presence ofMYD88mutation favors diagnosis of lymphoplasmacytic lymphoma",
                    "sub_points": [
                      "e.g., presence ofMYD88mutation favors diagnosis of lymphoplasmacytic lymphoma"
                    ]
                  }
                ],
                "Establish Prognosis": [
                  {
                    "text": "Certain molecular findings may refine prognostic expectations for patiente.g.,IGHVsomatic hypermutation in CLL",
                    "sub_points": [
                      "e.g.,IGHVsomatic hypermutation in CLL"
                    ]
                  }
                ],
                "Minimal Residual Disease detection": [
                  {
                    "text": "Highly sensitive detection of specificIGHor T-cell receptor gene rearrangements using NGS"
                  },
                  {
                    "text": "Currently used in MRD detection in pediatric and young adults with acute lymphoblastic leukemia (ALL)Detects leukemic blasts at levels ≤ 10⁻⁶ cellsHigh specificity attributable to resolution of rearrangements not only by size but also by sequence",
                    "sub_points": [
                      "Detects leukemic blasts at levels ≤ 10⁻⁶ cells",
                      "High specificity attributable to resolution of rearrangements not only by size but also by sequence"
                    ]
                  }
                ]
              },
              "Limitations of Techniques": {
                "Clonality Testing": [
                  {
                    "text": "Clonal population is not always equivalent to neoplasmProminent clonal expansion can occur in reactive conditions (e.g., EBV infection)Pseudoclonality can occur when sample has only scant lymphocytes",
                    "sub_points": [
                      "Prominent clonal expansion can occur in reactive conditions (e.g., EBV infection)",
                      "Pseudoclonality can occur when sample has only scant lymphocytes"
                    ]
                  },
                  {
                    "text": "Nonclonal population is not always equivalent to benignPrimer sets are optimized for broad detection (e.g., using framework regions) but may not bind in some casesParticular problem in post germinal center B-cell lymphomas, in which somatic hypermutation may alter primer binding sites",
                    "sub_points": [
                      "Primer sets are optimized for broad detection (e.g., using framework regions) but may not bind in some casesParticular problem in post germinal center B-cell lymphomas, in which somatic hypermutation may alter primer binding sites",
                      "Particular problem in post germinal center B-cell lymphomas, in which somatic hypermutation may alter primer binding sites"
                    ]
                  },
                  {
                    "text": "Clonal immunoglobulin region and T-cell receptor gene rearrangements may sometimes be detected in T-cell and B-cell lymphomas, respectivelyMay be due to background clonal or subclonal populations (e.g., B-cells in angioimmunoblastic T-cell lymphoma)Rearrangement of T-cell receptor and immunoglobulin regions may occasionally occur in B cells and T cells, respectively known as lineage infidelity",
                    "sub_points": [
                      "May be due to background clonal or subclonal populations (e.g., B-cells in angioimmunoblastic T-cell lymphoma)",
                      "Rearrangement of T-cell receptor and immunoglobulin regions may occasionally occur in B cells and T cells, respectively known as lineage infidelity"
                    ]
                  }
                ],
                "FISH and PCR": [
                  {
                    "text": "Only identify specific abnormalities targeted with given probe or primer set"
                  }
                ],
                "Karyotype": [
                  {
                    "text": "Obtaining karyotype from some types of lymphoma cells is difficult, even with mitogen stimulatione.g., plasma cells in myeloma may not easily divide in culture",
                    "sub_points": [
                      "e.g., plasma cells in myeloma may not easily divide in culture"
                    ]
                  }
                ]
              },
              "Utility of Testing Methods for Key Lymphoid Neoplasms": {
                "B-Lymphoblastic Leukemia/Lymphoma": [
                  {
                    "text": "Karyotype, FISH panel, and Ph-like signature testing critical for risk stratified treatment"
                  },
                  {
                    "text": "Highly sensitive MRD detection using NGS"
                  }
                ],
                "Chronic Lymphocytic Leukemia": [
                  {
                    "text": "FISH panel,IGHVsomatic hypermutation, andTP53mutation analysis useful for prognosis"
                  }
                ],
                "Lymphoplasmacytic Lymphoma": [
                  {
                    "text": "MYD88mutation has relatively high sensitivity and specificity for this diagnosis"
                  }
                ],
                "Plasma Cell Myeloma": [
                  {
                    "text": "FISH panel and karyotype critical for risk stratification"
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "Most cases positive forBCL2::IGHfusion associated with t(14;18)(q32;q21) by FISH or karyotype"
                  }
                ],
                "Mantle Cell Lymphoma": [
                  {
                    "text": "Almost all cases positive forCCND1::IGHfusion associated with t(11;14)(q13;q32) by FISH or karyotype"
                  }
                ],
                "Burkitt Lymphoma": [
                  {
                    "text": "CharacteristicMYCrearrangement, most commonly in t(8;14) by FISH or karyotype"
                  }
                ],
                "High-Grade B-Cell Lymphoma": [
                  {
                    "text": "Double-/triple-hit lymphoma shows translocation ofMYCas well asBCL2&/orBCL6"
                  },
                  {
                    "text": "Typically detected by FISH, though karyotype would also detect these abnormalities"
                  },
                  {
                    "text": "Markedly aggressive disease course, poorly responsive to standard therapies"
                  }
                ],
                "T-Cell Prolymphocytic Leukemia": [
                  {
                    "text": "Karyotype shows t(14;14)(q11;q32) or t(X;14)(q28;q11)"
                  }
                ],
                "T-Cell Leukemias and Lymphomas (Multiple Subtypes)": [
                  {
                    "text": "Clonality testing especially useful in distinguishing neoplastic from reactive T-cell infiltrates"
                  }
                ],
                "Anaplastic Large Cell Lymphoma": [
                  {
                    "text": "ALKrearrangement [most commonlyNPM1::ALK, t(2;5)] seen in ALK-positive ALCL by FISH or karyotypeNot usually required if ALK is positive by IHC",
                    "sub_points": [
                      "Not usually required if ALK is positive by IHC"
                    ]
                  },
                  {
                    "text": "ALK-negative ALCL may show rearrangement ofTP63andDUSP22by FISH with prognostic connotations"
                  }
                ],
                "Hodgkin Lymphoma": [
                  {
                    "text": "Molecular testing rarely useful"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Work-Up of Myeloid Neoplasms": {
            "name": "Molecular Work-Up of Myeloid Neoplasms",
            "url": "https://app.pathprimer.com/document/2fee7eb4-888a-4b34-8a73-db58660e373f/lesson/c0d3b1e7-91cf-47d0-b2bb-69e8cefb4376",
            "content": {
              "Molecular/Genetic Techniques Commonly Used": {
                "Chromosome Analysis (Karyotype)": [
                  {
                    "text": "Reveals large-scale structural changes in genome"
                  },
                  {
                    "text": "Clonal cytogenetic abnormalities often correlate with clonal hematopoiesis"
                  },
                  {
                    "text": "Karyotype derived from unstimulated bone marrow culture will typically reflect myeloid stem cells or blasts"
                  }
                ],
                "FISH": [
                  {
                    "text": "Uses fluorescently labeled probes to identify presence, absence, or rearrangement of specific genomic regions"
                  },
                  {
                    "text": "Important findings in myeloid neoplasmsNumerical abnormalitiesTranslocationsDeletions",
                    "sub_points": [
                      "Numerical abnormalities",
                      "Translocations",
                      "Deletions"
                    ]
                  }
                ],
                "PCR-Based Analysis": [
                  {
                    "text": "Numerous types of molecular assays derive from common technique of PCR"
                  },
                  {
                    "text": "Identifies gene mutations (via sequencing or other detection methods)"
                  },
                  {
                    "text": "RT-PCR identifies and quantifies presence of fusion transcripts"
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "Enables simultaneous assessment of many genes"
                  },
                  {
                    "text": "Significantly mutated genes identified in myeloid neoplasms by next-generation sequencing (NGS) technologyASXL1,BCOR,CALR,CBL,CEBPA,CSF3R,DNMT3A,EZH2,FLT3,IDH1,IDH2,JAK2,KIT,KRAS,MPL,NRAS,NPM1,RUNX1,SETBP1,SF3B1,SRSF2,TET2,TP53,U2AF1, andWT1",
                    "sub_points": [
                      "ASXL1,BCOR,CALR,CBL,CEBPA,CSF3R,DNMT3A,EZH2,FLT3,IDH1,IDH2,JAK2,KIT,KRAS,MPL,NRAS,NPM1,RUNX1,SETBP1,SF3B1,SRSF2,TET2,TP53,U2AF1, andWT1"
                    ]
                  },
                  {
                    "text": "Several additional less frequently mutated genes are included in broader myeloid gene panels"
                  },
                  {
                    "text": "Clinical utility of NGS myeloid gene panel assessmentMay improve diagnosisMay help in therapeutic decisionsMay provide prognostic information",
                    "sub_points": [
                      "May improve diagnosis",
                      "May help in therapeutic decisions",
                      "May provide prognostic information"
                    ]
                  },
                  {
                    "text": "DNMT3A,ASXL1,TET2,SF3B1, andSRSF2are also associated with clonal hematopoiesis in apparently healthy older individuals"
                  }
                ]
              },
              "Purposes of Molecular Analysis in Myeloid Neoplasms": {
                "Establish Diagnosis": [
                  {
                    "text": "Detection of specific abnormalities may establish presence of myeloid neoplasme.g., monosomy 7 and myelodysplastic syndrome",
                    "sub_points": [
                      "e.g., monosomy 7 and myelodysplastic syndrome"
                    ]
                  }
                ],
                "Establish Subtype of Myeloid Neoplasm": [
                  {
                    "text": "Even if diagnosis of myeloid neoplasia is known, certain molecular findings may establish presence of specific subtype of myeloid neoplasme.g., acute promyelocytic leukemia with t(1;17); acute myeloid leukemia (AML) with mutatedTP53, etc.",
                    "sub_points": [
                      "e.g., acute promyelocytic leukemia with t(1;17); acute myeloid leukemia (AML) with mutatedTP53, etc."
                    ]
                  }
                ],
                "Establish Prognosis": [
                  {
                    "text": "Certain molecular findings may refine prognostic expectations for patiente.g.,KITmutation in AML with t(8;21)",
                    "sub_points": [
                      "e.g.,KITmutation in AML with t(8;21)"
                    ]
                  }
                ]
              },
              "Limitations of Techniques": {
                "Karyotype": [
                  {
                    "text": "Myeloid neoplasms not infrequently have normal karyotype"
                  },
                  {
                    "text": "Some changes may be cryptic (invisible) on karyotypeSome are routinely cryptic or submicroscopice.g.,PDGFRA::FIP1L1rearrangementSome are only rarely cryptice.g.,BCR::ABL1rearrangement",
                    "sub_points": [
                      "Some are routinely cryptic or submicroscopice.g.,PDGFRA::FIP1L1rearrangement",
                      "e.g.,PDGFRA::FIP1L1rearrangement",
                      "Some are only rarely cryptice.g.,BCR::ABL1rearrangement",
                      "e.g.,BCR::ABL1rearrangement"
                    ]
                  },
                  {
                    "text": "Recently introduced optical genome mapping platform appears promising in refining chromosomal aberrations with high resolution compared to conventional karyotype"
                  }
                ],
                "FISH": [
                  {
                    "text": "Will only identify specific abnormalities targeted with given probe sete.g., FISH with MDS panel may be normal, but karyotype could reveal cytogenetic abnormalities not targeted by FISH probes",
                    "sub_points": [
                      "e.g., FISH with MDS panel may be normal, but karyotype could reveal cytogenetic abnormalities not targeted by FISH probes"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "Will only identify specific abnormalities targeted by given primer paire.g., RT-PCR forBCR::ABL1transcripts using primers directed to e1/a2- and e13-e14/a2-type transcripts would not identify e19/a2 transcripts if present",
                    "sub_points": [
                      "e.g., RT-PCR forBCR::ABL1transcripts using primers directed to e1/a2- and e13-e14/a2-type transcripts would not identify e19/a2 transcripts if present"
                    ]
                  }
                ]
              }
            }
          }
        }
      },
      "Somatic Alterations in Cancer: Solid Tumor": {
        "name": "Somatic Alterations in Cancer: Solid Tumor",
        "url": "https://app.pathprimer.com/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
        "topics": {
          "EWSR Rearrangement": {
            "name": "EWSR Rearrangement",
            "url": "https://app.pathprimer.com/document/5790cf59-dca8-4f8d-8e8a-aaf7624d1f68/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Fused with variety of partner genes in many types of sarcomaFusesEWSR1transcription activation domain (TAD) to DNA-binding domain (DBD) of partnerThought to constitutively activateEWSR1targets",
                    "sub_points": [
                      "FusesEWSR1transcription activation domain (TAD) to DNA-binding domain (DBD) of partner",
                      "Thought to constitutively activateEWSR1targets"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Angiomatoid fibrous histiocytoma: t(12;22)(q13;q12);EWSR1-ATF1"
                  },
                  {
                    "text": "Clear cell sarcoma of soft parts: t(12;22)(q13;q12);EWSR1-ATF1or t(2;22)(q34;q12);EWSR1-CREB1"
                  },
                  {
                    "text": "Desmoplastic round cell tumor: t(11;22)(p13;q12);EWSR1-WT1or t(21;22)(q22;q12);EWSR1-ERG"
                  },
                  {
                    "text": "Extraskeletal myxoid chondrosarcoma: t(9;22)(q22;q12);EWSR1-NR4A3"
                  },
                  {
                    "text": "Ewing sarcoma/PNET: Many fusion partners, includingFLI1, ERG, NFATC2, FEV, ETV1, E1AF, SP3, ZNF278,andPOU5FI"
                  },
                  {
                    "text": "Myxoid/round cell liposarcoma: t(12;22)(q13;q12);EWSR1-DDIT3"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Angiomatoid fibrous histiocytoma (AFH)"
                  },
                  {
                    "text": "Clear cell sarcoma (CCS)"
                  },
                  {
                    "text": "Desmoplastic round cell tumor (DRCT)"
                  },
                  {
                    "text": "Extraskeletal myxoid chondrosarcoma (EMC)"
                  },
                  {
                    "text": "Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET)"
                  },
                  {
                    "text": "Fluorescence in-situ hybridization (FISH)"
                  },
                  {
                    "text": "Myxoid liposarcoma (MLS)"
                  },
                  {
                    "text": "Next-generation sequencing (NGS)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "EWSR1Gene": [
                  {
                    "text": "Located at 22q12"
                  },
                  {
                    "text": "Fused with variety of partner genes in many types of sarcomaFusesEWSR1transcription activation domain (TAD) to DNA-binding domain (DBD) of partnerConstitutively activatesEWSR1targets",
                    "sub_points": [
                      "FusesEWSR1transcription activation domain (TAD) to DNA-binding domain (DBD) of partner",
                      "Constitutively activatesEWSR1targets"
                    ]
                  },
                  {
                    "text": "Member of TET family of proteins, which includes FUS and TAF15"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Angiomatoid fibrous histiocytomat(12;22)(q13;q12);EWSR1-ATF1Affects children and young adultsRarely metastasizes; local recurrence in ~ 15%Involves superficial soft tissue of head, neck, and trunkNodular proliferation of \"myoid\" cells with thick pseudocapsule surrounded by reactive lymphoplasmacytic infiltrateHemorrhage and cyst formation common",
                    "sub_points": [
                      "t(12;22)(q13;q12);EWSR1-ATF1",
                      "Affects children and young adults",
                      "Rarely metastasizes; local recurrence in ~ 15%",
                      "Involves superficial soft tissue of head, neck, and trunk",
                      "Nodular proliferation of \"myoid\" cells with thick pseudocapsule surrounded by reactive lymphoplasmacytic infiltrate",
                      "Hemorrhage and cyst formation common"
                    ]
                  },
                  {
                    "text": "Clear cell sarcoma of soft tissuet(12;22)(q13;q12);EWSR1-ATF1t(2;22)(q34;q12);EWSR1-CREB1Affects young to middle-aged patientsFrequent metastases to lung, liver, lymph node, brain, and bone with frequent local recurrenceInvolves tendons of feet and ankleNests of small round or spindled cells with clear or granular cytoplasm, occasionally with melanin pigmentTouton-like giant cells are frequent",
                    "sub_points": [
                      "t(12;22)(q13;q12);EWSR1-ATF1",
                      "t(2;22)(q34;q12);EWSR1-CREB1",
                      "Affects young to middle-aged patients",
                      "Frequent metastases to lung, liver, lymph node, brain, and bone with frequent local recurrence",
                      "Involves tendons of feet and ankle",
                      "Nests of small round or spindled cells with clear or granular cytoplasm, occasionally with melanin pigment",
                      "Touton-like giant cells are frequent"
                    ]
                  },
                  {
                    "text": "Desmoplastic round cell tumort(11;22)(p13;q12);EWSR1-WT1t(21;22)(q22;q12);EWSR1-ERGAffects children and young adultsMale predominanceRarely metastasizes; frequent local recurrenceInvolves peritoneal cavityNests of small round blue cells in desmoplastic background",
                    "sub_points": [
                      "t(11;22)(p13;q12);EWSR1-WT1",
                      "t(21;22)(q22;q12);EWSR1-ERG",
                      "Affects children and young adults",
                      "Male predominance",
                      "Rarely metastasizes; frequent local recurrence",
                      "Involves peritoneal cavity",
                      "Nests of small round blue cells in desmoplastic background"
                    ]
                  },
                  {
                    "text": "Extraskeletal myxoid chondrosarcomat(9;22)(q22;q12);EWSR1-NR4A3Affects adults; median age ~ 50 yearsMale predominanceFrequent metastases; frequent local recurrenceInvolves deep soft tissue of the limbsCords or clusters of small cells with eosinophilic cytoplasm in myxoid stroma",
                    "sub_points": [
                      "t(9;22)(q22;q12);EWSR1-NR4A3",
                      "Affects adults; median age ~ 50 years",
                      "Male predominance",
                      "Frequent metastases; frequent local recurrence",
                      "Involves deep soft tissue of the limbs",
                      "Cords or clusters of small cells with eosinophilic cytoplasm in myxoid stroma"
                    ]
                  },
                  {
                    "text": "Ewing sarcoma/PNETMany fusion partners, includingFLI1, ERG, NFATC2, FEV, ETV1, E1AF, SP3, ZNF278,andPOU5FIFirst 3 decades of lifeFrequent local recurrenceInvolves tubular long bones of extremities and flat bones of pelvisSheets of small round cells with fine chromatinHomer-Wright rosettesTumor cells rosetting around fibrillary core",
                    "sub_points": [
                      "Many fusion partners, includingFLI1, ERG, NFATC2, FEV, ETV1, E1AF, SP3, ZNF278,andPOU5FI",
                      "First 3 decades of life",
                      "Frequent local recurrence",
                      "Involves tubular long bones of extremities and flat bones of pelvis",
                      "Sheets of small round cells with fine chromatin",
                      "Homer-Wright rosettesTumor cells rosetting around fibrillary core",
                      "Tumor cells rosetting around fibrillary core"
                    ]
                  },
                  {
                    "text": "Myxoid/round cell liposarcomat(12;22)(q13;q12);EWSR1-DDIT3Affects patients in 3rd to 5th decade of lifeRarely metastasizes; local recurrence in ~ 30%Involves deep soft tissue of the limbsSpindle or round cell proliferation in myxoid backgroundArborizing capillary networkIncreased cellularity around blood vessels",
                    "sub_points": [
                      "t(12;22)(q13;q12);EWSR1-DDIT3",
                      "Affects patients in 3rd to 5th decade of life",
                      "Rarely metastasizes; local recurrence in ~ 30%",
                      "Involves deep soft tissue of the limbs",
                      "Spindle or round cell proliferation in myxoid background",
                      "Arborizing capillary network",
                      "Increased cellularity around blood vessels"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "KaryotypeDetects large abnormalitiesIdentifies regions of rearrangementRelatively low sensitivityNeed to culture cells, so results are delayed",
                    "sub_points": [
                      "Detects large abnormalitiesIdentifies regions of rearrangement",
                      "Identifies regions of rearrangement",
                      "Relatively low sensitivity",
                      "Need to culture cells, so results are delayed"
                    ]
                  },
                  {
                    "text": "FISHDetects break-apart ofEWSR1Partner gene not identifiedHigh sensitivityRapid",
                    "sub_points": [
                      "Detects break-apart ofEWSR1Partner gene not identified",
                      "Partner gene not identified",
                      "High sensitivity",
                      "Rapid"
                    ]
                  },
                  {
                    "text": "NGSIdentifies partner geneHigh sensitivityTesting takes longer than FISHExpensive",
                    "sub_points": [
                      "Identifies partner gene",
                      "High sensitivity",
                      "Testing takes longer than FISH",
                      "Expensive"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Breast Cancer": {
            "name": "Molecular Alterations in Breast Cancer",
            "url": "https://app.pathprimer.com/document/f4a2cbee-b71f-4e3b-a9a6-d8b6e7dfb6f9/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Atypical hyperplasia, in situ carcinoma, and infiltrating carcinoma represent morphologic continuum in tumorigenic pathway for major breast cancer types﻿Atypical hyperplasia and in situ carcinomas harbor similar molecular alterations as their invasive counterparts﻿",
                    "sub_points": [
                      "﻿Atypical hyperplasia and in situ carcinomas harbor similar molecular alterations as their invasive counterparts﻿"
                    ]
                  },
                  {
                    "text": "Hereditary factors (small fraction of overall breast cancers)﻿include first-degree relative with breast cancer and inherited germline mutationsBRCA1: familial breast-ovarian cancer 1; approximately 65% risk of breast cancer﻿BRCA2: familial breast-ovarian cancer 2; approximately 55% risk of breast cancer﻿TP53: Li-Fraumeni syndrome",
                    "sub_points": [
                      "BRCA1: familial breast-ovarian cancer 1; approximately 65% risk of breast cancer﻿",
                      "BRCA2: familial breast-ovarian cancer 2; approximately 55% risk of breast cancer﻿",
                      "TP53: Li-Fraumeni syndrome"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "E-cadherin is frequently mutated or deleted in lobular breast cancer; loss of expression is typically detected by IHC"
                  },
                  {
                    "text": "﻿ER expression in breast cancer is associated with well to moderately differentiated carcinomas and favorable outcomes﻿"
                  },
                  {
                    "text": "﻿PR expression in breast cancer is associated with favorable outcomes﻿"
                  },
                  {
                    "text": "Amplification ofHER2gene results in protein overexpression;HER2amplification/overexpression is associated with poorly differentiated histology and poor survival﻿"
                  },
                  {
                    "text": "Triple-negative breast cancers have no available targeted therapies"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Selective estrogen receptor modulator (SERM)"
                  },
                  {
                    "text": "Epidermal growth factor receptor (EGFR)"
                  },
                  {
                    "text": "Estrogen receptor (ER)"
                  },
                  {
                    "text": "Progesterone receptor (PR)"
                  },
                  {
                    "text": "Immunohistochemistry﻿ ﻿(IHC)﻿"
                  },
                  {
                    "text": "Fluorescence in situ hybridization (FISH)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Tumorigenesis": [
                  {
                    "text": "Atypical hyperplasia, in situ carcinoma, and infiltrating carcinoma represent morphologic continuum in tumorigenic pathway for major breast cancer typesAtypical ductal hyperplasia and ductal carcinoma in situ represent precursor lesions of infiltrating ductal carcinomaAtypical lobular hyperplasia and lobular carcinoma in situ represent precursor lesions of infiltrating lobular carcinoma﻿Atypical hyperplasia and in situ carcinomas harbor similar molecular alterations as their invasive counterparts﻿Infiltrating component occasionally is observed as arising from in situ lesion",
                    "sub_points": [
                      "Atypical ductal hyperplasia and ductal carcinoma in situ represent precursor lesions of infiltrating ductal carcinoma",
                      "Atypical lobular hyperplasia and lobular carcinoma in situ represent precursor lesions of infiltrating lobular carcinoma",
                      "﻿Atypical hyperplasia and in situ carcinomas harbor similar molecular alterations as their invasive counterparts﻿",
                      "Infiltrating component occasionally is observed as arising from in situ lesion"
                    ]
                  }
                ],
                "Risk Factors": [
                  {
                    "text": "Hereditary factorsSmall fraction of overall breast cancersFirst-degree relative with breast cancerCaucasian race (not strictly hereditary factor)Inherited germline mutationsBRCA1Familial breast-ovarian cancer 1﻿Approximately 65% risk of breast cancer﻿Increased risk of pancreatic, prostate, male breast cancer﻿BRCA2Familial breast-ovarian cancer 2﻿Approximately 55% risk of breast cancer﻿Increased risk of pancreatic, prostate, male breast cancer﻿TP53Li-Fraumeni syndrome﻿Increased risk of breast cancer, glioblastoma, sarcomas, adrenocortical carcinomas, several other malignanciesCHEK2Li-Fraumeni syndrome 2Similar clinical features as Li-Fraumeni syndromeCDH1Hereditary diffuse gastric cancer45% risk of infiltrating lobular carcinoma of breastIncreased risk of diffuse-type gastric cancer (linitis plastica)",
                    "sub_points": [
                      "Small fraction of overall breast cancers",
                      "First-degree relative with breast cancer",
                      "Caucasian race (not strictly hereditary factor)",
                      "Inherited germline mutationsBRCA1Familial breast-ovarian cancer 1﻿Approximately 65% risk of breast cancer﻿Increased risk of pancreatic, prostate, male breast cancer﻿BRCA2Familial breast-ovarian cancer 2﻿Approximately 55% risk of breast cancer﻿Increased risk of pancreatic, prostate, male breast cancer﻿TP53Li-Fraumeni syndrome﻿Increased risk of breast cancer, glioblastoma, sarcomas, adrenocortical carcinomas, several other malignanciesCHEK2Li-Fraumeni syndrome 2Similar clinical features as Li-Fraumeni syndromeCDH1Hereditary diffuse gastric cancer45% risk of infiltrating lobular carcinoma of breastIncreased risk of diffuse-type gastric cancer (linitis plastica)",
                      "BRCA1Familial breast-ovarian cancer 1﻿Approximately 65% risk of breast cancer﻿Increased risk of pancreatic, prostate, male breast cancer",
                      "Familial breast-ovarian cancer 1﻿",
                      "Approximately 65% risk of breast cancer﻿",
                      "Increased risk of pancreatic, prostate, male breast cancer",
                      "﻿BRCA2Familial breast-ovarian cancer 2﻿Approximately 55% risk of breast cancer﻿Increased risk of pancreatic, prostate, male breast cancer",
                      "Familial breast-ovarian cancer 2﻿",
                      "Approximately 55% risk of breast cancer﻿",
                      "Increased risk of pancreatic, prostate, male breast cancer",
                      "﻿TP53Li-Fraumeni syndrome﻿Increased risk of breast cancer, glioblastoma, sarcomas, adrenocortical carcinomas, several other malignancies",
                      "Li-Fraumeni syndrome﻿",
                      "Increased risk of breast cancer, glioblastoma, sarcomas, adrenocortical carcinomas, several other malignancies",
                      "CHEK2Li-Fraumeni syndrome 2Similar clinical features as Li-Fraumeni syndrome",
                      "Li-Fraumeni syndrome 2",
                      "Similar clinical features as Li-Fraumeni syndrome",
                      "CDH1Hereditary diffuse gastric cancer45% risk of infiltrating lobular carcinoma of breastIncreased risk of diffuse-type gastric cancer (linitis plastica)",
                      "Hereditary diffuse gastric cancer",
                      "45% risk of infiltrating lobular carcinoma of breast",
                      "Increased risk of diffuse-type gastric cancer (linitis plastica)"
                    ]
                  },
                  {
                    "text": "Nonhereditary factorsAge65% occur in women 45-75 yrEarly menarche (< 11 yr old)Late menopauseNulliparityFirst pregnancy at advanced maternal age (> 35 yr old)Postmenopausal hormone replacementPrior breast biopsy, regardless of findings",
                    "sub_points": [
                      "Age65% occur in women 45-75 yr",
                      "65% occur in women 45-75 yr",
                      "Early menarche (< 11 yr old)",
                      "Late menopause",
                      "Nulliparity",
                      "First pregnancy at advanced maternal age (> 35 yr old)",
                      "Postmenopausal hormone replacement",
                      "Prior breast biopsy, regardless of findings"
                    ]
                  },
                  {
                    "text": "Histologic findings on biopsyMild riskUsual ductal hyperplasia (moderate to florid)Sclerosis adenosisIntraductal papillomaModerate riskAtypical ductal hyperplasiaAtypical lobular hyperplasiaHigh riskLobular carcinoma in situDuctal carcinoma in situ",
                    "sub_points": [
                      "Mild riskUsual ductal hyperplasia (moderate to florid)Sclerosis adenosisIntraductal papilloma",
                      "Usual ductal hyperplasia (moderate to florid)",
                      "Sclerosis adenosis",
                      "Intraductal papilloma",
                      "Moderate riskAtypical ductal hyperplasiaAtypical lobular hyperplasia",
                      "Atypical ductal hyperplasia",
                      "Atypical lobular hyperplasia",
                      "High riskLobular carcinoma in situDuctal carcinoma in situ",
                      "Lobular carcinoma in situ",
                      "Ductal carcinoma in situ"
                    ]
                  }
                ],
                "Protective Factors": [
                  {
                    "text": "Oophorectomy"
                  },
                  {
                    "text": "Breast-feeding"
                  },
                  {
                    "text": "Exercise"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "246,660 new cases/yr29% of cancers in women (leading cause)",
                    "sub_points": [
                      "29% of cancers in women (leading cause)"
                    ]
                  },
                  {
                    "text": "40,450 deaths/yr14% of deaths in women (2nd leading cause)",
                    "sub_points": [
                      "14% of deaths in women (2nd leading cause)"
                    ]
                  },
                  {
                    "text": "During their lives, 1 in 8 women develop breast cancer"
                  }
                ],
                "Age": [
                  {
                    "text": "Median age approximately 62 yr"
                  }
                ],
                "Sex": [
                  {
                    "text": "F:M = ~95:1"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Mammographic density or calcifications"
                  },
                  {
                    "text": "Palpable breast mass"
                  },
                  {
                    "text": "Axillary lymphadenopathy"
                  },
                  {
                    "text": "Metastatic disease"
                  }
                ],
                "Treatment": [
                  {
                    "text": "PreventionChemopreventionSERMsTamoxifenBilateral prophylactic mastectomy",
                    "sub_points": [
                      "ChemopreventionSERMsTamoxifen",
                      "SERMsTamoxifen",
                      "Tamoxifen",
                      "Bilateral prophylactic mastectomy"
                    ]
                  },
                  {
                    "text": "Targeted therapies available"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Most patients present with localized disease (60%) or regional lymph node metastases (31%)Overall 5-yr survival is 90%",
                    "sub_points": [
                      "Overall 5-yr survival is 90%"
                    ]
                  },
                  {
                    "text": "5-yr survival by stageLocalized disease—99%Regional lymph node metastases—85%Metastatic disease—26%",
                    "sub_points": [
                      "Localized disease—99%",
                      "Regional lymph node metastases—85%",
                      "Metastatic disease—26%"
                    ]
                  },
                  {
                    "text": "﻿Tumor grade correlates with survival﻿"
                  },
                  {
                    "text": "HER2amplification predicts poor survival﻿"
                  },
                  {
                    "text": "ER/PR expression weak predictor of favorable outcome﻿"
                  },
                  {
                    "text": "Lobular and ductal carcinomas show no differences in survival when stratified by stage"
                  }
                ]
              },
              "MOLECULAR": {
                "Molecular Classification of Breast Cancer": [
                  {
                    "text": "Prognostic and predictive testing is correlated well by IHC﻿"
                  },
                  {
                    "text": "Gene expression profiling with microarrays identified 5 major groups of breast cancer with prognostic and predictive implicationsLuminal AER+, PR+,HER2-﻿Gene expression pattern similar to luminal/glandular breast epitheliumBest overall survivalResponsive to hormone therapiesLuminal BER+, PR-,HER2-, or ER+, PR+,HER2+﻿Gene expression pattern similar to luminal/glandular breast epitheliumFavorable survivalResponsive to hormone therapiesBasal-likeER-,HER2-, EGFR &/or CK5/6+﻿Gene expression pattern similar to basal (myoepithelial cells) including basal keratins (CK5/6)Associated with poor overall survivalHER2-enrichedER-,HER2+﻿Associated with poor overall survivalResponsive to anti-HER2antibodies",
                    "sub_points": [
                      "Luminal AER+, PR+,HER2-﻿Gene expression pattern similar to luminal/glandular breast epitheliumBest overall survivalResponsive to hormone therapies",
                      "ER+, PR+,HER2-﻿",
                      "Gene expression pattern similar to luminal/glandular breast epithelium",
                      "Best overall survival",
                      "Responsive to hormone therapies",
                      "Luminal BER+, PR-,HER2-, or ER+, PR+,HER2+﻿Gene expression pattern similar to luminal/glandular breast epitheliumFavorable survivalResponsive to hormone therapies",
                      "ER+, PR-,HER2-, or ER+, PR+,HER2+﻿",
                      "Gene expression pattern similar to luminal/glandular breast epithelium",
                      "Favorable survival",
                      "Responsive to hormone therapies",
                      "Basal-likeER-,HER2-, EGFR &/or CK5/6+﻿Gene expression pattern similar to basal (myoepithelial cells) including basal keratins (CK5/6)Associated with poor overall survival",
                      "ER-,HER2-, EGFR &/or CK5/6+﻿",
                      "Gene expression pattern similar to basal (myoepithelial cells) including basal keratins (CK5/6)",
                      "Associated with poor overall survival",
                      "HER2-enrichedER-,HER2+﻿Associated with poor overall survivalResponsive to anti-HER2antibodies",
                      "ER-,HER2+﻿",
                      "Associated with poor overall survival",
                      "Responsive to anti-HER2antibodies"
                    ]
                  },
                  {
                    "text": "Triple negativeER-, PR-,HER2-﻿Not all triple-negative tumors are basal-like but many areAssociated with poor overall survivalTreated with standard chemotherapiesNot eligible for targeted hormone or anti-HER2antibody therapies",
                    "sub_points": [
                      "ER-, PR-,HER2-﻿",
                      "Not all triple-negative tumors are basal-like but many are",
                      "Associated with poor overall survival",
                      "Treated with standard chemotherapiesNot eligible for targeted hormone or anti-HER2antibody therapies",
                      "Not eligible for targeted hormone or anti-HER2antibody therapies"
                    ]
                  }
                ],
                "Human Epidermal Growth Factor Receptor (HER2,ERBB2) Amplification": [
                  {
                    "text": "HER2is a cell surface membrane receptor of epidermal growth factor and other soluble ligands"
                  },
                  {
                    "text": "Binding of ligands toHER2receptor initiates signaling cascade that culminates in cellular proliferation and survival"
                  },
                  {
                    "text": "Amplification ofHER2gene results in protein overexpression"
                  },
                  {
                    "text": "HER2amplification/overexpression is associated with poorly differentiated histology and poor survival﻿Cases equivocal forHER2expression by IHC (2+) typically tested withHER2FISH to determineHER2 amplification status",
                    "sub_points": [
                      "Cases equivocal forHER2expression by IHC (2+) typically tested withHER2FISH to determineHER2 amplification status"
                    ]
                  },
                  {
                    "text": "HER2amplification/overexpression predicts response to anti-HER2antibodies (trastuzumab)﻿"
                  }
                ],
                "Estrogen Receptor": [
                  {
                    "text": "Nuclear receptor mediates growth and proliferation in response to estrogen"
                  },
                  {
                    "text": "ER expression in breast cancer associated with well to moderately differentiated carcinomas and favorable outcomes﻿"
                  },
                  {
                    "text": "Special types of breast cancer are most often ER+Lobular carcinomasTubular carcinomasColloid carcinomas",
                    "sub_points": [
                      "Lobular carcinomas",
                      "Tubular carcinomas",
                      "Colloid carcinomas"
                    ]
                  },
                  {
                    "text": "Predictive marker of response to SERM (tamoxifen)"
                  }
                ],
                "Progesterone Receptor": [
                  {
                    "text": "Nuclear receptor mediates growth and proliferation in response to progesterone"
                  },
                  {
                    "text": "PR expression in breast cancer associated with favorable outcomes﻿"
                  }
                ],
                "E-Cadherin (CDH1)": [
                  {
                    "text": "E-cadherin is cell surface adhesion protein"
                  },
                  {
                    "text": "E-cadherin is frequently mutated or deleted in lobular breast cancerDiscohesive/infiltrative feature attributed to loss of E-cadherin expression/function",
                    "sub_points": [
                      "Discohesive/infiltrative feature attributed to loss of E-cadherin expression/function"
                    ]
                  },
                  {
                    "text": "Loss of expression typically detected by IHC"
                  },
                  {
                    "text": "Ductal carcinomas rarely harbor molecular alterations inCDH1"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Glial Tumors": {
            "name": "Molecular Alterations in Glial Tumors",
            "url": "https://app.pathprimer.com/document/8990d43e-8bdc-4c03-8a5d-bf0f1aba9a62/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Gliomas: Malignant neoplasms arising from their tissue counterparts (glial cells), including astrocytes, oligodendrocytes, ependymal cells, and microglia"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Therapeutic ionizing radiation is the only proven risk factor"
                  },
                  {
                    "text": "Inherited cancer syndromes associated with glioma susceptibilityFamilial adenomatous polyposis syndrome, Li Fraumeni syndrome, neurofibromatosis I and II﻿",
                    "sub_points": [
                      "Familial adenomatous polyposis syndrome, Li Fraumeni syndrome, neurofibromatosis I and II﻿"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "﻿IDH Mutations﻿IDH mutated tumors accumulate methyl-CpG and acquire CpG island methylator phenotype﻿﻿IDH1 mutations (95%) are far more common than IDH2 mutations﻿﻿IHC only detects IDH1 p.R132H, which account for 95% of IDH1 mutations﻿",
                    "sub_points": [
                      "IDH mutated tumors accumulate methyl-CpG and acquire CpG island methylator phenotype﻿",
                      "﻿IDH1 mutations (95%) are far more common than IDH2 mutations﻿",
                      "﻿IHC only detects IDH1 p.R132H, which account for 95% of IDH1 mutations﻿"
                    ]
                  },
                  {
                    "text": "IDH mutations are defining features in 2016 WHO glioma classification"
                  },
                  {
                    "text": "﻿Oligodendroglioma, IDH mutant and 1p/19q codeleted﻿1p/19q codeletion has diagnostic, prognostic, and predictive utilityDefined as loss of whole short arm of one chromosome 1 AND whole long arm of one chromosome 19Observed in 60-90% of morphologic oligodendrogliomas, but rarely in other tumor types﻿﻿Best prognosis of all adult diffuse gliomas﻿",
                    "sub_points": [
                      "1p/19q codeletion has diagnostic, prognostic, and predictive utility",
                      "Defined as loss of whole short arm of one chromosome 1 AND whole long arm of one chromosome 19",
                      "Observed in 60-90% of morphologic oligodendrogliomas, but rarely in other tumor types﻿",
                      "﻿Best prognosis of all adult diffuse gliomas﻿"
                    ]
                  },
                  {
                    "text": "GBM, IDH wild type (primary/de novo GBM)90% of GBM are IDH wild type﻿FrequentEGFR(7q21) alterations﻿﻿PTENandTERTpromoter mutations are frequent﻿",
                    "sub_points": [
                      "90% of GBM are IDH wild type﻿",
                      "FrequentEGFR(7q21) alterations﻿",
                      "﻿PTENandTERTpromoter mutations are frequent﻿"
                    ]
                  },
                  {
                    "text": "GBM, IDH-mutant (secondary GBM)﻿10% of GBM demonstrates mutated IDH﻿Relatively slower disease course compared to de novo GBM; median survival = 2.5 yearsEGFRalterations,PTENmutations, andTERTpromoter mutations are rare﻿",
                    "sub_points": [
                      "﻿10% of GBM demonstrates mutated IDH﻿",
                      "Relatively slower disease course compared to de novo GBM; median survival = 2.5 years",
                      "EGFRalterations,PTENmutations, andTERTpromoter mutations are rare﻿"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "﻿Loss of MGMT predicts response to alkylating agents (temozolomide/Temodar) and can be detected using immunohistochemistry﻿"
                  },
                  {
                    "text": "﻿Promoter methylation correlates with loss of MGMT expression﻿"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Glioblastoma multiforme (GBM)"
                  },
                  {
                    "text": "Procarbazine, CCNU, vincristine (PCV)"
                  },
                  {
                    "text": "Isocitrate dehydrogenase gene (IDH)"
                  },
                  {
                    "text": "O(6)-methylguanine-DNA methyltransferase gene (﻿MGMT﻿)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Gliomas: Malignant neoplasms arising from their tissue counterparts (glial cells), including astrocytes, oligodendrocytes, and ependymal cells"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Inherited Predisposition": [
                  {
                    "text": "﻿Familial adenomatous polyposis syndrome﻿Mutations in theAPCgeneAssociated with multiple cancer types, including astrocytomas and medulloblastomas",
                    "sub_points": [
                      "Mutations in theAPCgene",
                      "Associated with multiple cancer types, including astrocytomas and medulloblastomas"
                    ]
                  },
                  {
                    "text": "﻿Li Fraumeni syndrome﻿Mutations inTP53geneAssociated with multiple cancer types, including choroid plexus papillomas and all types of diffuse gliomas",
                    "sub_points": [
                      "Mutations inTP53gene",
                      "Associated with multiple cancer types, including choroid plexus papillomas and all types of diffuse gliomas"
                    ]
                  },
                  {
                    "text": "﻿Neurofibromatosis I﻿Mutations inNF1geneAssociated with café-au-lait spots, neurofibromas, and various gliomas",
                    "sub_points": [
                      "Mutations inNF1gene",
                      "Associated with café-au-lait spots, neurofibromas, and various gliomas"
                    ]
                  },
                  {
                    "text": "Neurofibromatosis II, tuberous sclerosis, and nevoid basal cell carcinoma syndrome are all associated brain malignancies"
                  }
                ],
                "Risk Factors": [
                  {
                    "text": "Therapeutic ionizing radiation is the only proven, noninherited, risk factor﻿"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "1.4% of new cancers (16th leading cause)80% astrocytomas﻿5-15% oligodendrogliomas﻿",
                    "sub_points": [
                      "80% astrocytomas﻿",
                      "5-15% oligodendrogliomas﻿"
                    ]
                  },
                  {
                    "text": "2.7% of cancer deaths (10th leading cause)"
                  }
                ],
                "Age": [
                  {
                    "text": "13% occur before 20 years of age, and incidence declines until age 45"
                  },
                  {
                    "text": "Peaks again at 58 years of age"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Most common in whites, followed by blacks and Asians"
                  }
                ],
                "Site": [
                  {
                    "text": "Most common site is posterior fossa in children"
                  },
                  {
                    "text": "﻿In adults, most occur in cerebral hemispheres﻿"
                  },
                  {
                    "text": "Left and right sides are equally represented"
                  }
                ],
                "Presentation": [
                  {
                    "text": "SymptomsSeizures (most common)HeadacheMood changes",
                    "sub_points": [
                      "Seizures (most common)",
                      "Headache",
                      "Mood changes"
                    ]
                  },
                  {
                    "text": "SignsFocal motor or sensory deficitsIncreased intracranial pressureHydrocephalus",
                    "sub_points": [
                      "Focal motor or sensory deficits",
                      "Increased intracranial pressure",
                      "Hydrocephalus"
                    ]
                  },
                  {
                    "text": "In GBM, clinical presentation is abrupt and rapidly progressive"
                  },
                  {
                    "text": "In low-grade gliomas with an IDH mutation, clinical presentation is relatively milder and slowly progressive"
                  },
                  {
                    "text": "Low-grade gliomas with wild type IDH have intermediate clinical features"
                  },
                  {
                    "text": "Brain tumors rarely metastasize"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Depends on possibility of safe resectionTotal gross resection, if possibleOtherwise, partial resection",
                    "sub_points": [
                      "Total gross resection, if possible",
                      "Otherwise, partial resection"
                    ]
                  },
                  {
                    "text": "Chemotherapy &/or radiation therapy"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Variable depending on glioma type, molecular features, and age"
                  }
                ]
              },
              "MOLECULAR": {
                "WHO Classification 2016 Update Integrates Molecular and Morphologic Findings": [
                  {
                    "text": "Molecular integration stratifies patients better according to survival than histology alone"
                  },
                  {
                    "text": "Molecular classification based on commonly performed molecular/immunohistochemical testsIDHmutations﻿IDH1andIDH2genes encode homologous enzymes of citric acid cycle, collectively referred to asIDHIDHmissense mutations appear to be initiating events in low-grade gliomasMutantIDHenzymes produce 2-hydroxyglutarate metabolite, which inhibits 5′-methylcytosine hydroxylasesIDHmutated tumors accumulate methyl-CpG and acquire CpG island methylator phenotype﻿IDH1mutations (95%) are far more common thanIDH2mutations﻿Detection by immunohistochemistry (IHC)Antibodies that specifically detect mutant protein and not wild type protein are availableIHC only detectsIDH1p.R132H, which accounts for 95% ofIDH1mutations﻿Detection using molecular toolsVarious sequencing and PCR assays are available to detectIDH1andIDH2mutationsMay reflex to molecular tests when immunohistochemistry is negativeIDHmutations are defining features in 2016 WHO glioma classificationOligodendroglioma,IDHmutant, and 1p/19q codeleted﻿Astrocytoma,IDHmutantGBM,IDHmutant1p/19q codeletion has diagnostic, prognostic, and predictive utilityDefined as loss of whole short arm of one chromosome 1 AND whole long arm of one chromosome 19Observed in 60-90% of morphologic oligodendrogliomas,﻿but rarely in other tumor typesCodeletion distinguishes from astrocytoma,IDHmutantAssociated with favorable outcomesPredicts positive response to PCV, temozolomide, and radiation therapyRole of 1p/19q codeletion in tumorigenesis remains unclearMay result in loss of unidentified tumor suppressor(s)﻿Detection by fluorescence in situ hybridization (FISH)﻿Dual-color FISH probes against regions on 1p and 19q are appliedLoss of 1 signal for each locus in defined number of cells indicates codeletion﻿Does not require matching blood or normal tissue control from patient﻿Detection with short tandem repeat (STR) polymerase chain reaction﻿Numerous short tandemly repeated sequences of 1 to 5 nucleotides (i.e., short tandem repeats) are present on all chromosomesRepeat lengths for many STRs are highly polymorphic in humans and, therefore, most individuals are heterozygousHeterozygosity in germline tissue and ﻿loss of heterozygosity in tumor tissue for STR markers on 1p and 19q indicate codeletion﻿Requires matching blood or normal tissue (germline) control from patientMultiplex probe ligation amplification (MPLA) and quantitative polymerase chain reaction (qPCR) methods are also available",
                    "sub_points": [
                      "IDHmutations﻿IDH1andIDH2genes encode homologous enzymes of citric acid cycle, collectively referred to asIDHIDHmissense mutations appear to be initiating events in low-grade gliomasMutantIDHenzymes produce 2-hydroxyglutarate metabolite, which inhibits 5′-methylcytosine hydroxylasesIDHmutated tumors accumulate methyl-CpG and acquire CpG island methylator phenotype﻿IDH1mutations (95%) are far more common thanIDH2mutations﻿Detection by immunohistochemistry (IHC)Antibodies that specifically detect mutant protein and not wild type protein are availableIHC only detectsIDH1p.R132H, which accounts for 95% ofIDH1mutations﻿Detection using molecular toolsVarious sequencing and PCR assays are available to detectIDH1andIDH2mutationsMay reflex to molecular tests when immunohistochemistry is negativeIDHmutations are defining features in 2016 WHO glioma classificationOligodendroglioma,IDHmutant, and 1p/19q codeleted﻿Astrocytoma,IDHmutantGBM,IDHmutant",
                      "IDH1andIDH2genes encode homologous enzymes of citric acid cycle, collectively referred to asIDH",
                      "IDHmissense mutations appear to be initiating events in low-grade gliomasMutantIDHenzymes produce 2-hydroxyglutarate metabolite, which inhibits 5′-methylcytosine hydroxylasesIDHmutated tumors accumulate methyl-CpG and acquire CpG island methylator phenotype﻿",
                      "MutantIDHenzymes produce 2-hydroxyglutarate metabolite, which inhibits 5′-methylcytosine hydroxylases",
                      "IDHmutated tumors accumulate methyl-CpG and acquire CpG island methylator phenotype﻿",
                      "IDH1mutations (95%) are far more common thanIDH2mutations﻿",
                      "Detection by immunohistochemistry (IHC)Antibodies that specifically detect mutant protein and not wild type protein are availableIHC only detectsIDH1p.R132H, which accounts for 95% ofIDH1mutations﻿",
                      "Antibodies that specifically detect mutant protein and not wild type protein are available",
                      "IHC only detectsIDH1p.R132H, which accounts for 95% ofIDH1mutations﻿",
                      "Detection using molecular toolsVarious sequencing and PCR assays are available to detectIDH1andIDH2mutationsMay reflex to molecular tests when immunohistochemistry is negative",
                      "Various sequencing and PCR assays are available to detectIDH1andIDH2mutations",
                      "May reflex to molecular tests when immunohistochemistry is negative",
                      "IDHmutations are defining features in 2016 WHO glioma classificationOligodendroglioma,IDHmutant, and 1p/19q codeleted﻿Astrocytoma,IDHmutantGBM,IDHmutant",
                      "Oligodendroglioma,IDHmutant, and 1p/19q codeleted﻿",
                      "Astrocytoma,IDHmutant",
                      "GBM,IDHmutant",
                      "1p/19q codeletion has diagnostic, prognostic, and predictive utilityDefined as loss of whole short arm of one chromosome 1 AND whole long arm of one chromosome 19Observed in 60-90% of morphologic oligodendrogliomas,﻿but rarely in other tumor typesCodeletion distinguishes from astrocytoma,IDHmutantAssociated with favorable outcomesPredicts positive response to PCV, temozolomide, and radiation therapyRole of 1p/19q codeletion in tumorigenesis remains unclearMay result in loss of unidentified tumor suppressor(s)﻿Detection by fluorescence in situ hybridization (FISH)﻿Dual-color FISH probes against regions on 1p and 19q are appliedLoss of 1 signal for each locus in defined number of cells indicates codeletion﻿Does not require matching blood or normal tissue control from patient﻿Detection with short tandem repeat (STR) polymerase chain reaction﻿Numerous short tandemly repeated sequences of 1 to 5 nucleotides (i.e., short tandem repeats) are present on all chromosomesRepeat lengths for many STRs are highly polymorphic in humans and, therefore, most individuals are heterozygousHeterozygosity in germline tissue and ﻿loss of heterozygosity in tumor tissue for STR markers on 1p and 19q indicate codeletion﻿Requires matching blood or normal tissue (germline) control from patientMultiplex probe ligation amplification (MPLA) and quantitative polymerase chain reaction (qPCR) methods are also available",
                      "Defined as loss of whole short arm of one chromosome 1 AND whole long arm of one chromosome 19",
                      "Observed in 60-90% of morphologic oligodendrogliomas,﻿but rarely in other tumor typesCodeletion distinguishes from astrocytoma,IDHmutantAssociated with favorable outcomesPredicts positive response to PCV, temozolomide, and radiation therapy",
                      "Codeletion distinguishes from astrocytoma,IDHmutant",
                      "Associated with favorable outcomes",
                      "Predicts positive response to PCV, temozolomide, and radiation therapy",
                      "Role of 1p/19q codeletion in tumorigenesis remains unclearMay result in loss of unidentified tumor suppressor(s)",
                      "May result in loss of unidentified tumor suppressor(s)",
                      "﻿Detection by fluorescence in situ hybridization (FISH)﻿Dual-color FISH probes against regions on 1p and 19q are appliedLoss of 1 signal for each locus in defined number of cells indicates codeletion﻿Does not require matching blood or normal tissue control from patient",
                      "Dual-color FISH probes against regions on 1p and 19q are applied",
                      "Loss of 1 signal for each locus in defined number of cells indicates codeletion﻿",
                      "Does not require matching blood or normal tissue control from patient",
                      "﻿Detection with short tandem repeat (STR) polymerase chain reaction﻿Numerous short tandemly repeated sequences of 1 to 5 nucleotides (i.e., short tandem repeats) are present on all chromosomesRepeat lengths for many STRs are highly polymorphic in humans and, therefore, most individuals are heterozygousHeterozygosity in germline tissue and ﻿loss of heterozygosity in tumor tissue for STR markers on 1p and 19q indicate codeletion﻿Requires matching blood or normal tissue (germline) control from patient",
                      "Numerous short tandemly repeated sequences of 1 to 5 nucleotides (i.e., short tandem repeats) are present on all chromosomes",
                      "Repeat lengths for many STRs are highly polymorphic in humans and, therefore, most individuals are heterozygous",
                      "Heterozygosity in germline tissue and ﻿loss of heterozygosity in tumor tissue for STR markers on 1p and 19q indicate codeletion﻿",
                      "Requires matching blood or normal tissue (germline) control from patient",
                      "Multiplex probe ligation amplification (MPLA) and quantitative polymerase chain reaction (qPCR) methods are also available"
                    ]
                  }
                ],
                "Oligodendroglioma,IDH-mutant and 1p/19q Codeleted": [
                  {
                    "text": "2016 WHO classification requires both IDH mutation and 1p/19q codeletion for diagnosis"
                  },
                  {
                    "text": "Almost all haveTERTpromoter mutations, butATRXandTP53mutations are rarely identified"
                  },
                  {
                    "text": "FrequentCIC(60%),FUBP1(30%), PIK3CA (20%), PI3KR1 (10%), andNOTCH1(30%) mutations"
                  },
                  {
                    "text": "Cytogenetic alterations other than 1p and 19q deletions are uncommon, except for 19p13.3 gains"
                  },
                  {
                    "text": "﻿Best prognosis of all adult diffuse gliomas﻿Median survival ~ 8 years﻿",
                    "sub_points": [
                      "Median survival ~ 8 years﻿"
                    ]
                  },
                  {
                    "text": "Excellent response to chemotherapy and radiation therapy"
                  }
                ],
                "Diffuse Astrocytoma,IDHMutant": [
                  {
                    "text": "Presence of 1p/19q codeletion excludes this entity in low-grade gliomas, regardless of morphology"
                  },
                  {
                    "text": "Almost all haveTP53andATRXmutations, butTERTpromoter mutations are rarely identified"
                  },
                  {
                    "text": "CICandFUBP1are not present, and PI3K pathway andNOTCH1mutations are rarely identified"
                  },
                  {
                    "text": "Some haveCDK4,PDGFRA, orMYCamplifications"
                  },
                  {
                    "text": "Diffuse astrocytoma,IDHmutant tumors have relatively favorable prognosisMedian survival ~ 6 years",
                    "sub_points": [
                      "Median survival ~ 6 years"
                    ]
                  },
                  {
                    "text": "Higher grade tumors show 9p and 19q deletions and 10p gains"
                  }
                ],
                "Diffuse Astrocytoma,IDHWild Type": [
                  {
                    "text": "These have molecular/cytogenetic features and survival highly similar to GBM,IDHwild type and may be their immediate precursors or may represent poorly sampled GBMsMedian survival ~ 2 years",
                    "sub_points": [
                      "Median survival ~ 2 years"
                    ]
                  },
                  {
                    "text": "Morphologically heterogeneous group"
                  },
                  {
                    "text": "PTEN(20%),TP53(15%),EGFR(30%),NF1(20%),PIK3CA(10%) mutations may be present"
                  },
                  {
                    "text": "Loss of chromosome 10 and focal deletions ofCDKN2AandRB1"
                  },
                  {
                    "text": "Gains of chromosome 7 and focal amplifications ofEGFR,MDM4, andCDK4Frequently have amplification in form of double minutes (30%)Double minutes are small accessory chromsomes",
                    "sub_points": [
                      "Frequently have amplification in form of double minutes (30%)Double minutes are small accessory chromsomes",
                      "Double minutes are small accessory chromsomes"
                    ]
                  },
                  {
                    "text": "TERTpromoter mutations are present in slightly more than half of tumors"
                  },
                  {
                    "text": "May have fusions ofEGFRandFGFR3"
                  }
                ],
                "GBM,IDHWild Type (Primary/de novo GBM)": [
                  {
                    "text": "90% of GBM are IDH wild type﻿"
                  },
                  {
                    "text": "Median age at presentation ~ 62 years"
                  },
                  {
                    "text": "Slightly more common in males than females"
                  },
                  {
                    "text": "Rapid clinical course (few months)"
                  },
                  {
                    "text": "Median survival = ﻿1.5 years"
                  },
                  {
                    "text": "No identifiable precursor lesion (i.e., de novo)"
                  },
                  {
                    "text": "FrequentEGFR(7q21) alterations﻿EGFRmutationsEGFRamplificationPolysomy of chromosome 7",
                    "sub_points": [
                      "EGFRmutations",
                      "EGFRamplification",
                      "Polysomy of chromosome 7"
                    ]
                  },
                  {
                    "text": "﻿PTENandTERTpromoter mutations are frequent﻿"
                  },
                  {
                    "text": "ATRXandTP53mutations are uncommon"
                  },
                  {
                    "text": "Epithelioid GBM is subtype with melanoma-like morphology andBRAFV600E mutations"
                  }
                ],
                "GBM,IDH-mutant (Secondary GBM)": [
                  {
                    "text": "10% of GBM demonstrates mutatedIDH﻿"
                  },
                  {
                    "text": "Median age at presentation ~ 44 years"
                  },
                  {
                    "text": "Similarly affects men and women"
                  },
                  {
                    "text": "﻿Relatively slower disease course compared to de novo GBM﻿Median survival = 2.5 years",
                    "sub_points": [
                      "Median survival = 2.5 years"
                    ]
                  },
                  {
                    "text": "IDHmutation is defining feature"
                  },
                  {
                    "text": "Well-sampled tumors may show foci of low-grade gliomas"
                  },
                  {
                    "text": "EGFRalterations,PTENmutations, andTERTpromoter mutations are rare﻿"
                  },
                  {
                    "text": "TP53,NF1, andPIK3CAmutations may be present"
                  }
                ],
                "Oligoastrocytoma, NOS": [
                  {
                    "text": "No longer a specific disease entity"
                  },
                  {
                    "text": "Molecularly classified into one of the above low-grade glioma categories when molecular results are available"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Oligodendroglioma (WHO grade II and higher)WHO Grade IICytology: Tumor composed of monomorphic cells with modest amount of cytoplasm and round uniform nuclei with finely granular chromatin surrounded by clear haloArchitecture: Cells arranged in sheets and supplied by delicate capillary network with infiltration of surrounding brain parenchymaWHO grade III (anaplastic oligodendrogliomas)Increased cellularity, nuclear pleomorphism, mitotic activity, and necrosis",
                    "sub_points": [
                      "WHO Grade IICytology: Tumor composed of monomorphic cells with modest amount of cytoplasm and round uniform nuclei with finely granular chromatin surrounded by clear haloArchitecture: Cells arranged in sheets and supplied by delicate capillary network with infiltration of surrounding brain parenchyma",
                      "Cytology: Tumor composed of monomorphic cells with modest amount of cytoplasm and round uniform nuclei with finely granular chromatin surrounded by clear halo",
                      "Architecture: Cells arranged in sheets and supplied by delicate capillary network with infiltration of surrounding brain parenchyma",
                      "WHO grade III (anaplastic oligodendrogliomas)Increased cellularity, nuclear pleomorphism, mitotic activity, and necrosis",
                      "Increased cellularity, nuclear pleomorphism, mitotic activity, and necrosis"
                    ]
                  },
                  {
                    "text": "Diffuse (fibrillary) astrocytomas (WHO grade II and higher)WHO grade IICytology: Astrocytes with mild nuclear pleomorphism and fibrillary cellular processesArchitecture: Infiltrative appearance, including diffuse infiltration of brain parenchyma and fibrillary background due to cell processesWHO grade III (anaplastic astrocytoma): Densely cellular, moderate nuclear pleomorphism, and mitotic activityWHO grade IV (GBM): Additionally show necrosis (often pseudopalisading) and vascular proliferation",
                    "sub_points": [
                      "WHO grade IICytology: Astrocytes with mild nuclear pleomorphism and fibrillary cellular processesArchitecture: Infiltrative appearance, including diffuse infiltration of brain parenchyma and fibrillary background due to cell processes",
                      "Cytology: Astrocytes with mild nuclear pleomorphism and fibrillary cellular processes",
                      "Architecture: Infiltrative appearance, including diffuse infiltration of brain parenchyma and fibrillary background due to cell processes",
                      "WHO grade III (anaplastic astrocytoma): Densely cellular, moderate nuclear pleomorphism, and mitotic activity",
                      "WHO grade IV (GBM): Additionally show necrosis (often pseudopalisading) and vascular proliferation"
                    ]
                  },
                  {
                    "text": "Pilocytic astrocytoma (WHO grade I)Cytology: Cells with bland uniform nuclei and long bipolar processesArchitecture: Background of Rosenthal fibers, eosinophilic granular bodies, microcysts, rich vascular supply, and minimal infiltration of brain parenchyma",
                    "sub_points": [
                      "Cytology: Cells with bland uniform nuclei and long bipolar processes",
                      "Architecture: Background of Rosenthal fibers, eosinophilic granular bodies, microcysts, rich vascular supply, and minimal infiltration of brain parenchyma"
                    ]
                  },
                  {
                    "text": "Pleomorphic xanthoastrocytoma (WHO grade II)Cytology: Large bizarre neoplastic astrocytes with foamy cytoplasm and large pleomorphic nuclei with prominent nucleoliArchitecture: Circumscribed lesion with sheet-like arrangement of cells and background inflammatory cells",
                    "sub_points": [
                      "Cytology: Large bizarre neoplastic astrocytes with foamy cytoplasm and large pleomorphic nuclei with prominent nucleoli",
                      "Architecture: Circumscribed lesion with sheet-like arrangement of cells and background inflammatory cells"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "﻿MGMT﻿: DNA repair protein that normally removes alkyl groups on DNA that form when exposed to some carcinogenic compounds"
                  },
                  {
                    "text": "Some gliomas lose MGMT expression due toMGMTpromoter methylation, which makes them susceptible to alkylating chemotherapies"
                  },
                  {
                    "text": "﻿Loss of MGMT predicts response to alkylating agents (temozolomide/Temodar) and can be detected using immunohistochemistry﻿"
                  }
                ],
                "MGMT Promoter Methylation": [
                  {
                    "text": "When DNA is treated with bisulfite, methylated cytosines are converted to thymine"
                  },
                  {
                    "text": "Sanger sequencing of MGMT promoter region with and without bisulfite treatment can reveal if and which cytosine residues are methylated"
                  },
                  {
                    "text": "﻿Promoter methylation correlates with loss of MGMT expression﻿"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Tumors of Adipose Tissue": {
            "name": "Molecular Alterations in Tumors of Adipose Tissue",
            "url": "https://app.pathprimer.com/document/8e16fe22-7735-4c0d-ad56-17e7778cd115/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Liposarcomas are locally aggressive tumors (including atypical lipomatous tumor) that show phenotypic differentiation toward adipocytes"
                  }
                ],
                "Abbreviations": [
                  {
                    "text": "Liposarcoma (LPS)"
                  }
                ],
                "Classification of Intermediate and Malignant Fatty Tumors": [
                  {
                    "text": "Atypical lipomatous tumor/well-differentiated liposarcoma (well-diff LPS)Atypical lipomatous tumor (ALT) is morphologically and genetically identical to well-diff LPSTerm ALT is used when this tumor occurs in easily surgically resectable sitesSites include superficial and deep soft tissue of extremities, trunk, head and neckWell-differentiated liposarcoma is often used when this tumor occurs in non-easily resectable sitesThese sites include retroperitoneum, abdominal cavity, mediastinum, and spermatic cord regionAt these sites, this tumor usually eventually causes death due to multiple permeative local recurrencesALT has a much better prognosis than well-diff LPS, which is due entirely to site of tumorBoth tumors exhibit locally aggressive (infiltrative) growthBoth tumors can dedifferentiate (transform to a higher grade), acquiring metastatic potentialALT is now WHO-preferred term for this tumor, but \"well-differentiated LPS\" can still be used for tumors occurring in non-surgically resectable sites",
                    "sub_points": [
                      "Atypical lipomatous tumor (ALT) is morphologically and genetically identical to well-diff LPS",
                      "Term ALT is used when this tumor occurs in easily surgically resectable sitesSites include superficial and deep soft tissue of extremities, trunk, head and neck",
                      "Sites include superficial and deep soft tissue of extremities, trunk, head and neck",
                      "Well-differentiated liposarcoma is often used when this tumor occurs in non-easily resectable sitesThese sites include retroperitoneum, abdominal cavity, mediastinum, and spermatic cord regionAt these sites, this tumor usually eventually causes death due to multiple permeative local recurrences",
                      "These sites include retroperitoneum, abdominal cavity, mediastinum, and spermatic cord region",
                      "At these sites, this tumor usually eventually causes death due to multiple permeative local recurrences",
                      "ALT has a much better prognosis than well-diff LPS, which is due entirely to site of tumorBoth tumors exhibit locally aggressive (infiltrative) growthBoth tumors can dedifferentiate (transform to a higher grade), acquiring metastatic potential",
                      "Both tumors exhibit locally aggressive (infiltrative) growth",
                      "Both tumors can dedifferentiate (transform to a higher grade), acquiring metastatic potential",
                      "ALT is now WHO-preferred term for this tumor, but \"well-differentiated LPS\" can still be used for tumors occurring in non-surgically resectable sites"
                    ]
                  },
                  {
                    "text": "Dedifferentiated liposarcoma"
                  },
                  {
                    "text": "Myxoid liposarcomaRound cell liposarcoma is a higher grade of myxoid liposarcoma",
                    "sub_points": [
                      "Round cell liposarcoma is a higher grade of myxoid liposarcoma"
                    ]
                  },
                  {
                    "text": "Pleomorphic liposarcoma"
                  },
                  {
                    "text": "Spindle cell liposarcomaCurrently classified by WHO 2013 as a type of ALT; however, it shows different behavior and genetic findings than other variants of ALT",
                    "sub_points": [
                      "Currently classified by WHO 2013 as a type of ALT; however, it shows different behavior and genetic findings than other variants of ALT"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Atypical Lipomatous Tumor": [
                  {
                    "text": "Incidence2nd most common sarcoma in adults~ 50% of all liposarcomas",
                    "sub_points": [
                      "2nd most common sarcoma in adults",
                      "~ 50% of all liposarcomas"
                    ]
                  },
                  {
                    "text": "Age/genderMiddle-aged to older adults; M=F",
                    "sub_points": [
                      "Middle-aged to older adults; M=F"
                    ]
                  },
                  {
                    "text": "Body site locationAtypical lipomatous tumor: Deep (subfascial) tissue of extremities (thigh most common), uncommon in subcutis, trunk, head and neckWell-differentiated liposarcoma: Retroperitoneum most commonly, abdominal cavity, mediastinum, paratesticular soft tissue",
                    "sub_points": [
                      "Atypical lipomatous tumor: Deep (subfascial) tissue of extremities (thigh most common), uncommon in subcutis, trunk, head and neck",
                      "Well-differentiated liposarcoma: Retroperitoneum most commonly, abdominal cavity, mediastinum, paratesticular soft tissue"
                    ]
                  }
                ],
                "Dedifferentiated Liposarcoma": [
                  {
                    "text": "IncidenceOccurs in ~ 10% of well-differentiated LPS and less commonly in ALT~ 10-15% of undifferentiated pleomorphic sarcomas (UPS) of extremities are actually dedifferentiated LPSThese UPS show similar, relatively better behavior, identical to dedifferentiated LPSThese UPS also show identical O/E and amplification ofMDM2±CDK4",
                    "sub_points": [
                      "Occurs in ~ 10% of well-differentiated LPS and less commonly in ALT",
                      "~ 10-15% of undifferentiated pleomorphic sarcomas (UPS) of extremities are actually dedifferentiated LPSThese UPS show similar, relatively better behavior, identical to dedifferentiated LPSThese UPS also show identical O/E and amplification ofMDM2±CDK4",
                      "These UPS show similar, relatively better behavior, identical to dedifferentiated LPS",
                      "These UPS also show identical O/E and amplification ofMDM2±CDK4"
                    ]
                  },
                  {
                    "text": "Age/genderMiddle-aged to older adults/M = F",
                    "sub_points": [
                      "Middle-aged to older adults/M = F"
                    ]
                  },
                  {
                    "text": "Body site locationRetroperitoneum, abdominal cavity > extremities > trunk > head and neck",
                    "sub_points": [
                      "Retroperitoneum, abdominal cavity > extremities > trunk > head and neck"
                    ]
                  }
                ],
                "Myxoid Liposarcoma": [
                  {
                    "text": "Incidence3rd most common liposarcoma after ALT (#1) and dedifferentiated LPS (#2)~ 10% of adult sarcomas",
                    "sub_points": [
                      "3rd most common liposarcoma after ALT (#1) and dedifferentiated LPS (#2)",
                      "~ 10% of adult sarcomas"
                    ]
                  },
                  {
                    "text": "Age/genderYounger adults: 20s-50s most commonly; M = F",
                    "sub_points": [
                      "Younger adults: 20s-50s most commonly; M = F"
                    ]
                  },
                  {
                    "text": "Body site locationDeep (subfascial) tissue of extremities (thigh most common)",
                    "sub_points": [
                      "Deep (subfascial) tissue of extremities (thigh most common)"
                    ]
                  }
                ],
                "Spindle Cell Liposarcoma": [
                  {
                    "text": "IncidenceUncommon type of well-differentiated LPS",
                    "sub_points": [
                      "Uncommon type of well-differentiated LPS"
                    ]
                  },
                  {
                    "text": "Age/genderMiddle-aged to older adults; M = F",
                    "sub_points": [
                      "Middle-aged to older adults; M = F"
                    ]
                  },
                  {
                    "text": "Body site locationSuperficial or subcutis of trunk (shoulder region most commonly) > extremities > head and neck;notreported in deep body cavities",
                    "sub_points": [
                      "Superficial or subcutis of trunk (shoulder region most commonly) > extremities > head and neck;notreported in deep body cavities"
                    ]
                  }
                ],
                "Pleomorphic Liposarcoma": [
                  {
                    "text": "IncidenceRare: 5% of all LPS",
                    "sub_points": [
                      "Rare: 5% of all LPS"
                    ]
                  },
                  {
                    "text": "Age/genderOlder adults (50s and older); M = F",
                    "sub_points": [
                      "Older adults (50s and older); M = F"
                    ]
                  },
                  {
                    "text": "Body site locationDeep (subfascial) tissues of extremities >> trunk, retroperitoneum > paratesticular, mediastinum, head and neck",
                    "sub_points": [
                      "Deep (subfascial) tissues of extremities >> trunk, retroperitoneum > paratesticular, mediastinum, head and neck"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Atypical Lipomatous Tumor/Well-Differentiated LPS": [
                  {
                    "text": "Amplification of genes at 12q13-15"
                  }
                ],
                "Dedifferentiated LPS": [
                  {
                    "text": "Amplification of genes at 12q13-15, plus additional changes"
                  }
                ],
                "Myxoid/Round Cell LPS": [
                  {
                    "text": "Driver event: 1 of 2 specific gene fusions"
                  }
                ],
                "Spindle Cell LPS": [
                  {
                    "text": "Loss of RB1; monosomy of chromosome 7 (few cases studied)"
                  }
                ],
                "Pleomorphic LPS": [
                  {
                    "text": "Multiple chromosomal abnormalities with some recurrent findings"
                  }
                ],
                "Role of Inflammation in Liposarcomas": [
                  {
                    "text": "May play a role in pathogenesis or transformation to higher grade tumor"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Treatment": [
                  {
                    "text": "Atypical lipomatous tumorComplete surgical excisionDifficult to impossible to achieve negative margins at some sitesRecurrent tumor can dedifferentiateTreatment of dedifferentiated LPS is surgery ± multiagent therapy",
                    "sub_points": [
                      "Complete surgical excisionDifficult to impossible to achieve negative margins at some sites",
                      "Difficult to impossible to achieve negative margins at some sites",
                      "Recurrent tumor can dedifferentiateTreatment of dedifferentiated LPS is surgery ± multiagent therapy",
                      "Treatment of dedifferentiated LPS is surgery ± multiagent therapy"
                    ]
                  },
                  {
                    "text": "Myxoid liposarcomaComplete excision for smaller, lower grade tumors with localized diseaseRadiation therapy can be effective for local controlChemotherapy for high-grade, disseminated disease",
                    "sub_points": [
                      "Complete excision for smaller, lower grade tumors with localized disease",
                      "Radiation therapy can be effective for local control",
                      "Chemotherapy for high-grade, disseminated disease"
                    ]
                  },
                  {
                    "text": "Spindle cell liposarcomaComplete surgical excisionSeems to have zero risk for dedifferentiation",
                    "sub_points": [
                      "Complete surgical excision",
                      "Seems to have zero risk for dedifferentiation"
                    ]
                  },
                  {
                    "text": "Pleomorphic liposarcomaComplete excision for small, localized tumors with negative marginsRadiation ± chemotherapy for large tumors, with disseminated disease, or with positive margins",
                    "sub_points": [
                      "Complete excision for small, localized tumors with negative margins",
                      "Radiation ± chemotherapy for large tumors, with disseminated disease, or with positive margins"
                    ]
                  },
                  {
                    "text": "New targeted therapies under development"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Atypical lipomatous tumor/well differentiated LPSExtremity tumors: ~ 98% 10-year disease-specific survivalBody cavity tumors: ~ 20% 10-year disease-specific survival",
                    "sub_points": [
                      "Extremity tumors: ~ 98% 10-year disease-specific survival",
                      "Body cavity tumors: ~ 20% 10-year disease-specific survival"
                    ]
                  },
                  {
                    "text": "Dedifferentiated liposarcomaExtremity tumors: ~ 40% local recurrence rate over 10 years, 15% metastasis rate, 60-70% overall 5-year survivalBody cavity tumor: < 10% 10-year survivalLow-grade dedifferentiated component does not improve outcome",
                    "sub_points": [
                      "Extremity tumors: ~ 40% local recurrence rate over 10 years, 15% metastasis rate, 60-70% overall 5-year survival",
                      "Body cavity tumor: < 10% 10-year survival",
                      "Low-grade dedifferentiated component does not improve outcome"
                    ]
                  },
                  {
                    "text": "Myxoid liposarcomaLow-grade myxoid LPS: < 10% metastatic rateHigher grade (including > 5% round cell component): Worse outcomeOverall 10-year disease specific survival for localized disease: 87%Poor outcome associated with male gender, age > 45 years, higher grade, recurrent tumorGenetic prognostic indicators under study",
                    "sub_points": [
                      "Low-grade myxoid LPS: < 10% metastatic rate",
                      "Higher grade (including > 5% round cell component): Worse outcome",
                      "Overall 10-year disease specific survival for localized disease: 87%",
                      "Poor outcome associated with male gender, age > 45 years, higher grade, recurrent tumor",
                      "Genetic prognostic indicators under study"
                    ]
                  },
                  {
                    "text": "Pleomorphic liposarcoma30-50% metastatic rate60% overall 5-year survival",
                    "sub_points": [
                      "30-50% metastatic rate",
                      "60% overall 5-year survival"
                    ]
                  },
                  {
                    "text": "Spindle cell liposarcoma~ 100% 10-year disease-specific survival",
                    "sub_points": [
                      "~ 100% 10-year disease-specific survival"
                    ]
                  }
                ]
              },
              "Genetic Findings": {
                "Atypical Lipomatous Tumor": [
                  {
                    "text": "Similar genetic findings between ALT and well differentiated liposarcoma"
                  },
                  {
                    "text": "KaryotypeSupernumerary giant ring or marker (rod) chromosomesThese are true neochromosomes: Contain centromeres ± telomeresConsist predominantly of amplified regions of 12q13-151q21-25: Additional region commonly amplified in ring/marker chromosomeOtherwise karyotype is diploid, near diploid, or uncommonly tetraploidTelomeric associations are common",
                    "sub_points": [
                      "Supernumerary giant ring or marker (rod) chromosomesThese are true neochromosomes: Contain centromeres ± telomeresConsist predominantly of amplified regions of 12q13-151q21-25: Additional region commonly amplified in ring/marker chromosome",
                      "These are true neochromosomes: Contain centromeres ± telomeres",
                      "Consist predominantly of amplified regions of 12q13-15",
                      "1q21-25: Additional region commonly amplified in ring/marker chromosome",
                      "Otherwise karyotype is diploid, near diploid, or uncommonly tetraploid",
                      "Telomeric associations are common"
                    ]
                  },
                  {
                    "text": "Array CGHGain of 12q13-15",
                    "sub_points": [
                      "Gain of 12q13-15"
                    ]
                  },
                  {
                    "text": "Major genes altered = genes predominantly at 12q13-15MDM2,CDK4FISH forMDM2amplification can be used as a confirmatory diagnostic testOther amplified genes that may be contributory to oncogenesisHMGA2(12q15)YEATS4(12q13-q15)CPM(12q15)FRS2(12q15)HOXC13(12q13)AKT1(14q32) hyperactivated (27% of well- and dedifferentiated LPS)",
                    "sub_points": [
                      "MDM2,CDK4FISH forMDM2amplification can be used as a confirmatory diagnostic test",
                      "FISH forMDM2amplification can be used as a confirmatory diagnostic test",
                      "Other amplified genes that may be contributory to oncogenesisHMGA2(12q15)YEATS4(12q13-q15)CPM(12q15)FRS2(12q15)HOXC13(12q13)",
                      "HMGA2(12q15)",
                      "YEATS4(12q13-q15)",
                      "CPM(12q15)",
                      "FRS2(12q15)",
                      "HOXC13(12q13)",
                      "AKT1(14q32) hyperactivated (27% of well- and dedifferentiated LPS)"
                    ]
                  },
                  {
                    "text": "Major pathways dysregulatedCell cycleMDM2 inactivates TP53",
                    "sub_points": [
                      "Cell cycleMDM2 inactivates TP53",
                      "MDM2 inactivates TP53"
                    ]
                  }
                ],
                "Dedifferentiated Liposarcoma": [
                  {
                    "text": "KaryotypeSimilar findings to ALTMay have more structural and numerical changesGiant ring/marker neochromosomesNeochromosomes identical to those in ALTDouble minute chromosomes common",
                    "sub_points": [
                      "Similar findings to ALTMay have more structural and numerical changesGiant ring/marker neochromosomesNeochromosomes identical to those in ALTDouble minute chromosomes common",
                      "May have more structural and numerical changes",
                      "Giant ring/marker neochromosomes",
                      "Neochromosomes identical to those in ALT",
                      "Double minute chromosomes common"
                    ]
                  },
                  {
                    "text": "Array CGHRecurrent gains12q13-15 (97%), 12q24 (46%), 20q13 (41%), 6q22-q24 (24%), 9q33-q34 (24%)Recurrent losses13q14-q21(35%); 11q22-q23 (22%)",
                    "sub_points": [
                      "Recurrent gains12q13-15 (97%), 12q24 (46%), 20q13 (41%), 6q22-q24 (24%), 9q33-q34 (24%)",
                      "12q13-15 (97%), 12q24 (46%), 20q13 (41%), 6q22-q24 (24%), 9q33-q34 (24%)",
                      "Recurrent losses13q14-q21(35%); 11q22-q23 (22%)",
                      "13q14-q21(35%); 11q22-q23 (22%)"
                    ]
                  },
                  {
                    "text": "Major genes alteredAmplification of genes found in 12q13-q15 as in ALTMDM2amplification detected in ~90%FRS2abnormally activated and expressed in many casesAdditional genes alteredJUN(1p32) amplified and overexpressed (~ 25%)MAP3K5 (6q22) amplifiedRB1(13q14) loss or LOHAKT1 (14q32 hyperactivatedMAPKAP1(9q34) mutatedPTPN9(15q23) mutatedDAZAP2(12q13) mutatedCALR (19p13) overexpressedCDK11Boverexpressed (1p36; ~ 55% of LPS including dedifferentiated LPS)SDC1(2p24) overexpressed",
                    "sub_points": [
                      "Amplification of genes found in 12q13-q15 as in ALTMDM2amplification detected in ~90%FRS2abnormally activated and expressed in many cases",
                      "MDM2amplification detected in ~90%",
                      "FRS2abnormally activated and expressed in many cases",
                      "Additional genes alteredJUN(1p32) amplified and overexpressed (~ 25%)MAP3K5 (6q22) amplifiedRB1(13q14) loss or LOHAKT1 (14q32 hyperactivatedMAPKAP1(9q34) mutatedPTPN9(15q23) mutatedDAZAP2(12q13) mutatedCALR (19p13) overexpressedCDK11Boverexpressed (1p36; ~ 55% of LPS including dedifferentiated LPS)SDC1(2p24) overexpressed",
                      "JUN(1p32) amplified and overexpressed (~ 25%)",
                      "MAP3K5 (6q22) amplified",
                      "RB1(13q14) loss or LOH",
                      "AKT1 (14q32 hyperactivated",
                      "MAPKAP1(9q34) mutated",
                      "PTPN9(15q23) mutated",
                      "DAZAP2(12q13) mutated",
                      "CALR (19p13) overexpressed",
                      "CDK11Boverexpressed (1p36; ~ 55% of LPS including dedifferentiated LPS)",
                      "SDC1(2p24) overexpressed"
                    ]
                  },
                  {
                    "text": "Major pathways dysregulatedCell cycleApoptosis signalingAdipogenesis/differentiationPI3K-AKT pathwayCellular RNA transcription and processingβ-catenin signaling",
                    "sub_points": [
                      "Cell cycle",
                      "Apoptosis signaling",
                      "Adipogenesis/differentiation",
                      "PI3K-AKT pathway",
                      "Cellular RNA transcription and processing",
                      "β-catenin signaling"
                    ]
                  },
                  {
                    "text": "Epigenetic abnormalitiesCEBPA(19q13.1) methylated → loss of expression (24%)HDAC1(1p34) mutated (~ 9%)Many genes abnormally methylated (~ 700)miR-193b hypermethylated; miR-155 overexpressed",
                    "sub_points": [
                      "CEBPA(19q13.1) methylated → loss of expression (24%)",
                      "HDAC1(1p34) mutated (~ 9%)",
                      "Many genes abnormally methylated (~ 700)",
                      "miR-193b hypermethylated; miR-155 overexpressed"
                    ]
                  }
                ],
                "Myxoid Liposarcoma": [
                  {
                    "text": "Fusion Genest(12;16)(q13;p11);FUS-DDIT3(95% of cases)t(12;22)(q13;q12);EWSR1-DDIT3(~ 5% of cases)FUSandEWSR1are members of TET gene family = encode RNA binding proteinsMultifunctional proteinsHelp regulate gene expression, genomic integrity, mRNA and miRNA processing, among othersFUSandEWSR1are involved in other gene fusions in multiple tumors, predominantly mesenchymal",
                    "sub_points": [
                      "t(12;16)(q13;p11);FUS-DDIT3(95% of cases)",
                      "t(12;22)(q13;q12);EWSR1-DDIT3(~ 5% of cases)",
                      "FUSandEWSR1are members of TET gene family = encode RNA binding proteinsMultifunctional proteinsHelp regulate gene expression, genomic integrity, mRNA and miRNA processing, among others",
                      "Multifunctional proteins",
                      "Help regulate gene expression, genomic integrity, mRNA and miRNA processing, among others",
                      "FUSandEWSR1are involved in other gene fusions in multiple tumors, predominantly mesenchymal"
                    ]
                  },
                  {
                    "text": "KaryotypeDiploid to near diploid most commonlyRare cases hyperdiploid to near triploid",
                    "sub_points": [
                      "Diploid to near diploid most commonly",
                      "Rare cases hyperdiploid to near triploid"
                    ]
                  },
                  {
                    "text": "Array CGHRecurrent gains: 8p21-p23, 8q24 (29%), 13q, 20q13 (29%), 1q21-24 (21%)",
                    "sub_points": [
                      "Recurrent gains: 8p21-p23, 8q24 (29%), 13q, 20q13 (29%), 1q21-24 (21%)"
                    ]
                  },
                  {
                    "text": "Major genes altered in addition to fused genesPIK3CAactivating mutations (~ 18%)PTENhomozygous lossMutually exclusive withPIK3CAactivating mutationsGenes overexpressed:RET,IGF1R,IGF2,CTAG1B,PRAMETERT(telomerase reverse transcriptase; 5p15.33) mutated (~ 74%)",
                    "sub_points": [
                      "PIK3CAactivating mutations (~ 18%)",
                      "PTENhomozygous lossMutually exclusive withPIK3CAactivating mutations",
                      "Mutually exclusive withPIK3CAactivating mutations",
                      "Genes overexpressed:RET,IGF1R,IGF2,CTAG1B,PRAME",
                      "TERT(telomerase reverse transcriptase; 5p15.33) mutated (~ 74%)"
                    ]
                  },
                  {
                    "text": "Major pathways dysregulatedPI3K/AKT pathwayRAS-RAF-ERK-MAPK pathwayCell cycle",
                    "sub_points": [
                      "PI3K/AKT pathway",
                      "RAS-RAF-ERK-MAPK pathway",
                      "Cell cycle"
                    ]
                  }
                ],
                "Pleomorphic Liposarcoma": [
                  {
                    "text": "KaryotypeComplex aneuploid without specific highly recurrent findings",
                    "sub_points": [
                      "Complex aneuploid without specific highly recurrent findings"
                    ]
                  },
                  {
                    "text": "Array CGHRecurrent gains5p13-p15 (54%), 20q13 (60%), 6p21 (45%), 17p11.2-p12 (45%), 9q33-q34 (40%), 1p12-p21 (35%), 1q21-q24 (35%), 22q13 (35%), 12q24 (30%), 1p31 (30%), 13q33-q34 (30%), 21q21-q22 (30%)Recurrent losses11q22-q23 (30%), 1q42-q43 (30%), 2q33-q36 (25%), 13q14-q21 (25%)",
                    "sub_points": [
                      "Recurrent gains5p13-p15 (54%), 20q13 (60%), 6p21 (45%), 17p11.2-p12 (45%), 9q33-q34 (40%), 1p12-p21 (35%), 1q21-q24 (35%), 22q13 (35%), 12q24 (30%), 1p31 (30%), 13q33-q34 (30%), 21q21-q22 (30%)",
                      "5p13-p15 (54%), 20q13 (60%), 6p21 (45%), 17p11.2-p12 (45%), 9q33-q34 (40%), 1p12-p21 (35%), 1q21-q24 (35%), 22q13 (35%), 12q24 (30%), 1p31 (30%), 13q33-q34 (30%), 21q21-q22 (30%)",
                      "Recurrent losses11q22-q23 (30%), 1q42-q43 (30%), 2q33-q36 (25%), 13q14-q21 (25%)",
                      "11q22-q23 (30%), 1q42-q43 (30%), 2q33-q36 (25%), 13q14-q21 (25%)"
                    ]
                  },
                  {
                    "text": "Major genes alteredTP53mutated (~ 17%), or commonly deletedNF1mutated (~ 9%)5p13-5p15 amplified genes =TRIO,IRX2,NKD2CTAG1B(cancer/testis antigen 1B; Xq28) upregulatedProduces NY-ESO-1 protein, a cancer-testis antigen",
                    "sub_points": [
                      "TP53mutated (~ 17%), or commonly deleted",
                      "NF1mutated (~ 9%)",
                      "5p13-5p15 amplified genes =TRIO,IRX2,NKD2",
                      "CTAG1B(cancer/testis antigen 1B; Xq28) upregulatedProduces NY-ESO-1 protein, a cancer-testis antigen",
                      "Produces NY-ESO-1 protein, a cancer-testis antigen"
                    ]
                  },
                  {
                    "text": "Segmental acquired uniparental disomy (segmental aUPD)13q13.2-q13.3 (~ 74%)Codes forRB1,TNFSF11,SMAD9, and others",
                    "sub_points": [
                      "13q13.2-q13.3 (~ 74%)",
                      "Codes forRB1,TNFSF11,SMAD9, and others"
                    ]
                  },
                  {
                    "text": "Major pathways dysregulatedCell cycleAdipogenesis/cell differentiation",
                    "sub_points": [
                      "Cell cycle",
                      "Adipogenesis/cell differentiation"
                    ]
                  }
                ],
                "Spindle Cell Liposarcoma": [
                  {
                    "text": "KaryotypeFew cases studied, but lacks giant ring and marker chromosomes (which is characteristic of ALT)Monosomy 7 reported in 2 cases",
                    "sub_points": [
                      "Few cases studied, but lacks giant ring and marker chromosomes (which is characteristic of ALT)",
                      "Monosomy 7 reported in 2 cases"
                    ]
                  },
                  {
                    "text": "Major gene abnormalitiesRB1lostLacksMDM2amplification (which is characteristic of ALT)",
                    "sub_points": [
                      "RB1lost",
                      "LacksMDM2amplification (which is characteristic of ALT)"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Atypical Lipomatous Tumor": [
                  {
                    "text": "Identical morphology for atypical lipomatous tumor and well-differentiated liposarcoma"
                  },
                  {
                    "text": "ArchitectureLipoma-like variant: Mimics lipoma, but with great variation in adipocyte size (10x or more), and fibrous trabeculationsSclerosing variant: Large areas of relatively hypocellular fibrosis, usually with increase in stromal cellsInflammatory variant: Abundant chronic inflammatory cells ± fibrosis",
                    "sub_points": [
                      "Lipoma-like variant: Mimics lipoma, but with great variation in adipocyte size (10x or more), and fibrous trabeculations",
                      "Sclerosing variant: Large areas of relatively hypocellular fibrosis, usually with increase in stromal cells",
                      "Inflammatory variant: Abundant chronic inflammatory cells ± fibrosis"
                    ]
                  },
                  {
                    "text": "CellsRare to scattered atypical stromal cells, which often occur in fibrous septa; lipoblasts often sparse",
                    "sub_points": [
                      "Rare to scattered atypical stromal cells, which often occur in fibrous septa; lipoblasts often sparse"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: ~ 90% MDM2 overexpression ± CDK4 overexpressionGenetic tests:  > 90% showMDM2 ± CDK4amplified by FISH",
                    "sub_points": [
                      "IHC: ~ 90% MDM2 overexpression ± CDK4 overexpression",
                      "Genetic tests:  > 90% showMDM2 ± CDK4amplified by FISH"
                    ]
                  }
                ],
                "Dedifferentiated Liposarcoma": [
                  {
                    "text": "ArchitectureOften contains areas of ALTDedifferentiated areas are usually high grade, but may include low grade sarcomaDedifferentiated components can includeNonspecific high-grade sarcomaSpecific sarcoma subtypes such as leiomyosarcoma, osteosarcomaDedifferentiated component can uncommonly consist of pleomorphic liposarcoma",
                    "sub_points": [
                      "Often contains areas of ALT",
                      "Dedifferentiated areas are usually high grade, but may include low grade sarcoma",
                      "Dedifferentiated components can includeNonspecific high-grade sarcomaSpecific sarcoma subtypes such as leiomyosarcoma, osteosarcomaDedifferentiated component can uncommonly consist of pleomorphic liposarcoma",
                      "Nonspecific high-grade sarcoma",
                      "Specific sarcoma subtypes such as leiomyosarcoma, osteosarcoma",
                      "Dedifferentiated component can uncommonly consist of pleomorphic liposarcoma"
                    ]
                  },
                  {
                    "text": "CellsLipoblasts are usually presentOther cell types correlate with type of dedifferentiated sarcoma present, such as malignant smooth muscle cells, myofibroblastic cells, osteoblasts, etc.",
                    "sub_points": [
                      "Lipoblasts are usually present",
                      "Other cell types correlate with type of dedifferentiated sarcoma present, such as malignant smooth muscle cells, myofibroblastic cells, osteoblasts, etc."
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: > 90% MDM2 overexpression ± CDK4 overexpressionGenetic tests: > 90% showMDM2 ± CDK4amplified by FISHMore specific for diagnosis than MDM2 overexpression",
                    "sub_points": [
                      "IHC: > 90% MDM2 overexpression ± CDK4 overexpression",
                      "Genetic tests: > 90% showMDM2 ± CDK4amplified by FISHMore specific for diagnosis than MDM2 overexpression",
                      "More specific for diagnosis than MDM2 overexpression"
                    ]
                  }
                ],
                "Myxoid Liposarcoma": [
                  {
                    "text": "ArchitectureUsually lobular with peripheral hypercellularityChicken wire branching vasculatureMyxoid stroma± pulmonary edema pattern",
                    "sub_points": [
                      "Usually lobular with peripheral hypercellularity",
                      "Chicken wire branching vasculature",
                      "Myxoid stroma",
                      "± pulmonary edema pattern"
                    ]
                  },
                  {
                    "text": "CellsLipoblasts include signet ring-like, monovacuolated, and multivacuolated (less common)Lipoblasts often found in clusters or sheetsRound to oval to plump spindled cellsUniform small cells with normochromatic to hyperchromatic nucleiThese cells may form the higher grade \"round cell\" component but only when they are tightly crowded together",
                    "sub_points": [
                      "Lipoblasts include signet ring-like, monovacuolated, and multivacuolated (less common)Lipoblasts often found in clusters or sheets",
                      "Lipoblasts often found in clusters or sheets",
                      "Round to oval to plump spindled cellsUniform small cells with normochromatic to hyperchromatic nucleiThese cells may form the higher grade \"round cell\" component but only when they are tightly crowded together",
                      "Uniform small cells with normochromatic to hyperchromatic nuclei",
                      "These cells may form the higher grade \"round cell\" component but only when they are tightly crowded together"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: Negative for MDM2/CDK4Genetic studies: FISH positive forDDIT3translocations",
                    "sub_points": [
                      "IHC: Negative for MDM2/CDK4",
                      "Genetic studies: FISH positive forDDIT3translocations"
                    ]
                  }
                ],
                "Round Cell Liposarcoma (Higher Grade of Myxoid Liposarcoma)": [
                  {
                    "text": "ArchitectureHypercellular solid sheets or lobulesTransitional areas of low to moderate cellularity commonTransitional areas can include typical myxoid liposarcoma with gradually increasing cellularity culminating in back-to-back, highly cellular round cell areas",
                    "sub_points": [
                      "Hypercellular solid sheets or lobules",
                      "Transitional areas of low to moderate cellularity commonTransitional areas can include typical myxoid liposarcoma with gradually increasing cellularity culminating in back-to-back, highly cellular round cell areas",
                      "Transitional areas can include typical myxoid liposarcoma with gradually increasing cellularity culminating in back-to-back, highly cellular round cell areas"
                    ]
                  },
                  {
                    "text": "CellsBack-to-back primitive small cells with ↑ N:C ratio and vesicular to hyperchromatic nucleiSome cases contain larger cells with eosinophilic cytoplasmLipoblasts usually present, but may be sparse",
                    "sub_points": [
                      "Back-to-back primitive small cells with ↑ N:C ratio and vesicular to hyperchromatic nucleiSome cases contain larger cells with eosinophilic cytoplasm",
                      "Some cases contain larger cells with eosinophilic cytoplasm",
                      "Lipoblasts usually present, but may be sparse"
                    ]
                  },
                  {
                    "text": "Ancillary studiesSame as for myxoid LPS",
                    "sub_points": [
                      "Same as for myxoid LPS"
                    ]
                  }
                ],
                "Spindle Cell Liposarcoma": [
                  {
                    "text": "ArchitectureIntermixed spindle cells and adipocytic cells with myxoid ± fibrotic background",
                    "sub_points": [
                      "Intermixed spindle cells and adipocytic cells with myxoid ± fibrotic background"
                    ]
                  },
                  {
                    "text": "CellsSpindle cells short and plump as in spindle cell lipoma, or more elongate and neural-likeLipoblasts often present and more mature fat cells",
                    "sub_points": [
                      "Spindle cells short and plump as in spindle cell lipoma, or more elongate and neural-like",
                      "Lipoblasts often present and more mature fat cells"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: CD34 positive in spindle cells; RB1 protein expression lost, desmin positive in 20% ([+] in spindle cells)",
                    "sub_points": [
                      "IHC: CD34 positive in spindle cells; RB1 protein expression lost, desmin positive in 20% ([+] in spindle cells)"
                    ]
                  }
                ],
                "Pleomorphic Liposarcoma": [
                  {
                    "text": "ArchitectureDiffuse sheets of markedly atypical cells, often with necrosisMay have background myxoid matrix",
                    "sub_points": [
                      "Diffuse sheets of markedly atypical cells, often with necrosis",
                      "May have background myxoid matrix"
                    ]
                  },
                  {
                    "text": "CellsMarkedly atypical \"pleomorphic\" lipoblastsAlways present but may be sparseNuclei are enlarged, hyperchromatic with coarse chromatin ± nucleoliNuclear atypia >>  than lipoblasts in other liposarcomas, except dedifferentiated LPS when it contains pleomorphic LPSSpindled, polygonal, or large epithelioid-appearing, nonlipoblastic cells often predominate",
                    "sub_points": [
                      "Markedly atypical \"pleomorphic\" lipoblastsAlways present but may be sparseNuclei are enlarged, hyperchromatic with coarse chromatin ± nucleoliNuclear atypia >>  than lipoblasts in other liposarcomas, except dedifferentiated LPS when it contains pleomorphic LPS",
                      "Always present but may be sparse",
                      "Nuclei are enlarged, hyperchromatic with coarse chromatin ± nucleoli",
                      "Nuclear atypia >>  than lipoblasts in other liposarcomas, except dedifferentiated LPS when it contains pleomorphic LPS",
                      "Spindled, polygonal, or large epithelioid-appearing, nonlipoblastic cells often predominate"
                    ]
                  },
                  {
                    "text": "Ancillary studies: Negative for MDM2 and CDK4 O/E and gene amplification"
                  }
                ]
              },
              "Differential Diagnosis": {
                "DDx for Atypical Lipomatous Tumor": [
                  {
                    "text": "LipomaLacks marked variation in adipocyte size (except in areas of fat necrosis)Negative for atypical stromal cellsNegative forMDM2and CDK4 O/E and gene amplification",
                    "sub_points": [
                      "Lacks marked variation in adipocyte size (except in areas of fat necrosis)",
                      "Negative for atypical stromal cells",
                      "Negative forMDM2and CDK4 O/E and gene amplification"
                    ]
                  },
                  {
                    "text": "Pleomorphic/spindle cell lipomaSubcutaneous with pushing non-invasive marginNegative for MDM2 and CDK4 O/E and gene amplificationShows loss of RB1 protein on IHC",
                    "sub_points": [
                      "Subcutaneous with pushing non-invasive margin",
                      "Negative for MDM2 and CDK4 O/E and gene amplification",
                      "Shows loss of RB1 protein on IHC"
                    ]
                  },
                  {
                    "text": "Hibernoma, lipoma-like variantMicrovacuolated fat cells are relatively common and dispersed in tumor (can have a few in some ALT)Negative for MDM2 and CDK4 O/E and gene amplificationKaryotype shows 11q13 deletions or translocations",
                    "sub_points": [
                      "Microvacuolated fat cells are relatively common and dispersed in tumor (can have a few in some ALT)",
                      "Negative for MDM2 and CDK4 O/E and gene amplification",
                      "Karyotype shows 11q13 deletions or translocations"
                    ]
                  }
                ],
                "DDx for Dedifferentiated LPS": [
                  {
                    "text": "Pleomorphic LPSMarkedly atypical \"pleomorphic\" lipoblastsNegative for low-grade ALT areasNegative for MDM2/CDK4 O/E and gene amplification",
                    "sub_points": [
                      "Markedly atypical \"pleomorphic\" lipoblasts",
                      "Negative for low-grade ALT areas",
                      "Negative for MDM2/CDK4 O/E and gene amplification"
                    ]
                  },
                  {
                    "text": "Sclerosing variant of ALT: Not as hypercellular, although atypical cells are identical to scattered atypical stromal cells of ALTHypocellular rather than hypercellularAtypical stromal cells are often less atypical than malignant cells in dedifferentiated LPS",
                    "sub_points": [
                      "Hypocellular rather than hypercellular",
                      "Atypical stromal cells are often less atypical than malignant cells in dedifferentiated LPS"
                    ]
                  },
                  {
                    "text": "Undifferentiated pleomorphic sarcoma (UPS)UPS lacksMDM2amplification and usually lacks MDM2 O/EUPS lacks low grade ALT areas that are found in some dedifferentiated LPS",
                    "sub_points": [
                      "UPS lacksMDM2amplification and usually lacks MDM2 O/E",
                      "UPS lacks low grade ALT areas that are found in some dedifferentiated LPS"
                    ]
                  }
                ],
                "DDx for Myxoid LPS": [
                  {
                    "text": "LipoblastomaOccurs in infants → young childrenNegative forDDIT3(12q13) fusions by FISHPositive forPLAG1(8q12) rearrangements by FISH",
                    "sub_points": [
                      "Occurs in infants → young children",
                      "Negative forDDIT3(12q13) fusions by FISH",
                      "Positive forPLAG1(8q12) rearrangements by FISH"
                    ]
                  },
                  {
                    "text": "ALT with prominent myxoid stromaUsually (but not always) lacks prominent \"chicken-wire\" vasculatureNegative forDDIT3fusions by FISHPositive for MDM2 ± CDK4 O/E and gene amplification",
                    "sub_points": [
                      "Usually (but not always) lacks prominent \"chicken-wire\" vasculature",
                      "Negative forDDIT3fusions by FISH",
                      "Positive for MDM2 ± CDK4 O/E and gene amplification"
                    ]
                  }
                ],
                "DDx for Round Cell LPS (High-Grade Myxoid LPS)": [
                  {
                    "text": "Other small round cell sarcomasLack lipoblastsLack transitional myxoid LPS-like areasLackDDIT3fusions by FISHOften positive for other specific fusions by FISH",
                    "sub_points": [
                      "Lack lipoblasts",
                      "Lack transitional myxoid LPS-like areas",
                      "LackDDIT3fusions by FISH",
                      "Often positive for other specific fusions by FISH"
                    ]
                  }
                ],
                "DDx for Pleomorphic LPS": [
                  {
                    "text": "Dedifferentiated LPS with pleomorphic LPS componentLower grade ALT component often presentMDM2 ± CDK4 O/E and genes amplified",
                    "sub_points": [
                      "Lower grade ALT component often present",
                      "MDM2 ± CDK4 O/E and genes amplified"
                    ]
                  }
                ],
                "DDx for Spindle Cell LPS": [
                  {
                    "text": "Pleomorphic/spindle cell lipomaDiscrete pushing margin rather than infiltrativeProminent ropy collagen fibersBy IHC both CD34 positive and both show loss of RB1 protein",
                    "sub_points": [
                      "Discrete pushing margin rather than infiltrative",
                      "Prominent ropy collagen fibers",
                      "By IHC both CD34 positive and both show loss of RB1 protein"
                    ]
                  },
                  {
                    "text": "ALT with prominent spindled stromal cellsUsually deep soft tissue location or in body cavityPositive for MDM2 ± CDK4 O/E and gene amplification",
                    "sub_points": [
                      "Usually deep soft tissue location or in body cavity",
                      "Positive for MDM2 ± CDK4 O/E and gene amplification"
                    ]
                  }
                ]
              },
              "Pathologic Interpretation Pearls": {
                "Relationship Between ALT and Well-Differentiated Liposarcoma": [
                  {
                    "text": "ALT = Well-differentiated liposarcoma, morphologically and genetically"
                  },
                  {
                    "text": "Well-differentiated liposarcoma is term often used when tumor arises in surgically difficult sites (intraabdominal, retroperitoneal, mediastinal, paratesticular)"
                  }
                ],
                "Immunohistochemistry ± FISH Role in Subtyping Liposarcomas": [
                  {
                    "text": "MDM2 O/E helps distinguish ALT and dedifferentiated LPS from other liposarcomas"
                  },
                  {
                    "text": "MDM2amplification on FISH is more specific than IHC, because MDM2 can occasionally be overexpressed in other sarcoma types (non-liposarcomas)"
                  }
                ],
                "ALT With Prominent Myxoid Matrix Mimicking Liposarcoma": [
                  {
                    "text": "Keys to diagnosis of ALT are MDM2 O/E and gene amplification and lack ofDDIT3fusion on FISH"
                  },
                  {
                    "text": "Myxoid LPS rarely occurs in the retroperitoneum (common site for ALT/well-diff LPS), and then only as a metastasis from a primary site elsewhere"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Lung Cancer": {
            "name": "Molecular Alterations in Lung Cancer",
            "url": "https://app.pathprimer.com/document/ac46ad51-ca42-43e9-bac1-8481b4e0e9bb/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Commonly mutated oncogenes in lung cancer﻿EGFR,KRAS, andHER2mutations, andALK,ROS1, andRETfusions",
                    "sub_points": [
                      "EGFR,KRAS, andHER2mutations, andALK,ROS1, andRETfusions"
                    ]
                  },
                  {
                    "text": "EGFRpathophysiologyActivating mutations inEGFRoccur in tyrosine kinase domain (TKD, exons 18-24) and are different from those observed in glioblastoma multiformeLead to constitutive activation ofEGFRtyrosine kinase activityConfer sensitivity toEGFRTK inhibitors (TKIs), many of which are FDA approved for advanced-stage NSCLCMost patients develop resistance toEGFRTKIs within 1 year﻿",
                    "sub_points": [
                      "Activating mutations inEGFRoccur in tyrosine kinase domain (TKD, exons 18-24) and are different from those observed in glioblastoma multiforme",
                      "Lead to constitutive activation ofEGFRtyrosine kinase activity",
                      "Confer sensitivity toEGFRTK inhibitors (TKIs), many of which are FDA approved for advanced-stage NSCLC",
                      "Most patients develop resistance toEGFRTKIs within 1 year﻿"
                    ]
                  },
                  {
                    "text": "KRASpathophysiology﻿Vast majority are missense mutations at amino acids 12, 13, and 61Impair GTP hydrolysis activity ofKRAS, and result in constitutive activation ofKRAS; culminates in uncontrolled cell proliferation﻿﻿Strongly associated with smoking history﻿No FDA-approved targeted therapies to date",
                    "sub_points": [
                      "Vast majority are missense mutations at amino acids 12, 13, and 61",
                      "Impair GTP hydrolysis activity ofKRAS, and result in constitutive activation ofKRAS; culminates in uncontrolled cell proliferation﻿",
                      "﻿Strongly associated with smoking history﻿",
                      "No FDA-approved targeted therapies to date"
                    ]
                  },
                  {
                    "text": "ALKpathophysiology﻿ALKrearrangements lead to fusions with other genes to generate novel oncogenesResponsive toALKTKIs",
                    "sub_points": [
                      "ALKrearrangements lead to fusions with other genes to generate novel oncogenes",
                      "Responsive toALKTKIs"
                    ]
                  },
                  {
                    "text": "HER2amplification and overexpression is seen in 1/3 of ACAs﻿Only modest response to trastuzumab",
                    "sub_points": [
                      "Only modest response to trastuzumab"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "NCCN guidelines recommendEGFRandALKtesting in metastatic setting"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Major lung cancer categoriesAdenocarcinoma (ACA)Large cell carcinoma (LCC)Large cell neuroendocrine carcinoma (LCNEC)Non–small cell lung cancer (NSCLC)Small cell lung cancer (SCLC)Squamous cell carcinoma (SQCC)",
                    "sub_points": [
                      "Adenocarcinoma (ACA)",
                      "Large cell carcinoma (LCC)",
                      "Large cell neuroendocrine carcinoma (LCNEC)",
                      "Non–small cell lung cancer (NSCLC)",
                      "Small cell lung cancer (SCLC)",
                      "Squamous cell carcinoma (SQCC)"
                    ]
                  },
                  {
                    "text": "Major genes altered in lung cancerEGFR:Epidermal growth factor receptorKRAS:Kirsten rat sarcoma viral oncogene homologBRAF:B-Raf proto-oncogene, serine/threonine kinaseALK: Anaplastic lymphoma receptor tyrosine kinaseROS1:ROS proto-oncogene 1, receptor tyrosine kinaseRET﻿: R﻿et proto-oncogeneMET: MET proto-oncogene, receptor tyrosine kinaseTP53: Tumor protein p53",
                    "sub_points": [
                      "EGFR:Epidermal growth factor receptor",
                      "KRAS:Kirsten rat sarcoma viral oncogene homolog",
                      "BRAF:B-Raf proto-oncogene, serine/threonine kinase",
                      "ALK: Anaplastic lymphoma receptor tyrosine kinase",
                      "ROS1:ROS proto-oncogene 1, receptor tyrosine kinase",
                      "RET﻿: R﻿et proto-oncogene",
                      "MET: MET proto-oncogene, receptor tyrosine kinase",
                      "TP53: Tumor protein p53"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Commonly Mutated Oncogenes in Lung cancer": [
                  {
                    "text": "EGFR,KRAS, andHER2mutations, andALK,ROS1, andRETfusions"
                  },
                  {
                    "text": "National Comprehensive Cancer Network (NCCN) recommends testing forEGFRandALKin metastatic setting to guide therapy﻿"
                  }
                ],
                "EGFR": [
                  {
                    "text": "Pathophysiology﻿Activating mutations inEGFRoccur in tyrosine kinase domain (TKD, exons 18-24) and are different from those observed in glioblastoma multiformeLead to constitutive activation ofEGFRtyrosine kinase activityResult in unregulated activation of multiple cellular pathways, which culminate in cell growth, proliferation, survival, and differentiationMitogen-activated protein kinase (MAPK) pathwayJanus kinase/signal transducers and activators of transcription (JAK-STAT) pathwayPhosphatidylinositol-4,5-bisphosphate 3-kinase—v-akt murine thymoma viral oncogene homolog 1 (PI3K-AKT1) pathwayGains ofEGFRlocus by either amplification or polysomy of chromosome 7 may have similar effect on signaling pathways as TK domain mutations",
                    "sub_points": [
                      "Activating mutations inEGFRoccur in tyrosine kinase domain (TKD, exons 18-24) and are different from those observed in glioblastoma multiforme",
                      "Lead to constitutive activation ofEGFRtyrosine kinase activity",
                      "Result in unregulated activation of multiple cellular pathways, which culminate in cell growth, proliferation, survival, and differentiationMitogen-activated protein kinase (MAPK) pathwayJanus kinase/signal transducers and activators of transcription (JAK-STAT) pathwayPhosphatidylinositol-4,5-bisphosphate 3-kinase—v-akt murine thymoma viral oncogene homolog 1 (PI3K-AKT1) pathway",
                      "Mitogen-activated protein kinase (MAPK) pathway",
                      "Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathway",
                      "Phosphatidylinositol-4,5-bisphosphate 3-kinase—v-akt murine thymoma viral oncogene homolog 1 (PI3K-AKT1) pathway",
                      "Gains ofEGFRlocus by either amplification or polysomy of chromosome 7 may have similar effect on signaling pathways as TK domain mutations"
                    ]
                  },
                  {
                    "text": "Clinicopathologic features associated withEGFRmutations﻿EGFRmutations are observed in 21% of NSCLCs (rarely seen in de novo SCLC)﻿EGFRmutations in ACAs (40%) vs. other NSCLCs (3%)﻿Terminal respiratory unit (TRU) type of ACA (61%) vs. non-TRU ACA (13%)94% ofEGFRmutations occur in TRU typeTRU type ACAs are characterized by morphologic and immunohistochemical features of their nonneoplastic counterparts in terminal respiratory unitsType II pneumocytes, Clara cells, or nonciliated bronchiolesTTF-1 or surfactant protein expressionNever smokers (51%) vs. ever smokers (10%)Females (42%) vs. males (14%)East Asian (30%) vs. other ethnicities (8%)",
                    "sub_points": [
                      "EGFRmutations are observed in 21% of NSCLCs (rarely seen in de novo SCLC)﻿EGFRmutations in ACAs (40%) vs. other NSCLCs (3%)﻿",
                      "EGFRmutations in ACAs (40%) vs. other NSCLCs (3%)﻿",
                      "Terminal respiratory unit (TRU) type of ACA (61%) vs. non-TRU ACA (13%)94% ofEGFRmutations occur in TRU typeTRU type ACAs are characterized by morphologic and immunohistochemical features of their nonneoplastic counterparts in terminal respiratory unitsType II pneumocytes, Clara cells, or nonciliated bronchiolesTTF-1 or surfactant protein expression",
                      "94% ofEGFRmutations occur in TRU type",
                      "TRU type ACAs are characterized by morphologic and immunohistochemical features of their nonneoplastic counterparts in terminal respiratory units",
                      "Type II pneumocytes, Clara cells, or nonciliated bronchioles",
                      "TTF-1 or surfactant protein expression",
                      "Never smokers (51%) vs. ever smokers (10%)",
                      "Females (42%) vs. males (14%)",
                      "East Asian (30%) vs. other ethnicities (8%)"
                    ]
                  },
                  {
                    "text": "Clinical implications﻿Confer sensitivity toEGFRTK inhibitors (TKIs), ma﻿ny of which are FDA approved for advanced-stage NSCLCMostEGFRTK domain mutations occur in exons 18-21Most patients develop resistance toEGFRTKIs within 1 year﻿T790M is seen in 5% of treatment-naive patients, but is more commonly seen with acquired resistanceExon 20 insertions",
                    "sub_points": [
                      "Confer sensitivity toEGFRTK inhibitors (TKIs), ma﻿ny of which are FDA approved for advanced-stage NSCLC",
                      "MostEGFRTK domain mutations occur in exons 18-21",
                      "Most patients develop resistance toEGFRTKIs within 1 year﻿T790M is seen in 5% of treatment-naive patients, but is more commonly seen with acquired resistanceExon 20 insertions",
                      "T790M is seen in 5% of treatment-naive patients, but is more commonly seen with acquired resistance",
                      "Exon 20 insertions"
                    ]
                  }
                ],
                "KRAS": [
                  {
                    "text": "KRASpathophysiology﻿Vast majority are missense mutations at amino acids 12, 13, and 61Impair GTP hydrolysis activity ofKRAS, and result in constitutive activation ofKRAS﻿Increased MAPK pathway signaling﻿Culminates in uncontrolled cell proliferation﻿",
                    "sub_points": [
                      "Vast majority are missense mutations at amino acids 12, 13, and 61",
                      "Impair GTP hydrolysis activity ofKRAS, and result in constitutive activation ofKRAS﻿",
                      "Increased MAPK pathway signaling",
                      "﻿Culminates in uncontrolled cell proliferation﻿"
                    ]
                  },
                  {
                    "text": "Clinicopathologic features associated withKRASmutationsKRASmutations are observed in 30% of NSCLCs (mutations in SCLCs are rare)Distinct features compared toEGFR-mutated andEGFR/KRAS-nonmutated tumorsMore frequently associated with solid architectural pattern, which is strong predictor of aggressive behaviorMore frequently associated with mucinous histologyMore frequently associated with tumor-infiltrating lymphocytes﻿Strongly associated with smoking history﻿Western (25-35%) vs. East Asians (5-10%)Age, tumor size, and stage not significantly associated withKRASstatus",
                    "sub_points": [
                      "KRASmutations are observed in 30% of NSCLCs (mutations in SCLCs are rare)",
                      "Distinct features compared toEGFR-mutated andEGFR/KRAS-nonmutated tumorsMore frequently associated with solid architectural pattern, which is strong predictor of aggressive behaviorMore frequently associated with mucinous histologyMore frequently associated with tumor-infiltrating lymphocytes",
                      "More frequently associated with solid architectural pattern, which is strong predictor of aggressive behavior",
                      "More frequently associated with mucinous histology",
                      "More frequently associated with tumor-infiltrating lymphocytes",
                      "﻿Strongly associated with smoking history﻿",
                      "Western (25-35%) vs. East Asians (5-10%)",
                      "Age, tumor size, and stage not significantly associated withKRASstatus"
                    ]
                  },
                  {
                    "text": "Clinical implications ofKRASmutationsNo FDA-approved targeted therapies to datePatients treated with standard chemotherapy/radiation therapy",
                    "sub_points": [
                      "No FDA-approved targeted therapies to date",
                      "Patients treated with standard chemotherapy/radiation therapy"
                    ]
                  }
                ],
                "ALK": [
                  {
                    "text": "ALKpathophysiology﻿ALKrearrangements lead to fusions with other genes to generate novel oncogenesEML4is most common fusion partner (EML4-ALK)﻿Generated by inversion on chromosome 2, inv(2)(p21p23), with several possible breakpoint regions",
                    "sub_points": [
                      "ALKrearrangements lead to fusions with other genes to generate novel oncogenes",
                      "EML4is most common fusion partner (EML4-ALK)﻿Generated by inversion on chromosome 2, inv(2)(p21p23), with several possible breakpoint regions",
                      "Generated by inversion on chromosome 2, inv(2)(p21p23), with several possible breakpoint regions"
                    ]
                  },
                  {
                    "text": "Clinicopathologic features associated withALKrearrangementsALKrearrangements are observed in 6-7% of NSCLCs (rare in SCLC)11% of ACAs vs. 3% of non-ACAs13% of nonsmokers vs. 3% of smokersNo association with sex or age",
                    "sub_points": [
                      "ALKrearrangements are observed in 6-7% of NSCLCs (rare in SCLC)11% of ACAs vs. 3% of non-ACAs",
                      "11% of ACAs vs. 3% of non-ACAs",
                      "13% of nonsmokers vs. 3% of smokers",
                      "No association with sex or age"
                    ]
                  },
                  {
                    "text": "Clinical implications ofALKrearranged tumorsResponsive toALKTKIs",
                    "sub_points": [
                      "Responsive toALKTKIs"
                    ]
                  }
                ],
                "HER2": [
                  {
                    "text": "HER2amplification and overexpression is seen in 1/3 of ACAsSmall insertions in exon 20 account for 96% of mutations",
                    "sub_points": [
                      "Small insertions in exon 20 account for 96% of mutations"
                    ]
                  },
                  {
                    "text": "Only modest response to trastuzumab"
                  },
                  {
                    "text": "Present in 69% females and 52% never smokers"
                  },
                  {
                    "text": "Some success withEGFR/HER2dual kinase inhibitors"
                  }
                ],
                "ROS1": [
                  {
                    "text": "Fusions with various partner genes are seen in ~ 3% of lung ACAs"
                  },
                  {
                    "text": "Crizotinib was recently FDA-approved forROS1-mutated advanced NSCLC"
                  }
                ],
                "BRAF": [
                  {
                    "text": "Seen in about 5-10% of lung ACAs"
                  },
                  {
                    "text": "Mutations other than p.V600E are more common in lung cancers compared to melanomas, which almost exclusively have p.V600E"
                  },
                  {
                    "text": "Investigational therapy with vemurafenib (BRAFTKI) is in clinical trials"
                  }
                ],
                "Commonly Mutated Tumor Suppressor Genes in Lung Cancer": [
                  {
                    "text": "TP53is most commonly mutated tumor suppressor gene"
                  },
                  {
                    "text": "STK11,KEAP1,NFf1,CDKN2A, andNF1are other recurrently mutated tumor suppressor genes"
                  },
                  {
                    "text": "No FDA-approved therapies"
                  }
                ],
                "Molecular Alterations in SQCC": [
                  {
                    "text": "TP53is mutated in majority of cases"
                  },
                  {
                    "text": "CDKN2A,PTEN,PIK3CA,KEAP1,RB, andNOTCH1are other recurrently mutated genes"
                  },
                  {
                    "text": "SOX2,PDGFRA,KIT,EGFR,FGFR1, andCCND1amplifications"
                  },
                  {
                    "text": "CDKN2A,PTEN, andNF1deletions"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Leading cause of cancer and leading cause of cancer mortality (28% of cancer deaths)"
                  },
                  {
                    "text": "Males > females"
                  },
                  {
                    "text": "Incidence by histologic typeNSCLCACA: 53%SQCC: 25%LCC: 3%SCLC: 19%Incidences have changed dramatically due to changes in smoking habits",
                    "sub_points": [
                      "NSCLCACA: 53%SQCC: 25%LCC: 3%",
                      "ACA: 53%",
                      "SQCC: 25%",
                      "LCC: 3%",
                      "SCLC: 19%",
                      "Incidences have changed dramatically due to changes in smoking habits"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "12% incidental discovery on imaging (no symptoms)"
                  },
                  {
                    "text": "17-33% cough"
                  },
                  {
                    "text": "12-17% shortness of breath"
                  },
                  {
                    "text": "3-17% bloody sputum"
                  },
                  {
                    "text": "5-15% chest pain"
                  },
                  {
                    "text": "8% infection"
                  },
                  {
                    "text": "6-14% constitutional symptoms (e.g., weight loss, fatigue)"
                  }
                ],
                "Treatment": [
                  {
                    "text": "NSCLC (synopsis of complex treatment algorithms used in treating NSCLC; does not consider inoperable tumors, positive margin status, multifocal lung tumors, effusions, and several other considerations that would alter management)Stage IA, IB (if pN0 and low-risk patient), IIA (if pN0 and low-risk patient): Resection followed by observationStage IIA (if pN1 or high-risk patient), IIB (if pN1 and high-risk patient), IIIA (if pN1): Resection + chemotherapyStage IIIA (if pN2): Resection + sequential chemotherapy/radiotherapyStage IIIB: Resection + concurrent chemotherapy/radiotherapyStage IV: Palliative therapy + targeted therapy, if applicable",
                    "sub_points": [
                      "Stage IA, IB (if pN0 and low-risk patient), IIA (if pN0 and low-risk patient): Resection followed by observation",
                      "Stage IIA (if pN1 or high-risk patient), IIB (if pN1 and high-risk patient), IIIA (if pN1): Resection + chemotherapy",
                      "Stage IIIA (if pN2): Resection + sequential chemotherapy/radiotherapy",
                      "Stage IIIB: Resection + concurrent chemotherapy/radiotherapy",
                      "Stage IV: Palliative therapy + targeted therapy, if applicable"
                    ]
                  },
                  {
                    "text": "SCLC (similar caveats apply as for NSCLC treatment above)Clinically T1-2, N0: If mediastinal LNs are negative, lobectomy followed by chemotherapyClinically T1-2, N0: If mediastinal LNs are positive, chemotherapy +/- radiotherapyClinically extensive stage (>T1-2, N0): Chemotherapy +/- radiotherapy, depending on performance status",
                    "sub_points": [
                      "Clinically T1-2, N0: If mediastinal LNs are negative, lobectomy followed by chemotherapy",
                      "Clinically T1-2, N0: If mediastinal LNs are positive, chemotherapy +/- radiotherapy",
                      "Clinically extensive stage (>T1-2, N0): Chemotherapy +/- radiotherapy, depending on performance status"
                    ]
                  },
                  {
                    "text": "Additional therapies based on molecular alterations are discussed below"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Stage is major factor influencing survival (5-year survival indicated below)NSCLCStage I: 45-49%Stage II: 30-31%Stage III: 5-14%Stage IV: 1%SCLCStage I: 31%Stage II: 19%Stage III: 8%Stage IV: 2%",
                    "sub_points": [
                      "NSCLCStage I: 45-49%Stage II: 30-31%Stage III: 5-14%Stage IV: 1%",
                      "Stage I: 45-49%",
                      "Stage II: 30-31%",
                      "Stage III: 5-14%",
                      "Stage IV: 1%",
                      "SCLCStage I: 31%Stage II: 19%Stage III: 8%Stage IV: 2%",
                      "Stage I: 31%",
                      "Stage II: 19%",
                      "Stage III: 8%",
                      "Stage IV: 2%"
                    ]
                  }
                ],
                "Major Risk Factor: Smoking": [
                  {
                    "text": "Tumors in smokers show dominant C>A transversion signature"
                  },
                  {
                    "text": "KRASmutations strongly associated with smoking"
                  },
                  {
                    "text": "Deletion of 3p is early eventFollowed by loss of TP53 (17p deletion) and TP53 loss-of-function mutations",
                    "sub_points": [
                      "Followed by loss of TP53 (17p deletion) and TP53 loss-of-function mutations"
                    ]
                  }
                ],
                "Other Risk Factors": [
                  {
                    "text": "Secondhand smoke exposure"
                  },
                  {
                    "text": "Asbestos, radon, or arsenic exposure"
                  },
                  {
                    "text": "Radiation exposure (e.g., atomic bomb, uranium mining)"
                  },
                  {
                    "text": "HIV"
                  },
                  {
                    "text": "Family historyInherited polymorphismsERCC6gene (OMIM 609413)Nicotinic acetylcholine receptor gene cluster (OMIM 612052)EGFRpT790M has also been described as rare germline variant (in addition to well-established somatic variant) found in some some families with multiple generations having lung cancers",
                    "sub_points": [
                      "Inherited polymorphismsERCC6gene (OMIM 609413)Nicotinic acetylcholine receptor gene cluster (OMIM 612052)EGFRpT790M has also been described as rare germline variant (in addition to well-established somatic variant) found in some some families with multiple generations having lung cancers",
                      "ERCC6gene (OMIM 609413)",
                      "Nicotinic acetylcholine receptor gene cluster (OMIM 612052)",
                      "EGFRpT790M has also been described as rare germline variant (in addition to well-established somatic variant) found in some some families with multiple generations having lung cancers"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "ACA: Epithelial neoplasm with glandular differentiation arranged in various architectural patternsLepidic, acinar, papillary, micropapillary, and solid patternsFormer bronchoalveolar carcinoma is now called lepidic-predominant ACAMucinous adenocarcinomas have cytoplasmic mucin",
                    "sub_points": [
                      "Lepidic, acinar, papillary, micropapillary, and solid patterns",
                      "Former bronchoalveolar carcinoma is now called lepidic-predominant ACA",
                      "Mucinous adenocarcinomas have cytoplasmic mucin"
                    ]
                  },
                  {
                    "text": "SQCC: Epithelial neoplasm with squamous differentiationAbundant cytoplasmKeratinizationIntercellular bridgesSquamous pearls",
                    "sub_points": [
                      "Abundant cytoplasm",
                      "Keratinization",
                      "Intercellular bridges",
                      "Squamous pearls"
                    ]
                  },
                  {
                    "text": "LCC: Epithelial neoplasm with no evidence of squamous or glandular differentiationLarge polygonal cellsAnaplasiaNuclear pleomorphismAbundant cytoplasmProminent nucleoliGenetically, LCNEC is more similar to SCLCHas morphologic &/or immunohistochemical evidence of neuroendocrine differentiation",
                    "sub_points": [
                      "Large polygonal cells",
                      "Anaplasia",
                      "Nuclear pleomorphism",
                      "Abundant cytoplasm",
                      "Prominent nucleoliGenetically, LCNEC is more similar to SCLCHas morphologic &/or immunohistochemical evidence of neuroendocrine differentiation",
                      "Genetically, LCNEC is more similar to SCLC",
                      "Has morphologic &/or immunohistochemical evidence of neuroendocrine differentiation"
                    ]
                  },
                  {
                    "text": "SCLC: Neoplasm with epithelial and neuroendocrine differentiationSmaller cells than NSCLCHigh nuclear to cytoplasmic ratiosScant/indistinct cytoplasmSalt-and-pepper chromatin patternNo nucleoliHigh mitotic rateFrequent apoptotic cells and necrosisAzzopardi effectAbundant necrosis results in release of DNA, which then accumulates around blood vesselsFrequent crush artifact",
                    "sub_points": [
                      "Smaller cells than NSCLC",
                      "High nuclear to cytoplasmic ratiosScant/indistinct cytoplasm",
                      "Scant/indistinct cytoplasm",
                      "Salt-and-pepper chromatin pattern",
                      "No nucleoli",
                      "High mitotic rate",
                      "Frequent apoptotic cells and necrosis",
                      "Azzopardi effectAbundant necrosis results in release of DNA, which then accumulates around blood vessels",
                      "Abundant necrosis results in release of DNA, which then accumulates around blood vessels",
                      "Frequent crush artifact"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Renal Cell Carcinoma": {
            "name": "Molecular Alterations in Renal Cell Carcinoma",
            "url": "https://app.pathprimer.com/document/844d20d4-5a18-4264-94f9-bb9df072eb8a/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Hereditary RCCsOften have bilateral and multifocal tumorsOften have younger age of presentation",
                    "sub_points": [
                      "Often have bilateral and multifocal tumors",
                      "Often have younger age of presentation"
                    ]
                  },
                  {
                    "text": "FDA-approved drugs for metastatic (stage IV) or unresectable RCCTyrosine kinase inhibitors (including VEGFR): Axitinib, sorafenib, pazopanib, sunitinibAnti-VEGF antibody: BevacizumabImmune checkpoint inhibitors: Nivolumab (anti-PD-1 antibody)",
                    "sub_points": [
                      "Tyrosine kinase inhibitors (including VEGFR): Axitinib, sorafenib, pazopanib, sunitinib",
                      "Anti-VEGF antibody: Bevacizumab",
                      "Immune checkpoint inhibitors: Nivolumab (anti-PD-1 antibody)"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "ccRCC3p deletions are seen in majority of tumorsLoss-of-function mutations inVHLgene are most common genetic alterationsGermline alterations that predispose to ccRCC﻿von Hippel-Lindau diseaseTuberous sclerosis 1 and 2FLCN(Birt-Hogg-Dube syndrome)PTEN(Cowden syndrome)",
                    "sub_points": [
                      "3p deletions are seen in majority of tumors",
                      "Loss-of-function mutations inVHLgene are most common genetic alterations",
                      "Germline alterations that predispose to ccRCC﻿von Hippel-Lindau diseaseTuberous sclerosis 1 and 2FLCN(Birt-Hogg-Dube syndrome)PTEN(Cowden syndrome)",
                      "von Hippel-Lindau disease",
                      "Tuberous sclerosis 1 and 2",
                      "FLCN(Birt-Hogg-Dube syndrome)",
                      "PTEN(Cowden syndrome)"
                    ]
                  },
                  {
                    "text": "pRCCType I:METalterations are observed in 81%﻿Germline alterations that predispose to pRCC﻿MET(HPRC, type I pRCC)HLRCC (FH, type II-like pRCC)",
                    "sub_points": [
                      "Type I:METalterations are observed in 81%﻿",
                      "Germline alterations that predispose to pRCC﻿MET(HPRC, type I pRCC)HLRCC (FH, type II-like pRCC)",
                      "MET(HPRC, type I pRCC)",
                      "HLRCC (FH, type II-like pRCC)"
                    ]
                  },
                  {
                    "text": "chRCCLoss of most (or all) of chromosomes 1, 2, 6, 10, 13, and 17 in majority of chRCC﻿In nearly 50%, chromosome 17 loss is accompanied byTP53loss-of-function mutations﻿",
                    "sub_points": [
                      "Loss of most (or all) of chromosomes 1, 2, 6, 10, 13, and 17 in majority of chRCC﻿",
                      "In nearly 50%, chromosome 17 loss is accompanied byTP53loss-of-function mutations﻿"
                    ]
                  },
                  {
                    "text": "Germline Alterations That Predispose to chRCCPTEN(Cowden syndrome)FLCN(Birt-Hogg-Dube syndrome)",
                    "sub_points": [
                      "PTEN(Cowden syndrome)",
                      "FLCN(Birt-Hogg-Dube syndrome)"
                    ]
                  },
                  {
                    "text": "Medullary RCC is seen ﻿almost exclusively in sickle cell (SC) carriers﻿or SC compound heterozygotesFrequent loss of INI1 is seen",
                    "sub_points": [
                      "Frequent loss of INI1 is seen"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Renal cell carcinoma (RCC)Clear cell RCC (ccRCC)Papillary RCC (pRCC)Chromophobe RCC (chRCC)",
                    "sub_points": [
                      "Clear cell RCC (ccRCC)",
                      "Papillary RCC (pRCC)",
                      "Chromophobe RCC (chRCC)"
                    ]
                  },
                  {
                    "text": "Birt-Hogg-Dube syndrome (BHD, OMIM 135150)"
                  },
                  {
                    "text": "Hereditary leiomyomatosis and RCC (HLRCC, OMIM 150800)"
                  },
                  {
                    "text": "von Hippel-Lindau disease (VHL, OMIM 193300)"
                  },
                  {
                    "text": "Tuberous sclerosis (TSC1, OMIM 191100; and TSC2, OMIM 613254)"
                  },
                  {
                    "text": "Familial paraganglioma (PG; 4 phenotypic entries in OMIM)"
                  },
                  {
                    "text": "Hereditary papillary RCC (HPRC, OMIM 605074)"
                  },
                  {
                    "text": "Angiomyolipoma (AML)"
                  },
                  {
                    "text": "Fumarate hydratase (FH)"
                  },
                  {
                    "text": "Succinate dehydrogenase (SDH)"
                  },
                  {
                    "text": "CpG island methylator phenotype (CIMP)"
                  },
                  {
                    "text": "National Comprehensive Cancer Network (NCCN)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "RCC: Malignant renal epithelial neoplasm originating from nephron"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Heavy metals (cadmium)"
                  },
                  {
                    "text": "Organic solvents"
                  },
                  {
                    "text": "Herbicides"
                  }
                ],
                "Inherited Predisposition": [
                  {
                    "text": "Estimated 4% of RCCs"
                  },
                  {
                    "text": "Inherited germline variants"
                  }
                ],
                "Other Risk Factors": [
                  {
                    "text": "Age: Older age"
                  },
                  {
                    "text": "Sex: Males"
                  },
                  {
                    "text": "Ethnicity: African Americans, Native Americans"
                  },
                  {
                    "text": "Smoking"
                  },
                  {
                    "text": "Obesity"
                  },
                  {
                    "text": "Hypertension"
                  },
                  {
                    "text": "Medications: Phenacetin (discontinued), diuretics"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "62,700 new cases per year of kidney cancer (9th leading cause of cancer)"
                  },
                  {
                    "text": "14,240 deaths per year due to kidney cancer (8th leading cause of cancer death)"
                  },
                  {
                    "text": "~ 90% of kidney cancers are RCCs; remaining 10% are urothelial carcinomasccRCC: 80%pRCC: 15%chRCC: 5%Other RCCs: Each < 1%",
                    "sub_points": [
                      "ccRCC: 80%",
                      "pRCC: 15%",
                      "chRCC: 5%",
                      "Other RCCs: Each < 1%"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Median age at diagnosis: 64 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "M:F ~ 2:1"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "No racial predilection"
                  },
                  {
                    "text": "Medullary RCC is much more common in African Americans due to association with sickle cell trait and SC compound heterozygotes"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Clinical presentationOften incidental finding on imagingFlank/abdominal painHematuriaAbdominal massConstitutional symptoms (fever, weight loss, anorexia)",
                    "sub_points": [
                      "Often incidental finding on imaging",
                      "Flank/abdominal pain",
                      "Hematuria",
                      "Abdominal mass",
                      "Constitutional symptoms (fever, weight loss, anorexia)"
                    ]
                  },
                  {
                    "text": "Hereditary RCCsFamily history (inherited from parents) may or may not be presentCan be de novo mutationOften have bilateral and multifocal tumorsOften younger age of presentationMay be syndromic or nonsyndromicSyndromic RCCs have extrarenal manifestations, which may suggest clinical diagnosisNonsyndromic RCCs lack extrarenal manifestations",
                    "sub_points": [
                      "Family history (inherited from parents) may or may not be presentCan be de novo mutation",
                      "Can be de novo mutation",
                      "Often have bilateral and multifocal tumors",
                      "Often younger age of presentation",
                      "May be syndromic or nonsyndromicSyndromic RCCs have extrarenal manifestations, which may suggest clinical diagnosisNonsyndromic RCCs lack extrarenal manifestations",
                      "Syndromic RCCs have extrarenal manifestations, which may suggest clinical diagnosis",
                      "Nonsyndromic RCCs lack extrarenal manifestations"
                    ]
                  }
                ],
                "Treatment": [],
                "Adjuvant therapy": [
                  {
                    "text": "FDA-approved drugs for metastatic (stage IV) or unresectable RCCNo specific molecular testing has been recommended by NCCN for selecting targeted therapies in RCCTyrosine kinase inhibitors (including VEGFR): Axitinib, sorafenib, pazopanib, sunitinibAnti-VEGF antibody: BevacizumabImmune checkpoint inhibitors: Nivolumab (anti-PD-1 antibody)mTOR inhibitors: Everolimus, temsirolimusCytokines: IL-2, IFNα",
                    "sub_points": [
                      "No specific molecular testing has been recommended by NCCN for selecting targeted therapies in RCC",
                      "Tyrosine kinase inhibitors (including VEGFR): Axitinib, sorafenib, pazopanib, sunitinib",
                      "Anti-VEGF antibody: Bevacizumab",
                      "Immune checkpoint inhibitors: Nivolumab (anti-PD-1 antibody)",
                      "mTOR inhibitors: Everolimus, temsirolimus",
                      "Cytokines: IL-2, IFNα"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Stage is the major predictor of 5-year survivalStage I: 81%Stage II: 71%Stage III: 53%Stage IV: 8%",
                    "sub_points": [
                      "Stage I: 81%",
                      "Stage II: 71%",
                      "Stage III: 53%",
                      "Stage IV: 8%"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "ccRCC": [
                  {
                    "text": "Cytogenetic alterations﻿3p deletions are seen in majority of tumors﻿Deletion encompassesVHL,PBRM1,BAP1, andSETD2(all tumor suppressors and all are most commonly mutated genes in ccRCC)",
                    "sub_points": [
                      "﻿3p deletions are seen in majority of tumors﻿Deletion encompassesVHL,PBRM1,BAP1, andSETD2(all tumor suppressors and all are most commonly mutated genes in ccRCC)",
                      "Deletion encompassesVHL,PBRM1,BAP1, andSETD2(all tumor suppressors and all are most commonly mutated genes in ccRCC)"
                    ]
                  },
                  {
                    "text": "Molecular alterationsLoss-of-function mutations inVHLgene are the most common genetic alterations in ccRCC﻿> 1,000 somatic and germline alterations have been identified scattered throughout geneVHLis E3 ubiquitin ligase, which forms ubiquitin ligase complex with cullin 2, elongin A, elongin B, and Rbx1Under normoxic conditions,VHLubiquitinates hypoxia inducible factor HIF-1α, which marks it for proteosomal degradationUnder hypoxic conditions, ubiquitination of HIF-1α is inhibitedHIF-1α then accumulates and binds to HIF-1β to form heterodimeric transcription factor (HIF)HIF dimer translocates to nucleus where it activates several genes that allow adaptation in hypoxic conditionsVEGF,PDGF, erythropoietin, etc.When both copies ofVHLare inactivated, HIF-1α accumulates and is constitutively active even under normoxic statesBackground for tumor developmentExcess production of angiogenic and growth-promoting factorsTumors withVHLmutations (including inVHLsyndrome) tend to be highly vascularBiallelic inactivation ofVHL(Knudson 2-hit hypothesis of tumorigenesis)First \"hit\" may be germline or somaticMutation/deletion in 1 allele + deletion of 2nd allele (3p deletion)Mutation/deletion in 1 allele +VHLpromoter methylation in 2nd alleleSimilar biallelic inactivation ofVHLcomplex component elongin C has been described in 1-5% of tumors and are mutually exclusive of biallelicVHLinactivationGermline or somatic mutation in elongin C + deletion of 2nd allele (8q21.11 deletion)Other common mutations in ccRCCChromatin/histone modification:PBRM,SETD2,BAP1, KDM53, SMARD1PI3K pathway (28% of tumors):PI3KCA,PTEN,AKT1,AKT2,MTOR,TSC1/2,RHEB",
                    "sub_points": [
                      "Loss-of-function mutations inVHLgene are the most common genetic alterations in ccRCC﻿> 1,000 somatic and germline alterations have been identified scattered throughout geneVHLis E3 ubiquitin ligase, which forms ubiquitin ligase complex with cullin 2, elongin A, elongin B, and Rbx1Under normoxic conditions,VHLubiquitinates hypoxia inducible factor HIF-1α, which marks it for proteosomal degradationUnder hypoxic conditions, ubiquitination of HIF-1α is inhibitedHIF-1α then accumulates and binds to HIF-1β to form heterodimeric transcription factor (HIF)HIF dimer translocates to nucleus where it activates several genes that allow adaptation in hypoxic conditionsVEGF,PDGF, erythropoietin, etc.When both copies ofVHLare inactivated, HIF-1α accumulates and is constitutively active even under normoxic statesBackground for tumor developmentExcess production of angiogenic and growth-promoting factorsTumors withVHLmutations (including inVHLsyndrome) tend to be highly vascularBiallelic inactivation ofVHL(Knudson 2-hit hypothesis of tumorigenesis)First \"hit\" may be germline or somaticMutation/deletion in 1 allele + deletion of 2nd allele (3p deletion)Mutation/deletion in 1 allele +VHLpromoter methylation in 2nd alleleSimilar biallelic inactivation ofVHLcomplex component elongin C has been described in 1-5% of tumors and are mutually exclusive of biallelicVHLinactivationGermline or somatic mutation in elongin C + deletion of 2nd allele (8q21.11 deletion)",
                      "> 1,000 somatic and germline alterations have been identified scattered throughout gene",
                      "VHLis E3 ubiquitin ligase, which forms ubiquitin ligase complex with cullin 2, elongin A, elongin B, and Rbx1",
                      "Under normoxic conditions,VHLubiquitinates hypoxia inducible factor HIF-1α, which marks it for proteosomal degradation",
                      "Under hypoxic conditions, ubiquitination of HIF-1α is inhibited",
                      "HIF-1α then accumulates and binds to HIF-1β to form heterodimeric transcription factor (HIF)",
                      "HIF dimer translocates to nucleus where it activates several genes that allow adaptation in hypoxic conditionsVEGF,PDGF, erythropoietin, etc.",
                      "VEGF,PDGF, erythropoietin, etc.",
                      "When both copies ofVHLare inactivated, HIF-1α accumulates and is constitutively active even under normoxic statesBackground for tumor developmentExcess production of angiogenic and growth-promoting factorsTumors withVHLmutations (including inVHLsyndrome) tend to be highly vascular",
                      "Background for tumor development",
                      "Excess production of angiogenic and growth-promoting factors",
                      "Tumors withVHLmutations (including inVHLsyndrome) tend to be highly vascular",
                      "Biallelic inactivation ofVHL(Knudson 2-hit hypothesis of tumorigenesis)First \"hit\" may be germline or somaticMutation/deletion in 1 allele + deletion of 2nd allele (3p deletion)Mutation/deletion in 1 allele +VHLpromoter methylation in 2nd allele",
                      "First \"hit\" may be germline or somatic",
                      "Mutation/deletion in 1 allele + deletion of 2nd allele (3p deletion)",
                      "Mutation/deletion in 1 allele +VHLpromoter methylation in 2nd allele",
                      "Similar biallelic inactivation ofVHLcomplex component elongin C has been described in 1-5% of tumors and are mutually exclusive of biallelicVHLinactivationGermline or somatic mutation in elongin C + deletion of 2nd allele (8q21.11 deletion)",
                      "Germline or somatic mutation in elongin C + deletion of 2nd allele (8q21.11 deletion)",
                      "Other common mutations in ccRCCChromatin/histone modification:PBRM,SETD2,BAP1, KDM53, SMARD1PI3K pathway (28% of tumors):PI3KCA,PTEN,AKT1,AKT2,MTOR,TSC1/2,RHEB",
                      "Chromatin/histone modification:PBRM,SETD2,BAP1, KDM53, SMARD1",
                      "PI3K pathway (28% of tumors):PI3KCA,PTEN,AKT1,AKT2,MTOR,TSC1/2,RHEB"
                    ]
                  },
                  {
                    "text": "Germline Alterations That Predispose to ccRCCVHL(﻿VHL﻿syndrome)FLCN(BHD syndrome)TSC1 and TSC2(TS)SDHB,SDHC,SDHD(PG)PTEN(Cowden syndrome)BAP1(BAP1-associated familial kidney cancer)Chromosome 3 translocation (constitutional chromosome 3 translocation-associated RCC)",
                    "sub_points": [
                      "VHL(﻿VHL﻿syndrome)",
                      "FLCN(BHD syndrome)",
                      "TSC1 and TSC2(TS)",
                      "SDHB,SDHC,SDHD(PG)",
                      "PTEN(Cowden syndrome)",
                      "BAP1(BAP1-associated familial kidney cancer)",
                      "Chromosome 3 translocation (constitutional chromosome 3 translocation-associated RCC)"
                    ]
                  }
                ],
                "pRCC": [
                  {
                    "text": "Type I:METalterations observed in 81%﻿Most have trisomy 7 (location ofMETgene) and 17Associated with overexpression ofMETPreferential gain of chromosome 7 occurs with mutantMETallele when presentMostMETmutations are clustered in tyrosine kinase domainThis arrangement results in constitutive ﻿MET﻿tyrosine kinase activity and signaling",
                    "sub_points": [
                      "Most have trisomy 7 (location ofMETgene) and 17Associated with overexpression ofMETPreferential gain of chromosome 7 occurs with mutantMETallele when presentMostMETmutations are clustered in tyrosine kinase domainThis arrangement results in constitutive ﻿MET﻿tyrosine kinase activity and signaling",
                      "Associated with overexpression ofMET",
                      "Preferential gain of chromosome 7 occurs with mutantMETallele when present",
                      "MostMETmutations are clustered in tyrosine kinase domainThis arrangement results in constitutive ﻿MET﻿tyrosine kinase activity and signaling",
                      "This arrangement results in constitutive ﻿MET﻿tyrosine kinase activity and signaling"
                    ]
                  },
                  {
                    "text": "Type II: Separated into 3 prognostically relevant molecular subtypes﻿CpG island methylator phenotype (CIMP)﻿Widespread DNA hypermethylation (also observed in other tumor types, such as colon, lung, and endometrial cancers)Associated with germline or somatic loss-of-functionFHmutations &/or low levels ofFHmRNA; leads to the followingFumarate accumulation, which results in metabolic shift to glycolysis for energy generation (Warburg effect)Increased expression of glycolytic and fermentative enzymes and decreased expression of Krebs cycle enzymesUpregulation of hypoxia-related genes and subsequent suppression of fatty acid synthesisFrequentCDKN2Ainactivation results inPromoter hypermethylation, focal deletion, &/or upregulation of miR-10b-5p (targetsCDKN2Afor silencing)IncreasedRB1phosphorylation and marked upregulation of cell cycle genesPatients with CIMP are younger and have worse overall survival﻿Other 2 molecular subtypesDistinct DNA methylation, mRNA expression, and gene mutation patternsPatients are older and have better overall survival",
                    "sub_points": [
                      "﻿CpG island methylator phenotype (CIMP)﻿Widespread DNA hypermethylation (also observed in other tumor types, such as colon, lung, and endometrial cancers)Associated with germline or somatic loss-of-functionFHmutations &/or low levels ofFHmRNA; leads to the followingFumarate accumulation, which results in metabolic shift to glycolysis for energy generation (Warburg effect)Increased expression of glycolytic and fermentative enzymes and decreased expression of Krebs cycle enzymesUpregulation of hypoxia-related genes and subsequent suppression of fatty acid synthesisFrequentCDKN2Ainactivation results inPromoter hypermethylation, focal deletion, &/or upregulation of miR-10b-5p (targetsCDKN2Afor silencing)IncreasedRB1phosphorylation and marked upregulation of cell cycle genesPatients with CIMP are younger and have worse overall survival﻿",
                      "Widespread DNA hypermethylation (also observed in other tumor types, such as colon, lung, and endometrial cancers)",
                      "Associated with germline or somatic loss-of-functionFHmutations &/or low levels ofFHmRNA; leads to the followingFumarate accumulation, which results in metabolic shift to glycolysis for energy generation (Warburg effect)Increased expression of glycolytic and fermentative enzymes and decreased expression of Krebs cycle enzymesUpregulation of hypoxia-related genes and subsequent suppression of fatty acid synthesis",
                      "Fumarate accumulation, which results in metabolic shift to glycolysis for energy generation (Warburg effect)",
                      "Increased expression of glycolytic and fermentative enzymes and decreased expression of Krebs cycle enzymes",
                      "Upregulation of hypoxia-related genes and subsequent suppression of fatty acid synthesis",
                      "FrequentCDKN2Ainactivation results inPromoter hypermethylation, focal deletion, &/or upregulation of miR-10b-5p (targetsCDKN2Afor silencing)IncreasedRB1phosphorylation and marked upregulation of cell cycle genes",
                      "Promoter hypermethylation, focal deletion, &/or upregulation of miR-10b-5p (targetsCDKN2Afor silencing)",
                      "IncreasedRB1phosphorylation and marked upregulation of cell cycle genes",
                      "Patients with CIMP are younger and have worse overall survival﻿",
                      "Other 2 molecular subtypesDistinct DNA methylation, mRNA expression, and gene mutation patternsPatients are older and have better overall survival",
                      "Distinct DNA methylation, mRNA expression, and gene mutation patterns",
                      "Patients are older and have better overall survival"
                    ]
                  },
                  {
                    "text": "Germline alterations that predispose to pRCCMET(HPRC, type I pRCC)HLRCC (FH, type II-like pRCC)",
                    "sub_points": [
                      "MET(HPRC, type I pRCC)",
                      "HLRCC (FH, type II-like pRCC)"
                    ]
                  }
                ],
                "chRCC": [
                  {
                    "text": "Cytogenetic alterationsLoss of most (or all) of chromosomes 1, 2, 6, 10, 13, and 17 in majority of chRCC﻿Less common in eosinophilic variants of chRCCIn nearly 50%, chromosome 17 loss is accompanied byTP53loss-of-function mutations﻿Less commonly, deletion and loss-of-function mutations inPTENor homozygousPTENdeletions are observed",
                    "sub_points": [
                      "Loss of most (or all) of chromosomes 1, 2, 6, 10, 13, and 17 in majority of chRCC﻿Less common in eosinophilic variants of chRCC",
                      "Less common in eosinophilic variants of chRCC",
                      "In nearly 50%, chromosome 17 loss is accompanied byTP53loss-of-function mutations﻿",
                      "Less commonly, deletion and loss-of-function mutations inPTENor homozygousPTENdeletions are observed"
                    ]
                  },
                  {
                    "text": "Molecular alterationsLow overall mutation burden compared to most carcinomasTP53(32%),PTEN(9%),MTOR,TSC1,TSC2,NRAS, andTERT(promoter) are recurrently mutated genes",
                    "sub_points": [
                      "Low overall mutation burden compared to most carcinomas",
                      "TP53(32%),PTEN(9%),MTOR,TSC1,TSC2,NRAS, andTERT(promoter) are recurrently mutated genes"
                    ]
                  },
                  {
                    "text": "Germline alterations that predispose to chRCC﻿PTEN(Cowden syndrome)FLCN(BHD syndrome)",
                    "sub_points": [
                      "PTEN(Cowden syndrome)",
                      "FLCN(BHD syndrome)"
                    ]
                  }
                ],
                "Translocation-Associated RCC": [
                  {
                    "text": "TFE3(Xp11) orTFEBtranslocations generate fusion genes with various partners"
                  },
                  {
                    "text": "TFE3andTFEBare transcription factors"
                  },
                  {
                    "text": "Represent one-third of pediatric RCCs, but < 1% of adult RCCs"
                  },
                  {
                    "text": "In children, previous chemotherapy may be risk factor"
                  },
                  {
                    "text": "Detection by immunohistochemistry forTFE3orTFEB, FISH, or PCR"
                  }
                ],
                "Medullary RCC": [
                  {
                    "text": "Seen﻿ almost exclusively in sickle cell (SC) carriers﻿or SC compound heterozygotes"
                  },
                  {
                    "text": "Frequent loss of INI1 is seen"
                  }
                ],
                "National Comprehensive Cancer Network Guidelines": [
                  {
                    "text": "NCCN has made no specific recommendations for molecular testing in RCCs for diagnosis, prognostication, or prediction of response to therapy"
                  },
                  {
                    "text": "While targeted therapies exist for RCC, molecular testing is not required"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "ccRCCArchitecture: Neoplastic epithelial cells arranged in nests separated by rich network of delicate fibrovascular septae (alveolar architecture)Cytology: Round to polygonal cells with abundant clear cytoplasm (due to glycogen and lipids) and variable nuclear features depending on Fuhrman grade",
                    "sub_points": [
                      "Architecture: Neoplastic epithelial cells arranged in nests separated by rich network of delicate fibrovascular septae (alveolar architecture)",
                      "Cytology: Round to polygonal cells with abundant clear cytoplasm (due to glycogen and lipids) and variable nuclear features depending on Fuhrman grade"
                    ]
                  },
                  {
                    "text": "pRCCArchitecture: Branching fibrovascular cores containing foamy macrophages and lined by neoplastic epitheliumCytologyType I: Nonstratified cuboidal cells with scant to modest amount of pale amphophilic to basophilic cytoplasm and small bland ovoid nuclei with inconspicuous nucleoliType II: Large columnar cells with abundant intensely eosinophilic cytoplasm and large round nuclei with prominent nucleolus and open chromatinPsammoma bodies may be seen",
                    "sub_points": [
                      "Architecture: Branching fibrovascular cores containing foamy macrophages and lined by neoplastic epithelium",
                      "CytologyType I: Nonstratified cuboidal cells with scant to modest amount of pale amphophilic to basophilic cytoplasm and small bland ovoid nuclei with inconspicuous nucleoliType II: Large columnar cells with abundant intensely eosinophilic cytoplasm and large round nuclei with prominent nucleolus and open chromatinPsammoma bodies may be seen",
                      "Type I: Nonstratified cuboidal cells with scant to modest amount of pale amphophilic to basophilic cytoplasm and small bland ovoid nuclei with inconspicuous nucleoli",
                      "Type II: Large columnar cells with abundant intensely eosinophilic cytoplasm and large round nuclei with prominent nucleolus and open chromatin",
                      "Psammoma bodies may be seen"
                    ]
                  },
                  {
                    "text": "chRCCArchitecture: Nests and tubulesCytology: Large polygonal cells with abundant cytoplasm, hyperchromatic irregular nuclei, and sharply defined cell bordersClassic variant: Pale flocculent cytoplasmEosinophilic variant: Dense, intensely eosinophilic, granular cytoplasm with perinuclear halos",
                    "sub_points": [
                      "Architecture: Nests and tubules",
                      "Cytology: Large polygonal cells with abundant cytoplasm, hyperchromatic irregular nuclei, and sharply defined cell bordersClassic variant: Pale flocculent cytoplasmEosinophilic variant: Dense, intensely eosinophilic, granular cytoplasm with perinuclear halos",
                      "Classic variant: Pale flocculent cytoplasm",
                      "Eosinophilic variant: Dense, intensely eosinophilic, granular cytoplasm with perinuclear halos"
                    ]
                  },
                  {
                    "text": "Clear cell papillary RCCArchitecture: Papillary tufts with few or no branches, with fibrovascular cores lined by neoplastic epithelial cellsCytology: Uniform columnar cells with modest amount of clear cytoplasm and apically oriented linearly arranged bland nuclei",
                    "sub_points": [
                      "Architecture: Papillary tufts with few or no branches, with fibrovascular cores lined by neoplastic epithelial cells",
                      "Cytology: Uniform columnar cells with modest amount of clear cytoplasm and apically oriented linearly arranged bland nuclei"
                    ]
                  },
                  {
                    "text": "Translocation-associated RCCArchitecture: Neoplastic epithelium lining papillae with fibrovascular cores and in alveolar nestsCytology: Large polygonal cells with voluminous clear or eosinophilic cytoplasm, irregular nuclei with conspicuous nucleoli, and sharp cell bordersPsammoma bodies are abundant",
                    "sub_points": [
                      "Architecture: Neoplastic epithelium lining papillae with fibrovascular cores and in alveolar nests",
                      "Cytology: Large polygonal cells with voluminous clear or eosinophilic cytoplasm, irregular nuclei with conspicuous nucleoli, and sharp cell borders",
                      "Psammoma bodies are abundant"
                    ]
                  },
                  {
                    "text": "Medullary RCCArchitecture: Various patterns including solid, tubular, adenoid cystic, yolk sac-like, and reticularCytology: Hyperchromatic nuclei, with prominent nucleoli",
                    "sub_points": [
                      "Architecture: Various patterns including solid, tubular, adenoid cystic, yolk sac-like, and reticular",
                      "Cytology: Hyperchromatic nuclei, with prominent nucleoli"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Salivary Gland Carcinomas": {
            "name": "Molecular Alterations in Salivary Gland Carcinomas",
            "url": "https://app.pathprimer.com/document/db929b09-a15e-4994-9200-57b5e5b89699/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Pleomorphic adenoma (PA), mucoepidermoid carcinoma (MEC), adenoid cystic carcinoma (ADCC), mammary analog secretory carcinoma (MASC), hyalinizing clear cell carcinoma (HCCC)"
                  },
                  {
                    "text": "Primary salivary gland tumors that have specific gene translocations"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Targeted therapy is desirable in aggressive high-grade salivary gland tumorsMinority of salivary gland tumorsNo targeted therapy specific for gene fusion proteins in MEC, ADCC, MASC, HCCC",
                    "sub_points": [
                      "Minority of salivary gland tumors",
                      "No targeted therapy specific for gene fusion proteins in MEC, ADCC, MASC, HCCC"
                    ]
                  },
                  {
                    "text": "Tumors are rare so few cases of salivary gland tumors studies"
                  }
                ],
                "Molecular Pathology": [
                  {
                    "text": "Expression profiling per individual patient's high-grade tumor may identify targetable pathwaysEGFR antibodies, mTOR inhibitors, PI3K inhibitors may be beneficial in particular patientsActivating, targetable mutations individually rare and not generally restricted to specific salivary gland subtypes",
                    "sub_points": [
                      "EGFR antibodies, mTOR inhibitors, PI3K inhibitors may be beneficial in particular patients",
                      "Activating, targetable mutations individually rare and not generally restricted to specific salivary gland subtypes"
                    ]
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Specific salivary gland tumor translocations have diagnostic utility especially in clinically or histologically atypical cases"
                  },
                  {
                    "text": "High-quality biospecimens required to optimize detection of translocations"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Primary salivary gland tumors with specific gene translocations includePleomorphic adenoma (PA)Mucoepidermoid carcinoma (MEC)Adenoid cystic carcinoma (ADCC)Mammary analog secretory carcinoma (MASC)Hyalinizing clear cell carcinoma (HCCC)",
                    "sub_points": [
                      "Pleomorphic adenoma (PA)",
                      "Mucoepidermoid carcinoma (MEC)",
                      "Adenoid cystic carcinoma (ADCC)",
                      "Mammary analog secretory carcinoma (MASC)",
                      "Hyalinizing clear cell carcinoma (HCCC)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Pleomorphic Adenoma": [
                  {
                    "text": "Most show overexpression of PLAG1 protein"
                  },
                  {
                    "text": "Some haveHMGA2gene amplification or rearrangement"
                  },
                  {
                    "text": "Some show neither PLAG1 protein overexpression norHMGA2gene"
                  }
                ],
                "Mucoepidermoid Carcinoma": [
                  {
                    "text": "CRTC1-MAML2orCRTC3-MAML2fusion proteins disrupt Notch signaling pathway"
                  }
                ],
                "Adenoid Cystic Carcinoma": [
                  {
                    "text": "MYB-NFIBfusion protein upregulates MYB protein expression"
                  },
                  {
                    "text": "Rare cases do not rely on MYB overexpression for tumorigenesis"
                  }
                ],
                "Mammary Analog Secretory Carcinoma": [
                  {
                    "text": "ETV6-NTRK3gene fusionETV6: Transcriptional regulatorNTRK3: Membrane receptor kinase",
                    "sub_points": [
                      "ETV6: Transcriptional regulator",
                      "NTRK3: Membrane receptor kinase"
                    ]
                  }
                ],
                "Hyalinizing Clear Cell Carcinoma": [
                  {
                    "text": "EWSR1-ATF1gene fusion"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Pleomorphic adenoma is the most common benign salivary gland tumor"
                  },
                  {
                    "text": "MEC: Most common malignant salivary gland tumor"
                  },
                  {
                    "text": "Adenoid cystic carcinoma is 2nd most common malignant salivary gland tumor"
                  },
                  {
                    "text": "MASC and HCCC: Unusual salivary gland tumors that may be underdiagnosed due to histologic similarities with other tumor types"
                  }
                ],
                "Age": [
                  {
                    "text": "Pleomorphic adenomas and adenoid cystic carcinoma are most common in adults, but are also found in children"
                  },
                  {
                    "text": "MEC primarily affects adults, but also occurs in children"
                  },
                  {
                    "text": "MASC occurs in adults; average: Mid 40s"
                  },
                  {
                    "text": "HCCC occurs in adults, more commonly females"
                  }
                ],
                "Site": [
                  {
                    "text": "Pleomorphic adenoma and MEC: Majority occur in major salivary glands, especially parotid"
                  },
                  {
                    "text": "Mucoepidermoid carcinomaPalate most frequent minor salivary gland locationOther rare sites: Lacrimal glands, intraosseous in gnathic bones, lungs, others",
                    "sub_points": [
                      "Palate most frequent minor salivary gland locationOther rare sites: Lacrimal glands, intraosseous in gnathic bones, lungs, others",
                      "Other rare sites: Lacrimal glands, intraosseous in gnathic bones, lungs, others"
                    ]
                  },
                  {
                    "text": "Adenoid cystic carcinomaMajor salivary glands most common but accounts for 30% of epithelial tumors in minor salivary glandsOther rare sites: Lacrimal glands, lungs, uterine cervix, breast, and others",
                    "sub_points": [
                      "Major salivary glands most common but accounts for 30% of epithelial tumors in minor salivary glands",
                      "Other rare sites: Lacrimal glands, lungs, uterine cervix, breast, and others"
                    ]
                  },
                  {
                    "text": "Mammary analogue secretory carcinomaFairly common in minor salivary glands as well as major glandsOften misdiagnosed in minor salivary glands as acinic cell carcinoma",
                    "sub_points": [
                      "Fairly common in minor salivary glands as well as major glands",
                      "Often misdiagnosed in minor salivary glands as acinic cell carcinoma"
                    ]
                  },
                  {
                    "text": "Hyalinizing clear cell carcinoma: Minor salivary glands of oral cavity are most commonly involved"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Pleomorphic adenomaMost common: Painless mass or swelling present many yearsRecent rapid enlargement may indicate cystic degenerationormalignant transformationPain, hyperhydrosis, anhydrosis, or numbness: Strongly suspicious for malignant transformation",
                    "sub_points": [
                      "Most common: Painless mass or swelling present many years",
                      "Recent rapid enlargement may indicate cystic degenerationormalignant transformation",
                      "Pain, hyperhydrosis, anhydrosis, or numbness: Strongly suspicious for malignant transformation"
                    ]
                  },
                  {
                    "text": "Mucoepidermoid carcinomaFirm painless mass most common",
                    "sub_points": [
                      "Firm painless mass most common"
                    ]
                  },
                  {
                    "text": "Adenoid cystic carcinomaSlowly growing mass, usually painlessPain can occur due to infiltration of peripheral nerves",
                    "sub_points": [
                      "Slowly growing mass, usually painless",
                      "Pain can occur due to infiltration of peripheral nerves"
                    ]
                  },
                  {
                    "text": "Mammary analog secretory carcinomaSlowly growing mass, present for years",
                    "sub_points": [
                      "Slowly growing mass, present for years"
                    ]
                  },
                  {
                    "text": "Hyalinizing clear cell carcinomaSlowly growing painless mass",
                    "sub_points": [
                      "Slowly growing painless mass"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Complete surgical excision is required for all of these tumor typesPleomorphic adenoma has 6% rate of malignant transformation (carcinoma ex pleomorphic adenoma [Ca ex PA])Ca ex PA requires radical surgery alone or radical surgery ± radiation ± chemotherapyEnucleation of PA may lead to morbid recurrence (skin invasion, multiple nodules, nerve twig invasion) requiring more radical surgery ± radiationMucoepidermoid carcinoma requires adjuvant therapy for high-stage &/or high-grade tumorsAdenoid cystic carcinoma excision may be difficult to accomplish due to extensive, deeply permeative perineural invasionRadiation often adjuvantly used to attempt to control local recurrencesMammary analog secretory carcinoma and hyalinizing clear cell carcinoma with rare anaplastic or transformed variant may require radical excision and adjuvant therapy",
                    "sub_points": [
                      "Pleomorphic adenoma has 6% rate of malignant transformation (carcinoma ex pleomorphic adenoma [Ca ex PA])Ca ex PA requires radical surgery alone or radical surgery ± radiation ± chemotherapyEnucleation of PA may lead to morbid recurrence (skin invasion, multiple nodules, nerve twig invasion) requiring more radical surgery ± radiation",
                      "Ca ex PA requires radical surgery alone or radical surgery ± radiation ± chemotherapy",
                      "Enucleation of PA may lead to morbid recurrence (skin invasion, multiple nodules, nerve twig invasion) requiring more radical surgery ± radiation",
                      "Mucoepidermoid carcinoma requires adjuvant therapy for high-stage &/or high-grade tumors",
                      "Adenoid cystic carcinoma excision may be difficult to accomplish due to extensive, deeply permeative perineural invasionRadiation often adjuvantly used to attempt to control local recurrences",
                      "Radiation often adjuvantly used to attempt to control local recurrences",
                      "Mammary analog secretory carcinoma and hyalinizing clear cell carcinoma with rare anaplastic or transformed variant may require radical excision and adjuvant therapy"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Pleomorphic adenomaConventional PA: Local recurrence rate ~ 2% with complete excisionRecurrences often multifocal and difficult to resectRecurrences occur 5-10 years or later after initial excisionBenign metastasizing PA25% death due to diseaseCarcinoma ex PAPrognosis depends on degree of extension beyond periphery of parent PANon- or minimally invasive (<1.5 mm beyond capsule of PA): Excellent prognosis similar to conventional PAInvasion > 1.5 mm beyond capsule: 60% 5-year survival rateWidely invasive Ca ex PA: invasive tumor size and grade also affect prognosisRecent studies suggest early invasion up to 6 mm still confers good prognosis",
                    "sub_points": [
                      "Conventional PA: Local recurrence rate ~ 2% with complete excisionRecurrences often multifocal and difficult to resectRecurrences occur 5-10 years or later after initial excision",
                      "Recurrences often multifocal and difficult to resect",
                      "Recurrences occur 5-10 years or later after initial excision",
                      "Benign metastasizing PA25% death due to disease",
                      "25% death due to disease",
                      "Carcinoma ex PAPrognosis depends on degree of extension beyond periphery of parent PANon- or minimally invasive (<1.5 mm beyond capsule of PA): Excellent prognosis similar to conventional PAInvasion > 1.5 mm beyond capsule: 60% 5-year survival rateWidely invasive Ca ex PA: invasive tumor size and grade also affect prognosisRecent studies suggest early invasion up to 6 mm still confers good prognosis",
                      "Prognosis depends on degree of extension beyond periphery of parent PA",
                      "Non- or minimally invasive (<1.5 mm beyond capsule of PA): Excellent prognosis similar to conventional PA",
                      "Invasion > 1.5 mm beyond capsule: 60% 5-year survival rate",
                      "Widely invasive Ca ex PA: invasive tumor size and grade also affect prognosis",
                      "Recent studies suggest early invasion up to 6 mm still confers good prognosis"
                    ]
                  },
                  {
                    "text": "Mucoepidermoid carcinomaOverall relatively favorable prognosis with ~ 8% death rateHigh-grade tumors behave worseTumors with Ki-67 proliferation index > 10% behave worse",
                    "sub_points": [
                      "Overall relatively favorable prognosis with ~ 8% death rate",
                      "High-grade tumors behave worse",
                      "Tumors with Ki-67 proliferation index > 10% behave worse"
                    ]
                  },
                  {
                    "text": "Adenoid cystic carcinoma5-year survival high, but most patients eventually die of diseaseSolid and anaplastic variants pursue more rapid courseLow rate of regional lymph node metastasis, but confers worse prognosis if present",
                    "sub_points": [
                      "5-year survival high, but most patients eventually die of disease",
                      "Solid and anaplastic variants pursue more rapid course",
                      "Low rate of regional lymph node metastasis, but confers worse prognosis if present"
                    ]
                  },
                  {
                    "text": "Mammary analog secretory carcinomaLow local recurrence rate (10-15%) and low regional lymph node metastasis rate with only rare distant metastasesRare anaplastic/transformed variant behaves more aggressively",
                    "sub_points": [
                      "Low local recurrence rate (10-15%) and low regional lymph node metastasis rate with only rare distant metastases",
                      "Rare anaplastic/transformed variant behaves more aggressively"
                    ]
                  },
                  {
                    "text": "Hyalinizing clear cell carcinomaLow local recurrence rate (15-20%) and low regional lymph node metastasis rate with only rare distant metastasesVery rare anaplastic/transformed variant behaves more aggressively",
                    "sub_points": [
                      "Low local recurrence rate (15-20%) and low regional lymph node metastasis rate with only rare distant metastases",
                      "Very rare anaplastic/transformed variant behaves more aggressively"
                    ]
                  }
                ]
              },
              "MOLECULAR PATHOLOGY": {
                "In Situ Hybridization": [
                  {
                    "text": "Pleomorphic adenomaPLAG1(8q12) andHMGA2gene (12q15) fusions common (found in 66% by FISH)Histology and prognosis: Same for eitherPLAG1orHMGA2fusionsMost common fusion partner forPLAG1isCTNNB1in t(3;8)(p21;q12)Salivary duct carcinoma also shows rearrangement ofPLAG1orHMGA2,which suggests origin in prior pleomorphic adenoma with subsequent tumor transformationPLAG1rearrangements also seen in some myoepithelial tumors of skin/soft tissue",
                    "sub_points": [
                      "PLAG1(8q12) andHMGA2gene (12q15) fusions common (found in 66% by FISH)Histology and prognosis: Same for eitherPLAG1orHMGA2fusionsMost common fusion partner forPLAG1isCTNNB1in t(3;8)(p21;q12)Salivary duct carcinoma also shows rearrangement ofPLAG1orHMGA2,which suggests origin in prior pleomorphic adenoma with subsequent tumor transformationPLAG1rearrangements also seen in some myoepithelial tumors of skin/soft tissue",
                      "Histology and prognosis: Same for eitherPLAG1orHMGA2fusions",
                      "Most common fusion partner forPLAG1isCTNNB1in t(3;8)(p21;q12)",
                      "Salivary duct carcinoma also shows rearrangement ofPLAG1orHMGA2,which suggests origin in prior pleomorphic adenoma with subsequent tumor transformation",
                      "PLAG1rearrangements also seen in some myoepithelial tumors of skin/soft tissue"
                    ]
                  },
                  {
                    "text": "Mucoepidermoid carcinomaCRTC1-MAML2; t(11;19)(q21;p13)May be present in a higher percentage (~ 80%) of low-grade MEC than high grade MEC (~ 50%)High-grade \"MEC\" lacking t(11;19) may represent different tumorCRTC3recently reported as a gene partner withMAML2",
                    "sub_points": [
                      "CRTC1-MAML2; t(11;19)(q21;p13)May be present in a higher percentage (~ 80%) of low-grade MEC than high grade MEC (~ 50%)High-grade \"MEC\" lacking t(11;19) may represent different tumor",
                      "May be present in a higher percentage (~ 80%) of low-grade MEC than high grade MEC (~ 50%)",
                      "High-grade \"MEC\" lacking t(11;19) may represent different tumor",
                      "CRTC3recently reported as a gene partner withMAML2"
                    ]
                  },
                  {
                    "text": "Adenoid cystic carcinomaMYB-NFIB; t(6;9)(q22-23;p23-24)Present in ~ 90% of cases by FISH and RT-PCROther rare fusion gene reported:NFIB-AIG1",
                    "sub_points": [
                      "MYB-NFIB; t(6;9)(q22-23;p23-24)Present in ~ 90% of cases by FISH and RT-PCR",
                      "Present in ~ 90% of cases by FISH and RT-PCR",
                      "Other rare fusion gene reported:NFIB-AIG1"
                    ]
                  },
                  {
                    "text": "Mammary analog secretory carcinomaETV6-NTRK3;(t(12;15)(p13;q25)Other tumors withETV6-NTRK3fusions: Congenital fibrosarcoma, cellular mesoblastic nephroma, and acute myeloid leukemiaETV6break-apart probe can confirm diagnosis in appropriate clinical and histologic contextFISH may not be required for diagnosis in cases with typical histologic and IHC findings",
                    "sub_points": [
                      "ETV6-NTRK3;(t(12;15)(p13;q25)",
                      "Other tumors withETV6-NTRK3fusions: Congenital fibrosarcoma, cellular mesoblastic nephroma, and acute myeloid leukemia",
                      "ETV6break-apart probe can confirm diagnosis in appropriate clinical and histologic contextFISH may not be required for diagnosis in cases with typical histologic and IHC findings",
                      "FISH may not be required for diagnosis in cases with typical histologic and IHC findings"
                    ]
                  },
                  {
                    "text": "Hyalinizing clear cell carcinomaEWSR1-ATF1gene fusion present in ~ 100% of casesFusesEWSR1exon 11 toATF1exon 3Other tumors withEWSR1-ATF1fusions: Clear cell sarcoma, angiomatoid fibrous histiocytomas, and clear cell sarcoma of gastrointestinal tractClear cell ontogenic carcinoma: HasEWSR1-ATF1fusion and is intraosseous variant of HCCCEWSR1break-apart probe commercially available",
                    "sub_points": [
                      "EWSR1-ATF1gene fusion present in ~ 100% of casesFusesEWSR1exon 11 toATF1exon 3Other tumors withEWSR1-ATF1fusions: Clear cell sarcoma, angiomatoid fibrous histiocytomas, and clear cell sarcoma of gastrointestinal tractClear cell ontogenic carcinoma: HasEWSR1-ATF1fusion and is intraosseous variant of HCCC",
                      "FusesEWSR1exon 11 toATF1exon 3",
                      "Other tumors withEWSR1-ATF1fusions: Clear cell sarcoma, angiomatoid fibrous histiocytomas, and clear cell sarcoma of gastrointestinal tract",
                      "Clear cell ontogenic carcinoma: HasEWSR1-ATF1fusion and is intraosseous variant of HCCC",
                      "EWSR1break-apart probe commercially available"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "Pleomorphic adenomaHMGA2gene amplification: More common thanHMGA2gene translocationsMDM2also often amplified",
                    "sub_points": [
                      "HMGA2gene amplification: More common thanHMGA2gene translocationsMDM2also often amplified",
                      "MDM2also often amplified"
                    ]
                  }
                ],
                "Array CGH": [
                  {
                    "text": "Pleomorphic adenomaNormal genomic profile: ~ 60% of cases5 recurrent copy number alterationsLosses: 1pter-p31.3, 6q22.1-q24.3, 8q24.22-q24.3, 13q21.31-q21.33Gain: 9p23-p22.3 (NFIBlocation)Carcinoma ex pleomorphic adenoma: Gain of 22q12.3-qter",
                    "sub_points": [
                      "Normal genomic profile: ~ 60% of cases",
                      "5 recurrent copy number alterationsLosses: 1pter-p31.3, 6q22.1-q24.3, 8q24.22-q24.3, 13q21.31-q21.33Gain: 9p23-p22.3 (NFIBlocation)",
                      "Losses: 1pter-p31.3, 6q22.1-q24.3, 8q24.22-q24.3, 13q21.31-q21.33",
                      "Gain: 9p23-p22.3 (NFIBlocation)",
                      "Carcinoma ex pleomorphic adenoma: Gain of 22q12.3-qter"
                    ]
                  },
                  {
                    "text": "Mucoepidermoid carcinomaGood prognosis: Fusion positive low- or intermediate-grade with no to few genomic imbalancesPoor prognosis: Fusion-positive high-grade ±CDKN2Adeletions and multiple genomic imbalancesAlso poor prognosis: Fusion-negative MEC-like adenocarcinomas with multiple genomic imbalances",
                    "sub_points": [
                      "Good prognosis: Fusion positive low- or intermediate-grade with no to few genomic imbalances",
                      "Poor prognosis: Fusion-positive high-grade ±CDKN2Adeletions and multiple genomic imbalances",
                      "Also poor prognosis: Fusion-negative MEC-like adenocarcinomas with multiple genomic imbalances"
                    ]
                  },
                  {
                    "text": "Adenoid cystic carcinomaRelatively low number of gains/losses with more changes in solid (high-grade) variantLosses (deletions): 1p, 5q, 6q, 9p, 9q, 12q, 13q, 14q, 17p, XpGains: 1p, 8q, 9q, 11q, 16p, 16q, 17q, 19p, 19q, 22q9q, 11q, 19q contain numerous fibroblast growth factors and their receptors",
                    "sub_points": [
                      "Relatively low number of gains/losses with more changes in solid (high-grade) variant",
                      "Losses (deletions): 1p, 5q, 6q, 9p, 9q, 12q, 13q, 14q, 17p, Xp",
                      "Gains: 1p, 8q, 9q, 11q, 16p, 16q, 17q, 19p, 19q, 22q9q, 11q, 19q contain numerous fibroblast growth factors and their receptors",
                      "9q, 11q, 19q contain numerous fibroblast growth factors and their receptors"
                    ]
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "Pleomorphic adenomaFusions and amplifications ofPLAG1andHMGA2found in most cases of PACarcinoma ex pleomorphic adenoma: Retains same genetic abnormality as PA but with additional carcinogenic genetic changes",
                    "sub_points": [
                      "Fusions and amplifications ofPLAG1andHMGA2found in most cases of PA",
                      "Carcinoma ex pleomorphic adenoma: Retains same genetic abnormality as PA but with additional carcinogenic genetic changes"
                    ]
                  },
                  {
                    "text": "Mucoepidermoid carcinomaCRTC1/CRTC3-MAML2fusionsDisrupt Notch signaling pathwayUpregulateEGFRligand, amphiregulin → ↑ cell growth and survivalCDKN2A: Hypermethylated in 35%",
                    "sub_points": [
                      "CRTC1/CRTC3-MAML2fusionsDisrupt Notch signaling pathwayUpregulateEGFRligand, amphiregulin → ↑ cell growth and survival",
                      "Disrupt Notch signaling pathway",
                      "UpregulateEGFRligand, amphiregulin → ↑ cell growth and survival",
                      "CDKN2A: Hypermethylated in 35%"
                    ]
                  },
                  {
                    "text": "Adenoid cystic carcinomaLow exon mutation rate and high diversity of mutationsCell cycle regulatory genes:TP53(especially in high-grade ADCC),CDKN2A(also suppressed by hypermethylation)Other pathways or cell functions mutatedChromatin remodeling genes such as SMARC histones and histone modifiers (35%)FGF-IGF-PI3K pathway (30%; solid histology only)Cell adhesion molecules (30%), Notch signaling pathway (13%)",
                    "sub_points": [
                      "Low exon mutation rate and high diversity of mutations",
                      "Cell cycle regulatory genes:TP53(especially in high-grade ADCC),CDKN2A(also suppressed by hypermethylation)",
                      "Other pathways or cell functions mutatedChromatin remodeling genes such as SMARC histones and histone modifiers (35%)FGF-IGF-PI3K pathway (30%; solid histology only)Cell adhesion molecules (30%), Notch signaling pathway (13%)",
                      "Chromatin remodeling genes such as SMARC histones and histone modifiers (35%)",
                      "FGF-IGF-PI3K pathway (30%; solid histology only)",
                      "Cell adhesion molecules (30%), Notch signaling pathway (13%)"
                    ]
                  },
                  {
                    "text": "Mammary analog secretory carcinomaETV6-NTRK3 fusion protein: Chimeric protein tyrosine kinaseActivates RAS-MAPK pathway and  PI3K-AKT pathway",
                    "sub_points": [
                      "ETV6-NTRK3 fusion protein: Chimeric protein tyrosine kinaseActivates RAS-MAPK pathway and  PI3K-AKT pathway",
                      "Activates RAS-MAPK pathway and  PI3K-AKT pathway"
                    ]
                  },
                  {
                    "text": "Hyalinizing clear cell carcinomaEWSR1-ATF1 fusion protein: Constitutive transcription activatorMay suppressTP53May decrease expression ofSH3RF1",
                    "sub_points": [
                      "EWSR1-ATF1 fusion protein: Constitutive transcription activatorMay suppressTP53May decrease expression ofSH3RF1",
                      "May suppressTP53",
                      "May decrease expression ofSH3RF1"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Adenoid cystic carcinomaMYBoverexpressed in 100% of casesFusion gene product: ↑ MYB transcriptional regulatory activityMYB has at least 80 known target genes involved in cell cycle control, cell survival, proliferation, apoptosis and hemostasisOther overexpressed oncogenes:KIT,SNAI2,EGFR,VEGFA BDNF,NGFUnderexpressed genes:HOXC5,ACVRL1,AQP5,DUSP6,CDH1CDH1hypermethylated in 50%",
                    "sub_points": [
                      "MYBoverexpressed in 100% of casesFusion gene product: ↑ MYB transcriptional regulatory activityMYB has at least 80 known target genes involved in cell cycle control, cell survival, proliferation, apoptosis and hemostasis",
                      "Fusion gene product: ↑ MYB transcriptional regulatory activity",
                      "MYB has at least 80 known target genes involved in cell cycle control, cell survival, proliferation, apoptosis and hemostasis",
                      "Other overexpressed oncogenes:KIT,SNAI2,EGFR,VEGFA BDNF,NGF",
                      "Underexpressed genes:HOXC5,ACVRL1,AQP5,DUSP6,CDH1CDH1hypermethylated in 50%",
                      "CDH1hypermethylated in 50%"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Pleomorphic adenomaHaphazard mix of myoepithelial cells in sheets, strands, loose groups with bilayered ductsMyxoid to chondroid matrix &/or foci of keratinized squamous cellsCarcinoma ex PA shows features similar to typical PA, but also shows tumor cells with characteristics of a specific malignant salivary gland tumor or with nuclear pleomorphism (macronucleoli, coarse chromatin) and increased mitotic rate",
                    "sub_points": [
                      "Haphazard mix of myoepithelial cells in sheets, strands, loose groups with bilayered ducts",
                      "Myxoid to chondroid matrix &/or foci of keratinized squamous cells",
                      "Carcinoma ex PA shows features similar to typical PA, but also shows tumor cells with characteristics of a specific malignant salivary gland tumor or with nuclear pleomorphism (macronucleoli, coarse chromatin) and increased mitotic rate"
                    ]
                  },
                  {
                    "text": "Mucoepidermoid carcinomaVarying amounts of cysts and solid nestsMade of intermediate cells, squamous cells, mucous cells, and clear cellsHigher grade tumors show progressive loss of cysts and mucous cells and increasing nuclear atypia ± necrosis, ± mitoses > 4/10 HPF, ± perineural invasion, ± permeative invasion, ± lymphovascular invasion",
                    "sub_points": [
                      "Varying amounts of cysts and solid nests",
                      "Made of intermediate cells, squamous cells, mucous cells, and clear cells",
                      "Higher grade tumors show progressive loss of cysts and mucous cells and increasing nuclear atypia ± necrosis, ± mitoses > 4/10 HPF, ± perineural invasion, ± permeative invasion, ± lymphovascular invasion"
                    ]
                  },
                  {
                    "text": "Adenoid cystic carcinomaCribriform architecture: Punched-out pattern of myoepithelial cells, intermixed small ducts, and balls of basement membrane matrixHigh-grade tumors: Increasing proportion of solid growth often with increased nuclear atypia, mitotic activity, and apoptosisAnaplastic or transformed variant: Markedly pleomorphic tumor cells combined with lower grade tumor",
                    "sub_points": [
                      "Cribriform architecture: Punched-out pattern of myoepithelial cells, intermixed small ducts, and balls of basement membrane matrix",
                      "High-grade tumors: Increasing proportion of solid growth often with increased nuclear atypia, mitotic activity, and apoptosis",
                      "Anaplastic or transformed variant: Markedly pleomorphic tumor cells combined with lower grade tumor"
                    ]
                  },
                  {
                    "text": "Mammary analog secretory carcinomaLow-grade tumor: Resembles zymogen granule-poor acinic cell carcinomaTubules, microcysts, papillae, less commonly solid growth ± stromal hyalinizationAnaplastic or transformed variant: Markedly pleomorphic tumor cells combined with lower grade tumor",
                    "sub_points": [
                      "Low-grade tumor: Resembles zymogen granule-poor acinic cell carcinomaTubules, microcysts, papillae, less commonly solid growth ± stromal hyalinization",
                      "Tubules, microcysts, papillae, less commonly solid growth ± stromal hyalinization",
                      "Anaplastic or transformed variant: Markedly pleomorphic tumor cells combined with lower grade tumor"
                    ]
                  },
                  {
                    "text": "Hyalinizing clear cell carcinomaAnaplastic or transformed variant: Markedly pleomorphic tumor cells combined with lower grade tumorAll variant histologies at least focally contain clear cellsVariants include cases without hyalinized stroma, basaloid features, reticular pattern, squamous differentiation with keratin pearls, prominent mucinous cellsSheets, nests, trabeculae, cords of eosinophilic and clear cells traversing hyalinized, desmoplastic &/or myxoid stroma",
                    "sub_points": [
                      "Anaplastic or transformed variant: Markedly pleomorphic tumor cells combined with lower grade tumor",
                      "All variant histologies at least focally contain clear cellsVariants include cases without hyalinized stroma, basaloid features, reticular pattern, squamous differentiation with keratin pearls, prominent mucinous cells",
                      "Variants include cases without hyalinized stroma, basaloid features, reticular pattern, squamous differentiation with keratin pearls, prominent mucinous cells",
                      "Sheets, nests, trabeculae, cords of eosinophilic and clear cells traversing hyalinized, desmoplastic &/or myxoid stroma"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Pleomorphic Adenoma": [
                  {
                    "text": "ImmunohistochemistryClassic PA: IHC not usually performed but positive for myoepithelial markers (SMA, S100, GFAP, p63, calponin) and ductal epithelial markersCarcinoma ex pleomorphic adenoma: Higher Ki-67 proliferation rate (~ 35%) compared to PA, TP53 often overexpressed, ERBB2 (HER2) ± overexpressed",
                    "sub_points": [
                      "Classic PA: IHC not usually performed but positive for myoepithelial markers (SMA, S100, GFAP, p63, calponin) and ductal epithelial markers",
                      "Carcinoma ex pleomorphic adenoma: Higher Ki-67 proliferation rate (~ 35%) compared to PA, TP53 often overexpressed, ERBB2 (HER2) ± overexpressed"
                    ]
                  },
                  {
                    "text": "In situ hybridization: Not usually performed"
                  }
                ],
                "Mucoepidermoid Carcinoma": [
                  {
                    "text": "Immunohistochemistry (not usually performed in low-grade tumors)Keratin 7 and TP63 positivep27 (KIP1) expression associated with improved disease-free and overall survival",
                    "sub_points": [
                      "Keratin 7 and TP63 positive",
                      "p27 (KIP1) expression associated with improved disease-free and overall survival"
                    ]
                  },
                  {
                    "text": "In situ hybridizationCRTC1-MAML2;t(11;19)(q21;p13)MAML2FISH break-apart probe commercially available",
                    "sub_points": [
                      "CRTC1-MAML2;t(11;19)(q21;p13)MAML2FISH break-apart probe commercially available",
                      "MAML2FISH break-apart probe commercially available"
                    ]
                  }
                ],
                "Adenoid Cystic Carcinoma": [
                  {
                    "text": "Immunohistochemistry (not usually performed in low-grade tumors)Myoepithelial and ductal epithelial markers: PositiveC-kit: diffuse strong expression in most casesMutations ofKITare rare in ADCCmyb: Diffuse strong expression relatively specific but has low sensitivity for ADCCLoss of E-cadherin expression correlates with poorer clinical outcome",
                    "sub_points": [
                      "Myoepithelial and ductal epithelial markers: Positive",
                      "C-kit: diffuse strong expression in most casesMutations ofKITare rare in ADCC",
                      "Mutations ofKITare rare in ADCC",
                      "myb: Diffuse strong expression relatively specific but has low sensitivity for ADCC",
                      "Loss of E-cadherin expression correlates with poorer clinical outcome"
                    ]
                  },
                  {
                    "text": "In situ hybridizationMYB-NFIB;t(6;9)(q22-23;p23-24)Present in 90% of well-preserved samplesNFIB-AIG1Other rare translocation",
                    "sub_points": [
                      "MYB-NFIB;t(6;9)(q22-23;p23-24)Present in 90% of well-preserved samples",
                      "Present in 90% of well-preserved samples",
                      "NFIB-AIG1Other rare translocation",
                      "Other rare translocation"
                    ]
                  }
                ],
                "Mammary Analog Secretory Carcinoma": [
                  {
                    "text": "ImmunohistochemistryPositive for keratins, S100 protein, vimentin, MUC4, mammaglobinDistinctive histologic features combined with characteristic IHC reactivity allows diagnosis without recourse to FISH",
                    "sub_points": [
                      "Positive for keratins, S100 protein, vimentin, MUC4, mammaglobin",
                      "Distinctive histologic features combined with characteristic IHC reactivity allows diagnosis without recourse to FISH"
                    ]
                  },
                  {
                    "text": "In situ hybridizationETV6-NTRK3;t(12;15)(p13;q25)ETV6break-apart probe commercially available",
                    "sub_points": [
                      "ETV6-NTRK3;t(12;15)(p13;q25)ETV6break-apart probe commercially available",
                      "ETV6break-apart probe commercially available"
                    ]
                  }
                ],
                "Hyalinizing Clear Cell Carcinoma": [
                  {
                    "text": "ImmunohistochemistryPositive for keratins, including keratins 5/6 and p63 if squamous differentiation presentNegative for myoepithelial markers (S100 protein, SMA, calponin) in most cases",
                    "sub_points": [
                      "Positive for keratins, including keratins 5/6 and p63 if squamous differentiation present",
                      "Negative for myoepithelial markers (S100 protein, SMA, calponin) in most cases"
                    ]
                  },
                  {
                    "text": "In situ hybridizationEWSR1-ATF1;t(12;22)(q13;q12)EWSR1break-apart probe commercially available",
                    "sub_points": [
                      "EWSR1-ATF1;t(12;22)(q13;q12)EWSR1break-apart probe commercially available",
                      "EWSR1break-apart probe commercially available"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "DDx for Pleomorphic Adenoma": [
                  {
                    "text": "Myoepithelioma/myoepithelial carcinomaLacks chondroid matrix and ductal differentiation of PA",
                    "sub_points": [
                      "Lacks chondroid matrix and ductal differentiation of PA"
                    ]
                  },
                  {
                    "text": "Carcinoma ex pleomorphic adenomaMore pleomorphic than PA, often with increased mitoses and necrosisSpecific subtypes of salivary carcinoma can also form malignant component",
                    "sub_points": [
                      "More pleomorphic than PA, often with increased mitoses and necrosis",
                      "Specific subtypes of salivary carcinoma can also form malignant component"
                    ]
                  }
                ],
                "DDx for Mucoepidermoid Carcinoma": [
                  {
                    "text": "Necrotizing sialometaplasiaRetains lobular configuration, lacks mucous cells, shows inflamed desmoplastic stromaSquamous pearls common and absent in nearly all MEC",
                    "sub_points": [
                      "Retains lobular configuration, lacks mucous cells, shows inflamed desmoplastic stroma",
                      "Squamous pearls common and absent in nearly all MEC"
                    ]
                  },
                  {
                    "text": "Adenosquamous carcinomaControversial entity: May represent high-grade MEC",
                    "sub_points": [
                      "Controversial entity: May represent high-grade MEC"
                    ]
                  },
                  {
                    "text": "Salivary duct carcinomaCan have mucous cells like MEC but also commonly resembles comedo-type DCIS of breastTypically tumors cells more pleomorphic than MEC cellsAncillary studies such as IHC (positive androgen receptor, often positive ERBB2 [HER2] in salivary duct carcinoma) and negative FISH for t(11;19);CRTC1-MAML2fusion",
                    "sub_points": [
                      "Can have mucous cells like MEC but also commonly resembles comedo-type DCIS of breast",
                      "Typically tumors cells more pleomorphic than MEC cells",
                      "Ancillary studies such as IHC (positive androgen receptor, often positive ERBB2 [HER2] in salivary duct carcinoma) and negative FISH for t(11;19);CRTC1-MAML2fusion"
                    ]
                  },
                  {
                    "text": "Metastatic squamous cell carcinomaUsually much more cytologic atypia than in MECTends to be keratin 7(-)/p63(+) compared to MEC (diffusely CK7[+]/p63[+])FISH for t(11;19) is negative in metastatic squamous cell carcinoma",
                    "sub_points": [
                      "Usually much more cytologic atypia than in MEC",
                      "Tends to be keratin 7(-)/p63(+) compared to MEC (diffusely CK7[+]/p63[+])",
                      "FISH for t(11;19) is negative in metastatic squamous cell carcinoma"
                    ]
                  }
                ],
                "DDx for Adenoid Cystic Carcinoma": [
                  {
                    "text": "Polymorphous low-grade adenocarcinoma (PLGA)Haphazard array of patterns including targetoid, sheets, tubules, cribriformPale vesicular nuclei compared to more hyperchromatic nuclei of ACCFISH for t(6;9);MYB-NFIBfusion is negative in PLGAImmunohistochemistryPositive: S100 protein more diffusely strongly positive in most cases compared to weak patchy in ADCC; C-kit patchier than in most cases of ADCC; diffuse strong MYB expression in some ADCC and absent in PLGA",
                    "sub_points": [
                      "Haphazard array of patterns including targetoid, sheets, tubules, cribriform",
                      "Pale vesicular nuclei compared to more hyperchromatic nuclei of ACC",
                      "FISH for t(6;9);MYB-NFIBfusion is negative in PLGA",
                      "ImmunohistochemistryPositive: S100 protein more diffusely strongly positive in most cases compared to weak patchy in ADCC; C-kit patchier than in most cases of ADCC; diffuse strong MYB expression in some ADCC and absent in PLGA",
                      "Positive: S100 protein more diffusely strongly positive in most cases compared to weak patchy in ADCC; C-kit patchier than in most cases of ADCC; diffuse strong MYB expression in some ADCC and absent in PLGA"
                    ]
                  },
                  {
                    "text": "Basal cell adenoma/adenocarcinomaFISH for t(6;9);MYB-NFIBis negative in basal cell adenoma/adenocarcinomaLacks cribriform pattern found in many ADCC",
                    "sub_points": [
                      "FISH for t(6;9);MYB-NFIBis negative in basal cell adenoma/adenocarcinoma",
                      "Lacks cribriform pattern found in many ADCC"
                    ]
                  },
                  {
                    "text": "Adenocarcinoma, not otherwise specified (NOS), for high-grade ADCCLacks cribriform pattern found focally in some high-grade ADCCFISH for t(6;9);MYB-NFIBfusion is negative in adenocarcinoma, NOS of salivary gland",
                    "sub_points": [
                      "Lacks cribriform pattern found focally in some high-grade ADCC",
                      "FISH for t(6;9);MYB-NFIBfusion is negative in adenocarcinoma, NOS of salivary gland"
                    ]
                  }
                ],
                "DDx for Mammary Analog Secretory Carcinoma": [
                  {
                    "text": "Acinic cell carcinomaFISH is negative for t(12;15);ETV6-NTRK3fusion in acinic cell carcinoma and positive in MASCETV6break-apart probe commercially availableBasophilic cytoplasm due to ↑ number of zymogen granulesImmunohistochemistryNegative: S100 protein, mammaglobin, vimentin, MUC4 as in MASC",
                    "sub_points": [
                      "FISH is negative for t(12;15);ETV6-NTRK3fusion in acinic cell carcinoma and positive in MASCETV6break-apart probe commercially available",
                      "ETV6break-apart probe commercially available",
                      "Basophilic cytoplasm due to ↑ number of zymogen granules",
                      "ImmunohistochemistryNegative: S100 protein, mammaglobin, vimentin, MUC4 as in MASC",
                      "Negative: S100 protein, mammaglobin, vimentin, MUC4 as in MASC"
                    ]
                  },
                  {
                    "text": "Low-grade cribriform cystadenocarcinomaCan mimic MASC by histology and IHCFISH is negative forETV6break-apart probe in low-grade cribriform cystadenocarcinoma",
                    "sub_points": [
                      "Can mimic MASC by histology and IHC",
                      "FISH is negative forETV6break-apart probe in low-grade cribriform cystadenocarcinoma"
                    ]
                  }
                ],
                "DDx for Hyalinizing Clear Cell Carcinoma": [
                  {
                    "text": "Clear cell-containing salivary gland tumorsMay be positive for myoepithelial markers, which are absent in HCCC",
                    "sub_points": [
                      "May be positive for myoepithelial markers, which are absent in HCCC"
                    ]
                  },
                  {
                    "text": "Mucoepidermoid carcinomaUsually lacks prominent hyalinized stromaFISH forEWSR1break-apart probe is positive in HCCCFISH for  t(11;19);CRTC1-MAML2fusion is positive in MEC",
                    "sub_points": [
                      "Usually lacks prominent hyalinized stroma",
                      "FISH forEWSR1break-apart probe is positive in HCCC",
                      "FISH for  t(11;19);CRTC1-MAML2fusion is positive in MEC"
                    ]
                  },
                  {
                    "text": "Metastatic clear cell renal cell carcinomaLacks distinctive architectural patterns found in most cases of HCCCLacks squamous and mucinous cells that are fairly common in HCCCImmunohistochemistryPositive: RCC, vimentin, pax-8 in many cases; negative in HCCCFISH forEWSR1break-apart probe is positive in HCCC and negative in metastatic clear cell RCC",
                    "sub_points": [
                      "Lacks distinctive architectural patterns found in most cases of HCCC",
                      "Lacks squamous and mucinous cells that are fairly common in HCCC",
                      "ImmunohistochemistryPositive: RCC, vimentin, pax-8 in many cases; negative in HCCC",
                      "Positive: RCC, vimentin, pax-8 in many cases; negative in HCCC",
                      "FISH forEWSR1break-apart probe is positive in HCCC and negative in metastatic clear cell RCC"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Specific salivary gland tumor translocations have diagnostic utility, especially in clinically or histologically atypical cases"
                  },
                  {
                    "text": "High-quality biospecimens required to optimize detection of translocations"
                  },
                  {
                    "text": "Additional translocations likely to be found in other salivary gland tumors"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Colorectal Cancer": {
            "name": "Molecular Alterations in Colorectal Cancer",
            "url": "https://app.pathprimer.com/document/120903b6-be9c-47da-89e7-34958dbd56fd/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Molecular subtyping of CRC helps define patient prognosisMSI-H, CRC shows most favorable outcome, regardless ofBRAFstatusMSI-H,BRAF,andKRASwild-type CRC also shows favorable outcomeMSS,BRAF-mutated CRC shows worst prognosisMSI status appears to be the most clinically relevant prognostic molecular marker",
                    "sub_points": [
                      "MSI-H, CRC shows most favorable outcome, regardless ofBRAFstatus",
                      "MSI-H,BRAF,andKRASwild-type CRC also shows favorable outcome",
                      "MSS,BRAF-mutated CRC shows worst prognosis",
                      "MSI status appears to be the most clinically relevant prognostic molecular marker"
                    ]
                  },
                  {
                    "text": "Effectiveness of EGFR inhibition for advanced-stage disease depends on downstream mutationsKRASmutationsconfer resistance to anti-EGFR therapyBRAFandNRASmutationsconfer reduced sensitivity to anti-EGFR therapy",
                    "sub_points": [
                      "KRASmutationsconfer resistance to anti-EGFR therapy",
                      "BRAFandNRASmutationsconfer reduced sensitivity to anti-EGFR therapy"
                    ]
                  }
                ],
                "Molecular Pathology": [
                  {
                    "text": "Sporadic MSI-H CRCMLH1promoter hypermethylated,BRAFmutated",
                    "sub_points": [
                      "MLH1promoter hypermethylated,BRAFmutated"
                    ]
                  },
                  {
                    "text": "LS-associated MSI-H CRCGermline MMR genes mutated,MLH1promoter nonmethylated,BRAFwild type",
                    "sub_points": [
                      "Germline MMR genes mutated,MLH1promoter nonmethylated,BRAFwild type"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Features characteristic of MSI-H CRCMucinous, medullary, poorly differentiated, and signet ring cell phenotypesAbundant tumor-infiltrating lymphocytesCrohn-like peritumoral lymphoid aggregates",
                    "sub_points": [
                      "Mucinous, medullary, poorly differentiated, and signet ring cell phenotypes",
                      "Abundant tumor-infiltrating lymphocytes",
                      "Crohn-like peritumoral lymphoid aggregates"
                    ]
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "LS screening recommended in all patients with newly diagnosed CRC"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Colorectal adenocarcinoma (CRC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Colorectal adenocarcinoma is a malignant epithelial-derived neoplasm of the colonSporadic with chromosomal instability or microsatellite instabilityHereditary with multiple pathways",
                    "sub_points": [
                      "Sporadic with chromosomal instability or microsatellite instability",
                      "Hereditary with multiple pathways"
                    ]
                  },
                  {
                    "text": "Colorectal precancerous lesions are epithelial-derived dysplastic changes that typically present as adenomatous polyps or flat dysplastic lesions"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Chromosomal Instability Pathway": [
                  {
                    "text": "Adenoma-carcinoma sequenceAccount for ~ 60-70% of sporadic CRCInactivationAPCgene(initial mutation)Activating mutations inKRASgene (early event)Mutually exclusiveBRAFmutations in some18q loss of heterozygosityDCCandSMAD4genes mapped to this regionInactivation ofTP53gene",
                    "sub_points": [
                      "Account for ~ 60-70% of sporadic CRC",
                      "InactivationAPCgene(initial mutation)",
                      "Activating mutations inKRASgene (early event)",
                      "Mutually exclusiveBRAFmutations in some",
                      "18q loss of heterozygosityDCCandSMAD4genes mapped to this region",
                      "DCCandSMAD4genes mapped to this region",
                      "Inactivation ofTP53gene"
                    ]
                  }
                ],
                "Sessile Serrated Pathway": [
                  {
                    "text": "CpG island hypermethylation in tumor suppressor genes in sporadic cases"
                  },
                  {
                    "text": "Sessile serrated adenomas are precursor lesions that progress to CRCAccounts for up to 20% of CRCs",
                    "sub_points": [
                      "Accounts for up to 20% of CRCs"
                    ]
                  },
                  {
                    "text": "BRAFV600E mutation in majority of cases"
                  },
                  {
                    "text": "KRASmutations occur, but less commonKRASandBRAFmutations are mutually exclusive",
                    "sub_points": [
                      "KRASandBRAFmutations are mutually exclusive"
                    ]
                  }
                ],
                "Microsatellite Instability Pathway": [
                  {
                    "text": "Seen in both sporadic and hereditary nonpolyposis CRC (Lynch syndrome)"
                  },
                  {
                    "text": "Hypermethylation of promoterMLH1genein sporadic CRC cases leads to mismatch repair (MMR) protein deficiency and subsequent MSI-H CRCResults in loss of MMR via gene silencing",
                    "sub_points": [
                      "Results in loss of MMR via gene silencing"
                    ]
                  },
                  {
                    "text": "Account for ~ 12-15% of CRCs"
                  }
                ],
                "Hereditary CRC": [
                  {
                    "text": "Lynch syndrome (LS)Germline mutation in MMR genes, includingMSH2(50%),MLH1(30-40%),MSH6(7-10%),PMS2(< 5%)2nd-hit somatic mutation leads to MMR deficiency and subsequent MSI-H CRCConventional adenomatous polyps are precursors for LS-associated CRCLacksBRAFmutationsDeletions of 3' end ofEPCAMgene in 1-3% of LSGermlineMSH2mutation analysis usually includes testing forEPCAMdeletions",
                    "sub_points": [
                      "Germline mutation in MMR genes, includingMSH2(50%),MLH1(30-40%),MSH6(7-10%),PMS2(< 5%)",
                      "2nd-hit somatic mutation leads to MMR deficiency and subsequent MSI-H CRC",
                      "Conventional adenomatous polyps are precursors for LS-associated CRC",
                      "LacksBRAFmutations",
                      "Deletions of 3' end ofEPCAMgene in 1-3% of LS",
                      "GermlineMSH2mutation analysis usually includes testing forEPCAMdeletions"
                    ]
                  },
                  {
                    "text": "Serratedpolyposis syndrome (SPS)~ 25-40% risk of development of CRCGenetic alterations similar to serrated pathway CRC",
                    "sub_points": [
                      "~ 25-40% risk of development of CRC",
                      "Genetic alterations similar to serrated pathway CRC"
                    ]
                  },
                  {
                    "text": "Familialadenomatous polyposis (FAP)GermlineAPCmutation with 2nd-hit somatic mutation~ 90-100% risk of developing CRCOften thousands of colonic tubular adenomasAttenuated FAP has < 100 adenomas with ~ 70% risk for development of CRC",
                    "sub_points": [
                      "GermlineAPCmutation with 2nd-hit somatic mutation",
                      "~ 90-100% risk of developing CRC",
                      "Often thousands of colonic tubular adenomas",
                      "Attenuated FAP has < 100 adenomas with ~ 70% risk for development of CRC"
                    ]
                  },
                  {
                    "text": "MUTYH-associated polyposisMUTYHmutations result in heritable predisposition to colon and gastric cancerBiallelic mutations inMUTYHgene with 35-53% risk of CRC in adulthood",
                    "sub_points": [
                      "MUTYHmutations result in heritable predisposition to colon and gastric cancer",
                      "Biallelic mutations inMUTYHgene with 35-53% risk of CRC in adulthood"
                    ]
                  },
                  {
                    "text": "Juvenilepolyposis (JP)Inherited forms have an autosomal dominant patternGermline mutations inSMAD4orBMPR1APolyps appear benign, but patient has ~ 40% risk of developing CRC",
                    "sub_points": [
                      "Inherited forms have an autosomal dominant patternGermline mutations inSMAD4orBMPR1A",
                      "Germline mutations inSMAD4orBMPR1A",
                      "Polyps appear benign, but patient has ~ 40% risk of developing CRC"
                    ]
                  },
                  {
                    "text": "Peutz-Jegherssyndrome (PJS)Autosomal dominant disorder with germline mutations inSTK11gene~ 40% risk of developing CRC",
                    "sub_points": [
                      "Autosomal dominant disorder with germline mutations inSTK11gene",
                      "~ 40% risk of developing CRC"
                    ]
                  },
                  {
                    "text": "PTENhamartoma tumor syndromesGermline mutations inPTENassociated with a variety of syndromes, including Cowden, Bannayan-Riley-Ruvalcaba, and others~ 13-16% risk of developing CRC",
                    "sub_points": [
                      "Germline mutations inPTENassociated with a variety of syndromes, including Cowden, Bannayan-Riley-Ruvalcaba, and others",
                      "~ 13-16% risk of developing CRC"
                    ]
                  }
                ],
                "Environmental Exposure": [
                  {
                    "text": "Western-type dietHighly caloric food, rich in animal fat",
                    "sub_points": [
                      "Highly caloric food, rich in animal fat"
                    ]
                  }
                ],
                "Modifiable Risk Factors": [
                  {
                    "text": "Alcohol"
                  },
                  {
                    "text": "Smoking"
                  },
                  {
                    "text": "Obesity/sedentary lifestyle"
                  }
                ],
                "Chronic Inflammation": [
                  {
                    "text": "Increased incidence in inflammatory bowel disease"
                  }
                ],
                "Inverse Associations": [
                  {
                    "text": "Diet high in fruits, vegetables, and whole grains (high fiber, low fat)"
                  },
                  {
                    "text": "Prolonged use of NSAIDs"
                  },
                  {
                    "text": "Physical activity"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Often asymptomatic, identified on screening"
                  },
                  {
                    "text": "Change in bowel habits"
                  },
                  {
                    "text": "Iron-deficiency anemia (right sided tumors)"
                  },
                  {
                    "text": "Hematochezia (left-sided tumors)"
                  },
                  {
                    "text": "Tenesmus (rectal tumors)"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Surgical resection for stage I tumors"
                  },
                  {
                    "text": "Adjuvant chemotherapy after surgical resection for stage III CRC and high-risk stage II tumors withLymphovascular invasionPerineural invasionPoor differentiationT4 classificationObstructing or perforating tumorInadequate lymph node samplingTumor buddingPositive margins",
                    "sub_points": [
                      "Lymphovascular invasion",
                      "Perineural invasion",
                      "Poor differentiation",
                      "T4 classification",
                      "Obstructing or perforating tumor",
                      "Inadequate lymph node sampling",
                      "Tumor budding",
                      "Positive margins"
                    ]
                  },
                  {
                    "text": "Patients with stage II MSI-H CRC may not benefit from adjuvant 5-fluorouracil (5-FU)-based chemotherapy"
                  },
                  {
                    "text": "Targeted EGFR antibodies in advanced-stage disease with wild-typeKRASgene"
                  },
                  {
                    "text": "Anti-programmed death 1 (PD-1) checkpoint inhibitor (pembrolizumab) therapyMismatch repair-deficient CRC appear responsive to therapeutic blockade of PD-1",
                    "sub_points": [
                      "Mismatch repair-deficient CRC appear responsive to therapeutic blockade of PD-1"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Association of molecular subtypes and patient survivalMSI-H, CRC shows most favorable outcome, regardless ofBRAFstatusMSI-H,BRAF,andKRASwild-type CRC also shows favorable outcomeMSS,BRAF-mutated CRC shows worst prognosis",
                    "sub_points": [
                      "MSI-H, CRC shows most favorable outcome, regardless ofBRAFstatus",
                      "MSI-H,BRAF,andKRASwild-type CRC also shows favorable outcome",
                      "MSS,BRAF-mutated CRC shows worst prognosis"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Exophytic, fungating mass"
                  },
                  {
                    "text": "Annular mass with circumferential mural growth (apple core lesion)"
                  },
                  {
                    "text": "Diffusely infiltrative (least common)"
                  },
                  {
                    "text": "MSI-H and MSS/CpG island methylator phenotype (CIMP) tumors are frequently located in right colon"
                  },
                  {
                    "text": "MSS/non-CIMP tumors are frequently located in left colon"
                  }
                ]
              },
              "MOLECULAR PATHOLOGY": {
                "Sporadic Polyps": [
                  {
                    "text": "Tubular/tubulovillous adenomaPrecursor polyp to conventional CRCInactivatingAPCgene mutationLeads to development of dysplasia in aberrant crypt foci and early adenomasSequential accumulation of mutations inKRAS, DCC, SMAD4,andTP53drives progression to CRC",
                    "sub_points": [
                      "Precursor polyp to conventional CRC",
                      "InactivatingAPCgene mutationLeads to development of dysplasia in aberrant crypt foci and early adenomas",
                      "Leads to development of dysplasia in aberrant crypt foci and early adenomas",
                      "Sequential accumulation of mutations inKRAS, DCC, SMAD4,andTP53drives progression to CRC"
                    ]
                  },
                  {
                    "text": "Sessileserrated adenoma (SSA)Precursor polyp to CIMP, MSI-H CRCInitiatingBRAFmutation in sporadic casesProgressive CpG island hypermethylationMLH1promoter hypermethylation commonly seen with progression to cytologic dysplasiaLoss of MMR proteins results in rapid accumulation of other mutations that drive progression to CRC",
                    "sub_points": [
                      "Precursor polyp to CIMP, MSI-H CRC",
                      "InitiatingBRAFmutation in sporadic cases",
                      "Progressive CpG island hypermethylation",
                      "MLH1promoter hypermethylation commonly seen with progression to cytologic dysplasia",
                      "Loss of MMR proteins results in rapid accumulation of other mutations that drive progression to CRC"
                    ]
                  },
                  {
                    "text": "Traditionalserrated adenoma (TSA)Poorly characterized compared to tubular adenoma and SSAMolecularly diverseMay harborKRASorBRAFmutations, or neitherMay show low or high CIMP, or non-CIMPAssociated withMGMTpromoter methylationTypically do not showMLH1promoter hypermethylation or loss of MLH1 protein expression, and not associated with MSI-H CRCProposed to give rise toBRAF-orKRAS-mutated MSS CRC",
                    "sub_points": [
                      "Poorly characterized compared to tubular adenoma and SSA",
                      "Molecularly diverseMay harborKRASorBRAFmutations, or neitherMay show low or high CIMP, or non-CIMP",
                      "May harborKRASorBRAFmutations, or neither",
                      "May show low or high CIMP, or non-CIMP",
                      "Associated withMGMTpromoter methylation",
                      "Typically do not showMLH1promoter hypermethylation or loss of MLH1 protein expression, and not associated with MSI-H CRC",
                      "Proposed to give rise toBRAF-orKRAS-mutated MSS CRC"
                    ]
                  },
                  {
                    "text": "Microvesicularhyperplastic polypBRAFmutations present in ~ 70%~ 47-73% are CIMP positiveSpeculation that these may be precursors to SSAs",
                    "sub_points": [
                      "BRAFmutations present in ~ 70%",
                      "~ 47-73% are CIMP positive",
                      "Speculation that these may be precursors to SSAs"
                    ]
                  },
                  {
                    "text": "Gobletcell-rich hyperplastic polypHarborKRASmutations in ~ 50%",
                    "sub_points": [
                      "HarborKRASmutations in ~ 50%"
                    ]
                  }
                ],
                "Chromosomal Instability Pathway CRC": [
                  {
                    "text": "KRASmutationsActivating mutations in 40%-50% of CRC85-90% occur in codons 12 and 13Codons 61 and 146 are less commonMutations in codons 12, 13, and 61 render targeted EGFR inhibition ineffectiveKRASmutation testing mandatory for all patients with stage IV CRC who are candidates for anti-EGFR therapyPresence of a mutation precludes treatment with anti-EGFR monoclonal antibodies",
                    "sub_points": [
                      "Activating mutations in 40%-50% of CRC85-90% occur in codons 12 and 13Codons 61 and 146 are less common",
                      "85-90% occur in codons 12 and 13",
                      "Codons 61 and 146 are less common",
                      "Mutations in codons 12, 13, and 61 render targeted EGFR inhibition ineffective",
                      "KRASmutation testing mandatory for all patients with stage IV CRC who are candidates for anti-EGFR therapyPresence of a mutation precludes treatment with anti-EGFR monoclonal antibodies",
                      "Presence of a mutation precludes treatment with anti-EGFR monoclonal antibodies"
                    ]
                  },
                  {
                    "text": "BRAFmutationsMutually exclusive ofKRASmutationAssociated with reduced response toanti-EGFR targeted therapyIndicates poor prognosis in MSS or MSI-L CRC, but has no prognostic impact on MSI-H tumors",
                    "sub_points": [
                      "Mutually exclusive ofKRASmutation",
                      "Associated with reduced response toanti-EGFR targeted therapy",
                      "Indicates poor prognosis in MSS or MSI-L CRC, but has no prognostic impact on MSI-H tumors"
                    ]
                  },
                  {
                    "text": "NRASmutationsActivating mutations in 1-6% of CRCMajority occur in codons 12 and 13Reduced response to EGFR blockadeNRAStesting is recommended by NCCN",
                    "sub_points": [
                      "Activating mutations in 1-6% of CRCMajority occur in codons 12 and 13",
                      "Majority occur in codons 12 and 13",
                      "Reduced response to EGFR blockade",
                      "NRAStesting is recommended by NCCN"
                    ]
                  },
                  {
                    "text": "PIK3CAActivating mutations in 10-30% of all CRCsOccur in exons 1, 2, 9, and 20 (9 and 20 are most common)Unclear whether mutations are of prognostic significance, though poor survival reported in resectable stage I-III CRCNot mutually exclusive ofKRASorBRAFmutationsAdverse effect potentially limited toKRASwild-type CRCClinical effect ofPIK3CAmutations on response to anti-EGFR therapy has shown conflicting results",
                    "sub_points": [
                      "Activating mutations in 10-30% of all CRCsOccur in exons 1, 2, 9, and 20 (9 and 20 are most common)",
                      "Occur in exons 1, 2, 9, and 20 (9 and 20 are most common)",
                      "Unclear whether mutations are of prognostic significance, though poor survival reported in resectable stage I-III CRC",
                      "Not mutually exclusive ofKRASorBRAFmutationsAdverse effect potentially limited toKRASwild-type CRC",
                      "Adverse effect potentially limited toKRASwild-type CRC",
                      "Clinical effect ofPIK3CAmutations on response to anti-EGFR therapy has shown conflicting results"
                    ]
                  }
                ],
                "MSI Pathway CRC": [
                  {
                    "text": "MSI testing by PCRUsed as a screening test for Lynch syndrome (LS)Also used for prognostication in sporadic CRCIs an alternative test to MMR protein testing by IHCLaboratories may choose either or both as a first-line screening testMSI-H≥ 30% of the National Cancer Institute (NCI)-designated microsatellite markers (3 dinucleotide and 2 mononucleotide repeats) show instabilityMononucleotide markers have a higher sensitivity and specificity than dinucleotide markersMSI-L< 30% of NCI or commercially available mononucleotide markers show instability",
                    "sub_points": [
                      "Used as a screening test for Lynch syndrome (LS)",
                      "Also used for prognostication in sporadic CRC",
                      "Is an alternative test to MMR protein testing by IHC",
                      "Laboratories may choose either or both as a first-line screening test",
                      "MSI-H≥ 30% of the National Cancer Institute (NCI)-designated microsatellite markers (3 dinucleotide and 2 mononucleotide repeats) show instabilityMononucleotide markers have a higher sensitivity and specificity than dinucleotide markers",
                      "≥ 30% of the National Cancer Institute (NCI)-designated microsatellite markers (3 dinucleotide and 2 mononucleotide repeats) show instability",
                      "Mononucleotide markers have a higher sensitivity and specificity than dinucleotide markers",
                      "MSI-L< 30% of NCI or commercially available mononucleotide markers show instability",
                      "< 30% of NCI or commercially available mononucleotide markers show instability"
                    ]
                  },
                  {
                    "text": "MLH1gene promoter methylation assayReflexive test performed if CRC is MSI-H &/or IHC shows MMR protein lossPresence ofMLH1promoter hypermethylation indicatesMLH1gene silencingTypically seen in MSI-H sporadic CRCLack of significant promoter methylation suggests germline mutations in MMR genesTypically seen in Lynch syndromeReflexive test in MSI-H tumors to differentiate sporadic vs LS-associated CRC",
                    "sub_points": [
                      "Reflexive test performed if CRC is MSI-H &/or IHC shows MMR protein loss",
                      "Presence ofMLH1promoter hypermethylation indicatesMLH1gene silencingTypically seen in MSI-H sporadic CRC",
                      "Typically seen in MSI-H sporadic CRC",
                      "Lack of significant promoter methylation suggests germline mutations in MMR genesTypically seen in Lynch syndrome",
                      "Typically seen in Lynch syndrome",
                      "Reflexive test in MSI-H tumors to differentiate sporadic vs LS-associated CRC"
                    ]
                  },
                  {
                    "text": "ReflexiveBRAFtesting in MSI-H CRCPresence ofBRAFmutation indicates a sporadic tumorLess sensitive thanMLH1promoter methylation assay",
                    "sub_points": [
                      "Presence ofBRAFmutation indicates a sporadic tumor",
                      "Less sensitive thanMLH1promoter methylation assay"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Conventional CRCMost are well- to moderately differentiated glandular tumors~ 15% are poorly differentiated and may grow in solid massesGrowth patterns include expansile and infiltrative",
                    "sub_points": [
                      "Most are well- to moderately differentiated glandular tumors",
                      "~ 15% are poorly differentiated and may grow in solid masses",
                      "Growth patterns include expansile and infiltrative"
                    ]
                  },
                  {
                    "text": "Microscopic features characteristic of MSI-H CRCMucinous, medullary, poorly differentiated, and signet ring cell phenotypesIntratumoral morphologic heterogeneity (mixed phenotypes)Abundant tumor-infiltrating lymphocytesCrohn-like peritumoral lymphoid aggregates",
                    "sub_points": [
                      "Mucinous, medullary, poorly differentiated, and signet ring cell phenotypes",
                      "Intratumoral morphologic heterogeneity (mixed phenotypes)",
                      "Abundant tumor-infiltrating lymphocytes",
                      "Crohn-like peritumoral lymphoid aggregates"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "MMRprotein expression in CRCImmunohistochemical stains show intact nuclear expression of MLH1, PMS2, MSH2, and MSH6 in MMR-proficient tumorsNegative staining with positive internal control (mononuclear cells and stomal cells) indicates MMR deficiencyNegative staining with negative internal control is uninterpretable (repeat IHC)Mutated or methylatedMLH1leads to loss of MLH1 and PMS2 nuclear expression, but not vice versa for mutatedPMS2MutatedMSH2leads to loss of MSH2 and MSH6 nuclear expression, but not vice versa for mutatedMSH6Lack of MLH1 expression cannot differentiate LS-associated CRC from sporadic CRCBRAFmutation analysis &/orMLH1hypermethylation testing is necessary to make this distinctionLack of MSH2, MSH6, or isolated PMS2 expression is usually associated with LS-associated CRCGenetic counseling with targeted germline mutation testing is indicated~ 30-60% of patients with loss of MSH2 expression may have biallelic somatic mutations (not LS)False-positive loss of MSH6 expression can occur in neoadjuvant-treated CRCRepeat IHC on pretreatment diagnostic biopsy",
                    "sub_points": [
                      "Immunohistochemical stains show intact nuclear expression of MLH1, PMS2, MSH2, and MSH6 in MMR-proficient tumors",
                      "Negative staining with positive internal control (mononuclear cells and stomal cells) indicates MMR deficiency",
                      "Negative staining with negative internal control is uninterpretable (repeat IHC)Mutated or methylatedMLH1leads to loss of MLH1 and PMS2 nuclear expression, but not vice versa for mutatedPMS2MutatedMSH2leads to loss of MSH2 and MSH6 nuclear expression, but not vice versa for mutatedMSH6",
                      "Mutated or methylatedMLH1leads to loss of MLH1 and PMS2 nuclear expression, but not vice versa for mutatedPMS2",
                      "MutatedMSH2leads to loss of MSH2 and MSH6 nuclear expression, but not vice versa for mutatedMSH6",
                      "Lack of MLH1 expression cannot differentiate LS-associated CRC from sporadic CRCBRAFmutation analysis &/orMLH1hypermethylation testing is necessary to make this distinction",
                      "BRAFmutation analysis &/orMLH1hypermethylation testing is necessary to make this distinction",
                      "Lack of MSH2, MSH6, or isolated PMS2 expression is usually associated with LS-associated CRCGenetic counseling with targeted germline mutation testing is indicated~ 30-60% of patients with loss of MSH2 expression may have biallelic somatic mutations (not LS)",
                      "Genetic counseling with targeted germline mutation testing is indicated",
                      "~ 30-60% of patients with loss of MSH2 expression may have biallelic somatic mutations (not LS)",
                      "False-positive loss of MSH6 expression can occur in neoadjuvant-treated CRCRepeat IHC on pretreatment diagnostic biopsy",
                      "Repeat IHC on pretreatment diagnostic biopsy"
                    ]
                  },
                  {
                    "text": "MMRprotein expression in adenomasLost MMR proteins can identify potential LS patientsIntact MMR proteins cannot be used to exclude LS in an individual patientSome LS derived adenomas will not have acquired the 2nd-hit somatic mutation and will thus show intact MMR protein expression",
                    "sub_points": [
                      "Lost MMR proteins can identify potential LS patients",
                      "Intact MMR proteins cannot be used to exclude LS in an individual patientSome LS derived adenomas will not have acquired the 2nd-hit somatic mutation and will thus show intact MMR protein expression",
                      "Some LS derived adenomas will not have acquired the 2nd-hit somatic mutation and will thus show intact MMR protein expression"
                    ]
                  },
                  {
                    "text": "BRAFV600E mutation-specific antibodyAlternative to molecular testing, with good sensitivity and specificityCannot detect other variant mutations in codon 600",
                    "sub_points": [
                      "Alternative to molecular testing, with good sensitivity and specificity",
                      "Cannot detect other variant mutations in codon 600"
                    ]
                  },
                  {
                    "text": "EGFRIHC can demonstrate EGFR overexpression but does not predict response to anti-EGFR therapyNot useful in clinical practice",
                    "sub_points": [
                      "IHC can demonstrate EGFR overexpression but does not predict response to anti-EGFR therapy",
                      "Not useful in clinical practice"
                    ]
                  },
                  {
                    "text": "PTENLoss of PTEN protein expression may predict lack of response to anti-EGFR therapy in metastaticKRASwild-type tumorsNo recommendations at this time for routine analysis of PTEN protein expression",
                    "sub_points": [
                      "Loss of PTEN protein expression may predict lack of response to anti-EGFR therapy in metastaticKRASwild-type tumors",
                      "No recommendations at this time for routine analysis of PTEN protein expression"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Metastatic Carcinomas": [
                  {
                    "text": "May be confused with primary CRC"
                  },
                  {
                    "text": "Lack or only weakly express CRC markers such as CK20, CDX2, and SATB2"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "LS Screening Recommendations": [
                  {
                    "text": "Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommends screening all patients with newly diagnosed CRCRevised Bethesda criteria may miss up to 25% of LS patientsMSI PCR has an 80-90% sensitivity for identifying LSMMR IHC has an 85% sensitivity for identifying LSNear 100% sensitivity for combined MSI PCR and MMR IHC testingMLH1promoter hypermethylation testing &/orBRAFmutation analysis help to differentiate possible LS from sporadic MSI-H CRCGenetic counseling is crucial in all suspected LS cases",
                    "sub_points": [
                      "Revised Bethesda criteria may miss up to 25% of LS patients",
                      "MSI PCR has an 80-90% sensitivity for identifying LS",
                      "MMR IHC has an 85% sensitivity for identifying LS",
                      "Near 100% sensitivity for combined MSI PCR and MMR IHC testing",
                      "MLH1promoter hypermethylation testing &/orBRAFmutation analysis help to differentiate possible LS from sporadic MSI-H CRC",
                      "Genetic counseling is crucial in all suspected LS cases"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Gastrointestinal Stromal Tumors (GIST)": {
            "name": "Molecular Alterations in Gastrointestinal Stromal Tumors (GIST)",
            "url": "https://app.pathprimer.com/document/e2f1ee15-f7ad-4554-b5d8-7c1271b9fab1/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Mesenchymal tumor of GI tract with characteristic histologic, immunohistochemical, and molecular featuresSpindle cellsEpithelioid cellsCD117 &/or DOG1 positivityKIT,PDGFRA, SDH complex, orBRAFmutations",
                    "sub_points": [
                      "Spindle cells",
                      "Epithelioid cells",
                      "CD117 &/or DOG1 positivity",
                      "KIT,PDGFRA, SDH complex, orBRAFmutations"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Tumor behavior is primarily determined by location, size, and mitotic rate"
                  },
                  {
                    "text": "Specific mutations render important information regarding response to imatinib"
                  }
                ],
                "Molecular Pathology": [
                  {
                    "text": "Morphologic-molecular associationsSpindle cell GIST is typicallyKITmutatedAdult gastric epithelioid GIST =PDGFRAmutatedPediatric gastric epithelioid GIST = SDH deficient",
                    "sub_points": [
                      "Spindle cell GIST is typicallyKITmutated",
                      "Adult gastric epithelioid GIST =PDGFRAmutated",
                      "Pediatric gastric epithelioid GIST = SDH deficient"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CD117 plus DOG1 immunohistochemical stains capture nearly 100% of GISTs"
                  },
                  {
                    "text": "Molecular testing combined with clinicopathologic features provides comprehensive prognostic information"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Other mural-based mesenchymal tumorsSchwannomaSmooth muscle tumorsGlomus tumorClear cell sarcoma-like tumor of GI tract",
                    "sub_points": [
                      "Schwannoma",
                      "Smooth muscle tumors",
                      "Glomus tumor",
                      "Clear cell sarcoma-like tumor of GI tract"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Gastrointestinal stromal tumor (GIST)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Gastrointestinal leiomyoma/leiomyoblastoma, gastrointestinal autonomic nerve tumor (GANT)Used in older literature but are no longer considered accurate terminology",
                    "sub_points": [
                      "Used in older literature but are no longer considered accurate terminology"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "Mural-based mesenchymal tumor of gastrointestinal (GI) tract with characteristic histologic, immunohistochemical, and molecular featuresComposed of spindled &/or epithelioid cellsCD117 &/or DOG1 immunohistochemical positivity",
                    "sub_points": [
                      "Composed of spindled &/or epithelioid cells",
                      "CD117 &/or DOG1 immunohistochemical positivity"
                    ]
                  },
                  {
                    "text": "85-90% driven by mutually exclusiveKITorPDGFRAmutationsVast majority are sporadicRare autosomal dominant germlineKITor, less commonly,PDGFRAmutations define hereditary GIST syndrome< 25 families reported in literature",
                    "sub_points": [
                      "Vast majority are sporadic",
                      "Rare autosomal dominant germlineKITor, less commonly,PDGFRAmutations define hereditary GIST syndrome< 25 families reported in literature",
                      "< 25 families reported in literature"
                    ]
                  },
                  {
                    "text": "KITandPDGFRAwild-type GISTsMost demonstrate lack of function of succinate dehydrogenase (SDH) complex (SDH-deficient GISTs)Comprise 7.5% of all gastric GISTsMajority are sporadic and thus occur in absence of known syndrome10-20% are seen in Carney-Stratakis syndrome and Carney triadSmall subset withBRAFV600E mutationComprise 7-13% of all wild-type GISTs in stomach and small intestineFew wild-type GISTs arise in patients with neurofibromatosis type 1 (NF1)Constitute 1-2% of all GISTs",
                    "sub_points": [
                      "Most demonstrate lack of function of succinate dehydrogenase (SDH) complex (SDH-deficient GISTs)Comprise 7.5% of all gastric GISTsMajority are sporadic and thus occur in absence of known syndrome10-20% are seen in Carney-Stratakis syndrome and Carney triad",
                      "Comprise 7.5% of all gastric GISTs",
                      "Majority are sporadic and thus occur in absence of known syndrome",
                      "10-20% are seen in Carney-Stratakis syndrome and Carney triad",
                      "Small subset withBRAFV600E mutationComprise 7-13% of all wild-type GISTs in stomach and small intestine",
                      "Comprise 7-13% of all wild-type GISTs in stomach and small intestine",
                      "Few wild-type GISTs arise in patients with neurofibromatosis type 1 (NF1)Constitute 1-2% of all GISTs",
                      "Constitute 1-2% of all GISTs"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Most common GI mesenchymal neoplasm"
                  },
                  {
                    "text": "10-20 per million annually"
                  },
                  {
                    "text": "Subclinical GIST more commonUp to 25% incidence of small incidental gastric GISTs at autopsy",
                    "sub_points": [
                      "Up to 25% incidence of small incidental gastric GISTs at autopsy"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Older adults forKITandPDGFRA-mutated GISTs (median age: 60-65 years)"
                  },
                  {
                    "text": "Young adults and children for SDH-deficient GISTsNearly all gastric GISTs in patients < 21 years old are SDH deficient",
                    "sub_points": [
                      "Nearly all gastric GISTs in patients < 21 years old are SDH deficient"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "No gender preference for adult GISTs"
                  },
                  {
                    "text": "Strong female predilection for pediatric SDH-deficient GISTs"
                  }
                ],
                "Site": [
                  {
                    "text": "Stomach: ~ 60%"
                  },
                  {
                    "text": "Jejunum/ileum: ~ 30%"
                  },
                  {
                    "text": "Duodenum: ~ 5%"
                  },
                  {
                    "text": "Rectum: < 5%"
                  },
                  {
                    "text": "Very rare in esophagus and appendix"
                  }
                ],
                "Presentation": [
                  {
                    "text": "No specific symptomsGastric discomfortObstructionGI bleeding",
                    "sub_points": [
                      "Gastric discomfort",
                      "Obstruction",
                      "GI bleeding"
                    ]
                  }
                ],
                "Endoscopic Findings": [
                  {
                    "text": "Round mural non-mucosal-based mass"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Wedge resection for single gastric GIST < 5 cm"
                  },
                  {
                    "text": "Distal gastrectomy for large GISTs involving pylorus or lesser curvature"
                  },
                  {
                    "text": "Total gastrectomy for very large, multiple, or recurrent GISTs"
                  },
                  {
                    "text": "Segmental resection for intestinal GISTs"
                  },
                  {
                    "text": "Risk of peritoneal seeding with extensive tumor manipulation and rupture"
                  }
                ],
                "Drugs": [
                  {
                    "text": "Imatinib (Gleevec)Tumor response depends on specific mutationInhibits receptor tyrosine kinases including KITFirst-line drug of choice to prevent recurrence in high risk resected tumorsNeoadjuvant treatment to shrink tumor prior to surgeryAcquired resistance may occur due to secondary resistance-associated mutations",
                    "sub_points": [
                      "Tumor response depends on specific mutation",
                      "Inhibits receptor tyrosine kinases including KIT",
                      "First-line drug of choice to prevent recurrence in high risk resected tumors",
                      "Neoadjuvant treatment to shrink tumor prior to surgery",
                      "Acquired resistance may occur due to secondary resistance-associated mutations"
                    ]
                  },
                  {
                    "text": "2nd generation tyrosine kinase inhibitorsSunitinib, regorafenib, sorafenib, among othersMultikinase inhibitors, which act on other tyrosine kinases such as VEGFRA in addition to PDGFRA and KITUsed to overcome imatinib resistance",
                    "sub_points": [
                      "Sunitinib, regorafenib, sorafenib, among others",
                      "Multikinase inhibitors, which act on other tyrosine kinases such as VEGFRA in addition to PDGFRA and KIT",
                      "Used to overcome imatinib resistance"
                    ]
                  },
                  {
                    "text": "Other drugs under investigationMTOR inhibitorsHeat shock protein inhibitorsKIT transcriptional antagonists",
                    "sub_points": [
                      "MTOR inhibitors",
                      "Heat shock protein inhibitors",
                      "KIT transcriptional antagonists"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Site specific, primarily related to tumor size and mitotic rate per 50 high power fields forKIT-andPDGFRA-mutated GISTs"
                  },
                  {
                    "text": "Less aggressive behavior is seen inGastric GISTsPDGFRA-mutated GISTs",
                    "sub_points": [
                      "Gastric GISTs",
                      "PDGFRA-mutated GISTs"
                    ]
                  },
                  {
                    "text": "SDH-deficient GISTs are much less predictable thanKIT-mutated GISTs with same prognostic factorsLifelong follow-up required due to 20-25% risk of liver metastases and risk of developing other syndrome-related tumorsLonger survival with metastatic disease compared toKIT-mutated GISTTendency toward lymph node metastases (up to 10%) compared to other GISTs, though this does not adversely affect prognosisMore prone to recurrence compared toKITandPDGFRA-mutated GIST",
                    "sub_points": [
                      "Lifelong follow-up required due to 20-25% risk of liver metastases and risk of developing other syndrome-related tumors",
                      "Longer survival with metastatic disease compared toKIT-mutated GIST",
                      "Tendency toward lymph node metastases (up to 10%) compared to other GISTs, though this does not adversely affect prognosis",
                      "More prone to recurrence compared toKITandPDGFRA-mutated GIST"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "MR Findings": [
                  {
                    "text": "T1 weightedLow signal intensity in solid componentGadolinium enhancement occurs, usually at tumor periphery",
                    "sub_points": [
                      "Low signal intensity in solid component",
                      "Gadolinium enhancement occurs, usually at tumor periphery"
                    ]
                  },
                  {
                    "text": "T2 weightedHigh signal intensity in solid component",
                    "sub_points": [
                      "High signal intensity in solid component"
                    ]
                  }
                ],
                "CT Findings": [
                  {
                    "text": "Peripheral contrast enhancement most common"
                  },
                  {
                    "text": "Homogeneous enhancement uncommon"
                  },
                  {
                    "text": "Central low attenuation corresponds to hemorrhage and necrosis"
                  },
                  {
                    "text": "Rare calcification"
                  }
                ],
                "Endoscopic Ultrasound": [
                  {
                    "text": "Muscularis propria-based tumor"
                  },
                  {
                    "text": "Homogeneous hypoechoic round lesion with smooth margins"
                  },
                  {
                    "text": "Heterogeneity, cystic spaces, irregular borders, and size > 3 cm more common in aggressive tumors"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Well-defined round to oval tumor with its epicenter in muscularis propria"
                  },
                  {
                    "text": "Firm to fleshy or gelatinous cut surface"
                  },
                  {
                    "text": "Hemorrhage and cystic degeneration in large tumors"
                  },
                  {
                    "text": "Tumor necrosis uncommon (poor prognostic factor)"
                  }
                ]
              },
              "MOLECULAR PATHOLOGY": {
                "KITMutations": [
                  {
                    "text": "Relative frequency 75-80%"
                  },
                  {
                    "text": "Exon 11Highest imatinib response rateFound in 70% of GISTsCommon in gastric GISTMutations include deletions, insertions, and substitutionsIsolated inframe deletions most common and usually involve 5' end between codons 550-560558-559 deletions associated with aggressive behavior compared to other exon 11 mutations in gastric GISTPoint mutations usually associated with benign behaviorProbability of primary resistance (defined as tumor progression within first 6 months) to imatinib is ~ 5%",
                    "sub_points": [
                      "Highest imatinib response rate",
                      "Found in 70% of GISTsCommon in gastric GIST",
                      "Common in gastric GIST",
                      "Mutations include deletions, insertions, and substitutions",
                      "Isolated inframe deletions most common and usually involve 5' end between codons 550-560558-559 deletions associated with aggressive behavior compared to other exon 11 mutations in gastric GIST",
                      "558-559 deletions associated with aggressive behavior compared to other exon 11 mutations in gastric GIST",
                      "Point mutations usually associated with benign behavior",
                      "Probability of primary resistance (defined as tumor progression within first 6 months) to imatinib is ~ 5%"
                    ]
                  },
                  {
                    "text": "Exon 9Found in 7-10% of GISTs, more common in jejunum/ileum6 bp insertion/duplication of AY residues encoded by codons 502-503, most commonProbability of primary resistance is ~ 16%Shorter progression-free and overall survival compared to imatinib-treated exon 11-mutated GISTsMore responsive to treatment with sunitinib",
                    "sub_points": [
                      "Found in 7-10% of GISTs, more common in jejunum/ileum",
                      "6 bp insertion/duplication of AY residues encoded by codons 502-503, most common",
                      "Probability of primary resistance is ~ 16%",
                      "Shorter progression-free and overall survival compared to imatinib-treated exon 11-mutated GISTs",
                      "More responsive to treatment with sunitinib"
                    ]
                  },
                  {
                    "text": "Exon 13 and 17Each found in ~ 1% of GISTsPoint mutations most commonCodon 642 in exon 13Codon 822 in exon 17Exon 13 mutations may indicate poor prognosis in gastric GISTsNo prognostic significance for exon 17 mutationsVariably sensitive to imatinib",
                    "sub_points": [
                      "Each found in ~ 1% of GISTs",
                      "Point mutations most commonCodon 642 in exon 13Codon 822 in exon 17",
                      "Codon 642 in exon 13",
                      "Codon 822 in exon 17",
                      "Exon 13 mutations may indicate poor prognosis in gastric GISTs",
                      "No prognostic significance for exon 17 mutations",
                      "Variably sensitive to imatinib"
                    ]
                  }
                ],
                "PDGFRAMutations": [
                  {
                    "text": "Relative frequency ~ 10%"
                  },
                  {
                    "text": "Lower malignant potential thanKIT-mutated GISTs"
                  },
                  {
                    "text": "No significant prognostic differences among differentPDGFRAmutations"
                  },
                  {
                    "text": "Exon 18D842V most commonPDGFRAmutationFound in 5% of GISTsStrongly resistant to imatinib",
                    "sub_points": [
                      "D842V most commonPDGFRAmutation",
                      "Found in 5% of GISTs",
                      "Strongly resistant to imatinib"
                    ]
                  },
                  {
                    "text": "Other exon 18 mutations (deletions and substitutions) uncommonFound in 1% of GISTsVariable mutation-specific response to imatinib",
                    "sub_points": [
                      "Found in 1% of GISTs",
                      "Variable mutation-specific response to imatinib"
                    ]
                  },
                  {
                    "text": "Exon 12V561D common, followed by insertions and deletionsFound in 1% of GISTsMost respond to imatinib",
                    "sub_points": [
                      "V561D common, followed by insertions and deletions",
                      "Found in 1% of GISTs",
                      "Most respond to imatinib"
                    ]
                  },
                  {
                    "text": "Exon 14N659K commonFound in < 1% of GISTsNo data on imatinib response",
                    "sub_points": [
                      "N659K common",
                      "Found in < 1% of GISTs",
                      "No data on imatinib response"
                    ]
                  }
                ],
                "SDH Deficiency": [
                  {
                    "text": "SDH complex consists of 4 subunits: SDHA, SDHB, SDHC, and SDHD, which are encoded by their similarly named genes"
                  },
                  {
                    "text": "Estimated that at least half of SDH-deficient GISTs contain SDH subunit mutationsRemainder may harbor undetected mutations, epigenetic alterations, or mutations in genes encoding other cofactor proteinsMutations include frameshift deletions, missense, nonsense, and splice-site mutationsNo significant prognostic differences among various SDH mutations",
                    "sub_points": [
                      "Remainder may harbor undetected mutations, epigenetic alterations, or mutations in genes encoding other cofactor proteins",
                      "Mutations include frameshift deletions, missense, nonsense, and splice-site mutations",
                      "No significant prognostic differences among various SDH mutations"
                    ]
                  },
                  {
                    "text": "SDHAis the most commonly mutated subunit with estimated frequency of 28%Usually germline mutationsSo far, not associated with familial tumor syndromesOccurs in older patients (median age: 34 years) with lower disease penetrance",
                    "sub_points": [
                      "Usually germline mutations",
                      "So far, not associated with familial tumor syndromes",
                      "Occurs in older patients (median age: 34 years) with lower disease penetrance"
                    ]
                  },
                  {
                    "text": "SDHB,SDHC, andSDHDsubunit mutations are less frequent, estimated at 20-30%Usually germline mutations",
                    "sub_points": [
                      "Usually germline mutations"
                    ]
                  },
                  {
                    "text": "Most SDH-deficient GISTs are not associated with a known syndrome"
                  },
                  {
                    "text": "10-20% are associated with Carney triad or Carney-Stratakis syndromeCarney triad defined by SDH-deficient GIST, no SDH gene mutations, and paraganglioma plus pulmonary chondromaMechanism of SDH deficiency in Carney triad related GIST is unknownCarney-Stratakis syndrome defined bySDHB,SDHC, orSDHDgermline mutations with GIST plus paraganglioma",
                    "sub_points": [
                      "Carney triad defined by SDH-deficient GIST, no SDH gene mutations, and paraganglioma plus pulmonary chondromaMechanism of SDH deficiency in Carney triad related GIST is unknown",
                      "Mechanism of SDH deficiency in Carney triad related GIST is unknown",
                      "Carney-Stratakis syndrome defined bySDHB,SDHC, orSDHDgermline mutations with GIST plus paraganglioma"
                    ]
                  },
                  {
                    "text": "Resistant to imatinib"
                  },
                  {
                    "text": "Potentially better efficacy with 2nd and 3rd generation tyrosine kinase inhibitors with anti-VEGFRA activity"
                  }
                ],
                "BRAFV600E Mutation": [
                  {
                    "text": "Prognostic significance still unclear"
                  },
                  {
                    "text": "May be candidate for therapy with BRAF-targeted drugs"
                  }
                ],
                "Secondary Mutations": [
                  {
                    "text": "Lead to development of imatinib resistance (secondary resistance-associated mutations)"
                  },
                  {
                    "text": "Secondary resistance defined as tumor progression after 12-36 months following period of good response or stable disease"
                  },
                  {
                    "text": "Reported in 44-83% of GISTs progressing after imatinib treatment"
                  },
                  {
                    "text": "KITexons 13, 14, 17, and 18 are common targets"
                  },
                  {
                    "text": "Sunitinib effective against secondary exon 13 and 14 mutations but not exon 17 and 18 mutations"
                  },
                  {
                    "text": "SecondaryPDGFRAmutations (usually in exons 14 and 18) less frequent"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features Indicating Aggressive Behavior for All GISTs": [
                  {
                    "text": "High mitotic rate"
                  },
                  {
                    "text": "Tumor necrosis"
                  },
                  {
                    "text": "Hypercellularity and sarcomatous appearanceEpithelioid sarcomatous tumors have a slightly better prognosis than their spindle cell counterparts",
                    "sub_points": [
                      "Epithelioid sarcomatous tumors have a slightly better prognosis than their spindle cell counterparts"
                    ]
                  },
                  {
                    "text": "Tumor extension into mucosa"
                  }
                ],
                "KIT-Mutated GIST": [
                  {
                    "text": "Spindle cell type most common; epithelioid and mixed types also occur"
                  },
                  {
                    "text": "Spindle cells arranged in fascicles or nodules"
                  },
                  {
                    "text": "Eosinophilic cytoplasm"
                  },
                  {
                    "text": "Elongated nuclei with vesicular chromatin and inconspicuous nucleoli"
                  },
                  {
                    "text": "Paranuclear vacuoles (diagnostically useful artifact of fixation)"
                  },
                  {
                    "text": "Nuclear palisades in gastric tumors"
                  },
                  {
                    "text": "Skeinoid fibers in benign small intestinal tumors"
                  }
                ],
                "PDGFRA-Mutated GIST": [
                  {
                    "text": "Commonly epithelioid type"
                  },
                  {
                    "text": "Round to polygonal cells with distinct cell borders or with syncytial appearance"
                  },
                  {
                    "text": "Eosinophilic to pale or clear cytoplasm"
                  },
                  {
                    "text": "May have stromal sclerosis, myxoid change, or scant interstitial matrix"
                  },
                  {
                    "text": "Rhabdoid and plasmacytoid forms, binucleate and multinucleated giant cells"
                  }
                ],
                "SDH-Deficient GIST": [
                  {
                    "text": "Usually pure epithelioid type, less commonly mixed spindle/epithelioid"
                  },
                  {
                    "text": "Often multinodular or plexiform growth patternMost characteristic feature",
                    "sub_points": [
                      "Most characteristic feature"
                    ]
                  },
                  {
                    "text": "Hypercellularity common"
                  },
                  {
                    "text": "Pleomorphism and tumor necrosis are rare"
                  },
                  {
                    "text": "Lymphovascular invasion common (seen in up to 50% of cases)"
                  }
                ],
                "BRAFV600E-Mutated GIST": [
                  {
                    "text": "No known distinguishing histologic features"
                  }
                ],
                "Features Described Following Imatinib Treatment": [
                  {
                    "text": "Hypocellularity"
                  },
                  {
                    "text": "Stromal hyalinization, fibrosis, &/or myxoid change"
                  },
                  {
                    "text": "Necrosis"
                  },
                  {
                    "text": "Rhabdomyoblastic differentiation"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD117Positive in > 90% of GISTs, including nearly allKIT-mutated tumorsUsually diffuse cytoplasmic positivity but may show membranous and perinuclear dot-like positivityStaining patterns and extent of staining do not correlate with type ofKITmutation or likelihood of response to imatinibCD117 negative or only weakly positive GISTs are usually epithelioid withPDGFRAmutationsSDH-deficient andBRAF-mutated GISTs strongly express CD117",
                    "sub_points": [
                      "Positive in > 90% of GISTs, including nearly allKIT-mutated tumors",
                      "Usually diffuse cytoplasmic positivity but may show membranous and perinuclear dot-like positivity",
                      "Staining patterns and extent of staining do not correlate with type ofKITmutation or likelihood of response to imatinib",
                      "CD117 negative or only weakly positive GISTs are usually epithelioid withPDGFRAmutations",
                      "SDH-deficient andBRAF-mutated GISTs strongly express CD117"
                    ]
                  },
                  {
                    "text": "DOG1Highly sensitive and specific marker for GISTPositive in > 95% of tumorsUsually captures CD117-negative GISTsRare small bowel tumors are negative (usually captured by CD117)",
                    "sub_points": [
                      "Highly sensitive and specific marker for GIST",
                      "Positive in > 95% of tumors",
                      "Usually captures CD117-negative GISTs",
                      "Rare small bowel tumors are negative (usually captured by CD117)"
                    ]
                  },
                  {
                    "text": "PDGFRAExpressed in GIST of any typeNot a surrogate marker forPDGFRAmutationAlso expressed in other tumors",
                    "sub_points": [
                      "Expressed in GIST of any typeNot a surrogate marker forPDGFRAmutationAlso expressed in other tumors",
                      "Not a surrogate marker forPDGFRAmutation",
                      "Also expressed in other tumors"
                    ]
                  },
                  {
                    "text": "SDHBExpression lost inallSDH-deficient GISTs regardless of specific subunit alterationBest stain for identifying SDH-deficient GISTNo genotype/phenotype correlation",
                    "sub_points": [
                      "Expression lost inallSDH-deficient GISTs regardless of specific subunit alterationBest stain for identifying SDH-deficient GISTNo genotype/phenotype correlation",
                      "Best stain for identifying SDH-deficient GIST",
                      "No genotype/phenotype correlation"
                    ]
                  },
                  {
                    "text": "SDHALoss of expression reliably predicts tumor and subsequent germlineSDHAmutationGood genotype/phenotype correlation",
                    "sub_points": [
                      "Loss of expression reliably predicts tumor and subsequent germlineSDHAmutationGood genotype/phenotype correlation",
                      "Good genotype/phenotype correlation"
                    ]
                  },
                  {
                    "text": "CD34Positive in 70% of all GISTs but not specificMore frequently negative in gastric epithelioid GIST if not SDH deficientConsistently expressed in gastric spindle cell GISTs",
                    "sub_points": [
                      "Positive in 70% of all GISTs but not specificMore frequently negative in gastric epithelioid GIST if not SDH deficientConsistently expressed in gastric spindle cell GISTs",
                      "More frequently negative in gastric epithelioid GIST if not SDH deficient",
                      "Consistently expressed in gastric spindle cell GISTs"
                    ]
                  },
                  {
                    "text": "Smooth muscle actin (SMA)Negative or only focally positive in ~ 19-30% of tumorsAlmost never expressed in SDH-deficient GISTs",
                    "sub_points": [
                      "Negative or only focally positive in ~ 19-30% of tumors",
                      "Almost never expressed in SDH-deficient GISTs"
                    ]
                  },
                  {
                    "text": "DesminUsually negativeFocally expressed in 5% of tumors, usually epithelioid typesExpressed in imatinib-treated tumors with rhabdomyoblastic differentiation",
                    "sub_points": [
                      "Usually negative",
                      "Focally expressed in 5% of tumors, usually epithelioid types",
                      "Expressed in imatinib-treated tumors with rhabdomyoblastic differentiation"
                    ]
                  },
                  {
                    "text": "S100Usually negativeFocally expressed in < 1% of tumors, usually epithelioid types",
                    "sub_points": [
                      "Usually negative",
                      "Focally expressed in < 1% of tumors, usually epithelioid types"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Leiomyoma": [
                  {
                    "text": "Brightly eosinophilic spindle cells arranged in intersecting fascicles"
                  },
                  {
                    "text": "Nuclei with blunted ends"
                  },
                  {
                    "text": "SMA(+), desmin (+), CD117(-), DOG1(-)Potential pitfall: CD117 and DOG1 may stain colonizing Cajal cells interspersed among smooth muscle bundles",
                    "sub_points": [
                      "Potential pitfall: CD117 and DOG1 may stain colonizing Cajal cells interspersed among smooth muscle bundles"
                    ]
                  }
                ],
                "Schwannoma": [
                  {
                    "text": "Prominent lymphoid cuff"
                  },
                  {
                    "text": "Gastric schwannomas lack typical features of soft tissue counterparts such asVerocay bodiesHyalinized vesselsEncapsulation",
                    "sub_points": [
                      "Verocay bodies",
                      "Hyalinized vessels",
                      "Encapsulation"
                    ]
                  },
                  {
                    "text": "S100(+), CD117(-), DOG1(-)"
                  }
                ],
                "Fibromatosis": [
                  {
                    "text": "Arises in mesentry and extends into muscularis propria"
                  },
                  {
                    "text": "Poorly circumscribed with infiltrative growth pattern"
                  },
                  {
                    "text": "Sweeping fascicles of uniform spindle cells within a collagenous stroma"
                  },
                  {
                    "text": "Bipolar cells with with pale cytoplasm, open chromatin, and prominent nucleoli"
                  },
                  {
                    "text": "Nuclear β-catenin (+), CD34(-), DOG1(-), CD117 usually negative, though some show weak cytoplasmic positivity"
                  }
                ],
                "Inflammatory Fibroid Polyp": [
                  {
                    "text": "Submucosal lesion, not centered in muscularis propria"
                  },
                  {
                    "text": "Bland spindle cells within a loose collagenous stroma"
                  },
                  {
                    "text": "Spindle cells cuff blood vessels (onion skinning)"
                  },
                  {
                    "text": "Numerous stromal eosinophils"
                  },
                  {
                    "text": "PDGRFAmutations and CD34(+) overlap with GIST"
                  },
                  {
                    "text": "CD117(-), DOG1(-)"
                  }
                ],
                "Glomus Tumor": [
                  {
                    "text": "Rare in gastrointestinal tract"
                  },
                  {
                    "text": "May mimic epithelioid GISTComposed of round sharply demarcated cells with cytoplasmic clearingMay be multiple mimicking SDH-deficient epithelioid GIST, but median age is 55 years",
                    "sub_points": [
                      "Composed of round sharply demarcated cells with cytoplasmic clearing",
                      "May be multiple mimicking SDH-deficient epithelioid GIST, but median age is 55 years"
                    ]
                  },
                  {
                    "text": "Positive for smooth muscle markers (SMA, H-caldesmon, calponin) but lacks desmin"
                  },
                  {
                    "text": "CD117(-), DOG1(-)"
                  }
                ],
                "Clear Cell Sarcoma-Like Tumor of GI Tract": [
                  {
                    "text": "Sheet-like or nested epithelioid or spindle cells with eosinophilic to clear cytoplasm"
                  },
                  {
                    "text": "Eccentric nuclei may impart a plasmacytoid appearance"
                  },
                  {
                    "text": "S100(+), CD56(+/-), synaptophysin (+/-), CD117(-), DOG1(-), CD34(-)"
                  },
                  {
                    "text": "EWSR1-ATF1orEWSR1-CREB1fusions"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "KIT-andPDGFRA-mutated GISTTumor behavior is primarily determined by location, size, and mitotic rateSpecific mutations render important information regarding response to imatinib",
                    "sub_points": [
                      "Tumor behavior is primarily determined by location, size, and mitotic rate",
                      "Specific mutations render important information regarding response to imatinib"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "General morphologic-molecular associationsSpindle cell GIST is typicallyKITmutatedAdult gastric epithelioid GIST is typicallyPDGFRAmutatedPediatric gastric epithelioid GIST is typically SDH deficient",
                    "sub_points": [
                      "Spindle cell GIST is typicallyKITmutated",
                      "Adult gastric epithelioid GIST is typicallyPDGFRAmutated",
                      "Pediatric gastric epithelioid GIST is typically SDH deficient"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Melanoma": {
            "name": "Molecular Alterations in Melanoma",
            "url": "https://app.pathprimer.com/document/528db8e9-5af1-4375-8846-e1473a536ae5/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Proliferation of atypical melanocytes, often present both as irregular nests and single cells"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "6th most common malignancy in United States; continuously increasing in incidence"
                  }
                ],
                "Molecular Pathology": [
                  {
                    "text": "BRAFmutations are the most common aberration in sporadic melanoma"
                  },
                  {
                    "text": "PCR for V600E mutation are often performed to assess for treatment responsiveness to BRAF inhibitors"
                  },
                  {
                    "text": "Fluorescent in situ hybridization (FISH) is typically done with 4 probes for known genes often altered in melanoma"
                  },
                  {
                    "text": "Complex rearrangements with multiple amplifications and deletions are typically seen by CGH"
                  },
                  {
                    "text": "Familial cases often show mutations ofCDKN2Agene on chromosome 9p21"
                  },
                  {
                    "text": "PTENmutations are relatively common, reported in up to 30-40% of cases"
                  },
                  {
                    "text": "NRASmutations are next most common, up to 15% of cases"
                  },
                  {
                    "text": "HRASmutations seen in some Spitz nevi"
                  },
                  {
                    "text": "KITmutations are seen in cases of acral lentiginous and lentigo maligna melanoma"
                  },
                  {
                    "text": "GNAQmutations are rare in cutaneous melanomas, commonly seen in uveal melanomas and blue nevi"
                  },
                  {
                    "text": "ALKfusions recently described in some Spitz nevi and atypical Spitz tumors"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Malignant melanoma (MM)"
                  },
                  {
                    "text": "Melanoma in situ (MIS)"
                  },
                  {
                    "text": "Lentigo maligna melanoma (LMM)"
                  },
                  {
                    "text": "Superficial spreading melanoma (SSM)"
                  },
                  {
                    "text": "Desmoplastic melanoma (DM)"
                  },
                  {
                    "text": "Acral lentiginous melanoma (ALM)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Proliferation of atypical melanocytes, often present both as irregular nests and single cellsMelanoma in situ: Lesions confined to epidermis (or mucosal epithelium if mucosal melanoma)Invasive melanoma: Tumor cells infiltrating into dermis or stroma; can be as single cells, nests, or sheet-like collections",
                    "sub_points": [
                      "Melanoma in situ: Lesions confined to epidermis (or mucosal epithelium if mucosal melanoma)",
                      "Invasive melanoma: Tumor cells infiltrating into dermis or stroma; can be as single cells, nests, or sheet-like collections"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "6th most common malignancy in United States; continuously increasing in incidence"
                  }
                ],
                "Age": [
                  {
                    "text": "Usually occurs in older patients in chronically sun-damaged skin"
                  },
                  {
                    "text": "Familial melanoma typically occurs at a younger age; autosomal dominant inheritance in most casesOften have atypical nevi and may develop multiple melanomas",
                    "sub_points": [
                      "Often have atypical nevi and may develop multiple melanomas"
                    ]
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Most cases occur in Caucasians; lighter skin types and red hair confer higher risk"
                  },
                  {
                    "text": "ALM tends to occur more in Asians, Hispanics, and Africans"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Macular, papular or nodular lesion, often with  irregular color, shape, and bordersNodular lesions may be symmetric appearingLesions typically > 1 cm in diameter",
                    "sub_points": [
                      "Nodular lesions may be symmetric appearing",
                      "Lesions typically > 1 cm in diameter"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Surgical excision with clear margins remains standard treatment and can be curative for early-stage lesions"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Depends on size (Breslow depth), presence or absence of ulceration, lymphovascular invasion, and dermal mitotic index"
                  },
                  {
                    "text": "Sentinel lymph node biopsy remains controversial, but involvement is a poor prognostic sign"
                  },
                  {
                    "text": "Molecular findings are increasingly being utilized to attempt to predict prognosis and treatment responsiveness"
                  }
                ]
              },
              "MOLECULAR PATHOLOGY": {
                "Cytogenetics": [
                  {
                    "text": "Not typically done for melanoma, but show complex alterations in most cases"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "Fluorescent in situ hybridization (FISH) is typically done with 4 probes for known genes often altered in melanomaProbes most commonly used include 6p25 (RREB1), 6p23 (MYB), 11q13 (CCND1), and a centromeric chromosome 6 probeNewer probes of potential utility include 8q24 and 9p21Relatively high sensitivity (up to 85-90%) and specificity (up to 95%) are reported, but some difficult or histologically ambiguous cases have not been well characterizedSeverely atypical Spitz nevi, atypical/dysplastic nevi, and atypical cellular blue nevi do not always show unambiguous resultsStudies have not shown good sensitivity for desmoplastic melanoma",
                    "sub_points": [
                      "Probes most commonly used include 6p25 (RREB1), 6p23 (MYB), 11q13 (CCND1), and a centromeric chromosome 6 probeNewer probes of potential utility include 8q24 and 9p21",
                      "Newer probes of potential utility include 8q24 and 9p21",
                      "Relatively high sensitivity (up to 85-90%) and specificity (up to 95%) are reported, but some difficult or histologically ambiguous cases have not been well characterizedSeverely atypical Spitz nevi, atypical/dysplastic nevi, and atypical cellular blue nevi do not always show unambiguous resultsStudies have not shown good sensitivity for desmoplastic melanoma",
                      "Severely atypical Spitz nevi, atypical/dysplastic nevi, and atypical cellular blue nevi do not always show unambiguous results",
                      "Studies have not shown good sensitivity for desmoplastic melanoma"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "PCR studies for V600E mutation are often performed to assess for treatment responsiveness to BRAF inhibitorsV600E mutation is most common (up to 80% of cases); V600K is next most common (up to 20% of cases)",
                    "sub_points": [
                      "V600E mutation is most common (up to 80% of cases); V600K is next most common (up to 20% of cases)"
                    ]
                  },
                  {
                    "text": "Some newer tests utilize PCR panel for multiple genes thought to be up- or down-regulated in melanomaShow high sensitivity and specificity, but studies limited to date",
                    "sub_points": [
                      "Show high sensitivity and specificity, but studies limited to date"
                    ]
                  }
                ],
                "Array CGH": [
                  {
                    "text": "Complex rearrangements with multiple amplifications and deletions are typically seen"
                  },
                  {
                    "text": "96% of melanomas reportedly show at least 1 aberration; most nevi, including Spitz nevi, show no abnormalities"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "Familial cases often show mutations ofCDKN2Agene on chromosome 9p21Encodes for p16 and p14 proteins; p16 is a tumor suppressor protein, which inhibits CDK4 (which regulates G1-S transition via RB phosphorylation)",
                    "sub_points": [
                      "Encodes for p16 and p14 proteins; p16 is a tumor suppressor protein, which inhibits CDK4 (which regulates G1-S transition via RB phosphorylation)"
                    ]
                  },
                  {
                    "text": "BRAFmutations are the most common aberration in sporadic melanomaSeen in up to 50% of cases, tend to correlate with superficial spreading type histologicallyOften seen in younger patients and in skin with less chronic sun damagePart of Ras/Raf/MAPK pathway, and mutations lead to activation of this cascadeV600E mutation is most common (80-90% ofBRAFmutations), leading to constitutive activation of RafV600K is next most common (up to 20% of cases)BRAF inhibitors target V600E mutation",
                    "sub_points": [
                      "Seen in up to 50% of cases, tend to correlate with superficial spreading type histologically",
                      "Often seen in younger patients and in skin with less chronic sun damage",
                      "Part of Ras/Raf/MAPK pathway, and mutations lead to activation of this cascade",
                      "V600E mutation is most common (80-90% ofBRAFmutations), leading to constitutive activation of RafV600K is next most common (up to 20% of cases)BRAF inhibitors target V600E mutation",
                      "V600K is next most common (up to 20% of cases)",
                      "BRAF inhibitors target V600E mutation"
                    ]
                  },
                  {
                    "text": "PTENmutations are relatively common, reported in up to 30-40% of casesActs as an inhibitor of PI3K-AKT pathway",
                    "sub_points": [
                      "Acts as an inhibitor of PI3K-AKT pathway"
                    ]
                  },
                  {
                    "text": "NRASmutations are the next most common, up to 15% of casesLess commonly seen in SSM, more common in nodular melanomaIncrease MAPK and PI3K pathways signaling",
                    "sub_points": [
                      "Less commonly seen in SSM, more common in nodular melanoma",
                      "Increase MAPK and PI3K pathways signaling"
                    ]
                  },
                  {
                    "text": "HRASmutations seen in some Spitz neviUp to 17% of Spitz nevi; not identified in spitzoid melanomas",
                    "sub_points": [
                      "Up to 17% of Spitz nevi; not identified in spitzoid melanomas"
                    ]
                  },
                  {
                    "text": "ALKfusions recently described in some Spitz nevi and atypical Spitz tumorsReportedly correlate with predominantly dermal tumors showing plexiform morphologyFusion partners includeTPM3andDCTN1",
                    "sub_points": [
                      "Reportedly correlate with predominantly dermal tumors showing plexiform morphology",
                      "Fusion partners includeTPM3andDCTN1"
                    ]
                  },
                  {
                    "text": "KITmutations are seen in some cases of melanomaMore commonly seen in LMM, ALM, and mucosal melanomas, not in SSMKITgene encodes the stem cell factor receptor tyrosine kinaseLeads to activation of MAPK, PI3 and JAK-STAT pathwaysAlso regulates MITF (microopthalmia-associated transcription factor), which is involved in melanogenesis, differentiation, growth, and survival",
                    "sub_points": [
                      "More commonly seen in LMM, ALM, and mucosal melanomas, not in SSM",
                      "KITgene encodes the stem cell factor receptor tyrosine kinase",
                      "Leads to activation of MAPK, PI3 and JAK-STAT pathways",
                      "Also regulates MITF (microopthalmia-associated transcription factor), which is involved in melanogenesis, differentiation, growth, and survival"
                    ]
                  },
                  {
                    "text": "GNAQmutations are rare in cutaneous melanomas, but commonly seen in uveal melanomas and blue nevi~ 50% of uveal melanomas showGNAQorGNA11mutationsAlso seen in cellular blue nevi and atypical and malignant blue nevi (melanoma arising in or mimicking a blue nevus)",
                    "sub_points": [
                      "~ 50% of uveal melanomas showGNAQorGNA11mutations",
                      "Also seen in cellular blue nevi and atypical and malignant blue nevi (melanoma arising in or mimicking a blue nevus)"
                    ]
                  },
                  {
                    "text": "TERTmutations recently described in many melanomasEncodes for telomerase; mutations may lead to increased transcriptional activity and immortalization of tumor cells",
                    "sub_points": [
                      "Encodes for telomerase; mutations may lead to increased transcriptional activity and immortalization of tumor cells"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "MIS: Proliferation of atypical junctional lentiginous or nested melanocytes with foci of confluence and pagetoid upward scatterLentigo maligna MIS: Single cells predominate over nests, often show spindle cell features, peripheral trailing off of single cells, adnexal involvementSuperficial spreading MIS: Nests predominate over single cells, often show epithelioid cell features with prominent pagetoid spread",
                    "sub_points": [
                      "Lentigo maligna MIS: Single cells predominate over nests, often show spindle cell features, peripheral trailing off of single cells, adnexal involvement",
                      "Superficial spreading MIS: Nests predominate over single cells, often show epithelioid cell features with prominent pagetoid spread"
                    ]
                  },
                  {
                    "text": "Invasive melanoma: Extension of atypical single cells &/or nests into dermisLMM: Invasion of dermis by atypical oval to spindle-shaped cells, often with associated desmoplastic melanomaSSM: Invasion of dermis by nests of atypical epithelioid-shaped cells; no evidence of maturation with dermal descent; dermal mitoses seen oftenDM: Proliferation of single atypical, infiltrative spindle cells associated with prominent stromal sclerosis (desmoplasia)May be very subtle and easily misdiagnosed as scar, dermatofibroma, or neurofibroma in some casesALM: Acral site, lentiginous junctional proliferation of atypical cells overlying infiltrative dermal spindle cell proliferation (similar to LMM)Nodular-type melanoma: Large, predominantly dermal-based nodular to sheet-like proliferation of markedly atypical cells; often only a small junctional component",
                    "sub_points": [
                      "LMM: Invasion of dermis by atypical oval to spindle-shaped cells, often with associated desmoplastic melanoma",
                      "SSM: Invasion of dermis by nests of atypical epithelioid-shaped cells; no evidence of maturation with dermal descent; dermal mitoses seen often",
                      "DM: Proliferation of single atypical, infiltrative spindle cells associated with prominent stromal sclerosis (desmoplasia)May be very subtle and easily misdiagnosed as scar, dermatofibroma, or neurofibroma in some cases",
                      "May be very subtle and easily misdiagnosed as scar, dermatofibroma, or neurofibroma in some cases",
                      "ALM: Acral site, lentiginous junctional proliferation of atypical cells overlying infiltrative dermal spindle cell proliferation (similar to LMM)",
                      "Nodular-type melanoma: Large, predominantly dermal-based nodular to sheet-like proliferation of markedly atypical cells; often only a small junctional component"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Enlarged atypical and pleomorphic-appearing cells, often with prominent nucleoli"
                  },
                  {
                    "text": "Mitoses usually easily identified in invasive and metastatic melanomas"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Atypical (Dysplastic) Nevi": [
                  {
                    "text": "Show symmetry, circumscription, dermal maturation in most cases"
                  },
                  {
                    "text": "Lack significant pagetoid spread and mitoses (rare junctional or superficial ones may be seen)"
                  },
                  {
                    "text": "Severely atypical nevi can be very difficult to distinguish from melanoma in some cases, especially in a partial biopsyAdditional studies, including immunohistochemistry &/or molecular studies, may be useful in such casesFISH and CGH studies should be negative; BRAF mutations are common (seen in up to 80% of nevi)",
                    "sub_points": [
                      "Additional studies, including immunohistochemistry &/or molecular studies, may be useful in such casesFISH and CGH studies should be negative; BRAF mutations are common (seen in up to 80% of nevi)",
                      "FISH and CGH studies should be negative; BRAF mutations are common (seen in up to 80% of nevi)"
                    ]
                  }
                ],
                "Spitz Nevi and Atypical Spitz Nevi/Tumors": [
                  {
                    "text": "Cells are usually large and show some degree of atypia, pleomorphism, and pagetoid spread"
                  },
                  {
                    "text": "Often more symmetric and well circumscribed compared to melanoma"
                  },
                  {
                    "text": "May have dermal mitoses, but should be superficial and nonatypical"
                  },
                  {
                    "text": "Severely atypical Spitz nevi/tumors very difficult, if not impossible, to distinguish from melanoma by histologic features alone in some casesFISH and CGH studies may be helpful in the differential with melanomaHRASmutations are seen in a minority of cases;BRAFmutations typically absent",
                    "sub_points": [
                      "FISH and CGH studies may be helpful in the differential with melanoma",
                      "HRASmutations are seen in a minority of cases;BRAFmutations typically absent"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Depth of invasion (Breslow depth)"
                  },
                  {
                    "text": "Ulceration"
                  },
                  {
                    "text": "Lymphovascular invasion"
                  },
                  {
                    "text": "Lymph node involvement or other metastatic sites"
                  },
                  {
                    "text": "Invasive pattern (tumor type)"
                  },
                  {
                    "text": "Mitotic rate"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Rare Sarcomas of Uncertain Differentiation With Specific Molecular Alterations": {
            "name": "Rare Sarcomas of Uncertain Differentiation With Specific Molecular Alterations",
            "url": "https://app.pathprimer.com/document/43eb6b4d-2d11-45e5-ae4e-402ebaa389eb/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Sarcomas that donotdifferentiate toward a known cell type but have specific genetic and histologic findings"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Synovial Sarcoma": [
                  {
                    "text": "Age/genderYoung → middle-aged adults most commonlyM > F",
                    "sub_points": [
                      "Young → middle-aged adults most commonly",
                      "M > F"
                    ]
                  },
                  {
                    "text": "Body site locationExtremities (upper > lower; 70% of cases) > trunk > head and neck > other sites including bone and pleura",
                    "sub_points": [
                      "Extremities (upper > lower; 70% of cases) > trunk > head and neck > other sites including bone and pleura"
                    ]
                  },
                  {
                    "text": "Behavior~ 50% local recurrence rate; 40-80% 5-year survivalGood prognostic features: Pediatric age, superficial location, small size (< 5 cm), extremity locationPoor prognostic features: High stage at presentation; ↑ mitotic rate, > 20% poorly differentiated component",
                    "sub_points": [
                      "~ 50% local recurrence rate; 40-80% 5-year survival",
                      "Good prognostic features: Pediatric age, superficial location, small size (< 5 cm), extremity location",
                      "Poor prognostic features: High stage at presentation; ↑ mitotic rate, > 20% poorly differentiated component"
                    ]
                  }
                ],
                "Epithelioid Sarcoma": [
                  {
                    "text": "Age/genderYoung adults most commonly, but broad age range from children → older adultsM > F",
                    "sub_points": [
                      "Young adults most commonly, but broad age range from children → older adults",
                      "M > F"
                    ]
                  },
                  {
                    "text": "Body site locationClassic type: Most commonly in superficial tissue of extremities, forming multiple nodules that may ulcerate; when deep, often forms multiple nodules running along tendons or fasciaProximal type: Usually deep soft tissue at limb girdle > perineum/vulva, but can be superficial and in distal extremities",
                    "sub_points": [
                      "Classic type: Most commonly in superficial tissue of extremities, forming multiple nodules that may ulcerate; when deep, often forms multiple nodules running along tendons or fascia",
                      "Proximal type: Usually deep soft tissue at limb girdle > perineum/vulva, but can be superficial and in distal extremities"
                    ]
                  },
                  {
                    "text": "BehaviorClassic type: ~ 70% local recurrence rate; 45% metastasis rate; 50-80% 5-year survivalAdverse prognostic factors in both classic and proximal types include higher stage, male sex, older age, deep location, extensive necrosis, multifocality, and high mitotic rateProximal type: ~ 70% local recurrence rate; 35% 5-year survivalRhabdoid cell histology confers worse prognosis",
                    "sub_points": [
                      "Classic type: ~ 70% local recurrence rate; 45% metastasis rate; 50-80% 5-year survivalAdverse prognostic factors in both classic and proximal types include higher stage, male sex, older age, deep location, extensive necrosis, multifocality, and high mitotic rate",
                      "Adverse prognostic factors in both classic and proximal types include higher stage, male sex, older age, deep location, extensive necrosis, multifocality, and high mitotic rate",
                      "Proximal type: ~ 70% local recurrence rate; 35% 5-year survivalRhabdoid cell histology confers worse prognosis",
                      "Rhabdoid cell histology confers worse prognosis"
                    ]
                  }
                ],
                "Alveolar Soft Part Sarcoma": [
                  {
                    "text": "Age/genderAdolescents → young adults most commonly, but any age may be affectedF slightly > M when < 30 years",
                    "sub_points": [
                      "Adolescents → young adults most commonly, but any age may be affected",
                      "F slightly > M when < 30 years"
                    ]
                  },
                  {
                    "text": "Body site locationExtremities (thigh or buttock most commonly) > head and neck >> bone, viscera",
                    "sub_points": [
                      "Extremities (thigh or buttock most commonly) > head and neck >> bone, viscera"
                    ]
                  },
                  {
                    "text": "Behavior< 10% local recurrence rate; ~ 80% metastasis rate, 60% 5-year survival dropping to ~ 35% at 10 years",
                    "sub_points": [
                      "< 10% local recurrence rate; ~ 80% metastasis rate, 60% 5-year survival dropping to ~ 35% at 10 years"
                    ]
                  }
                ],
                "Clear Cell Sarcoma of Soft Tissue": [
                  {
                    "text": "Age/genderYoung adults most commonly, but any age may be affected",
                    "sub_points": [
                      "Young adults most commonly, but any age may be affected"
                    ]
                  },
                  {
                    "text": "Body site locationMost perifascial infiltrating tendons, but a few are exclusively superficialExtremities (foot, ankle, hand, thigh most commonly) > trunk > other sites; related tumor occurs in gastrointestinal tract",
                    "sub_points": [
                      "Most perifascial infiltrating tendons, but a few are exclusively superficial",
                      "Extremities (foot, ankle, hand, thigh most commonly) > trunk > other sites; related tumor occurs in gastrointestinal tract"
                    ]
                  },
                  {
                    "text": "Behavior~ 20% local recurrence rate; ~ 60% metastasis rate; 50-60% 5-year survival",
                    "sub_points": [
                      "~ 20% local recurrence rate; ~ 60% metastasis rate; 50-60% 5-year survival"
                    ]
                  }
                ],
                "Extraskeletal Myxoid Chondrosarcoma": [
                  {
                    "text": "Age/genderMiddle-aged → older adults most commonly",
                    "sub_points": [
                      "Middle-aged → older adults most commonly"
                    ]
                  },
                  {
                    "text": "Body site locationDeep soft tissue of proximal extremities (thigh most common) and limb girdles > trunk > foot > head and neck >> rare locations elsewhere",
                    "sub_points": [
                      "Deep soft tissue of proximal extremities (thigh most common) and limb girdles > trunk > foot > head and neck >> rare locations elsewhere"
                    ]
                  },
                  {
                    "text": "Behavior~ 45% local recurrence rate, ~ 45% metastasis rate, ~ 90% 5-year survival, dropping to 70% at 10 yearsPoor prognostic features: Older age, proximal location, higher grade ± rhabdoid tumor cells, higher stage, tumor > 10 cm",
                    "sub_points": [
                      "~ 45% local recurrence rate, ~ 45% metastasis rate, ~ 90% 5-year survival, dropping to 70% at 10 years",
                      "Poor prognostic features: Older age, proximal location, higher grade ± rhabdoid tumor cells, higher stage, tumor > 10 cm"
                    ]
                  }
                ],
                "Extrarenal Rhabdoid Tumor": [
                  {
                    "text": "Age/genderInfants (including neonates) → young children most commonly >> young adults > middle-aged adults",
                    "sub_points": [
                      "Infants (including neonates) → young children most commonly >> young adults > middle-aged adults"
                    ]
                  },
                  {
                    "text": "Body site locationDeep tissue of neck, paraspinous tissues > perineum, retroperitoneum, abdominal cavity; rarely elsewhere, including viscera",
                    "sub_points": [
                      "Deep tissue of neck, paraspinous tissues > perineum, retroperitoneum, abdominal cavity; rarely elsewhere, including viscera"
                    ]
                  },
                  {
                    "text": "Behavior~ 30% local recurrence rate; ~ 10% 5-year survival; ~ 0% 10-year survival",
                    "sub_points": [
                      "~ 30% local recurrence rate; ~ 10% 5-year survival; ~ 0% 10-year survival"
                    ]
                  }
                ],
                "Perivascular Epithelioid Cell Tumor (PEComa)": [
                  {
                    "text": "Age/genderYoung → middle-aged adults most commonly, but broad age rangeF >> M (6:1)",
                    "sub_points": [
                      "Young → middle-aged adults most commonly, but broad age range",
                      "F >> M (6:1)"
                    ]
                  },
                  {
                    "text": "Body site locationMost commonly in organ sites or body cavities such as retroperitoneum, abdominal cavity; also uterus, gastrointestinal tractLess common sites include skin, soft tissue, and bone",
                    "sub_points": [
                      "Most commonly in organ sites or body cavities such as retroperitoneum, abdominal cavity; also uterus, gastrointestinal tract",
                      "Less common sites include skin, soft tissue, and bone"
                    ]
                  },
                  {
                    "text": "BehaviorMalignant-appearing PEComas can metastasize and cause deathTumors without atypia, necrosis, high mitotic rate, infiltrative growth rarely metastasize or cause death (majority of cases)",
                    "sub_points": [
                      "Malignant-appearing PEComas can metastasize and cause death",
                      "Tumors without atypia, necrosis, high mitotic rate, infiltrative growth rarely metastasize or cause death (majority of cases)"
                    ]
                  }
                ],
                "Intimal Sarcoma": [
                  {
                    "text": "Age/genderMiddle-aged → older adults most commonlyF ~ M",
                    "sub_points": [
                      "Middle-aged → older adults most commonly",
                      "F ~ M"
                    ]
                  },
                  {
                    "text": "Body site locationLeft heart, pulmonary artery > aorta > other large vesselsTumor grows in lumen of vessel with peripheral embolization",
                    "sub_points": [
                      "Left heart, pulmonary artery > aorta > other large vessels",
                      "Tumor grows in lumen of vessel with peripheral embolization"
                    ]
                  },
                  {
                    "text": "Behavior< 2-year overall survival",
                    "sub_points": [
                      "< 2-year overall survival"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Synovial Sarcoma": [
                  {
                    "text": "ArchitectureClassicMonophasic: Plump spindle cells in streaming fascicles or sheets ± tigroid (striped alternating hypo- and hypercellular bands)Biphasic: Plump spindle cells and epithelial cells in nests, cords, glands dispersed among fascicles of plump spindle cellsStroma: Usually scant but can be fibrotic or myxoidCalcifications sometimes including osseous metaplasia present in ~ 33%Poorly differentiatedHypercellular ± geographic necrosis",
                    "sub_points": [
                      "ClassicMonophasic: Plump spindle cells in streaming fascicles or sheets ± tigroid (striped alternating hypo- and hypercellular bands)Biphasic: Plump spindle cells and epithelial cells in nests, cords, glands dispersed among fascicles of plump spindle cellsStroma: Usually scant but can be fibrotic or myxoidCalcifications sometimes including osseous metaplasia present in ~ 33%",
                      "Monophasic: Plump spindle cells in streaming fascicles or sheets ± tigroid (striped alternating hypo- and hypercellular bands)",
                      "Biphasic: Plump spindle cells and epithelial cells in nests, cords, glands dispersed among fascicles of plump spindle cells",
                      "Stroma: Usually scant but can be fibrotic or myxoid",
                      "Calcifications sometimes including osseous metaplasia present in ~ 33%",
                      "Poorly differentiatedHypercellular ± geographic necrosis",
                      "Hypercellular ± geographic necrosis"
                    ]
                  },
                  {
                    "text": "CellsClassicSpindled cells: Plump with relatively uniform, often overlapping nuclei, moderate N:C ratio, normo- to hyperchromatic; inconspicuous nucleoliEpithelial cells: Pale eosinophilic with round nuclei; may form intraluminal mucin, rarely show granular or squamous featuresPoorly differentiatedCan have 3 cell shapes but all are characterized by crowding, increased mitoses, ± apoptosis3 cell shapes include: Small round blue cell, mimicking Ewing sarcoma, spindled cells with increased nuclear atypia compared to conventional areas, or epithelioid with macronucleoli, irregular chromatin distribution",
                    "sub_points": [
                      "ClassicSpindled cells: Plump with relatively uniform, often overlapping nuclei, moderate N:C ratio, normo- to hyperchromatic; inconspicuous nucleoliEpithelial cells: Pale eosinophilic with round nuclei; may form intraluminal mucin, rarely show granular or squamous features",
                      "Spindled cells: Plump with relatively uniform, often overlapping nuclei, moderate N:C ratio, normo- to hyperchromatic; inconspicuous nucleoli",
                      "Epithelial cells: Pale eosinophilic with round nuclei; may form intraluminal mucin, rarely show granular or squamous features",
                      "Poorly differentiatedCan have 3 cell shapes but all are characterized by crowding, increased mitoses, ± apoptosis3 cell shapes include: Small round blue cell, mimicking Ewing sarcoma, spindled cells with increased nuclear atypia compared to conventional areas, or epithelioid with macronucleoli, irregular chromatin distribution",
                      "Can have 3 cell shapes but all are characterized by crowding, increased mitoses, ± apoptosis",
                      "3 cell shapes include: Small round blue cell, mimicking Ewing sarcoma, spindled cells with increased nuclear atypia compared to conventional areas, or epithelioid with macronucleoli, irregular chromatin distribution"
                    ]
                  },
                  {
                    "text": "Ancillary studiesImmunohistochemistrySpindled and epithelial areas positive for EMA and often keratins (keratins 7,8,14,18,19 most commonly)Many cases show diffuse strong expression of TLE1CD99 often positive and can show membranous reactivity, mimicking Ewing sarcoma family of tumorsOthers: Only rarely positive (< 5%) for CD34; up to 40% focally S100 reactiveGenetic testsBreak-apart FISH for t(X;18) helps confirm diagnosis in > 95% of casesRT-PCR for fusion transcript also used",
                    "sub_points": [
                      "ImmunohistochemistrySpindled and epithelial areas positive for EMA and often keratins (keratins 7,8,14,18,19 most commonly)Many cases show diffuse strong expression of TLE1CD99 often positive and can show membranous reactivity, mimicking Ewing sarcoma family of tumorsOthers: Only rarely positive (< 5%) for CD34; up to 40% focally S100 reactive",
                      "Spindled and epithelial areas positive for EMA and often keratins (keratins 7,8,14,18,19 most commonly)",
                      "Many cases show diffuse strong expression of TLE1",
                      "CD99 often positive and can show membranous reactivity, mimicking Ewing sarcoma family of tumors",
                      "Others: Only rarely positive (< 5%) for CD34; up to 40% focally S100 reactive",
                      "Genetic testsBreak-apart FISH for t(X;18) helps confirm diagnosis in > 95% of casesRT-PCR for fusion transcript also used",
                      "Break-apart FISH for t(X;18) helps confirm diagnosis in > 95% of cases",
                      "RT-PCR for fusion transcript also used"
                    ]
                  }
                ],
                "Epithelioid Sarcoma": [
                  {
                    "text": "ArchitectureClassic/conventionalOval to sinuous nests of tumor cells seen at low power with central necrosis mimics caseating granulomasSome tumors may have solid growth without classic pseudogranulomasEpithelioid cells often present in central portion of tumor with spindled cells at peripheryProximal typeSheets or nodules of tumor cellsMixed classic and proximal type comprise rare casesUncommon patternsAngiomatoid: Tumor has prominent intermingled blood-filled cystsFibrous: Tumor has prominent fibrotic stroma, usually with spindled tumor cellsMyxoid: Tumor has prominent mucin-rich stromaDystrophic calcifications ± metaplastic bone (20%)",
                    "sub_points": [
                      "Classic/conventionalOval to sinuous nests of tumor cells seen at low power with central necrosis mimics caseating granulomasSome tumors may have solid growth without classic pseudogranulomasEpithelioid cells often present in central portion of tumor with spindled cells at periphery",
                      "Oval to sinuous nests of tumor cells seen at low power with central necrosis mimics caseating granulomas",
                      "Some tumors may have solid growth without classic pseudogranulomas",
                      "Epithelioid cells often present in central portion of tumor with spindled cells at periphery",
                      "Proximal typeSheets or nodules of tumor cellsMixed classic and proximal type comprise rare cases",
                      "Sheets or nodules of tumor cells",
                      "Mixed classic and proximal type comprise rare cases",
                      "Uncommon patternsAngiomatoid: Tumor has prominent intermingled blood-filled cystsFibrous: Tumor has prominent fibrotic stroma, usually with spindled tumor cellsMyxoid: Tumor has prominent mucin-rich stromaDystrophic calcifications ± metaplastic bone (20%)",
                      "Angiomatoid: Tumor has prominent intermingled blood-filled cysts",
                      "Fibrous: Tumor has prominent fibrotic stroma, usually with spindled tumor cells",
                      "Myxoid: Tumor has prominent mucin-rich stroma",
                      "Dystrophic calcifications ± metaplastic bone (20%)"
                    ]
                  },
                  {
                    "text": "CellsClassic/conventionalEpithelioid cells: Large ovoid to polygonal with mild atypia of vesicular nuclei and small nucleoli; eosinophilic cytoplasmSpindled cells: Plump spindled cells with ovoid vesicular nuclei and small nucleoliChronic inflammation common, especially at periphery of tumor nodulesRhabdoid cells may occurMitotic rate usually ↓Proximal typeLarge round to polygonal cells with round vesicular nuclei and macronucleoliMitotic rate may be ↑",
                    "sub_points": [
                      "Classic/conventionalEpithelioid cells: Large ovoid to polygonal with mild atypia of vesicular nuclei and small nucleoli; eosinophilic cytoplasmSpindled cells: Plump spindled cells with ovoid vesicular nuclei and small nucleoliChronic inflammation common, especially at periphery of tumor nodulesRhabdoid cells may occurMitotic rate usually ↓",
                      "Epithelioid cells: Large ovoid to polygonal with mild atypia of vesicular nuclei and small nucleoli; eosinophilic cytoplasm",
                      "Spindled cells: Plump spindled cells with ovoid vesicular nuclei and small nucleoli",
                      "Chronic inflammation common, especially at periphery of tumor nodules",
                      "Rhabdoid cells may occur",
                      "Mitotic rate usually ↓",
                      "Proximal typeLarge round to polygonal cells with round vesicular nuclei and macronucleoliMitotic rate may be ↑",
                      "Large round to polygonal cells with round vesicular nuclei and macronucleoli",
                      "Mitotic rate may be ↑"
                    ]
                  },
                  {
                    "text": "Ancillary studiesImmunohistochemistryPositive: Pankeratin (95%), keratins 8/18, often keratin 19; EMA, CD34 (50%); INI1 (SMARCB1 protein) lost in ~ 90%Rarely positive: Desmin (focal), CD99 (25%), SMA (in spindled cells primarily, ~ 20%)Genetic testsFISH showsSMARCB1homozygous deletions in ~ 90% of cases",
                    "sub_points": [
                      "ImmunohistochemistryPositive: Pankeratin (95%), keratins 8/18, often keratin 19; EMA, CD34 (50%); INI1 (SMARCB1 protein) lost in ~ 90%Rarely positive: Desmin (focal), CD99 (25%), SMA (in spindled cells primarily, ~ 20%)",
                      "Positive: Pankeratin (95%), keratins 8/18, often keratin 19; EMA, CD34 (50%); INI1 (SMARCB1 protein) lost in ~ 90%",
                      "Rarely positive: Desmin (focal), CD99 (25%), SMA (in spindled cells primarily, ~ 20%)",
                      "Genetic testsFISH showsSMARCB1homozygous deletions in ~ 90% of cases",
                      "FISH showsSMARCB1homozygous deletions in ~ 90% of cases"
                    ]
                  }
                ],
                "Alveolar Soft Part Sarcoma": [
                  {
                    "text": "ArchitectureClassic/conventionalNests with central sloughing of tumor cells resembling lung alveoli, &/or organoid growth of solid nests separated by thin vascular septa, &/or solid sheet-like growth (less common)",
                    "sub_points": [
                      "Classic/conventionalNests with central sloughing of tumor cells resembling lung alveoli, &/or organoid growth of solid nests separated by thin vascular septa, &/or solid sheet-like growth (less common)",
                      "Nests with central sloughing of tumor cells resembling lung alveoli, &/or organoid growth of solid nests separated by thin vascular septa, &/or solid sheet-like growth (less common)"
                    ]
                  },
                  {
                    "text": "CellsRound to polygonal cells with eosinophilic to amphophilic granular cytoplasmNuclei usually fairly uniform, round with prominent nucleoliMitotic rate usually ↓Cytoplasmic crystals commonly present but may be sparsePAS positive/diastase resistantRange from granular to rod shaped",
                    "sub_points": [
                      "Round to polygonal cells with eosinophilic to amphophilic granular cytoplasmNuclei usually fairly uniform, round with prominent nucleoliMitotic rate usually ↓",
                      "Nuclei usually fairly uniform, round with prominent nucleoli",
                      "Mitotic rate usually ↓",
                      "Cytoplasmic crystals commonly present but may be sparsePAS positive/diastase resistantRange from granular to rod shaped",
                      "PAS positive/diastase resistant",
                      "Range from granular to rod shaped"
                    ]
                  },
                  {
                    "text": "Ancillary studiesImmunohistochemistryPositive: Strong diffuse TFE3 nuclear reactivity; focal desmin (50%), S100 protein in a few casesGenetic testsFISH forTFE3rearrangement is diagnostically helpfulRT-PCR can also be used to detectASPSCR1-TFE3fusion",
                    "sub_points": [
                      "ImmunohistochemistryPositive: Strong diffuse TFE3 nuclear reactivity; focal desmin (50%), S100 protein in a few cases",
                      "Positive: Strong diffuse TFE3 nuclear reactivity; focal desmin (50%), S100 protein in a few cases",
                      "Genetic testsFISH forTFE3rearrangement is diagnostically helpfulRT-PCR can also be used to detectASPSCR1-TFE3fusion",
                      "FISH forTFE3rearrangement is diagnostically helpful",
                      "RT-PCR can also be used to detectASPSCR1-TFE3fusion"
                    ]
                  }
                ],
                "Clear Cell Sarcoma of Soft Tissue": [
                  {
                    "text": "ArchitectureMost common pattern: Nests of cells separated by fibrous septaOther patterns: Sheets of tumor cells; cutaneous examples often have dense sclerotic stroma",
                    "sub_points": [
                      "Most common pattern: Nests of cells separated by fibrous septa",
                      "Other patterns: Sheets of tumor cells; cutaneous examples often have dense sclerotic stroma"
                    ]
                  },
                  {
                    "text": "CellsMost common: Round to polygonal with eosinophilic to amphophilic cytoplasmMultinucleated tumor cells with wreath-like array of nuclei relatively common and a diagnostic clueNuclei usually uniform, vesicular with macronucleoliMitotic rate: Usually ↓Melanin usually not detectable on H&E but present in ~ 66% on Fontana stainOther tumor cell variantsSpindled tumor cells: Relatively common as a small component but may be predominant or sole componentPlasmacytoid cells: UncommonRhabdoid cells: UncommonSmall round blue cells: Rare",
                    "sub_points": [
                      "Most common: Round to polygonal with eosinophilic to amphophilic cytoplasmMultinucleated tumor cells with wreath-like array of nuclei relatively common and a diagnostic clueNuclei usually uniform, vesicular with macronucleoliMitotic rate: Usually ↓Melanin usually not detectable on H&E but present in ~ 66% on Fontana stain",
                      "Multinucleated tumor cells with wreath-like array of nuclei relatively common and a diagnostic clue",
                      "Nuclei usually uniform, vesicular with macronucleoli",
                      "Mitotic rate: Usually ↓",
                      "Melanin usually not detectable on H&E but present in ~ 66% on Fontana stain",
                      "Other tumor cell variantsSpindled tumor cells: Relatively common as a small component but may be predominant or sole componentPlasmacytoid cells: UncommonRhabdoid cells: UncommonSmall round blue cells: Rare",
                      "Spindled tumor cells: Relatively common as a small component but may be predominant or sole component",
                      "Plasmacytoid cells: Uncommon",
                      "Rhabdoid cells: Uncommon",
                      "Small round blue cells: Rare"
                    ]
                  },
                  {
                    "text": "Ancillary studiesImmunohistochemistryPositive: Strongly positive for at least 1 melanocytic marker (S100 protein, HMB-45, MITF, Melan-A, etc.)Genetic testsFISH showsEWSR1gene rearrangement (~ 100% of cases)RT-PCR shows t(12;22)(q13;q12) or t(2;22)(q32;q12)",
                    "sub_points": [
                      "ImmunohistochemistryPositive: Strongly positive for at least 1 melanocytic marker (S100 protein, HMB-45, MITF, Melan-A, etc.)",
                      "Positive: Strongly positive for at least 1 melanocytic marker (S100 protein, HMB-45, MITF, Melan-A, etc.)",
                      "Genetic testsFISH showsEWSR1gene rearrangement (~ 100% of cases)RT-PCR shows t(12;22)(q13;q12) or t(2;22)(q32;q12)",
                      "FISH showsEWSR1gene rearrangement (~ 100% of cases)",
                      "RT-PCR shows t(12;22)(q13;q12) or t(2;22)(q32;q12)"
                    ]
                  }
                ],
                "Extraskeletal Myxoid Chondrosarcoma": [
                  {
                    "text": "ArchitectureMyxoid lobules with cords, clusters, and cribriform arrays of small tumor cells",
                    "sub_points": [
                      "Myxoid lobules with cords, clusters, and cribriform arrays of small tumor cells"
                    ]
                  },
                  {
                    "text": "CellsClassic/conventionalRound to plump spindled cells with finely granular eosinophilic to amphophilic to vacuolated cytoplasmNuclei usually relatively uniform, round to ovoid, vesicular with small nucleolusMitotic figures usually ↓Poorly differentiated or high gradeHypercellular epithelioid or rhabdoid morphology with increased nuclear pleomorphism, increased mitoses, ± necrosis",
                    "sub_points": [
                      "Classic/conventionalRound to plump spindled cells with finely granular eosinophilic to amphophilic to vacuolated cytoplasmNuclei usually relatively uniform, round to ovoid, vesicular with small nucleolusMitotic figures usually ↓",
                      "Round to plump spindled cells with finely granular eosinophilic to amphophilic to vacuolated cytoplasm",
                      "Nuclei usually relatively uniform, round to ovoid, vesicular with small nucleolus",
                      "Mitotic figures usually ↓",
                      "Poorly differentiated or high gradeHypercellular epithelioid or rhabdoid morphology with increased nuclear pleomorphism, increased mitoses, ± necrosis",
                      "Hypercellular epithelioid or rhabdoid morphology with increased nuclear pleomorphism, increased mitoses, ± necrosis"
                    ]
                  },
                  {
                    "text": "Ancillary studiesImmunohistochemistryPositive: Vimentin (100%); C-kit (30%), S100 protein (20%); few cases positive for synaptophysinINI1 may be completely absent in few cases (especially with rhabdoid cells) or show patchy pattern of nuclear reactivityGenetic testsFISH positive forNR4A2gene rearrangement (~ 90%): Diagnostically helpful and specific for this sarcoma",
                    "sub_points": [
                      "ImmunohistochemistryPositive: Vimentin (100%); C-kit (30%), S100 protein (20%); few cases positive for synaptophysinINI1 may be completely absent in few cases (especially with rhabdoid cells) or show patchy pattern of nuclear reactivity",
                      "Positive: Vimentin (100%); C-kit (30%), S100 protein (20%); few cases positive for synaptophysin",
                      "INI1 may be completely absent in few cases (especially with rhabdoid cells) or show patchy pattern of nuclear reactivity",
                      "Genetic testsFISH positive forNR4A2gene rearrangement (~ 90%): Diagnostically helpful and specific for this sarcoma",
                      "FISH positive forNR4A2gene rearrangement (~ 90%): Diagnostically helpful and specific for this sarcoma"
                    ]
                  }
                ],
                "Extrarenal Rhabdoid Tumor": [
                  {
                    "text": "ArchitectureSheets often with cellular dyscohesion",
                    "sub_points": [
                      "Sheets often with cellular dyscohesion"
                    ]
                  },
                  {
                    "text": "CellsSmall to medium-sized round cells with round to reniform nuclei, macronucleoli, and glassy, globoid cytoplasmic inclusionSmall round blue cell component may be presentMitotic rate usually ↑",
                    "sub_points": [
                      "Small to medium-sized round cells with round to reniform nuclei, macronucleoli, and glassy, globoid cytoplasmic inclusion",
                      "Small round blue cell component may be present",
                      "Mitotic rate usually ↑"
                    ]
                  },
                  {
                    "text": "Ancillary studiesImmunohistochemistryLoss of INI1 nuclear expression (> 95% of cases); EMA, keratins often positive in inclusions (which are intermediate filaments); vimentin, synaptophysin, and CD99 positiveGenetic testsRT-PCR detectsSMARCB1gene alterations that include mutations or homozygous deletions~ 35% of patients have germlineSMARCB1alterationsRarely,SMARCA4(19p13.2) somatic ± germline mutations account for pathogenesis",
                    "sub_points": [
                      "ImmunohistochemistryLoss of INI1 nuclear expression (> 95% of cases); EMA, keratins often positive in inclusions (which are intermediate filaments); vimentin, synaptophysin, and CD99 positive",
                      "Loss of INI1 nuclear expression (> 95% of cases); EMA, keratins often positive in inclusions (which are intermediate filaments); vimentin, synaptophysin, and CD99 positive",
                      "Genetic testsRT-PCR detectsSMARCB1gene alterations that include mutations or homozygous deletions~ 35% of patients have germlineSMARCB1alterationsRarely,SMARCA4(19p13.2) somatic ± germline mutations account for pathogenesis",
                      "RT-PCR detectsSMARCB1gene alterations that include mutations or homozygous deletions",
                      "~ 35% of patients have germlineSMARCB1alterations",
                      "Rarely,SMARCA4(19p13.2) somatic ± germline mutations account for pathogenesis"
                    ]
                  }
                ],
                "PEComa": [
                  {
                    "text": "ArchitectureClassic/conventional: Nests of cells usually with at least some centered on thin walled blood vessels ± subendothelial growthCell nests girded by thin-walled vessel or slips of collagenMalignant PEComa: Nests and sheets of pleomorphic cells ± perivascular arrangementSclerosing variant (~ 15% of cases): Marked stromal sclerosis with corded or trabecular arrangement of tumor cellsTFE3translocation associated PEComa: Nests or sheets of cells",
                    "sub_points": [
                      "Classic/conventional: Nests of cells usually with at least some centered on thin walled blood vessels ± subendothelial growthCell nests girded by thin-walled vessel or slips of collagen",
                      "Cell nests girded by thin-walled vessel or slips of collagen",
                      "Malignant PEComa: Nests and sheets of pleomorphic cells ± perivascular arrangement",
                      "Sclerosing variant (~ 15% of cases): Marked stromal sclerosis with corded or trabecular arrangement of tumor cells",
                      "TFE3translocation associated PEComa: Nests or sheets of cells"
                    ]
                  },
                  {
                    "text": "CellsClassic/conventional and sclerosing variant: Uniform bland epithelioid cells with relatively ↓ N:C ratioCytoplasm: Abundant, pale eosinophilic and slightly granular to clearMalignant PEComa: Increased nuclear pleomorphism often with ↑ mitotic rate, necrosis, ± atypical mitotic figuresTFE3translocation-associated PEComa: Clear epithelioid cells with low or high nuclear atypia ± spindled tumor cells (uncommon)",
                    "sub_points": [
                      "Classic/conventional and sclerosing variant: Uniform bland epithelioid cells with relatively ↓ N:C ratioCytoplasm: Abundant, pale eosinophilic and slightly granular to clear",
                      "Cytoplasm: Abundant, pale eosinophilic and slightly granular to clear",
                      "Malignant PEComa: Increased nuclear pleomorphism often with ↑ mitotic rate, necrosis, ± atypical mitotic figures",
                      "TFE3translocation-associated PEComa: Clear epithelioid cells with low or high nuclear atypia ± spindled tumor cells (uncommon)"
                    ]
                  },
                  {
                    "text": "Ancillary studiesImmunohistochemistryMyoid markers positive: SMA, caldesmonMelanocytic markers positive: HMB-45, Melan-A, S100 protein (10%)TFE3translocation associated PEComa: Strong diffuse nuclear TFE3, HMB-45, and cathepsin-K ± weak SMAGenetic testsConventional and sclerotic PEComas:TSC2loss of heterozygosity with rare cases also showingTSC1LOHTFE3rearranged PEComas:TFE3gene rearrangement detectable by FISH",
                    "sub_points": [
                      "ImmunohistochemistryMyoid markers positive: SMA, caldesmonMelanocytic markers positive: HMB-45, Melan-A, S100 protein (10%)TFE3translocation associated PEComa: Strong diffuse nuclear TFE3, HMB-45, and cathepsin-K ± weak SMA",
                      "Myoid markers positive: SMA, caldesmon",
                      "Melanocytic markers positive: HMB-45, Melan-A, S100 protein (10%)",
                      "TFE3translocation associated PEComa: Strong diffuse nuclear TFE3, HMB-45, and cathepsin-K ± weak SMA",
                      "Genetic testsConventional and sclerotic PEComas:TSC2loss of heterozygosity with rare cases also showingTSC1LOHTFE3rearranged PEComas:TFE3gene rearrangement detectable by FISH",
                      "Conventional and sclerotic PEComas:TSC2loss of heterozygosity with rare cases also showingTSC1LOH",
                      "TFE3rearranged PEComas:TFE3gene rearrangement detectable by FISH"
                    ]
                  }
                ],
                "Intimal Sarcoma": [
                  {
                    "text": "ArchitectureIntravascular tumor most commonly composed of sheets of cells, but also can be fascicularStroma: May be myxoid or include neoplastic bone if osteosarcomatous component present",
                    "sub_points": [
                      "Intravascular tumor most commonly composed of sheets of cells, but also can be fascicular",
                      "Stroma: May be myxoid or include neoplastic bone if osteosarcomatous component present"
                    ]
                  },
                  {
                    "text": "CellsDiverse array of cell types reported from large polygonal to epithelioid to spindledUsually at least moderate nuclear pleomorphismSpecific differentiation can be present, such as osteosarcoma or rhabdomyosarcoma",
                    "sub_points": [
                      "Diverse array of cell types reported from large polygonal to epithelioid to spindled",
                      "Usually at least moderate nuclear pleomorphism",
                      "Specific differentiation can be present, such as osteosarcoma or rhabdomyosarcoma"
                    ]
                  },
                  {
                    "text": "Ancillary studiesImmunohistochemistry70% positive for MDM2; other positive markers can include SATB2 (if osteosarcoma present), myogenin (if rhabdomyosarcoma present), desmin, and SMAGenetic tests: Nonspecific high-level amplification ofPDGFRA(~ 80%),MDM2 (~ 65%),EGFR(~ 70%) by FISH",
                    "sub_points": [
                      "Immunohistochemistry70% positive for MDM2; other positive markers can include SATB2 (if osteosarcoma present), myogenin (if rhabdomyosarcoma present), desmin, and SMA",
                      "70% positive for MDM2; other positive markers can include SATB2 (if osteosarcoma present), myogenin (if rhabdomyosarcoma present), desmin, and SMA",
                      "Genetic tests: Nonspecific high-level amplification ofPDGFRA(~ 80%),MDM2 (~ 65%),EGFR(~ 70%) by FISH"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "DDx for Synovial Sarcoma": [
                  {
                    "text": "Malignant peripheral nerve sheath tumor: Can be TLE1 positive, usually focal; negative for t(X;18)"
                  },
                  {
                    "text": "Small round blue cell sarcomas: Negative for TLE1 in most cases; negative for t(X;18)"
                  },
                  {
                    "text": "Solitary fibrous tumor:Positive for STAT6; negative for t(X;18)"
                  }
                ],
                "DDx for Epithelioid Sarcoma": [
                  {
                    "text": "Metastatic carcinoma: Negative for CD34, positive for INI1; negative forEWSR1rearrangement"
                  },
                  {
                    "text": "Melanoma: Negative for CD34 ,keratins, EMA; positive for melanocytic markers; almost always negative forEWSR1rearrangement"
                  },
                  {
                    "text": "Pleomorphic high-grade undifferentiated sarcoma with epithelioid morphology: Positive for INI1; negative forEWSR1rearrangement"
                  },
                  {
                    "text": "Pseudomyogenic hemangioendothelioma"
                  },
                  {
                    "text": "Other sarcomas with epithelioid &/or rhabdoid cell morphology"
                  }
                ],
                "DDx for Alveolar Soft Part Sarcoma": [
                  {
                    "text": "Metastatic carcinoma: Negative for TFE3 nuclear expression; positive for keratins"
                  },
                  {
                    "text": "PEComa: Positive for HMB45, Melan-A; can be positive for TFE3 by IHC"
                  },
                  {
                    "text": "Granular cell tumor: Can be positive for TFE3; lacks crystals, lacks der(17)t(X;17)(p11;q25)"
                  }
                ],
                "DDx for Clear Cell Sarcoma of Soft Tissue": [
                  {
                    "text": "Melanoma: Epithelial component; usually more nuclear atypia, negative forEWSR1rearrangement by FISH"
                  }
                ],
                "DDx for Extraskeletal Myxoid Chondrosarcoma": [
                  {
                    "text": "Myoepithelial tumor of soft tissue: Positive for keratins; negative forNR4A3gene rearrangement by FISH"
                  }
                ],
                "DDx for Extrarenal Rhabdoid Tumor": [
                  {
                    "text": "Other tumors that may have rhabdoid appearing cells: Many tumor types including other sarcomas, carcinomasImmunohistochemistry and genetic testing may be required to make correct diagnosis",
                    "sub_points": [
                      "Immunohistochemistry and genetic testing may be required to make correct diagnosis"
                    ]
                  }
                ],
                "DDx for PEComa": [
                  {
                    "text": "Melanoma: Negative for myoid markers in most cases; negative forTSC2LOH; often positive forBRAFV600E mutation"
                  },
                  {
                    "text": "GIST: Negative for HMB45, Melan-A; positive for C-kit; positive forALKmutations"
                  },
                  {
                    "text": "Renal cell carcinoma: Positive for keratins, pax-8; negative for HMB45, Melan-A"
                  }
                ],
                "DDx for Intimal Sarcoma": [
                  {
                    "text": "Leiomyosarcoma of large vessel: More consistent fascicular architecture with eosinophilic smooth muscle tumor cells; positive for desmin, SMA, caldesmon (at least 2 muscle markers)"
                  },
                  {
                    "text": "Pleomorphic high-grade undifferentiated sarcoma: Location is not intravascular"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Thyroid Cancer": {
            "name": "Molecular Alterations in Thyroid Cancer",
            "url": "https://app.pathprimer.com/document/cd6b6b8c-066a-426f-9827-0f5a3d689b56/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Diagnostic Checklist": [
                  {
                    "text": "BRAFmutations most common in papillary thyroid carcinoma; associated with aggressive courseBRAF V600E: Most common activating mutation﻿",
                    "sub_points": [
                      "BRAF V600E: Most common activating mutation﻿"
                    ]
                  },
                  {
                    "text": "﻿RAS family mutations most common in follicular thyroid carcinoma﻿"
                  },
                  {
                    "text": "RETmutations most common in medullary thyroid carcinoma﻿Found in multiple endocrine neoplasia 2 (MEN2) hereditary cancer syndrome﻿Associated with > 95% familial MTC﻿",
                    "sub_points": [
                      "﻿Found in multiple endocrine neoplasia 2 (MEN2) hereditary cancer syndrome﻿",
                      "Associated with > 95% familial MTC﻿"
                    ]
                  },
                  {
                    "text": "TERTpromoter mutations found in all subtypes; associated with aggressive course"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Thyroid cancer (TC)"
                  },
                  {
                    "text": "Anaplastic thyroid cancer (ATC)"
                  },
                  {
                    "text": "Follicular thyroid cancer (FTC)"
                  },
                  {
                    "text": "Medullary thyroid cancer (MTC)"
                  },
                  {
                    "text": "Poorly differentiated thyroid cancer (PDTC)"
                  },
                  {
                    "text": "Papillary thyroid cancer (PTC)"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Often present as nodules"
                  },
                  {
                    "text": "May show rapid growth"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Surgical excision"
                  },
                  {
                    "text": "Radioiodine therapy"
                  },
                  {
                    "text": "Radiation therapy"
                  },
                  {
                    "text": "Chemotherapy"
                  }
                ],
                "Risk Factors": [
                  {
                    "text": "Female gender"
                  },
                  {
                    "text": "Increased age (median age at diagnosis: 51)"
                  },
                  {
                    "text": "Radiation exposure"
                  },
                  {
                    "text": "Low iodine diet"
                  },
                  {
                    "text": "Multiple endocrine neoplasia type 2 (MEN2)"
                  }
                ]
              },
              "MOLECULAR": {
                "﻿BRAF﻿Mutations": [
                  {
                    "text": "Serine-threonine kinase in MAP kinase signaling pathway"
                  },
                  {
                    "text": "Mutations activateBRAFand increase pathway activationBRAF V600E = most common activating mutation﻿",
                    "sub_points": [
                      "BRAF V600E = most common activating mutation﻿"
                    ]
                  },
                  {
                    "text": "﻿Associated with more aggressive disease﻿"
                  },
                  {
                    "text": "﻿Most common mutation in PTC (40-45%)﻿Particularly tall cell variant (80-100%)",
                    "sub_points": [
                      "Particularly tall cell variant (80-100%)"
                    ]
                  },
                  {
                    "text": "Also observed in ATC (20-30%) and PDTC (10-15%)"
                  }
                ],
                "CTNNB1Mutations": [
                  {
                    "text": "Encodes β-catenin, an adhesion molecule that also functions as transcription factor in Wnt signaling pathway"
                  },
                  {
                    "text": "Mutations lead to activation of β-catenin transcriptional targets and increase pathway activation"
                  },
                  {
                    "text": "Common in ATC (60-70%)"
                  },
                  {
                    "text": "Also observed in PDTC (10-25%)"
                  }
                ],
                "PIK3CAMutations": [
                  {
                    "text": "Encodes p110α catalytic subunit of phosphoinositide 3-kinase (PI3K) in PI3K signaling pathway"
                  },
                  {
                    "text": "Mutations activate kinase and downstream targets"
                  },
                  {
                    "text": "Observed in ATC (15-25%) and FTC (5-15%)"
                  }
                ],
                "PTENMutations": [
                  {
                    "text": "Encodes phosphatase that inhibits PI3K signaling pathway"
                  },
                  {
                    "text": "Mutations inactivatePTENand increase pathway activation"
                  },
                  {
                    "text": "Observed in ATC (10-20%) and FTC (10-15%)"
                  }
                ],
                "RAS Family Mutations": [
                  {
                    "text": "RAS family encompassesKRAS,NRAS, andHRAS"
                  },
                  {
                    "text": "RAS family members are GTPases and transduce signals from receptors to MAPK and PI3K signaling pathways"
                  },
                  {
                    "text": "Mutations in RAS family members disrupt GTPase activity and increase pathway activation"
                  },
                  {
                    "text": "Observed in FTC (30-50%), ATC (20-50%), PDTC (20-40%), and PTC (10-20%)"
                  }
                ],
                "RETAlterations": [
                  {
                    "text": "Encodes receptor tyrosine kinase, which activates MAPK and PI3K signaling pathways"
                  },
                  {
                    "text": "Alterations (point mutations and fusions) lead to activation of downstream targets"
                  },
                  {
                    "text": "RETMutations﻿Found in multiple endocrine neoplasia 2 (MEN2) hereditary cancer syndrome﻿Associated with > 95% familial MTC﻿﻿Also common in sporadic MTC (40-50%)﻿",
                    "sub_points": [
                      "﻿Found in multiple endocrine neoplasia 2 (MEN2) hereditary cancer syndrome﻿Associated with > 95% familial MTC﻿",
                      "Associated with > 95% familial MTC﻿",
                      "﻿Also common in sporadic MTC (40-50%)﻿"
                    ]
                  },
                  {
                    "text": "RET/PTCFusionsEleven fusion partners identified to datePTC1most common partner (60-70%)PTC3second most common partner (20-30%)Observed in PTC (10-20%)",
                    "sub_points": [
                      "Eleven fusion partners identified to datePTC1most common partner (60-70%)PTC3second most common partner (20-30%)",
                      "PTC1most common partner (60-70%)",
                      "PTC3second most common partner (20-30%)",
                      "Observed in PTC (10-20%)"
                    ]
                  }
                ],
                "TERTPromoter Mutations": [
                  {
                    "text": "TERTencodes reverse transcriptase unit of telomerase complex, which maintains ends of chromosomes during cell division"
                  },
                  {
                    "text": "Mutations increase synthesis of TERT protein and allow telomere maintenance through increased rounds of cell division"
                  },
                  {
                    "text": "﻿Associated with more aggressive disease﻿"
                  },
                  {
                    "text": "Observed in ATC (30-50%), PDTC (30-50%), FTC (15-35%), and PTC (10-15%)"
                  }
                ],
                "TP53Mutations": [
                  {
                    "text": "Encodes major tumor suppressor involved in regulating DNA damage checkpoint in apoptosis"
                  },
                  {
                    "text": "Mutations inactiveTP53and allow unrestrained growth"
                  },
                  {
                    "text": "Observed in ATC (70-80%) and PDTC (20-30%)"
                  }
                ],
                "PAX8-PPARγFusions": [
                  {
                    "text": "FusesPAX8transcription factor toPPARγligand-dependent nuclear transcription factor"
                  },
                  {
                    "text": "Mechanism of oncogenesis is unclear, but both activation ofPAX8targets and disruption of normalPPARγsignaling have been proposed"
                  },
                  {
                    "text": "Observed in FTC (30-35%)"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "FIne-Needle Aspiration": [
                  {
                    "text": "Morphology may be similar between different subtypes"
                  },
                  {
                    "text": "Molecular features may favor specific pathologic diagnosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Urothelial Carcinoma": {
            "name": "Molecular Alterations in Urothelial Carcinoma",
            "url": "https://app.pathprimer.com/document/d98648af-1c10-46e8-a82b-6d88f2ddb210/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Malignant neoplasm derived from urothelium"
                  }
                ],
                "Molecular Pathology": [
                  {
                    "text": "2 important clinicopathologic categories of urothelial carcinoma"
                  },
                  {
                    "text": "Non-muscle-invasive bladder cancerTends to recur rather than progressTypically associated with low-grade papillary histologyAssociated withFGFR3, HRAS, and PIK3CAmutations, and chromosome 9 losses",
                    "sub_points": [
                      "Tends to recur rather than progress",
                      "Typically associated with low-grade papillary histology",
                      "Associated withFGFR3, HRAS, and PIK3CAmutations, and chromosome 9 losses"
                    ]
                  },
                  {
                    "text": "Muscle invasive  bladder cancer (MIBC)Tends to progress and metastasizeUsually high-grade histologyHas a high rate of mutations and genomic amplifications",
                    "sub_points": [
                      "Tends to progress and metastasize",
                      "Usually high-grade histology",
                      "Has a high rate of mutations and genomic amplifications"
                    ]
                  },
                  {
                    "text": "Recent comprehensive genomic analysis of MIBC has shown dysregulation of 3 main pathwaysCell cycle regulation (dysregulated in 93% of tumors), including frequent mutations inTP53, CDKN2A, RB1, CDKN1AKinase and PI(3)K signaling (dysregulated in 72%), including mutations inFGFR3, EGFR, ERBB2, ERBB3, PIK3CA, PTENChromatin remodeling, with abnormalities in histone-modifying genes (89%) and components of SWI/SNF nucleosome remodeling complex (64%), including mutations inARID1A, KMT2D, KDM6A, EP300",
                    "sub_points": [
                      "Cell cycle regulation (dysregulated in 93% of tumors), including frequent mutations inTP53, CDKN2A, RB1, CDKN1A",
                      "Kinase and PI(3)K signaling (dysregulated in 72%), including mutations inFGFR3, EGFR, ERBB2, ERBB3, PIK3CA, PTEN",
                      "Chromatin remodeling, with abnormalities in histone-modifying genes (89%) and components of SWI/SNF nucleosome remodeling complex (64%), including mutations inARID1A, KMT2D, KDM6A, EP300"
                    ]
                  },
                  {
                    "text": "Expression profiling studies of MIBC have revealed multiple subtypes, including luminal and basal subtypes analogous to breast cancer"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Transitional cell carcinoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Malignant neoplasm derived from urothelium2 important clinicopathological phenotypes of urothelial carcinomaSuperficial non-muscle-invasive bladder cancerMuscle invasive bladder cancer",
                    "sub_points": [
                      "2 important clinicopathological phenotypes of urothelial carcinomaSuperficial non-muscle-invasive bladder cancerMuscle invasive bladder cancer",
                      "Superficial non-muscle-invasive bladder cancer",
                      "Muscle invasive bladder cancer"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Tobacco smokeCarcinogens such as 4-aminophenolSmokers have 2-5x increased risk than nonsmokersEstimated to give rise to 30-50% of bladder cancers",
                    "sub_points": [
                      "Carcinogens such as 4-aminophenol",
                      "Smokers have 2-5x increased risk than nonsmokers",
                      "Estimated to give rise to 30-50% of bladder cancers"
                    ]
                  },
                  {
                    "text": "Occupational carcinogen exposureEspecially in rubber and dye industries with exposure to aniline dyes, β-naphthylamine, and benzidine",
                    "sub_points": [
                      "Especially in rubber and dye industries with exposure to aniline dyes, β-naphthylamine, and benzidine"
                    ]
                  },
                  {
                    "text": "DrugsCyclophosphamide, phenacetin",
                    "sub_points": [
                      "Cyclophosphamide, phenacetin"
                    ]
                  },
                  {
                    "text": "Arsenic in drinking water"
                  },
                  {
                    "text": "Pelvic radiation"
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "VirusesMay contribute to development of a small percentage of bladder tumorsViral DNA and viral RNA transcripts described in 4-6% of casesViruses reported include CMV, BK polyomavirus, HPV-16",
                    "sub_points": [
                      "May contribute to development of a small percentage of bladder tumorsViral DNA and viral RNA transcripts described in 4-6% of casesViruses reported include CMV, BK polyomavirus, HPV-16",
                      "Viral DNA and viral RNA transcripts described in 4-6% of cases",
                      "Viruses reported include CMV, BK polyomavirus, HPV-16"
                    ]
                  },
                  {
                    "text": "Schistosoma haematobiumParticularly associated with urothelial squamous cell carcinoma",
                    "sub_points": [
                      "Particularly associated with urothelial squamous cell carcinoma"
                    ]
                  }
                ],
                "2 Separate Tumorigenic Pathways": [
                  {
                    "text": "Papillary pathway"
                  },
                  {
                    "text": "Flat (carcinoma in situ) pathwayInvasive carcinoma can arise from both",
                    "sub_points": [
                      "Invasive carcinoma can arise from both"
                    ]
                  }
                ],
                "Pathogenic Role ofAPOBEC3B": [
                  {
                    "text": "Highly expressed in all muscle invasive bladder cancers (MIBC) testedLikely play a significant mutagenic role in MIBCHigh rate of mutations in MIBC51% of mutations mediated by a DNA cytosine deaminase of APOBEC family",
                    "sub_points": [
                      "Likely play a significant mutagenic role in MIBCHigh rate of mutations in MIBC51% of mutations mediated by a DNA cytosine deaminase of APOBEC family",
                      "High rate of mutations in MIBC",
                      "51% of mutations mediated by a DNA cytosine deaminase of APOBEC family"
                    ]
                  }
                ],
                "Hereditary Factors": [
                  {
                    "text": "In general, not a major contributor"
                  },
                  {
                    "text": "Polymorphisms inNAT2andGSTM1(carcinogen detoxifying genes) genes confer some increased risk"
                  },
                  {
                    "text": "Lynch syndrome associated with increased risk of urothelial cancer of ureter and renal pelvis (upper urinary tract)"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Geographic variabilityHighest incidence in Southern Europe and EgyptLowest incidence in Far East",
                    "sub_points": [
                      "Highest incidence in Southern Europe and Egypt",
                      "Lowest incidence in Far East"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "7th most common cancer worldwide"
                  },
                  {
                    "text": "150,000 deaths worldwide per year"
                  }
                ],
                "Age": [
                  {
                    "text": "Most diagnosed in 6th decade or older"
                  }
                ],
                "Sex": [
                  {
                    "text": "4x more common in men"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Painless gross or microscopic hematuria"
                  },
                  {
                    "text": "Bladder irritative symptoms including urinary frequency, urgency, dysuria"
                  },
                  {
                    "text": "Mass or obstructive symptoms"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Intravesical therapyChemotherapy (e.g., Mitomycin C)Low-intermediate risk Ta papillary tumorsBacillus Calmette-Guerin (BCG) therapyIntermediate-high-risk Ta papillary tumorsT1 tumorsCarcinoma in situ",
                    "sub_points": [
                      "Chemotherapy (e.g., Mitomycin C)Low-intermediate risk Ta papillary tumors",
                      "Low-intermediate risk Ta papillary tumors",
                      "Bacillus Calmette-Guerin (BCG) therapyIntermediate-high-risk Ta papillary tumorsT1 tumorsCarcinoma in situ",
                      "Intermediate-high-risk Ta papillary tumors",
                      "T1 tumors",
                      "Carcinoma in situ"
                    ]
                  },
                  {
                    "text": "Systemic chemotherapyCisplatin-based protocolsMetastatic diseaseNeoadjuvant therapy prior to cystectomy",
                    "sub_points": [
                      "Cisplatin-based protocolsMetastatic diseaseNeoadjuvant therapy prior to cystectomy",
                      "Metastatic disease",
                      "Neoadjuvant therapy prior to cystectomy"
                    ]
                  }
                ],
                "Surgical approaches": [
                  {
                    "text": "Transurethral resectionNoninvasive papillary tumors (Ta)T1 tumors",
                    "sub_points": [
                      "Noninvasive papillary tumors (Ta)",
                      "T1 tumors"
                    ]
                  },
                  {
                    "text": "CystectomyT2/T3 tumorsSometimes for T1/Ta tumors",
                    "sub_points": [
                      "T2/T3 tumors",
                      "Sometimes for T1/Ta tumors"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Muscle invasive bladder cancer (MIBC)Overall 5-year cancer-specific survival rate < 50%Stage is most important prognostic factorPrognosis worsens with increase in stage5-year survival with tumor spread to regional lymph nodes: ~ 34%5-year survival with distant metastasis: ~ 6%Certain histologies have poorer outcome, including small cell, micropapillary, and sarcomatoidGrade is not as important a prognostic factor after muscle invasion has occurred",
                    "sub_points": [
                      "Overall 5-year cancer-specific survival rate < 50%",
                      "Stage is most important prognostic factorPrognosis worsens with increase in stage5-year survival with tumor spread to regional lymph nodes: ~ 34%5-year survival with distant metastasis: ~ 6%",
                      "Prognosis worsens with increase in stage",
                      "5-year survival with tumor spread to regional lymph nodes: ~ 34%",
                      "5-year survival with distant metastasis: ~ 6%",
                      "Certain histologies have poorer outcome, including small cell, micropapillary, and sarcomatoid",
                      "Grade is not as important a prognostic factor after muscle invasion has occurred"
                    ]
                  },
                  {
                    "text": "Non-muscle-invasive bladder cancer (NMIBC)5-year survival ~ 90%Risk of recurrence: Up to 75%Risk of progression: ~ 10-15%Risk increases with tumor size, number of tumors, grade, prior recurrence, presence of lamina propria invasion, and additional presence of CIS",
                    "sub_points": [
                      "5-year survival ~ 90%",
                      "Risk of recurrence: Up to 75%",
                      "Risk of progression: ~ 10-15%",
                      "Risk increases with tumor size, number of tumors, grade, prior recurrence, presence of lamina propria invasion, and additional presence of CIS"
                    ]
                  }
                ],
                "American Joint Committee on Cancer (AJCC) TNM Staging Summary": [
                  {
                    "text": "T0: No evidence of primary tumor"
                  },
                  {
                    "text": "Ta: Noninvasive papillary carcinoma"
                  },
                  {
                    "text": "Tis: Carcinoma in situ (flat)"
                  },
                  {
                    "text": "T1: Tumor invades subepithelial connective tissue"
                  },
                  {
                    "text": "T2a: Tumor invades superficial muscularis propria"
                  },
                  {
                    "text": "T2b: Tumor invades deep muscularis propria"
                  },
                  {
                    "text": "T3a: Tumor invades perivesical tissue microscopically"
                  },
                  {
                    "text": "T3b: Tumor invades perivesical tissue macroscopically"
                  },
                  {
                    "text": "T4a: Tumor invades prostate stroma, seminal vesicles, uterus, vagina"
                  },
                  {
                    "text": "T4b: Tumor invades pelvic wall, abdominal wall"
                  },
                  {
                    "text": "N0: No lymph node metastasis"
                  },
                  {
                    "text": "N1: Single regional lymph node metastasis in true pelvis"
                  },
                  {
                    "text": "N2: Multiple regional lymph node metastases in true pelvis"
                  },
                  {
                    "text": "N3: Lymph node metastasis to common iliac lymph nodes"
                  },
                  {
                    "text": "M0: No distant metastasis"
                  },
                  {
                    "text": "M1: Distant metastasis"
                  }
                ]
              },
              "MOLECULAR PATHOLOGY": {
                "Cytogenetics": [
                  {
                    "text": "NMIBCChromosome 9 deletion in > 50%Appear to be an early event in carcinogenesisGains of 3q, 7p, and 17q can be seenTesting (UroVysion) for these chromosomal aberrancies may provide diagnostic and prognostic informationOther early events include 9q, 9p, 11p deletionsOther later events include 8p, 17p, 11q deletions and gain of 20qFew genomic rearrangements and a near diploid karyotype compared to muscle-invasive bladder cancer",
                    "sub_points": [
                      "Chromosome 9 deletion in > 50%Appear to be an early event in carcinogenesis",
                      "Appear to be an early event in carcinogenesis",
                      "Gains of 3q, 7p, and 17q can be seenTesting (UroVysion) for these chromosomal aberrancies may provide diagnostic and prognostic information",
                      "Testing (UroVysion) for these chromosomal aberrancies may provide diagnostic and prognostic information",
                      "Other early events include 9q, 9p, 11p deletions",
                      "Other later events include 8p, 17p, 11q deletions and gain of 20q",
                      "Few genomic rearrangements and a near diploid karyotype compared to muscle-invasive bladder cancer"
                    ]
                  },
                  {
                    "text": "Muscle invasive bladder cancer (MIBC)Frequently aneuploid with multiple alterations",
                    "sub_points": [
                      "Frequently aneuploid with multiple alterations"
                    ]
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "Non-muscle-invasive bladder cancerFGFR3mutationsActivating point mutations in ~ 60-70%HRASandKRASPoint mutations in 5-10% and 5%, respectivelyHRASorKRASmutations are mutually exclusive withFGFR3mutationsPIK3CAmutationsSeen in ~ 25% of casesFrequently co-occur withFGFR3mutationsSTAG2mutationsInactivating mutations reported in ~ 32-36%CCND1gene amplificationDetected in ~ 20%miR-99a and miR-100Negatively regulateFGFR3expression and are frequently downregulated",
                    "sub_points": [
                      "FGFR3mutationsActivating point mutations in ~ 60-70%",
                      "Activating point mutations in ~ 60-70%",
                      "HRASandKRASPoint mutations in 5-10% and 5%, respectivelyHRASorKRASmutations are mutually exclusive withFGFR3mutations",
                      "Point mutations in 5-10% and 5%, respectively",
                      "HRASorKRASmutations are mutually exclusive withFGFR3mutations",
                      "PIK3CAmutationsSeen in ~ 25% of casesFrequently co-occur withFGFR3mutations",
                      "Seen in ~ 25% of cases",
                      "Frequently co-occur withFGFR3mutations",
                      "STAG2mutationsInactivating mutations reported in ~ 32-36%",
                      "Inactivating mutations reported in ~ 32-36%",
                      "CCND1gene amplificationDetected in ~ 20%",
                      "Detected in ~ 20%",
                      "miR-99a and miR-100Negatively regulateFGFR3expression and are frequently downregulated",
                      "Negatively regulateFGFR3expression and are frequently downregulated"
                    ]
                  },
                  {
                    "text": "Muscle-invasive bladder cancerThe Cancer Genome Atlas (TCGA) project has shown deregulation of several pathwaysCell cycle pathway in ~ 93%; kinase and PI(3)K pathway in ~ 72%Chromatin remodeling (89%) and components of  SWI/SNF nucleosome remodeling complex (64%)High level of genomic amplifications and deletions27 significantly amplified and 30 significantly deleted recurrent focal somatic copy number alterations (CNAs) in TCGA studyCDKN2Adeletion in 47%Other likely targeted deleted genes includeRB1, KDM6A, CCSER1,LRP1B, WWOX, PDE4D, FOXQ1, CREBBPAmplified genes includeEGFR, CCND1, PPARG, MDM2, E2F3andSOX4, ERBB2, YAP1, MYC, CCNE1, FGFR3, MYCL, ZNF703, BCL2L1TP53gene mutationsDetected in ~ 50%Mutually exclusive withMDM2amplificationCDKN2Agene alterationsDeletions in 47%; mutations in 5%High frequency of homozygous deletion inFGFR3-mutated cases, suggesting that this may be a progression pathway to invasionRB1gene alterationsDeletions in 15%; inactivating mutations in ~ 10%CDKN1Agene alterationsNull or truncating mutations in 14%; deletions in 6%Not significantly mutated in any other TCGA tumor type to dateFGFR3gene mutationsMutations in 12%Less common than in NMIBCActivatingFGFR3-TACC3fusion gene in 3%ERBB2(HER2)gene alterationsMutated in 5%, amplified in 7%ERBB3gene alterationsMutated in 11%; amplified in 2%PIK3CAgene mutationsPresent in ~ 20%PTENgene alterationsMutated in ~ 3%, deleted in ~ 13%TSC1gene mutationsPresent in ~ 8%; most truncating, some homozygousPotential target for mTOR inhibitor therapyTSC2gene mutationsReported in ~ 2%KMT2Dgene mutationsDetected in ~ 27%ARID1Agene mutationsPresent in ~ 25%KDM6AInactivating mutations/deletions in ~ 20%EP300gene mutationsDetected in ~ 15%KMT2C, KMT2A, CREBBP, CHD7, SRCAPgenesMutated in at least 10%NFE2L2gene mutationsMissense mutations in ~ 8%TXNIPgene mutationsDetected in ~ 7%, mutually exclusive withNFE2L2mutationsRXRAgene mutationsPresent in ~ 9%Other gene abnormalitiesERCC2gene mutationsMissense mutations in ~ 12%May correlate with cisplatin sensitivitySTAG2gene mutationsDetected in ~ 11%, less frequent than in NMIBC",
                    "sub_points": [
                      "The Cancer Genome Atlas (TCGA) project has shown deregulation of several pathwaysCell cycle pathway in ~ 93%; kinase and PI(3)K pathway in ~ 72%Chromatin remodeling (89%) and components of  SWI/SNF nucleosome remodeling complex (64%)",
                      "Cell cycle pathway in ~ 93%; kinase and PI(3)K pathway in ~ 72%",
                      "Chromatin remodeling (89%) and components of  SWI/SNF nucleosome remodeling complex (64%)",
                      "High level of genomic amplifications and deletions27 significantly amplified and 30 significantly deleted recurrent focal somatic copy number alterations (CNAs) in TCGA studyCDKN2Adeletion in 47%Other likely targeted deleted genes includeRB1, KDM6A, CCSER1,LRP1B, WWOX, PDE4D, FOXQ1, CREBBPAmplified genes includeEGFR, CCND1, PPARG, MDM2, E2F3andSOX4, ERBB2, YAP1, MYC, CCNE1, FGFR3, MYCL, ZNF703, BCL2L1",
                      "27 significantly amplified and 30 significantly deleted recurrent focal somatic copy number alterations (CNAs) in TCGA study",
                      "CDKN2Adeletion in 47%",
                      "Other likely targeted deleted genes includeRB1, KDM6A, CCSER1,LRP1B, WWOX, PDE4D, FOXQ1, CREBBP",
                      "Amplified genes includeEGFR, CCND1, PPARG, MDM2, E2F3andSOX4, ERBB2, YAP1, MYC, CCNE1, FGFR3, MYCL, ZNF703, BCL2L1",
                      "TP53gene mutationsDetected in ~ 50%Mutually exclusive withMDM2amplification",
                      "Detected in ~ 50%",
                      "Mutually exclusive withMDM2amplification",
                      "CDKN2Agene alterationsDeletions in 47%; mutations in 5%High frequency of homozygous deletion inFGFR3-mutated cases, suggesting that this may be a progression pathway to invasion",
                      "Deletions in 47%; mutations in 5%",
                      "High frequency of homozygous deletion inFGFR3-mutated cases, suggesting that this may be a progression pathway to invasion",
                      "RB1gene alterationsDeletions in 15%; inactivating mutations in ~ 10%",
                      "Deletions in 15%; inactivating mutations in ~ 10%",
                      "CDKN1Agene alterationsNull or truncating mutations in 14%; deletions in 6%Not significantly mutated in any other TCGA tumor type to date",
                      "Null or truncating mutations in 14%; deletions in 6%",
                      "Not significantly mutated in any other TCGA tumor type to date",
                      "FGFR3gene mutationsMutations in 12%Less common than in NMIBCActivatingFGFR3-TACC3fusion gene in 3%",
                      "Mutations in 12%",
                      "Less common than in NMIBC",
                      "ActivatingFGFR3-TACC3fusion gene in 3%",
                      "ERBB2(HER2)gene alterationsMutated in 5%, amplified in 7%",
                      "Mutated in 5%, amplified in 7%",
                      "ERBB3gene alterationsMutated in 11%; amplified in 2%",
                      "Mutated in 11%; amplified in 2%",
                      "PIK3CAgene mutationsPresent in ~ 20%",
                      "Present in ~ 20%",
                      "PTENgene alterationsMutated in ~ 3%, deleted in ~ 13%",
                      "Mutated in ~ 3%, deleted in ~ 13%",
                      "TSC1gene mutationsPresent in ~ 8%; most truncating, some homozygousPotential target for mTOR inhibitor therapy",
                      "Present in ~ 8%; most truncating, some homozygous",
                      "Potential target for mTOR inhibitor therapy",
                      "TSC2gene mutationsReported in ~ 2%",
                      "Reported in ~ 2%",
                      "KMT2Dgene mutationsDetected in ~ 27%",
                      "Detected in ~ 27%",
                      "ARID1Agene mutationsPresent in ~ 25%",
                      "Present in ~ 25%",
                      "KDM6AInactivating mutations/deletions in ~ 20%",
                      "Inactivating mutations/deletions in ~ 20%",
                      "EP300gene mutationsDetected in ~ 15%",
                      "Detected in ~ 15%",
                      "KMT2C, KMT2A, CREBBP, CHD7, SRCAPgenesMutated in at least 10%",
                      "Mutated in at least 10%",
                      "NFE2L2gene mutationsMissense mutations in ~ 8%",
                      "Missense mutations in ~ 8%",
                      "TXNIPgene mutationsDetected in ~ 7%, mutually exclusive withNFE2L2mutations",
                      "Detected in ~ 7%, mutually exclusive withNFE2L2mutations",
                      "RXRAgene mutationsPresent in ~ 9%",
                      "Present in ~ 9%",
                      "Other gene abnormalities",
                      "ERCC2gene mutationsMissense mutations in ~ 12%May correlate with cisplatin sensitivity",
                      "Missense mutations in ~ 12%",
                      "May correlate with cisplatin sensitivity",
                      "STAG2gene mutationsDetected in ~ 11%, less frequent than in NMIBC",
                      "Detected in ~ 11%, less frequent than in NMIBC"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Luminal and basal molecular subtypes in muscle invasive bladder cancer (MIBC)Analogous to breast cancer",
                    "sub_points": [
                      "Analogous to breast cancer"
                    ]
                  },
                  {
                    "text": "Reported in several studies, including The Cancer Genome Atlas (TCGA) projectCluster I: Papillary-likeEnriched in tumors with papillary morphologyFGFR3copy number gains, elevatedFGFR3expression, highERBB2(HER2) expression levelsFeatures similar to luminal A breast cancerCluster IINo papillary or overexpressedFGFR3associationOtherwise similar to cluster ICluster III: Basal/squamous-likeGene signature similar to basal-like breast cancers and squamous carcinomas of head and neck and lungExpress epithelial lineage genes includingKRT14, KRT5, KRT6A, EGFRSome tumors show variant squamous histology",
                    "sub_points": [
                      "Cluster I: Papillary-likeEnriched in tumors with papillary morphologyFGFR3copy number gains, elevatedFGFR3expression, highERBB2(HER2) expression levelsFeatures similar to luminal A breast cancer",
                      "Enriched in tumors with papillary morphology",
                      "FGFR3copy number gains, elevatedFGFR3expression, highERBB2(HER2) expression levels",
                      "Features similar to luminal A breast cancer",
                      "Cluster IINo papillary or overexpressedFGFR3associationOtherwise similar to cluster I",
                      "No papillary or overexpressedFGFR3association",
                      "Otherwise similar to cluster I",
                      "Cluster III: Basal/squamous-likeGene signature similar to basal-like breast cancers and squamous carcinomas of head and neck and lungExpress epithelial lineage genes includingKRT14, KRT5, KRT6A, EGFRSome tumors show variant squamous histology",
                      "Gene signature similar to basal-like breast cancers and squamous carcinomas of head and neck and lung",
                      "Express epithelial lineage genes includingKRT14, KRT5, KRT6A, EGFR",
                      "Some tumors show variant squamous histology"
                    ]
                  },
                  {
                    "text": "Other studies report \"basal\", \"luminal,\" and p53-like subtypesBasal MIBCSquamous differentiation, p63 activationEnriched forRB1mutations/deletions,CCND1,CCNE1,SOX4,andE2F3amplificationAssociated with poorest prognosisLuminal MIBCExpress luminal breast cancer markersExpress markers of urothelial differentiationEnriched forFGFR3andTSC1mutationsTP53-like MIBCGene expression similar to luminal MIBCPoor response to neoadjuvant cisplatin, methotrexate, vinblastine, and doxorubicin chemotherapyVirtually all chemoresistant tumors adopt a TP53-like phenotype after therapy",
                    "sub_points": [
                      "Basal MIBCSquamous differentiation, p63 activationEnriched forRB1mutations/deletions,CCND1,CCNE1,SOX4,andE2F3amplificationAssociated with poorest prognosis",
                      "Squamous differentiation, p63 activation",
                      "Enriched forRB1mutations/deletions,CCND1,CCNE1,SOX4,andE2F3amplification",
                      "Associated with poorest prognosis",
                      "Luminal MIBCExpress luminal breast cancer markersExpress markers of urothelial differentiationEnriched forFGFR3andTSC1mutations",
                      "Express luminal breast cancer markers",
                      "Express markers of urothelial differentiation",
                      "Enriched forFGFR3andTSC1mutations",
                      "TP53-like MIBCGene expression similar to luminal MIBCPoor response to neoadjuvant cisplatin, methotrexate, vinblastine, and doxorubicin chemotherapyVirtually all chemoresistant tumors adopt a TP53-like phenotype after therapy",
                      "Gene expression similar to luminal MIBC",
                      "Poor response to neoadjuvant cisplatin, methotrexate, vinblastine, and doxorubicin chemotherapy",
                      "Virtually all chemoresistant tumors adopt a TP53-like phenotype after therapy"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Papillary lesionsPapilloma and papillary urothelial neoplasm of low malignant potential (PUNLMP)Hyperplastic and neoplastic urothelium thrown into papillary structures with a central thin fibrovascular coreUrothelium appears normal and hyperplastic respectivelyLow-grade urothelial carcinomaLow-grade cytologic atypia; branching and fusion of papillaeHigh-grade urothelial carcinomaHigh-grade cytologic atypia, more branching and fusion of papillae, may have associated invasion",
                    "sub_points": [
                      "Papilloma and papillary urothelial neoplasm of low malignant potential (PUNLMP)Hyperplastic and neoplastic urothelium thrown into papillary structures with a central thin fibrovascular coreUrothelium appears normal and hyperplastic respectively",
                      "Hyperplastic and neoplastic urothelium thrown into papillary structures with a central thin fibrovascular core",
                      "Urothelium appears normal and hyperplastic respectively",
                      "Low-grade urothelial carcinomaLow-grade cytologic atypia; branching and fusion of papillae",
                      "Low-grade cytologic atypia; branching and fusion of papillae",
                      "High-grade urothelial carcinomaHigh-grade cytologic atypia, more branching and fusion of papillae, may have associated invasion",
                      "High-grade cytologic atypia, more branching and fusion of papillae, may have associated invasion"
                    ]
                  },
                  {
                    "text": "Flat lesionsCarcinoma in situ (CIS)Noninvasive, usually multifocalDisordered, mitotically active, cytologically high-grade cellsSubepithelial proliferation of small capillaries common",
                    "sub_points": [
                      "Carcinoma in situ (CIS)Noninvasive, usually multifocalDisordered, mitotically active, cytologically high-grade cellsSubepithelial proliferation of small capillaries common",
                      "Noninvasive, usually multifocal",
                      "Disordered, mitotically active, cytologically high-grade cells",
                      "Subepithelial proliferation of small capillaries common"
                    ]
                  },
                  {
                    "text": "Invasive carcinomaTumor invades through basement membrane into lamina propria (T1) or muscularis propria (T2)Most are high grade, and most arise from dysplasia or CIS, or from high-grade papillary tumorsVariant histology includes nested, micropapillary, plasmacytoid, small cellAberrant differentiation, including squamous and glandular, can occur",
                    "sub_points": [
                      "Tumor invades through basement membrane into lamina propria (T1) or muscularis propria (T2)",
                      "Most are high grade, and most arise from dysplasia or CIS, or from high-grade papillary tumors",
                      "Variant histology includes nested, micropapillary, plasmacytoid, small cell",
                      "Aberrant differentiation, including squamous and glandular, can occur"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Carcinoma in situ (flat)Full-thickness staining for cytokeratin 20; p53 nuclear staining",
                    "sub_points": [
                      "Full-thickness staining for cytokeratin 20; p53 nuclear staining"
                    ]
                  },
                  {
                    "text": "Urothelial carcinomaFrequently positive for cytokeratins 7 and 20Positive for high molecular weight cytokeratins, p63, and GATA3",
                    "sub_points": [
                      "Frequently positive for cytokeratins 7 and 20",
                      "Positive for high molecular weight cytokeratins, p63, and GATA3"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "UroVysionInterphase FISH-based assay testing for aneuploidy of chromosomes 3, 7, and 17, and for loss of 9q21 in urothelial cells in urineFDA approved for surveillance of recurrence in patients with previously diagnosed urothelial carcinomaAlso approved for screening of high-risk patients (smokers) with hematuriaImproves sensitivity of urine cytology for detection of urothelial carcinomaReported sensitivity: 69-87% specificity: 89-96%May provide prognostic information for NMIBC recurrenceWhen performed after BCG therapy, may provide predictive information for therapy failure",
                    "sub_points": [
                      "Interphase FISH-based assay testing for aneuploidy of chromosomes 3, 7, and 17, and for loss of 9q21 in urothelial cells in urine",
                      "FDA approved for surveillance of recurrence in patients with previously diagnosed urothelial carcinoma",
                      "Also approved for screening of high-risk patients (smokers) with hematuria",
                      "Improves sensitivity of urine cytology for detection of urothelial carcinoma",
                      "Reported sensitivity: 69-87% specificity: 89-96%",
                      "May provide prognostic information for NMIBC recurrence",
                      "When performed after BCG therapy, may provide predictive information for therapy failure"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Papillary/Polypoid Cystitis": [
                  {
                    "text": "Commonly associated with indwelling catheters"
                  },
                  {
                    "text": "Stromal edema and inflammation"
                  },
                  {
                    "text": "No significant cytologic atypia"
                  }
                ],
                "Pseudocarcinomatous Hyperplasia": [
                  {
                    "text": "Benign reactive epithelial proliferation"
                  },
                  {
                    "text": "Usually in setting of prior radiation or chemotherapy"
                  },
                  {
                    "text": "Inflammation and edema; may have atypia"
                  }
                ],
                "Nonurothelial Tumors": [
                  {
                    "text": "Local extension from tumors such as prostate, cervix, or other high-grade gynecologic carcinomas can mimic high-grade invasive urothelial carcinoma"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Tumors of Fibrous Tissue": {
            "name": "Molecular Alterations in Tumors of Fibrous Tissue",
            "url": "https://app.pathprimer.com/document/2e22191f-9455-4b6e-bd08-1bf3c4555e4e/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Mesenchymal tumors that show differentiation toward fibroblasts &/or myofibroblasts, and that have intermediate or malignant behavior"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Desmoid-Type Fibromatosis": [
                  {
                    "text": "Age/genderChildren → middle ageM = F, except in abdominal wall where F >> M",
                    "sub_points": [
                      "Children → middle age",
                      "M = F, except in abdominal wall where F >> M"
                    ]
                  },
                  {
                    "text": "Body site locationSporadicDeep soft tissue of shoulder, chest and back, thigh, head and neck, mesenteryFamilial/hereditaryIntraabdominal",
                    "sub_points": [
                      "SporadicDeep soft tissue of shoulder, chest and back, thigh, head and neck, mesentery",
                      "Deep soft tissue of shoulder, chest and back, thigh, head and neck, mesentery",
                      "Familial/hereditaryIntraabdominal",
                      "Intraabdominal"
                    ]
                  },
                  {
                    "text": "Behavior: Locally aggressive; may be multifocal in hereditary/familial cases"
                  },
                  {
                    "text": "Treatment: Ranges from none to conservative resection &/or NSAIDs, radiation, chemotherapy of various types"
                  }
                ],
                "Inflammatory Myofibroblastic Tumor (IMFT)": [
                  {
                    "text": "Age/genderChildren → young adults most commonlyF > M",
                    "sub_points": [
                      "Children → young adults most commonly",
                      "F > M"
                    ]
                  },
                  {
                    "text": "Body site locationLung, mesentery, omentum > soft tissues, mostly head and neck > boneRare epithelioid variant of IMFT is almost exclusively intraabdominal",
                    "sub_points": [
                      "Lung, mesentery, omentum > soft tissues, mostly head and neck > bone",
                      "Rare epithelioid variant of IMFT is almost exclusively intraabdominal"
                    ]
                  },
                  {
                    "text": "Behavior: Most cases benign; 25% local recurrence rate; rare metastasesIntraabdominal epithelioid IMFT is aggressive, with high mortality rate",
                    "sub_points": [
                      "Intraabdominal epithelioid IMFT is aggressive, with high mortality rate"
                    ]
                  },
                  {
                    "text": "Treatment: Marginal resection in most; wide resection in aggressive cases"
                  }
                ],
                "Low-Grade Myofibroblastic Sarcoma": [
                  {
                    "text": "Age/genderAdults > children",
                    "sub_points": [
                      "Adults > children"
                    ]
                  },
                  {
                    "text": "Body site locationExtremities, head and neck (especially oral cavity and tongue)",
                    "sub_points": [
                      "Extremities, head and neck (especially oral cavity and tongue)"
                    ]
                  },
                  {
                    "text": "Behavior: Can locally recur; rarely metastasizes"
                  },
                  {
                    "text": "Treatment: Complete conservative resection"
                  }
                ],
                "Dermatofibrosarcoma Protuberans (DFSP)": [
                  {
                    "text": "Age/genderAdults (20s-40s) most commonly; rarely in children, except giant cell fibroblastoma variantM > F",
                    "sub_points": [
                      "Adults (20s-40s) most commonly; rarely in children, except giant cell fibroblastoma variant",
                      "M > F"
                    ]
                  },
                  {
                    "text": "Body site locationSuperficial tissues of trunk, proximal upper extremity, proximal lower extremity > others",
                    "sub_points": [
                      "Superficial tissues of trunk, proximal upper extremity, proximal lower extremity > others"
                    ]
                  },
                  {
                    "text": "Behavior: High rate of local recurrence (~ 50%); cases with high-grade sarcoma show ~ 15% metastasis rate"
                  },
                  {
                    "text": "Treatment: Wide resection ± adjuvant therapy"
                  }
                ],
                "Solitary Fibrous Tumor (SFT)": [
                  {
                    "text": "Age/genderYoung → older adultsM = F, except fat-forming SFT, where M > F",
                    "sub_points": [
                      "Young → older adults",
                      "M = F, except fat-forming SFT, where M > F"
                    ]
                  },
                  {
                    "text": "Body site location60%: Deep soft tissue of trunk, extremities, and head and neck, many visceral and mesothelial-lined spaces40%: Superficial tissue",
                    "sub_points": [
                      "60%: Deep soft tissue of trunk, extremities, and head and neck, many visceral and mesothelial-lined spaces",
                      "40%: Superficial tissue"
                    ]
                  },
                  {
                    "text": "Behavior: Classic type 85% benign, but 10% may metastasize sometimes after many years; malignant type commonly metastasizes; dedifferentiated type is aggressive"
                  },
                  {
                    "text": "Treatment: Surgical resection ± adjuvant therapy"
                  }
                ],
                "Myxoinflammatory Fibroblastic Sarcoma": [
                  {
                    "text": "Age/genderAdults >> childrenM = F",
                    "sub_points": [
                      "Adults >> children",
                      "M = F"
                    ]
                  },
                  {
                    "text": "Body site locationAcral >> elbow, knee",
                    "sub_points": [
                      "Acral >> elbow, knee"
                    ]
                  },
                  {
                    "text": "Behavior: High local recurrence rate (up to 70%); rarely metastasizes"
                  },
                  {
                    "text": "Treatment: Complete resection"
                  }
                ],
                "Myxofibrosarcoma": [
                  {
                    "text": "Age/genderOlder adults (≥ 50s) >> young adults > childrenM slightly > F",
                    "sub_points": [
                      "Older adults (≥ 50s) >> young adults > children",
                      "M slightly > F"
                    ]
                  },
                  {
                    "text": "Body site location60%: Deep soft tissues of extremities > trunk > head and neck > acral40% superficial soft tissue",
                    "sub_points": [
                      "60%: Deep soft tissues of extremities > trunk > head and neck > acral",
                      "40% superficial soft tissue"
                    ]
                  },
                  {
                    "text": "Behavior: Grade 2 and 3 tumors can metastasize; grade 1 recurrences can transform to higher grade; better prognosis for smaller and superficial tumors; 5-year survival: of 70%"
                  },
                  {
                    "text": "Treatment: Complete resection ± adjuvant therapy"
                  }
                ],
                "Low-Grade Fibromyxoid Sarcoma": [
                  {
                    "text": "Age/genderYoung → middle-aged adults most commonlyM slightly > F",
                    "sub_points": [
                      "Young → middle-aged adults most commonly",
                      "M slightly > F"
                    ]
                  },
                  {
                    "text": "Body site locationDeep soft tissue of proximal extremities, trunk >> other sitesRarely may occur in superficial soft tissue (more commonly in children)",
                    "sub_points": [
                      "Deep soft tissue of proximal extremities, trunk >> other sites",
                      "Rarely may occur in superficial soft tissue (more commonly in children)"
                    ]
                  },
                  {
                    "text": "Behavior: High rate of local recurrences and ~ 40% disease-related mortality; often after many years"
                  },
                  {
                    "text": "Treatment: complete resection"
                  }
                ],
                "Sclerosing Epithelioid Fibrosarcoma": [
                  {
                    "text": "Age/genderMiddle aged → older adultsM = F",
                    "sub_points": [
                      "Middle aged → older adults",
                      "M = F"
                    ]
                  },
                  {
                    "text": "Body site locationDeep soft tissue of lower extremity, limb girdle > upper extremity > trunk > head and neck; rare reports in viscera, bone",
                    "sub_points": [
                      "Deep soft tissue of lower extremity, limb girdle > upper extremity > trunk > head and neck; rare reports in viscera, bone"
                    ]
                  },
                  {
                    "text": "Behavior: High local recurrence rate (~ 50%); up to 80% metastatic rate"
                  },
                  {
                    "text": "Treatment: Complete resection ± adjuvant therapy"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Desmoid-Type Fibromatosis": [
                  {
                    "text": "ArchitectureInfiltrative tumor frontLong, sweeping fasciclesVariably collagenized background to the point of appearing keloidal; rarely myxoidThin-walled vessels that are squeezed shut or ectatic± perivascular congeries of chronic inflammatory cells",
                    "sub_points": [
                      "Infiltrative tumor front",
                      "Long, sweeping fascicles",
                      "Variably collagenized background to the point of appearing keloidal; rarely myxoid",
                      "Thin-walled vessels that are squeezed shut or ectatic± perivascular congeries of chronic inflammatory cells",
                      "± perivascular congeries of chronic inflammatory cells"
                    ]
                  },
                  {
                    "text": "CellsBland plump to elongate spindled myofibroblastsCytoplasm often amphophilicNuclei vesicular ± small nucleoliMast cells (average ~ 1 per HPF)",
                    "sub_points": [
                      "Bland plump to elongate spindled myofibroblastsCytoplasm often amphophilic",
                      "Cytoplasm often amphophilic",
                      "Nuclei vesicular ± small nucleoli",
                      "Mast cells (average ~ 1 per HPF)"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: Positive for aberrant nuclear β-catenin expression in ~ 70%Nuclear expression is often focal, with many cells showing normal expressionIHC: Often positive for SMA; may rarely be positive (patchy) for S100 protein",
                    "sub_points": [
                      "IHC: Positive for aberrant nuclear β-catenin expression in ~ 70%Nuclear expression is often focal, with many cells showing normal expression",
                      "Nuclear expression is often focal, with many cells showing normal expression",
                      "IHC: Often positive for SMA; may rarely be positive (patchy) for S100 protein"
                    ]
                  }
                ],
                "Inflammatory Myofibroblastic Tumor (IMFT)": [
                  {
                    "text": "Architecture4 patternsPattern 1: Granulation tissue-like or nodular fasciitis-likePattern 2: Hypercellular spindled fascicularPattern 3: Hypocellular scar-like or desmoid-likePattern 4: Hypercellular sheets of predominantly epithelioid cells in a usually myxoid stromal backgroundInflammation always presentPatterns 1-3: Usually lymphocytes, eosinophils, plasma cellsPattern 4: Often many neutrophils or eosinophils, few lymphocytes, uncommonly plasma cells",
                    "sub_points": [
                      "4 patternsPattern 1: Granulation tissue-like or nodular fasciitis-likePattern 2: Hypercellular spindled fascicularPattern 3: Hypocellular scar-like or desmoid-likePattern 4: Hypercellular sheets of predominantly epithelioid cells in a usually myxoid stromal background",
                      "Pattern 1: Granulation tissue-like or nodular fasciitis-like",
                      "Pattern 2: Hypercellular spindled fascicular",
                      "Pattern 3: Hypocellular scar-like or desmoid-like",
                      "Pattern 4: Hypercellular sheets of predominantly epithelioid cells in a usually myxoid stromal background",
                      "Inflammation always presentPatterns 1-3: Usually lymphocytes, eosinophils, plasma cellsPattern 4: Often many neutrophils or eosinophils, few lymphocytes, uncommonly plasma cells",
                      "Patterns 1-3: Usually lymphocytes, eosinophils, plasma cells",
                      "Pattern 4: Often many neutrophils or eosinophils, few lymphocytes, uncommonly plasma cells"
                    ]
                  },
                  {
                    "text": "CellsMyofibroblasts most commonly, with plump spindled to polygonal shapeReed-Sternberg-like or ganglion-like cells may be presentPattern 4 epithelioid cells are large with vesicular nuclei and often single macronucleoliCytoplasm is usually amphophilic, but may uncommonly be eosinophilic",
                    "sub_points": [
                      "Myofibroblasts most commonly, with plump spindled to polygonal shapeReed-Sternberg-like or ganglion-like cells may be presentPattern 4 epithelioid cells are large with vesicular nuclei and often single macronucleoliCytoplasm is usually amphophilic, but may uncommonly be eosinophilic",
                      "Reed-Sternberg-like or ganglion-like cells may be present",
                      "Pattern 4 epithelioid cells are large with vesicular nuclei and often single macronucleoli",
                      "Cytoplasm is usually amphophilic, but may uncommonly be eosinophilic"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHCPatterns 1-3 IMFT: 50% positive for ALK, variable positivity for SMA and CAM5.2 keratins; a few positive for desmin; negative for caldesmon; may be positive for MDM2Pattern 4 IMFT: ALK positive (usually cell membrane or paranuclear), desmin positive, SMA ±; CD30 positive; keratins/EMA, S100, caldesmon negativeFISH: Positive forALKgene rearrangementAggressive epithelioid IMFT is mostly positive forRANBP2-ALKfusion",
                    "sub_points": [
                      "IHCPatterns 1-3 IMFT: 50% positive for ALK, variable positivity for SMA and CAM5.2 keratins; a few positive for desmin; negative for caldesmon; may be positive for MDM2Pattern 4 IMFT: ALK positive (usually cell membrane or paranuclear), desmin positive, SMA ±; CD30 positive; keratins/EMA, S100, caldesmon negative",
                      "Patterns 1-3 IMFT: 50% positive for ALK, variable positivity for SMA and CAM5.2 keratins; a few positive for desmin; negative for caldesmon; may be positive for MDM2",
                      "Pattern 4 IMFT: ALK positive (usually cell membrane or paranuclear), desmin positive, SMA ±; CD30 positive; keratins/EMA, S100, caldesmon negative",
                      "FISH: Positive forALKgene rearrangementAggressive epithelioid IMFT is mostly positive forRANBP2-ALKfusion",
                      "Aggressive epithelioid IMFT is mostly positive forRANBP2-ALKfusion"
                    ]
                  }
                ],
                "Low-Grade Myofibroblastic Sarcoma": [
                  {
                    "text": "ArchitectureLong, sweeping fascicles of spindled tumor cellsStoriform pattern less commonUsually no fibrosis± thin-walled capillaries",
                    "sub_points": [
                      "Long, sweeping fascicles of spindled tumor cells",
                      "Storiform pattern less common",
                      "Usually no fibrosis",
                      "± thin-walled capillaries"
                    ]
                  },
                  {
                    "text": "CellsElongate spindled cells, but may be plumpNuclei vary mildly in size and are hyperchromatic",
                    "sub_points": [
                      "Elongate spindled cells, but may be plump",
                      "Nuclei vary mildly in size and are hyperchromatic"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: Variable positivity for SMA, desmin; few cases may be CD34 positive, negative for H-caldesmon",
                    "sub_points": [
                      "IHC: Variable positivity for SMA, desmin; few cases may be CD34 positive, negative for H-caldesmon"
                    ]
                  }
                ],
                "Dermatofibrosarcoma Protuberans": [
                  {
                    "text": "ArchitectureStoriform or cartwheel whorls with characteristic \"honeycomb\" infiltration of subcutaneous fatHigher grade foci most commonly consist of fibrosarcomatous herringbone or fascicular arrangementsGiant cell fibroblastoma is hypocellular myxoid or fibrotic ± pseudovascular cleftsFocal myoid differentiation uncommon (nest of eosinophilic, actin-positive myofibroblastic cells)",
                    "sub_points": [
                      "Storiform or cartwheel whorls with characteristic \"honeycomb\" infiltration of subcutaneous fat",
                      "Higher grade foci most commonly consist of fibrosarcomatous herringbone or fascicular arrangements",
                      "Giant cell fibroblastoma is hypocellular myxoid or fibrotic ± pseudovascular clefts",
                      "Focal myoid differentiation uncommon (nest of eosinophilic, actin-positive myofibroblastic cells)"
                    ]
                  },
                  {
                    "text": "CellsOvoid to spindled most commonly, with pale ovoid to spindled nuclei without atypiaContain melanin pigment in Bednar variantGiant cell fibroblastoma has scattered giant cells, which are mostly multinucleatedHigher grade areas usually contain elongated spindled cells with hyperchromasia and increased mitosesRare, high-grade area may resemble high-grade pleomorphic undifferentiated sarcoma",
                    "sub_points": [
                      "Ovoid to spindled most commonly, with pale ovoid to spindled nuclei without atypia",
                      "Contain melanin pigment in Bednar variant",
                      "Giant cell fibroblastoma has scattered giant cells, which are mostly multinucleated",
                      "Higher grade areas usually contain elongated spindled cells with hyperchromasia and increased mitosesRare, high-grade area may resemble high-grade pleomorphic undifferentiated sarcoma",
                      "Rare, high-grade area may resemble high-grade pleomorphic undifferentiated sarcoma"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: CD34 positive in almost all cases; high-grade areas often CD34 negativeFISH: Positive for rearrangement ofPDGFRB",
                    "sub_points": [
                      "IHC: CD34 positive in almost all cases; high-grade areas often CD34 negative",
                      "FISH: Positive for rearrangement ofPDGFRB"
                    ]
                  }
                ],
                "Solitary Fibrous Tumor": [
                  {
                    "text": "ArchitectureClassic formhas a \"patternless\" pattern of hypocellular and hypercellular zones haphazardly arrangedCellular formis hypercellular with a hemangiopericytomatous growth patternFat-forming SFThas classic features with many interspersed adipocytesGiant cell angiofibroma formcontains multinucleated giant cells ± pseudovascular spaces and classic featuresMalignant SFTshows increased cellularity, increased mitoses (> 4/10 HPF), increased hyperchromasia of tumor nuclei, ± necrosis, ± infiltrative marginsDedifferentiated SFTshows abrupt transition from classic variant to high-grade sarcoma",
                    "sub_points": [
                      "Classic formhas a \"patternless\" pattern of hypocellular and hypercellular zones haphazardly arranged",
                      "Cellular formis hypercellular with a hemangiopericytomatous growth pattern",
                      "Fat-forming SFThas classic features with many interspersed adipocytes",
                      "Giant cell angiofibroma formcontains multinucleated giant cells ± pseudovascular spaces and classic features",
                      "Malignant SFTshows increased cellularity, increased mitoses (> 4/10 HPF), increased hyperchromasia of tumor nuclei, ± necrosis, ± infiltrative margins",
                      "Dedifferentiated SFTshows abrupt transition from classic variant to high-grade sarcoma"
                    ]
                  },
                  {
                    "text": "CellsLow-grade forms: Ovoid to plump spindled cells with relatively uniform ovoid and slightly vesicular nucleiGiant cell angiofibroma form: Also includes scattered multinucleated giant cells without marked atypiaDedifferentiated form: Marked nuclear pleomorphism in large and variably shaped tumor cells in dedifferentiated areas",
                    "sub_points": [
                      "Low-grade forms: Ovoid to plump spindled cells with relatively uniform ovoid and slightly vesicular nuclei",
                      "Giant cell angiofibroma form: Also includes scattered multinucleated giant cells without marked atypia",
                      "Dedifferentiated form: Marked nuclear pleomorphism in large and variably shaped tumor cells in dedifferentiated areas"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: Most cases show diffuse CD34 reactivity; high-grade areas may lack CD34; nearly all cases diffusely positive for STAT6PCR: Positive forNAB2-STAT6gene fusion",
                    "sub_points": [
                      "IHC: Most cases show diffuse CD34 reactivity; high-grade areas may lack CD34; nearly all cases diffusely positive for STAT6",
                      "PCR: Positive forNAB2-STAT6gene fusion"
                    ]
                  }
                ],
                "Myxoinflammatory Fibroblastic Sarcoma": [
                  {
                    "text": "ArchitectureMultilobulated predominantly subcutaneous with infiltrative bordersIntermixed myxoid and fibrotic lobules, which are intensely inflamed (acute and chronic)± hemosiderin depositionSome cases have areas resembling hemosiderotic fibrolipomatous tumor (HSFLT) or pleomorphic hyalinizing angiectatic tumor (PHAT)A few cases may progress to myxofibrosarcoma morphologically",
                    "sub_points": [
                      "Multilobulated predominantly subcutaneous with infiltrative borders",
                      "Intermixed myxoid and fibrotic lobules, which are intensely inflamed (acute and chronic)",
                      "± hemosiderin deposition",
                      "Some cases have areas resembling hemosiderotic fibrolipomatous tumor (HSFLT) or pleomorphic hyalinizing angiectatic tumor (PHAT)",
                      "A few cases may progress to myxofibrosarcoma morphologically"
                    ]
                  },
                  {
                    "text": "CellsMononuclear epithelioid fibroblasts, plump spindle fibroblasts most commonLarge Reed-Sternberg-like or virocyte-like fibroblasts are scattered throughoutCytoplasmic vacuolation common, mimicking lipoblasts in some casesMarked inflammation",
                    "sub_points": [
                      "Mononuclear epithelioid fibroblasts, plump spindle fibroblasts most common",
                      "Large Reed-Sternberg-like or virocyte-like fibroblasts are scattered throughout",
                      "Cytoplasmic vacuolation common, mimicking lipoblasts in some cases",
                      "Marked inflammation"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: Vimentin positive, variable CD34/CD68 positive; usually negative for actinsFISH: Positive for t(1:10) in almost all cases",
                    "sub_points": [
                      "IHC: Vimentin positive, variable CD34/CD68 positive; usually negative for actins",
                      "FISH: Positive for t(1:10) in almost all cases"
                    ]
                  }
                ],
                "Myxofibrosarcoma": [
                  {
                    "text": "Architecture3 grades, but all contain myxoid lobules with incomplete fibrous septaAll grades also include thin-walled curvilinear vessels, often with perivascular hypercellularity ± inflammationGrade 1: HypocellularGrade 2: Moderately cellularGrade 3: Includes sheets of cellsMany cases contain mixtures of low- and higher grade tumor",
                    "sub_points": [
                      "3 grades, but all contain myxoid lobules with incomplete fibrous septaAll grades also include thin-walled curvilinear vessels, often with perivascular hypercellularity ± inflammation",
                      "All grades also include thin-walled curvilinear vessels, often with perivascular hypercellularity ± inflammation",
                      "Grade 1: Hypocellular",
                      "Grade 2: Moderately cellular",
                      "Grade 3: Includes sheets of cells",
                      "Many cases contain mixtures of low- and higher grade tumor"
                    ]
                  },
                  {
                    "text": "CellsSpindled to polygonal to large pleomorphic multinucleated tumor giant cellsNuclear are mildly to markedly atypical (hyperchromatic, coarse irregular chromatin, macronucleoli) depending on gradeNecrosis and mitoses increase with gradeRare epithelioid cell variantPseudolipoblasts (vacuolated tumor cells containing mucin) common",
                    "sub_points": [
                      "Spindled to polygonal to large pleomorphic multinucleated tumor giant cellsNuclear are mildly to markedly atypical (hyperchromatic, coarse irregular chromatin, macronucleoli) depending on gradeNecrosis and mitoses increase with grade",
                      "Nuclear are mildly to markedly atypical (hyperchromatic, coarse irregular chromatin, macronucleoli) depending on grade",
                      "Necrosis and mitoses increase with grade",
                      "Rare epithelioid cell variant",
                      "Pseudolipoblasts (vacuolated tumor cells containing mucin) common"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: ~ 50% have CD34 reactivity; ± scattered actin reactivityKaryotype: Complex aneuploid in almost all cases",
                    "sub_points": [
                      "IHC: ~ 50% have CD34 reactivity; ± scattered actin reactivity",
                      "Karyotype: Complex aneuploid in almost all cases"
                    ]
                  }
                ],
                "Low-Grade Fibromyxoid Sarcoma": [
                  {
                    "text": "ArchitectureMyxoid and fibrous areas, usually with abrupt interfaceWhorls and fascicles of spindled cells form entire tumorFibrous areas usually similar to desmoid tumor in cellularityMyxoid areas usually contain waterfall- or arcade-like arrangements of blood vessels20% of cases may contain hypercellular areasGiant rosettes with central collagenous cores uncommonly occur",
                    "sub_points": [
                      "Myxoid and fibrous areas, usually with abrupt interfaceWhorls and fascicles of spindled cells form entire tumor",
                      "Whorls and fascicles of spindled cells form entire tumor",
                      "Fibrous areas usually similar to desmoid tumor in cellularity",
                      "Myxoid areas usually contain waterfall- or arcade-like arrangements of blood vessels",
                      "20% of cases may contain hypercellular areas",
                      "Giant rosettes with central collagenous cores uncommonly occur"
                    ]
                  },
                  {
                    "text": "CellsSpindled cells with ovoid or blunt-ended nucleiNuclei usually show minimal variation in shape and size with few mitoses",
                    "sub_points": [
                      "Spindled cells with ovoid or blunt-ended nuclei",
                      "Nuclei usually show minimal variation in shape and size with few mitoses"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHC: MUC4 positive in almost all cases; EMA positive in 80%; ± focal actinsFISH: Positive forFUSrearrangement in almost all cases",
                    "sub_points": [
                      "IHC: MUC4 positive in almost all cases; EMA positive in 80%; ± focal actins",
                      "FISH: Positive forFUSrearrangement in almost all cases"
                    ]
                  }
                ],
                "Sclerosing Epithelioid Fibrosarcoma": [
                  {
                    "text": "ArchitectureProminently sclerotic to myxohyaline tumor± osteochondroid metaplasia± areas resembling LGFMS or fibrosarcoma with fascicles of spindled cells",
                    "sub_points": [
                      "Prominently sclerotic to myxohyaline tumor",
                      "± osteochondroid metaplasia",
                      "± areas resembling LGFMS or fibrosarcoma with fascicles of spindled cells"
                    ]
                  },
                  {
                    "text": "CellsSmall epithelioid often with clear cytoplasmRound nuclei with little variation, and usually low mitotic rate",
                    "sub_points": [
                      "Small epithelioid often with clear cytoplasm",
                      "Round nuclei with little variation, and usually low mitotic rate"
                    ]
                  },
                  {
                    "text": "Ancillary studiesShares same IHC and FISH findings as in LGFMS",
                    "sub_points": [
                      "Shares same IHC and FISH findings as in LGFMS"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Differential Diagnosis (DDx) for Desmoid-Type Fibromatosis": [
                  {
                    "text": "Superficial fibromatosis:Location helpful; often more cellular than desmoid-type fibromatosis, can show nuclear β-catenin"
                  },
                  {
                    "text": "Exuberant scar:Noninfiltrative margin; more variable histologically with scattered inflammation, macrophages; negative for nuclear β-catenin"
                  }
                ],
                "DDx for Inflammatory Myofibroblastic Tumor": [
                  {
                    "text": "Nodular fasciitis: Small, rapidly growing; acute hemorrhage; often more mitoses than IMFT; negative forALKgene fusion"
                  },
                  {
                    "text": "Inflamed smooth muscle tumor:Eosinophilic spindled cells with cigar-shaped nuclei present at least focally; strong, diffuse reactivity for 2 muscle markers, often including caldesmon"
                  }
                ],
                "DDx for Low-Grade Myofibroblastic Sarcoma": [
                  {
                    "text": "Leiomyosarcoma:Eosinophilic cells have features of smooth muscle, including contraction band-like clearing; strongly positive for caldesmon in many cases"
                  }
                ],
                "DDx for Dermatofibrosarcoma Protuberans": [
                  {
                    "text": "Adult fibrosarcoma:Diagnosis of exclusion; negative for CD34"
                  },
                  {
                    "text": "Fibrous histiocytoma:More variable cell population than DFSP; lacks honeycomb invasive pattern"
                  },
                  {
                    "text": "Plaque-like CD34-positive dermal fibroma: Usually less cellular than DFSP; negative forPDGFBfusion"
                  }
                ],
                "DDx for Solitary Fibrous Tumor": [
                  {
                    "text": "Malignant peripheral nerve sheath tumor:Usually more cytologically atypical with infiltrative borders, S100 positive in ~ 60%; usually CD34 and STAT6 negative"
                  },
                  {
                    "text": "Synovial sarcoma:Often more monotonous in appearance ± epithelial differentiation; usually negative for CD34 and STAT6, and diffusely positive for TLE1; positive for t(X;18) in almost all cases"
                  }
                ],
                "DDx for Myxoinflammatory Fibroblastic Sarcoma": [
                  {
                    "text": "Hodgkin lymphoma: Classically positive for CD30 and CD115; negative for t(1;10)"
                  },
                  {
                    "text": "Hemosiderotic fibrolipomatous tumor (HSFLT): May be closely related to MIFS; spindled fibroblasts mixed with adipocytes, macrophages, osteoclastic giant cells, and hemosiderin"
                  },
                  {
                    "text": "Pleomorphic hyalinizing angiectatic tumor (PHAT): May be closely related to MIFS; prominent hyalinized ectatic vessels and pleomorphic cells"
                  }
                ],
                "DDx for Myxofibrosarcoma": [
                  {
                    "text": "High grade pleomorphic undifferentiated sarcoma:Lacks prominent myxoid matrix, often CD34 negative"
                  },
                  {
                    "text": "Intramuscular myxoma: No atypia, usually less cellular than myxofibrosarcoma"
                  }
                ],
                "DDx for Low-Grade Fibromyxoid Sarcoma": [
                  {
                    "text": "Low grade myxofibrosarcoma:More cytologic atypia, pseudolipoblasts, lacksFUSgene fusion; negative for MUC4"
                  },
                  {
                    "text": "Perineurioma: Fibrosis usually absent, MUC4 negative, EMA positive, negative forFUSgene fusion"
                  },
                  {
                    "text": "Intramuscular myxoma:Usually lacks fibrosis; MUC4 negative"
                  }
                ],
                "DDx for Sclerosing Epithelioid Fibrosarcoma": [
                  {
                    "text": "Epithelioid sarcoma:Not usually so sclerotic; may show INI1 loss; positive for keratins 8 and 19; negative for MUC4; negative forFUSgene fusion"
                  },
                  {
                    "text": "Spindle cell/sclerosing rhabdomyosarcoma:Often includes spindled tumor cells; positive for muscle markers; noFUSfusion"
                  },
                  {
                    "text": "High-grade pleomorphic undifferentiated sarcoma with epithelioid cells:Usually more cytologically atypical, higher mitotic rate; negative forFUSfusion"
                  },
                  {
                    "text": "Metastatic carcinoma:Usually more cytologically atypical, negative forFUSfusion"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Human Papillomavirus (HPV)-Related Tumors": {
            "name": "Human Papillomavirus (HPV)-Related Tumors",
            "url": "https://app.pathprimer.com/document/3dfc985c-7e21-466b-a9f4-e9b4fcbe70c1/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "\"High-risk\" HPV types are associated with malignancyHPV 16 and 18 are most common types; they﻿produce potent E6 and E7 oncoproteins﻿E6﻿is E3 ubiquitin ligase that recruits E6AP, an E2 ubiquitin conjugating enzyme, to ubiquitinate (\"mark\") p53 for proteosomal degradation and leads to loss of DNA damage checkpoint control of cell cycle﻿E7﻿binds to Rb1 protein and recruits calpain, a calcium-activated cysteine protease, which degrades Rb1 and leads to uncontrolled passage through cell cycle﻿High levels of expression of E6 and E7 and integration of HPV genome are associated with invasive lesions; invasive tumors show clonal pattern of HPV DNA integration into human genome",
                    "sub_points": [
                      "HPV 16 and 18 are most common types; they﻿produce potent E6 and E7 oncoproteins﻿E6﻿is E3 ubiquitin ligase that recruits E6AP, an E2 ubiquitin conjugating enzyme, to ubiquitinate (\"mark\") p53 for proteosomal degradation and leads to loss of DNA damage checkpoint control of cell cycle﻿E7﻿binds to Rb1 protein and recruits calpain, a calcium-activated cysteine protease, which degrades Rb1 and leads to uncontrolled passage through cell cycle﻿",
                      "E6﻿is E3 ubiquitin ligase that recruits E6AP, an E2 ubiquitin conjugating enzyme, to ubiquitinate (\"mark\") p53 for proteosomal degradation and leads to loss of DNA damage checkpoint control of cell cycle﻿",
                      "E7﻿binds to Rb1 protein and recruits calpain, a calcium-activated cysteine protease, which degrades Rb1 and leads to uncontrolled passage through cell cycle﻿",
                      "High levels of expression of E6 and E7 and integration of HPV genome are associated with invasive lesions; invasive tumors show clonal pattern of HPV DNA integration into human genome"
                    ]
                  },
                  {
                    "text": "\"Low-risk\" HPV types are associated with warts; these also have E6 and E7 proteins, but they have weak ability to inactivate p53 and Rb1, respectively"
                  },
                  {
                    "text": "HPV 6 and 11 are most common types associated with genital lesions﻿"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "All squamous lined surfaces of gastrointestinal and genitourinary tract may be involvedCommon wart is verruca vulgarisIntraepithelial neoplasias (formerly dysplasias) are graded according to thickness of involved epitheliumOn cytology specimens, grading is based on degree of dysplasia",
                    "sub_points": [
                      "Common wart is verruca vulgaris",
                      "Intraepithelial neoplasias (formerly dysplasias) are graded according to thickness of involved epithelium",
                      "On cytology specimens, grading is based on degree of dysplasia"
                    ]
                  },
                  {
                    "text": "HPV is also associated with cervical adenocarcinoma in situ and invasive cervical adenocarcinoma"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Viral cytopathic effects include koilocytic changes: multinucleation, perinuclear halos, and irregular \"raisinoid\" nuclei of superficial squamous cells"
                  },
                  {
                    "text": "Low-grade dysplasias show slight nuclear enlargement, mild nuclear hyperchromasia, and thickening of basal layer"
                  },
                  {
                    "text": "High-grade dysplasias show more nuclear enlargement, decreased N:C ratio, nuclear pleomorphism, and nuclear hyperchromasia involving intermediate to superficial layers"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "\"High-risk\" human papillomavirus (HPV) types are associated with malignancyHPV 16 and 18 are most common types85%-90% of HPV-positive squamous cell carcinomas in head and neck> 70% of cervical squamous cell carcinomas﻿Produce potent E6 and E7 oncoproteins﻿Respective genes can individually transform fibroblasts in cultureE6 is E3 ubiquitin ligase that recruits E6 associated protein (E6AP), an E2 ubiquitin conjugating enzyme, to ubiquitinate (\"mark\") p53 for proteosomal degradationIncreased p53 degradationLoss of p53 tumor suppressor functionLoss of DNA damage checkpoint control of cell cycle﻿E7 binds to Rb1 protein and recruits calpain, a calcium-activated cysteine protease, which degrades Rb1Increased Rb1 degradationLoss of Rb1 tumor suppressor functionUncontrolled passage through cell cycle﻿E6 and E7 have numerous other oncogenic rolesHigh levels of expression of E6 and E7 and integration of HPV genome associated with invasive lesionsInvasive tumors show clonal pattern of HPV DNA integration into human genome",
                    "sub_points": [
                      "HPV 16 and 18 are most common types85%-90% of HPV-positive squamous cell carcinomas in head and neck> 70% of cervical squamous cell carcinomas",
                      "85%-90% of HPV-positive squamous cell carcinomas in head and neck",
                      "> 70% of cervical squamous cell carcinomas",
                      "﻿Produce potent E6 and E7 oncoproteins﻿Respective genes can individually transform fibroblasts in culture",
                      "Respective genes can individually transform fibroblasts in culture",
                      "E6 is E3 ubiquitin ligase that recruits E6 associated protein (E6AP), an E2 ubiquitin conjugating enzyme, to ubiquitinate (\"mark\") p53 for proteosomal degradationIncreased p53 degradationLoss of p53 tumor suppressor functionLoss of DNA damage checkpoint control of cell cycle﻿",
                      "Increased p53 degradation",
                      "Loss of p53 tumor suppressor function",
                      "Loss of DNA damage checkpoint control of cell cycle﻿",
                      "E7 binds to Rb1 protein and recruits calpain, a calcium-activated cysteine protease, which degrades Rb1Increased Rb1 degradationLoss of Rb1 tumor suppressor functionUncontrolled passage through cell cycle﻿",
                      "Increased Rb1 degradation",
                      "Loss of Rb1 tumor suppressor function",
                      "Uncontrolled passage through cell cycle﻿",
                      "E6 and E7 have numerous other oncogenic roles",
                      "High levels of expression of E6 and E7 and integration of HPV genome associated with invasive lesions",
                      "Invasive tumors show clonal pattern of HPV DNA integration into human genome"
                    ]
                  },
                  {
                    "text": "\"Low-risk\" HPV types are associated with warts﻿These also have E6 and E7 proteinsThey have weak ability to inactivate p53 and Rb1, respectivelyHPV 6 and 11 are most common types associated with genital lesions﻿",
                    "sub_points": [
                      "These also have E6 and E7 proteinsThey have weak ability to inactivate p53 and Rb1, respectively",
                      "They have weak ability to inactivate p53 and Rb1, respectively",
                      "HPV 6 and 11 are most common types associated with genital lesions﻿"
                    ]
                  }
                ],
                "Cofactors for Malignant Transformation": [
                  {
                    "text": "Most who acquire HPV are able to clear infection"
                  },
                  {
                    "text": "Small percentage of patients develop neoplasia after long latency period"
                  },
                  {
                    "text": "Additional cofactors may be associated with HPV persistence &/or progression to intraepithelial neoplasia and invasive carcinoma﻿SmokingMultiple sexual partnersOral contraceptive useInfectionHIVGonorrheaChlamydiaSyphilisImmunodeficiency",
                    "sub_points": [
                      "Smoking",
                      "Multiple sexual partners",
                      "Oral contraceptive use",
                      "InfectionHIVGonorrheaChlamydiaSyphilis",
                      "HIV",
                      "Gonorrhea",
                      "Chlamydia",
                      "Syphilis",
                      "Immunodeficiency"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Benign HPV lesions may involve various sitesCommon wart—verruca vulgarisPalms—verruca palmarisSoles—verruca plantarisGenital wart—condyloma acuminatum",
                    "sub_points": [
                      "Common wart—verruca vulgarisPalms—verruca palmarisSoles—verruca plantaris",
                      "Palms—verruca palmaris",
                      "Soles—verruca plantaris",
                      "Genital wart—condyloma acuminatum"
                    ]
                  },
                  {
                    "text": "Premalignant HPV lesions (intraepithelial neoplasias) are named according to siteAll squamous lined surfaces of gastrointestinal and genitourinary tract may be involvedVaginal intraepithelial neoplasia (VAIN)Vulvar intraepithelial neoplasia (VIN)Penile intraepithelial neoplasia (PeIN)Anal intraepithelial neoplasia (AIN)Cervical intraepithelial neoplasia (CIN)Oral intraepithelial neoplasia (OIN)",
                    "sub_points": [
                      "All squamous lined surfaces of gastrointestinal and genitourinary tract may be involvedVaginal intraepithelial neoplasia (VAIN)Vulvar intraepithelial neoplasia (VIN)Penile intraepithelial neoplasia (PeIN)Anal intraepithelial neoplasia (AIN)Cervical intraepithelial neoplasia (CIN)Oral intraepithelial neoplasia (OIN)",
                      "Vaginal intraepithelial neoplasia (VAIN)",
                      "Vulvar intraepithelial neoplasia (VIN)",
                      "Penile intraepithelial neoplasia (PeIN)",
                      "Anal intraepithelial neoplasia (AIN)",
                      "Cervical intraepithelial neoplasia (CIN)",
                      "Oral intraepithelial neoplasia (OIN)"
                    ]
                  },
                  {
                    "text": "Intraepithelial neoplasias (formerly dysplasias) are graded according to thickness of involved epitheliumI—less than one-third of epithelial thicknessII—between one-third and two-thirds of epithelial thicknessIII—greater than two-thirds of epithelial thickness",
                    "sub_points": [
                      "I—less than one-third of epithelial thickness",
                      "II—between one-third and two-thirds of epithelial thickness",
                      "III—greater than two-thirds of epithelial thickness"
                    ]
                  },
                  {
                    "text": "HPV is also associated with cervical adenocarcinoma in situ and invasive cervical adenocarcinoma"
                  },
                  {
                    "text": "On cytology specimens, grading is based on degree of dysplasiaHigh-grade squamous intraepithelial lesion (HSIL)Low-grade squamous intraepithelial lesion (LSIL)",
                    "sub_points": [
                      "High-grade squamous intraepithelial lesion (HSIL)",
                      "Low-grade squamous intraepithelial lesion (LSIL)"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment depends on grade, extent, and location of lesionCryotherapyLaser fulgurationTopical 5-fluorouracilExcisionVulvectomyCervical conizationPenectomyRadical resection",
                    "sub_points": [
                      "Cryotherapy",
                      "Laser fulguration",
                      "Topical 5-fluorouracil",
                      "ExcisionVulvectomyCervical conizationPenectomyRadical resection",
                      "Vulvectomy",
                      "Cervical conization",
                      "Penectomy",
                      "Radical resection"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "HPV-Related Head and Neck Squamous Cell Carcinomas": [
                  {
                    "text": "FrequentPIK3CAmutations, loss ofTRAF3, and amplification of cell cycle geneE2F1Smoking-related tumors show frequentTP53mutations andCDKN2Ainactivation",
                    "sub_points": [
                      "Smoking-related tumors show frequentTP53mutations andCDKN2Ainactivation"
                    ]
                  }
                ],
                "HPV-Related Gynecologic Squamous Cell Carcinomas": [
                  {
                    "text": "Frequent mutations inEP300,FBXW7,PIK3CA,HLA-B, andTP53"
                  }
                ],
                "HPV-Related Cervical Adenocarcinomas": [
                  {
                    "text": "Recurrent mutations inELF3andCBFB"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Viral cytopathic effects include koilocytic changesMultinucleation, perinuclear halos, and irregular \"raisinoid\" nuclei of superficial squamous cells",
                    "sub_points": [
                      "Multinucleation, perinuclear halos, and irregular \"raisinoid\" nuclei of superficial squamous cells"
                    ]
                  },
                  {
                    "text": "Low-grade dysplasiaSlight nuclear enlargementMild nuclear hyperchromasiaThickening of basal layer",
                    "sub_points": [
                      "Slight nuclear enlargement",
                      "Mild nuclear hyperchromasia",
                      "Thickening of basal layer"
                    ]
                  },
                  {
                    "text": "High-grade dysplasiaModerate to marked nuclear enlargementDecreased nuclear-to-cytoplasmic (N:C) ratioNuclear pleomorphismNuclear hyperchromasia involving intermediate to superficial layers",
                    "sub_points": [
                      "Moderate to marked nuclear enlargement",
                      "Decreased nuclear-to-cytoplasmic (N:C) ratio",
                      "Nuclear pleomorphism",
                      "Nuclear hyperchromasia involving intermediate to superficial layers"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular Alterations in Hepatocellular Carcinoma": {
            "name": "Molecular Alterations in Hepatocellular Carcinoma",
            "url": "https://app.pathprimer.com/document/9ef1c312-794e-473f-8b62-08b2e1df6b61/lesson/222d474b-aa28-43af-b3fa-76c4e95a9a87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Commonly mutated genes in hepatocellular carcinomaTERT(telomerase reverse transcriptase)CTNNB1(catenin beta 1)DNAJB1-PRKACAfusionDNAJB1-PRKACAfusion",
                    "sub_points": [
                      "TERT(telomerase reverse transcriptase)",
                      "CTNNB1(catenin beta 1)",
                      "DNAJB1-PRKACAfusion",
                      "DNAJB1-PRKACAfusion"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "~ 90% of HCC arise in context of cirrhotic liver"
                  },
                  {
                    "text": "Major risk factorsChronic alcohol abuseHepatitis B virusHepatitis C virusAflatoxin B₁ is a carcinogen produced by mold (Aspergilus flavus) growing on improperly stored foodsAlkylates and intercalates of DNAFrequentTP53mutationsInherited conditionsHemochromatosisWilson diseaseAlpha-1 antitrypsin deficiencyTyrosinemia",
                    "sub_points": [
                      "Chronic alcohol abuse",
                      "Hepatitis B virus",
                      "Hepatitis C virus",
                      "Aflatoxin B₁ is a carcinogen produced by mold (Aspergilus flavus) growing on improperly stored foodsAlkylates and intercalates of DNAFrequentTP53mutations",
                      "Alkylates and intercalates of DNA",
                      "FrequentTP53mutations",
                      "Inherited conditionsHemochromatosisWilson diseaseAlpha-1 antitrypsin deficiencyTyrosinemia",
                      "Hemochromatosis",
                      "Wilson disease",
                      "Alpha-1 antitrypsin deficiency",
                      "Tyrosinemia"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "Hepatocellular carcinomaAlmost 1/3 of cases show whole genome duplication with gross chromosomal loss (hypotetraploid)HBV integration nearTERTgene (22% of HBV-related HCCs)TERTalterations (70%)WNT pathway alterations (35-45%)TP53-RB1pathway alterations (72%)Chromatin remodeling pathway alterations (67%)PI3K-mTOR pathway alterations (45%)",
                    "sub_points": [
                      "Almost 1/3 of cases show whole genome duplication with gross chromosomal loss (hypotetraploid)",
                      "HBV integration nearTERTgene (22% of HBV-related HCCs)",
                      "TERTalterations (70%)",
                      "WNT pathway alterations (35-45%)",
                      "TP53-RB1pathway alterations (72%)",
                      "Chromatin remodeling pathway alterations (67%)",
                      "PI3K-mTOR pathway alterations (45%)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hepatocellular carcinoma (HCC)"
                  },
                  {
                    "text": "Nonalcoholic steatohepatitis (NASH)"
                  },
                  {
                    "text": "Commonly mutated genes in HCCTP53(tumor protein p53)TERT(telomerase reverse transcriptase)CTNNB1(catenin beta 1)DNAJB1-PRKACAfusionDnaJ heat shock protein family (Hsp40) member B1Protein kinase cAMP-activated catalytic subunit alpha",
                    "sub_points": [
                      "TP53(tumor protein p53)",
                      "TERT(telomerase reverse transcriptase)",
                      "CTNNB1(catenin beta 1)",
                      "DNAJB1-PRKACAfusionDnaJ heat shock protein family (Hsp40) member B1Protein kinase cAMP-activated catalytic subunit alpha",
                      "DnaJ heat shock protein family (Hsp40) member B1",
                      "Protein kinase cAMP-activated catalytic subunit alpha"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "HCC: Malignant neoplasm of liver with hepatocellular differentiation"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Chronic alcohol abuse"
                  },
                  {
                    "text": "ThorotrastDiscontinued radiocontrast agent",
                    "sub_points": [
                      "Discontinued radiocontrast agent"
                    ]
                  },
                  {
                    "text": "Aflatoxin B₁Carcinogen produced byAspergillus flavusgrowing on improperly stored foods, especially grainsImportant cause of HCC in developing areas, especially China and South AfricaAlkylates and intercalates of DNAFrequentTP53mutations",
                    "sub_points": [
                      "Carcinogen produced byAspergillus flavusgrowing on improperly stored foods, especially grains",
                      "Important cause of HCC in developing areas, especially China and South Africa",
                      "Alkylates and intercalates of DNA",
                      "FrequentTP53mutations"
                    ]
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "Hepatitis B virusMost common etiology worldwide (85% of cases), especially prevalent in Asia and AfricaHigh frequency of vertical transmission in endemic areasHCC often shows HBV DNA integrationFrequent integration nearTERTlocus may be pathogenic",
                    "sub_points": [
                      "Most common etiology worldwide (85% of cases), especially prevalent in Asia and Africa",
                      "High frequency of vertical transmission in endemic areas",
                      "HCC often shows HBV DNA integration",
                      "Frequent integration nearTERTlocus may be pathogenic"
                    ]
                  },
                  {
                    "text": "Hepatitis C virusMost common viral etiology in Western world",
                    "sub_points": [
                      "Most common viral etiology in Western world"
                    ]
                  },
                  {
                    "text": "Clonorchis sinensis"
                  },
                  {
                    "text": "Schistosoma japonicum"
                  }
                ],
                "NASH": [
                  {
                    "text": "Frequently associated with metabolic syndrome"
                  }
                ],
                "Inherited Conditions": [
                  {
                    "text": "Hemochromatosis"
                  },
                  {
                    "text": "Wilson disease"
                  },
                  {
                    "text": "Alpha-1 antitrypsin deficiency"
                  },
                  {
                    "text": "Glycogen storage disease, type Ia"
                  },
                  {
                    "text": "Tyrosinemia (40% develop HCC)"
                  }
                ],
                "Cirrhosis": [
                  {
                    "text": "Cirrhosis is end-stage of most chronic liver diseases~ 90% of HCC arise in context of cirrhotic liver﻿",
                    "sub_points": [
                      "~ 90% of HCC arise in context of cirrhotic liver﻿"
                    ]
                  }
                ],
                "Precursor Lesions": [
                  {
                    "text": "Model for tumorigenesis similar to adenoma-carcinoma sequence in colorectal cancer has been proposed for HCC"
                  },
                  {
                    "text": "HCC may be seen arising from precursor lesions"
                  },
                  {
                    "text": "Precursors often share morphologic, immunohistochemical, and molecular/cytogenetic features with HCC"
                  },
                  {
                    "text": "Four different precursors to HCC with different morphology, molecular features, and risk of transformation to malignancySmall cell change: Microscopic foci with hepatocytes distinctly smaller than surrounding nonneoplastic hepatocytesLarge cell change﻿: Microscopic foci with hepatocytes distinctly larger than surrounding nonneoplastic hepatocytesDysplastic nodules: Grossly apparent tumor with small cell or large cell change, cytologic, &/or architectural atypiaHepatocellular adenomas (4 types)Beta-catenin activated typeBeta-catenin (+, nuclear) and glutamine synthetase (+) by immunohistochemistryMalignant transformation is more commonHNF1-alpha inactivated typeLiver fatty acid binding protein (-) by immunohistochemistryMalignant transformation is rareInflammatory type: No riskUnclassified type: No risk",
                    "sub_points": [
                      "Small cell change: Microscopic foci with hepatocytes distinctly smaller than surrounding nonneoplastic hepatocytes",
                      "Large cell change﻿: Microscopic foci with hepatocytes distinctly larger than surrounding nonneoplastic hepatocytes",
                      "Dysplastic nodules: Grossly apparent tumor with small cell or large cell change, cytologic, &/or architectural atypia",
                      "Hepatocellular adenomas (4 types)Beta-catenin activated typeBeta-catenin (+, nuclear) and glutamine synthetase (+) by immunohistochemistryMalignant transformation is more commonHNF1-alpha inactivated typeLiver fatty acid binding protein (-) by immunohistochemistryMalignant transformation is rareInflammatory type: No riskUnclassified type: No risk",
                      "Beta-catenin activated typeBeta-catenin (+, nuclear) and glutamine synthetase (+) by immunohistochemistryMalignant transformation is more common",
                      "Beta-catenin (+, nuclear) and glutamine synthetase (+) by immunohistochemistry",
                      "Malignant transformation is more common",
                      "HNF1-alpha inactivated typeLiver fatty acid binding protein (-) by immunohistochemistryMalignant transformation is rare",
                      "Liver fatty acid binding protein (-) by immunohistochemistry",
                      "Malignant transformation is rare",
                      "Inflammatory type: No risk",
                      "Unclassified type: No risk"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "M:F ≈ 3:1"
                  },
                  {
                    "text": "Median age at diagnosis: 63 years"
                  },
                  {
                    "text": "Relatively uncommon in North America (2-3% of cancers)"
                  },
                  {
                    "text": "Highest incidence in Asia (76% of cancers) followed by Africa"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Cirrhosis often dominates clinical picture"
                  },
                  {
                    "text": "Abdominal signs and symptomsLiver mass or nodularityAbdominal fullnessAbdominal painAscites",
                    "sub_points": [
                      "Liver mass or nodularity",
                      "Abdominal fullness",
                      "Abdominal pain",
                      "Ascites"
                    ]
                  },
                  {
                    "text": "Constitutional symptoms include malaise, fatigue, weight loss"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "AFP may be elevated"
                  },
                  {
                    "text": "No official guidelines for molecular testing have been issued by the National Comprehensive Cancer Network for diagnosis, prognostication, or prediction"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Various strategies, depending on functional status, stage, and size/location of tumorResectionAblationChemoembolizationExternal beam radiationTransplant",
                    "sub_points": [
                      "Resection",
                      "Ablation",
                      "Chemoembolization",
                      "External beam radiation",
                      "Transplant"
                    ]
                  },
                  {
                    "text": "Inoperable or metastatic diseaseSorafenib = only FDA-approved drug for HCC",
                    "sub_points": [
                      "Sorafenib = only FDA-approved drug for HCC"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Five-year survival varies by stageLocalized disease: 31%Regional lymph node metastases: 11%Distant organ metastases: 3%",
                    "sub_points": [
                      "Localized disease: 31%",
                      "Regional lymph node metastases: 11%",
                      "Distant organ metastases: 3%"
                    ]
                  },
                  {
                    "text": "Fibrolamellar hepatocellular carcinoma carries relatively good prognosis"
                  }
                ]
              },
              "MOLECULAR": {
                "Chromosomal Alterations": [
                  {
                    "text": "Almost 1/3 show whole genome duplication with gross chromosomal loss (hypotetraploid)"
                  },
                  {
                    "text": "HBV integration nearTERTgene (22% of HBV-related HCCs)"
                  }
                ],
                "Molecular Alterations": [
                  {
                    "text": "TERTalterations (70%)TERTfocal amplifications (5-8%)TERTpromoter mutations (40-60%)HBV integration nearTERTpromoter (20%)",
                    "sub_points": [
                      "TERTfocal amplifications (5-8%)",
                      "TERTpromoter mutations (40-60%)",
                      "HBV integration nearTERTpromoter (20%)"
                    ]
                  },
                  {
                    "text": "WNT pathway alterations (35-45%)Axin1Beta-cateninAPCCCND1-FGF19focal amplification",
                    "sub_points": [
                      "Axin1",
                      "Beta-catenin",
                      "APC",
                      "CCND1-FGF19focal amplification"
                    ]
                  },
                  {
                    "text": "TP53-RB1pathway alterations (72%)TP53mutations and 17p deletionsATM mutations and 11q deletionsRPS6KA3mutations and deletionsCDKN2Amutation and focal homozygous deletionCDKN1AmutationsCCND1-FGF19focal amplificationFBXW7deletions",
                    "sub_points": [
                      "TP53mutations and 17p deletions",
                      "ATM mutations and 11q deletions",
                      "RPS6KA3mutations and deletions",
                      "CDKN2Amutation and focal homozygous deletion",
                      "CDKN1Amutations",
                      "CCND1-FGF19focal amplification",
                      "FBXW7deletions"
                    ]
                  },
                  {
                    "text": "Chromatin remodeling pathway alterations (67%)"
                  },
                  {
                    "text": "PI3K-mTOR pathway alterations (45%)"
                  }
                ],
                "Fibrolamellar HCC": [
                  {
                    "text": "Vast majority haveDNAJB1-PRKACAfusion"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Hepatoblastoma": [
                  {
                    "text": "Hepatocellular differentiation, but smaller and more primitive appearing (fetal hepatocyte-like) cellsMay show acinar or papillary architecture",
                    "sub_points": [
                      "May show acinar or papillary architecture"
                    ]
                  },
                  {
                    "text": "Most common liver malignancy in children"
                  },
                  {
                    "text": "Frequent mutations in Wnt/beta-catenin signaling pathwayCTNNB1mutations in 55%APCmutations in 24%",
                    "sub_points": [
                      "CTNNB1mutations in 55%",
                      "APCmutations in 24%"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Somatic Alterations in Cancer: Genes": {
        "name": "Somatic Alterations in Cancer: Genes",
        "url": "https://app.pathprimer.com/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
        "topics": {
          "KITMutations": {
            "name": "KITMutations",
            "url": "https://app.pathprimer.com/document/b90d0be5-9e5c-4168-8b6e-bc069b45a529/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "KITOfficial name: KIT protooncogene receptor tyrosine kinasePrevious name: Feline sarcoma viral oncogene homolog v-kitHGNC ID: 6342Gene locus: 4q12Genomic positionCh4: 54,657,957-54,740,715 (GRCh38.p14)Number of exons: 21RefSeq: NG_007456.1Aliases: PBT, SCFR, C-kit, CD117, and MASTC",
                    "sub_points": [
                      "Official name: KIT protooncogene receptor tyrosine kinasePrevious name: Feline sarcoma viral oncogene homolog v-kit",
                      "Previous name: Feline sarcoma viral oncogene homolog v-kit",
                      "HGNC ID: 6342",
                      "Gene locus: 4q12",
                      "Genomic positionCh4: 54,657,957-54,740,715 (GRCh38.p14)Number of exons: 21",
                      "Ch4: 54,657,957-54,740,715 (GRCh38.p14)",
                      "Number of exons: 21",
                      "RefSeq: NG_007456.1",
                      "Aliases: PBT, SCFR, C-kit, CD117, and MASTC"
                    ]
                  },
                  {
                    "text": "KITLGOfficial name: KIT ligandHGNC ID: 6343Gene locus: 12q21.32Genomic positionCh12: 88,492,793-88,580,471Number of exons: 10RefSeq: NG_012098.2Aliases: MGF (mast cell growth factor), SCF (stem cell factor), SF, SLF, Kitl, KL-1, DFNA69, DCUA, SHEP7, FPHH, and FPH2",
                    "sub_points": [
                      "Official name: KIT ligand",
                      "HGNC ID: 6343",
                      "Gene locus: 12q21.32",
                      "Genomic positionCh12: 88,492,793-88,580,471Number of exons: 10",
                      "Ch12: 88,492,793-88,580,471",
                      "Number of exons: 10",
                      "RefSeq: NG_012098.2",
                      "Aliases: MGF (mast cell growth factor), SCF (stem cell factor), SF, SLF, Kitl, KL-1, DFNA69, DCUA, SHEP7, FPHH, and FPH2"
                    ]
                  }
                ],
                "KITFunction": [
                  {
                    "text": "Encodes type III receptor tyrosine kinaseFormerly known as PDGF (platelet-derived growth factor) receptor familyOther proteins in this category include PDGFRA, PDGFRB, CSF1R, and FLT3145 kDa protein (976 amino acids)Monomer in absence of bound ligandHomodimer in presence of ligand with further oligomerization forming heterotetramerExtracellular portion contains 5 immunoglobulin-like domains (positions 26-524)Hydrophobic transmembrane domain with 21 amino acids (positions 525-545)Intracellular portion with 2 tyrosine kinase domains separated by kinase insert region (positions 546-976)",
                    "sub_points": [
                      "Formerly known as PDGF (platelet-derived growth factor) receptor familyOther proteins in this category include PDGFRA, PDGFRB, CSF1R, and FLT3",
                      "Other proteins in this category include PDGFRA, PDGFRB, CSF1R, and FLT3",
                      "145 kDa protein (976 amino acids)Monomer in absence of bound ligandHomodimer in presence of ligand with further oligomerization forming heterotetramerExtracellular portion contains 5 immunoglobulin-like domains (positions 26-524)Hydrophobic transmembrane domain with 21 amino acids (positions 525-545)Intracellular portion with 2 tyrosine kinase domains separated by kinase insert region (positions 546-976)",
                      "Monomer in absence of bound ligand",
                      "Homodimer in presence of ligand with further oligomerization forming heterotetramer",
                      "Extracellular portion contains 5 immunoglobulin-like domains (positions 26-524)",
                      "Hydrophobic transmembrane domain with 21 amino acids (positions 525-545)",
                      "Intracellular portion with 2 tyrosine kinase domains separated by kinase insert region (positions 546-976)"
                    ]
                  },
                  {
                    "text": "KIT protein normal functionExpressed in hematopoietic stem cellsExpression lost with cell differentiationLinked to proliferation, survival, and migration of melanocytes from neural crest during embryogenesisNecessary for successful gametogenesis through PIK3/AKT in mTOR pathwayImportant for development of interstitial cells of Cajal in gastrointestinal tractAssociated with migration of neural stem cells to sites of injury in brainAssociated with spatial learning function in hippocampusInvolved in maintenance of vasculature and regulatory functions in angiogenesisPossible role in maintaining integrity of lung tissue",
                    "sub_points": [
                      "Expressed in hematopoietic stem cellsExpression lost with cell differentiation",
                      "Expression lost with cell differentiation",
                      "Linked to proliferation, survival, and migration of melanocytes from neural crest during embryogenesis",
                      "Necessary for successful gametogenesis through PIK3/AKT in mTOR pathway",
                      "Important for development of interstitial cells of Cajal in gastrointestinal tract",
                      "Associated with migration of neural stem cells to sites of injury in brain",
                      "Associated with spatial learning function in hippocampus",
                      "Involved in maintenance of vasculature and regulatory functions in angiogenesis",
                      "Possible role in maintaining integrity of lung tissue"
                    ]
                  },
                  {
                    "text": "Role of KIT in signaling pathwaysEffector ligand is KITLG (KIT ligand)In utero acts in germ cell and neural cell development, hematopoiesis, and cell migrationIn adults, has pleiotropic effects with broad expression across multiple tissue types and continued requirement in hematopoiesisActivation of KIT signaling pathwayResults in phosphorylation of numerous proteins, including PIK3R1, PLCG1, SH2B2, and CBLPromotes phosphorylation of many other protein phosphatases and transcription factorsKITLG binding activates several downstream signaling pathways, includingPI3K/AKT/mTORRAS/RAF/MEK/ERKSTAT3Associated pathways are involved in mediation of progrowth, prosurvival, and migration signaling",
                    "sub_points": [
                      "Effector ligand is KITLG (KIT ligand)In utero acts in germ cell and neural cell development, hematopoiesis, and cell migrationIn adults, has pleiotropic effects with broad expression across multiple tissue types and continued requirement in hematopoiesis",
                      "In utero acts in germ cell and neural cell development, hematopoiesis, and cell migration",
                      "In adults, has pleiotropic effects with broad expression across multiple tissue types and continued requirement in hematopoiesis",
                      "Activation of KIT signaling pathwayResults in phosphorylation of numerous proteins, including PIK3R1, PLCG1, SH2B2, and CBLPromotes phosphorylation of many other protein phosphatases and transcription factors",
                      "Results in phosphorylation of numerous proteins, including PIK3R1, PLCG1, SH2B2, and CBL",
                      "Promotes phosphorylation of many other protein phosphatases and transcription factors",
                      "KITLG binding activates several downstream signaling pathways, includingPI3K/AKT/mTORRAS/RAF/MEK/ERKSTAT3",
                      "PI3K/AKT/mTOR",
                      "RAS/RAF/MEK/ERK",
                      "STAT3",
                      "Associated pathways are involved in mediation of progrowth, prosurvival, and migration signaling"
                    ]
                  }
                ],
                "KITMutations": [
                  {
                    "text": "Variety of mutations are described throughoutKIT"
                  },
                  {
                    "text": "Oncogenic gain-of-function mutationsGenerally disrupt protein autoinhibitory mechanismsCommonly affected regions includeExon 8 (extracellular dimerization motif) and 9-10 (transmembrane region)Regions are involved in dimer interactions and stabilizationExon 11 juxtamembrane domainKey autoregulatory domain that stabilizes inactive protein conformationExons 17-18 kinase domain 2Includes activation loop of kinase domain",
                    "sub_points": [
                      "Generally disrupt protein autoinhibitory mechanisms",
                      "Commonly affected regions includeExon 8 (extracellular dimerization motif) and 9-10 (transmembrane region)Regions are involved in dimer interactions and stabilizationExon 11 juxtamembrane domainKey autoregulatory domain that stabilizes inactive protein conformationExons 17-18 kinase domain 2Includes activation loop of kinase domain",
                      "Exon 8 (extracellular dimerization motif) and 9-10 (transmembrane region)Regions are involved in dimer interactions and stabilization",
                      "Regions are involved in dimer interactions and stabilization",
                      "Exon 11 juxtamembrane domainKey autoregulatory domain that stabilizes inactive protein conformation",
                      "Key autoregulatory domain that stabilizes inactive protein conformation",
                      "Exons 17-18 kinase domain 2Includes activation loop of kinase domain",
                      "Includes activation loop of kinase domain"
                    ]
                  },
                  {
                    "text": "Loss-of-function mutations found in many regions, including exons 2-6, 11, 12-14, and 17-19"
                  }
                ],
                "Diseases Associated WithKITSomatic Mutations": [
                  {
                    "text": "Gastrointestinalstromaltumor (GIST)ActivatingKITmutations in ~ 80% of cases; 5-10% havePDGFRAalterationExon 11 mutations in ~ 70%Exon 9 mutations in ~ 10-15%Less common mutations in exons 10, 13, 14, and 17GIST lackingKITandPDGFRAmutation often has SDH deficiencyPresence and type ofKITandPDGFRAalterations not strongly correlated with prognosis or biologic potential of individual casesTumor mutation status linked to imatinib response ratesExon 11 mutation associated with better response rates and survival (median progression-free and overall) compared to exon 9 mutations or nonmutatedKITExon 9 mutations have lower response rates and progression-free survival than exon 11 mutated cases at 400 mg dailyHigher dosing (e.g., 400 mg 2x daily) in exon 9 mutated cases associated with better progression-free survivalCases with exon 11 deletions benefit from longer duration of therapyExon 11 deletions and exon 9 duplications associated with worse disease-free survivalPrior to targeted kinase inhibitor therapy, metastatic GIST was refractory to existing therapyPatients may acquire imatinib resistance due to 2nd mutation in primary mutant KIT alleleExon 17 mutations may confer resistance to tyrosine kinase inhibitors, including sunitinib",
                    "sub_points": [
                      "ActivatingKITmutations in ~ 80% of cases; 5-10% havePDGFRAalterationExon 11 mutations in ~ 70%Exon 9 mutations in ~ 10-15%Less common mutations in exons 10, 13, 14, and 17GIST lackingKITandPDGFRAmutation often has SDH deficiency",
                      "Exon 11 mutations in ~ 70%",
                      "Exon 9 mutations in ~ 10-15%",
                      "Less common mutations in exons 10, 13, 14, and 17",
                      "GIST lackingKITandPDGFRAmutation often has SDH deficiency",
                      "Presence and type ofKITandPDGFRAalterations not strongly correlated with prognosis or biologic potential of individual cases",
                      "Tumor mutation status linked to imatinib response ratesExon 11 mutation associated with better response rates and survival (median progression-free and overall) compared to exon 9 mutations or nonmutatedKITExon 9 mutations have lower response rates and progression-free survival than exon 11 mutated cases at 400 mg dailyHigher dosing (e.g., 400 mg 2x daily) in exon 9 mutated cases associated with better progression-free survivalCases with exon 11 deletions benefit from longer duration of therapy",
                      "Exon 11 mutation associated with better response rates and survival (median progression-free and overall) compared to exon 9 mutations or nonmutatedKIT",
                      "Exon 9 mutations have lower response rates and progression-free survival than exon 11 mutated cases at 400 mg daily",
                      "Higher dosing (e.g., 400 mg 2x daily) in exon 9 mutated cases associated with better progression-free survival",
                      "Cases with exon 11 deletions benefit from longer duration of therapy",
                      "Exon 11 deletions and exon 9 duplications associated with worse disease-free survival",
                      "Prior to targeted kinase inhibitor therapy, metastatic GIST was refractory to existing therapyPatients may acquire imatinib resistance due to 2nd mutation in primary mutant KIT alleleExon 17 mutations may confer resistance to tyrosine kinase inhibitors, including sunitinib",
                      "Patients may acquire imatinib resistance due to 2nd mutation in primary mutant KIT allele",
                      "Exon 17 mutations may confer resistance to tyrosine kinase inhibitors, including sunitinib"
                    ]
                  },
                  {
                    "text": "MelanomaKITactivating mutations found with variable incidence~ 10-15% in mucosal- and acral-based melanomas~ 2-3% in cases arising in chronic sun-damaged skinTypically absent in uveal melanomas and melanomas arising in non-sun-damaged skinKITmutations mutually exclusive ofBRAF,NRAS, and other driver mutationsMutations typically involve exons 11, 13, and 17Mutations found to cluster in 4 hotspotsL576 and W557-V560 of exon 11K642 of exon 13D816-A829 of exon 17Mutations generally confer imatinib sensitivityExon 17 mutations (e.g., D816V and A829P) are associated with resistance to imatinibMinimal or no sensitivity with KIT amplification",
                    "sub_points": [
                      "KITactivating mutations found with variable incidence~ 10-15% in mucosal- and acral-based melanomas~ 2-3% in cases arising in chronic sun-damaged skinTypically absent in uveal melanomas and melanomas arising in non-sun-damaged skin",
                      "~ 10-15% in mucosal- and acral-based melanomas",
                      "~ 2-3% in cases arising in chronic sun-damaged skin",
                      "Typically absent in uveal melanomas and melanomas arising in non-sun-damaged skin",
                      "KITmutations mutually exclusive ofBRAF,NRAS, and other driver mutations",
                      "Mutations typically involve exons 11, 13, and 17",
                      "Mutations found to cluster in 4 hotspotsL576 and W557-V560 of exon 11K642 of exon 13D816-A829 of exon 17",
                      "L576 and W557-V560 of exon 11",
                      "K642 of exon 13",
                      "D816-A829 of exon 17",
                      "Mutations generally confer imatinib sensitivityExon 17 mutations (e.g., D816V and A829P) are associated with resistance to imatinibMinimal or no sensitivity with KIT amplification",
                      "Exon 17 mutations (e.g., D816V and A829P) are associated with resistance to imatinib",
                      "Minimal or no sensitivity with KIT amplification"
                    ]
                  },
                  {
                    "text": "Systemicmastocytosis (SM)High-sensitivity, quantitative, PCR-based assays preferredNext-generation sequencing (NGS) panel testing may not be sufficiently sensitiveNeoplastic cell yield from blood may be lower; marrow preferable for testing, if availableTesting in skin or other solid tissue may be considered if marrow mast-cell burden is lowKITexon 17 D816V occurs in > 90% of SMPresence of D816V mutation is WHO-defined minor criterion for diagnosisMutations possible in non-mast-cell component of SM associated with hematologic malignanciesKITmutations are detected in ~ 75% of cutaneous mastocytosis with only ~ 1/3 harboring D816VLess common (< 5-10%) mutations may include V560G, D815K, D816Y, D816F, D816H, and D820GKITD816 mutations are resistant to imatinib at clinically achievable dosesMay reflect favored active protein conformation, to which imatinib cannot bindNilotinib may be effective in some cases, including those withKITD816V mutationRare cases with juxtamembrane domainKITmutations may respond to imatinibMidostaurin may be effective in mastocytosis harboringKITD816V mutationWell-differentiated SM (rare variant) often lacks D816V and has mutations in exons 10-11Exon 10-11 mutations may increase potential for responsiveness to imatinib",
                    "sub_points": [
                      "High-sensitivity, quantitative, PCR-based assays preferredNext-generation sequencing (NGS) panel testing may not be sufficiently sensitiveNeoplastic cell yield from blood may be lower; marrow preferable for testing, if availableTesting in skin or other solid tissue may be considered if marrow mast-cell burden is low",
                      "Next-generation sequencing (NGS) panel testing may not be sufficiently sensitive",
                      "Neoplastic cell yield from blood may be lower; marrow preferable for testing, if availableTesting in skin or other solid tissue may be considered if marrow mast-cell burden is low",
                      "Testing in skin or other solid tissue may be considered if marrow mast-cell burden is low",
                      "KITexon 17 D816V occurs in > 90% of SMPresence of D816V mutation is WHO-defined minor criterion for diagnosisMutations possible in non-mast-cell component of SM associated with hematologic malignanciesKITmutations are detected in ~ 75% of cutaneous mastocytosis with only ~ 1/3 harboring D816V",
                      "Presence of D816V mutation is WHO-defined minor criterion for diagnosis",
                      "Mutations possible in non-mast-cell component of SM associated with hematologic malignancies",
                      "KITmutations are detected in ~ 75% of cutaneous mastocytosis with only ~ 1/3 harboring D816V",
                      "Less common (< 5-10%) mutations may include V560G, D815K, D816Y, D816F, D816H, and D820G",
                      "KITD816 mutations are resistant to imatinib at clinically achievable dosesMay reflect favored active protein conformation, to which imatinib cannot bindNilotinib may be effective in some cases, including those withKITD816V mutation",
                      "May reflect favored active protein conformation, to which imatinib cannot bind",
                      "Nilotinib may be effective in some cases, including those withKITD816V mutation",
                      "Rare cases with juxtamembrane domainKITmutations may respond to imatinib",
                      "Midostaurin may be effective in mastocytosis harboringKITD816V mutation",
                      "Well-differentiated SM (rare variant) often lacks D816V and has mutations in exons 10-11Exon 10-11 mutations may increase potential for responsiveness to imatinib",
                      "Exon 10-11 mutations may increase potential for responsiveness to imatinib"
                    ]
                  },
                  {
                    "text": "Childhood-onsetmastocytosisSeen with germline or acquired activatingKITmutations~ 40% harbor exon 17 alterations at codon D816Other rare mutations associated with familial mastocytosis includeF522CA533DR634W (reported in 3 siblings with urticaria pigmentosa)",
                    "sub_points": [
                      "Seen with germline or acquired activatingKITmutations",
                      "~ 40% harbor exon 17 alterations at codon D816",
                      "Other rare mutations associated with familial mastocytosis includeF522CA533DR634W (reported in 3 siblings with urticaria pigmentosa)",
                      "F522C",
                      "A533D",
                      "R634W (reported in 3 siblings with urticaria pigmentosa)"
                    ]
                  },
                  {
                    "text": "Core-binding factor (CBF) acute myeloid leukemia (AML)KITmutations found in ~ 20-30% of CBF AMLAML with t(8;21)(q22;q22)AML with inv(16)(p13q22)/t(16;16)(p13;q22)KITmutations in CBF AMLNo impact on complete remission (CR)Higher incidence of relapse and decreased overall survival inKIT-mutated AML with t(8;21)Prognostic associations less clear in AML with inv(16)/t(16;16)Frequently involve exon 17 codon D816 (e.g., D816V, D816Y, D816H, etc.)Other exon 17 codons less frequently involvedInfrequent mutations involveKITexon 8Mutations in exon 8 include inframe indelsRare alterations also reported in exons 10 and 11ConcurrentKIT+FLT3mutations seen in ~ 6% of casesKITmutations are typically absent inKRAS-orNRAS-mutated casesMinimal residual disease (MRD) status stronger prognostic/risk factor for CBF-AML risk (AML clinical practice guidelines, NCCN, 2.2022)",
                    "sub_points": [
                      "KITmutations found in ~ 20-30% of CBF AMLAML with t(8;21)(q22;q22)AML with inv(16)(p13q22)/t(16;16)(p13;q22)",
                      "AML with t(8;21)(q22;q22)",
                      "AML with inv(16)(p13q22)/t(16;16)(p13;q22)",
                      "KITmutations in CBF AMLNo impact on complete remission (CR)Higher incidence of relapse and decreased overall survival inKIT-mutated AML with t(8;21)Prognostic associations less clear in AML with inv(16)/t(16;16)Frequently involve exon 17 codon D816 (e.g., D816V, D816Y, D816H, etc.)Other exon 17 codons less frequently involvedInfrequent mutations involveKITexon 8Mutations in exon 8 include inframe indelsRare alterations also reported in exons 10 and 11ConcurrentKIT+FLT3mutations seen in ~ 6% of casesKITmutations are typically absent inKRAS-orNRAS-mutated casesMinimal residual disease (MRD) status stronger prognostic/risk factor for CBF-AML risk (AML clinical practice guidelines, NCCN, 2.2022)",
                      "No impact on complete remission (CR)",
                      "Higher incidence of relapse and decreased overall survival inKIT-mutated AML with t(8;21)Prognostic associations less clear in AML with inv(16)/t(16;16)",
                      "Prognostic associations less clear in AML with inv(16)/t(16;16)",
                      "Frequently involve exon 17 codon D816 (e.g., D816V, D816Y, D816H, etc.)Other exon 17 codons less frequently involved",
                      "Other exon 17 codons less frequently involved",
                      "Infrequent mutations involveKITexon 8Mutations in exon 8 include inframe indels",
                      "Mutations in exon 8 include inframe indels",
                      "Rare alterations also reported in exons 10 and 11",
                      "ConcurrentKIT+FLT3mutations seen in ~ 6% of cases",
                      "KITmutations are typically absent inKRAS-orNRAS-mutated cases",
                      "Minimal residual disease (MRD) status stronger prognostic/risk factor for CBF-AML risk (AML clinical practice guidelines, NCCN, 2.2022)"
                    ]
                  },
                  {
                    "text": "Germcell tumorsActivatingKITmutations in ~ 8% of germ cell tumorsMutations arise in juxtamembrane domain, tyrosine kinase 2 domain, and tyrosine kinase 1 domainMajority arise in seminomas/dysgerminomasKIT-mutated seminoma has distinct DNA methylation and immune infiltration profilesAlso described in extragonadal sites, such as mediastinumFocal amplifications ofKITalso describedKITmutations do not appear to be increased risk factor for bilateral gonadal involvement",
                    "sub_points": [
                      "ActivatingKITmutations in ~ 8% of germ cell tumorsMutations arise in juxtamembrane domain, tyrosine kinase 2 domain, and tyrosine kinase 1 domainMajority arise in seminomas/dysgerminomasKIT-mutated seminoma has distinct DNA methylation and immune infiltration profilesAlso described in extragonadal sites, such as mediastinum",
                      "Mutations arise in juxtamembrane domain, tyrosine kinase 2 domain, and tyrosine kinase 1 domain",
                      "Majority arise in seminomas/dysgerminomasKIT-mutated seminoma has distinct DNA methylation and immune infiltration profiles",
                      "KIT-mutated seminoma has distinct DNA methylation and immune infiltration profiles",
                      "Also described in extragonadal sites, such as mediastinum",
                      "Focal amplifications ofKITalso described",
                      "KITmutations do not appear to be increased risk factor for bilateral gonadal involvement"
                    ]
                  }
                ],
                "Disease Associated With Germline Mutations": [
                  {
                    "text": "Piebaldism (partial albinism)Loss-of-function mutationsAutosomal dominant inheritance patternDefective melanocytes migration characterized by congenital areas of unpigmented skin and hairOther genes may also modify expressed phenotype",
                    "sub_points": [
                      "Loss-of-function mutations",
                      "Autosomal dominant inheritance pattern",
                      "Defective melanocytes migration characterized by congenital areas of unpigmented skin and hair",
                      "Other genes may also modify expressed phenotype"
                    ]
                  }
                ],
                "Detection Methods": [
                  {
                    "text": "Sequencing modalities commonly usedHigh-sensitivity, allele-specific oligonucleotide (ASO)-PCR, digital droplet PCR, etc.NGSLess sensitive than ASO-PCR but can interrogate multiple exon targets at onceLimitations in identifying larger deletions",
                    "sub_points": [
                      "High-sensitivity, allele-specific oligonucleotide (ASO)-PCR, digital droplet PCR, etc.",
                      "NGSLess sensitive than ASO-PCR but can interrogate multiple exon targets at onceLimitations in identifying larger deletions",
                      "Less sensitive than ASO-PCR but can interrogate multiple exon targets at once",
                      "Limitations in identifying larger deletions"
                    ]
                  },
                  {
                    "text": "Nonsequencing molecular techniques, such as allelic discrimination assays, fragment analysis, or high-resolution melting curve analysis may be usedFurther direct sequencing may be required to identify specific mutationsThese may target only specific variants and may not exclude otherKITalteration",
                    "sub_points": [
                      "Further direct sequencing may be required to identify specific mutations",
                      "These may target only specific variants and may not exclude otherKITalteration"
                    ]
                  },
                  {
                    "text": "No correlation between immunohistochemical expression of CD117 andKITmutations"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "IDH1andIDH2Mutations": {
            "name": "IDH1andIDH2Mutations",
            "url": "https://app.pathprimer.com/document/94ed7f10-404c-4308-bbec-b93e9622fba2/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "IDH1Official name: Isocitrate dehydrogenase [NADP(+)] 1, cytosolicHGNC ID: 5382Gene locus: 2q34Chr2: 208,236,227-208,255,071 (GRCh38.p14)RefSeq: NG_023319.2Number of exons: 12 (first 2 exons are untranslated)",
                    "sub_points": [
                      "Official name: Isocitrate dehydrogenase [NADP(+)] 1, cytosolic",
                      "HGNC ID: 5382",
                      "Gene locus: 2q34Chr2: 208,236,227-208,255,071 (GRCh38.p14)",
                      "Chr2: 208,236,227-208,255,071 (GRCh38.p14)",
                      "RefSeq: NG_023319.2",
                      "Number of exons: 12 (first 2 exons are untranslated)"
                    ]
                  },
                  {
                    "text": "IDH2Official name: Isocitrate dehydrogenase [NADP(+)] 2, mitochondrialHGNC ID: 5383Gene locus: 15q26.1Chr15: 90,083,045-90,102,468 (GRCh38.p14)RefSeq: NG_023302.1Number of exons: 12",
                    "sub_points": [
                      "Official name: Isocitrate dehydrogenase [NADP(+)] 2, mitochondrial",
                      "HGNC ID: 5383",
                      "Gene locus: 15q26.1Chr15: 90,083,045-90,102,468 (GRCh38.p14)",
                      "Chr15: 90,083,045-90,102,468 (GRCh38.p14)",
                      "RefSeq: NG_023302.1",
                      "Number of exons: 12"
                    ]
                  }
                ]
              },
              "Normal Gene Function": {
                "Encode Isocitrate Dehydrogenase Enzymes": [
                  {
                    "text": "Catalyzes decarboxylation of isocitrate to α-ketoglutarate (a.k.a. 2-oxoglutarate, 2-OG)"
                  },
                  {
                    "text": "5 human isocitrate dehydrogenase (IDH) isoforms describedIDH1 and IDH2 are NADP(+) dependentOther IDH isoenzymes are NAD(+) dependent",
                    "sub_points": [
                      "IDH1 and IDH2 are NADP(+) dependent",
                      "Other IDH isoenzymes are NAD(+) dependent"
                    ]
                  },
                  {
                    "text": "IDH1localizes to cytoplasm and peroxisomes"
                  },
                  {
                    "text": "IDH2localizes to mitochondria"
                  },
                  {
                    "text": "Necessary for metabolism and energy productionFunctions as protein homodimerCatalyzes 3rd step of citric acid cycle",
                    "sub_points": [
                      "Functions as protein homodimer",
                      "Catalyzes 3rd step of citric acid cycle"
                    ]
                  }
                ]
              },
              "Somatic IDH1 and IDH2 Mutations": {
                "Typically Heterozygous Gain-of-Function Missense Mutations": [
                  {
                    "text": "Usually occur at 1 of 3 highly conserved arginine residues"
                  },
                  {
                    "text": "Mutant converts isocitrate to R-2-hydroxyglutarate (R-2-HG)R-2-HG is oncometabolite that mediates transforming effect of mutant IDHSome epigenetic regulators are 2-OG dependent and inhibited by r-2-HG (e.g., TET and KDM protein families)R-2-HG accumulation observed in both acute myeloid leukemia (AML) and in glial neoplasmsAML associated withIDH1/IDH2mutation is characterized by global promoter hypermethylation",
                    "sub_points": [
                      "R-2-HG is oncometabolite that mediates transforming effect of mutant IDH",
                      "Some epigenetic regulators are 2-OG dependent and inhibited by r-2-HG (e.g., TET and KDM protein families)R-2-HG accumulation observed in both acute myeloid leukemia (AML) and in glial neoplasmsAML associated withIDH1/IDH2mutation is characterized by global promoter hypermethylation",
                      "R-2-HG accumulation observed in both acute myeloid leukemia (AML) and in glial neoplasms",
                      "AML associated withIDH1/IDH2mutation is characterized by global promoter hypermethylation"
                    ]
                  },
                  {
                    "text": "Mutation leads to impaired 2-OG production, elevated cellular R-2-HG, and wide-ranging alterations to metabolism and redox homeostasis"
                  }
                ],
                "Common Mutations": [
                  {
                    "text": "IDH1mutations often involve exon 2, codon 132c.395G>A p.R132Hc.394C>T p.R132Cc.394C>G p.R132G",
                    "sub_points": [
                      "c.395G>A p.R132H",
                      "c.394C>T p.R132C",
                      "c.394C>G p.R132G"
                    ]
                  },
                  {
                    "text": "IDH2mutations often involve exon 4, codons 140 or 172c.515G>A p.R172Kc.515G>T p.R172Mc.419G>A p.R140Q",
                    "sub_points": [
                      "c.515G>A p.R172K",
                      "c.515G>T p.R172M",
                      "c.419G>A p.R140Q"
                    ]
                  }
                ]
              },
              "Methods of Detection of IDH1 and IDH2 Mutations": {
                "Gene Sequencing": [
                  {
                    "text": "Whole-exome approach often used for initial associative discovery in tumors, but targeted sequencing preferred in most clinical settingsVariety of sequencing modalities are available (e.g., Sanger, pyrosequencing, massively parallel, etc.)",
                    "sub_points": [
                      "Variety of sequencing modalities are available (e.g., Sanger, pyrosequencing, massively parallel, etc.)"
                    ]
                  }
                ],
                "Nonsequencing Molecular Methods": [
                  {
                    "text": "Other approaches, such as allelic discrimination assays or high-resolution melting curve analysis, may be used"
                  }
                ],
                "Immunohistochemical Staining": [
                  {
                    "text": "Mutation-specific antibodies for variety of specificIDH1/IDH2variants are available"
                  },
                  {
                    "text": "Only informative for specifically targeted variant; other variants will be missed"
                  }
                ]
              },
              "Clinical Implications of IDH1 and IDH2 Mutations": {
                "Targeted Inhibitor Therapies": [
                  {
                    "text": "Ivosidenib and enasidenib are oral small-molecule inhibitors of mutantIDH1andIDH2, respectivelyIvosidenib FDA approved in AML and cholangiocarcinomaEnasidenib FDA approved in relapsed/refractory AMLPromising treatments in ~ 10% of cases ofIDH-mutated myelodysplasiaEvaluation is ongoing for usage in other cancersMay qualify for clinical trials in other tumor types",
                    "sub_points": [
                      "Ivosidenib FDA approved in AML and cholangiocarcinoma",
                      "Enasidenib FDA approved in relapsed/refractory AML",
                      "Promising treatments in ~ 10% of cases ofIDH-mutated myelodysplasia",
                      "Evaluation is ongoing for usage in other cancersMay qualify for clinical trials in other tumor types",
                      "May qualify for clinical trials in other tumor types"
                    ]
                  },
                  {
                    "text": "PARP inhibitors may have utility inIDH-mutant tumors due to impaired PARP1-mediated DNA repair"
                  }
                ],
                "Gliomas": [
                  {
                    "text": "Diagnostic valueDefine grade 4IDH-mutant astrocytomasTrue 1° glioblastomas areIDH-wildtypeIDH-mutant grade 4 astrocytoma behavior still not as severe as IDH wildtype glioblastomaDefine WHO grades 2 and 3 astrocytomas and oligodendrogliomasATRX deficiency paired withIDHmutation is typical of astrocytomaOligodendrogliomas defined as tumors that have 1p/19q codeletion andIDHmutation (unless molecular data are not available and cannot be obtained)IDH-mutant gliomas without loss of ATRX should be considered for 1p/19q testing, even if not oligodendroglial by histologyIfIDH-wildtype, then 1p/19q testing is unnecessary, and tumors should not be regarded as 1p/19q codeletedAnaplastic gliomas subdivided byIDHmutation statusPresence of mutation can differentiate grade 2 diffusely infiltrative glioma from gliosisTrue grade 1 noninfiltrative gliomas (pilocytic astrocytoma, ganglioglioma) areIDH-wildtype",
                    "sub_points": [
                      "Define grade 4IDH-mutant astrocytomasTrue 1° glioblastomas areIDH-wildtypeIDH-mutant grade 4 astrocytoma behavior still not as severe as IDH wildtype glioblastoma",
                      "True 1° glioblastomas areIDH-wildtype",
                      "IDH-mutant grade 4 astrocytoma behavior still not as severe as IDH wildtype glioblastoma",
                      "Define WHO grades 2 and 3 astrocytomas and oligodendrogliomasATRX deficiency paired withIDHmutation is typical of astrocytomaOligodendrogliomas defined as tumors that have 1p/19q codeletion andIDHmutation (unless molecular data are not available and cannot be obtained)IDH-mutant gliomas without loss of ATRX should be considered for 1p/19q testing, even if not oligodendroglial by histologyIfIDH-wildtype, then 1p/19q testing is unnecessary, and tumors should not be regarded as 1p/19q codeletedAnaplastic gliomas subdivided byIDHmutation statusPresence of mutation can differentiate grade 2 diffusely infiltrative glioma from gliosis",
                      "ATRX deficiency paired withIDHmutation is typical of astrocytoma",
                      "Oligodendrogliomas defined as tumors that have 1p/19q codeletion andIDHmutation (unless molecular data are not available and cannot be obtained)IDH-mutant gliomas without loss of ATRX should be considered for 1p/19q testing, even if not oligodendroglial by histologyIfIDH-wildtype, then 1p/19q testing is unnecessary, and tumors should not be regarded as 1p/19q codeleted",
                      "IDH-mutant gliomas without loss of ATRX should be considered for 1p/19q testing, even if not oligodendroglial by histology",
                      "IfIDH-wildtype, then 1p/19q testing is unnecessary, and tumors should not be regarded as 1p/19q codeleted",
                      "Anaplastic gliomas subdivided byIDHmutation status",
                      "Presence of mutation can differentiate grade 2 diffusely infiltrative glioma from gliosis",
                      "True grade 1 noninfiltrative gliomas (pilocytic astrocytoma, ganglioglioma) areIDH-wildtype"
                    ]
                  },
                  {
                    "text": "Prognostic valueAssociated with relatively favorable prognosis compared toIDH-wildtype casesAssociated with survival benefit for patient treated with radiation or alkylating-agent chemotherapyAssociated with MGMT promoter methylationGrade II-III gliomasIDH-mutant, 1p/19q-codeletion group has best prognosisIDH-wildtype has worst prognosisIDH1single nucleotide variant (G>A polymorphism) at p.G105 (rs11554137) associated with adverse outcomes in malignant glioma",
                    "sub_points": [
                      "Associated with relatively favorable prognosis compared toIDH-wildtype casesAssociated with survival benefit for patient treated with radiation or alkylating-agent chemotherapy",
                      "Associated with survival benefit for patient treated with radiation or alkylating-agent chemotherapy",
                      "Associated with MGMT promoter methylation",
                      "Grade II-III gliomasIDH-mutant, 1p/19q-codeletion group has best prognosisIDH-wildtype has worst prognosis",
                      "IDH-mutant, 1p/19q-codeletion group has best prognosis",
                      "IDH-wildtype has worst prognosis",
                      "IDH1single nucleotide variant (G>A polymorphism) at p.G105 (rs11554137) associated with adverse outcomes in malignant glioma"
                    ]
                  }
                ],
                "Myeloid Neoplasms": [
                  {
                    "text": "IDH1mutated in 6-9% of AML and in 8-16% of normal-karyotype casesAssociated with worse outcomes in normal-karyotype AML with favorable or intermediate-risk diseaseImplication in co-occurrence with other gene mutations is still poorly definedAssociation ofIDH1c.315C>T (p.Gly105=) synonymous SNP with survival in adult AML in recent studiesPrevious studies claimed negative impact on survivalMore recent studies have shown no significant negative impact",
                    "sub_points": [
                      "Associated with worse outcomes in normal-karyotype AML with favorable or intermediate-risk disease",
                      "Implication in co-occurrence with other gene mutations is still poorly defined",
                      "Association ofIDH1c.315C>T (p.Gly105=) synonymous SNP with survival in adult AML in recent studiesPrevious studies claimed negative impact on survivalMore recent studies have shown no significant negative impact",
                      "Previous studies claimed negative impact on survival",
                      "More recent studies have shown no significant negative impact"
                    ]
                  },
                  {
                    "text": "IDH2mutated in 8-12% of AML and up to ~ 19% in normal-karyotype casesEssentially mutually exclusive fromIDH1mutationReports on prognostic value in AML have been inconsistent",
                    "sub_points": [
                      "Essentially mutually exclusive fromIDH1mutation",
                      "Reports on prognostic value in AML have been inconsistent"
                    ]
                  },
                  {
                    "text": "IDH1/IDH2mutation with < 5% incidence in myelodysplasiaAssociated with worse prognosis and higher rate of transformation to AML",
                    "sub_points": [
                      "Associated with worse prognosis and higher rate of transformation to AML"
                    ]
                  },
                  {
                    "text": "Rare in myeloproliferative neoplasms at diagnosis, but in ~ 20% of cases at blast phase"
                  }
                ],
                "Angioimmunoblastic T-Cell Lymphoma": [
                  {
                    "text": "IDH2mutations (principally at codon R172) detected in up to 20-45% of angioimmunoblastic T-cell lymphomas"
                  },
                  {
                    "text": "Preliminarily associated with higher response rates to epigenetic modifier therapy"
                  }
                ],
                "Conventional Central and Periosteal Cartilaginous Tumors": [
                  {
                    "text": "Seen in ~ 56% of cartilaginous tumors but not in other mesenchymal tumors"
                  },
                  {
                    "text": "No histologic or clinical differences found with mutant vs. wildtype tumors"
                  },
                  {
                    "text": "Osteochondromas and 2° peripheral chondrosarcomas areIDH-wildtype and instead showEXT1/EXT2mutations"
                  }
                ],
                "Cholangiocarcinoma": [
                  {
                    "text": "Identified in 10-23% of intrahepatic but < 1% of extrahepatic cholangiocarcinoma"
                  },
                  {
                    "text": "IDH1mutation may be poor prognostic marker in extrahepatic cholangiocarcinoma"
                  },
                  {
                    "text": "Mutations not generally seen in gallbladder or other gastrointestinal cancers"
                  },
                  {
                    "text": "No histologic or clinical differences found with mutant vs. wildtype tumors"
                  }
                ],
                "Other Neoplasms": [
                  {
                    "text": "Mutations are also identified in variety other cancers (e.g., thyroid carcinoma, prostate carcinoma, colorectal carcinoma, etc.)"
                  }
                ],
                "Constitutional Disorders": [
                  {
                    "text": "Mutations also detected in constitutional disorders, such as Maffucci syndrome, Ollier disease, and 2-hydroxyglutaric aciduria"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "NOTCH1Mutation": {
            "name": "NOTCH1Mutation",
            "url": "https://app.pathprimer.com/document/44a83e88-b211-4ce9-a608-3c415ba15168/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: Notch receptor 1"
                  },
                  {
                    "text": "Official symbol:NOTCH1"
                  },
                  {
                    "text": "HGNC ID: 7881"
                  },
                  {
                    "text": "Chromosomal location: 9q34.3"
                  },
                  {
                    "text": "RefSeq: NG_007458.1"
                  },
                  {
                    "text": "Number of exons: 34"
                  },
                  {
                    "text": "Aliases: hN1 (homolog notch 1), TAN1 (translocation-associated notch 1)"
                  }
                ]
              },
              "NOTCH1 Functions": {
                "Characteristics of Encoded NOTCH1 Protein": [
                  {
                    "text": "Transmembrane protein receptor"
                  },
                  {
                    "text": "Upon activation, intracellular domain is cleaved, released, and translocated to nucleus to interact with specific DNA-binding proteins to activate transcription of target genesMost prominent nuclear targets include helix-loop factors of Hes and Hey families",
                    "sub_points": [
                      "Most prominent nuclear targets include helix-loop factors of Hes and Hey families"
                    ]
                  },
                  {
                    "text": "Additional noncanonical signaling pathways are also involved"
                  }
                ],
                "NOTCH1 Protein Structure": [
                  {
                    "text": "Extracellular domain subunit (NECD)Consist of multiple epidermal growth factor (EGF)-like repeatsCystine-rich Lin 12 NOTCH repeats",
                    "sub_points": [
                      "Consist of multiple epidermal growth factor (EGF)-like repeats",
                      "Cystine-rich Lin 12 NOTCH repeats"
                    ]
                  },
                  {
                    "text": "Negative regulatory unit (NRR)Regulates receptor activation3 Lin 12/Notch repeats (LNRs)HD",
                    "sub_points": [
                      "Regulates receptor activation",
                      "3 Lin 12/Notch repeats (LNRs)",
                      "HD"
                    ]
                  },
                  {
                    "text": "Transmembrane subunit"
                  },
                  {
                    "text": "Intracellular domain subunit (NICD)RBP-Jkappa-associated module (RAM) domainAnkyrin repeat domainNOTCH cysteine response domainTranscriptional activation domain (TAD)Proline, glutamine, serine, and threonine (PEST)-rich domain",
                    "sub_points": [
                      "RBP-Jkappa-associated module (RAM) domain",
                      "Ankyrin repeat domain",
                      "NOTCH cysteine response domain",
                      "Transcriptional activation domain (TAD)",
                      "Proline, glutamine, serine, and threonine (PEST)-rich domain"
                    ]
                  }
                ],
                "Cellular Functions": [
                  {
                    "text": "Critical functions in cellular homeostasis, including cell differentiation, proliferation, and survival"
                  },
                  {
                    "text": "Notch signaling is involved in important biological functions, including embryonic development, neurogenesis, angiogenesis, and hematopoiesis"
                  },
                  {
                    "text": "Due to many diverse functions of NOTCH1 protein, gene is considered to act as oncogene in some instances and tumor suppressor gene in others"
                  }
                ]
              },
              "NOTCH1 Mutations": {
                "Activating Mutations": [
                  {
                    "text": "MostNOTCH1mutations seen in hematologic disorders lead to constitutive activation of Notch signaling (oncogene function)"
                  },
                  {
                    "text": "Majority of activating mutations cluster in 2 regionsHeterodimerization domain (HD)Leads to ligand-independent cleavage of NOTCH receptorMost are missense mutations and inframe insertions/deletions (indels)PEST-rich domainLeads to reduced degradation of NOTCH1 intracellular domainMost mutations are missense, nonsense, and frameshift mutations",
                    "sub_points": [
                      "Heterodimerization domain (HD)Leads to ligand-independent cleavage of NOTCH receptorMost are missense mutations and inframe insertions/deletions (indels)",
                      "Leads to ligand-independent cleavage of NOTCH receptor",
                      "Most are missense mutations and inframe insertions/deletions (indels)",
                      "PEST-rich domainLeads to reduced degradation of NOTCH1 intracellular domainMost mutations are missense, nonsense, and frameshift mutations",
                      "Leads to reduced degradation of NOTCH1 intracellular domain",
                      "Most mutations are missense, nonsense, and frameshift mutations"
                    ]
                  }
                ],
                "Loss-of-Function Mutations": [
                  {
                    "text": "Most commonly present in solid tumors, particularly head and neck squamous cell carcinomas (HNSCC)"
                  },
                  {
                    "text": "Its presence highlights importance ofNOTCH1as tumor-suppressor gene"
                  },
                  {
                    "text": "Mutations mainly present in EGF-like region and ankyrin domainMost mutations are missense, nonsense, and indels resulting in truncated NOTCH1 protein that lacks domains important for transcriptional activity",
                    "sub_points": [
                      "Most mutations are missense, nonsense, and indels resulting in truncated NOTCH1 protein that lacks domains important for transcriptional activity"
                    ]
                  }
                ],
                "Other Mutations and Alterations": [
                  {
                    "text": "Additional less frequent mechanisms have been reported that lead to increasedNOTCH1expression in cancer cellsMutations other than stop codon in PEST-rich domainLeads to reduced CDC4/Fbw7-mediated degradation and stabilization of intracellular domain",
                    "sub_points": [
                      "Mutations other than stop codon in PEST-rich domainLeads to reduced CDC4/Fbw7-mediated degradation and stabilization of intracellular domain",
                      "Leads to reduced CDC4/Fbw7-mediated degradation and stabilization of intracellular domain"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "T-Lymphoblastic Leukemia/Lymphoma": [
                  {
                    "text": "Neoplasm of lymphoblasts committed to T-cell lineage"
                  },
                  {
                    "text": "Accounts for ~ 15% of newly diagnosed acute lymphoblastic leukemia (ALL) cases (most commonly seen in pediatric populations)"
                  },
                  {
                    "text": "NOTCH1-activating mutations are found in 70-80% of casesMost mutations are located in HD domainNumerous missense, nonsense, and frameshift mutations",
                    "sub_points": [
                      "Most mutations are located in HD domain",
                      "Numerous missense, nonsense, and frameshift mutations"
                    ]
                  },
                  {
                    "text": "Most studies suggest favorable long-term prognosis, decreased relapses, and increased overall survival inNOTCH1-mutated cases"
                  }
                ],
                "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma": [
                  {
                    "text": "Most common leukemia in adults"
                  },
                  {
                    "text": "B-cell neoplasm composed of small, round, mature lymphoid cells"
                  },
                  {
                    "text": "NOTCH1mutations present in 15-25% of cases at diagnosis"
                  },
                  {
                    "text": "Most mutations located in C-terminal PEST (exons 33-34) and TAD domainsMost frequently (~ 80%) occurring mutation is c.7541_7542delCT (P2514R)Increases stability and defective degradation of NOTCH1 proteinMutations are typically associated with unmutated variable region of immunoglobulin heavy chainMutations are usually associated with expression of ZAP70 and CD38 expressionAlso associated with trisomy 12",
                    "sub_points": [
                      "Most frequently (~ 80%) occurring mutation is c.7541_7542delCT (P2514R)Increases stability and defective degradation of NOTCH1 protein",
                      "Increases stability and defective degradation of NOTCH1 protein",
                      "Mutations are typically associated with unmutated variable region of immunoglobulin heavy chain",
                      "Mutations are usually associated with expression of ZAP70 and CD38 expression",
                      "Also associated with trisomy 12"
                    ]
                  },
                  {
                    "text": "Usually seen (20-40%) with refractory/relapsed disease, Richter transformation, and overall worse outcomes"
                  }
                ],
                "Head and Neck Squamous Cell Carcinoma": [
                  {
                    "text": "6th most common cancer in world"
                  },
                  {
                    "text": "NOTCH1mutations have been identified in ~ 15-20% of HNSCC2nd most frequently mutated gene afterTP53Most mutations are loss-of-function mutations leading to protein truncation and functional downregulation (missense, nonsense, indels)Mutations are mainly located in N-terminal EGF-like ligand binding domainAlters NOTCH1 protein N-terminal to transmembrane regionNOTCH1is considered to play bimodal role as tumor suppressor and oncogeneRecent studies have associatedNOTCH1-mutated HNSCC cases with HPV(-) status and more aggressive disease with shorter overall and disease-free survival",
                    "sub_points": [
                      "2nd most frequently mutated gene afterTP53",
                      "Most mutations are loss-of-function mutations leading to protein truncation and functional downregulation (missense, nonsense, indels)",
                      "Mutations are mainly located in N-terminal EGF-like ligand binding domainAlters NOTCH1 protein N-terminal to transmembrane region",
                      "Alters NOTCH1 protein N-terminal to transmembrane region",
                      "NOTCH1is considered to play bimodal role as tumor suppressor and oncogene",
                      "Recent studies have associatedNOTCH1-mutated HNSCC cases with HPV(-) status and more aggressive disease with shorter overall and disease-free survival"
                    ]
                  }
                ],
                "Other Tumors": [
                  {
                    "text": "Activating mutations also described in non-small cell lung cancer, adenoid cystic carcinoma, breast cancer"
                  },
                  {
                    "text": "Other B-cell lymphomas and T-cell lymphomas, includingMantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and adult T-cell leukemia lymphomaNOTCH1mutations is independently associated with poor complete response and progression-free survival in DLBCL per some studies",
                    "sub_points": [
                      "Mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and adult T-cell leukemia lymphomaNOTCH1mutations is independently associated with poor complete response and progression-free survival in DLBCL per some studies",
                      "NOTCH1mutations is independently associated with poor complete response and progression-free survival in DLBCL per some studies"
                    ]
                  },
                  {
                    "text": "Loss-of-function mutations reported in chronic myelomonocytic leukemia (CMML), small cell lung cancer, esophageal squamous cell carcinoma, bladder cancer, and some subtypes of breast cancerClinical implications ofNOTCH1mutations in these tumors remain under investigation",
                    "sub_points": [
                      "Clinical implications ofNOTCH1mutations in these tumors remain under investigation"
                    ]
                  }
                ]
              },
              "TESTING": {
                "High-Resolution DNA Melting Curve Analysis": [
                  {
                    "text": "Can be used as screening method for hot spot mutations"
                  },
                  {
                    "text": "Regions with high numbers of single nucleotide polymorphisms (SNPs) should be avoided"
                  },
                  {
                    "text": "Sequencing studies are needed to determine specific mutation type"
                  }
                ],
                "Sequencing": [
                  {
                    "text": "Common techniques include Sanger sequencing, next-generation sequencing (NGS), and pyrosequencing"
                  },
                  {
                    "text": "Can be done as standalone test or as part of larger panel"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Pearls": [
                  {
                    "text": "NOTCH1mutations can function as oncogene or tumor suppressor gene"
                  },
                  {
                    "text": "Important associations withT-lymphoblastic leukemia/lymphoma (T-ALL)More favorable outcomeChronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Associated with trisomy 12More aggressive diseaseHNSCCHPV(-) casesMore aggressive disease",
                    "sub_points": [
                      "T-lymphoblastic leukemia/lymphoma (T-ALL)More favorable outcome",
                      "More favorable outcome",
                      "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Associated with trisomy 12More aggressive disease",
                      "Associated with trisomy 12",
                      "More aggressive disease",
                      "HNSCCHPV(-) casesMore aggressive disease",
                      "HPV(-) cases",
                      "More aggressive disease"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "BRAFMutations": {
            "name": "BRAFMutations",
            "url": "https://app.pathprimer.com/document/ab4b7a82-a8e8-44ac-b10d-158b43c2d8a5/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: B-Raf protooncogene, serine/threonine kinase"
                  },
                  {
                    "text": "Official symbol:BRAF"
                  },
                  {
                    "text": "HGNC ID: 1097"
                  },
                  {
                    "text": "Chromosomal location: 7q34"
                  },
                  {
                    "text": "Genomic location: Chr7:140,713,328-140,924,929 (GRCh38/hg38)"
                  },
                  {
                    "text": "Size: 766 amino acids"
                  },
                  {
                    "text": "Number of exons: 24"
                  },
                  {
                    "text": "Aliases: BRAF1, RAFB1, protooncogene B-RAF"
                  }
                ]
              },
              "STRUCTURE AND FUNCTIONS OF BRAF PROTEIN": {
                "Structure": [
                  {
                    "text": "BRAF protein is serine/threonine kinase"
                  },
                  {
                    "text": "Composed of 3 conserved regions (CR)CR1 and CR2 are regulatory domainsCR3 contains catalytic protein kinase domain",
                    "sub_points": [
                      "CR1 and CR2 are regulatory domains",
                      "CR3 contains catalytic protein kinase domain"
                    ]
                  }
                ],
                "Functions": [
                  {
                    "text": "Member of rapidly accelerated fibrosarcoma (RAF) kinase family of serine/threonine kinases (ARAF, BRAF, CRAF) involved in RAS/RAF/MEK/ERK pathwayActivated RAS proteins induce dimerization of RAF proteins, leading to cascade of kinase activation from MEK1/MEK2 to ERK1/ERK2, subsequently causing changes in gene expression",
                    "sub_points": [
                      "Activated RAS proteins induce dimerization of RAF proteins, leading to cascade of kinase activation from MEK1/MEK2 to ERK1/ERK2, subsequently causing changes in gene expression"
                    ]
                  },
                  {
                    "text": "Enzymatic activity of BRAF proteins in cytoplasm is tightly controlled in normal cells"
                  }
                ]
              },
              "BRAF GENE ALTERATIONS": {
                "BRAFSomatic Missense Mutations": [
                  {
                    "text": "Class I mutations (mutations in codon V600, independent of both upstream RAS activation and need for dimerization)Most commonly identifiedBRAFmutations in human cancersBRAFc.1799T>A, p.V600E mutation, 80-90% of all V600 codon mutationsc.1798_1799delGTinsAA, p.V600K in 5-12%c.1798_1799delGTinsAG, p.V600R in ~ 5%c.1799_1800delTGinsAT, p.V600D in ~ 1%c.1798G>A, p.V600M in < 1%",
                    "sub_points": [
                      "Most commonly identifiedBRAFmutations in human cancers",
                      "BRAFc.1799T>A, p.V600E mutation, 80-90% of all V600 codon mutations",
                      "c.1798_1799delGTinsAA, p.V600K in 5-12%",
                      "c.1798_1799delGTinsAG, p.V600R in ~ 5%",
                      "c.1799_1800delTGinsAT, p.V600D in ~ 1%",
                      "c.1798G>A, p.V600M in < 1%"
                    ]
                  },
                  {
                    "text": "Class II mutations (non-V600 mutations, inducing constitutive activation via Ras-independent dimerization)Substitutions atBRAFactivation segmentK601E, K601N, K601T, L597QSubstitutions within P loopG464, G469A, G469V, G469R",
                    "sub_points": [
                      "Substitutions atBRAFactivation segmentK601E, K601N, K601T, L597Q",
                      "K601E, K601N, K601T, L597Q",
                      "Substitutions within P loopG464, G469A, G469V, G469R",
                      "G464, G469A, G469V, G469R"
                    ]
                  },
                  {
                    "text": "Class III mutations (non-V600 mutations, lack or possess low kinase activity; increase signaling via enhanced RAS binding and enhancement of CRAF activation)G466V, G466E, N581S, D594N, D594G, G596D",
                    "sub_points": [
                      "G466V, G466E, N581S, D594N, D594G, G596D"
                    ]
                  }
                ],
                "Fusions": [
                  {
                    "text": "Function similarly to class II BRAF mutants"
                  },
                  {
                    "text": "C-terminal portion of BRAF is fused in-frame with another protein at N-terminus"
                  },
                  {
                    "text": "BRAFfusions cause autophosphorylation due to loss of regulatory domain of BRAF protein resulting in constitutively active BRAF dimers"
                  },
                  {
                    "text": "Found in various neoplasms, such asAGAP3::BRAF,AGK::BRAF,AKAP9::BRAF, andZNF767P::BRAFin melanomaAGK::BRAF,AKAP9::BRAF,KIAA1549::BRAF, andCCDC6::BRAFin gliomaZC3HAV1::BRAF,AGTRAP::BRAF, andMKRN1::BRAFin GI tract carcinomasSND1::BRAFandMYRIP::BRAFin pancreatic carcinomaBTF3L4::BRAF,NUP214::BRAF,ARMC10::BRAF, andNUP214::BRAFin lung carcinomaKLHL7::BRAF,RBMS3::BRAF, andTANK::BRAFin thyroid carcinomaMKRN1::BRAFin head and neck carcinomaNUB1::BRAFandSLC45A3::BRAFin prostate cancerKIAA1549::BRAFin metastatic breast carcinomaMIGA1::BRAFfusion in Langerhans cell histiocytosis",
                    "sub_points": [
                      "AGAP3::BRAF,AGK::BRAF,AKAP9::BRAF, andZNF767P::BRAFin melanoma",
                      "AGK::BRAF,AKAP9::BRAF,KIAA1549::BRAF, andCCDC6::BRAFin glioma",
                      "ZC3HAV1::BRAF,AGTRAP::BRAF, andMKRN1::BRAFin GI tract carcinomas",
                      "SND1::BRAFandMYRIP::BRAFin pancreatic carcinoma",
                      "BTF3L4::BRAF,NUP214::BRAF,ARMC10::BRAF, andNUP214::BRAFin lung carcinoma",
                      "KLHL7::BRAF,RBMS3::BRAF, andTANK::BRAFin thyroid carcinoma",
                      "MKRN1::BRAFin head and neck carcinoma",
                      "NUB1::BRAFandSLC45A3::BRAFin prostate cancer",
                      "KIAA1549::BRAFin metastatic breast carcinoma",
                      "MIGA1::BRAFfusion in Langerhans cell histiocytosis"
                    ]
                  }
                ],
                "BRAFGermline Mutations": [
                  {
                    "text": "Involved in developmental disorders and includeA246P, Q257R, G469E, L485F, K499E, E501K, and N581D, among others",
                    "sub_points": [
                      "A246P, Q257R, G469E, L485F, K499E, E501K, and N581D, among others"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Melanoma": [
                  {
                    "text": "BRAFsomatic missense mutations are most common oncogenic driver in melanomaDetected in ~ 60% of melanomas",
                    "sub_points": [
                      "Detected in ~ 60% of melanomas"
                    ]
                  },
                  {
                    "text": "BRAF inhibitorsSmall molecule that binds mutatedBRAFand renders BRAF protein inactivationFDA-approved inhibitors: Vemurafenib, dabrafenib, trametinib, cobimetinib, atezolizumabResistance to BRAF inhibitorsDevelops in almost all patients, usually within 1 yearThought to be due to alternative survival pathways, includingPDGFR,NRAS, andHGF",
                    "sub_points": [
                      "Small molecule that binds mutatedBRAFand renders BRAF protein inactivation",
                      "FDA-approved inhibitors: Vemurafenib, dabrafenib, trametinib, cobimetinib, atezolizumab",
                      "Resistance to BRAF inhibitorsDevelops in almost all patients, usually within 1 yearThought to be due to alternative survival pathways, includingPDGFR,NRAS, andHGF",
                      "Develops in almost all patients, usually within 1 year",
                      "Thought to be due to alternative survival pathways, includingPDGFR,NRAS, andHGF"
                    ]
                  }
                ],
                "Colorectal Carcinoma": [
                  {
                    "text": "BRAFmutations occurs in 6-15% of colorectal carcinoma (CRC)"
                  },
                  {
                    "text": "Sporadic CRC with microsatellite instability high (MSI-H) vs. hereditary nonpolyposis colorectal carcinoma (HNPCC)Majority of sporadic CRC with MSI-H haveBRAFmutationHNPCC patients almost never haveBRAFmutationTestingBRAFV600E status can avoid expense of full gene sequencing for mismatch repair genes",
                    "sub_points": [
                      "Majority of sporadic CRC with MSI-H haveBRAFmutation",
                      "HNPCC patients almost never haveBRAFmutation",
                      "TestingBRAFV600E status can avoid expense of full gene sequencing for mismatch repair genes"
                    ]
                  },
                  {
                    "text": "Resistance to EGFR-targeted therapy by cetuximab and panitumumab is common in CRC withBRAFmutations"
                  },
                  {
                    "text": "FDA has approved cetuximab + encorafenib for metastatic CRC withBRAFV600E mutation"
                  }
                ],
                "Papillary Thyroid Carcinoma": [
                  {
                    "text": "BRAFV600E mutation is most common genetic alteration~ 69% have V600E mutation; mainly in classic variant, rare in other variantsV600E is virtually absent in follicular, Hürthle cell carcinoma, medullary thyroid carcinomas, and in benign thyroid tumorsRecurrence, lymph node metastases, extrathyroidal extension, and advanced stage are common in tumors withBRAFV600E mutation",
                    "sub_points": [
                      "~ 69% have V600E mutation; mainly in classic variant, rare in other variants",
                      "V600E is virtually absent in follicular, Hürthle cell carcinoma, medullary thyroid carcinomas, and in benign thyroid tumors",
                      "Recurrence, lymph node metastases, extrathyroidal extension, and advanced stage are common in tumors withBRAFV600E mutation"
                    ]
                  }
                ],
                "Non-Small Cell Lung Cancer": [
                  {
                    "text": "1-4% haveBRAFsomatic mutations"
                  },
                  {
                    "text": "Types ofBRAFmutationsV600E in ~ 50%, G469A in 39%, and D594G in 11%",
                    "sub_points": [
                      "V600E in ~ 50%, G469A in 39%, and D594G in 11%"
                    ]
                  },
                  {
                    "text": "BRAFmutations are mutually exclusive withKRASandEGFRmutations"
                  }
                ],
                "Hairy Cell Leukemia": [
                  {
                    "text": "Nearly 100% of patients carryBRAFV600E mutation"
                  },
                  {
                    "text": "BRAFV600E typically negative in other B-cell lymphomas, includingSplenic marginal zone lymphomaHairy cell leukemia variantSplenic red pulp small B-cell lymphoma",
                    "sub_points": [
                      "Splenic marginal zone lymphoma",
                      "Hairy cell leukemia variant",
                      "Splenic red pulp small B-cell lymphoma"
                    ]
                  }
                ],
                "Langerhans Cell Histiocytosis": [
                  {
                    "text": "BRAFV600E mutation found in ~ 60%"
                  },
                  {
                    "text": "Increased risk of initial treatment failure in patients with this mutation"
                  },
                  {
                    "text": "Associated with 2x increased risk for recurrence or relapse"
                  },
                  {
                    "text": "Other isolated case reports of rare types ofBRAFmutationsBRAFexon 12 in-frame deletion,MIGA1::BRAFfusion",
                    "sub_points": [
                      "BRAFexon 12 in-frame deletion,MIGA1::BRAFfusion"
                    ]
                  }
                ],
                "Glioma": [
                  {
                    "text": "BRAFmutations are significant driver of disease in both pediatric and adult gliomas"
                  },
                  {
                    "text": "BRAFV600E is associated with improved survival overall in adults with glioma"
                  },
                  {
                    "text": "FDA-approved dabrafenib with trametinib for pediatric patients with low-grade glioma withBRAFV600E"
                  }
                ],
                "Cardiofaciocutaneous Syndrome, LEOPARD Syndrome, and Noonan Syndrome": [
                  {
                    "text": "All linked to gene alterations in RAS/RAF/MEK/ERK signaling pathway"
                  },
                  {
                    "text": "Different germlineBRAFmutations35-75% in cardiofaciocutaneous syndromeUp to 17% in LEOPARD syndrome~ 2% in Noonan syndrome",
                    "sub_points": [
                      "35-75% in cardiofaciocutaneous syndrome",
                      "Up to 17% in LEOPARD syndrome",
                      "~ 2% in Noonan syndrome"
                    ]
                  }
                ]
              },
              "DETECTION TECHNIQUES": {
                "Next-Generation Sequencing": [
                  {
                    "text": "Highly accurate due to much higher degree of sequence coverage"
                  },
                  {
                    "text": "Most ofBRAFmutations are covered in targeted NGS panels"
                  }
                ],
                "Pyrosequencing": [
                  {
                    "text": "Efficient method to detectBRAFmutations; commonly used in molecular diagnostics laboratoriesSimple, robust, and sensitive method with detection limit of ~ 5% mutant alleles",
                    "sub_points": [
                      "Simple, robust, and sensitive method with detection limit of ~ 5% mutant alleles"
                    ]
                  }
                ],
                "Digital PCR": [
                  {
                    "text": "Can accurately detect and quantify low nucleic acid targets"
                  },
                  {
                    "text": "High sensitivity and specificity"
                  }
                ],
                "Allele-Specific Real-Time PCR": [
                  {
                    "text": "Simple; high sensitivity and specificity"
                  },
                  {
                    "text": "Low-cost and fast diagnostic tool for accurate detection ofBRAFmutations"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "BRAFV600E mutation-specific antibody (VE1) is targeted to BRAF V600E proteinHas high concordance with DNA-based methods detectingBRAFV600E",
                    "sub_points": [
                      "Has high concordance with DNA-based methods detectingBRAFV600E"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "KRASMutations": {
            "name": "KRASMutations",
            "url": "https://app.pathprimer.com/document/a9d2d94f-3bf9-4a59-b662-636c7653729b/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: KRAS protooncogene, GTPase"
                  },
                  {
                    "text": "Official symbol:KRAS"
                  },
                  {
                    "text": "HGNC ID: 6407"
                  },
                  {
                    "text": "Chromosome location: 12p12.1"
                  },
                  {
                    "text": "Genomic location: Chr12:25,205,246-25,250,929 (GRCh38.p14)"
                  },
                  {
                    "text": "Size: 2 isoforms, KRAS4A:189 amino acids; KRAS4B:188 amino acids"
                  },
                  {
                    "text": "Number of exons: 7"
                  },
                  {
                    "text": "Aliases: KRAS2, v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog"
                  }
                ]
              },
              "Molecular Features": {
                "Structure and Tissue Expressions of KRAS Protein": [
                  {
                    "text": "Structural features of KRAS proteinN-terminal portion (amino acid 1-164): Highly conserved G domain, including catalytic domain with P loop, switch I, and switch II domainForms basis of biological functionality of KRAS proteinC-terminal portion (amino acid 165-188): Hypervariable region with membrane anchoring function",
                    "sub_points": [
                      "N-terminal portion (amino acid 1-164): Highly conserved G domain, including catalytic domain with P loop, switch I, and switch II domainForms basis of biological functionality of KRAS protein",
                      "Forms basis of biological functionality of KRAS protein",
                      "C-terminal portion (amino acid 165-188): Hypervariable region with membrane anchoring function"
                    ]
                  },
                  {
                    "text": "KRAS4A is weakly expressed in normal human cells"
                  },
                  {
                    "text": "KRAS4B is much more highly expressed in normal human cells; dominant form"
                  }
                ],
                "Functions of KRAS Protein": [
                  {
                    "text": "Small intracellular GTPase, mainly in GDP-bound (\"off\" or \"inactive\") state"
                  },
                  {
                    "text": "Activated when GTP is bound (Ras-GTP)"
                  },
                  {
                    "text": "Inactivated when guanosine diphosphate is bound (Ras-GDP)"
                  },
                  {
                    "text": "KRAS functions in signal transduction cascades initiated by epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor, hepatocyte growth factor receptor, insulin-like growth factor receptor"
                  },
                  {
                    "text": "Activated KRAS activates RAL, RAF/MEK/ERK, and PI3K/AKT pathwaysInvolving proliferation, differentiation, apoptosis suppression, angiogenesis, cytoskeletal organization, vesicle trafficking, and calcium signaling",
                    "sub_points": [
                      "Involving proliferation, differentiation, apoptosis suppression, angiogenesis, cytoskeletal organization, vesicle trafficking, and calcium signaling"
                    ]
                  },
                  {
                    "text": "KRASgene alterations lead to oncogenesis and developmental disorders"
                  }
                ],
                "Classification": [
                  {
                    "text": "Ras (rat sarcoma) protein is prototypical member of Ras superfamily of proteins"
                  },
                  {
                    "text": "3 Ras genes (HRAS,KRAS, andNRAS)"
                  },
                  {
                    "text": "All Ras protein family members belong to class of small guanosine triphosphate hydrolase (GTPase)"
                  }
                ],
                "KRASAlterations": [
                  {
                    "text": "MutationsSomatic mutations66 of 188KRAScodons may harbor at least 1 mutation> 99% of alterations are simple substitution missense mutationsMajority of mutations associated with cancer occur at 3 hotspotsG12 is most common mutation site (~ 83%)G13 is 2nd most common mutation site (~ 14%)Q61 is 3rd most common mutation site (~ 2%)Frequency of hotspot mutations in KRAS proteins varies depending on tissue of originThese mutations result in constitutive activation of KRAS proteins and subsequent oncogenesisGermline mutationsMany germline mutations, including K5E, V14I, Q22R/E, P34L/R/Q, I36M, T58I, G60R, N116S, D153V, and F156I/LMost are gain-of-function mutations but are less activated than oncogenic KRAS proteins, such as G12D",
                    "sub_points": [
                      "Somatic mutations66 of 188KRAScodons may harbor at least 1 mutation> 99% of alterations are simple substitution missense mutationsMajority of mutations associated with cancer occur at 3 hotspotsG12 is most common mutation site (~ 83%)G13 is 2nd most common mutation site (~ 14%)Q61 is 3rd most common mutation site (~ 2%)Frequency of hotspot mutations in KRAS proteins varies depending on tissue of originThese mutations result in constitutive activation of KRAS proteins and subsequent oncogenesis",
                      "66 of 188KRAScodons may harbor at least 1 mutation",
                      "> 99% of alterations are simple substitution missense mutations",
                      "Majority of mutations associated with cancer occur at 3 hotspotsG12 is most common mutation site (~ 83%)G13 is 2nd most common mutation site (~ 14%)Q61 is 3rd most common mutation site (~ 2%)Frequency of hotspot mutations in KRAS proteins varies depending on tissue of origin",
                      "G12 is most common mutation site (~ 83%)",
                      "G13 is 2nd most common mutation site (~ 14%)",
                      "Q61 is 3rd most common mutation site (~ 2%)",
                      "Frequency of hotspot mutations in KRAS proteins varies depending on tissue of origin",
                      "These mutations result in constitutive activation of KRAS proteins and subsequent oncogenesis",
                      "Germline mutationsMany germline mutations, including K5E, V14I, Q22R/E, P34L/R/Q, I36M, T58I, G60R, N116S, D153V, and F156I/LMost are gain-of-function mutations but are less activated than oncogenic KRAS proteins, such as G12D",
                      "Many germline mutations, including K5E, V14I, Q22R/E, P34L/R/Q, I36M, T58I, G60R, N116S, D153V, and F156I/L",
                      "Most are gain-of-function mutations but are less activated than oncogenic KRAS proteins, such as G12D"
                    ]
                  },
                  {
                    "text": "AmplificationCan induce downstream activation of RAF/ERK pathwayOccurs much more often in metastatic cancers than in primary cancersSignificantly correlates with poor prognosisEssentially confers resistance to anti-EGFR antibody treatment in colorectal carcinoma (CRC)Top malignancies withKRASamplification include non-small cell lung cancer (NSCLC) (1.6-15%), adenocarcinoma of gastroesophageal junction (9.4-26%), gastric adenocarcinoma (4.7%), malignant female reproductive system neoplasms (1.8%), head and neck squamous cell carcinoma (1%), and CRC (0.9%)",
                    "sub_points": [
                      "Can induce downstream activation of RAF/ERK pathway",
                      "Occurs much more often in metastatic cancers than in primary cancers",
                      "Significantly correlates with poor prognosis",
                      "Essentially confers resistance to anti-EGFR antibody treatment in colorectal carcinoma (CRC)",
                      "Top malignancies withKRASamplification include non-small cell lung cancer (NSCLC) (1.6-15%), adenocarcinoma of gastroesophageal junction (9.4-26%), gastric adenocarcinoma (4.7%), malignant female reproductive system neoplasms (1.8%), head and neck squamous cell carcinoma (1%), and CRC (0.9%)"
                    ]
                  },
                  {
                    "text": "KRASfusionRareUBE2L3::KRASfusion reported in prostatic cancerMRPS35::KRAS,TMBIM4::KRAS, andC12orf4::KRASfusions reported in NSCLC",
                    "sub_points": [
                      "Rare",
                      "UBE2L3::KRASfusion reported in prostatic cancer",
                      "MRPS35::KRAS,TMBIM4::KRAS, andC12orf4::KRASfusions reported in NSCLC"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Pancreatic Ductal Adenocarcinoma": [
                  {
                    "text": "Highest prevalence ofKRASmutations is detected in pancreatic carcinomas"
                  },
                  {
                    "text": "> 90% of pancreatic ductal carcinomas harborKRASmutations"
                  },
                  {
                    "text": "G12D is most common mutation"
                  },
                  {
                    "text": "Tobacco exposure has been associated withKRASmutations and pancreatic carcinoma"
                  }
                ],
                "Colorectal Carcinoma": [
                  {
                    "text": "2nd-highest prevalence ofKRASmutations"
                  },
                  {
                    "text": "~ 50% of cases harborKRASmutations"
                  },
                  {
                    "text": "KRASmutations found in both colonic adenomas and carcinomas but with much lower frequency in adenomas"
                  },
                  {
                    "text": "Codon 12 is most common mutation site ofKRASin CRCG12D is most common mutationOther codon 12 mutations include G12V, G12C, G12A, G12S, and G12R",
                    "sub_points": [
                      "G12D is most common mutation",
                      "Other codon 12 mutations include G12V, G12C, G12A, G12S, and G12R"
                    ]
                  },
                  {
                    "text": "KRASmutation is most important predictor of resistance to anti-EGFR monoclonal antibodies cetuximab or panitumumab in CRC"
                  },
                  {
                    "text": "KRASmutations in CRC confer more aggressive phenotype with reduced survival rates"
                  }
                ],
                "Lung Non-Small Cell Carcinoma": [
                  {
                    "text": "10-30% of lung carcinomas harborKRASmutationsMore frequent in adenocarcinomas than in squamous carcinomasG12C is most commonKRASmutation in lung carcinoma and conveys poor prognosis",
                    "sub_points": [
                      "More frequent in adenocarcinomas than in squamous carcinomas",
                      "G12C is most commonKRASmutation in lung carcinoma and conveys poor prognosis"
                    ]
                  },
                  {
                    "text": "History of smoking is associated withKRASmutations in lung cancer and conveys poor prognosisKRASmutations in lung cancer essentially confer resistance to EGFR tyrosine kinase inhibitor (TKI) therapySotorasib is approved in 2021 for treatment of NSCLC harboringKRASG12C mutation",
                    "sub_points": [
                      "KRASmutations in lung cancer essentially confer resistance to EGFR tyrosine kinase inhibitor (TKI) therapy",
                      "Sotorasib is approved in 2021 for treatment of NSCLC harboringKRASG12C mutation"
                    ]
                  }
                ],
                "Biliary Tract Cancer": [
                  {
                    "text": "20-50% of cholangiocarcinomas harborKRASmutationsCodon 12 is most common site",
                    "sub_points": [
                      "Codon 12 is most common site"
                    ]
                  },
                  {
                    "text": "Considered early molecular event from epithelial dysplasia to carcinoma"
                  },
                  {
                    "text": "KRASmutation has been associated with shorter overall survival in some studies"
                  }
                ],
                "Developmental Disorders": [
                  {
                    "text": "Strength &/or duration of signaling through RAS/RAF/MEK/ERK pathway regulate developmental programs"
                  },
                  {
                    "text": "KRASmutations that cause developmental disorders encode proteins with aberrant biochemical and functional propertiesMost mutations encode gain-of-function proteins but are less activated than oncogenic KRAS proteinsMost germline mutations not associated with cancers",
                    "sub_points": [
                      "Most mutations encode gain-of-function proteins but are less activated than oncogenic KRAS proteins",
                      "Most germline mutations not associated with cancers"
                    ]
                  },
                  {
                    "text": "At least 13KRASgermline mutations have been reported in RASopathy, group of developmental disorders"
                  },
                  {
                    "text": "Cardiofaciocutaneous syndrome~ 4% of cases harbor germlineKRASmutations",
                    "sub_points": [
                      "~ 4% of cases harbor germlineKRASmutations"
                    ]
                  },
                  {
                    "text": "Noonan syndrome2-4% of cases harbor germlineKRASmutations",
                    "sub_points": [
                      "2-4% of cases harbor germlineKRASmutations"
                    ]
                  }
                ]
              },
              "DETECTION OF KRAS MUTATIONS": {
                "Next-Generation Sequencing": [
                  {
                    "text": "Highly accurate due to much higher degree of sequence coverage"
                  },
                  {
                    "text": "Mutations occurring inKRASare typically included in targeted NGS panels, widely used in molecular diagnostics laboratories"
                  }
                ],
                "Pyrosequencing": [
                  {
                    "text": "Simple, robust, and sensitive method with detection limit of ~ 5% mutant alleles"
                  },
                  {
                    "text": "Very efficient method to detectKRASmutations"
                  }
                ],
                "Digital PCR": [
                  {
                    "text": "Can accurately detect and quantify low nucleic acid targets"
                  },
                  {
                    "text": "Highly sensitive and accurate in detection of pathogenic mutations"
                  }
                ],
                "Allele-Specific Real-Time PCR": [
                  {
                    "text": "Simple, high sensitivity and specificity"
                  },
                  {
                    "text": "Low-cost and fast diagnostic tool for accurate detection ofKRASmutations"
                  }
                ],
                "Sanger Sequencing": [
                  {
                    "text": "Can detect all mutated base pairs, small insertions, and deletions"
                  },
                  {
                    "text": "Disadvantage: Low sensitivity, 20-40% of tumor purity of sample needed for reliable detectionNot commonly used for routine clinical service forKRASmutation detection due to low assay sensitivity",
                    "sub_points": [
                      "Not commonly used for routine clinical service forKRASmutation detection due to low assay sensitivity"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "ALKGene Rearrangements and Mutations": {
            "name": "ALKGene Rearrangements and Mutations",
            "url": "https://app.pathprimer.com/document/d5154182-19bb-4b73-bec1-1bd4ca2b91e1/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name:ALKreceptor tyrosine kinasePrevious name: Anaplastic lymphoma kinase (Ki-1)",
                    "sub_points": [
                      "Previous name: Anaplastic lymphoma kinase (Ki-1)"
                    ]
                  },
                  {
                    "text": "Official symbol:ALK"
                  },
                  {
                    "text": "HGNC ID: 427"
                  },
                  {
                    "text": "Chromosomal location: 2p23.2-p23.1"
                  },
                  {
                    "text": "Number of exons: 29"
                  },
                  {
                    "text": "Size: 1,620 amino acids with MW of 177 kDa"
                  }
                ]
              },
              "Molecular Features": {
                "Normal Functions ofALK": [
                  {
                    "text": "Encodes ALK receptor tyrosine kinaseMember of insulin receptor superfamilyALKAL1 and ALKAL2 identified as ALK ligands",
                    "sub_points": [
                      "Member of insulin receptor superfamily",
                      "ALKAL1 and ALKAL2 identified as ALK ligands"
                    ]
                  },
                  {
                    "text": "ALK receptor tyrosine kinase functionsBinding of ligand induces homodimerization of ALK and leads to downstream activations of 4 different pathwaysRAS/RAF/MEK/ERK, JAK/STAT, PLC-Υ, and PI3K/AKTLead to cell proliferation and mediate cell survivalAct early in development to help regulate proliferation of nerve cells",
                    "sub_points": [
                      "Binding of ligand induces homodimerization of ALK and leads to downstream activations of 4 different pathwaysRAS/RAF/MEK/ERK, JAK/STAT, PLC-Υ, and PI3K/AKTLead to cell proliferation and mediate cell survival",
                      "RAS/RAF/MEK/ERK, JAK/STAT, PLC-Υ, and PI3K/AKT",
                      "Lead to cell proliferation and mediate cell survival",
                      "Act early in development to help regulate proliferation of nerve cells"
                    ]
                  }
                ],
                "ALKAlterations": [
                  {
                    "text": "Chromosomal translocations main type ofALKalterations> 90ALK-related translocations identifiedC-terminus of ALK protein fuses with N-terminus portion of partner proteinALK fusion proteins lead to ligand-independent constitutive activation of key pathways involved in oncogenesis and tumor progressiont(2;5)(p23;q35)/NPM1::ALKwas 1st translocation involvingALKidentified in anaplastic large cell lymphoma (ALCL) in 1994",
                    "sub_points": [
                      "> 90ALK-related translocations identified",
                      "C-terminus of ALK protein fuses with N-terminus portion of partner proteinALK fusion proteins lead to ligand-independent constitutive activation of key pathways involved in oncogenesis and tumor progression",
                      "ALK fusion proteins lead to ligand-independent constitutive activation of key pathways involved in oncogenesis and tumor progression",
                      "t(2;5)(p23;q35)/NPM1::ALKwas 1st translocation involvingALKidentified in anaplastic large cell lymphoma (ALCL) in 1994"
                    ]
                  },
                  {
                    "text": "ALKgain-of-function mutationsActivating mutations ofALKare primarily seen in neuroblastomas, both familial and sporadicMutations are primarily point mutations in kinase domain ofALKFew reports in anaplastic thyroid carcinoma and lung cancerMutations are also frequently acquired in kinase domain withinALKfusion gene leading to resistance to tyrosine kinase inhibitors (TKIs)",
                    "sub_points": [
                      "Activating mutations ofALKare primarily seen in neuroblastomas, both familial and sporadicMutations are primarily point mutations in kinase domain ofALK",
                      "Mutations are primarily point mutations in kinase domain ofALK",
                      "Few reports in anaplastic thyroid carcinoma and lung cancer",
                      "Mutations are also frequently acquired in kinase domain withinALKfusion gene leading to resistance to tyrosine kinase inhibitors (TKIs)"
                    ]
                  },
                  {
                    "text": "ALKamplificationReported in various malignancies, including neuroblastoma, non-small cell lung cancer (NSCLC), rhabdomyosarcoma",
                    "sub_points": [
                      "Reported in various malignancies, including neuroblastoma, non-small cell lung cancer (NSCLC), rhabdomyosarcoma"
                    ]
                  }
                ]
              },
              "Clinical Implications": {
                "Anaplastic Large Cell Lymphoma, ALK(+)": [
                  {
                    "text": "Translocations involvingALKare frequent in ALCL, ALK(+)t(2;5)(p23;q35)/NPM1::ALKin ~ 75-80% of casest(1;2)(q21;p23)/TPM3::ALKin 12-18% of casesOther fusions at lower frequency (< 2%) include t(2;22)(p23;q12)/MYH9::ALK, inv(2)(p23;q35)/ATIC::ALK,t(2;17)(p23;q23)/CLTC::ALK, t(2;3)(p23;q12)/TFG::ALK, and (X;2)(q12;p23)/MSN::ALK",
                    "sub_points": [
                      "t(2;5)(p23;q35)/NPM1::ALKin ~ 75-80% of cases",
                      "t(1;2)(q21;p23)/TPM3::ALKin 12-18% of cases",
                      "Other fusions at lower frequency (< 2%) include t(2;22)(p23;q12)/MYH9::ALK, inv(2)(p23;q35)/ATIC::ALK,t(2;17)(p23;q23)/CLTC::ALK, t(2;3)(p23;q12)/TFG::ALK, and (X;2)(q12;p23)/MSN::ALK"
                    ]
                  },
                  {
                    "text": "ALCL, ALK(+) has more favorable prognosis than ALCL, ALK(-)"
                  }
                ],
                "Large B-Cell Lymphoma, ALK(+)": [
                  {
                    "text": "Accounts for < 1% of diffuse large B-cell lymphoma (DLBCL) cases"
                  },
                  {
                    "text": "t(2;17)(p23;q23)/CLTC::ALKin ~ 70%"
                  },
                  {
                    "text": "t(2;5)(p23;q35)/NPM1::ALKin 10%"
                  },
                  {
                    "text": "Cytoplasmic granular ALK immunohistochemical staining in cases with t(2;17)/CLTC::ALK"
                  }
                ],
                "Non-Small Cell Lung Cancer": [
                  {
                    "text": "ALKrearrangement~ 2-7% of NSCLC haveALKrearrangement; ~ 19 different fusion partners identified, includinginv(2)(p21;p23)/EML4::ALK,t(2;7)(p23;q11.23)/HIP1::ALK,t(2;10)(p23;p11)/KIF5B::ALK,and t(2;14)(p23;q32)/KLC1::ALKreportedEML4::ALKmost commonALKfusion type in NSCLCMultiple variants: Same cytoplasmic portion ofALKjoins with different truncatedEML4ALK-rearranged NSCLC is typically seen in adenocarcinoma with signet-ring or acinar histology in nonsmokers and younger patientsMutually exclusive ofEGFRorKRASmutationsALK-rearranged NSCLC are highly sensitive to therapy with ALK TKI1st-generation ALK TKI, crizotinib, 1st targeted therapy inALK-rearranged NSCLCResistance to ALK inhibitors occur due to mutations in kinase domain ofALKfusion geneResistance-associated variants include L1196M, F1174L, L1198F, G1202R, G1206Y, G1269A, L1152R, and C1156Y2nd-generation ALK TKIs: Ceritinib, alectinib, brigatinib, indicated for tumors with acquired resistance to crizotinib3rd-generation ALK TKI, lorlatinib, indicated for acquired resistance to earlier generation ALK TKIs",
                    "sub_points": [
                      "~ 2-7% of NSCLC haveALKrearrangement; ~ 19 different fusion partners identified, includinginv(2)(p21;p23)/EML4::ALK,t(2;7)(p23;q11.23)/HIP1::ALK,t(2;10)(p23;p11)/KIF5B::ALK,and t(2;14)(p23;q32)/KLC1::ALKreportedEML4::ALKmost commonALKfusion type in NSCLCMultiple variants: Same cytoplasmic portion ofALKjoins with different truncatedEML4",
                      "inv(2)(p21;p23)/EML4::ALK,t(2;7)(p23;q11.23)/HIP1::ALK,t(2;10)(p23;p11)/KIF5B::ALK,and t(2;14)(p23;q32)/KLC1::ALKreportedEML4::ALKmost commonALKfusion type in NSCLCMultiple variants: Same cytoplasmic portion ofALKjoins with different truncatedEML4",
                      "EML4::ALKmost commonALKfusion type in NSCLC",
                      "Multiple variants: Same cytoplasmic portion ofALKjoins with different truncatedEML4",
                      "ALK-rearranged NSCLC is typically seen in adenocarcinoma with signet-ring or acinar histology in nonsmokers and younger patients",
                      "Mutually exclusive ofEGFRorKRASmutations",
                      "ALK-rearranged NSCLC are highly sensitive to therapy with ALK TKI",
                      "1st-generation ALK TKI, crizotinib, 1st targeted therapy inALK-rearranged NSCLC",
                      "Resistance to ALK inhibitors occur due to mutations in kinase domain ofALKfusion geneResistance-associated variants include L1196M, F1174L, L1198F, G1202R, G1206Y, G1269A, L1152R, and C1156Y2nd-generation ALK TKIs: Ceritinib, alectinib, brigatinib, indicated for tumors with acquired resistance to crizotinib3rd-generation ALK TKI, lorlatinib, indicated for acquired resistance to earlier generation ALK TKIs",
                      "Resistance-associated variants include L1196M, F1174L, L1198F, G1202R, G1206Y, G1269A, L1152R, and C1156Y",
                      "2nd-generation ALK TKIs: Ceritinib, alectinib, brigatinib, indicated for tumors with acquired resistance to crizotinib",
                      "3rd-generation ALK TKI, lorlatinib, indicated for acquired resistance to earlier generation ALK TKIs"
                    ]
                  },
                  {
                    "text": "Amplification ofALK10% of NSCLC showALKamplification; 63% of NSCLC haveALKcopy number gainsALKamplification is not involved in mRNA production and protein productionMay not play role in pathogenesis of NSCLC or indicate specific clinical application",
                    "sub_points": [
                      "10% of NSCLC showALKamplification; 63% of NSCLC haveALKcopy number gains",
                      "ALKamplification is not involved in mRNA production and protein productionMay not play role in pathogenesis of NSCLC or indicate specific clinical application",
                      "May not play role in pathogenesis of NSCLC or indicate specific clinical application"
                    ]
                  }
                ],
                "Inflammatory Myofibroblastic Tumor": [
                  {
                    "text": "ALKrearrangements reported in 36-50%TPM3::ALK,RANBP2::ALK,CARS1::ALK,TPM4::ALK,ATIC::ALK,SEC31A::ALK,CLTC::ALK",
                    "sub_points": [
                      "TPM3::ALK,RANBP2::ALK,CARS1::ALK,TPM4::ALK,ATIC::ALK,SEC31A::ALK,CLTC::ALK"
                    ]
                  },
                  {
                    "text": "Rare cases ofALKamplification withoutALKrearrangement were reported"
                  }
                ],
                "Familial and Sporadic Neuroblastomas": [
                  {
                    "text": "ALKis major familial neuroblastoma predisposition gene"
                  },
                  {
                    "text": "Germline and somatic activating mutations inALKtyrosine kinase domain linked to hereditary and acquired neuroblastomas50% of familial neuroblastoma cases with germline mutationsR1275Q, G1128A, R1192P, I1250T6-12% of sporadic neuroblastomas show acquiredALKmutationsR1275Q, T1151M, I1171N, D1091N, F1174C, F1174I, F1174L, F1174V, F1245C, F1245L, F1245V, Y1278SR1275Q found in both familial and sporadic neuroblastomas",
                    "sub_points": [
                      "50% of familial neuroblastoma cases with germline mutationsR1275Q, G1128A, R1192P, I1250T",
                      "R1275Q, G1128A, R1192P, I1250T",
                      "6-12% of sporadic neuroblastomas show acquiredALKmutationsR1275Q, T1151M, I1171N, D1091N, F1174C, F1174I, F1174L, F1174V, F1245C, F1245L, F1245V, Y1278S",
                      "R1275Q, T1151M, I1171N, D1091N, F1174C, F1174I, F1174L, F1174V, F1245C, F1245L, F1245V, Y1278S",
                      "R1275Q found in both familial and sporadic neuroblastomas"
                    ]
                  },
                  {
                    "text": "ALKamplification in neuroblastomas~ 23% of sporadic neuroblastomas show gain of 2p region, includingALKlocus~ 3% show high-level focal amplification ofALKPresence of aberrantALKcopy number status is highly associated with aggressive clinical phenotype",
                    "sub_points": [
                      "~ 23% of sporadic neuroblastomas show gain of 2p region, includingALKlocus",
                      "~ 3% show high-level focal amplification ofALK",
                      "Presence of aberrantALKcopy number status is highly associated with aggressive clinical phenotype"
                    ]
                  }
                ],
                "Anaplastic Thyroid Carcinoma": [
                  {
                    "text": "~ 10% of anaplastic thyroid carcinoma patients harbor activating mutations inALK, such as L1198F, G1201E"
                  }
                ],
                "ALK-Rearranged Renal Cell Carcinoma": [
                  {
                    "text": "ALKfusions identified:VCL::ALK,TPM3::ALK,EML4::ALK,STRN::ALK,HOOK1::ALK,PLEKHA7::ALK,CLIP1::ALK,KIF5B::ALK, andKIAA1217::ALKFusion proteins constitutively drive downstream growth promoting pathwaysVCL::ALK-affected young patients with sickle cell trait with distinctive histologic featuresOtherALK-rearranged renal cell carcinomas show heterogeneous histologic features",
                    "sub_points": [
                      "Fusion proteins constitutively drive downstream growth promoting pathways",
                      "VCL::ALK-affected young patients with sickle cell trait with distinctive histologic features",
                      "OtherALK-rearranged renal cell carcinomas show heterogeneous histologic features"
                    ]
                  },
                  {
                    "text": "Some metastatic diseases show dramatic responses to ALK TKI"
                  }
                ],
                "ALKFusion in Colorectal Adenocarcinomas": [
                  {
                    "text": "ALKfusions identified:CAD::ALK,DIAPH2::ALK,EML4::ALK,LOC101929227::ALK,SLMAP::ALK,SPTBN1::ALK, andSTRN::ALK"
                  },
                  {
                    "text": "Rare (< 1% of colorectal adenocarcinomas)"
                  }
                ]
              },
              "Testing for ALK Alterations": {
                "Fluorescence In Situ Hybridization": [
                  {
                    "text": "Dual-color break-apart probe strategy"
                  },
                  {
                    "text": "Red and green signals become separated if rearrangement present"
                  },
                  {
                    "text": "Detects virtually allALKrearrangements"
                  },
                  {
                    "text": "Cannot identifyALKfusion partner, but knowing partner is usually not clinically relevant"
                  },
                  {
                    "text": "Recommend by CAP/IASLC/AMP guideline to determine eligibility for ALK inhibitors"
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "ALKrearrangements can be detected by NGSCommonly included in commercially available NGS panelsWidely used in molecular diagnostics laboratories",
                    "sub_points": [
                      "Commonly included in commercially available NGS panels",
                      "Widely used in molecular diagnostics laboratories"
                    ]
                  },
                  {
                    "text": "Activating point mutations inALKcan be detected by NGS with broad coverage"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Equivalent alternative to FISH forALKtesting for targeted therapy in NSCLC, recommended in CAP/IASLC/AMP guidelineStrong granular cytoplasmic staining ± membrane accentuationVentana ALK (D5F3) CDx assay, FDA-approved diagnostics",
                    "sub_points": [
                      "Strong granular cytoplasmic staining ± membrane accentuation",
                      "Ventana ALK (D5F3) CDx assay, FDA-approved diagnostics"
                    ]
                  },
                  {
                    "text": "Commonly used for diagnostic purposes for ALCL, ALK(+), inflammatory myofibroblastic tumor, andALK(+) large B-cell lymphoma"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "ROS1Rearrangements": {
            "name": "ROS1Rearrangements",
            "url": "https://app.pathprimer.com/document/5d6adfe6-efe8-4c7a-86d9-4b091f17772c/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: ROS protooncogene 1, receptor tyrosine kinase"
                  },
                  {
                    "text": "Official symbol:ROS1"
                  },
                  {
                    "text": "HGNC ID: 10261"
                  },
                  {
                    "text": "Gene locus: 6q22.1"
                  },
                  {
                    "text": "Genomic positionCh6: 117,287,353-117,425,942 (GRCh38.p14)",
                    "sub_points": [
                      "Ch6: 117,287,353-117,425,942 (GRCh38.p14)"
                    ]
                  },
                  {
                    "text": "RefSeq: NG_033929.1"
                  },
                  {
                    "text": "Number of exons: 46"
                  },
                  {
                    "text": "Size: 137.9 kb"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Normal Function ofROS1": [
                  {
                    "text": "Encodes cell surface receptor tyrosine kinaseInsulin receptor subfamily",
                    "sub_points": [
                      "Insulin receptor subfamily"
                    ]
                  },
                  {
                    "text": "\"Orphan receptor\" without known ligand"
                  },
                  {
                    "text": "Activation gives rise to signaling through multiple pathways, including MAPK and PI3KAlso leads to modification of cytoskeletal proteins",
                    "sub_points": [
                      "Also leads to modification of cytoskeletal proteins"
                    ]
                  },
                  {
                    "text": "Mice withoutROS1are healthy, though males are infertile"
                  }
                ],
                "Abnormal Function ofROS1Fusion Gene": [
                  {
                    "text": "ROS1rearrangement leads to fusion geneJoins C-terminal (intracellular tyrosine kinase domain) ofROS1to N-terminal portion of partner geneROS1 tyrosine kinase domain is entirely retained in fusion proteinROS1breakpoints occur 5' to exons 32, 34, 35, or 36Partner genes includeSLC34A2,CD74,EZR,TPM3,SDC4,GOPC,TFG,YWHAE,LIMA1,MSN,LRIG3,KDELR2,CCDC6,CEP85L,TMEM106B,TPD52L1,CLTC,SLC6A17,CEP72,ZCCHC8,SLMAP,WNK1,KMT2C, andRBPMSActivates ROS1 signaling in absence of ligand, leading to tumor cell growth and proliferation",
                    "sub_points": [
                      "Joins C-terminal (intracellular tyrosine kinase domain) ofROS1to N-terminal portion of partner geneROS1 tyrosine kinase domain is entirely retained in fusion proteinROS1breakpoints occur 5' to exons 32, 34, 35, or 36",
                      "ROS1 tyrosine kinase domain is entirely retained in fusion protein",
                      "ROS1breakpoints occur 5' to exons 32, 34, 35, or 36",
                      "Partner genes includeSLC34A2,CD74,EZR,TPM3,SDC4,GOPC,TFG,YWHAE,LIMA1,MSN,LRIG3,KDELR2,CCDC6,CEP85L,TMEM106B,TPD52L1,CLTC,SLC6A17,CEP72,ZCCHC8,SLMAP,WNK1,KMT2C, andRBPMS",
                      "SLC34A2,CD74,EZR,TPM3,SDC4,GOPC,TFG,YWHAE,LIMA1,MSN,LRIG3,KDELR2,CCDC6,CEP85L,TMEM106B,TPD52L1,CLTC,SLC6A17,CEP72,ZCCHC8,SLMAP,WNK1,KMT2C, andRBPMS",
                      "Activates ROS1 signaling in absence of ligand, leading to tumor cell growth and proliferation"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "ROS1Fusion Genes in Non-Small Cell Lung Cancer": [
                  {
                    "text": "ROS1rearrangements are driver oncogenic events"
                  },
                  {
                    "text": "Occur in ~ 1-2% of non-small cell lung cancer (NSCLC)Generally mutually exclusive with other major driver mutations in NSCLC, such asALKrearrangementHowever, rare cases with concomitantROS1rearrangement andEGFRmutation have been reported",
                    "sub_points": [
                      "Generally mutually exclusive with other major driver mutations in NSCLC, such asALKrearrangementHowever, rare cases with concomitantROS1rearrangement andEGFRmutation have been reported",
                      "However, rare cases with concomitantROS1rearrangement andEGFRmutation have been reported"
                    ]
                  },
                  {
                    "text": "More common inFemale patientsYoung patientsNever smokersAdenocarcinoma histology",
                    "sub_points": [
                      "Female patients",
                      "Young patients",
                      "Never smokers",
                      "Adenocarcinoma histology"
                    ]
                  },
                  {
                    "text": "Epidemiologic distribution is similar to that ofALK-rearranged NSCLC"
                  },
                  {
                    "text": "In absence of targeted therapy, no inherent survival difference betweenROS1-positive andROS1-negative NSCLC"
                  }
                ],
                "ROS1Fusion Genes in Other Malignancies": [
                  {
                    "text": "ROS1fusions were 1st identified in glioblastoma cell line"
                  },
                  {
                    "text": "CEP85L::ROS1fusion is subsequently reported in adult patients with glioblastoma"
                  },
                  {
                    "text": "ROS1fusions have also been documented inCholangiocarcinomaInflammatory myofibroblastic tumorGastric adenocarcinomaOvarian tumor of low malignant potentialAngiosarcomaColorectal carcinomaEpithelioid hemangioendotheliomaSpitzoid melanoma",
                    "sub_points": [
                      "Cholangiocarcinoma",
                      "Inflammatory myofibroblastic tumor",
                      "Gastric adenocarcinoma",
                      "Ovarian tumor of low malignant potential",
                      "Angiosarcoma",
                      "Colorectal carcinoma",
                      "Epithelioid hemangioendothelioma",
                      "Spitzoid melanoma"
                    ]
                  }
                ],
                "Targeted Therapy forROS1": [
                  {
                    "text": "CrizotinibEfficacy and safety were demonstrated in phase 1 crizotinib studyObjective response rate of 72%Median progression-free survival of ~ 19 monthsApproved by FDA in 2016 forROS1-rearranged NSCLCResistance to crizotinib develops in subset ofROS1-rearranged casesResults in disease progression on therapyROS1G2032R variant is most common resistance-associated mutationOther crizotinib resistance mutations includeD2033N, L2155S, S1986Y/F, L2026M, L1951R, and G2101A",
                    "sub_points": [
                      "Efficacy and safety were demonstrated in phase 1 crizotinib studyObjective response rate of 72%Median progression-free survival of ~ 19 months",
                      "Objective response rate of 72%",
                      "Median progression-free survival of ~ 19 months",
                      "Approved by FDA in 2016 forROS1-rearranged NSCLC",
                      "Resistance to crizotinib develops in subset ofROS1-rearranged casesResults in disease progression on therapyROS1G2032R variant is most common resistance-associated mutationOther crizotinib resistance mutations includeD2033N, L2155S, S1986Y/F, L2026M, L1951R, and G2101A",
                      "Results in disease progression on therapy",
                      "ROS1G2032R variant is most common resistance-associated mutation",
                      "Other crizotinib resistance mutations includeD2033N, L2155S, S1986Y/F, L2026M, L1951R, and G2101A",
                      "D2033N, L2155S, S1986Y/F, L2026M, L1951R, and G2101A"
                    ]
                  },
                  {
                    "text": "Inhibitors with potential activity against crizotinib resistance mutationsLorlatinib is highly potent inhibitor with robust CNS penetration and in vitro activity against several crizotinib-resistant mutationsCabozantinib is multitargeted tyrosine kinase inhibitor with activity againstROS1resistance mutations, including G2032R and D2033NCeritinib has activity against L2026M resistance mutation but not G2032R or D2033N mutationsBrigatinib has in vitro activity against L2026M but not other resistance-associated mutations",
                    "sub_points": [
                      "Lorlatinib is highly potent inhibitor with robust CNS penetration and in vitro activity against several crizotinib-resistant mutations",
                      "Cabozantinib is multitargeted tyrosine kinase inhibitor with activity againstROS1resistance mutations, including G2032R and D2033N",
                      "Ceritinib has activity against L2026M resistance mutation but not G2032R or D2033N mutations",
                      "Brigatinib has in vitro activity against L2026M but not other resistance-associated mutations"
                    ]
                  }
                ],
                "Testing forROS1Fusion": [
                  {
                    "text": "RT-PCRCan be challenging due to large number of partner genes, each of which would necessitate additional primers",
                    "sub_points": [
                      "Can be challenging due to large number of partner genes, each of which would necessitate additional primers"
                    ]
                  },
                  {
                    "text": "ROS1 IHCEffective screening tool with high sensitivity and variable specificityGreat advantage over FISH in samples with paucity of tumor cells or abundance of nonneoplastic cellsCost-effective method for screening of lung cancer samples forROS1rearrangementsWeak expression may be seen in nonneoplastic type II pneumocytes and alveolar macrophagesConfirmation of IHC-positive and indeterminate cases by FISH or molecular methods is recommended",
                    "sub_points": [
                      "Effective screening tool with high sensitivity and variable specificity",
                      "Great advantage over FISH in samples with paucity of tumor cells or abundance of nonneoplastic cells",
                      "Cost-effective method for screening of lung cancer samples forROS1rearrangements",
                      "Weak expression may be seen in nonneoplastic type II pneumocytes and alveolar macrophages",
                      "Confirmation of IHC-positive and indeterminate cases by FISH or molecular methods is recommended"
                    ]
                  },
                  {
                    "text": "Next-generation sequencingPossible role for fusion gene detection but evolving in application to clinical practice",
                    "sub_points": [
                      "Possible role for fusion gene detection but evolving in application to clinical practice"
                    ]
                  },
                  {
                    "text": "FISHSimple and straightforward approach to identifyingROS1rearrangementUsed to determine eligibility forROS1-targeted therapyBreak-apart probe strategyRed and green signals straddleROS1breakpointsIf rearrangement occurs, red and green signals become separatedDoes not identify partner gene, but this information has no established clinical relevance",
                    "sub_points": [
                      "Simple and straightforward approach to identifyingROS1rearrangementUsed to determine eligibility forROS1-targeted therapy",
                      "Used to determine eligibility forROS1-targeted therapy",
                      "Break-apart probe strategyRed and green signals straddleROS1breakpointsIf rearrangement occurs, red and green signals become separatedDoes not identify partner gene, but this information has no established clinical relevance",
                      "Red and green signals straddleROS1breakpoints",
                      "If rearrangement occurs, red and green signals become separated",
                      "Does not identify partner gene, but this information has no established clinical relevance"
                    ]
                  }
                ],
                "ROS1Point Mutations": [
                  {
                    "text": "Acquired crizotinib resistance mutations inROS1may be seen (e.g., G2032R, L2155S)"
                  },
                  {
                    "text": "In addition,ROS1mutations are seen in other tumors, including melanoma, colorectal carcinoma, endometrial carcinoma, and gastric carcinomaFunctional significance of these mutations is unknown",
                    "sub_points": [
                      "Functional significance of these mutations is unknown"
                    ]
                  },
                  {
                    "text": "Direct sequencing analysis, not FISH, would be necessary to detect these point mutations"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "RETRearrangements": {
            "name": "RETRearrangements",
            "url": "https://app.pathprimer.com/document/ed53202e-c664-4cf3-a1ab-3d0debdcf996/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: Ret protooncogeneRET stands for \"rearranged during transfection\"",
                    "sub_points": [
                      "RET stands for \"rearranged during transfection\""
                    ]
                  },
                  {
                    "text": "Official symbol:RET"
                  },
                  {
                    "text": "HGNC ID: 9967"
                  },
                  {
                    "text": "Gene locus: 10q11.21Chr10: 43,077,069-43,130,351 (GRCh38.p14)",
                    "sub_points": [
                      "Chr10: 43,077,069-43,130,351 (GRCh38.p14)"
                    ]
                  },
                  {
                    "text": "Number of exons: 20"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Normal Function ofRET": [
                  {
                    "text": "Encodes transmembrane receptor tyrosine kinaseActivates MAPK- and AKT-signaling pathways; important for cell differentiation, growth, migration, and survivalReceptor for glial cell-derived neurotrophic factor family ligandsGlial-derived neurotrophic factor (GDNF)Neurturin (NRTN)Artemin (ARTN)Persephin (PSPN)Ligand binding stimulates receptor dimerization, transphosphorylation of kinase domains, and activation of signaling",
                    "sub_points": [
                      "Activates MAPK- and AKT-signaling pathways; important for cell differentiation, growth, migration, and survival",
                      "Receptor for glial cell-derived neurotrophic factor family ligandsGlial-derived neurotrophic factor (GDNF)Neurturin (NRTN)Artemin (ARTN)Persephin (PSPN)",
                      "Glial-derived neurotrophic factor (GDNF)",
                      "Neurturin (NRTN)",
                      "Artemin (ARTN)",
                      "Persephin (PSPN)",
                      "Ligand binding stimulates receptor dimerization, transphosphorylation of kinase domains, and activation of signaling"
                    ]
                  },
                  {
                    "text": "Important in development of nervous system, intestine, kidneys, and organs derived from neural crest"
                  },
                  {
                    "text": "Required for survival and proliferation of undifferentiated spermatogonia"
                  },
                  {
                    "text": "Isoforms generated by alternative 3' splicing may exert different cellular effects"
                  }
                ],
                "Abnormal Function ofRETFusion Gene": [
                  {
                    "text": "Somatic rearrangements involve 3' region ofRET, including tyrosine kinase domain and 5' region of partner genesRETbreakpoints commonly involve intron 11, less often introns 7 and 10> 35 partner genes described",
                    "sub_points": [
                      "RETbreakpoints commonly involve intron 11, less often introns 7 and 10",
                      "> 35 partner genes described"
                    ]
                  },
                  {
                    "text": "Downstream pathway activation via multiple means, including ligand-independent activation of RET kinase, increased expression of RET, or altered fusion partner function"
                  },
                  {
                    "text": "RETfusions and MAPK-signaling pathway alterations are mutually exclusive"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "RETRearrangements in Non-Small Cell Lung Cancer": [
                  {
                    "text": "~ 1-2% incidence in non-small cell lung cancer (NSCLC), particularly adenocarcinoma"
                  },
                  {
                    "text": "CommonRETfusion partner genesKIF5BNCOA4CCDC6",
                    "sub_points": [
                      "KIF5B",
                      "NCOA4",
                      "CCDC6"
                    ]
                  },
                  {
                    "text": "Associated with responsiveness to oral RET tyrosine kinase inhibitor therapy, regardless of fusion partner"
                  },
                  {
                    "text": "Rearrangement correlates with never-smoking status, younger age, more advanced disease stage, and coexistence of other genomic alterations"
                  },
                  {
                    "text": "RETrearrangements are mutually exclusive with mutations in other major driver oncogenes, includingALK,EGFR, andKRAS"
                  },
                  {
                    "text": "Mechanism of acquired resistance to EGFR small molecule inhibitors therapy"
                  }
                ],
                "RETRearrangements in Papillary Thyroid Carcinoma": [
                  {
                    "text": "Incidence ofRETrearrangement is 10-20% in papillary thyroid carcinomaIncidence may be higher if more sensitive detection techniques are usedStudies show significant geographic variationMutually exclusive withBRAF,HRAS,NRAS, andKRASmutations",
                    "sub_points": [
                      "Incidence may be higher if more sensitive detection techniques are used",
                      "Studies show significant geographic variation",
                      "Mutually exclusive withBRAF,HRAS,NRAS, andKRASmutations"
                    ]
                  },
                  {
                    "text": "CommonRETpartner genes in papillary thyroid carcinomaCCDC6NCOA4",
                    "sub_points": [
                      "CCDC6",
                      "NCOA4"
                    ]
                  },
                  {
                    "text": "Less commonRETpartner fusion gene in papillary thyroid carcinomaPRKAR1A",
                    "sub_points": [
                      "PRKAR1A"
                    ]
                  },
                  {
                    "text": "RETrearrangements in papillary thyroid carcinoma have strong association with radiation exposure"
                  },
                  {
                    "text": "Impact on prognosis is controversial and may depend on specific partner gene"
                  },
                  {
                    "text": "Detection ofRETrearrangement can assist in diagnosis"
                  },
                  {
                    "text": "Selpercatinib or pralsetinib are FDA-approved targeted inhibitors"
                  }
                ],
                "RETFusion Genes Reported in Other Malignancies": [
                  {
                    "text": "Salivary gland intraductal carcinoma (~ 47% of cases)"
                  },
                  {
                    "text": "Lung carcinosarcoma (~ 15% of cases)"
                  },
                  {
                    "text": "Spitz tumors and spitzoid melanoma"
                  },
                  {
                    "text": "Breast cancer (~ 0.2% of cases)"
                  },
                  {
                    "text": "Secondary acute myeloid leukemia"
                  }
                ],
                "Testing forRETFusion": [
                  {
                    "text": "Next-generation sequencing (NGS)RNA-based NGS can detect fusions with high specificityMore efficient than single-target assays for fusion gene detectionNGS may also permit determination of fusion partner gene and sequence alterations",
                    "sub_points": [
                      "RNA-based NGS can detect fusions with high specificity",
                      "More efficient than single-target assays for fusion gene detection",
                      "NGS may also permit determination of fusion partner gene and sequence alterations"
                    ]
                  },
                  {
                    "text": "FISHCommonly use break-apart probe strategyRed and green signals straddleRETbreakpointsIf rearrangement occurs, red and green signals become separatedDoes not identify fusion partner geneMay underdetect some fusions",
                    "sub_points": [
                      "Commonly use break-apart probe strategyRed and green signals straddleRETbreakpointsIf rearrangement occurs, red and green signals become separatedDoes not identify fusion partner gene",
                      "Red and green signals straddleRETbreakpoints",
                      "If rearrangement occurs, red and green signals become separated",
                      "Does not identify fusion partner gene",
                      "May underdetect some fusions"
                    ]
                  },
                  {
                    "text": "Targeted RT-PCRDetection limited to utilized primersFusion partners that have developed primers may be identifiedWill not detect fusions with novel partners",
                    "sub_points": [
                      "Detection limited to utilized primersFusion partners that have developed primers may be identifiedWill not detect fusions with novel partners",
                      "Fusion partners that have developed primers may be identified",
                      "Will not detect fusions with novel partners"
                    ]
                  },
                  {
                    "text": "ImmunohistochemistryRET protein overexpressed by IHC in manyRET-rearranged cases but unreliable for rearrangement detection",
                    "sub_points": [
                      "RET protein overexpressed by IHC in manyRET-rearranged cases but unreliable for rearrangement detection"
                    ]
                  }
                ],
                "RETMutations": [
                  {
                    "text": "Direct sequencing is necessary to detect sequence alterations"
                  },
                  {
                    "text": "GermlineRETmutationsActivating mutations cause multiple endocrine neoplasia (MEN) types 2A, 2B, and familial medullary thyroid carcinomaTypically gain-of-function point mutationsLoss-of-function mutations cause Hirschsprung disease",
                    "sub_points": [
                      "Activating mutations cause multiple endocrine neoplasia (MEN) types 2A, 2B, and familial medullary thyroid carcinomaTypically gain-of-function point mutations",
                      "Typically gain-of-function point mutations",
                      "Loss-of-function mutations cause Hirschsprung disease"
                    ]
                  },
                  {
                    "text": "SomaticRETmutationsCommon in sporadic medullary thyroid carcinoma",
                    "sub_points": [
                      "Common in sporadic medullary thyroid carcinoma"
                    ]
                  }
                ],
                "Targeted Therapies": [
                  {
                    "text": "Multikinase inhibitors with RET activity explored in tumors with activating RET alterationsModest efficacy but many off-target adverse effects (rash, hypertension, diarrhea)",
                    "sub_points": [
                      "Modest efficacy but many off-target adverse effects (rash, hypertension, diarrhea)"
                    ]
                  },
                  {
                    "text": "Selective RET inhibitors (pralsetinib and selpercatinib) now availableMay have improved efficacy and more favorable toxicity profile",
                    "sub_points": [
                      "May have improved efficacy and more favorable toxicity profile"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "FISH forMETAmplifications": {
            "name": "FISH forMETAmplifications",
            "url": "https://app.pathprimer.com/document/5c5ae7fd-5da5-4d49-b0fc-bd6bc69bdf7f/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name:METprotooncogene, receptor tyrosine kinaseOther names: Hepatocyte growth factor receptor (HGFR), RCCP2, and c-MET",
                    "sub_points": [
                      "Other names: Hepatocyte growth factor receptor (HGFR), RCCP2, and c-MET"
                    ]
                  },
                  {
                    "text": "HGNC ID: 7029"
                  },
                  {
                    "text": "Chromosomal location: 7q31.2"
                  },
                  {
                    "text": "Number of exons: 22"
                  },
                  {
                    "text": "Preferred protein name: Hepatocyte growth factor receptora.k.a. c-met, Met",
                    "sub_points": [
                      "a.k.a. c-met, Met"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "METProtooncogene": [
                  {
                    "text": "Widely expressed throughout variety of tissue typesMost highly expressed in liver and placentaExpressed primarily in epithelial cells",
                    "sub_points": [
                      "Most highly expressed in liver and placenta",
                      "Expressed primarily in epithelial cells"
                    ]
                  },
                  {
                    "text": "Dimeric receptor tyrosine kinaseGene produces single-chain precursor proteinPrecursor is cleaved to produce short α-chain and longer β-chain2 chains form disulfide-linked heterodimerα-chain is extracellular and includes semaphorin (sema) ligand-binding domainβ-chain is transmembrane and cytoplasmic and includes inhibitory juxtamembrane region that inhibits MET kinase activity and leads to receptor degradation, intracellular tyrosine kinase domain, and docking site that recruits downstream signaling pathwaysBinds hepatocyte growth factor (HGF)HGF is paracrine growth factor with effects on many cell types, including epithelial cells, endothelial cells, and hematopoietic cellsHGF binding causes dimerization and phosphorylation of tyrosine kinase domain",
                    "sub_points": [
                      "Gene produces single-chain precursor protein",
                      "Precursor is cleaved to produce short α-chain and longer β-chain2 chains form disulfide-linked heterodimerα-chain is extracellular and includes semaphorin (sema) ligand-binding domainβ-chain is transmembrane and cytoplasmic and includes inhibitory juxtamembrane region that inhibits MET kinase activity and leads to receptor degradation, intracellular tyrosine kinase domain, and docking site that recruits downstream signaling pathways",
                      "2 chains form disulfide-linked heterodimer",
                      "α-chain is extracellular and includes semaphorin (sema) ligand-binding domain",
                      "β-chain is transmembrane and cytoplasmic and includes inhibitory juxtamembrane region that inhibits MET kinase activity and leads to receptor degradation, intracellular tyrosine kinase domain, and docking site that recruits downstream signaling pathways",
                      "Binds hepatocyte growth factor (HGF)HGF is paracrine growth factor with effects on many cell types, including epithelial cells, endothelial cells, and hematopoietic cellsHGF binding causes dimerization and phosphorylation of tyrosine kinase domain",
                      "HGF is paracrine growth factor with effects on many cell types, including epithelial cells, endothelial cells, and hematopoietic cells",
                      "HGF binding causes dimerization and phosphorylation of tyrosine kinase domain"
                    ]
                  },
                  {
                    "text": "Signaling pathways activated following HGF bindingPI3K/Akt pathwayImportant for cell spreading and motilityRA/MAP kinase pathwayControls cell proliferation and motilitySTAT and NF-κB pathwayInduces MET-dependent formation of branched tubules",
                    "sub_points": [
                      "PI3K/Akt pathwayImportant for cell spreading and motility",
                      "Important for cell spreading and motility",
                      "RA/MAP kinase pathwayControls cell proliferation and motility",
                      "Controls cell proliferation and motility",
                      "STAT and NF-κB pathwayInduces MET-dependent formation of branched tubules",
                      "Induces MET-dependent formation of branched tubules"
                    ]
                  },
                  {
                    "text": "Signaling cascades lead to invasive growth programCells dissociate and become motile, stimulating migrationCells invade new environmentCells proliferate and stimulate angiogenesisCells form branched tubule structuresApoptosis is inhibited throughout this process",
                    "sub_points": [
                      "Cells dissociate and become motile, stimulating migration",
                      "Cells invade new environment",
                      "Cells proliferate and stimulate angiogenesis",
                      "Cells form branched tubule structures",
                      "Apoptosis is inhibited throughout this process"
                    ]
                  },
                  {
                    "text": "Signaling is important part of embryological developmentPlays role in gastrulation, epithelial morphogenesis, angiogenesis, myoblast migration, bone remodeling, and nerve sprouting",
                    "sub_points": [
                      "Plays role in gastrulation, epithelial morphogenesis, angiogenesis, myoblast migration, bone remodeling, and nerve sprouting"
                    ]
                  },
                  {
                    "text": "Signaling is normal in wound healing in adulthoodLeads to cell proliferation and migration to edges of wounds to regenerate damaged tissueHGF (ligand) expression is upregulated by interleukin-1 and interleukin-6 cytokines",
                    "sub_points": [
                      "Leads to cell proliferation and migration to edges of wounds to regenerate damaged tissue",
                      "HGF (ligand) expression is upregulated by interleukin-1 and interleukin-6 cytokines"
                    ]
                  },
                  {
                    "text": "MET expression is increased following liver, kidney, or heart injuryPlays role in liver regeneration",
                    "sub_points": [
                      "Plays role in liver regeneration"
                    ]
                  }
                ],
                "Aberrant MET Signaling": [
                  {
                    "text": "OverexpressionCan occur throughMETamplification or epigenetic changesSignificance of overexpression in absence of amplification is not clearCan also occur through multiple copies (polysomy) of chromosome 7MET overexpression leads to increased signaling and tumorigenesis and metastasisActivation in carcinomas usually occurs in paracrine fashionTumors with overexpression of MET also show ligand-independent activation of tyrosine kinase",
                    "sub_points": [
                      "Can occur throughMETamplification or epigenetic changesSignificance of overexpression in absence of amplification is not clear",
                      "Significance of overexpression in absence of amplification is not clear",
                      "Can also occur through multiple copies (polysomy) of chromosome 7",
                      "MET overexpression leads to increased signaling and tumorigenesis and metastasisActivation in carcinomas usually occurs in paracrine fashionTumors with overexpression of MET also show ligand-independent activation of tyrosine kinase",
                      "Activation in carcinomas usually occurs in paracrine fashion",
                      "Tumors with overexpression of MET also show ligand-independent activation of tyrosine kinase"
                    ]
                  },
                  {
                    "text": "METmutationsMissense mutations in kinase, juxtamembrane, and ligand-binding domains have been identifiedGermline mutations in ligand-binding (sema) domain have been describedLung tumors tend to include mutations in extracellular and juxtamembrane domainsOther tumors more commonly include mutations in kinase domainMay lead to MET autophosphorylation and constitutive activation of signaling cascadesMay be tested for, particularly as part of next-generation sequencing panels",
                    "sub_points": [
                      "Missense mutations in kinase, juxtamembrane, and ligand-binding domains have been identifiedGermline mutations in ligand-binding (sema) domain have been describedLung tumors tend to include mutations in extracellular and juxtamembrane domainsOther tumors more commonly include mutations in kinase domain",
                      "Germline mutations in ligand-binding (sema) domain have been described",
                      "Lung tumors tend to include mutations in extracellular and juxtamembrane domains",
                      "Other tumors more commonly include mutations in kinase domain",
                      "May lead to MET autophosphorylation and constitutive activation of signaling cascades",
                      "May be tested for, particularly as part of next-generation sequencing panels"
                    ]
                  },
                  {
                    "text": "METexon 14 skipping mutationsAlterations leading to aberrant splicing with exon 14 skippingExon 14 includes juxtamembrane domainOccur in cases ±METoverexpressionDecreased ubiquitination and protein degradationLeads to increased signaling",
                    "sub_points": [
                      "Alterations leading to aberrant splicing with exon 14 skippingExon 14 includes juxtamembrane domain",
                      "Exon 14 includes juxtamembrane domain",
                      "Occur in cases ±METoverexpression",
                      "Decreased ubiquitination and protein degradationLeads to increased signaling",
                      "Leads to increased signaling"
                    ]
                  },
                  {
                    "text": "METtranslocationsUnusual finding in lung cancerClinical significance is unclear",
                    "sub_points": [
                      "Unusual finding in lung cancer",
                      "Clinical significance is unclear"
                    ]
                  },
                  {
                    "text": "Constitutive kinase activationIncreases autocrine or paracrine HGF stimulation",
                    "sub_points": [
                      "Increases autocrine or paracrine HGF stimulation"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "MET Overexpression in Tumors": [
                  {
                    "text": "METoriginally identified in human osteosarcoma cell line"
                  },
                  {
                    "text": "Overexpression described in many neoplasms, including pancreas, lung, liver, and gastric carcinomas; leiomyosarcoma and osteosarcoma; glioblastoma; and hematologic malignancies, such as multiple myeloma and acute myeloid leukemiaMET protein overexpression correlates with poor prognosis in many tumor typesPlays role in metastasis and shows greater expression in metastatic than in primary lesions",
                    "sub_points": [
                      "MET protein overexpression correlates with poor prognosis in many tumor typesPlays role in metastasis and shows greater expression in metastatic than in primary lesions",
                      "Plays role in metastasis and shows greater expression in metastatic than in primary lesions"
                    ]
                  },
                  {
                    "text": "Role ofMETin lung cancer tumorigenesis is well describedCan be primary oncogenic driver mutation or occur later in tumor developmentMice given MET inhibitors and exposed to tobacco smoke develop fewer lung tumorsMET expression is greatest along invasive front of non-small cell lung cancer (NSCLC)1-6% of NSCLC showsMETamplificationAverage copy number is higher in squamous cell cancersVery high copy number correlates with high-grade tumors3-4% of NSCLC showMETexon 14 skipping mutations",
                    "sub_points": [
                      "Can be primary oncogenic driver mutation or occur later in tumor development",
                      "Mice given MET inhibitors and exposed to tobacco smoke develop fewer lung tumors",
                      "MET expression is greatest along invasive front of non-small cell lung cancer (NSCLC)",
                      "1-6% of NSCLC showsMETamplificationAverage copy number is higher in squamous cell cancersVery high copy number correlates with high-grade tumors",
                      "Average copy number is higher in squamous cell cancers",
                      "Very high copy number correlates with high-grade tumors",
                      "3-4% of NSCLC showMETexon 14 skipping mutations"
                    ]
                  },
                  {
                    "text": "METamplificationOccurs secondary to treatment with anti-EGFR tyrosine kinase inhibitors (TKIs)Patients with resistance to EGFR inhibitors are more likely to haveMETamplification than those with EGFR inhibitor-sensitive tumors15-20% of patients with resistance to EGFR inhibitors haveMETamplificationMETamplification leads to EGFR-independent activation of PI3K/AKT pathwayMETamplification is independent predictive factor of poor outcomes in lung cancerCorrelates with high-grade and advanced stage of diseaseEvent-free survival inMET-amplified cases is 25.8-38.0 months, compared to 47.5-51.0 months in wildtype cases, irrespective of grade and stageCorrelates with greater numbers of metastatic sites than nonamplified casesIncreased MET activity has also been associated with more aggressive disease in prostate, breast, gastroesophageal, and renal tumors",
                    "sub_points": [
                      "Occurs secondary to treatment with anti-EGFR tyrosine kinase inhibitors (TKIs)Patients with resistance to EGFR inhibitors are more likely to haveMETamplification than those with EGFR inhibitor-sensitive tumors15-20% of patients with resistance to EGFR inhibitors haveMETamplificationMETamplification leads to EGFR-independent activation of PI3K/AKT pathway",
                      "Patients with resistance to EGFR inhibitors are more likely to haveMETamplification than those with EGFR inhibitor-sensitive tumors",
                      "15-20% of patients with resistance to EGFR inhibitors haveMETamplification",
                      "METamplification leads to EGFR-independent activation of PI3K/AKT pathway",
                      "METamplification is independent predictive factor of poor outcomes in lung cancerCorrelates with high-grade and advanced stage of diseaseEvent-free survival inMET-amplified cases is 25.8-38.0 months, compared to 47.5-51.0 months in wildtype cases, irrespective of grade and stageCorrelates with greater numbers of metastatic sites than nonamplified casesIncreased MET activity has also been associated with more aggressive disease in prostate, breast, gastroesophageal, and renal tumors",
                      "Correlates with high-grade and advanced stage of disease",
                      "Event-free survival inMET-amplified cases is 25.8-38.0 months, compared to 47.5-51.0 months in wildtype cases, irrespective of grade and stage",
                      "Correlates with greater numbers of metastatic sites than nonamplified cases",
                      "Increased MET activity has also been associated with more aggressive disease in prostate, breast, gastroesophageal, and renal tumors"
                    ]
                  },
                  {
                    "text": "METamplification can be sole abnormality or may occur in association with other oncogene mutationsMutations inKRASandEGFRcan be presentHigher prevalence ofBRAFmutation andPTENloss compared to non-MET-amplified tumors",
                    "sub_points": [
                      "Mutations inKRASandEGFRcan be present",
                      "Higher prevalence ofBRAFmutation andPTENloss compared to non-MET-amplified tumors"
                    ]
                  }
                ],
                "METAmplification and Chemotherapy": [
                  {
                    "text": "METamplification testing is primarily performed in NSCLCLung cancer is leading cause of cancer-related death in USAMedian survival with standard 1st-line chemotherapy is 10 monthsTargeted therapies are sought to improve outcomes",
                    "sub_points": [
                      "Lung cancer is leading cause of cancer-related death in USA",
                      "Median survival with standard 1st-line chemotherapy is 10 monthsTargeted therapies are sought to improve outcomes",
                      "Targeted therapies are sought to improve outcomes"
                    ]
                  },
                  {
                    "text": "Targeted anti-MET chemotherapeutic agents have been developed primarily for NSCLC"
                  },
                  {
                    "text": "Tumors withMETalterations are sensitive to MET inhibitors29% overall response in patients withMETamplification41% overall response in patients with exon 14 skipping mutationsSelective MET TKIsDecrease MET phosphorylation and downstream signalingDecrease vascular growth factors and lead to decreased angiogenesisIncreased apoptosis of tumor cells and decrease of premalignant lesions also occurTreated tumors show inhibition of growthPhase II clinical trials show significant increase in progression-free survival (PFS) and overall survival (OS) in patients treated with anti-MET TKI tivantinib combined with erlotinibPhase III trial showed improvement of PFS but not OS in random patients; however, OS may be improved in patients with MET-amplified tumorsALK inhibitor crizotinib also shows activity as MET inhibitorMET inhibitors in combination with other chemotherapeutic agentsGreater effects in combination with other chemotherapeutic agentsSynergistic effect with anti-EGFR TKIsMET inhibitors can restore sensitivity to anti-EGFR TKIsInhibition of both MET and EGFR leads to improved clinical outcomesAdditive effect with ALK and VEGFA inhibitorsCombination regimens show increased inhibition of tumor growthAcquired resistance during therapy with MET inhibitorsMay result from resistance-associated point mutation in tyrosine kinase domainMay also result from TGF-α overexpression that can activate alternate EGFR signaling pathwaysAnti-HGF monoclonal antibodiesCurrently in phase I/II clinical trialsAnti-HGFR antibodiesBlocks ligand binding and prevents receptor dimerizationCurrently in phases II and III clinical trials",
                    "sub_points": [
                      "29% overall response in patients withMETamplification",
                      "41% overall response in patients with exon 14 skipping mutations",
                      "Selective MET TKIsDecrease MET phosphorylation and downstream signalingDecrease vascular growth factors and lead to decreased angiogenesisIncreased apoptosis of tumor cells and decrease of premalignant lesions also occurTreated tumors show inhibition of growthPhase II clinical trials show significant increase in progression-free survival (PFS) and overall survival (OS) in patients treated with anti-MET TKI tivantinib combined with erlotinibPhase III trial showed improvement of PFS but not OS in random patients; however, OS may be improved in patients with MET-amplified tumorsALK inhibitor crizotinib also shows activity as MET inhibitor",
                      "Decrease MET phosphorylation and downstream signaling",
                      "Decrease vascular growth factors and lead to decreased angiogenesis",
                      "Increased apoptosis of tumor cells and decrease of premalignant lesions also occur",
                      "Treated tumors show inhibition of growth",
                      "Phase II clinical trials show significant increase in progression-free survival (PFS) and overall survival (OS) in patients treated with anti-MET TKI tivantinib combined with erlotinib",
                      "Phase III trial showed improvement of PFS but not OS in random patients; however, OS may be improved in patients with MET-amplified tumors",
                      "ALK inhibitor crizotinib also shows activity as MET inhibitor",
                      "MET inhibitors in combination with other chemotherapeutic agentsGreater effects in combination with other chemotherapeutic agentsSynergistic effect with anti-EGFR TKIsMET inhibitors can restore sensitivity to anti-EGFR TKIsInhibition of both MET and EGFR leads to improved clinical outcomesAdditive effect with ALK and VEGFA inhibitorsCombination regimens show increased inhibition of tumor growth",
                      "Greater effects in combination with other chemotherapeutic agents",
                      "Synergistic effect with anti-EGFR TKIs",
                      "MET inhibitors can restore sensitivity to anti-EGFR TKIs",
                      "Inhibition of both MET and EGFR leads to improved clinical outcomes",
                      "Additive effect with ALK and VEGFA inhibitors",
                      "Combination regimens show increased inhibition of tumor growth",
                      "Acquired resistance during therapy with MET inhibitorsMay result from resistance-associated point mutation in tyrosine kinase domainMay also result from TGF-α overexpression that can activate alternate EGFR signaling pathways",
                      "May result from resistance-associated point mutation in tyrosine kinase domain",
                      "May also result from TGF-α overexpression that can activate alternate EGFR signaling pathways",
                      "Anti-HGF monoclonal antibodiesCurrently in phase I/II clinical trials",
                      "Currently in phase I/II clinical trials",
                      "Anti-HGFR antibodiesBlocks ligand binding and prevents receptor dimerizationCurrently in phases II and III clinical trials",
                      "Blocks ligand binding and prevents receptor dimerization",
                      "Currently in phases II and III clinical trials"
                    ]
                  }
                ]
              },
              "Testing for MET Amplification": {
                "Lung Cancer Testing Algorithms": [
                  {
                    "text": "METamplification is usually performed as part of series or panel of molecular and genetic tests in NSCLCEGFRexon 18-21 mutation testing is priorityALKrearrangement by FISH as reflex test inEGFRwildtype casesROS1fusions in cases with wildtypeEGFRand noALKrearrangementRETfusion FISH assay typically performed in cases with wildtypeEGFRand no rearrangement ofALKorROS1KRASmutation is mutually exclusive ofEGFRmutation andALKrearrangements in most casesBRAFmutation is rare in NSCLCERBB2(HER2) mutations and amplification occur in NSCLC with low frequencyOther gene alterations may occur in NSCLC",
                    "sub_points": [
                      "EGFRexon 18-21 mutation testing is priority",
                      "ALKrearrangement by FISH as reflex test inEGFRwildtype cases",
                      "ROS1fusions in cases with wildtypeEGFRand noALKrearrangement",
                      "RETfusion FISH assay typically performed in cases with wildtypeEGFRand no rearrangement ofALKorROS1",
                      "KRASmutation is mutually exclusive ofEGFRmutation andALKrearrangements in most cases",
                      "BRAFmutation is rare in NSCLC",
                      "ERBB2(HER2) mutations and amplification occur in NSCLC with low frequency",
                      "Other gene alterations may occur in NSCLC"
                    ]
                  }
                ],
                "FISH forMETAmplification": [
                  {
                    "text": "Preferred testing modalityNGS approaches often less sensitive",
                    "sub_points": [
                      "NGS approaches often less sensitive"
                    ]
                  },
                  {
                    "text": "Performed on formalin-fixed, paraffin-embedded tissue"
                  },
                  {
                    "text": "Utilizes 2 probes1 probe covering entireMETlocus at 7q31.2Marker ofMETcopy number1 additional hybridizes to α-satellite DNA at centromere of chromosome 7 (CEP7)Marker of chromosome 7 aneusomy",
                    "sub_points": [
                      "1 probe covering entireMETlocus at 7q31.2Marker ofMETcopy number",
                      "Marker ofMETcopy number",
                      "1 additional hybridizes to α-satellite DNA at centromere of chromosome 7 (CEP7)Marker of chromosome 7 aneusomy",
                      "Marker of chromosome 7 aneusomy"
                    ]
                  },
                  {
                    "text": "Number of signals for each probe per cell is countedAbsolute number ofMETsignals per cell is recordedNumber ofMETsignals in relation to CEP7 signals is recordedAmplification, identified by increasedMETsignals, may be focal or patchy within tumor",
                    "sub_points": [
                      "Absolute number ofMETsignals per cell is recorded",
                      "Number ofMETsignals in relation to CEP7 signals is recorded",
                      "Amplification, identified by increasedMETsignals, may be focal or patchy within tumor"
                    ]
                  },
                  {
                    "text": "Interpretation ofMETFISH resultsNot well standardizedCells with normal numbers of chromosome 7 andMETwill show 2 signals for each probeRatio ofMETsignals to CEP7 signals of ≥ 2 is defined as positive forMETamplificationRatios between 1.8 and 2.0 should be interpreted with cautionAdditional cells may be counted in these casesIn general, average of ≥ 5METsignals per cell is present inMET-amplified casesPatients with meanMETcopy number per cell > 5 have worse survival outcomesSome centers use higher cut-offRatio may correlate better with poor prognosis than meanMETcopy number",
                    "sub_points": [
                      "Not well standardized",
                      "Cells with normal numbers of chromosome 7 andMETwill show 2 signals for each probe",
                      "Ratio ofMETsignals to CEP7 signals of ≥ 2 is defined as positive forMETamplificationRatios between 1.8 and 2.0 should be interpreted with cautionAdditional cells may be counted in these cases",
                      "Ratios between 1.8 and 2.0 should be interpreted with caution",
                      "Additional cells may be counted in these cases",
                      "In general, average of ≥ 5METsignals per cell is present inMET-amplified casesPatients with meanMETcopy number per cell > 5 have worse survival outcomesSome centers use higher cut-off",
                      "Patients with meanMETcopy number per cell > 5 have worse survival outcomes",
                      "Some centers use higher cut-off",
                      "Ratio may correlate better with poor prognosis than meanMETcopy number"
                    ]
                  }
                ],
                "Other Methods": [
                  {
                    "text": "Comparative genomic hybridizationNot cost effective compared to FISH analysis",
                    "sub_points": [
                      "Not cost effective compared to FISH analysis"
                    ]
                  },
                  {
                    "text": "PCRCan offer qualitative as well as quantitative results for gene copy numberDifficult to isolate pure tumor specimensResults are affected by intermixed normal epithelial cells, inflammatory cells, and fibroblastsCan identify mutations and exon 14 skipping alterations",
                    "sub_points": [
                      "Can offer qualitative as well as quantitative results for gene copy number",
                      "Difficult to isolate pure tumor specimens",
                      "Results are affected by intermixed normal epithelial cells, inflammatory cells, and fibroblasts",
                      "Can identify mutations and exon 14 skipping alterations"
                    ]
                  },
                  {
                    "text": "IHCAnti-MET monoclonal antibodies are availableEvaluates MET protein expressionCorrelates well with FISH resultsProtein overexpression is highly associated with high-level amplificationIntermediate protein expression shows weaker correlation with amplification resultsCorrelation with clinical outcomes not well established",
                    "sub_points": [
                      "Anti-MET monoclonal antibodies are available",
                      "Evaluates MET protein expression",
                      "Correlates well with FISH resultsProtein overexpression is highly associated with high-level amplificationIntermediate protein expression shows weaker correlation with amplification results",
                      "Protein overexpression is highly associated with high-level amplification",
                      "Intermediate protein expression shows weaker correlation with amplification results",
                      "Correlation with clinical outcomes not well established"
                    ]
                  }
                ]
              },
              "Predictive Cancer Testing Summary": {
                "Test Interpretation": [
                  {
                    "text": "MET:CEP7 ratio < 2: Nonamplified"
                  },
                  {
                    "text": "MET:CEP7 ratio ≥ 2: Amplified"
                  },
                  {
                    "text": "Average number ofMETsignals < 5: Nonamplified"
                  },
                  {
                    "text": "Average number ofMETsignals ≥ 5: Amplified"
                  }
                ],
                "Treatment Implications": [
                  {
                    "text": "Tumors withMETamplification show increased sensitivity to TKIs with activity against MET protein, such as crizotinib and MET-specific TKIsMETamplification is also associated with resistance to EGFR inhibitors",
                    "sub_points": [
                      "METamplification is also associated with resistance to EGFR inhibitors"
                    ]
                  },
                  {
                    "text": "Absence ofMETamplification provides no evidence of increased sensitivity to MET inhibitors"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "FISH forERBB2(HER2) Gene Amplifications": {
            "name": "FISH forERBB2(HER2) Gene Amplifications",
            "url": "https://app.pathprimer.com/document/aa188b5f-08b0-4567-a998-0223691f72be/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name:erb-b2 receptor tyrosine kinase 2a.k.a. HER2Terminology used extensively and interchangeably",
                    "sub_points": [
                      "a.k.a. HER2Terminology used extensively and interchangeably",
                      "Terminology used extensively and interchangeably"
                    ]
                  },
                  {
                    "text": "Official symbol: ERBB2"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "ERBB2amplification in breast cancer~ 30% of invasive breast cancerCorrelates with poor prognosisImportant to evaluate for anti-ERBB2 therapy",
                    "sub_points": [
                      "~ 30% of invasive breast cancer",
                      "Correlates with poor prognosis",
                      "Important to evaluate for anti-ERBB2 therapy"
                    ]
                  },
                  {
                    "text": "Other malignancies withERBB2amplificationsGastric and gastroesophageal carcinoma (9-38%), colorectal cancer (~ 3% and 5-15% in RAS/RAF-negative tumors), gallbladder (5-10%), cholangiocarcinoma (5-15%), uterine serous carcinoma (25-30%), invasive bladder cancer (~ 9%)",
                    "sub_points": [
                      "Gastric and gastroesophageal carcinoma (9-38%), colorectal cancer (~ 3% and 5-15% in RAS/RAF-negative tumors), gallbladder (5-10%), cholangiocarcinoma (5-15%), uterine serous carcinoma (25-30%), invasive bladder cancer (~ 9%)"
                    ]
                  },
                  {
                    "text": "Malignancies with reported low frequency ofERBB2(HER2) amplificationCervical, testicular, non-small cell lung and other epithelial-derived tumors",
                    "sub_points": [
                      "Cervical, testicular, non-small cell lung and other epithelial-derived tumors"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "NormalERBB2Function": [
                  {
                    "text": "Part of epidermal growth factor receptor (EGFR) family"
                  },
                  {
                    "text": "Tyrosine kinase receptor involved in growth signaling"
                  },
                  {
                    "text": "No known ligand-binding domain of its ownBinds to other EGFR family members to form heterodimer",
                    "sub_points": [
                      "Binds to other EGFR family members to form heterodimer"
                    ]
                  }
                ],
                "Overexpression ofERBB2in Cancer": [
                  {
                    "text": "Usually result of gene amplification"
                  },
                  {
                    "text": "Can lead to oncogenic transformation"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Treatment": [
                  {
                    "text": "Patients with amplifiedERBB2or 3+ IHC-positive tumors can benefit fromERBB2-targeted specific therapiesTrastuzumab (Herceptin)Monoclonal antibody againstERBB2Significantly improves outcome inERBB2(+) cancers",
                    "sub_points": [
                      "Trastuzumab (Herceptin)Monoclonal antibody againstERBB2Significantly improves outcome inERBB2(+) cancers",
                      "Monoclonal antibody againstERBB2",
                      "Significantly improves outcome inERBB2(+) cancers"
                    ]
                  },
                  {
                    "text": "New indication for trastuzumab-deruxtecanBased on DESTINY-Breast04 phase III trialPatients with nonamplifiedERBB2by FISH and 1+ or 2+ IHC-positive breast cancer treated with trastuzumab-deruxtecan showed significant improvement in survivalPatients with IHC 0 score were not included in trial and thus not eligible",
                    "sub_points": [
                      "Based on DESTINY-Breast04 phase III trial",
                      "Patients with nonamplifiedERBB2by FISH and 1+ or 2+ IHC-positive breast cancer treated with trastuzumab-deruxtecan showed significant improvement in survival",
                      "Patients with IHC 0 score were not included in trial and thus not eligible"
                    ]
                  }
                ],
                "Guidelines": [
                  {
                    "text": "2018 American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) recommendations to determineERBB2status for all newly diagnosed invasive breast cancer and subsequent metastatic diseaseIHC or ISH methods acceptableIf results are equivocal, reflex testing using alternate method should be performedTesting must be performed in CAP-accredited laboratoryPreferably use FDA-approved IHC, brightfield ISH, or FISHOptimal specimen handlingSlice at 5- to 10-mm intervalsFix in 10% neutral buffered formalin for 6-72 hoursResults important to determine appropriate therapyAnti-ERBB2 therapy shouldnotbe used with negative or equivocal results or while waiting for result",
                    "sub_points": [
                      "IHC or ISH methods acceptableIf results are equivocal, reflex testing using alternate method should be performed",
                      "If results are equivocal, reflex testing using alternate method should be performed",
                      "Testing must be performed in CAP-accredited laboratoryPreferably use FDA-approved IHC, brightfield ISH, or FISH",
                      "Preferably use FDA-approved IHC, brightfield ISH, or FISH",
                      "Optimal specimen handlingSlice at 5- to 10-mm intervalsFix in 10% neutral buffered formalin for 6-72 hours",
                      "Slice at 5- to 10-mm intervals",
                      "Fix in 10% neutral buffered formalin for 6-72 hours",
                      "Results important to determine appropriate therapyAnti-ERBB2 therapy shouldnotbe used with negative or equivocal results or while waiting for result",
                      "Anti-ERBB2 therapy shouldnotbe used with negative or equivocal results or while waiting for result"
                    ]
                  },
                  {
                    "text": "2023 ASCO-CAP guideline update2018 ASCO-CAP recommendations forERBB2testing are affirmedAcknowledges new indication for trastuzumab-deruxtecanRecommends pathologists make best practice efforts to distinguish IHC 0 from 1+ resultsRecommends adding comment provided by ASCO-CAP to all HER2 test reports",
                    "sub_points": [
                      "2018 ASCO-CAP recommendations forERBB2testing are affirmed",
                      "Acknowledges new indication for trastuzumab-deruxtecanRecommends pathologists make best practice efforts to distinguish IHC 0 from 1+ resultsRecommends adding comment provided by ASCO-CAP to all HER2 test reports",
                      "Recommends pathologists make best practice efforts to distinguish IHC 0 from 1+ results",
                      "Recommends adding comment provided by ASCO-CAP to all HER2 test reports"
                    ]
                  },
                  {
                    "text": "National Comprehensive Cancer Network (NCCN)ERBB2testing recommendations for patients with followingMetastatic colorectal cancer with noRAS/RAFmutationsAdvanced gastroesophageal or gastric adenocarcinomaUnresectable or metastatic gallbladder cancer or cholangiocarcinomaAdvanced-stage or recurrent serous endometrial carcinoma or carcinosarcoma",
                    "sub_points": [
                      "Metastatic colorectal cancer with noRAS/RAFmutations",
                      "Advanced gastroesophageal or gastric adenocarcinoma",
                      "Unresectable or metastatic gallbladder cancer or cholangiocarcinoma",
                      "Advanced-stage or recurrent serous endometrial carcinoma or carcinosarcoma"
                    ]
                  }
                ]
              },
              "Predictive Cancer Testing Summary": {
                "Test Interpretation": [
                  {
                    "text": "ERBB2 IHC on tumor tissueGraded from 0-3+0 = no staining, or incomplete/barely perceptible in ≤ 10% of tumor cellsInterpreted as negative1+ = barely perceptible, incomplete membrane staining in > 10% of tumor cellsInterpreted as negative2+ = weak to moderate complete membrane staining in > 10% of tumor cellsInterpreted as equivocal2+ criteria were redefined in 2018 ASCO/CAP updateReflex to ISH using same specimenorwith new specimen can repeat IHC or reflex to ISH3+ = complete, intense membrane staining in > 10% cellsInterpreted as positive",
                    "sub_points": [
                      "Graded from 0-3+",
                      "0 = no staining, or incomplete/barely perceptible in ≤ 10% of tumor cellsInterpreted as negative",
                      "Interpreted as negative",
                      "1+ = barely perceptible, incomplete membrane staining in > 10% of tumor cellsInterpreted as negative",
                      "Interpreted as negative",
                      "2+ = weak to moderate complete membrane staining in > 10% of tumor cellsInterpreted as equivocal2+ criteria were redefined in 2018 ASCO/CAP updateReflex to ISH using same specimenorwith new specimen can repeat IHC or reflex to ISH",
                      "Interpreted as equivocal",
                      "2+ criteria were redefined in 2018 ASCO/CAP update",
                      "Reflex to ISH using same specimenorwith new specimen can repeat IHC or reflex to ISH",
                      "3+ = complete, intense membrane staining in > 10% cellsInterpreted as positive",
                      "Interpreted as positive"
                    ]
                  },
                  {
                    "text": "ERBB2FISH reflex testing should be performed on IHC 2+ (equivocal) casesSingle-probe assays (ERBB2only) require average of ≥ 6 signals per cell to be called positiveDual-signal assay (ERBB2/CEP17) requires ratio > 2.0 to be deemed positive resultIf ratio is < 2.0 butERBB2signal number is still > 6, this is also considered positiveIf ratio is < 2.0 with ERBB2 copy number between 4.0 and 6.0, this is considered equivocal and requires reflex testing to alternate method",
                    "sub_points": [
                      "Single-probe assays (ERBB2only) require average of ≥ 6 signals per cell to be called positive",
                      "Dual-signal assay (ERBB2/CEP17) requires ratio > 2.0 to be deemed positive resultIf ratio is < 2.0 butERBB2signal number is still > 6, this is also considered positiveIf ratio is < 2.0 with ERBB2 copy number between 4.0 and 6.0, this is considered equivocal and requires reflex testing to alternate method",
                      "If ratio is < 2.0 butERBB2signal number is still > 6, this is also considered positive",
                      "If ratio is < 2.0 with ERBB2 copy number between 4.0 and 6.0, this is considered equivocal and requires reflex testing to alternate method"
                    ]
                  }
                ],
                "Pathology Review of Concurrent H&E": [
                  {
                    "text": "Important to avoid inclusion of adjacent in situ carcinoma lesions during FISH read"
                  }
                ],
                "General Issues": [
                  {
                    "text": "Repeat testing should be performedOn relapse in patients with previouslyERBB2(-) tumorsOn excision specimen in patients withERBB2(-) core needle biopsy specimen",
                    "sub_points": [
                      "On relapse in patients with previouslyERBB2(-) tumors",
                      "On excision specimen in patients withERBB2(-) core needle biopsy specimen"
                    ]
                  },
                  {
                    "text": "Testing must be reported asindeterminateif technical issues preclude diagnosisInadequate specimen handlingSignificant artifacts, including crush and edge artifactsFailed analytical testing demonstrated by failed controlsReport as indeterminate and request another specimen",
                    "sub_points": [
                      "Inadequate specimen handling",
                      "Significant artifacts, including crush and edge artifacts",
                      "Failed analytical testing demonstrated by failed controls",
                      "Report as indeterminate and request another specimen"
                    ]
                  }
                ]
              },
              "FISH Method for ERBB2 Amplification": {
                "Methodology": [
                  {
                    "text": "Paraffin-embedded, formalin-fixed tumor tissue sections"
                  },
                  {
                    "text": "Fluorescent DNA probe binds to sequence inERBB2region at 17q12"
                  },
                  {
                    "text": "Used with chromosome 17 centromeric probe (CEP17)"
                  },
                  {
                    "text": "Ratio ofERBB2signals to CEP17 signals is calculated"
                  },
                  {
                    "text": "Chromogenic ISH (CISH) is alternativeCan correlate better with morphology",
                    "sub_points": [
                      "Can correlate better with morphology"
                    ]
                  }
                ],
                "Single-Probe ISH Assay": [
                  {
                    "text": "Positive if ≥ 6.0 signals/cell"
                  },
                  {
                    "text": "If ≥ 4.0 but < 6.0 signals per cell, need concurrent IHC evaluationPositive if IHC 3+ or dual-probe ISH group 1Negative if IHC 0-2+ or dual-probe ISH group 5",
                    "sub_points": [
                      "Positive if IHC 3+ or dual-probe ISH group 1",
                      "Negative if IHC 0-2+ or dual-probe ISH group 5"
                    ]
                  },
                  {
                    "text": "If < 4.0 signals/cell, considered negative"
                  }
                ],
                "Dual-Probe ISH Assay": [
                  {
                    "text": "HER2:CEP17 ratio ≥ 2.0Group 1: AverageHER2copy number ≥ 4.0 signals/cellConsidered ISH positive andHER2(+)Group 2: AverageHER2copy number < 4.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results are obtained, this is consideredHER2(-) with comment (unclear benefit of trastuzumab in small sample size clinical trial)If IHC is 0-2+, consideredHER2(-)If IHC is 3+, consideredHER2(+)",
                    "sub_points": [
                      "Group 1: AverageHER2copy number ≥ 4.0 signals/cellConsidered ISH positive andHER2(+)",
                      "Considered ISH positive andHER2(+)",
                      "Group 2: AverageHER2copy number < 4.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results are obtained, this is consideredHER2(-) with comment (unclear benefit of trastuzumab in small sample size clinical trial)If IHC is 0-2+, consideredHER2(-)If IHC is 3+, consideredHER2(+)",
                      "Reflex back to IHC from same tissue",
                      "If IHC is 2+, recount ISHIf same ISH results are obtained, this is consideredHER2(-) with comment (unclear benefit of trastuzumab in small sample size clinical trial)",
                      "If same ISH results are obtained, this is consideredHER2(-) with comment (unclear benefit of trastuzumab in small sample size clinical trial)",
                      "If IHC is 0-2+, consideredHER2(-)",
                      "If IHC is 3+, consideredHER2(+)"
                    ]
                  },
                  {
                    "text": "HER2:CEP17 ratio < 2.0Group 3: AverageHER2copy number ≥ 6.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results obtained, consideredHER2(+)If IHC is 0-1+, consideredHER2(-)If IHC is 2-3+, consideredHER2(+)Group 4: AverageHER2copy number ≥ 4.0 and < 6.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results are obtained, consideredHER2(-) with comment (unclear benefit of trastuzumab)If IHC is 0-2+, consideredHER2(-)If IHC is 3+, consideredHER2(+)Group 5: AverageHER2copy number < 4.0 signals/cellConsidered ISH negative andHER2(-)",
                    "sub_points": [
                      "Group 3: AverageHER2copy number ≥ 6.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results obtained, consideredHER2(+)If IHC is 0-1+, consideredHER2(-)If IHC is 2-3+, consideredHER2(+)",
                      "Reflex back to IHC from same tissue",
                      "If IHC is 2+, recount ISHIf same ISH results obtained, consideredHER2(+)",
                      "If same ISH results obtained, consideredHER2(+)",
                      "If IHC is 0-1+, consideredHER2(-)",
                      "If IHC is 2-3+, consideredHER2(+)",
                      "Group 4: AverageHER2copy number ≥ 4.0 and < 6.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results are obtained, consideredHER2(-) with comment (unclear benefit of trastuzumab)If IHC is 0-2+, consideredHER2(-)If IHC is 3+, consideredHER2(+)",
                      "Reflex back to IHC from same tissue",
                      "If IHC is 2+, recount ISHIf same ISH results are obtained, consideredHER2(-) with comment (unclear benefit of trastuzumab)",
                      "If same ISH results are obtained, consideredHER2(-) with comment (unclear benefit of trastuzumab)",
                      "If IHC is 0-2+, consideredHER2(-)",
                      "If IHC is 3+, consideredHER2(+)",
                      "Group 5: AverageHER2copy number < 4.0 signals/cellConsidered ISH negative andHER2(-)",
                      "Considered ISH negative andHER2(-)"
                    ]
                  }
                ],
                "Alternate Patterns": [
                  {
                    "text": "Aneuploidy"
                  },
                  {
                    "text": "Monosomy 17~ 2% incidenceCEP17 signals are < 1.4 copies per cellIfERBB2signals are at same/similar number (ratio still < 2.0), these are reported as nonamplified",
                    "sub_points": [
                      "~ 2% incidence",
                      "CEP17 signals are < 1.4 copies per cell",
                      "IfERBB2signals are at same/similar number (ratio still < 2.0), these are reported as nonamplified"
                    ]
                  },
                  {
                    "text": "Heterogeneity1 group of tumor cells shows amplification, while another region does not; both groups should be reported with ratio calculated for each",
                    "sub_points": [
                      "1 group of tumor cells shows amplification, while another region does not; both groups should be reported with ratio calculated for each"
                    ]
                  },
                  {
                    "text": "High-signal numbers for both CEP17 andERBB2Interpretation may depend on patternIf colocalized (fused \"yellow\" signal), may indicate amplification of both and should be reported as such, even though ratio appears normalIf not colocalized (increased numbers but clearly distinct), meaning is unclear, but according to current guidelines, if ratios are normal, these should be reported as nonamplified",
                    "sub_points": [
                      "Interpretation may depend on patternIf colocalized (fused \"yellow\" signal), may indicate amplification of both and should be reported as such, even though ratio appears normalIf not colocalized (increased numbers but clearly distinct), meaning is unclear, but according to current guidelines, if ratios are normal, these should be reported as nonamplified",
                      "If colocalized (fused \"yellow\" signal), may indicate amplification of both and should be reported as such, even though ratio appears normal",
                      "If not colocalized (increased numbers but clearly distinct), meaning is unclear, but according to current guidelines, if ratios are normal, these should be reported as nonamplified"
                    ]
                  }
                ]
              },
              "Other Methods for Evaluation of ERBB2 Status": {
                "Quantitative Real-Time PCR": [
                  {
                    "text": "Emerging alternate method can be used in cases (~ 5%) where FISH fails"
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "For cases with limited available diagnostic tissue or when patient is unable to undergo traditional biopsy"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "EGFRMutations": {
            "name": "EGFRMutations",
            "url": "https://app.pathprimer.com/document/24987eb1-b769-4f7e-8549-e75e11105c38/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: Epidermal growth factor receptor"
                  },
                  {
                    "text": "Official symbol:EGFR"
                  },
                  {
                    "text": "HGNC ID: 3236"
                  },
                  {
                    "text": "Chromosomal location: 7p11.2"
                  },
                  {
                    "text": "Genomic location: Chr7:55,019,017-55,211,628 (GRCh38/hg38)"
                  },
                  {
                    "text": "Size: 1,210 amino acids"
                  },
                  {
                    "text": "Number of exons: 28"
                  },
                  {
                    "text": "Aliases: Receptor tyrosine-protein kinase ErbB-1, ERBB1, ERBB, ERRP, HER1"
                  }
                ]
              },
              "STRUCTURE AND FUNCTIONS OF EGFR PROTEIN": {
                "EGFR Structure": [
                  {
                    "text": "Plasma transmembrane glycoprotein composed ofExtracellular ligand-binding domains with 2 cysteine-rich regionsSingle transmembrane helix domainIntracellular region containing tyrosine kinase domain and autophosphorylation regions",
                    "sub_points": [
                      "Extracellular ligand-binding domains with 2 cysteine-rich regions",
                      "Single transmembrane helix domain",
                      "Intracellular region containing tyrosine kinase domain and autophosphorylation regions"
                    ]
                  },
                  {
                    "text": "Ligands of EGFR7 ligands binding EGFREpidermal growth factor (EGF), transforming growth factor alpha (TGFA), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPR), and epigenIn general, EGFR ligands are synthesized as type 1 transmembrane precursors that undergo extracellular domain cleavage to release soluble ligands",
                    "sub_points": [
                      "7 ligands binding EGFREpidermal growth factor (EGF), transforming growth factor alpha (TGFA), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPR), and epigen",
                      "Epidermal growth factor (EGF), transforming growth factor alpha (TGFA), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPR), and epigen",
                      "In general, EGFR ligands are synthesized as type 1 transmembrane precursors that undergo extracellular domain cleavage to release soluble ligands"
                    ]
                  }
                ],
                "EGFR Functions": [
                  {
                    "text": "Binding of ligand to extracellular domain results in activation ofEGFRpathway"
                  },
                  {
                    "text": "Activation of downstream pathways leads to cell proliferation, differentiation, migration/motility, adhesion, protection from apoptosis, and transformation"
                  }
                ]
              },
              "EGFR ALTERATIONS": {
                "Extracellular Domain Mutations": [
                  {
                    "text": "EGFRvariant III: Most common type of extracellular domain mutationDeletion of exons 2-7 ofEGFRin extracellular domainRenders mutant receptor incapable of binding any known ligandsDisplays low-level constitutive EGFR activityDrives tumor progression and correlates with poor prognosisMainly occur in glioblastoma multiforme (GBM) (~ 60%)Rarely occur in epithelial neoplasms, including breast, prostate, ovarian, and non-small cell lung carcinoma (NSCLC)",
                    "sub_points": [
                      "Deletion of exons 2-7 ofEGFRin extracellular domain",
                      "Renders mutant receptor incapable of binding any known ligands",
                      "Displays low-level constitutive EGFR activity",
                      "Drives tumor progression and correlates with poor prognosis",
                      "Mainly occur in glioblastoma multiforme (GBM) (~ 60%)",
                      "Rarely occur in epithelial neoplasms, including breast, prostate, ovarian, and non-small cell lung carcinoma (NSCLC)"
                    ]
                  },
                  {
                    "text": "Deletion of amino acids 521-603 in extracellular domain: Much less common thanEGFRvariant III"
                  }
                ],
                "Intracellular Kinase Domain Mutations": [
                  {
                    "text": "Most are activating mutations affecting exons 18-21"
                  },
                  {
                    "text": "Mutations result in constitutive activation of EGFR protein and subsequent oncogenesis"
                  },
                  {
                    "text": "Majority of mutations show enhanced sensitivity to 1st-generation tyrosine kinase inhibitors (TKIs)"
                  },
                  {
                    "text": "Found in NSCLC with adenocarcinoma histology~ 10-15% of NSCLC patients in western nations harborEGFRmutations~ 40% of NSCLC in Asian populations harborEGFRmutationsMore common in female patients who are nonsmokers or light smokers",
                    "sub_points": [
                      "~ 10-15% of NSCLC patients in western nations harborEGFRmutations",
                      "~ 40% of NSCLC in Asian populations harborEGFRmutations",
                      "More common in female patients who are nonsmokers or light smokers"
                    ]
                  },
                  {
                    "text": "SpecificEGFRmutations in tyrosine kinase domainExon 18 mutationsAccount for ~ 5% ofEGFRmutationsRelatively common mutations include G719C, G719S, and G719A; less common mutations include V689M, E709K, E709Q, and N700DExon 19 mutationsDeletion mutations, 9-18 bp deletions in exon 19Account for ~ 45% ofEGFRmutations; most frequent is p.E746_A750delD761Y (< 1%) is associated with resistance to TKIsExon 20 mutationsT790MConfers resistance to 1st- and 2nd-generation TKIsAccounts for ~ 50% of resistance-associated mutations to TKIsDevelops post EGFR TKI treatment in NSCLCCan also be primary event before drug exposureExon 20 in-frame insertion mutationsHeterogeneous in-frame insertions of 1-7 amino acids within D761-C775 in exon 20Results in constitutive activation of EGFR proteinAssociated with de novo resistance to targeted EGFR inhibitors and correlated with poor prognosise.g., D770-N771insX, V769-D770insX, H773-V774insX, P772-H773insX, N771-P772insXExon 21 mutationsAccount for 40-45% ofEGFRmutationsL858R is most common point mutation inEGFR",
                    "sub_points": [
                      "Exon 18 mutationsAccount for ~ 5% ofEGFRmutationsRelatively common mutations include G719C, G719S, and G719A; less common mutations include V689M, E709K, E709Q, and N700D",
                      "Account for ~ 5% ofEGFRmutations",
                      "Relatively common mutations include G719C, G719S, and G719A; less common mutations include V689M, E709K, E709Q, and N700D",
                      "Exon 19 mutationsDeletion mutations, 9-18 bp deletions in exon 19Account for ~ 45% ofEGFRmutations; most frequent is p.E746_A750delD761Y (< 1%) is associated with resistance to TKIs",
                      "Deletion mutations, 9-18 bp deletions in exon 19Account for ~ 45% ofEGFRmutations; most frequent is p.E746_A750del",
                      "Account for ~ 45% ofEGFRmutations; most frequent is p.E746_A750del",
                      "D761Y (< 1%) is associated with resistance to TKIs",
                      "Exon 20 mutationsT790MConfers resistance to 1st- and 2nd-generation TKIsAccounts for ~ 50% of resistance-associated mutations to TKIsDevelops post EGFR TKI treatment in NSCLCCan also be primary event before drug exposureExon 20 in-frame insertion mutationsHeterogeneous in-frame insertions of 1-7 amino acids within D761-C775 in exon 20Results in constitutive activation of EGFR proteinAssociated with de novo resistance to targeted EGFR inhibitors and correlated with poor prognosise.g., D770-N771insX, V769-D770insX, H773-V774insX, P772-H773insX, N771-P772insX",
                      "T790MConfers resistance to 1st- and 2nd-generation TKIsAccounts for ~ 50% of resistance-associated mutations to TKIsDevelops post EGFR TKI treatment in NSCLCCan also be primary event before drug exposure",
                      "Confers resistance to 1st- and 2nd-generation TKIs",
                      "Accounts for ~ 50% of resistance-associated mutations to TKIs",
                      "Develops post EGFR TKI treatment in NSCLC",
                      "Can also be primary event before drug exposure",
                      "Exon 20 in-frame insertion mutationsHeterogeneous in-frame insertions of 1-7 amino acids within D761-C775 in exon 20Results in constitutive activation of EGFR proteinAssociated with de novo resistance to targeted EGFR inhibitors and correlated with poor prognosise.g., D770-N771insX, V769-D770insX, H773-V774insX, P772-H773insX, N771-P772insX",
                      "Heterogeneous in-frame insertions of 1-7 amino acids within D761-C775 in exon 20",
                      "Results in constitutive activation of EGFR protein",
                      "Associated with de novo resistance to targeted EGFR inhibitors and correlated with poor prognosis",
                      "e.g., D770-N771insX, V769-D770insX, H773-V774insX, P772-H773insX, N771-P772insX",
                      "Exon 21 mutationsAccount for 40-45% ofEGFRmutationsL858R is most common point mutation inEGFR",
                      "Account for 40-45% ofEGFRmutations",
                      "L858R is most common point mutation inEGFR"
                    ]
                  },
                  {
                    "text": "EGFRmutations in exons 18, 19, 20, and 21 are mutually exclusive withKRASandBRAFmutations"
                  }
                ],
                "EGFRAmplification": [
                  {
                    "text": "CNS tumorsGlioblastoma, IDH-wildtype~ 50% of tumors showEGFRamplificationPresent solely in IDH-wildtype gliomas (26%) andTERT-mutated gliomas (27%)Diffuse pediatric type high-grade glioma, IDH-wildtypeEGFRamplification occurs in ~ 50% patients",
                    "sub_points": [
                      "Glioblastoma, IDH-wildtype~ 50% of tumors showEGFRamplificationPresent solely in IDH-wildtype gliomas (26%) andTERT-mutated gliomas (27%)",
                      "~ 50% of tumors showEGFRamplification",
                      "Present solely in IDH-wildtype gliomas (26%) andTERT-mutated gliomas (27%)",
                      "Diffuse pediatric type high-grade glioma, IDH-wildtypeEGFRamplification occurs in ~ 50% patients",
                      "EGFRamplification occurs in ~ 50% patients"
                    ]
                  },
                  {
                    "text": "Lung cancerEGFRamplification is more prevalent in squamous cell carcinoma than adenocarcinomaNSCLC withEGFRamplification may respond to TKIs",
                    "sub_points": [
                      "EGFRamplification is more prevalent in squamous cell carcinoma than adenocarcinoma",
                      "NSCLC withEGFRamplification may respond to TKIs"
                    ]
                  },
                  {
                    "text": "Breast cancer~ 6% showEGFRamplificationEGFRamplification can coexist withERRB2(HER2) amplificationMetaplastic breast carcinoma has highestEGFRamplification rate (~ 70%)",
                    "sub_points": [
                      "~ 6% showEGFRamplification",
                      "EGFRamplification can coexist withERRB2(HER2) amplification",
                      "Metaplastic breast carcinoma has highestEGFRamplification rate (~ 70%)"
                    ]
                  },
                  {
                    "text": "Ovarian cancerEGFRamplification and high polysomy present in 20% of primary and recurrent ovarian carcinomasEGFRmutation is extremely rare in ovarian cancer",
                    "sub_points": [
                      "EGFRamplification and high polysomy present in 20% of primary and recurrent ovarian carcinomas",
                      "EGFRmutation is extremely rare in ovarian cancer"
                    ]
                  },
                  {
                    "text": "Gastroesophageal adenocarcinomaEGFR-amplified tumors are associated with higher stage, more poorly differentiated histology, increased vascular invasion, and potentially shorter survival",
                    "sub_points": [
                      "EGFR-amplified tumors are associated with higher stage, more poorly differentiated histology, increased vascular invasion, and potentially shorter survival"
                    ]
                  },
                  {
                    "text": "Metastatic colorectal carcinoma (mCRC)EGFR amplification occurs in ~ 1% of mCRCMostEGFR-amplified tumors are microsatellite stable and HER2 nonamplified",
                    "sub_points": [
                      "EGFR amplification occurs in ~ 1% of mCRC",
                      "MostEGFR-amplified tumors are microsatellite stable and HER2 nonamplified"
                    ]
                  }
                ],
                "EGFR Small Molecule Inhibitors": [
                  {
                    "text": "1st-generation EGFR TKIs include erlotinib and gefitinib"
                  },
                  {
                    "text": "2nd-generation EGFR TKIs include neratinib, dacomitinib, and afatinib"
                  },
                  {
                    "text": "3rd-generation EGFR TKIs include rociletinib and osimertinib"
                  },
                  {
                    "text": "EGFRmutation testing should be used to select patients for EGFR-targeted TKI therapy"
                  }
                ],
                "Anti-EGFR Monoclonal Antibodies for Chemotherapy-Refectory Metastatic Colorectal Carcinoma": [
                  {
                    "text": "Cetuximab (Erbitux) and panitumumab (Vectibix)"
                  },
                  {
                    "text": "Resistance to EGFR blockade in mCRC with constitutive activation mutation inKRAS,NRAS, orBRAF"
                  },
                  {
                    "text": "Recommend testingKRAS,NRAS, andBRAFmutation status before treatment"
                  },
                  {
                    "text": "Mutation status ofEGFRcatalytic domain does not correlate with disease response with anti-EGFR monoclonal antibodies"
                  }
                ]
              },
              "DETECTION OF EGFR GENE ALTERATIONS": {
                "Detection of Gene Mutations": [
                  {
                    "text": "Next-generation sequencing (NGS)EGFRmutations are typically included in targeted gene panel; commonly used in clinical laboratoriesHighly sensitive and accurate when adequate sequencing depth of coverage present",
                    "sub_points": [
                      "EGFRmutations are typically included in targeted gene panel; commonly used in clinical laboratories",
                      "Highly sensitive and accurate when adequate sequencing depth of coverage present"
                    ]
                  },
                  {
                    "text": "Sanger sequencingUsed in some clinical laboratories to detectEGFRmutationsCan reliably detect many possible mutationsLess sensitive compared to NGSRequires 20-25% mutant alleles in background of wildtype alleles for reliable detection of mutations",
                    "sub_points": [
                      "Used in some clinical laboratories to detectEGFRmutations",
                      "Can reliably detect many possible mutations",
                      "Less sensitive compared to NGSRequires 20-25% mutant alleles in background of wildtype alleles for reliable detection of mutations",
                      "Requires 20-25% mutant alleles in background of wildtype alleles for reliable detection of mutations"
                    ]
                  }
                ],
                "Detection ofEGFRAmplification": [
                  {
                    "text": "Fluorescence in situ hybridization (FISH)Standard method for detectingEGFRamplificationDetectsEGFRgene copy number gain, high degrees of polysomy",
                    "sub_points": [
                      "Standard method for detectingEGFRamplification",
                      "DetectsEGFRgene copy number gain, high degrees of polysomy"
                    ]
                  },
                  {
                    "text": "Digital PCR (dPCR)Can accurately detect and quantify low nucleic acid targetsHighly sensitive and high specificity",
                    "sub_points": [
                      "Can accurately detect and quantify low nucleic acid targets",
                      "Highly sensitive and high specificity"
                    ]
                  },
                  {
                    "text": "NGSCan be used to detectEGFRamplificationCommonly included in targeted solid tumor panels",
                    "sub_points": [
                      "Can be used to detectEGFRamplification",
                      "Commonly included in targeted solid tumor panels"
                    ]
                  },
                  {
                    "text": "ImmunohistochemistryUsed to detect EGFR protein overexpression",
                    "sub_points": [
                      "Used to detect EGFR protein overexpression"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Targeted Hotspot Gene Panel Using Massively Parallel Sequencing (Next-Generation Sequencing)": {
            "name": "Targeted Hotspot Gene Panel Using Massively Parallel Sequencing (Next-Generation Sequencing)",
            "url": "https://app.pathprimer.com/document/92277e33-37b4-48af-9d86-dc8c46ced7a3/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Hotspot: Region within genome that is commonly mutated, giving rise to specific clinically significant phenotype"
                  }
                ]
              },
              "Basic Aspects of Hotspot Gene Panels": {
                "Next-Generation Sequencing": [
                  {
                    "text": "a.k.a. massively parallel sequencing"
                  },
                  {
                    "text": "Permits amplification and sequencing of many regions simultaneously"
                  }
                ],
                "General NGS Procedure": [
                  {
                    "text": "Sample preparationAssessment of adequacy and quality of submitted sample is 1st step in clinical NGS analysisTumor content in hematologic specimen may require separate analysis, such as flow cytometrySolid tumor samples require microscopic review by certified pathologist before accepted for NGS testingMicroscopic review used to assess adequacy and mark tumor areas for macrodissectionIncludes assessment for required tumor percentage as determined during validation in given lab",
                    "sub_points": [
                      "Assessment of adequacy and quality of submitted sample is 1st step in clinical NGS analysis",
                      "Tumor content in hematologic specimen may require separate analysis, such as flow cytometry",
                      "Solid tumor samples require microscopic review by certified pathologist before accepted for NGS testingMicroscopic review used to assess adequacy and mark tumor areas for macrodissectionIncludes assessment for required tumor percentage as determined during validation in given lab",
                      "Microscopic review used to assess adequacy and mark tumor areas for macrodissection",
                      "Includes assessment for required tumor percentage as determined during validation in given lab"
                    ]
                  },
                  {
                    "text": "Library preparationGenerates DNA or cDNA of specific size rangeAmplicon-based library preparationMultiplex PCR amplification to enrich target sequencesLigation-based library preparationUses long biotinylated oligonucleotide probes",
                    "sub_points": [
                      "Generates DNA or cDNA of specific size rangeAmplicon-based library preparationMultiplex PCR amplification to enrich target sequencesLigation-based library preparationUses long biotinylated oligonucleotide probes",
                      "Amplicon-based library preparationMultiplex PCR amplification to enrich target sequences",
                      "Multiplex PCR amplification to enrich target sequences",
                      "Ligation-based library preparationUses long biotinylated oligonucleotide probes",
                      "Uses long biotinylated oligonucleotide probes"
                    ]
                  },
                  {
                    "text": "SequencingSequencing by synthesis or ion semiconductor-based sequencingAll fragments sequenced simultaneously",
                    "sub_points": [
                      "Sequencing by synthesis or ion semiconductor-based sequencing",
                      "All fragments sequenced simultaneously"
                    ]
                  },
                  {
                    "text": "Data analysisBioinformatic pipelineBase calling, read alignment, variant identification, and variant annotation and variant identificationAnnotate clinical significance of detected variants",
                    "sub_points": [
                      "Bioinformatic pipelineBase calling, read alignment, variant identification, and variant annotation and variant identificationAnnotate clinical significance of detected variants",
                      "Base calling, read alignment, variant identification, and variant annotation and variant identification",
                      "Annotate clinical significance of detected variants"
                    ]
                  }
                ],
                "Scope of Sequencing": [
                  {
                    "text": "Hotspot panels represent middle ground between single-gene and whole-exome sequencing"
                  },
                  {
                    "text": "Allows cost-effective analysis by concentrating on specific mutations felt to be most common &/or most clinically significant"
                  }
                ],
                "Common Platforms": [
                  {
                    "text": "Ion torrentGenerates sequence by measuring change in pH when H⁺ is released from incorporated bases (ion semiconductor-based)Susceptible to noise calls in homopolymer tractsPersonal Genome Machine (PGM) vs. Ion Proton systems for sequencing capacity",
                    "sub_points": [
                      "Generates sequence by measuring change in pH when H⁺ is released from incorporated bases (ion semiconductor-based)",
                      "Susceptible to noise calls in homopolymer tracts",
                      "Personal Genome Machine (PGM) vs. Ion Proton systems for sequencing capacity"
                    ]
                  },
                  {
                    "text": "IlluminaGenerates sequence by reversible dye termination (sequencing by synthesis)",
                    "sub_points": [
                      "Generates sequence by reversible dye termination (sequencing by synthesis)"
                    ]
                  }
                ],
                "Source of Hotspot Panels": [
                  {
                    "text": "Several panels commercially available"
                  },
                  {
                    "text": "Laboratories often create custom hotspot panels"
                  }
                ],
                "Panels for Specific Clinical Settings": [
                  {
                    "text": "Panels for hematologic malignancies often have different genes than panels designed for solid tumors"
                  },
                  {
                    "text": "Panels for specific inherited conditionsMay include multiple genes that can cause single phenotypeMay include groups of genes that, when mutated, cause clinically overlapping or similar phenotypesCan greatly simplify genetic work-up and avoid lengthy \"diagnostic odysseys\"",
                    "sub_points": [
                      "May include multiple genes that can cause single phenotype",
                      "May include groups of genes that, when mutated, cause clinically overlapping or similar phenotypes",
                      "Can greatly simplify genetic work-up and avoid lengthy \"diagnostic odysseys\""
                    ]
                  }
                ]
              },
              "Hotspot Genes": {
                "Commonly Mutated Genes": [
                  {
                    "text": "Common tumor suppressor genes and oncogenes"
                  },
                  {
                    "text": "May or may not have associated targeted therapeutic options"
                  },
                  {
                    "text": "e.g.,TP53,RB1"
                  }
                ],
                "Genes Mutated in Specific Neoplasms": [
                  {
                    "text": "May or may not have associated targeted therapeutic options but could theoretically assist in diagnosis and subclassificatione.g.,GNA11(uveal melanoma),MPL(essential thrombocythemia, primary myelofibrosis)",
                    "sub_points": [
                      "e.g.,GNA11(uveal melanoma),MPL(essential thrombocythemia, primary myelofibrosis)"
                    ]
                  }
                ],
                "Genes for Targeted Therapy": [
                  {
                    "text": "NGS panels offer more extensive coverage than achieved with standalone single-gene assays"
                  },
                  {
                    "text": "With increasing demands for testing for multiple genes via both sequencing and FISH, NGS panels may optimize yield from scant tumor samples"
                  },
                  {
                    "text": "e.g.,EGFR,KRAS,NRAS,BRAF"
                  }
                ]
              },
              "Technical and Interpretive Challenges": {
                "Validation": [
                  {
                    "text": "Challenging due to number of mutated genes/targets"
                  },
                  {
                    "text": "Extensive and costly validation is necessary to fulfill CLIA requirements"
                  },
                  {
                    "text": "Some reference standards for NGS are commercially available\"Cocktails\" that combine many different mutations in single sample",
                    "sub_points": [
                      "\"Cocktails\" that combine many different mutations in single sample"
                    ]
                  }
                ],
                "Size of Panel": [
                  {
                    "text": "Optimal number of genes to include is moving target"
                  },
                  {
                    "text": "Must achieve balance between cost and practical benefit"
                  }
                ],
                "Biopsy Specimen Quality": [
                  {
                    "text": "Tissue obtained for molecular analysis is often very small with scant tumor cells"
                  },
                  {
                    "text": "Macrodissection is typically employed to maximize specimen yield"
                  }
                ],
                "Variant Annotation": [
                  {
                    "text": "Must distinguish between somatic mutation and possible rare population polymorphisms [single nucleotide polymorphism (SNP)]Useful databases include dbSNP, COSMIC, ClinVar, and cBioPortal, but these are not exhaustive or error free",
                    "sub_points": [
                      "Useful databases include dbSNP, COSMIC, ClinVar, and cBioPortal, but these are not exhaustive or error free"
                    ]
                  },
                  {
                    "text": "Must attempt to distinguish between \"driver\" and \"passenger\" somatic mutationsSoftware tools for functional prediction (e.g., PolyPhen-2) of impact of variant on protein function are sometimes contradictory or otherwise unhelpfulExtensive literature and database searches are often necessary",
                    "sub_points": [
                      "Software tools for functional prediction (e.g., PolyPhen-2) of impact of variant on protein function are sometimes contradictory or otherwise unhelpful",
                      "Extensive literature and database searches are often necessary"
                    ]
                  },
                  {
                    "text": "Many genes on somatic cancer hotspot panels are also affected by germline mutationse.g.,TP53in Li-Fraumeni syndromeHotspot panels run on tumor tissue alone usually cannot reliably differentiate between somatic and germline variants",
                    "sub_points": [
                      "e.g.,TP53in Li-Fraumeni syndrome",
                      "Hotspot panels run on tumor tissue alone usually cannot reliably differentiate between somatic and germline variants"
                    ]
                  }
                ],
                "Reporting": [
                  {
                    "text": "4-tier system proposed to categorize somatic sequence variantsTier I: Variants with strong clinical significanceTier II: Variants of potential clinical significanceTier III: Variants of unknown clinical significanceTier IV: Benign or likely benign variants",
                    "sub_points": [
                      "Tier I: Variants with strong clinical significance",
                      "Tier II: Variants of potential clinical significance",
                      "Tier III: Variants of unknown clinical significance",
                      "Tier IV: Benign or likely benign variants"
                    ]
                  },
                  {
                    "text": "Reports should include information about clinical trials and targeted therapy"
                  },
                  {
                    "text": "Some reports are voluminous and challenging for clinicians to utilize"
                  }
                ]
              },
              "Limits of Hotspot Approach": {
                "Coverage": [
                  {
                    "text": "While these assays are intended to cover most common &/or most significant mutations, pathogenic mutations outside of target regions will not be identifiedEven for genes included in assay, some exons may be excludedOther clinically significant genes may not be included",
                    "sub_points": [
                      "Even for genes included in assay, some exons may be excluded",
                      "Other clinically significant genes may not be included"
                    ]
                  }
                ],
                "Large-Scale Genetic Changes": [
                  {
                    "text": "Hotspot panels may not identify medium- to large-scale genetic changesLarger insertions or deletions may not be identified",
                    "sub_points": [
                      "Larger insertions or deletions may not be identified"
                    ]
                  },
                  {
                    "text": "Insertions or deletions of small to intermediate size are typically detectable"
                  },
                  {
                    "text": "Additional types of genetic changes may be detected on some panelsTranslocations and fusion genesChanges in copy number (including gene amplification or deletion)These alterations require specialized analytic &/or bioinformatic approaches",
                    "sub_points": [
                      "Translocations and fusion genes",
                      "Changes in copy number (including gene amplification or deletion)These alterations require specialized analytic &/or bioinformatic approaches",
                      "These alterations require specialized analytic &/or bioinformatic approaches"
                    ]
                  }
                ],
                "Analytic Sensitivity": [
                  {
                    "text": "Largely function of depth of coverage"
                  },
                  {
                    "text": "Common limit of detection is in range of 5% mutated alleles in wildtype background"
                  },
                  {
                    "text": "For certain mutations (e.g.,JAK2V617F), clinically recommended limit of detection may be lower than achieved by typical hotspot panel"
                  }
                ],
                "Clinical Applicability": [
                  {
                    "text": "Some mutations identified via hotspot panels are not clearly actionableMay lack FDA-approved targeted therapyFDA-approved drug may exist for different indication, mutation, or tumor typePreclinical data may exist to support personalized therapy for some targets, but clinical data may be lacking",
                    "sub_points": [
                      "May lack FDA-approved targeted therapy",
                      "FDA-approved drug may exist for different indication, mutation, or tumor type",
                      "Preclinical data may exist to support personalized therapy for some targets, but clinical data may be lacking"
                    ]
                  },
                  {
                    "text": "Insurance providers may not cover cost of hotspot panel &/or therapy suggested by resultsCan prompt bioethical dilemmas regarding proper treatment approach",
                    "sub_points": [
                      "Can prompt bioethical dilemmas regarding proper treatment approach"
                    ]
                  },
                  {
                    "text": "Patients may be eligible for clinical trials, depending on trial availability"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "MGMT Promoter Gene Methylation Assay": {
            "name": "MGMT Promoter Gene Methylation Assay",
            "url": "https://app.pathprimer.com/document/419226f8-66ce-4ffb-af3c-943e095733e6/lesson/a2274e18-2ee6-4532-ad15-7805591337a1",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: O-6-methylguanine-DNA methyltransferase"
                  },
                  {
                    "text": "Official symbol:MGMT"
                  },
                  {
                    "text": "HGNC ID: 7059"
                  },
                  {
                    "text": "Chromosomal location: 10q26.3"
                  },
                  {
                    "text": "Preferred protein name: Methylated-DNA-protein-cysteine methyltransferaseAlternative protein names: Methylguanine-DNA methyltransferase, O-6-methylguanine-DNA-alkyltransferase, O-6-methylguanine-DNA methyltransferase, 6-O-methylguanine-DNA methyltransferase",
                    "sub_points": [
                      "Alternative protein names: Methylguanine-DNA methyltransferase, O-6-methylguanine-DNA-alkyltransferase, O-6-methylguanine-DNA methyltransferase, 6-O-methylguanine-DNA methyltransferase"
                    ]
                  }
                ],
                "Function ofMGMT": [
                  {
                    "text": "DNA repair geneProtects against cytotoxic and mutagenic alkyl adducts to O-6-guanine residues in DNAChemical carcinogens (including N-nitrosamines, aflatoxins, aromatic amines, and polycyclic aromatic hydrocarbons) cause creation of DNA alkyl adductsAlkyl adducts also occur naturally in vivo at low rateRecognizes alkyl adducts and removes them from DNA by transfer of alkyl group to internal cysteine acceptor siteAlso repairs O-6 ethylguanine and O-4 methylthymineFollowing transfer of alkyl group, alkylated MGMT is degradedExpression of MGMT is induced by DNA damage, glucocorticoids, cyclic AMP, and protein kinase C",
                    "sub_points": [
                      "Protects against cytotoxic and mutagenic alkyl adducts to O-6-guanine residues in DNAChemical carcinogens (including N-nitrosamines, aflatoxins, aromatic amines, and polycyclic aromatic hydrocarbons) cause creation of DNA alkyl adductsAlkyl adducts also occur naturally in vivo at low rate",
                      "Chemical carcinogens (including N-nitrosamines, aflatoxins, aromatic amines, and polycyclic aromatic hydrocarbons) cause creation of DNA alkyl adducts",
                      "Alkyl adducts also occur naturally in vivo at low rate",
                      "Recognizes alkyl adducts and removes them from DNA by transfer of alkyl group to internal cysteine acceptor siteAlso repairs O-6 ethylguanine and O-4 methylthymineFollowing transfer of alkyl group, alkylated MGMT is degradedExpression of MGMT is induced by DNA damage, glucocorticoids, cyclic AMP, and protein kinase C",
                      "Also repairs O-6 ethylguanine and O-4 methylthymine",
                      "Following transfer of alkyl group, alkylated MGMT is degraded",
                      "Expression of MGMT is induced by DNA damage, glucocorticoids, cyclic AMP, and protein kinase C"
                    ]
                  }
                ],
                "Methylation ofMGMTPromoter": [
                  {
                    "text": "Promoter region includes at least 97 CpG sequences, constituting CpG island"
                  },
                  {
                    "text": "Epigenetic modification of promoter region of gene decreases gene transcriptionMethylated CpG sites bind methylated CpG binding proteins 1 and 2 (MECP1/MECP2)MECP proteins decrease transcription directly through transcription repression domainMECP proteins bind other factors that cause chromatin condensation and block transcriptionMECP proteins block binding of transcription factors",
                    "sub_points": [
                      "Methylated CpG sites bind methylated CpG binding proteins 1 and 2 (MECP1/MECP2)MECP proteins decrease transcription directly through transcription repression domainMECP proteins bind other factors that cause chromatin condensation and block transcriptionMECP proteins block binding of transcription factors",
                      "MECP proteins decrease transcription directly through transcription repression domain",
                      "MECP proteins bind other factors that cause chromatin condensation and block transcription",
                      "MECP proteins block binding of transcription factors"
                    ]
                  },
                  {
                    "text": "Methyl groups are added to cytosines followed by guanines (CpG dinucleotides)CpG islands are DNA regions with many cytosine-guanine linear sequence pairs in 5' to 3' directionCpG islands are often found in promoter region of genes, where transcription machinery binds",
                    "sub_points": [
                      "CpG islands are DNA regions with many cytosine-guanine linear sequence pairs in 5' to 3' direction",
                      "CpG islands are often found in promoter region of genes, where transcription machinery binds"
                    ]
                  },
                  {
                    "text": "Associated with several cancer typesIncluding colorectal cancer, lung cancer, lymphoma, and glioblastoma",
                    "sub_points": [
                      "Including colorectal cancer, lung cancer, lymphoma, and glioblastoma"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Loss ofMGMTExpression in Tumors": [
                  {
                    "text": "Loss ofMGMTexpression has been described in many neoplasms, including gliomas, lymphomas, breast and prostate cancer, germ cell tumors, and retinoblastomaTypically results fromMGMTpromoter hypermethylation, which is predictive marker in high-grade gliomas (GBM)GBM is most common primary brain tumor in adultsTreatment includes surgery, radiation therapy, and chemotherapyMedian survival with standard of care treatment is 14.6 monthsMethylated MGMT promoter region correlates with improved survival in gliomas treated with alkylating agentsPercentage of GBM with epigenetic methylation ofMGMTpromoter regions varies by grade and methylation detection method",
                    "sub_points": [
                      "Typically results fromMGMTpromoter hypermethylation, which is predictive marker in high-grade gliomas (GBM)GBM is most common primary brain tumor in adultsTreatment includes surgery, radiation therapy, and chemotherapyMedian survival with standard of care treatment is 14.6 monthsMethylated MGMT promoter region correlates with improved survival in gliomas treated with alkylating agents",
                      "GBM is most common primary brain tumor in adults",
                      "Treatment includes surgery, radiation therapy, and chemotherapy",
                      "Median survival with standard of care treatment is 14.6 months",
                      "Methylated MGMT promoter region correlates with improved survival in gliomas treated with alkylating agents",
                      "Percentage of GBM with epigenetic methylation ofMGMTpromoter regions varies by grade and methylation detection method"
                    ]
                  }
                ],
                "MGMTPromoter Methylation and Survival in High-Grade Gliomas": [
                  {
                    "text": "MGMTmethylation status is essential part of work-up for high-grade gliomasEvidence suggests methylation may correlate with response in low-grade tumor as well",
                    "sub_points": [
                      "Evidence suggests methylation may correlate with response in low-grade tumor as well"
                    ]
                  },
                  {
                    "text": "MGMTpromoter methylation is well characterized as predictive factor in GBMMGMTmethylation is associated with increased overall survival in patients treated with radiotherapy and chemotherapyPatients with hypermethylatedMGMTpromoter show survival rates of 49% and 14% at 2 years and 5 years when treated with temozolomide and radiotherapyPatients with unmethylatedMGMTpromoter show survival rates of 15% and 8% at 2 years and 5 years with same treatmentMGMTmethylation status used for risk stratification in clinical trialsDetection of MGMT protein expression by immunohistochemistry does not correlate well with results ofMGMTpromoter methylation assays or patient outcomes and has high intraobserver variabilityMGMTexpression by quantitative RT-PCR does not correlate well with results ofMGMTpromoter methylation assays but is widely used in clinical trial registration",
                    "sub_points": [
                      "MGMTmethylation is associated with increased overall survival in patients treated with radiotherapy and chemotherapyPatients with hypermethylatedMGMTpromoter show survival rates of 49% and 14% at 2 years and 5 years when treated with temozolomide and radiotherapyPatients with unmethylatedMGMTpromoter show survival rates of 15% and 8% at 2 years and 5 years with same treatment",
                      "Patients with hypermethylatedMGMTpromoter show survival rates of 49% and 14% at 2 years and 5 years when treated with temozolomide and radiotherapy",
                      "Patients with unmethylatedMGMTpromoter show survival rates of 15% and 8% at 2 years and 5 years with same treatment",
                      "MGMTmethylation status used for risk stratification in clinical trials",
                      "Detection of MGMT protein expression by immunohistochemistry does not correlate well with results ofMGMTpromoter methylation assays or patient outcomes and has high intraobserver variability",
                      "MGMTexpression by quantitative RT-PCR does not correlate well with results ofMGMTpromoter methylation assays but is widely used in clinical trial registration"
                    ]
                  },
                  {
                    "text": "Methylation is associated withIDHmutations and genome-wide epigenetic changes"
                  }
                ],
                "MGMTPromoter Methylation and GBM Treatment": [
                  {
                    "text": "Temozolomide and lomustine are alkylating agents that cross blood-brain barrier and are standard of care for treatment of high-grade gliomaCauses cell death by creating O-6 methylguanine adductsMethylguanine preferentially pairs with thymine rather than cytosine, creating mismatchMismatch repair genes attempt to repair mismatch, but methylguanine continues to pair with thymine, causing futile cycle of mismatch repairAfter several futile attempts to repair, cell eventually undergoes apoptosis",
                    "sub_points": [
                      "Causes cell death by creating O-6 methylguanine adducts",
                      "Methylguanine preferentially pairs with thymine rather than cytosine, creating mismatchMismatch repair genes attempt to repair mismatch, but methylguanine continues to pair with thymine, causing futile cycle of mismatch repairAfter several futile attempts to repair, cell eventually undergoes apoptosis",
                      "Mismatch repair genes attempt to repair mismatch, but methylguanine continues to pair with thymine, causing futile cycle of mismatch repair",
                      "After several futile attempts to repair, cell eventually undergoes apoptosis"
                    ]
                  },
                  {
                    "text": "Methylated MGMT promoter regionResults in suppression ofMGMTexpression in tumor cellsDecreases function of mismatch repair genes and increases incidence of acquired mutationsLeads to unrepaired alkylated guanine residues in tumor cellsPromotes apoptosis of tumor cells",
                    "sub_points": [
                      "Results in suppression ofMGMTexpression in tumor cellsDecreases function of mismatch repair genes and increases incidence of acquired mutationsLeads to unrepaired alkylated guanine residues in tumor cellsPromotes apoptosis of tumor cells",
                      "Decreases function of mismatch repair genes and increases incidence of acquired mutations",
                      "Leads to unrepaired alkylated guanine residues in tumor cells",
                      "Promotes apoptosis of tumor cells"
                    ]
                  },
                  {
                    "text": "Nonmethylated MGMT promoter regionResults in expression ofMGMTin tumor cellsRemoves alkyl groupAllows mismatch repair proteins to successfully repair G:T mismatchesPromotes tumor cell survivalResults in resistance to treatment with alkylating agents, such as temozolomide",
                    "sub_points": [
                      "Results in expression ofMGMTin tumor cellsRemoves alkyl groupAllows mismatch repair proteins to successfully repair G:T mismatchesPromotes tumor cell survivalResults in resistance to treatment with alkylating agents, such as temozolomide",
                      "Removes alkyl group",
                      "Allows mismatch repair proteins to successfully repair G:T mismatches",
                      "Promotes tumor cell survival",
                      "Results in resistance to treatment with alkylating agents, such as temozolomide"
                    ]
                  },
                  {
                    "text": "MGMT methylation status is used to guide treatmentPatients with methylatedMGMTpromoter region have improved outcomes with temozolomideDifference in response is particularly marked in patients > 65 years of ageMethylation status greater predictor of treatment response than other tumor or patient factors",
                    "sub_points": [
                      "Patients with methylatedMGMTpromoter region have improved outcomes with temozolomide",
                      "Difference in response is particularly marked in patients > 65 years of age",
                      "Methylation status greater predictor of treatment response than other tumor or patient factors"
                    ]
                  },
                  {
                    "text": "Therapies inhibitingMGMTfunction are in developmentEarly trials show no improvement in temazolomide response",
                    "sub_points": [
                      "Early trials show no improvement in temazolomide response"
                    ]
                  }
                ]
              },
              "Testing Methods": {
                "Bisulfite Conversion Dependent": [
                  {
                    "text": "Most common method of assessment of methylation status"
                  },
                  {
                    "text": "Genomic tumor DNA is isolated and treated with sodium bisulfite"
                  },
                  {
                    "text": "Bisulfite causes chemical conversion of all unmethylated cytosines to uracilUracil will be replaced by thymine during PCR",
                    "sub_points": [
                      "Uracil will be replaced by thymine during PCR"
                    ]
                  },
                  {
                    "text": "5-methyl-cytosine is protected from conversion by bisulfite5-methyl-cytosine will be replaced by cytosine during PCR",
                    "sub_points": [
                      "5-methyl-cytosine will be replaced by cytosine during PCR"
                    ]
                  },
                  {
                    "text": "Bisulfite-treated DNA is amplified using primers to CpG island, including part of promoter region and exon 1This region contains 98 CpG methylation sitesMost assays target limited number of sitesMethylation may be heterogeneous, and studies targeting very limited numbers of sites may give misleading resultsAverage level of methylation over tested sites is used to determine if statistically significant level of methylation is present above backgroundThese CpG sites are unmethylated in normal tissueCut-offs are not well defined or standardizedVary based on measurement technique and between laboratoriesPresence of methylation at or above validated cut-off for positive correlates with improved survival with alkylating chemotherapy compared to unmethylated tumorsGray zone result is defined by partially, weakly, or inconsistently methylated caseBy pyrosequencing, 1/2 of all high-grade gliomas have methylation ofMGMTpromoter regionsOther methods are less sensitiveAlternative analysis involves determining normal methylation levels at individual CpG sitesAnything above normal is considered positive at particular site> 3 positive sites is considered methylated for treatment purposesPredictive of temozolomide response",
                    "sub_points": [
                      "This region contains 98 CpG methylation sites",
                      "Most assays target limited number of sitesMethylation may be heterogeneous, and studies targeting very limited numbers of sites may give misleading results",
                      "Methylation may be heterogeneous, and studies targeting very limited numbers of sites may give misleading results",
                      "Average level of methylation over tested sites is used to determine if statistically significant level of methylation is present above backgroundThese CpG sites are unmethylated in normal tissue",
                      "These CpG sites are unmethylated in normal tissue",
                      "Cut-offs are not well defined or standardizedVary based on measurement technique and between laboratoriesPresence of methylation at or above validated cut-off for positive correlates with improved survival with alkylating chemotherapy compared to unmethylated tumorsGray zone result is defined by partially, weakly, or inconsistently methylated caseBy pyrosequencing, 1/2 of all high-grade gliomas have methylation ofMGMTpromoter regionsOther methods are less sensitive",
                      "Vary based on measurement technique and between laboratories",
                      "Presence of methylation at or above validated cut-off for positive correlates with improved survival with alkylating chemotherapy compared to unmethylated tumorsGray zone result is defined by partially, weakly, or inconsistently methylated case",
                      "Gray zone result is defined by partially, weakly, or inconsistently methylated case",
                      "By pyrosequencing, 1/2 of all high-grade gliomas have methylation ofMGMTpromoter regionsOther methods are less sensitive",
                      "Other methods are less sensitive",
                      "Alternative analysis involves determining normal methylation levels at individual CpG sitesAnything above normal is considered positive at particular site> 3 positive sites is considered methylated for treatment purposesPredictive of temozolomide response",
                      "Anything above normal is considered positive at particular site",
                      "> 3 positive sites is considered methylated for treatment purposes",
                      "Predictive of temozolomide response"
                    ]
                  }
                ],
                "Measuring Rate of Conversion": [
                  {
                    "text": "Methylation-specific pyrosequencingAmplified DNA is sequencedRatio of cytosine to thymine at each potential conversion site is measuredBest correlation with prognosis",
                    "sub_points": [
                      "Amplified DNA is sequenced",
                      "Ratio of cytosine to thymine at each potential conversion site is measured",
                      "Best correlation with prognosis"
                    ]
                  },
                  {
                    "text": "Methylation-specific PCR (MS-PCR)2 different primer sets are usedMethylated primer pair is specific for nonconverted sequenceNonmethylated primer pair is specific for sequences with cytosine residues converted to uracilAgarose gel electrophoresis is performed to visualize presence of PCR products",
                    "sub_points": [
                      "2 different primer sets are usedMethylated primer pair is specific for nonconverted sequenceNonmethylated primer pair is specific for sequences with cytosine residues converted to uracil",
                      "Methylated primer pair is specific for nonconverted sequence",
                      "Nonmethylated primer pair is specific for sequences with cytosine residues converted to uracil",
                      "Agarose gel electrophoresis is performed to visualize presence of PCR products"
                    ]
                  },
                  {
                    "text": "Real-time MS-PCRUtilizes probe specific to nonconverted sequence with attached fluorophore and quencherDuring PCR, probe is degraded, leading to separation of fluorophore and quencherResulting fluorescence is quantifiedResults are expressed as methylation index (MI): Ratio of amplification of methylatedMGMTto control geneMI < 4 is unmethylated, 4-16 is borderline, and > 16 is methylated",
                    "sub_points": [
                      "Utilizes probe specific to nonconverted sequence with attached fluorophore and quencher",
                      "During PCR, probe is degraded, leading to separation of fluorophore and quencher",
                      "Resulting fluorescence is quantified",
                      "Results are expressed as methylation index (MI): Ratio of amplification of methylatedMGMTto control geneMI < 4 is unmethylated, 4-16 is borderline, and > 16 is methylated",
                      "MI < 4 is unmethylated, 4-16 is borderline, and > 16 is methylated"
                    ]
                  },
                  {
                    "text": "Methylation-specific high-resolution melting curveFollowing bisulfite conversion, methylated and nonmethylated sequences have different melting points",
                    "sub_points": [
                      "Following bisulfite conversion, methylated and nonmethylated sequences have different melting points"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "MGMT protein positive with preserved expression"
                  },
                  {
                    "text": "Has high interobserver variability"
                  },
                  {
                    "text": "Poor correlation with molecular methods"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Pharmacogenomics": {
        "name": "Pharmacogenomics",
        "url": "https://app.pathprimer.com/lesson/ece04267-db48-479c-816f-419b2e3c8e58",
        "topics": {
          "Overview of Pharmacogenomics": {
            "name": "Overview of Pharmacogenomics",
            "url": "https://app.pathprimer.com/document/506625df-adec-4d23-9a1d-82344799c94f/lesson/ece04267-db48-479c-816f-419b2e3c8e58",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adverse drug reaction (ADR)"
                  },
                  {
                    "text": "Clinical Pharmacogenetics Implementation Consortium (CPIC)"
                  },
                  {
                    "text": "Pharmacogenomics Research Network (PGRN)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Precision medicine: Branch of medicine concerned with use of genetic information to tailor medical care for an individual patient to improve clinical outcomes and reduce complications"
                  },
                  {
                    "text": "Pharmacogenetics: Application of precision medicine that uses DNA sequence information to inform drug selection, dosing, or drug development"
                  },
                  {
                    "text": "﻿Pharmacogenomics: Uses genomic sequence information to individualize drug therapy and guide drug development"
                  },
                  {
                    "text": "Pharmacokinetics: Branch of pharmacology that deals with drug absorption, distribution, metabolism, and excretion"
                  },
                  {
                    "text": "Pharmacodynamics: Branch of pharmacology concerned with interaction of a drug with its target and resulting physiologic response"
                  },
                  {
                    "text": "Prodrugs: Medications that require metabolism in the body to become active drugs"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Precision medicine: Personalized medicine, personalized genetic medicine"
                  },
                  {
                    "text": "Pharmacogenetics and pharmacogenomicsSome use these terms interchangeably",
                    "sub_points": [
                      "Some use these terms interchangeably"
                    ]
                  }
                ],
                "Regulatory Bodies and Professional Organizations": [
                  {
                    "text": "US Federal Drug AdministrationFederal law enforcement agency responsible for protecting public health by ensuring safety and efficacy of drugs, food, and other products (www.fda.gov)",
                    "sub_points": [
                      "Federal law enforcement agency responsible for protecting public health by ensuring safety and efficacy of drugs, food, and other products (www.fda.gov)"
                    ]
                  },
                  {
                    "text": "PharmGKBPharmacogenomics resource sponsored by National Institutes of Health that collects information on human genetic variation and drug responses (www.pharmgkb.org)",
                    "sub_points": [
                      "Pharmacogenomics resource sponsored by National Institutes of Health that collects information on human genetic variation and drug responses (www.pharmgkb.org)"
                    ]
                  },
                  {
                    "text": "Pharmacogenomics Research NetworkLeads research for discovery and translation of genomic variation influencing drug effects (www.pgrn.org)",
                    "sub_points": [
                      "Leads research for discovery and translation of genomic variation influencing drug effects (www.pgrn.org)"
                    ]
                  },
                  {
                    "text": "Clinical Pharmacogenetics Implementation ConsortiumCollaboration between PharmGKB and the PRN that provides guidelines (published in peer reviewed journals) that enable translation of genetic laboratory test results into actionable prescribing decisions for specific drugs (www.cpicpgx.org)",
                    "sub_points": [
                      "Collaboration between PharmGKB and the PRN that provides guidelines (published in peer reviewed journals) that enable translation of genetic laboratory test results into actionable prescribing decisions for specific drugs (www.cpicpgx.org)"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "Annual prescription drug use (United States)> 2 billion prescriptions, or approximately 10 prescriptions/person> 10,000 different medications",
                    "sub_points": [
                      "> 2 billion prescriptions, or approximately 10 prescriptions/person",
                      "> 10,000 different medications"
                    ]
                  },
                  {
                    "text": "Annual burden of ADR (United States)2 million serious ADRs in hospitalized patients100,000 deaths in hospitalized patients$136 billion",
                    "sub_points": [
                      "2 million serious ADRs in hospitalized patients",
                      "100,000 deaths in hospitalized patients",
                      "$136 billion"
                    ]
                  },
                  {
                    "text": "Increased incidence of ADR in certain demographic groupsAge > 55 yearsMalesAfrican AmericansLow socioeconomic status",
                    "sub_points": [
                      "Age > 55 years",
                      "Males",
                      "African Americans",
                      "Low socioeconomic status"
                    ]
                  }
                ]
              },
              "Paradigms in Therapeutic Decision Making": {
                "Individual Patient Response Dependencies": [
                  {
                    "text": "Demographic factorsAgeSexRaceEthnicity",
                    "sub_points": [
                      "Age",
                      "Sex",
                      "Race",
                      "Ethnicity"
                    ]
                  },
                  {
                    "text": "Genetic factorsVariants in genes involved in metabolism of the drug or the drug target itselfEnvironmental factorsDietSupplemental drugsDrug-drug interactions",
                    "sub_points": [
                      "Variants in genes involved in metabolism of the drug or the drug target itself",
                      "Environmental factorsDietSupplemental drugsDrug-drug interactions",
                      "Diet",
                      "Supplemental drugs",
                      "Drug-drug interactions"
                    ]
                  },
                  {
                    "text": "Other factorsHeightWeightComorbidities (especially liver disease and kidney disease)",
                    "sub_points": [
                      "Height",
                      "Weight",
                      "Comorbidities (especially liver disease and kidney disease)"
                    ]
                  }
                ],
                "Trial-and-Error Paradigm": [
                  {
                    "text": "Many therapeutic strategies are developed through trial and errorInclude antidepressants, antihypertensives, analgesics",
                    "sub_points": [
                      "Include antidepressants, antihypertensives, analgesics"
                    ]
                  },
                  {
                    "text": "DisadvantagesPotential for ADRPatients undergoing trials with multiple drugs at increased risk of ADRVariability of individual responses increases risk of ADR for some patientsDelay in optimizing doseVariability in individual patient responses can require multiple dosing adjustments to achieve therapeutic levelsDelay in identifying effective drugSome drugs (antidepressants, in particular) may take months to demonstrate therapeutic efficacyHigh failure rate of some drugs can necessitate multiple trials for the patientDuring trial period, patient is at risk for complications from or progression of the disease the drug is intended to treatDelay in therapeutic response may decrease patient satisfaction and possibly lead to decreased compliance with medication",
                    "sub_points": [
                      "Potential for ADRPatients undergoing trials with multiple drugs at increased risk of ADRVariability of individual responses increases risk of ADR for some patients",
                      "Patients undergoing trials with multiple drugs at increased risk of ADR",
                      "Variability of individual responses increases risk of ADR for some patients",
                      "Delay in optimizing doseVariability in individual patient responses can require multiple dosing adjustments to achieve therapeutic levels",
                      "Variability in individual patient responses can require multiple dosing adjustments to achieve therapeutic levels",
                      "Delay in identifying effective drugSome drugs (antidepressants, in particular) may take months to demonstrate therapeutic efficacyHigh failure rate of some drugs can necessitate multiple trials for the patientDuring trial period, patient is at risk for complications from or progression of the disease the drug is intended to treatDelay in therapeutic response may decrease patient satisfaction and possibly lead to decreased compliance with medication",
                      "Some drugs (antidepressants, in particular) may take months to demonstrate therapeutic efficacy",
                      "High failure rate of some drugs can necessitate multiple trials for the patient",
                      "During trial period, patient is at risk for complications from or progression of the disease the drug is intended to treat",
                      "Delay in therapeutic response may decrease patient satisfaction and possibly lead to decreased compliance with medication"
                    ]
                  }
                ],
                "Pharmacogenetic Testing Paradigm": [
                  {
                    "text": "Goals and advantagesPatient genotype may provide valuable informationLikelihood that patient will have ADRLikelihood that patient will respond to a drug and at what doseAvoid delaysMore readily identify the most efficacious drug for that patientMore readily achieve therapeutic levels by optimizing dosing at time of implementationCircumvent need to try drugs that are unlikely to be effectiveDecrease patient costsDecrease ADRIncrease patient satisfactionPromote patient compliance with medication",
                    "sub_points": [
                      "Patient genotype may provide valuable informationLikelihood that patient will have ADRLikelihood that patient will respond to a drug and at what dose",
                      "Likelihood that patient will have ADR",
                      "Likelihood that patient will respond to a drug and at what dose",
                      "Avoid delaysMore readily identify the most efficacious drug for that patientMore readily achieve therapeutic levels by optimizing dosing at time of implementation",
                      "More readily identify the most efficacious drug for that patient",
                      "More readily achieve therapeutic levels by optimizing dosing at time of implementation",
                      "Circumvent need to try drugs that are unlikely to be effective",
                      "Decrease patient costs",
                      "Decrease ADR",
                      "Increase patient satisfaction",
                      "Promote patient compliance with medication"
                    ]
                  }
                ]
              },
              "Drug Response Dependencies": {
                "Pharmacokinetic Factors": [
                  {
                    "text": "Drug metabolizing enzymes have been a major target of pharmacogenetic testing"
                  },
                  {
                    "text": "Traditionally, drugs are metabolized by phase I and phase II reactions in sequencePhase I reactionsEnzymes oxidize, reduce, or hydrolyze drugs, mostly cytochrome P450 (CYP) enzymesCYP enzymes are principally expressed in liver endoplasmic reticulum and form the hepatic microsomal cytochrome P450 systemMost drugs are inactivated by cytochrome P450 enzymesSome drugs are not biologically active (prodrugs) and require metabolism by CYP enzymes to become activeSome drugs have metabolites that retain biological activityPhase II reactionsVarious enzymes conjugate hydrophilic functional groups to the end product of phase I reactions to enhance their solubility and facilitate their excretion by the liver or kidneysSome drugs only undergo phase I or phase II reactions, or undergo phase II reactions before phase I reactions, or are metabolized by multiple pathways",
                    "sub_points": [
                      "Phase I reactionsEnzymes oxidize, reduce, or hydrolyze drugs, mostly cytochrome P450 (CYP) enzymesCYP enzymes are principally expressed in liver endoplasmic reticulum and form the hepatic microsomal cytochrome P450 systemMost drugs are inactivated by cytochrome P450 enzymesSome drugs are not biologically active (prodrugs) and require metabolism by CYP enzymes to become activeSome drugs have metabolites that retain biological activity",
                      "Enzymes oxidize, reduce, or hydrolyze drugs, mostly cytochrome P450 (CYP) enzymesCYP enzymes are principally expressed in liver endoplasmic reticulum and form the hepatic microsomal cytochrome P450 systemMost drugs are inactivated by cytochrome P450 enzymesSome drugs are not biologically active (prodrugs) and require metabolism by CYP enzymes to become activeSome drugs have metabolites that retain biological activity",
                      "CYP enzymes are principally expressed in liver endoplasmic reticulum and form the hepatic microsomal cytochrome P450 system",
                      "Most drugs are inactivated by cytochrome P450 enzymes",
                      "Some drugs are not biologically active (prodrugs) and require metabolism by CYP enzymes to become active",
                      "Some drugs have metabolites that retain biological activity",
                      "Phase II reactionsVarious enzymes conjugate hydrophilic functional groups to the end product of phase I reactions to enhance their solubility and facilitate their excretion by the liver or kidneys",
                      "Various enzymes conjugate hydrophilic functional groups to the end product of phase I reactions to enhance their solubility and facilitate their excretion by the liver or kidneys",
                      "Some drugs only undergo phase I or phase II reactions, or undergo phase II reactions before phase I reactions, or are metabolized by multiple pathways"
                    ]
                  },
                  {
                    "text": "CYP genes are highly polymorphic in humans"
                  },
                  {
                    "text": "Variants comprise small mutations (gain-of-function, loss-of-function, and neutral) and copy number alterations (gains and losses)"
                  },
                  {
                    "text": "Some variability in individual patient drug response is attributable to the genetic variability in CYP genes"
                  },
                  {
                    "text": "Genotype-phenotype correlations exist for many common variants, allowing prediction of effect on drug metabolism and drug response"
                  },
                  {
                    "text": "Allelic variants of drug metabolizing enzymes with diminished enzymatic activity or deleted copies of alleles result in accumulation of the parent compoundFor most drugs: Results in accumulation of toxic levels of parent drug and risk of ADRs (﻿poor metabolizers)For prodrugs: Results in failure to convert to active drug and increased potential for therapeutic failure",
                    "sub_points": [
                      "For most drugs: Results in accumulation of toxic levels of parent drug and risk of ADRs (﻿poor metabolizers)",
                      "For prodrugs: Results in failure to convert to active drug and increased potential for therapeutic failure"
                    ]
                  },
                  {
                    "text": "Allelic variants of drug metabolizing enzymes with enhanced enzymatic activity or increased allelic copies result in increased metabolism of parent compound to its metabolite(s)For most drugs: Results in shorter half-life of active compound and possibility of treatment failureRapid formation and accumulation of metabolites can also result in adverse reactionsFor prodrugs: Results in increased conversion to active drug and risk of toxicity (﻿ultra-rapid metabolizers)",
                    "sub_points": [
                      "For most drugs: Results in shorter half-life of active compound and possibility of treatment failureRapid formation and accumulation of metabolites can also result in adverse reactions",
                      "Rapid formation and accumulation of metabolites can also result in adverse reactions",
                      "For prodrugs: Results in increased conversion to active drug and risk of toxicity (﻿ultra-rapid metabolizers)"
                    ]
                  },
                  {
                    "text": "Pharmacodynamic FactorsInteraction of the drug with its target molecules depends on the followingConcentration of drug at the site of actionConcentration of target moleculeAffinity of drug to its target moleculePolymorphisms in the gene encoding a target protein may influence its expression (concentration) &/or its ability to bind to a drug (affinity)Pharmacogenetic testing for pharmacodynamic markers is limited in comparison to pharmacokinetic markersOncology is the major field where pharmacogenetic testing is targeted to pharmacodynamic biomarkersGoal of molecular oncology is to direct therapy at cancer cells while sparing healthy normal cells, thereby minimizing side effectsSome targeted therapies are directed at the protein products of the somatically mutated genes in cancer cellsOther therapies are directed at molecules downstream of the pathways that are activated in cancer due to mutations in or overexpression of proto-oncogenesIn other settings, loss-of-function mutations in tumor suppressor genes may predict increased sensitivity to cytotoxic chemotherapiesCertain mutations may also predict lack of response to certain therapies, allowing patient to forego therapy that is unlikely to be effective",
                    "sub_points": [
                      "Interaction of the drug with its target molecules depends on the followingConcentration of drug at the site of actionConcentration of target moleculeAffinity of drug to its target molecule",
                      "Concentration of drug at the site of action",
                      "Concentration of target molecule",
                      "Affinity of drug to its target molecule",
                      "Polymorphisms in the gene encoding a target protein may influence its expression (concentration) &/or its ability to bind to a drug (affinity)",
                      "Pharmacogenetic testing for pharmacodynamic markers is limited in comparison to pharmacokinetic markers",
                      "Oncology is the major field where pharmacogenetic testing is targeted to pharmacodynamic biomarkersGoal of molecular oncology is to direct therapy at cancer cells while sparing healthy normal cells, thereby minimizing side effectsSome targeted therapies are directed at the protein products of the somatically mutated genes in cancer cellsOther therapies are directed at molecules downstream of the pathways that are activated in cancer due to mutations in or overexpression of proto-oncogenesIn other settings, loss-of-function mutations in tumor suppressor genes may predict increased sensitivity to cytotoxic chemotherapiesCertain mutations may also predict lack of response to certain therapies, allowing patient to forego therapy that is unlikely to be effective",
                      "Goal of molecular oncology is to direct therapy at cancer cells while sparing healthy normal cells, thereby minimizing side effects",
                      "Some targeted therapies are directed at the protein products of the somatically mutated genes in cancer cells",
                      "Other therapies are directed at molecules downstream of the pathways that are activated in cancer due to mutations in or overexpression of proto-oncogenes",
                      "In other settings, loss-of-function mutations in tumor suppressor genes may predict increased sensitivity to cytotoxic chemotherapies",
                      "Certain mutations may also predict lack of response to certain therapies, allowing patient to forego therapy that is unlikely to be effective"
                    ]
                  }
                ]
              },
              "Additional Resources": {
                "FDA (www.fda.gov)": [
                  {
                    "text": "Provides list of drugs for which pharmacogenetic testing recommendations are part of the label"
                  }
                ],
                "GeneTests (www.genetests.org)": [
                  {
                    "text": "Provides list of testing sites"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Clopidogrel Pharmacogenomics": {
            "name": "Clopidogrel Pharmacogenomics",
            "url": "https://app.pathprimer.com/document/1d6548bb-0b64-4922-b0fc-77d58387c9d6/lesson/ece04267-db48-479c-816f-419b2e3c8e58",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Clinical Pharmacogenetics Implementation Consortium (CPIC)"
                  },
                  {
                    "text": "Cytochrome p450, subfamily IIC, polypeptide 19 (CYP2C19) (OMIM 124020)"
                  },
                  {
                    "text": "Glycoprotein IIB/IIIA (GPIIB/IIIA)"
                  },
                  {
                    "text": "Myocardial infarction (MI)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Clopidogrel: Plavix"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clopidogrel: Prodrug containing metabolites with antiplatelet activity"
                  },
                  {
                    "text": "Prodrug: Inactive drug until metabolized by the body to form biologically active drug"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "FDA-Approved Clinical Indications for Clopidogrel Therapy": [
                  {
                    "text": "Decrease risk of cardiovascular death, MI, and stroke in patients with MI"
                  },
                  {
                    "text": "Decrease risk of new ischemic stroke, new MI, and other vascular death in patients with recent MI, recent stroke, or peripheral vascular disease"
                  }
                ],
                "Clopidogrel Pharmacodynamics": [
                  {
                    "text": "Platelet activationADP receptor P2Y₁₂ on the surface of platelets mediates autocrine/paracrine signaling from ADP secreted from platelet-dense granulesBinding of ADP to P2Y₁₂ culminates in activation of GPIIB/IIIA and platelet aggregationPlatelet aggregation is an important contributor to thrombotic events (e.g., stroke, MI)",
                    "sub_points": [
                      "ADP receptor P2Y₁₂ on the surface of platelets mediates autocrine/paracrine signaling from ADP secreted from platelet-dense granules",
                      "Binding of ADP to P2Y₁₂ culminates in activation of GPIIB/IIIA and platelet aggregation",
                      "Platelet aggregation is an important contributor to thrombotic events (e.g., stroke, MI)"
                    ]
                  },
                  {
                    "text": "Mechanism of actionActive metabolites of clopidogrel irreversibly bind and inhibit the P2Y₁₂ receptor during the 10-day life span of plateletsPrevents platelet aggregationReduces risk of thrombotic events",
                    "sub_points": [
                      "Active metabolites of clopidogrel irreversibly bind and inhibit the P2Y₁₂ receptor during the 10-day life span of plateletsPrevents platelet aggregationReduces risk of thrombotic events",
                      "Prevents platelet aggregation",
                      "Reduces risk of thrombotic events"
                    ]
                  }
                ],
                "Clopidogrel Pharmacokinetics": [
                  {
                    "text": "85% metabolized by esterases to inactive products"
                  },
                  {
                    "text": "15% metabolized to the 2-oxo-clopidogrel intermediate, and finally to an active thiol derivative by various cytochrome P450 enzymes"
                  },
                  {
                    "text": "CYP2C19 is primarily expressed in the liver and is the principle isozyme involved in formation of intermediate and active metabolite of clopidogrel"
                  }
                ],
                "Challenges to Clopidogrel Dosing": [
                  {
                    "text": "Underdosing results in inadequate platelet inhibition and risk for thrombosis"
                  },
                  {
                    "text": "Overdosing results in increased platelet inhibition and risk for hemorrhage"
                  },
                  {
                    "text": "Wide variability in patient response"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Variable Clopidogrel Pharmacokinetics": [
                  {
                    "text": "Wide variability among patients in metabolism of clopidogrel to active product by CYP2C19Four phenotypic groups of clopidogrel metabolizers identifiedUltrarapid metabolizersIncreased CYP2C19 activityRapid formation of active metabolitePossible risk of bleeding (toxicity)Extensive metabolizersNormal CYP2C19 activityNormal production of active metaboliteNormal platelet inhibition (normal therapeutic effect)Intermediate metabolizersLess than normal CYP2C19 activityDecreased formation of active metaboliteReduced platelet inhibition (reduced therapeutic effect)Poor metabolizersMinimal or no CYP2C19 activityNo significant formation of active metaboliteLack of platelet inhibition (no therapeutic effect)",
                    "sub_points": [
                      "Four phenotypic groups of clopidogrel metabolizers identifiedUltrarapid metabolizersIncreased CYP2C19 activityRapid formation of active metabolitePossible risk of bleeding (toxicity)Extensive metabolizersNormal CYP2C19 activityNormal production of active metaboliteNormal platelet inhibition (normal therapeutic effect)Intermediate metabolizersLess than normal CYP2C19 activityDecreased formation of active metaboliteReduced platelet inhibition (reduced therapeutic effect)Poor metabolizersMinimal or no CYP2C19 activityNo significant formation of active metaboliteLack of platelet inhibition (no therapeutic effect)",
                      "Ultrarapid metabolizersIncreased CYP2C19 activityRapid formation of active metabolitePossible risk of bleeding (toxicity)",
                      "Increased CYP2C19 activity",
                      "Rapid formation of active metabolite",
                      "Possible risk of bleeding (toxicity)",
                      "Extensive metabolizersNormal CYP2C19 activityNormal production of active metaboliteNormal platelet inhibition (normal therapeutic effect)",
                      "Normal CYP2C19 activity",
                      "Normal production of active metabolite",
                      "Normal platelet inhibition (normal therapeutic effect)",
                      "Intermediate metabolizersLess than normal CYP2C19 activityDecreased formation of active metaboliteReduced platelet inhibition (reduced therapeutic effect)",
                      "Less than normal CYP2C19 activity",
                      "Decreased formation of active metabolite",
                      "Reduced platelet inhibition (reduced therapeutic effect)",
                      "Poor metabolizersMinimal or no CYP2C19 activityNo significant formation of active metaboliteLack of platelet inhibition (no therapeutic effect)",
                      "Minimal or no CYP2C19 activity",
                      "No significant formation of active metabolite",
                      "Lack of platelet inhibition (no therapeutic effect)"
                    ]
                  },
                  {
                    "text": "Some of this variability in metabolism of clopidogrel is related to polymorphisms in theCYP2C19geneCYP2C19-related poor drug metabolism (OMIM 609535; autosomal recessive)Multiple CYP2C19 alleles exist (*1, *2, *3, and *17 are most common)*1: Wild-type allele encoding an enzyme with normal activityObserved in 60% of Europeans, Asians, and Africans*2: (c.681G>A; splicing defect) encodes nonfunctional enzymesObserved in 15% of Africans and EuropeansObserved in 30-35% of Asians*3: (c.636G>A; W212X) encodes nonfunctional enzymes< 2% across most racial groups*17: (c.-806C>T) demonstrates increased transcription (increased activity)Observed in 15-25% across most racial groupsPossible risk of increased bleeding risk in homozygotes due to increased conversion of prodrug to active drug",
                    "sub_points": [
                      "CYP2C19-related poor drug metabolism (OMIM 609535; autosomal recessive)",
                      "Multiple CYP2C19 alleles exist (*1, *2, *3, and *17 are most common)*1: Wild-type allele encoding an enzyme with normal activityObserved in 60% of Europeans, Asians, and Africans*2: (c.681G>A; splicing defect) encodes nonfunctional enzymesObserved in 15% of Africans and EuropeansObserved in 30-35% of Asians*3: (c.636G>A; W212X) encodes nonfunctional enzymes< 2% across most racial groups*17: (c.-806C>T) demonstrates increased transcription (increased activity)Observed in 15-25% across most racial groupsPossible risk of increased bleeding risk in homozygotes due to increased conversion of prodrug to active drug",
                      "*1: Wild-type allele encoding an enzyme with normal activityObserved in 60% of Europeans, Asians, and Africans",
                      "Observed in 60% of Europeans, Asians, and Africans",
                      "*2: (c.681G>A; splicing defect) encodes nonfunctional enzymesObserved in 15% of Africans and EuropeansObserved in 30-35% of Asians",
                      "Observed in 15% of Africans and Europeans",
                      "Observed in 30-35% of Asians",
                      "*3: (c.636G>A; W212X) encodes nonfunctional enzymes< 2% across most racial groups",
                      "< 2% across most racial groups",
                      "*17: (c.-806C>T) demonstrates increased transcription (increased activity)Observed in 15-25% across most racial groupsPossible risk of increased bleeding risk in homozygotes due to increased conversion of prodrug to active drug",
                      "Observed in 15-25% across most racial groups",
                      "Possible risk of increased bleeding risk in homozygotes due to increased conversion of prodrug to active drug"
                    ]
                  }
                ],
                "Guidelines for Molecular Testing to Guide Dosing": [
                  {
                    "text": "FDABlack box warningPlavix at recommended doses forms less of that metabolite and has smaller effect on platelet function in patients who are CYP2C19 poor metabolizersTesting for CYP2C19 should be performed to identify poor metabolizersAlternative treatments in poor metabolizers recommendedPoor metabolizers have higher risk of cardiovascular events at standard doses",
                    "sub_points": [
                      "Black box warning",
                      "Plavix at recommended doses forms less of that metabolite and has smaller effect on platelet function in patients who are CYP2C19 poor metabolizersTesting for CYP2C19 should be performed to identify poor metabolizersAlternative treatments in poor metabolizers recommendedPoor metabolizers have higher risk of cardiovascular events at standard doses",
                      "Testing for CYP2C19 should be performed to identify poor metabolizers",
                      "Alternative treatments in poor metabolizers recommended",
                      "Poor metabolizers have higher risk of cardiovascular events at standard doses"
                    ]
                  },
                  {
                    "text": "CPICMakes no recommendations for or against testingIf genotype is known, then dosing should be based on genotype",
                    "sub_points": [
                      "Makes no recommendations for or against testing",
                      "If genotype is known, then dosing should be based on genotype"
                    ]
                  },
                  {
                    "text": "American College of Cardiology Foundation and American Heart AssociationTesting may be considered in select patients who experience recurrent MI despite clopidogrel therapy",
                    "sub_points": [
                      "Testing may be considered in select patients who experience recurrent MI despite clopidogrel therapy"
                    ]
                  }
                ]
              },
              "Additional Resources": {
                "Pharmacogenomics Knowledgebase (www.pharmgkb.org)": [
                  {
                    "text": "Genotype-phenotype correlation CYP2C19 alleles"
                  },
                  {
                    "text": "Dosing recommendations based on CYP2C19 diplotypes"
                  }
                ],
                "Genetests (www.genetests.org)": [
                  {
                    "text": "Testing sites for CYP2C19 genotyping"
                  }
                ],
                "Human Cytochrome P450 Allele Nomenclature Database (www.cypalleles.ki.se)": [
                  {
                    "text": "Listing of all known CYP2C19 alleles, genotypes, protein effect, and phenotype"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Codeine Pharmacogenomics": {
            "name": "Codeine Pharmacogenomics",
            "url": "https://app.pathprimer.com/document/7f77cde3-e990-46ef-813f-e984a4ec5362/lesson/ece04267-db48-479c-816f-419b2e3c8e58",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Cytochrome P450, subfamily IID, polypeptide 6 (CYP2D6) (OMIM 124030)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Codeine: Opioid analgesic used for treating mild to moderate pain"
                  },
                  {
                    "text": "Prodrug: Drug that is inactive until metabolized in the body to its active form"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "1-2% of patients are codeine ultrametabolizers"
                  },
                  {
                    "text": "5-10% of patients are poor metabolizers of codeine"
                  }
                ]
              },
              "Codeine Pharmacokinetics": {
                "Therapeutic Effect": [
                  {
                    "text": "Codeine, as a prodrug, must be metabolized to its active form (morphine) to exert therapeutic effect as an opioid analgesic"
                  },
                  {
                    "text": "CYP2D6 converts approximately 5-15% of codeine to morphine by demethylation"
                  },
                  {
                    "text": "Majority of codeine is glucuronidated by UGT2B7 to an inactive metabolite, codeine-6-glucuronide"
                  }
                ],
                "Response to Codeine": [
                  {
                    "text": "MultifactorialAge: Use caution in pediatricsComorbidity: Especially liver diseaseMedications: Especially CYP2D6 inhibitorsGenetics: Variations in CYP2D6",
                    "sub_points": [
                      "Age: Use caution in pediatrics",
                      "Comorbidity: Especially liver disease",
                      "Medications: Especially CYP2D6 inhibitors",
                      "Genetics: Variations in CYP2D6"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Codeine Ultrarapid Metabolizers": [
                  {
                    "text": "Ultrarapid metabolizers have gained additional copies of CYP2D6 allelesMost common diplotypes: *1/*1xN, *1/*2xN, *2/*1xN, *2/*2xN (N = number of copies)*1: Wild-type allele and has normal enzymatic activity*2: Next most common allele (2850C>T; 4180G>C) and also has normal enzymatic activity",
                    "sub_points": [
                      "Most common diplotypes: *1/*1xN, *1/*2xN, *2/*1xN, *2/*2xN (N = number of copies)*1: Wild-type allele and has normal enzymatic activity*2: Next most common allele (2850C>T; 4180G>C) and also has normal enzymatic activity",
                      "*1: Wild-type allele and has normal enzymatic activity",
                      "*2: Next most common allele (2850C>T; 4180G>C) and also has normal enzymatic activity"
                    ]
                  },
                  {
                    "text": "Ultrarapid metabolizers convert a greater fraction of the codeine to morphine"
                  },
                  {
                    "text": "Ultrarapid metabolizers taking codeine at prescribed doses may experience symptoms similar to those who overdose"
                  },
                  {
                    "text": "Serious side effectsRespiratory depression (major/lethal complication)Bradycardia/shock/cardiac arrestSyncopeSeizuresParalytic ileus",
                    "sub_points": [
                      "Respiratory depression (major/lethal complication)",
                      "Bradycardia/shock/cardiac arrest",
                      "Syncope",
                      "Seizures",
                      "Paralytic ileus"
                    ]
                  },
                  {
                    "text": "More common side effectsSedationLightheadedness/dizzinessNauseaVomitingConstipationFlushingEuphoriaPalpitationsAgitation",
                    "sub_points": [
                      "Sedation",
                      "Lightheadedness/dizziness",
                      "Nausea",
                      "Vomiting",
                      "Constipation",
                      "Flushing",
                      "Euphoria",
                      "Palpitations",
                      "Agitation"
                    ]
                  },
                  {
                    "text": "Deaths have resultedIn infants with ultrarapid metabolizer phenotypes when breastfeeding from mothers taking codeineIn children with ultrarapid metabolizer phenotypes following tonsillectomy",
                    "sub_points": [
                      "In infants with ultrarapid metabolizer phenotypes when breastfeeding from mothers taking codeine",
                      "In children with ultrarapid metabolizer phenotypes following tonsillectomy"
                    ]
                  }
                ],
                "Codeine Poor Metabolizers": [
                  {
                    "text": "Poor metabolizers have deleted copies of CYP2D6 or alleles with various loss-of-function mutationsDeletion: *5 has no activityFrame shift mutations: *3 (2549delA) and *6(1707delT) have no activitySplicing mutation: *4 (100C>T; 1846G>A) has no activitySplicing mutation: *41(2850C>T; 2988G>A) has reduced activity",
                    "sub_points": [
                      "Deletion: *5 has no activity",
                      "Frame shift mutations: *3 (2549delA) and *6(1707delT) have no activity",
                      "Splicing mutation: *4 (100C>T; 1846G>A) has no activity",
                      "Splicing mutation: *41(2850C>T; 2988G>A) has reduced activity"
                    ]
                  },
                  {
                    "text": "Ultimate metabolic effect depends on the diplotype (i.e., both alleles)"
                  }
                ]
              },
              "Additional Resources": {
                "PharmGKB: Pharmacogenomics Knowledgebase (www.pharmgkb.org)": [
                  {
                    "text": "Provides phenotype based on diplotype; dosing guidelines"
                  }
                ],
                "Human Cytochrome P450 Allele Nomenclature Database (www.cypalleles.ki.se)": [
                  {
                    "text": "Provides listing of cytochrome P450 enzymes; nomenclature rules; genotype-phenotype correlations; references"
                  }
                ],
                "GeneTests (www.genetests.org/disorders)": [
                  {
                    "text": "Provides sites that test for CYP2D6 variants"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Tacrolimus Pharmacogenomics": {
            "name": "Tacrolimus Pharmacogenomics",
            "url": "https://app.pathprimer.com/document/77f90391-e96c-4e6c-8b2f-ef37692ede03/lesson/ece04267-db48-479c-816f-419b2e3c8e58",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Clinical Pharmacogenetics Implementation Consortium (CPIC)"
                  },
                  {
                    "text": "Cytochrome P450, subfamily IIIA, polypeptide (CYP3A5) (OMIM 605325)"
                  },
                  {
                    "text": "FK506-binding protein 1A (FKBP1A)"
                  },
                  {
                    "text": "Interleukin-2 (IL2)"
                  },
                  {
                    "text": "Nuclear factor of activated T cells (NFAT)"
                  },
                  {
                    "text": "Posttransplant lymphoproliferative disorder (PTLD)"
                  },
                  {
                    "text": "Progressive multifocal leukoencephalopathy (PML)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Tacrolimus: FK506"
                  },
                  {
                    "text": "Protein phosphatase 3 (PPP3): Calcineurin"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Tacrolimus: Immunosuppressive medication"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Clinical Indications for Tacrolimus Therapy": [
                  {
                    "text": "Prophylaxis for solid organ (liver, kidney, and heart) transplant rejection"
                  },
                  {
                    "text": "Prophylaxis for hematopoietic stem cell transplant rejection"
                  },
                  {
                    "text": "Graft-versus-host disease"
                  },
                  {
                    "text": "Glomerulonephritis"
                  },
                  {
                    "text": "Atopic dermatitis"
                  },
                  {
                    "text": "Other inflammatory conditions"
                  }
                ],
                "Tacrolimus Pharmacodynamics": [
                  {
                    "text": "IL-2 is a major cytokine mediating various aspects of transplant rejection via NFAT signaling pathway"
                  },
                  {
                    "text": "NFAT is a transcription factor that regulates expression of IL-2In quiescent T cells, NFAT is phosphorylated, localized to cytoplasm (no IL-2 expression)Following T-cell activation (e.g., after organ transplant)Calcium flows into the cell, activating calcineurin, a calcium-calmodulin-dependent serine/threonine protein phosphataseCalcineurin dephosphorylates NFATDephosphorylated NFAT translocates to the nucleus and activates IL-2 transcription",
                    "sub_points": [
                      "In quiescent T cells, NFAT is phosphorylated, localized to cytoplasm (no IL-2 expression)",
                      "Following T-cell activation (e.g., after organ transplant)Calcium flows into the cell, activating calcineurin, a calcium-calmodulin-dependent serine/threonine protein phosphataseCalcineurin dephosphorylates NFATDephosphorylated NFAT translocates to the nucleus and activates IL-2 transcription",
                      "Calcium flows into the cell, activating calcineurin, a calcium-calmodulin-dependent serine/threonine protein phosphatase",
                      "Calcineurin dephosphorylates NFAT",
                      "Dephosphorylated NFAT translocates to the nucleus and activates IL-2 transcription"
                    ]
                  },
                  {
                    "text": "Mechanism of action of tacrolimusTacrolimus (FK506) binds to FKBP1A, forming a tacrolimus-FKBP1A complexTacrolimus-FKBP1A complex inhibits calcineurinNFAT remains phosphorylated and IL-2 is not transcribed",
                    "sub_points": [
                      "Tacrolimus (FK506) binds to FKBP1A, forming a tacrolimus-FKBP1A complex",
                      "Tacrolimus-FKBP1A complex inhibits calcineurin",
                      "NFAT remains phosphorylated and IL-2 is not transcribed"
                    ]
                  }
                ],
                "Tacrolimus Pharmacokinetics": [
                  {
                    "text": "Tacrolimus is metabolized to an inactive product by CYP3A5"
                  }
                ],
                "Challenges to Tacrolimus Dosing": [
                  {
                    "text": "Tacrolimus has a narrow therapeutic window and is associated with significant adverse reactionsIncreased risk of infections (BK virus nephropathy, CMV, and others due to immunosuppression; FDA black box warning)Increased risk of PTLD and PML; FDA black box warningNeurotoxicity (tremor, headache, seizure)Nephrotoxicity (hyperkalemia, QT prolongation, increased creatinine)Bone marrow toxicity (pure red cell aplasia, hemolytic anemia, thrombocytopenic purpura)",
                    "sub_points": [
                      "Increased risk of infections (BK virus nephropathy, CMV, and others due to immunosuppression; FDA black box warning)",
                      "Increased risk of PTLD and PML; FDA black box warning",
                      "Neurotoxicity (tremor, headache, seizure)",
                      "Nephrotoxicity (hyperkalemia, QT prolongation, increased creatinine)",
                      "Bone marrow toxicity (pure red cell aplasia, hemolytic anemia, thrombocytopenic purpura)"
                    ]
                  },
                  {
                    "text": "Therapeutic drug monitoring helps ensure patients achieve appropriate levels, but does not guarantee efficacy or freedom from adverse reactions"
                  },
                  {
                    "text": "Achieving therapeutic levels rapidly after transplantation may be important"
                  },
                  {
                    "text": "Time to achieve therapeutic levels is variable, which is partly inheritedStandard dosing based on poor metabolizersIntermediate and extensive metabolizers require higher doses",
                    "sub_points": [
                      "Standard dosing based on poor metabolizers",
                      "Intermediate and extensive metabolizers require higher doses"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Variable Tacrolimus Pharmacokinetics": [
                  {
                    "text": "Some variability in achieving therapeutic levels is attributable to variations in theCYP3Agene"
                  },
                  {
                    "text": "CYP3A5gene encodes a major enzyme, metabolizing tacrolimus to an inactive product"
                  },
                  {
                    "text": "CYP3A5is polymorphic and shows significant racial variation*1 is the wild-type alleleMost common allele in African Americans (60%)*3 (c.6986T>C; splicing defect) encodes a nonfunctional enzymeMost common allele in Asians (74%) and Caucasians (92%)*6 (c.14690C>T; splicing defect) and *7 (c.27131_27132insA; frameshift) encode nonfunctional enzymesSeen in about 10% of African Americans and very rarely in Asians and Caucasians",
                    "sub_points": [
                      "*1 is the wild-type alleleMost common allele in African Americans (60%)",
                      "Most common allele in African Americans (60%)",
                      "*3 (c.6986T>C; splicing defect) encodes a nonfunctional enzymeMost common allele in Asians (74%) and Caucasians (92%)",
                      "Most common allele in Asians (74%) and Caucasians (92%)",
                      "*6 (c.14690C>T; splicing defect) and *7 (c.27131_27132insA; frameshift) encode nonfunctional enzymesSeen in about 10% of African Americans and very rarely in Asians and Caucasians",
                      "Seen in about 10% of African Americans and very rarely in Asians and Caucasians"
                    ]
                  },
                  {
                    "text": "Standard dosing of tacrolimus based on patients who are poor metabolizers (2 nonfunctional alleles, mostly Caucasians)"
                  }
                ],
                "Guidelines of Molecular Testing to Guide Dosing": [
                  {
                    "text": "CPIC does not recommend for or against genotyping of CYP3A4 to guide tacrolimus therapyHowever, if genotype information is available, then CPIC recommends dosing based on genotype information",
                    "sub_points": [
                      "However, if genotype information is available, then CPIC recommends dosing based on genotype information"
                    ]
                  },
                  {
                    "text": "Higher doses recommended for patients who inherit at least 1 functional allele (intermediate and extensive metabolizers)"
                  }
                ]
              },
              "Additional Resources": {
                "Pharmacogenomics Knowledgebase (www.pharmgkb.org)": [
                  {
                    "text": "Genotype-phenotype correlation CYP3A5 alleles"
                  },
                  {
                    "text": "Dosing recommendations based on CYP3A5 diplotypes"
                  }
                ],
                "GeneTests (www.genetests.org)": [
                  {
                    "text": "Testing sites for CYP3A5 genotyping"
                  }
                ],
                "Human Cytochrome P450 Allele Nomenclature Database (www.cypalleles.ki.se)": [
                  {
                    "text": "Listing of all known CYP3A5 alleles, genotypes, protein effect, and phenotype"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Warfarin Pharmacogenomics": {
            "name": "Warfarin Pharmacogenomics",
            "url": "https://app.pathprimer.com/document/4935acd7-e43d-443c-8d71-a9874651f9ff/lesson/ece04267-db48-479c-816f-419b2e3c8e58",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "American College of Medical Genetics (ACMG)"
                  },
                  {
                    "text": "Centers for Medicare and Medicaid Services (CMS)"
                  },
                  {
                    "text": "Clinical Pharmacogenetics Implementation Consortium (CPIC)"
                  },
                  {
                    "text": "Cytochrome P450, subfamily IIC, polypeptide 9 (CYP2C9) (OMIM 601130)"
                  },
                  {
                    "text": "International normalized ratio (INR)"
                  },
                  {
                    "text": "Vitamin K epoxide reductase complex, subunit 1 (VKORC1) (OMIM 608547)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Warfarin = Coumadin"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Variability in Dosing": [
                  {
                    "text": "Genetic factors account for 40% of variability in warfarin dosingVKORC1 variants: 30%CYP2C9 variants: 10%Other cytochrome P450 genes and coagulation factor gene variants: Small fraction",
                    "sub_points": [
                      "VKORC1 variants: 30%",
                      "CYP2C9 variants: 10%",
                      "Other cytochrome P450 genes and coagulation factor gene variants: Small fraction"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "FDA-Approved Clinical Indications for Warfarin Therapy": [
                  {
                    "text": "Prophylaxis and treatmentVenous thrombosis and pulmonary embolismThromboembolic complications secondary to atrial fibrillation &/or cardiac valve replacement",
                    "sub_points": [
                      "Venous thrombosis and pulmonary embolism",
                      "Thromboembolic complications secondary to atrial fibrillation &/or cardiac valve replacement"
                    ]
                  },
                  {
                    "text": "ReducedRisk of deathRecurrent myocardial infarctionThromboembolic events (e.g., stroke or systemic embolization after myocardial infarction)",
                    "sub_points": [
                      "Risk of death",
                      "Recurrent myocardial infarction",
                      "Thromboembolic events (e.g., stroke or systemic embolization after myocardial infarction)"
                    ]
                  }
                ],
                "Warfarin Pharmacodynamics": [
                  {
                    "text": "γ-glutamyl carboxylase catalyzes the posttranslational γ-carboxylation of certain glutamic acid residues in coagulation factors II, VII, IX, and X; protein C; and protein S; this is required for their functional activity"
                  },
                  {
                    "text": "Coenzyme vitamin K is oxidized (consumed) in this reaction and must be reduced to its original state (regenerated) by VKOR in order to participate in another round of γ-carboxylation"
                  },
                  {
                    "text": "Warfarin inhibits VKOR, preventing regeneration of vitamin K and synthesis of functional coagulation factors (thus, its therapeutic basis as anticoagulant)"
                  }
                ],
                "Warfarin Metabolism": [
                  {
                    "text": "Warfarin is racemic mixture of R and S enantiomers"
                  },
                  {
                    "text": "R-warfarin and S-warfarin are metabolized by cytochrome P450 systemCytochrome P450 2C9 (CYP2C9) is major metabolizer of S-warfarin (more potent enantiomer)",
                    "sub_points": [
                      "Cytochrome P450 2C9 (CYP2C9) is major metabolizer of S-warfarin (more potent enantiomer)"
                    ]
                  }
                ],
                "Challenges to Warfarin Dosing": [
                  {
                    "text": "Proper dosing of warfarin is challenging due to its narrow therapeutic window requiring regular monitoring of INRInsufficient dosing results in subtherapeutic INR and risk of thrombosisExcess dosing results in supratherapeutic INR and risk of catastrophic bleeding",
                    "sub_points": [
                      "Insufficient dosing results in subtherapeutic INR and risk of thrombosis",
                      "Excess dosing results in supratherapeutic INR and risk of catastrophic bleeding"
                    ]
                  },
                  {
                    "text": "Time interval from initiation of warfarin therapy to the achievement of therapeutic levels varies greatly between individualsDuring this interval, patient is at risk of thrombotic complications; thus, proper initial dosing of warfarin is paramount to narrowing this window of time",
                    "sub_points": [
                      "During this interval, patient is at risk of thrombotic complications; thus, proper initial dosing of warfarin is paramount to narrowing this window of time"
                    ]
                  },
                  {
                    "text": "Considerations for proper dosingClinical indicationAgeSexRaceEthnicityBody weightDrug interactionsDietAlcohol consumptionSmokingGenetic factors",
                    "sub_points": [
                      "Clinical indication",
                      "Age",
                      "Sex",
                      "Race",
                      "Ethnicity",
                      "Body weight",
                      "Drug interactions",
                      "Diet",
                      "Alcohol consumption",
                      "Smoking",
                      "Genetic factors"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Warfarin Resistance and Sensitivity": [
                  {
                    "text": "30-50% of variability in warfarin dosing is attributable to VKORC1 and CYP2C9 gene variants"
                  }
                ],
                "Guidelines for Molecular Testing to Guide Dosing": [
                  {
                    "text": "ACMG found insufficient evidence to recommend testing for VKORC1 and CYP2C9 variants in warfarin-naive patients"
                  },
                  {
                    "text": "ACMG suggested that testing may be useful in select settings where patients have unusual therapeutic responses to warfarin"
                  },
                  {
                    "text": "CPIC recommends that the pharmacogenetic algorithms (which take into consideration genetic and nongenetic factors) be used to predict optimal warfarin dose (www.warfarindosing.org)"
                  },
                  {
                    "text": "CMS found no evidence to support improved clinical outcomes with CYP2C9 or VKORC1 testing to predict warfarin responsivenessFurther meta-analysis of molecular-based dosing indicated the followingDid not increase time spent within therapeutic rangeDid not decrease excessive anticoagulationDid not decrease major bleeding or thrombosis",
                    "sub_points": [
                      "Further meta-analysis of molecular-based dosing indicated the followingDid not increase time spent within therapeutic rangeDid not decrease excessive anticoagulationDid not decrease major bleeding or thrombosis",
                      "Did not increase time spent within therapeutic range",
                      "Did not decrease excessive anticoagulation",
                      "Did not decrease major bleeding or thrombosis"
                    ]
                  }
                ],
                "Germline Variants in VKORC1 (OMIM 122700)": [
                  {
                    "text": "Autosomal dominant transmission"
                  },
                  {
                    "text": "ACMG recommends testing for VKORC1 -1639G>A and 1173C>T variants in select situations"
                  },
                  {
                    "text": "VKORC1 missense variants also existAssociated with warfarin resistancePatients who inherit these variants require higher doses to achieve therapeutic INR",
                    "sub_points": [
                      "Associated with warfarin resistance",
                      "Patients who inherit these variants require higher doses to achieve therapeutic INR"
                    ]
                  }
                ],
                "Germline Variants in CYP2C9": [
                  {
                    "text": "Predict increased sensitivity to warfarin (OMIM 122700)"
                  },
                  {
                    "text": "Autosomal dominant transmission"
                  },
                  {
                    "text": "CYP2C9 is major enzyme metabolizing S-warfarin to inactive product"
                  },
                  {
                    "text": "Certain variants in CYP2C9 gene abolish or reduce the enzymatic activity of its encoded proteinAssociated with ﻿warfarin sensitivityPatients who inherit these variants require lower doses to achieve therapeutic INR",
                    "sub_points": [
                      "Associated with ﻿warfarin sensitivity",
                      "Patients who inherit these variants require lower doses to achieve therapeutic INR"
                    ]
                  },
                  {
                    "text": "ACMG recommends testing for the following 2 variants in select patientsCYP2C9*2 (c.430C>T, p.R144C): Variant has decreased catalytic activityCYP2C9*3 (c.1075A>C, p.I359L): Variant has decreased catalytic activity",
                    "sub_points": [
                      "CYP2C9*2 (c.430C>T, p.R144C): Variant has decreased catalytic activity",
                      "CYP2C9*3 (c.1075A>C, p.I359L): Variant has decreased catalytic activity"
                    ]
                  }
                ],
                "Testing Laboratories": [
                  {
                    "text": "Many centers offer testing for VKORC1, CYP2C9, &/or other genes influencing warfarin response either in form of single gene tests or as part of panel"
                  },
                  {
                    "text": "Some testing sites can be found at www.genetests.org"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      }
    }
  }
}